<SEC-DOCUMENT>0001213900-25-021165.txt : 20250306
<SEC-HEADER>0001213900-25-021165.hdr.sgml : 20250306
<ACCEPTANCE-DATETIME>20250306160205
ACCESSION NUMBER:		0001213900-25-021165
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		122
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250306
DATE AS OF CHANGE:		20250306

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Oruka Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		25715110

	BUSINESS ADDRESS:	
		STREET 1:		855 OAK GROVE AVE.
		STREET 2:		SUITE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-606-7910

	MAIL ADDRESS:	
		STREET 1:		855 OAK GROVE AVE.
		STREET 2:		SUITE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARCA biopharma, Inc.
		DATE OF NAME CHANGE:	20090128

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ea0230445-10k_orukathe.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 06 01:03:35 UTC 2025 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:orka="http://www.orukatx.com/20241231" xmlns:srt="http://fasb.org/srt/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="text-indent: 0.25in; margin: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"><b>UNITED STATES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Washington,
D.C. 20549</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
<ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-24140">10-K</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(Mark
One)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="ixv-24141">&#9746;</ix:nonNumeric>
<b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>For
the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-24142"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-24143">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-24144">2024</ix:nonNumeric></ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>OR</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="ixv-24145">&#9744;</ix:nonNumeric>
<b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>FOR
THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Commission
File Number <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-24146">000-22873</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-116"><span style="font-family: Times New Roman, Times, Serif"><b>Oruka
Therapeutics, Inc.</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(Exact
name of Registrant as specified in its Charter)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; width: 49%; font-size: 10pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-140"><span style="font-family: Times New Roman, Times, Serif"><b>Delaware</b></span></ix:nonNumeric></td> <td style="padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 49%; font-size: 10pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber" id="ixv-146"><span style="font-family: Times New Roman, Times, Serif"><b>36-3855489</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom"> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(State or other jurisdiction of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>incorporation or organization)</b></span></p></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(I.R.S. Employer<br/> Identification No.)</b></span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-173"><span style="font-family: Times New Roman, Times, Serif"><b>855 Oak Grove Avenue</b></span></ix:nonNumeric></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2" id="ixv-177"><span style="font-family: Times New Roman, Times, Serif"><b>Suite 100</b></span></ix:nonNumeric></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-24147">Menlo Park</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="ixv-24148">California</ix:nonNumeric></b></span></p></td> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-186"><span style="font-family: Times New Roman, Times, Serif"><b>94025</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address of principal executive offices)</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Zip Code)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Registrant&#8217;s
telephone number, including area code: <ix:nonNumeric contextRef="c0" name="dei:CityAreaCode" id="ixv-24149">(650)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber" id="ixv-24150">606-7910</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Securities
registered pursuant to Section 12(b) of the Act:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of Each Class</span></td> <td style="padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol(s)</span></td> <td style="padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Each Exchange on Which Registered</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-240"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, par value $0.001 per share</span></ix:nonNumeric></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-245"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORKA</span></ix:nonNumeric></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-24151">Nasdaq</ix:nonNumeric> Global Market</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Securities
registered pursuant to Section 12(g) of the Act: None</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <span style="text-transform: uppercase">Yes
</span>&#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-274"><span style="text-transform: uppercase">No</span></ix:nonNumeric> &#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. <span style="text-transform: uppercase">Yes
</span>&#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-283"><span style="text-transform: uppercase">No</span></ix:nonNumeric> &#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-291"><span style="text-transform: uppercase">Yes</span></ix:nonNumeric> &#9746; <span style="text-transform: uppercase">No
</span>&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant
was required to submit such files). <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-300"><span style="text-transform: uppercase">Yes</span></ix:nonNumeric> &#9746; <span style="text-transform: uppercase">No
</span>&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif; width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 46%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-331"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="ixv-344"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-352"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></ix:nonNumeric></td> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="ixv-24152">&#9744;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-24153">&#9744;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). <span style="text-transform: uppercase">Yes
</span>&#9744; <span style="text-transform: uppercase">No</span> <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-24154">&#9746;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant as of June 30, 2024, was approximately
$<ix:nonFraction contextRef="c1" decimals="-5" name="dei:EntityPublicFloat" scale="6" unitRef="usd" id="ixv-24155">39.7</ix:nonFraction> million based on the closing price of the Registrant&#8217;s shares of common stock on The Nasdaq Capital Market on such date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
number of the Registrant&#8217;s Common Stock shares outstanding as of February 28, 2025 was <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-24156">37,440,510</ix:nonFraction>.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;<span style="clear: both; display: block;"><br/></span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Table
of Contents</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="padding-bottom: 1.5pt; width: 10%; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 81%; background-color: white; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 9%; background-color: white; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Page</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_001"><b>PART
    I</b></a></span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 6.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
    1.</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_002">Business</a></span></td>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">1</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 6.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
    1A.</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_003">Risk
    Factors</a></span></td>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">38</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 6.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
    1B.</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_004">Unresolved
    Staff Comments</a></span></td>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">70</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 6.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
    1C.</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_005">Cybersecurity</a></span></td>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">70</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 6.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
    2.</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_006">Properties</a></span></td>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">70</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 6.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
    3.</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_007">Legal
    Proceedings</a></span></td>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">70</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 6.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
    4.</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_008">Mine
    Safety Disclosures</a></span></td>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">70</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"/>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_009"><b>PART
    II</b></a></span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"/>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 6.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
    5.</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_010">Market
    for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">71</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 6.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
    6.</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_011">[Reserved]</a></span></td>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">71</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 6.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
    7.</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_012">Management&#8217;s
    Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">72</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 6.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
    7A.</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_013">Quantitative
    and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">85</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 6.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
    8.</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_014">Financial
    Statements and Supplementary Data</a></span></td>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">F-1</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 6.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
    9.</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_015">Changes
    in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">86</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 6.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
    9A.</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_016">Controls
    and Procedures</a></span></td>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">86</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 6.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
    9B.</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_017">Other
    Information</a></span></td>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">87</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 6.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
    9C.</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_018">Disclosure
    Regarding Foreign Jurisdictions that Prevent Inspections</a></span></td>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">87</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"/>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_019"><b>PART
    III</b></a></span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"/>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 6.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
    10.</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_020">Directors,
    Executive Officers and Corporate Governance</a></span></td>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">88</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 6.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
    11.</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_021">Executive
    Compensation</a></span></td>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">93</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 6.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
    12.</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_022">Security
    Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">100</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 6.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
    13.</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_023">Certain
    Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">104</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 6.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
    14.</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_024">Principal
    Accounting Fees and Services</a></span></td>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">108</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"/>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_025"><b>PART
    IV</b></a></span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"/>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 6.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
    15.</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_026">Exhibits,
    Financial Statement Schedules</a></span></td>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">109</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 6.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
    16.</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_027">Form
    10-K Summary</a></span></td>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">111</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 6.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_028">Signatures</a></span></td>
    <td style="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">112</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 2; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">This
Annual Report on Form 10-K, or Annual Report, contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).
These forward-looking statements reflect the current views of Oruka Therapeutics, Inc. (&#8220;Oruka&#8221;, the &#8220;Company&#8221;,
&#8220;we&#8221;, or &#8220;us&#8221;) with respect to future events and are based on assumptions and subject to known and unknown risks
and uncertainties and other factors that may cause our actual results, performance, time frames or achievements to be materially different
from any future results, performance, time frames or achievements expressed or implied by the forward-looking statements. Factors that
might cause such a difference are disclosed in the section titled &#8220;Risk Factors&#8221; in this Annual Report. We caution readers
that any forward-looking statement is not a guarantee of future performance and that actual results could differ materially from those
contained in the forward-looking statement. These statements are based on current expectations of future events. You should evaluate
all forward-looking statements made in this Annual Report in the context of these risks and uncertainties. We caution you that the risks,
uncertainties and other factors referred to in this Annual Report may not contain all of the risks, uncertainties and other factors that
may affect our future results and operations. Moreover, we operate in a very competitive and rapidly changing environment, and new risks
and uncertainties emerge from time to time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">All
statements, other than statements of historical facts contained in this Annual Report, including, without limitation, statements regarding:
our future results of operations and financial position, business strategy, the length of time that we believe our existing cash resources
will fund our operations, our market size, our competition, our potential growth opportunities, our clinical development activities and
timeline, the efficacy and safety profile of our product candidates, the potential therapeutic benefits and economic value of our product
candidates, the timing and results of preclinical studies and clinical trials, the expected impact of macroeconomic conditions, including
inflation, increasing interest rates and volatile market conditions, current or potential bank failures, as well as global events, including
military conflicts and geopolitical tensions on our operations, and the receipt and timing of potential regulatory designations, approvals
and commercialization of product candidates, are forward-looking statements. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221;
&#8220;potentially,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;predict,&#8221; &#8220;target,&#8221;
&#8220;intend,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221;
and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although
not all forward-looking statements contain these identifying words.&#160;These forward-looking statements are based on information available
to us as of the date of this Annual Report and are subject to a number of risks, uncertainties and assumptions, including those described
in Item 1A, &#8220;Risk Factors&#8221; and elsewhere in this Annual Report. Moreover, we operate in a very competitive and rapidly changing
environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the
impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions,
the forward-looking events and circumstances discussed in this Annual Report may not occur and actual results could differ materially
and adversely from those anticipated or implied in the forward-looking statements. While we believe that such information provides a
reasonable basis for these statements, such information may be limited or incomplete. Our statements should not be read to indicate that
we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and
investors are cautioned not to unduly rely on these statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">All
subsequent written or oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in
their entirety by the cautionary statements contained or referred to in this section. We do not undertake any obligation to release publicly
any revisions to these forward-looking statements to reflect events or circumstances after the date of this Annual Report or to reflect
the occurrence of unanticipated events, except as may be required under applicable U.S. securities laws. You should read this Annual
Report with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially
different from what we expect. If we do update one or more forward-looking statements, no inference should be drawn that we will make
additional updates with respect to those or other forward-looking statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Unless
the context indicates otherwise, as used in this Annual Report, the terms &#8220;Oruka,&#8221; &#8220;ARCA biopharma, Inc.,&#8221; &#8220;the
Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Oruka Therapeutics, Inc., a Delaware corporation,
and its consolidated subsidiaries taken as a whole. &#8220;Oruka&#8221; and all product candidate names are our common law trademarks.
This Annual Report contains additional trade names, trademarks and service marks of other companies, which are the property of their
respective owners. We do not intend our use or display of other companies&#8217; trade names, trademarks or service marks to imply a
relationship with, or endorsement or sponsorship of us by, these other companies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">All
references to &#8220;our product candidates,&#8221; &#8220;our programs&#8221; and &#8220;our pipeline&#8221; in this Annual Report refer
to the research programs with respect to which we have exercised the option to acquire intellectual property license rights to or have
the option to acquire intellectual property license rights to pursuant to those certain antibody discovery and option agreements by and
among the Company, Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) and Paruka Holding LLC (&#8220;Paruka&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>PART
I</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
1. Business. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Acquisition
of Pre-Merger Oruka</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">On
August 29, 2024 (the &#8220;Merger Closing&#8221;), we completed our acquisition (the &#8220;Merger&#8221;) of Oruka Therapeutics, Inc.
(&#8220;Pre-Merger Oruka&#8221;) pursuant to an Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024 (the &#8220;Merger
Agreement&#8221;). Following the transactions contemplated by the Merger Agreement, Pre-Merger Oruka merged with and into Atlas Merger
Sub Corp., a wholly owned subsidiary of ARCA biopharma, Inc. (&#8220;ARCA&#8221;) and following that, Pre-Merger Oruka then merged with
and into Atlas Merger Sub II, LLC (&#8220;Second Merger Sub&#8221;), with Second Merger Sub being the surviving entity. Second Merger
Sub changed its corporate name to &#8220;Oruka Therapeutics Operating Company, LLC.&#8221; Pre-Merger Oruka was a pre-clinical stage
biotechnology company that was incorporated on February 6, 2024 under the direction of Peter Harwin, a Managing Member of Fairmount Funds
Management LLC (&#8220;Fairmount&#8221;), for the purposes of holding rights to certain intellectual property being developed by Paragon
Therapeutics, Inc. (&#8220;Paragon&#8221;). On August 29, 2024, we changed our name from &#8220;ARCA biopharma, Inc.&#8221; (&#8220;ARCA&#8221;)
to &#8220;Oruka Therapeutics, Inc.&#8221; and our Nasdaq ticker symbol from &#8220;ABIO&#8221; to &#8220;ORKA&#8221;.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Company
Overview </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
are a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (&#8220;PsO&#8221;)
and other inflammatory and immunology (&#8220;I&amp;I&#8221;) indications. Our name is derived from <i>or</i>, for &#8220;skin,&#8221;
and <i>arukah</i>, for &#8220;restoration,&#8221; and reflects our mission to deliver therapies for chronic skin diseases that provide
patients the most possible freedom from their condition. Our strategy is to apply antibody engineering and format innovations to validated
modes of action, which we believe will enable us to improve meaningfully upon the efficacy and dosing regimens of standard-of-care medicines
while significantly reducing technical and biological risk. Our programs aim to treat and potentially modify disease by targeting mechanisms
with proven efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (&#8220;TRMs&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (&#8220;IL-23p19&#8221;) for the treatment of PsO. Our
co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (&#8220;IL-17A/F&#8221;) for the treatment of PsO,
psoriatic arthritis (&#8220;PsA&#8221;), and other conditions. These programs each bind their respective targets at high affinity and
incorporate half-life extension technology with the aim to increase exposure and decrease dosing frequency. We believe that our focused
strategy, differentiated portfolio, and deep expertise position us to set a new treatment standard in large I&amp;I markets with continued
unmet need.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Our
Pipeline </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg" style="width: 580px"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>ORKA-001</i>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">ORKA-001
is a high affinity, extended half-life monoclonal antibody (&#8220;mAb&#8221;) designed to target IL-23p19. IL-23 is a pro-inflammatory
cytokine that plays a critical role in the proliferation and development of T helper 17 (&#8220;Th17&#8221;) cells, which are the primary
drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit that is shared
with IL-12 and a p19 subunit that is specific to IL-23. First-generation IL-23 antibodies bound p40 and inhibited both IL-12 and IL-23
signaling, while more recent IL-23 antibodies targeting the p19 subunit have shown improved efficacy and safety. Based on preclinical
evidence, we believe that ORKA-001 could achieve higher response rates than established therapies in PsO while requiring less frequent
dosing and maintaining the favorable safety profile of therapies targeting IL-23p19. ORKA-001 is engineered with YTE half-life extension
technology, a specific three amino acid change in the fragment crystallizable (&#8220;Fc&#8221;) domain to modify the pH-dependent binding
to the neonatal Fc receptor (&#8220;FcRn&#8221;). As a result, it has a pharmacokinetic profile designed to support a subcutaneous (&#8220;SQ&#8221;)
injection as infrequently as once or twice a year. In addition, emerging evidence suggests that IL-23 blockade can modify the disease
biology of PsO, possibly leading to durable remissions and preventing the development of PsA.&#160;We believe that the expected characteristics
of ORKA-001 increase its potential to deliver these disease-modifying benefits.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
initiated dosing of healthy volunteers in a Phase 1 trial of ORKA-001 in the fourth quarter of 2024. We expect to share interim data
from the first-in-human trial in healthy volunteers, including initial pharmacokinetic data, in the second half of 2025 and initial efficacy
on patients with PsO in the second half of 2026. Based on recent precedent for PsO, we anticipate that the entire development program
from first-in-human to biologics license application (&#8220;BLA&#8221;) filing could take as little as six to seven&#160;years based
on the averages for recently approved medicines. However, we have no control over the length of time needed for United States Food and
Drug Administration (&#8220;FDA&#8221;) review, and this timeline could vary.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>ORKA-002</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">ORKA-002
is a high affinity, extended half-life mAb designed to target IL-17A and IL-17F (&#8220;IL-17A/F&#8221;). IL-17 inhibition has become
central to the treatment of psoriatic diseases, including PsO and PsA, and has also shown efficacy in other&#160;I&amp;I indications,
such as hidradenitis suppurativa (&#8220;HS&#8221;) and axial spondyloarthritis (&#8220;axSpA&#8221;). More recently, the importance
of inhibiting the IL-17F isoform along with IL-17A has become appreciated, and dual blockade with the recently approved therapy Bimzelx
(bimekizumab) has led to higher response rates in patients than blockade of IL-17A alone. ORKA-002 is designed to bind IL-17A/F at similar
epitopes, or binding sites, and affinity ranges as bimekizumab, but incorporates half-life extension technology that could enable more
convenient dosing intervals. We plan to initiate dosing of healthy volunteers in a Phase&#160;1 trial of ORKA-002 in the third quarter
of 2025. We expect to share interim data from the first-in-human trial in healthy volunteers, including initial pharmacokinetic data,
in the first half of 2026.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
                                            view ORKA-002 and ORKA-001 as highly complementary. Patients with moderate-to-severe PsO
                                            that have purely skin manifestations are most often treated with IL-23 inhibitors due to
                                            the high efficacy and tolerability of this mechanism. However, for patients who also have
                                            joint involvement or signs and symptoms of PsA, an IL-17 inhibitor is typically used due
                                            to its efficacy in addressing both skin and joint symptoms. In addition, IL-17 inhibitors
                                            are often used in patients with highly resistant skin symptoms that do not adequately resolve
                                            through treatment with an IL-23 inhibitor. Furthermore, we have the potential opportunity
                                            to administer ORKA-002 and ORKA-001 sequentially, called ORKA-021, to combine two attractive
                                            features of each program: the rapid response of an IL-17 inhibitor with the ideal maintenance
                                            profile of an IL-23 inhibitor. We believe that ORKA-001 and ORKA-002 provide the potential
                                            to offer a highly compelling product profile for most patients with PsO and/or PsA, as well
                                            as the opportunity to address additional I&amp;I indications.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Additional
Pipeline Program</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
have a third mAb program, ORKA-003, designed to target an undisclosed pathway. Our strategy as a company is to remain highly focused
on&#160;I&amp;I diseases, and specifically on inflammatory dermatology conditions. Our third program provides the potential for indication
expansion beyond PsO and may create combination opportunities with our more advanced programs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Our
Team, Investors, and Paragon Collaboration&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
are led by a management team with significant experience in developing novel treatments for patients at biopharmaceutical companies such
as CRISPR Therapeutics, Celgene, Novartis, CymaBay Therapeutics and Protagonist Therapeutics. Together, our team has a proven track record
of building successful biotech organizations in high-growth environments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Pre-Merger
Oruka was founded in February&#160;2024 by leading healthcare investor Fairmount. Fairmount founded Paragon in 2021 to conduct biologics
discovery and optimization, including acting as the firm&#8217;s discovery engine for biologics that potentially overcome limitations
of existing therapies. We have entered into license agreements with Paragon pursuant to which Paragon granted us a royalty-bearing, world-wide,
exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting IL-23 outside
of the field of inflammatory bowel disease for ORKA-001 and for ORKA-002, certain antibodies and products targeting IL-17A/F.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Our
Strategy</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">To
achieve our goal of developing leading therapeutic antibodies for patients with inflammatory skin diseases, we are applying antibody
engineering to validated modes of action. We believe this approach will enable us to improve meaningfully upon the efficacy and convenience
of standard-of-care medicines while significantly reducing technical and biological risk. The key elements of our strategy include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Employ
                                            advanced antibody engineering to build biologics that could significantly improve upon existing
                                            therapies:&#160;&#160;&#160;&#160;</i></b>We and our collaborators at Paragon have optimized
                                            a variety of parameters using a suite of antibody technologies to develop candidates with
                                            the potential to improve upon existing therapies. These parameters include extending half-life
                                            to increase exposure and reduce dosing frequency, enhancing affinity and specificity to maximize
                                            potency and safety, and optimizing developability to ensure consistency and enable convenient,
                                            high-dose formulations. Together, we believe these features have the potential to translate
                                            into more efficacious and convenient medicines for patients.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Target
                                            validated mechanisms of action:&#160;&#160;&#160;&#160;</i></b>Our initial targets, IL-23p19
                                            and IL-17A/F, have established efficacy and safety for the treatment of PsO, PsA, and other
                                            indications. The FDA has approved four biologics in the IL-23 class, including three targeting
                                            IL-23p19, and four biologics in the IL-17 class, including one targeting IL-17A/F.&#160;While
                                            these therapies have advanced the standard of care in PsO and PsA, they have not addressed
                                            these diseases completely, and a significant fraction of patients do not achieve complete
                                            skin clearance. By applying our advanced antibody engineering to these validated targets,
                                            we believe we can maximize our chances of developing superior medicines for patients. In
                                            addition, the reduced technical and biological risk of these validated mechanisms may allow
                                            us to progress our programs more efficiently and rapidly.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Leverage
                                            insights from earlier entrants to optimize our approach:&#160;&#160;&#160;&#160;</i></b>We
                                            benefit from a large body of clinical evidence generated by prior therapies targeting IL-23
                                            and IL-17. We continue to extract and apply learnings from this precedent to our programs,
                                            including in development candidate selection, clinical trial design, dosing regimens, formulations
                                            and presentations, regulatory pathway, and indication prioritization. For instance, based
                                            on correlations between affinity and efficacy, we have designed ORKA-001 and ORKA-002 to
                                            bind to similar epitopes and at similar or greater affinities as the leading antibodies in
                                            each class: risankizumab and bimekizumab, respectively, with the aim of maximizing efficacy.
                                            Also, by understanding the exposure-response relationships for efficacy and safety for other
                                            therapies, we plan to select dose levels and regimens that could maximize efficacy and maintenance
                                            of response while maintaining safety.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Pursue
                                            opportunities with strong prospects of yielding meaningful new medicines as a &#8220;base
                                            case&#8221; and the potential to shift the treatment paradigm entirely as an &#8220;upside
                                            case&#8221;:&#160;&#160;&#160;&#160;</i></b>Our strategy seeks to maximize the potential
                                            for our programs to reach a base case product profile that could meaningfully advance the
                                            standard of care&#8212;for instance, for ORKA-001, SQ dosing one or twice a year with equal
                                            or greater efficacy compared to today&#8217;s standard of care. At the same time, we aim
                                            to deliver an upside case that dramatically improves outcomes for patients&#8212;for instance,
                                            significantly increasing rates of complete skin clearance via higher antibody exposures or
                                            offering patients durable remissions free from therapy by introducing patient-specific dosing
                                            intervals.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Build
                                            a preeminent biotechnology company focused on chronic skin disease and other&#160;I&amp;I
                                            indications:&#160;&#160;&#160;&#160;</i></b>We are assembling a team of exceptional people
                                            and helping them reach their full potential and flourish so that together we can bring forward
                                            meaningful new medicines for patients.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
believe that pursuing the focused strategy outlined above will help us to succeed in our mission of offering patients living with PsO,
PsA, and other dermatologic and inflammatory diseases the greatest possible freedom from their condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Targeting
IL-23 and IL-17 to Treat Multiple&#160;I&amp;I Indications</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
programs benefit from significant advances in the understanding of the biology of&#160;I&amp;I diseases over the past four decades. ORKA-001
and ORKA-002 are designed to target two key cytokines that play a related role in multiple indications. IL-23 is an upstream regulator
of Th17 cells, a pro-inflammatory subset of T helper cells characterized by their production of IL-17. IL-23 has a critical role in maintaining
Th17 cells in the tissue as well as activating these cells to secrete IL-17, which acts downstream to trigger inflammation and other
disease symptoms. Th17 cells are involved in PsO, PsA, HS, axSpA, and many other diseases. They play a particularly central role in PsO
and PsA. The diagram below depicting the immunopathogenesis of PsO provides an example of how Th17 cells can mediate disease and how
blocking IL-23 or IL-17 can break the inflammatory cycle that drives disease.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Immunopathogenesis
of PsO and the role of IL-23 and IL-17</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_002.jpg" style="height: 403px; width: 550px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">PsO
develops when environmental triggers and a genetic predisposition combine to cause activation of an inflammatory cycle in the skin that
leads to the formation of plaques and other disease manifestations. This process begins with the aberrant activation of the dendritic
cells (&#8220;DCs&#8221;), specifically those producing IL-23 and other cytokines like IL-1&#946;, IL-21, TNF-&#945;, and IL-12. These
cytokines induce the differentiation of Th17 cells, as well as other cell types, such as T helper type 1 (&#8220;Th1&#8221;) cells that
produce IFN&#947; and TNF-&#945; and T helper type 22 (&#8220;Th22&#8221;) cells that produce IL-22. IL-23 plays a key role in the
differentiation and activation of Th17 cells to secrete IL-17, as well as Th22 cells to produce IL-22. IL-17 and these other cytokines
induce keratinocyte hyperproliferation leading to plaque formation and a feedforward inflammatory response, with changes in gene expression
in keratinocytes, the production of antimicrobial peptides, and neutrophil recruitment driving further inflammation. While many cytokines
and cell types contribute to the pathogenesis of PsO, the IL-23/IL-17 axis plays an important role, as supported by the success of therapies
targeting this axis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">While
the successful treatment of PsO&#160;&#8212;&#160;for instance, with mAbs targeting IL-23 or IL-17 &#8212;&#160;can result in lesional
skin returning to an apparently normal state, disease tends to recur at previously affected sites following cessation of therapy, suggesting
a mechanism of &#8220;immunological memory&#8221; that predisposes individuals to recurrence in the same locations. Evidence suggests
that pathogenic TRMs play a critical role in this memory. TRMs may arise from the Th17 cells and other cells that drove disease in the
first place and remain in their resident tissue, in this case the epidermis and dermis, for long periods of time. Upon a disease trigger,
these TRMs can actively produce proinflammatory cytokines, causing disease recurrence. IL-23 appears to play an important role in maintaining
and potentiating TRMs, as indicated by the depletion of TRMs following treatment with an IL-23 inhibitor but not an IL-17 inhibitor,
which may explain the longer remissions observed with IL-23 inhibitors following withdrawal of therapy. This type of data has raised
the prospect that efficient IL-23 blockade could modify the disease biology of PsO, possibly leading to durable remissions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
scientific discoveries that refined our understanding of the immunopathogenesis of PsO have led to waves of therapeutic advances, ultimately
leading to today&#8217;s standard of care. Before the 1980s, PsO was not even thought of as an immunologic disease, but rather a disease
of keratinocyte dysfunction, leading to treatments such as phototherapy, methotrexate, and retinoids. The discovery in the 1980s that
PsO results from immune dysfunction led to the use of broad immunosuppressants like cyclosporine. From 1990 to 2008, it was believed
that Th1 cells were the predominant mediators of the disease, which led to the use of biologics targeting TNF-&#945; such as Enbrel
(etanercept) and Humira (adalimumab). Finally, the revelation that PsO is driven principally by Th17 cells resulted in the development
of the primary therapies used today, which target IL-23 and IL-17. This increasingly refined understanding of the disease has narrowed
the standard of care from broad immunosuppressive agents (such as cyclosporine) to more specific immunomodulators (TNF-&#945; inhibitors)
to precise biologic therapies targeting the key cytokines involved in disease pathology (IL-23 and IL-17 inhibitors), with each new therapeutic
class raising the bar on both safety and efficacy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Biologic
therapies, especially mAbs, are now mainstays in the treatment of a wide variety of&#160;I&amp;I diseases, including PsO and PsA.&#160;Therapies
that have improved upon efficacy and/or reduced dosing frequency have achieved the most commercial success, even when launched many&#160;years
after other biologics. Enbrel was first approved for PsO in 2004 with a weekly maintenance dosing schedule. Four&#160;years later, Humira
was approved for PsO with an every-other-week (Q2W) dosing schedule. Stelara (ustekinumab) was approved a year later with similar Phase&#160;3
data to Humira, but with a significantly improved dosing schedule of every twelve&#160;weeks (Q12W). Several drugs for PsO have been
approved since 2009 that demonstrated higher efficacy in their pivotal studies compared to Stelara, but with more burdensome dosing schedules,
including Tremfya (guselkumab), which has a dosing schedule of every eight&#160;weeks (Q8W), and Cosentyx (secukinumab) and Taltz (ixekizumab),
which have dosing schedules of every four&#160;weeks (Q4W). While these therapies have all become generally successful products, the
most commercially successful drug in the PsO market today is Skyrizi (risankizumab), which combines Stelara&#8217;s Q12W dosing schedule
with improvements in efficacy, as evidenced by a higher psoriasis area severity index (PASI) score of PASI 90 and PASI 100 rates (i.e.,
a 90% improvement in PASI score and a 100% improvement in PASI score (complete clearance), respectively) in clinical trials. In addition,
Bimzelx (bimekizumab), approved by the FDA in 2023, has shown evidence of efficacy that exceeds even Skyrizi, though with a less convenient
Q8W dosing schedule. Although many biologics have entered the PsO market over the past two decades, new entrants have had significant
commercial success when they have improved upon efficacy and/or dosing frequency, and room remains to improve in both areas to set a
new standard for the treatment of PsO.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Biologics
have raised the bar on the standard of care in PsO, but leave room for improvement</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_003.jpg" style="width: 690px; height: 233px"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_003a.jpg" style="width: 690px; height: 61px"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
biology driving PsO and PsA is well understood today, and the standard of care has progressed dramatically. We believe that it is unlikely
that a novel mechanism will emerge that is as safe and efficacious as targeting the IL-23/IL-17 axis. Therefore, we believe that innovation
now should be focused on optimizing the product profile that can be offered to patients. While much effort is being directed toward daily
oral formats to inhibit this axis, oral medicines have yet to match the efficacy of biologics. We believe that a better biologic with
a longer dosing interval and the potential for improved efficacy will present a more attractive product profile for most patients.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Overview
of Psoriasis (PsO)</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">PsO
is a chronic autoimmune skin disorder that affects an estimated 125&#160;million people worldwide with steadily increasing prevalence,
estimated to be around&#160;2&#160;&#8211;&#160;3% of the population currently, according to the World Psoriasis Day consortium. It is
the largest pharmaceutical market within dermatology, with annual sales of approximately $25.0&#160;billion in 2022, which is estimated
to grow to $32&#160;billion by 2028. The most common form of PsO is plaque psoriasis. Patients with chronic plaque psoriasis have well-demarcated,
erythematous plaques with overlying, coarse, silvery-scaled patches. These plaques can occur anywhere on the body, though are typically
found on the scalp, extensor areas of the knees and elbows, and gluteal cleft. Involvement of the palms, soles, or nails, and intertriginous
areas, including the genitals, can also occur and can be particularly difficult to treat. Between one-quarter and one-half of PsO patients
have moderate disease, defined as having 3% to 10% of the body surface area (&#8220;BSA&#8221;) involved, or severe disease, defined
as having more than 10% BSA involvement. The chronic inflammation in PsO is associated with multiple comorbidities, including PsA, obesity,
metabolic syndrome, hypertension, diabetes, and atherosclerotic cardiovascular disease.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
discussed earlier, PsO is a complex immune-mediated disease driven primarily by Th17 cells and the cytokines IL-23 and IL-17. The interplay
of environmental and behavioral risk factors and genetics is believed to trigger PsO.&#160;Multiple lines of evidence support a genetic
component to the disease, including the observation that approximately 40% of patients with PsO and PsA have a family history of the
disease and the identification of multiple susceptibility loci, many containing genes related to the regulation of the immune system,
in genome-wide association studies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Current
PsO Treatments and Limitations</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">While
patients with mild PsO typically rely on topical corticosteroids or oral therapies like Otezla (apremilast), these agents often do not
provide an adequate response for patients with moderate-to-severe PsO.&#160;As a result, the American Academy of Dermatology-National
Psoriasis Foundation recommends biologics as first-line therapy for moderate-to-severe PsO.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Several
classes of biologic therapies have been approved for PsO over the past 20&#160;years, resulting in progressively more complete symptom
relief. Efficacy in PsO is typically measured via the PASI scoring system. The first biologics approved for PsO were tumor necrosis alpha
(&#8220;TNF-&#945;&#8221;) inhibitors such as Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab), which achieved a
PASI score of PASI 90 at 16&#160;weeks in around&#160;25&#160;&#8211;&#160;50% of patients and a PASI score of PASI 100 in&#160;around
5&#160;&#8211;&#160;20% of patients. Stelara (ustekinumab), which targets the p40 subunit of IL-23 that is shared with IL-12, was approved
next and achieved efficacy on par with Humira. IL-17 inhibitors Cosentyx (secukinumab), Taltz (ixekizumab), and Siliq (brodalumab) followed
and achieved responses of PASI 90 in around&#160;70% of patients and PASI 100 in&#160;around 40% of patients with some risk of certain
side effects such as oral candidiasis. Most recently, IL-23p19 inhibitors such as Ilumya (tildrakizumab), Tremfya (guselkumab), and Skyrizi
(risankizumab) have achieved responses of PASI 90 in&#160;around 70&#160;&#8211;&#160;80% of patients and PASI 100 in around 30&#160;&#8211;&#160;50%
of patients with highly tolerable profiles. Finally, IL-17A/F inhibitors such as Bimzelx (bimekizumab) have recently shown even higher
response rates than IL-23 inhibitors, but with slightly less tolerable profiles.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Treatment
expectations in PsO have evolved progressively with this continued innovation. A 75% improvement in PASI score was previously thought
to be an adequate depth of response, and weekly SQ dosing was viewed as acceptable. With each subsequent generation of innovation, patient
and caregiver expectations have advanced. Today, Skyrizi (risankizumab) is widely viewed as the leader in PsO biologic therapy. In Phase&#160;3
clinical trials, 43% and 58% of patients achieved PASI 100 at 16 and 52&#160;weeks, respectively, with SQ maintenance dosing every three&#160;months.
Most recently, Bimzelx (bimekizumab) has shown evidence of efficacy that exceeds even Skyrizi, achieving a 64% PASI 100 rate at 16&#160;weeks
in Phase&#160;3 trials. However, the increased efficacy comes with a less convenient Q8W dosing schedule and an increased risk of certain
side effects, most notably oral candidiasis. While agents like Skyrizi and Bimzelx reflect the remarkable advancement in PsO treatment,
there remains significant unmet need. Approximately half of moderate-to-severe PsO patients do not achieve full skin clarity, and while
early signs are present, the promise of disease modifying therapy remains unrealized. In addition, a continued desire for more convenient
dosing options has driven significant interest in orally delivered medicines targeting these same pathways. However, oral therapies have
yet to match the efficacy and safety profile of biologics. We believe that ORKA-001 and ORKA-002 could represent the next step in biologic
innovation in PsO, with the potential for higher rates of complete skin clearance, more durable remissions, and markedly more convenient
dosing regimens.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Overview
of Psoriatic Arthritis (PsA)</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">PsA
is a chronic inflammatory condition that affects both the skin and joints, and often coexists with PsO.&#160;Around a quarter to a third
of patients with moderate-to-severe PsO also have PsA.&#160;Most individuals develop PsO before being diagnosed with PsA, with a median
gap of seven to eight&#160;years between the diagnosis of skin and joint disease, though in up to 30% of patients with PsA, joint symptoms
appear before or simultaneously with skin manifestations. Patients with PsA present with joint pain, stiffness, and swelling affecting
the peripheral joints, axial skeleton, or both. Enthesitis, dactylitis, nail lesions, fatigue, and ocular inflammation all occur commonly.
PsA can lead to irreversible joint damage, including bony fusion across a joint (ankylosis). The pathogenesis of PsA is likely to be
closely related to the mechanisms that underlie PsO.&#160;Like PsO, the exact cause of PsA remains unknown, but environmental triggers,
including infection and trauma, and genetic factors play a role.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Current
PsA Treatments and Limitations</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Effective
treatment of PsA requires a coordinated approach to address the unique combination of disease manifestations each patient has, which
can include peripheral and axial arthritis, enthesitis, dactylitis, and skin and nail involvement. Many patients with milder disease
symptoms will start with nonsteroidal anti-inflammatory drugs (&#8220;NSAIDs&#8221;) and/or local treatments to address specific disease
manifestations. However, those with more moderate or severe disease and/or multidomain involvement will typically receive a biologic
therapy targeting TNF-&#945; or IL-17, or less commonly an oral Janus kinase (&#8220;JAK&#8221;) inhibitor. Comorbid conditions can
also influence treatment selection. For example, an IL-17 inhibitor would be preferred for a patient with significant skin involvement,
but not for patients with IBD or ocular symptoms, where a TNF-&#945; inhibitor would be preferred. The most common endpoint used to
measure the efficacy of TNF-&#945; or IL-17 inhibitors in PsA is ACR response, or the proportion of patients achieving a specified percent
improvement in American College of Rheumatology (&#8220;ACR&#8221;) score, which measures peripheral joint disease. Approved TNF-&#945;
inhibitors, including Humira (adalimumab) and Cimzia (certolizumab), achieved a placebo-adjusted ACR50 response of around&#160;30&#160;&#8211;&#160;35%
at 24&#160;weeks with Q2W dosing. Approved IL-17 inhibitors, including Cosentyx (secukinumab) and Taltz (ixekizumab), achieved a slightly
lower placebo-adjusted ACR50 response of around&#160;25&#160;&#8211;&#160;30% at 24&#160;weeks, but with more convenient Q4W dosing.
Bimzelx (bimekizumab), which was recently approved in the United&#160;States for PsA, achieved a placebo-adjusted ACR50 response of approximately
35% at 16&#160;weeks with Q4W dosing. A significant fraction of patients with PsA still do not achieve a satisfactory response with available
therapies, and even the most convenient regimens require monthly SQ dosing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Overview
of additional opportunities</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition to PsO and PsA, inhibition of IL-23 or IL-17 has demonstrated efficacy in a number of additional&#160;I&amp;I indications, including
HS and axSpA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">HS
is a chronic inflammatory skin disease characterized by lesions that include deep-seated nodules and abscesses, draining tracts, and
fibrotic scars that occur most commonly in intertriginous areas, such as the armpits and groin. Due to the associated pain, sensitive
locations, drainage, odor, and scarring, this condition can have a particularly negative psychosocial impact on affected individuals.
HS is believed to be underdiagnosed and could have a prevalence well above 1% worldwide. Treatment varies depending on severity and can
include topical and systemic antibiotics, hormone therapy, immune modulators, and surgery. Humira (adalimumab) was the only FDA-approved
medication for the treatment of moderate-to-severe HS from its approval in 2015 until the approval of Cosentyx (secukinumab) in October&#160;2023
and Bimzelx (bimekizumab) in November 2024. Now multiple other biologics are advancing through development and have demonstrated encouraging
data in Phase 2 clinical trials, though a significant fraction of patients still do not achieve adequate responses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">axSpA
is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints that comprise the axial skeleton. The disease
causes severe pain, stiffness, and fatigue, and can have additional clinical manifestations like uveitis, enthesitis, peripheral arthritis,
and PsO.&#160;Patients with axSpA may develop further structural damage in their spine, which can lead to the fusion of vertebra (spinal
ankylosis), which has a massive negative impact on mobility, physical function, and quality of life. The overall prevalence of axSpA
is estimated to be around 1% in the United&#160;States. Treatment of axSpA starts with physical therapy and NSAIDs. If patients do not
have an adequate response to NSAIDs, a TNF-&#945; inhibitor is typically used, followed by an IL-17 inhibitor, such as Cosentyx (secukinumab),
Taltz (ixekizumab), or Bimzelx (bimekizumab), or less frequently a JAK inhibitor. Patients often need to cycle through therapies over
time due to inadequate responses or loss of response.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Our
Solution: Half-Life Extension and Antibody Engineering Technologies</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
antibody engineering campaigns are designed to optimize multiple attributes in parallel: binding affinity, potency in a variety of assays,
developability, and consistently extended serum half-life in non-human primates (&#8220;NHPs&#8221;). Half-life extension is possible
by modifying the pH-dependent binding affinity of the antibody Fc domain for FcRn. A primary mechanism of elimination of antibodies from
the serum is through pinocytosis and degradation in the lysosomes of cells. Throughout this process, antibodies can be recycled back
into the serum by binding to FcRn while they are in endosomes. The interior of the endosome is acidic, and therefore the efficiency of
this recycling process depends on the ability of the antibody Fc domain to bind to FcRn at low pH.&#160;If this low pH binding is efficient
enough, antibody recycling can be favored over degradation, potentially resulting in a much longer serum half-life.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Antibody
engineers have discovered methods of modifying the Fc domain to optimize the efficiency of recycling via FcRn binding. Several engineering
strategies have been identified over the past two decades, with the so-called &#8220;YTE&#8221; mutations (M252Y/S254T/T256E) and &#8220;LS&#8221;
mutations (M428L/N434S) being the most frequently used. Importantly, while these strategies have been known for some time, it was only
relatively recently that enough clinical precedent was established to provide confidence in how these mutations perform in humans. Two
products incorporating YTE modification were approved in 2023 by the FDA, Beyfortus (nirsevimab) and Evusheld (tixagevimab and cilgavimab),
and several more candidates are in clinical trials. Two products using LS mutations were approved in 2021 and 2022, Xevudy (sotrovima)
and Ultomiris (ravulizumab), respectively, and several more candidates are in clinical trials. Based on clinical data in humans, antibodies
with YTE mutations typically have a half-life that is two to four times longer than wildtype antibodies. In addition, preclinical data
in NHPs can be used to predict the approximate half-life in humans, with the human half-life equaling around two to four&#160;times the
NHP half-life.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Clinical
experience with YTE-modified mAbs predicts significant half-life extension over wildtype mAbs</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_004.jpg"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">While
this increasing body of clinical precedent serves to validate half-life extension, we do not yet have clinical data showing that the
introduction of these amino acid substitutions in our programs leads to a longer serum half-life. However, we aim to establish this favorable
pharmacokinetic profile early in the clinical development of our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>ORKA-001</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Summary</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">ORKA-001
is a high affinity, extended half-life mAb designed to target the p19 subunit of IL-23. Based on preclinical data generated to date,
we believe ORKA-001 has the potential to become the leading IL-23 inhibitor and achieve an optimal product profile in PsO consisting
of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>One
                                            to two maintenance doses per year.&#160;&#160;&#160;&#160;</i></b>Standard-of-care therapies
                                            targeting IL-23 require maintenance dosing every eight to twelve&#160;weeks. We engineered
                                            the Fc portion of ORKA-001 to include YTE mutations to increase the half-life of ORKA-001
                                            in circulation, which may enable dosing every six to twelve&#160;months&#160;&#8212;&#160;a
                                            dosing interval made feasible by half-life extension technology. In preclinical studies,
                                            serum levels from&#160;NHPs indicated an elimination half-life of over 30&#160;days following
                                            SQ administration of ORKA-001. Based on published scientific literature on other antibodies
                                            incorporating YTE mutations and pharmacokinetic modeling, we anticipate this half-life in
                                            NHPs to translate to a half-life in humans that could allow subcutaneous dosing every six
                                            to twelve&#160;months while maintaining high antibody exposures.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Higher
                                            PASI 100.&#160;&#160;&#160;&#160;</i></b>ORKA-001 benefits from the robust validation of
                                            IL-23 inhibition in PsO by multiple approved therapies, such as Skyrizi (risankizumab) and
                                            Tremfya (guselkumab), while leveraging insights from these therapies to improve upon their
                                            clinical profile. ORKA-001 is designed to bind a similar epitope to the market-leading anti-IL-23
                                            antibody, Skyrizi, with similar or greater affinity and could achieve much higher exposures
                                            in patients due to half-life extension and higher dosing. Skyrizi and Tremfya both have a
                                            robust exposure-response relationship, with higher drug exposures leading to higher response
                                            rates. Published data indicates that these therapies have not saturated this exposure-response
                                            relationship, and ORKA-001 could lead to higher response rates, including higher rates of
                                            complete skin clearance, or PASI 100, through increased exposure, even while having more
                                            convenient dosing with as few as one or two maintenance doses per year.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Validated
                                            IL-23p19 safety profile.&#160;&#160;&#160;&#160;</i></b>Existing commercially approved antibodies
                                            targeting IL-23 provide a robust precedent for the safety of IL-23 inhibition. Across thousands
                                            of patients dosed in dermatology and IBD indications, no correlations have been observed
                                            at the patient level between exposure and safety. While we are not pursuing IBD, the approved
                                            Skyrizi regimens for Crohn&#8217;s disease and ulcerative colitis supports the safety of
                                            high peak exposures. Peak Skyrizi exposures during the&#160;IV induction phase in Crohn&#8217;s
                                            disease and ulcerative colitis are multiple times higher than the anticipated peak ORKA-001
                                            exposures at dose levels we currently plan to evaluate in PsO.&#160;In addition, an exposure-response
                                            analysis for Skyrizi in ulcerative colitis showed no relationship between exposures and evaluated
                                            safety endpoints in the 12-week induction or 52-week maintenance periods. In this assessment,
                                            the top quartile of average exposures were significantly higher than the highest anticipated
                                            exposures with ORKA-001 in the same periods.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Potential
                                            to offer longer term remission to some patients.&#160;&#160;&#160;&#160;</i></b>Emerging
                                            evidence suggests that IL-23 blockade can modify the disease biology of PsO, possibly leading
                                            to durable remissions and preventing the development of PsA.&#160;Dr.&#160;Andrew Blauvelt,
                                            chair of our Scientific Advisory Board, pioneered some of this work by using two- and four-times
                                            the approved dose levels of risankizumab to achieve best-in-indication response rates. This
                                            study, called KNOCKOUT, showed a robust depletion of TRMs following high dose IL-23 inhibition,
                                            which could lead to longer-lasting remissions in some patients. Additional evidence from
                                            a study of guselkumab, called GUIDE, showed that intervention early in the disease course
                                            can lead to longer treatment-free remissions. In addition, retrospective claims data suggests
                                            that treatment with an IL-23 inhibitor could help prevent progression to PsA, though this
                                            finding has yet to be confirmed by a prospective clinical trial. Given the high antibody
                                            exposures expected with ORKA-001, we believe that ORKA-001 could lead to durable remissions
                                            for some patients, especially those with short disease duration. We plan to pursue patient-specific
                                            dosing intervals to provide each patient the greatest possible freedom from their disease.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
believe that this target profile for ORKA-001 could offer improved freedom from disease to many patients affected by PsO and represent
a step forward in the standard of care.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Preclinical
Data</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
evaluated ORKA-001 in numerous preclinical studies for several key features:&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Potency
that matches or exceeds Skyrizi (risankizumab) in vitro</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
have tested the potency of ORKA-001 in vitro&#160;in multiple assays, including assays evaluating the inhibition of IL-17 release from
human peripheral mononuclear blood cells, in comparison to risankizumab generated recombinantly based on amino acid sequences from patent
filings. Based on the results of these experiments, we believe ORKA-001 binds a similar epitope as risankizumab with similar potency.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>ORKA-001
binds to a similar epitope as risankizumab with similar potency</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_005.jpg" style="height: 295px; width: 650px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Significant
half-life extension in NHPs that could enable a maintenance dosing interval of once or twice a year in humans</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
assessed ORKA-001 in NHPs in comparison to risankizumab generated recombinantly based on amino acid sequences from patent filings. ORKA-001
had a significantly longer half-life, reaching over 30&#160;days with SQ administration. Based on clinical experience with YTE-modified
mAbs and pharmacokinetic modeling, we believe that this half-life extension could enable dosing once or twice per year, as shown in the
figure below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>The
incorporation of YTE mutations significantly extends half-life in NHPs, which could enable once or twice yearly dosing</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_006.jpg" style="height: 287px; width: 650px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition to enabling less frequent dosing, an extended half-life would increase the exposure of ORKA-001, which has the potential to
increase efficacy. Based on published literature, Skyrizi (risankizumab) demonstrates a clear relationship between antibody exposure
and efficacy, with higher average serum antibody concentration correlating with higher PASI 90 and PASI 100 rates short-term (at 16&#160;weeks)
and long-term (at 52&#160;weeks), as shown for PASI 100 in the figure below. In addition, the KNOCKOUT study, which evaluated two- and
four-times higher doses of Skyrizi than the approved regimen, yielded some of the highest PASI 100 rates observed to date, reaching 67%
at 16&#160;weeks. Based on our pharmacokinetic modeling, ORKA-001 could achieve four-fold higher average exposures than the approved
Skyrizi regimen over the first 16&#160;weeks and over two-fold higher average exposures at steady-state, exceeding even the exposures
in KNOCKOUT.&#160;Based on the exposure-response relationship observed with other IL-23 inhibiting antibodies, we believe that these
increased exposures could result in higher efficacy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>ORKA-001
is projected to extend the exposure-response relationship established by studies of Skyrizi</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_007.jpg" style="width: 620px"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Safety
in vitro and in vivo</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
have evaluated ORKA-001 in several&#160;in vitro&#160;and&#160;in vivo&#160;preclinical studies to assess safety. In addition, we have
a nonclinical program to characterize the toxicology, toxicokinetics, and anti-drug antibody profile of ORKA-001 in NHPs. Our nonclinical
program supported the initiation of our Phase 1 clinical trial for ORKA-001 and our continuing clinical development.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Characteristics
that support ease of manufacturing and potentially enable high-concentration formulations</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Finally,
we have assessed a variety of attributes essential for manufacturability and high-concentration formulation, including viscosity, solubility,
and stability, among others. ORKA-001 shows evidence of desirable properties across these characteristics, which we believe will enhance
our ability to manufacture ORKA-001 successfully and consistently and to deliver high doses of ORKA-001 subcutaneously using convenient,
low-volume presentations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Clinical
Development</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;ORKA-001</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
dosed the first participants in a Phase 1 clinical trial of ORKA-001 in healthy volunteers in the fourth quarter of 2024. This trial
is a double-blind, placebo-controlled, single ascending dose study evaluating the safety, tolerability, and pharmacokinetics of ORKA-001
in healthy volunteers. The trial is expected to enroll approximately 24 healthy volunteers across three subcutaneous dose cohorts. We
expect to share interim data from this trial in the second half of 2025. We believe this data has the potential to provide key validation
of initial safety and pharmacokinetics data, including half-life, to support extended dosing intervals.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
plan to initiate a Phase 2a proof-of-concept study of ORKA-001 in moderate-to-severe PsO in the second half of 2025. We believe that
several aspects of PsO facilitate clinical development, including well-established, reproducible endpoints based on PASI scores, low
placebo rates, particularly with PASI 90 and PASI 100, a rapid efficacy readout at 16 weeks, and potentially rapid enrollment due to
the large patient population. Our Phase 2a clinical trial is anticipated to evaluate the safety and efficacy of a single dose level of
ORKA-001 versus placebo in approximately 80 subjects, followed by randomization to one of two maintenance dosing arms. In one maintenance
arm, subjects will receive ORKA-001 every six months. In the other, subjects will receive only induction dosing to assess the length
of time patients maintain clear skin, which could support once-yearly dosing or even longer-term durability in some patients. The anticipated
primary endpoint is PASI 100 at Week 16. After completing the trial, subjects may have the option to roll over to an open-label extension
study. We expect to share initial data from the Phase 2a trial in the second half of 2026. We believe this data has the potential to
inform efficacy at Week 16, as well as later timepoints, and provide us information on preliminary durability, including the potential
for extended dosing intervals and longer-term remissions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>ORKA-002</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;Summary</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">ORKA-002
is a high affinity, extended half-life mAb designed to target IL-17A/F.&#160;Dual inhibition of both IL-17A and IL-17F has shown superior
efficacy compared to IL-17A inhibition alone in PsO and other indications, as shown by the performance of Bimzelx (bimekizumab) compared
to Cosentyx (secukinumab) and Taltz (ixekizumab) in Phase&#160;3 trials. These therapies all utilize Q4W maintenance dosing in PsO and
PsA, except Bimzelx, where Q8W maintenance dosing in PsO patients &lt;120 kg is recommended.&#160;By binding IL-17A/F at similar epitopes
and affinity ranges as Bimzelx while incorporating half-life extension technology to potentially enable dosing two to three times a year
in PsO and PsA, we believe that ORKA-002 could become the leading therapy in the IL-17 class.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Preclinical
Data</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
preclinical program we are conducting for ORKA-002 mirrors that for ORKA-001 and spans potency, pharmacokinetics, safety, and manufacturing
characteristics. Based on the results of these experiments, we believe ORKA-002 has the potential for comparable potency to bimekizumab,
but with a significantly longer half-life, which we believe could support dosing two or three times per year based on extrapolation from
clinical precedent and pharmacokinetic modeling.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Clinical
Development Plans</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
plan to initiate dosing of healthy volunteers in a Phase&#160;1 trial of ORKA-002 in the third quarter of 2025. As with ORKA-001, initial
data on ORKA-002 in healthy volunteers has the potential to provide key validation of both early safety and pharmacokinetics to support
extended dosing intervals. Though clinical development of ORKA-002 will initially focus on one lead indication, we plan to evaluate ORKA-002
in a range of indications over time. We see ORKA-002 as highly complementary to ORKA-001, with the potential to provide an optimal therapy
for the approximately one-quarter to one-third of moderate-to-severe PsO patients who have PsA, as well as for PsO patients with highly
resistant skin symptoms that do not respond adequately to an IL-23 inhibitor. Furthermore, ORKA-002 could address indications beyond
PsO, including PsA with limited skin involvement, HS, axSpA, and additional&#160;I&amp;I diseases.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>ORKA-021</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
IL-17 and IL-23 classes each have distinct advantages. IL-17 inhibitors tend to have the fastest onset and highest peak response, while
IL-23 inhibitors have less frequent dosing and better durability and safety. Combining the two mechanisms sequentially has the potential
to provide two attractive features of each program: the rapid response of an IL-17 inhibitor with the ideal maintenance profile of an
IL-23 inhibitor. As a result, following ORKA-002 and ORKA-001, we plan to explore a sequential combination regimen of ORKA-002 and ORKA-001,
called &#8220;ORKA-021.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Additional
Pipeline Program</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
have a third mAb program, ORKA-003, that targets an undisclosed pathway. A core tenet of our strategy is to remain highly focused on&#160;I&amp;I
diseases, and specifically on inflammatory dermatology conditions. ORKA-003 provides the potential for indication expansion beyond PsO
as well as combination opportunities with our more advanced programs. In the future, we may add additional programs to our portfolio
beyond ORKA-001, ORKA-002, ORKA-021 and ORKA-003 that fit our strategic focus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Intellectual
Property</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
strive to protect the proprietary programs and technologies that we believe are important to our business, including seeking and maintaining
patent protection intended to cover the composition of matter of our programs, their methods of use and manufacture, related technologies,
diagnostics, and other inventions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Paragon
has filed, on our behalf, provisional patent applications, and we have filed non-provisional patent applications, and may file additional
patent applications directed to antibodies that target IL-23, including applications covering composition of matter, pharmaceutical formulations,
and methods of using such antibodies, including ORKA-001. In addition, Paragon has filed, on our behalf, provisional patent applications,
and we may file additional patent applications directed to antibodies that target IL-17, including applications covering composition
of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA-002. We have exclusive rights to ORKA-001
and ORKA-002 and the corresponding IL-23 and IL-17 patent applications pursuant to license agreements with Paragon. If the patent applications
mature into one or more issued patents covering ORKA-001 or ORKA-002, we would expect those patents to expire in 2045, absent any applicable
patent term adjustments or extensions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Commercial</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Should
any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United&#160;States
and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable us to realize the full
commercial value of our programs. Given our stage of development, we have not yet established a commercial organization or distribution
capabilities. We have exclusive worldwide rights to develop and commercialize ORKA-001 and ORKA-002 pursuant to license agreements with
Paragon.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Manufacturing</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
do not currently own or operate facilities for product manufacturing, testing, storage, and distribution. We have contracted and expect
to continue to contract with third parties for the manufacture and distribution of our product candidates. Because we rely on contract
manufacturers, we employ personnel with extensive technical, manufacturing, analytical, and quality experience. Our team has deep knowledge
and understanding of the regulations that govern manufacturing, documentation, quality assurance, and quality control of drug supply
that are required to support our regulatory filings.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Competition</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
biotechnology and biopharmaceutical industries are characterized by continuing technological advancement and significant competition.
While we believe that our programs, technology, development experience and scientific knowledge provide us with competitive advantages,
we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and
private research institutions, among others. Any product candidates that we successfully develop and commercialize will compete with
existing therapies and therapies that may become available in the future. Many of the companies with which we are currently competing
or will compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing,
preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers
and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller
number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific
and management personnel, establishing clinical trial sites, patient enrollment for clinical trials as well as in acquiring technologies
complementary to, or necessary for, our programs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Key
competitive factors affecting the success of all our product candidates that we develop, if approved, are likely to be efficacy, safety,
convenience, presentation, price, the level of generic competition, and the availability of reimbursement from government and other third-party
payors. Our competitors may also obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval
for our products, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Specifically,
there are several companies developing or marketing treatments that may be approved for the same indications and/or diseases as our two
most advanced programs, ORKA-001 and ORKA-002, including major pharmaceutical companies. We do not yet have clinical data for any of
our programs and there can be no assurance that our programs will have similar or comparable results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">There
are several approved biologic therapies for the treatment of moderate-to-severe PsO.&#160;These include mAbs targeting IL-23, such as
Skyrizi (risankizumab) from AbbVie, Tremfya (guselkumab) from Janssen, and Ilumya (tildrakizumab) from Sun Pharma, also marketed as Ilumetri
by Almirall in Europe, which all target the p19 subunit, and Stelara (ustekinumab) from Janssen, which targets the p40 subunit; mAbs
targeting IL-17, such as Bimzelx (bimekizumab) from UCB, which targets IL-17A/F, Cosentyx (secukinumab) from Novartis and Taltz (ixekizumab)
from Eli Lilly, which both target IL-17A, and Siliq (brodalumab) from Ortho Dermatologics, also marketed as Kyntheum by LEO Pharma in
Europe, which targets IL-17 receptor/A; and biologics targeting TNF-&#945;, such as Humira (adalimumab) from AbbVie, Enbrel (etanercept)
from Amgen, and Remicade (infliximab) from Janssen, and various biosimilar versions of each. In addition, there are several approved
oral medicines in these indications, including the phosphodiesterase-4 (PDE4) inhibitor Otezla (apremilast) from Amgen and the tyrosine
kinase 2 (TYK2) inhibitor Sotyktu (deucravacitinib) from Bristol-Myers Squibb. Many of these therapies also are approved or in development
for PsA, HS, axSpA, and other&#160;I&amp;I indications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition, we are aware of several product candidates in clinical development for moderate-to-severe PsO, along with PsA, HS, axSpA, and
other indications. These include the biologics picankibart from Innovent Biologics targeting IL-23p19 and sonelokimab from MoonLake Immunotherapeutics
targeting IL-17A/F.&#160;Also, there are several oral agents in development, including JNJ-2113 from Janssen targeting the IL-23 receptor,
DC-853 from Eli Lilly targeting IL-17A, and TAK-279 from Takeda and ESK-001 from Alumis, both targeting TYK2.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Significant
Agreements&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Paragon
Therapeutics &#8211; Option Agreements</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">In March&#160;2024, we entered
into two antibody discovery and option agreements (&#8220;Option Agreements&#8221;) with Paragon and Paruka Holding, LLC (&#8220;Paruka&#8221;).
Paruka is an entity formed by Paragon as a vehicle to hold equity in our Company in order to share profits with certain employees of Paragon.
Under the terms of each agreement, Paragon identifies, evaluates, and develops antibodies directed against certain mutually agreed therapeutic
targets of interest to us. From time to time, we can choose to add additional targets to the collaboration upon agreement with Paragon
and Paruka. Under the Option Agreements, we have the exclusive option to, on a research program-by-research program basis, be granted
an exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from
the applicable research program to develop, manufacture, and commercialize the antibodies and products directed to the selected target(s)&#160;(each,
an &#8220;Option&#8221;). We have initiated certain research programs with Paragon that generally focus on discovering, generating, identifying
and/or characterizing antibodies directed to a particular target (each, a &#8220;Research Program&#8221;), including for IL-23 and IL-17A/F
for ORKA-001 and ORKA-002, respectively. Our exclusive option with respect to each Research Program is exercisable at our sole discretion
at such time as specified in the Option Agreements (the &#8220;Option Period&#8221;). There is no payment due upon exercise of an Option
pursuant to the Option Agreements. For each of these agreements, once we enter into the corresponding license agreements, we will be required
to make non-refundable milestone payments to Paragon of up to $12.0 million under each respective agreement upon the achievement of certain
clinical development milestones, up to $10.0 million under each respective agreement upon the achievement of certain regulatory milestones,
as well as a low single-digit percentage royalty for antibody products beginning on the first commercial sale in each program.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
                                            may terminate any Option Agreement or any Research Program at any time for any or no reason
                                            upon 30&#160;days&#8217; prior written notice to Paragon, provided that we must pay certain
                                            unpaid fees due to Paragon upon such termination, as well as any non-cancellable obligations
                                            reasonably incurred by Paragon in connection with its activities under any terminated Research
                                            Program. Paragon may terminate any Option Agreement or a Research Program immediately upon
                                            written notice to us if, as a result of any action or failure to act by us or our affiliates,
                                            such Research Program or all material activities under the applicable Research Plan are suspended,
                                            discontinued or otherwise delayed for a certain consecutive number of&#160;months. Each party
                                            has the right to terminate the Option Agreements or any Research Program upon material breach
                                            that remains uncured or the other party&#8217;s bankruptcy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Additionally, as part of the
Option Agreements, on December&#160;31, 2024 and December 31, 2025, we granted and will grant, respectively, Paruka a warrant to purchase
a number of shares equal to 1.00% of outstanding shares as of the date of the grant on a fully-diluted basis, with an exercise price equal
to the fair market value of the underlying shares on the grant date.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Paragon
Therapeutics &#8211; License Agreements</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
September 2024, we exercised the Option to acquire certain rights to ORKA-001, and in December 2024, we entered into the corresponding
license agreement with Paragon (the &#8220;ORKA-001 License Agreement&#8221;), pursuant to which Paragon granted us a royalty-bearing,
world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting IL-23
in all fields other than the field of inflammatory bowel disease (&#8220;ORKA-001 Field&#8221;). In December 2024, we exercised the Option
with respect to ORKA-002 for the IL-17A/F program, and in February 2025, we entered into the corresponding license agreement with Paragon
(the &#8220;ORKA-002 License Agreement&#8221; and together with the ORKA-001 License Agreement, the &#8220;License Agreements&#8221;),
pursuant to which Paragon granted us a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize or otherwise
exploit certain antibodies and products targeting IL-17A/F in all fields (&#8220;ORKA-002 Field&#8221; and together with the ORKA-001
Field, the &#8220;Fields&#8221;).</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
License Agreements provide us with exclusive licenses in the Fields to Paragon&#8217;s patent applications covering the related antibodies,
their method of use and their method of manufacture and Paragon has agreed not to conduct any new campaigns that generate anti-IL-23
monospecific antibodies or anti-IL-17A/F monospecific antibodies for the ORKA-001 Field or the ORKA-002 Field, respectively, for at least
five years. Each of the ORKA-001 and ORKA-002 License Agreements may be terminated on 60 days&#8217; notice to Paragon, on material breach
without cure, and on a party&#8217;s insolvency or bankruptcy to the extent permitted by law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the terms of each of the ORKA-001 and ORKA-002 License Agreements, we are obligated to pay Paragon non-refundable milestone payments
of up to $12.0 million under each respective agreement upon the achievement of certain clinical development milestones and up to $10.0
million under each respective agreement upon the achievement of certain regulatory milestones, including a $1.5 million fee for nomination
of a development candidate (or initiation of an investigational new drug (&#8220;IND&#8221;) enabling toxicology study) and a further
milestone payment of $2.5 million upon the first dosing of a human patient in a Phase 1 trial for each of ORKA-001 and ORKA-002. In addition,
we are obligated to pay Paragon a low single-digit percentage royalty for antibody products for each of ORKA-001 and ORKA-002. For each
of the License Agreements, the royalty term ends on the later of (i) the last-to-expire licensed patent or our patent directed to the
manufacture, use or sale of a licensed antibody in the country at issue or (ii) 12 years from the date of first sale of a Company product.
There is also a royalty step-down if there is no Paragon patent in effect during the royalty term for each program.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Cell
Line License Agreement</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
March 2024, we entered into the Cell Line License Agreement (the &#8220;Cell Line License Agreement&#8221;) with WuXi Biologics Ireland
Limited (&#8220;WuXi Biologics&#8221;). Under the Cell Line License Agreement, we received a non-exclusive, worldwide, sublicensable
license to certain of WuXi Biologics&#8217; know-how, cell line, biological materials (the &#8220;WuXi Biologics Licensed Technology&#8221;)
and media and feeds to make, have made, use, sell and import certain therapeutic products produced through the use of the cell line licensed
by WuXi Biologics under the Cell Line License Agreement (the &#8220;WuXi Biologics Licensed Products&#8221;). Specifically, the WuXi
Biologics Licensed Technology is used in certain manufacturing activities in support of the ORKA-001 and ORKA-002 programs.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
consideration for the license, we agreed to pay WuXi Biologics a non-refundable license fee of $150,000. Additionally, to the extent
that we manufacture our commercial supplies of bulk drug product with a manufacturer other than WuXi Biologics or its affiliates, we
are required to make royalty payments to WuXi Biologics at a rate of less than one percent of net sales of WuXi Biologics Licensed Products
manufactured by the third-party manufacturer. Pursuant to an amendment to the Cell Line License Agreement effective in November 2024,
a provision was added that permits the royalties owed under the agreement to be bought out on a&#160;product-by-product&#160;basis for
a&#160;lump-sum&#160;payment.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Cell Line License Agreement will continue indefinitely unless terminated (i) by us upon six months&#8217; prior written notice and our
payment of all undisputed amounts due to WuXi Biologics through the effective date of termination, (ii) by WuXi Biologics for a material
breach by us that remains uncured for 60 days after written notice, (iii) by WuXi Biologics if we fail to make a payment and such failure
continues for 30 days after receiving notice of such failure, or (iv) by either party upon the other party&#8217;s bankruptcy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Government
Regulation </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among
other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging,
storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting
of biologics such as those we are developing. We, along with our third-party contractors, will be required to navigate the various preclinical,
clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies
or seek approval or licensure of our product candidates. Generally, before a new therapeutic product can be marketed, considerable data
demonstrating a biological product candidate&#8217;s quality, safety, purity and potency, or a small molecule drug candidate&#8217;s
quality, safety and efficacy, must be obtained, organized into a format specific for each regulatory authority, submitted for review
and approved by the regulatory authority. For biological product candidates, potency is similar to efficacy and is interpreted to mean
the specific ability or capacity of the product, as indicated by appropriate laboratory tests or by adequately controlled clinical data
obtained through the administration of the product in the manner intended, to effect a given result.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Failure
to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-marketing
may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s
refusal to approve pending applications from the sponsor, withdrawal of an approval, a clinical hold, untitled or warning letters, product
recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals
of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have
a material adverse effect on our company and our products or product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>United
States Biologics Regulation </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
the United States, biological products are subject to regulation under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;),
the Public Health Service Act (&#8220;PHSA&#8221;) and other federal, state, local, and foreign statutes and regulations. The process
of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, and local statutes and regulations requires
the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during
the product development process, approval process or following approval may subject an applicant to administrative action and judicial
sanctions. The process required by the FDA before biologic product candidates may be marketed in the United States generally involves
the following:</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">completion
                                            of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s
                                            current Good Laboratory Practices (&#8220;GLP&#8221;) regulation;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">submission
                                            to the FDA of an IND, which must become effective before clinical trials may begin and must
                                            be updated annually or when significant changes are made;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">approval
                                            by an independent institutional review board (&#8220;IRB&#8221;), or ethics committee at
                                            each clinical site before the trial is commenced;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">manufacture
                                            of the proposed biologic candidate in accordance with current Good Manufacturing Practices
                                            (&#8220;cGMPs&#8221;);</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">performance
                                            of adequate and well-controlled human clinical trials in accordance with current Good Clinical
                                            Practice (&#8220;GCP&#8221;) requirements to establish the safety, purity and potency of
                                            the proposed biologic product candidate for its intended purpose;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">preparation
                                            of and submission to the FDA of a BLA, after completion of all pivotal clinical trials;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">satisfactory
                                            completion of an FDA Advisory Committee review, if applicable;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">a
                                            determination by the FDA within 60 days of its receipt of a BLA to file the application for
                                            review;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">satisfactory
                                            completion of an FDA pre-approval inspection of the manufacturing facility or facilities
                                            at which the proposed product is produced to assess compliance with cGMPs, and to assure
                                            that the facilities, methods and controls are adequate to preserve the biological product&#8217;s
                                            continued safety, purity and potency, and of selected clinical investigation sites to assess
                                            compliance with GCPs; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">FDA
                                            review and approval of a BLA to permit commercial marketing of the product for particular
                                            indications for use in the United States.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Preclinical
and Clinical Development </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Prior
to beginning any clinical trial with a product candidate in the United States, we must submit an IND to the FDA. An IND is a request
for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is
on the general investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND also includes
results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of
the product, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the
investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective
30 days after receipt by the FDA, unless the FDA, within the 30-day period, raises safety concerns or questions about the proposed clinical
trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or
questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical
trial.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition to the IND submission process, supervision of human gene transfer trials includes evaluation and assessment by an institutional
biosafety committee (&#8220;IBC&#8221;), a local institutional committee that reviews and oversees research utilizing recombinant or
synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to
public health or the environment and such review may result in some delay before initiation of a clinical trial.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Clinical
trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in
accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation
in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the
parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND
must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore,
an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and
its informed consent form before the clinical trial begins at that site, and must monitor the study until completed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Regulatory
authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects
are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include
oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board,
which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from
the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such
as no demonstration of efficacy. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials
and clinical study results to public registries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">For
purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Phase
                                            1. The investigational product is initially introduced into healthy human subjects or patients
                                            with the target disease or condition. These studies are designed to test the safety, dosage
                                            tolerance, absorption, metabolism and distribution of the investigational product in humans,
                                            the side effects associated with increasing doses, and, if possible, to gain early evidence
                                            on effectiveness.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Phase
                                            2. The investigational product is administered to a limited patient population with a specified
                                            disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule
                                            and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical
                                            trials may be conducted to obtain information prior to beginning larger and more expensive
                                            Phase 3 clinical trials.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Phase
                                            3. The investigational product is administered to an expanded patient population to further
                                            evaluate dosage, to provide statistically significant evidence of clinical efficacy and to
                                            further test for safety, generally at multiple geographically dispersed clinical trial sites.
                                            These clinical trials are intended to establish the overall risk/benefit ratio of the investigational
                                            product and to provide an adequate basis for product approval.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain
more information about the product. These so-called Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical
trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the
product candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements.
The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things,
must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity
and potency. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate
that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">A
sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted
under an IND, all IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor
must ensure that the study complies with certain FDA regulatory requirements in order to use the study as support for an IND or application
for marketing approval or licensure, including that the study was conducted in accordance with GCP, including review and approval by
an independent ethics committee and use of proper procedures for obtaining informed consent from subjects, and the FDA is able to validate
the data from the study through an onsite inspection if the FDA deems such inspection necessary. The GCP requirements encompass both
ethical and data integrity standards for clinical studies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>BLA
Submission and Review </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Assuming
successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development,
nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or
more indications. The BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including
negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry,
manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to
test the safety and effectiveness of the product, or from a number of alternative sources, including studies initiated and sponsored
by investigators. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption
applies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition, under the Pediatric Research Equity Act (&#8220;PREA&#8221;), a BLA or supplement to a BLA must contain data to assess the
safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric subpopulations and
to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The Food and Drug
Administration Safety and Innovation Act requires that a sponsor who is planning to submit a marketing application for a biological product
that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial
pediatric study plan within sixty days after an end-of-Phase 2 meeting or as may be agreed between the sponsor and FDA. Unless otherwise
required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Within
60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before
the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time
of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. Once
a BLA has been accepted for filing, the FDA&#8217;s goal is to review standard applications within ten months after the filing date,
or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and
priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews
a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed,
packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory
committee to provide clinical insight on application review questions. The FDA is not bound by the recommendations of an advisory committee,
but it considers such recommendations carefully when making decisions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Before
approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve
an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate
to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically
inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process
or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional
testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the
application does not satisfy the regulatory criteria for approval.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">After
the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance
will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing
of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies
that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate
to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted
product lots and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant
might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay
or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require
post-marketing testing and surveillance to monitor safety or efficacy of a product.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">If
regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the
indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a risk evaluation and mitigation
strategy (&#8220;REMS&#8221;) to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known
or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their
safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution
methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to
proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval
if compliance with pre-&#8201;and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace.
The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety
and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing
studies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Combination
Therapy</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Combination
therapy is a treatment modality that involves the use of two or more drugs to be used in combination to treat a disease or condition.
If those drugs are combined in one dosage form, such as one pill, that is known as a fixed dose combination product and it is reviewed
pursuant to the FDA&#8217;s Combination Rule at 21 CFR 300.50. The rule provides that two or more drugs may be combined in a single dosage
form when each component contributes to the claimed effects and the dosage of each component (amount, frequency, duration) is such that
the combination is safe and effective for a significant patient population requiring such concurrent therapy as defined in the labeling
for the drug. But not all combination therapy falls under the category of a fixed dose combination. For example, the FDA recognizes that
two drugs in separate dosage forms and in separate packaging, that otherwise might be administered as monotherapy for an indication,
also may be used in combination for the same indication. In 2013, the FDA issued guidance to assist sponsors that were developing the
range of combination therapies that fall outside the category of fixed dose combinations. That guidance provides recommendations and
advice on such topics as: (1) assessment at the outset whether two or more therapies are appropriate for use in combination; (2) guiding
principles for nonclinical and clinical development of the combination; (3) options for regulatory pathways to seek marketing approval
of the combination; and (4) post-marketing safety monitoring and reporting obligations. Given the wide range of potential combination
therapy variations, the FDA indicated it intends to assess each potential combination on a case-by case basis and encouraged sponsors
to engage in early and regular consultation with the relevant review division at the agency throughout the development process for its
proposed combination.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Regulation
of Combination Products</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Certain
therapeutic products are comprised of multiple components, such as drug components, biologic components, and device components, that
would normally be subject to different regulatory frameworks by the FDA and frequently regulated by different centers at the FDA. These
products are known as combination products. Under the FDCA, the FDA is charged with assigning a center with primary jurisdiction, or
a lead center, for review of a combination product. The determination of which center will be the lead center is based on the &#8220;primary
mode of action&#8221; of the combination product. Thus, if the primary mode of action of drug/biologic-device combination product is
attributable to the drug or biological product, the FDA center responsible for premarket review of the drug or biological product would
have primary jurisdiction for the combination product. The FDA has also established the Office of Combination Products to address issues
surrounding combination products and provide more certainty to the regulatory review process. That office serves as a focal point for
combination product issues for agency reviewers and industry. It is also responsible for developing guidance and regulations to clarify
the regulation of combination products, and for assignment of the FDA center that has primary jurisdiction for review of combination
products where the jurisdiction is unclear or in dispute. A combination product with a primary mode of action attributable to the drug
or biologic component generally would be reviewed and approved pursuant to the drug or biologic approval processes set forth in the FDCA.
In reviewing the new drug application or BLA for such a product, however, FDA reviewers would consult with their counterparts in the
FDA&#8217;s Center for Devices and Radiological Health to ensure that the device component of the combination product met applicable
requirements regarding safety, effectiveness, durability and performance. In addition, under FDA regulations, combination products are
subject to cGMP requirements applicable to both drugs and devices, including the Quality System Regulation applicable to medical devices.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Post-Approval
Requirements </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Any
products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including,
among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and
distribution, and advertising and promotion of the product. As part of the manufacturing process, the manufacturer is required to perform
certain tests on each lot of the product before it is released for distribution. After a BLA is approved for a biological product, the
product also may be subject to official lot release. If the product is subject to official release by the FDA, the manufacturer submits
samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot
and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA also may perform certain confirmatory tests on
lots of some products before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research
related to the regulatory standards on the safety, purity, and potency or effectiveness of biologics. After approval, most changes to
the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also
are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved BLA.
Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies,
and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain
procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly
regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations
also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon us and any third-party
manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production
and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product
reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity
or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved
labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition
of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">restrictions
                                            on the marketing or manufacturing of a product, complete withdrawal of the product from the
                                            market or product recalls;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">fines,
                                            warning letters or holds on post-approval clinical studies;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">refusal
                                            of the FDA to approve pending applications or supplements to approved applications, or suspension
                                            or revocation of existing product approvals;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">product
                                            seizure or detention, or refusal of the FDA to permit the import or export of products;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">consent
                                            decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">mandated
                                            modification of promotional materials and labeling and the issuance of corrective information;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications
                                            containing warnings or other safety information about the product; or</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">injunctions
                                            or the imposition of civil or criminal penalties.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating
to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label.
The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with
these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil
and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling
and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians
may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the
behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject
of off-label use of their products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Biosimilars
and Reference Product Exclusivity </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Reconciliation Act (the &#8220;ACA&#8221;) includes
a subtitle called the Biologics Price Competition and Innovation Act&#160;of&#160;2009 (&#8220;BPCIA&#8221;), which created an abbreviated
approval pathway for biological products that are highly similar, or &#8220;biosimilar,&#8221; to or interchangeable with an FDA-approved
reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Biosimilarity,
which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of
safety, purity, and potency, is generally shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability
requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the
same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual,
the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety
risks or risks of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable
with an FDA-approved reference biological product may rely in part on the FDA&#8217;s previous determination of safety and effectiveness
for the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product.
Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which
such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked
out by the FDA. The FDA has issued guidance documents intended to inform prospective applicants and facilitate the development of proposed
biosimilars and interchangeable biosimilars, as well as to describe the FDA&#8217;s interpretation of certain statutory requirements
added by the BPCIA.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Under
the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference
product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12
years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may
still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s
own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its
product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it
is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which
are governed by state pharmacy law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">A
reference biologic is granted twelve years of exclusivity from the time of first licensure of the reference product. The first biologic
product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity
against other biologics submitted under the abbreviated approval pathway for the lesser of (i) one year after the first commercial marketing,
(ii) 18 months after approval if there is no legal challenge, (iii) 18 months after the resolution in the applicant&#8217;s favor of
a lawsuit challenging the biologics&#8217; patents if an application has been submitted, or (iv) 42 months after the application has
been approved if a lawsuit is ongoing within the 42-month period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">A
biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months
to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection
or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written
Request&#8221; for such a study. The BPCIA is complex and continues to be interpreted and implemented by the FDA. In July 2018, the FDA
announced an action plan to encourage the development and efficient review of biosimilars, including the establishment of a new office
within the agency that will focus on therapeutic biologics and biosimilars. On December 20, 2020, Congress amended the PHSA as part of
the COVID-19 relief bill to further simplify the biosimilar review process by making it optional to show that conditions of use proposed
in labeling have been previously approved for the reference product, which used to be a requirement of the application. In addition,
government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which
may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation,
and impact of the BPCIA is subject to significant uncertainty.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
discussed below, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) is a significant new law that intends to foster generic and
biosimilar competition and to lower drug and biologic costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Patent
Term Extension</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
the United States, after a BLA is approved, owners of relevant drug patents may apply for up to a five-year patent extension, which permits
patent term restoration as compensation for the patent term lost during the FDA regulatory process. The allowable patent term extension
is typically calculated as one-half the time between, the latter of the effective date of an IND and issue date of the patent for which
extension is sought, and the submission date of a BLA, plus the time between BLA submission date and the BLA approval date up to a maximum
of five years. The time can be shortened if the FDA determines that the applicant did not pursue licensure with due diligence. The total
patent term after the extension may not exceed 14 years from the date of product licensure. Only one patent applicable to a licensed
biological product is eligible for extension and only those claims covering the product, a method for using it, or a method for manufacturing
it may be extended and the application for the extension must be submitted prior to the expiration of the patent in question. However,
we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory
review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing
to satisfy applicable requirements. Some, but not all, foreign jurisdictions possess patent term extension or other additional patent
exclusivity mechanisms that may be more or less stringent and comprehensive than those of the United States.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Other
Healthcare Laws and Compliance Requirements </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Pharmaceutical
companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states
and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the federal Anti-Kickback Statute
(&#8220;AKS&#8221;); the federal False Claims Act (&#8220;FCA&#8221;); the Health Insurance Portability and Accountability Act of 1996
(&#8220;HIPAA&#8221;) and similar foreign, federal and state fraud, abuse and transparency laws.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
AKS prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration,
to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which
payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand, and prescribers and purchasers on
the other. The government often takes the position that to violate the AKS, only one purpose of the remuneration need be to induce referrals,
even if there are other legitimate purposes for the remuneration. There are a number of statutory exceptions and regulatory safe harbors
protecting some common activities from AKS prosecution, but they are drawn narrowly and practices that involve remuneration, such as
consulting agreements, that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny
if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for protection under
a statutory exception or regulatory safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception
or regulatory safe harbor does not make the conduct per se illegal under the AKS. Instead, the legality of the arrangement will be evaluated
on a case-by-case basis based on a cumulative review of all of its facts and circumstances. A person or entity does not need to have
actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Civil
and criminal false claims laws, including the FCA, and civil monetary penalty laws, which can be enforced through civil whistleblower
or qui tam actions, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims
for payment of federal government funds, including in federal healthcare programs, that are false or fraudulent. Pharmaceutical and other
healthcare companies have been prosecuted under these laws for engaging in a variety of different types of conduct that &#8220;caused&#8221;
the submission of false claims to federal healthcare programs. Under the AKS, for example, a claim resulting from a violation of the
AKS is deemed to be a false or fraudulent claim for purposes of the FCA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">HIPAA
created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit
program, including private third-party payors, and making false statements relating to healthcare matters. A person or entity does not
need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate the statute in order
to have committed a violation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
FDCA addresses, among other things, the design, production, labeling, promotion, manufacturing, and testing of drugs, biologics and medical
devices, and prohibits such acts as the introduction into interstate commerce of adulterated or misbranded drugs or devices. The PHSA
also prohibits the introduction into interstate commerce of unlicensed or mislabeled biological products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which
payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually
report to the Centers for Medicaid &amp; Medicare Services (&#8220;CMS&#8221;) information related to payments or other transfers of
value to various healthcare professionals including physicians, physician assistants, nurse practitioners, clinical nurse specialists,
certified nurse anesthetists, certified nurse-midwives, and teaching hospitals, as well as ownership and investment interests held by
physicians and their immediate family members. Beginning on January 1, 2023, California Assembly Bill 1278 requires California physicians
and surgeons to notify patients of the Open Payments database established under the federal Physician Payments Sunshine Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
are also subject to federal price reporting laws and federal consumer protection and unfair competition laws. Federal price reporting
laws require manufacturers to calculate and report complex pricing metrics to government programs, where such reported prices may be
used in the calculation of reimbursement and/ or discounts on approved products. Federal consumer protection and unfair competition laws
broadly regulate marketplace activities and activities that potentially harm consumers.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
are also subject to additional similar U.S. state and foreign law equivalents of each of the above federal laws, which, in some cases,
differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If our operations
are found to be in violation of any of such laws or any other governmental regulations that apply, we may be subject to penalties, including,
without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs,
such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations
to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits
and the curtailment or restructuring of our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Data
Privacy and Security </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Numerous
state, federal, and foreign laws govern the collection, dissemination, use, access to, confidentiality, and security of personal information,
including health-related information. In the United States, numerous federal and state laws and regulations, including state data breach
notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations, govern the
collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations
of our partners. For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health (&#8220;HITECH&#8221;),
and their respective implementing regulations imposes data privacy, security, and breach notification obligations on certain health care
providers, health plans, and health care clearinghouses, known as covered entities, as well as their business associates and their covered
subcontractors that perform certain services that involve using, disclosing, creating, receiving, maintaining, or transmitting individually
identifiable protected health information (&#8220;PHI&#8221;) for or on behalf of such covered entities. These requirements imposed by
HIPAA and the HITECH Act on covered entities and business associates include entering into agreements that require business associates
protect PHI provided by the covered entity against improper use or disclosure, among other things; following certain standards for the
privacy of PHI, which limit the disclosure of a patient&#8217;s past, present, or future physical or mental health or condition or information
about a patient&#8217;s receipt of health care if the information identifies, or could reasonably be used to identify, the individual;
ensuring the confidentiality, integrity, and availability of all PHI created, received, maintained, or transmitted in electronic form,
to identify and protect against reasonably anticipated threats or impermissible uses or disclosures to the security and integrity of
such PHI; and reporting of breaches of PHI to individuals and regulators. Entities that are found to be in violation of HIPAA may be
subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations
if required to enter into a resolution agreement and corrective action plan with the U.S. Department of Health and Human Services (&#8220;HHS&#8221;)
to settle allegations of HIPAA non-compliance. A covered entity or business associate is also liable for civil money penalties for a
violation that is based on an act or omission of any of its agents, which may include a downstream business associate, as determined
according to the federal common law of agency. HITECH also increased the civil and criminal penalties applicable to covered entities
and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts
to enforce HIPAA and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. To the extent that we submit
electronic healthcare claims and payment transactions that do not comply with the electronic data transmission standards established
under HIPAA and HITECH, payments to us may be delayed or denied.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition, state health information privacy laws, such as California&#8217;s Confidentiality of Medical Information Act and Washington&#8217;s
My Health My Data Act, govern the privacy and security of health-related information, specifically, may apply even when HIPAA does not
and impose additional requirements.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Even
when HIPAA and state health information privacy laws do not apply, according to the FTC and state Attorneys General, violating consumers&#8217;
privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or
practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act and state consumer protection laws.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition, certain state laws, such as the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of
2020 (&#8220;CCPA&#8221;), govern the privacy and security of personal information, including health-related information in certain circumstances,
some of which are more stringent than HIPAA in various ways. Numerous other states have passed similar laws, but many differ from each
other in significant ways and may not have the same effect, thus complicating compliance efforts. The CCPA applies to personal data of
consumers, business representatives, and employees, and imposes obligations on certain businesses that do business in California, including
to provide specific disclosures in privacy notices, and affords rights to California residents in relation to their personal information.
Health information falls under the CCPA&#8217;s definition of personal information where it identifies, relates to, describes, or is
reasonably capable of being associated with or could reasonably be linked, directly or indirectly, with a particular consumer or household
- unless it is subject to HIPAA - and is included under a new category of personal information, &#8220;sensitive personal information,&#8221;
which is offered greater protection. The numerous other comprehensive privacy laws that have passed or are being considered in other
states, as well as at the federal and local levels, also exempt some data processed in the context of clinical trials; but others exempt
covered entities and business associates subject to HIPAA altogether, further complicating compliance efforts, and increasing legal risk
and compliance costs for us and the third parties upon whom we rely. Additionally, our use of artificial intelligence and machine learning
may be subject to laws and evolving regulations regarding the use of artificial intelligence/machine learning, controlling for data bias,
and antidiscrimination.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Failure
to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private
litigation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate
compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties
and restrictions on data processing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Coverage
and Reimbursement </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
the United States and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs
associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid,
and commercial payors is critical to new product acceptance. Our ability to successfully commercialize our product candidates will depend
in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government
health administration authorities, private health insurers and other organizations. Even if coverage is provided, the approved reimbursement
amount may not be high enough to allow it to establish or maintain pricing sufficient to realize a sufficient return on its investment.
Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications
they will pay for and establish reimbursement levels.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Significant
uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory
approval. Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third-party payors,
such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the
level of reimbursement, if any, for such product by third-party payors. Decisions regarding whether to cover any of our product candidates,
if approved, the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Further, no uniform
policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor
to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates,
but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process
is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product
candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained
in the first instance. Factors payors consider in determining reimbursement are based on whether the product is:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">a
                                            covered benefit under its health plan;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;
&#160; &#160;</span></p><div>



</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">safe,
                                            effective and medically necessary;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;
&#160; &#160;</span></p><div>



</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">cost-effective;
                                            and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;
&#160; &#160;</span></p><div>



</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">neither
                                            experimental nor investigational.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Third-party
payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing
the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety
and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with
existing controls and measures, could further limit sales of any product that receives approval. Decreases in third-party reimbursement
for any product or a decision by a third-party not to cover a product could reduce physician usage and patient demand for the product.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">For
products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult
because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment
or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic
tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or
biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products,
will apply to companion diagnostics.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including
price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. The IRA provides CMS
with significant new authorities intended to curb drug costs and to encourage market competition. For the first time, CMS will be able
to directly negotiate prescription drug prices and to cap out-of-pocket costs. Each year, CMS will select and negotiate a preset number
of high-spend drugs and biologics that are covered under Medicare Part B and Part D that do not have generic or biosimilar competition.
On August 29, 2023, HHS announced the list of the first ten drugs subject to price negotiations. These price negotiations occurred in
2024. In January 2025, CMS announced a list of 15 additional Medicare Part D drugs that will be subject to price negotiations. The IRA
also provides a new &#8220;inflation rebate&#8221; covering Medicare patients that took effect in 2023 and is intended to counter certain
price increases in prescriptions drugs. The inflation rebate provision requires drug manufacturers to pay a rebate to the federal government
if the price for a drug or biologic under Medicare Part B and Part D increases faster than the rate of inflation. To support biosimilar
competition, beginning in October 2022, qualifying biosimilars may receive a Medicare Part B payment increase for a period of five years.
Separately, if a biologic drug for which no biosimilar exists delays a biosimilar&#8217;s market entry beyond two years, CMS will be
authorized to subject the biologics manufacturer to price negotiations intended to ensure fair competition. Notwithstanding these provisions,
the IRA&#8217;s impact on commercialization and competition remains largely uncertain.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition, net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private
payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices
than in the United States. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts
from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available
for any product candidate that we may commercialize and, if reimbursement is available, the level of reimbursement. In addition, many
pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price
and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for
drugs may be reduced by mandatory discounts or rebates required by government healthcare programs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Finally,
in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing
drug pricing vary widely from country to country. For example, the European Union (&#8220;EU&#8221;) provides options for its member
states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control
the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the
completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies.
A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls
on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has
price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for
any of our product candidates. Historically, products launched in the EU do not follow price structures of the United States and generally
prices tend to be significantly lower.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Healthcare
Reform</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system.
There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving
quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been
significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement
of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental
control of drug pricing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
ACA, which was enacted in March 2010, substantially changed the way healthcare is financed by both governmental and private insurers
in the United States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import
to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs,
a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled,
infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health
care programs. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect
there will be additional challenges and amendments to the ACA in the future. For example, the IRA, among other things, extends enhanced
subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the
&#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket
cost and creating a new manufacturer discount program.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Other
legislative changes have been proposed and adopted since the ACA was enacted, including automatic aggregate reductions of Medicare payments
to providers of on average 2% per fiscal year as part of the federal budget sequestration under the Budget Control Act of 2011. These
reductions went into effect in April 2013 and, due to subsequent legislative amendments, will remain in effect until 2032 unless additional
action is taken by Congress.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the Bipartisan Budget Act of 2018, among other things, amended the Medicare Act (as amended by the ACA) to increase the point-of-sale
discounts that manufacturers must agree to offer under the Medicare Part D coverage discount program from 50% to 70% off negotiated prices
of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient
drugs being covered under Medicare Part D.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Moreover,
there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products,
which has resulted in several Congressional inquiries and proposed and enacted federal and state measures designed to, among other things,
reduce the cost of prescription drugs, bring more transparency to product pricing, review the relationship between pricing and manufacturer
patient programs, and reform government program reimbursement methodologies for drug products. For example, in May 2019, CMS adopted
a final rule allowing Medicare Advantage Plans the option to use step therapy for Part B drugs, permitting Medicare Part D plans to apply
certain utilization controls to new starts of five of the six protected class drugs, and requiring the Explanation of Benefits for Part
D beneficiaries to disclose drug price increases and lower cost therapeutic alternatives, which went into effect on January 1, 2021.
In response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three
new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility,
and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further,
on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in
rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft
Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product
as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised,
it is uncertain if that will continue under the new framework.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Notwithstanding
the IRA, continued legislative and enforcement interest exists in the United States with respect to specialty drug pricing practices.
Specifically, we expect regulators to continue pushing for transparency to drug pricing, reducing the cost of prescription drugs under
Medicare, reviewing the relationship between pricing and manufacturer patient programs, and reforming government program reimbursement
methodologies for drugs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Individual
states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control
pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain
drug access and marketing cost disclosure and transparency measures, and designed to encourage importation from other countries and bulk
purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial
condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly
using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and
other healthcare programs. This could reduce the ultimate demand for its drugs or put pressure on its drug pricing, which could negatively
affect our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Other
Government Regulation Outside of the United States </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other
things, research and development, clinical trials, testing, manufacturing, safety, efficacy, quality control, labeling, packaging, storage,
record keeping, distribution, reporting, export and import, advertising, marketing and other promotional practices involving biological
products as well as authorization, approval as well as post-approval monitoring and reporting of our products. Because biologically sourced
raw materials are subject to unique contamination risks, their use may be restricted in some countries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Whether
or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries
prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United
States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement
of human clinical trials. &#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
requirements and process governing the conduct of clinical trials, including requirements to conduct additional clinical trials, product
licensing, safety reporting, post-authorization requirements, marketing and promotion, interactions with healthcare professionals, pricing
and reimbursement may vary widely from country to country. No action can be taken to market any product in a country until an appropriate
approval application has been approved by the regulatory authorities in that country. The current approval process varies from country
to country, and the time spent in gaining approval varies from that required for FDA approval. In certain countries, the sales price
of a product must also be approved. The pricing review period often begins after market approval is granted. Even if a product is approved
by a regulatory authority, satisfactory prices may not be approved for such product, which would make launch of such products commercially
unfeasible in such countries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Regulation
in the European Union </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>European
Data Laws </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
collection and use of personal health data and other personal data in the EU is governed by the provisions of the European General Data
Protection Regulation (EU) 2016/679 (&#8220;GDPR&#8221;), which came into force in May 2018, and related data protection laws in individual
EU Member States. The GDPR imposes a number of strict obligations and restrictions on the ability to process, including collecting, analyzing
and transferring, personal data of individuals, in particular with respect to health data from clinical trials and adverse event reporting.
The GDPR includes requirements relating to the legal basis of the processing (such as consent of the individuals to whom the personal
data relates), the information provided to the individuals prior to processing their personal data, the personal data breaches which
may have to be notified to the national data protection authorities and data subjects, the measures to be taken when engaging processors,
and the security and confidentiality of the personal data. EU Member States may also impose additional requirements in relation to health,
genetic and biometric data through their national legislation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the GDPR imposes specific restrictions on the transfer of personal data to countries outside of the European Economic Area
(&#8220;EEA&#8221;) that are not considered by the European Commission (&#8220;EC&#8221;) to provide an adequate level of data protection.
Appropriate safeguards are required to enable such transfers. Among the appropriate safeguards that can be used, the data exporter may
use the standard contractual clauses (&#8220;SCCs&#8221;). When relying on SCCs, data exporters are also required to conduct a transfer
risk assessment to verify if anything in the law and/or practices of the third country may impinge on the effectiveness of the SCCs in
the context of the transfer at stake and, if so, to identify and adopt supplementary measures that are necessary to bring the level of
protection of the data transferred to the EU standard of essential equivalence. Where no supplementary measure is suitable, the data
exporter should avoid, suspend or terminate the transfer. With regard to the transfer of data from the EEA to the United States, on July
10, 2023, the EC adopted its adequacy decision for the EU-US Data Privacy Framework. On the basis of the new adequacy decision, personal
data can flow from the EEA to U.S. companies participating in the framework. With regard to the transfer of data from the EU to the United
Kingdom (&#8220;UK&#8221;), personal data may freely flow from the EEA to the UK since the UK is deemed to have an adequate data protection
level. However, the adequacy decisions include a &#8217;sunset clause&#8217; which entails that the decisions will automatically expire
four years after their entry into force, unless renewed.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Failure
to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States may result in significant
monetary fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever
is greater, other administrative penalties and a number of criminal offenses for organizations and, in certain cases, their directors
and officers, as well as civil liability claims from individuals whose personal data was processed. Data protection authorities from
the different EU Member States may still implement certain variations, enforce the GDPR and national data protection laws differently,
and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the EU.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
there are specific requirements relating to processing health data from clinical trials, including public disclosure obligations provided
in the EU Clinical Trials Regulation No. 536/2014 (&#8220;CTR&#8221;), European Medical Agency (&#8220;EMA&#8221;) disclosure initiatives
and voluntary commitments by industry. Failure to comply with these obligations could lead to government enforcement actions and significant
penalties against us, harm to our reputation, and adversely impact our business and operating results.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Additionally,
following the UK&#8217;s withdrawal from the EU and the EEA, companies also have to comply with the UK&#8217;s data protection laws (including
the UK GDPR (as defined in section 3(10) (as supplemented by section 205(4)) of the Data Protection Act 2018 (the &#8220;DPA 2018&#8221;)),
the DPA 2018, and related data protection laws in the UK). Separate from the fines that can be imposed by the GDPR, the UK regime has
the ability to fine up to the greater of &#163;17.5 million or 4% of global turnover.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Companies
are subject to specific transfer rules under the UK regime, which broadly mirror the GDPR rules. On February 2, 2022, the UK Secretary
of State laid before the UK Parliament the international data transfer agreement (&#8220;IDTA&#8221;) and the international data transfer
addendum to the EC&#8217;s standard contractual clauses for international data transfers (Addendum) and a document setting out transitional
provisions. The IDTA and Addendum came into force on March 21, 2022 and replaced the old SCCs for the purposes of the UK regime.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Regarding
transfers from the UK to the EEA, personal data may flow freely since the EEA is deemed to have an adequate data protection level for
purposes of the UK regime. With regard to the transfer of personal data from the UK to the United States, the UK government has adopted
an adequacy decision for the United States, the UK-US Data Bridge, which came into force on October 12, 2023. The UK-US Data Bridge recognizes
the United States as offering an adequate level of data protection where the transfer is to a U.S. company participating in the EU-US
Data Privacy Framework and the UK Extension.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Drug
and Biologic Development Process </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;Regardless
of where they are conducted, all clinical trials included in applications for marketing authorization (&#8220;MA&#8221;) for human medicines
in the EU/EEA must have been carried out in accordance with EU regulations. This means that clinical trials conducted in the EU/EEA have
to comply with EU clinical trial legislation but also that clinical trials conducted outside the EU/EEA have to comply with ethical principles
equivalent to those set out in the EEA, including adhering to international good clinical practice and the Declaration of Helsinki. The
conduct of clinical trials in the EU is governed by the CTR, which entered into force on January 31, 2022. The CTR replaced the Clinical
Trials Directive 2001/20/EC, (&#8220;Clinical Trials Directive&#8221;) and introduced a complete overhaul of the existing regulation
of clinical trials for medicinal products in the EU.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Under
the former regime, which will expire after a transition period of three years as outlined below in more detail, before a clinical trial
can be initiated it must be approved in each EU member state where there is a site at which the clinical trial is to be conducted. The
approval must be obtained from two separate entities: the National Competent Authority (&#8220;NCA&#8221;) and one or more Ethics Committees.
The NCA of the EU Member States in which the clinical trial will be conducted must authorize the conduct of the trial, and the independent
Ethics Committee must grant a positive opinion in relation to the conduct of the clinical trial in the relevant EU member state before
the commencement of the trial. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications
must be submitted to or approved by the relevant NCA and Ethics Committees. Under the current regime all suspected unexpected serious
adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and to the Ethics Committees
of the EU member state where they occur.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">A
more unified procedure will apply under the new CTR. A sponsor will be able to submit a single application for approval of a clinical
trial through a centralized EU clinical trials portal (the Clinical Trials Information System or &#8220;CTIS&#8221;). One national regulatory
authority (the reporting EU member state proposed by the applicant) will take the lead in validating and evaluating the application and
consult and coordinate with the other concerned EU Member States. If an application is rejected, it may be amended and resubmitted through
the EU clinical trials portal. If an approval is issued, the sponsor may start the clinical trial in all concerned EU Member States.
However, a concerned EU member state may in limited circumstances declare an &#8220;opt-out&#8221; from an approval and prevent the clinical
trial from being conducted in such member state. The CTR also aims to streamline and simplify the rules on safety reporting, and introduces
enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU Database. The CTR
foresees a three-year transition period. EU Member States will work in CTIS immediately after the system has gone live. Since January
31, 2023, submission of initial clinical trial applications via CTIS is mandatory and CTIS serves as the single entry point for submission
of clinical trial-related information and data. By January 31, 2025, all ongoing trials approved under the former Clinical Trials Directive
will need to comply with the CTR and have to be transitioned to CTIS. On July 19, 2023, the EC published guidance concerning the steps
to be taken in this transition. This guidance provides, among other things, that (i) documentation which was previously assessed will
not be reassessed, (ii) templates that were developed and endorsed by the EU Clinical Trials Expert Group to provide compliance with
the CTR do not need to be updated and (iii) there is no need to retrospectively create a site suitability form, which are only necessary
for new trial sites.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Under
both the former regime and the new CTR, national laws, regulations, and the applicable GCP and GLP standards must also be respected during
the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human
Use guidelines on Good Clinical Practice and the ethical principles that have their origin in the Declaration of Helsinki.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">During
the development of a medicinal product, the EMA and national regulators within the EU provide the opportunity for dialogue and guidance
on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee
for Medicinal Products for Human Use (&#8220;CHMP&#8221;) on the recommendation of the Scientific Advice Working Party. A fee is incurred
with each scientific advice procedure, but is significantly reduced for designated orphan medicines. Advice from the EMA is typically
provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and
clinical studies, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future Marketing
Authorization Application (&#8220;MAA&#8221;) of the product concerned.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Drug
Marketing Authorization </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
the EEA, after completion of all required clinical testing, pharmaceutical products may only be placed on the market after obtaining
a MA. To obtain a MA of a drug under EU regulatory systems, an applicant can submit an MAA through, amongst others, a centralized or
decentralized procedure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">To
be used or sold in the UK, a drug must have an effective MA obtained by a centralized application through EMA or a national application.
National applications are governed by the Human Medicines Regulations (SI 2012/1916). Applications are made electronically through the
Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) Submissions Portal. The process from application to authorizations
generally takes up to 210 days, excluding time taken to provide any additional information or data required by the MHRA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">On
August 30, 2023, the MHRA published detailed guidance on its recently announced new International Reliance Procedure (&#8220;IRP&#8221;)
for MAAs. The IRP applies since January 1, 2024 and replaces existing EU reliance procedures to apply for authorizations from seven international
regulators (e.g. Health Canada, Swiss Medic, FDA, EMA, among others). The IRP allows medicinal products approved in other jurisdictions
that meet certain criteria to undergo a fast-tracked MHRA review to obtain and/or update a MA in the UK.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Applicants
can submit initial MAAs to the IRP but the procedure can also be used throughout the lifecycle of a product for post-authorization procedures
including line extensions, variations and renewals. &#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Centralized
Authorization Procedure </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
centralized procedure provides for the grant of a single MA that is issued by the EC following the scientific assessment of the application
by the EMA that is valid for all EU Member States as well as in the three additional EEA Member States (Norway, Iceland and Liechtenstein).
The centralized procedure is compulsory for specific medicinal products, including for medicines developed by means of certain biotechnological
processes, products designated as orphan medicinal products, advanced therapy medicinal products (&#8220;ATMP&#8221;) (gene therapy,
somatic cell therapy or tissue engineered medicines) and medicinal products with a new active substance indicated for the treatment of
certain diseases (HIV/AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases). For medicinal products containing
a new active substance not yet authorized in the EEA before May 20, 2004 and indicated for the treatment of other diseases, medicinal
products that constitute significant therapeutic, scientific or technical innovations or for which the grant of a MA through the centralized
procedure would be in the interest of public health at EU level, an applicant may voluntarily submit an application for a MA through
the centralized procedure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Under
the centralized procedure, the CHMP established at the EMA, is responsible for conducting the initial assessment of a drug. The CHMP
is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions
to an existing MA. Under the centralized procedure, the timeframe for the evaluation of an MAA by the EMA&#8217;s CHMP is, in principle,
210 days from receipt of a valid MAA. However, this timeline excludes clock stops, when additional written or oral information is to
be provided by the applicant in response to questions asked by the CHMP, so the overall process typically takes a year or more, unless
the application is eligible for an accelerated assessment. Accelerated evaluation might be granted by the CHMP in exceptional cases,
when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation.
Upon request, the CHMP can reduce the time frame to 150 days if the applicant provides sufficient justification for an accelerated assessment.
The CHMP will provide a positive opinion regarding the application only if it meets certain quality, safety and efficacy requirements.
This opinion is then transmitted to the EC, which has the ultimate authority for granting MA within 67 days after receipt of the CHMP
opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Decentralized
Authorization Procedure </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Medicines
that fall outside the mandatory scope of the centralized procedure have three routes to authorization: (i) they can be authorized under
the centralized procedure if they concern a significant therapeutic, scientific or technical innovation, or if their authorization would
be in the interest of public health; (ii) they can be authorized under a decentralized procedure where an applicant applies for simultaneous
authorization in more than one EU member state; or (iii) they can be authorized in an EU member state in accordance with that state&#8217;s
national procedures and then be authorized in other EU countries by a procedure whereby the countries concerned agree to recognize the
validity of the original, national MA (mutual recognition procedure).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
decentralized procedure permits companies to file identical MA applications for a medicinal product to the competent authorities in various
EU Member States simultaneously if such medicinal product has not received marketing approval in any EU Member State before. This procedure
is available for pharmaceutical products not falling within the mandatory scope of the centralized procedure. The competent authority
of a single EU Member State, the reference member state, is appointed to review the application and provide an assessment report. The
competent authorities of the other EU Member States, the concerned member states, are subsequently required to grant a MA for their territories
on the basis of this assessment. The only exception to this is where the competent authority of an EU Member State considers that there
are concerns of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually
be referred to the EC, whose decision is binding for all EU Member States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Risk
Management Plan </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">All
new MAAs must include a Risk Management Plan (&#8220;RMP&#8221;) describing the risk management system that the company will put in place
and documenting measures to prevent or minimize the risks associated with the product. RMPs are continually modified and updated throughout
the lifetime of the medicine as new information becomes available. An updated RMP must be submitted: (i) at the request of EMA or a national
competent authority, or (ii) whenever the risk-management system is modified, especially as the result of new information being received
that may lead to a significant change to the benefit-risk profile or as a result of an important pharmacovigilance or risk-minimization
milestone being reached. The regulatory authorities may also impose specific obligations as a condition of the MA. Since October 20,
2023, all RMPs for centrally authorized products are published by the EMA, subject only to limited redactions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>MA
Validity Period </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">MAs
have an initial duration of five years. After these five years, the authorization may subsequently be renewed on the basis of a reevaluation
of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the EC or the national competent authority
decides, on justified grounds relating to pharmacovigilance, to proceed with only one additional five-year renewal. Applications for
renewal must be made to the EMA at least nine months before the five-year period expires.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Any
authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market
of the authorizing member state within three years after authorization ceases to be valid.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">For
the UK, the period of three years during which the drug has not been marketed in Great Britain will be restarted from the date of conversion
to a Great Britain MA. Conversion refers to the procedure by which, as of January 1, 2021, MAs granted on the basis of a centralized
procedure in the EU are only valid in Northern Ireland but not in Great Britain, whereas, prior EU authorizations have all been automatically
converted into UK MAs effective in Great Britain only.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">On
the other hand, for the EU, in the case the drug has been marketed in the UK, the placing on the UK market before the end of the period
starting when the UK left the EU on January 31, 2020 and ending on December 31, 2020 (the &#8220;Brexit Transition Period&#8221;) will
be taken into account. If, after the end of the Brexit Transition Period, the drug is not placed on any other market of the remaining
EU Member States, the three-year period will start running from the last date the drug was placed on the UK market before the end of
the Brexit Transition Period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Advanced
Therapy Medicinal Products </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
the EU, medicinal products, including ATMPs are subject to extensive pre- and post-market regulation by regulatory authorities at both
the EU and national levels. ATMPs comprise gene therapy products, somatic cell therapy products and tissue engineered products, which
are genes, cells or tissues that have undergone substantial manipulation and that are administered to human beings in order to cure,
diagnose or prevent diseases or regenerate, repair or replace a human tissue. Pursuant to the Regulation (EC) No 1394/2007, the Committee
for Advanced Therapies (&#8220;CAT&#8221;) is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CHMP and CAT
are also responsible for providing guidelines on ATMPs. These guidelines provide additional guidance on the factors that the EMA will
consider in relation to the development and evaluation of ATMPs and include, among other things, the preclinical studies required to
characterize ATMPs. Although such guidelines are not legally binding, compliance with them is often necessary to gain and maintain approval
for product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition to the mandatory RMP, the holder of a MA for an ATMP must put in place and maintain a system to ensure that each individual
product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may contain, can
be traced through the sourcing, manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where
the product is used.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Exceptional
Circumstances/Conditional Approval</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Similar
to accelerated approval regulations in the United States, conditional MAs can be granted in the EU in exceptional circumstances. A conditional
MA can be granted for medicinal products where, although comprehensive clinical data referring to the safety and efficacy of the medicinal
product have not been supplied, a number of criteria are fulfilled: (i) the benefit/risk balance of the product is positive, (ii) it
is likely that the applicant will be in a position to provide the comprehensive clinical data, (iii) unmet medical needs will be fulfilled
by the grant of the MA and (iv) the benefit to public health of the immediate availability on the market of the medicinal product concerned
outweighs the risk inherent in the fact that additional data are still required. Once a conditional MA has been granted, the MA holder
must fulfil specific obligations within defined timelines. A conditional MA is valid for one year and must be renewed annually, but it
can be converted into a standard MA once the MA holder fulfils the obligations imposed and the complete data confirm that the medicine&#8217;s
benefits continue to outweigh its risks.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Data
and Market Exclusivity </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
in the United States, it may be possible to obtain a period of market and / or data exclusivity in the EU that would have the effect
of postponing the entry into the marketplace of a competitor&#8217;s generic, hybrid or biosimilar product (even if the pharmaceutical
product has already received a MA) and prohibiting another applicant from relying on the MA holder&#8217;s pharmacological, toxicological
and clinical data in support of another MA for the purposes of submitting an application, obtaining MA or placing the product on the
market. Innovative medicinal products, referred to as New Chemical Entities (&#8220;NCEs&#8221;) approved in the EU qualify for eight
years of data exclusivity and 10 years of marketing exclusivity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">An
additional non-cumulative one-year period of marketing exclusivity is possible if during the data exclusivity period (the first eight
years of the 10-year marketing exclusivity period), the MA holder obtains an authorization for one or more new therapeutic indications
that are deemed to bring a significant clinical benefit compared to existing therapies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
data exclusivity period begins on the date of the product&#8217;s first MA in the EU. After eight years, a generic product application
may be submitted and generic companies may rely on the MA holder&#8217;s data. However, a generic product cannot launch until two years
later (or a total of 10 years after the first MA in the EU of the innovator product), or three years later (or a total of 11 years after
the first MA in the EU of the innovator product) if the MA holder obtains MA for a new indication with significant clinical benefit within
the eight-year data exclusivity period. Additionally, another non-cumulative one-year period of data exclusivity can be added to the
eight years of data exclusivity where an application is made for a new indication for a well-established substance, provided that significant
pre-clinical or clinical studies were carried out in relation to the new indication.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Another
year of data exclusivity may be added to the eight years, where a change of classification of a pharmaceutical product has been authorized
on the basis of significant pre-trial tests or clinical trials (when examining an application by another applicant for or holder of MA
for a change of classification of the same substance the competent authority will not refer to the results of those tests or trials for
one year after the initial change was authorized).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Products
may not be granted data exclusivity since there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities
to include an NCE. Even if a compound is considered to be an NCE and the MA applicant is able to gain the prescribed period of data exclusivity,
another company nevertheless could also market another version of the medicinal product if such company can complete a full MAA with
their own complete database of pharmaceutical tests, preclinical studies and clinical trials and obtain MA of its product.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">On
April 26, 2023, the EC submitted a proposal for the reform of the European pharmaceutical legislation. The current draft envisages e.g.,
a shortening of the periods of data exclusivity, however, there is currently neither a final version of this draft nor a date for its
entry into force. While the European Parliament adopted its approving position on the reform on April 10, 2024, no further required legislative
steps have been taken since.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Pediatric
Development </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
the EU, companies developing a new medicinal product are obligated to study their product in children and must therefore submit a PIP
together with a request for agreement to the EMA. The EMA issues a decision on the PIP based on an opinion of the EMA&#8217;s Pediatric
Committee. Companies must conduct pediatric clinical trials in accordance with the PIP approved by the EMA, unless a deferral (e.g. until
enough information to demonstrate its effectiveness and safety in adults is available) or waiver (e.g. because the relevant disease or
condition occurs only in adults) has been granted by the EMA. The MAA for the medicinal product must include the results of all pediatric
clinical trials performed and details of all information collected in compliance with the approved PIP, unless a waiver or a deferral
has been granted, in which case the pediatric clinical trials may be completed at a later date. Medicinal products that are granted an
MA on the basis of the pediatric clinical trials conducted in accordance with the approved PIP are eligible for a six-month extension
of the protection under a supplementary protection certificate (if any is in effect at the time of approval), or, in the case of orphan
medicinal products, a two-year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and
is not automatically available when data in compliance with the approved PIP are developed and submitted. An approved PIP is also required
when a MA holder wants to add a new indication, medicinal form or route of administration for a medicine that is already authorized and
covered by intellectual property rights.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
the UK, the MHRA has published guidance on the procedures for UK Paediatric Investigation Plans (&#8220;PIPs&#8221;) which, where possible,
mirror the submission format and requirements of the EU system. EU PIPs remain applicable for Northern Ireland and EU PIPs agreed by
the EMA prior to January 1, 2021 have been adopted as UK PIPs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Post-Approval
Regulation </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Similar
to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the
EMA, the EC and/or the competent regulatory authorities of the EU Member States. This oversight applies both before and after grant of
manufacturing licenses and MAs. It includes control of compliance with EU good manufacturing practices rules, manufacturing authorizations,
pharmacovigilance rules and requirements governing advertising, promotion, sale, and distribution, recordkeeping, importing and exporting
of medicinal products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Failure
by us or by any of our third-party partners, including suppliers, manufacturers and distributors to comply with EU laws and the related
national laws of individual EU Member States governing the conduct of clinical trials, manufacturing approval, MA of medicinal products
and marketing of such products, both before and after grant of MA, statutory health insurance, bribery and anti-corruption or other applicable
regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to
authorize the conduct of clinical trials or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or
variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions,
injunctions, suspension of licenses, fines and criminal penalties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
holder of an MA for a medicinal product must also comply with EU pharmacovigilance legislation and its related regulations and guidelines,
which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">These
pharmacovigilance rules can impose on holders of MAs the obligation to conduct a labor intensive collection of data regarding the risks
and benefits of marketed medicinal products and to engage in ongoing assessments of those risks and benefits, including the possible
requirement to conduct additional clinical studies or post-authorization safety studies to obtain further information on a medicine&#8217;s
safety, or to measure the effectiveness of risk-management measures, which may be time consuming and expensive and could impact our profitability.
MA holders must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, who
is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission
of Periodic Safety Update Reports (&#8220;PSURs&#8221;) in relation to medicinal products for which they hold MAs. The EMA reviews PSURs
for medicinal products authorized through the centralized procedure. If the EMA has concerns that the risk benefit profile of a product
has varied, it can adopt an opinion advising that the existing MA for the product be suspended, withdrawn or varied. The agency can advise
that the MA holder be obliged to conduct post-authorization Phase 4 safety studies. If the EC agrees with the opinion, it can adopt a
decision varying the existing MA. Failure by the MA holder to fulfill the obligations for which the EC&#8217;s decision provides can
undermine the ongoing validity of the MA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">More
generally, non-compliance with pharmacovigilance obligations can lead to the variation, suspension or withdrawal of the MA for the product
or imposition of financial penalties or other enforcement measures.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
manufacturing process for pharmaceutical products in the EU is highly regulated and regulators may shut down manufacturing facilities
that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization
holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including Directive 2001/83/EC,
Directive 2003/94/EC (repealed by Directive 2017/1572 on January 31, 2022), Regulation (EC) No 726/2004 and the European Commission Guidelines
for Good Manufacturing Practice (&#8220;GMP&#8221;). These requirements include compliance with EU GMP standards when manufacturing pharmaceutical
products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the EU with
the intention to import the active pharmaceutical ingredients into the EU. Amendments or replacements of at least Directive 2001/83/EC
and Regulation (EC) No 726/2004 are part of the reform proposal for European pharmaceutical legislation. Similarly, the distribution
of pharmaceutical products into and within the EU is subject to compliance with the applicable EU laws, regulations and guidelines, including
the requirement to hold appropriate authorizations for distribution granted by the competent authorities of the EU Member States. The
manufacturer or importer must have a qualified person who is responsible for certifying that each batch of product has been manufactured
in accordance with GMP, before releasing the product for commercial distribution in the EU or for use in a clinical trial. Manufacturing
facilities are subject to periodic inspections by the competent authorities for compliance with GMP.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Sales
and Marketing Regulations </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
advertising and promotion of our products is also subject to EU laws concerning promotion of medicinal products, interactions with physicians,
misleading and comparative advertising and unfair commercial practices. In addition, other national legislation of individual EU Member
States may apply to the advertising and promotion of medicinal products and may differ from one country to another. These laws require
that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s SmPC as approved by the
competent regulatory authorities. The SmPC is the document that provides information to physicians concerning the safe and effective
use of the medicinal product. It forms an intrinsic and integral part of the MA granted for the medicinal product. Promotion of a medicinal
product that does not comply with the SmPC is considered to constitute off-label promotion. All advertising and promotional activities
for the product must be consistent with the approved SmPC and therefore all off-label promotion is prohibited. Direct-to-consumer advertising
of prescription-only medicines is also prohibited in the EU. Violations of the rules governing the promotion of medicinal products in
the EU could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising
and promotion of our products to the general public and may also impose limitations on its promotional activities with healthcare professionals.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">EU
regulation with regards to dispensing, sale and purchase of medicines has generally been preserved in the UK following Brexit, through
the Human Medicines Regulations 2012. However, organizations wishing to sell medicines online need to register with the MHRA. Following
Brexit, the requirements to display the common logo no longer apply to UK-based online sellers, except for those established in Northern
Ireland.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Anti-Corruption
Legislation </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
the EU, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation
codes of conduct and physicians&#8217; codes of professional conduct both at EU level and in the individual EU Member States. The provision
of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order
or use of medicinal products is prohibited in the EU. The provision of benefits or advantages to physicians is also governed by the national
anti-bribery laws of the EU Member States. Violation of these laws could result in substantial fines and imprisonment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Payments
made to physicians in certain EU Member States also must be publicly disclosed. Moreover, agreements with physicians must often be the
subject of prior notification and approval by the physician&#8217;s employer, his/her regulatory professional organization, and/or the
competent authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional
codes of conduct, applicable in the individual EU Member States. Failure to comply with these requirements could result in reputational
risk, public reprimands, administrative penalties, fines or imprisonment.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
the UK, the pharmaceutical sector is recognized as being particularly vulnerable to corrupt practices, some of which fall within the
scope of the Bribery Act 2010. Due to the Bribery Act 2010&#8217;s far-reaching territorial application, the potential penalized act
does not have to occur in the UK to become within its scope. If the act or omission does not take place in the UK, but the person&#8217;s
act or omission would constitute an offense if carried out there and the person has a close connection with the UK, an offense will still
have been committed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Bribery Act 2010 is comprised of four offenses that cover (i) individuals, companies and partnerships that give, promise or offer bribes,
(ii) individuals, companies and partnerships that request, agree to receive or accept bribes, (iii) individuals, companies and partnerships
that bribe foreign public officials, and (iv) companies and partnerships that fail to prevent persons acting on their behalf from paying
bribes. The penalties imposed under the Bribery Act 2010 depend on the offence committed, harm and culpability and penalties range from
unlimited fines to imprisonment for a maximum term of ten years and in some cases both.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Regulations
in the UK and Other Markets </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
UK formally left the EU on January 31, 2020 and EU laws now only apply to the UK in respect of Northern Ireland as laid out in the Protocol
on Ireland and Northern Ireland and as amended by the Windsor Framework sets out a long-term set of arrangements for the supply of medicines
into Northern Ireland. The EU and the UK agreed on a trade and cooperation agreement (&#8220;TCA&#8221;), which includes provisions affecting
the life sciences sector (including on customs and tariffs). There are some specific provisions concerning pharmaceuticals, including
the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP issued documents. The TCA does
not, however, contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
UK government has adopted the Medicines and Medical Devices Act 2021 (the &#8220;MMDA&#8221;) to enable the UK&#8217;s regulatory frameworks
to be updated following the UK&#8217;s departure from the EU. The MMDA introduces regulation-making, delegated powers covering the fields
of human medicines, clinical trials of human medicines, veterinary medicines and medical devices. The MHRA has since been consulting
on future regulations for medicines and medical devices in the UK.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">For
other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct
of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials
must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin
in the Declaration of Helsinki.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">If
we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical
trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Corporate
Information</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
were formed as a Delaware corporation in 1992 under the name &#8220;Nuvelo, Inc.&#8221; and subsequently, in 2009, we completed a business
combination with ARCA biopharma, Inc. On August 29, 2024, we completed the Merger with Pre-Merger Oruka and changed our name from &#8220;ARCA
biopharma, Inc.&#8221; to &#8220;Oruka Therapeutics, Inc.&#8221; Our corporate headquarters are located at 855 Oak Grove Avenue, Suite
100, Menlo Park, California 94025. The telephone number at our corporate headquarters is (650) 606-7910. Our corporate website address
is <i>www.orukatx.com</i>. We do not incorporate information contained on, or accessible through, our website into this Annual Report
on Form 10-K, and you should not consider it part of this Annual Report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Employees
and Human Capital Resources</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2024 and as of February 28, 2025, we had 28 full-time employees and 36 full-time employees, respectively. We also engage
temporary employees and consultants to augment our existing workforce. None of our employees are represented by a labor union or covered
under a collective bargaining agreement. We consider our relationship with our employees to be good.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
recognize that attracting, motivating, and retaining talent at all levels is vital to continuing our success. We invest in our employees
through high-quality benefits, professional development opportunities, and various health and wellness initiatives and offer competitive
compensation packages (base salary and incentive plans), ensuring fairness in internal compensation practices. The principal purposes
of our incentive plans (bonus and equity) are to align with the long-term interests of our stakeholders and stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Item
1A. Risk Factors. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Risk
Factors Summary</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
are subject to a number of risks that could harm our business, financial condition, results of operations and/or growth prospects or
cause our actual results to differ materially from those contained in forward-looking statements we have made in this Form 10-K and those
we may make from time to time. The success of our product candidates will depend on a variety of factors. We do not have complete control
over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats
to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any current or future collaborator.
In addition, some of the factors, events and contingencies discussed below may have occurred in the past, but the disclosures below are
not representations as to whether or not the factors, events or contingencies have occurred in the past and instead reflect our beliefs
and opinions as to the factors, events, or contingencies that could materially and adversely affect us in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following summary is not exhaustive and is qualified by reference to the full set of risk factors set forth in Item 1A &#8220;Risk Factors&#8221;
of this Form 10-K. Please carefully consider all the information in this Form 10-K, including the full set of risks set forth in the
&#8220;Risk Factors&#8221; section and in our other filings with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), before
making an investment decision regarding Oruka.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Drug Development and Regulatory Approval</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Drug
                                            development and obtaining and maintaining regulatory approval for drug products is costly,
                                            time-consuming, and highly uncertain.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
                                            are substantially dependent on the success of our two most advanced programs, ORKA-001 and
                                            ORKA-002. Our projected development goals, including our clinical trials, may not be successful
                                            or we may fail to achieve our projected development goals in the time frames we announce
                                            and expect.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
                                            may not be able to meet requirements for the chemistry, manufacturing and control of our
                                            programs.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            U.S. Food and Drug Administration (&#8220;FDA&#8221;) and comparable foreign regulatory approval
                                            processes are lengthy and time consuming and we may not be able to obtain or may be delayed
                                            in obtaining regulatory approvals for our product candidates. Moreover, even if we obtain
                                            regulatory approval, we will be subject to ongoing regulatory obligations.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
                                            face competition from entities that have developed or may develop programs for the diseases
                                            addressed by product candidates developed by us.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Our Financial Condition and Capital Requirements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
                                            are a clinical stage biopharmaceutical company with a limited operating history on which
                                            to assess our business; we have not completed any clinical trials, and have no products approved
                                            for commercial sale.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
                                            have historically incurred losses and we anticipate that we will continue to incur losses
                                            for the foreseeable future.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
                                            have never generated revenue from product sales and may never be profitable.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
                                            may not be able to raise the capital that we need to support our business plans.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Raising
                                            additional capital may cause dilution to our stockholders, restrict our operations or require
                                            us to relinquish rights to our technologies or product candidates.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Our Intellectual Property</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
                                            ability to obtain and protect our patents and other proprietary rights is uncertain and we
                                            may fail in obtaining or maintaining necessary rights to our programs.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
                                            may become subject to claims challenging the inventorship or ownership of our intellectual
                                            property and may be subject to patent infringement claims or may need to file such claims.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
                                            patents and our ability to protect our products may be impaired by changes to patent laws,
                                            and our patent protection could be reduced or eliminated for non-compliance with legal requirements.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
                                            may fail to identify or interpret relevant third-party patents.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Patent
                                            terms may be inadequate to protect our competitive position of our programs.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our technology
    licensed from third parties may be subject to retained rights.&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Our Reliance on Third Parties</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
                                            currently rely on agreements with third parties to develop our product candidates. If we
                                            are unable to maintain collaborations or licensing arrangements, or if our collaborations
                                            or licensing arrangements are not successful, our business could be negatively impacted.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Third
                                            parties we rely on for the execution of nonclinical studies and clinical trials may fail
                                            to carry out their contractual duties.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
                                            may be unable to use third-party manufacturing sites, our third-party manufacturers may encounter
                                            difficulties in production or we may need to switch or create third-party manufacturer redundancies.&#160;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>Other
Risk Factors - Risks Related to Employee Matters, Managing Growth, Other Risks Related to Our Business, and Owning Our Common Stock </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
                                            estimates of market opportunity and forecasts of market growth may prove to be inaccurate,
                                            and even if the markets in which we compete achieve the forecasted growth, our business may
                                            not grow at similar rates, or at all.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business
    is dependent on key personnel, and we will be harmed if we cannot recruit and retain highly qualified personnel to successfully implement
    our business strategy.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            order to successfully implement our plans and strategies, we will need to grow the size of
                                            our organization, and we may experience difficulties in managing this growth.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Significant
                                            disruptions of information technology systems or breaches of data security could adversely
                                            affect our business.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Changes
                                            in and failures to comply with United States and foreign privacy and data protection laws,
                                            regulations and standards may adversely affect our business, operations and consolidated
                                            financial performance.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
                                            may become exposed to costly and damaging liability claims and our insurance may not cover
                                            all damages from such claims.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
                                            business could be adversely affected by macroeconomic or geopolitical conditions.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
                                            do not anticipate paying any dividends in the foreseeable future.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Future
                                            sales of shares by existing stockholders could cause our stock price to decline.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Future
                                            sales and issuances of equity and debt could result in additional dilution to our stockholders
                                            and could cause our stock price to decline.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Risk Factors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Our Financial Condition and Capital Requirements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
are a clinical stage biopharmaceutical company with a limited operating history on which to assess our business; we have not completed
any clinical trials, have no products approved for commercial sale, have historically incurred losses, and we anticipate that we will
continue to incur significant losses for the foreseeable future. Moreover, we have never generated revenue from product sales and may
never be profitable.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
are a clinical stage biopharmaceutical company with a limited operating history. We will need to raise substantial additional capital
to continue to fund our operations in the future. We have based our estimates on assumptions that may prove to be wrong, and could exhaust
our available financial resources sooner than we currently anticipate. We have devoted substantially all of our financial resources to
identify, acquire, and develop our product candidates, organizing and staffing our company, and providing general and administrative
support for our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Biopharmaceutical
product development is a highly speculative undertaking and involves a substantial degree of risk. We expect our losses to increase as
our product candidates enter advanced clinical trials. It may be several&#160;years, if ever, before we complete pivotal clinical trials
or have a product candidate approved for commercialization. We expect to invest significant funds into the research and development of
our programs to determine the potential to advance product candidates to regulatory approval. If we obtain regulatory approval to market
a product candidate, our future revenue will depend upon the size of any markets in which our product candidates may receive approval,
and our ability to achieve sufficient market acceptance, pricing, coverage and adequate reimbursement from third-party&#160;payors, and
adequate market share for our product candidates in those markets. Even if we obtain adequate market share for our product candidates,
we may never become profitable despite obtaining such market share and acceptance of our products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
expect to continue to incur significant expenses and increasing operating losses for the foreseeable future and our expenses will increase
substantially if and as we:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">continue
                                            the clinical development of our product candidates, including advancing our product candidates
                                            into larger, more expensive trials;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">continue
                                            efforts to discover and develop new product candidates, including initiating preclinical
                                            studies or clinical trials;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">progress
                                            our chemistry, manufacturing and control development, registration, and validation, including
                                            the manufacture of our product candidates by third parties, including increasing volumes
                                            manufactured by third parties;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">seek
                                            regulatory and marketing approvals and reimbursement for our product candidates;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">establish
                                            a sales, marketing, and distribution infrastructure to commercialize any products for which
                                            we may obtain marketing approval and market for ourselves;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">make
                                            milestone, royalty, or other payments under third-party&#160;license agreements;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">seek
                                            to maintain, protect, and expand our intellectual property portfolio; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">experience
                                            any delays or encounter issues with the development and potential regulatory approval of
                                            our product candidates such as safety issues, manufacturing delays, clinical trial delays,
                                            longer&#160;follow-up&#160;for planned studies or trials, additional major studies or trials,
                                            or supportive trials necessary to support marketing approval.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">If
we are unable to raise additional capital when required or on acceptable terms, we may be required to curtail our product development
activities and other activities commensurate with the magnitude of the shortfall and our product development activities may cease altogether,
which could materially harm our business, financial condition, and results of operations. To the extent that the costs of our activities
exceed our current estimates and we are unable to raise sufficient additional capital to cover such costs, we will need to reduce operating
expenses, sell assets, enter into strategic transactions, or effect a combination of the above. No assurance can be given that we will
be able to enter into any of such transactions on acceptable terms, if at all. Any of the following events could have a material adverse
effect on our business, operating results, and prospects:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">a
                                            delay, scaling back, or discontinuation of the development or commercialization of our product
                                            candidates;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">seeking
                                            strategic partnerships, or amending existing partnerships, for research and development programs
                                            at an earlier stage than otherwise would be desirable or that we otherwise would have sought
                                            to develop independently, or on terms that are less favorable than might otherwise be available
                                            in the future;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disposal
                                            of technology assets, or the relinquishing or licensing of assets on unfavorable terms, of
                                            our rights to technologies or any of our product candidates that we otherwise would seek
                                            to develop or commercialize ourselves;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">pursuing
                                            the sale of the company to a third party at a price that may result in a loss on investment
                                            for our stockholders; or</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">filing
                                            for bankruptcy or cease operations altogether.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Even
if we are successful in raising new capital, we could be limited in the amount of capital we raise due to investor demand restrictions
placed on the amount of capital we raise, or other reasons.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Raising
additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">To
the extent that we raise additional capital through the sale of equity securities or convertible debt securities, the ownership interest
of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect
the rights of holders of our common stock. Debt financing and preferred equity financing, if available, may involve agreements that include
covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures,
or declaring dividends. For example, in September 2024, we entered into a Securities Purchase Agreement with certain new institutional
and accredited investors, whereby the investors purchased an aggregate of 5,600,000 shares of common stock, 2,439 shares of Series A
Preferred Stock and pre-funded warrants to purchase an aggregate of 680,000 shares of common stock for an aggregate purchase price of
approximately $200.5 million. Each share of Series A Preferred Stock is convertible into 1,000 shares of common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">If
we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third
parties, we may be required to relinquish valuable rights to our research programs or product candidates or grant licenses on terms that
may not be favorable to us. Debt financing, if available, would likely involve agreements that include covenants limiting or restricting
our ability to take specific actions, such as incurring additional debt, making capital expenditures, making additional product acquisitions,
or declaring dividends.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Clinical Development, Regulatory Approval and Commercialization&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
face competition from entities that have developed or may develop programs for the diseases addressed by our product candidates.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
development and commercialization of drugs is highly competitive. Product candidates developed by us, if approved, will face significant
competition and our failure to effectively compete may prevent us from achieving significant market penetration. We compete with a variety
of biopharmaceutical companies as well as academic institutions, governmental agencies, and public and private research institutions,
among others. Many of the companies with which we are currently competing or will compete against in the future have significantly greater
financial resources and expertise in research and development, manufacturing, preclinical testing, clinical trials, regulatory approvals,
and marketing than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources
being concentrated among a smaller number of our competitors. Smaller or early-stage&#160;companies may also prove to be significant
competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with
us in establishing clinical trial sites, recruiting participants for clinical trials, as well as in acquiring technologies complementary
to, or necessary for, our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
competitors have developed, are developing or will develop programs and processes competitive with our programs and processes. Competitive
therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments. Our
success will depend partially on our ability to develop and commercialize products that have a competitive safety, efficacy, dosing and/or
presentation profile. Our commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective,
have a more attractive dosing profile or presentation or are less expensive than the products we develop, or if biosimilars enter the
market and are able to gain market acceptance more quickly than we do or at wider scale.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
product candidates may fail in development or suffer delays. We depend on the successful initiation and completion of clinical trials
for our product candidates to advance our product development plans.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
have no products on the market, and all of our programs are in preclinical or clinical stages of development. As a result, we expect
it will be many&#160;years before we can obtain regulatory approval for and commercialize any product candidate, if ever. Clinical testing
is expensive, difficult to design and implement, and can take years to complete and is uncertain as to outcome. A failure of one or more
of our clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive
of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover,
preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their
product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval
for their products. It may be difficult for us to raise additional capital if we experience any issues that delay or prevent the regulatory
approval or the ability to commercialize our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
may experience a number of unforeseen events affecting our product development timeline, including the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            clinical trials may fail to show safety or efficacy, produce negative or inconclusive results,
                                            or our product candidates may have undesirable side effects or unexpected characteristics,
                                            and we may decide, or regulators may require that we conduct additional preclinical studies
                                            or clinical trials or we may decide to abandon product development programs;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            supply or quality of our clinical trial materials or other materials necessary to conduct
                                            clinical trials of our product candidates may be insufficient or inadequate;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">regulators
                                            or IRBs, the FDA, or ethics committees may not authorize us or our investigators to commence
                                            or conduct a clinical trial at one or more prospective trial sites; or may require that we
                                            or our investigators materially modify, suspend or terminate clinical research or trials
                                            for various reasons, including noncompliance with regulatory requirements or a finding that
                                            the participants in our trials are being exposed to unacceptable health risks;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
                                            failure to establish an appropriate safety profile for a product candidate based on clinical
                                            or preclinical data as well as data emerging from other therapies in the same class as our
                                            product candidates;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            number of subjects required for clinical trials of any product candidates may be larger than
                                            we anticipate, especially if regulatory bodies require completion of non-inferiority or superiority
                                            trials; enrollment in these clinical trials may be slower than we anticipate or subjects
                                            may drop out of these clinical trials or fail to return for post-treatment follow-up at a
                                            higher rate than we anticipate;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">trial
                                            conduct or data analysis errors may occur, including, but not limited to, failure by investigators
                                            or participants to adhere to the study protocol or data entry and/or labeling errors;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">we
                                            may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective
                                            trial sites and/or contract research organizations (&#8220;CROs&#8221;);</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
                                            third-party&#160;contractors or clinical trial sites may fail to comply with regulatory requirements
                                            or meet their contractual obligations to us in a timely manner, or at all, or may deviate
                                            from the clinical trial protocol or drop out of the trial, which may require that we add
                                            new clinical trial sites or investigators and could potentially complicate the analysis of
                                            data;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            cost of clinical trials of any of our programs may be greater than we anticipate;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">reports
                                            from clinical testing of other therapies may raise safety or efficacy concerns about our
                                            programs; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            FDA or other regulatory authorities may require us to submit additional data or impose other
                                            requirements and our product development timeline may be adversely affected.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">If
our clinical trials do not produce favorable results, our ability to obtain regulatory approval for our product candidates will be adversely
impacted. Moreover, the combined data from our trials may be inconclusive or may not be sufficient to ultimately gain marketing approval
from the FDA or other regulatory authorities. There are equivalent processes and risks applicable to clinical trial applications in other
countries outside of the United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition, because of the competitive landscape for&#160;immunology and inflammation (commonly referred to as &#8220;I&amp;I&#8221;) indications,
we may also face competition for clinical trial enrollment. Clinical trial enrollment will depend on many factors, including if potential
clinical trial participants choose to undergo treatment with approved products or enroll in competitors&#8217; ongoing clinical trials
for programs that are under development for the same indications as our programs. An increase in the number of approved products for
the indications we are targeting with our programs may further exacerbate this competition. Our inability to enroll a sufficient number
of participants could, among other things, delay our development timeline, which may further harm our competitive position and have an
adverse effect on our business and operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
are substantially dependent on the success of our two most advanced programs, ORKA-001 and ORKA-002, and our clinical trials of such
programs may not be successful.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
future success is substantially dependent on our ability to develop and timely obtain marketing approval for, and then successfully commercialize,
our two most advanced programs, ORKA-001&#160;and ORKA-002. We are investing a majority of our efforts and financial resources into the
research and development of these programs. We have initiated a Phase&#160;1 clinical trial of ORKA-001 in healthy volunteers and anticipate
initiating a Phase 1 clinical trial of ORKA-002 in healthy volunteers&#160;in the second half of 2025, subject to the filing of an IND
or foreign equivalent and regulatory approval. Currently, we believe that the success of our programs is dependent on observing a longer
half-life&#160;of our product candidates in humans than monoclonal antibodies (&#8220;mAbs&#8221;) currently marketed and in development
as we believe this longer half-life&#160;has the potential to result in a more favorable dosing schedule for our product candidates,
assuming they successfully complete clinical development and obtain marketing approval. This is based in part on the assumption that
the longer half-life&#160;we have observed in NHPs will translate into an extended half-life&#160;of our product candidates in humans.
To the extent we do not observe this extended half-life&#160;in humans, it would significantly and adversely affect the clinical and
commercial potential of our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
we do not achieve our projected development goals in the time frames we announce and expect, the development and potential commercialization
of our product candidates may be delayed and our expenses may increase and, as a result, our business may be materially harmed and our
stock price may decline.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">From
time to time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product
development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of scientific
studies and clinical trials, such as the expected timing of our clinical trials in our target indications, anticipated data analysis
and results from our clinical trials, as well as the submission of regulatory filings. From time to time, we may publicly announce the
expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing
of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet
these milestones as publicly announced, or at all, the development and potential commercialization of our product candidates may be delayed
or never achieved and, as a result, our business may be materially harmed and our stock price may decline. Additionally, delays relative
to our projected timelines are likely to cause overall expenses to increase, which may require us to raise additional capital sooner
than expected and prior to achieving targeted development milestones.&#160;</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Any
drug delivery device that we may use to deliver our product candidates may have its own regulatory, development, supply and other risks.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
expect to deliver our product candidates via a drug delivery device, such as an injector or other delivery system. There may be unforeseen
technical complications related to the development activities required to bring such a product to market, including primary container
compatibility and/or dose volume requirements. If our product candidates are intended to be used with drug delivery devices, we expect
to utilize drug delivery devices authorized for marketing under clearances of approvals held by third parties. Our product candidates
may not be approved or may be substantially delayed in receiving approval if the devices that we choose to develop do not gain and/or
maintain their own regulatory approvals or clearances. Where approval of the drug product and device is sought under a single application,
the increased complexity of the review process may delay approval. In addition, some drug delivery devices are provided by single-source&#160;third-party&#160;companies.
We may be dependent on the sustained cooperation and effort of those third-party&#160;companies both to supply the devices and, in some
cases, to conduct the studies required for approval or other regulatory clearance of the devices. Even if approval is obtained for our
products, we may also be dependent on those third-party&#160;companies continuing to maintain such approvals or clearances, if required,
for their drug delivery devices once they have been received. Failure of third-party&#160;companies to supply the devices on time and
in accordance with the agreed-upon specifications, to successfully complete studies on the devices in a timely manner, or to obtain or
maintain required approvals or clearances of the devices could result in increased development costs, delays in or failure to obtain
regulatory approval and delays in product candidates reaching patients.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
approach to the discovery and development of our programs is unproven, and we may not be successful in our efforts to build a pipeline
of programs with commercial value.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
approach to the discovery and development of the research programs with respect to which we have signed a license agreement, exercised
the Option to acquire intellectual property license rights to or have the Option to acquire intellectual property license rights to pursuant
to the Option Agreements, leverages clinically validated mechanisms of action and incorporates advanced antibody engineering to optimize
half-life&#160;and other properties designed to overcome limitations of existing therapies. Our programs are purposefully designed to
improve upon existing product candidates and products while maintaining the same, well-established&#160;mechanisms of action. However,
the scientific research that forms the basis of our efforts to develop programs using half-life&#160;extension technologies is ongoing
and may not result in viable programs. There is limited clinical data available on product candidates utilizing half-life&#160;extension
technologies, especially in&#160;I&amp;I indications, demonstrating whether they are safe or effective for long-term&#160;treatment in
humans. The long-term&#160;safety and efficacy of these technologies and the extended half-lives&#160;and exposure profiles of our programs
compared to currently approved products are unknown.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
may ultimately discover that utilizing half-life&#160;extension technologies for our specific targets and indications and any programs
resulting therefrom does not possess certain properties required for therapeutic effectiveness. In addition, programs using half-life&#160;extension
technologies may demonstrate different chemical and pharmacological properties in human participants than they do in laboratory studies
or preclinical studies. This technology and any programs resulting therefrom may not demonstrate the same chemical and pharmacological
properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition, we may in the future seek to discover and develop programs that are based on novel targets and technologies that are unproven.
If our discovery activities fail to identify novel targets or technologies for drug discovery, or such targets prove to be unsuitable
for treating human disease, we may not be able to develop viable additional programs. We and our existing or future collaborators may
never receive approval to market and commercialize any product candidate. Even if we or an existing or future collaborator obtains regulatory
approval, the approval may be for targets, disease indications or patient populations that are not as broad as we intended or desired
or may require labeling that includes significant use or distribution restrictions or safety warnings. If the products resulting from
the research programs with respect to which we have signed license agreements with Paragon, exercised the Option to acquire intellectual
property license rights to or have the Option to acquire intellectual property license rights to pursuant to the Option Agreements prove
to be ineffective, unsafe or commercially unviable, such programs would have little, if any, value, which would have a material and adverse
effect on our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Preclinical
and clinical development involves a lengthy and expensive process that is subject to delays and uncertain outcomes, and results of earlier
studies and trials may not be predictive of future clinical trial results. If our preclinical studies and clinical trials are not sufficient
to support regulatory approval of any of our product candidates, we may incur additional costs or experience delays in completing, or
ultimately be unable to complete, the development of such product candidate.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Before
obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical studies
and then conduct extensive clinical trials to demonstrate the safety and efficacy of such product candidate in humans. Our clinical trials
may not be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or
clinical trial process.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
a failure of one or more clinical trials can occur at any stage of testing. Clinical data is often susceptible to varying interpretations
and analyses, and in addition, we expect to rely on participants to provide feedback on measures such as measures of quality of life,
which are subjective and inherently difficult to evaluate. These measures can be influenced by factors outside of our control, and can
vary widely from&#160;day-to-day&#160;for a particular participant, and from participant to participant and from site to site within
a clinical trial.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
cannot be sure that the FDA, or comparable foreign regulatory authority, as applicable, will agree with our clinical development plan.
We plan to use the data from our Phase&#160;1 trials of our ORKA-001&#160;and ORKA-002&#160;programs in healthy volunteers to support
Phase&#160;2 trials in PsO and potentially other&#160;I&amp;I indications. If the FDA and/or comparable foreign regulatory authority
requires us to materially modify our proposed trial designs, conduct additional trials or enroll additional participants, our development
timelines may be delayed. We cannot be sure that submission of an IND, Clinical Trial Application or similar application will result
in the FDA or comparable foreign regulatory authorities, as applicable, allowing clinical trials to begin in a timely manner, if at all.
Moreover, even if these trials begin, issues may arise that could suspend or terminate such clinical trials. Events that may prevent
successful or timely initiation or completion of clinical trials include: inability to generate sufficient preclinical, toxicology or
other&#160;in vivo&#160;or&#160;in vitro&#160;data to support the initiation or continuation of clinical trials; delays in reaching a
consensus with regulatory authorities on study design or implementation of the clinical trials; delays or failure in obtaining regulatory
authorization to commence a trial; delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites; recruiting
and training suitable clinical investigators; delays in obtaining required IRB approval at each clinical trial site; delays in manufacturing,
testing, releasing, validating or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials
or the inability to do any of the foregoing; failure by our CROs, other third parties or us to adhere to clinical trial protocols; failure
to perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s current GCP requirements or applicable regulatory
guidelines in other countries; changes to the clinical trial protocols; clinical sites deviating from trial protocol or dropping out
of a trial; delays or failure by our third party vendors or us in the manufacturing, packaging, labeling and proper delivery of clinical
trial materials; and third parties being unwilling or unable to satisfy their contractual obligations to us.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
could also encounter delays if a clinical trial is required to be materially modified or suspended or terminated by us, the IRBs, by
the Data Safety Monitoring Board, if any, or by the FDA or comparable foreign regulatory authorities. Such authorities may suspend, put
on clinical hold or terminate a clinical trial due to a number of factors, including not aligning with or supporting our clinical trial
designs or our failure to conduct the clinical trial in accordance with regulatory requirements or our clinical trial protocols, inspection
of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of
a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from the programs, changes in governmental
regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we are required to conduct additional
clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully
complete clinical trials of our product candidates, if the results of these trials are not positive or are only moderately positive or
if there are safety concerns, our business and results of operations may be adversely affected and we may need to adjust or abandon our
business plans and we may incur significant additional costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
we encounter difficulties enrolling participants in our current and future clinical trials, our clinical development activities could
be delayed or otherwise adversely affected.&#160;We depend on the successful completion of clinical trials for our product candidates.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
may experience difficulties in patient participant enrollment in our clinical trials for a variety of reasons. The timely completion
of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of participants
who remain in the trial until conclusion. The enrollment of participants in future trials for any of our programs will depend on many
factors, including if participants choose to enroll in clinical trials, rather than using approved products, or if our competitors have
ongoing clinical trials for programs that are under development for the same indications as our programs, and participants instead enroll
in such clinical trials. Even if we are able to enroll a sufficient number of participants for our clinical trials, it may have difficulty
maintaining participants in our clinical trials. Our inability to enroll or maintain a sufficient number of participants would result
in significant delays in completing clinical trials and increased development costs or may require us to abandon one or more clinical
trials altogether.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Preliminary,
&#8220;topline&#8221; or interim data from our clinical trials may change as more participant data becomes available and are subject
to audit and verification procedures, and should be viewed with caution until the final data are available.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">From
time to time, we may publicly disclose preliminary or topline data from our preclinical studies and clinical trials, which are based
on a preliminary analysis of then-available&#160;data, and the results and related findings and conclusions are subject to change following
a more comprehensive review of the data. We also make assumptions, estimations, calculations and conclusions as part of our analyses
of these data without the opportunity to fully and carefully evaluate complete data. As a result, the preliminary or topline results
that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results,
once additional data have been received and fully evaluated or subsequently made subject to audit and verification procedures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">From
time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data are subject to the risk
that one or more of the clinical outcomes may materially change as participant enrollment continues and more participant data become
available or as participants from our clinical trials continue other treatments. Further, others, including regulatory agencies, may
not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of
data differently, which could impact the value of the particular product candidate, the approvability or commercialization of the particular
product candidate and our company in general. In addition, the information we choose to publicly disclose regarding a particular preclinical
study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is
material or otherwise appropriate information to include in our disclosure. If the preliminary, topline or interim data that we report
differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain
approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or
financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
clinical trials may reveal significant adverse events, undesirable side effects or patient intolerance not seen in our preclinical studies
or earlier clinical trials, and may result in a safety profile that could halt clinical development, inhibit regulatory approval or limit
commercial potential or market acceptance of any of our product candidates.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Results
of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or patient intolerance, adverse events
or unexpected characteristics, and any of these occurrences could harm our business, financial condition, results of operations and prospects
significantly. If significant adverse events or other side effects are observed in any of our clinical trials, we may have difficulty
recruiting participants to such trials, participants may drop out of the trials, or we may have to suspend, materially modify or abandon
the trials or our development efforts of one or more programs altogether. We, the FDA or other applicable regulatory authorities, or
an IRB, may suspend or require the material modification of any clinical trials of any program at any time for various reasons, including
a belief that participants in such trials are being exposed to unacceptable health risks or adverse side effects. Moreover, negative
or inconclusive results could cause the FDA or other regulatory agencies to require that we repeat or conduct additional clinical trials.
If our clinical trials do not produce favorable results, our ability to obtain regulatory approval for our product candidates may be
adversely impacted.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Even
if side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may
inhibit market acceptance of the approved product due to their tolerability versus other therapies. In addition, an extended half-life&#160;could
prolong the duration of undesirable side effects, which could also affect our clinical trials or inhibit market acceptance. Potential
side effects associated with our product candidates may not be appropriately recognized or managed by the treating medical staff, as
toxicities resulting from our product candidates may not be normally encountered in the general patient population and by medical personnel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition, even if we successfully advance our product candidates through clinical trials, such trials will only include a limited number
of participants and limited duration of exposure to our product candidates. As a result, we cannot be assured that adverse effects of
our product candidates will not be uncovered when a significantly larger number of participants are exposed to the product candidate
after approval. Further, any clinical trials may not be sufficient to determine the effect and safety consequences of using our product
candidates over a multi-year&#160;period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">If
any of the foregoing events occur or if one or more of the research programs with respect to which we have signed a licensed agreement
for or exercised the Option to acquire intellectual property license rights to or have the Option to acquire intellectual property license
rights to pursuant to the Option Agreements prove to be unsafe, our pipeline could be affected, which would have a material adverse effect
on our business, financial condition, results of operations and prospects.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may expend our limited resources to pursue a particular program and fail to capitalize on programs that may be more profitable or for
which there is a greater likelihood of success.&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
are initially focused on our most advanced programs, ORKA-001&#160;and ORKA-002, and as a result, we may forgo or delay pursuit of opportunities
with other programs that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to
capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development
programs for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial
potential or target market for a particular product candidate, we may be in a position where we may have to relinquish valuable rights
to that product candidate through collaboration, licensing or other arrangements in cases in which we would have been more advantageous
for us to retain sole development and commercialization rights to such product candidate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Any
approved products resulting from our programs may not achieve adequate market acceptance among clinicians, patients, healthcare third-party
payors and others in the medical community necessary for commercial success and we may not generate any future revenue from the sale
or licensing of such products.&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Even
if regulatory approval is obtained for a product candidate resulting from one of our current or future programs, it may not gain market
acceptance among physicians, patients, healthcare payors or the medical community. Market acceptance of our product candidates will depend
on many factors, including factors that are not within our control. While there are several approved products and product candidates
in later stages of development for the treatment of PsO, our programs incorporate advanced antibody engineering to optimize the half-life&#160;and
formulation of antibodies, and to date, no such antibody has been approved by the FDA for the treatment of PsO.&#160;Market participants
with influence over acceptance of new treatments, such as clinicians and third-party&#160;payors, may not adopt a biologic that incorporates
half-life&#160;extension for our targeted indications, and we may not be able to convince the medical community and third-party&#160;payors
to accept and use, or to provide favorable reimbursement for, any programs developed by us or our existing or future collaborators. Moreover,
an extended half-life&#160;may make it more difficult for patients to change treatments and there may be a perception that half-life&#160;extension
could exacerbate side effects, each of which may adversely affect our ability to gain market acceptance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Sales
of medical products also depend on the willingness of healthcare providers to prescribe the treatment, and if any of our product candidates
is approved but does not achieve an adequate level of acceptance, we may not generate or derive sufficient revenue from that product
candidate and may not become or remain profitable.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Certain
of our programs may compete with our other programs, which could negatively impact our business and reduce our future revenue.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
are developing product candidates for the same indication, PsO, and may in the future develop our programs for other&#160;I&amp;I indications.
Each such program targets a different mechanism of action. However, developing multiple programs for a single indication may negatively
impact our business if the programs compete with each other. For example, if multiple programs are conducting clinical trials at the
same time, they could compete for the enrollment of participants. In addition, if multiple product candidates are approved for the same
indication, they may compete for market share, which could limit our future revenue.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may conduct clinical trials for programs at sites outside the United&#160;States, and the FDA may not accept data from trials conducted
in such locations. Moreover, conducting clinical trials outside of the U.S. presents additional risks that may delay our clinical trials.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
may choose to conduct one or more of our future clinical trials outside the United&#160;States. Although the FDA may accept data from
clinical trials conducted outside the United&#160;States, acceptance of this data is subject to conditions imposed by the FDA.&#160;
If the FDA does not accept the data from any trial that we conduct outside the United&#160;States, it would likely result in the need
for additional trials, which would be costly and time-consuming&#160;and would delay or permanently halt our development of the applicable
product candidates. Even if the FDA accepted such data, it could impose additional conditions, such as requiring us to modify our planned
clinical trials to receive clearance to initiate such trials in the United&#160;States or to continue such trials once initiated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Further,
conducting clinical trials outside of the U.S. presents additional risks that may delay completion of our clinical trials. These risks
include the failure of investigators or enrolled participants in foreign countries to adhere to clinical protocol as a result of differences
in healthcare services or cultural customs that could restrict or limit our ability to conduct our clinical trials, the administrative
burdens of conducting clinical trials under multiple sets of foreign regulations, potential restrictions, such as local privacy restrictions,
on data generated from the clinical trial, diminished protection of intellectual property in some countries, as well as political and
economic risks relevant to foreign countries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Government Regulation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>The
regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and unpredictable.
If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we may not
be able to commercialize, or may be delayed in commercializing, our product candidates, and our ability to generate revenue may be materially
impaired.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
lengthy regulatory approval process as well as the unpredictability of clinical trial results may result in our failing to obtain or
be delayed in obtaining approval to market our product candidates, which would significantly harm our business, results of operations
and prospects. Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory
approval processes and are commercialized. The process of obtaining regulatory approvals, both in the United&#160;States and abroad,
is unpredictable, expensive and typically takes many&#160;years following commencement of clinical trials. Approval may never be obtained
and the approval process can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product
candidates involved. Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through
lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for each
targeted indication. Securing regulatory approval also requires the submission of information about the drug manufacturing process to,
and inspection of manufacturing facilities by, the relevant regulatory authority. Further, our product candidates may not be effective,
may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that
may preclude our obtaining marketing approval. The FDA and comparable foreign regulatory authorities have substantial discretion in the
approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional
preclinical, clinical or other data. Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for
many reasons, including: the failure to demonstrate that a product candidate&#8217;s benefits outweigh safety risks; regulatory authorities
may disagree with our interpretation of clinical data or the data collected may not be acceptable or sufficient to support submission;
or the results may not meet the level of statistical significance required for approval by the relevant regulatory authorities or otherwise
considered insufficient by the FDA or comparable foreign regulatory authorities. Regulatory authorities may require the addition of labeling
statements, such as black box or other warnings or contraindications that could diminish the usage of the product or otherwise limit
the commercial success of the affected product.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Moreover,
regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, including failing
to approve the most commercially promising indications, may grant approval contingent on the performance of costly post-marketing&#160;clinical
trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful
commercialization of that product candidate. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals
for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates and our
ability to generate revenue will be materially impaired.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may not be able to meet requirements for the chemistry, manufacturing and control of our programs.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
order to receive approval of our products by the FDA and comparable foreign regulatory authorities, we must show that we and our CMO
partners are able to characterize, control and manufacture our drug products safely and in accordance with regulatory requirements. This
includes manufacturing the active ingredient, developing an acceptable formulation, manufacturing the drug product, performing tests
to adequately characterize the formulated product, documenting a repeatable manufacturing process, and demonstrating that our drug products
meet stability requirements. As noted above, we may deliver our product candidates via a drug delivery device, which also requires us
to meet certain chemistry, manufacturing and control requirements set forth by the FDA and other foreign regulatory authorities. Meeting
these chemistry, manufacturing and control requirements is a complex task that requires specialized expertise. If we are not able to
meet the chemistry, manufacturing and control requirements, we may not be successful in getting our products approved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
product candidates for which we intend to seek approval as biologics may face competition sooner than anticipated.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Reconciliation Act (the &#8220;ACA&#8221;), includes
a subtitle called the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable
with an&#160;FDA-licensed&#160;reference biological product. Under the BPCIA, an application for a highly similar or &#8220;biosimilar&#8221;
product may not be submitted to the FDA until four&#160;years following the date that the reference product was first approved by the
FDA.&#160;In addition, the approval of a biosimilar product may not be made effective by the FDA until 12&#160;years from the date on
which the reference product was first approved. During this&#160;12-year&#160;period of exclusivity, another company may still market
a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s
own preclinical data and data from adequate and well-controlled&#160;clinical trials to demonstrate the safety, purity and potency of
their product.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
believe that any of our product candidates approved as biologics under a BLA should qualify for the&#160;12-year&#160;period of exclusivity.
However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not
consider our product candidates to be reference products for competing products, potentially creating the opportunity for competition
sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject
of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference products in a
way that is similar to traditional generic substitution for&#160;non-biological&#160;products is not yet clear, and will depend on a
number of marketplace and regulatory factors that are still developing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Even
if we receive regulatory approval of our product candidates, we will be subject to extensive ongoing regulatory obligations and continued
regulatory review and may result in restrictions on the use of the product, which may result in significant additional expense and we
may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Any
regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities
and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions
for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval&#160;study or risk management
requirements. For example, the FDA may require a REMS in order to approve our product candidates. In addition, even if our product candidates
receive approval, our product candidates and the activities associated with their development and commercialization, including their
design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution,
import and export will be subject to comprehensive regulation by the FDA and other regulatory agencies in the United&#160;States and
by comparable foreign regulatory authorities. These requirements include submissions of safety and other post-marketing&#160;information
and reports, registration, as well as&#160;on-going&#160;compliance with current CGMPs and GCPs for any clinical trials that we conduct
following approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced
inspections by the FDA and other regulatory authorities for compliance with CGMPs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">If
we or a regulatory authority discover previously unknown problems with a product or problems with the facilities where the product is
manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or us, including requiring recall
or withdrawal of the product from the market or suspension of manufacturing, restrictions on our ability to conduct clinical trials,
including full or partial clinical holds on ongoing or planned trials, restrictions on the manufacturing process, warning or untitled
letters, civil and criminal penalties, injunctions, product seizures, detentions or import bans, voluntary or mandatory publicity requirements
and imposition of restrictions on operations, including costly new manufacturing requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Disruptions
at the FDA, the SEC and other government agencies and regulatory authorities caused by funding shortages or global health concerns could
hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or
commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation
of our business may rely, which could negatively impact our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
ability of the FDA to review regulatory filings and our ability to commence human clinical trials can be affected by a variety of factors,
including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory,
regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government
funding of the SEC, and other government agencies on which our operations may rely, including those that fund research and development
activities is subject to the political process, which is inherently fluid and unpredictable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Disruptions
at the FDA and other agencies or comparable foreign regulatory authorities, may also slow the time necessary for the review and approval
of applications for clinical trial or marketing authorization, which would adversely affect our business. For example, in recent years,
including in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC,
had to furlough critical employees and stop critical activities. Additionally, action by the new Trump Administration to limit federal
agency budgets or personnel may result in reductions to the FDA&#8217;s budget, employees, and operations, which may lead to slower response
times and longer review periods, potentially affecting our ability to progress development of our product candidates or obtain regulatory
approval for our product candidates. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA
to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future
government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize
and continue our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">If
a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting
their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory
authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may face difficulties from legislative or regulatory reform measures.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
may be faced with additional or changing regulatory and governmental regulations that could prevent, limit or delay regulatory approval
of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation
or administrative or executive action, either in the United&#160;States or abroad. For example, the Trump Administration has discussed
several changes to the reach and oversight of the FDA, which could affect its relationship with the pharmaceutical industry, transparency
in decision making and ultimately the cost and availability of prescription drugs. If we are slow or unable to adapt to changes in existing
requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any
marketing approval that we may have obtained and we may not achieve or sustain profitability.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
price of pharmaceuticals has been a topic of considerable public discussion that could lead to price controls or other price-limiting
strategies by payors that have the effect of lowering payment and reimbursement rates for drugs or otherwise making the commercialization
of pharmaceuticals less profitable. Many federal and state legislatures have considered, and adopted, healthcare policies intended to
curb rising healthcare costs, such as the IRA. These cost-containment measures may include, among other measures: requirements for pharmaceutical
companies to negotiate prescription drug prices with government healthcare programs; controls on government-funded reimbursement for
drugs; new or increased requirements to pay prescription drug rebates to government healthcare programs, including if drug prices increase
at a higher rate than inflation; controls on healthcare providers; challenges to or limits on the pricing of drugs, including pricing
controls or limits or prohibitions on reimbursement for specific products through other means; requirements to try less expensive products
or generics before a more expensive branded product; and public funding for cost effectiveness research, which may be used by government
and private third-party payors to make coverage and payment decisions. Political, economic and regulatory developments may further complicate
developments in healthcare systems and pharmaceutical drug pricing. These developments could, for example, impact our potential licensing
agreements as commercial and collaborative partners may also consider the impact of these pressures on their licensing strategies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Any
new laws or regulations that have the effect of imposing additional costs or regulatory burden on pharmaceutical manufacturers, or otherwise
negatively affect the industry, could adversely affect our ability to successfully commercialize our product candidates. The implementation
of any price controls, caps on prescription drugs or price transparency requirements could adversely affect our business, operating results
and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors,
patient organizations and customers will be subject to applicable healthcare regulatory laws, including conflicts of interest rules,
which could expose us to penalties.&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party&#160;payors,
patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These
laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we
research, market, sell and distribute our product candidates, if approved. Principal investigators for our clinical trials may serve
as scientific advisors or consultants to us or may be affiliated with our other service providers, including CROs or site management
organizations, and from time to time may receive cash compensation in connection with such services. If these relationships and any related
compensation result in perceived or actual conflicts of interest, the integrity of the data generated at the applicable clinical trial
site or in the applicable trial may be questioned or jeopardized.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Ensuring
that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations
will involve costs and management attention. If our operations are found to be in violation of any of these laws or any other governmental
laws and regulations that may apply to it, we may be subject to significant penalties, including civil, criminal and administrative penalties,
damages, fines, exclusion from government-funded&#160;healthcare programs, integrity oversight and reporting obligations to resolve allegations
of&#160;non-compliance,&#160;disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the
curtailment or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming&#160;and
may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought
against us, our business may be impaired.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Even
if we are able to commercialize any product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement
policies, we may not be able to offer such product candidates at competitive prices, which would seriously harm our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
intend to seek approval to market our product candidates in the United&#160;States and in selected foreign jurisdictions, and we will
be subject to rules and regulations in those jurisdictions where we obtain approval. Our ability to successfully commercialize any product
candidates that we may develop will depend in part on the extent to which reimbursement for these product candidates and related treatments
will be available from government health administration authorities, private health insurers and other organizations. In some jurisdictions,
government authorities and other third-party&#160;payors decide which medications they will pay for and establish reimbursement levels,
and have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. These entities may
create preferential access policies for a competitor&#8217;s product, including a branded or generic/biosimilar product, over our products
in an attempt to reduce their costs, which may reduce our commercial opportunity. Additionally, if any of our product candidates are
approved and we are found to have improperly promoted off-label&#160;uses of those product candidates, we may become subject to significant
liability, which would materially adversely affect our business and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
are subject to U.S.&#160;and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering
laws and regulations. We can face criminal liability and other serious consequences for violations, which can harm our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
are subject to export control and import laws and regulations, including the U.S.&#160;Export Administration Regulations, U.S.&#160;Customs
regulations, various economic and trade sanctions regulations administered by the U.S.&#160;Treasury Department&#8217;s Office of Foreign
Assets Controls, the U.S.&#160;Foreign Corrupt Practices Act&#160;of&#160;1977, as amended, the U.S.&#160;domestic bribery statute contained
in 18 U.S.C. &#167; 201, the U.S.&#160;Travel Act, the USA PATRIOT Act, the U.S. Physician Payments Sunshine Act and other state and
national anti-bribery&#160;and anti-money&#160;laundering laws in the countries in which we conduct activities. Anti-corruption&#160;laws
are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising,
offering, or providing, directly or indirectly, improper payments or anything else of value to or from recipients in the public or private
sector. We may engage third parties to sell our products outside the United&#160;States, to conduct clinical trials, and/or to obtain
necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials
and employees of government agencies or government-affiliated&#160;hospitals, universities, and other organizations. We can be held liable
for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly
authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial
civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of
contract and fraud litigation, reputational harm, and other consequences.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Governments
outside the United&#160;States tend to impose strict price controls, which may adversely affect our revenue, if any.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
some countries, particularly member states of the EU (&#8220;EU Member States&#8221;), the pricing of prescription drugs is subject to
governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt
of marketing approval for a therapeutic. In addition, there can be considerable pressure by governments and other stakeholders on prices
and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further
complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used
by various EU Member States and parallel distribution, or arbitrage between&#160;low-priced&#160;and high-priced&#160;EU Member States,
can further reduce prices. To obtain coverage and reimbursement or pricing approvals in some countries, we or current or future collaborators
may be required to conduct a clinical trial or other studies that compare the cost-effectiveness&#160;of our product candidates to other
available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party&#160;payors
or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries.
If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at
unsatisfactory levels, our business, financial condition, results of operations or prospects could be materially and adversely affected.
If the UK or EU Member States were to significantly alter their regulations affecting the pricing of prescription pharmaceuticals, we
could face significant new costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Our Intellectual Property</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
ability to obtain and protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive
advantage.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
rely upon a combination of patents, trademarks, trade secret protection, confidentiality agreements and the Option and License Agreements
to protect the intellectual property related to our programs and technologies and to prevent third parties from competing unfairly with
it. Our success depends in large part on our ability to obtain and maintain patent protection for our programs and our product candidates
and their uses, as well as our ability to operate without infringing on or violating the proprietary rights of others. Paragon has filed,
on our behalf, provisional patent applications and we have filed non-provisional patent applications directed to antibodies that target
IL-23, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including
ORKA-001. In addition, Paragon has filed, on our behalf, provisional patent applications and we intend to file one or more additional
provisional patent applications directed to antibodies that target IL-17, including applications covering composition of matter, pharmaceutical
formulations, and methods of using such antibodies, including ORKA-002. However, we may not be able to protect our intellectual property
rights throughout the world and the legal systems in certain countries may not favor enforcement or protection of patents, trade secrets
and other intellectual property. Filing, prosecuting and defending patents on programs worldwide is expensive and our intellectual property
rights in some foreign jurisdictions can be less extensive than those in the United&#160;States; the reverse may also occur. As such,
we may not have patents in all countries or all major markets and may not be able to obtain patents in all jurisdictions even if we apply
for them. Our competitors may operate in countries where we do not have patent protection and can freely use our technologies and discoveries
in such countries to the extent such technologies and discoveries are publicly known or disclosed in countries where we do have patent
protection or pending patent applications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
pending and future patent applications may not result in patents being issued. Any issued patents may not afford sufficient protection
of our programs or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed,
designed around, invalidated by third parties, or effectively prevent others from commercializing competitive technologies, products
or programs. Even if these patents are granted, they may be difficult to enforce. Further, any issued patents that we may license or
own covering our programs could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies
in the United&#160;States or abroad, including the United&#160;States Patent and Trademark Office (&#8220;USPTO&#8221;). Further, if
we encounter delays in our clinical trials or delays in obtaining regulatory approval, the period of time during which we could market
our product candidates under patent protection would be reduced. Thus, the patents that we may own and license may not afford us any
meaningful competitive advantage.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition to seeking patents for some of our technology and programs, we may also rely on trade secrets, including unpatented&#160;know-how,&#160;technology
and other proprietary information, to maintain our competitive position. Any disclosure, either intentional or unintentional, by our
employees, the personnel of third parties with whom we share our facilities or third-party&#160;consultants and vendors that we engage
to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity
breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements,
thus eroding our competitive position in our market. In order to protect our proprietary technology and processes, we rely in part on
agreements, such as confidentiality agreements, with our vendors, collaborators, employees, consultants, outside scientific collaborators
and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of confidential information and
may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. We may need to share our proprietary
information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened
risk of theft of trade secrets, including through direct intrusion by private parties or state actors and those affiliated with or controlled
by state actors. In addition, while we undertake efforts to protect our trade secrets and other confidential information from disclosure,
others may independently discover trade secrets and proprietary information, and in such cases, we may not be able to assert any trade
secret rights against such party. Enforcing a claim that a party illegally obtained and is using our trade secrets is challenging and
the outcome is unpredictable. In addition, courts outside of the U.S. may be less willing to protect trade secrets. Costly and time-consuming&#160;litigation
could be necessary to enforce and determine the scope of our proprietary rights and failure to obtain or maintain trade secret protection
could adversely affect our competitive business position.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Lastly,
if our trademarks and trade names are not registered or adequately protected, then we may not be able to build name recognition in our
markets of interest and our business may be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may not be successful in obtaining or maintaining necessary rights to our programs through acquisitions and&#160;in-licenses.&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Because
our development programs currently do and may in the future require the use of proprietary rights held by third parties, the growth of
our business may depend in part on our ability to acquire,&#160;in-license,&#160;or use these third-party&#160;proprietary rights. It
is possible that we may be unable to obtain licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain
a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We may be unable to
acquire or&#160;in-license&#160;any compositions, methods of use, processes or other third-party&#160;intellectual property rights from
third parties that we identify as necessary for our programs. The licensing and acquisition of third-party&#160;intellectual property
rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party&#160;intellectual
property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due
to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive
us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party&#160;intellectual
property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully
obtain rights to required third-party&#160;intellectual property rights or maintain the existing intellectual property rights we do obtain,
we may have to abandon development of the relevant program, which could have a material adverse effect on our business, financial condition,
results of operations, and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">While
we plan to obtain the right to control prosecution, maintenance and enforcement of the patents relating to our programs, there may be
times when the filing and prosecution activities for patents and patent applications relating to our programs are controlled by our current
and future licensors or collaboration partners. If any of our current and future licensors or collaboration partners fail to prosecute,
maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, we could lose
our rights to the intellectual property or our exclusivity with respect to those rights, our ability to develop and commercialize those
product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products.
In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed to and from
third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensees, our future licensors and our
counsel that took place prior to the date upon which we assumed control over patent prosecution. Moreover, if other third parties have
ownership rights to our future in-licensed patents, they may be able to license such patents to our competitors, and our competitors
could market competing products and technology.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Failure
to obtain licenses at a reasonable cost or terms may require us to expend significant time and resources to redesign our technology,
programs, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on
a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates.
This could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Disputes
may arise between us and our future licensors regarding intellectual property subject to a license agreement, including: the scope of
rights granted under the license agreement and other interpretation-related&#160;issues; whether and the extent to which our technology
and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; our right to sublicense
patents and other rights to third parties; our right to transfer or assign the license; the inventorship and ownership of inventions
and&#160;know-how&#160;resulting from the joint creation or use of intellectual property by our future licensors and us and our partners;
and the priority of invention of patented technology.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may be subject to patent infringement claims or may need to file claims to protect our intellectual property, which could result in substantial
costs and liability and prevent us from commercializing our potential products.&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Because
the intellectual property landscape in the biopharmaceutical industry is rapidly evolving and interdisciplinary, it is difficult to conclusively
assess our freedom to operate and guarantee that we can operate without infringing on or violating third-party&#160;rights. Third party
patent rights, if found to be valid and enforceable, could be alleged to render one or more of our product candidates infringing. If
a third party successfully brings a claim against us, we may be required to pay substantial damages, be forced to abandon any affected
product candidate and/or seek a license from the patent holder. Any intellectual property claims brought against us, whether or not successful,
may cause us to incur significant legal expenses and divert the attention of our management and key personnel from other business concerns.
We cannot be certain that patents owned or licensed by us will not be challenged by others in the course of litigation. Some of our competitors
may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially
greater resources. In addition, any litigation could have a material adverse effect on our business and operations, including our ability
to raise funds.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Competitors
may infringe or otherwise violate our patents, trademarks, copyrights or other intellectual property. To counter infringement or other
violations, we may be required to file claims, which can be expensive and time-consuming, and any such claims could provoke these parties
to assert counterclaims against us. In addition, in a patent infringement proceeding, a court or administrative body may decide that
one or more of the patents we assert is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or
refuse to prevent the other party from using the technology at issue on the grounds that our patents do not cover the technology. Similarly,
if we assert trademark infringement claims, a court or administrative body may determine that the marks we have asserted are invalid
or unenforceable or that the party against whom we have asserted trademark infringement has superior rights to the marks in question.
In such a case, we could ultimately be forced to cease use of such marks. In any intellectual property litigation, even if we are successful,
any award of monetary damages or other remedy we receive may not be commercially valuable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Further,
we may be required to protect our patents through procedures created to attack the validity of a patent at the USPTO.&#160;An adverse
determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which
could adversely affect our competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary
standard in U.S.&#160;federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO
proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim
if first presented in a district court action.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition, if our programs are found to infringe the intellectual property rights of third parties, these third parties may assert infringement
claims against our future licensees and other parties with whom we have business relationships and we may be required to indemnify those
parties for any damages they suffer as a result of these claims, which may require us to initiate or defend protracted and costly litigation
on behalf of licensees and other parties regardless of the merits of such claims. If any of these claims succeed, we may be forced to
pay damages on behalf of those parties or may be required to obtain licenses for the products they use.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings
relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure
during this type of litigation or other proceedings.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may be subject to claims that we have wrongfully hired an employee from a competitor or that our employees, consultants or independent
contractors have wrongfully used or disclosed confidential information of third parties.&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
is common in the biopharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the
development of our programs. Many of these consultants, and many of our employees, were previously employed at, or may have previously
provided or may be currently providing consulting services to, other biotechnology or pharmaceutical companies including our competitors
or potential competitors. We could in the future be subject to claims that we, our employees or our consultants have inadvertently or
otherwise used or disclosed alleged intellectual property, such as trade secrets, or other confidential information of former employers
or competitors. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information,&#160;know-how&#160;or
trade secrets of others in their work for us, we may become subject to claims that we caused an individual to breach the terms of his
or her&#160;non-competition&#160;or&#160;non-solicitation&#160;agreement, or that we or these individuals have, inadvertently or otherwise,
used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">While
we may litigate to defend ourselves against these claims, even if we are successful, litigation could result in substantial costs and
could be a distraction to management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court
could prohibit us from using technologies or features that are essential to our programs, if such technologies or features are found
to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation
or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators,
engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results
of operations and financial condition. Even if we are successful in defending against such claims, litigation could result in substantial
costs and be a distraction to management.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Changes
to patent laws in the United&#160;States and other jurisdictions could diminish the value of patents in general, thereby impairing our
ability to protect our products.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Changes
in either the patent laws or interpretation of patent laws in the United&#160;States and foreign jurisdictions could increase the uncertainties
and costs surrounding the prosecution of our owned and&#160;in-licensed&#160;patent applications and the maintenance, enforcement or
defense of our owned and&#160;in-licensed&#160;issued patents. Additionally, there have been proposals for additional changes to the
patent laws of the United States and other countries that, if adopted, could impact our ability to enforce our proprietary technology.
This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending
on future actions by the U.S. Congress, the federal courts, the USPTO and the relevant law-making bodies in other countries, the laws
and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and
our ability to protect, defend and enforce our patent rights in the future. In addition, geopolitical instability could increase the
uncertainties and costs surrounding the prosecution or maintenance of patent applications and the maintenance, enforcement or defense
of issued patents.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. U.S.&#160;Supreme
Court and U.S.&#160;Court of Appeals for the Federal Circuit rulings have narrowed the scope of patent protection available in certain
circumstances and weakened the rights of patent owners in certain situations, including in the antibody arts. For example, the United&#160;States
Supreme Court in&#160;Amgen, Inc. v. Sanofi&#160;(Amgen) stated that if patent claims are directed to an entire class of compositions
of matter, then the patent specification must enable a person skilled in the art to make and use the entire class of compositions. This
decision makes it unlikely that we will be granted U.S.&#160;patents with composition of matter claims directed to antibodies functionally
defined by their ability to bind a particular antigen. Even if we are granted claims directed to functionally defined antibodies, it
is possible that a third party may challenge our patents, when issued, relying on the reasoning in&#160;Amgen&#160;or other recent precedential
court decisions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition, a European Unified Patent Court (&#8220;UPC&#8221;) entered into force on June&#160;1, 2023. The UPC is a common patent court
that hears patent infringement and revocation proceedings effective for EU Member States. This could enable third parties to seek revocation
of a European patent in a single proceeding at the UPC rather than through multiple proceedings in each of the jurisdictions in which
the European patent is validated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Although
we do not currently own any European patents or applications, if we obtain such patents and applications in the future, any such revocation
and loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology
and products. Moreover, the controlling laws and regulations of the UPC will develop over time, and may adversely affect our ability
to enforce or defend the validity of any European patents we may obtain. We may decide to opt out from the UPC any future European patent
applications that we may file and any patents we may obtain. If certain formalities and requirements are not met, however, such European
patents and patent applications could be challenged for&#160;non-compliance&#160;and brought under the jurisdiction of the UPC.&#160;We
cannot be certain that future European patents and patent applications will avoid falling under the jurisdiction of the UPC, if we decide
to opt out of the UPC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Obtaining
and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for&#160;non-compliance&#160;with these
requirements.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Periodic
maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be
paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO
and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other
similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late
fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment
or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.&#160;Non-compliance&#160;events
that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official
actions within prescribed time limits,&#160;non-payment&#160;of fees and failure to properly legalize and submit formal documents. If
we fail to maintain the patents and patent applications covering our programs, our competitive position would be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent,
which might adversely affect our ability to develop and market our products.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims
or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party&#160;patent
and pending application in the United&#160;States and abroad that is relevant to or necessary for the commercialization of our product
candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in
a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application
may be incorrect. For example, we may incorrectly determine that our products are not covered by a third-party&#160;patent or may incorrectly
predict whether a third-party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration
date of any patent in the United&#160;States or abroad that we consider relevant may be incorrect. Our failure to identify and correctly
interpret relevant patents may negatively impact our ability to develop and market our products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition, because some patent applications in the United&#160;States may be maintained in secrecy until the patents are issued, patent
applications in the United&#160;States and many foreign jurisdictions are typically not published until 18&#160;months after filing,
and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent
applications for technology covered by our issued patents or our pending applications, or that we were the first to invent the technology.
Our competitors may have filed, and may in the future file, patent applications covering products or technology similar to ours. Any
such patent application may have priority over our patent applications or patents, which could require us to obtain rights to issued
patents covering such technologies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual
property as an inventor or&#160;co-inventor.&#160;The failure to name the proper inventors on a patent application can result in the
patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different
individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter
of the patent, conflicting obligations of third parties involved in developing our programs or as a result of questions regarding&#160;co-ownership&#160;of
potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership.
Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we
fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as
exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our
business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management and other employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Patent
terms may be inadequate to protect the competitive position of our product candidates for an adequate amount of time.&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Patents
have a limited lifespan. In the United&#160;States, if all maintenance fees are timely paid, the natural expiration of a patent is generally
20&#160;years from its earliest United&#160;States&#160;non-provisional&#160;filing date. Various extensions may be available, but the
life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent
life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time
required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might
expire before or shortly after such product candidates are commercialized. As a result, our owned and licensed patent portfolio may not
provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
technology licensed from various third parties may be subject to retained rights.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
future licensors may retain certain rights under the relevant agreements with us, including the right to use the underlying technology
for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make
customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors
limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology
in the event of misuse.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition, our future licensors may rely on third-party&#160;consultants or collaborators or on funds from third parties, such as the
U.S.&#160;government, such that our licensors would not be the sole and exclusive owners of any patents we&#160;in-license.&#160;If other
third parties have ownership rights or other rights to our&#160;in-licensed&#160;patents, they may be able to license such patents to
our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our
competitive position, business, financial conditions, results of operations, and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Our Reliance on Third Parties</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
currently rely on licensing arrangements with Paragon through the License Agreements. If we are unable to maintain collaborations or
licensing arrangements, or if our collaborations or licensing arrangements are not successful, our business could be negatively impacted.&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
currently rely on our licensing arrangements with Paragon through the License Agreements for a substantial portion of our in-licenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Collaborations
or licensing arrangements that we enter into may not be successful, and any success will depend heavily on the efforts and activities
of such collaborators or licensors. If any of our current or future collaborators or licensors experience delays in performance of, or
fails to perform our obligations under their agreement with us, disagrees with our interpretation of the terms of such agreement or terminates
their agreement with us, the research programs with respect to which we have the option to acquire intellectual property license rights
to pursuant to the Option Agreements, the licensing agreements we have pursuant to the License Agreements and our development timeline
could be adversely affected. If we fail to comply with any of the obligations under our collaborations or license agreements, including
payment terms and diligence terms, our collaborators or licensors may have the right to terminate such agreements, in which event we
may lose intellectual property rights and may not be able to develop, manufacture, market or sell the products covered by our agreements
or may face other penalties under our agreements. Our collaborators and licensors may also fail to properly maintain or defend the intellectual
property we have licensed from them, if required by our agreement with them, or even infringe upon, our intellectual property rights,
leading to the potential invalidation of our intellectual property or subjecting us to litigation or arbitration, any of which would
be time-consuming&#160;and expensive and could harm our ability to commercialize our product candidates. In addition, collaborators could
independently develop, or develop with third parties, products that compete directly or indirectly with our programs and products if
the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms
that are more economically attractive than ours.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
part of our strategy, we plan to evaluate additional opportunities to enhance our capabilities and expand our development pipeline or
provide development or commercialization capabilities that complement ours. We may not realize the benefits of such collaborations, alliances
or licensing arrangements. Any of these relationships may require us to incur&#160;non-recurring&#160;and other charges, increase our
near and long-term&#160;expenditures, issue securities that dilute our existing stockholders or disrupt our management and business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
may face significant competition in attracting appropriate collaborators, and more established companies may also be pursuing strategies
to license or acquire third-party&#160;intellectual property rights that we consider attractive. These companies may have a competitive
advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition,
companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Whether we reach a definitive agreement
for a collaboration will depend upon, among other things, our assessment of the collaborator&#8217;s resources and expertise, the terms
and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Collaborations
are complex and time-consuming&#160;to negotiate, document and execute. In addition, consolidation among large pharmaceutical and biotechnology
companies has reduced the number of potential future collaborators. We may not be able to negotiate collaborations on a timely basis,
on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the
necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to
market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
currently rely, and plan to rely in the future, on third parties to conduct and support our preclinical studies and clinical trials.
If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be
able to obtain regulatory approval of or commercialize our product candidates.&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
have utilized and plan to continue to utilize and depend upon independent investigators and collaborators, such as medical institutions,
CROs, contract testing labs, CMOs and strategic partners, to supply, conduct and support our preclinical studies and clinical trials
under agreements with us. We will rely heavily on these third parties over the course of our preclinical studies and clinical trials,
and we control only certain aspects of their activities. As a result, we will have less direct control over the conduct, timing and completion
of these preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials
than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our
studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance
on these third parties does not relieve us of our regulatory responsibilities. We and our third-party&#160;contractors and CROs are required
to comply with GCP regulations, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities
for all of our programs in clinical development. If we or any of these third parties fail to comply with applicable GCP regulations,
the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities
may require us to perform additional clinical trials before approving our marketing applications or refuse to approve our marketing applications.
We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical
trials comply with GCP regulations. In addition, our clinical trials must be conducted with products produced under cGMP regulations.
Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.
Moreover, our business may be implicated if any of these third parties violate federal or state fraud and abuse or false claims laws
and regulations or healthcare privacy and security laws.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Any
third parties conducting our clinical trials will not be our employees and, except for remedies available to us under our agreements
with such third parties, we cannot control whether they devote sufficient time and resources to our programs. These third parties may
have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or
other product development activities, which could negatively affect their performance on our behalf and the timing thereof and could
lead to products that compete directly or indirectly with our product candidates. If these third parties do not successfully carry out
their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the
clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other
reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory
approval of or successfully commercialize our product candidates.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
currently rely and expect to rely in the future on the use of manufacturing suites in third-party facilities or on third parties to manufacture
our product candidates, and we may rely on third parties to produce and process our products, if approved. Our business could be adversely
affected if we are unable to use third-party manufacturing suites or if the third-party manufacturers encounter difficulties in production.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
do not currently own any facility that may be used as our clinical or commercial manufacturing and processing facility and must currently
rely on CMOs to manufacture our product candidates. We have not yet caused any product candidates to be manufactured on a commercial
scale and may not be able to do so for any of our product candidates, if approved. We currently have a sole source relationship for our
supply of the ORKA-001&#160;and ORKA-002&#160;programs. If there should be any disruption in such supply arrangement, including any adverse
events affecting our sole supplier, it could have a negative effect on the clinical development of our programs and other operations
while we work to identify and qualify an alternate supply source. We may not control the manufacturing process of, and may be completely
dependent on, our contract manufacturing partners for compliance with cGMP requirements and any other regulatory requirements of the
FDA or comparable foreign regulatory authorities for the manufacture of our product candidates. Beyond periodic audits, we have limited
control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a
comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws
any approval in the future, we may need to find alternative manufacturing facilities, which would require the incurrence of significant
additional costs, delays, and materially adversely affect our ability to develop, obtain regulatory approval for or market our product
candidates, if approved. Similarly, our failure, or the failure of our CMOs, to comply with applicable regulations could result in sanctions
being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation,
seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly
and adversely affect supplies of our product candidates or drugs and harm our business and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Moreover,
our CMOs may experience manufacturing difficulties due to resource constraints, supply chain issues, proposed or actual legislative changes
or requirements, or as a result of labor disputes or unstable political environments. If any CMOs on which we will rely fail to manufacture
quantities of our product candidates at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated
demand at a cost that allows us to achieve profitability, our business, financial condition and prospects could be materially and adversely
affected. In addition, our CMOs are responsible for transporting&#160;temperature-controlled&#160;materials that can be inadvertently
degraded during transport due to several factors, rendering certain batches unsuitable for trial use for failure to meet, among others,
our integrity and purity specifications. We and any of our CMOs may also face product seizure or detention or refusal to permit the import
or export of products. Our business could be materially adversely affected by business disruptions to our third-party&#160;providers
that could materially adversely affect our anticipated timelines, potential future revenue and financial condition and increase our costs
and expenses. Each of these risks could delay or prevent the completion of our preclinical studies and clinical trials or the approval
of any of our product candidates by the FDA, result in higher costs or adversely impact commercialization of our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Foreign
CMOs may be subject to U.S.&#160;legislation, including the proposed BIOSECURE bill, trade restrictions and other foreign regulatory
requirements, which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such
material or have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies.
We currently rely on foreign CROs and CMOs, including WuXi Biologics (Hong&#160;Kong) Limited and its affiliates (&#8220;WuXi Biologics&#8221;)
and will likely continue to rely on foreign CROs and CMOs in the future. WuXi Biologics is identified in the U.S. legislation known as
the BIOSECURE Act, which was proposed in the 118<sup>th</sup> Congress, as a &#8220;biotechnology company of concern.&#8221; The version
of the BIOSECURE Act introduced in the U.S. House of Representatives during the 118<sup>th</sup> Congress would prohibit federal agencies
from entering into procurement contracts with, as well as providing grants and loans to, an entity that uses biotechnology equipment
or services from a biotechnology company of concern, and includes a grandfathering provision allowing biotechnology equipment and services
provided or produced by named &#8220;biotechnology companies of concern&#8221; under a contract or agreement entered into before the
effective date until January 1, 2032. The pathway and timing for the BIOSECURE Act or its provisions to become law are uncertain. Depending
on whether the BIOSECURE Act becomes law, what the final language of the BIOSECURE Act includes, and how the law is interpreted by U.S.
federal agencies, we could be potentially restricted from pursuing U.S. federal government business or grants in the future if we continue
to use WuXi or other parties identified as &#8220;biotechnology companies of concern&#8221; beyond the grandfathering period.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
our operations and financial condition may be negatively impacted as a result of any delays or increased costs arising from the trade
restrictions and other foreign regulatory requirements affecting such collaborators. In addition, while we have established relationships
with CROs and CMOs outside of China, moving to those suppliers in the event of geopolitical instability affecting our collaborators in
China could introduce delays into the development program.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Employee Matters, Managing Growth and Other Risks Related to Our Business</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>In
order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties
in managing this growth.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of
preclinical and clinical drug development, technical operations, clinical operations, regulatory affairs and, potentially, sales and
marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial
personnel and systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial
resources and the limited experience of our management team working together in managing a company with such anticipated growth, we may
not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining
highly qualified personnel, we may not be able to successfully implement our business strategy.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
ability to pursue our growth strategy will be limited if we are unable to continue to attract and retain high quality personnel. We have
been and will continue to be highly dependent on the research and development, clinical and business development expertise of our executive
officers, as well as the other principal members of our management, scientific and clinical team. Any of our management team members
may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or
other employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Attracting
and retaining qualified personnel will also be critical to our success, including with respect to any strategic transaction that we may
pursue. The loss of our executive officers or other key employees could impede the achievement of our research, development and commercialization
objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers
and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry
with the breadth of skills and experience required to successfully develop, facilitate regulatory approval of and commercialize product
candidates. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key
personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel,
as well as from universities and research institutions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition, we rely on consultants and advisors to assist us in formulating our discovery and nonclinical and clinical development and
commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting
or advisory contracts with other entities that may limit their availability to us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens
and other risks and uncertainties.&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets for which we
may rely on collaboration with third parties. If we fail to comply with the regulatory requirements in foreign markets and receive applicable
marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates
will be harmed and our business will be adversely affected. Moreover, even if we obtain approval of our product candidates and ultimately
commercialize our product candidates in foreign markets, we would be subject to the risks and uncertainties, including the burden of
complying with complex and changing foreign regulatory, tax, accounting and legal requirements and reduced protection of intellectual
property rights in some foreign countries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete
achieve the forecasted growth, our business may not grow at similar rates, or at all.&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that
may not prove to be accurate. Even if the markets in which we compete meet our size estimates and growth forecasts, our business may
not grow at similar rates, or at all.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted
price for the product, the ability to obtain coverage and reimbursement and whether we own the commercial rights for that territory.
If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is
narrower than we expect or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not
generate significant revenue from sales of such products, even if approved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors
may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators,
CROs, CMOs, suppliers and vendors acting for or on our behalf may engage in misconduct or other improper activities. We have adopted
a code of conduct and ethics, but it is not always possible to identify and deter misconduct by these parties and the precautions we
take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us
from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
internal information technology systems, or those of any of our third-party service providers, or potential future collaborators, may
fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary
or confidential data, employee data or personal data, which could result in additional costs, loss of revenue, significant liabilities,
harm to our brand and material disruption of our operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
the ordinary course of our business, we and the third parties upon which we rely collect, receive, store, process, generate, use, transfer,
disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) proprietary, confidential, and sensitive
data, including personal data, intellectual property, trade secrets, and other sensitive data (collectively, sensitive information).
If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we
may experience adverse consequences. While we have implemented security measures designed to protect against security incidents, there
can be no assurance that these measures will be effective. Further, cybersecurity breaches or other cybersecurity incidents may allow
hackers access to our preclinical compounds, strategies, discoveries, trade secrets, and/or other confidential information. Additionally,
sensitive data could be leaked, disclosed, or revealed as a result of or in connection with our employees&#8217;, personnel&#8217;s,
vendors&#8217; or partners&#8217; use of generative AI technologies. Our ability to monitor third parties&#8217; information security
practices is limited, and these third parties may not have adequate security measures in place. We may be unable in the future to detect
vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated
in nature, and may not be detected until after a security incident has occurred. Further, we may experience delays in developing and
deploying remedial measures designed to address any such identified vulnerabilities. Applicable data privacy and security obligations
may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosure or the failure
to comply with such requirements could lead to adverse consequences. Moreover, while we may be entitled to damages if our third-party
service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient or we may be unable
to recover such award. Security incidents and attendant consequences may negatively impact our ability to grow and operate our business.
The risk of a cybersecurity incident or other informational technology disruption, particularly through cyber-attacks, has generally
increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">To
the extent that any disruption or security breach were to result in loss, destruction, unavailability, alteration or dissemination of,
or damage to, our data (including clinical trial data) or applications, or for it to be believed or reported that any of these occurred,
we could incur liability, including under laws and regulations governing the protection of protected health information and other personal
data, and reputational damage and the development and commercialization of our product candidates could be delayed. Further, our insurance
policies may not be adequate to compensate us for the potential losses arising from any such disruption in, or failure or security breach
of, our systems or third-party&#160;systems where information important to our business operations or commercial development is stored.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Despite
the implementation of security measures in an effort to protect systems that store our information, given their size and complexity and
the increasing amounts of information maintained on our internal information technology systems and those of our third-party&#160;CROs,
contractors (including sites performing our clinical trials), third-party&#160;service providers and supply chain companies, and consultants,
these systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction,
natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional
actions or from cyber-attacks&#160;by malicious third parties, or ransomware attacks, which, in each case, may compromise our system
infrastructure or lead to the loss, destruction, alteration or dissemination of, or damage to, our data.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
hybrid-remote&#160;workforce may create additional risks for our information technology systems and data because our employees work remotely
and utilize network connections, computers, and devices working at home, while in transit and in public locations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in
our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.
We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out
of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or
that such coverage will pay future claims.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
are subject to stringent and changing laws, regulations and standards, and contractual obligations relating to privacy, data protection,
and data security. The actual or perceived failure to comply with such obligations could lead to government enforcement actions (which
could include civil or criminal penalties), fines and sanctions, private litigation and/or adverse publicity and could negatively affect
our operating results and business.&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
and third parties who we work with are or may become subject to numerous domestic and foreign laws, regulations, and standards relating
to privacy, data protection, data transfer, and data security, the scope of which is changing, subject to differing applications and
interpretations, and may be inconsistent among countries, or conflict with other rules. We are or may become subject to the terms of
contractual obligations related to privacy, data protection and data security. Our obligations may also change or expand as our business
grows. The actual or perceived failure by us or third parties related to us to comply with such laws, regulations and obligations could
increase our compliance and operational costs, expose us to regulatory scrutiny, actions, fines and penalties, result in reputational
harm, lead to a loss of customers, result in litigation and liability, and otherwise cause a material adverse effect on our business,
financial condition, and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur
costs that could have a material adverse effect on the success of our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the
handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations may involve the use of hazardous and
flammable materials, including chemicals and biological and radioactive materials. In addition, we may incur substantial costs in order
to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations
may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result
in substantial fines, penalties or other sanctions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
rules dealing with U.S.&#160;federal, state and local income taxation are constantly under review by persons involved in the legislative
process and by the Internal Revenue Service and the U.S.&#160;Treasury Department. Changes to tax laws (which may have retroactive application)
could adversely affect our stockholders or us. We continue to assess the impact of various tax reform proposals and modifications to
existing tax treaties in all jurisdictions where we have operations or employees to determine the potential effect on our business and
any assumptions we make about our future taxable income. We cannot predict whether any specific proposals will be enacted, the terms
of any such proposals or what effect, if any, such proposals would have on our business if they were to be enacted. For example, the
United&#160;States enacted the IRA, which implements, among other changes, a 1% excise tax on certain stock buybacks. In addition, beginning
in 2022, the Tax Cuts and&#160;Jobs Act&#160;eliminated the previously available option to deduct research and development expenditures
and requires taxpayers to amortize them generally over five&#160;years for research activities conducted in the United&#160;States and
over 15&#160;years for research activities conducted outside the United&#160;States. Such changes, among others, may adversely affect
our effective tax rate, results of operation and general business condition.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that we believe
will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able
to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and
company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new product candidates or products
resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business.
There is no assurance that, following any such acquisition, we will achieve the synergies expected in order to justify the transaction,
which could result in a material adverse effect on our business and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
maintain our cash at financial institutions, often in balances that exceed federally-insured limits. The failure of financial institutions
could adversely affect our ability to pay our operational expenses or make other payments.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
cash held in&#160;non-interest-bearing&#160;and interest-bearing&#160;accounts exceeds the Federal Deposit Insurance Corporation insurance
limits. If such banking institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance limitations.
In addition, even if account holders are ultimately made whole with respect to a future bank failure, account holders&#8217; access to
their accounts and assets held in their accounts may be substantially delayed. Any material loss that we may experience in the future
or inability for a material time period to access our cash and cash equivalents could have an adverse effect on our ability to pay our
operational expenses or make other payments, which could adversely affect our business.&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>General
Risk Factors&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
estimates&#160;of market&#160;opportunity&#160;and forecasts&#160;of market&#160;growth may&#160;prove&#160;to be inaccurate,&#160;and
even if the markets&#160;in which we compete&#160;achieve&#160;the forecasted&#160;growth, our business&#160;may&#160;not grow at similar&#160;rates,
or at all.&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that
may not prove to be accurate. Even if the markets in which we compete meet our size estimates and growth forecasts, our business may
not grow at similar rates, or at all. Our growth is subject to many factors, including our success in implementing our business strategy,
which is subject to many risks and uncertainties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted
price for the product, the ability to obtain coverage and reimbursement and whether we own the commercial rights for that territory.
If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is
narrower than we expect or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not
generate significant revenue from sales of such products, even if approved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may become exposed to costly and damaging liability claims, either when testing a product candidate in the clinical or at the commercial
stage, and our insurance may not cover all damages from such claims.</i></b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing,
marketing, and use of pharmaceutical products. The use of a product candidate in clinical trials and the sale of any approved products
in the future may expose us to liability claims. An individual or group of individuals may bring a liability claim against us if one
of our product candidates causes, or merely appears to have caused, an injury. Any claims against us, regardless of their merit, could
be difficult and costly to defend and could materially and adversely affect our business. While we carry product liability insurance
for our clinical trials, it is possible that any liabilities could exceed our insurance coverage or that in the future we may not be
able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability
that may arise. On occasion, large judgments have been awarded in class action or individual lawsuits. A successful product liability
claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage,
could decrease our cash and our business operations could be impaired.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Litigation
costs and the outcome of litigation could have a material adverse effect on our business.&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">From
time to time&#160;we&#160;may&#160;be&#160;subject&#160;to&#160;litigation&#160;claims through the ordinary course of our business operations
regarding, but not limited to, employment matters, security of patient and employee personal information, contractual relations with
collaborators and intellectual property rights. Litigation to defend ourselves against claims by third parties, or to enforce any rights
that we may have against third parties, may continue to be necessary, which could result in substantial costs and diversion of our resources,
causing a material adverse effect on our business, financial condition, results of operations or cash flows.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
business could be adversely affected by economic downturns, inflation, fluctuation in interest rates, natural disasters, public health
crises, political crises, geopolitical events or other macroeconomic conditions, which could have a material and adverse effect on our
results of operations and financial condition.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
global economy, including credit and financial markets, has experienced and may experience in the future extreme volatility and disruptions,
including, among other things, diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth,
supply chain shortages, new or increased tariffs and other barriers to trade, trade and other international disputes, increases in inflation
rates, fluctuation in interest rates, slower growth or recession, tighter credit, volatility in financial markets, high unemployment,
labor availability constraints, public health crises, significant natural disasters, including as a result of climate change, changes
to fiscal and monetary policy or government budget dynamics (particularly in the pharmaceutical and biotech areas), particularly in the
pharmaceutical and biotech areas, political and military conflict, and uncertainty about economic stability. Fluctuation in interest
rates, coupled with reduced government spending and volatility in financial markets, may increase economic uncertainty and affect consumer
spending. Similarly, the ongoing military conflict between Russia and Ukraine and in the Middle East and rising tensions with China have
created extreme volatility in the global capital markets and may have further global economic consequences, including disruptions of
the global supply chain. Any such volatility and disruptions may adversely affect our business or the third parties on whom we rely.
If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity
financing more costly, more dilutive, or more difficult to obtain in a timely manner or on favorable terms, if at all. Increased inflation
rates can adversely affect us by increasing our costs, including materials, operational, labor and employee benefit costs.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
may in the future experience disruptions as a result of such macroeconomic conditions, including delays or difficulties in initiating
or expanding clinical trials and manufacturing sufficient quantities of materials. Any one or a combination of these events could have
a material and adverse effect on our results of operations and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Geopolitical
events and global economic conditions may also affect the ability of the FDA and other regulatory authorities to perform routine functions.
If such concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory
activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory
submissions, which could have a material adverse effect on our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Owning Our Stock</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>The
market price of our common stock has been, and may continue to be volatile.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
market price of our common stock has been and is likely to be highly volatile and is subject to significant fluctuations. Some of the
factors that may cause the market price of our common stock to fluctuate include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">timing
                                            and results of clinical trials and preclinical studies of our product candidates, or those
                                            of our competitors or our existing or future collaborators;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">failure
                                            to meet or exceed financial and development projections that we may provide to the public;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">announcements
                                            of significant or potential equity or debt sales by us;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">actions
                                            taken by regulatory agencies with respect to our product candidates, clinical studies, manufacturing
                                            process or sales and marketing terms;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">failure
                                            to meet or exceed the financial and development projections of the investment community or
                                            if securities or industry analysts do not publish research or reports about our business,
                                            or if they issue adverse or misleading opinions regarding our business and stock;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">announcements
                                            of significant acquisitions, strategic collaborations, joint ventures or capital commitments
                                            by us or our competitors;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">general
                                            market, macroeconomic or geopolitical conditions or market conditions in the pharmaceutical
                                            and biotechnology sectors;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">disputes
                                            or other developments relating to proprietary rights, including patents, litigation matters,
                                            and our ability to obtain patent protection for our technologies;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">additions
                                            or departures of key personnel, including scientific or management personnel;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">significant
                                            lawsuits, including patent or stockholder litigation;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">changes
                                            in the market valuations of similar companies;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">sales
                                            of securities by us or our securityholders in the future;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">if
                                            we fail to raise an adequate amount of capital to fund our operations or continued development
                                            of our product candidates;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">trading
                                            volume of our common stock;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">announcements
                                            by competitors of new products, clinical progress or lack thereof, significant contracts,
                                            commercial relationships or capital commitments;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            introduction of technological innovations or new therapies that compete with our products;
                                            and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">period-to-period
                                            fluctuations in our financial results.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Moreover,
the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual
companies. These broad market fluctuations may also adversely affect the trading price of our common stock. In addition, a recession,
depression or other sustained adverse market event could materially and adversely affect our business and the value of our common stock.
In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted
class action securities litigation against such companies.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
market volatility may lead to securities litigation or increased stockholder activism if we experience a market valuation that activists
believe is not reflective of our intrinsic value. Activist campaigns that contest or conflict with our strategic direction or seek changes
in the composition of our board of directors could have an adverse effect on our operating results, financial condition and cash flows.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
certificate of incorporation and bylaws, as well as provisions under Delaware law, could make an acquisition of the company more difficult
and may prevent attempts by our stockholders to replace or remove management.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Provisions
in our certificate of incorporation and bylaws may discourage, delay or prevent a merger, acquisition or other change in control of the
company that stockholders may consider favorable, including transactions in which our common stockholders might otherwise receive a premium
price for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of
our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible
for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace
or remove current management by making it more difficult for stockholders to replace members of our board of directors. Among other things,
these provisions:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">establish
                                            a classified board of directors such that all members of the board are not elected at one
                                            time;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">allow
                                            the authorized number of our directors to be changed only by resolution of our board of directors;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">limit
                                            the manner in which stockholders can remove directors from the board;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">establish
                                            advance notice requirements for nominations for election to the board of directors or for
                                            proposing matters that can be acted on at stockholder meetings;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">require
                                            that stockholder actions must be effected at a duly called stockholder meeting and prohibit
                                            actions by our stockholders by written consent;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">limit
                                            who may call a special meeting of stockholders;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">authorize
                                            our board of directors to issue preferred stock without stockholder approval, which could
                                            be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership
                                            of a potential hostile acquirer, effectively preventing acquisitions that have not been approved
                                            by our board of directors; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">require
                                            the approval of the holders of at least 66 2/3% of the votes that all stockholders would
                                            be entitled to cast to amend or repeal certain provisions of our charter or bylaws.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Moreover,
because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law (&#8220;DGCL&#8221;),
which prohibits stockholders owning more than 15% of our outstanding voting stock from merging or combining with us. Although we believe
these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirors to negotiate with
our board of directors, they would apply even if the offer may be considered beneficial by some stockholders.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
governing documents provide that, unless we consent in writing to the selection of an alternative forum, certain designated courts will
be the sole and exclusive forum for certain legal actions between us and our stockholders, which could limit our stockholders&#8217;
ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
governing documents provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware
is the sole and exclusive forum for state law claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action
asserting a claim of or based on a breach of a fiduciary duty owed by any of our current or former directors, officers, or other employees
or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL, the certificate of incorporation
or the bylaws, (iv) any action to interpret, apply, enforce or determine the validity of the certificate of incorporation or bylaws,
or (v) any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery
having personal jurisdiction over the indispensable parties named as defendants therein, which for purposes of this risk factor refers
to herein as the &#8220;Delaware Forum Provision.&#8221; Our governing documents further provide that, unless we consent in writing to
an alternative forum, the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting
a cause of action arising under the Securities Act, which for purposes of this risk factor refers to herein as the &#8220;Federal Forum
Provision.&#8221; Neither the Delaware Forum Provision nor the Federal Forum Provision will apply to any causes of action arising under
the Exchange Act. In addition, any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will
be deemed to have notice of and consented to the foregoing Delaware Forum Provision and Federal Forum Provision; provided, however, that
stockholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations
thereunder.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Delaware Forum Provision and the Federal Forum Provision may impose additional litigation costs on our stockholders in pursuing any such
claims, particularly if such stockholders do not reside in or near the State of Delaware. Additionally, these forum selection clauses
may limit our stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors,
officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action,
if successful, might benefit our stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Future
sales of shares by existing stockholders could cause our stock price to decline.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">If
our stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after legal restrictions
on resale lapse, the trading price of our common stock could decline. In addition, shares of our common stock that are subject to our
outstanding options will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements
and Rules 144 and 701 under the Securities Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
do not anticipate that we will pay any cash dividends in the foreseeable future.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
do not anticipate that we will pay any cash dividends in the foreseeable future. The current expectation is that we will retain our future
earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock
will be your sole source of gain, if any, for the foreseeable future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted
to our stockholders for approval.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
executive officers, directors and principal stockholders beneficially own a significant percentage of our outstanding common stock. As
a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters
submitted to our stockholders for approval, as well as our management and affairs. For example, these stockholders, if they choose to
act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of
all or substantially all of our assets. This concentration of voting power could delay or prevent our acquisition on terms that other
stockholders may desire.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
equity research analysts do not publish research or reports, or publish unfavorable research or reports about us, our business or our
market, our stock price and trading volume could decline.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
trading market for our common stock will be influenced by the research and reports that equity research analysts publish about us and
our business. Equity research analysts may elect to not provide research coverage of our common stock, and such lack of research coverage
may adversely affect the market price of our common stock. If we do have equity research analyst coverage, we will not have any control
over the analysts or the content and opinions included in their reports. The price of our common stock could decline if one or more equity
research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases
coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our
stock price or trading volume to decline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
1B. Unresolved Staff Comments. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">None.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
1C. Cybersecurity.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="ixv-6294"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
collect, use, store, and transmit confidential, sensitive, proprietary, personal, and health-related information in the ordinary course
of our business. As such, we leverage third-party information technology service providers who have implemented and maintain various
information security processes designed to identify, assess, and manage material risks from cybersecurity threats to our information
technology systems, including critical computer networks, third party hosted services, communications systems, hardware and software,
and our data residing on these systems. Our Senior Vice President, Finance is responsible for overseeing these third-party service providers
and processes.</span></p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><ix:continuation id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Cybersecurity
risks are identified by monitoring and evaluating our threat environment, and then assessed by various methods, for example, by manual
and automated tools designed to identify and combat cybersecurity threats, analyzing reports of threats, conducting scans and assessments
of the threat environment and to identify vulnerabilities, the use of detection and response services and conducting reviews of third-party
service providers, among other things. Depending on the threat environment, we implement and maintain various technical, physical, and
organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats
to our information systems and data, including, for example, physical security and access controls, asset management, systems monitoring,
incident detection and response, risk assessment, the implementation of security standards and certifications, encryption of data, network
security controls, and a recovery/business continuity plan, among other mitigation tactics. Our recovery/business continuity plan is
designed to mitigate and remediate identified cybersecurity incidents and escalate certain incidents as appropriate to management and
the Audit Committee. We plan to conduct due diligence on and audits of key technology vendors, contract research organizations, and other
third-party contractors and suppliers. Additionally, we conduct periodic employee training that covers cyber and information security,
among other topics.</span></p></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="ixv-24157"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="ixv-24158">Our assessment and management
of material risks from cybersecurity threats are integrated into the Company&#8217;s overall risk management process.</ix:nonNumeric> Our Senior Vice
President, Finance, who reports directly to the Chief Executive Officer, together with our senior management, is responsible for assessing
and managing cybersecurity risks with support from our third-party information technology service providers that employ information technology
consultants with over 20 years of experience managing cybersecurity programs. Our cybersecurity program aligns to the National Institute
of Standards and Technology (NIST) Cybersecurity Framework (CSF) and is consistently updated as NIST recommendations change year over
year. Our Senior Vice President, Finance, together with our senior management and other employees works closely with our information technology
service providers to evaluate material cybersecurity threats against our overall business objectives as part of our cybersecurity incident
response.</ix:nonNumeric> <ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="ixv-24159">The Board of Directors, as a whole and at the committee level, has oversight for the most significant risks facing us and for
our processes to identify, prioritize, assess, manage and mitigate those risks. <ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="ixv-24160">The Audit Committee has been designated by our Board to
oversee cybersecurity risks.</ix:nonNumeric> The Audit Committee receives regular updates on cybersecurity and information technology matters and related
risk exposures from our Senior Vice President, Finance. <ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="ixv-24161">The Board also receives updates from management and the Audit Committee on cybersecurity
risks on a regular basis.</ix:nonNumeric></ix:nonNumeric></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
the last fiscal year, <ix:nonNumeric contextRef="c0" escape="true" name="cyd:MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" id="ixv-24162">we have <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="ixv-24163">not identified</ix:nonNumeric> any risks from known cybersecurity threats, including as a result of any prior cybersecurity
incidents, that have materially affected us, but we face certain ongoing cybersecurity risks or threats that, if realized, are reasonably
likely to materially affect us.</ix:nonNumeric> For a description of the risks from cybersecurity threats that may materially affect the Company and
how they may do so, see our &#8220;Risk Factors&#8221; under Part 1 Item 1A. Risk Factors, in this Annual Report on Form 10-K.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
2. Properties. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Our corporate headquarters
are in Menlo Park, California and we have an additional office in Waltham, Massachusetts. Our lease for our Menlo Park headquarters expires
on September 30, 2027 and our lease for our Waltham office expires in 2029. We believe our current facilities are
sufficient for our needs for the foreseeable future.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
3. Legal Proceedings. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">From
time to time, we may become involved in legal proceedings relating to claims arising from the ordinary course of business. Our management
believes that there are currently no claims or actions pending against us, the ultimate disposition of which could reasonably be expected
to have a material adverse effect on our results of operations, financial condition or cash flows.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
4. Mine Safety Disclosures.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>PART
II</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Market
Information</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
common stock is traded on the Nasdaq Global Market under the symbol &#8220;ORKA.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Holders
of Record</b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">As of February 28, 2025, there
were approximately 20 stockholders of record of our common stock based on information provided by our transfer agent. The actual number
of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are
held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may
be held in trust by other entities.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Dividends</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future
earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on
our common stock for the foreseeable future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Recent
Sales of Unregistered Securities</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">None.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Purchases
of Equity Securities by the Issuer and Affiliated Purchasers</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">None.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Performance
Graph</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
a &#8220;smaller reporting company,&#8221; as defined by Rule 12b-2 of the Exchange Act, and pursuant to Instruction 6 to Item 201(e)
of Regulation S-K, we are not required to provide the stock performance graph.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
6. [Reserved] </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>You
should read the following discussion and analysis of our financial condition and results of operations together with our consolidated
financial statements and the related notes included elsewhere in this Annual Report on Form 10-K for the year ended December 31, 2024
(this &#8220;Annual Report&#8221;). This discussion contains forward-looking statements that involve risks and uncertainties, such as
statements regarding our plans, objectives, expectations, intentions, hopes, beliefs, strategies or projections regarding the future
of its pipeline and business and words such as &#8220;may,&#8221; &#8220;will,&#8221;, &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221;
&#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221;
&#8220;potential,&#8221; &#8220;seek,&#8221; &#8220;target,&#8221; &#8220;goal,&#8221; &#8220;intend&#8221; and variations of such words
and any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying
assumptions, and similar expressions are intended to identify forward-looking statements. You should not place undue reliance on these
forward-looking statements. These forward-looking statements are based on current expectations and beliefs concerning future developments
and their potential effects. There can be no assurance that future developments affecting us will be those that have been anticipated.
These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions
that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.
Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this Annual
Report entitled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report. These and many other factors could affect our future
financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date
of this Annual Report. As used in this Annual Report, unless the context suggests otherwise, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221;
&#8220;the Company,&#8221; &#8220;Oruka Therapeutics, Inc.,&#8221; &#8220;Oruka,&#8221; &#8220;ARCA biopharma, Inc.,&#8221; &#8220;ARCA,&#8221;
refers to Oruka Therapeutics, Inc. and its consolidated subsidiaries, including Oruka Therapeutics Operating Company LLC, taken as a
whole.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
are a clinical-stage biotechnology company focused on developing novel monoclonal antibody therapeutics for psoriasis (&#8220;PsO&#8221;)
and other inflammatory and immunology (&#8220;I&amp;I&#8221;) indications. Our name is derived from <i>or</i>, for &#8220;skin,&#8221;
and <i>arukah</i>, for &#8220;restoration,&#8221;&#160;and reflects our mission to deliver therapies for chronic skin diseases that provide
patients the most possible freedom from their condition. Our strategy is to apply antibody engineering and format innovations to validated
modes of action, which we believe will enable us to improve meaningfully upon the efficacy and dosing regimens of standard-of-care medicines
while significantly reducing technical and biological risk. Our programs aim to treat and potentially modify disease by targeting mechanisms
with proven efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (&#8220;TRMs&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (&#8220;IL-23p19&#8221;) for the treatment of PsO. Our
co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (&#8220;IL-17A/F&#8221;) for the treatment of PsO,
psoriatic arthritis (&#8220;PsA&#8221;), and other conditions. These programs each bind their respective targets at high affinity and
incorporate half-life extension technology with the aim to increase exposure and decrease dosing frequency. We believe that our focused
strategy, differentiated portfolio, and deep expertise position us to set a new treatment standard in large&#160;I&amp;I markets with
continued unmet need.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Since
our inception in February&#160;2024, we have devoted substantially all of our resources to raising capital, organizing and staffing the
company, business and scientific planning, conducting discovery and research activities, establishing arrangements with third parties
for the manufacture of our programs and component materials, and providing general and administrative support for these operations. We
do not have any programs approved for sale and have not generated any revenue from product sales. To date, we have funded our operations
primarily with proceeds from the issuance of convertible preferred stock, common stock, a convertible note, pre-funded warrants, and
the proceeds from the reverse recapitalization and merger with ARCA biopharma, Inc., our Pre-Closing Financing and subsequent PIPE Financing
(as defined and further described in &#8220;Recent developments&#8221; below).&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Since
our inception, we have incurred significant losses and negative cash flows from our operations. Our ability to generate product revenue
sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of any programs
we may develop. We generated net losses of $83.7 million for the period from February&#160;6, 2024 (inception) to December 31, 2024.
For the period from February 6 (inception) to December 31, 2024, we have used net cash of $57.8 million for our operating activities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
had cash, cash equivalents, and marketable securities of $393.7 million as of December 31, 2024. We expect that our existing cash, cash
equivalents, and marketable securities will be sufficient to fund our operating plans for at least twelve months from the date of filing
of this Annual Report. We expect to continue to incur substantial losses for the foreseeable future, and our transition to profitability
will depend upon successful development, approval and commercialization of our product candidates and upon achievement of sufficient
revenues to support our cost structure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ORKA-001</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">ORKA-001
is a high affinity, extended half-life monoclonal antibody (&#8220;mAb&#8221;) designed to target IL-23p19. IL-23 is a pro-inflammatory
cytokine that plays a critical role in the proliferation and development of T helper 17 (&#8220;Th17&#8221;) cells, which are the primary
drivers of several autoimmune and inflammatory disorders, including PsO.&#160;IL-23 is composed of two subunits: a p40 subunit that is
shared with IL-12 and a p19 subunit that is specific to IL-23. First-generation IL-23 antibodies bound p40 and inhibited both IL-12 and
IL-23 signaling, while more recent IL-23 antibodies targeting the p19 subunit have shown improved efficacy and safety. Based on preclinical
evidence, we believe that ORKA-001 could achieve higher response rates than established therapies in PsO while requiring less frequent
dosing and maintaining the favorable safety profile of therapies targeting IL-23p19.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">ORKA-001
is engineered with YTE half-life extension technology, a specific three amino acid change in the fragment crystallizable (&#8220;Fc&#8221;)
domain to modify the pH-dependent binding to the neonatal Fc receptor. As a result, it has a pharmacokinetic profile designed to support
a subcutaneous (&#8220;SQ&#8221;) injection as infrequently as once or twice a year. In addition, emerging evidence suggests that IL-23
blockade can modify the disease biology of PsO, possibly leading to durable remissions and preventing the development of PsA.&#160;We
believe that the expected characteristics of ORKA-001 increase its potential to deliver these disease-modifying benefits.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
initiated the dosing of healthy volunteers in a Phase 1 trial of ORKA-001 in the fourth quarter of 2024. We expect to share interim data
from the first-in-human trial in healthy volunteers, including initial pharmacokinetic data, in the second half of 2025 and initial efficacy
data in PsO patients in the second half of 2026.&#160;Based on recent precedent for PsO, we anticipate that the entire development program
from first-in-human to biologics license application (&#8220;BLA&#8221;) filing could take as little as six to seven&#160;years based
on the averages for recently approved medicines. However, we have no control over the length of time needed for United States Food and
Drug Administration (&#8220;FDA&#8221;) review, and this timeline could vary.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ORKA-002</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">ORKA-002
is a high affinity, extended half-life mAb designed to target IL-17A and IL-17F (&#8220;IL-17A/F&#8221;).&#160;IL-17 inhibition has become
central to the treatment of psoriatic diseases, including PsO and PsA, and has also shown efficacy in other&#160;I&amp;I indications,
such as hidradenitis suppurativa and axial spondyloarthritis.&#160;More recently, the importance of inhibiting the IL-17F isoform along
with IL-17A has become appreciated, and dual blockade with the recently approved therapy Bimzelx (bimekizumab) has led to higher response
rates in patients than blockade of IL-17A alone. ORKA-002 is designed to bind IL-17A/F at similar epitopes, or binding sites, and affinity
ranges as bimekizumab, but incorporates half-life extension technology that could enable more convenient dosing intervals. We plan to
initiate the dosing of healthy volunteers in a Phase&#160;1 trial of ORKA-002 in the third quarter of 2025. We expect to share interim
data from the first-in-human trial in healthy volunteers, including initial pharmacokinetic data, in the first half of 2026.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
view ORKA-002 and ORKA-001 as highly complementary. Patients with moderate-to-severe PsO that have purely skin manifestations are most
often treated with IL-23 inhibitors due to the high efficacy and tolerability of this mechanism. However, for patients who also have
joint involvement, or signs and symptoms of PsA, an IL-17 inhibitor is typically used due to its efficacy in addressing both skin and
joint symptoms. In addition, IL-17 inhibitors are often used in patients with highly resistant skin symptoms that do not adequately resolve
through treatment with an IL-23 inhibitor. Furthermore, we have the potential opportunity to administer ORKA-002 and ORKA-001 sequentially,
called ORKA-021, to combine two features of each program: the rapid response of an IL-17 inhibitor with the ideal maintenance profile
of an IL-23 inhibitor. We believe that ORKA-001 and ORKA-002 provide the potential to offer a highly compelling product profile for most
patients with PsO and/or PsA, as well as the opportunity to address additional I&amp;I indications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Additional
Pipeline Program</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
have a third mAb program, ORKA-003, designed to target an undisclosed pathway. Our strategy as a company is to remain highly focused
on&#160;I&amp;I diseases, and specifically on inflammatory dermatology conditions. Our third program provides the potential for indication
expansion beyond PsO and may create combination opportunities with our more advanced programs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Recent
Developments</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Acquisition
of Pre-Merger Oruka</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">On
August 29, 2024 (the &#8220;Merger Closing&#8221;), we completed our acquisition (the &#8220;Merger&#8221;) of Oruka Therapeutics, Inc.
(&#8220;Pre-Merger Oruka&#8221;) pursuant to an Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024 (the &#8220;Merger
Agreement&#8221;). Following the transactions contemplated by the Merger Agreement, Pre-Merger Oruka merged with and into Atlas Merger
Sub Corp., a wholly owned subsidiary of ARCA biopharma, Inc. (&#8220;ARCA&#8221;) and following that, Pre-Merger Oruka then merged with
and into Atlas Merger Sub II, LLC (&#8220;Second Merger Sub&#8221;), with Second Merger Sub being the surviving entity. Second Merger
Sub changed its corporate name to &#8220;Oruka Therapeutics Operating Company, LLC.&#8221; Pre-Merger Oruka was a pre-clinical stage
biotechnology company that was incorporated on February 6, 2024 under the direction of Peter Harwin, a Managing Member of Fairmount Funds
Management LLC (&#8220;Fairmount&#8221;), for the purposes of holding rights to certain intellectual property being developed by Paragon
Therapeutics, Inc. (&#8220;Paragon&#8221;). On August 29, 2024, we changed our name from &#8220;ARCA biopharma, Inc.&#8221; (&#8220;ARCA&#8221;)
to &#8220;Oruka Therapeutics, Inc.&#8221; and our Nasdaq ticker symbol from &#8220;ABIO&#8221; to &#8220;ORKA&#8221;.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Pre-Closing
Financing</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Immediately
prior to the execution and delivery of the Merger Agreement on April 3, 2024, certain new and existing investors of Pre-Merger Oruka
entered into a subscription agreement with Pre-Merger Oruka (the &#8220;Subscription Agreement&#8221;), pursuant to which, and on the
terms and subject to the conditions of which, immediately prior to the Closing, those investors purchased shares of common stock of Pre-Merger
Oruka (&#8220;Pre-Merger Oruka Common Stock&#8221;) and Pre-Merger Oruka pre-funded warrants for gross proceeds of approximately $275.0
million (which includes $25.0 million of proceeds previously received from the issuance of the Convertible Note (refer to Note 7 in our
consolidated financial statements included in Part II &#8211; Item 8 of this Annual Report for additional details) and accrued interest
on such note which converted to shares of Pre-Merger Oruka Common Stock) (the &#8220;Pre-Closing Financing&#8221;). We incurred transaction
costs of $20.5 million, which was recorded as a reduction to additional paid-in capital in the consolidated financial statements. At
the Closing, the shares of Pre-Merger Oruka Common Stock and Pre-Merger Oruka pre-funded warrants issued pursuant to the Subscription
Agreement were converted into shares of Company Common Stock and pre-funded warrants of Company Common Stock in accordance with the Exchange
Ratio (defined below).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
accordance with an Exchange Ratio determined by terms of the Merger Agreement and upon the effective time of the First Merger (the &#8220;First
Effective Time&#8221;), (i) each then-issued and outstanding share of Pre-Merger Oruka Common Stock including outstanding and unvested
Pre-Merger Oruka restricted stock and shares of Pre-Merger Oruka Common Stock issued in connection with the Subscription Agreement, were
converted into the right to receive a number of shares of Company Common Stock, equal to the exchange ratio of 6.8569 shares of Company
Common Stock (the &#8220;Exchange Ratio&#8221;), which were subject to the same vesting provisions as those immediately prior to the
Merger, (ii) each share of Pre-Merger Oruka Series A convertible preferred stock, par value $0.0001 (&#8220;Pre-Merger Oruka Series A
Preferred Stock&#8221;), outstanding immediately prior to the First Effective Time was converted into the right to receive a number of
shares of ARCA Series B non-voting convertible preferred stock, par value $0.001 per share, which are convertible into shares of Company
Common Stock at a conversion ratio of approximately 83.3332:1 after the reverse stock split discussed below, (iii) each outstanding option
to purchase Pre-Merger Oruka Common Stock was converted into an option to purchase shares of Company Common Stock, (iv) each outstanding
warrant to purchase shares of Pre-Merger Oruka Common Stock was converted into a warrant to purchase shares of Company Common Stock,
and (v) each share of Company Common Stock issued and outstanding at the First Effective Time remain issued and outstanding in accordance
with its terms and such shares. Subsequent to the close of the merger, the common stock shares were then, subject to a reverse stock
split of 1-for-12 effected on September 3, 2024 (&#8220;Reverse Stock Split&#8221;).</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
part of the Pre-Closing Financing and the Closing, the investors in the Pre-Closing Financing received 22,784,139 shares of Company Common
Stock in exchange for 39,873,706 shares of Pre-Merger Oruka Common Stock (which includes the issuance of 2,722,207 shares of Company
Common Stock in exchange for 4,764,032 shares of Pre-Merger Oruka Common Stock on the conversion of Convertible Note along with the accrued
interest through the conversion date) and 5,522,207 Company pre-funded warrants in exchange for 9,664,208 Pre-Merger pre-funded warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Pre-Merger Oruka
was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the fact that, immediately
following the Merger: (i) Pre-Merger Oruka stockholders own a substantial majority of the voting rights in the combined company; (ii)
Pre-Merger Oruka&#8217;s largest stockholders retain the largest interest in the combined company; (iii) Pre-Merger Oruka designated
a majority of the initial members of the board of directors of the combined company; and (iv) Pre-Merger Oruka&#8217;s executive management
team became the management team of the combined company. Accordingly, for accounting purposes: (i) the Merger was treated as the equivalent
of Pre-Merger Oruka issuing stock to acquire the net assets of ARCA; (ii) the reported historical operating results of the combined company
prior to the Merger are those of Pre-Merger Oruka; and (iii) Pre-Merger Oruka was not a variable interest entity as it had sufficient
equity at risk in order to fund its next development milestones at the time of the reverse recapitalization. Additional information regarding
the Merger is included in Note 3 to the consolidated financial statements included in Part II &#8211; Item 8 of this Annual Report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Reverse
Stock Split</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">On
September 3, 2024, we effected the Reverse Stock Split, a 1-for-12 reverse stock split of Company Common Stock. The par value per share
and the number of authorized shares were not adjusted as a result of the Reverse Stock Split. The shares of Company Common Stock underlying
outstanding stock options, common stock warrants and other equity instruments were proportionately reduced and the respective exercise
prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. All references
to common stock, options to purchase common stock, outstanding common stock warrants, common stock share data, per share data, and related
information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse
Stock Split for all periods presented, unless otherwise specifically indicated or the context otherwise requires.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>PIPE
Financing</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">On
September 11, 2024, we entered into a Securities Purchase Agreement for a private placement (the &#8220;PIPE Financing&#8221;) with certain
institutional and accredited investors. The closing of the PIPE Financing occurred on September 13, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Securities Purchase Agreement, the investors purchased an aggregate of 5,600,000 shares of Company Common Stock at a purchase
price of $23.00 per share, an aggregate of 2,439 shares of the Company&#8217;s Series A non-voting convertible preferred stock, par value
$0.001 per share (&#8220;Company Series A Preferred Stock&#8221;), at a purchase price of $23,000.00 per share (each Company Series A
Preferred Stock is convertible into 1,000 shares of Company Common Stock), and pre-funded warrants to purchase an aggregate of 680,000
shares of Company Common Stock at a purchase price of $22.999 per pre-funded warrant, for aggregate net proceeds of approximately $188.7
million (net of issuance costs of $11.9 million).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Components
of Results of Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Revenue</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">To
date, we have not generated revenue from any sources, including product sales, and do not expect to generate any revenue from the sale
of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory
approval, we may generate revenue in the future from product sales or payments from future collaboration or license agreements that we
may enter into with third parties, or any combination thereof. We cannot predict if, when, or to what extent we will generate revenue
from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product
candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Operating
Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Research
and Development</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Research
and development expenses consist primarily of costs incurred in connection with the development and research of our programs. These expenses
include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">costs
                                            of funding research performed by third parties, including Paragon, that conduct research
                                            and development activities on our behalf;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">costs
                                            incurred, and milestone payments under license and option agreements;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">expenses
                                            incurred in connection with continuing our current research programs and discovery-phase
                                            development of any programs we may identify, including under future agreements with third
                                            parties, such as consultants and contractors;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">expenses
                                            incurred under agreements with contract research organizations (&#8220;CROs&#8221;), contract
                                            manufacturing organizations (&#8220;CMOs&#8221;), and with clinical trial sites that conduct
                                            research and development activities on our behalf;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            cost of development and validating our manufacturing process for use in our preclinical studies
                                            and current and future clinical trials;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">personnel-related
                                            expenses, including salaries, bonuses, employee benefits, travel, and stock-based compensation
                                            expense, including stock-based compensation related to the Paruka warrant; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">allocated
                                            human resource costs, information technology costs, and facility-related costs, including
                                            rent, maintenance, utilities, and depreciation for our leased office space.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
expense research and development costs as incurred. Non-refundable advance payments that we make for goods or services to be received
in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the
related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered or the services
rendered. Our primary focus since inception has been the identification and development of our pipeline programs. Our research and development
expenses primarily consist of external costs, such as fees paid to Paragon under the Option Agreements. See &#8220;&#8212;Contractual
Obligations and Commitments&#8221; below for further details on the Option Agreements.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
expect our research and development expenses will increase substantially for the foreseeable future as we continue to invest in research
and development activities related to the continued development of our programs, developing any future programs, including investments
in manufacturing, as we advance any program we may identify and continue to conduct clinical trials. The success of programs we may identify
and develop will depend on many factors, including the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">timely
                                            and successful completion of preclinical studies;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">effective
                                            investigational new drug (&#8220;IND&#8221;) or comparable foreign applications that allow
                                            commencement of our planned clinical trials or future clinical trials for any programs we
                                            may develop;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">successful
                                            enrollment and completion of clinical trials;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">positive
                                            results from our future clinical trials that support a finding of safety and effectiveness,
                                            acceptable pharmacokinetics profile, and an acceptable risk-benefit profile in the intended
                                            populations;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">receipt
                                            of marketing approvals from applicable regulatory authorities;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">establishment
                                            of arrangements through our own facilities or with third-party manufacturers for clinical
                                            supply and, where applicable, commercial manufacturing capabilities; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">maintenance
                                            of a continued acceptable safety, tolerability, and efficacy profile of any programs we may
                                            develop following approval.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Any
changes in the outcome of any of these variables with respect to the development of programs that we may identify could mean a significant
change in the costs and possible delays in timing associated with the development of such programs. For example, if the FDA or another
regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the
completion of clinical development of a program, or if we experience significant delays in our clinical trials due to patient enrollment
or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development.
We may never obtain regulatory approval for any of our programs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>General
and Administrative</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">General
and administrative expenses consist primarily of personnel-related expenses, including salaries, bonuses, employee benefits, travel,
and stock-based compensation, for our executive and other administrative personnel. Other significant general and administrative expenses
include legal services, including intellectual property and corporate matters; professional fees for accounting, auditing, tax, insurance,
and allocated human resource costs, information technology costs, and facility-related costs, including rent, utilities, maintenance,
and depreciation for our leased office space.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
expect our general and administrative expenses will increase substantially for the foreseeable future as we anticipate an increase in
our personnel headcount to support the expansion of research and development activities, as well as to support our operations generally.
We also expect to continue to incur significant expenses associated with being a public company, including costs related to accounting,
audit, legal, regulatory, and tax-related&#160;services associated with maintaining compliance with applicable Nasdaq and SEC requirements;
director and officer insurance costs; and investor and public relations costs. We also expect to incur additional intellectual property-related
expenses as we file patent applications to protect innovations arising from our research and development activities.<b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Other
Income, Net</i></b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Other
income, net consists of interest earned on our cash, cash equivalents, and marketable securities; interest expense on the convertible
note from a related party (see discussion herein); and foreign currency transactions gains and losses. Interest expense relates to a
convertible note (the &#8220;Convertible Note&#8221;) issued to Fairmount Healthcare Fund&#160;II, L.P. (&#8220;Fairmount&#8221;), a
related party, in March&#160;2024. At the effective time of the Merger, the Convertible Note, along with the accrued interest, was automatically
converted into Company Common Stock.&#160;</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Income
Taxes</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">No
provision for income taxes was recorded for the period from February&#160;6, 2024 (inception) through December 31, 2024. Deferred tax
assets generated from our net operating losses have been fully offset by the valuation allowance as we believe it is not more likely
than not that the benefit will be realized due to our cumulative losses generated to date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Results
of Operations for the Period from February 6, 2024 (inception) to December 31, 2024</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes our results of operations for the period presented (in thousands):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from February&#160;6,<br/> 2024 (Inception) to<br/> December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Operating expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development<sup>(1)</sup></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">75,060</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative<sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,063</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Total
    operating expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">88,123</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss from operations</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(88,123</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other income (expense)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Interest income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,863</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense<sup>(3)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,468</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Other
    income, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Total
    other income, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,399</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(83,724</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Includes
                                            related party amount of $42,640 for the period from February 6, 2024 (inception) to December
                                            31, 2024</span></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Includes
                                            related party amount of $1,364 for the period from February 6, 2024 (inception) to December
                                            31, 2024</span></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Includes
                                            related party amount of $1,468 for the period from February 6, 2024 (inception) to December
                                            31, 2024</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Research
and Development Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes our research and development expenses for the period presented (in thousands):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from February 6,<br/> 2024 (Inception) to<br/> December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">External research
    and development expenses<sup>(1)</sup></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">57,680</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other research and development expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Personnel-related (excluding
    stock-based compensation)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,959</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation<sup>(2)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,992</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,429</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Total
    research and development expenses</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">75,060</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Rule-Page --><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>



</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Includes
                                            related party amount of $32,283 for the period from February 6, 2024 (inception) to December
                                            31, 2024</span></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Includes
                                            related party amount of $10,357 for the period from February 6, 2024 (inception) to December
                                            31, 2024</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Research
and development expenses were $75.1&#160;million for the period from February&#160;6, 2024 (inception) to December 31, 2024 and consisted
primarily of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$57.7&#160;million
    of research and development expense primarily includes: $18.3 million related to Paragon services rendered under the Option Agreements
    for ORKA-001, including $4.8 million for milestones achieved under the Option and License Agreements upon exercise of the option
    to enter into a license agreement and achievement of development candidate for IL-23 and dosing of the first subject in a Phase 1
    clinical trial; $13.3 million of research and development expense primarily related to Paragon services rendered under the Option
    Agreements for ORKA-002, including $2.3 million for milestones achieved under the Option and License Agreements upon exercise of
    the option to enter into a license agreement and achievement of development candidate for IL-17; $0.7 million of other research and
    development expense due to Paragon; $16.5 million of research and development expense on chemistry, manufacturing, and development
    costs; $5.7 million in toxicology testing with a third-party contract research organization; and $3.2 million of other external research
    and development costs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">$4.0&#160;million
                                            of personnel-related costs related to salaries, benefits, and other compensation-related
                                            costs;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">$12.0
                                            million of stock-based compensation expense, including $10.4 million of stock-based compensation
                                            related to the Paruka warrant; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">$1.4
                                            million of other expense and allocated human resource costs, information technology costs,
                                            and facility-related costs, including rent, maintenance, utilities, and depreciation for
                                            our leased office space.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>General
and Administrative Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes our general and administrative expenses for the period presented (in thousands):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from February&#160;6,<br/>
    2024 (Inception) to<br/>
    December&#160;31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Personnel-related (including stock-based
    compensation)<sup>(1)</sup></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,981</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Professional and consulting fees<sup>(2)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,606</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other<sup>(3)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">476</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Total
    general and administrative expenses</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,063</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>



</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Includes
                                            related party amount of $609 for the period from February 6, 2024 (inception) to December
                                            31, 2024</span></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Includes
                                            related party amount of $575 for the period from February 6, 2024 (inception) to December
                                            31, 2024</span></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Includes
                                            related party amount of $180 for the period from February 6, 2024 (inception) to December
                                            31, 2024</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">General
and administrative expenses were $13.1 million for the period from February&#160;6, 2024 (inception) to December 31, 2024 and consisted
primarily of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$8.0&#160;million
    of personnel-related costs related to salaries, benefits, other compensation-related costs, recruiting costs, including stock-based
    compensation of $2.9&#160;million, and $0.6 million of personnel-related costs are recruiting costs reimbursed to Paragon for hiring
    of our executive team, legal, and finance and accounting functions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">$4.6&#160;million
                                            of professional and consulting fees associated with accounting, audit, and legal fees associated
                                            with becoming a public company, including $0.6&#160;million of legal fees due to Paragon
                                            associated with patent-related activities; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">$0.5
                                            million of other business expenses and net of allocated human resource costs, information
                                            technology costs, and facility-related costs, including rent, maintenance, utilities, and
                                            depreciation for our leased office space to research and development expenses, including
                                            $0.2&#160;million of other business expenses due to Paragon.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Total
Other Income, Net</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Interest
income from cash equivalents and marketable securities was $5.9 million for the period from February 6, 2024 (inception) to December
31, 2024.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Interest
expense was $1.5 million for the period from February 6, 2024 (inception) to December 31, 2024 relating to the Convertible Note from
Fairmount.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Liquidity
and Capital Resources</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2024, we had $393.7 million of cash, cash equivalents, and marketable securities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Since
our inception, we have incurred significant operating losses and negative cash flow from operations. We expect to incur significant expenses
and operating losses for the foreseeable future as we continue the pre-clinical and clinical development of our programs and our early-stage
research activities. We have not yet commercialized any products, and we do not expect to generate revenue from sales of products for
several&#160;years, if at all. Through December 31, 2024, we had funded our operations primarily with proceeds from issuances of convertible
preferred stock, common stock, a convertible note, and pre-funded warrants. In March&#160;2024, we received $2.9&#160;million in net
proceeds from the issuance of Pre-Merger Oruka Series&#160;A Preferred Stock and $25.0&#160;million in gross proceeds from the issuance
of the Convertible Note, both of which were related party transactions. In August 2024, we raised approximately $228.0 million in net
proceeds from Pre-Closing Financing and received $4.9 million in cash from ARCA upon consummation of the Merger. In September 2024, we
received approximately $188.7 million in net proceeds from the issuance of common stock, Company Series A Preferred Stock, and pre-funded
warrants in connection with the PIPE Financing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
primary use of cash is to fund the development of our product candidates and advance our pipeline. This includes both the research and
development costs and the general and administrative expenses required to support those operations. Since we are a clinical stage biotechnology
company, we have incurred significant operating losses since our inception and we anticipate such losses, in absolute dollar terms, to
increase as we continue to pursue clinical development of our product candidates, prepare for the potential commercialization of our
product candidates, and expand our development efforts in our pipeline of nonclinical candidates. We expect that our existing cash, cash
equivalents, and marketable securities will be sufficient to fund our operating plans for at least twelve months from the date of filing
of this Annual Report. We will need to secure additional financing in the future to fund additional research and development, and before
a commercial drug can be produced, marketed, and sold. If we are unable to obtain additional financing or generate license or product
revenue, the lack of liquidity could have a material adverse effect on our company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Cash
Flows</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes our cash flows for the period presented (in thousands):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from February&#160;6,<br/>
    2024 (Inception)&#160;to<br/>
    December 31,&#160;<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net cash used in operating activities</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(57,837</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net cash used in investing activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(330,127</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net cash provided by
    financing activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">449,539</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Net
    increase in cash and cash equivalents</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">61,575</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Operating
Activities</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">From
February&#160;6, 2024 (inception) to December&#160;31, 2024, net cash used in operating activities was $57.8 million, which was primarily
attributable to a net loss of $83.7 million, offset by net non-cash charges of $14.3 million and net changes in operating activities
of $11.6 million. Non-cash charges primarily consisted of $14.9 million in stock-based compensation expense (including $10.4 million
related to the Paruka warrant) and $1.5 million of non-cash interest expense, partially offset by net accretion of premiums and discounts
on marketable securities of $2.2 million. Net changes in our operating activities primarily consisted of a $3.5 million increase in accounts
payable, a $3.3 million increase in accrued expenses and other current liabilities, a $6.0 million increase in related parties accounts
payable and other current liabilities, partially offset by a $1.1 million increase in prepaid expenses and other current assets. The
increase in amounts due to related parties, accounts payable, and accrued expenses and other current liabilities was primarily due to
an increase in our business activity, as well as vendor invoicing and payments. The increase in prepaid expenses and other current assets
was primarily due to prepaid research and development expenses with our contract research organization.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Investing
Activities</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">From
February&#160;6, 2024 (inception) to December 31, 2024, net cash used in investing activities was $330.1 million, which was primarily
attributable to purchases of marketable securities.<i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Financing
Activities</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">From
February&#160;6, 2024 (inception) to December 31, 2024, net cash provided by financing activities was $449.5 million, consisting of $228.0
million of net proceeds from the Pre-Closing Financing, $188.7 million of net proceeds from the PIPE Financing, $25.0 million of net
proceeds from the issuance of notes payable to related parties, $4.9 million of cash acquired in connection with the reverse recapitalization
and $2.9 million of net proceeds from issuance of the Pre-Merger Oruka Series A Preferred Stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Contractual
Obligations and Commitments</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
enter into contracts in the normal course of business with CROs, CMOs and with other vendors for preclinical research studies, clinical
trials, manufacturing, and other services and products for operating purposes. These contracts generally provide for termination on&#160;notice
or may have a potential termination fee if a purchase order is cancelled within a specified time, and therefore, are cancelable contracts.
We do not expect any such contract terminations and did not have any non-cancellable obligations under these agreements as of December
31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Paragon
Therapeutics - Option Agreements</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
                                            March&#160;2024, we entered into two antibody discovery and option agreements (&#8220;Option
                                            Agreements&#8221;) with Paragon and Paruka Holding, LLC (&#8220;Paruka&#8221;). Under the
                                            terms of each agreement, Paragon identifies, evaluates, and develops antibodies directed
                                            against certain mutually agreed therapeutic targets of interest to us. From time to time,
                                            we can choose to add additional targets to the collaboration upon agreement with Paragon
                                            and Paruka. Under the Option Agreements, we have the exclusive option to, on a research program-by-research
                                            program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right,
                                            title, and interest in and to the intellectual property resulting from the applicable research
                                            program to develop, manufacture, and commercialize the antibodies and products directed to
                                            the selected target(s)&#160;(each, an &#8220;Option&#8221;). We have initiated certain research
                                            programs with Paragon that generally focus on discovering, generating, identifying and/or
                                            characterizing antibodies directed to a particular target (each, a &#8220;Research Program&#8221;),
                                            including for IL-23 and IL-17A/F for ORKA-001 and ORKA-002, respectively. Our exclusive option
                                            with respect to each Research Program is exercisable at our sole discretion at such time
                                            as specified in the Option Agreements (the &#8220;Option Period&#8221;). There is no payment
                                            due upon exercise of an Option pursuant to the Option Agreements. For each of these agreements,
                                            once we enter into the corresponding license agreements, we will be required to make non-refundable
                                            milestone payments to Paragon of up to $12.0 million under each respective agreement upon
                                            the achievement of certain clinical development milestones, up to $10.0 million under each
                                            respective agreement upon the achievement of certain regulatory milestones, as well as a
                                            low single-digit percentage royalty for antibody products beginning on the first commercial
                                            sale in each program.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
may terminate any Option Agreement or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior written notice
to Paragon, provided that we must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable obligations
reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate any Option
Agreement or a Research Program immediately upon written notice to us if, as a result of any action or failure to act by us or our affiliates,
such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed
for a certain consecutive number of&#160;months. Each party has the right to terminate the Option Agreements or any Research Program
upon material breach that remains uncured or the other party&#8217;s bankruptcy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Additionally,
as part of the Option Agreements, on December&#160;31, 2024 and December 31, 2025, we granted and will grant, respectively, Paruka a
warrant to purchase a number of shares equal to 1.00% of outstanding shares as of the date of the grant on a fully-diluted basis, with
an exercise price equal to the fair market value of the underlying shares on the grant date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
warrant is liability-classified and after the initial recognition, the liability is adjusted to fair value at the end of each reporting
period, with changes in fair value recorded in the consolidated statement of operations and comprehensive loss as stock-based compensation
expenses under research and development expenses. On issuance of the December 31, 2024 warrant to Paruka, the change in fair value of
the warrant immediately prior to issuance was recorded in the consolidated statement of operations and comprehensive loss and the resultant
carrying value of the liability was reclassified to equity on the consolidated balance sheet as of December 31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Option Agreements, on a research program-by-research program basis following the finalization of the research plan for each respective
research program, we were required to pay Paragon a one-time, nonrefundable research initiation fee of $0.8&#160;million related to the
ORKA-001 program. This amount was recognized as a research and development expense during the period from February&#160;6, 2024 (inception)
to December 31, 2024. In June 2024, pursuant to the Option Agreements with Paragon, we completed the selection process of our development
candidate for IL-23 antibody for ORKA-001 program. We were responsible for 50% of the development costs incurred through the completion
of the IL-23 selection process. We received the rights to at least one selected IL-23 antibody in June 2024. During the period from February
6, 2024 (inception) to December 31, 2024, we exercised our option for ORKA-001 and recorded a $1.5 million milestone payment related
to the achievement of development candidate as research and development expense in our consolidated statement of operations and comprehensive
loss. In addition, during the period from February 6, 2024 (inception) to December 31, 2024, we recorded a $2.5 million milestone payment
related to the first dosing of a human subject in a Phase 1 trial of ORKA-001 in December 2024 as research and development expense in
our consolidated statement of operations and comprehensive loss. Our share of development costs incurred for the period from February
6, 2024 (inception) to December 31, 2024 was $13.5 million, which was recorded as research and development expenses. An amount of $2.8
million related to ORKA-001 is included in related party accounts payable and other current liabilities as of December 31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
were also required to reimburse Paragon $3.3&#160;million for development costs related to ORKA-002 incurred by Paragon through December&#160;31,
2023 and certain other development costs incurred by Paragon between January&#160;1, 2024 and March&#160;6, 2024 as stipulated by the
Option Agreements. This amount was recognized as a research and development expense during the period from February&#160;6, 2024 (inception)
to December 31, 2024. We are also responsible for the development costs incurred by Paragon from January&#160;1, 2024 through the completion
of the IL-17 selection process. We recognized an amount of $0.8&#160;million payable to Paragon for the research initiation fee related
to ORKA-002 following the finalization of the ORKA-002 research plan. This was recognized as research and development expenses in the
period from February 6, 2024 (inception) to December 31, 2024. During the period from February 6, 2024 (inception) to December 31, 2024,
we exercised our option for ORKA-002 and recorded a $1.5 million milestone payment related to the achievement of development candidate
as research and development expense in our consolidated statement of operations and comprehensive loss. We accounted for development
costs of $7.8 million for the period from February 6, 2024 (inception) to December 31, 2024 as research and development expenses. An
amount of $2.7 million related to ORKA-002 is included in related party accounts payable and other current liabilities as of December
31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
                                            expense the service fees as the associated costs are incurred when the underlying services
                                            are rendered. Such amounts are classified within research and development expenses in the
                                            accompanying consolidated statement of operations and comprehensive loss.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
concluded that the rights obtained under the Option Agreements represent an asset acquisition whereby the underlying assets comprise
in-process research and development assets with no alternative future use. The Option Agreements did not qualify as a business combination
because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent
a group of similar identifiable assets. The research initiation fee represents a one-time cost on a research program-by-research program
basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts
paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of on-going development cost,
monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior
to the effective date of the Option Agreements that is associated with services being rendered under the related Research Programs are
recognized as research and development expense when incurred.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">For
the period from February&#160;6, 2024 (inception) to December 31, 2024, we recognized $42.0 million of expenses in connection with services
provided by Paragon and Paruka under the Option Agreements.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Paragon
Therapeutics &#8211; License Agreements</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
September 2024, we exercised the Option to acquire certain rights to ORKA-001, and in December 2024, we entered into the corresponding
license agreement with Paragon (the &#8220;ORKA-001 License Agreement&#8221;), pursuant to which Paragon granted us a royalty-bearing,
world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting IL-23
in all fields other than the field of inflammatory bowel disease (&#8220;ORKA-001 Field&#8221;). In December 2024, we exercised the Option
with respect to ORKA-002 for the IL-17A/F program, and in February 2025, we entered into the corresponding license agreement with Paragon
(the &#8220;ORKA-002 License Agreement&#8221; and together with the ORKA-001 License Agreement, the &#8220;License Agreements&#8221;),
pursuant to which Paragon granted us a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize or otherwise
exploit certain antibodies and products targeting IL-17A/F in all fields (&#8220;ORKA-002 Field&#8221; and together with the ORKA-001
Field, the &#8220;Fields&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
License Agreements provide us with exclusive licenses in the Fields to Paragon&#8217;s patent applications covering the related antibodies,
their method of use and their method of manufacture and Paragon has agreed not to conduct any new campaigns that generate anti-IL-23
monospecific antibodies or anti-IL-17A/F monospecific antibodies for the ORKA-001 Field or the ORKA-002 Field, respectively, for at least
five years. Each of the ORKA-001 and ORKA-002 License Agreements may be terminated on 60 days&#8217; notice to Paragon, on material breach
without cure, and on a party&#8217;s insolvency or bankruptcy to the extent permitted by law.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
                                            to the terms of each of the ORKA-001 and ORKA-002 License Agreements, we are obligated to
                                            pay Paragon non-refundable milestone payments of up to $12.0 million under each respective
                                            agreement upon the achievement of certain clinical development milestones and up to $10.0
                                            million under each respective agreement upon the achievement of certain regulatory milestones,
                                            including a $1.5 million fee for nomination of a development candidate (or initiation of
                                            an IND-enabling toxicology study) and a further milestone payment of $2.5 million upon the
                                            first dosing of a human patient in a Phase 1 trial for each of ORKA-001 and ORKA-002. In
                                            addition, we are obligated to pay Paragon a low single-digit percentage royalty for antibody
                                            products for each of ORKA-001 and ORKA-002. For each of the License Agreements, the royalty
                                            term ends on the later of (i) the last-to-expire licensed patent or our patent directed to
                                            the manufacture, use or sale of a licensed antibody in the country at issue or (ii) 12 years
                                            from the date of first sale of a Company product. There is also a royalty step-down if there
                                            is no Paragon patent in effect during the royalty term for each program.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Cell
Line License Agreement</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In March 2024, we entered
into the Cell Line License Agreement (the &#8220;Cell Line License Agreement&#8221;) with WuXi Biologics Ireland Limited (&#8220;WuXi
Biologics&#8221;). Under the Cell Line License Agreement, we received a non-exclusive, worldwide, sublicensable license to certain of
WuXi Biologics&#8217; know-how, cell line, biological materials (the &#8220;WuXi Biologics Licensed Technology&#8221;) and media and feeds
to make, have made, use, sell and import certain therapeutic products produced through the use of the cell line licensed by WuXi Biologics
under the Cell Line License Agreement (the &#8220;WuXi Biologics Licensed Products&#8221;). Specifically, the WuXi Biologics Licensed
Technology is used in certain manufacturing activities in support of the ORKA-001 and ORKA-002 programs.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
consideration for the license, we agreed to pay WuXi Biologics a non-refundable license fee of $150,000, which was recognized as a research
and development expense during the period from February&#160;6, 2024 (inception) to December 31, 2024. Additionally, to the extent that
we manufacture our commercial supplies of bulk drug product with a manufacturer other than WuXi Biologics or its affiliates, we are required
to make royalty payments to WuXi Biologics at a rate of less than one percent of net sales of WuXi Biologics Licensed Products manufactured
by the third-party manufacturer. Pursuant to an amendment to the Cell Line License Agreement effective in November 2024, a provision
was added that permits the royalties owed under the agreement to be bought out on a&#160;product-by-product&#160;basis for a&#160;lump-sum&#160;payment.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Cell Line License Agreement will continue indefinitely unless terminated (i) by us upon six months&#8217; prior written notice and our
payment of all undisputed amounts due to WuXi Biologics through the effective date of termination, (ii) by WuXi Biologics for a material
breach by us that remains uncured for 60 days after written notice, (iii) by WuXi Biologics if we fail to make a payment and such failure
continues for 30 days after receiving notice of such failure, or (iv) by either party upon the other party&#8217;s bankruptcy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Note&#160;Payable
with Related Party</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
March&#160;2024, we entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;)
with Fairmount, whereby we issued the Convertible Note, with an initial principal amount of $25.0 million that, at the time of issuance,
could be converted into Pre-Merger Oruka Series&#160;A Preferred Stock (or a series&#160;of preferred shares that is identical in respect
to the shares of preferred shares issued in its next equity financing) or shares of Pre-Merger Oruka Common Stock in exchange for aggregate
proceeds of $25.0&#160;million. The Convertible Note accrued interest at a rate of 12.0% per annum. At issuance, the Convertible Note
required all unpaid interest and principal to mature on December&#160;31, 2025 (the &#8220;Maturity Date&#8221;) and prepayment was not
permitted without prior written consent of Fairmount. At issuance, the principal payment along with the accrued interest on the Convertible
Note was due in full on the Maturity Date. Pursuant to the Purchase Agreement, we had the right to sell and issue additional convertible
notes up to an aggregate principal amount equal to $30.0 million, in addition to the $25.0 million initial principal amount of the Convertible
Note.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Immediately
prior to the completion of the Merger, the Convertible Note was converted into shares of Pre-Merger Oruka Common Stock based on the aggregate
principal amount of $25.0 million, plus unpaid accrued interest of $1.5 million divided by the conversion price, which was determined
based upon the Company&#8217;s fully-diluted capitalization immediately prior to the Merger. At the effective time of the Merger, the
Pre-Merger Oruka Common Stock issued upon the conversion of the Convertible Note (including accrued interest) automatically converted
into shares of Company Common Stock. 2,722,207 shares of Company Common Stock were issued on conversion of the Convertible Note and accrued
interest. As of December 31, 2024, there is no note payable to a related party.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Lease
Agreement</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
contractual obligations include minimum lease payments under our operating lease obligation for our headquarters in Menlo Park, California.
See Note 13 to the consolidated financial statements elsewhere in this report for additional information.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Critical
Accounting Policies and Significant Judgments and Estimates</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
management&#8217;s discussion and analysis of its financial condition and results of operations is based on its financial statements,
which have been prepared in accordance with U.S. GAAP.&#160;The preparation of these consolidated financial statements requires us to
make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and
liabilities at the date of the financial statements, as well as the reported revenues recognized and expenses incurred during the reporting
periods. Our estimates are based on its historical experience and on various other factors that we believe are reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent
from other sources. Actual results may differ from these estimates under different assumptions or conditions.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">While
our significant accounting policies are described in more detail in Note&#160;2 to our consolidated financial statements appearing elsewhere
in this Annual Report, we believe the following accounting policies used in the preparation of our financial statements require the most
significant judgments and estimates.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Research
and Development Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Research
and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and
development activities, including salaries and bonuses, overhead costs, contract services and other related costs. The value of goods
and services received from contract research organizations and contract manufacturing organizations in the reporting period are estimated
based on the level of services performed, and progress in the period in cases when we have not received an invoice from the supplier.
In circumstances where amounts have been paid in excess of costs incurred, we record a prepaid expense. When billing terms under these
contracts do not coincide with the timing of when the work is performed, we are required to make estimates of outstanding obligations
to those third parties as of period end. Any accrual estimates are based on a number of factors, including our knowledge of the progress
towards completion of the specific tasks to be performed, invoicing to date under the contracts, communication from the vendors of any
actual costs incurred during the period that have not yet been invoiced and the costs included in the contracts. Significant judgments
and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the
estimates made by us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock-Based
Compensation</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
measure stock options granted to employees and non-employees based on the estimated fair values of the awards as of the grant date using
the Black-Scholes option-pricing model. The model requires management to make a number of assumptions, including common stock fair value,
expected volatility, expected term, risk-free interest rate and expected dividend yield. For restricted stock awards and restricted stock
units, the estimated fair value is the fair market value of the underlying stock on the grant date. We expense the fair value of our
equity-based compensation awards on a straight-line basis over the requisite service period, which is the period in which the related
services are received. We account for award forfeitures as they occur. The expense for stock-based awards with performance conditions
is recognized when it is probable that a performance condition is met during the vesting period.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Determination
of Fair Value of Common Stock&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">A
public trading market for Company Common Stock has been established in connection with the completion of the Merger. As such, it is no
longer necessary for our board of directors to estimate the fair value of our stock-based awards in connection with its accounting for
granted stock-based awards or other such awards we may grant, as the fair value of Company Common Stock and share-based awards is determined
based on the quoted market price of Company Common Stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Prior
to the merger, Pre-Merger Oruka&#8217;s common stock valuations were prepared using a hybrid method, including an option pricing method
(&#8220;OPM&#8221;). The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise
prices based on the value thresholds at which the allocation among the various holders of a company&#8217;s securities changes. Under
this method, the common stock has value only if the funds available for distribution to stockholders exceed the value of the preferred
stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. The hybrid method is a probability-weighted
expected return method (&#8220;PWERM&#8221;), where the equity value in one or more of the scenarios is calculated using an OPM. The
PWERM is a scenario-based methodology that estimates the fair value of common stock based upon an analysis of future values for the Company,
assuming various outcomes. The common stock value is based on the probability-weighted present value of expected future investment returns
considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the common stock
under each outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to
arrive at an indication of value for the common stock. A discount for lack of marketability of the common stock is then applied to arrive
at an indication of value for the common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
assumptions underlying these valuations represented management&#8217;s best estimate, which involved inherent uncertainties and the application
of management&#8217;s judgment. As a result, if Pre-Merger Oruka had used significantly different assumptions or estimates, the fair
value of Pre-Merger Oruka&#8217;s incentive shares and its stock-based compensation expense could have been materially different.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Recently
Issued Accounting Pronouncements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">See
Note 2 to the consolidated financial statements included in Part II - Item 8 of this Annual Report for more information regarding recently
issued accounting pronouncements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Off-Balance
Sheet Arrangements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2024, we did not have any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
7A. Quantitative and Qualitative Disclosures About Market Risk. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
are a smaller reporting company, as defined by Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
Act&#8221;), and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
8. Financial Statements and Supplementary Data.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ORUKA
THERAPEUTICS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Page</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Audited Financial Statements:</b></span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#f_001">Report of Independent Registered Public Accounting Firm (PCAOB ID <ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-24164">238</ix:nonNumeric>)</a></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">F-2</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#f_002">Consolidated Balance Sheets</a></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">F-3</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#f_003">Consolidated Statement of Operations and Comprehensive Loss</a></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">F-4</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#f_004">Consolidated Statement of Convertible Preferred Stock and Stockholders&#8217; Equity</a></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">F-5</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#f_005">Consolidated Statement of Cash Flows</a></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">F-6</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#f_006">Notes to Consolidated Financial Statements</a></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">F-7</span></td></tr> </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 89; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Board of Directors and Stockholders of
Oruka Therapeutics, Inc.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AuditorOpinionTextBlock-c0_cont_1" escape="true" name="dei:AuditorOpinionTextBlock" id="ixv-8269"><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Opinion on the Financial Statements</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation id="_AuditorOpinionTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have audited the accompanying
consolidated balance sheets of Oruka Therapeutics, Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2024
and February 6, 2024, and the related consolidated statements of operations and comprehensive loss, of convertible preferred stock and
stockholders&#8217; equity and of cash flows for the period from February&#160;6,&#160;2024 (inception) to December&#160;31,&#160;2024, including
the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial
statements present fairly, in all material respects, the financial position of the Company as of December&#160;31,&#160;2024 and February
6, 2024, and the results of its operations and its cash flows for the period from February&#160;6,&#160;2024 (inception) to December&#160;31,&#160;2024
in conformity with accounting principles generally accepted in the United States of America.</p></ix:continuation><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basis for Opinion</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These consolidated financial
statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conducted our audits of
these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform
the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether
due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the
purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express
no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audits included performing
procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates
made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits
provide a reasonable basis for our opinion.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Critical Audit Matters</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The critical audit matter
communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or
required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated
financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit
matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating
the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which
it relates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>External Research and Development Costs</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As described in Note 2 to
the consolidated financial statements, research and development costs are expensed as incurred. Research and development costs include
salaries and bonuses, stock-based compensation, employee benefits, and external costs of vendors and consultants engaged to conduct research
and development activities, as well as allocated human resource costs, information technology costs, and facility-related costs, including
rent, maintenance, utilities, and depreciation. As disclosed by management, the Company&#8217;s research and development expense for the
period from February 6, 2024 (inception) to December 31, 2024 was $75.1 million, $57.7 million of which relates to external research and
development costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The principal consideration
for our determination that performing procedures relating to external research and development costs is a critical audit matter is a high
degree of auditor effort in performing procedures related to the Company&#8217;s external research and development costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Addressing the matter involved
performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements.
These procedures included, among others, testing external research and development costs, on a sample basis, by obtaining and agreeing
the contractual terms of the agreement, amounts incurred to date, and estimates of work performed to date to the (i) underlying agreements
with vendors engaged to conduct research and development; (ii) purchase orders; (iii) invoices received; (iv) underlying payments made
for expenses incurred on the contracts; and (v) external confirmations or communications obtained by management from vendors.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ <ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-24165">PricewaterhouseCoopers LLP</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-24166">Boston, Massachusetts</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">March 6, 2025</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have served as the Company&#8217;s auditor
since 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 90 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ORUKA
THERAPEUTICS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(In
thousands, except share and per share data)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">February 6,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Current assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-24167">61,575</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-0; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Marketable
    securities, current</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-24168">314,073</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-1; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Subscription
    receivable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-2; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="orka:SubscriptionReceivables" scale="3" unitRef="usd" id="ixv-24169">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other current assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-24170">1,221</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-3; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt"><span style="font-family: Times New Roman, Times, Serif">Total
    current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-24171">376,869</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-24172">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Marketable
    securities, long-term</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-24173">18,069</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-4; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Property
    and equipment, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-24174">162</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-5; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    lease right-of-use assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-24175">876</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-6; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Other
    non-current assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-24176">43</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-7; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total
    assets</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-24177">396,019</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-24178">1</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Liabilities,
    Convertible Preferred Stock and Stockholders&#8217; Equity</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Current
    liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Accounts
    payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" unitRef="usd" id="ixv-24179">3,462</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-8; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Accrued
    expenses and other current liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" unitRef="usd" id="ixv-24180">3,346</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-9; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Operating
    lease liability, current</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-24181">213</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-10; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Related
    party accounts payable and other current liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-24182">6,022</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-11; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt"><span style="font-family: Times New Roman, Times, Serif">Total
    current liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-24183">13,043</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-12; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    lease liability, non-current</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-24184">755</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-13; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt"><span style="font-family: Times New Roman, Times, Serif">Total
    liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-24185">13,798</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-14; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Commitments
    and contingencies (Note 13)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Series A convertible preferred stock, $<ix:nonFraction contextRef="c7" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-24186"><ix:nonFraction contextRef="c8" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-24187">0.0001</ix:nonFraction></ix:nonFraction> par value; <span style="-sec-ix-hidden: hidden-fact-23">no</span> shares and <ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" unitRef="shares" id="ixv-24188">20,000,000</ix:nonFraction> shares authorized as of December 31, 2024 and February 6, 2024, respectively; <span style="-sec-ix-hidden: hidden-fact-19"><span style="-sec-ix-hidden: hidden-fact-20"><span style="-sec-ix-hidden: hidden-fact-21"><span style="-sec-ix-hidden: hidden-fact-22">none</span></span></span></span> issued and outstanding as of December 31, 2024 and February 6, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-17; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-18; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Series A non-voting convertible preferred stock, $<ix:nonFraction contextRef="c9" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-24189"><ix:nonFraction contextRef="c10" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-24190">0.001</ix:nonFraction></ix:nonFraction> par value; <span style="-sec-ix-hidden: hidden-fact-26"><span style="-sec-ix-hidden: hidden-fact-28"><span style="-sec-ix-hidden: hidden-fact-30">none</span></span></span> authorized as of December 31, 2024 and February 6, 2024; <span style="-sec-ix-hidden: hidden-fact-27"><span style="-sec-ix-hidden: hidden-fact-29"><span style="-sec-ix-hidden: hidden-fact-31">none</span></span></span> issued and outstanding as of December 31, 2024 and February 6, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-24; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-25; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Stockholders&#8217;
    equity:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Series B non-voting convertible preferred stock, $<ix:nonFraction contextRef="c11" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-24191"><ix:nonFraction contextRef="c12" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-24192">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-24193">251,504</ix:nonFraction> and <span style="-sec-ix-hidden: hidden-fact-34"><span style="-sec-ix-hidden: hidden-fact-35">no</span></span> shares authorized as of December 31, 2024 and February 6, 2024, respectively; <ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-24194"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-24195">137,138</ix:nonFraction></ix:nonFraction> and <span style="-sec-ix-hidden: hidden-fact-33">no</span> shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="3" unitRef="usd" id="ixv-24196">2,931</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-32; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Common stock, $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-24197">0.001</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-24198">0.001</ix:nonFraction> par value as of December 31, 2024 and February 6, 2024, respectively; <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-24199">545,000,000</ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-24200">65,000,000</ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-24201"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-24202">37,440,510</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-24203"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-24204">3,197,975</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-24205">37</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-36; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Additional
    paid-in capital</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-24206">463,018</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-24207">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    other comprehensive loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-24208">41</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-37; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-24209">83,724</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-38; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt"><span style="font-family: Times New Roman, Times, Serif">Total
    stockholders&#8217; equity</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-24210">382,221</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-24211">1</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total
    liabilities, convertible preferred stock and stockholders&#8217; equity</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-24212">396,019</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-24213">1</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 91 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ORUKA
THERAPEUTICS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>CONSOLIDATED
STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(In
thousands, except share and per share data)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Period
    from<br/>
    February 6,<br/>
    2024<br/>
    (Inception) to<br/>
    December 31, <br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Operating expenses</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research
    and development <sup>(1)</sup></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">75,060</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General
    and administrative <sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">13,063</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    operating expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-24216">88,123</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss from operations</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-24217">88,123</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other income (expense)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-24218">5,863</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest expense <sup>(3)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" id="ix_2_fact" name="us-gaap:InterestExpenseNonoperating" scale="3" unitRef="usd">1,468</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other
    income, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" unitRef="usd" id="ixv-24220">4</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    other income, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-24221">4,399</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-24222">83,724</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Unrealized
    loss on marketable securities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-24223">41</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Comprehensive loss</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-24224">83,765</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Net loss per share attributable
    to common stockholders, basic and diluted</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-24225"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-24226">3.87</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c16" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-24227"><ix:nonFraction contextRef="c16" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-24228">3,873.25</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c17" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-24229"><ix:nonFraction contextRef="c17" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-24230">322.81</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Weighted-average
    shares used in computing net loss per share attributable to common stockholders, basic and diluted</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-24231"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-24232">16,789,362</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Weighted-average
    shares used in computing net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-24233"><ix:nonFraction contextRef="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-24234">495</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Weighted-average
    shares used in computing net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c17" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-24235"><ix:nonFraction contextRef="c17" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-24236">51,946</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>




</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0%"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif">Includes related party amount of $<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpensesRelatedParty" scale="3" unitRef="usd" id="ixv-24237">42,640</ix:nonFraction> for the period from February 6, 2024 (inception) to December 31, 2024</span></ix:footnote></td></tr></table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0%"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif">Includes related party amount of $<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpensesRelatedParty" scale="3" unitRef="usd" id="ixv-24238">1,364</ix:nonFraction> for the period from February 6, 2024 (inception) to December 31, 2024</span></ix:footnote></td></tr></table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0%"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif">Includes related party amount of $<ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpensesRelatedParty" scale="3" unitRef="usd" id="ixv-24239">1,468</ix:nonFraction> for the period from February 6, 2024 (inception) to December 31, 2024</span></ix:footnote></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 92 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ORUKA
THERAPEUTICS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>CONSOLIDATED
STATEMENT OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(In
thousands, except share data)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Series
    A<br/> Convertible<br/> Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Series
    A<br/> Non-Voting<br/> Convertible<br/> Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Series
    B<br/> Non-Voting<br/> Convertible<br/> Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Common
    Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Additional<br/>
    Paid-In</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated<br/>
    Other<br/> Comprehensive</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total<br/>
    Stockholders&#8217;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Gain
    (Loss)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -0.125in; padding-left: 0.125in; width: 24.4%"><span style="font-family: Times New Roman, Times, Serif">Balances
    as of February 6, 2024 (inception)</span></td><td style="width: 0.1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-39; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 0.1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 0.1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-40; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 0.1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 0.1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-41; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 0.1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 0.1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-42; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 0.1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-left: Black 1.5pt solid; width: 0.1%"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 0.1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 0.1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-44; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 0.1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 0.1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c21" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-24240">3,197,975</ix:nonFraction></span></td><td style="width: 0.1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 0.1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-24241">3</ix:nonFraction></span></td><td style="width: 0.1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 0.1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-24242">2</ix:nonFraction></span></td><td style="width: 0.1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 0.1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 0.1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 0.1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 0.1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 0.1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-24243">1</ix:nonFraction></span></td><td style="width: 0.1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c29" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-24244">2,207,553</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-24245">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" sign="-" unitRef="usd" id="ixv-24246">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-54; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-55; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Issuance of Series A convertible preferred stock, net of issuance costs of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" scale="3" unitRef="usd" id="ixv-24247">69</ix:nonFraction></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c26" decimals="INF" format="ixt:num-dot-decimal" name="orka:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-24248">20,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-24249">2,931</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-56; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-57; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-58; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-59; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Exchange
    of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse capitalization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c26" decimals="INF" format="ixt:num-dot-decimal" name="orka:TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" sign="-" unitRef="shares" id="ixv-24250">20,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" sign="-" unitRef="usd" id="ixv-24251">2,931</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c28" decimals="INF" format="ixt:num-dot-decimal" name="orka:TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares" id="ixv-24252">137,138</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" unitRef="usd" id="ixv-24253">2,931</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" unitRef="usd" id="ixv-24254">2,931</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Conversion
    of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-74; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-75; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-76; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-77; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-78; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c29" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" unitRef="shares" id="ixv-24255">2,722,207</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" unitRef="usd" id="ixv-24256">3</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" unitRef="usd" id="ixv-24257">26,445</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-79; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" unitRef="usd" id="ixv-24258">26,448</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of common stock and pre-funded warrants in the Pre-Closing Financing</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c29" decimals="INF" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" scale="0" unitRef="shares" id="ixv-24259">20,061,932</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" scale="3" unitRef="usd" id="ixv-24260">20</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" scale="3" unitRef="usd" id="ixv-24261">248,437</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" scale="3" unitRef="usd" id="ixv-24262">248,457</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Issuance
    costs of Pre-Closing Financing and reverse recapitalization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-90; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-91; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-92; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" unitRef="usd" id="ixv-24263">20,504</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" unitRef="usd" id="ixv-24264">20,504</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-97; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-98; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-99; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-100; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c29" decimals="INF" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" scale="0" unitRef="shares" id="ixv-24265">1,208,883</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" scale="3" unitRef="usd" id="ixv-24266">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" scale="3" unitRef="usd" id="ixv-24267">4,999</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-101; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-102; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" scale="3" unitRef="usd" id="ixv-24268">5,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-103; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-104; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c27" decimals="INF" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" scale="0" unitRef="shares" id="ixv-24269">2,439</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" scale="3" unitRef="usd" id="ixv-24270">56,097</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-105; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-106; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c29" decimals="INF" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" scale="0" unitRef="shares" id="ixv-24271">5,600,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" scale="3" unitRef="usd" id="ixv-24272">6</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" scale="3" unitRef="usd" id="ixv-24273">144,433</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-107; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-108; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" scale="3" unitRef="usd" id="ixv-24274">144,439</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Issuance
    costs of PIPE Financing</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-109; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceCostOfPIPEFinancing" scale="3" sign="-" unitRef="usd" id="ixv-24275">3,263</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-110; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-111; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceCostOfPIPEFinancing" scale="3" sign="-" unitRef="usd" id="ixv-24276">8,592</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-112; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-113; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceCostOfPIPEFinancing" scale="3" sign="-" unitRef="usd" id="ixv-24277">8,592</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Conversion
    of Series A non-voting convertible preferred stock to common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-114; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-115; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c27" decimals="INF" format="ixt:num-dot-decimal" name="orka:ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" scale="0" sign="-" unitRef="shares" id="ixv-24278">2,439</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" scale="3" sign="-" unitRef="usd" id="ixv-24279">52,834</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-116; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-117; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c29" decimals="INF" format="ixt:num-dot-decimal" name="orka:ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" scale="0" unitRef="shares" id="ixv-24280">2,439,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" scale="3" unitRef="usd" id="ixv-24281">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" scale="3" unitRef="usd" id="ixv-24282">52,832</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-118; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-119; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" scale="3" unitRef="usd" id="ixv-24283">52,834</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of common stock under employee stock purchase plan</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-124; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-125; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c29" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" unitRef="shares" id="ixv-24284">2,960</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-126; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" unitRef="usd" id="ixv-24285">53</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-127; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-128; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" unitRef="usd" id="ixv-24286">53</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Reclassification
    of the Paruka warrant from liability to equity</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-129; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-130; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-131; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-132; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd" id="ixv-24287">10,357</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-133; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-134; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd" id="ixv-24288">10,357</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Stock-based
    compensation expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-135; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-136; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-137; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-138; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-24289">4,562</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-139; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-140; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-24290">4,562</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Unrealized
    loss on marketable securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-141; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-142; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-143; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-144; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-145; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-24291">41</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-146; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-24292">41</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-147; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-148; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-left: Black 1.5pt solid; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-149; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-150; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-151; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-24293">83,724</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-24294">83,724</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Balances
    as of December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-152; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-153; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-154; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-155; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-left: Black 1.5pt solid; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c35" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-24295">137,138</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-24296">2,931</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c36" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-24297">37,440,510</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-24298">37</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-24299">463,018</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-24300">41</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-24301">83,724</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-24302">382,221</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="f_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ORUKA
THERAPEUTICS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>CONSOLIDATED
STATEMENT OF CASH FLOWS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(In
thousands)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from<br/>
    February 6,<br/>
    2024<br/>
    (Inception) to<br/>
    December 31, <br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Cash flows from operating activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-24303">83,724</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Adjustments to reconcile
    net loss to net cash used in operating activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation
    expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-24304">14,919</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net accretion of premiums
    and discounts on marketable securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" unitRef="usd" id="ixv-24305">2,245</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-cash interest expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashExpense" scale="3" unitRef="usd" id="ixv-24306">1,468</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-cash lease expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd" id="ixv-24307">127</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Depreciation expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-24308">27</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Changes in operating
    assets and liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid expenses and
    other current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" unitRef="usd" id="ixv-24309">1,128</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other non-current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" unitRef="usd" id="ixv-24310">43</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" unitRef="usd" id="ixv-24311">3,462</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued expenses and
    other current liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" unitRef="usd" id="ixv-24312">3,292</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-24313">14</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Related
    party accounts payable and other current liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" scale="3" unitRef="usd" id="ixv-24314">6,022</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash used in operating activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-24315">57,837</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash flows from investing
    activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Purchases of property
    and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-24316">189</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Purchases
    of marketable securities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" unitRef="usd" id="ixv-24317">329,938</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash used in investing activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-24318">330,127</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash flows from financing
    activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds
    from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="3" unitRef="usd" id="ixv-24319">2,931</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds
    from issuance of notes payable to related party, net of issuance costs paid</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromNotesPayable" scale="3" unitRef="usd" id="ixv-24320">24,980</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds from the Pre-Closing
    Financing, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="3" unitRef="usd" id="ixv-24321">227,953</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds from the PIPE
    Financing, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="3" unitRef="usd" id="ixv-24322">188,681</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash acquired in connection
    with the reverse recapitalization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:CashAcquiredInConnectionWithTheReverseRecapitalization" scale="3" unitRef="usd" id="ixv-24323">4,940</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Proceeds
    from issuance of common stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-24324">54</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash provided by financing activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-24325">449,539</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net increase in cash and
    cash equivalents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" unitRef="usd" id="ixv-24326">61,575</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash at beginning of period</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-156; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents
    at end of period</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-24327">61,575</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Supplemental disclosures
    of non-cash operating and financing activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease liability
    arising from obtaining operating right-of-use asset</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-24328">982</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Assets acquired in connection
    with the reverse capitalization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" scale="3" unitRef="usd" id="ixv-24329">114</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other liabilities assumed
    in connection with the reverse recapitalization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" scale="3" unitRef="usd" id="ixv-24330">54</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-cash accrued interest
    on convertible note converted to common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" scale="3" unitRef="usd" id="ixv-24331">1,468</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-cash
    exchange of Pre-Merger Oruka Series A preferred stock for Series B convertible preferred stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock" scale="3" unitRef="usd" id="ixv-24332">2,931</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Conversion of Series
    A non-voting convertible preferred stock to common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" unitRef="usd" id="ixv-24333">52,834</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Reclassification of
    the Paruka warrant from liability to equity</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:ReclassificationOfTheParukaWarrantFromLiabilityToEquity" scale="3" unitRef="usd" id="ixv-24334">10,357</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these consolidated financial statements</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 94 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="f_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ORUKA
THERAPEUTICS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_1" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="ixv-11731"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>1.
Nature of the Business and Basis of Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Background
and Basis of Presentation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Oruka
Therapeutics, Inc., together with its subsidiaries (collectively, the &#8220;Company&#8221;), formerly known as ARCA biopharma, Inc.
(&#8220;ARCA&#8221;), is a clinical-stage biotechnology company that is the result of the reverse recapitalization discussed below. Prior
to the reverse recapitalization, the private company Oruka Therapeutics, Inc. (&#8220;Pre-Merger Oruka&#8221;) was established and incorporated
under the laws of the state of Delaware on February&#160;6, 2024 (referred to in the Notes as the inception of the Company). The Company
is headquartered in Menlo Park, California. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis
(&#8220;PsO&#8221;) and other inflammatory and immunology (&#8220;I&amp;I&#8221;) indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
accompanying consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiaries. Intercompany
balances and transactions have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared
in conformity with United States (&#8220;U.S.&#8221;) generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in
these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;)
and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Reverse
Recapitalization and Pre-Closing&#160;Financing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">On
August 29, 2024 (the &#8220;Merger Closing&#8221;), the Company completed the acquisition (the &#8220;Merger&#8221;) of Pre-Merger Oruka
pursuant to an Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024 (the &#8220;Merger Agreement&#8221;). Following
the transactions contemplated by the Merger Agreement, Pre-Merger Oruka merged with and into Atlas Merger Sub Corp., a wholly owned subsidiary
of ARCA and following that, Pre-Merger Oruka then merged with and into Atlas Merger Sub II, LLC (&#8220;Second Merger Sub&#8221;), with
Second Merger Sub being the surviving entity. Second Merger Sub changed its corporate name to &#8220;Oruka Therapeutics Operating Company,
LLC.&#8221; On August 29, 2024, the Company changed its name from &#8220;ARCA biopharma, Inc.&#8221; to &#8220;Oruka Therapeutics, Inc.&#8221;
and its Nasdaq ticker symbol from &#8220;ABIO&#8221; to &#8220;ORKA&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Following
consummation of the Merger, the Company effected a <ix:nonNumeric contextRef="c40" name="us-gaap:StockholdersEquityReverseStockSplit" id="ixv-24335">1-for-12</ix:nonNumeric> reverse stock split (the &#8220;Reverse Stock Split&#8221;) of the common
stock, par value $<ix:nonFraction contextRef="c41" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-24336">0.001</ix:nonFraction> per share, of the Company (&#8220;Company Common Stock&#8221;), which became effective on September 3, 2024.
The Company Common Stock commenced trading on a post-Reverse Stock Split, post-Merger basis at the opening of trading on September 3,
2024. The Company is led by the Pre-Merger Oruka management team and remains focused on developing biologics to optimize the treatment
of inflammatory skin diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Immediately
prior to the execution and delivery of the Merger Agreement on April 3, 2024, certain new and existing investors of Pre-Merger Oruka
entered into a subscription agreement with Pre-Merger Oruka (the &#8220;Subscription Agreement&#8221;), pursuant to which, and on the
terms and subject to the conditions of which, immediately prior to the Closing, those investors purchased shares of common stock of Pre-Merger
Oruka (&#8220;Pre-Merger Oruka Common Stock&#8221;) and Pre-Merger Oruka pre-funded warrants for gross proceeds of approximately $<ix:nonFraction contextRef="c42" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="6" unitRef="usd" id="ixv-24337">275.0</ix:nonFraction>
million (which includes $<ix:nonFraction contextRef="c42" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" unitRef="usd" id="ixv-24338">25.0</ix:nonFraction> million of proceeds previously received from the issuance of the Convertible Note (as defined in Note 7)
and accrued interest on such note which converted to shares of Pre-Merger Oruka Common Stock) (the &#8220;Pre-Closing Financing&#8221;).
The Company incurred transaction costs of $<ix:nonFraction contextRef="c43" decimals="-5" format="ixt:num-dot-decimal" name="orka:AdditionalPaidInCapitalTransacationCost" scale="6" unitRef="usd" id="ixv-24339">20.5</ix:nonFraction> million which was recorded as a reduction to additional paid-in capital in the consolidated
financial statements. At the Merger Closing, the shares of Pre-Merger Oruka Common Stock and Pre-Merger Oruka pre-funded warrants issued
pursuant to the Subscription Agreement were converted into shares of Company Common Stock and pre-funded warrants of Company Common Stock
in accordance with the Exchange Ratio (defined below).</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 95 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_2" id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
accordance with an Exchange Ratio determined by terms of the Merger Agreement and upon the effective time of the First Merger (the &#8220;First
Effective Time&#8221;), (i) each then-issued and outstanding share of Pre-Merger Oruka Common Stock including outstanding and unvested
Pre-Merger Oruka restricted stock and shares of Pre-Merger Oruka Common Stock issued in connection with the Subscription Agreement, were
converted into the right to receive a number of shares of Company Common Stock, equal to the Exchange Ratio of <ix:nonFraction contextRef="c44" decimals="4" format="ixt:num-dot-decimal" name="orka:ExchangeRatio" scale="0" unitRef="pure" id="ixv-24340">6.8569</ix:nonFraction> shares of Company
Common Stock, which were subject to the same vesting provisions as those immediately prior to the Merger, (ii) each share of Pre-Merger
Oruka Series A convertible preferred stock, par value $<ix:nonFraction contextRef="c45" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-24341">0.0001</ix:nonFraction> (&#8220;Pre-Merger Oruka Series A Preferred Stock&#8221;), outstanding
immediately prior to the First Effective Time was converted into the right to receive a number of shares of ARCA Series B non-voting
convertible preferred stock, par value $<ix:nonFraction contextRef="c46" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-24342">0.001</ix:nonFraction> per share (&#8220;Company Series B Preferred Stock&#8221;), which are convertible into
shares of Company Common Stock, at a conversion ratio of approximately <ix:nonNumeric contextRef="c47" name="orka:CommonStocksConversionRatio" id="ixv-24343">83:3332:1</ix:nonNumeric> (iii) each outstanding option to purchase Pre-Merger
Oruka Common Stock was converted into an option to purchase shares of Company Common Stock, (iv) each outstanding warrant to purchase
shares of Pre-Merger Oruka Common Stock was converted into a warrant to purchase shares of Company Common Stock, and (v) each share of
Company Common Stock issued and outstanding at the First Effective Time remain issued and outstanding in accordance with its terms and
such shares. Subsequent to the close of the merger, the common stock shares were then subject to the reverse stock split of 1-for-12
effected on September 3, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
part of the Pre-Closing Financing and the Merger Closing, investors in the Pre-Closing Financing received <ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="orka:InvestorsClosingShares" scale="0" unitRef="shares" id="ixv-24344">22,784,139</ix:nonFraction> shares of Company
Common Stock in exchange for <ix:nonFraction contextRef="c49" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-24345">39,873,706</ix:nonFraction> shares of Pre-Merger Oruka Common Stock (which includes the issuance of <ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-24346">2,722,207</ix:nonFraction> shares of Company
Common Stock in exchange for <ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-24347">4,764,032</ix:nonFraction> shares of Pre-Merger Oruka Common Stock on the conversion of Convertible Note along with the accrued
interest through the conversion date) and <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="orka:PreFundedWarrantsOfCommonStockShares" scale="0" unitRef="shares" id="ixv-24348">5,522,207</ix:nonFraction> Company pre-funded warrants in exchange for <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightUnissued" scale="0" unitRef="shares" id="ixv-24349">9,664,208</ix:nonFraction> Pre-Merger pre-funded warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Pre-Merger Oruka
was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the fact that, immediately
following the Merger: (i) Pre-Merger Oruka stockholders own a substantial majority of the voting rights in the combined company; (ii)
Pre-Merger Oruka&#8217;s largest stockholders retain the largest interest in the combined company; (iii) Pre-Merger Oruka designated
a majority of the initial members of the board of directors of the combined company; and (iv) Pre-Merger Oruka&#8217;s executive management
team became the management team of the combined company. Accordingly, for accounting purposes: (i) the Merger was treated as the equivalent
of Pre-Merger Oruka issuing stock to acquire the net assets of ARCA, and (ii) the reported historical operating results of the combined
company prior to the Merger are those of Pre-Merger Oruka. Additional information regarding the Merger is included in Note 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">On
September 3, 2024, the Company effected the Reverse Stock Split, a 1-for-12 reverse stock split of Company Common Stock. The par value
per share and the number of authorized shares were not adjusted as a result of the Reverse Stock Split. The shares of Company Common
Stock underlying outstanding stock options, common stock warrants and other equity instruments were proportionately reduced and the respective
exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.
All references to common stock, options to purchase common stock, outstanding common stock warrants, common stock share data, per share
data, and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect
of the Reverse Stock Split for all periods presented, unless otherwise specifically indicated or the context otherwise requires.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>PIPE
Financing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">On
September 11, 2024, the Company entered into a Securities Purchase Agreement for a private placement (the &#8220;PIPE Financing&#8221;)
with certain institutional and accredited investors. The closing of the PIPE Financing occurred on September 13, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;Pursuant
to the Securities Purchase Agreement, the investors purchased an aggregate of <ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="orka:NumberOfSharesPurchased" scale="0" unitRef="shares" id="ixv-24350">5,600,000</ix:nonFraction> shares of Company Common Stock at a purchase
price of $<ix:nonFraction contextRef="c50" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-24351">23.00</ix:nonFraction> per share, an aggregate of <ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="orka:NumberofAggregateShares" scale="0" unitRef="shares" id="ixv-24352">2,439</ix:nonFraction> shares of the Company&#8217;s Series A non-voting convertible preferred stock, par value
$<ix:nonFraction contextRef="c52" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-24353">0.001</ix:nonFraction> per share (&#8220;Company Series A Preferred Stock&#8221;), at a purchase price of $<ix:nonFraction contextRef="c9" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-24354">23,000.00</ix:nonFraction> per share (each Company Series A
Preferred Stock is convertible into <ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-24355">1,000</ix:nonFraction> shares of Company Common Stock), and pre-funded warrants to purchase an aggregate of <ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="orka:PrefundedWarrantstoPurchaseAnAggregateShares" scale="0" unitRef="shares" id="ixv-24356">680,000</ix:nonFraction>
shares of Company Common Stock at a purchase price of $<ix:nonFraction contextRef="c54" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-24357">22.999</ix:nonFraction> per pre-funded warrant, for aggregate net proceeds of approximately $<ix:nonFraction contextRef="c55" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="6" unitRef="usd" id="ixv-24358">188.7</ix:nonFraction>
million (net of issuance costs of $<ix:nonFraction contextRef="c55" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="6" unitRef="usd" id="ixv-24359">11.9</ix:nonFraction> million).</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 96 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Liquidity
and Going Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Since
its inception, the Company has devoted substantially all of its resources to advancing the development of its portfolio of programs,
organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations.
Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and
regulatory approvals to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever,
the Company expects to finance its operating activities through a combination of equity offerings and debt financings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative
cash flows from operations since inception. For the period from February 6, 2024 (inception) to December 31, 2024, the Company has incurred
a net loss of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" sign="-" unitRef="usd" id="ixv-24360">83.7</ix:nonFraction> million and used net cash of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" sign="-" unitRef="usd" id="ixv-24361">57.8</ix:nonFraction> million for its operating activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2024, the Company had cash, cash equivalents, and marketable securities of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsAndCash" scale="6" unitRef="usd" id="ixv-24362">393.7</ix:nonFraction> million. The Company&#8217;s management
expects that the existing cash, cash equivalents, and marketable securities will be sufficient to fund the Company&#8217;s operating
plans for at least twelve months from the date these consolidated financial statements were issued. The Company expects that its research
and development and general and administrative costs will continue to increase significantly, including in connection with conducting
future pre-clinical activities and clinical trials and manufacturing for its existing product candidates and any future product candidates
to support commercialization and providing general and administrative support for its operations, including the costs associated with
operating as a public company. The Company&#8217;s ability to access capital when needed is not assured and, if capital is not available
to the Company when, and in the amounts needed, the Company may be required to significantly curtail, delay, or discontinue one or more
of its research or development programs or the commercialization of any product candidate, or be unable to expand its operations or otherwise
capitalize on the Company&#8217;s business opportunities, as desired, which could materially harm the Company&#8217;s business, financial
condition and results of operations.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-11859"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>2.
Summary of Significant Accounting Policies </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-11867"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Use
of Estimates</i></b>&#160;</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
preparation of the Company&#8217;s consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates,
assumptions, and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at
the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant
estimates and assumptions reflected within these consolidated financial statements include but are not limited to research and development
expenses and related prepaid or accrued costs and the valuation of stock-based compensation awards and related expenses. The Company
bases its estimates on known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances.
On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results
could differ materially from those estimates or assumptions.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-11879"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Concentrations
of Credit Risk and Other Risks and Uncertainties</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Financial
instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities.
The Company&#8217;s investment policy limits investments to high credit quality securities issued by the U.S. government, U.S. government-sponsored
agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company&#8217;s
cash, cash equivalents and marketable securities are held by financial institutions that management believes are of high credit quality.
The financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits.
Accounts at the Company&#8217;s U.S. banking institution are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;)
up to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FederalDepositInsuranceCorporationPremiumExpense" scale="0" unitRef="usd" id="ixv-24363">250,000</ix:nonFraction> per depositor. As of December 31, 2024, the balance at the Company&#8217;s U.S. banking institution exceeded the FDIC
limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its accounts are monitored by management
to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash
equivalents, and bond issuers.</span></p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 97 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company is dependent on third-party organizations to research, develop, manufacture, and process its product candidates for its development
programs, including its two most advanced programs, ORKA-001 and ORKA-002. The Company expects to continue to be dependent on a small
number of manufacturers to supply it with its requirements for all products. The Company&#8217;s research and development programs could
be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company&#8217;s
research and development activities are performed under its agreements with Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) (see Note&#160;12).</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-11912"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Cash
and Cash Equivalents</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to
be cash equivalents. The cash equivalents were comprised of investments in money market funds, U. S. treasury securities, U.S. government
agency securities, and debt securities and are stated at fair value.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_MarketableSecuritiesPolicy-c0_cont_1" escape="true" name="us-gaap:MarketableSecuritiesPolicy" id="ixv-11924"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Marketable
Securities</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_MarketableSecuritiesPolicy-c0_cont_2" id="_MarketableSecuritiesPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company invests in marketable securities, primarily securities issued by the U.S. government and its agencies, commercial paper and corporate
debt securities. The Company&#8217;s marketable securities are classified as available-for-sale and reported at fair value, with unrealized
gains and losses included as a component of accumulated other comprehensive loss.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_MarketableSecuritiesPolicy-c0_cont_3" id="_MarketableSecuritiesPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">For
available-for-sale debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more
likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria
regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value and recognized
in other income (expense) in the results of operations. For available-for-sale debt securities that do not meet the aforementioned criteria,
the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment,
management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating
agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit
loss exists, an allowance is recorded for the difference between the present value of cash flows expected to be collected and the amortized
cost basis of the security. Impairment losses attributable to credit loss factors are charged against the allowance when management believes
an available-for-sale security is uncollectible or when either of the criteria regarding intent or requirement to sell is met.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_MarketableSecuritiesPolicy-c0_cont_4" id="_MarketableSecuritiesPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Any
unrealized losses from declines in fair value below the amortized cost basis as a result of non-credit loss factors are recognized as
a component of accumulated other comprehensive loss, net of unrealized gains. Realized gains and losses and declines in fair value, if
any, on available-for-sale securities are included in other income, net, in the results of operations.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_MarketableSecuritiesPolicy-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Marketable
securities with stated maturities of greater than three months from the date of purchase but less than one year from the consolidated
balance sheet date are classified as current, while marketable securities with maturities in one year or beyond one year from the consolidated
balance sheet date are classified as long-term. The cost of securities sold is determined using the specific-identification method. Interest
earned and adjustments for the amortization of premiums and discounts on investments are included in interest income on the consolidated
statements of operations and comprehensive loss.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DebtPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtPolicyTextBlock" id="ixv-11951"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Debt
Issuance Costs</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DebtPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Debt
issuance costs incurred in connection with the Convertible Note (see Note&#160;7) are recorded as a reduction of the carrying value of
the notes payable liability on the Company&#8217;s balance sheet and are amortized to interest expense over the term of the loan using
the effective interest method. At the effective time of the Merger the Converted Note was converted to common stock and is no longer
on the balance sheet as of December 31, 2024.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="orka_SubscriptionReceivablePolicyTextBlock-c0_cont_1" escape="true" name="orka:SubscriptionReceivablePolicyTextBlock" id="ixv-11963"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Subscription
Receivable&#160;</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="orka_SubscriptionReceivablePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable
is paid prior to the date the financial statement is available to be issued.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 98 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-11991"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Fair
Value Measurements&#160;</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Certain
assets and liabilities are carried at fair value under U.S.&#160;GAAP.&#160;Fair value is defined as the exchange price that would be
received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize
the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are
to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered
observable and the last is considered unobservable:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
                                            1&#160;&#8212;&#160;Quoted prices in active markets that are identical assets or liabilities.</span></td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level&#160;2&#160;&#8212;&#160;Observable
                                            inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar
                                            assets or liabilities, quoted prices in markets that are not active for identical or similar
                                            assets or liabilities, or other inputs that are observable or can be corroborated by observable
                                            market data.</span></td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level&#160;3&#160;&#8212;&#160;Unobservable
                                            inputs that are supported by little or no market activity that are significant to determining
                                            the fair value of the assets or liabilities, including pricing models, discounted cash flow
                                            methodologies, and similar techniques.</span></td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy
described above (see Note 4). The carrying values of the Company&#8217;s prepaid expenses and other current assets, accounts payable
and accrued expenses and other current liabilities approximate their fair values due to their relatively short maturity period.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-12038"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Property
and Equipment</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-12045"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Property
and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over
the estimated useful life of each asset as follows:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Estimated<br/>
    Useful Life</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Furniture and fixtures</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c56" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-24364">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c57" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-24365">5</ix:nonNumeric> years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computer and office equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c58" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-24366">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c59" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-24367">5</ix:nonNumeric> years</span></td></tr>
  </table></ix:continuation></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock-c0_cont_1" escape="true" name="orka:ClassificationOfConvertiblePreferredStockPolicyTextBlock" id="ixv-12079"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Classification
of Convertible Preferred Stock</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock-c0_cont_2" id="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Prior
to the reverse recapitalization, the Company had classified its Pre-Merger Oruka Series A Preferred Stock outside of stockholders&#8217;
equity on the Company&#8217;s consolidated balance sheet because the holders of such stock have certain liquidation rights in the event
of a deemed liquidation event that, in certain situations, is not solely within the control of the Company and would require the redemption
of the then-outstanding convertible preferred stock.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock-c0_cont_3" id="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Upon
the closing of the Merger, the Company converted its Pre-Merger Oruka Series A Preferred Stock to Company Series B Preferred Stock and
has classified the Company Series B Preferred Stock within stockholders&#8217; equity on its consolidated balance sheet because the Company
Series B Preferred Stock is not redeemable or puttable to the Company by the holder under any circumstances.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
connection with the PIPE Financing (see Note 1) the Company issued Company Series A Preferred Stock, and has classified the Company Series
A Preferred Stock outside of stockholders&#8217; equity on the Company&#8217;s consolidated balance sheet because the holders of such
stock have certain rights (see Note 8) that, in certain situations, is not solely within the control of the Company and would require
the redemption of the then-outstanding convertible preferred stock. In November 2024, the Company Series A Preferred Stock shares were
converted to common stock, and as of December 31, 2024, there were no shares of Company Series A Preferred Stock outstanding.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 99 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="orka_NotePayableToRelatedPartyPolicyTextBlock-c0_cont_1" escape="true" name="orka:NotePayableToRelatedPartyPolicyTextBlock" id="ixv-12117"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Note&#160;Payable
to Related Party</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="orka_NotePayableToRelatedPartyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company accounted for the Convertible Note (as defined in Note 7) at amortized cost. The Company considered if optional conversion features
are required to be bifurcated and separately accounted for as a derivative. Costs related to the issuance of the Convertible Note were
recorded as a debt discount, amortized over the term of the Convertible Note (see&#160;Note&#160;7) and were accounted for as interest
expense in other income (expenses) within the consolidated statement of operations and comprehensive loss using the effective interest
method. At the effective time of the Merger, shares of Pre-Merger Oruka Common Stock issued pursuant to the conversion of the Convertible
Note (including accrued interest) automatically converted into shares of Company Common Stock (see Note 1).</span></p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock-c0_cont_1" escape="true" name="orka:ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" id="ixv-12129"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Research
and Development Contract Costs Accruals</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock-c0_cont_2" id="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component
of the Company&#8217;s research and development expenses, with a substantial portion of the Company&#8217;s ongoing research and development
activities conducted by third-party service providers, including contract research organizations (&#8220;CROs&#8221;) and contract manufacturing
organizations (&#8220;CMOs&#8221;), and the Company&#8217;s related-party Paragon (see Note&#160;12).</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company accrues for expenses resulting from obligations under its two antibody discovery and option agreements (the &#8220;Option Agreements&#8221;)
(see Note 12), by and among Paragon, Paruka Holding LLC (&#8220;Paruka&#8221;), an entity formed by Paragon as a vehicle to hold equity
in the Company, and the Company as well as agreements with CROs, CMOs, and other outside service providers for which payment flows do
not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services
received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These
estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with
internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant
judgments and estimates in determining the accrual balance in each reporting period. If advance payments are made to Paragon, a CRO,
CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services
are performed. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the
Company&#8217;s results of operations. As of December 31, 2024, the Company has not experienced any material deviations between accrued
and actual research and development expenses.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-12146"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Leases</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_2" id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">At
the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies
a lease as either an operating or finance lease and recognizes a right-of-use (&#8220;ROU&#8221;) asset and a current and non-current
lease liability, as applicable, in the balance sheet if the lease has a term greater than one year. Lease terms may include options to
extend or terminate the lease when it is reasonably certain that the Company will exercise its option.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_3" id="_LesseeLeasesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">At
the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future
minimum lease payments over the expected remaining lease term. The Company determines the present value of lease payments using the implicit
rate, if it is readily determinable, or the risk-free discount rate for a period comparable with that of the lease term. For operating
leases, lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, lease expense
includes amortization expense of the ROU asset recognized on a straight-line basis over the lease term and interest expense recognized
on the finance lease liability. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments,
incentives received or initial direct costs. As of December 31, 2024, the Company has one operating lease and no finance leases.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for lease and non-lease components related to operating leases as a single lease component. The Company has elected
that costs associated with leases having an initial term of 12 months or less are recognized in the consolidated statement of operations
and comprehensive loss on a straight-line basis over the lease term and are not recorded on its consolidated balance sheets. Variable
lease expense is recognized as incurred and consists primarily of real estate taxes, utilities, and other office space related expenses.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 100 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-12184"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Segment
Reporting</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company operates as a
single reportable and operating segment. Its Chief Executive Officer, serving as the Chief Operating Decision Maker (&#8220;CODM&#8221;),
oversees operations on an aggregated basis to allocate resources effectively. In assessing the Company&#8217;s financial performance,
the CODM regularly reviews total operating expenses and consolidated net loss.</p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-12196"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Research
and Development Costs</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_2" id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Research
and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock-based compensation,
employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities, as well as allocated
human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Nonrefundable
advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid
expenses on the accompanying consolidated balance sheet. The prepaid amounts are expensed as the related goods are delivered or the services
are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable advance
payments represent a one-time cost for obtaining goods or services, with anticipated benefits to be utilized within a year of period
end, the payment is expensed immediately.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_SellingGeneralAndAdministrativeExpensesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="ixv-12213"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>General
and Administrative Expenses</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_SellingGeneralAndAdministrativeExpensesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">General
and administrative expenses consist primarily of salaries and bonuses, stock-based compensation, employee benefits, finance and administration
costs, patent and intellectual property costs, professional fees, as well as allocated human resource costs, information technology costs,
and facility-related costs, including rent, maintenance, utilities and depreciation.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="ixv-12225"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Commitments
and Contingencies</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities.
The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the
loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the
balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but
not probable; however, it discloses the range of reasonably possible losses. As of December 31, 2024, no liabilities were recorded for
loss contingencies (see Note&#160;13).</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-12237"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock-Based
Compensation</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company estimates the fair value of its stock awards using the Black-Scholes option pricing model, which uses as inputs the fair value
of the Company&#8217;s common stock, and certain management estimates, including the expected stock price volatility, the expected term
of the award, the risk-free interest rate, and expected dividends. Expected volatility is calculated based on reported volatility data
for a representative group of publicly traded companies for which historical information is available. The Company selects companies
with comparable characteristics with historical share price information that approximates the expected term of the equity-based awards.
The Company computes the historical volatility data using the daily closing prices for the selected companies&#8217; shares during the
equivalent period that approximates the calculated expected term of the stock options. The Company will continue to apply this method
until a sufficient amount of historical information regarding the volatility of its stock price becomes available. The risk-free interest
rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. For employee
and non-employee awards (except the Paruka warrant) the Company uses the simplified method, under which the expected term is presumed
to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to lack of historical
exercise data. For the Paruka warrant, the contractual term is used for the expected term. The expected dividend yield is assumed to
be zero as the Company has no current plans to pay any dividends on common stock.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company measures restricted common stock awards (&#8220;RSAs&#8221;) using the difference, if any, between the purchase price per share
of the award and the fair value of the Company&#8217;s common stock at the date of grant.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_4" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company grants stock options, restricted stock awards, and warrants that are subject to service or performance-based vesting conditions.
Compensation expense for awards to employees and directors with service-based vesting conditions is recognized using the straight-line
method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards
to non-employees with service-based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for
the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each
reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation
expense until it is probable that the performance-based vesting condition will be achieved.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_5" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company has issued stock options, warrants, and RSAs with service-based and performance-based vesting conditions.</span></p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_6" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company recognizes the compensation expense for the option to purchase common stock under the Employee Stock Purchase Plan (&#8220;ESPP&#8221;),
based on the fair value of the common stock estimated using the closing price of the Company&#8217;s common stock as reported on the
date of offering, less the purchase discount percentage provided for in the plan.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company classifies stock-based compensation expense in its consolidated statement of operations and comprehensive loss in the same manner
in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified,
as applicable.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="orka_ComprehensiveLossPolicyPolicyTextBlock-c0_cont_1" escape="true" name="orka:ComprehensiveLossPolicyPolicyTextBlock" id="ixv-12290"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Comprehensive
Loss</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="orka_ComprehensiveLossPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Comprehensive
loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and events other than those
with stockholders. The Company&#8217;s unrealized gains and losses on marketable securities represent the only component of other comprehensive
loss that are excluded from the reported net loss and that are presented in the consolidated statement of comprehensive loss.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-12302"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Net
Loss per Share Attributable to Stockholders</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Basic
and diluted net loss attributable to stockholders per share is presented in conformity with the two-class method required for participating
securities (Pre-Merger Oruka Series A Preferred Stock). Basic earnings per share is computed by dividing net income available to each
class of shares by the weighted-average number of shares of common stock and participating securities outstanding during the period.
Pre-funded warrants were included as the exercise price is negligible and these warrants are fully vested and exercisable. Company Series
A Preferred Stock and Company Series B Preferred Stock share the same characteristics as Common Stock and have no substantive preference
attributed to them and, accordingly, have been considered as classes of Common Stock in the computation of net loss per share regardless
of their legal form.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_3" id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Net
loss is allocated to common stock based on its proportional ownership on an as-converted basis. Net loss is not allocated to participating
securities as they do not have an obligation to fund losses. The weighted-average number of shares outstanding of common stock reflects
changes in ownership over the periods presented. See Note 8 &#8212; Convertible Preferred Stock and Stockholders&#8217; Equity.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_4" id="_EarningsPerSharePolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Diluted
net loss per share is computed by dividing the net loss attributable to stockholders adjusted for income (expenses), net of tax, related
to any diluted securities, by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for
the period. For purposes of this calculation, stock options to purchase common stock, employee warrants to purchase common stock, and
unvested RSAs are considered potential dilutive common shares.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company generated a net loss for the periods presented. Accordingly, basic and diluted net loss per share is the same because the inclusion
of the potentially dilutive securities would be anti-dilutive.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="orka_OtherIncomeExpenseNetPolicyTextBlock-c0_cont_1" escape="true" name="orka:OtherIncomeExpenseNetPolicyTextBlock" id="ixv-12329"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Other
income, net</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="orka_OtherIncomeExpenseNetPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Other
income, net, consists of interest earned on the Company&#8217;s cash, cash equivalents, and marketable securities; interest expense on
the convertible note from a related party and foreign currency transactions gains and losses.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 102 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-12357"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Income
Taxes</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#8217;s tax
returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis
of assets and liabilities using enacted tax rates in effect for the&#160;years in which the differences are expected to reverse. Changes
in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred
tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence,
that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established
through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable
profits expected and considering prudent and feasible tax planning strategies.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to
determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will
be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained,
the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount
of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement.
The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered
appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or penalties related to
uncertain tax positions as of December 31, 2024.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="orka:RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-12374"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Recently
Adopted Accounting Pronouncements</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
November&#160;2023, the FASB issued ASU 2023-07, Segment Reporting (Topic&#160;280): Improvements to Reportable Segment Disclosures (&#8220;ASU&#160;2023-07&#8221;),
which enhances the segment disclosure requirements for public entities on an annual and interim basis. Under this standard, public entities
will be required to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure
of segment profit or loss. Additionally, current annual disclosures about a reportable segment&#8217;s profit or loss and assets will
be required on an interim basis. Entities will also be required to disclose information about the CODM&#8217;s title and position at
the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment of segment
performance and deciding how to allocate resources. Finally, ASU&#160;2023-07 requires all segment disclosures for public entities that
have only a single reportable segment. The amendments in ASU&#160;2023-07 are effective for fiscal&#160;years beginning after December&#160;15,
2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. Early adoption is permitted. The Company adopted
ASU 2023-07 in 2024 and additional required disclosures have been included in Note 10.</span></p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-12386"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Recently
Issued Accounting Pronouncements</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
December&#160;2023, the FASB issued ASU&#160;2023-09, Income Taxes (Topic&#160;740): Improvements to Income Tax Disclosures. This ASU
expands disclosures in an entity&#8217;s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S.&#160;and
foreign jurisdictions. This update is effective beginning with the Company&#8217;s 2025 fiscal year annual reporting period. The Company
is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
November 2024, the FASB issued ASU 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU requires more detailed disclosures, on an annual and interim
basis, about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense
captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and
interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. This ASU may be applied either prospectively
or retrospectively. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 103 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="ixv-12420"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>3.
Reverse Recapitalization and Pre-Closing Financing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
described within the Reverse Recapitalization and Pre-Closing Financing section in Note 1, on August 29, 2024, the reverse recapitalization
between Pre-Merger Oruka and ARCA was consummated. The Merger was accounted for as a reverse recapitalization in accordance with U.S.
GAAP. At the effective time of the Merger, substantially all of the assets of ARCA consisted of cash and cash equivalents and other nominal
non-operating assets and liabilities. No goodwill or intangible assets were recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="ixv-12430"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
part of the recapitalization, the Company acquired the assets and liabilities listed below (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">August
    29,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" unitRef="usd" id="ixv-24368">4,940</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="3" unitRef="usd" id="ixv-24369">114</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="3" unitRef="usd" id="ixv-24370">54</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 6.85pt"><span style="font-family: Times New Roman, Times, Serif">Net
    assets acquired</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="3" unitRef="usd" id="ixv-24371">5,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" id="ixv-12495"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>4.
Fair Value Measurements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="ixv-12501"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following tables present the Company&#8217;s fair value hierarchy for financial assets measured as of December 31, 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    3</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Cash equivalents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Money market
    funds</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-24372">6,350</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-157; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-158; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-24373">6,350</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. treasury securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-24374">19,660</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-159; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-24375">19,660</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. government agency
    securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-160; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-24376">3,988</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-161; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-24377">3,988</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Commercial
    papers</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-162; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-24378">22,177</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-163; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-24379">22,177</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    cash equivalents</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-24380">6,350</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-24381">45,825</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-164; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-24382">52,175</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable securities,
    current</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. treasury securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-24383">190,792</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-165; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-24384">190,792</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. government agency
    securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-166; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-24385">12,966</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-167; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-24386">12,966</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commercial papers</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-168; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-24387">34,811</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-169; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-24388">34,811</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Corporate
    debt securities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-170; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-24389">75,504</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-171; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-24390">75,504</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    marketable securities, current</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-24391">314,073</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-172; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-24392">314,073</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable securities,
    long-term</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. treasury securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-24393">13,607</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-173; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-24394">13,607</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">U.S.
    government agency securities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-174; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-24395">4,462</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-175; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-24396">4,462</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    marketable securities, long-term</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-24397">18,069</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-176; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-24398">18,069</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total cash equivalents
    and marketable securities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="orka:FairValueCashEquivalentsAndMarketableSecurities" scale="3" unitRef="usd" id="ixv-24399">6,350</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="orka:FairValueCashEquivalentsAndMarketableSecurities" scale="3" unitRef="usd" id="ixv-24400">377,967</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-177; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="orka:FairValueCashEquivalentsAndMarketableSecurities" scale="3" unitRef="usd" id="ixv-24401">384,317</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There were no transfers in
or out of Level&#160;3 during the period from February 6, 2024 (inception) to December 31, 2024.</p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 104 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CashCashEquivalentsAndMarketableSecuritiesTextBlock-c0_cont_1" escape="true" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="ixv-13185"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>5.
Cash equivalents and marketable Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:MarketableSecuritiesTextBlock" id="ixv-13191"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Cash
equivalents and marketable securities, which are classified as available-for-sale, consisted of the following as of December 31, 2024
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Amortized
    Cost</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Gross
    Unrealized Gains</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Gross
    Unrealized Losses</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Fair
    Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Cash equivalents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Money market
    funds</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c83" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-24402">6,350</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-178; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-179; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c83" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-24403">6,350</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. treasury securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-24404">19,656</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" unitRef="usd" id="ixv-24405">4</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-180; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-24406">19,660</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. government agency
    securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c85" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-24407">3,988</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-181; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-182; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c85" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-24408">3,988</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Commercial
    papers</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c86" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-24409">22,180</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-183; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c86" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" unitRef="usd" id="ixv-24410">3</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c86" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-24411">22,177</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    cash equivalents</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c87" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-24412">52,174</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c87" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" unitRef="usd" id="ixv-24413">4</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c87" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" unitRef="usd" id="ixv-24414">3</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c87" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-24415">52,175</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable securities,
    current</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. treasury securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c88" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-24416">190,748</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c88" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" unitRef="usd" id="ixv-24417">55</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c88" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" unitRef="usd" id="ixv-24418">11</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c88" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-24419">190,792</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. government agency
    securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c89" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-24420">12,967</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c89" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" unitRef="usd" id="ixv-24421">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c89" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" unitRef="usd" id="ixv-24422">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c89" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-24423">12,966</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commercial papers</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-24424">34,808</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" unitRef="usd" id="ixv-24425">3</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-184; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-24426">34,811</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Corporate
    debt securities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c91" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-24427">75,537</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c91" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" unitRef="usd" id="ixv-24428">7</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c91" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" unitRef="usd" id="ixv-24429">40</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c91" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-24430">75,504</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    marketable securities, current</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-24431">314,060</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" unitRef="usd" id="ixv-24432">66</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" unitRef="usd" id="ixv-24433">53</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-24434">314,073</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable securities,
    long-term</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. treasury securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-24435">13,639</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-185; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" unitRef="usd" id="ixv-24436">32</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-24437">13,607</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">U.S.
    government agency securities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-24438">4,485</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-186; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" unitRef="usd" id="ixv-24439">23</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-24440">4,462</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    marketable securities, long-term</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-24441">18,124</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-187; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" unitRef="usd" id="ixv-24442">55</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-24443">18,069</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total cash equivalents
    and marketable securities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd" id="ixv-24444">384,358</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" unitRef="usd" id="ixv-24445">70</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" unitRef="usd" id="ixv-24446">111</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" unitRef="usd" id="ixv-24447">384,317</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="ixv-13857"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the available-for-sale securities in an unrealized loss position, aggregated by major security type and length
of time in a continuous unrealized loss position, for which an allowance for credit losses was not recorded as of December&#160;31, 2024,
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>Less
    than 12 months</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>12
    months or longer</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>Fair
    <br/>
    Value</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Unrealized<br/>
    Losses</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Fair
    <br/>
    Value</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Unrealized<br/>
    Losses</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>Fair<br/>
    Value</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Unrealized<br/>
    Losses</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Cash equivalents</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commercial
    papers</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" unitRef="usd" id="ixv-24448">18,199</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" unitRef="usd" id="ixv-24449">3</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-188; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-189; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" unitRef="usd" id="ixv-24450">18,199</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" unitRef="usd" id="ixv-24451">3</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable
    securities</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable
    securities, current</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S.
    treasury securities</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" unitRef="usd" id="ixv-24452">49,904</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" unitRef="usd" id="ixv-24453">11</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-190; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-191; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" unitRef="usd" id="ixv-24454">49,904</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" unitRef="usd" id="ixv-24455">11</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S.
    government agency securities</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c98" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" unitRef="usd" id="ixv-24456">4,713</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c98" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" unitRef="usd" id="ixv-24457">2</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-192; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-193; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c98" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" unitRef="usd" id="ixv-24458">4,713</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c98" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" unitRef="usd" id="ixv-24459">2</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Corporate
    debt securities</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" unitRef="usd" id="ixv-24460">39,468</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" unitRef="usd" id="ixv-24461">40</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-194; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-195; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" unitRef="usd" id="ixv-24462">39,468</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" unitRef="usd" id="ixv-24463">40</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable
    securities, long-term</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S.
    treasury securities</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c100" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" unitRef="usd" id="ixv-24464">13,607</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c100" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" unitRef="usd" id="ixv-24465">32</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-196; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-197; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c100" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" unitRef="usd" id="ixv-24466">13,607</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c100" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" unitRef="usd" id="ixv-24467">32</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">U.S.
    government agency securities</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" unitRef="usd" id="ixv-24468">4,462</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" unitRef="usd" id="ixv-24469">23</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-198; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-199; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" unitRef="usd" id="ixv-24470">4,462</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" unitRef="usd" id="ixv-24471">23</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.5in; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" unitRef="usd" id="ixv-24472">130,353</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" unitRef="usd" id="ixv-24473">111</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-200; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-201; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" unitRef="usd" id="ixv-24474">130,353</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" unitRef="usd" id="ixv-24475">111</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company evaluated its securities for credit losses and considered the decline in market value to be primarily attributable to current
economic and market conditions and not to a credit loss or other factors. Additionally, the Company does not intend to sell the securities
in an unrealized loss position and it is not more likely than not that the Company will be required to sell the securities before recovery
of the unamortized cost basis, which may be at maturity. There were no material realized gains or realized losses on marketable securities
for the period presented. Given the Company&#8217;s intent and ability to hold such securities until recovery, and the lack of significant
change in credit risk of these investments, the Company does not consider these marketable securities to be impaired as of December 31,
2024. As of December 31, 2024, the Company did not record an allowance for credit losses.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 105 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="ixv-14512"><ix:continuation id="_CashCashEquivalentsAndMarketableSecuritiesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the contractual maturities of the Company&#8217;s marketable securities at estimated fair value (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Due in one year or less</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd" id="ixv-24476">314,073</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Due in 1-2 years</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" unitRef="usd" id="ixv-24477">18,069</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecurities" scale="3" unitRef="usd" id="ixv-24478">332,142</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="ixv-14567"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>6.
Accrued Expenses and Other Current Liabilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="ixv-14573"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Accrued
expenses and other current liabilities consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31, <br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued employee compensation and
    benefits</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" unitRef="usd" id="ixv-24479">2,041</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued professional and consulting</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" unitRef="usd" id="ixv-24480">221</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued research and
    development</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="orka:AccruedResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-24481">1,084</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" unitRef="usd" id="ixv-24482">3,346</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DebtDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock" id="ixv-14638"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>7.
Note&#160;Payable with Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
March&#160;2024, Pre-Merger Oruka entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the &#8220;Purchase
Agreement&#8221;) with Fairmount Healthcare Fund&#160;II, L.P. (&#8220;Fairmount&#8221;), whereby Pre-Merger Oruka issued a convertible
note (the &#8220;Convertible Note&#8221;), with an initial principal amount of $<ix:nonFraction contextRef="c102" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" unitRef="usd" id="ixv-24483">25.0</ix:nonFraction> million that, at the time of issuance, could be
converted into Pre-Merger Oruka Series&#160;A Preferred Stock (or a series&#160;of preferred shares that is identical in respect to the
shares of preferred shares issued in its next equity financing) or shares of Pre-Merger Oruka Common Stock in exchange for aggregate
proceeds of $<ix:nonFraction contextRef="c103" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" unitRef="usd" id="ixv-24484">25.0</ix:nonFraction>&#160;million. The Convertible Note accrued interest at a rate of <ix:nonFraction contextRef="c104" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-24485">12.0</ix:nonFraction>% per annum. At issuance, the Convertible Note
required all unpaid interest and principal to mature on <ix:nonNumeric contextRef="c104" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-24486">December&#160;31, 2025</ix:nonNumeric> (the &#8220;Maturity Date&#8221;) and prepayment was not
permitted without prior written consent of Fairmount.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company assessed all terms and features of the Convertible Note in order to identify any potential embedded features that would require
bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the embedded features. The Company
determined that the share settled redemption feature was clearly and closely related to the debt host and did not require separate accounting.
The Company determined that the conversion options of the Convertible Note were not clearly and closely associated with a debt host.
However, these features did not meet the definition of a derivative under ASC&#160;815, Derivatives and Hedging, and as a result, did
not require separate accounting as a derivative liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company paid debt issuance costs of less than $<ix:nonFraction contextRef="c105" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" unitRef="usd" id="ixv-24487">0.1</ix:nonFraction>&#160;million in relation to the Convertible Note. The debt issuance costs were reflected
as a reduction of the carrying value of Convertible Note on the consolidated balance sheet and were being amortized as interest expense
over the term of the Convertible Note using the effective interest method. For the period from February&#160;6, 2024 (inception) to December
31, 2024, the Company recognized interest expenses related to the Convertible Note of $<ix:nonFraction contextRef="c106" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="6" unitRef="usd" id="ixv-24488">1.5</ix:nonFraction> million, which includes non-cash interest
expense related to the amortization of debt issuance.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 106 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_DebtDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Immediately
prior to the completion of the Merger (see Note 1), the Convertible Note was converted into shares of Pre-Merger Oruka Common Stock based
on the aggregate principal amount of $<ix:nonFraction contextRef="c107" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" unitRef="usd" id="ixv-24489">25.0</ix:nonFraction> million, plus unpaid accrued interest of $<ix:nonFraction contextRef="c105" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="6" unitRef="usd" id="ixv-24490">1.5</ix:nonFraction> million divided by the conversion price which
was determined based upon the Company&#8217;s fully-diluted capitalization immediately prior to the Merger. At the effective time of
the Merger, the Pre-Merger Oruka Common Stock issued upon the conversion of the Convertible Note (including accrued interest) automatically
converted into <ix:nonFraction contextRef="c108" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-24491">2,722,207</ix:nonFraction> shares of Company Common Stock. As of December 31, 2024, the Convertible Note is not outstanding.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-14678"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>8.
Convertible Preferred Stock and Stockholders&#8217; Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Pre-Funded
Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
August 2024, pursuant to the Subscription Agreement and immediately prior to the Closing, certain new and current investors purchased
pre-funded&#160;warrants, which, at the effective time of the Merger, were exercisable for <ix:nonFraction contextRef="c109" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-24492">5,522,207</ix:nonFraction> shares of Company Common Stock at
a purchase price of approximately $<ix:nonFraction contextRef="c110" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-24493">9.70</ix:nonFraction> per warrant. After the Merger, there are <ix:nonFraction contextRef="c110" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-24494">5,522,207</ix:nonFraction> pre-funded warrants outstanding and are exercisable
for <ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="orka:ClassOfWarrantsExercisable" scale="0" unitRef="shares" id="ixv-24495">5,522,207</ix:nonFraction> shares of the Company Common Stock at an exercise price of $<ix:nonFraction contextRef="c112" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-24496">0.01</ix:nonFraction> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
September 2024, in connection with the PIPE Financing, the Company issued and sold <ix:nonFraction contextRef="c113" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-24497">680,000</ix:nonFraction> pre-funded warrants, at a purchase price of
$<ix:nonFraction contextRef="c114" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-24498">22.999</ix:nonFraction> per warrant, exercisable for <ix:nonFraction contextRef="c115" decimals="INF" format="ixt:num-dot-decimal" name="orka:ClassOfWarrantsExercisable" scale="0" unitRef="shares" id="ixv-24499">680,000</ix:nonFraction> shares of Company Common Stock at an exercise price of $<ix:nonFraction contextRef="c116" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-24500">0.001</ix:nonFraction> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
pre-funded warrants were recorded as a component of stockholders&#8217; equity within additional paid-in-capital and have <span style="-sec-ix-hidden: hidden-fact-202">no</span> expiration
date. As of December 31, 2024, <span style="-sec-ix-hidden: hidden-fact-203">none</span> of the pre-funded warrants have been exercised and <ix:nonFraction contextRef="c118" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-24501">6,202,207</ix:nonFraction> pre-funded warrants remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Employee
Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
July 2024, Pre-Merger Oruka entered into a Subscription Agreement that provided for, among other things, the issuance of warrants to
certain of Pre-Merger Oruka&#8217;s employees and directors immediately prior to the closing of the Merger. During the period from February
6, 2024 (inception) to December 31, 2024, <ix:nonFraction contextRef="c119" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-24502">3,054,358</ix:nonFraction> employee warrants were issued at an exercise price of $<ix:nonFraction contextRef="c119" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-24503">7.80</ix:nonFraction> per warrant. These warrants
vest over a period of <ix:nonNumeric contextRef="c120" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-24504">four years</ix:nonNumeric>. Per the terms of the Employee Warrant Agreement, the holders of the Company&#8217;s warrants shall
not have any of the rights or privileges of a stockholder of the Company in respect of any shares purchasable upon the exercise of the
warrant or any portion thereof unless and until a certificate or certificates representing such shares have been issued or a book entry
representing such shares has been made and such shares have been deposited with the appropriate registered book-entry custodian. The
Company recognizes compensation cost related to warrants on a straight-line basis over the requisite service period, which is the period
in which the related services are received. As of December 31, 2024, <span style="-sec-ix-hidden: hidden-fact-204">none</span> of the warrants have been exercised and <ix:nonFraction contextRef="c119" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-24505">3,054,358</ix:nonFraction> warrants
remain outstanding.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Convertible
Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
March&#160;2024, Pre-Merger Oruka issued and sold an aggregate of <ix:nonFraction contextRef="c121" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-24506">20,000,000</ix:nonFraction> shares of Pre-Merger Oruka Series&#160;A Preferred Stock
to Fairmount (see Note 15), at a purchase price of approximately $<ix:nonFraction contextRef="c122" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-24507">0.15</ix:nonFraction> per share, for aggregate gross proceeds of $<ix:nonFraction contextRef="c123" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" unitRef="usd" id="ixv-24508">3.0</ix:nonFraction>&#160;million.
Pre-Merger Oruka incurred less than $<ix:nonFraction contextRef="c124" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" unitRef="usd" id="ixv-24509">0.1</ix:nonFraction>&#160;million of issuance costs in connection with this transaction. Upon the issuance of the
Pre-Merger Oruka Series&#160;A Preferred Stock, the Company assessed the embedded conversion and liquidation features of the securities
as described below and determined that such features did not require the Company to separately account for these features.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
August 2024, upon the closing of the Merger, the Company converted the Pre-Merger Oruka Series A Preferred Stock to <ix:nonFraction contextRef="c125" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-24510">137,138</ix:nonFraction> shares of
Company Series B Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
September 2024, in connection with the PIPE Financing, the Company issued and sold an aggregate of <ix:nonFraction contextRef="c126" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-24511">2,439</ix:nonFraction> shares of the Company Series
A Preferred Stock at a purchase price of $<ix:nonFraction contextRef="c127" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-24512">23,000.00</ix:nonFraction> per share.&#160;In November 2024, the <ix:nonFraction contextRef="c128" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-24513">2,439</ix:nonFraction> shares of the Company Series A Preferred
Stock were converted to <ix:nonFraction contextRef="c129" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-24514">2,439,000</ix:nonFraction> shares of Company Common Stock. As of December 31, 2024, there are <span style="-sec-ix-hidden: hidden-fact-205">no</span> outstanding shares of Company
Series A Preferred Stock.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 107 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="orka:ScheduleOfConvertiblePreferredStockTableTextBlock" id="ixv-14752"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2024, convertible preferred stock consisted of the following (in thousands, except share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Preferred<br/>
                                            Stock<br/>
                                            Authorized</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Preferred<br/>
    Stock Issued <br/>
    and<br/>
    Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Carrying<br/>
    Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Common
    Stock<br/>
    Issuable<br/>
    Upon<br/>
    Conversion</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series B convertible preferred
    stock</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c134" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-24515">251,504</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c134" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-24516"><ix:nonFraction contextRef="c134" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-24517">137,138</ix:nonFraction></ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c134" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="3" unitRef="usd" id="ixv-24518">2,931</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c134" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-24519">11,428,149</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock (the
&#8220;Series A Certificate of Designation&#8221;) filed in connection with the PIPE Financing, holders of Company Series A Preferred
Stock were entitled to receive dividends on shares of Company Series A Preferred Stock equal to, on an as-if-converted-to-Company Common
Stock basis, and in the same form as, dividends actually paid on shares of Company Common Stock. Except as provided in the Series A Certificate
of Designation or as otherwise required by law, the Company Series A Preferred Stock did not have voting rights. The Company Series A
Preferred Stock shall rank on parity with the Company Common Stock and Company Series B Preferred Stock upon any liquidation, dissolution
or winding-up of the Company. Subject to the terms and limitations contained in the Series A Certificate of Designation, the Company
Series A Preferred Stock issued in the PIPE Financing will not become convertible until the Company&#8217;s stockholders approve the
conversion of the Company Series A Preferred Stock into shares of Company Common Stock in accordance with the listing rules of the Nasdaq
Stock Market (the &#8220;Stockholder Approval&#8221;), which, on issuance, resulted in the Company Series A Preferred Stock being classified
outside of stockholders&#8217; equity on the Company&#8217;s consolidated balance sheet. Following the Stockholder Approval in November
2024, each share of Company Series A Preferred Stock was automatically converted into <ix:nonFraction contextRef="c129" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" unitRef="shares" id="ixv-24520">1,000</ix:nonFraction> shares of Company Common Stock.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock (the
&#8220;Series B Certificate of Designation&#8221;) filed in connection with the Merger, holders of Company Series B Preferred Stock are
entitled to receive dividends on shares of Company Series B Preferred Stock equal to, on an as-if-converted-to-Company Common Stock basis,
and in the same form as, dividends actually paid on shares of Company Common Stock. Except as provided in the Series B Certificate of
Designation or as otherwise required by law, the Company Series B Preferred Stock does not have voting rights. The Company Series B Preferred
Stock shall rank on parity with the Company Common Stock as to the distribution of assets upon any liquidation, dissolution, or winding-up
of the Company. Each share of Company Series B Preferred Stock is convertible at the option of the holder, at any time, and without the
payment of additional consideration by the holder. As of December 31, 2024, each outstanding share of Company Series B Preferred Stock
was convertible into common stock at a ratio of approximately <ix:nonNumeric contextRef="c47" name="orka:CommonStockConversionRatio" id="ixv-24521">83.3332:1</ix:nonNumeric>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Paruka
Warrant</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">On
December 31, 2024, the Company settled its 2024 obligations under the Paruka Warrant Obligation (defined below) by issuing Paruka a warrant
to purchase <ix:nonFraction contextRef="c131" decimals="INF" format="ixt:num-dot-decimal" name="orka:WarrantsToPurchaseCommonStock" scale="0" unitRef="shares" id="ixv-24522">596,930</ix:nonFraction> shares of Company Common Stock at an exercise price of $<ix:nonFraction contextRef="c131" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-24523">19.39</ix:nonFraction> per share. The warrant has a term of <ix:nonNumeric contextRef="c132" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-24524">10</ix:nonNumeric> years, is fully
vested, and is exercisable in part or full at any time during the term of the warrant. As of December 31, 2024, the warrant issued under
the Paruka Warrant Obligation is outstanding and unexercised. See Note 9 for additional information on the Paruka Warrant Obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2024, the Certificate of Incorporation provides for <ix:nonFraction contextRef="c36" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-24525">545,000,000</ix:nonFraction> authorized shares of Company Common Stock. As of December
31, 2024, <ix:nonFraction contextRef="c36" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-24526"><ix:nonFraction contextRef="c36" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-24527">37,440,510</ix:nonFraction></ix:nonFraction> shares of Company Common Stock were issued and outstanding, including <ix:nonFraction contextRef="c133" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-24528"><ix:nonFraction contextRef="c133" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-24529">2,207,553</ix:nonFraction></ix:nonFraction> shares of RSAs issued and outstanding.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 108 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="orka:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" id="ixv-14885"><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2024, the Company had common stock reserved for future issuance as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares issuable on conversion of
    Company Series B Preferred Stock</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c134" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-24530">11,428,149</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Shares issuable upon exercise of pre-funded warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c54" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-24531">6,202,207</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares issuable upon exercise of warrant under
    the Paruka Warrant Obligation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c135" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-24532">596,930</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding and issued stock options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c136" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-24533">1,567,760</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding and issued employee warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c119" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-24534">3,054,358</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares available for grant under 2024 Stock
    Incentive Plan</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c137" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-24535">4,246,324</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Shares available for
    grant under 2024 Employee Stock Purchase Plan</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c138" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-24536">460,529</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 13.7pt"><span style="font-family: Times New Roman, Times, Serif">Total
    shares of common stock reserved</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-24537">27,556,257</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-14995"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>9.
Stock-Based Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>2024
Equity Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
2024 Equity Incentive Plan (&#8220;2024 Plan&#8221;) was adopted by the board of directors of Pre-Merger Oruka on February&#160;6, 2024.
The 2024 Plan provided for Pre-Merger Oruka to grant stock options, restricted stock awards, restricted stock units, and other stock-based
awards to employees, officers, directors, consultants, and advisors. Equity Incentive Stock options granted under the 2024 Plan generally
vest over four&#160;years, subject to the participant&#8217;s continued service, and expire after ten&#160;years, although two non-employee
stock options were &#160;granted with vesting terms less than four&#160;years. As of December 31, 2024, there are no shares of common
stock available for issuance.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>2024
Stock Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">On
August 22, 2024, the 2024 Stock Incentive Plan (&#8220;2024 Stock Plan&#8221;) was approved by the Company&#8217;s stockholders and on
August 29, 2024, the board of directors of the Company (the &#8220;Board&#8221;) ratified the 2024 Stock Plan. The 2024 Stock Plan allows
for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock units, other stockholder-based awards
and incentive bonuses. The 2024 Stock Plan is administered by the Compensation Committee of the Board (the &#8220;Compensation Committee&#8221;)
or another committee designated by the Board to administer the Plan. The initial share pool under the 2024 Stock Plan is <ix:nonFraction contextRef="c139" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-24538">4,634,891</ix:nonFraction> shares
of Company Common Stock. During the period from February 6, 2024 (inception) to December 31, 2024, <ix:nonFraction contextRef="c140" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-24539">388,567</ix:nonFraction> shares were subject to outstanding
stock options, and as of December 31, 2024, there were <ix:nonFraction contextRef="c141" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-24540">4,246,324</ix:nonFraction> shares available in the pool. The shares that may be issued under the
2024 Stock Plan will be automatically increased on January 1 of each year beginning in 2025 and ending with a final increase on January
1, 2034 in an amount equal to <ix:nonFraction contextRef="c142" decimals="2" format="ixt:num-dot-decimal" name="orka:ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares" scale="-2" unitRef="pure" id="ixv-24541">5</ix:nonFraction>% of the diluted stock (including Company Common Stock, preferred stock and unexercised pre-funded warrants)
on the preceding December 31, unless a lower, or no, increase is determined by the Compensation Committee. Current or prospective employees,
officers, non-employee directors, and other independent service providers of the Company and its subsidiaries are eligible to participate
in the 2024 Stock Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>2024
Employee Stock Purchase Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
2024 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) became effective on August 29, 2024, at which time <ix:nonFraction contextRef="c143" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-24542">463,489</ix:nonFraction> shares of Company
Common Stock were reserved for issuance. Eligible employees may purchase shares of Company Common Stock under the ESPP at&#160;<ix:nonFraction contextRef="c144" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" unitRef="pure" id="ixv-24543">85</ix:nonFraction>% of
the lower of the fair market value of the Company Common Stock as of the first or the last day of each offering period. Employees are
limited to contributing&#160;<ix:nonFraction contextRef="c143" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" unitRef="pure" id="ixv-24544">15</ix:nonFraction>% of the employee&#8217;s eligible compensation and may not purchase more than $<ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="orka:EmployeeStockPurchasePlanESPPCashContributionsToESPP" scale="0" unitRef="usd" id="ixv-24545">25,000</ix:nonFraction>&#160;of stock during
any calendar year. The ESPP will terminate&#160;ten years&#160;from the first purchase date under the plan, unless terminated earlier
by the board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
shares that may be issued under the ESPP will be automatically increased on January 1 of each year beginning in 2025 and ending with
a final increase on January 1, 2034 in an amount equal to <ix:nonFraction contextRef="c145" decimals="2" format="ixt:num-dot-decimal" name="orka:ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares" scale="-2" unitRef="pure" id="ixv-24546">1</ix:nonFraction>% of the diluted stock (including Company Common Stock, preferred stock and
unexercised pre-funded warrants) on the preceding December 31, unless a lower, or no increase is determined by the Compensation Committee.
During the period from February 6, 2024 (inception) to December 31, 2024, <ix:nonFraction contextRef="c138" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-24547">2,960</ix:nonFraction> shares of Company Common Stock were issued out of the
ESPP and as of December 31, 2024, there were <ix:nonFraction contextRef="c138" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-24548">460,529</ix:nonFraction> shares of Company Common Stock available in the pool.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">For
the period February 6, 2024 (inception) to December 31, 2024, stock-based compensation expense related to the ESPP was less than $<ix:nonFraction contextRef="c145" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-24549">0.1</ix:nonFraction>
million.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 109 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock
Option Valuation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ixv-15063"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the weighted-average assumptions used in calculating the fair value of the awards for the period from February&#160;6,
2024 (inception) to December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period from<br/> February 6,<br/> 2024<br/> (Inception) to<br/> December 31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (in years)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c146" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-15091"><span style="font-family: Times New Roman, Times, Serif">6.1</span></ix:nonNumeric></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c146" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-24550">100.21</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c146" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-24551">4.26</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-206; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock
Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-15138"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the stock option activities under the 2024 Plan and 2024 Stock Plan for the period of February&#160;6, 2024
(inception) through December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number of<br/> Stock<br/> Options<br/> Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/> Average<br/> Exercise<br/> Price Per<br/> Share</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term <br/> (in Years)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Aggregate<br/> Intrinsic<br/> Value<br/> (in&#160;Thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Balance as of February 6, 2024 (inception)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-208; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-209; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-210; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-211; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; width: 52%"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-24552">1,567,760</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-24553">11.39</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-212; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-213; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-214; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-215; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-24554">1,567,760</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-24555">11.39</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-15350"><span style="font-family: Times New Roman, Times, Serif">9.4</span></ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" unitRef="usd" id="ixv-24556">15,470</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Vested and expected to vest, December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-24557">1,567,760</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-24558">11.39</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ixv-15386"><span style="font-family: Times New Roman, Times, Serif">9.4</span></ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" unitRef="usd" id="ixv-24559">15,470</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable, December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-216; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-217; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-218; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-219; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif">The
weighted average grant-date fair value per share of stock options granted during the period from February&#160;6, 2024 (inception) to
December 31, 2024 was $<ix:nonFraction contextRef="c146" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-24560">9.12</ix:nonFraction> per share. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying
Company Common Stock and the exercise price of outstanding, in-the-money employee stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Restricted
Stock Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
February 2024 and March&#160;2024, the Company issued <ix:nonFraction contextRef="c147" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" unitRef="shares" id="ixv-24561">2,207,553</ix:nonFraction> shares of RSAs to certain employees, directors, and consultants at a
price of $<ix:nonFraction contextRef="c133" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-24562">0.0001</ix:nonFraction> per share, the then par value of Pre-Merger Oruka Common Stock. Such RSAs have service-based vesting conditions only
and vest over a four-year period, during which time all unvested shares are subject to forfeiture in the event the holder&#8217;s service
with the Company voluntarily or involuntarily terminates. As of December 31, 2024, none of the RSAs had vested. For the period February
6, 2024 (inception) to December 31, 2024, stock-based compensation expense related to RSAs was less than $<ix:nonFraction contextRef="c147" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-24563">0.1</ix:nonFraction> million.</span></p></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 110 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="ixv-15465"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the RSA activity for the period from February&#160;6, 2024 (inception) through December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/>
    RSAs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/>
    Average<br/>
    Grant Date<br/>
    Fair Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Unvested balance as of February 6, 2024 (inception)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-220; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-221; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; padding-bottom: 1.5pt; padding-left: 13.7pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c147" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-24564">2,207,553</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-222; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Unvested balance as of December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c133" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-24565">2,207,553</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-223; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Option
Agreements and the Paruka Warrant Obligation</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
part of the Option Agreements, on December&#160;31, 2024 the Company granted and on December&#160;31, 2025, will grant Paruka a warrant
to purchase a number of shares equal to <ix:nonFraction contextRef="c148" decimals="4" format="ixt:num-dot-decimal" name="orka:ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" scale="-2" unitRef="pure" id="ixv-24566">1.00</ix:nonFraction>% of outstanding shares as of the date of the grant on a fully-diluted basis, with an exercise
price equal to the fair market value of the underlying shares on the grant date (the &#8220;Paruka Warrant Obligation&#8221;).</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
grant dates for the issuance of warrants were expected to be December&#160;31, 2024 and December&#160;31, 2025 as all terms of the award,
including number of shares and exercise price, will be known by all parties. The Company determined that the 2024 and 2025 grants are
two separate grants, as there would be no obligation for the 2025 grant had the Company exercised or terminated all of the options under
the Option Agreements prior to December 31, 2024. The service inception period for the grant precedes the grant date, with the full award
being vested as of the grant date with no post-grant date service requirement. Accordingly, the warrant expected to be granted to Paruka
was accounted for as a liability on the balance sheet on the service inception date and, after the initial recognition, the liability
is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the consolidated statement of operations
and comprehensive loss as stock-based compensation expenses under research and development expenses. Accordingly, the Company measured
the grant date fair value of the warrant granted on December 31, 2024 at $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="orka:EstimatedFairValueOfWarrantsToBeGranted" scale="6" unitRef="usd" id="ixv-24567">10.4</ix:nonFraction> million. For the period from February 6, 2024 (inception)
to December 31, 2024, $<ix:nonFraction contextRef="c148" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-24568">10.4</ix:nonFraction> million was recognized as stock-based compensation expense related to the Paruka Warrant Obligation in the
consolidated statement of operations and comprehensive loss. As of December 31, 2024, there was no unamortized expense related to the
December 31, 2024 Paruka Warrant Obligation. On issuance of the warrant to Paruka, the fair value of the warrant was reclassified from
liability to equity on the consolidated balance sheet as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Employee
Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As stated above, on July
3, 2024, the Subscription Agreement was amended and restated, among other things, for employee warrants to be issued to certain Pre-Merger
Oruka employees and directors immediately prior to the closing of the Merger. Pursuant to this amendment, during the period from February
6, 2024 (inception) to December 31, 2024, the Company issued <ix:nonFraction contextRef="c120" decimals="INF" format="ixt:num-dot-decimal" name="orka:ClassOfWarrantOrRight" scale="0" unitRef="shares" id="ixv-24569">3,054,358</ix:nonFraction> warrants at an exercise price of $<ix:nonFraction contextRef="c119" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-24570">7.80</ix:nonFraction> per warrant, which are accounted
as equity in the consolidated financial statements. The employee warrants were subject to performance and service based vesting requirements
and upon completion of the Merger the performance-based requirements had been achieved.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="orka:ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock" id="ixv-15574"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the warrant activity for the period from February&#160;6, 2024 (inception) through December 31, 2024:&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/>
Employee<br/> Warrants<br/>
Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/> Average<br/> Exercise<br/> Price Per<br/> Share</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term <br/> (in Years)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Aggregate<br/> Intrinsic<br/> Value<br/> (in&#160;Thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Balance as of February 6, 2024 (inception)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-224; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-225; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-226; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; width: 52%"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c152" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-24571">3,054,358</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c152" decimals="2" format="ixt:num-dot-decimal" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-24572">7.80</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-227; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-228; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-229; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-230; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c119" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-24573">3,054,358</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c119" decimals="2" format="ixt:num-dot-decimal" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-24574">7.80</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><ix:nonNumeric contextRef="c152" format="ixt-sec:duryear" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm" id="ixv-15785"><span style="font-family: Times New Roman, Times, Serif">9.5</span></ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c119" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" unitRef="usd" id="ixv-24575">35,400</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Vested and expected to vest, December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c119" decimals="INF" format="ixt:num-dot-decimal" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-24576">3,054,358</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c119" decimals="2" format="ixt:num-dot-decimal" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-24577">7.80</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><ix:nonNumeric contextRef="c152" format="ixt-sec:duryear" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" id="ixv-15821"><span style="font-family: Times New Roman, Times, Serif">9.5</span></ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c119" decimals="-3" format="ixt:num-dot-decimal" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest" scale="3" unitRef="usd" id="ixv-24578">35,400</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable, December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-231; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-232; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-233; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
weighted average grant-date fair value per share of warrants granted during the period from February&#160;6, 2024 (inception) to December
31, 2024 was $<ix:nonFraction contextRef="c120" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-24579">6.27</ix:nonFraction> per share. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying
Company Common Stock and the exercise price of outstanding, in-the-money warrants.</span></p></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 111 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3"><ix:continuation id="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the weighted-average assumptions used in calculating the fair value of the warrants for the period from February&#160;6,
2024 (inception) to December 31, 2024:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period from<br/> February 6,<br/> 2024<br/> (Inception) to<br/> December 31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (in years)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c120" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-15918"><span style="font-family: Times New Roman, Times, Serif">6.1</span></ix:nonNumeric></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c120" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-24580">99.02</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c120" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-24581">4.15</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-207; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock-Based
Compensation Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="ixv-15965"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the classification of the Company&#8217;s stock-based compensation expense in the consolidated statement of
operations and comprehensive loss (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from<br/>
    February 6,<br/>
    2024<br/>
    (Inception) to<br/>
    December 31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-24582">11,992</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-24583">2,927</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 13.7pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-24584">14,919</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2024, total unrecognized compensation cost related to the unvested stock options was $<ix:nonFraction contextRef="c136" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" unitRef="usd" id="ixv-24585">12.7</ix:nonFraction> million, which is expected
to be recognized over a weighted average period of approximately <ix:nonNumeric contextRef="c146" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-24586">3.2</ix:nonNumeric> years. As of December 31, 2024, total unrecognized compensation
cost related to the unvested RSAs was less than $<ix:nonFraction contextRef="c133" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" unitRef="usd" id="ixv-24587">0.1</ix:nonFraction> million, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c147" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-24588">3.1</ix:nonNumeric>
years. As of December 31, 2024, the unrecognized compensation cost related to the employee warrants was $<ix:nonFraction contextRef="c119" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" unitRef="usd" id="ixv-24589">16.3</ix:nonFraction> million, which is expected
to be recognized over a weighted average period of <ix:nonNumeric contextRef="c120" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-24590">3.3</ix:nonNumeric> years.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="ixv-16024"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the award types of the Company&#8217;s stock-based compensation expense in the consolidated statement of operations
and comprehensive loss (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from<br/>
    February 6,<br/>
    2024<br/>
    (Inception) to <br/>
    December 31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paruka Warrant Obligation</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c153" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-24591">10,357</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Employee warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c154" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-24592">2,899</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c155" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-24593">1,626</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Employee stock purchase
    plan</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c156" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-24594">37</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-24595">14,919</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 112 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock" id="ixv-16118"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>10.
Segment disclosures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company operates and manages its business activities on a consolidated basis and operates in <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitRef="pure" id="ixv-24596"><ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" unitRef="pure" id="ixv-24597">one</ix:nonFraction></ix:nonFraction> reportable segment.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company operates as a single reportable and operating segment.
Its Chief Executive Officer, serving as the Chief Operating Decision Maker (&#8220;CODM&#8221;), oversees operations on an aggregated
basis to allocate resources effectively. In assessing the Company&#8217;s financial performance, the CODM regularly reviews total operating
expenses and consolidated net loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">The
measure of segment assets is reported on the balance sheet as total consolidated assets. The Company&#8217;s long-lived assets consist
primarily of property and equipment, net. As of December&#160;31, 2024 all of long-lived assets were in the U.S.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="ixv-16135"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">The
table below is a summary of the segment loss from operations, including significant segment expenses (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from<br/>
    February 6,<br/>
    2024<br/>
    (Inception) to December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development personnel-related
    (excluding stock-based compensation)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c157" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-24598">3,959</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative personnel-related
    (excluding stock-based compensation)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c157" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-24599">5,054</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development stock-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-24600">11,992</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative stock-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-24601">2,927</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">External research and development</span></td><td/>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c158" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-24602">57,680</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c159" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-24603">1,429</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">General and administrative,
    excluding personnel-related and stock-based compensation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c160" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-24604">5,082</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Total
    operating expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-24605">88,123</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Loss
    from operations</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-24606">88,123</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-16253"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>11.
Income Taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: hidden-fact-238">No</span>
provision for income taxes was recorded for the period from February&#160;6, 2024 (inception) to December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="ixv-16264"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the loss before income tax expense by jurisdiction for the periods indicated:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from<br/>
    February 6,<br/>
    2024<br/>
    (Inception) to <br/>
    December 31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="font-family: Times New Roman, Times, Serif">Domestic</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right">(<span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" sign="-" unitRef="usd" id="ixv-24607">83,724</ix:nonFraction></span></td><td style="width: 1%; text-align: left">)<span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Foreign</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-234; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Loss
    before income tax expense</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right">(<span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-24608">83,724</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)<span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For the period from February
6, 2024 (inception) to December&#160;31, 2024, the Company recognized&#160;no&#160;provision or benefit from income taxes. <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-24609">The difference
between the Company&#8217;s provision for income taxes and the amounts computed by applying the statutory federal income tax rate to income
before income taxes is as follows:</ix:nonNumeric></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<ix:continuation id="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period from<br/> February 6,<br/> 2024 <br/> (Inception)&#160;to<br/> December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Tax benefit derived by applying the federal statutory rate to income before income taxes</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-24610">21.00</ix:nonFraction></td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" unitRef="pure" id="ixv-24611">0.18</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" sign="-" unitRef="pure" id="ixv-24612">3.41</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" unitRef="pure" id="ixv-24613">0.87</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in the valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" sign="-" unitRef="pure" id="ixv-24614">25.46</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Income tax (benefit) expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-24615">0.00</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 113 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-16391"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
components of the deferred tax assets and liabilities consist of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 9pt">Net operating loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-24616">2,260</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" unitRef="usd" id="ixv-24617">3,080</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" unitRef="usd" id="ixv-24618">3,063</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Accruals and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" scale="3" unitRef="usd" id="ixv-24619">424</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="orka:DeferredTaxAssetsLeaseLiabilities" scale="3" unitRef="usd" id="ixv-24620">203</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Intangibles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" unitRef="usd" id="ixv-24621">1,477</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Capitalized R&amp;D expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-24622">10,994</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-24623">21,501</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Right- of- use asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="orka:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" unitRef="usd" id="ixv-24624">184</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Total deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" unitRef="usd" id="ixv-24625">184</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-24626">21,317</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Deferred tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">T<ix:nonNumeric contextRef="c0" continuedAt="_SummaryOfValuationAllowanceTextBlock-c0_cont_1" escape="true" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="ixv-24627">he Company has established
a full federal and state valuation allowance equal to the net deferred tax assets due to uncertainties regarding the realization of the
deferred tax asset based on the Company&#8217;s lack of earnings history. The valuation allowance increased by $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" scale="6" unitRef="usd" id="ixv-24628">21.3</ix:nonFraction>&#160;million primarily
due to continuing loss from operations.</ix:nonNumeric></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<ix:continuation id="_SummaryOfValuationAllowanceTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Beginning balance as of February 6, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" unitRef="usd" id="ixv-24629">21,317</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Ending balance as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-24630">21,317</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of December&#160;31, 2024, the Company had U.S. net operating loss carryforwards (&#8220;NOL&#8221;) of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOtherLossCarryforwards" scale="6" unitRef="usd" id="ixv-24631">10.8</ix:nonFraction>&#160;million. The federal
NOL carryforwards do not expire and can be utilized to offset up to <ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="orka:OperatingLossCarryforwardsAsAPercentageOfTaxableIncome" scale="-2" unitRef="pure" id="ixv-24632">80</ix:nonFraction>% of the taxable income in any tax year. For the period from February
6, 2024 (inception) to December&#160;31, 2024 the Company had federal tax credit carryforwards and state tax credit carryforwards of
$<ix:nonFraction contextRef="c161" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" unitRef="usd" id="ixv-24633">3.8</ix:nonFraction>&#160;million and $<ix:nonFraction contextRef="c162" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" unitRef="usd" id="ixv-24634">0.4</ix:nonFraction>&#160;million, respectively. The federal credits will expire starting in 2044 if not utilized, and the state
research credit can be carried forward indefinitely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tax Reform Act of 1986 limits the use of net operating loss carryforwards in certain situations where changes occur in the stock ownership
of a company. The annual limitation may result in the expiration of net operating losses and credits before utilization. The Company
has not performed a Section 382 analysis through December 31, 2024. To the extent that an assessment is completed in the future, the
Company&#8217;s ability to utilize tax attributes could be restricted on a year-by-year basis and certain attributes could expire before
they are utilized. The Company will examine the impact of any potential ownership changes in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="ixv-16531"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">A
reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from<br/>
    February 6,<br/>
    2024<br/>
    (Inception) to<br/>
    December 31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Beginning balance as of February 6, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-237; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Changes
    related to tax positions taken in the current year</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" unitRef="usd" id="ixv-24635">1,047</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Ending balance
    as of December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" unitRef="usd" id="ixv-24636">1,047</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 114 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_2"><p style="text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The
Company includes penalties and interest expense related to income taxes as a component of income tax expense, as necessary. As of December
31, 2024, the Company had&#160;no&#160;accrued interest or penalties related to uncertain tax positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company will be filing initial year income tax returns in the United States federal jurisdiction and state jurisdictions. Due to net
operating loss carryforwards, the statute of limitations will remain open for income tax examination.</span></p></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="orka_OptionAgreementsAndLicenseAgreementsTextBlock-c0_cont_1" escape="true" name="orka:OptionAgreementsAndLicenseAgreementsTextBlock" id="ixv-16612"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>12.
Option Agreements and License Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
March&#160;2024, the Company entered into two antibody discovery and option agreements (&#8220;Option Agreements&#8221;) with Paragon
and Paruka. Under the terms of each agreement, Paragon identifies, evaluates, and develops antibodies directed against certain mutually
agreed therapeutic targets of interest to the Company. From time to time, the Company can choose to add additional targets to the collaboration
upon agreement with Paragon and Paruka. Under the Option Agreements, the Company has the exclusive option to, on a research program-by-research
program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual
property resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and products directed
to the selected target(s)&#160;(each, an &#8220;Option&#8221;). The Company has initiated certain research programs with Paragon that
generally focus on discovering, generating, identifying and/or characterizing antibodies directed to a particular target (each, a &#8220;Research
Program&#8221;), including for IL-23 and IL-17A/F for ORKA-001 and ORKA-002, respectively. The exclusive option with respect to each
Research Program is exercisable at the Company&#8217;s sole discretion at such time as specified in the Option Agreements (the &#8220;Option
Period&#8221;). There is no payment due upon exercise of an Option pursuant to the Option Agreements. For each of these agreements, once
the Company enters into the corresponding license agreements, it will be required to make non-refundable milestone payments to Paragon
of up to $<ix:nonFraction contextRef="c163" decimals="-5" format="ixt:num-dot-decimal" name="orka:NonRefundableMilestonePayments" scale="6" unitRef="usd" id="ixv-24637">12.0</ix:nonFraction> million under each respective agreement upon the achievement of certain clinical development milestones, up to $<ix:nonFraction contextRef="c164" decimals="-5" format="ixt:num-dot-decimal" name="orka:NonRefundableMilestonePayments" scale="6" unitRef="usd" id="ixv-24638">10.0</ix:nonFraction> million
under each respective agreement upon the achievement of certain regulatory milestones, as well as a low single-digit percentage royalty
for antibody products beginning on the first commercial sale in each program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company may terminate any Option Agreement or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior written
notice to Paragon, provided that it must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable
obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate
any Option Agreement or a Research Program immediately upon written notice to the Company if, as a result of any action or failure to
act by the Company or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended,
discontinued or otherwise delayed for a certain consecutive number of&#160;months. Each party has the right to terminate the Option Agreements
or any Research Program upon material breach that remains uncured or the other party&#8217;s bankruptcy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Paragon
Therapeutics &#8211; License Agreements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
September 2024, the Company exercised the Option to acquire certain rights to ORKA-001, and in December 2024, it entered into the corresponding
license agreement with Paragon (the &#8220;ORKA-001 License Agreement&#8221;), pursuant to which Paragon granted the Company a royalty-bearing,
world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting IL-23
in all fields other than the field of inflammatory bowel disease (&#8220;ORKA-001 Field&#8221;). In December 2024, the Company exercised
the Option with respect to ORKA-002 for the IL-17A/F program, and in February 2025, it entered into the corresponding license agreement
with Paragon (the &#8220;ORKA-002 License Agreement&#8221; and together with the ORKA-001 License Agreement, the &#8220;License Agreements&#8221;),
pursuant to which Paragon granted the Company a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize
or otherwise exploit certain antibodies and products targeting IL-17A/F in all fields (&#8220;ORKA-002 Field&#8221; and together with
the ORKA-001 Field, the &#8220;Fields&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
License Agreements provide the Company with exclusive licenses in the Fields to Paragon&#8217;s patent applications covering the related
antibodies, their method of use and their method of manufacture and Paragon has agreed not to conduct any new campaigns that generate
anti-IL-23 monospecific antibodies or anti-IL-17A/F monospecific antibodies for the ORKA-001 Field or the ORKA-002 Field, respectively,
for at least five years. Each of the ORKA-001 and ORKA-002 License Agreements may be terminated on 60 days&#8217; notice to Paragon,
on material breach without cure, and on a party&#8217;s insolvency or bankruptcy to the extent permitted by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the terms of each of the ORKA-001 and ORKA-002 License Agreements, the Company is obligated to pay Paragon non-refundable milestone
payments of up to $<ix:nonFraction contextRef="c165" decimals="-5" format="ixt:num-dot-decimal" name="orka:NonRefundableMilestonePayments" scale="6" unitRef="usd" id="ixv-24639"><ix:nonFraction contextRef="c166" decimals="-5" format="ixt:num-dot-decimal" name="orka:NonRefundableMilestonePayments" scale="6" unitRef="usd" id="ixv-24640">12.0</ix:nonFraction></ix:nonFraction> million under each respective agreement upon the achievement of certain clinical development milestones and up
to $<ix:nonFraction contextRef="c167" decimals="-5" format="ixt:num-dot-decimal" name="orka:NonRefundableMilestonePayments" scale="6" unitRef="usd" id="ixv-24641">10.0</ix:nonFraction> million under each respective agreement upon the achievement of certain regulatory milestones, including a $<ix:nonFraction contextRef="c168" decimals="-5" format="ixt:num-dot-decimal" name="orka:NonRefundableMilestonePayments" scale="6" unitRef="usd" id="ixv-24642">1.5</ix:nonFraction> million fee
for nomination of a development candidate (or initiation of an IND-enabling toxicology study) and a further milestone payment of $<ix:nonFraction contextRef="c169" decimals="-5" format="ixt:num-dot-decimal" name="orka:NonRefundableMilestonePayments" scale="6" unitRef="usd" id="ixv-24643"><ix:nonFraction contextRef="c170" decimals="-5" format="ixt:num-dot-decimal" name="orka:NonRefundableMilestonePayments" scale="6" unitRef="usd" id="ixv-24644">2.5</ix:nonFraction></ix:nonFraction>
million upon the first dosing of a human patient in a Phase 1 trial for each of ORKA-001 and ORKA-002. In addition, the Company is obligated
to pay Paragon a <ix:nonNumeric contextRef="c171" name="orka:RoyaltyPayableOnProductSales" id="ixv-24645">low single-digit percentage royalty for antibody products</ix:nonNumeric> for each of ORKA-001 and ORKA-002. For each of the License
Agreements, the royalty term ends on the later of (i) the last-to-expire licensed patent or our patent directed to the manufacture, use
or sale of a licensed antibody in the country at issue or (ii) 12 years from the date of first sale of a Company product. There is also
a royalty step-down if there is no Paragon patent in effect during the royalty term for each program.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 115 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="orka_OptionAgreementsAndLicenseAgreementsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Additionally,
as part of the Option Agreements, on December&#160;31, 2024 the Company granted and on December&#160;31, 2025, will grant Paruka a warrant
to purchase a number of shares equal to <ix:nonFraction contextRef="c172" decimals="4" format="ixt:num-dot-decimal" name="orka:ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" scale="-2" unitRef="pure" id="ixv-24646">1.00</ix:nonFraction>% of outstanding shares as of the date of the grant on a fully-diluted basis, with an exercise
price equal to the fair market value of the underlying shares on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Option Agreements, on a research program-by-research program basis following the finalization of the research plan for each respective
research program, the Company was required to pay Paragon a one-time, nonrefundable research initiation fee of $<ix:nonFraction contextRef="c173" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="6" unitRef="usd" id="ixv-24647">0.8</ix:nonFraction>&#160;million related
to the ORKA-001 program. This amount was recognized as a research and development expense during the period from February&#160;6, 2024
(inception) to December 31, 2024. In June 2024, pursuant to the Option Agreements with Paragon, the Company completed the selection process
of its development candidate for IL-23 antibody for ORKA-001 program. The Company was responsible for <ix:nonFraction contextRef="c174" decimals="2" format="ixt:num-dot-decimal" name="orka:DevelopmentCostsPercentage" scale="-2" unitRef="pure" id="ixv-24648">50</ix:nonFraction>% of the development costs incurred
through the completion of the IL-23 selection process. The Company received the rights to at least one selected IL-23 antibody in June
2024. During the period from February 6, 2024 (inception) to December 31, 2024, the Company exercised its option for ORKA-001 and recorded
a $<ix:nonFraction contextRef="c175" decimals="-5" format="ixt:num-dot-decimal" name="orka:MilestoneConsiderationPaid" scale="6" unitRef="usd" id="ixv-24649">1.5</ix:nonFraction> million milestone payment related to the achievement of development candidate as research and development expense in the Company&#8217;s
consolidated statement of operations and comprehensive loss. In addition, during the period from February 6, 2024 (inception) to December
31, 2024, the Company recorded a $<ix:nonFraction contextRef="c176" decimals="-5" format="ixt:num-dot-decimal" name="orka:MilestoneConsiderationPaid" scale="6" unitRef="usd" id="ixv-24650">2.5</ix:nonFraction> million milestone payment related to the first dosing of a human subject in a Phase 1 trial of
ORKA-001 in December 2024 as research and development expense in its consolidated statement of operations and comprehensive loss. The
Company&#8217;s share of development costs incurred for the period from February 6, 2024 (inception) to December 31, 2024 was $<ix:nonFraction contextRef="c174" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="6" unitRef="usd" id="ixv-24651">13.5</ix:nonFraction> million
(excluding research initiation fee and milestones), which were recorded as research and development expenses. An amount of $<ix:nonFraction contextRef="c177" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="6" unitRef="usd" id="ixv-24652">2.8</ix:nonFraction> million
related to ORKA-001 is included in related party accounts payable and other current liabilities as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company was also required to reimburse Paragon $<ix:nonFraction contextRef="c178" decimals="-5" format="ixt:num-dot-decimal" name="orka:OtherDevelopmentCost" scale="6" unitRef="usd" id="ixv-24653">3.3</ix:nonFraction>&#160;million for development costs related to ORKA-002 incurred by Paragon through
December&#160;31, 2023 and certain other development costs incurred by Paragon between January&#160;1, 2024 and March&#160;6, 2024 as
stipulated by the Option Agreements. This amount was recognized as a research and development expense during the period from February&#160;6,
2024 (inception) to December 31, 2024. The Company is also responsible for the development costs incurred by Paragon from January&#160;1,
2024 through the completion of the IL-17 selection process. The Company recognized an amount of $<ix:nonFraction contextRef="c179" decimals="-5" format="ixt:num-dot-decimal" name="orka:ResearchInitialFee" scale="6" unitRef="usd" id="ixv-24654">0.8</ix:nonFraction>&#160;million payable to Paragon
for the research initiation fee related to ORKA-002 following the finalization of the ORKA-002 research plan. This was recognized as
research and development expenses in the period from February 6, 2024 (inception) to December 31, 2024. During the period from February
6, 2024 (inception) to December 31, 2024, the Company exercised its option for ORKA-002 and recorded a $<ix:nonFraction contextRef="c180" decimals="-5" format="ixt:num-dot-decimal" name="orka:MilestoneConsiderationPaid" scale="6" unitRef="usd" id="ixv-24655">1.5</ix:nonFraction> million milestone payment
related to the achievement of development candidate as research and development expense in its consolidated statement of operations and
comprehensive loss. The Company accounted for development costs of $<ix:nonFraction contextRef="c179" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="6" unitRef="usd" id="ixv-24656">7.8</ix:nonFraction> million (excluding research initiation fee, milestone, and reimbursements
of development costs through December 31, 2023) for the period from February 6, 2024 (inception) to December 31, 2024 as research and
development expenses. An amount of $<ix:nonFraction contextRef="c181" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="6" unitRef="usd" id="ixv-24657">2.7</ix:nonFraction> million related to ORKA-002 is included in related party accounts payable and other current liabilities
as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company expenses the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified
within research and development expenses in the accompanying consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company concluded that the rights obtained under the Option Agreements represent an asset acquisition whereby the underlying assets comprise
in-process research and development assets with no alternative future use. The Option Agreements did not qualify as a business combination
because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent
a group of similar identifiable assets. The research initiation fee represents a one-time cost on a research program-by-research program
basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts
paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of ongoing development cost,
monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior
to the effective date of the Option Agreements that is associated with services being rendered under the related Research Programs are
recognized as research and development expense when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif">For
the period from February&#160;6, 2024 (inception) to December 31, 2024, the Company recognized $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="6" unitRef="usd" id="ixv-24658">42.0</ix:nonFraction> </span>&#160;<span style="font-family: Times New Roman, Times, Serif">million
of expenses in connection with services provided by Paragon and Paruka under the Option Agreements.&#160;</span></p></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 116 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-16700"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>13.
Commitment and Contingencies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>Leases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
April 2024, the Company entered into an operating lease agreement for the Company&#8217;s headquarters in Menlo Park, California, which
commenced on June 15, 2024 with an initial term of <ix:nonNumeric contextRef="c182" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-24659">39.5</ix:nonNumeric> months. The Company leases office space under this noncancelable operating lease
agreement. Lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining
the present value of lease payments, the Company used its incremental borrowing rate when measuring operating lease liabilities as discount
rates were not implicit or readily determinable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2024, the Company had $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" unitRef="usd" id="ixv-24660">0.9</ix:nonFraction> million of operating lease right-of-use assets, operating lease liability, current of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" unitRef="usd" id="ixv-24661">0.2</ix:nonFraction>
million, and operating lease liability, noncurrent of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" unitRef="usd" id="ixv-24662">0.8</ix:nonFraction> million on its consolidated balance sheet. As of December 31, 2024, the operating
lease arrangement had a remaining lease term of <ix:nonNumeric contextRef="c183" format="ixt-sec:durmonth" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-24663">33</ix:nonNumeric> months and a discount rate of <ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" unitRef="pure" id="ixv-24664">17.95</ix:nonFraction>%. For the period from February 6, 2024 (inception)
to December 31, 2024, the Company recorded operating and variable lease expense of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseVariableLeaseIncome" scale="6" unitRef="usd" id="ixv-24665">0.3</ix:nonFraction> million in general and administrative expenses
in its consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="ixv-16721"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table presents the Company&#8217;s supplemental cash flow information related to leases (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from<br/>
    February 6,<br/>
    2024<br/>
    (Inception) to<br/>
    December 31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash paid for amounts included
    in the measurement of lease liabilities</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd" id="ixv-24666">116</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-16754"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes a maturity analysis of the Company&#8217;s operating lease liabilities showing the aggregate lease payments
as of December 31, 2024 (in thousands):&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>Year
    ending December 31,</b></span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-24667">369</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd" id="ixv-24668">494</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2027</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" unitRef="usd" id="ixv-24669">380</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total undiscounted lease
    payments</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-24670">1,243</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    imputed interest</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-24671">275</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total discounted lease
    payments</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-24672">968</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    current portion of lease liability</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-24673">213</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.375in; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Non-current
    portion of lease liability</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-24674">755</ix:nonFraction></span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>Cell
Line License Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In March 2024, the Company
entered into the Cell Line License Agreement (the &#8220;Cell Line License Agreement&#8221;) with WuXi Biologics Ireland Limited (&#8220;WuXi
Biologics&#8221;). Under the Cell Line License Agreement, the Company received a non-exclusive, worldwide, sublicensable license to certain
of WuXi Biologics&#8217; know-how, cell line, biological materials (the &#8220;WuXi Biologics Licensed Technology&#8221;) and media and
feeds to make, have made, use, sell and import certain therapeutic products produced through the use of the cell line licensed by WuXi
Biologics under the Cell Line License Agreement (the &#8220;WuXi Biologics Licensed Products&#8221;). Specifically, the WuXi Biologics
Licensed Technology is used in certain manufacturing activities in support of the ORKA-001 and ORKA-002 programs.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
consideration for the license, the Company agreed to pay WuXi Biologics a non-refundable license fee of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="orka:NonRefundableLicenseFee" scale="0" unitRef="usd" id="ixv-24675">150,000</ix:nonFraction>, which was recognized
as a research and development expense during the period from February&#160;6, 2024 (inception) to December 31, 2024. Additionally, to
the extent that the Company manufactures its commercial supplies of bulk drug product with a manufacturer other than WuXi Biologics or
its affiliates, the Company is required to make royalty payments to WuXi Biologics at a rate of less than one percent of net sales of
WuXi Biologics Licensed Products manufactured by the third-party manufacturer. Pursuant to an amendment to the Cell Line License Agreement
effective in November 2024, a provision was added that permits the royalties owed under the agreement to be bought out on a&#160;product-by-product&#160;basis
for a&#160;lump-sum&#160;payment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
                                            Cell Line License Agreement will continue indefinitely unless terminated (i) by the Company
                                            upon six months&#8217; prior written notice and its payment of all undisputed amounts due
                                            to WuXi Biologics through the effective date of termination, (ii) by WuXi Biologics for a
                                            material breach by the Company that remains uncured for 60 days after written notice, (iii)
                                            by WuXi Biologics if the Company fails to make a payment and such failure continues for 30
                                            days after receiving notice of such failure, or (iv) by either party upon the other party&#8217;s
                                            bankruptcy.</span></p></ix:nonNumeric><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 117 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerShareTextBlock" id="ixv-16894"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>14.
Net Loss per Share</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="ixv-16900"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Basic
and diluted net loss per share attributable to stockholders were calculated as follows (in thousands, except share and per share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from February 6, 2024<br/>
    (Inception) to <br/>
    December 31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Loss<br/>
    Allocation</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/>
    Average<br/>
    Shares<br/>
    Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Loss
    Per<br/>
    Share,<br/>
    Basic and<br/>
    Diluted</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common Stock</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-24676">65,037</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c29" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-24677"><ix:nonFraction contextRef="c29" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-24678">16,789,362</ix:nonFraction></ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c29" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-24679"><ix:nonFraction contextRef="c29" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-24680">3.87</ix:nonFraction></ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Company Series A Preferred Stock <sup>(1)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c184" decimals="-3" format="ixt:num-dot-decimal" id="ix_3_fact" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">1,918</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c184" decimals="INF" format="ixt:num-dot-decimal" id="ix_4_fact" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares"><ix:nonFraction contextRef="c184" decimals="INF" format="ixt:num-dot-decimal" id="ix_5_fact" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">495</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c184" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-24684"><ix:nonFraction contextRef="c184" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-24685">3,873.25</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Company Series B Preferred
    Stock <sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" id="ix_6_fact" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">16,769</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c47" decimals="INF" format="ixt:num-dot-decimal" id="ix_7_fact" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares"><ix:nonFraction contextRef="c47" decimals="INF" format="ixt:num-dot-decimal" id="ix_8_fact" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">51,946</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c47" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-24689"><ix:nonFraction contextRef="c47" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-24690">322.81</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-24691">83,724</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>



</div><ix:continuation id="_EarningsPerShareTextBlock-c0_cont_1"><ix:continuation id="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_1"><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><ix:footnote id="ix_3_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif">The weighted-average number of shares of as-converted Company Series A Preferred Stock used in the loss allocation was <ix:nonFraction contextRef="c184" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable" scale="0" unitRef="shares" id="ixv-24692">495,191</ix:nonFraction> for the period from February 6, 2024 (inception) to December 31, 2024.</span></ix:footnote></td></tr></table>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><ix:footnote id="ix_4_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif">The weighted-average number of shares of as-converted Company Series B Preferred Stock used in the loss allocation was <ix:nonFraction contextRef="c47" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable" scale="0" unitRef="shares" id="ixv-24693">4,328,844</ix:nonFraction> for the period from February 6, 2024 (inception) to December 31, 2024.</span></ix:footnote></td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">For
the computation of basic net loss per share attributable to stockholders, the amount of weighted-average shares outstanding excludes
all shares of unvested restricted common stock as such shares are not considered outstanding for accounting purposes until vested. The
amount of weighted-average shares outstanding includes the pre-funded warrants as the exercise price is negligible and these warrants
are fully vested and exercisable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-17087"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to stockholders for
the periods presented because including them would have had an anti-dilutive effect were as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31, <br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding employee warrants to
    purchase common stock</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c185" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-24694">3,054,358</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding unvested restricted stock awards</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c186" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-24695">2,207,553</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding and issued common stock options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c187" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-24696">1,567,760</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding and issued
    warrant to Paruka</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c188" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-24697">596,930</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 13.7pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-24698">7,426,601</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-17163"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>15.
Related Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Paragon
and Paruka each <ix:nonNumeric contextRef="c190" name="orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" id="ixv-24699"><ix:nonNumeric contextRef="c189" name="orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" id="ixv-24700">beneficially own less than 5%</ix:nonNumeric></ix:nonNumeric> of the Company&#8217;s capital stock through their respective holdings of Company Common
Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Fairmount
beneficially owns more than 5% of the Company&#8217;s capital, currently has one representative appointed to the Board, and <ix:nonNumeric contextRef="c192" name="orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" id="ixv-24701"><ix:nonNumeric contextRef="c191" name="orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" id="ixv-24702">beneficially
owns more than 5%</ix:nonNumeric></ix:nonNumeric> of Paragon. Fairmount appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment
of any executive officers of Paragon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="ixv-17177"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following is a summary of related party accounts payable and other current liabilities (in thousands):&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31, <br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paragon reimbursable Option Agreements&#8217;
    fees</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c193" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-24703">1,482</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paragon milestone payments for Option Agreement</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c194" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-24704">4,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paragon reimbursable other research expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c195" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-24705">515</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Paragon reimbursable
    patent expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c196" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-24706">25</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-24707">6,022</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-17253"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>16.
Subsequent Events</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
February 2025, the Company entered into a lease agreement for an office space located in Waltham, Massachusetts. The lease is for an
initial period of <ix:nonNumeric contextRef="c197" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-24708">54</ix:nonNumeric> months. The Company expects to pay approximately $<ix:nonFraction contextRef="c197" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" unitRef="usd" id="ixv-24709">1.6</ix:nonFraction> million over the lease term.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 118 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">None.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
9A. Controls and Procedures. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Management&#8217;s
Evaluation of Disclosure Controls and Procedures</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
management, with the participation of our Principal Executive Officer and our Principal Financial Officer, evaluated the effectiveness
of our disclosure controls and procedures as of December 31, 2024. Based on the foregoing evaluation, our Principal Executive Officer
and Principal Financial Officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level
as of December 31, 2024. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under
the Exchange Act means controls and other procedures of a company that are designed to ensure that information required to be disclosed
by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the
time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and
procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act
is accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial Officer, or persons
performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Management
recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving
their objectives, and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls
and procedures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Management&#8217;s
Report on Internal Control over Financial Reporting</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over
financial reporting is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process designed by, or under
the supervision of, our principal executive and principal financial officers and effected by our board of directors, management and other
personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with U.S. GAAP. Our internal control over financial reporting includes those policies and procedures
that:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">pertain
                                            to the maintenance of records that, in reasonable detail, accurately and fairly reflect our
                                            transactions and dispositions of our assets;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">provide
                                            reasonable assurance that transactions are recorded as necessary to permit preparation of
                                            financial statements in accordance with U.S. GAAP, and that our receipts and expenditures
                                            are being made only in accordance with authorizations of our management and directors; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">provide
                                            reasonable assurance regarding prevention or timely detection of unauthorized acquisition,
                                            use or disposition of our assets that could have a material effect on our financial statements.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of
any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions,
or that the degree of compliance with the policies or procedures may deteriorate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
management, with the participation of our principal executive officer and principal financial officer, assessed the effectiveness of
our internal control over financial reporting as of December 31, 2024. In making this assessment, management used the criteria set forth
by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in its 2013 Internal Control &#8211; Integrated Framework.
Based on our assessment, our management has concluded that, as of December 31, 2024, our internal control over financial reporting was
effective based on those criteria.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 119; Options: NewSection; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">This
Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm regarding internal
control over financial reporting. For as long as we remain a &#8220;smaller reporting company&#8221; as defined by Rule 12b-2 of the
Exchange Act and report less than $100 million of annual revenues in our most recent fiscal year, we intend to take advantage of the
exemption permitting us not to comply with the requirement that our independent registered public accounting firm provide an attestation
on the effectiveness of our internal control over financial reporting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Changes
in Internal Control over Financial Reporting</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">There
were no changes in our internal control over financial reporting during the quarter ended December 31, 2024 that have materially affected,
or are reasonably likely to materially affect, our internal control over financial reporting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
9B. Other Information. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">During
the quarter ended December 31, 2024, no director or Section 16 officer (as defined in Section 16 of the Securities Exchange Act of 1934,
as amended) <ix:nonNumeric contextRef="c198" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="ixv-24710"><ix:nonNumeric contextRef="c198" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="ixv-24711">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c198" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="ixv-24712"><ix:nonNumeric contextRef="c198" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="ixv-24713">terminated</ix:nonNumeric></ix:nonNumeric> any Rule 10b5-1 trading arrangements or non-Rule 10b5-1 trading arrangements (in each case, as defined
in Item 408(a) of Regulation S-K).&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 120; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>PART
III</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
10. Directors, Executive Officers and Corporate Governance. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Executive
Officers and Directors</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets
forth the names, ages as of March 6, 2025, and positions of the individuals who currently serve as executive officers and directors of
the Company.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; background-color: white">
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 35%; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif"><b>Name</b></span></td>
    <td style="padding: 0.75pt 0.75pt 1.5pt 6.85pt; font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 7%; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; width: 1%; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 56%; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif"><i>Executive
    Officers and Employee Director</i></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Lawrence
    Klein, Ph.D.</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">42</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">President,
    Chief Executive Officer and Director</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Arjun
    Agarwal</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">49</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Senior
    Vice President, Finance and Treasurer</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Joana
    Goncalves, MBChB</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">51</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Chief
    Medical Officer</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Paul
    Quinlan</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">62</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">General
    Counsel and Corporate Secretary</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif"><i>Non-Employee
    Directors</i></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Samarth
    Kulkarni, Ph.D.<sup>(2)(3)</sup></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">46</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Chair
    and Director</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Kristine
    Ball<sup>(1)(3)</sup></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">53</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Director</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Carl
    Dambkowski, M.D.<sup>(1)</sup></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">40</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Director</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Peter
    Harwin<sup>(2)(3)</sup></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">39</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Director</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Cameron
    Turtle, D.Phil.<sup>(1)(2)</sup></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">35</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Director</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>



</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Member
                                            of the Audit Committee.</span></td></tr></table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Member
                                            of the Compensation Committee.</span></td></tr></table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Member
                                            of the Nominating and Governance Committee (the &#8220;Governance Committee&#8221;).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
business affairs are managed under the direction of our Board, which currently consists of six members. Our Board is divided into three
classes, with members of each class holding office for staggered three-year terms. There are currently two Class I directors, who are
up for election at the 2025 Annual Meeting of Stockholders for a term expiring at the 2028 Annual Meeting of Stockholders; two Class
II directors, whose terms expire at the 2026 Annual Meeting of Stockholders; and two Class III directors, whose terms expire at the 2027
Annual Meeting of Stockholders. Each executive officer serves at the discretion of the of the Board and holds office until their successor
is duly appointed and qualified or until their earlier resignation or removal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Biographical
and other information regarding our executive officers and directors is set forth below. There are no family relationships among any
of our executive officers or directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Executive
Officers and Employee Director</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Lawrence
Klein, Ph.D.</i></b> Dr.&#160;Klein has served as Chief Executive Officer and as a member of the board of directors of the Company since
the Merger Closing and of Pre-Merger Oruka from February 2024 through the Merger Closing. Prior to joining Pre-Merger Oruka, Dr.&#160;Klein
was a Partner at Versant Venture Management, LLC, a healthcare and biotechnology venture capital firm, from January&#160;2023 to February&#160;2024,
where he invested in and helped to grow early-stage&#160;biotechnology companies. Prior to Versant, Dr.&#160;Klein served in various
positions at CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, including Chief Operating Officer from January&#160;2020
to October&#160;2022, Chief Business Officer from January&#160;2019 to January&#160;2020, Senior Vice President, Business Development
and Strategy from November&#160;2017 to December&#160;2018 and as Vice President, Strategy from February&#160;2016 to November&#160;2017,
where he helped to initiate and execute on several transformative partnerships, establish the strategic direction of the company, oversee
important pipeline programs and led several functions, including program and portfolio management. Before joining CRISPR, Dr.&#160;Klein
was an Associate Partner at McKinsey&#160;&amp; Company, a global management consulting firm, from October&#160;2014 to February&#160;2016.
Dr.&#160;Klein served as a member of the board of directors of Dyne Therapeutics, Inc. (Nasdaq: DYN) from September&#160;2019 to May&#160;2023
and of Jasper Therapeutics, Inc. (Nasdaq: JSPR) from September&#160;2021 to June&#160;2023. Dr.&#160;Klein received his B.S. in biochemistry
and physics from the University of Wisconsin-Madison&#160;and his Ph.D. in biophysics from Stanford University.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
believe Dr. Klein is qualified to serve as a member of the Board because of his business development, operational and senior management
experience in the biotechnology industry and his academic expertise and accomplishments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Joana
Goncalves, MBChB.</i></b> Dr.&#160;Goncalves has served as the Chief Medical Officer of the Company since the Merger Closing and of Pre-Merger
Oruka from April&#160;2024 through the Merger Closing. Prior to joining Pre-Merger Oruka, Dr.&#160;Goncalves served as Chief Medical
Officer of Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company, from October&#160;2018 to April&#160;2024, where she
was responsible for representing Cara Therapeutics in interactions with regulatory agencies, the investor and scientific communities
and the board of directors, building multifunctional terms and developing the clinical development strategy in dermatological conditions.
Prior to Cara, Dr.&#160;Goncalves held various positions at Celgene Corporation, a pharmaceutical company, which was later acquired by
Bristol-Myers&#160;Squibb Company, from April&#160;2014 to October&#160;2018, where she most recently served as Vice President, Medical
Affairs for Dermatology and Neurology and was instrumental in planning and executing medical support activities for a number of programs,
including OTEZLA&#174; for psoriasis. Prior to Celgene, Dr.&#160;Goncalves served as Vice President, Medical Strategy and Scientific Affairs
at LEO Pharma Inc., the U.S.&#160;subsidiary of LEO Pharma A/S, a global healthcare company specializing in dermatology and critical
care, from February&#160;2012 to April&#160;2014. She began her pharmaceutical career at Novartis Pharmaceuticals, working on a range
of products across various therapeutic areas from 2001 to 2012. Dr.&#160;Goncalves received her MBChB from the University of Cape Town,
South Africa.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Paul
Quinlan.</i></b> Mr.&#160;Quinlan has served as General Counsel and Corporate Secretary of the Company since the Merger Closing and of
Pre-Merger Oruka since April&#160;2024 through the Merger Closing. Prior to joining Pre-Merger Oruka, Mr.&#160;Quinlan served as General
Counsel, Chief Compliance Officer and Corporate Secretary of CymaBay Therapeutics, Inc., a biopharmaceutical company, from October&#160;2020
to March&#160;2024, where he was responsible for the general supervision of the company&#8217;s legal affairs. From December&#160;2017
to February&#160;2020, he served as General Counsel and Corporate Secretary of CymaBay, where he was responsible for the general supervision
of the company&#8217;s legal affairs. Prior to CymaBay, Mr.&#160;Quinlan served as General Counsel and Secretary, from 2010 to January&#160;2018,
and Chief Legal Officer from 2016 to January&#160;2018, of TerraVia Holdings, Inc., a biotechnology company, where he was responsible
for the general supervision of the company&#8217;s legal affairs. Prior to joining TerraVia, Mr.&#160;Quinlan served as General Counsel
of Metabolex, Inc., a biopharmaceutical company, from 2005 to 2010. Prior to joining Metabolex, Mr.&#160;Quinlan held various positions
at Maxygen, Inc., a biopharmaceutical company, from 2000 to 2005. Prior to Maxygen, Mr.&#160;Quinlan practiced law at Cooley LLP and
Cravath, Swaine,&#160;&amp; Moore LLP.&#160;Mr.&#160;Quinlan received a law degree from Columbia Law School and an M.Sc. in Medical Biophysics
from the University of Toronto.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Arjun
Agarwal.</i></b>&#160;Mr.&#160;Agarwal has served as the Senior Vice President of Finance of the Company since the Merger Closing and
of Pre-Merger Oruka from March&#160;2024 through the Merger Closing, where he is responsible for overseeing the company&#8217;s finance
and accounting functions. Prior to joining Pre-Merger Oruka, Mr.&#160;Agarwal served as VP of Finance at Jasper Therapeutics, Inc. (Nasdaq:
JSPR), a biotechnology company, from June&#160;2021 to March&#160;2024, including through multiple financings and the company&#8217;s
successful transition to become a publicly traded entity. Before joining Jasper, Mr.&#160;Agarwal served as Vice President, Corporate
Controller at Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a biotechnology company, from August&#160;2019 to June&#160;2021, where
he was responsible for overseeing the company&#8217;s finance and accounting functions. Prior to joining Protagonist, Mr.&#160;Agarwal
served in various roles of increasing responsibility at McKesson Corporation (NYSE:&#160;MCK),&#160;an international healthcare services
company, from 2009 to 2019. Prior to McKesson, Mr.&#160;Agarwal worked at PricewaterhouseCoopers LLP, where he managed a portfolio of
audit clients. He is a graduate of Sydenham College of Commerce and Economics at Mumbai University, India. He is a Certified Public Accountant
(CPA) and a Chartered Accountant accredited by the Institute of Chartered Accountants of India.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 122; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Non-Employee
Directors</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Samarth
Kulkarni, Ph.D.</i></b> Dr.&#160;Kulkarni has served as Chair and a member of the board of directors of the Company since the Merger
Closing and as a member of the board of directors of Pre-Merger Oruka from February&#160;2024 through the Merger Closing. Dr.&#160;Kulkarni
has served as the Chief Executive Officer of CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, since December&#160;2017,
where he has also served as a member and chair of the board of directors since June&#160;2018 and September&#160;2023, respectively.
Previously, Dr.&#160;Kulkarni served as CRISPR&#8217;s President and Chief Business Officer from May&#160;2017 to November&#160;2017
and as Chief Business Officer from August&#160;2015. Prior to joining CRISPR, Dr.&#160;Kulkarni was at McKinsey&#160;&amp; Company, a
global management consulting firm, from 2006 to 2015, with various titles, his most recent being Partner within the Pharmaceuticals and
Biotechnology practice. Dr.&#160;Kulkarni has also served as a member of the boards of directors of Black Diamond Therapeutics, Inc.
(Nasdaq: BDTX), Repare Therapeutics Inc. (Nasdaq: RPTX), and Centessa Pharmaceuticals plc (Nasdaq: CNTA). Dr.&#160;Kulkarni received
a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B.&#160;Tech. from the Indian Institute of Technology.
Dr.&#160;Kulkarni has authored several publications in leading scientific and business journals.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
believe that Dr. Kulkarni is qualified to serve as a member of the Board because of his experience as a consultant and an executive in
the biopharmaceutical industry and his academic expertise and accomplishments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"><b><i>Kristine Ball.</i></b>
Ms. Ball has served as a member of the board of directors of the Company since the Merger Closing and of Pre-Merger Oruka since May&#160;2024
through the Merger Closing. Ms.&#160;Ball has served as President and Chief Executive Officer of Antiva Biosciences, Inc., a private biopharmaceutical
company, since April&#160;2023. Prior to Antiva, Ms. Ball served as Chief Executive Officer of Soteria Biotherapeutics, Inc., a private
biotechnology company, from September&#160;2020 to August&#160;2022. Prior to joining Soteria, Ms. Ball served as Senior Vice President,
Corporate Strategy and Chief Financial Officer of Menlo Therapeutics, Inc., a Nasdaq-listed&#160;biopharmaceutical company, which later
became VYNE Therapeutics Inc. (Nasdaq: VYNE), from September&#160;2017 to March&#160;2020, where she was responsible for leading all non-R&amp;D
functions, including strategic planning, corporate development, commercial, human resources, legal, finance and information technology.
Prior to joining Menlo, Ms. Ball served as Chief Financial Officer and Senior Vice President of Relypsa, Inc., a Nasdaq-listed&#160;pharmaceutical
company, which was later acquired by Galenica Group, from November&#160;2012 to October&#160;2016. Prior to Relypsa, Ms. Ball held various
other finance roles in the life sciences industry, including Senior Vice President of Finance&#160;&amp; Administration and Chief Financial
Officer of KAI Pharmaceuticals, Inc., a biopharmaceutical company, and Vice President of Finance at Exelixis, Inc. (Nasdaq: EXEL), a biotechnology
company. Prior to that, Ms. Ball served as a senior manager in the life sciences audit practice of Ernst&#160;&amp; Young LLP. Ms.&#160;Ball
has previously served on the boards of directors of Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company, from 2020 to 2024, Soteria
from 2020 to 2022 and Forty Seven, Inc. (Nasdaq: FTSV), a Nasdaq-listed&#160;biotechnology company, which was acquired by Gilead Sciences,
Inc., from 2018 to 2020. Ms. Ball received a B.S. from Babson College.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
believe Ms. Ball is qualified to serve as a member of the Board because of her experience as an executive officer and director of life
sciences companies and her background in finance, corporate development and strategic planning.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Carl
Dambkowski, M.D.</i></b> Dr.&#160;Dambkowski has served as a member of the board of directors of the Company since the Merger Closing
and of Pre-Merger Oruka from February&#160;2024 through the Merger Closing. Dr.&#160;Dambkowski has served as the Chief Medical Officer
of Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company, since September&#160;2022. Prior to joining Apogee, Dr.&#160;Dambkowski
served as a strategic and clinical leader for a variety of companies, including as Chief Medical Officer of QED Therapeutics, Inc., a
private biotechnology company, from July&#160;2021 to September&#160;2022; Chief Strategy Officer and EVP of Operations of Origin Biosciences,
Inc., a private bioecology company, from March&#160;2018 to June&#160;2021; and Chief Medical Officer of Navire Pharma, Inc., a private
biotechnology company, from January&#160;2020 to September&#160;2022, where he served as the clinical lead starting prior to IND for
BBP-398&#160;through the out licensing of the compound to Bristol-Myers&#160;Squibb based on initial clinical data and for low-dose&#160;infigratinib
in achondroplasia through initial proof-of-concept&#160;data. He was part of the core team that brought TRUSELTIQ&#174;&#160;(infigratinib)
and NULIBRY&#174;&#160;(fosdenopterin) through regulatory review and FDA approval at QED Therapeutics and Origin Biosciences, respectively.
From July&#160;2016 to March&#160;2018, Dr.&#160;Dambkowski was an associate at McKinsey&#160;&amp; Company, a global management consulting
firm, where he advised biotech and pharmaceutical companies across the world on a range of research and development activities. Dr.&#160;Dambkowski
co-founded&#160;Novonate, Inc., a private medical device company focused on building life-saving&#160;devices for neonates, in January&#160;2015.
Dr.&#160;Dambkowski has coauthored numerous peer-reviewed&#160;publications and scientific abstracts and is a named inventor on multiple
published and granted patents. Dr.&#160;Dambkowski was trained as a physician at Stanford University, where he also received his M.D.
with a concentration in bioengineering. He also received a B.A. (with honors) from Stanford University and an M.A. from Columbia University.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
believe Dr. Dambkowski is qualified to serve as a member of the Board because of his significant experience and innovations in the biotechnology
industry and his academic expertise and accomplishments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Peter
Harwin.</i></b> Mr.&#160;Harwin has served as a member of the board of directors of the Company since the Merger Closing and of Pre-Merger
Oruka from February&#160;2024 through the Merger Closing. Mr.&#160;Harwin is a Managing Member at Fairmount Funds Management, a healthcare
investment firm he co-founded&#160;in April&#160;2016. Prior to Fairmount Funds Management, Mr.&#160;Harwin was a member of the investment
team at Boxer Capital, LLC, an investment fund that was part of the Tavistock Group, based in San Diego. Mr.&#160;Harwin also serves
as chairman of the board of directors of Cogent Biosciences, Inc. (Nasdaq: COGT) and is a member of the board of directors of Apogee
Therapeutics, Inc. (Nasdaq: APGE), Viridian Therapeutics, Inc. (Nasdaq: VRDN) and Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics,
Inc.) (Nasdaq: SYRE). Mr.&#160;Harwin received a B.B.A. from Emory University.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
believe Mr. Harwin is qualified to serve as a member of the Board because of his experience serving as a director of biotechnology companies
and as a manager of funds specializing in the area of life sciences.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Cameron
Turtle, D.Phil.</i></b> Dr.&#160;Turtle has served as a member of the board of directors of the Company since the Merger Closing and
of Pre-Merger Oruka from February&#160;2024 through the Merger Closing. Dr.&#160;Turtle has served as Chief Executive Officer and a member
of the board of directors of Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.) (Nasdaq: SYRE), a biotechnology company,
since November&#160;2023 and, before that, as Chief Operating Officer from June&#160;2023 to November&#160;2023. Prior to joining Spyre,
Dr.&#160;Turtle was an advisor to Spyre Therapeutics, Inc., a private biotechnology company, from May&#160;2023 to June&#160;2023. Previously,
he served as Venture Partner at Foresite Labs, a life sciences investment firm, from July&#160;2022 to May&#160;2023; Chief Strategy
Officer of BridgeBio Pharma (Nasdaq: BBIO), a biotechnology company, from January&#160;2021 to April&#160;2022; and Chief Business Officer
of Eidos Therapeutics (Nasdaq: EIDX), a biopharmaceutical company, from November&#160;2018 to January&#160;2021, where he led business
development, investor relations, and multiple operational functions as the company advanced an investigational medicine for a form of
heart failure. Prior to joining BridgeBio and Eidos, he was a consultant at McKinsey&#160;&amp; Company, a global management consulting
firm, where he worked with pharmaceutical and medical device companies on topics including M&amp;A, growth strategy, clinical trial strategy,
and sales force optimization. Dr.&#160;Turtle received his B.S. with honors in Bioengineering from the University of Washington and his
D.Phil. in Cardiovascular Medicine from the University of Oxford, St. John&#8217;s College. He is the recipient of several awards, including
a Rhodes Scholarship, Goldwater Scholarship, Forbes 30 Under&#160;30, San Francisco Business Times 40 Under&#160;40, and the Biocom Life
Sciences Catalyst Award.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
believe Dr. Turtle is qualified to serve as a member of the Board because of his experience as a leader in building, financing, and shaping
biopharmaceutical organizations from preclinical development to late-stage clinical trials and commercialization.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Code
of Business Conduct and Ethics</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
have adopted a Code of Business Conduct and Ethics that establishes the standards of ethical conduct applicable to all our directors,
officers and employees, including our principal executive officer, principal financial officer and principal accounting officer, or persons
performing similar functions. It addresses, among other matters, compliance with laws and policies, conflicts of interest, corporate
opportunities, regulatory reporting, external communications, confidentiality requirements, insider trading, proper use of assets and
how to report compliance concerns. A copy of the code is available on our website located at&#160;https://ir.oruka.com/corporate-governance&#160;under
&#8220;Governance Documents.&#8221; We intend to disclose any amendments to the code, or any waivers of its requirements, on our website
to the extent required by applicable rules. The Audit Committee is responsible for applying and interpreting the code in situations where
questions are presented to it. Information contained on, or that can be accessed through, the Company&#8217;s website is not incorporated
by reference into this report, and you should not consider information on the Company&#8217;s website to be part of this report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Insider
Trading Policy</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
have adopted insider trading policies and procedures governing the purchase, sale and other transactions in Company securities by our
directors, officers and employees, and other covered persons, as well as the Company itself, that we believe are reasonably designed
to promote compliance with insider trading laws, rules and regulations, and Nasdaq Stock Market (&#8220;Nasdaq&#8221;) listing rules,
as applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
part of these policies and procedures, we prohibit any employee, director or other covered person from engaging in short sales, transactions
involving publicly traded options or other derivative securities based on the Company&#8217;s securities, hedging transactions, margin
accounts, pledges, or other inherently speculative transactions with respect to the Company&#8217;s securities at any time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Audit
Committee and Audit Committee Financial Expert</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
have a separately designated standing Audit Committee. The members of our Audit Committee are Ms. Ball, Dr. Dambkowski, and Dr. Turtle,
each of whom qualifies as an &#8220;independent&#8221; director for audit committee purposes as defined under Nasdaq listing rules and
the rules and regulations established by the SEC. Ms. Ball chairs the Audit Committee and qualifies as an &#8220;audit committee financial
expert&#8221; as that term is defined under the rules and regulations established by the SEC, and all members of the Audit Committee
are financially literate under Nasdaq listing rules.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Delinquent
Section 16(a) Reports</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Section
16(a) of the Exchange Act requires our directors, officers and persons who beneficially own more than 10% of a registered class of our
equity securities to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock and other
equity securities. To our knowledge, based solely on our review of Forms 3, 4 and 5 filed with the SEC or written representations that
no Form 5 was required, during the year ended December 31, 2024, we believe that all of our directors, officers and persons who beneficially
own more than 10% of a registered class of our equity securities timely filed all reports required under Section 16(a) of the Exchange
Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Stockholder
Proposals and Director Nominations for 2025 Annual Meeting of Stockholders</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
will hold our 2025 Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;) on Monday, June 2, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to Rule&#160;14a-8&#160;of the Exchange Act, stockholders who wish to submit proposals for inclusion in the proxy statement for the Annual
Meeting must send such proposals to our Corporate Secretary at the address 855 Oak Grove Avenue, Suite 100, Menlo Park, CA 94025. Such
proposals must be received by us a reasonable time before we begin to print and mail our proxy materials and must comply with Rule 14a-8
of the Exchange Act. The submission of a stockholder proposal does not guarantee that it will be included in the proxy statement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On August 29, 2024, in connection
with the Merger Closing, the Board adopted an amendment and restatement of our Bylaws, effective as of such date, as described in our
Current Report on Form 8-K filed on September 5, 2024. As set forth in our Bylaws, if a stockholder intends to make a nomination for director
election or present a proposal for other business (other than pursuant to Rule&#160;14a-8&#160;of the Exchange Act) at the Annual Meeting,
the stockholder&#8217;s notice must be received by our Corporate Secretary at the address 855 Oak Grove Avenue, Suite 100, Menlo Park,
CA 94025 no earlier than the 120th&#160;day and no later than the close of business on the 90th day before the anniversary of the last
annual meeting; provided, however, that if the date of the annual meeting is more than 30 days before or more than 60 days after such
anniversary date, the stockholder&#8217;s notice must be delivered not earlier than the close of business on the 120th day prior to such
annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting or the 10th day following
the date on which the first public announcement of the date of such annual meeting is made by the Company. Therefore, notice of proposed
nominations or proposals (other than pursuant to Rule&#160;14a-8&#160;of the Exchange Act) must be received by our Corporate Secretary
no later than the close of business on March 16, 2025. Any such director nomination or stockholder proposal must be a proper matter for
stockholder action and must comply with the terms and conditions set forth in our Bylaws (which includes the timing and information required
under Rule&#160;14a-19 of the Exchange Act). If a stockholder fails to meet these deadlines or fails to satisfy the requirements of Rule
14a-4 of the Exchange Act, we may exercise discretionary voting authority under proxies we solicit to vote on any such proposal as we
determine appropriate. We reserve the right to reject, rule out of order or take other appropriate action with respect to any nomination
or proposal that does not comply with these and other applicable requirements.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 125; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
11. Executive Compensation. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">This
section provides information regarding the compensation of our principal executive officer (Dr.&#160;Klein), and our two other highest
paid executive officers who were serving as executive officers on December&#160;31, 2024 (Dr. Goncalves and Mr. Quinlan). This section
also includes compensation information for certain former executives of the Company (then known as ARCA). The individuals listed below
are collectively referred to herein as the &#8220;NEOs&#8221; or &#8220;Named Executive Officers.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; background-color: white">
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 35%"><span style="font-family: Times New Roman, Times, Serif"><b>Name</b></span></td>
    <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 63%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: #CFF0FC">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Lawrence
    Klein, Ph.D.</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Chief Executive Officer<sup>(1)</sup></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: white">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Joana Goncalves,
    MBChB</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Chief Medical Officer<sup>(1)</sup></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: #CFF0FC">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Paul Quinlan</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">General Counsel and
    Corporate Secretary<sup>(1)</sup></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: white">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Michael Bristow,
    M.D.</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Former President
    and Chief Executive Officer<sup>(2)</sup></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: #CFF0FC">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Thomas A. Keuer</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Former President
    and Chief Operating Officer<sup>(3)</sup></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: white">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">C. Jeffrey Dekker</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Former Chief Financial
    Officer<sup>(3)</sup></span></td></tr>
  </table><div>


</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>


</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Drs.
                                            Klein and Goncalves and Mr. Quinlan were appointed to these positions in connection with
                                            the consummation of the Merger. Prior to the Merger, they each served in these positions
                                            at Pre-Merger Oruka.</span></td></tr></table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Dr.
                                            Bristow&#8217;s employment with the Company terminated on April 3, 2024. Following his termination,
                                            Dr. Bristow provided transition services as a consultant.</span></td></tr></table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Mr.
                                            Keuer&#8217;s and Mr. Dekker&#8217;s employment with the Company terminated in connection
                                            with the Merger. Following the Merger, Mr. Dekker provided transition services as a consultant.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>A
Year of Transition </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">2024
was a year of transition for the Company as we completed the Merger, shifted our drug candidate pipeline to focus on novel biologics
designed to set a new standard for the treatment of chronic skin diseases and transformed our management team. Our mission is to offer
patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high
rates of complete disease clearance with dosing as infrequently as once or twice per year. The compensation described below reflects
both compensatory decisions necessary to engage a new leadership team that is critical to lead the advancement of the Company&#8217;s
pipeline of novel biologics and improve the standard of care for the treatment of chronic skin diseases and compensatory decisions made
by ARCA prior to the consummation of the Merger with respect to the former executive officers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 126; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>2024
Summary Compensation Table</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table shows information regarding the compensation earned by the NEOs during the fiscal years ending December&#160;31, 2024
and 2023, by our named executive officers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    and Principal Position<sup>(1)</sup></b></span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary<br/>
    ($)<sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>Bonus<br/>
    ($)<sup>(3)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>Option
                                            Awards</b></span></p> <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>($)<sup>(4)</sup></b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Equity<br/>
    Incentive Plan<br/> Compensation<br/> ($)<sup>(5)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">All
    Other<br/> Compensation<br/> ($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total<br/>
    ($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 22%; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Lawrence
    Klein, Ph.D.</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">203,288</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">317,623</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">520,911</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Chief
    Executive Officer</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Joana
    Goncalves, MBChB</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">155,854</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">162,132</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">317,986</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Chief
    Medical Officer</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Paul
    Quinlan</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">155,854</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">154,591</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">310,445</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">General
    Counsel</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Michael
    Bristow, M.D.</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">96,865</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,676</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">373,875</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(6)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">510,416</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Former
    President and Chief Executive Officer</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">345,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,800</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">358,800</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Thomas
    A. Keuer</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">235,385</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">165,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,484</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">430,651</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(7)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">853,520</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Former
    President and Chief Operating Officer</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">340,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">60,802</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">400,802</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">C.
    Jeffrey Dekker</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">206,923</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">165,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,947</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">359,734</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(8)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">756,604</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Former
    Chief Financial Officer</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">270,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">53,072</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">323,072</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>



</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            amounts reflected herein for Drs. Klein and Goncalves and Mr. Quinlan do not include any
                                            compensation they received from Pre-Merger Oruka prior to the Merger.</span></td></tr></table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Includes
                                            $157,595 of consulting fees for Dr. Bristow and $20,000 of consulting fees for Mr. Keuer,
                                            in each case, pursuant to their respective consulting agreements as described in more detail
                                            under &#8220;<i>Narrative Disclosure to Summary Compensation Table&#8212;ARCA Arrangements</i>&#8221;
                                            below.</span></td></tr></table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Amounts
                                            reported in this column represent retention bonuses, as described in more detail under &#8220;<i>Narrative
                                            Disclosure to Summary Compensation Table&#8212;ARCA Arrangements</i>&#8221; below.</span></td></tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(4)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Amounts
                                            reported in this column represent the incremental fair value under Accounting Standards Codification
                                            Topic 718 (&#8220;ASC 718&#8221;) resulting from the acceleration of the Named Executive
                                            Officer&#8217;s stock options in the Merger, as described in more detail under &#8220;Narrative
                                            to Summary Compensation Table&#8212;ARCA Arrangements&#8221; below.</span></td>
</tr></table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(5)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Amounts
                                            reported in this column represent the annual bonuses earned under the 2024 annual bonus program,
                                            as described in more detail under &#8220;<i>Narrative to Summary Compensation Table&#8212;Elements
                                            of Compensation&#8212;Annual Bonus Program</i>&#8221; below.</span></td></tr></table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(6)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Includes
                                            $3,875 of Company contributions under the ARCA 401(k) plan and $370,000 of severance payments
                                            and benefits, as described in more detail under &#8220;<i>Narrative Disclosure to Summary
                                            Compensation Table&#8212;ARCA Arrangements</i>&#8221; below.</span></td></tr></table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(7)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Includes
                                            $16,800 of Company contributions under the ARCA 401(k) plan, $340,000 of severance payments
                                            and $69,715 in COBRA continuation premiums, as described in more detail under &#8220;<i>Narrative
                                            Disclosure to Summary Compensation Table&#8212;ARCA Arrangements</i>&#8221; below, and $4,136
                                            for group term life insurance premiums.</span></td></tr></table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(8)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Includes
                                            $14,687 of Company contributions under the ARCA 401(k) plan, $270,000 of severance payments
                                            and $69,715 in COBRA continuation premiums, as described in more detail under &#8220;<i>Narrative
                                            Disclosure to Summary Compensation Table&#8212;ARCA Arrangements</i>&#8221; below, $2,692
                                            for group term life insurance premiums and $2,640 for healthcare reimbursements.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Narrative
Disclosure to Summary Compensation Table</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
December 2024, our Compensation Committee adopted a compensation philosophy to frame future compensation decisions for the Company. Under
this philosophy, compensation positioning is used to attract and retain key employees for the Company&#8217;s continued success and growth.
While market data is helpful to the Compensation Committee in setting compensation framework and guiding decisions, other factors such
as Company strategy, stockholder feedback, tenure, performance and criticality are also considered. The compensation philosophy serves
as the foundation to reinforce the Company&#8217;s business strategy and desired culture, while balancing internal and external alignment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 127; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Peer
Group</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
July 2024, Pre-Merger Oruka, in consultation with Alpine, the Compensation Committee&#8217;s independent compensation consultant, established
a peer group that focuses on U.S.-based, pre-clinical or early clinical biopharma companies (with priority placed on companies with a
similar therapeutic focus) with a market capitalization ranging from $250 million to $2 billion and less than 100 employees. The peer
group, which was used in making compensation decisions in connection with establishing post-Merger executive compensation for 2024, includes
the following companies (the &#8220;Peer Group&#8221;):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 32%; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Apogee
    Therapeutics</span></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 32%; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Astria
    Therapeutics</span></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 32%; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Cabaletta
    Bio</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">CARGO
    Therapeutics</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Celldex
    Therapeutics</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Contineum
    Therapeutics</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Entrada
    Therapeutics</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Janux
    Therapeutics</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Kymera
    Therapeutics</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Kyverna
    Therapeutics</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Lexeo
    Therapeutics</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Longboard
    Pharmaceuticals</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Lyell
    Immunopharma</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Pliant
    Therapeutics</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Prime
    Medicine</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Spyre
    Therapeutics</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Structure
    Therapeutics</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-top: 0.75pt; padding-right: 0.75pt"><span style="font-family: Times New Roman, Times, Serif">Third
    Harmonic Bio</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Elements
of Compensation</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>Base
Salaries</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
Compensation Committee recognizes the importance of base salary as an element of compensation to provide our executive officers with
steady cash flow during the year that is not contingent on short-term variations in our corporate performance. The setting of base salaries
also includes an evaluation of each individual&#8217;s job duties, responsibilities, performance and experience, as well as internal
pay equity among the executive officer team. The Compensation Committee reviews base salaries at least annually and may recommend adjustment
from time to time based on the results of that review. The Compensation Committee determines salary increases using a combination of
relevant competitive market data, scope of responsibilities and assessment of individual performance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">For
2024, the annual base salaries of Drs. Klein and Goncalves and Mr. Quinlan were established in connection with the consummation of their
employment with Pre-Merger Oruka as a result of negotiations in the context of a competitive recruitment process. The annual base salaries
as of December 31, 2024 for each of our continuing NEOs were as follows: $600,000 for Dr. Klein and $460,000 for each of Dr. Goncalves
and Mr. Quinlan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>Annual
Bonus Program</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
have an annual cash incentive plan under which cash incentives may be paid to each of our employees, including our executive officers,
after the end of each calendar year. The Compensation Committee generally determines target bonuses based on Peer Group practices and
each individual&#8217;s job duties. For 2024, the target bonuses for each NEO (excluding the former ARCA executive officers), which were
established by Pre-Merger Oruka in connection with the consummation of their employment with Pre-Merger Oruka, were as follows: 50% of
base salary for Dr. Klein and 40% of base salary for each of Dr. Goncalves and Mr. Quinlan, in each case, pro-rated based on their respective
start dates with Pre-Merger Oruka.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Pre-Merger
Oruka established the corporate goals and targets for the 2024 bonus program, which were heavily weighted towards the preclinical development
of ORKA-001 and ORKA-002, progress towards the commencement of their respective Phase 1 clinical studies and regulatory progress. In
addition, the corporate goals included measures designed to ensure adequate funding for the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Board, upon the recommendation of the Compensation Committee, reviewed our achievement against our 2024 corporate goals and determined
the achievement to have been 125% of target, based on the achievement of substantially all the goals, with overperformance on several
of the goals.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Based
on our corporate performance, the 2024 annual bonuses awarded to our continuing NEOs were as follows: $317,623 for Dr. Klein, $162,132
for Dr. Goncalves and $154,591 for Mr. Quinlan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 128; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>Long-Term
Incentives</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
intend our equity incentive program to reward longer-term performance and to align the interests of our executive officers with those
of our stockholders. We also believe that our equity incentive program, which currently consists predominantly of time-based stock options
(or, for certain grants by Pre-Merger Oruka, time-based compensatory warrants), is an important retention tool for our employees, including
our NEOs. The Compensation Committee believes that stock options, which require increased stock price performance for value realization,
create a key connection between the interests of the NEOs and stockholders. Each of the grants described below are presented after giving
effect to the share conversion completed in the Merger and the subsequent 1-for-12 reverse stock split.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
connection with his appointment as Chief Executive Officer of Pre-Merger Oruka, Dr. Klein purchased 852,338 shares of restricted stock
at fair market value, which vests as to 25% on February 26, 2025 and in equal monthly installments thereafter through February 26, 2028.
In accordance with the anti-dilution provisions of his offer letter, as described in more detail below, on July 15, 2024, Dr. Klein received
a compensatory warrant to purchase 1,628,513 shares of our common stock, which vests as to 25% on April 3, 2025 and in equal monthly
installments thereafter through April 3, 2028.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
connection with her appointment as Chief Medical Officer of Pre-Merger Oruka, Dr. Goncalves was granted stock options to purchase 228,563
shares of our common stock, which vests as to 25% on April 18, 2025 and in equal monthly installments thereafter through April 18, 2028.
On July 15, 2024, Dr. Goncalves was granted a compensatory warrant to purchase 199,992 shares of our common stock, which vests on the
same schedule as her initial stock option grant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
connection with his appointment as General Counsel of Pre-Merger Oruka, Mr. Quinlan was granted stock options to purchase 228,563 shares
of our common stock, which vests as to 25% on April 30, 2025 and in equal monthly installments thereafter through April 30, 2028. On
July 15, 2024, Mr. Quinlan was granted a compensatory warrant to purchase 99,996 shares of our common stock, which vests on the same
schedule as his initial stock option grant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">None
of the former ARCA executive officers received grants of equity incentive awards during 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Offer
Letters</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
connection with their appointments, we entered into offer letters with each of Dr. Klein, Dr. Goncalves and Mr. Quinlan, each of which
was amended and restated as of October 3, 2024 (for Dr. Klein) or October 1, 2024 (for Dr. Goncalves and Mr. Quinlan) following the Merger
(collectively, the &#8220;Offer Letters&#8221;). The Offer Letters provided for each NEO&#8217;s initial base salary, target annual bonus
and initial equity incentive award. The Offer Letter with Dr. Klein also provided for periodic grants of stock options sufficient to
maintain Dr.&#160;Klein&#8217;s ownership at approximately 5% on a fully-diluted&#160;basis until Oruka raised an aggregate of $200 million
in financing, which obligations were fully satisfied prior to the consummation of the Merger through the warrant issued on July 15, 2024.
The Offer Letter with Dr. Goncalves also provided for a sign-on bonus of $100,000, which is subject to repayment in the event of a termination
for cause or resignation without good reason prior to April 18, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Under
the Offer Letters, the NEOs are eligible for certain payments or benefits upon certain terminations of employment, as described under
&#8220;Additional Narrative Disclosure&#8212;Potential Payments Upon Termination or Change in Control&#8221; below. Each of Dr. Klein,
Dr. Goncalves and Mr. Quinlan is also party to our standard employee invention assignment, confidentiality and non-competition agreement,
which, among other things, provides standard protections regarding our ownership of intellectual property, the confidentiality of our
proprietary information, non-competition and non-solicitation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>ARCA
Arrangements</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Michael
Bristow, M.D.</i> Dr.&#160;Bristow served as the Company&#8217;s President and Chief Executive Officer through April 3, 2024. In connection
with his separation, the Company (then known as ARCA) and Dr.&#160;Bristow entered into a separation agreement pursuant to which Dr.
Bristow provided a release of claims in favor of the Company and the Company paid Dr.&#160;Bristow a lump sum severance payment of $370,000.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 129; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company and Dr.&#160;Bristow also entered into a consulting agreement, effective April&#160;3, 2024, pursuant to which Dr.&#160;Bristow
provided certain consulting services to the Company through the Merger. Under the consulting agreement, Dr.&#160;Bristow continued to
vest in his outstanding equity awards during the consulting term.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Thomas
A.&#160;Keuer and C. Jeffrey Dekker.</i> Mr.&#160;Keuer served as the Company&#8217;s President and Chief Operating Officer and Mr. Dekker
served as the Company&#8217;s Chief Financial Officer, in each case, through the consummation of the Merger. Pursuant to retention bonus
letters approved by the ARCA Compensation Committee prior to the Merger, each of Messrs. Keuer and Dekker were paid a retention bonus
upon consummation of the Merger of $165,000.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
a result of the Merger and the accompanying termination of their employment, the Company and each of Mr. Keuer and Mr. Dekker entered
into a separation agreement, pursuant to which Mr. Keuer and Mr. Dekker each provided a release of claims in favor of the Company and
the Company provided the following severance payments and benefits, in accordance with the terms of their employment agreement: (i) a
lump sum cash severance payment equal to 12 months of their respective annual base salary ($340,000 and $270,000, respectively) and (ii)
a lump sum cash payment of $69,715 in lieu of 12 months of group health plan continuation premiums.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Treatment
of ARCA Equity Awards.</i> In connection with the Merger, all outstanding ARCA stock options held by the NEOs were accelerated and cashed
out for an amount equal to the difference between $3.9489 and the applicable per share exercise price; however, any ARCA stock options
having an exercise price in excess of $3.9489 were cancelled for no consideration.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Outstanding
Equity Awards at Fiscal Year End</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table presents information regarding outstanding stock options, compensatory warrants and restricted stock held by each NEO
as of December&#160;31, 2024. The equity awards reflected below give effect to the share conversion completed in the Merger and the subsequent
1-for-12 reverse stock split. None of the former ARCA executive officers held any outstanding equity awards as of December 31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Option
    Awards</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Stock
    Awards</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Name</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/>
    Securities<br/>
    Underlying<br/>
    Unexercised<br/>
    Options (#)<br/>
    Exercisable</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/>
    Securities<br/>
    Underlying<br/>
    Unexercised<br/>
    Options (#)<br/>
    Unexercisable</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Option<br/>
    Exercise Price<br/>
    ($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Option
    Expiration<br/>
    Date</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/>
    Shares or<br/>
    Units of Stock <br/>
    That Have Not<br/>
    Vested <br/>
    (#)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
    Value<br/>
    of Shares or<br/>
    Units of Stock<br/>
    That Have Not<br/>
    Vested<br/>
    ($)<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lawrence Klein, Ph.D.</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,628,513</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(2)</sup></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.80</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/14/2034</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">852,338</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(3)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,526,834</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Joana Goncalves, MBChB</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">228,563</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(4)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.84</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/30/2034</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">199,992</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(4)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.80</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/14/2034</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paul Quinlan</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">228,563</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(5)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.84</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/30/2034</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">99,996</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(5)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.80</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/14/2034</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Michael Bristow, M.D.</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Thomas A. Keuer</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">C. Jeffrey Dekker</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>


</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            market value was determined by multiplying the numbers of shares by $19.39, the closing price
                                            of our common stock on December 31, 2024.</span></td></tr></table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">These
                                            compensatory warrants vest as to 25% on April 3, 2025 and in equal monthly installments thereafter
                                            through April 3, 2028, subject to Dr. Klein&#8217;s continued services to us.</span></td></tr></table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">These
                                            restricted shares vest as to 25% on February 26, 2025 and in equal monthly installments thereafter
                                            through February 26, 2028, subject to Dr. Klein&#8217;s continued services to us.</span></td></tr></table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(4)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">These
                                            stock options and compensatory warrants vest as to 25% on April 18, 2025 and in equal monthly
                                            installments thereafter through April 18, 2028, subject to Dr. Goncalves&#8217; continued
                                            services to us.</span></td></tr></table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(5)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">These
                                            stock options and compensatory warrants vest as to 25% on April 30, 2025 and in equal monthly
                                            installments thereafter through April 30, 2028, subject to Mr. Quinlan&#8217;s continued
                                            services to us.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 130; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Additional
Narrative Disclosures</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Employee
Benefits and Perquisites</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
NEOs are eligible to participate in our employee benefit plans, including our health and welfare plans, term life insurance, disability
insurance and a 401(k) plan, in each case on the same basis as all our other employees. During 2024, following the Merger, we did not
provide any Company contributions under the 401(k) plan; however, in 2025, the Company will make matching contributions of 100% of the
first 3% of eligible compensation deferred by participants, subject to legal maximum contributions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Following
the Merger, we generally do not provide perquisites or personal benefits to our NEOs, except in limited circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Potential
Payments Upon Termination or Change in Control</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the terms of the Offer Letters, in the event each NEO that is a current executive officer is terminated by the Company without &#8220;cause&#8221;
or as a result of a resignation for &#8220;good reason&#8221; (collectively, an &#8220;Involuntary Termination&#8221;), such NEO will,
subject to the execution of a release in favor of the Company, receive: (i) severance payments equal to 12 months of base salary; (ii)
Company-paid continuation coverage under the Company&#8217;s group health plans for up to 12 months; and (iii) in the case of Dr. Klein,
accelerated vesting of 30% of any outstanding time-based equity. However, if the Involuntary Termination is within three months before
or 12 months after a change in control of the Company, the NEO will instead receive: (A) severance payments equal to 1.0 times (or, for
Dr. Klein, 1.5x times) the sum of the NEO&#8217;s base salary and target bonus; (B) Company-paid continuation coverage under the Company&#8217;s
group health plans for up to 12 months (or, for Dr. Klein, up to 18 months); and (C) full acceleration of all equity awards. In addition,
upon severance due to the death or disability of the named executive officer, the officer&#8217;s equity awards shall accelerate in full.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
used in the Offer Letters:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#8220;Cause&#8221;
generally means the NEO&#8217;s (i) dishonest statements or acts with respect to the Company or any affiliate of the Company, or any
current or prospective customers, suppliers, vendors or other third parties with which such entity does business that results in or is
reasonably anticipated to result in material harm to the Company; (ii) conviction or plea of no contest to a felony or misdemeanor involving
moral turpitude, deceit, dishonesty or fraud; (iii) failure to perform his or her duties or responsibilities, subject to a 30-day cure
period; (iv) gross negligence, willful misconduct that results in or is reasonably anticipated to result in material harm to the Company;
or (v) violation of any material provision of any agreement with the Company or any written Company policies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#8220;Good
reason&#8221; generally means (i) a material diminution in the named executive officer&#8217;s base salary or target bonus (excluding
across-the-board reductions of less than 10%); (ii) a material geographic relocation or requirement to change the named executive officer&#8217;s
remote work location; (iii) a material reduction in the named executive officer&#8217;s duties, authority or responsibilities; (iv) the
failure of the Company to obtain the assumption of the Offer Letter by a successor; or (v) the material breach of any agreement between
the NEO and the Company, in each case, subject to standard notice and cure periods.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Clawback
Policy</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
maintain a Compensation Recoupment (Clawback) Policy, which is intended to comply with the requirements of Nasdaq Listing Standard 5608
implementing Rule 10D-1 under the Exchange Act. In the event the Company is required to prepare an accounting restatement of the Company&#8217;s
financial statements due to material non-compliance with any financial reporting requirement under the federal securities laws, the Company
will recover, on a reasonably prompt basis, the excess incentive-based compensation received by any covered executive, including the
NEOs, during the prior three fiscal years that exceeds the amount that the executive otherwise would have received had the incentive-based
compensation been determined based on the restated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Equity
Grant Practices</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Following
the Merger, we generally grant annual equity awards, including stock options, in January of each year. We also grant stock options as
new hire awards as of their date of employment commencement. Employees, including the NEOs, may enroll to purchase shares under the terms
of our 2024 Employee Stock Purchase Plan, as amended (the &#8220;ESPP&#8221;), with purchase dates generally occurring during open trading
windows in June and December of each year using payroll deductions accumulated during the prior six-month period. During 2024, the Compensation
Committee did not take material nonpublic information into account when determining the timing and terms of stock options, and the Company
did not time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Director
Compensation</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table provides information for the year ended December 31, 2024 regarding all compensation awarded to, earned by or paid to
each person who served as a non-employee director for some portion of 2024. Employees who served on our Board during 2024 did not receive
additional compensation for such service:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name<sup>(1)(2)</sup></b></span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Fees<br/>
    Earned or<br/> Paid in<br/> Cash<br/> ($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option
    Awards<br/> ($)<sup>(3)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total
    <br/> ($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Kristine Ball</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,548</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,548</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Carl Dambkowski, M.D.</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,267</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,267</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Peter Harwin</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,178</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,178</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Samarth Kulkarni, Ph.D.</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,740</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,740</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cameron Turtle, D.Phil.<sup>(4)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,377</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,377</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dan Mitchell</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">30,810</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">30,810</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Raymond Woosley</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Robert Conway</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">197,916</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,739</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">200,655</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">James Flynn</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">71,042</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,620</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">83,662</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Linda Grais</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">168,124</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,739</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">170,863</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Anders Hove</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">159,583</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,739</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">162,322</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Jacob Ma-Weaver</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">119,167</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,215</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">127,382</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>



</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            amounts reflected herein for directors who served on the Pre-Merger Oruka board of directors
                                            do not include any compensation they received from Pre-Merger Oruka prior to the Merger.</span></td></tr></table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Messrs.
                                            Woosley and Mitchell resigned from our Board effective as of February 2, 2024. In connection
                                            with the Merger on August 29, 2024, Drs. Hove and Grais as well as Messrs. Conway, Ma-Weaver
                                            and Flynn resigned from our Board and Drs. Turtle, Dambkowski and Kulkarni as well as Ms.
                                            Ball and Mr. Harwin were appointed to our Board.</span></td></tr></table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
                                            connection with the Merger, all outstanding ARCA stock options held by Drs. Hove and Grais
                                            and Messrs. Conway, Ma-Weaver and Flynn were accelerated and cashed out for an amount equal
                                            to the difference between $3.9489 and the applicable per share exercise price; however, any
                                            ARCA stock options having an exercise price in excess of $3.9489 were cancelled for no consideration.
                                            Amounts reported in this column represent the incremental fair value under ASC Topic 718
                                            resulting from the acceleration of the stock options in the Merger. As of December 31, 2024,
                                            each of Drs. Turtle and Dambkowski and Ms. Ball held outstanding options or compensatory
                                            warrants to purchase 94,282 shares of our common stock (which were assumed by the Company
                                            in connection with the Merger), Dr. Kulkarni held outstanding options or compensatory warrants
                                            to purchase 199,992 shares of our common stock (which were assumed by the Company in connection
                                            with the Merger), and no other non-employee directors held any outstanding options or compensatory
                                            warrants.</span></td></tr></table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(4)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Prior
                                            to the Merger, Dr. Turtle purchased 85,233 shares (after giving effect to the share conversion
                                            completed in the Merger and the subsequent 1-for-12 reverse stock split) of restricted common
                                            stock that vest as to 25% on March 1, 2025 and in and in equal monthly installments thereafter
                                            through March 1, 2028. All of such restricted shares were outstanding as of December 31,
                                            2024.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 132; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Non-Employee
Director Compensation Program</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Non-employee
members of the Board are eligible to receive cash and equity compensation in accordance with our non-employee director compensation program.
This program provides for the following annual cash retainers:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Pre-Merger</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Post-Merger</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Annual Cash Retainer</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Annual Board Chair Retainer</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">30,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">30,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Audit Committee Retainers:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Chair</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-Chair Member</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Compensation Committee Retainers:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Chair</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-Chair Member</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Nominating and Corporate Governance Committee
    Retainers</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Chair</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-Chair Member</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
connection with the Company&#8217;s annual meeting of stockholders, each member of the Board will receive an annual grant of stock options
to purchase 17,500 shares of common stock, which will vest in equal monthly installments over 12 months so long as such director joined
the Board prior to January 1 of the year in which such annual meeting occurs. Prior to the Merger, the annual grant of stock options
was for 6,000 shares of common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition, in connection with a non-employee director&#8217;s initial appointment to the Board, they will receive an initial grant of
stock options to purchase 35,000 shares of common stock, which will vest in equal monthly installments over 36 months. Prior to the Merger,
the initial grant of stock options was for 12,000 shares of common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">All
members of the Board are also reimbursed for reasonable and documented out-of-pocket travel and lodging expenses incurred in connection
with attending meetings and activities of the Board and its committees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Security
Ownership of Certain Beneficial Owners and Management</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table sets forth information, to the extent known by us or ascertainable from public filings, with respect to the beneficial
ownership of our Common Stock as of February 15, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">each
                                            person or group of affiliated persons, who is known by us to be the beneficial owner of more
                                            than 5% of Common Stock;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">each
                                            of our directors;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">each
                                            of our named executive officers; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">all
                                            of our current directors and executive officers as a group.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
column entitled &#8220;Percentage of Shares Outstanding Beneficially Owned&#8221; is based on a total of 37,440,510 shares of our Common
Stock outstanding as of February 15, 2025.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Beneficial
ownership is determined in accordance with the rules and regulations of the SEC and includes voting or investment power with respect
to the Common Stock. Shares of Common Stock subject to options that are currently exercisable or exercisable within 60 days of the date
of this table are considered outstanding and beneficially owned by the person holding the options for the purpose of calculating the
percentage ownership of that person but not for the purpose of calculating the percentage ownership of any other person. Except as otherwise
noted, the persons and entities in this table have sole voting and investing power with respect to all the shares of Common Stock beneficially
owned by them, subject to community property laws, where applicable. Except as otherwise indicated in the table below, addresses of named
beneficial owners are in care of Oruka Therapeutics, Inc., 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Name of
    Beneficial Owner</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of Shares<br/> Beneficially<br/> Owned</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Percentage<br/>
    of Shares<br/> Outstanding<br/> Beneficially<br/> Owned</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic"><span style="font-family: Times New Roman, Times, Serif">5% Stockholders:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities affiliated
    with Fairmount Funds Management LLC<sup>(1)</sup></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,511,824</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19.99</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FMR LLC<sup>(2)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,561,808</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14.86</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities affiliated with Venrock
    Healthcare Capital Partners<sup>(3)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,148,428</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11.08</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities affiliated with RTW
    Investments, LP<sup>(4)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,058,147</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.50</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Named
    Executive Officers and Directors:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lawrence Klein<sup>(5)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,522,440</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.02</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arjun Agarwal<sup>(6)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">61,068</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joana Goncalves<sup>(7)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,347</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul Quinlan<sup>(8)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,156</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael R. Bristow<sup>(9)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">399</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas A. Keuer<sup>(10)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,394</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C. Jeffrey Dekker<sup>(11)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,333</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cameron Turtle<sup>(12)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">110,579</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Samarth Kulkarni<sup>(13)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">35,713</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter Harwin<sup>(1)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,511,824</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">19.99</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carl Dambkowski<sup>(14)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,058</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Kristine Ball</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All current executive officers
    and directors as a group (9&#160;persons)<sup>(15)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,287,185</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">24.69</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>



</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Less
                                            than 1%.</span></td></tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Consists
                                            of (i) (A) 798,614 shares of common stock, (B) 409,326 shares of common stock issuable upon
                                            the exercise of pre-funded warrants and (C) 4,730,576 shares of common stock issuable upon
                                            conversion of 56,767 shares of Series B Preferred Stock held by Fairmount Healthcare Fund
                                            II L.P. (&#8220;Fairmount Fund II&#8221;) and (ii) 2,573,308 shares of common stock held
                                            by Fairmount Healthcare Co-Invest III L.P. (&#8220;Fairmount Fund III&#8221;). Excludes (i)
                                            4,888,338 shares of common stock issuable upon the exercise of the pre-funded warrants and
                                            (ii) 6,697,573 shares of common stock issuable upon the conversion of 80,371 shares of Series
                                            B Preferred Stock. The pre-funded warrants are subject to a beneficial ownership limitation
                                            of 9.99% and the shares of Series B Preferred Stock are subject to a beneficial ownership
                                            limitation of 19.99%, which such limitations restrict Fairmount Funds Management LLC (&#8220;Fairmount&#8221;)
                                            and its affiliates from exercising that portion of the warrants and converting those shares
                                            of preferred stock that would result in Fairmount and its affiliates owning, after exercise
                                            or conversion, a number of shares of common stock in excess of the applicable ownership limitation.
                                            At such time as Fairmount and its affiliates beneficially own 9.0% or less of the shares
                                            of common stock, the beneficial ownership limitation applicable to the shares of Series B
                                            Preferred Stock will automatically reduce to 9.99%. Fairmount serves as investment manager
                                            for Fairmount Fund II and Fairmount Fund III. Fairmount Fund II and Fairmount Fund III have
                                            delegated to Fairmount the sole power to vote and the sole power to dispose of all securities
                                            held in Fairmount Fund II and Fairmount Fund III&#8217;s portfolios. Because Fairmount Fund
                                            II and Fairmount Fund III have divested themselves of voting and investment power over the
                                            securities they hold and may not revoke that delegation on less than 61 days&#8217; notice,
                                            Fairmount Fund II and Fairmount Fund III disclaim beneficial ownership of the securities
                                            they hold. As managers of Fairmount, Peter Harwin and Tomas Kiselak may be deemed
                                            to have voting and investment power over the shares held by Fairmount Fund II and Fairmount
                                            Fund III. Fairmount, Peter Harwin and Tomas Kiselak disclaim beneficial ownership
                                            of such shares, except to the extent of any pecuniary interest therein. The address of the
                                            entities and individuals listed is 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA
                                            19428.</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 134; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            of the shares listed in the table above are owned by funds or accounts managed by direct
                                            or indirect subsidiaries of FMR LLC, all of which shares are beneficially owned, or may be
                                            deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates,
                                            and other companies. Abigail P. Johnson is a Director, the Chairman and the Chief Executive
                                            Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the
                                            predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC,
                                            representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series
                                            B shareholders have entered into a shareholders&#8217; voting agreement under which all Series
                                            B voting common shares will be voted in accordance with the majority vote of Series B voting
                                            common shares. Accordingly, through their ownership of voting common shares and the execution
                                            of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed,
                                            under the Investment Company Act of 1940, to form a controlling group with respect to FMR
                                            LLC. The address of FMR LLC is 245 Summer Street, Boston, MA 02210.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Consists
                                            of (i) 3,205,865 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P.
                                            (&#8220;VHCPEG&#8221;), (ii) 856,747 shares of common stock held by Venrock Healthcare Capital
                                            Partners III, L.P. (&#8220;VHCP3&#8221;), and (iii) 85,816 shares of common stock held by
                                            VHCP Co-Investment Holdings III, LLC (&#8220;VHCPCo3&#8221;). Excludes 405,980, 107,788 and
                                            10,775 shares of common stock issuable upon the exercise of the pre-funded warrants held
                                            by VHCPEG, VHCP3 and VHCPCo3, respectively. The pre-funded warrants are subject to a beneficial
                                            ownership limitation of 9.99%, which such limitations restrict Venrock Healthcare Capital
                                            Partners and its affiliates from exercising that portion of the warrants that would result
                                            in Venrock Healthcare Capital Partners and its affiliates owning, after exercise, a number
                                            of shares of common stock in excess of the applicable ownership limitation. VHCP Management
                                            III, LLC (&#8220;VHCPM3&#8221;) is the sole general partner of VHCP3 and the sole manager
                                            of VHCPCo3. VHCP Management EG, LLC (&#8220;VHCPM EG&#8221;) is the sole general partner
                                            of VHCPEG. As voting members of VHCPM3 and VHCPM EG, Dr. Bong Koh and Nimish Shah may be
                                            deemed beneficial owners of any securities beneficially owned by VHCPM3 and VHCPM EG. The
                                            principal business address of each of these persons and entities is 7 Bryant Park, 23rd Floor,
                                            New York, NY 10018.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
                                            of 2,058,147 shares of common stock held in the aggregate by RTW Master Fund, Ltd. (&#8220;RTW
                                            Master Fund&#8221;), RTW Innovation Master Fund, Ltd. (&#8220;RTW Innovation Master Fund&#8221;),
                                            and RTW Biotech Opportunities Operating Ltd. (&#8220;RTW Biotech&#8221; and together with
                                            RTW Master Fund and RTW Innovation Fund, the &#8220;RTW Funds&#8221;). RTW Investments, LP
                                            (&#8220;RTW&#8221;), in its capacity as the investment manager of the RTW Funds, has the
                                            power to vote and the power to direct the disposition of the shares held by the RTW Funds.
                                            Accordingly, RTW may be deemed to be the beneficial owner of such securities. Roderick Wong,
                                            M.D., as the Managing Partner of RTW, has the power to direct the vote and disposition of
                                            the securities held by RTW. Dr. Wong disclaims beneficial ownership of the shares held by
                                            the RTW Funds, except to the extent of his pecuniary interest therein. The principal business
                                            address of RTW Investments, LP is 40 10th Avenue, Floor 7, New York, NY 10014, and the address
                                            of Dr. Wong and each of the RTW Funds is c/o RTW Investments, LP, 40 10th Avenue, Floor 7,
                                            New York, NY 10014.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            (i) 852,338 shares of common stock, (ii) 421,503 shares of common stock issuable upon the
                                            exercise of options that will vest within 60 days of the date of this table and (iii) 248,599
                                            shares of common stock issuable upon the vesting of restricted stock awards that will vest
                                            within 60 days of the date of this table.</span></td>
</tr></table><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            61,068 shares of common stock issuable upon the exercise of options that will vest within
                                            60 days of the date of this table.</span></td>
</tr></table><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            (i) 191 shares of common stock and (ii) 10,156 shares of common stock issuable upon the exercise
                                            of options that will vest within 60 days of the date of this table</span></td>
</tr></table><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            10,156 shares of common stock issuable upon the exercise of options that will vest within
                                            60 days of the date of this table</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
(i) 92 shares owned by Investocor Trust, of which Dr. Bristow is the sole trustee and (ii) 117 shares owned by NFS as Custodian for Michael
Bristow&#8217;s IRA. Dr. Bristow and ARCA mutually agreed to conclude Dr. Bristow&#8217;s employment effective April 3, 2024.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Keuer resigned as named executive officer at the Merger Closing and his last day of employment was September 1, 2024, which termination
was considered to be without &#8220;cause&#8221; related to a change in control for purposes of his employment agreement with ARCA.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Dekker resigned as named executive officer at the Merger Closing and his last day of employment was September 1, 2024, which termination
was considered to be without &#8220;cause&#8221; related to a change in control for purposes of his employment agreement with ARCA.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
(i) 85,233 shares of common stock held by the Turtle Family Trust, for which Mr. Turtle serves as Trustee, (ii) 2,262 shares of common
stock issuable upon the exercise of options that will vest within 60 days of the date of this table and (iii) 23,084 shares of common
stock issuable upon the vesting of restricted stock awards that will vest within 60 days of the date of this table.</span></td>
</tr></table><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
35,713 shares of common stock issuable upon the exercise of options that will vest within 60 days of the date of this table</span></td>
</tr></table><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
25,058 shares of common stock issuable upon the exercise of options that will vest within 60 days of the date of this table</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
notes (1), (5), (6), (7), (8), (12), (13) and (14) above.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 135; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Securities
Authorized for Issuance Under Equity Compensation Plans</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table provides information with respect to all our equity compensation plans in effect as of December&#160;31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of<br/>
    Securities to be Issued<br/> upon Exercise of<br/> Outstanding<br/> Options</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average<br/>
    Exercise Price of<br/> Outstanding<br/> Options</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number of<br/>
    Securities<br/> Remaining<br/> Available for<br/> Future Issuances<br/> under Equity<br/> Compensation Plans<br/> (excluding<br/> securities<br/>
    reflected in<br/> column <br/> (a))</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Plan Category</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">(a)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">(b)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">(c)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Equity Compensation Plans Approved by Security Holders:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-style: italic; text-align: left; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">2024
    Stock Incentive Plan</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">388,567</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26.91</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,246,324</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">2024
    Employee Stock Purchase Plan</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">460,529</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(2)</sup></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif"><i>2024
    Equity Incentive Plan</i><sup>(3)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,179,193</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.27</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Equity Compensation Plans Not Approved by Security
    Holders:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-style: italic; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><i>Non-Plan
    Compensatory Warrants</i><sup>(4)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,054,358</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.80</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,622,118</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.02</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,706,853</span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>



</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            2024 Stock Incentive Plan (the &#8220;2024 SIP&#8221;) provides for an automatic increase
                                            in the number of shares reserved for issuance thereunder on January&#160;1 of each year through
                                            and including January 1, 2034 equal to (a) 5% of number of issued and outstanding shares
                                            of common stock plus outstanding preferred stock and shares underlying unexercised pre-funded
                                            warrants on an as-converted basis) (collectively, &#8220;Shares Outstanding&#8221;) on December&#160;31
                                            of the immediately preceding year, or (b)&#160;a lesser amount as approved by the Board each
                                            year. Pursuant to this provision, the number of shares available for issuance under the 2024
                                            SIP increased by 2,753,543 shares on January&#160;1, 2025.</span></td></tr></table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            ESPP provides for an automatic annual increase in the number of shares reserved for issuance
                                            thereunder on January&#160;1 of each year through and including January 1, 2034 equal to
                                            (a) 1% of the number of Shares Outstanding on December&#160;31 of the immediately preceding
                                            year, or (2)&#160;a lesser amount as approved by the Board each year. Pursuant to this provision,
                                            the number of shares available for issuance under the ESPP increased by 550,709 shares on
                                            January&#160;1, 2025.</span></td></tr></table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Stock
                                            options granted by Pre-Merger Oruka under the 2024 Equity Incentive Plan were assumed by
                                            the Company in connection with the Merger. No further awards may be made under the 2024 Equity
                                            Incentive Plan.</span></td></tr></table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(4)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Non-plan
                                            compensatory warrants granted by Pre-Merger Oruka were assumed by the Company in connection
                                            with the Merger. No further non-plan compensatory warrants are expected to be granted following
                                            the Merger.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
13. Certain Relationships and Related Transactions, and Director Independence. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Certain
Relationships and Related Transactions</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Other
than the compensation agreements and other arrangements disclosed above under &#8220;Executive Compensation,&#8221; below we describe
the transactions to which we or Pre-Merger Oruka were or are a party since January 1, 2023, in which the amount involved exceeds the
lesser of $120,000 or one percent of the average of our or Pre-Merger Oruka&#8217;s total assets at year-end for the last two completed
fiscal years and in which our or Pre-Merger Oruka directors, executive officers, holders of more than 5% of our common stock, or members
of their immediate family had a direct or indirect material interest.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>ARCA
Transactions </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Transactions
With ARCA&#8217;s Former President and Chief Executive Officer</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">ARCA
previously entered into unrestricted research grants with its former President and Chief Executive Officer&#8217;s academic research
laboratory at the University of Colorado. Funding of any unrestricted research grants was contingent upon ARCA&#8217;s financial condition,
and could be deferred or terminated at ARCA&#8217;s discretion. There was no expense under these arrangements for the year ended December&#160;31,
2024. Total expense under these arrangements for the&#160;year ended December&#160;31, 2023 was $(91,000). In December&#160;2023, ARCA
made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements. In April&#160;2024,
the President and Chief Executive Officer resigned.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Pre-Merger
Oruka Transactions</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Private
Placements of Securities</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>Pre-Merger
Oruka Series&#160;A Preferred Stock and Convertible Note&#160;Financing</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">On
March&#160;6, 2024, Oruka entered into a Convertible Note Purchase Agreement with Fairmount Healthcare Fund II, L.P. (&#8220;Fairmount
Fund II&#8221;), whereby Oruka issued and sold to Fairmount Fund II (i)&#160;an aggregate of 20,000,000 shares of Pre-Merger Oruka Series
A Preferred Stock at a purchase price of $0.15 per share and (ii)&#160;a convertible note (the &#8220;Convertible Note&#8221;) with an
initial principal amount of $25.0 million at an interest rate of 12% per annum, for aggregate gross proceeds of $28&#160;million. Fairmount
Fund II contributed the aggregate principal amount of $25.0 million and all accrued interest under the Convertible Note (unpaid accrued
interest of $1.5 million divided by the conversion price of $66.62 ($5.55 prior to the impact of the Reverse Stock Split) per share)
in exchange for Pre-Merger Oruka Common Stock and Pre-Merger Oruka pre-funded warrants in connection with the Pre-Merger Closing Financing
(as defined below), immediately prior to the completion of the Merger. Fairmount Funds Management (&#8220;Fairmount&#8221;) is the investment
manager of Fairmount Fund II. Peter Harwin, one of our directors, is a managing member of Fairmount.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 137; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><i>Pre-Merger
Oruka Pre-Merger Closing Financing</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">On
April&#160;3, 2024, in connection with the execution of the Merger Agreement, Pre-Merger Oruka entered into the Subscription Agreement
to consummate the Pre-Merger Closing Financing. Pursuant to the Subscription Agreement, the Financing Investors purchased 39,873,706
shares of Pre-Merger Oruka common stock and 9,664,208 Pre-Merger Oruka pre-funded warrants for gross proceeds of approximately $275.0
million (which includes $25.0 million of proceeds previously received from the issuance of the Convertible Note and accrued interest
on such note, which converted to 4,764,032 shares of Pre-Merger Oruka common stock), immediately prior to the Merger Closing and before
the effect of the Reverse Stock Split. Three of the investors or their affiliates were beneficial holders of more than 5% of Pre-Merger
Oruka&#8217;s capital stock, and the table below sets forth the number of shares of Pre-Merger Oruka common stock and Pre-Merger Oruka
pre-funded warrants purchased by such holders at the closing of the Pre-Merger Closing Financing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Participant</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Shares
    of<br/>
    Pre-Merger<br/>
    Oruka<br/>
    Common<br/>
    Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Pre-funded<br/>
    Warrants of<br/>
    Pre-Merger<br/>
    Oruka</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total<br/>
    Purchase<br/>
    Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Entities affiliated with Fairmount</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,139,797</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,271,241</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">79,907,282</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Entities affiliated with Venrock Healthcare
    Capital Partners</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,011,172</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">392,967</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">29,996,067</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Entities affiliated with FMR LLC</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,503,445</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,999,974</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>


</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Includes
                                            $25.0 million of proceeds previously received by Pre-Merger Oruka from the issuance of the
                                            Convertible Note and accrued interest on such note, with the remainder of the purchase price
                                            paid in cash.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Company
Transactions</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>September
2024 Private Placement </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">On
September 11, 2024, the Company entered into a Securities Purchase Agreement (the &#8220;SPA&#8221;) with certain selling stockholders
to consummate a private placement (the &#8220;Private Placement&#8221;). Pursuant to the SPA, the selling stockholders purchased (i)
an aggregate of 5,600,000 shares of Common Stock, at a price per share of $23.00, (ii) an aggregate of 2,439 shares of Series A Preferred
Stock, at a price per share of $23,000.00, and (iii) pre-funded warrants to purchase an aggregate of 680,000 shares of Common Stock at
a purchase price of $22.999 per pre-funded warrant, which represents the per share purchase price of the Private Placement Common Shares
less the $0.001 per share exercise price for each pre-funded warrant, for an aggregate purchase price of approximately $200.5 million.
Three of the selling stockholders or their affiliates were beneficial holders of more than 5% of the Company&#8217;s capital stock, and
the table below sets forth the number of shares of Common Stock, Series A Preferred Stock and pre-funded warrants purchased by such holders
at the closing of the Private Placement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Participant</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Shares
    of<br/>
    Common<br/>
    Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Series
    A<br/>
    Preferred<br/>
    Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Pre-Funded<br/>
    Warrants</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total<br/>
    Purchase<br/>
    Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Entities affiliated with FMR LLC</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,105,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">830</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">67,505,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Entities affiliated with Venrock Healthcare
    Capital Partners</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">150,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">200</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">300,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,949,700</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Entities affiliated with Fairmount</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">275,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">160</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,005,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
Relationship with Paragon and Paruka</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
are party to a number of agreements with Paragon and Paruka. Paragon and Paruka do not beneficially own more than 5% of our capital stock
through their joint holdings of our Common Stock. Fairmount beneficially owns more than 5% of our capital, one of Fairmount&#8217;s employees
serves on our Board, and Fairmount beneficially owns more than 5% of Paragon. Fairmount appointed Paragon&#8217;s board of directors
and has the contractual right to approve the appointment of any executive officers of Paragon, but is not the beneficial owner of Paragon&#8217;s
securities. Paruka is an entity formed by Paragon as a vehicle to hold equity in our Company in order to share profits with certain employees
of Paragon.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
                                            March&#160;2024, Pre-Merger Oruka entered into the Option Agreements with Paragon and Paruka.
                                            Under the terms of the Option Agreements, Paragon identifies, evaluates and develops antibodies
                                            directed against certain mutually agreed therapeutic targets of interest to us. The Option
                                            Agreements include two selected targets, IL-23 (ORKA-001) and IL-17A/F (ORKA-002). Under
                                            each of the Option Agreements, we have the exclusive option to, on a research program-by-research
                                            program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right,
                                            title and interest in and to the intellectual property resulting from the applicable research
                                            program to develop, manufacture, and commercialize the antibodies and potential products
                                            directed to the selected targets (each, an &#8220;Option&#8221;), with the exception of pursuing
                                            ORKA-001 for the treatment of inflammatory bowel disease. In September 2024, we exercised
                                            our Option to acquire the rights to ORKA-001 and executed the corresponding license agreement
                                            (the &#8220;IL-23 License Agreement&#8221;) on December 17, 2024. In December 2024 we exercised
                                            our Option to acquire the rights to ORKA-002 and executed the corresponding license agreement
                                            (the IL-17A/F License Agreement) on February 4, 2025. Under each license agreement we are
                                            required to make non-refundable milestone payments to Paragon of up to $12.0 million under
                                            each respective agreement upon the achievement of certain clinical development milestones,
                                            up to $10.0 million under each respective agreement upon the achievement of certain regulatory
                                            milestones, as well as a low single-digit percentage royalty for antibody products beginning
                                            on the first commercial sale in each program. From time to time, we can choose to add additional
                                            targets to the collaboration by mutual agreement with Paragon. During 2024, we accrued two
                                            $1.5 million milestone payments related to the achievement of development candidates as research
                                            and development expense in our consolidated statements of operations and comprehensive loss
                                            for the year ended December 31, 2024. As of December 31, 2024, this amount is included under
                                            related party accounts payable and other current liabilities on the consolidated balance
                                            sheet.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the terms of the Option Agreements, the parties initiated certain Research Programs. Each Research Program is aimed at discovering,
generating, identifying and/or characterizing antibodies directed to the respective target. For each Research Program, the parties established
a Research Plan (each, a &#8220;Research Plan&#8221;) that sets forth the activities that will be conducted, and the associated research
budget. We and Paragon agreed on initial Research Plans that outlined the services that were performed commencing at inception of the
arrangement related to IL-17 and IL-23. Our exclusive option with respect to each Research Program was exercisable at our sole discretion
at any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified
number of days following the delivery of the data package from Paragon related to the results of the Research Plan activities. There
is no payment due upon exercise of an Option pursuant to the Option Agreements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Option Agreements, on a research program-by-research program basis following the finalization of the Research Plan for each respective
research program, the Company was required to pay Paragon a one-time nonrefundable research initiation fee of $0.8 million related to
the ORKA-001 program. This amount was recognized as a research and development expense during the period from February 6 (inception)
to December 31, 2024. In June 2024, pursuant to the Option Agreements with Paragon, the Company completed the selection process of its
development candidate for IL-23 antibodies for the ORKA-001 program. The Company was responsible for 50% of the development costs incurred
through the completion of the IL-23 selection process. The Company received the rights to at least one selected IL-23 antibody in June
2024. During 2024, the Company exercised its option for ORKA-001 and recorded a $1.5 million milestone payment related to the achievement
of development candidate as research and development expense in the Company&#8217;s consolidated statement of operations and comprehensive
loss. In addition, during the period from February 6, 2024 (inception) to December 31, 2024, the Company recorded a $2.5 million milestone
payment related to the first dosing of a human subject in a Phase 1 trial of ORKA-001 in December 2024 as research and development expense
in its consolidated statement of operations and comprehensive loss. The Company&#8217;s share of development costs incurred during the
period from February 6, 2024 (inception) to December 31, 2024 was $13.5 million, which was recorded as research and development expenses.
An amount of $2.8 million related to ORKA-001 is included in related party accounts payable and other current liabilities as of December
31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company is also required to reimburse Paragon $3.3 million for development costs related to ORKA-002 incurred by Paragon through December
31, 2023 and certain other development costs incurred by Paragon between January 1, 2024 and March 6, 2024 as stipulated by the Option
Agreements. This amount was recognized as a research and development expense during the period from February 6 (inception) to December
31, 2024. The Company is also responsible for development costs incurred by Paragon from January 1, 2024 through the completion of the
IL-17 selection process. The Company recognized an amount of $0.8 million payable to Paragon for the research initiation fee related
to ORKA-002 following the finalization of the ORKA-002 research plan. This was recognized as research and development expenses in the
period from February 6 (inception) to December 31, 2024. During the period from February 6, 2024 (inception) to December 31, 2024, the
Company exercised its option for ORKA-002 and recorded a $1.5 million milestone payment related to the achievement of development candidate
as research and development expense in its consolidated statement of operations and comprehensive loss. The Company accounted for development
costs of $7.8 million during the period from February 6, 2024 (inception) to December 31, 2024 as research and development expenses.
An amount of $2.7 million related to ORKA-002 is included in related party accounts payable and other current liabilities as of December
31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
the Option Agreements provide for an annual equity grant of warrants to purchase a number of shares equal to 1.00% of the then outstanding
shares of our stock, on a fully diluted basis, on each of December 31, 2024 and December 31, 2025, during the term of the Option Agreements,
at the fair market value determined by our Board.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><i>Indemnification
Agreements and Insurance</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
have entered into an indemnification agreement with each of our directors and senior officers and purchased directors&#8217; and officers&#8217;
liability insurance. The indemnification agreements require us to indemnify our directors and officers to the fullest extent permitted
under Delaware law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Review,
Approval or Ratification of Transactions with Related Parties </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Prior
to the Merger Closing, Pre-Merger Oruka did not have a formal policy regarding approval of transactions with related parties. All disclosable
transactions with related parties that occurred prior to the Merger Closing were approved by the directors not interested in such transactions,
pursuant to Section 144(a)(1) of the DGCL.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
Board has adopted a written related person transactions policy. Under this policy, our executive officers, directors, nominees for election
as a director, beneficial owners of more than 5% of our Common Stock, and any members of the immediate family of and any entity affiliated
with any of the foregoing persons, are not permitted to enter into a material related person transaction with us without the review and
approval of our Audit Committee, or a committee composed solely of independent directors in the event it is inappropriate for our Audit
Committee to review such transaction due to a conflict of interest. The policy provides that, subject to limited exceptions, any transaction,
arrangement or relationship or series of similar transactions, arrangements or relationships in which (1) the aggregate amount involved
since the beginning of the Company&#8217;s last completed fiscal year exceeds or is expected to exceed $120,000, (2) the Company or any
of our subsidiaries is a participant, and (3) any related person has or will have a direct or indirect interest, will be presented to
our Audit Committee for review, consideration and approval. In approving or rejecting any such proposal, our Audit Committee will consider
the material facts and other factors it deems appropriate, including, but not limited to, whether the transaction is on terms no less
favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the
related person&#8217;s interest in the transaction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 140; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Director
Independence</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
Board has reviewed the independence of all directors in light of each director&#8217;s (or any family member&#8217;s, if applicable)
affiliations with the Company and members of management, as well as significant holdings of our securities and all other facts and circumstances
that the Board has deemed relevant in determining the independence of each director. The Board has determined that each of the directors
other than Lawrence Klein, our current President and Chief Executive Officer, including Kristine Ball, Carl Dambkowski, Peter Harwin,
Samarth Kulkarni and Cameron Turtle, qualify as &#8220;independent directors&#8221; as defined by the Nasdaq listing rules.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Nasdaq
listing rules have objective tests and a subjective test for determining who is an &#8220;independent director.&#8221; The subjective
test states that an independent director must be a person who lacks a relationship that, in the opinion of the Board, would interfere
with the exercise of independent judgment in carrying out the responsibilities of a director. The Board has not established categorical
standards or guidelines to make these subjective determinations but considers all relevant facts and circumstances.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition, ARCA&#8217;s board of directors determined that former directors Drs. Linda Grais, Anders Hove and Raymond Woosley, and Messrs.
Robert Conway, Daniel Mitchell and James Flynn were independent during the period each served on the Board in 2024. ARCA&#8217;s board
of directors determined Dr. Michael R. Bristow, ARCA&#8217;s former President and Chief Executive Officer, was not an independent director
in 2024 by virtue of his employment relationship with ARCA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
14. Principal Accountant Fees and Services. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Principal
Accountant Fees and Services</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following is a summary of the audit fees billed and expected to be billed for the indicated fiscal year to Oruka by PricewaterhouseCoopers
LLP (&#8220;PwC&#8221;), Pre-Merger Oruka&#8217;s independent registered public accounting firm and Oruka&#8217;s independent registered
public accounting firm on and after August 30, 2024, and the fees billed by PwC for all other services rendered during the indicated
fiscal year. All services associated with such fees on and after August 30, 2024 were pre-approved by our Audit Committee in accordance
with the &#8220;Pre-Approval Policies and Procedures&#8221; described below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Fiscal
    Year ended<br/> December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit Fees<sup>(1)</sup></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,928,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-Related Fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax Fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    Other Fees<sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,930,000</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>



</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Audit
                                            Fees consisted of fees and expenses covering the audit of our consolidated financial statements,
                                            reviews of our interim quarterly reports, accounting and financial reporting consultations,
                                            and the issuance of consents and comfort letters in connection with registration statement
                                            filings with the Securities and Exchange Commission (the &#8220;SEC&#8221;).</span></td></tr></table><div>



</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">All
                                            Other Fees consist of all other services and fees billed for an annual subscription to PwC&#8217;s
                                            online resource library.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b>Pre-Approval
Policies and Procedures</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
connection with the Merger Closing, our Board and Audit Committee adopted a policy and procedures for the&#160;pre-approval&#160;of audit
and&#160;non-audit&#160;services performed by our independent registered public accounting firm. These procedures generally approve the
performance of specific services subject to a cost limit for all such services. This general approval is reviewed, and if necessary modified,
at least annually. Management must obtain the specific prior approval of the Audit Committee for each engagement of our independent registered
public accounting firm to perform other audit-related or non-audit services. The Audit Committee does not delegate its responsibility
to pre-approve services performed by our independent registered public accounting firm to any member of management. The Audit Committee
has delegated authority to the Audit Committee chair to pre-approve audit and non-audit services to be provided to us by our independent
registered public accounting firm provided that the fees for such services do not exceed $100,000. Any pre-approval of services by the
Audit Committee chair pursuant to this delegated authority must be reported to the Audit Committee at its next regularly scheduled meeting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 141; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>PART
IV</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
15. Exhibits, Financial Statement Schedules. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: -22.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0%"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(a)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            following documents are filed as part of this Annual Report:</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -22.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financial
                                            Statements</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">See
Index to Financial Statements included in Part II, Item 8 of this Annual Report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -22.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financial
                                            Statement Schedules</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">All
schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -22.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">List
                                            of Exhibits required by Item 601 of Regulation S-K</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="5" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporation
    By Reference</b></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br/>
    Number</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 59%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br/>
    No.</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 13%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">2.1&#8224;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex21.htm">Agreement
    and Plan of Merger and Reorganization, dated as of April 3, 2024, by and among ARCA biopharma, Inc., Atlas Merger Sub Corp., Atlas
    Merger Sub II, LLC and Oruka Therapeutics, Inc.</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2.1</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">4/3/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">3.1</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex3-5_oruka.htm">Second
    Amended and Restated Certificate of Incorporation</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3.5</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">9/5/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">3.2</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex3-6_oruka.htm">Amended
    and Restated Bylaws</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3.6</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">9/5/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">3.3</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513233692/d507513dex31b.htm">Form
    of Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">S-1/A</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3.1(b)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">5/24/2013</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">3.4</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex3-8_oruka.htm">Certificate
    of Elimination of Series A Convertible Preferred Stock, dated August 29, 2024</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3.8</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">9/5/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">3.5</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex3-9_oruka.htm">Certificate
    of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3.9</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">9/5/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">3.6</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024078549/ea021443901ex3-1_oruka.htm">Certificate
    of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3.1</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">9/13/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">4.1</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="ea023044501ex4-1_orukathe.htm">Description
    of Securities</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Filed
    herewith</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">4.2</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex4-3_arcabio.htm">Investors&#8217;
    Rights Agreement by and among Oruka Therapeutics, Inc. and certain investors, dated March&#160;6, 2024</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">S-4</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">4.3</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">5/14/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">4.3</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="ea023044501ex4-3_orukathe.htm">Form
    of Pre-Funded Warrant, dated August 29, 2024</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Filed
    herewith</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">4.4</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024078549/ea021443901ex4-1_oruka.htm">Form
    of Pre-Funded Warrant, dated September 13, 2024</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">4.1</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">9/13/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.1#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex10-10_oruka.htm">Oruka
Therapeutics, Inc. 2024 Stock Incentive Plan</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.10</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">9/5/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.2#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex10-11_oruka.htm">Oruka
Therapeutics, Inc. 2024 Employee Stock Purchase Plan</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.11</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">9/5/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.3#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-40_arcabio.htm">Amended
    and Restated 2024 Equity Incentive Plan</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">S-4</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.40</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">5/14/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.4#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex10-13_oruka.htm">Second
    Amendment to the Oruka Therapeutics, Inc. Amended and Restated 2024 Equity Incentive Plan</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.13</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">9/5/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.5#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex10-16_oruka.htm">Form
    of Employee Warrant Agreement</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.16</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">9/5/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.6#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024098574/ea022059801ex99-2_oruka.htm">Form
    of Grant Notice for Nonqualified Stock Option and Standard Terms and Conditions for Stock Options (Directors)</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">S-8</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">99.2</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">11/14/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.7#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024098574/ea022059801ex99-3_oruka.htm">Form
    of Grant Notice for Stock Option and Standard Terms and Conditions for Stock Options (Employees)</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">S-8</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">99.3</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">11/14/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.8#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-42_arcabio.htm">Form
    of Stock Option Agreement under the Oruka Therapeutics, Inc. Amended and Restated 2024 Equity Incentive Plan</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">S-4</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.42</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">5/14/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.9#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/907654/000095017024041846/abio-ex10_1.htm">Separation
    Agreement and Release by and between Michael Bristow and ARCA biopharma, Inc., dated April 3, 2024</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.1</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">4/4/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.10#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/907654/000095017024046918/abio-ex10_1.htm">Second
    Amendment to Retention Bonus Letter by and between ARCA biopharma, Inc. and Thomas A. Keuer, dated April 22, 2024</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.1</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">4/23/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.11#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/907654/000095017024046918/abio-ex10_2.htm">Second
    Amendment to Retention Bonus Letter by and between ARCA biopharma, Inc. and C. Jeffrey Dekker</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.2</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">4/23/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.12&#8224;#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex10-25_oruka.htm">Consulting
    Agreement, effective as of August 30, 2024, by and between the Company and Jeff Dekker</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.25</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">9/5/2024</span></td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 142; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif">10.13#</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 59%"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-43_arcabio.htm">Amended
    and Restated Director Offer Letter, dated March 22, 2024, by and between Oruka Therapeutics, Inc. and Samarth Kulkarni</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif">S-4</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif">10.43</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; width: 13%"><span style="font-family: Times New Roman, Times, Serif">5/14/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.14#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-44_arcabio.htm">Director
    Offer Letter, dated April 24, 2024, by and between Oruka Therapeutics, Inc. and Kristine Ball</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">S-4</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.44</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">5/14/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.15#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024085543/ea021674601ex10-1_oruka.htm">Amended
    and Restated Employment Letter Agreement by and between Oruka Therapeutics, Inc. and Lawrence Klein, dated October 3, 2024</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.1</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10/4/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.16#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024085543/ea021674601ex10-2_oruka.htm">Amended
    and Restated Employment Letter Agreement by and between Oruka Therapeutics, Inc. and Arjun Agarwal, dated October 3, 2024</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.2</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10/4/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.17*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="ea023044501ex10-17_orukathe.htm">Amended and Restated Employment Letter Agreement by and between Oruka Therapeutics, Inc. and Paul Quinlan, dated October 1, 2024</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Filed
    herewith</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.18*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="ea023044501ex10-18_orukathe.htm">Amended and Restated Employment Letter Agreement by and between Oruka Therapeutics, Inc. and Joana Goncalves, dated October 1, 2024</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Filed
    herewith</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.19*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="ea023044501ex10-19_orukathe.htm">Form of Indemnification Agreement</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Filed
    herewith</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.20*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="ea023044501ex10-20_orukathe.htm">Non-Employee Directors Compensation Program</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Filed
    herewith</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.21</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex104.htm">Form
    of Lock-Up Agreement</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.4</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">4/3/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.22</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024060156/ea020913401ex10-1_arcabio.htm">Form
    of Amendment to Subscription Agreement</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.1</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">7/9/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.23</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024060156/ea020913401ex10-2_arcabio.htm">Form
    of Amended &amp; Restated Subscription Agreement</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.2</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">7/9/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.24</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024097443/ea021692901ex10-4_oruka.htm">Form
    of Registration Rights Agreement, dated August 29, 2024</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10-Q</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.4</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">11/13/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.25&#8224;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024078549/ea021443901ex10-1_oruka.htm">Securities
    Purchase Agreement by and between Oruka Therapeutics, Inc. and each of the entities listed on Exhibit A thereto, dated September
    11, 2024</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.1</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">9/13/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.26</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024078549/ea021443901ex10-2_oruka.htm">Form
    of Registration Rights Agreement, dated as of September 13, 2024</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.2</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">9/13/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.27</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024069662/ea021147201ex10-1_arcabio.htm">Asset
    Purchase Agreement, dated August 14, 2024, by and between ARCA biopharma, Inc. and Genvara Biopharma, Inc.</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.1</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8/15/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.28&#8224;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024053881/ea020512202ex10-50_arcabio.htm">Amended
    and Restated Antibody Discovery and Option Agreement (IL-17) by and among Paragon Therapeutics, Inc., Paruka Holding, LLC, and Oruka
    Therapeutics, Inc. dated March 28, 2024</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">S-4/A</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.50</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">6/18/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.29*&#8224;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="ea023044501ex10-29_orukathe.htm">IL-17 License Agreement by and between Paragon Therapeutics, Inc. and Oruka Therapeutics, Inc., dated February 4, 2025</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Filed
    herewith</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.30&#8224;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024053881/ea020512202ex10-51_arcabio.htm">Amended
    and Restated Antibody Discovery and Option Agreement (IL-23) by and among Paragon Therapeutics, Inc., Paruka Holding, LLC, and Oruka
    Therapeutics, Inc. dated March 28, 2024</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">S-4/A</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">10.51</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">6/18/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.31*&#8224;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="ea023044501ex10-31_orukathe.htm">IL-23 License Agreement by and between Paragon Therapeutics, Inc. and Oruka Therapeutics, Inc., dated December 17, 2024</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Filed
    herewith</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.32*&#8224;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="ea023044501ex10-32_orukathe.htm">Cell
    Line License Agreement by and between WuXi Biologics Ireland Limited and Oruka Therapeutics, Inc., dated March 4,
    2024</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Filed
    herewith</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.33*&#8224;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="ea023044501ex10-33_orukathe.htm">Amendment
    No. 1 to the Cell Line License Agreement by and between WuXi Biologics Ireland Limited and Oruka Therapeutics, Inc., dated November
    20, 2024</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Filed
    herewith</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">14.1</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex14-1_oruka.htm">Code
    of Business Conduct and Ethics</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">14.1</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">9/5/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">16.1</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex16-1_oruka.htm">Letter
    from KPMG LLP, dated September 5, 2024</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">8-K</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">16.1</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">9/5/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">19.1*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="ea023044501ex19-1_orukathe.htm">Insider Trading Policy</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Filed
    herewith</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">21.1*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="ea023044501ex21-1_orukathe.htm">List of subsidiaries of the Registrant</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Filed
    herewith</span></td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif">23.1*</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif"><a href="ea023044501ex23-1_orukathe.htm">Consent of Independent Registered Public Accounting Firm</a></td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center">Filed
    herewith</td></tr>
<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif">24.1*</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif"><a href="#aaa_001">Power of Attorney (Incorporated by reference to the signature page of this Annual Report on Form 10-K)</a></td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center">Filed herewith</td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 143; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif">31.1*</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 59%"><span style="font-family: Times New Roman, Times, Serif"><a href="ea023044501ex31-1_orukathe.htm">Certification
    of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) promulgated under the Securities Exchange Act of 1934</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; width: 13%"><span style="font-family: Times New Roman, Times, Serif">Filed
    herewith</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">31.2*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="ea023044501ex31-2_orukathe.htm">Certification
    of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) promulgated under the Securities Exchange Act of 1934</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Filed
    herewith</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">32.1**</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="ea023044501ex32-1_orukathe.htm">Certification
    of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350 and Rule 13a-14(B) promulgated
    under the Securities Exchange Act of 1934</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Furnished
    herewith</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">97.1*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="ea023044501ex97-1_orukathe.htm">Incentive
    Compensation Clawback Policy</a></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Filed
    herewith</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">101.INS*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Inline XBRL Instance
    Document</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Filed
    herewith</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">101.SCH</span>*</td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Inline XBRL Taxonomy
    Extension Schema with Embedded Linkbases Document</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Filed
    herewith</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">101.CAL</span>*</td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document.</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Filed
    herewith</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">101.DEF*</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Inline
    XBRL Taxonomy Extension Definition Linkbase Document.</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Filed
    herewith</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">101.LAB</span>*</td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Inline
    XBRL Taxonomy Extension Label Linkbase Document.</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Filed
    herewith</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">101.PRE</span>*</td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document.</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Filed
    herewith</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">104</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Cover Page Interactive
    Data File (embedded within the Inline XBRL document)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>


</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Filed
                                            herewith.</span></td></tr></table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">**</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Furnished
                                            herewith. The certifications on Exhibit 32.1 hereto are deemed not &#8220;filed&#8221; for
                                            purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that
                                            Section. Such certifications will not be deemed incorporated by reference into any filing
                                            under the Securities Act or the Exchange Act.</span></td></tr></table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">#</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicates
                                            management contract or compensatory plan.</span></td></tr></table><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#8224;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Exhibits
                                            and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company
                                            hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules
                                            upon request by the SEC; provided, however, that the Company may request confidential treatment
                                            pursuant to Rule 24b-2 under the Exchange Act for any exhibits or schedules so furnished.
                                            Certain portions of this exhibit (indicated by &#8220;[***]&#8221;) have been omitted because
                                            they are both (i) not material and (ii) is the type of information that the registrant both
                                            customarily and actually treats as private and confidential.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_027"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Item
16. Form 10-K Summary</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">None.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 144; Value: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>SIGNATURES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report
to be signed on its behalf by the undersigned, thereunto duly authorized<b>.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; background-color: white">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Oruka
    Therapeutics, Inc.</b></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: white">
    <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; width: 4%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; width: 36%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: white">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Date:
    March 6, 2025</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">/s/
    Lawrence Klein</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: white">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">Lawrence
    Klein</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>President
                                            and Chief Executive Officer</i></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>(Principal
    Executive Officer)</i></span></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="aaa_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>POWER
OF ATTORNEY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Dr. Lawrence Klein and Mr. Arjun
Agarwal, jointly and severally, his or her attorneys-in-fact, each with the power of substitution, for him or her in any and all capacities,
to sign any amendments to this Report on Form 10-K and to file same, with exhibits thereto and other documents in connection therewith,
with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitutes,
may do or cause to be done by virtue hereof.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on
behalf of the Registrant in the capacities and on the dates indicated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Signature</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 53%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Title</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Date</b></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">/s/
    Lawrence Klein</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Chief
    Executive Officer &amp; Director</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    6, 2025</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lawrence
    Klein</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Principal
    Executive Officer)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">/s/
    Arjun Agarwal</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Senior
    Vice President, Finance and Treasurer</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    6, 2025</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Arjun
    Agarwal</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Principal
    Financial Officer and Principal Accounting Officer)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">/s/
    Samarth Kulkarni</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Chairman
    of the Board</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    6, 2025</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Samarth
    Kulkarni</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">/s/
    Kristine Ball</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Director</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    6, 2025</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Kristine
    Ball</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">/s/
    Carl Dambkowski</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Director</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    6, 2025</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Carl
    Dambkowski</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">/s/
    Peter Harwin</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Director</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    6, 2025</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Peter
    Harwin</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">/s/
    Cameron Turtle</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Director</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">March
    6, 2025</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Cameron
    Turtle</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">112</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c4" id="hidden-fact-0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-1" name="us-gaap:MarketableSecuritiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="orka:SubscriptionReceivables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-4" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-5" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-6" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-7" name="us-gaap:OtherAssetsNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-8" name="us-gaap:AccountsPayableTradeCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-9" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-10" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-11" name="us-gaap:AccountsPayableOtherCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-12" name="us-gaap:LiabilitiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-13" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-14" name="us-gaap:Liabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-15" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-16" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-17" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-18" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-19" name="us-gaap:TemporaryEquitySharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-20" name="us-gaap:TemporaryEquitySharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-21" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-22" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-23" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-24" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-25" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-26" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-27" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-28" name="us-gaap:TemporaryEquitySharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-29" name="us-gaap:TemporaryEquitySharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-30" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-31" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-32" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-33" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-34" name="us-gaap:PreferredStockSharesAuthorized" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-35" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-36" name="us-gaap:CommonStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-37" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-38" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-39" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-40" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-41" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-42" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-43" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-44" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-45" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-46" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-47" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-48" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-49" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-50" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-51" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-52" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-53" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-54" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-55" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-56" name="orka:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-57" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-58" name="orka:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-59" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-60" name="orka:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-61" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-62" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-63" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-64" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-65" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-66" name="orka:TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-67" name="orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-68" name="orka:TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-69" name="orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-70" name="orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-71" name="orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-72" name="orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-73" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-74" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-75" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-76" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-77" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-78" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-79" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-80" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-81" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-82" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-83" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-84" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-85" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-86" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-87" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-88" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-89" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-90" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-91" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-92" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-93" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-94" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-95" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-96" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-97" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-98" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-99" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-100" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-101" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-102" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-103" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-104" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-105" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-106" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-107" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-108" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-109" name="orka:IssuanceCostOfPIPEFinancing" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-110" name="orka:IssuanceCostOfPIPEFinancing" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-111" name="orka:IssuanceCostOfPIPEFinancing" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-112" name="orka:IssuanceCostOfPIPEFinancing" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-113" name="orka:IssuanceCostOfPIPEFinancing" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-114" name="orka:ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-115" name="orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-116" name="orka:ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-117" name="orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-118" name="orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-119" name="orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-120" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-121" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-122" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-123" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-124" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-125" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-126" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-127" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-128" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-129" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-130" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-131" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-132" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-133" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-134" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-135" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-136" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-137" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-138" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-139" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-140" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-141" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-142" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-143" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-144" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-145" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-146" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-147" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-148" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-149" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-150" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-151" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-152" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-153" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-154" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-155" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-156" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-157" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-158" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-159" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c68" id="hidden-fact-160" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c70" id="hidden-fact-161" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-162" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-163" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c78" id="hidden-fact-164" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-165" name="us-gaap:MarketableSecuritiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c68" id="hidden-fact-166" name="us-gaap:MarketableSecuritiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c70" id="hidden-fact-167" name="us-gaap:MarketableSecuritiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-168" name="us-gaap:MarketableSecuritiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-169" name="us-gaap:MarketableSecuritiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c79" id="hidden-fact-170" name="us-gaap:MarketableSecuritiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c81" id="hidden-fact-171" name="us-gaap:MarketableSecuritiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c78" id="hidden-fact-172" name="us-gaap:MarketableSecuritiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-173" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c68" id="hidden-fact-174" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c70" id="hidden-fact-175" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c78" id="hidden-fact-176" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c78" id="hidden-fact-177" name="orka:FairValueCashEquivalentsAndMarketableSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c83" id="hidden-fact-178" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c83" id="hidden-fact-179" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c84" id="hidden-fact-180" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c85" id="hidden-fact-181" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c85" id="hidden-fact-182" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c86" id="hidden-fact-183" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c90" id="hidden-fact-184" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c93" id="hidden-fact-185" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c94" id="hidden-fact-186" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c95" id="hidden-fact-187" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c96" id="hidden-fact-188" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c96" id="hidden-fact-189" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c97" id="hidden-fact-190" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c97" id="hidden-fact-191" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c98" id="hidden-fact-192" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c98" id="hidden-fact-193" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c99" id="hidden-fact-194" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c99" id="hidden-fact-195" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-196" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-197" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c101" id="hidden-fact-198" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c101" id="hidden-fact-199" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-200" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-201" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c117" id="hidden-fact-202" name="orka:ClassOfWarrantOrRightExpirationDate" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c117" id="hidden-fact-203" name="orka:ClassOfWarrantOrRightWarrantsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c120" id="hidden-fact-204" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c130" id="hidden-fact-205" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c146" id="hidden-fact-206" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c120" id="hidden-fact-207" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-208" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-209" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c149" id="hidden-fact-210" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c4" id="hidden-fact-211" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-212" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-213" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-214" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-215" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-216" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-217" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" id="hidden-fact-218" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c3" id="hidden-fact-219" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c150" id="hidden-fact-220" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c150" id="hidden-fact-221" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c133" id="hidden-fact-222" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c133" id="hidden-fact-223" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c151" id="hidden-fact-224" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c151" id="hidden-fact-225" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c151" id="hidden-fact-226" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c152" id="hidden-fact-227" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c152" id="hidden-fact-228" name="orka:WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c152" id="hidden-fact-229" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c152" id="hidden-fact-230" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c119" id="hidden-fact-231" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c119" id="hidden-fact-232" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c119" id="hidden-fact-233" name="orka:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-234" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-235" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-236" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-237" name="us-gaap:UnrecognizedTaxBenefits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-238" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-24955">0000907654</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-24956">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-24957">FY</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="orka-20241231.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="ix_0_fact" toRefs="ix_0_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_1_fact" toRefs="ix_1_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_2_fact" toRefs="ix_2_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_3_fact ix_4_fact ix_5_fact" toRefs="ix_3_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_6_fact ix_7_fact ix_8_fact" toRefs="ix_4_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-03</xbrli:startDate>
    <xbrli:endDate>2024-09-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PrefundedWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:ARCACommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PIPEFinancingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PIPEFinancingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PIPEFinancingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra9a2jfwGt44jro+lUyqzQL6/x1O9iJrf+dH3ymvrZRNb86/I06x7A9ljBSSeLHwUVO8zSU2wTDcbvo9VMwGaa97CnFY/03o9uN+p3vuWpjO+delTt6UkRTcW0ow0twDKhn42QRPQiXZ8W6BtQZBlbaaE/ZqMIFvXldcHURFnzzSEFkycIw+onLjKElg+fX0XqSMIr7KQdjfiP8BeKLKMGU69+JjAA0fvPQQsyOoCLeXV0lVmA5Po9g0sJvozkfQc4=] CSR-->
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesLongTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesLongTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesLongTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="orka:MarketableSecuritiesAxis">orka:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="orka:MarketableSecuritiesAxis">orka:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:USGovernmentAgencySecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="orka:MarketableSecuritiesAxis">orka:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="orka:MarketableSecuritiesAxis">orka:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="orka:MarketableSecuritiesAxis">orka:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:USGovernmentAgencySecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:FairmountHealthcareFundIILPMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:FairmountHealthcareFundIILPMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-01</xbrli:startDate>
    <xbrli:endDate>2024-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-01</xbrli:startDate>
    <xbrli:endDate>2024-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:FairmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:FairmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:FairmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PIPEFinancingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-09-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PIPEFinancingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:ParukaWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:ParukaWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:ParukaWarrantObligationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-29</xbrli:startDate>
    <xbrli:endDate>2024-08-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:ParukaWarrantObligationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-02-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-07</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:ParukaWarrantObligationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:OperatingExpenseExcludingStockBasedCompensationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:ExternalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:OtherMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:RegulatoryMilestonesMemberMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:RegulatoryMilestonesMemberMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:NominationOfADevelopmentCandidateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:AntibodyProductsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:ParukaWarrantObligationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:AchievementOfDevelopmentCandidateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:AchievementOfDevelopmentCandidateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:RestrictedStockAwardsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:ParukaWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">orka:ParukaMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">orka:FairmountHealthcareFundIILPMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">orka:FairmountsOwnershipInterestInParagonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:ParagonReimbursableOptionAgreementsFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:ParagonMilestonePaymentsForOptionAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:ParagonReimbursableOtherResearchExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:ParagonReimbursablePatentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-10-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ea023044501ex4-1_orukathe.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>DESCRIPTION OF THE REGISTRANT&rsquo;S SECURITIES
REGISTERED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECTION 12 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>DESCRIPTION OF CAPITAL STOCK</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following description summarizes the material
terms of the capital stock of Oruka Therapeutics, Inc. (&ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our&rdquo; or the &ldquo;Company&rdquo;),
as well as other material terms of certain provisions of the Delaware General Corporation Law (the &ldquo;DGCL&rdquo;), our second amended
and restated certificate of incorporation (&ldquo;Certificate of Incorporation&rdquo;) and amended and restated bylaws (&ldquo;Bylaws&rdquo;),
both of which have been filed as exhibits to our Annual Report on Form 10-K of which this Exhibit 4.1 is a part, and are incorporated
by reference herein. This summary does not purport to be complete and is qualified in its entirety by the provisions of our Certificate
of Incorporation and Bylaws. We encourage you to read our Certificate of Incorporation, our Bylaws, and the applicable provisions of the
DGCL for more information.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our authorized capital stock consists of 545,000,000
shares of Common Stock, $0.001 par value per share, and 5,000,000 shares of preferred stock, $0.001 par value per share (&ldquo;Preferred
Stock&rdquo;), of which 251,504 shares have been designated as Series B Preferred Stock, $0.001 par value per share (the &ldquo;Series
B Preferred Stock&rdquo;).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of December 31, 2024, there were 37,440,510
shares of our Common Stock and 137,138 shares of Series B Preferred Stock outstanding.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">Our Certificate of Incorporation authorizes the
issuance of up to 545,000,000 shares of Common Stock. All outstanding shares of Common Stock are validly issued, fully paid and nonassessable.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Dividend rights </I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to preferences that may apply to any shares
of Preferred Stock outstanding at the time, the holders of our Common Stock are entitled to receive dividends out of funds legally available
if our board of directors (our &ldquo;Board&rdquo;), in its discretion, determines to issue dividends and then only at the times and in
the amounts that our Board may determine.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Voting rights </I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to our Bylaws, holders of our Common Stock
are entitled to one vote for each share held on all matters submitted to a vote of stockholders. We have not provided for cumulative voting
for the election of directors in our Certificate of Incorporation. Accordingly, pursuant to our Certificate of Incorporation, holders
of a majority of the shares of our Common Stock are able to elect all of our directors. Our Certificate of Incorporation establishes a
classified Board, divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual
meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>No preemptive or similar rights </I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Common Stock is not entitled to preemptive
rights, and is not subject to conversion, redemption or sinking fund provisions.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Right to receive liquidation distributions </I>&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon our liquidation, dissolution or winding-up,
the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our Common Stock
and any participating Preferred Stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities
and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding shares of Preferred Stock.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Preferred Stock</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the terms of our Certificate of Incorporation,
our Board is authorized, subject to limitations prescribed by Delaware law, to issue up to 5,000,000 shares of Preferred Stock in one
or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers,
preferences and rights of the shares of each series and any of their qualifications, limitations or restrictions, in each case without
further vote or action by our stockholders. Subject to any certificates of designation, the Board can also increase or decrease the number
of shares of any series of Preferred Stock, but not below the number of shares of that series then outstanding, without any further vote
or action by our stockholders. Our Board may authorize the issuance of Preferred Stock with voting or conversion rights that could adversely
affect the voting power or other rights of the holders of our Common Stock. The issuance of Preferred Stock, while providing flexibility
in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring
or preventing a change in control of our Company and might adversely affect the market price of our Common Stock and the voting and other
rights of the holders of our Common Stock.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Series B Preferred Stock </I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Certain holders of our Series B Preferred Stock
are entitled to receive dividends on shares of Series B Preferred Stock equal to, on an as-if-converted-to-common-stock basis, and in
the same form as dividends actually paid on shares of our Common Stock. Except as provided in the Series B Certificate of Designation
or as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B
Preferred Stock are outstanding, we will not, without the affirmative vote of the holders of a majority of the then outstanding shares
of the Series B Preferred Stock: (a) (i) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock,
(ii) alter or amend the Series B Certificate of Designation, or (iii) amend or repeal any provision of, or add any provision to, our Certificate
of Incorporation or Bylaws in a manner that adversely affects any rights of the holders of the Series B Preferred Stock, or file any articles
of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock, if such action
would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series
B Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Certificate of Incorporation
or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (b) issue further shares of Series B Preferred
Stock beyond those contemplated for issuance in the Merger Agreement or increase or decrease (other than by conversion) the number of
authorized shares of Series B Preferred Stock, (c) at any time while at least 30% of the originally issued Series B Preferred Stock remains
issued and outstanding, consummate either: (x) any Fundamental Transaction (as defined in the Series B Certificate of Designation) or
(y) any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which
the stockholders of the Company immediately before such transaction do not hold at least a majority of our capital stock immediately after
such transaction, or (d) enter into any agreement with respect to any of the foregoing. The Series B Preferred Stock shall rank on parity
with the Common Stock as to the distribution of assets upon any liquidation, dissolution, or winding-up of the Company. Each share of
Series B Preferred Stock is convertible at the option of the holder, at any time, and without the payment of additional consideration
by the holder. As of December 31, 2024, each outstanding share of Series B Preferred Stock was convertible into common stock at a ratio
of approximately 83.3332:1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anti-Takeover Provisions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The provisions of Delaware law, our Certificate
of Incorporation and our Bylaws could have the effect of delaying, deferring or discouraging another person from acquiring control of
our Company. These provisions, which are summarized below, may have the effect of discouraging takeover bids. They are also designed,
in part, to encourage persons seeking to acquire control of us to negotiate first with our Board. We believe that the benefits of increased
protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging
a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Delaware law </I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the provisions of Section 203
of the DGCL regulating corporate takeovers. In general, Section 203 prohibits a publicly-held Delaware corporation from engaging in a
business combination with an interested stockholder for a period of three years following the date on which the person became an interested
stockholder unless:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">prior
to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction
which resulted in the stockholder becoming an interested stockholder;</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.65pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">upon
completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at
least 85% of the voting stock of the corporation outstanding upon consummation of the transaction, excluding for purposes of determining
the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (1) shares owned by persons who
are directors and also officers and (2) shares owned by employee stock plans in which employee participants do not have the right to
determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.65pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">at
or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized
at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding
voting stock which is not owned by the interested stockholder.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.65pt; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 203 defines a &ldquo;business combination&rdquo; to include:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
merger or consolidation involving the corporation and the interested stockholder;</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.65pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.65pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">subject
to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested
stockholder;</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.65pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of
the corporation beneficially owned by the interested stockholder; and</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.65pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided
by or through the corporation.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.65pt; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, Section 203 defines an &ldquo;interested
stockholder&rdquo; as an entity or person who, together with the person&rsquo;s affiliates and associates, beneficially owns, or within
three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of
the corporation.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.65pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certificate of Incorporation and Bylaw Provisions </B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Certificate of Incorporation and our Bylaws
include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our Company, including the
following:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Board
of Directors vacancies</I></B>. Our Certificate of Incorporation and Bylaws require that the Board, and not stockholders, fill any directorships
that become vacant or are created by an increase in the authorized number of directors by the affirmative vote of a majority of the remaining
directors or by the sole remaining director. In addition, pursuant to our bylaws, the number of directors constituting our Board is permitted
to be set only by a resolution adopted by a majority vote of the entire Board. These provisions prevent a stockholder from increasing
the size of our Board and then gaining control of the Board by filling the resulting vacancies with its own nominees. This makes it more
difficult to change the composition of the Board but promotes continuity of management.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.65pt; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 38.65pt; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.65pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Classified
board</I></B>. Our Certificate of Incorporation provides that our Board is classified into three classes of directors, each with staggered
three-year terms. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is
more difficult and time consuming for stockholders to replace a majority of the directors on a classified board of directors.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.65pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Stockholder
action; special meetings of stockholders</I></B>. Our Certificate of Incorporation and Bylaws provide that our stockholders may not take
action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling
a majority of our capital stock would not be able to amend our Bylaws or remove directors without holding a meeting of our stockholders
called in accordance with our Bylaws. Further, our Bylaws provide that special meetings of stockholders may be called only by the Board,
thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force
consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal
of directors.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.65pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Advance
notice requirements for stockholder proposals and director nominations</I></B>. Our Bylaws provide advance notice procedures for stockholders
seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual
meeting of stockholders. Our Bylaws also specify certain requirements regarding the form and content of a stockholder&rsquo;s notice.
These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations
for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions might
also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&rsquo;s own slate of directors
or otherwise attempting to obtain control of our Company.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.65pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>No
cumulative voting</I></B>. The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors
unless a corporation&rsquo;s certificate of incorporation provides otherwise. Our Certificate of Incorporation and Bylaws do not provide
for cumulative voting.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.65pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Directors
removed only for cause</I></B>. Our Bylaws provide that stockholders may remove directors only for cause, and only by the affirmative
vote of the holders of at least 66 2/3% of the voting power of the stock outstanding and entitled to vote generally in the election of
directors.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.65pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Amendment
of charter provisions</I></B>. Any amendment of the above provisions in our Certificate of Incorporation requires approval by holders
of at least two-thirds of our outstanding Common Stock.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.65pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Issuance
of Preferred Stock</I></B>. Our Board has the authority, without further action by the stockholders, to issue up to 5,000,000 shares
of Preferred Stock with rights and preferences, including voting rights, designated from time to time by our Board. The existence of
authorized but unissued shares of Preferred Stock enables our Board to render more difficult or to discourage an attempt to obtain control
of us by merger, tender offer, proxy contest or other means.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.65pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Choice
of forum</I></B>. Our Certificate of Incorporation and Bylaws provide that the Court of Chancery of the State of Delaware is the sole
and exclusive forum for any complaint asserting any internal corporate claims. In addition, our Bylaws also provide that the federal
district courts of the United States are the exclusive forum for the resolution of any complaint asserting a cause of action arising
under the Securities Act. These choice of forum provisions do not apply to claims brought to enforce a duty or liability created by the
Exchange Act.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.65pt; text-indent: -0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transfer Agent and Registrar</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent and registrar for our Common Stock and Series B
Preferred Stock is Computershare Trust Company, N.A. The transfer agent&rsquo;s address is 150 Royall Street, Suite 101, Canton, MA 02021,
and its telephone number is (800) 344-5128.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Listing</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Common Stock is listed on The Nasdaq Global Market under the symbol
&ldquo;ORKA.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>3
<FILENAME>ea023044501ex4-3_orukathe.htm
<DESCRIPTION>FORM OF PRE-FUNDED WARRANT, DATED AUGUST 29, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-indent: 0.25in; text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 4.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE OFFER AND SALE OF THESE SECURITIES AND THE SECURITIES ISSUABLE
UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;),
OR ANY APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED
OF (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OR (B) AN AVAILABLE EXEMPTION
FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN EACH CASE IN ACCORDANCE WITH APPLICABLE
STATE SECURITIES LAWS OR BLUE SKY LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY AND ITS TRANSFER
AGENT OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER THE SECURITIES ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED
IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES; PROVIDED, THAT IN CONNECTION
WITH ANY FORECLOSURE OR TRANSFER OF THE SECURITIES, THE TRANSFEROR SHALL COMPLY WITH THE PROVISIONS HEREIN AND IN THE SECURITIES PURCHASE
AGREEMENT, AND UPON FORECLOSURE OR TRANSFER OF THE SECURITIES, SUCH FORECLOSING PERSON OR TRANSFEREE SHALL COMPLY WITH ALL PROVISIONS
CONTAINED HEREIN AND IN THE SECURITIES PURCHASE AGREEMENT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ORUKA THERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt; width: 52%"><FONT STYLE="font-size: 10pt">Warrant No. W-[001]</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt; text-align: right; width: 47%"><FONT STYLE="font-size: 10pt">Original Issue Date: August 29, 2024</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Oruka Therapeutics, Inc., a Delaware corporation (the &ldquo;<I>Company</I>&rdquo;),
hereby certifies that, for value received, [___________] or its permitted registered assigns (the &ldquo;<I>Holder</I>&rdquo;), is entitled
to purchase from the Company up to a total of [___________] shares of common stock, $0.0001 par value per share (the &ldquo;<I>Common
Stock</I>&rdquo;), of the Company (each such share, a &ldquo;<I>Warrant Share</I>&rdquo; and all such shares, the &ldquo;<I>Warrant Shares</I>&rdquo;)
at an exercise price per share equal to $0.01 per share (as adjusted from time to time as provided in <U>Section 9</U> herein, the &ldquo;<I>Exercise
Price</I>&rdquo;), at any time and from time to time on or after August 29, 2024(the &ldquo;<I>Original Issue Date</I>&rdquo;) and until
this Pre-Funded Warrant is exercised in full (the &ldquo;<I>Expiration Date</I>&rdquo;), and subject to the following terms and conditions:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Pre-Funded Warrant (this &ldquo;<I>Warrant</I>&rdquo;) is one
of a series of similar warrants issued pursuant to that certain Subscription Agreement, dated April 3, 2024, by and among the Company
and the Purchasers identified therein (the &ldquo;<I>Purchase Agreement</I>&rdquo;). All such Warrants are referred to herein, collectively,
as the &ldquo;<I>Warrants</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. <U>Definitions</U>. In addition to the terms defined elsewhere in
this Warrant, capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Purchase Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">2. <U>Registration of Warrants</U>. The Company shall register this
Warrant, upon records to be maintained by or on behalf of the Company for that purpose (the &ldquo;<I>Warrant Register</I>&rdquo;), in
the name of the record Holder (which shall include the initial Holder or, as the case may be, any registered assignee to which this Warrant
is permissibly assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute
owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice
to the contrary.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3. <U>Registration of Transfers</U>. Subject to the restrictions on
transfer set forth in Section 7.01 of the Purchase Agreement and compliance with all applicable securities laws, the Company shall register
the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, with the Form of Assignment
attached as <U>Schedule 2</U> hereto duly completed and signed, to the Company&rsquo;s transfer agent or to the Company at its address
specified in the Purchase Agreement and (x) delivery, at the request of the Company, of an opinion of counsel reasonably satisfactory
to the Company to the effect that the transfer of such portion of this Warrant may be made pursuant to an available exemption from the
registration requirements of the Securities Act and all applicable state securities or blue sky laws and (y) delivery by the transferee
of a written statement to the Company certifying that the transferee is an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)
under the Securities Act and making the representations and certifications set forth in Section 3 of the Purchase Agreement, to the Company
at its address specified in the Purchase Agreement. Upon any such registration or transfer, a new warrant to purchase Common Stock in
substantially the form of this Warrant (any such new warrant, a &ldquo;<I>New Warrant</I>&rdquo;) evidencing the portion of this Warrant
so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred,
if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance
by such transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant.
The Company shall prepare, issue and deliver at its own expense any New Warrant under this <U>Section 3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4. <U>Exercise and Duration of Warrants</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) All or any part of this Warrant shall be exercisable by the registered
Holder in any manner permitted by <U>Section&nbsp;10</U> of this Warrant at any time and from time to time on or after the Original Issue
Date and through and including 5:30 P.M., New York City time, on the Expiration Date, subject to the conditions and restrictions contained
in this Warrant. At 5:30 P.M., New York City time, on the Expiration Date, the portion of this Warrant not exercised prior thereto shall
be and become void and of no value and this Warrant shall be terminated and no longer outstanding.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) The Holder may exercise this Warrant by delivering to the Company
(i) an exercise notice, in the form attached as <U>Schedule 1</U> hereto (the &ldquo;<I>Exercise Notice</I>&rdquo;), completed and duly
signed, and (ii) payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being exercised (which may
take the form of a &ldquo;cashless exercise&rdquo; if so indicated in the Exercise Notice pursuant to <U>Section 10</U> below). The date
on which the Exercise Notice is delivered to the Company (as determined in accordance with the notice provisions hereof) is an &ldquo;<I>Exercise
Date</I>.&rdquo; Within two (2) days following the delivery of the Exercise Notice (the &ldquo;<I>Payment Deadline</I>&rdquo;), the Holder
shall make payment with respect to the Exercise Price for the number of Warrant Shares as to which this Warrant is being exercised (which
may take the form of a &ldquo;cashless exercise&rdquo; if so indicated in the Exercise Notice); provided that the Company&rsquo;s obligations
to deliver such Warrant Shares shall be delayed on a day-for-day basis each day after the Payment Deadline such payment of the Exercise
Price is not paid. The delivery by (or on behalf of) the Holder of the Exercise Notice and the applicable Exercise Price as provided above
shall constitute the Holder&rsquo;s certification to the Company that its representations contained in Sections 3.01 and 3.03 through
3.08 of the Purchase Agreement are true and correct as of the Exercise Date as if remade in their entirety (or, in the case of any transferee
Holder that is not a party to the Purchase Agreement, such transferee Holder&rsquo;s certification to the Company that such representations
are true and correct as to such transferee Holder as of the Exercise Date). The Holder shall not be required to physically surrender this
Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised
in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date
the final Exercise Notice is delivered to the Company; provided that delivery of an electronic copy of the Warrant for surrender shall
be sufficient and Holder shall not be required to surrender any physical copy of the Warrant, provide a medallion or other bank guarantee
or take any similar action in connection therewith. Execution and delivery of the Exercise Notice shall have the same effect as cancellation
of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any.
For purposes hereof, &ldquo;<I>Trading Day</I>&rdquo; means (i) if the Warrant Shares are traded on a National Exchange, any day on which
the Warrant Share is traded on a National Exchange or (ii) if the Warrant Shares are not traded on a National Exchange, a Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c) The aggregate exercise price of this Warrant, except for a nominal
exercise price of $0.01 per Warrant Share, was pre-funded to the Company on or prior to the Original Issue Date and, consequently, no
additional consideration (other than the nominal Exercise Price) shall be required to be paid by the Holder to any Person to effect any
exercise of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate
exercise price under any circumstance or for any reason whatsoever, including in the event this Warrant shall not have been exercised
prior to the Expiration Date.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5. <U>Delivery of Warrant Shares</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) Subject to <U>Section 4(b)</U>, upon exercise of this Warrant,
the Company shall promptly (but no later than two (2) Trading Days after the Exercise Date (or three (3) Trading Days after the Exercise
Date if the last of the Exercise Notice, the Exercise Price (if applicable) and the opinion of counsel referred to below in this <U>Section
5(a)</U> (if applicable) is delivered after 5:00 P.M., New York City time, on the Exercise Date) or as soon as reasonably practicable
in the event that a certificate is requested) issue or cause to be issued and cause to be delivered to or upon the written order of the
Holder and in such name or names as the Holder may designate (provided that, if the Holder directs the Company to deliver a certificate
for the Warrant Shares in a name other than that of the Holder or an Affiliate of the Holder, it shall deliver to the Company on the Exercise
Date an opinion of counsel reasonably satisfactory to the Company to the effect that the issuance of such Warrant Shares in such other
name may be made pursuant to an available exemption from the registration requirements of the Securities Act and all applicable state
securities or blue sky laws), (i) an electronic delivery of the Warrant Shares to the Holder&rsquo;s account at the Depository Trust Company
(&ldquo;<I>DTC</I>&rdquo;) or a similar organization, or (ii), if requested by the Holder, a certificate for the Warrant Shares issuable
upon such exercise, free of restrictive legends, unless in the case of clause (i) and (ii) a registration statement covering the resale
of the Warrant Shares and naming the Holder as a selling stockholder thereunder is not then effective or the Warrant Shares are not freely
transferable without volume and manner of sale restrictions pursuant to Rule 144 under the Securities Act, in which case such Holder shall
receive a book-entry notation for the Warrant Shares issuable upon such exercise with appropriate restrictive legends. The Holder, or
any Person permissibly so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such
Warrant Shares as of the Exercise Date. If the Warrant Shares are to be issued free of all restrictive legends, the Company shall, upon
the written request of the Holder, use its commercially reasonable efforts to deliver, or cause to be delivered, Warrant Shares hereunder
electronically through DTC or another established clearing corporation performing similar functions, if available; provided, that, the
Company may, but will not be required to, change its transfer agent if its current transfer agent cannot deliver Warrant Shares electronically
through such a clearing corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) To the extent permitted by law, the Company&rsquo;s obligations
to issue and deliver Warrant Shares in accordance with and subject to the terms hereof (including the limitations set forth in <U>Section
12</U> below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or
consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c) In addition to any other rights available to the Holder, if the
Company fails to cause its transfer agent to transmit to the Holder the Warrant Shares in accordance with the provisions of <U>Section
5(a)</U> above pursuant to an exercise on or before the deadline set forth in this <U>Section 5</U>, and if, after such date, the Holder
is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases,
Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such
exercise (a &ldquo;<I>Buy-In</I>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the Common Stock so purchased exceeds (y) the amount obtained by multiplying
(1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times
(2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either
reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such
exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the
Company timely complied with its exercise and delivery obligations hereunder. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing
herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver Warrant
Shares upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6. <U>Charges, Taxes and Expenses</U>. Issuance and delivery of the
Warrant Shares upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent
fee or other incidental tax or expense in respect of the issuance of the Warrant Shares, all of which taxes and expenses shall be paid
by the Company; <I>provided</I>, <I>however</I>, that the Company shall not be required to pay any tax that may be payable in respect
of any transfer involved in the registration Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof.
The Holder shall be responsible for all other tax liabilities that may arise as a result of holding or transferring this Warrant or receiving
Warrant Shares upon exercise hereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7. <U>Replacement of Warrant</U>. If this Warrant is mutilated, lost,
stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in
lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of
such loss, theft or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety bond, if requested by
the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures
and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation
of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company&rsquo;s obligation
to issue the New Warrant.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8. <U>Reservation of Warrant Shares</U>. The Company covenants that
it will at all times reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock,
solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant
Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other
contingent purchase rights of persons other than the Holder (taking into account the adjustments and restrictions of <U>Section 9</U>).
The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise
Price (or upon a &ldquo;cashless exercise&rdquo; pursuant to <U>Section 10</U>) in accordance with the terms hereof, be duly and validly
authorized, issued and fully paid and nonassessable. The Company will take all commercially reasonable actions as may be necessary to
assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of
any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9. <U>Certain Adjustments</U>. The Exercise Price and number of Warrant
Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth in this <U>Section 9</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) <U>Stock Dividends and Splits</U>. If the Company, at any time
while this Warrant is outstanding, (i) pays a stock dividend on its Common Stock or otherwise makes a distribution on any class of capital
stock that is payable in shares of Common Stock, (ii) subdivides its outstanding shares of Common Stock into a larger number of shares,
or (iii) combines its outstanding shares of Common Stock into a smaller number of shares, then in each such case, the Exercise Price shall
be multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately before such
event and the denominator of which shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment
made pursuant to clause (i) of this paragraph shall become effective immediately after the record date for the determination of stockholders
entitled to receive such dividend or distribution, and any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become
effective immediately after the effective date of such subdivision or combination.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) <U>Pro Rata Distributions</U>. If the Company, at any time while
this Warrant is outstanding, distributes to all holders of Common Stock for no consideration (i) evidences of its indebtedness, (ii) any
security (other than a distribution of Common Stock covered by the preceding paragraph) or (iii) rights or warrants to subscribe for or
purchase any security, or (iv) any other asset (in each case, &ldquo;<I>Distributed Property</I>&rdquo;), then, upon any exercise of this
Warrant that occurs after the record date fixed for determination of stockholders entitled to receive such distribution, the Holder shall
be entitled to receive, in addition to the Warrant Shares otherwise issuable upon such exercise (if applicable), the Distributed Property
that such Holder would have been entitled to receive in respect of such number of Warrant Shares had the Holder been the record holder
of such Warrant Shares immediately prior to such record date without regard to any limitation on exercise contained therein. Notwithstanding
anything herein to the contrary, the foregoing provisions in this <U>Section 9(b)</U> shall not apply to, or be triggered by, any rights
issued by the Company (either separately or that attach to any securities of the Company) in connection with any stockholders rights agreement,
poison pill or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation, bylaws or other documents.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c) <U>Fundamental Transactions</U>. If, at any time while this Warrant
is outstanding, the Company effects a &ldquo;<I>Fundamental Transaction</I>&rdquo; (defined as (i) any merger or consolidation of the
Company with or into another Person, including, for avoidance of doubt, the Merger, (ii) any sale of all or substantially all of the Company&rsquo;s
and its subsidiaries&rsquo; assets, taken as a whole, in one or a series of related transactions, (iii) any reclassification of the Common
Stock (other than a change to par value, or from par value to no par value or changes resulting from a combination or subdivision), (iv)
any tender offer or exchange offer (whether by the Company or another Person) that is accepted by holders of capital stock representing
more than 50% of the outstanding Common Stock of the Company and the Company or such other Person, as applicable, accepts such tender
for payment, (v) any business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement)
with another Person whereby such other Person acquires more than the 50% of the voting power of the capital stock of the Company (except
for any such transaction in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the
same proportions, the voting power of such Person immediately after the transaction) or (vi) any statutory exchange of the outstanding
shares of Common Stock, as a result of which, the holders of the Common Stock would be entitled to receive, or their Common Stock would
be converted into, or exchanged for, shares, stock, other securities, or other property or assets (including cash or any combination thereof)),
then, to the extent then permitted under applicable laws, rules and regulations (including the rules of the Nasdaq Stock Market or any
exchange on which the Common Stock is then listed), upon any subsequent exercise of this Warrant, the Holder shall have the right to receive,
for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction,
the same kind and amount of securities, cash, assets or property as it would have been entitled to receive upon the occurrence of such
Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of Warrant Shares
then issuable upon exercise in full of this Warrant without regard to any limitations on exercise contained herein (the &ldquo;<I>Alternate
Consideration</I>&rdquo;). Except for the Merger pursuant to the Merger Agreement, the Company shall not effect any such Fundamental Transaction
unless prior to or simultaneously with the consummation thereof, any successor to the Company or surviving entity shall assume the obligation
to deliver to the Holder, such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to
receive, and the other obligations under this Warrant. The provisions of this <U>Section 9(c)</U> shall similarly apply to subsequent
transactions analogous of a Fundamental Transaction type.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">(d) <U>Number of Warrant Shares</U>. Simultaneously with any adjustment
to the Exercise Price pursuant to <U>Section 9(a)</U>, the number of Warrant Shares that may be purchased upon exercise of this Warrant
shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the
increased or decreased number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such
adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">(e) <U>Calculations</U>. All calculations under this <U>Section 9</U>
shall be rounded down to the nearest whole cent or the nearest whole share, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">(f) <U>Notice of Adjustments</U>. Upon the occurrence of each adjustment
pursuant to this <U>Section 9</U>, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment,
in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement
of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant
(as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment
is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Company&rsquo;s
transfer agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">(g) <U>Notice of Corporate Events</U>. If, while this Warrant is outstanding,
the Company (i) declares a dividend or any other distribution of cash, securities or other property in respect of its Common Stock, including,
without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company, (ii) enters into
any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution,
liquidation or winding up of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute
material non-public information, the Company shall deliver to the Holder a notice of such transaction at least three (3) Trading Days
prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote
with respect to such transaction; provided, however, that the failure to deliver such notice or any defect therein shall not affect the
validity of the corporate action required to be described in such notice. To the extent that any notice provided hereunder constitutes,
or contains, material, non-public information regarding the Company or any of its subsidiaries and the Company is subject to the reporting
requirements of the Exchange Act, the Company shall use commercially reasonable efforts to promptly file the information contained in
such notice with the Commission pursuant to a Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">10. <U>Payment of Exercise Price</U>.
The Holder shall pay the Exercise Price in immediately available funds by wire transfer to an account designated by the Company; provided,
however, that the Holder may, in its sole discretion, satisfy its obligation to pay the Exercise Price at such time through a &ldquo;cashless
exercise&rdquo;, in which event the Company shall issue to the Holder the number of Warrant Shares equal to the quotient obtained by dividing
[(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(A) &nbsp;&nbsp;=</TD><TD STYLE="text-align: justify"> the VWAP per share of Common Stock on the National Exchange on the Trading Day immediately preceding
the Exercise Date (the &ldquo;<I>Closing Sale Price</I>&rdquo;);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(B)&nbsp;&nbsp;=</TD><TD STYLE="text-align: justify">the Exercise Price of this Warrant, as adjusted hereunder;
and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(X)&nbsp;&nbsp;=</TD><TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable upon exercise
of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless
exercise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">For purposes of this Warrant:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<I>VWAP</I>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a National Exchange, the daily volume weighted average price of a share of Common Stock for such date (or the nearest preceding
date) on the National Exchange on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day
from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), or (b)&nbsp; if the Common Stock is not then listed on any National
Exchange, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders
of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall
be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">If Warrant Shares are issued
in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, and the
holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant, the Warrant Shares shall take
on the characteristics of the Warrants being exercised.&nbsp;The Company agrees not to take any position to the contrary.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">11. <U>Company-Elected Conversion</U>. The Company shall provide to
the Holder prompt written notice if after the Original Issue Date the Company is unable to issue the Warrant Shares without restrictive
legend, because the Commission has issued a stop order with respect to, or the Commission or Company has otherwise suspended or withdrawn,
a registration statement covering the resale of the Warrant Shares, either temporarily or permanently, or otherwise (each a &ldquo;<I>Restrictive
Legend Event</I>&rdquo;). To the extent that (A) a Restrictive Legend Event occurs, (B) at such time the Warrant Shares would be saleable
under Rule 144 without compliance with the manner of sale or volume restrictions, (C) the Company has delivered the notice described in
the immediately preceding sentence, and (D) the Holder attempts to exercise the Warrant after receipt of such notice by paying cash, the
Company shall (i) if the Fair Market Value (as calculated above) of the Warrant Shares is greater than the Exercise Price, provide written
notice to the Holder that the Company will deliver that number of Warrant Shares to the Holder as should be delivered in a cashless exercise
in accordance with <U>Section 10</U>, and return to the Holder all consideration paid to the Company in connection with the Holder&rsquo;s
attempted exercise of this Warrant (a &ldquo;<I>Company-Elected Conversion</I>&rdquo;), or (ii) at the election of the Holder to be given
within five (5) days of receipt of notice of a Company-Elected Conversion, the Holder shall be entitled to rescind the previously submitted
Exercise Notice and the Company shall return all consideration paid by Holder for such Warrant Shares upon such rescission.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">12. <U>Limitations on Exercise</U>. Notwithstanding anything to the
contrary contained herein, the number of Warrant Shares that may be acquired by the Holder upon any exercise of this Warrant (or otherwise
in respect hereof) shall be limited to the extent necessary to ensure that, following such exercise (or other issuance), the total number
of shares of Common Stock then beneficially owned by the Holder and its Attribution Parties as determined in accordance with Section 13(d)
of the Exchange Act, does not exceed 9.9999% (the &ldquo;<I>Maximum Percentage</I>&rdquo;) of the total number of then issued and outstanding
shares of Common Stock (including for such purpose the shares of Common Stock issuable upon such exercise). For purposes of the foregoing
sentence, the aggregate number of shares of Common Stock beneficially owned by the Holder and its Attribution Parties shall include the
number of shares of Common Stock issuable upon exercise of this Warrant with respect to which the determination of such sentence is being
made, but shall exclude shares of Common Stock which would be issuable upon (i) exercise of the remaining, unexercised portion of this
Warrant beneficially owned by such Person and its Attribution Parties and (ii) exercise or conversion of the unexercised or unconverted
portion of any other securities of the Company beneficially owned by the Holder and its Attribution Parties (including, without limitation,
any convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion or exercise analogous to the limitation
contained herein; provided that in no event shall the aggregate number of shares beneficially owned by the Holder and its Affiliates,
calculated in accordance with Section 13(d) of the Exchange Act, exceed the Maximum Percentage. Except as set forth in the preceding sentence
(other than the proviso thereto), for purposes of this paragraph (including the proviso in the immediately preceding sentence), beneficial
ownership shall be calculated in accordance with Section 13(d) of the Exchange Act; it being acknowledged by the Holder that the Company
is not representing to such Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the rules promulgated
thereunder and such Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the
limitation contained in this <U>Section 12</U> applies, the determination of whether this Warrant is exercisable (in relation to other
securities owned by such Holder) and of which a portion of this Warrant is exercisable shall be in the sole discretion of a Holder, and
the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in
relation to other securities owned by such Holder and its Attribution Parties) and of which portion of this Warrant is exercisable, in
each case subject to such aggregate percentage limitation, and the Company shall have no obligation to verify or confirm the accuracy
of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with
Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this <U>Section 12</U>, in determining
the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected
in (x) if the Company is subject to the reporting requirements of the Exchange Act, the Company&rsquo;s most recent Form 10-Q or Form
10-K, as the case may be, (y) a more recent public announcement by the Company or (z) any other notice by the Company or its transfer
agent setting forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within
three (3) Trading Days confirm in writing to such Holder the number of shares of Common Stock then outstanding. In any case, the number
of outstanding shares Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company,
including the Warrants, by the Holder and its Affiliates since the date as of which such number of outstanding shares of Common Stock
was reported. By written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other
percentage not in excess of 9.9999% specified in such notice; provided, that (i) any such increase will not be effective until the sixty-first
(61st) day after such notice is delivered to the Company, and (ii) any such increase or decrease will apply only to the Holder and not
to any other holder of Warrants. The provisions of this paragraph shall not apply to the Holder if the aggregate number of shares beneficially
owned by the Holder and its Affiliates, calculated in accordance with Section 13(d) of the Exchange Act, exceed 9.9999% immediately prior
to the Closing. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with
the terms of this <U>Section 12</U> to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the
intended beneficial ownership limitation herein contained or to make changes or supplements necessary or desirable to properly give effect
to such limitation. Any purported delivery of any number of shares of Common Stock or any other security upon exercise of this Warrant
shall be void and have no effect to the extent, but only to the extent, that before or after such delivery, the exercising Holder, together
with its Attribution Parties, would have beneficial ownership in excess of the Maximum Percentage. For purposes hereof, &ldquo;<I>Attribution
Parties</I>&rdquo; means, collectively, the following Persons and entities: (i) any direct or indirect Affiliates of the Holder, (ii)
any Person acting or who reasonably could be deemed to be acting as a group together with the Holder or any of the foregoing and (iii)
any other Persons whose beneficial ownership of Common Stock reasonably could be aggregated with the Holder&rsquo;s and the other Attribution
Parties for purposes of Section 13(d) or Section 16 of the Exchange Act (for clarity, the purpose of the foregoing is to subject collectively
the Holder and all other Attribution Parties to the Maximum Percentage).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">13. <U>No Fractional Shares</U>. No fractional Warrant Shares will
be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number
of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market
value (based on the Closing Sale Price) for any such fractional shares.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">14. <U>Notices</U>. Any and all notices or other communications or
deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective
on the earliest of (i) the date of transmission, if such notice or communication is delivered via email at the email address specified
in the Purchase Agreement prior to 5:30 P.M., New York City time, on a Trading Day, (ii) the next Trading Day after the date of transmission,
if such notice or communication is delivered via email at the email address specified in the Purchase Agreement on a day that is not a
Trading Day or later than 5:30 P.M., New York City time, on any Trading Day, (iii) the Trading Day following the date of mailing, if sent
by nationally recognized overnight courier service specifying next business day delivery, and (iv) upon actual receipt by the Person to
whom such notice is required to be given, if by hand delivery. The address and email address of a Person for such notices or communications
shall be as set forth in the Purchase Agreement unless changed by such Person by two (2) Trading Days&rsquo; prior written notice to the
other Persons in accordance with this <U>Section 14</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">15. <U>Warrant Agent</U>. The Company shall serve as warrant agent
under this Warrant. Upon notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or
any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent
shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or
stockholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant
agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder
at the Holder&rsquo;s last address as shown on the Warrant Register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">16. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) <U>No Rights as a Stockholder</U>. The Holder, solely in such Person&rsquo;s
capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the
Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person&rsquo;s
capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent
to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance
or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder
of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained
in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (except upon exercise of this
Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the
Company.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) <U>No Avoidance</U>. Except and to the extent as waived or consented
to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate or articles of incorporation
or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary
action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith
assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights
of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (a) not
increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in
par value, (b) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid
and nonassessable Warrant Shares upon the exercise of this Warrant, and (c) use commercially reasonable efforts to obtain all such authorizations,
exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform
its obligations under this Warrant.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c) <U>Successors and Assigns</U>. Subject to the restrictions on transfer
set forth in this Warrant and in Section 7.01 of the Purchase Agreement, and compliance with applicable securities laws, this Warrant
may be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the Holder except to a successor
in the event of a Fundamental Transaction. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and
their respective successors and permitted assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give
to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant
may be amended only in writing signed by the Company and the Holder, or their successors and assigns.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) <U>Authorized Shares</U>. The Company further covenants that its
issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant
Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary
to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements
of the National Exchange upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued
upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant
and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free
from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer
occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(e) <U>Amendment and Waiver</U>. Except as otherwise provided herein
and subject to the restrictions set forth in Section 9.01 of the Purchase Agreement, the provisions of the Warrants may be amended and
the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company
has obtained the written consent of the Holders of Warrants representing no less than a majority of the Warrant Shares obtainable upon
exercise of the Warrants then outstanding.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(f) <U>Acceptance</U>. Receipt of this Warrant by the Holder shall
constitute acceptance of and agreement to all of the terms and conditions contained herein.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(g) <U>Governing Law; Jurisdiction</U>. All questions concerning the
construction, validity, enforcement and interpretation of this warrant shall be governed by and construed and enforced in accordance with
the laws of the state of New York, without regard to the principles of conflicts of law thereof. Each of the Company and the Holder hereby
irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City and County of New York for the adjudication
of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect
to the enforcement of any of the transaction documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or
proceeding, any claim that it is not personally subject to the jurisdiction of any such courts. Each of the Company and the Holder hereby
irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing
a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such person at the address in effect
for notices to it under the purchase agreement and agrees that such service shall constitute good and sufficient service of process and
notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.
Each of the Company and the Holder hereby waives all rights to a trial by jury.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(h) <U>Headings</U>. The headings herein are for convenience only,
do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(i) <U>Severability</U>. In case any one or more of the provisions
of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions
of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree
upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate
such substitute provision in this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly
executed by its authorized officer as of the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-top: 0.25pt">ORUKA THERAPEUTICS, INC.</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 1.5pt; width: 60%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; vertical-align: top; padding-top: 0.25pt; font-size: 10pt; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; padding-top: 0.25pt; width: 35%">&nbsp;</TD></TR>

  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Lawrence Klein</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Chief Executive Officer </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SCHEDULE 1 </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF EXERCISE NOTICE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[To be executed by the Holder to purchase shares
of Common Stock under the Warrant]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) The undersigned is the Holder of Warrant No. __________ (the &ldquo;<I>Warrant</I>&rdquo;)
issued by Oruka Therapeutics, Inc., a Delaware corporation (the &ldquo;<I>Company</I>&rdquo;). Capitalized terms used herein and not otherwise
defined herein have the respective meanings set forth in the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2) The undersigned hereby exercises its right to purchase __________
Warrant Shares pursuant to the Warrant.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(3) The Holder intends that payment of the Exercise Price shall be
made as (check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding: 0.25pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; vertical-align: top; width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Cash Exercise </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding: 0.25pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; vertical-align: top; width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&ldquo;Cashless Exercise&rdquo; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(4) If the Holder has elected a Cash Exercise, the Holder shall pay
the sum of $___________ in immediately available funds to the Company in accordance with the terms of the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(5) Pursuant to this Exercise Notice, the Company shall deliver to
the Holder Warrant Shares determined in accordance with the terms of the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(6) By its delivery of this Exercise Notice, the undersigned represents
and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the
number of shares of Common Stock (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934) permitted to
be owned under <U>Section 12</U> of the Warrant to which this notice relates.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(7) By its delivery of this Exercise Notice and pursuant to Section
4(b) of the Warrant, the undersigned certifies to the Company that its representations listed in Section 4(b) of the Warrant are true
and correct as of the date hereof as if remade in their entirety (or, in the case of any transferee Holder that is not a party to the
Purchase Agreement, such transferee Holder&rsquo;s certification to the Company that such representations are true and correct as to such
transferee Holder as of the date hereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Dated:______________________</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Name of Holder: _____________________</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding: 0.25pt; vertical-align: top; font-size: 10pt; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0.25pt; vertical-align: top; font-size: 10pt; width: 35%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt; width: 60%"></TD></TR>
  <TR>
    <TD STYLE="padding: 0.25pt; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0.25pt; vertical-align: top; font-size: 10pt"></TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding: 0.25pt; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0.25pt; vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">(Signature must conform in all respects to name of Holder as specified
on the face of the Warrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SCHEDULE 2 </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF ASSIGNMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[To be completed and executed by the Holder only
upon transfer of the Warrant]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers
unto (the &ldquo;<I>Transferee</I>&rdquo;) the right represented by the within Warrant to purchase shares of Common Stock of Oruka Therapeutics,
Inc. (the &ldquo;<I>Company</I>&rdquo;) to which the within Warrant relates and appoints attorney to transfer said right on the books
of the Company with full power of substitution in the premises. In connection therewith, the undersigned represents, warrants, covenants
and agrees to and with the Company that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 4%; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">the offer and sale of the Warrant contemplated hereby is being made in compliance with Section 4(a)(2) of the United States Securities Act of 1933, as amended (the &ldquo;<I>Securities Act</I>&rdquo;) or another valid exemption from the registration requirements of Section 5 of the Securities Act and in compliance with all applicable securities laws of the states of the United States; </FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 4%; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">the undersigned has not offered to sell the Warrant by any form of general solicitation or general advertising, including, but not limited to, any advertisement, article, notice or other communication published in any newspaper, magazine or similar media or broadcast over television or radio, and any seminar or meeting whose attendees have been invited by any general solicitation or general advertising; </FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 4%; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">the undersigned has read the Transferee&rsquo;s investment letter included herewith, and to its actual knowledge, the statements made therein are true and correct; and </FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 4%; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">the undersigned understands that the Company may condition the transfer of the Warrant contemplated hereby upon the delivery to the Company by the undersigned or the Transferee, as the case may be, of a written opinion of counsel (which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that such transfer may be made without registration under the Securities Act and under applicable securities laws of the states of the United States. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 5%"><FONT STYLE="font-size: 10pt">Dated:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 40%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; vertical-align: bottom; font-size: 10pt; width: 50%">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; vertical-align: bottom; font-size: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0.25pt; vertical-align: bottom; font-size: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">(Signature must conform in all respects to name of holder as specified on the face of the Warrant)</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0.25pt; vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Address of Transferee</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0.25pt; vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0.25pt; vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0.25pt; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">In the presence of:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0.25pt; vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0.25pt; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">12</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>4
<FILENAME>ea023044501ex10-17_orukathe.htm
<DESCRIPTION>AMENDED AND RESTATED EMPLOYMENT LETTER AGREEMENT BY AND BETWEEN ORUKA THERAPEUTICS, INC. AND PAUL QUINLAN, DATED OCTOBER 1, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 10.17</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-17_001.jpg" ALT="" STYLE="width: 300px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">October 1, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Paul Quinlan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">c/o Oruka Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">855 Oak Grove Avenue, Suite 100 <BR>
Menlo Park,
CA 94025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Re: Amended and Restated Employment Letter
Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Dear Paul:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On behalf of Oruka Therapeutics, Inc.
(the &ldquo;<U>Company</U>&rdquo;), I am pleased to offer you a continuing position as General Counsel (the &ldquo;<U>Role</U>&rdquo;)
pursuant to this letter agreement (the &ldquo;<U>Agreement</U>&rdquo;). Your Role commenced on April 30, 2024 pursuant to your letter
agreement dated April 12, 2024. This Agreement will amend and restate that April 12, 2024 letter agreement, provided you accept this offer
as indicated by your signature below, to be effective as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>1.   Position</B>.
While serving in the Role, you will report to the Company&rsquo;s Chief Executive Officer. You will have such duties, authorities, and
responsibilities as are customarily associated with the Role. This is a full-time employment position. It is understood and agreed that,
while you are employed by the Company, you will not engage in any other employment, consulting or other business activities (whether full-time
or part-time), except as expressly authorized in writing by the Company. Notwithstanding the foregoing, you may engage in religious, charitable
and other community activities so long as such activities do not unreasonably interfere or conflict with your obligations to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>2.   Base
Salary</B>. Upon and following the date hereof, as cash compensation for your services, the Company will pay you an initial base salary
of $460,000 per year, payable in accordance with the Company&rsquo;s standard payroll schedule and subject to applicable deductions and
withholdings. Your base salary will be subject to periodic review and potential adjustment in the Company&rsquo;s discretion. Your base
salary in effect at any given time is referred to herein as the &ldquo;<U>Base Salary</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>3.   Annual
Bonus</B>. You will continue to be eligible to receive an annual performance bonus targeted at 40% of your Base Salary. The target annual
bonus in effect at any given time is referred to herein as &ldquo;<U>Target Bonus</U>.&rdquo; Your 2024 annual bonus will be prorated
based on your period of employment following April 30, 2024. The actual bonus amount is discretionary and may be subject to achievement
of performance targets established by the Company for such year. To earn an annual bonus, you must be employed by the Company as of the
payment date of such bonus. Any annual bonus will be paid no later than March 15th of the calendar year following the calendar year to
which such bonus relates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>4.   Benefits/Paid
Time Off. </B>You will continue to be eligible, subject to the terms of the applicable plans and programs, to participate in the employee
benefits and insurance programs generally made available to the Company&rsquo;s full-time employees. Details of such benefits programs,
including applicable employee contributions and waiting periods, if applicable, will be made available to you as such benefit(s) become
available. You will be entitled to paid time off consistent with the terms of the Company&rsquo;s paid time off policy, as in effect from
time to time. The Company reserves the right to modify, limit, amend or cancel any of its benefits plans or programs at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>5.   Expense
Reimbursement. </B>The Company will reimburse you for all reasonable and necessary expenses incurred by you in connection with performing
your duties as an employee of the Company and that are pre-approved by the Company, provided that you comply with any Company policy or
practice on incurring, submitting, accounting for and documenting such expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>6.   Location</B>.
Your primary work location will continue to be in Menlo Park, CA, provided that you may be required to engage in reasonable travel for
business, consistent with the Company&rsquo;s business needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>7.   At-Will
Employment; Resignation from Subsidiaries</B>. At all times, your employment with the Company is &ldquo;at will,&rdquo; meaning you or
the Company may terminate it at any time for any or no reason, subject to the terms of this Agreement. Although your job duties, title,
reporting structure, compensation and benefits, as well as the Company&rsquo;s benefit plans and personnel policies and procedures, may
change from time to time (subject to the terms of this Agreement), the &ldquo;at will&rdquo; nature of your employment may only be changed
in an express written agreement signed by you and an authorized executive officer of the Company. Your last day of employment for any
reason is referred to herein as the &ldquo;Date of Termination.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">To the extent applicable, you shall be
deemed to have resigned from all officer and board member positions that you hold with the Company or any of its respective subsidiaries
and affiliates upon the termination of your employment for any reason. You shall execute any documents in reasonable form as may be requested
to confirm or effectuate any such resignations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>8.   Accrued
Obligations</B>. In the event of the ending of your employment for any reason, the Company shall pay you (i) your Base Salary and, if
applicable, any accrued but unused vacation, through the Date of Termination, and (ii) the amount of any documented expenses properly
incurred by you on behalf of the Company prior to any such termination and not yet reimbursed. (the &ldquo;<U>Accrued Obligations</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>9.   Severance
Pay and Benefits Outside of the Change in Control Period</B>. If the Company terminates your employment without Cause (and not as a result
of your death or Disability) or you resign with Good Reason, in each case, outside of the Change in Control Period (as such capitalized
terms are defined in <U>Appendix A</U>), then, in addition to the Accrued Obligations, and subject to (i) your execution and non-revocation
of a separation agreement and release in a form acceptable to the Company, which shall include a general release of claims against the
Company and all related persons and entities and a reaffirmation of the Continuing Obligations (as defined below) and shall provide that
if you breach the Continuing Obligations, all payments of the following severance pay and benefits shall immediately cease (the &ldquo;<U>Separation
Agreement and Release</U>&rdquo;), and (ii) the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date
of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven-day revocation
period:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Company shall pay you an amount equal to 12 months of your Base Salary (the &ldquo;<U>Severance Amount</U>&rdquo;),
payable in substantially equal installments over the 12-month period following the Date of Termination in accordance with the Company&rsquo;s
regular payroll practices beginning on the Company&rsquo;s first regularly scheduled payroll date following the date that is 60 days after
the Date of Termination; provided, however, that the first installment shall include any amounts that would have been paid following the
Date of Termination had such installments commenced on the first regularly scheduled payroll date following the Date of Termination.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Subject to your copayment of premium amounts at the applicable active employees&rsquo; rate and your proper
election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&ldquo;<U>COBRA</U>&rdquo;),
the Company shall pay to the group health plan provider(s), the COBRA provider or you a monthly payment equal to the monthly employer
contribution that the Company would have made to provide health insurance to you if you had remained employed by the Company until the
earliest of (A) the 12-month anniversary of the Date
of Termination; (B) your eligibility for group health plan benefits under any other employer&rsquo;s group health plan; or (C) the cessation
of your continuation rights under COBRA; provided, however, that if the Company reasonably determines that it cannot pay such amounts
to the group health plan provider(s) or the COBRA provider (if applicable) without potentially violating applicable law (including, without
limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly
to you for the time period specified above. Such payments, if to you, shall be subject to tax-related deductions and withholdings and
paid on the Company&rsquo;s regular payroll dates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Notwithstanding anything to the contrary
in this Agreement, for the avoidance of doubt:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">if your employment ends as a result of a termination by the Company for Cause or a resignation by you
without Good Reason, you will be entitled to the Accrued Obligations and will not be entitled to any further compensation from the Company;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">if your employment ends due to your death or Disability, (i) you will receive the Accrued Obligations
and (ii) all outstanding equity-based awards subject to time-based vesting (the &ldquo;<U>Time-Based Equity Awards</U>&rdquo;) as of the
Termination Date shall immediately accelerate and become vested or nonforfeitable as of the Date of Termination, but you will not be eligible
for any other severance pay or benefits, whether pursuant to <U>Section 9</U>, <U>Section 10</U> or otherwise.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>10.   Severance
Pay and Benefits Within the Change in Control Period</B>. If the Company terminates your employment without Cause (and not as a result
of your death or Disability) or you resign with Good Reason, in each case, within the Change in Control Period, then, in addition to you
being entitled to the Accrued Obligations, and subject to your execution and non-revocation of the Separation Agreement and Release and
it becoming fully effective, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement
and Release), which shall include a seven-day revocation period:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 35.95pt">(a)</TD><TD STYLE="text-align: justify">The Company shall pay you an amount equal 1.0 times the sum of (i) your Base Salary and (ii) your Target Bonus for the year in
which the termination occurs (in each case, calculated by reference to your Base Salary rate and Target Bonus as in effect immediately
prior to your termination, but without giving effect to any prior reduction in Base Salary or Target Bonus by the Company that would give
rise to your right to resign for Good Reason) (such salary and bonuses together, the &ldquo;<U>CIC Severance Amount</U>&rdquo;), payable
in substantially equal installments over the 12-month period following the Date of Termination in accordance with the Company&rsquo;s
regular payroll practices beginning on the Company&rsquo;s first regularly scheduled payroll date following the date that is 60 days after
the Date of Termination; provided, however, that the first installment shall include any amounts that would have been paid following the
Date of Termination had such installments commenced on the first regularly scheduled payroll date following the Date of Termination.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Notwithstanding anything to the contrary in any applicable equity-based award agreement or plan, all of
the unvested portion of your then outstanding Time-Based Equity Awards as of the Termination Date shall immediately accelerate and become
vested or nonforfeitable as of the later of (i) the Date of Termination or (ii) the effective date of the Separation Agreement and Release
(such later date being the &ldquo;<U>Accelerated Vesting Date</U>&rdquo;); and provided further that any termination or forfeiture of
the unvested portion of such Time- Based Equity Awards that would otherwise occur on the Date of Termination in the absence of this Agreement
will be delayed until the effective date of the Separation Agreement and Release and will only occur if the vesting pursuant to this subsection
does not occur due to the absence of the Separation Agreement and Release becoming fully effective within the time period set forth therein.
Notwithstanding the foregoing, no additional vesting of the Time-Based Equity Awards shall occur during the period between the Date of
Termination and the Accelerated Vesting Date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">All of your outstanding equity-based awards subject to performance-based vesting (the &ldquo;<U>Performance-Based
Equity Awards</U>&rdquo;) shall immediately accelerate and become vested or nonforfeitable as of the Accelerated Vesting Date with the
performance criteria being deemed to have been met based on the greater of target or, if determinable, actual performance; provided, however,
that the applicable award agreement for any Performance-Based Equity Award may provide for alternative treatment upon a termination covered
by this <U>Section 10.</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">The Company shall pay to the group health plan provider(s), the COBRA provider or you a monthly payment
equal to the monthly COBRA continuation premiums until the earliest of (A) the 12-month anniversary of the Date of Termination; (B) your
eligibility for group health plan benefits under any other employer&rsquo;s group health plan; or (C) the cessation of your continuation
rights under COBRA; provided, however, that if the Company reasonably determines that it cannot pay such amounts to the group health plan
provider(s) or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section
2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to you for the time
period specified above. Such payments, if to you, shall be subject to tax-related deductions and withholdings and paid on the Company&rsquo;s
regular payroll dates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">For the avoidance of doubt, <U>Section
9</U> and <U>Section 10</U> of this Agreement are mutually exclusive and in no event shall you be entitled to payments or benefits pursuant
to both <U>Section 9</U> and <U>Section 10</U> of this Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">11.</TD><TD>Continuing Obligations<FONT STYLE="font-weight: normal">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><B>Business Protection Agreement</B>. You have previously entered into an Invention Assignment, Non-Disclosure
and Business Protection Agreement (the &ldquo;<U>Business Protection Agreement</U>&rdquo;). For purposes of this Agreement, the obligations
in this <U>Section 11</U> and those that arise in the Business Protection Agreement and any other agreement relating to confidentiality,
assignment of inventions, or other restrictive covenants shall collectively be referred to as the &ldquo;<U>Continuing Obligations</U>.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><B>Third Party Agreements and Rights</B>. You hereby confirm that you are not bound by the terms of any
agreement with any previous employer or other party that would prevent you from performing your obligations hereunder. You represent to
the Company that your execution of this Agreement, your employment with the Company and the performance of your proposed duties for the
Company will not violate any obligations you may have to any such previous employer or other party. In your work for the Company, you
will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other
party, and you will not bring to the premises of the Company or load or access on any electronic system of the Company, any copies or
other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><B>Litigation and Regulatory Cooperation</B>. You shall reasonably cooperate with the Company in (i) the
defense or prosecution of any claims or actions now in existence or that may be brought in the future against or on behalf of the Company
that relate to events or occurrences that transpired while you were engaged or employed by the Company, and (ii) the investigation, whether
internal or external, of any matters about which the Company believes you may have knowledge or information. Your full cooperation in
connection with such claims, actions or investigations shall include, but not be limited to, being reasonably available to meet with counsel
to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times.
During and after your engagement and employment, you also shall reasonably cooperate with the Company in connection with any investigation
or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that
transpired while you were employed by the Company. The Company shall reimburse you for any reasonable out-of-pocket expenses incurred
in connection with your performance of obligations pursuant to this <U>Section 11(c)</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><B>Relief</B>. You agree that it would be difficult to measure any damages caused to the Company that
might result from your breach of any of the Continuing Obligations, and that in any event money damages may be an inadequate remedy for
any such breach. Accordingly, you agree that if you breach, or propose to breach, any portion of the Continuing Obligations, the Company
shall be entitled, in addition to all other remedies that it may have, to seek an injunction or other appropriate
equitable relief to restrain any such breach without showing or proving any actual damage to the Company or posting any bond.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">12.</TD><TD>Golden Parachute Taxes<FONT STYLE="font-weight: normal">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><B>Best After-Tax Result</B>. In the event that any payment or benefit received or to be received by you
pursuant to this Agreement or otherwise (&ldquo;<U>Payments</U>&rdquo;) would (i) constitute a &ldquo;parachute payment&rdquo; within
the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the &ldquo;<U>Code</U>&rdquo;), and (ii) but for this subsection
(a), be subject to the excise tax imposed by Section 4999 of the Code, any successor provisions, or any comparable federal, state, local
or foreign excise tax (&ldquo;<U>Excise Tax</U>&rdquo;), then, subject to the provisions of Section 14, such Payments shall be either
(A) provided in full pursuant to the terms of this Agreement or any other applicable agreement, or (B) provided as to such lesser extent
that would result in the Payments being $1.00 less than the amount at which any portion of the Payments would be subject to the Excise
Tax, whichever of the foregoing amounts, taking into account the applicable federal, state, local and foreign income, employment and other
taxes and the Excise Tax (including, without limitation, any interest or penalties on such taxes), results in the receipt, on an after-tax
basis, of the greatest amount of payments and benefits provided for hereunder or otherwise, notwithstanding that all or some portion of
such Payments may be subject to the Excise Tax. Unless the Company and you otherwise agree in writing, any determination required under
this Section shall be made by independent tax counsel designated by the Company and reasonably acceptable to you (&ldquo;<U>Independent
Tax Counsel</U>&rdquo;), whose determination shall be conclusive and binding upon you and the Company for all purposes. For purposes of
making the calculations required under this Section, Independent Tax Counsel may make reasonable assumptions and approximations concerning
applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code;
provided that Independent Tax Counsel shall assume that you pay all taxes at the highest marginal rate. The Company and you shall furnish
to Independent Tax Counsel such information and documents as Independent Tax Counsel may reasonably request in order to make a determination
under this Section. The Company shall bear all costs that Independent Tax Counsel may reasonably incur in connection with any calculations
contemplated by this Section. In the event that <U>Section 13(a)(ii)(B)</U> above applies, then based on the information provided to you
and the Company by Independent Tax Counsel, the cutback described hereunder will apply as to compensation not subject to Section 409A
of the Code prior to compensation subject to Section 409A of the Code and will otherwise apply on a reverse chronological basis from payments
latest in time. If the Internal Revenue Service (the &ldquo;<U>IRS</U>&rdquo;) determines that any Payment is subject to the Excise Tax,
then <U>Section 12(b)</U> hereof shall apply, and the enforcement of <U>Section 12(b)</U> shall be the exclusive remedy to the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><B>Adjustments</B>. If, notwithstanding any reduction described in <U>Section 12(a)</U> hereof (or in
the absence of any such reduction), the IRS determines that you are liable for the Excise Tax as a result of the receipt of one or more
Payments, then you shall be obligated to surrender or pay back to the Company within one-hundred 120 days after a final IRS determination,
an amount of such payments or benefits equal to the &ldquo;<U>Repayment Amount</U>.&rdquo; The Repayment Amount with respect to such Payments
shall be the smallest such amount, if any, as shall be required to be surrendered
or paid to the Company so that your net proceeds with respect to such Payments (after taking into account the payment of the Excise Tax
imposed on such Payments) shall be maximized. Notwithstanding the foregoing, the Repayment Amount with respect to such Payments shall
be zero if a Repayment Amount of more than zero would not eliminate the Excise Tax imposed on such Payments or if a Repayment Amount of
more than zero would not maximize the net amount received from the Payments. If the Excise Tax is not eliminated pursuant to this <U>Section
12(b)</U>, you shall pay the Excise Tax.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">13.</TD><TD>Section 409A<FONT STYLE="font-weight: normal">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service
within the meaning of Section 409A of the Code, the Company determines that you are a &ldquo;specified employee&rdquo; within the meaning
of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement or
otherwise on account of your separation from service would be considered deferred compensation otherwise subject to the additional tax
imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall
not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after your separation
from service, or (B) your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall
include a catch- up payment covering amounts that would otherwise have been paid during the six- month period but for the application
of this provision (without interest), and the balance of the installments shall be payable in accordance with their original schedule.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided
by the Company or incurred by you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively
practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which
the expense was incurred. The amount of in- kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect
the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other
aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or
exchange for another benefit.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">To the extent that any payment or benefit described in this Agreement constitutes &ldquo;non- qualified
deferred compensation&rdquo; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the termination
of your employment, then such payments or benefits shall be payable only upon your &ldquo;separation from service.&rdquo; The determination
of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation
Section 1.409A-l(h).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">The parties intend that this Agreement will be administered in accordance with Section 409A of the Code.
To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall
be read in such a manner so that all payments hereunder
comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes
of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either
party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve
the payments and benefits provided hereunder without additional cost to either party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">The Company makes no representation or warranty and shall have no liability to you or any other person
if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not
satisfy an exemption from, or the conditions of, such Section.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>14.   Withholding;
Tax Effect</B>. All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and
payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation
policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to
tax liabilities arising from your compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>15.   Recoupment</B>.
Amounts paid or payable under this Agreement shall be subject to the provisions of any applicable clawback or recoupment policies or procedures
adopted by the Company, which clawback or recoupment policies may provide for forfeiture and/or recoupment of amounts paid or payable
under this Agreement. No forfeiture or recoupment under such policies or procedures will give rise to a right to resign for Good Reason
under this Agreement or under any other agreement between you and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>16.   Interpretation
and Enforcement</B>. This Agreement, together with <U>Appendix A</U>, the Business Protection Agreement and any award agreement between
you and the Company constitute the complete agreement between you and the Company, contains all of the terms of your employment with the
Company and supersedes any prior agreements, representations or understandings (whether written, oral or implied) between you and the
Company. The terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement
or arising out of, related to, or in any way connected with this Agreement, your employment with the Company or any other relationship
between you and the Company (the &ldquo;<U>Disputes</U>&rdquo;) will be governed by federal law to the extent applicable and otherwise
by California law, excluding laws relating to conflicts or choice of law and excluding Disputes arising in connection with any equity
incentive plan, which shall be governed by the terms of the applicable equity incentive plan. You and the Company submit to the exclusive
personal jurisdiction of the federal and state courts located in the County of San Mateo and State of California in connection with any
Dispute or any claim related to any Dispute, except for Disputes arising under any equity incentive plan, which shall be governed by the
terms of the applicable equity incentive plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>17. Assignment</B>.
Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise,
without the prior written consent of the other; <I>provided, however</I>, that the Company may assign its rights and obligations
under this Agreement without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a
reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets;
provided further, that if you remain employed or become employed by the Company, the purchaser or any of their affiliates in
connection with any such transaction, then you shall not be entitled to any payments, benefits or vesting pursuant to <U>Section
9</U> or pursuant to <U>Section 10</U> of this Agreement solely as a result of such transaction. This Agreement shall inure to the
benefit of and be binding upon you and the Company, and each of your and its respective successors, executors, administrators, heirs
and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>18.   Waiver;
Amendment</B>. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure
of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this
Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. This
Agreement may be amended or modified only by a written instrument signed by you and by a duly authorized executive officer of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>19.   Enforceability</B>.
If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement)
shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or
the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable,
shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted
by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>20.   Conditions</B>.
You must submit satisfactory proof of your identity, successfully complete a criminal background check, which you hereby expressly authorize
by your execution of this Agreement, and provide documentation of your legal authorization to work in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>21.   Employee
Representations</B>. It is the policy of the Company not to solicit or accept proprietary information and/or trade secrets of other companies
or third parties. If you have or have had access to trade secrets or other confidential, proprietary information from your former employer
or another third party, the use of such information in performing your duties at the Company is prohibited. This may include, but is not
limited to, confidential or proprietary information in the form of documents, magnetic media, software, customer lists, and business plans
or strategies. In making this employment offer, the Company has relied on your representation that: (a) you are not currently a party
to any agreement that would restrict your ability to accept this offer or to perform services for the Company; (b) you are not subject
to any noncompetition or non-solicitation agreement or other restrictive covenants that might restrict your employment by the Company
as contemplated by this offer; (c) you have the full right, power and authority to execute and deliver the Agreement and to perform all
of your obligations thereunder; and (d) you will not bring with you to the Company or use in the performance of your responsibilities
at the Company any materials, documents or work product of a former employer or other third party that are not generally available to
the public, unless you have obtained written authorization from such former employer or third party for their possession and use and have
provided the Company with a copy of same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>22. Other
Terms</B>. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of your
employment to the extent necessary to effectuate the terms contained herein. The headings and other captions in this Agreement are
for convenience and reference only and shall not be used in interpreting, construing or enforcing any of the provisions of this
Agreement. This Agreement may be executed in separate counterparts. When both counterparts are signed, they shall be treated
together as one and the same document. PDF copies of signed counterparts shall be equally effective as originals. This Agreement may
also be executed electronically by any means that satisfies applicable electronic signature laws (e.g., DocuSign).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">To indicate your
acceptance of the Company&rsquo;s offer, please sign this Agreement in the space provided below and return it to me. If you have any
questions regarding this letter agreement, feel free to contact me.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">I look forward to working with you to make
the Company a great success.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">/s/ Lawrence Klein</TD>
  <TD STYLE="width: 60%">&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Lawrence Klein</TD>
  <TD>&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Chief Executive Officer</TD>
  <TD>&nbsp;</TD>
  </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Accepted and acknowledged:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">/s/ Paul Quinlan</TD>
  <TD STYLE="width: 60%">&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Paul Quinlan</TD>
  <TD>&nbsp;</TD>
  </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>Appendix A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">&ldquo;<U>Cause</U>&rdquo; shall mean (i) your dishonest
statements or acts with respect to the Company or any affiliate of the Company, or any current or prospective customers, suppliers, vendors
or other third parties with which such entity does business that results in or is reasonably anticipated to result in material harm to
the Company; (ii) your conviction or plea of no contest to: (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty
or fraud; (iii) your failure to perform in all material respects your lawful assigned duties and responsibilities to the reasonable satisfaction
of the Board, which failure continues, in the reasonable judgment of the Board, for 30 days after written notice given to you describing
such failure; (iv) your gross negligence, willful misconduct that results in or is reasonably anticipated to result in material harm
to the Company; or (v) your violation of any material violation of any agreement(s) between you and the Company or any written Company
policies including, without limitation, agreements relating to non-solicitation, non-disclosure and/or assignment of inventions or policies
related to ethics or workplace conduct.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">&ldquo;<U>Change in Control</U>&rdquo; shall have the meaning
set forth in the Company&rsquo;s 2024 Stock Incentive Plan (or the meaning provided to any word of similar import under any successor
plan).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">&ldquo;<U>Change in Control Period</U>&rdquo; shall mean
the period commencing three months prior to the first event constituting a Change in Control and ending 12 months following the first
event constituting a Change in Control.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">&ldquo;<U>Disability</U>&rdquo; shall mean a permanent and
total disability as defined in Section 22(e) (3) of the Code.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">&ldquo;<U>Good Reason</U>&rdquo; shall mean that you have
complied with the Good Reason Process (hereinafter defined) following the occurrence, without your written consent, of any of the following
events: (i) a material diminution in your base salary or Target Bonus except for across-the-board salary and target bonus reductions
of no more than 10% based on the Company&rsquo;s financial performance similarly affecting all or substantially all senior management
employees of the Company; (ii) a material change in the geographic location at which you are required to provide services to the Company
or a requirement that you change your remote location from your then-current residence; (iii) a material reduction in your duties, authority
or responsibilities; (iv) the failure of the Company to obtain the assumption of this Agreement by a successor; or (v) the material breach
of this Agreement (or any other agreements with you) by the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">6.</TD><TD STYLE="text-align: justify">&ldquo;<U>Good Reason Process</U>&rdquo; shall mean that
(i) you reasonably determine in good faith that a &ldquo;Good Reason&rdquo; condition has occurred; (ii) you notify the Company in writing
of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii) you cooperate in
good faith with the Company&rsquo;s efforts, for a period not less than 30 days following such notice (the &ldquo;<U>Cure Period</U>&rdquo;),
to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) you terminate your
employment within 30 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good
Reason shall be deemed not to have occurred.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>5
<FILENAME>ea023044501ex10-18_orukathe.htm
<DESCRIPTION>AMENDED AND RESTATED EMPLOYMENT LETTER AGREEMENT BY AND BETWEEN ORUKA THERAPEUTICS, INC. AND JOANA GONCALVES, DATED OCTOBER 1, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.18</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-18_001.jpg" ALT="" STYLE="height: 108px; width: 300px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">October 1, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Joana Goncalves</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">c/o Oruka Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">855 Oak Grove Avenue, Suite 100 <BR>
Menlo Park, CA 94025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Re: Amended and Restated Employment Letter Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Dear Jo:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On behalf of Oruka Therapeutics, Inc. (the &ldquo;<U>Company</U>&rdquo;),
I am pleased to offer you a continuing position as Chief Medical Officer (the &ldquo;<U>Role</U>&rdquo;) pursuant to this letter agreement
(the &ldquo;<U>Agreement</U>&rdquo;). Your Role commenced on April 18, 2024 pursuant to your letter agreement dated March 15, 2024. This
Agreement will amend and restate that March 15, 2024 letter agreement, provided you accept this offer as indicated by your signature below,
to be effective as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1.   Position</B>.
While serving in the Role, you will report to the Company&rsquo;s Chief Executive Officer. You will have such duties, authorities, and
responsibilities as are customarily associated with the Role. This is a full-time employment position. It is understood and agreed that,
while you are employed by the Company, you will not engage in any other employment, consulting or other business activities (whether full-time
or part-time), except as expressly authorized in writing by the Company. Notwithstanding the foregoing, you may engage in religious, charitable
and other community activities so long as such activities do not unreasonably interfere or conflict with your obligations to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.   Base
Salary</B>. Upon and following the date hereof, as cash compensation for your services, the Company will pay you an initial base salary
of $460,000 per year, payable in accordance with the Company&rsquo;s standard payroll schedule and subject to applicable deductions and
withholdings. Your base salary will be subject to periodic review and potential adjustment in the Company&rsquo;s discretion. Your base
salary in effect at any given time is referred to herein as the &ldquo;<U>Base Salary</U>.&rdquo;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 3. Bonus Compensation<FONT STYLE="font-weight: normal">.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify"><B>Signing Bonus</B>. In connection with your commencement
of employment with the Company on April 18, 2024, the Company advanced you a signing bonus of $100,000, less applicable deductions and
withholdings, which was paid to you in the first payroll after your employment commencement. If you resign your employment with the Company
for any reason or the Company terminates your employment for Cause, in either case prior to April 18, 2025, you agree to repay the Company,
within 30 days following your separation date, a prorated portion of the signing bonus (based on the number of full months you worked
for the Company).</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify"><B>Annual Bonus</B>. You will continue to be eligible to receive an annual performance bonus targeted
at 40% of your Base Salary. The target annual bonus in effect at any given time is referred to herein as &ldquo;<U>Target Bonus</U>.&rdquo;
Your 2024 annual bonus will be prorated based on your period of employment following April 18, 2024. The actual bonus amount is discretionary
and may be subject to achievement of performance targets established by the Company for such year. To earn an annual bonus, you must be
employed by the Company as of the payment date of such bonus. Any annual bonus will be paid no later than March 15th of the calendar year
following the calendar year to which such bonus relates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4.   Benefits/Paid
Time Off. </B>You will continue to be eligible, subject to the terms of the applicable plans and programs, to participate in the employee
benefits and insurance programs generally made available to the Company&rsquo;s full-time employees. Details of such benefits programs,
including applicable employee contributions and waiting periods, if applicable, will be made available to you as such benefit(s) become
available. You will be entitled to paid time off consistent with the terms of the Company&rsquo;s paid time off policy, as in effect from
time to time. The Company reserves the right to modify, limit, amend or cancel any of its benefits plans or programs at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>5.   Expense
Reimbursement. </B>The Company will reimburse you for all reasonable and necessary expenses incurred by you in connection with performing
your duties as an employee of the Company and that are pre-approved by the Company, provided that you comply with any Company policy or
practice on incurring, submitting, accounting for and documenting such expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>6.   Location</B>.
Your primary work location will continue to be remote in Connecticut, provided that you may be required to engage in reasonable travel
for business, consistent with the Company&rsquo;s business needs. You may change your remote work location with prior written notice to
and approval from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>7.   At-Will
Employment; Resignation from Subsidiaries</B>. At all times, your employment with the Company is &ldquo;at will,&rdquo; meaning you or
the Company may terminate it at any time for any or no reason, subject to the terms of this Agreement. Although your job duties, title,
reporting structure, compensation and benefits, as well as the Company&rsquo;s benefit plans and personnel policies and procedures, may
change from time to time (subject to the terms of this Agreement), the &ldquo;at will&rdquo; nature of your employment may only be changed
in an express written agreement signed by you and an authorized executive officer of the Company. Your last day of employment for any
reason is referred to herein as the &ldquo;Date of Termination.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent applicable, you shall be deemed
to have resigned from all officer and board member positions that you hold with the Company or any of its respective subsidiaries and
affiliates upon the termination of your employment for any reason. You shall execute any documents in reasonable form as may be requested
to confirm or effectuate any such resignations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>8.   Accrued
Obligations</B>. In the event of the ending of your employment for any reason, the Company shall pay you (i) your Base Salary and, if
applicable, any accrued but unused vacation, through the Date of Termination, and (ii) the amount of any documented expenses properly
incurred by you on behalf of the Company prior to any such termination and not yet reimbursed. (the &ldquo;<U>Accrued Obligations</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>9.   Severance
Pay and Benefits Outside of the Change in Control Period</B>. If the Company terminates your employment without Cause (and not as a result
of your death or Disability) or you resign with Good Reason, in each case, outside of the Change in Control Period (as such capitalized
terms are defined in <U>Appendix A</U>), then, in addition to the Accrued Obligations, and subject to (i) your execution and non-revocation
of a separation agreement and release in a form acceptable to the Company, which shall include a general release of claims against the
Company and all related persons and entities and a reaffirmation of the Continuing Obligations (as defined below) and shall provide that
if you breach the Continuing Obligations, all payments of the following severance pay and benefits shall immediately cease (the &ldquo;<U>Separation
Agreement and Release</U>&rdquo;), and (ii) the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date
of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven-day revocation
period:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">The Company shall pay you an amount equal to 12 months of your Base Salary (the &ldquo;<U>Severance Amount</U>&rdquo;),
payable in substantially equal installments over the 12-month period following the Date of Termination in accordance with the Company&rsquo;s
regular payroll practices beginning on the Company&rsquo;s first regularly scheduled payroll date following the date that is 60 days after
the Date of Termination; provided, however, that the first installment shall include any amounts that would have been paid following the
Date of Termination had such installments commenced on the first regularly scheduled payroll date following the Date of Termination.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Subject to your copayment of premium amounts at the applicable active employees&rsquo; rate and your proper
election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&ldquo;<U>COBRA</U>&rdquo;),
the Company shall pay to the group health plan provider(s), the COBRA provider or you a monthly payment equal to the monthly employer
contribution that the Company would have made to provide health insurance to you if you had remained employed by the Company until the
earliest of (A) the 12-month anniversary of the Date
of Termin(A) the 12-month anniversary of the Date
of Termination; (B) your eligibility for group health plan benefits under any other employer&rsquo;s group health plan; or (C) the cessation
of your continuation rights under COBRA; provided, however, that if the Company reasonably determines that it cannot pay such amounts
to the group health plan provider(s) or the COBRA provider (if applicable) without potentially violating applicable law (including, without
limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly
to you for the time period specified above. Such payments, if to you, shall be subject to tax-related deductions and withholdings and
paid on the Company&rsquo;s regular payroll dates.ation; (B) your eligibility for group health plan benefits under any other employer&rsquo;s group health plan; or (C) the cessation
of your continuation rights under COBRA; provided, however, that if the Company reasonably determines that it cannot pay such amounts
to the group health plan provider(s) or the COBRA provider (if applicable) without potentially violating applicable law (including, without
limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly
to you for the time period specified above. Such payments, if to you, shall be subject to tax-related deductions and withholdings and
paid on the Company&rsquo;s regular payroll dates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Notwithstanding anything to the contrary in this
Agreement, for the avoidance of doubt:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">if your employment ends as a result of a termination by the Company for Cause or a resignation by you
without Good Reason, you will be entitled to the Accrued Obligations and will not be entitled to any further compensation from the Company;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">if your employment ends due to your death or Disability, (i) you will receive the Accrued
                                                                 Obligations and (ii) all outstanding equity-based awards subject to time-based vesting (the &ldquo;<U>Time-Based Equity
                                                                 Awards</U>&rdquo;) as of the Termination Date shall immediately accelerate and become vested or nonforfeitable as of the Date of
                                                                 Termination, but you will not be eligible for any other severance pay or benefits,
whether pursuant to <U>Section 9</U>, <U>Section 10</U> or otherwise.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>10.   Severance
Pay and Benefits Within the Change in Control Period</B>. If the Company terminates your employment without Cause (and not as a result
of your death or Disability) or you resign with Good Reason, in each case, within the Change in Control Period, then, in addition to you
being entitled to the Accrued Obligations, and subject to your execution and non-revocation of the Separation Agreement and Release and
it becoming fully effective, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement
and Release), which shall include a seven-day revocation period:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">The Company shall pay you an amount equal 1.0 times the sum of (i) your Base Salary and (ii) your Target Bonus for the year in
which the termination occurs (in each case, calculated by reference to your Base Salary rate and Target Bonus as in effect immediately
prior to your termination, but without giving effect to any prior reduction in Base Salary or Target Bonus by the Company that would give
rise to your right to resign for Good Reason) (such salary and bonuses together, the &ldquo;<U>CIC Severance Amount</U>&rdquo;), payable
in substantially equal installments over the 12-month period following the Date of Termination in accordance with the Company&rsquo;s
regular payroll practices beginning on the Company&rsquo;s first regularly scheduled payroll date following the date that is 60 days after
the Date of Termination; provided, however, that the first installment shall include any amounts that would have been paid following the
Date of Termination had such installments commenced on the first regularly scheduled payroll date following the Date of Termination.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Notwithstanding anything to the contrary in any applicable equity-based award agreement or plan, all of
the unvested portion of your then outstanding Time-Based Equity Awards as of the Termination Date shall immediately accelerate and become
vested or nonforfeitable as of the later of (i) the Date of Termination or (ii) the effective date of the Separation Agreement and Release
(such later date being the &ldquo;<U>Accelerated Vesting Date</U>&rdquo;); and provided further that any termination or forfeiture of
the unvested portion of such Time- Based Equity Awards that would otherwise occur on the Date of Termination in the absence of this Agreement
will be delayed until the effective date of the Separation Agreement and Release and will only occur if the vesting pursuant to this subsection
does not occur due to the absence of the Separation Agreement and Release becoming fully effective within the time period set forth therein.
Notwithstanding the foregoing, no additional vesting of the Time-Based Equity Awards shall occur during the period between the Date of
Termination and the Accelerated Vesting Date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">All of your outstanding equity-based awards subject to performance-based vesting (the &ldquo;<U>Performance-Based
Equity Awards</U>&rdquo;) shall immediately accelerate and become vested or nonforfeitable as of the Accelerated Vesting Date with the
performance criteria being deemed to have been met based on the greater of target or, if determinable, actual performance; provided, however,
that the applicable award agreement for any Performance-Based Equity Award may provide for alternative treatment upon a termination covered
by this <U>Section 10.</U></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">The Company shall pay to the group health plan provider(s), the COBRA provider or you a monthly payment
equal to the monthly COBRA continuation premiums until the earliest of (A) the 12-month anniversary of the Date of Termination; (B) your
eligibility for group health plan benefits under any other employer&rsquo;s group health plan; or (C) the cessation of your continuation
rights under COBRA; provided, however, that if the Company reasonably determines that it cannot pay such amounts to the group health plan
provider(s) or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section
2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to you for the time
period specified above. Such payments, if to you, shall be subject to tax-related deductions and withholdings and paid on the Company&rsquo;s
regular payroll dates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the avoidance of doubt, <U>Section 9</U> and
<U>Section 10</U> of this Agreement are mutually exclusive and in no event shall you be entitled to payments or benefits pursuant to both
<U>Section 9</U> and <U>Section 10</U> of this Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 11. Continuing Obligations<FONT STYLE="font-weight: normal">.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify"><B>Business Protection Agreement</B>. You have previously entered into an Invention Assignment, Non-Disclosure
and Business Protection Agreement (the &ldquo;<U>Business Protection Agreement</U>&rdquo;). For purposes of this Agreement, the obligations
in this <U>Section 11</U> and those that arise in the Business Protection Agreement and any other agreement relating to confidentiality,
assignment of inventions, or other restrictive covenants shall collectively be referred to as the &ldquo;<U>Continuing Obligations</U>.&rdquo;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify"><B>Third Party Agreements and Rights</B>. You hereby confirm that you are not bound by the terms of any
agreement with any previous employer or other party that would prevent you from performing your obligations hereunder. You represent to
the Company that your execution of this Agreement, your employment with the Company and the performance of your proposed duties for the
Company will not violate any obligations you may have to any such previous employer or other party. In your work for the Company, you
will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other
party, and you will not bring to the premises of the Company or load or access on any electronic system of the Company, any copies or
other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify"><B>Litigation and Regulatory Cooperation</B>. You shall reasonably cooperate with the Company in (i) the
defense or prosecution of any claims or actions now in existence or that may be brought in the future against or on behalf of the Company
that relate to events or occurrences that transpired while you were engaged or employed by the Company, and (ii) the investigation, whether
internal or external, of any matters about which the Company believes you may have knowledge or information. Your full cooperation in
connection with such claims, actions or investigations shall include, but not be limited to, being reasonably available to meet with counsel
to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times.
During and after your engagement and employment, you also shall reasonably cooperate with the Company in connection with any investigation
or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that
transpired while you were employed by the Company. The Company shall reimburse you for any reasonable out-of-pocket expenses incurred
in connection with your performance of obligations pursuant to this <U>Section 11(c)</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify"><B>Relief</B>. You agree that it would be difficult to measure any damages caused to the Company that
might result from your breach of any of the Continuing Obligations, and that in any event money damages may be an inadequate remedy for
any such breach. Accordingly, you agree that if you breach, or propose to breach, any portion of the Continuing Obligations, the Company
shall be entitled, in addition to all other remedies that it may have, to seek an injunction or other appropriate equitable relief to
restrain any such breach without showing or proving any actual damage to the Company or posting any bond.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 12. Golden Parachute Taxes<FONT STYLE="font-weight: normal">.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify"><B>Best After-Tax Result</B>. In the event that any payment or benefit received or to be received by you
pursuant to this Agreement or otherwise (&ldquo;<U>Payments</U>&rdquo;) would (i) constitute a &ldquo;parachute payment&rdquo; within
the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the &ldquo;<U>Code</U>&rdquo;), and (ii) but for this subsection
(a), be subject to the excise tax imposed by Section 4999 of the Code, any successor provisions, or any comparable federal, state, local
or foreign excise tax (&ldquo;<U>Excise Tax</U>&rdquo;), then, subject to the provisions of Section 14, such Payments shall be either
(A) provided in full pursuant to the terms of this Agreement or any other applicable agreement, or (B) provided as to such lesser extent
that would result in the Payments being $1.00 less than the amount at which any portion of the Payments would be subject to the Excise
Tax, whichever of the foregoing amounts, taking into account the applicable federal, state, local and foreign income, employment and other
taxes and the Excise Tax (including, without limitation, any interest or penalties on such taxes), results in the receipt, on an after-tax
basis, of the greatest amount of payments and benefits provided for hereunder or otherwise, notwithstanding that all or some portion of
such Payments may be subject to the Excise Tax. Unless the Company and you otherwise agree in writing, any determination required under
this Section shall be made by independent tax counsel designated by the Company and reasonably acceptable to you (&ldquo;<U>Independent
Tax Counsel</U>&rdquo;), whose determination shall be conclusive and binding upon you and the Company for all purposes. For purposes of
making the calculations required under this Section, Independent Tax Counsel may make reasonable assumptions and approximations concerning
applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code;
provided that Independent Tax Counsel shall assume that you pay all taxes at the highest marginal rate. The Company and you shall furnish
to Independent Tax Counsel such information and documents as Independent Tax Counsel may reasonably request in order to make a determination
under this Section. The Company shall bear all costs that Independent Tax Counsel may reasonably incur in connection with any calculations
contemplated by this Section. In the event that <U>Section 13(a)(ii)(B)</U> above applies, then based on the information provided to you
and the Company by Independent Tax Counsel, the cutback described hereunder will apply as to compensation not subject to Section 409A
of the Code prior to compensation subject to Section 409A of the Code and will otherwise apply on a reverse chronological basis
from payments latest in time. If the Internal Revenue Service (the &ldquo;<U>IRS</U>&rdquo;) determines that any Payment is subject to
the Excise Tax, then <U>Section 12(b)</U> hereof shall apply, and the enforcement of <U>Section 12(b)</U> shall be the exclusive remedy
to the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify"><B>Adjustments</B>. If, notwithstanding any reduction described in <U>Section 12(a)</U> hereof (or in
the absence of any such reduction), the IRS determines that you are liable for the Excise Tax as a result of the receipt of one or more
Payments, then you shall be obligated to surrender or pay back to the Company within one-hundred 120 days after a final IRS determination,
an amount of such payments or benefits equal to the &ldquo;<U>Repayment Amount</U>.&rdquo; The Repayment Amount with respect to such Payments
shall be the smallest such amount, if any, as shall be required to be surrendered or paid to the Company so that your net proceeds with
respect to such Payments (after taking into account the payment of the Excise Tax imposed on such Payments) shall be maximized. Notwithstanding
the foregoing, the Repayment Amount with respect to such Payments shall be zero if a Repayment Amount of more than zero would not eliminate
the Excise Tax imposed on such Payments or if a Repayment Amount of more than zero would not maximize the net amount received from the
Payments. If the Excise Tax is not eliminated pursuant to this <U>Section 12(b)</U>, you shall pay the Excise Tax.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 13. Section 409A<FONT STYLE="font-weight: normal">.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service
within the meaning of Section 409A of the Code, the Company determines that you are a &ldquo;specified employee&rdquo; within the meaning
of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement or
otherwise on account of your separation from service would be considered deferred compensation otherwise subject to the additional tax
imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall
not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after your separation
from service, or (B) your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall
include a catch- up payment covering amounts that would otherwise have been paid during the six- month period but for the application
of this provision (without interest), and the balance of the installments shall be payable in accordance with their original schedule.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided
by the Company or incurred by you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively
practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which
the expense was incurred. The amount of in- kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect
the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other
aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or
exchange for another benefit.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">To the extent that any payment or benefit described in this Agreement constitutes &ldquo;non- qualified
deferred compensation&rdquo; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the termination
of your employment, then such payments or benefits shall be payable only upon your &ldquo;separation from service.&rdquo; The determination
of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation
Section 1.409A-l(h).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">The parties intend that this Agreement will be administered in accordance with Section 409A of the Code.
To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall
be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement
is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Agreement
may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all
related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify">The Company makes no representation or warranty and shall have no liability to you or any other person
if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not
satisfy an exemption from, or the conditions of, such Section.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>14.   Withholding;
Tax Effect</B>. All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and
payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation
policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to
tax liabilities arising from your compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>15.   Recoupment</B>.
Amounts paid or payable under this Agreement shall be subject to the provisions of any applicable clawback or recoupment policies or procedures
adopted by the Company, which clawback or recoupment policies may provide for forfeiture and/or recoupment of amounts paid or payable
under this Agreement. No forfeiture or recoupment under such policies or procedures will give rise to a right to resign for Good Reason
under this Agreement or under any other agreement between you and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>16.   Interpretation
and Enforcement</B>. This Agreement, together with <U>Appendix A</U>, the Business Protection Agreement and any award agreement between
you and the Company constitute the complete agreement between you and the Company, contains all of the terms of your employment with the
Company and supersedes any prior agreements, representations or understandings (whether written, oral or implied) between you and the
Company. The terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement
or arising out of, related to, or in any way connected with this Agreement, your employment with the Company or any other relationship
between you and the Company (the &ldquo;<U>Disputes</U>&rdquo;) will be governed by federal law to the extent applicable and otherwise
by California law, excluding laws relating to conflicts or choice of law and excluding Disputes arising in connection with any equity
incentive plan, which shall be governed by the terms of the applicable equity incentive plan. You and the Company submit to the exclusive
personal jurisdiction of the federal and state courts located in the County of San Mateo and State of California in connection with any
Dispute or any claim related to any Dispute, except for Disputes
arising under any equity incentive plan, which shall be governed by the terms of the applicable equity incentive plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>17.   Assignment</B>.
Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without
the prior written consent of the other; <I>provided, however</I>, that the Company may assign its rights and obligations under this Agreement
without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate
with, or merge into or to whom it transfers all or substantially all of its properties or assets; provided further, that if you remain
employed or become employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then you
shall not be entitled to any payments, benefits or vesting pursuant to <U>Section 9</U> or pursuant to <U>Section 10</U> of this Agreement
solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon you and the Company, and each
of your and its respective successors, executors, administrators, heirs and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>18.   Waiver;
Amendment</B>. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure
of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this
Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. This
Agreement may be amended or modified only by a written instrument signed by you and by a duly authorized executive officer of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>19.   Enforceability</B>.
If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement)
shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or
the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable,
shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted
by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>20.   Conditions</B>.
You must submit satisfactory proof of your identity, successfully complete a criminal background check, which you hereby expressly authorize
by your execution of this Agreement, and provide documentation of your legal authorization to work in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>21.   Employee
Representations</B>. It is the policy of the Company not to solicit or accept proprietary information and/or trade secrets of other companies
or third parties. If you have or have had access to trade secrets or other confidential, proprietary information from your former employer
or another third party, the use of such information in performing your duties at the Company is prohibited. This may include, but is not
limited to, confidential or proprietary information in the form of documents, magnetic media, software, customer lists, and business plans
or strategies. In making this employment offer, the Company has relied on your representation that: (a) you are not currently a party
to any agreement that would restrict your ability to accept this offer or to perform services for the Company; (b) you are not subject
to any noncompetition or non-solicitation agreement or other restrictive covenants that might restrict your employment by the Company
as contemplated by this offer; (c) you have the full right, power and authority to execute and deliver the Agreement and to perform all
of your obligations thereunder; and (d) you will not bring with you to the Company or use in the performance of your responsibilities
at the Company any materials, documents or work product of a former employer or other third party that are not generally available to
the public, unless you have obtained written authorization from such former employer or third party for their possession and use and have
provided the Company with a copy of same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>22.   Other
Terms</B>. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of your employment
to the extent necessary to effectuate the terms contained herein. The headings and other captions in this Agreement are for convenience
and reference only and shall not be used in interpreting, construing or enforcing any of the provisions of this Agreement. This Agreement
may be executed in separate counterparts. When both counterparts are signed, they shall be treated together as one and the same document.
PDF copies of signed counterparts shall be equally effective as originals. This Agreement may also be executed electronically by any means
that satisfies applicable electronic signature laws (e.g., DocuSign).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To indicate your acceptance of the Company&rsquo;s
offer, please sign this Agreement in the space provided below and return it to me. If you have any questions regarding this letter agreement,
feel free to contact me.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">I look forward to working with you to make the Company
a great success.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">/s/ Lawrence Klein</TD>
  <TD STYLE="width: 60%">&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Lawrence Klein</TD>
  <TD>&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Chief Executive Officer</TD>
  <TD>&nbsp;</TD>
  </TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Accepted and acknowledged:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">/s/ Joana Goncalves</TD>
  <TD STYLE="width: 60%">&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Joana Goncalves</TD>
  <TD>&nbsp;</TD>
  </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Appendix A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">&ldquo;<U>Cause</U>&rdquo; shall mean (i) your dishonest
statements or acts with respect to the Company or any affiliate of the Company, or any current or prospective customers, suppliers, vendors
or other third parties with which such entity does business that results in or is reasonably anticipated to result in material harm to
the Company; (ii) your conviction or plea of no contest to: (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty
or fraud; (iii) your failure to perform in all material respects your lawful assigned duties and responsibilities to the reasonable satisfaction
of the Board, which failure continues, in the reasonable judgment of the Board, for 30 days after written notice given to you describing
such failure; (iv) your gross negligence, willful misconduct that results in or is reasonably anticipated to result in material harm
to the Company; or (v) your violation of any material violation of any agreement(s) between you and the Company or any written Company
policies including, without limitation, agreements relating to non-solicitation, non-disclosure and/or assignment of inventions or policies
related to ethics or workplace conduct.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">&ldquo;<U>Change in Control</U>&rdquo; shall have the meaning
set forth in the Company&rsquo;s 2024 Stock Incentive Plan (or the meaning provided to any word of similar import under any successor
plan).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">&ldquo;<U>Change in Control Period</U>&rdquo; shall mean
the period commencing three months prior to the first event constituting a Change in Control and ending 12 months following the first
event constituting a Change in Control.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">&ldquo;<U>Disability</U>&rdquo; shall mean a permanent and
total disability as defined in Section 22(e) (3) of the Code.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">&ldquo;<U>Good Reason</U>&rdquo; shall mean that you have
complied with the Good Reason Process (hereinafter defined) following the occurrence, without your written consent, of any of the following
events: (i) a material diminution in your base salary or Target Bonus except for across-the-board salary and target bonus reductions
of no more than 10% based on the Company&rsquo;s financial performance similarly affecting all or substantially all senior management
employees of the Company; (ii) a material change in the geographic location at which you are required to provide services to the Company
or a requirement that you change your remote location from your then-current residence; (iii) a material reduction in your duties, authority
or responsibilities; (iv) the failure of the Company to obtain the assumption of this Agreement by a successor; or (v) the material breach
of this Agreement (or any other agreements with you) by the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">6.</TD><TD STYLE="text-align: justify">&ldquo;<U>Good Reason Process</U>&rdquo; shall mean that
(i) you reasonably determine in good faith that a &ldquo;Good Reason&rdquo; condition has occurred; (ii) you notify the Company in writing
of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii) you cooperate in
good faith with the Company&rsquo;s efforts, for a period not less than 30 days following such notice (the &ldquo;<U>Cure Period</U>&rdquo;),
to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) you terminate your
employment within 30 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good
Reason shall be deemed not to have occurred.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>6
<FILENAME>ea023044501ex10-19_orukathe.htm
<DESCRIPTION>FORM OF INDEMNIFICATION AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.19</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEMNIFICATION AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Indemnification Agreement (this &ldquo;<U>Agreement</U>&rdquo;)
is entered into as of __________ by and between Oruka Therapeutics, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and
__________ (the &ldquo;<U>Indemnitee</U>&rdquo;) and shall be deemed effective upon the earliest date that the Indemnitee is duly elected
or appointed as a director or officer of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RECITALS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WHEREAS, the Board of Directors of the Company (the &ldquo;<U>Board</U>&rdquo;)
has determined that the inability to attract and retain qualified persons as directors and officers is detrimental to the best interests
of the Company&rsquo;s stockholders and that the Company should act to assure such persons that there shall be adequate certainty of protection
through insurance and indemnification against risks of claims and actions against them arising out of their service to and activities
on behalf of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WHEREAS, the Company has adopted provisions in its Amended and Restated
Bylaws (as may be amended or restated from time to time, the &ldquo;<U>Bylaws</U>&rdquo;) providing for indemnification and advancement
of expenses of its directors and officers to the fullest extent authorized by the General Corporation Law of the State of Delaware (the
&ldquo;<U>DGCL</U>&rdquo;), and the Company wishes to clarify and enhance the rights and obligations of the Company and the Indemnitee
with respect to indemnification and advancement of expenses;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WHEREAS, in order to induce and encourage highly experienced and capable
persons such as the Indemnitee to serve and continue to serve as directors and officers of the Company and in any other capacity with
respect to the Company as the Company may request, and to otherwise promote the desirable end that such persons shall resist what they
consider unjustified lawsuits and claims made against them in connection with the good faith performance of their duties to the Company,
with the knowledge that certain costs, judgments, penalties, fines, liabilities and expenses incurred by them in their defense of such
litigation are to be borne by the Company and they shall receive appropriate protection against such risks and liabilities, the Board
has determined that the following Agreement is reasonable and prudent to promote and ensure the best interests of the Company and its
stockholders; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WHEREAS, the Company desires to have the Indemnitee serve or continue
to serve as a director or officer of the Company and in any other capacity with respect to the Company as the Company may request, as
the case may be, free from undue concern for unpredictable, inappropriate, or unreasonable legal risks and personal liabilities by reason
of the Indemnitee acting in good faith in the performance of the Indemnitee&rsquo;s duty to the Company; and the Indemnitee desires to
continue so to serve the Company, <U>provided</U>, and on the express condition, that he or she is furnished with the protections set
forth hereinafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AGREEMENT </B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOW, THEREFORE, in consideration of the Indemnitee&rsquo;s service
or continued service as a director or officer of the Company, the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. <U>Definitions</U>. For purposes of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) A &ldquo;<U>Change in Control</U>&rdquo; will be deemed to have
occurred if, with respect to any particular 24-month period, the individuals who, at the beginning of such 24-month period, constituted
the Board (the &ldquo;<U>Incumbent Board</U>&rdquo;) cease for any reason to constitute at least a majority of the Board; <U>provided</U>,
<U>however</U>, that any individual becoming a director subsequent to the beginning of such 24-month period whose election, or nomination
for election by the stockholders of the Company, was approved by a vote of at least a majority of the directors then comprising the Incumbent
Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual
whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal
of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a person other than the Board.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) &ldquo;<U>Disinterested Director</U>&rdquo; means a director of
the Company who is not or was not a party to the Proceeding in respect of which indemnification is being sought by the Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c) &ldquo;<U>Expenses</U>&rdquo; includes, without limitation, expenses
incurred in connection with the defense or settlement of any action, suit, arbitration, alternative dispute resolution mechanism, inquiry,
judicial, administrative, or legislative hearing, investigation, or any other threatened, pending, or completed proceeding, whether brought
by or in the right of the Company or otherwise, including any and all appeals, whether of a civil, criminal, administrative, legislative,
investigative, or other nature, attorneys&rsquo; fees, witness fees and expenses, fees and expenses of accountants and other advisors,
retainers and disbursements and advances thereon, the premium, security for, and other costs relating to any bond (including cost bonds,
appraisal bonds, or their equivalents), and any expenses of establishing a right to indemnification or advancement under this Agreement,
but shall not include the amount of judgments, fines, ERISA excise taxes, or penalties actually levied against the Indemnitee, or any
amounts paid in settlement by or on behalf of the Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) &ldquo;<U>Independent Counsel</U>&rdquo; means a law firm or a
member of a law firm that neither is presently nor in the past five years has been retained to represent (i) the Company or the Indemnitee
in any matter material to either such party or (ii) any other party to the Proceeding giving rise to a request for indemnification hereunder.
Notwithstanding the foregoing, the term &ldquo;Independent Counsel&rdquo; shall not include any person who, under the applicable standards
of professional conduct then prevailing, would have a conflict of interest in representing either the Company or the Indemnitee in an
action to determine the Indemnitee&rsquo;s right to indemnification under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(e) &ldquo;<U>Proceeding</U>&rdquo; means any action, suit, arbitration,
alternative dispute resolution mechanism, inquiry, judicial, administrative, or legislative hearing, investigation, or any other threatened,
pending, or completed proceeding, whether brought by or in the right of the Company or otherwise, including any and all appeals, whether
of a civil, criminal, administrative, legislative, investigative, or other nature, to which the Indemnitee was or is a party or is threatened
to be made a party or is otherwise involved in by reason of the fact that the Indemnitee is or was a director, officer, employee, agent,
or trustee of the Company or while a director, officer, employee, agent, or trustee of the Company is or was serving at the request of
the Company as a director, officer, employee, agent, or trustee of another corporation or of a partnership, joint venture, trust, or other
enterprise, including service with respect to an employee benefit plan (such status, the Indemnitee&rsquo;s &ldquo;<U>Corporate Status</U>&rdquo;),
or by reason of anything done or not done by the Indemnitee in any such capacity, whether or not the Indemnitee is serving in such capacity
at the time any expense, liability, or loss is incurred for which indemnification or advancement can be provided under this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. <U>Service by the Indemnitee</U>. The Indemnitee shall serve and/or
continue to serve as a director or officer of the Company faithfully and to the best of the Indemnitee&rsquo;s ability so long as the
Indemnitee is duly elected or appointed and until such time as the Indemnitee&rsquo;s successor is elected and qualified or the Indemnitee
is removed as permitted by applicable law or tenders a resignation in writing.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3. <U>Indemnification and Advancement of Expenses</U>. The Company
shall indemnify and hold harmless the Indemnitee, and shall pay to the Indemnitee in advance of the final disposition of any Proceeding
all Expenses incurred by the Indemnitee in defending any such Proceeding, to the fullest extent authorized by the DGCL, as the same exists
or may hereafter be amended, all on the terms and conditions set forth in this Agreement. Without diminishing the scope of the rights
provided by this Section, the rights of the Indemnitee to indemnification and advancement of Expenses provided hereunder shall include
but shall not be limited to those rights hereinafter set forth, except that no indemnification or advancement of Expenses shall be paid
to the Indemnitee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) to the extent expressly prohibited by applicable law or the Amended
and Restated Certificate of Incorporation of the Company (as may be amended or restated from time to time, the &ldquo;<U>Certificate of
Incorporation</U>&rdquo;) and the Bylaws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) for and to the extent that payment is actually made to the Indemnitee
under a valid and collectible insurance policy or under a valid and enforceable indemnity clause, provision of the certificate of incorporation
or bylaws, or agreement of the Company or any other company or other enterprise (and the Indemnitee shall reimburse the Company for any
amounts paid by the Company and subsequently so recovered by the Indemnitee); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c) in connection with an action, suit, or proceeding, or part thereof
voluntarily initiated by the Indemnitee (including claims and counterclaims, whether such counterclaims are asserted by (i) the Indemnitee,
or (ii) the Company in an action, suit, or proceeding initiated by the Indemnitee), except a judicial proceeding pursuant to Section 11
to enforce rights under this Agreement, unless (A) the action, suit, or proceeding, or part thereof, was authorized or ratified by the
Board or the Board otherwise determines that indemnification or advancement of Expenses is appropriate or (B) the Company provides the
indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4. <U>Action or Proceedings Other than an Action by or in the Right
of the Company</U>. Except as limited by Section 3 above, the Indemnitee shall be entitled to the indemnification rights provided in this
Section if the Indemnitee was or is a party or is threatened to be made a party to, or was or is otherwise involved in, any Proceeding
(other than an action by or in the right of the Company) by reason of the Indemnitee&rsquo;s Corporate Status, or by reason of anything
done or not done by the Indemnitee in any such capacity. Pursuant to this Section, the Indemnitee shall be indemnified against all expense,
liability, and loss (including judgments, fines, ERISA excise taxes or penalties, amounts paid in settlement by or on behalf of the Indemnitee,
and Expenses) actually and reasonably incurred by the Indemnitee, or on behalf of the Indemnitee, in connection with such Proceeding,
if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in or not opposed to the best interests
of the Company, and with respect to any criminal Proceeding, had no reasonable cause to believe his or her conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5. <U>Indemnity in Proceedings by or in the Right of the Company</U>.
Except as limited by Section 3 above, the Indemnitee shall be entitled to the indemnification rights provided in this Section if the Indemnitee
was or is a party or is threatened to be made a party to, or was or is otherwise involved in, any Proceeding brought by or in the right
of the Company to procure a judgment in its favor by reason of the Indemnitee&rsquo;s Corporate Status, or by reason of anything done
or not done by the Indemnitee in any such capacity. Pursuant to this Section, the Indemnitee shall be indemnified against all Expenses
actually and reasonably incurred by the Indemnitee, or on behalf of the Indemnitee, in connection with such Proceeding if the Indemnitee
acted in good faith and in a manner the Indemnitee reasonably believed to be in or not opposed to the best interests of the Company; <U>provided</U>,
<U>however</U>, that no such indemnification shall be made in respect of any claim, issue, or matter as to which the DGCL expressly prohibits
such indemnification by reason of any adjudication of liability of the Indemnitee to the Company, unless and only to the extent that the
Court of Chancery of the State of Delaware or the court in which such Proceeding was brought shall determine upon application that, despite
the adjudication of liability but in view of all the circumstances of the case, the Indemnitee is entitled to indemnification for such
expense, liability, and loss as such court shall deem proper.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6. <U>Indemnification for Costs, Charges, and Expenses of Successful
Party</U>. Notwithstanding any limitations of Sections 3(c), 4, and 5 above, to the extent that the Indemnitee has been successful, on
the merits or otherwise, in whole or in part, in defense of any Proceeding, or in defense of any claim, issue, or matter therein, including,
without limitation, the dismissal of any action without prejudice, or if it is ultimately determined, by final judicial decision of a
court of competent jurisdiction from which there is no further right to appeal, that the Indemnitee is otherwise entitled to be indemnified
against Expenses, the Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by the Indemnitee in connection
therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7. <U>Partial Indemnification</U>. If the Indemnitee is entitled under
any provision of this Agreement to indemnification by the Company for some or a portion of the expense, liability, and loss (including
judgments, fines, ERISA excise taxes or penalties, amounts paid in settlement by or on behalf of the Indemnitee, and Expenses) actually
and reasonably incurred in connection with any Proceeding, or in connection with any judicial proceeding pursuant to Section 11 to enforce
rights under this Agreement, but not, however, for all of the total amount thereof, the Company shall nevertheless indemnify the Indemnitee
for the portion of such expense, liability, and loss actually and reasonably incurred to which the Indemnitee is entitled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8. <U>Indemnification for Expenses of a Witness</U>. Notwithstanding
any other provision of this Agreement, to the maximum extent permitted by the DGCL, the Indemnitee shall be entitled to indemnification
against all Expenses actually and reasonably incurred by the Indemnitee or on the Indemnitee&rsquo;s behalf if the Indemnitee appears
as a witness or otherwise incurs legal expenses as a result of or related to the Indemnitee&rsquo;s service as a director or officer of
the Company, in any threatened, pending, or completed action, suit, arbitration, alternative dispute resolution mechanism, inquiry, judicial,
administrative, or legislative hearing, investigation, or any other threatened, pending, or completed proceeding, whether of a civil,
criminal, administrative, legislative, investigative, or other nature, to which the Indemnitee neither is, nor is threatened to be made,
a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9. <U>Determination of Entitlement to Indemnification</U>. To receive
indemnification under this Agreement, the Indemnitee shall submit a written request to the Secretary of the Company. Such request shall
include documentation or information that is necessary for such determination and is reasonably available to the Indemnitee. Upon receipt
by the Secretary of the Company of a written request by the Indemnitee for indemnification pursuant to this Agreement, the entitlement
of the Indemnitee to indemnification, to the extent not provided pursuant to the terms of this Agreement, shall be determined by the following
person or persons who shall be empowered to make such determination (as selected by the Board, except with respect to Section 9(e) below):
(a) the Board by a majority vote of Disinterested Directors, whether or not such majority constitutes a quorum; (b) a committee of Disinterested
Directors designated by a majority vote of such directors, whether or not such majority constitutes a quorum; (c) if there are no Disinterested
Directors, or if the Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall
be delivered to the Indemnitee; (d) the stockholders of the Company; or (e) in the event that a Change in Control has occurred, by Independent
Counsel in a written opinion to the Board, a copy of which shall be delivered to the Indemnitee. Such Independent Counsel shall be selected
by the Board and approved by the Indemnitee, except that in the event that a Change in Control has occurred, Independent Counsel shall
be selected by the Indemnitee. Upon failure of the Board so to select such Independent Counsel or upon failure of the Indemnitee so to
approve (or so to select, in the event a Change in Control has occurred), such Independent Counsel shall be selected upon application
to a court of competent jurisdiction. The determination of entitlement to indemnification shall be made and, unless a contrary determination
is made, such indemnification shall be paid in full by the Company not later than 60 calendar days after receipt by the Secretary of the
Company of a written request for indemnification. If the person making such determination shall determine that the Indemnitee is entitled
to indemnification as to part (but not all) of the application for indemnification, such person shall reasonably prorate such partial
indemnification among the claims, issues, or matters at issue at the time of the determination.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10. <U>Presumptions and Effect of Certain Proceedings</U>. The Secretary
of the Company shall, promptly upon receipt of the Indemnitee&rsquo;s written request for indemnification, advise in writing the Board
or such other person or persons empowered to make the determination as provided in Section 9 that the Indemnitee has made such request
for indemnification. Upon making such request for indemnification, the Indemnitee shall be presumed to be entitled to indemnification
hereunder and the Company shall have the burden of proof in making any determination contrary to such presumption. If the person or persons
so empowered to make such determination shall have failed to make the requested determination with respect to indemnification within 60
calendar days after receipt by the Secretary of the Company of such request, a requisite determination of entitlement to indemnification
shall be deemed to have been made and the Indemnitee shall be absolutely entitled to such indemnification, absent actual fraud in the
request for indemnification. The termination of any Proceeding described in Sections 4 or 5 by judgment, order, settlement, or conviction,
or upon a plea of <I>nolo contendere</I> or its equivalent, shall not, of itself (a) create a presumption that the Indemnitee did not
act in good faith and in a manner the Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, or
with respect to any criminal Proceeding, had reasonable cause to believe his or her conduct was unlawful or (b) otherwise adversely affect
the rights of the Indemnitee to indemnification except as may be provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">11. <U>Remedies of the Indemnitee in Cases of Determination Not to
Indemnify or to Advance Expenses; Right to Bring Suit</U>. In the event that a determination is made that the Indemnitee is not entitled
to indemnification hereunder or if payment is not timely made following a determination of entitlement to indemnification pursuant to
Sections 9 and 10, or if an advancement of Expenses is not timely made pursuant to Section 16, the Indemnitee may at any time thereafter
bring suit against the Company seeking an adjudication of entitlement to such indemnification or advancement of Expenses, and any such
suit shall be brought in the Court of Chancery of the State of Delaware unless, if the Indemnitee is an employee of the Company, otherwise
required by the law of the state in which the Indemnitee primarily resides and works. The Company shall not oppose the Indemnitee&rsquo;s
right to seek any such adjudication. In any suit brought by the Indemnitee to enforce a right to indemnification hereunder (but not in
a suit brought by the Indemnitee to enforce a right to an advancement of Expenses), it shall be a defense that the Indemnitee has not
met any applicable standard of conduct for indemnification set forth in the DGCL, including the standard described in Section 4 or 5,
as applicable. Further, in any suit brought by the Company to recover an advancement of Expenses pursuant to the terms of an undertaking,
the Company shall be entitled to recover such Expenses upon a final judicial decision of a court of competent jurisdiction from which
there is no further right to appeal that the Indemnitee has not met the standard of conduct described above. Neither the failure of the
Company (including the Disinterested Directors, a committee of Disinterested Directors, Independent Counsel, or its stockholders) to have
made a determination prior to the commencement of such suit that indemnification of the Indemnitee is proper in the circumstances because
the Indemnitee has met the standard of conduct described above, nor an actual determination by the Company (including the Disinterested
Directors, a committee of Disinterested Directors, Independent Counsel, or its stockholders) that the Indemnitee has not met the standard
of conduct described above shall create a presumption that the Indemnitee has not met the standard of conduct described above, or, in
the case of such a suit brought by the Indemnitee, be a defense to such suit. In any suit brought by the Indemnitee to enforce a right
to indemnification or to an advancement of Expenses hereunder, or brought by the Company to recover an advancement of Expenses pursuant
to the terms of an undertaking, the burden of proving that the Indemnitee is not entitled to be indemnified, or to such advancement of
Expenses, under this Section 11 or otherwise shall be on the Company. If a determination is made or deemed to have been made pursuant
to the terms of Section 9 or 10 that the Indemnitee is entitled to indemnification, the Company shall be bound by such determination and
is precluded from asserting that such determination has not been made or that the procedure by which such determination was made is not
valid, binding, and enforceable. The Company further agrees to stipulate in any court pursuant to this Section 11 that the Company is
bound by all the provisions of this Agreement and is precluded from making any assertions to the contrary. If the court shall determine
that the Indemnitee is entitled to any indemnification or advancement of Expenses hereunder, the Company shall pay all Expenses actually
and reasonably incurred by the Indemnitee in connection with such adjudication (including, but not limited to, any appellate proceedings)
to the fullest extent permitted by law, and in any suit brought by the Company to recover an advancement of Expenses pursuant to the terms
of an undertaking, the Company shall pay all Expenses actually and reasonably incurred by the Indemnitee in connection with such suit
to the extent the Indemnitee has been successful, on the merits or otherwise, in whole or in part, in defense of such suit, to the fullest
extent permitted by law.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">12. <U>Non-Exclusivity of Rights; Survival of Rights; Insurance; Subrogation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) The rights provided by this Agreement shall not be deemed exclusive
of any other rights to which the Indemnitee may at any time be entitled under applicable law, the Certificate of Incorporation, or Bylaws,
any agreement, a vote of stockholders, a resolution of the Board, or otherwise. No amendment, alteration or repeal of this Agreement or
of any provision of this Agreement shall limit or restrict any right of the Indemnitee under this Agreement in respect of any action taken
or omitted by the Indemnitee in his or her Corporate Status prior to such amendment, alteration or repeal. To the extent that a change
in the DGCL, whether by statute or judicial decision, permits greater indemnification than would be afforded under the current Certificate
of Incorporation or Bylaws and this Agreement, it is the intent of the parties hereto that the Indemnitee shall enjoy by this Agreement
the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or
remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or
hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall
not prevent the concurrent assertion or employment of any other right or remedy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) To the extent that the Company maintains an insurance policy or
policies providing liability insurance for directors, officers, employees, or agents or fiduciaries of the Company or of any other corporation,
partnership, joint venture, trust, employee benefit plan or other enterprise that such person serves at the request of the Company, the
Company shall obtain coverage for the Indemnitee under such policy or policies in accordance with its or their terms to the maximum extent
of the coverage available for any other director (if the Indemnitee is a director) or officer (if the Indemnitee is not a director but
is an officer) of the Company under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms
of this Agreement, the Company has director and officer liability insurance in effect, the Company shall give notice of the commencement
of such proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter
take all commercially reasonable steps to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of
such proceeding in accordance with the terms of such policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c) In the event of any payment under this Agreement, [subject to the
exceptions contained in Section 12(d) below,]<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1</SUP></FONT> the Company
shall be subrogated to the extent of such payment to all of the rights of recovery of the Indemnitee, who shall execute all papers required
and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company effectively
to bring suit to enforce such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT></TD><TD STYLE="text-align: justify"><B><U>Note to Draft</U></B>: This clause will only apply to
directors who are separately indemnified by an entity in connection with their appointment to the Board.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) [The Company hereby acknowledges that Indemnitee has certain rights
to indemnification, advancement of expenses and/or insurance provided by ____________ and/or [their/its] affiliates (collectively, the
&ldquo;<U>Designee Indemnitors</U>&rdquo;). The Company hereby agrees (i) that it is the indemnitor of first resort vis-&agrave;-vis the
Designee Indemnitors (i.e., its obligations to Indemnitee are primary and any obligation of the Designee Indemnitors to advance expenses
or to provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary), (ii) that it shall be required
to advance the full amount of Expenses incurred by Indemnitee and shall be liable for the full amount of all indemnity amounts to the
extent required by the terms of this Agreement and the Bylaws, without regard to any rights Indemnitee may have against the Designee Indemnitors,
and (iii) notwithstanding any other provision in this Agreement or the Bylaws, that it irrevocably waives, relinquishes and releases the
Designee Indemnitors from any and all claims against the Designee Indemnitors for contribution, subrogation or any other recovery of any
kind in respect thereof. The Company further agrees that no advancement or payment by the Designee Indemnitors on behalf of Indemnitee
with respect to any claim for which Indemnitee has sought indemnification from the Company shall affect the foregoing and the Designee
Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights
of recovery of Indemnitee against the Company. The Designee Indemnitors are express third-party beneficiaries of this Section 12(d).]<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>2</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(e) The Company shall not be liable under this Agreement to make any
payment of amounts otherwise indemnifiable hereunder if and to the extent that the Indemnitee has otherwise actually received such payment
under any insurance policy, contract, agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(f) The Company&rsquo;s obligation to indemnify or advance Expenses
hereunder to the Indemnitee who is or was serving at the request of the Company as a director, officer, employee or agent of any other
corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount the Indemnitee
has actually received as indemnification or advancement of expenses from such other corporation, partnership, joint venture, trust, employee
benefit plan or other enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">13. <U>Expenses to Enforce Agreement</U>. In the event that the Indemnitee
is subject to or intervenes in any action, suit, or proceeding in which the validity or enforceability of this Agreement is at issue or
seeks an adjudication to enforce the Indemnitee&rsquo;s rights under, or to recover damages for breach of, this Agreement, the Indemnitee,
if the Indemnitee prevails in whole or in part in such action, suit, or proceeding, shall be entitled to recover from the Company and
shall be indemnified by the Company against any Expenses actually and reasonably incurred by the Indemnitee in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">14. <U>Continuation of Indemnity</U>. All agreements and obligations
of the Company contained herein shall continue during the period the Indemnitee is a director, officer, employee, agent, or trustee of
the Company or while a director, officer, employee, agent, or trustee is serving at the request of the Company as a director, officer,
employee, agent, or trustee of another corporation or of a partnership, joint venture, trust, or other enterprise, including service with
respect to an employee benefit plan, and shall continue thereafter with respect to any possible claims based on the fact that the Indemnitee
was a director, officer, employee, agent, or trustee of the Company or was serving at the request of the Company as a director, officer,
employee, agent, or trustee of another corporation or of a partnership, joint venture, trust, or other enterprise, including service with
respect to an employee benefit plan. This Agreement shall be binding upon all successors and assigns of the Company (including any transferee
of all or substantially all of its assets and any successor by merger or operation of law) and shall inure to the benefit of the Indemnitee&rsquo;s
heirs, executors, and administrators.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT></TD><TD STYLE="text-align: justify"><B><U>Note to Draft</U></B>: This clause will only apply to
directors who are separately indemnified by an entity in connection with their appointment to the Board.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">15. <U>Notification and Defense of Proceeding</U>. Promptly after receipt
by the Indemnitee of notice of any Proceeding, the Indemnitee shall, if a request for indemnification or an advancement of Expenses in
respect thereof is to be made against the Company under this Agreement, notify the Company in writing of the commencement thereof; but
the omission so to notify the Company shall not relieve it from any liability that it may have to the Indemnitee unless, and to the extent
that, such failure actually and materially prejudices the interests of the Company. Notwithstanding any other provision of this Agreement,
with respect to any such Proceeding of which the Indemnitee notifies the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) The Company shall be entitled to participate therein at its own
expense;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) Except as otherwise provided in this Section 15(b), to the extent
that it may wish, the Company, jointly with any other indemnifying party similarly notified, shall be entitled to assume the defense thereof,
with counsel satisfactory to the Indemnitee. After notice from the Company to the Indemnitee of its election so to assume the defense
thereof, the Company shall not be liable to the Indemnitee under this Agreement for any expenses of counsel subsequently incurred by the
Indemnitee in connection with the defense thereof except as otherwise provided below. The Indemnitee shall have the right to employ the
Indemnitee&rsquo;s own counsel in such Proceeding, but the fees and expenses of such counsel incurred after notice from the Company of
its assumption of the defense thereof shall be at the expense of the Indemnitee unless (i) the employment of counsel by the Indemnitee
has been authorized by the Company, (ii) the Indemnitee shall have reasonably concluded that there may be a conflict of interest between
the Company and the Indemnitee in the conduct of the defense of such Proceeding, or (iii) the Company shall not within 60 calendar days
of receipt of notice from the Indemnitee in fact have employed counsel to assume the defense of the Proceeding, in each of which cases
the fees and expenses of the Indemnitee&rsquo;s counsel shall be at the expense of the Company. The Company shall not be entitled to assume
the defense of any Proceeding brought by or on behalf of the Company or as to which the Indemnitee shall have made the conclusion provided
for in (ii) above; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c) Notwithstanding any other provision of this Agreement, the Company
shall not be liable to indemnify the Indemnitee under this Agreement for any amounts paid in settlement of any Proceeding effected without
the Company&rsquo;s written consent, or for any judicial or other award, if the Company was not given an opportunity, in accordance with
this Section 15, to participate in the defense of such Proceeding. The Company shall not settle any Proceeding in any manner that would
impose any penalty or limitation on or disclosure obligation with respect to the Indemnitee, or that would directly or indirectly constitute
or impose any admission or acknowledgment of fault or culpability with respect to the Indemnitee, without the Indemnitee&rsquo;s written
consent. Neither the Company nor the Indemnitee shall unreasonably withhold its consent to any proposed settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">16. <U>Advancement of Expenses</U>. All Expenses incurred by the Indemnitee
in defending any Proceeding described in Sections 4 or 5 shall be paid by the Company in advance of the final disposition of such Proceeding
at the request of the Indemnitee. Notwithstanding the foregoing, the Company shall not advance or continue to advance Expenses to the
Indemnitee if a determination is reasonably made that the facts known at the time such determination is made demonstrate clearly and convincingly
that the Indemnitee acted in bad faith or in a manner that the Indemnitee did not reasonably believe to be in or not opposed to the best
interests of the Company, or, with respect to any criminal Proceeding, that the Indemnitee had reasonable cause to believe his or her
conduct was unlawful. Such determination shall be made: (i) by the Board by a majority vote of directors who are not parties to such proceeding,
whether or not such majority constitutes a quorum; (ii) by a committee of such directors designated by a majority vote of such directors,
whether or not such majority constitutes a quorum; or (iii) if there are no such directors, or if such directors so direct, by Independent
Counsel in a written opinion to the Board, a copy of which shall be delivered to the Indemnitee. To receive an advancement of Expenses
under this Agreement, the Indemnitee shall submit a written request to the Secretary of the Company. Such request shall reasonably evidence
the Expenses incurred by the Indemnitee and shall include or be accompanied by an undertaking, by or on behalf of the Indemnitee, to repay
all amounts so advanced if it shall ultimately be determined, by final judicial decision of a court of competent jurisdiction from which
there is no further right to appeal, that the Indemnitee is not entitled to be indemnified for such Expenses by the Company as provided
by this Agreement or otherwise. The Indemnitee&rsquo;s undertaking to repay any such amounts is not required to be secured. Each such
advancement of Expenses shall be made within 20 calendar days after the receipt by the Secretary of the Company of such written request.
The Indemnitee&rsquo;s entitlement to Expenses under this Agreement shall include those incurred in connection with any action, suit,
or proceeding by the Indemnitee seeking an adjudication pursuant to Section 11 of this Agreement (including the enforcement of this provision)
to the extent the court shall determine that the Indemnitee is entitled to an advancement of Expenses hereunder.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">17. <U>Severability; Prior Indemnification Agreements</U>. If any provision
or provisions of this Agreement shall be held to be invalid, illegal, or unenforceable as applied to any person or entity or circumstance
for any reason whatsoever, then, to the fullest extent permitted by law (a) the validity, legality, and enforceability of such provision
in any other circumstance and of the remaining provisions of this Agreement (including, without limitation, all portions of any paragraphs
of this Agreement containing any such provision held to be invalid, illegal, or unenforceable, that are not by themselves invalid, illegal,
or unenforceable) and the application of such provision to other persons or entities or circumstances shall not in any way be affected
or impaired thereby, and (b) to the fullest extent possible, the provisions of this Agreement (including, without limitation, all portions
of any paragraph of this Agreement containing any such provision held to be invalid, illegal, or unenforceable, that are not themselves
invalid, illegal, or unenforceable) shall be construed so as to give effect to the intent of the parties that the Company provide protection
to the Indemnitee to the fullest enforceable extent set forth in this Agreement. This Agreement shall supersede and replace any prior
indemnification agreements entered into by and between the Company and the Indemnitee and any such prior agreements shall be terminated
upon execution of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">18. <U>Headings; References; Pronouns</U>. The headings of the sections
of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction
thereof. References herein to section numbers are to sections of this Agreement. All pronouns and any variations thereof shall be deemed
to refer to the singular or plural as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">19. <U>Other Provisions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) This Agreement and all disputes or controversies arising out of
or related to this Agreement shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without
regard to the laws of any other jurisdiction that might be applied because of conflicts of laws principles of the State of Delaware, unless,
if the Indemnitee is an employee of the Company, otherwise required by the law of the state in which the Indemnitee primarily resides
and works.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) This Agreement may be executed in two or more counterparts, all
of which shall be considered one and the same instrument and shall become effective when one or more counterparts have been signed by
each of the parties and delivered to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c) This Agreement shall not be deemed an employment contract between
the Company and any Indemnitee who is an officer of the Company, and, if the Indemnitee is an officer of the Company, the Indemnitee specifically
acknowledges that the Indemnitee may be discharged at any time for any reason, with or without cause, and with or without severance compensation,
except as may be otherwise provided in a separate written contract between the Indemnitee and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) This Agreement may not be amended, modified, or supplemented in
any manner, whether by course of conduct or otherwise, except by an instrument in writing specifically designated as an amendment hereto,
signed on behalf of each party. No failure or delay of either party in exercising any right or remedy hereunder shall operate as a waiver
thereof, and no single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such right
or power, or any course of conduct, shall preclude any other or further exercise thereof or the exercise of any other right or power.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[The remainder of this page is intentionally left
blank.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IN WITNESS WHEREOF, the Company and the Indemnitee have caused this
Agreement to be executed as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">ORUKA THERAPEUTICS, INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Indemnitee: </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">[Signature
Page to Indemnification Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>7
<FILENAME>ea023044501ex10-20_orukathe.htm
<DESCRIPTION>NON-EMPLOYEE DIRECTORS COMPENSATION PROGRAM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.20</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Oruka Therapeutics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Non-Employee Directors Compensation
Program</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Each of our non-employee directors receives compensation
pursuant to the non-employee director cash and equity compensation program adopted by our Board. This program provides for the following
annual cash retainers:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Annual Cash Retainer</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">40,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Annual Board Chair Retainer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Audit Committee Retainers:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">Chair</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">15,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Non-Chair Member</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Compensation Committee Retainers:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in">Chair</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Non-Chair Member</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Nominating and Corporate Governance Committee Retainers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">Chair</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Non-Chair Member</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
connection with the Company&rsquo;s annual meeting of stockholders, each member of the Board will receive an annual grant of stock options
</FONT>to purchase 17,500 shares of common stock, which will vest in equal monthly installments over 12 months so long as such director
joined the Board prior to January 1 of the year in which such annual meeting occurs. In addition, in connection with a non-employee director&rsquo;s
initial appointment to the Board, they will receive an initial grant of stock options to purchase 35,000 shares of common stock, which
will vest in equal monthly installments over 36 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 13pt">All members of the Board are
also reimbursed for reasonable and documented out-of-pocket travel and lodging expenses incurred in connection with attending meetings
and activities of the Board and its committees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 13pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>8
<FILENAME>ea023044501ex10-29_orukathe.htm
<DESCRIPTION>IL-17 LICENSE AGREEMENT BY AND BETWEEN PARAGON THERAPEUTICS, INC. AND ORUKA THERAPEUTICS, INC., DATED FEBRUARY 4, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 10.29</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>[***]
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>INFORMATION (I)&nbsp;IS
NOT MATERIAL AND (II) IS THE TYPE THAT THE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</B></FONT></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">IL-17 LICENSE AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>This
License Agreement</B></FONT> (&ldquo;<B>Agreement</B>&rdquo;) is entered into and effective as of February 4, 2025 (the &ldquo;<B>Effective
Date</B>&rdquo;), by and between Paragon Therapeutics, Inc., a Delaware corporation (&ldquo;<B>Paragon</B>&rdquo;), and Oruka Therapeutics,
Inc., a Delaware corporation (&ldquo;<B>Oruka</B>&rdquo;). Paragon and Oruka are also referred to herein individually as a &ldquo;<B>Party</B>&rdquo;,
or collectively as the &ldquo;<B>Parties</B>.&rdquo;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: normal; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: normal; text-transform: uppercase">Recitals</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Whereas</B>,</FONT>
Paragon has developed a proprietary platform technology for the discovery and development of antibodies against therapeutically relevant
targets<FONT STYLE="background-color: white">;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps; background-color: white"><B>Whereas</B>,</FONT>
<FONT STYLE="background-color: white">pursuant to that certain Amended and Restated Antibody Discovery and Option Agreement by and among
Paragon, Oruka and Paruka Holding, LLC, a Delaware limited liability company, dated as of March 28, 2024 (as such agreement may be further
amended from time to time, the &ldquo;<B>Option Agreement</B>&rdquo;), </FONT>Oruka has engaged Paragon to identify, evaluate and develop
one or more antibody candidates directed to certain therapeutic targets and has been granted an exclusive option to enter into one or
more separate license agreements to develop, manufacture and commercialize the resulting antibodies with respect to a given target;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Whereas</B></FONT>,
Oruka has exercised such option with respect to the Licensed Target (as defined below), and the Parties desire to memorialize the exclusive
license from Paragon to Oruka with respect to such Licensed Target, all on the terms and subject to the conditions set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Now
Therefore, </B></FONT>in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article&nbsp;I</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"></FONT>DEFINITIONS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following initially capitalized
terms have the following meanings (and derivative forms of them shall be interpreted accordingly):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1&nbsp;&ldquo;<B>Achievement
of Development Candidate</B>&rdquo; means the first to occur of: (a)&nbsp;nomination by Oruka&rsquo;s Board of Directors of an Oruka Product
as a &ldquo;Development Candidate&rdquo;; and (b)&nbsp;the&nbsp;initiation by or on behalf of Oruka or its Affiliate or Sublicensee of
a toxicology study with respect to an Oruka Product that employs applicable then-current good laboratory practice standards, the results
of which are intended to be submitted as part of an IND.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.2&nbsp;&ldquo;<B>Acquired
Program</B>&rdquo; has the meaning set forth in Section 2.2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.3&nbsp;&ldquo;<B>Acquiring
Entity</B>&rdquo; means, collectively, the Third Party referenced in the definition of Change of Control and such Third Party&rsquo;s
Affiliates, other than (a) the applicable Party in the definition of Change of Control, and (b) such Party&rsquo;s Affiliates, determined
immediately prior to the closing of such Change of Control ((a) and (b) collectively, the &ldquo;<B>Pre-Existing Entities</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.4&nbsp;&ldquo;<B>Affiliate</B>&rdquo;
means any entity controlled by, controlling, or under common control with a Party hereto. For the purpose of this definition, &ldquo;control&rdquo;
(including, with correlative meaning, the terms &ldquo;controlled by&rdquo; or &ldquo;under common control&rdquo;) means the direct or
indirect ownership of more than fifty percent (50%) of the voting interest in, or more than fifty percent (50%) in the equity of, or the
right to appoint more than fifty percent (50%) of the directors or management of, such corporation or other business entity. Notwithstanding
the foregoing, (a) with respect to either Party, Affiliates of such Party do not include <FONT STYLE="font-variant: small-caps">[***]</FONT>
or its Affiliates other than such Party and its subsidiaries, (b) Paragon and its Affiliates, on the one hand, and Oruka and its subsidiaries,
on the other hand, shall not be deemed to be Affiliates of each other, and (c) Affiliates of Paragon do not include new entities formed
by or on behalf of Paragon for the sole <I>bona fide </I>purpose of further developing, manufacturing, commercializing or otherwise exploiting
Antibodies and Antibody products (excluding any Licensed Antibody Technology or Other Licensed Technology) using, among other sources,
funds from Third Party investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.5&nbsp;&ldquo;<B>Agreement</B>&rdquo;
has the meaning set forth in the preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.6&nbsp;&ldquo;<B>Annual
Net Sales</B>&rdquo; means total Net Sales by Oruka, its Affiliates and Sublicensees in the Territory of all of the Products in a particular
Calendar Year, calculated in accordance with U.S. generally accepted accounting principles (GAAP) consistently applied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.7&nbsp;&ldquo;<B>Anti-Corruption
Laws</B>&rdquo; has the meaning set forth in Section 7.2(q)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.8&nbsp;&ldquo;<B>Antibody</B>&rdquo;
means any molecule, including <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.9&nbsp;&ldquo;<B>Applicable
Law</B>&rdquo; means any national, supra-national, federal, state or local laws, rules, guidances, and regulations, in each case, as applicable
to the subject matter and the Party at issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.10&nbsp;&ldquo;<B>Bankruptcy
Code</B>&rdquo; has the meaning set forth in Section 8.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.11&nbsp;&ldquo;<B>Bankruptcy
Event</B>&rdquo; has the meaning set forth in Section 8.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.12&nbsp;&ldquo;<B>Business
Day</B>&rdquo; means any day other than Saturday, Sunday or a national holiday in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.13&nbsp;&ldquo;<B>Calendar
Quarter</B>&rdquo; means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and
December 31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.14&nbsp;&ldquo;<B>Calendar
Year</B>&rdquo; means each successive period of twelve (12) months commencing on January 1 and ending on December 31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.15&nbsp;&ldquo;<B>Change
of Control</B>&rdquo; means, with respect to any entity, any of the following: (a)&nbsp;the sale or disposition of all or substantially
all of the assets of such entity or its direct or indirect controlling Affiliate to a Third Party; or (b) (i) the acquisition by a Third
Party, alone or together with any of its Affiliates, other than an employee benefit plan (or related trust) sponsored or maintained by
such entity or any of its Affiliates, of more than fifty percent (50%) of the then-outstanding shares of voting capital stock of such
entity or its direct or indirect parent entity that holds, directly or indirectly, beneficial ownership of more than fifty percent (50%)
of the then-outstanding shares of voting capital stock of such entity (a &ldquo;<B>Parent Entity</B>&rdquo;), or (ii) the acquisition,
merger or consolidation of such entity or its Parent Entity with or into another entity, other than, in the case of clause (i) or (ii),
an acquisition or a merger or consolidation of such entity or its Parent Entity in which the holders of shares of voting capital stock
of such entity or its Parent Entity, as the case may be, immediately prior to such acquisition, merger or consolidation will beneficially
own, directly or indirectly, at least fifty percent (50%) of the shares of voting capital stock of the acquiring Third Party or the surviving
corporation in such acquisition, merger or consolidation, as the case may be, immediately after such acquisition, merger or consolidation,
and in each case of (a) or (b), whether through a single transaction or a series of related transactions, but excluding any and all <I>bona
fide</I> financing transactions or internal reorganizations for tax purposes (including the change of place of incorporation or domicile
of such entity).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.16&nbsp;&ldquo;<B>Claim</B>&rdquo;
has the meaning set forth in Section 9.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.17&nbsp;&ldquo;<B>COC
Program</B>&rdquo; has the meaning set forth in Section 2.2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.18&nbsp;&ldquo;<B>Combination
Product</B>&rdquo; has the meaning set forth in Section 1.59.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.19&nbsp;&ldquo;<B>Commercialize</B>&rdquo;
or &ldquo;<B>Commercializing</B>&rdquo; means any and all activity to market, promote, distribute, offer for sale, sell, have sold, seek
reimbursement, import, have imported, export, have exported, or otherwise commercialize an Antibody or product, including any Licensed
Antibody, Derived Antibody, Product, Multispecific Antibody, Multispecific Product, as applicable, and including interacting with Regulatory
Authorities following receipt of Regulatory Approval and seeking and maintaining any required Reimbursement Approval. When used as a noun,
&ldquo;<B>Commercialization</B>&rdquo; means any and all activities involved in Commercializing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.20&nbsp;&ldquo;<B>Commercially
Reasonable Efforts</B>&rdquo; means those efforts and resources, including reasonably necessary and qualified personnel, equivalent to
the efforts and resources that a reasonable international biopharmaceutical company or a pharmaceutical company, in each case, that is
of comparable size and resources to the applicable Party would typically devote as part of an active and continuing program of development
and commercialization of a pharmaceutical or biologic product of similar market potential, at a similar stage of its product life, taking
into account the competitiveness of the marketplace and the proprietary position, regulatory status, and relative safety and efficacy
of such product. Commercially Reasonable Efforts requires, with respect to an obligation, that the applicable Party (a) assign responsibility
for such obligation to specific employees who are held accountable for progress and monitor such progress on an on-going basis, (b) set
and seek to achieve reasonable objectives for carrying out such obligation, and (c) make and implement reasonable decisions and allocate
resources designed to advance progress with respect to such objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.21&nbsp;&ldquo;<B>Confidential
Information</B>&rdquo; of a Party means Know-How and any and all non-public scientific, business, regulatory or technical information
that is disclosed or made available by or on behalf of one Party (the &ldquo;<B>Disclosing Party</B>&rdquo;) to the other Party (the &ldquo;<B>Receiving
Party</B>&rdquo;) in connection with this Agreement, regardless of whether such information is specifically marked or designated confidential,
whether in writing, orally, visually, or otherwise. Notwithstanding any provision of this Agreement to the contrary, the Licensed Antibody
Technology shall be the Confidential Information of Oruka.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.22&nbsp;&ldquo;<B>Control</B>&rdquo;
(including any variations such as &ldquo;<B>Controlled</B>&rdquo; and &ldquo;<B>Controlling</B>&rdquo;) means, with respect to any technology
(including Know-How) or other Intellectual Property Rights, possession by a Party or one of its Affiliates of the ability (whether by
ownership, license or otherwise (other than by a license, sublicense or other right granted pursuant to this Agreement)) to grant a license
or a sublicense of or under such technology or Intellectual Property Rights without violating the terms of any agreement or other arrangement
with any Third Party; <I>provided, that</I> if following the Effective Date (a)&nbsp;Paragon would Control any Patent that would be included
in the Licensed Antibody Technology or Other Licensed Patents but for an obligation to pay royalties or other consideration for the Development,
Manufacture or Commercialization of an Oruka Product in the Territory in connection with a grant to Oruka of a license under such Patent,
and (b)&nbsp;Oruka, pursuant to Section 2.8, consents to being a sublicensee of such Patent and complies with the Reimbursement Obligation,
then such Patent shall be deemed Controlled by Paragon. Notwithstanding the foregoing, a Party and its Affiliates shall not be deemed
to &ldquo;Control&rdquo; any technology or Intellectual Property Rights that (i) prior to the consummation of a Change of Control of such
Party is owned or in-licensed, or (ii)&nbsp;after the consummation of a Change of Control of such Party, becomes owned or in-licensed
(to the extent such technology or Intellectual Property Rights are developed outside of the scope of the activities conducted hereunder
and without use of or reference to any technology or Intellectual Property Rights Controlled by such Party or any Affiliate of such Party
immediately before such Change of Control, or any Confidential Information of the other Party), in each case ((i) or (ii)), by a Third
Party that becomes an Affiliate of such Party after the Effective Date as a result of such Change of Control or an assignee of such Party
after the Effective Date as the result of an assignment of this Agreement in connection with a Change of Control unless prior to the consummation
of such Change of Control or assignment, such Party or any of its Affiliates also Controlled such technology or Intellectual Property
Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.23&nbsp;&ldquo;<B>Cover</B>&rdquo;
or &ldquo;<B>Covering</B>&rdquo; means, with respect to a particular product, any Patent, that, in the absence of a license granted under,
or ownership of, such Patent, the making, using, selling, importation, or exportation of such product would infringe a valid and unexpired
claim of such Patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.24&nbsp;<B>&ldquo;Derived
Antibody&rdquo;</B> means any Antibody that is created by or on behalf of Oruka (other than an Antibody created by Paragon under the Option
Agreement), its Affiliates or its or their licensees and: (a) is derived from or constitutes a modification of a Licensed Antibody, including
<FONT STYLE="font-variant: small-caps">[***]</FONT>, (b) <FONT STYLE="font-variant: small-caps">[***]</FONT>and (c) <FONT STYLE="font-variant: small-caps">[***]</FONT>.
For avoidance of doubt, any Antibody <FONT STYLE="font-size: 10pt">that </FONT><FONT STYLE="font-variant: small-caps">[***]</FONT> <FONT STYLE="font-size: 10pt">will
be deemed a Derived Antibody, irrespective of origin.</FONT> Notwithstanding the foregoing, a Derived Antibody shall not include (i) <FONT STYLE="font-variant: small-caps">[***]</FONT>,
or (ii) <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.25&nbsp;&ldquo;<B>Designated
Multispecific Antibody</B>&rdquo; has the meaning set forth in Section&nbsp;2.6(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.26&nbsp;&ldquo;<B>Develop</B>&rdquo;
or &ldquo;<B>Developing</B>&rdquo; means any and all activity to discover, evaluate, test (including clinical and non-clinical testing),
research, or otherwise develop an Antibody or product, including any Licensed Antibody, Derived Antibody, Product, Multispecific Antibody,
or Multispecific Product, as applicable. When used as a noun, &ldquo;<B>Development</B>&rdquo; means any and all activities involved in
Developing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.27&nbsp;&ldquo;<B>Directed
To</B>&rdquo; means, with regard to an Antibody or product, that such Antibody or product is developed or designed to (a) <FONT STYLE="font-variant: small-caps">[***]</FONT>,
and (b) <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.28&nbsp;&ldquo;<B>Disclosing
Party</B>&rdquo; has the meaning set forth in Section 1.21.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.29&nbsp;&ldquo;<B>Dispute</B>&rdquo;
has the meaning set forth in Section 10.7(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.30&nbsp;&ldquo;<B>Dollar</B>&rdquo;
means a U.S. dollar, and &ldquo;$&rdquo; shall be interpreted accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.31&nbsp;&ldquo;<B>Effective
Date</B>&rdquo; has the meaning set forth in the preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.32&nbsp;&ldquo;<B>Exclusivity
Period</B>&rdquo; means the period commencing on the Effective Date and continuing until the fifth (5th) anniversary of the Effective
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.33&nbsp;&ldquo;<B>FDA</B>&rdquo;
means the United States Food and Drug Administration, or a successor federal agency thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.34&nbsp;&ldquo;<B>Field</B>&rdquo;
means the prophylaxis, palliation, treatment and diagnosis of human disease and disorders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.35&nbsp;&ldquo;<B>First
Commercial Sale</B>&rdquo; means the first sale of an Oruka Product by Oruka, or one of its Affiliates or its or their Sublicensees, to
a Third Party after receipt of all Regulatory Approvals required to market and sell the Oruka Product have been obtained in the country
in the Territory in which such Oruka Product is sold. Sales for purposes of testing the Oruka Product and sample purposes shall not be
deemed a First Commercial Sale. Furthermore, for purposes of clarity, the term &ldquo;First Commercial Sale&rdquo; as used in this Agreement
shall not include: (a) <FONT STYLE="font-variant: small-caps">[***]</FONT>; (b) <FONT STYLE="font-variant: small-caps">[***]</FONT>; nor
(c) <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.36&nbsp;&ldquo;<B>Force
Majeure</B>&rdquo; has the meaning set forth in Section 10.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.37&nbsp;&ldquo;<B>Governmental
Authority</B>&rdquo; means any national, international, federal, state, provincial, or local government, or political subdivision thereof,
or any multinational organization or any authority, agency, or commission entitled to exercise any administrative, executive, judicial,
legislative, police, regulatory, or taxing authority or power, or any court or tribunal (or any department, bureau or division thereof,
or any governmental arbitrator or arbitral body).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.38&nbsp;&ldquo;<B>IND</B>&rdquo;
means an investigational new drug application or equivalent application that is required to commence clinical trials for a product in
the Territory and filed with the applicable Regulatory Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.39&nbsp;&ldquo;<B>Indemnified
Party</B>&rdquo; has the meaning set forth in Section 9.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.40&nbsp;&ldquo;<B>Indemnifying
Party</B>&rdquo; has the meaning set forth in Section 9.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.41&nbsp;&ldquo;<B>Intellectual
Property Rights</B>&rdquo; means any and all proprietary rights provided under (a) patent law, including any Patents; (b) copyright law;
(c) trademark law; or (d) any other applicable statutory provision or common law principle, including trade secret law, that may provide
a right in Know-How, or the expression or use thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.42&nbsp;&ldquo;<B>Inventions</B>&rdquo;
means all Know-How, and all Intellectual Property Rights therein, that are conceived, reduced to practice, discovered, developed, or made
by or on behalf of either Party or any Third Parties acting on their behalf (or any of their Representatives, Affiliates, licensees, or
sublicensees) in the course of performing activities under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.43&nbsp;&ldquo;<B>JAMS
Rules</B>&rdquo; has the meaning set forth in Section 10.7(a)(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.44&nbsp;&ldquo;<B>Know-How</B>&rdquo;
means all technical information and know-how in any tangible or intangible form, including (a) inventions, discoveries, trade secrets,
data, specifications, instructions, processes, formulae, materials (including cell lines, vectors, plasmids, nucleic acids and the like),
methods, protocols, expertise and any other technology, including the applicability of any of the foregoing to formulations, compositions
or products or to their manufacture, development, registration, use or marketing or to methods of assaying or testing them or processes
for their manufacture, formulations containing them or compositions incorporating or comprising them, and (b) all data, instructions,
processes, formulae, strategies, and expertise, whether biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical,
physical, analytical, or otherwise and whether related to safety, quality control, manufacturing or other disciplines. Notwithstanding
the foregoing, Know-How excludes any Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.45&nbsp;&ldquo;<B>Licensed
Antibody</B>&rdquo; means any and all Antibodies that are Directed To the Licensed Target and that were discovered, generated, identified
or characterized by Paragon in the course of performing the Research Program. Notwithstanding the foregoing, the Licensed Antibodies shall
not include (a) <FONT STYLE="font-variant: small-caps">[***]</FONT>, or (b) <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.46&nbsp;&ldquo;<B>Licensed
Antibody Invention</B>&rdquo; means (a) any invention or discovery, whether or not patentable, that was discovered or reduced to practice
by or on behalf of Paragon under the Research Program that constitutes the composition of matter of, or any method of specifically making
or using, any Licensed Antibody; and (b) all Intellectual Property Rights therein, that in each case is Controlled by Paragon or its Affiliates
as of the Effective Date or during the Term. Notwithstanding the foregoing, the Licensed Antibody Inventions shall not include (i) <FONT STYLE="font-variant: small-caps">[***]</FONT>,
(x) <FONT STYLE="font-variant: small-caps">[***]</FONT>, or (y) <FONT STYLE="font-variant: small-caps">[***]</FONT>, or (ii) any Intellectual
Property Rights therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.47&nbsp;&ldquo;<B>Licensed
Antibody Patents</B>&rdquo; means all Patents that Cover the composition of matter of, or any method of specifically making or using,
any Licensed Antibody, that in each case are Controlled by Paragon or its Affiliates as of the Effective Date or during the Term, excluding
in each case any claims in such Patents that Cover the composition of matter of, or any method of specifically making or using (a) <FONT STYLE="font-variant: small-caps">[***]</FONT>,
or (b) <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.48&nbsp;&ldquo;<B>Licensed
Antibody Technology</B>&rdquo; means (a) the Licensed Antibody Inventions; (b) the Licensed Antibody Patents; (c) the Sequence Information;
(d) the Results; (e) the Research Program Materials; and (f)&nbsp;all Intellectual Property Rights therein Controlled by Paragon or its
Affiliates as of the Effective Date and during the Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.49&nbsp;&ldquo;<B>Licensed
Component</B>&rdquo; has the meaning set forth in Section 1.59.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.50&nbsp;&ldquo;<B>Licensed
Target</B>&rdquo; means IL-17A/F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.51&nbsp;&ldquo;<B>Losses</B>&rdquo;
has the meaning set forth in Section 9.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.52&nbsp;&ldquo;<B>MAA</B>&rdquo;
means (a) a New Drug Application in the United States, as defined in the United States Federal Food, Drug and Cosmetics Act, and applicable
regulations promulgated thereunder by the FDA; (b) a Biologics License Application in the United States, as defined in the United States
Public Health Service Act; or (c) any application filed with any Regulatory Authority in a country other than the United States that is
equivalent to either of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.53&nbsp;&ldquo;<B>Major
Market Country</B>&rdquo; means any of the following: <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.54&nbsp;&ldquo;<B>Manufacture</B>&rdquo;
or &ldquo;<B>Manufacturing</B>&rdquo; <FONT STYLE="font-size: 10pt">means </FONT>any and all activity <FONT STYLE="font-size: 10pt">to
make, have made, produce, manufacture, process, fill, finish, package, label, perform quality assurance testing, release, or ship </FONT>an
Antibody or product, including any Licensed Antibody, Derived Antibody, Product, Multispecific Antibody, or Multispecific Product, as
applicable, <FONT STYLE="font-size: 10pt">or any component thereof.</FONT> When used as a noun, &ldquo;<B>Manufacture</B>&rdquo; or &ldquo;<B>Manufacturing</B>&rdquo;
means any and all activities involved in Manufacturing an Antibody or product, including any Licensed Antibody, Derived Antibody, Product,
Multispecific Antibody, or Multispecific Product, as applicable, or any component thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.55&nbsp;&ldquo;<B>Milestone</B>&rdquo;
has the meaning set forth in Section 4.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.56&nbsp;&ldquo;<B>Milestone
Payment</B>&rdquo; has the meaning set forth in Section 4.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.57&nbsp;&ldquo;<B>Multispecific
Antibody</B>&rdquo; means any Antibody that is comprised of (a) <FONT STYLE="font-variant: small-caps">[***]</FONT>, and (b) <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.58&nbsp;&ldquo;<B>Multispecific
Product</B>&rdquo; means any product that comprises or contains any Multispecific Antibody.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.59&nbsp;&ldquo;<B>Net
Sales</B>&rdquo; means the gross amounts received for Oruka Product by Oruka, its Affiliates and Sublicensees for sales or other commercial
disposition of such Oruka Product in the Territory to unrelated Third Parties, less the following, in each case related specifically to
the Oruka Product and actually incurred, paid or accrued by Oruka, its Affiliates or Sublicensees and not otherwise recovered by or reimbursed
to Oruka, its Affiliates or Sublicensees;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;<FONT STYLE="font-variant: small-caps">[***]</FONT>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;<FONT STYLE="font-variant: small-caps">[***]</FONT>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;<FONT STYLE="font-variant: small-caps">[***]</FONT>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;<FONT STYLE="font-variant: small-caps">[***]</FONT>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;<FONT STYLE="font-variant: small-caps">[***]</FONT>;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;<FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net Sales will include <FONT STYLE="font-variant: small-caps">[***]</FONT>.
Net Sales will be calculated only once for the first <I>bona fide</I> arm&rsquo;s length sale of the Oruka Product by Oruka, its Affiliates
or its Sublicensees to a Third Party, and will not include sales between or among <FONT STYLE="font-variant: small-caps">[***]</FONT>.
Net Sales shall not include any amounts invoiced for <FONT STYLE="font-variant: small-caps">[***]</FONT> (i) <FONT STYLE="font-variant: small-caps">[***]</FONT>,
(ii) <FONT STYLE="font-variant: small-caps">[***]</FONT>, or (iii) <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net Sales shall be determined from the books and
records of Oruka<I>, </I>Affiliates of Oruka or any Sublicensee maintained in accordance with U.S. generally accepted accounting principles
(GAAP) consistently applied. Oruka further agrees in determining Net Sales, it (or its applicable Affiliate or Sublicensee) will use Oruka&rsquo;s
(or such Affiliate&rsquo;s or Sublicensee&rsquo;s) then current standard procedures and methodology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an Oruka Product is sold as a Combination Product (as defined below),
the Net Sales of such Combination Product for the purpose of calculating royalties and sales-based milestones owed under this Agreement
for sales of such Combination Product, shall be determined as follows: <FONT STYLE="font-variant: small-caps">[***]</FONT>. If any Other
Component in the Combination Product is not sold separately, Net Sales shall be calculated by <FONT STYLE="font-variant: small-caps">[***]</FONT>.
If both the Licensed Component and any of the Other Components are not sold separately, the adjustment to Net Sales shall be determined
by the Parties <FONT STYLE="font-variant: small-caps">[***]</FONT> to reasonably reflect <FONT STYLE="font-variant: small-caps">[***]
</FONT>of such Licensed Component in the Combination Product to the total fair market value of such Combination Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For purposes of this definition, &ldquo;<B>Combination Product</B>&rdquo;
means any pharmaceutical product that contains two (2) or more active ingredients, including (A) one (1) or more Licensed Antibodies,
Derived Antibodies or Multispecific Antibodies (the &ldquo;<B>Licensed Component</B>&rdquo;), and (B) one (1) or more active pharmaceutical
or biological ingredients that are not (x) a Licensed Antibody, Derived Antibody or Multispecific Antibody, or (y) an Antibody owned or
controlled by Paragon or its Affiliate, the rights to which have been licensed to Oruka or its Affiliate under a separate agreement (&ldquo;<B>Other
Component(s)</B>&rdquo;), either as a <FONT STYLE="font-variant: small-caps">[***]</FONT>, <FONT STYLE="font-variant: small-caps">[***]</FONT>
or <FONT STYLE="font-variant: small-caps">[***]</FONT>, and <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.60&nbsp;&ldquo;<B>Notice
of Dispute</B>&rdquo; has the meaning set forth in 10.7(a)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.61&nbsp;&ldquo;<B>Oruka</B>&rdquo;
has the meaning set forth in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.62&nbsp;&ldquo;<B>Oruka
Antibody Patents</B>&rdquo; means all Patents that Cover the composition of matter of, or any method of specifically making or using any
Licensed Antibody or Derived Antibody that, in each case, are owned or in-licensed by Oruka or its Affiliates or Sublicensees as of the
Effective Date or during the Term, <I>provided that</I>, if a Change of Control of Oruka occurs, the Oruka Antibody Patents shall not
include any Patents owned or in-licensed by the Acquiring Entity as of the closing of such Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.63&nbsp;&ldquo;<B>Oruka
Indemnitee</B>&rdquo; has the meaning set forth in Section&nbsp;9.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.64&nbsp;&ldquo;<B>Oruka
Intellectual Property</B>&rdquo; means any Patents, Know-How or other Intellectual Property Rights that are Controlled by Oruka and are
necessary for, and actually used (or held for use) by Oruka or its Affiliates as of the effective date of termination of this Agreement
in the Development, Manufacturing, or Commercialization of Oruka Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.65&nbsp;&ldquo;<B>Oruka
Invention</B>&rdquo; means (a) any Invention that is owned or Controlled by Oruka, and (b) all Intellectual Property Rights therein, <I>provided
that</I>, in each case (a) &ndash; (b), Oruka Inventions shall not include (i) any Inventions owned or Controlled by Paragon or its Affiliate,
the rights to which have been licensed to Oruka or its Affiliate under this Agreement or a separate agreement, or (ii) any Intellectual
Property Rights therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.66&nbsp;&ldquo;<B>Oruka
Multispecific Antibody</B>&rdquo; means any Multispecific Antibody that is Developed, Manufactured, Commercialized or otherwise exploited
by Oruka, its Affiliates or Sublicensees, excluding in each case, and subject to Section 2.7, any Paragon Multispecific Antibody.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.67&nbsp;&ldquo;<B>Oruka
Multispecific Patents</B>&rdquo; means those Patents that Cover the composition of matter of, or any method of specifically making or
using, an Oruka Multispecific Antibody.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.68&nbsp;&ldquo;<B>Oruka
Multispecific Product</B>&rdquo; means any product that comprises or contains any Oruka Multispecific Antibody.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.69&nbsp;&ldquo;<B>Oruka
Product</B>&rdquo; means, individually or collectively, as applicable, Licensed Antibodies, Derived Antibodies, Products, Oruka Multispecific
Antibodies and Oruka Multispecific Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.70&nbsp;&ldquo;<B>Other
Component(s)</B>&rdquo; has the meaning set forth in Section 1.59.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.71&nbsp;&ldquo;<B>Other
Licensed Know-How</B>&rdquo; means all Know-How Controlled by Paragon or its Affiliates on the Effective Date or during the Term that
(a) was used by or on behalf of Paragon in the performance of the Research Program, and (b) is necessary to Develop, Manufacture, Commercialize
or otherwise exploit (i) Licensed Antibodies, or (ii) Products, Multispecific Antibodies or Multispecific Products, in each case solely
to the extent comprising or containing a Licensed Antibody. For clarity, the Other Licensed Know-How shall exclude (x)&nbsp;the Licensed
Antibody Technology, and (y) any Know-How Controlled by Paragon or its Affiliates relating to (1) that <FONT STYLE="font-variant: small-caps">[***]</FONT>,
or (2) <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.72&nbsp;&ldquo;<B>Other
Licensed Patents</B>&rdquo; means any Patents other than Licensed Antibody Patents Controlled by Paragon or its Affiliates as of the Effective
Date or during the Term that (a) include a claim that expressly recites the sequence of a Licensed Antibody or Derived Antibody, and (b)
are necessary to Develop, Manufacture or Commercialize Licensed Antibodies or Derived Antibodies in the Field in the Territory. Notwithstanding
the foregoing, the Other Licensed Patents shall not include (i) Paragon Multispecific Patents, (ii) the Paragon Platform Patents (as defined
in the Option Agreement), or (iii) any Patents that Cover (x) <FONT STYLE="font-variant: small-caps">[***]</FONT>, or (y) <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.73&nbsp;&ldquo;<B>Other
Licensed Technology</B>&rdquo; means all (a) Other Licensed Know-How, and (b)&nbsp;Other Licensed Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.74&nbsp;&ldquo;<B>Paragon</B>&rdquo;
has the meaning set forth in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.75&nbsp;&ldquo;<B>Paragon
Indemnitee</B>&rdquo; has the meaning set forth in Section 9.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.76&nbsp;&ldquo;<B>Paragon
Multispecific Antibody</B>&rdquo; means any Multispecific Antibody that is Developed, Manufactured, Commercialized or otherwise exploited
by Paragon or its Affiliate or licensees (other than Oruka and its Affiliates and Sublicensees), excluding in each case any Oruka Multispecific
Antibodies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.77&nbsp;&ldquo;<B>Paragon
Multispecific Patents</B>&rdquo; means those Patents that Cover the composition of matter of, or any method of specifically making or
using, a Paragon Multispecific Antibody, in each case excluding the Licensed Antibody Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.78&nbsp;&ldquo;<B>Paragon
Patents</B>&rdquo; has the meaning set forth in Section 5.2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.79&nbsp;&ldquo;<B>Paragon
Third Party Agreement</B>&rdquo; has the meaning set forth in Section 2.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.80&nbsp;&ldquo;<B>Parent
Entity</B>&rdquo; has the meaning set forth in Section 1.15.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.81&nbsp;&ldquo;<B>Party</B>&rdquo;
has the meaning set forth in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.82&nbsp;&ldquo;<B>Patent
Challenge</B>&rdquo; has the meaning set forth in Section 5.3(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.83&nbsp;&ldquo;<B>Patent
Infringement</B>&rdquo; has the meaning set forth in Section 5.3(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.84&nbsp;&ldquo;<B>Patents</B>&rdquo;
means <FONT STYLE="font-size: 10pt">(a) unexpired patents and patent applications, (b) any and all patent applications filed either from
such patent or patent applications or from a patent application claiming priority from any of those, including divisionals, provisionals,
continuations, continuations-in-part, and reissues, (c) substitutions, renewals, registrations, re-examinations, revalidations, extensions,
supplementary protection certificates and the like of any such patents and patent applications, and (d) any and all foreign equivalents
of the foregoing</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.85&nbsp;&ldquo;<B>Phase
I Trial</B>&rdquo; means a human clinical trial in any country of the type described in 21 C.F.R. &sect;312.21(a), or the foreign equivalent
thereof, regardless of where such clinical trial is conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.86&nbsp;&ldquo;<B>Phase
II Trial</B>&rdquo; means a human clinical trial in any country of the type described in 21 C.F.R. &sect;312.21(b), or the foreign equivalent
thereof, regardless of where such clinical trial is conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.87&nbsp;&ldquo;<B>Phase
III Trial</B>&rdquo; means a human clinical trial in any country of the type described in 21 C.F.R. &sect;312.21(c), or the foreign equivalent
thereof, regardless of where such clinical trial is conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.88&nbsp;&ldquo;<B>Post-Effective
Date Patents</B>&rdquo; has the meaning set forth in Section 5.2(b)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.89&nbsp;&ldquo;<B>Pre-Existing
Entities</B>&rdquo; has the meaning set forth in Section 1.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.90&nbsp;&ldquo;<B>Product</B>&rdquo;
means any product that comprises or contains any Licensed Antibody or Derived Antibody other than as part of a Multispecific Antibody
or a Multispecific Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.91&nbsp;&ldquo;<B>Prosecute</B>&rdquo;
or &ldquo;<B>Prosecution</B>&rdquo; has the meaning set forth in Section 5.2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.92&nbsp;&ldquo;<B>Prosecuting
Party</B>&rdquo; has the meaning set forth in Section 5.2(b)(iii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.93&nbsp;&ldquo;<B>Publication</B>&rdquo;
has the meaning set forth in Section 6.6(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.94&nbsp;&ldquo;<B>Receiving
Party</B>&rdquo; has the meaning set forth in Section 1.21.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.95&nbsp;&ldquo;<B>Regulatory
Approval</B>&rdquo; means all clearances, approvals (including approval of an MAA as well as any applicable pricing and/or reimbursement
approvals), licenses, registrations or authorizations of any Regulatory Authority necessary to commercially distribute, sell and market
a pharmaceutical product in a country or territory under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.96&nbsp;&ldquo;<B>Regulatory
Authority</B>&rdquo; means any supranational, multinational, federal, national, state, provincial or local regulatory agency, department,
bureau or other Governmental Authority with authority over the clinical development, manufacture marketing or sale of an Oruka Product
in a country or region, including the FDA in the United States and the EMA in Europe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.97&nbsp;&ldquo;<B>Reimbursement
Obligation</B>&rdquo; has the meaning set forth in Section 2.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.98&nbsp;&ldquo;<B>Remaining
Recovery</B>&rdquo; has the meaning set forth in Section 5.3(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.99&nbsp;&ldquo;<B>Representatives</B>&rdquo;
of a Party means such Party&rsquo;s officers, directors, employees, contractors, subcontractors, agents and consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.100&nbsp;&ldquo;<B>Research
Program</B>&rdquo; means the Research Program (as defined in the Option Agreement) conducted by the Parties pursuant to the Option Agreement
with respect to the Licensed Target.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.101&nbsp;&ldquo;<B>Research
Program Materials</B>&rdquo; means the tangible materials resulting from the Research Program that are Controlled by Paragon or its Affiliates
as of the Effective Date or during the Term that are listed in <U>Exhibit C</U> attached hereto, as may be amended in writing from time
to time upon mutual agreement of the Parties. For clarity, Research Program Materials shall not include materials that are consumed or
destroyed in the performance of the Research Program or that are not available to be transferred by Paragon to Oruka without violating
the terms of any agreement or other arrangement with a Third Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.102&nbsp;&ldquo;<B>Results</B>&rdquo;
means all data, results, analysis, conclusions, outcomes, information, documentation and reports that are generated by or on behalf of
Paragon in performance of the Research Program, excluding in each case any other Licensed Antibody Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.103&nbsp;&ldquo;<B>Reversion
Products</B>&rdquo; has the meaning set forth in Section 8.5(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.104&nbsp;&ldquo;<B>Review
Period</B>&rdquo; has the meaning set forth in Section 6.6(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.105&nbsp;&ldquo;<B>ROFN
Information</B>&rdquo; has the meaning set forth in Section 2.7(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.106&nbsp;&ldquo;<B>ROFN
Negotiation Period</B>&rdquo; has the meaning set forth in Section 2.7(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.107&nbsp;&ldquo;<B>ROFN
Period</B>&rdquo; has the meaning set forth in Section 2.7(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.108&nbsp;&ldquo;<B>Royalty
Payments</B>&rdquo; has the meaning set forth in Section&nbsp;4.2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.109&nbsp;&ldquo;<B>Royalty
Term</B>&rdquo; means, on an Oruka Product-by-Oruka Product and country-by-country basis, the period commencing on First Commercial Sale
of the applicable Oruka Product in the applicable country in the Territory and ending, with respect to the particular Oruka Product and
country at issue on the latest of the following dates: (a) the twelfth (12th) anniversary of the date of First Commercial Sale of such
Oruka Product in such country; or (b) the expiration of the last-to-expire Valid Claim of a Licensed Antibody Patent or an Oruka Antibody
Patent Covering the Manufacture, use or sale of such Oruka Product in the country at issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.110&nbsp;&ldquo;<B>Sequence
Information</B>&rdquo; means any files of Paragon containing all Licensed Antibody sequences generated under the Research Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.111&nbsp;&ldquo;<B>Sublicensee</B>&rdquo;
means any Affiliate of Oruka or any Third Party with respect to Oruka, to whom Oruka grants a sublicense of, or other authorization or
permission granted under, the rights granted to Oruka in Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.112&nbsp;&ldquo;<B>Target</B>&rdquo;
means a protein molecule that (a) is chemically distinct from other molecules, and (b) wherein a binding entity derives recognized therapeutic
value from binding to such molecule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.113&nbsp;&ldquo;<B>Term</B>&rdquo;
has the meaning set forth in Section&nbsp;8.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.114&nbsp;&ldquo;<B>Territory</B>&rdquo;
means worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.115&nbsp;&ldquo;<B>Third
Party</B>&rdquo; means any person or entity other than Paragon or Oruka or an Affiliate of either Paragon or Oruka.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.116&nbsp;&ldquo;<B>Third
Party Claim</B>&rdquo; has the meaning set forth in Section 9.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.117&nbsp;&ldquo;<B>Transfer
Period</B>&rdquo; has the meaning set forth in Section 2.5(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.118&nbsp;&ldquo;<B>US</B>&rdquo;
or &ldquo;<B>United States</B>&rdquo; means the United States of America and its possessions and territories, including Puerto Rico.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.119&nbsp;&ldquo;<B>Valid
Claim</B>&rdquo; means, with respect to a particular country, a claim (including a process, use or composition of matter claim) of an
issued and unexpired patent (or a supplementary protection certificate thereof) that has not (a) irretrievably lapsed or been abandoned,
permanently revoked, dedicated to the public or disclaimed, or (b) been held invalid, unenforceable or not patentable by a court, governmental
agency, national or regional patent office or other appropriate body that has competent jurisdiction, which holding, finding or decision
is final and unappealable or unappealed within the time allowed for appeal.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article&nbsp;II</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"></FONT>LICENSES;
TECHNOLOGY TRANSFER; MULTISPECIFIC ANTIBODIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1&nbsp;<B>License
Grants</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;Subject
to the terms of this Agreement, Paragon hereby grants to Oruka a royalty-bearing, exclusive (even as to Paragon and its Affiliates, subject
to Paragon&rsquo;s retained rights under Section 2.4) license, including the right to sublicense through multiple tiers, under the Licensed
Antibody Technology to Develop, Manufacture, Commercialize, or otherwise exploit Licensed Antibodies, Derived Antibodies and Products
in the Field in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;Subject
to the terms of this Agreement, including Section 2.7, Paragon hereby grants to Oruka a royalty-bearing, non-exclusive right and license,
including the right to sublicense through multiple tiers, under the Licensed Antibody Technology to Develop, Manufacture, Commercialize
or otherwise exploit Multispecific Antibodies and Multispecific Products in the Field in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;Subject
to the terms of this Agreement, Paragon hereby grants to Oruka a royalty-bearing, non-exclusive license, including the right to sublicense
through multiple tiers, under the Other Licensed Patents to Develop, Manufacture, Commercialize or otherwise exploit Licensed Antibodies,
Derived Antibodies, Multispecific Antibodies, Products and Multispecific Products in the Field in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;Subject
to the terms of this Agreement, Paragon hereby grants to Oruka a royalty-bearing, non-exclusive license, including the right to sublicense
through multiple tiers, under the Other Licensed Know-How to Develop, Manufacture, Commercialize or otherwise exploit (i) Licensed Antibodies,
or (ii) Products, Multispecific Antibodies or Multispecific Products, in each case solely to the extent comprising or containing a Licensed
Antibody, in the Field in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2&nbsp;<B>Exclusivity</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;Subject
to the terms of this Section 2.2, to the maximum extent permissible under Applicable Law, during the Exclusivity Period, Paragon shall
not, and shall ensure that its Affiliates do not, directly or indirectly, conduct any activity, either on its own or with, for the benefit
of, or sponsored by, any Third Party, including granting any license to any Third Party that would permit such Third Party, to develop,
manufacture, commercialize or otherwise exploit any monospecific Antibody that is Directed To the Licensed Target in the Field. It will
not be a violation of this Section 2.2(a) if Paragon or its Affiliate, directly or through a Third Party, (i)&nbsp;conducts screening
activities solely for the purposes of ensuring compliance with this Section&nbsp;2.2(a), (ii)&nbsp;conducts activities in accordance with
the terms of this Agreement, the Option Agreement or any other written agreement between the Parties, or (iii) conducts activities with
the prior written consent of Oruka.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;Notwithstanding
anything herein to the contrary, if a Change of Control occurs with respect to Paragon or its Parent Entity, and the Acquiring Entity
(or any of such Acquiring Entity&rsquo;s successors or assigns, other than the relevant Pre-Existing Entities) as of the Change of Control
has a program or product (or rights thereto) that would otherwise violate Section&nbsp; 2.2(a) (each, a &ldquo;<B>COC Program</B>&rdquo;),
then (i) Section&nbsp;2.2(a) shall not apply with respect to such COC Program, and (ii) such Acquiring Entity will be permitted to continue
such COC Program after such Change of Control and such continuation will not constitute a violation of Section&nbsp;2.2(a), <I>provided,
that</I> the Licensed Antibody Technology and Confidential Information of Paragon and Oruka relating to the Oruka Products is not used
in the COC Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;Notwithstanding
anything herein to the contrary, if Paragon or its Parent Entity (i) acquires a Third Party entity that has a program or product (or rights
thereto) that would otherwise violate Section&nbsp;2.2(a), or (ii) acquires asset(s) from a Third Party entity that would otherwise violate
Section&nbsp;2.2(a) (each, an &ldquo;<B>Acquired Program</B>&rdquo;), then (1) Section&nbsp;2.2(a) shall not apply with respect to such
Acquired Program, and (2) Paragon or its Parent Entity will be permitted to continue such Acquired Program after such acquisition and
such continuation will not constitute a violation of Section&nbsp;2.2(a), <I>provided, that</I> the Licensed Antibody Technology and Confidential
Information of Paragon and Oruka relating to the Oruka Products is not used in the Acquired Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3&nbsp;<B>Sublicenses</B>.
Oruka shall have the right to grant sublicenses under the rights granted to it in Section&nbsp;2.1 to its Affiliates and Third Parties;
<I>provided, that</I> (a)&nbsp;each such sublicense shall be granted in writing and each such relevant sublicense agreement shall be consistent
with all relevant terms, conditions and restrictions of this Agreement, (b) Oruka will provide Paragon with a true and complete copy of
each sublicense agreement (other than sublicense agreements with Third Party service providers) and any amendments thereto within <FONT STYLE="font-variant: small-caps">[***]</FONT>
days following the execution thereof (which sublicense agreement and amendments may be redacted except to the extent necessary for Paragon
to determine Oruka&rsquo;s compliance with this Agreement), and (c)&nbsp;Oruka shall remain responsible for all of its payments and other
performance obligations due under this Agreement, notwithstanding any license or sublicense that it may grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.4&nbsp;<B>No
Implied Licenses; Reservation of Rights</B>. Except as expressly set forth herein, no right or license under any Patents, Know-How or
Intellectual Property Right of either Party is granted or shall be granted by implication hereunder. All such rights or licenses are or
shall be granted only as expressly provided in this Agreement, and each Party reserves to itself all rights not expressly granted under
this Agreement. Notwithstanding anything to the contrary under this Agreement, Paragon retains rights under the Licensed Antibody Technology
solely to perform its obligations and exercise its rights under this Agreement and the Option Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.5&nbsp;<B>Information
Transfer and Support to Oruka</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;As
soon as possible and within not more than <FONT STYLE="font-variant: small-caps">[***]</FONT> days after the Effective Date, Paragon shall
provide Oruka with the Results and Sequence Information in existence as of the Effective Date not already provided to Oruka under the
Option Agreement. Additionally, on a continuing basis during the term of the Research Program, as soon as possible and within not more
than <FONT STYLE="font-variant: small-caps">[***]</FONT> days after additional Results or Sequence Information come into existence or
are identified by Paragon that in each case have not already been provided to Oruka under the Option Agreement, Paragon shall disclose
and transfer such additional Results and Sequence Information to Oruka.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;Upon
the reasonable request of Oruka made from time to time during the Term, Paragon shall promptly disclose and transfer to Oruka tangible
embodiments of the Other Licensed Know-How that is the subject of Oruka&rsquo;s request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;The
Parties acknowledge and agree that <U>Exhibit C</U> has been agreed by the Parties as of the Effective Date, and that materials that are
different than or in addition to the materials set forth on <U>Exhibit C</U> may result from the Research Program to the extent that the
Research Program continues to be performed following the Effective Date. Upon the reasonable request of Oruka made at any time prior to
the end of the <FONT STYLE="font-variant: small-caps">[***]</FONT> day period following the expiration of the Research Term (as defined
in the Option Agreement), the Parties shall update <U>Exhibit C</U> to reflect the tangible materials, including samples, reagents, nucleic
acids and Antibodies, resulting from the Research Program that constitute Research Program Materials hereunder. During the period beginning
on the Effective Date and ending <FONT STYLE="font-variant: small-caps">[***]</FONT> months after the expiration of the Research Term
(the &ldquo;<B>Transfer Period</B>&rdquo;), at <FONT STYLE="font-variant: small-caps">[***]</FONT> request and expense, Paragon will provide
Oruka or a Third Party designated by Oruka with any Research Program Materials, provided that any Third Party recipient of such Research
Program Materials shall be bound by the relevant terms of this Agreement and that the Research Program Materials are used solely to further
Develop, Manufacture and Commercialize the Oruka Products. For clarity, <FONT STYLE="font-variant: small-caps">[***]</FONT> shall be responsible
for any out-of-pocket costs incurred by Paragon or its Affiliates to store and maintain the Research Program Materials during the Transfer
Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;Each
Party shall bear all costs and expenses incurred by such Party in connection with the disclosure and transfer of any Results and Sequence
Information as set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;During
the <FONT STYLE="font-variant: small-caps">[***]</FONT> day period following completion of the Research Program, in the event Oruka makes
any reasonable request for assistance in order to understand the Licensed Antibody Technology and use the Licensed Antibody Technology
to continue the uninterrupted Development of the Licensed Antibodies, Paragon shall provide up to <FONT STYLE="font-variant: small-caps">[***]</FONT>
month of additional assistance during such period, at <FONT STYLE="font-variant: small-caps">[***]</FONT> cost and expense at the then
current <FONT STYLE="font-variant: small-caps">[***]</FONT> Rate (as defined in the Option Agreement) in the Option Agreement.&nbsp; Paragon
shall consider and discuss in good faith any additional requests for assistance made by Oruka, which assistance may be provided upon mutual
agreement of the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.6&nbsp;<B>Paragon
Rights with Respect to Multispecific Antibodies</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;Subject
to the terms of this Agreement, including Section 2.6(b) below and Section 2.7, Paragon reserves and retains the non-exclusive right under
the Licensed Antibody Technology to Develop, Manufacture, Commercialize and otherwise exploit Multispecific Antibodies and Multispecific
Products in the Field in the Territory. If Paragon exercises such right, then Paragon shall pay royalties to Oruka in accordance with
Article&nbsp;IV (at the rate specified in Section 4.2(b)), <I>mutatis mutandis</I>, with respect to any Multispecific Antibodies and Multispecific
Products that are Commercialized by Paragon or its Affiliates or sublicensees (other than Oruka and its Affiliates and Sublicensees) in
the Field in the Territory, <I>provided, that</I> references to Oruka Antibody Patents in clause (b) of the Royalty Term definition and
Section 4.3 shall be disregarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;Oruka
has designated <FONT STYLE="font-variant: small-caps">[***]</FONT> Licensed Antibody or Derived Antibody as its lead compound and <FONT STYLE="font-variant: small-caps">[***]</FONT>
Licensed Antibody or Derived Antibody as its backup compound, as set forth on <U>Exhibit B</U> (each such designated Licensed Antibody
or Derived Antibody, a &ldquo;<B>Designated Multispecific Antibody</B>&rdquo;). Paragon&rsquo;s rights under Section&nbsp;2.6(a) shall
expressly exclude the right to Develop, Manufacture, Commercialize or otherwise exploit (i) Multispecific Antibodies that have identical
sequence identity within their complementarity-determining regions as a Designated Multispecific Antibody, or (ii)&nbsp;Multispecific
Products that comprise or contain any Multispecific Antibody referenced in clause (i). For the avoidance of doubt, if Paragon engaged
in Development or Manufacture of a Multispecific Antibody that meets the criteria of clause (i) or (ii) above prior to the Effective Date,
then Paragon shall not be in breach of this Agreement, <I>provided that</I>, Paragon ceases all such Development or Manufacture within
<FONT STYLE="font-variant: small-caps">[***]</FONT> days following the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.7&nbsp;<B>Right
of First Negotiation</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;Commencing
on the Effective Date and continuing until the <FONT STYLE="font-variant: small-caps">[***] </FONT>anniversary thereof (the &ldquo;<B>ROFN
Period</B>&rdquo;), Paragon will promptly notify Oruka in writing if (i)&nbsp;Paragon has developed a descriptive research plan with respect
to the Development of a Multispecific Antibody or a plan to license or grant rights in a Multispecific Antibody to a Third Party, or (ii)
Paragon enters into <FONT STYLE="font-variant: small-caps">[***]</FONT> negotiations pursuant to an offer to or from any Third Party relating
to the foregoing. Together with such notice, Paragon will provide to Oruka all material information and research plans developed by Paragon
with respect to such Multispecific Antibody (the &ldquo;<B>ROFN Information</B>&rdquo;). Oruka will have <FONT STYLE="font-variant: small-caps">[***]</FONT>
days from receipt of the ROFN Information to deliver a written notice to Paragon of Oruka&rsquo;s desire to engage in negotiations for
an agreement concerning the Development, or exclusive license or grant of rights to, such Multispecific Antibody.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;If
Oruka does not provide such written notice to Paragon of its interest to engage in such negotiations within such <FONT STYLE="font-variant: small-caps">[***]</FONT>
day period, then (i) Paragon shall be free to enter into an agreement with a Third Party with respect to the grant of a license or other
rights to such Multispecific Antibody and corresponding Multispecific Products without further obligation to Oruka under this Section
2.7, and (ii) Oruka&rsquo;s license under Section 2.1(b) shall automatically exclude any right to Develop, Manufacture, Commercialize
or otherwise exploit the identical Multispecific Antibodies Developed by or on behalf of Paragon and corresponding Multispecific Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;If
Oruka does provide Paragon such written notice within such <FONT STYLE="font-variant: small-caps">[***]</FONT> day period, the Parties
will negotiate <FONT STYLE="font-variant: small-caps">[***]</FONT> on an exclusive basis for a period of up to <FONT STYLE="font-variant: small-caps">[***]</FONT>
months from the date of Oruka&rsquo;s notice (&ldquo;<B>ROFN Negotiation Period</B>&rdquo;), an agreement for the Development, or exclusive
license or grant of rights to, such Multispecific Antibody and corresponding Multispecific Products. Prior to and during the ROFN Negotiation
Period, Paragon shall not enter into an agreement with respect to such Multispecific Antibody with any Third Party that will prevent Paragon
from entering into an agreement with Oruka for the Development, or exclusive license or grant of rights to, such Multispecific Antibody
and corresponding Multispecific Products. Unless and until the Parties have entered into an agreement with respect to such Multispecific
Antibody and corresponding Multispecific Products, Oruka shall have no rights or license with respect to such Multispecific Antibody and
corresponding Multispecific Products except as otherwise expressly provided in Section 2.1. In the event that the Parties have not entered
into an agreement with respect to such Multispecific Antibody and corresponding Multispecific Products prior to the expiration of the
ROFN Negotiation Period, then (i) Paragon shall be free to enter into an agreement with a Third Party with respect to the grant of a license
or other rights to such Multispecific Antibody and corresponding Multispecific Products without further obligation to Oruka under this
Section&nbsp;2.7, and (ii) Oruka&rsquo;s license under Section 2.1(b) shall automatically exclude any right to Develop, Manufacture, Commercialize
or otherwise exploit the identical Multispecific Antibodies Developed by or on behalf of Paragon and corresponding Multispecific Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.8&nbsp;<B>Third
Party In-Licenses</B>. If Paragon (or its Affiliate) enters into any in-license agreement with a Third Party after the Effective Date
with respect to any Patent that would, if Controlled by Paragon, be included within the Licensed Antibody Patents or the Other Licensed
Patents (each such agreement, a &ldquo;<B>Paragon Third Party Agreement</B>&rdquo;), Paragon shall notify Oruka in writing that it entered
into such Paragon Third Party Agreement and provide a copy of such Paragon Third Party Agreement to Oruka, which may be redacted solely
concerning <FONT STYLE="font-variant: small-caps">[***] </FONT>or other confidential terms not applicable to sublicensees. Oruka shall
have the right, by delivery of notice to Paragon, to elect to take a sublicense under such Patents in-licensed by Paragon under such Paragon
Third Party Agreement. If Oruka elects to become a sublicensee thereunder pursuant to this Section 2.8, then (a) the applicable Patents
under such Paragon Third Party Agreement shall be included within the Licensed Antibody Patents or the Other Licensed Patents, as applicable,
that are licensed to Oruka under Section 2.1, (b)&nbsp;Oruka shall reimburse Paragon for Paragon&rsquo;s pro rata share of royalties or
other consideration, as mutually agreed by the Parties, payable by Paragon under the Paragon Third Party Agreement for Oruka&rsquo;s Development,
Manufacture, Commercialization or other exploitation of an Oruka Product in the Field in the Territory in connection with the grant to
Oruka of such Patents (the &ldquo;<B>Reimbursement Obligation</B>&rdquo;), and (c)&nbsp;Oruka shall comply with the terms of such Paragon
Third Party Agreement to the extent applicable to Oruka as a sublicensee of such Patents. In the event of any conflict between the terms
of this Agreement and any Paragon Third Party Agreement applicable to a sublicense granted by Paragon to Oruka in accordance with this
Section 2.8, the terms of the Paragon Third Party Agreement shall control solely to the extent necessary for the Parties to maintain compliance
with such Paragon Third Party Agreement. Oruka shall comply with the Reimbursement Obligation by paying to Paragon any amounts subject
to the Reimbursement Obligation within the earlier of (i)&nbsp;<FONT STYLE="font-variant: small-caps">[***]</FONT> days after Oruka&rsquo;s
receipt from Paragon of an invoice for such payment, and (ii) the date when such payment is due to the counterparty licensor under the
applicable Paragon Third Party Agreement, <I>provided that</I> such payment shall not be due prior to the date when such amounts are payable
by Paragon to the counterparty licensor under the applicable Paragon Third Party Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article&nbsp;III</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"></FONT>DEVELOPMENT,
MANUFACTURING &amp; COMMERCIALIZATION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1&nbsp;<B>Oruka
Responsibilities</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;As
between the Parties, Oruka shall be solely responsible for and shall have the sole right to control, all aspects of the Development, Manufacturing,
and Commercialization of the Oruka Products in the Field in the Territory during the Term, including distribution, product positioning,
product strategy, product branding, core messaging, marketing, promotion, detailing activities and all decisions relating to the setting
of prices in the Territory, invoicing and booking sales, establishing all terms of sale, and all regulatory activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;As
between the Parties, Oruka shall be solely responsible for, and shall have the sole right to control, the selection, registration and
maintenance of all trademarks associated with the Oruka Products in the Field in the Territory. As between the Parties, Oruka shall solely
own such trademarks in the Territory and pay all relevant costs thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2&nbsp;<B>Regulatory</B>.
As between the Parties, Oruka shall control all regulatory matters, including the regulatory strategy, regulatory filings, regulatory
activities (including clinical trials for Oruka Products) and communication with each Regulatory Authority for the Oruka Products in the
Field in the Territory. Oruka shall have the right to reference any relevant data included within the Licensed Antibody Technology for
the purposes of regulatory filings and safety reporting, including all nonclinical data, pre-approval and post-approval clinical use data,
and regulatory data with respect thereto, and Paragon shall cooperate as reasonably requested by Oruka with respect to providing to Oruka
when requested, and on a timely basis, any of the foregoing information, data filings or reporting. Oruka or its designee shall be the
party to file an application to each applicable Regulatory Authority in the Territory for, and to obtain and maintain, in its own name,
Regulatory Approval for the Oruka Products in each country in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3&nbsp;<B>Diligence;
Reporting</B>. Oruka shall use Commercially Reasonable Efforts (a)&nbsp;to Develop and seek Regulatory Approval for at least one Oruka
Product in the Field in the United States and at least one other Major Market Country, and (b) upon receipt of Regulatory Approval for
a given Oruka Product in a given country, to Commercialize such Oruka Product in such country, in each case ((a) or (b)) either by itself
or through its Affiliates or Sublicensees or its or their respective contractors. Additionally, on or before <FONT STYLE="font-variant: small-caps">[***]</FONT>
of each year during the Term, Oruka shall deliver to Paragon a report summarizing its material development efforts with respect to the
Oruka Products, including a summary of current and anticipated preclinical and clinical activities, a summary of the status of any regulatory
filings and any anticipated regulatory filings, and achievement of any Milestones, during the preceding <FONT STYLE="font-variant: small-caps">[***]</FONT>;
<I>provided, however</I>, that Oruka may satisfy the reporting obligations set forth in this Section 3.3 by providing Paragon with copies
of any annual report or other filings with a securities exchange that include the relevant information. For the avoidance of doubt, if
Oruka determines, in its sole discretion, that it is inconsistent with the use of Commercially Reasonable Efforts to pursue Commercialization
of an Oruka Product in any country (other than the United States), it will not be considered a material breach of this Agreement to cease
Development or Commercialization of such Oruka Product with respect to such country.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article&nbsp;IV</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"></FONT>FINANCIAL
TERMS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1&nbsp;<B>Milestone
Payments</B>. Oruka shall make the following one-time, non-refundable and non-creditable payments to Paragon (or to such other designee(s),
as requested by Paragon in an invoice) (each payment, a &ldquo;<B>Milestone Payment</B>&rdquo;), based on the achievement of the corresponding
milestone (each, a &ldquo;<B>Milestone</B>&rdquo;) by Oruka, its Affiliates, or its Sublicensees with respect to the first Oruka Product
to achieve such Milestone. Oruka shall, within <FONT STYLE="font-variant: small-caps">[***]</FONT> Business Days after it or its Affiliates
achieve a Milestone, or within <FONT STYLE="font-variant: small-caps">[***]</FONT> Business Days after it learns that its or its Affiliate&rsquo;s
Sublicensee has achieved a Milestone, notify Paragon of the achievement of such Milestone in writing. Following receipt of such notice,
Paragon shall invoice Oruka for such Milestone Payment, which invoice shall specify whether Paragon or its designee should receive such
Milestone Payment and the bank account information into which such Milestone Payment should be paid. Oruka shall make such Milestone Payment
to Paragon or Paragon&rsquo;s designee within <FONT STYLE="font-variant: small-caps">[***]</FONT> days after receipt of Paragon&rsquo;s
invoice. Each Milestone Payment shall be paid no more than once, and Oruka&rsquo;s total Milestone Payments hereunder shall not exceed
Twenty-Two Million Dollars ($22,000,000). For avoidance of doubt, upon achievement of any Milestone, all prior unachieved Milestones shall
be deemed thereby achieved and, if the Milestone Payment for any such prior Milestone has not previously been paid, it shall thereupon
also be paid at the same time that the Milestone Payment for such subsequent achieved Milestone is paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Milestone</TD><TD STYLE="vertical-align: bottom; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Milestone Payment</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 8%; font-weight: bold; text-align: center">#1</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 45%; text-align: left">Achievement of Development Candidate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: center">One Million Five Hundred Thousand Dollars ($1,500,000)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center">#2</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">First dosing of a human patient in a Phase I Trial of an Oruka Product</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Two Million Five Hundred Thousand Dollars ($2,500,000)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center">#3</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">First dosing of a human patient in a Phase II Trial of an Oruka Product</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Three Million Dollars ($3,000,000)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center">#4</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">First dosing of a human patient in a Phase III Trial of an Oruka Product</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Five Million Dollars ($5,000,000)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center">#5</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Receipt of Regulatory Approval from the FDA of an Oruka Product</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Ten Million Dollars ($10,000,000)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2&nbsp;<B>Royalties</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;<B>Royalty
Rate for Products</B>. During the applicable Royalty Term (which shall be measured on a country-by-country and Product-by-Product basis),
Oruka shall pay tiered royalties to Paragon (or to such other designee(s), as requested by Paragon) as set forth in the table below on
Annual Net Sales of all Products sold by Oruka, its Affiliates or its Sublicensees in the Field in the Territory (together with any royalties
payable under Section 4.2(b), the &ldquo;<B>Royalty Payments</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; text-align: justify"></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>Annual
                                            Net Sales of the Products in a Given Calendar Year</B></FONT></P></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>Royalty
    Rate</B></FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Portion
    of Annual Net Sales of the Products in a Given Calendar Year Above $0 but Up to and Including $[***]</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">[***]</FONT></P></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">%</FONT></TD></TR>
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Portion
    of Annual Net Sales of the Products in a Given Calendar Year of More Than $[***], Up to and Including $1.0 Billion</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">[***]</FONT></P></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">%</FONT></TD></TR>
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Portion
    of Annual Net Sales of the Products in a Given Calendar Year of More Than $[***]</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">[***]</FONT></P></TD><TD STYLE="font-variant: small-caps; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">%</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;<B>Royalty
Rate for Oruka Multispecific Products</B>. During the applicable Royalty Term (which shall be measured on a country-by-country and Oruka
Multispecific Product-by-Oruka Multispecific Product basis), Oruka shall pay royalties to Paragon (or to such other designee(s), as requested
by Paragon) equal to <FONT STYLE="font-variant: small-caps">[***] </FONT>percent (<FONT STYLE="font-variant: small-caps">[***]</FONT>%)
of Net Sales of all Oruka Multispecific Products sold by Oruka, its Affiliates or its Sublicensees in the Field in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;If
any Oruka Product contains (a) a combination of more than one Licensed Antibody, Derived Antibody and/or Multispecific Antibody, or (b)
a combination of (i) one or more Licensed Antibodies, Derived Antibodies or Multispecific Antibodies, and (ii)&nbsp;one or more other
Antibodies owned or Controlled by Paragon or its Affiliates, the rights to which have been licensed to Oruka or its Affiliates under a
separate agreement, then, in each case (a) or (b) unless otherwise agreed by the Parties, the royalty rate for the Royalty Payments payable
to Paragon with respect to such Oruka Product (x) shall be determined in accordance with the Royalty Rate chart set forth in Section 4.2(a)
if such Oruka Product does not contain a Multispecific Antibody, and (y) shall be determined in accordance with Section 4.2(b) if such
Oruka Product contains a Multispecific Antibody.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3&nbsp;<B>Royalty
Reductions for No Valid Claim</B>. If, during any Calendar Quarter during the Royalty Term for a particular Oruka Product in a particular
country, no Valid Claim of a Licensed Antibody Patent Covers the Manufacture or Commercialization of such Oruka Product in such country,
then the applicable royalty rate for the Royalty Payments set forth in Section 4.2 for such Calendar Quarter shall be reduced by <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4&nbsp;<B>Payment
Reports</B>. Within <FONT STYLE="font-variant: small-caps">[***]</FONT> days after the end of <FONT STYLE="font-variant: small-caps">[***]</FONT>
days for <FONT STYLE="font-variant: small-caps">[***]</FONT> in which an Oruka Product is sold, Oruka shall provide to Paragon a written
report, on an <FONT STYLE="font-variant: small-caps">[***]</FONT> basis, stating the <FONT STYLE="font-variant: small-caps">[***]</FONT>,
including <FONT STYLE="font-variant: small-caps">[***]</FONT>; <FONT STYLE="font-variant: small-caps">[***]</FONT>. All Royalty Payments
described in such written report shall be made by Oruka at the same time it submits such written report to Paragon. All such Royalty Payments
shall be paid to Paragon or Paragon&rsquo;s designee, <I>provided that</I> in the case of payment to a designee, Paragon has notified
Oruka in writing <FONT STYLE="font-variant: small-caps">[***]</FONT> days prior to the due date for any Royalty Payment of the designee
to be paid and the bank account information for such designee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5&nbsp;<B>Payment
Method</B>. All payments due under this Agreement to Paragon shall be made in U.S. Dollars by bank wire transfer in funds to an account
designated by Paragon from time to time reasonably in advance of any payment due date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.6&nbsp;<B>Taxes</B>.
The Parties agree to cooperate with one another and use reasonable efforts to minimize obligations for any and all income or other taxes
required by Applicable Law to be withheld or deducted from any Royalty Payments, Milestone Payments or other payments made by Oruka to
Paragon or its designee(s) under this Agreement, including by completing all procedural steps, and taking all reasonable measures, to
ensure that any withholding tax is reduced or eliminated to the extent permitted under Applicable Law, including income tax treaty provisions
and related procedures for claiming treaty relief. To the extent that Oruka is required to deduct and withhold taxes on any payment to
Paragon or its designee(s), Oruka shall: (i) deduct such taxes from such payment to Paragon or its designee(s), (ii) pay the amounts of
such taxes to the proper Governmental Authority in a timely manner, and (iii) promptly submit to Paragon an official tax certificate or
other available evidence of such withholding sufficient to enable Paragon or its designee(s) to claim such payment of taxes. For the avoidance
of doubt, Oruka&rsquo;s remittance of such withheld amounts to the appropriate Governmental Authority, together with payment to Paragon
or its designee(s) of the remaining amount owed, shall constitute full satisfaction of the applicable payment due to Paragon. Oruka shall
provide Paragon with any reasonably requested tax forms or certificates available to Oruka in order to allow Paragon or its designee(s)
to recover, as permitted by Applicable Law, withholding taxes, value added taxes or similar obligations resulting from payments made hereunder
or to obtain the benefit of any present or future treaty against double taxation that may apply to such payments. Paragon shall promptly
provide Oruka with any requested tax forms that may be reasonably necessary in order for Oruka to not withhold tax or to withhold tax
at a reduced rate under an applicable bilateral tax income treaty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.7&nbsp;<B>Foreign
Exchange</B>. If any currency conversion shall be required in connection with the calculation of amounts payable hereunder, including
in connection with the calculation of Net Sales, such conversions shall be made using the methodology used by Oruka in preparing its publicly
filed financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.8&nbsp;<B>Late
Payments</B>. Any amount owed by Oruka to Paragon under this Agreement that is not paid within the applicable time period set forth herein
will accrue interest at the per annum rate of <FONT STYLE="font-variant: small-caps">[***]</FONT> percentage point above the then-applicable
United States prime rate as quoted in the <I>Wall Street Journal (East Coast Edition)</I> (or if it no longer exists, a similarly authoritative
source), calculated on a <FONT STYLE="font-variant: small-caps">[***] </FONT>basis, or, if lower, the highest rate permitted under Applicable
Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.9&nbsp;<B>Blocked
Currency</B>. If by Applicable Law of a country in which Net Sales occurred, conversion of funds into Dollars or transfer of funds from
such country to the United States is restricted, forbidden or delayed for more than <FONT STYLE="font-variant: small-caps">[***]</FONT>
days, then Oruka can elect, at its sole discretion, that the amounts accrued in such country and owed by Oruka to Paragon under this Agreement
shall be paid to Paragon in such country in local currency by deposit in a local bank designated by Paragon, unless the Parties otherwise
agree in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.10&nbsp;<B>Records;
Inspection</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;Oruka
shall, and shall cause its applicable Affiliates to, create and keep complete and accurate records of its sales and other dispositions
of all Oruka Products, including all records that are reasonably necessary for the purposes of calculating all payments due under this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;Upon
reasonable advance written notice to Oruka, Paragon shall have the right to retain a nationally recognized (in the US) independent certified
public accounting firm to perform on behalf of Paragon an audit, conducted in accordance with U.S. generally accepted accounting principles
(GAAP), of such books and records of Oruka or its applicable Affiliates as may be reasonably necessary to verify the accuracy of any reports
provided pursuant to Section 4.4 hereunder for any Calendar Quarter in which an Oruka Product was sold, ending not more than <FONT STYLE="font-variant: small-caps">[***]</FONT>
calendar months prior to the date of such request. Such audits shall be conducted during normal business hours, shall not occur more frequently
than <FONT STYLE="font-variant: small-caps">[***]</FONT> in each Calendar Year and shall not be conducted more than <FONT STYLE="font-variant: small-caps">[***]</FONT>
with respect to any reporting period, in each case other than for cause. All information disclosed or observed during any audit pursuant
to this Section&nbsp;4.10 shall be the Confidential Information of Oruka, and Paragon shall cause the accounting firm to retain all such
information as Confidential Information, including, if requested by Oruka, by requiring such accounting firm to enter into a customary
confidentiality agreement with Oruka prior to the initiation of any such audit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;Upon
completion of any audit hereunder, the accounting firm shall provide both Oruka and Paragon a written report disclosing whether the reports
submitted by Oruka are correct or incorrect, whether the amounts paid are correct or incorrect, and in each case, the specific details
concerning any discrepancies. No other information regarding Oruka&rsquo;s records shall be provided to Paragon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;Paragon
shall bear its internal expenses and the out-of-pocket costs for engaging such accounting firm in connection with performing such audits;
<I>provided, however</I>, that if any such audit uncovers an underpayment by Oruka that exceeds <FONT STYLE="font-variant: small-caps">[***]</FONT>
percent (<FONT STYLE="font-variant: small-caps">[***]</FONT>%) of the total owed for such payment or payment period, as applicable, then
Oruka shall reimburse Paragon or its designee(s) for the amounts actually paid to such accounting firm for performing such audit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;If
such accounting firm concludes that Oruka has in aggregate underpaid amounts owed to Paragon during the audited period, Oruka shall pay
Paragon or its designee(s) the amount of the discrepancy within <FONT STYLE="font-variant: small-caps">[***]</FONT> days of the date Paragon
delivers to Oruka such accounting firm&rsquo;s written report and an invoice for such amounts. If such accounting firm concludes that
Oruka has in aggregate overpaid amounts owed to Paragon during the audited period, then Oruka may, at its election, either credit such
overpaid amount against any future payment obligation to Paragon or require Paragon to refund such amounts within <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article&nbsp;V</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"></FONT>INTELLECTUAL
PROPERTY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1&nbsp;<B>Ownership</B>.
As between the Parties (a) Paragon solely owns the Licensed Antibody Technology and the Other Licensed Patents, (b) Oruka solely owns
the Oruka Inventions, including any Derived Antibodies and Oruka Multispecific Antibodies to the extent they constitute Oruka Inventions,
(c) each Party solely owns all Intellectual Property Rights owned or Controlled by such Party as of the Effective Date or that come into
the ownership or control of such Party during the Term outside the scope of this Agreement, and (d) ownership of Inventions shall be determined
in accordance with U.S. laws of inventorship. Other than rights granted to Oruka under this Agreement with respect to the Licensed Antibody
Technology and the Other Licensed Patents, nothing in this Agreement shall affect Paragon&rsquo;s rights in any Patents, Know-How or other
Intellectual Property Rights owned or controlled by Paragon or its Affiliates, now or in the future. Other than rights granted to Paragon
under Section 8.5(c) of this Agreement with respect to the Oruka Intellectual Property, nothing in the Agreement shall affect Oruka&rsquo;s
rights in any Patents, Know-How or other Intellectual Property Rights owned or controlled by Oruka or its Affiliates, now or in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2&nbsp;<B>Patent
Prosecution</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;<B>Prosecution
Generally</B>. For the purpose of this Article&nbsp;V, &ldquo;<B>Prosecute</B>&rdquo; and &ldquo;<B>Prosecution</B>&rdquo; shall include
any patent interference, opposition, pre-issuance Third Party submission, <I>ex parte</I> re-examination, post-grant review, <I>inter
partes</I> review or other similar proceeding, appeals or petitions to any board of appeals in a patent office, appeals to any court for
any patent office decisions, reissue proceedings and applications for patent term extensions and the like.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;<B>Prosecution
of Licensed Antibody Patents</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;As
between the Parties, with respect to any patent applications for Licensed Antibody Patents that have not been filed prior to the Effective
Date and any resulting patents (the &ldquo;<B>Post-Effective Date Patents</B>&rdquo;), Paragon shall have the sole right, but not the
obligation, to prepare, file, Prosecute and maintain the Post-Effective Date Patents until the date on which the Final Deliverable (as
defined in the Option Agreement) for the Research Program is delivered to Oruka, and during such period Paragon shall provide Oruka with
drafts of all proposed filings to any patent office with respect to Post-Effective Date Patents in reasonably adequate time before submission
of such filings for Oruka&rsquo;s review and comment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;As
between the Parties, with respect to (x) any patent applications and resulting patents for Licensed Antibody Patents that were filed prior
to the Effective Date, and (y) the Post-Effective Date Patents after the date on which the Final Deliverable (as defined in the Option
Agreement) for the Research Program is delivered to Oruka, Oruka shall have the first right to prepare, file, Prosecute and maintain the
Licensed Antibody Patents, in each case, at Oruka&rsquo;s sole expense. Oruka shall provide Paragon with copies of all material correspondence
from and to any patent office relating to such Licensed Antibody Patents, and Oruka shall provide Paragon with drafts of all proposed
filings to any patent office with respect to such Licensed Antibody Patents before submission of such filings, with reasonably adequate
time for Paragon&rsquo;s review and comment, which review shall be at Paragon&rsquo;s sole expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&nbsp;Each
Party, when acting as the prosecuting Party (in such capacity, the &ldquo;<B>Prosecuting Party</B>&rdquo;) will take into consideration
the non-Prosecuting Party&rsquo;s reasonable comments prior to submitting such filings. At the Prosecuting Party&rsquo;s request, the
non-Prosecuting Party will sign all documents and take any other actions required for filing, maintenance and grant of Licensed Antibody
Patents. Oruka shall reimburse Paragon for any costs and expenses actually incurred by Paragon to the extent Paragon is prosecuting or
maintaining any Licensed Antibody Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&nbsp;The
Prosecuting Party shall notify the non-Prosecuting Party of any decision not to prepare or file, or to abandon, cease Prosecution or not
maintain any Licensed Antibody Patent anywhere in the Territory. The Prosecuting Party shall provide such notice at least <FONT STYLE="font-variant: small-caps">[***]</FONT>
days prior to any filing or payment due date, or any other due date that requires action, in connection with such Licensed Antibody Patent.
In such event, the non-Prosecuting Party shall have a backup right, but not the obligation, to prepare, file, or continue Prosecution
or maintenance of, such Licensed Antibody Patent, at its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)&nbsp;Each
Party shall cooperate with the other Party in the preparation, filing, Prosecution and maintenance of Licensed Antibody Patents, including
in each case by providing the prosecuting Party with data and other information as appropriate and executing all necessary affidavits,
assignments and other paperwork.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;<B>Prosecution
by Paragon</B>. Except with respect to Licensed Antibody Patents (which are addressed in Section 5.2(b)), Paragon shall be solely responsible
for, and have sole discretion over, preparing, filing, Prosecuting and maintaining any Patents (including the Other Licensed Patents and
Paragon Multispecific Patents) that it owns in whole or in part or otherwise Controls (the &ldquo;<B>Paragon Patents</B>&rdquo;). Paragon&rsquo;s
Prosecution of any Paragon Patents shall be at Paragon&rsquo;s sole expense. Notwithstanding the foregoing, in Prosecuting any Paragon
Multispecific Patents, Paragon hereby agrees that during the Term, neither Paragon nor any of its Affiliates or licensees will file, or
assist any Third Party in filing, any Patent that includes a claim that expressly recites the sequence of a Licensed Antibody or Derived
Antibody other than as part of a Paragon Multispecific Antibody.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;<B>Patent
Prosecution Costs Prior to the Effective Date</B>. No later than <FONT STYLE="font-variant: small-caps">[***]</FONT> days after the Effective
Date, Oruka shall reimburse Paragon for any actual costs and expenses incurred by Paragon that are related to the Prosecution of any Licensed
Antibody Patents prior to the Effective Date and that have not already been paid by Oruka. Oruka will promptly reimburse Paragon for any
future Prosecution costs and expenses incurred by Paragon with respect to the Licensed Antibody Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;<FONT STYLE="background-color: white"><B>CREATE
Act</B>. Notwithstanding anything to the contrary in this Agreement, each Party will have the right to invoke the Cooperative Research
and Technology Enhancement Act of 2004, 35 U.S.C. &sect; 103(c)(2)-(c)(3) (the &ldquo;<B>CREATE Act</B>&rdquo;) when exercising its rights
under Article&nbsp;V of this Agreement, without the prior written consent of the other Party. Where such Party intends to invoke the CREATE
Act, it will notify the other Party and the other Party will cooperate and coordinate its activities with such Party with respect to any
submissions, filings or other activities in support thereof. </FONT>The Parties acknowledge and agree that this Agreement is a joint research
agreement (JRA) as defined in the CREATE Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;<FONT STYLE="background-color: white"><B>Disclosure
of Antibody Patents</B>. Upon the request of Paragon, Oruka shall deliver to Paragon a list of the then-existing Oruka Antibody Patents.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3&nbsp;<B>Patent
Enforcement and Defense</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;<B>Notice
of Patent Infringement and Patent Challenge</B>. Each Party shall give the other Party notice of any known or suspected infringement by
a Third Party (&ldquo;<B>Patent Infringement</B>&rdquo;) of any Licensed Antibody Patent and any known or suspected challenge by a Third
Party against the validity or enforceability (&ldquo;<B>Patent Challenge</B>&rdquo;) of any Licensed Antibody Patent within <FONT STYLE="font-variant: small-caps">[***]</FONT>
days after such Patent Infringement or Patent Challenge comes to such Party&rsquo;s attention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;<B>Oruka&rsquo;s
First Right to Enforce or Defend</B>. Oruka shall have the first right, but not the obligation, to bring and control any legal action,
including by declaratory judgment action, patent litigation or similar proceeding, in connection with any Patent Infringement or Patent
Challenge with respect to the Licensed Antibody Patents in the Territory at its own expense and discretion as it reasonably determines
appropriate. Oruka shall keep Paragon informed and reasonably consult with Paragon in the course of such legal action. Paragon shall have
the right to be represented in any such legal action by counsel of its choice at its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;<B>Paragon&rsquo;s
First Right to Enforce or Defend</B>. Paragon shall have the sole right, but not the obligation, to bring and control any legal action,
including by declaratory judgment action, patent litigation or similar proceeding, in connection with any Patent Infringement or Patent
Challenge with respect to the Paragon Patents in the Territory at its own expense and discretion as it reasonably determines appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;<B>Settlement</B>.
In connection with any such legal action or proceeding, Oruka shall not enter into any settlement admitting the invalidity or unenforceability
of Licensed Antibody Patents without the prior written consent of Paragon (such consent not to be unreasonably conditioned, withheld,
or delayed).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;<B>Paragon&rsquo;s
Backup Right to Enforce or Defend</B>. If Oruka does not initiate a legal action for Patent Infringement or Patent Challenge with respect
to any Licensed Antibody Patent within <FONT STYLE="font-variant: small-caps">[***]</FONT> days after a notice from Paragon under Section
5.3(a), then Paragon shall have a backup right, but not the obligation, to initiate such legal action at its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;<B>Allocation
of Recoveries</B>. Any recoveries resulting from such legal action initiated by Oruka or Paragon hereunder relating to Patent Infringement
or Patent Challenge in each case solely with respect to the Licensed Antibody Patents, including pursuant to a settlement, shall be applied
as follows: (i) first to reimburse the <FONT STYLE="font-variant: small-caps">[***]</FONT> of each of the Parties in such action; and
(ii) second, any amounts remaining after paying the amounts due each Party under clause (i) (the &ldquo;<B>Remaining Recovery</B>&rdquo;)
shall be allocated as follows: (1) <FONT STYLE="font-variant: small-caps">[***]</FONT>; or (2) <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&nbsp;<B>Cooperation
with Patent Enforcement</B>. At the request of the enforcing Party (and at the requesting Party&rsquo;s expense), the other Party shall
reasonably cooperate and provide any information or assistance in connection with any legal action under this Section 5.3, including executing
reasonably appropriate documents, cooperating in discovery and, if required by Applicable Law, joining as a party to the legal action
at its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4&nbsp;<B>Third
Party Patent Proceedings</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;<B>Oruka&rsquo;s
First Right to Challenge Third Party Patents</B>. Oruka shall have the sole and exclusive right, but not the obligation, to bring and
control any legal action to challenge any Patents controlled by a Third Party, including by declaratory judgment action, patent interference,
opposition, pre-issuance submission, <I>ex parte</I> re-examination, post-grant review, <I>inter partes</I> review, patent litigation
or similar proceeding, in each case that are necessary or useful to Develop, Manufacture, Commercialize or otherwise exploit any Oruka
Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;<B>Cooperation
by Paragon</B>. At the request of Oruka, Paragon shall cooperate and provide any information or assistance in connection with any legal
action under this Section&nbsp;5.4, including executing reasonably appropriate documents, cooperating in discovery and, if required by
Applicable Law, joining as a party to the action at Oruka&rsquo;s cost and expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.5&nbsp;<B>Common
Interest Agreement</B>. At the request of either Party to conduct the activities under this Article&nbsp;V, the Parties shall cooperate
in good faith to enter into a customary, mutually-agreed common-interest agreement intended to preserve attorney-client privilege with
respect to disclosures and communications by or on behalf of either Party or its Affiliates in connection with such activities.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article&nbsp;VI</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"></FONT><FONT STYLE="font-variant: small-caps">PROTECTION
OF CONFIDENTIAL INFORMATION.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.1&nbsp;<B>Confidentiality</B>.
Except to the extent expressly authorized by this Agreement, the Receiving Party agrees that, during the Term, for <FONT STYLE="font-variant: small-caps">[***]</FONT>
years thereafter, and, with respect to any Know-How that constitutes a trade secret, for long as such Know-How constitutes a trade secret,
it shall keep confidential and shall not publish or otherwise disclose to any Third Party, and shall not use for any purpose other than
as expressly provided for in this Agreement, any Confidential Information of the Disclosing Party. The Receiving Party may disclose Confidential
Information of the Disclosing Party to those of the Receiving Party&rsquo;s Representatives who have a need for such information, <I>provided
that</I> the Receiving Party shall advise such Representatives of the confidential nature thereof, shall ensure that each such Representative
is bound in writing by obligations of confidentiality and non-use at least as stringent as those contained in this Agreement, and shall
be responsible for the compliance of its Representatives with the terms of this Agreement. The Receiving Party shall use at least the
same standard of care as it uses to protect proprietary or confidential information of its own (but in no event less than reasonable care)
to ensure that its Representatives do not disclose or make any unauthorized use of the Confidential Information of the Disclosing Party.
The Receiving Party shall promptly notify the Disclosing Party upon discovery of any unauthorized use or disclosure of the Confidential
Information of the Disclosing Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.2&nbsp;<B>Exceptions</B>.
The Receiving Party&rsquo;s obligations under Section 6.1 shall not apply to any Confidential Information of the Disclosing Party that
the Receiving Party can prove by competent evidence: (a) is now, or hereafter becomes, through no act or failure to act on the part of
the Receiving Party in breach of this Agreement, generally known or available; (b) is known by the Receiving Party at the time of receiving
such information from the Disclosing Party; (c) is hereafter furnished to the Receiving Party by a Third Party, as a matter of right and
without restriction on disclosure; or (d) is independently discovered or developed by the Receiving Party, without the aid, use or application
of any Confidential Information of the Disclosing Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.3&nbsp;<B>Authorized
Disclosure</B>. Notwithstanding the provisions of this Article&nbsp;VI, the Receiving Party may disclose Confidential Information of the
Disclosing Party, without violating its obligations under this Agreement, to the extent the disclosure is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;required
by a valid order of a court or other Governmental Authority of competent jurisdiction or as otherwise required by Applicable Law, rule,
regulation (including securities laws), government requirement, or as may be required in connection with any filings made with, or by
the disclosure policies of, a stock exchange (including, for clarity, any such disclosures required to be made by Paragon or its Affiliates
or licensees in connection with the Development, Manufacture, Commercialization or other exploitation of Multispecific Antibodies), <I>provided
that</I> the Receiving Party shall give reasonable prior written notice to the Disclosing Party of such required disclosure and, at the
<FONT STYLE="font-variant: small-caps">[***]</FONT> request and expense, shall cooperate with the Disclosing Party&rsquo;s efforts to
contest such requirement, to obtain a protective order requiring that the Confidential Information so disclosed be used only for the purposes
for which the order was issued or the law required, or to obtain other confidential treatment of such Confidential Information;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;reasonably
necessary to file or Prosecute patent applications, Prosecute or defend litigation or otherwise establish rights or enforce obligations
under this Agreement, or obtain or maintain approval to conduct clinical trials or Regulatory Approvals, in each case, in accordance with
this Agreement (including, for clarity, any such disclosures that are reasonably necessary to made by Paragon or its Affiliates or licensees
in connection with the Development, Manufacture, Commercialization or other exploitation of Multispecific Antibodies); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;under
appropriate confidentiality provisions substantially equivalent to those in this Agreement (but of shorter duration if customary in the
case of subclause (ii)): (i) in connection with the performance of its obligations or as reasonably necessary or useful in the exercise
of its rights under this Agreement, including the right to grant licenses or sublicenses as permitted hereunder and the right to Develop,
Manufacture, Commercialize and otherwise exploit Antibodies and products (including Multispecific Antibodies and Multispecific Products)
to which it has rights hereunder, or (ii) to actual or <I>bona fide</I> potential licensees, acquirers, merger partners, assignees, collaborators,
investment bankers, investors or lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.4&nbsp;<B>Use
of Names</B>. Except as set forth in Section 6.6(b), neither Party shall use the other Party&rsquo;s name or trademarks in any advertising,
sales, or promotional material or in any publication without the prior written consent of the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.5&nbsp;<B>Confidentiality
of this Agreement</B>. This Agreement and its terms are considered Confidential Information of both Parties, and each Party shall keep
confidential and shall not publish or otherwise disclose the terms of this Agreement without the prior written consent of the other Party,
except as expressly permitted by Section 6.3, and except that both Parties may disclose this Agreement and its terms to its legal, financial
and investment banking advisors; <I>bona fide</I> potential and actual investors, acquirers, merger partners, assignees, collaborators,
investment bankers, lenders, licensees, sublicensees or strategic partners in connection with license or partnering transactions, due
diligence or similar investigations by such Third Parties or in confidential financing documents; and counsel or other advisors for the
foregoing; <I>provided</I>, in each case, that any such Third Party agrees to be bound by obligations of confidentiality and non-use at
least as restrictive as those set forth in this Article&nbsp;VI (<I>provided that</I> the confidentiality term applicable to such Third
Party may be shorter so long as it is commercially reasonable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.6&nbsp;<B>Publicity</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;Subject
to Section 6.6(b), neither Party will generate or allow any publicity regarding this Agreement or the transactions contemplated hereunder
without the other Party first approving such press release or publication in writing, except for any public disclosure by or on behalf
of a Party that is, upon the advice of such Party&rsquo;s counsel, required by Applicable Law or the rules of a stock exchange on which
the securities of such Party are listed (or to which an application for listing has been submitted) and except that a Party may, once
a press release or other public written statement is approved in writing by both Parties, make subsequent public disclosure of the information
contained in such press release or other public written statement without the further approval of the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;The
Parties shall collaborate and cooperate <FONT STYLE="font-variant: small-caps">[***]</FONT> to devise a Publication (as defined below)
strategy for the Oruka Products that is acceptable to both Parties. Prior to publicly presenting or publishing any data, results or analyses
relating to an Oruka Product generated by or on behalf of Oruka pursuant to this Agreement (each such proposed presentation or publication,
a &ldquo;<B>Publication</B>&rdquo;), Oruka will provide Paragon with a copy of such proposed Publication to review with adequate time
for Paragon&rsquo;s review and comment prior to the earlier of its presentation or intended submission for publication (such applicable
period, the &ldquo;<B>Review Period</B>&rdquo;). Oruka will take into consideration Paragon&rsquo;s reasonable comments prior to finalizing
the Publication. Upon Paragon&rsquo;s request, Oruka shall remove any Confidential Information of Paragon from such Publication that Oruka
is not required to disclose pursuant to Applicable Law or the rules of a stock exchange on which the securities of Oruka are listed.&nbsp;
In addition, Paragon shall have the right to request the delay of such Publication for up to <FONT STYLE="font-variant: small-caps">[***]</FONT>
days to enable filing of Patents, which request Oruka will take into consideration and discuss with Paragon before release of the Publication.
Paragon will not publicly present or publish any Publication including Confidential Information of Oruka relating specifically to the
Licensed Antibodies or Derived Antibodies without Oruka&rsquo;s prior written consent, which consent may be withheld for any reason or
no reason; <I>provided, that</I> the foregoing shall not limit Paragon&rsquo;s right to publicly present or publish any Publication relating
to Multispecific Antibodies. Each Publication shall include proper attribution, including the use of such Party&rsquo;s trademarks and
name, to the non-publishing Party, as applicable, and each non-publishing Party expressly authorizes the inclusion of such reference in
the applicable Publication and licenses the use of such trademarks and name solely for inclusion in any such Publication.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article&nbsp;VII</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"></FONT>REPRESENTATIONS,
WARRANTIES AND COVENANTS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.1&nbsp;<B>Mutual
Representations</B>. Each Party represents and warrants to the other Party that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;it
is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other
power and authority to enter into this Agreement and to carry out the provisions hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;it
is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;no
consent, approval, permit, governmental order, declaration or filing with, or notice to, any Governmental Authority or any Third Party
is required by or with respect to such in connection with the execution and delivery of this Agreement and the consummation of the transactions
contemplated hereby; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;this
Agreement is legally binding upon it, enforceable in accordance with its terms, and does not and will not conflict with any agreement,
instrument, or understanding, oral or written, to which it is or may become a party or by which it may be or become bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.2&nbsp;<B>Representations
of Paragon</B>. Paragon hereby represents and warrants to Oruka as of the Effective Date that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;Paragon
has set forth in <U>Exhibit A</U> a true, correct and complete list of all the Licensed Antibody Patents existing as of the Effective
Date (including title, all inventors, owners, assignees, filing date, grant date, expiration date and status);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;Unless
otherwise set forth in <U>Exhibit A</U>, Paragon exclusively owns all Licensed Antibody Patents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;There
are no licenses or sublicenses pursuant to which Paragon licenses as of the Effective Date any of the Licensed Antibody Technology, nor,
to Paragon&rsquo;s actual knowledge, are any such licenses necessary to Develop, Manufacture and Commercialize the Licensed Antibodies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;Paragon
has the right under the Licensed Antibody Technology to grant to Oruka the licenses and other rights set forth in this Agreement, and
it has not granted any license or other right under the Licensed Antibody Technology that is inconsistent with the licenses and other
rights granted to Oruka hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;There
is no pending or, to Paragon&rsquo;s knowledge, threatened litigation, nor has Paragon received any written notice from any Third Party,
asserting or alleging that the development, manufacture or commercialization of the Licensed Antibody Technology prior to the Effective
Date infringed or misappropriated the intellectual property rights of such Third Party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;To
Paragon&rsquo;s knowledge, Paragon has not withheld from Oruka any information with respect to the Licensed Antibody Technology that would
reasonably be expected to be materially adverse to Oruka&rsquo;s Development, Manufacture, or Commercialization of any Product in the
Territory as contemplated under this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&nbsp;To
Paragon&rsquo;s knowledge, Paragon has, and any of Paragon&rsquo;s Affiliates involved in the Research Program have, (i) conducted all
research and development under the Research Program in accordance with Research Plan (as defined in the Option Agreement), and (ii) conducted
the Research Program in compliance with all Applicable Laws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&nbsp;To
Paragon&rsquo;s knowledge, Paragon has provided true, correct and complete copies of all Results developed under the Research Program
and all other deliverables required under the Research Program have been provided or delivered to Oruka and are true, correct and complete
in all material respects;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;Paragon
has properly filed, Prosecuted and maintained all Licensed Antibody Patents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&nbsp;Paragon
has complied with all duties of disclosure and has not engaged in any inequitable conduct with respect to all Licensed Antibody Patents
that were filed prior to the Effective Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&nbsp;All
Licensed Antibody Patents listed in <U>Exhibit A</U> that have been issued as of the Effective Date are in full force and effect and are,
to Paragon&rsquo;s knowledge, valid and enforceable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)&nbsp;Other
than the Patents listed in <U>Exhibit A</U>, as of the Effective Date, neither Paragon nor any of its Affiliates own or have any rights
in, to or under any Patents Covering the composition of matter of, or any method of specifically making or using, any Licensed Antibody;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)&nbsp;There
are no judgments against or awards or settlements against Paragon or any of its Affiliates, and there are no claims, actions, or proceedings
pending or, to Paragon&rsquo;s knowledge, threatened, nor to Paragon&rsquo;s knowledge are there any formal inquiries initiated or written
notices received that are reasonably likely to lead to the institution of any such legal proceedings, in each case (i) relating to any
Licensed Antibodies, Derived Antibodies or Licensed Antibody Technology or alleging that any Third Party has any right to or under any
Products, Licensed Antibodies, Derived Antibodies or Licensed Antibody Technology that would conflict with the rights granted in this
Agreement; or (ii) alleging that any Licensed Antibody Patent is unpatentable, invalid, unenforceable or infringed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(n)&nbsp;(i)
Each Representative employed or engaged by Paragon or its Affiliate to conduct the activities under the Research Program have assigned
or licensed, or are under contractual obligations to assign or license, to Paragon all inventions conceived, reduced to practice or otherwise
related to Licensed Antibodies, Derived Antibodies and Licensed Antibody Technology; (ii) to Paragon&rsquo;s knowledge, no Representative
employed by Paragon or its Affiliate that conducts activities under a Research Program has any obligations under agreements or Applicable
Law to assign any interest in any such inventions to any Third Party; and (iii) each Representative employed or engaged by Paragon or
its Affiliate to conduct the activities under a Research Program have existing obligations under agreements or Applicable Law to maintain
as confidential Paragon&rsquo;s Confidential Information as well as confidential information of other parties (including of Oruka and
its Affiliates);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(o)&nbsp;None
of Paragon, its Representatives, or any other person used by Paragon in the performance of the Research Program or otherwise in connection
with this Agreement has been or is (i) debarred, convicted, or is subject to a pending debarment or conviction, pursuant to section 306
of the United States Food Drug and Cosmetic Act, 21 U.S.C. &sect; 335a, (ii) listed by any government or regulatory agencies as ineligible
to participate in any government healthcare programs or government procurement or non-procurement programs (as that term is defined in
42 U.S.C. &sect; 1320a-7b(f)), or excluded, debarred, suspended or otherwise made ineligible to participate in any such program, or (iii)
convicted of a criminal offense related to the provision of healthcare items or services, or is subject to any such pending action. Paragon
agrees to inform Oruka in writing promptly if Paragon or any person who is performing activities on its behalf under the Agreement is
subject to the foregoing, or if any action, suit, claim, investigation, or proceeding relating to the foregoing is pending or threatened;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(p)&nbsp;No
funding, facilities, or personnel of any Governmental Authority or any public or private educational or research institutions were used
to develop or create any Licensed Antibody Technology, and neither Paragon nor any of its Affiliates has entered into a government funding
relationship that would result in rights to any Products, Licensed Antibodies, Derived Antibodies or Licensed Antibody Technology residing
in the U.S. Government, the National Institutes of Health, or other agency, and the licenses granted hereunder are not subject to overriding
obligations to the U.S. Government as set forth in Public Law 96-517 (35 U.S.C. &sect;&sect;&nbsp;200-204), or any similar obligations
under the laws of any other country in the Territory; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(q)&nbsp;To
the <FONT STYLE="font-variant: small-caps">[***]</FONT> knowledge of <FONT STYLE="font-variant: small-caps">[***]</FONT> of Paragon, with
respect to this Agreement and the Option Agreement, neither Paragon nor any of its directors, officers, employees, distributors, consultants,
agents, representatives, sales intermediaries, or other Third Parties acting on behalf of Paragon or any of its Affiliates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;has
taken any action in violation of any applicable anti-corruption laws, anti-money laundering laws or laws restricting or regulating global
trade (collectively, &ldquo;<B>Anti-Corruption Laws</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;has
conducted or initiated any internal investigation with respect to any alleged act or omission arising under or relating to any potential
noncompliance with any Anti-Corruption Law, or been the subject of current, pending, or threatened investigation, formal or informal inquiry,
enforcement proceedings, or received any notice, request, or citation for alleged violations of such laws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&nbsp;has
engaged in any direct or indirect dealings or transactions in or with a person, entity or country found on the Specially Designated Nationals
and Blocked Persons List maintained by the U.S. Office of Foreign Assets Control, or engaged in any direct or indirect dealings with Sudan,
individuals ordinarily resident in Sudan, or entities incorporated under the laws of Sudan prior to October 12, 2017; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&nbsp;has
offered, paid, given, promised to pay or give, or authorized the payment or gift of, received, or solicited anything of value, directly
or indirectly, to any public official, for the purposes of: influencing any act or decision of any public official in his or her official
capacity; inducing any public official to do or omit to do any act in violation of his or her lawful duty; securing any improper or undue
advantage; or inducing any public official to use his or her influence with a government, Governmental Authority, or commercial enterprise
owned or controlled by any government (including state-owned or controlled veterinary, laboratory or medical facilities) in obtaining
or retaining any business whatsoever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.3&nbsp;<B>Covenants
of Paragon</B>. Paragon hereby covenants to Oruka during the Term that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;Paragon
will not grant a Third Party any license or other right in the Licensed Antibody Technology or the Other Licensed Technology that would
conflict with the rights and licenses granted to Oruka hereunder with respect to such Licensed Antibody Technology;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;Paragon
will, and will direct each Affiliate of Paragon and subcontractor conducting activities under this Agreement to, conduct all such activities
in compliance with Applicable Laws, including all applicable Anti-Corruption Laws and U.S. sanctions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;Paragon
will comply with the terms of each Paragon Third Party Agreement, will maintain each Paragon Third Party Agreement, will not amend a Paragon
Third Party Agreement in a manner that (i) adversely effects Oruka in any material respect, or (ii)&nbsp;increases any financial obligations
under a Paragon Third Party Agreement that will result in an increase in Oruka&rsquo;s Reimbursement Obligation, in each case of (i) and
(ii) without Oruka&rsquo;s prior written consent, and will not take any actions that could reasonably cause any Paragon Third Party Agreement
to lapse or terminate; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;Paragon
will, and will direct each applicable Affiliate of Paragon to, execute and deliver such additional documents and instruments and to perform
such additional acts as may be necessary or appropriate to enable Oruka to exercise its rights and obligations under Sections 5.2, 5.3
and 5.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.4&nbsp;<B>Compliance
with Laws</B>. Each Party shall, and shall ensure that its Affiliates and its and its Affiliates&rsquo; Representatives and sublicensees,
comply with Applicable Laws in all material respects in the performance of its obligations and the exercise of its rights under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.5&nbsp;<B>DISCLAIMER
OF WARRANTIES</B>. EXCEPT AS EXPRESSLY SET FORTH HEREIN, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, DURABILITY, MERCHANTABLE QUALITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT
OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article&nbsp;VIII</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"></FONT>TERM;
TERMINATION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.1&nbsp;<B>Term</B>.
The term of this Agreement shall commence on the Effective Date and shall expire on a country-by-country and Oruka Product-by-Oruka Product
basis on the expiration of the Royalty Term for such Oruka Product in such country, in each case, unless earlier terminated by a Party
as set forth below in this Article&nbsp;VIII (the &ldquo;<B>Term</B>&rdquo;). Upon expiration (but not termination) of the Agreement,
the licenses granted in Section 2.1 shall survive and become royalty-free, fully paid-up, perpetual and irrevocable with respect to the
applicable Oruka Product in the applicable country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2&nbsp;<B>Termination
by Oruka</B>. Oruka shall have the right to terminate this Agreement in its entirety or on a country-by-country or Oruka Product-by-Oruka
Product basis for any or no reason upon sixty (60) days&rsquo; prior written notice to Paragon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.3&nbsp;<B>Material
Breach</B>. Either Party may terminate this Agreement in its entirety for the material breach of this Agreement by the other Party, if
such material breach remains uncured ninety (90) days (or thirty (30) days with respect to any failure to make any payments owing to a
Party hereunder) following notice from the non-breaching Party to the breaching Party specifying such breach, <I>provided that</I>, in
the event of a dispute regarding the existence or cure of a material breach, no termination shall become effective until such dispute
is finally resolved pursuant to Section 10.7 in favor of the non-breaching Party and the breaching Party fails to cure such material breach
within ninety (90) days thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.4&nbsp;<B>Insolvency</B>.
Each Party will have the right to terminate this Agreement in the event of a Bankruptcy Event with respect to the other Party. &ldquo;<B>Bankruptcy
Event</B>&rdquo; means the occurrence of any of the following: (a) the institution of any bankruptcy, receivership, insolvency, reorganization
or other similar proceedings by or against a Party under any bankruptcy, insolvency, or other similar law now or hereinafter in effect,
including any section or chapter of the United States Bankruptcy Code, as amended or under any similar laws of the United States or any
state thereof (the &ldquo;<B>Bankruptcy Code</B>&rdquo;), where in the case of involuntary proceedings such proceedings have not been
dismissed or discharged within <FONT STYLE="font-variant: small-caps">[***]</FONT> days after they are instituted, (b) the insolvency
or making of an assignment for the benefit of creditors, (c) the institution of any reorganization, arrangement or other readjustment
of debt plan of a Party not involving the Bankruptcy Code, or (d)&nbsp;appointment of a receiver for all or substantially all of a Party&rsquo;s
assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.5&nbsp;<B>Effect
of Termination of this Agreement</B>. If this Agreement terminates for any reason (excluding expiration under Section 8.1), whether with
respect to a particular Oruka Product, particular country or in its entirety, then the following shall apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;All
licenses and other rights granted by Paragon under this Agreement with respect to the terminated Oruka Product(s) and terminated country(ies)
shall terminate, except as required for Oruka, its Affiliates and/or its Sublicensees to perform any of its obligations that survive termination,
including to continue to complete or wind down (at <FONT STYLE="font-variant: small-caps">[***]</FONT> expense in the event of a termination
by Oruka under Section 8.3) any ongoing clinical trials for any Oruka Product, as may be required by Applicable Law or ethical principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;No
later than <FONT STYLE="font-variant: small-caps">[***]</FONT> days after the effective date of such termination, each Party shall return
or cause to be returned to the other Party, or destroy, all Confidential Information received from the other Party and all copies thereof
related to the terminated Oruka Product(s) in the terminated country(ies); <I>provided, however</I>, that each Party may retain any Confidential
Information reasonably necessary for such Party&rsquo;s ongoing obligations and rights under this Agreement which do not terminate, and
each Party may keep one (1) copy of Confidential Information received from the other Party in its confidential files for record purposes
and such copy shall remain subject to Article&nbsp;VI of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;Upon
Paragon&rsquo;s written request to Oruka (which must be provided to Oruka within <FONT STYLE="font-variant: small-caps">[***]</FONT> days
after the effective date of termination), Paragon and Oruka shall <FONT STYLE="font-variant: small-caps">[***]</FONT> discuss <FONT STYLE="font-variant: small-caps">[***]</FONT>,
for a period of up to <FONT STYLE="font-variant: small-caps">[***]</FONT> days following such written request, terms and conditions under
which Oruka may be willing to grant to Paragon <FONT STYLE="font-variant: small-caps">[***]</FONT>, <FONT STYLE="font-variant: small-caps">[***]</FONT>
license under the Oruka Intellectual Property to Develop, Manufacture, Commercialize or otherwise exploit the terminated Oruka Products
in the Field in the terminated countries that were the subject of any Development, Manufacturing or Commercialization activities performed
by Oruka or its Affiliates under this Agreement prior to such termination, (&ldquo;<B>Reversion Products</B>&rdquo;), as well as the potential
transfer of materials, ongoing clinical trials, and applicable regulatory filings and relevant data generated by Oruka with respect to
the Reversion Products and necessary for the continued Development, Manufacture, Commercialization and exploitation of such Reversion
Products, such agreement to include commercially reasonable financial and other terms, which terms shall take into consideration Oruka&rsquo;s
contributions made in the Development, Manufacture, Commercialization and other exploitation of the Reversion Products, provided, that
Oruka is under no obligation to enter into such license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.6&nbsp;<B>Survival
of Sublicenses</B>. Upon termination of this Agreement, at the written request of any Sublicensee who is not then in breach of its sublicense
agreement, such sublicense agreement will survive such termination of this Agreement, and Paragon will negotiate <FONT STYLE="font-variant: small-caps">[***]</FONT>
the terms and conditions of a direct license with such Sublicensee that is consistent with the terms of this Agreement (as adjusted for
the scope of license, products, field of use and other provisions of the original sublicense). Each sublicense that may be amended to
become a direct license between Paragon and a Sublicensee shall ensure that any and all economic rights, payments or benefits due to Oruka
will be preserved and payable to Oruka and will designate Oruka a third-party beneficiary to enforce such rights. In each such instance,
Oruka will have the right to review and approve the terms of such agreement between Paragon and such Sublicensee as related to Oruka&rsquo;s
economic rights, which approval shall not be unreasonably withheld, conditioned or delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.7&nbsp;<B>Accrued
Rights; Survival</B>. The expiration or termination of this Agreement for any reason shall not release either Party from any liability
or obligation that, at the time of such expiration or termination, has already accrued to the other Party or that is attributable to a
period prior to such expiration or termination, nor will expiration or any termination of this Agreement preclude either Party from pursuing
all rights and remedies it may have under this Agreement, or at law or in equity, with respect to breach of this Agreement. In the event
of expiration or any termination of this Agreement, the following provisions of this Agreement shall survive such expiration or termination
in accordance with their respective terms and conditions: Article&nbsp;I (Definitions); Section 2.1 (License Grant from Paragon) (upon
expiration (but not termination) of this Agreement as set forth in Section 8.1 (Term)); Section 2.3 (Sublicenses) (with respect to any
payments or other performance obligations prior to conversion (if any) to a direct license pursuant to Section 8.6); Section 2.4 (No Implied
Licenses; Reservation of Rights); Section 4.1 (Milestone Payments) (with respect to any outstanding payment obligations incurred prior
to the date of termination or expiration); Section 4.2 (Royalties) (with respect to any outstanding payments accrued prior to the effective
date of termination); Section 4.4 (Payment Reports) (with respect to the last Calendar Quarter of the Term to the extent not already reported
and any outstanding payment obligation with respect to any royalty payments accrued prior to the date of termination or expiration); Section
4.5 (Payment Method) to 4.9 (Blocked Currency) (for the duration of any outstanding payment obligations under this Agreement); Section
4.10 (Records; Inspection) (for the duration set forth therein); Section 5.1 (Ownership); Section 7.5 (Disclaimer of Warranties); Article&nbsp;VI
(Protection of Confidential Information) (for the duration set forth therein); Section 8.5 (Effect of Termination of this Agreement);
Section 8.6 (Survival of Sublicenses); Section 8.7 (Accrued Rights; Survival); Article&nbsp;IX (Indemnification); and Article&nbsp;X (Miscellaneous).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article&nbsp;IX</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"></FONT>INDEMNIFICATION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">9.1&nbsp;</FONT><B>By
Oruka</B>. Oruka hereby agrees to defend, indemnify and hold harmless Paragon, its Affiliates and its or their Representatives (each,
an &ldquo;<B>Paragon Indemnitee</B>&rdquo;) from and against any and all losses, damages, liabilities, expenses and costs, including reasonable
legal expense and attorneys&rsquo; fees (collectively, &ldquo;<B>Losses</B>&rdquo;), to which any Paragon Indemnitee may become subject
(a) as a result of any claim, demand, action, or other proceeding by any Third Party (&ldquo;<B>Third Party Claim</B>&rdquo;) to the extent
such Losses result from: (i) the gross negligence, recklessness or willful misconduct of any Oruka Indemnitee in the performance of this
Agreement; (ii)&nbsp;Oruka&rsquo;s breach of any of its representations, warranties or covenants under this Agreement; or (iii) Oruka&rsquo;s
Development, Manufacture and Commercialization of the Oruka Products; and (b) to the extent such Losses result from the termination, suspension,
revocation or other loss of any Licensed Antibody Patents as a result of any negligence or breach of this Agreement by Oruka, its Affiliates
or Sublicensees, in each case ((a) to (b)), except in each case to the extent that any Losses are attributable to the breach of this Agreement
by, or the negligence, recklessness or willful misconduct of, or otherwise indemnifiable by, any Paragon Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"></FONT></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">9.2&nbsp;</FONT><B>By
Paragon</B>. Paragon hereby agrees to defend, indemnify, and hold harmless Oruka, its Affiliates, and its or their Representatives (each,
a &ldquo;<B>Oruka Indemnitee</B>&rdquo;) from and against any and all Losses to which any Oruka Indemnitee may become subject (a) as a
result of any Third Party Claim to the extent such Losses result from: (i) the gross negligence, recklessness or willful misconduct of
any Paragon Indemnitee in the performance of this Agreement; or (ii) Paragon&rsquo;s breach of any of its representations, warranties
or covenants under this Agreement; and (b) to the extent such Losses result from: (i) the termination, suspension, revocation or other
loss of any Licensed Antibody Patents as a result of any negligence or breach of this Agreement by Paragon or its Affiliates; or (ii)
any claim or demand from any employee or contractor of Paragon or its Affiliates who is an inventor of any Licensed Antibody Patents with
respect to ownership thereof, in each case ((a) to (b)), except to the extent that any Losses are attributable to the breach of this Agreement
by, or the negligence, recklessness or willful misconduct of, or otherwise indemnifiable by, any Oruka Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.3&nbsp;<B>Indemnification
<FONT STYLE="background-color: white">Procedures</FONT></B><FONT STYLE="background-color: white">. </FONT>The Party claiming indemnity
under this Article&nbsp;IX (the &ldquo;<B>Indemnified Party</B>&rdquo;) will give written notice to the Party from whom indemnity is being
sought (the &ldquo;<B>Indemnifying Party</B>&rdquo;) promptly after learning of the Third Party Claim for which indemnity is being sought
(&ldquo;<B>Claim</B>&rdquo;). The Indemnifying Party&rsquo;s obligation to defend, indemnify and hold harmless pursuant to Section&nbsp;9.1
or Section&nbsp;9.2, as applicable, will be reduced to the extent the Indemnified Party&rsquo;s delay in providing notification pursuant
to the previous sentence results in material prejudice to the Indemnifying Party; <I>provided, however,</I> that the failure by an Indemnified
Party to give such notice or otherwise meet its obligations under this Section 9.3 will not relieve the Indemnifying Party of its indemnification
obligation under this Agreement. At its option, the Indemnifying Party may assume the defense and have exclusive control, at its own expense,
of any Claim for which indemnity is being sought by giving written notice to the Indemnified Party within <FONT STYLE="font-variant: small-caps">[***]</FONT>
days after receipt of the notice of the Claim. The Indemnified Party will provide the Indemnifying Party with reasonable assistance, at
the Indemnifying Party&rsquo;s expense, in connection with the defense. The Indemnified Party may participate in and monitor such defense
with counsel of its own choosing at its sole expense; <I>provided, however, </I>the Indemnifying Party will have the right to assume and
conduct the defense of the Claim with counsel of its choice. The Indemnifying Party will not settle any Claim without the prior written
consent of the Indemnified Party, not to be unreasonably withheld, unless the settlement involves only the payment of money. The Indemnified
Party will not settle any such Claim without the prior written consent of the Indemnifying Party. If the Indemnifying Party does not assume
and conduct the defense of the Claim as provided above, (i) the Indemnified Party may defend against, and consent to the entry of any
judgment or enter into any settlement with respect to the Claim in any manner the Indemnified Party may deem reasonably appropriate, <I>provided,
that</I> the Indemnified Party reasonably consults with the Indemnifying Party prior to entering into any settlement, and (ii) the Indemnified
Party reserves any right it may have under this Article&nbsp;IX to obtain indemnification from the Indemnifying Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.4&nbsp;<B>Limitation
of Liability</B>. EXCEPT FOR LIABILITY FOR BREACH OF <FONT STYLE="text-transform: uppercase">Article&nbsp;VI, FOR Breach of Sections 2.1
or 2.2, for breach of any intellectual property rights held by a party, for the fraud or willful misconduct of a party</FONT> OR FOR INDEMNIFICATION
CLAIMS UNDER THIS <FONT STYLE="text-transform: uppercase">Article&nbsp;IX</FONT>, IN NO EVENT SHALL EITHER PARTY BE ENTITLED TO RECOVER
FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT, EVEN IF THE OTHER PARTY
HAD NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.5&nbsp;<B>Insurance</B>.
During the Term and for a period of <FONT STYLE="font-variant: small-caps">[***]</FONT> years thereafter, each Party shall maintain at
its expense insurance coverage consistent with normal business practices and adequate to cover the risks associated with its performance
of any activities hereunder. Each Party hereby expressly acknowledges and agrees that the maintenance of such insurance coverage shall
not relieve it of its obligations under this Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article&nbsp;X</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"></FONT>MISCELLANEOUS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.1&nbsp;<B>Independent
Contractor Relationship</B>. Paragon&rsquo;s relationship with Oruka is that of an independent contractor, and nothing in this Agreement
should be construed to create a partnership, joint venture, or employer-employee relationship. Neither Party is an agent of the other
Party or authorized to make any representation, contract, or commitment on behalf of the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.2&nbsp;<B>Force
Majeure</B>. Neither Party will be charged with any liability for delay or failure in performance of an obligation under this Agreement
(other than any obligation to pay monies when due) to the extent such delay or failure is due to a cause beyond the reasonable control
of the affected Party, such as war, riots, labor disturbances, epidemic, pandemic, fire, explosion, and compliance in good faith with
any Applicable Law (in each case, a &ldquo;<B>Force Majeure</B>&rdquo;). In addition, a Force Majeure event may include reasonable measures
affirmatively taken by a Party or its Affiliates to respond to the COVID-19 pandemic or any other pandemic (or other Force Majeure event),
such as requiring employees to stay home, closures of facilities, delays of clinical trials, or cessation of activities in response to
the pandemic. The Party affected by a Force Majeure will give prompt written notice to the other Party of the nature of the cause of any
material delay or failure to perform, its anticipated duration and any action being taken to avoid or minimize the effect. The Party affected
will use its diligent efforts to avoid or remove such causes of delay or failure to perform and to mitigate the effect of such occurrence,
and will continue performance in accordance with the terms of this Agreement whenever such causes are removed. The Party affected will
give prompt written notice to the other Party of such resumed performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.3&nbsp;<B>Entire
Agreement; Amendment</B>. This Agreement and the Option Agreement, together with all Exhibits attached hereto, constitutes the final,
complete, and exclusive agreement of the Parties with respect to the subject matter hereof and supersedes all prior and contemporaneous
understandings and agreements, relating to its subject matter. This Agreement (including its Exhibits) may not be changed, modified, amended,
or supplemented except by a written instrument signed by both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.4&nbsp;<B>Non-Waiver</B>.
The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this
Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that
instance or in any other instance. Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular
matter and, if applicable, for a particular period of time and shall be signed by such Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.5&nbsp;<B>Severability</B>.
Should one or more of the provisions of this Agreement become void or unenforceable as a matter of Applicable Law, then this Agreement
shall be construed as if such provision were not contained herein and the remainder of this Agreement shall be in full force and effect,
and the Parties will use their best efforts to substitute for the invalid or unenforceable provision a valid and enforceable provision
which conforms as nearly as possible with the original intent of the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.6&nbsp;<B>Assignment</B>.
Neither this Agreement nor any rights or obligations hereunder may be assigned by either Party without the prior written consent of the
other Party (which consent shall not be unreasonably withheld); <I>provided, however</I>, that (a) Paragon may assign to an Affiliate
or a Third Party financing source its rights to receive some or all of the payments payable hereunder together with the right to receive
Confidential Information of Oruka, <I>provided</I> Paragon shall not be permitted to share Oruka Confidential Information unless and except
to the extent necessary to obtain Affiliate or Third-Party financing, <I>provided, further, that</I> any such Affiliate or Third Party
agrees to be bound by obligations of confidentiality and non-use at least as restrictive as those set forth in Article&nbsp;VI; and (b)&nbsp;either
Party may assign this Agreement and its rights and obligations hereunder without the other Party&rsquo;s consent to (i) its Affiliates
or (ii) its successor to all or substantially all of the business of such Party to which this Agreement relates, whether by merger, sale
of stock, sale of assets or otherwise. The assigning Party shall provide the other Party with prompt written notice of any such assignment
set forth in clauses (a) and (b) above. Except for an assignment pursuant to clause (a) above, the rights and obligations of the Parties
under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties, and the name
of a Party appearing herein will be deemed to include the name of such Party&rsquo;s successors and permitted assigns to the extent necessary
to carry out the intent of this section. Any assignment not in accordance with this Agreement shall be void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.7&nbsp;<B>Dispute
Resolution</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;The
Parties recognize that a <I>bona fide </I>dispute as to certain matters may arise from time to time during the Term relating to either
Party&rsquo;s rights or obligations hereunder or otherwise relating to the validity, enforceability or performance of this Agreement,
including disputes relating to alleged breach or termination of this Agreement but excluding any disputes relating to Article&nbsp;VI
or disputes relating to the determination of the validity, scope, infringement, enforceability, inventorship or ownership of the Parties&rsquo;
respective Intellectual Property Rights (hereinafter, a &ldquo;<B>Dispute</B>&rdquo;). In the event of the occurrence of any Dispute,
the Parties will follow the following procedures in an attempt to resolve the dispute or disagreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;The
Party claiming that such a Dispute exists will give notice in writing (a &ldquo;<B>Notice of Dispute</B>&rdquo;) to the other Party of
the nature of the Dispute. The Dispute will be referred to the then Chief Executive Officer of Paragon and the then Chief Executive Officer
of Oruka who will meet no later than <FONT STYLE="font-variant: small-caps">[***]</FONT> days following the initial receipt of the Notice
of Dispute and use reasonable endeavors to resolve the Dispute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;If,
within <FONT STYLE="font-variant: small-caps">[***]</FONT> days of initial receipt of the Notice of Dispute, the Dispute has not been
resolved, or if, for any reason, the meeting described in Section 10.7(a)(i) hereof has not been held within <FONT STYLE="font-variant: small-caps">[***]</FONT>
days of initial receipt of the Notice of Dispute, then the Parties agree that such Dispute will be finally resolved through binding arbitration
to be administered by JAMS pursuant to its Comprehensive Arbitration Rules and Procedures and in accordance with the Expedited Procedures
in those Rules (the &ldquo;<B>JAMS Rules</B>&rdquo;), as specifically modified by the provisions of this Section 10.7(a)(ii) and Section
10.7(a)(iii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&nbsp;The
arbitration will be conducted by a panel of three arbitrators. Within <FONT STYLE="font-variant: small-caps">[***]</FONT> days after the
initiation of the arbitration, each Party will nominate one person to act as arbitrator, and the two arbitrators so named will then jointly
appoint the third arbitrator within <FONT STYLE="font-variant: small-caps">[***]</FONT> days of their appointment, who will serve as chairman
of the panel. All three arbitrators must be independent Third Parties having at least <FONT STYLE="font-variant: small-caps">[***]</FONT>
years of dispute resolution experience (which may include judicial experience) or legal or business experience in the biotech or pharmaceutical
industry. If either Party fails to nominate its arbitrator, or if the arbitrators selected by the Parties cannot agree on a person to
be named as chairman within such <FONT STYLE="font-variant: small-caps">[***]</FONT>-day period, JAMS will make the necessary appointments
for such arbitrator(s) or the chairman. Once appointed by a Party, such Party will have no <I>ex parte </I>communication with its appointed
arbitrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&nbsp;Notwithstanding
the provisions of Section 10.7(a)(iii), if the Dispute involves an amount in question of less than $<FONT STYLE="font-variant: small-caps">[***]</FONT>,
then the arbitration will be conducted by one arbitrator, selected in accordance with the JAMS Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)&nbsp;The
place of arbitration will be in Boston, Massachusetts or such other venue as the Parties may mutually agree. The arbitration proceedings
and all communications with respect thereto will be in English. Any written evidence originally in another language will be submitted
in English translation accompanied by the original or a true copy thereof. The arbitrator(s) shall have the power to decide all matters
in Dispute, including any questions of whether or not such matters are subject to arbitration hereunder. The arbitration will be governed
by the Federal Arbitration Act, 9 U.S.C. &sect;&sect;1 <I>et seq., </I>and judgment upon the award rendered by the arbitrators may be
entered in any court having competent jurisdiction thereof. The existence, content and results of any arbitration proceedings pursuant
to this Section 10.7 will be deemed the Confidential Information of both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;Notwithstanding
any provision of this Agreement to the contrary, either Party may immediately initiate litigation in any court of competent jurisdiction
seeking any remedy at law or in equity, including the issuance of a preliminary, temporary or permanent injunction, to preserve or enforce
its rights under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;The
Parties agree that any disputes relating to Article&nbsp;VI or disputes relating to the determination of the validity, scope, infringement,
enforceability, inventorship or ownership of the Parties&rsquo; respective Intellectual Property Rights shall be subject to the exclusive
jurisdiction of the state and federal courts in Boston, Massachusetts and each Party hereby submits to such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.8&nbsp;<B>Governing
Law</B>. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without reference
to conflicts of laws principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.9&nbsp;<B>Notices</B>.
Any notice to be given under this Agreement must be in writing and delivered either in person, by internationally recognized express courier,
or by email, to the Party to be notified at its address(es) given below, or at any address such Party has previously designated by prior
written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earliest of: (a) the date of actual receipt;
(b) if delivered by express courier, the next Business Day the express courier regularly makes deliveries; or (c) if delivered by email,
upon the date upon which the receipt of such email is confirmed by return email. Together with any notice provided by a Party to the other
Party in accordance with this Section 10.9, the Party shall send a copy of such notice by email to the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="width: 13%"><FONT STYLE="font-family: Times New Roman, Times, Serif">If to Paragon:</FONT></TD>
  <TD STYLE="width: 80%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Paragon Therapeutics, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">221 Crescent Street</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Building 23, Suite 105</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Waltham, MA 02453</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Attn: Chief Operating Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Email: <FONT STYLE="font-variant: small-caps">[***]</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">If to Oruka:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Oruka Therapeutics, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">855 Oak Grove Avenue, Suite 100</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Menlo Park, CA 94025</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Attn: General Counsel</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Email: <FONT STYLE="font-variant: small-caps">[***]</FONT></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.10&nbsp;<B>Interpretation</B>.
Except where the context expressly requires otherwise, (a)&nbsp;the use of any gender herein shall be deemed to encompass references to
either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b)&nbsp;the words &ldquo;include&rdquo;,
&ldquo;includes&rdquo; and &ldquo;including&rdquo; shall be deemed to be followed by the phrase &ldquo;without limitation&rdquo;, (c)&nbsp;the
word &ldquo;will&rdquo; shall be construed to have the same meaning and effect as the word &ldquo;shall&rdquo;, (d)&nbsp;any definition
of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or
other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements
or modifications set forth herein), (e) any reference herein to any person or entity shall be construed to include such person&rsquo;s
or entity&rsquo;s successors and assigns, (f) the words &ldquo;herein&rdquo;, &ldquo;hereof&rdquo; and &ldquo;hereunder&rdquo;, and words
of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references
herein to Sections or Exhibits shall be construed to refer to Sections or Exhibits of this Agreement, and references to this Agreement
include all Exhibits hereto, (h) the word &ldquo;notice&rdquo; means notice in writing (whether or not specifically stated) and shall
include notices, consents, approvals and other written communications contemplated under this Agreement, (i) provisions that require that
a Party, the Parties or any committee hereunder &ldquo;agree,&rdquo; &ldquo;consent&rdquo; or &ldquo;approve&rdquo; or the like shall
require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or
otherwise (but excluding e-mail and instant messaging), (j) references to any specific law, or article, section or other division thereof,
shall be deemed to include the then-current amendments thereto or any replacement or successor law thereof, and (k) the term &ldquo;or&rdquo;
shall be interpreted in the inclusive sense commonly associated with the term &ldquo;or.&rdquo; The headings of clauses contained in this
Agreement preceding the text of the sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference
only and shall not constitute any part of this Agreement or have any effect on its interpretation or construction. Ambiguities and uncertainties
in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the
ambiguity or uncertainty to exist. This Agreement has been prepared in the English language, and the English language shall control its
interpretation. In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral, or other communications
between the Parties regarding this Agreement shall be in the English language. To the extent there is any inconsistency or conflict between
the terms and conditions of this Agreement and any Exhibit, the terms and conditions of this Agreement will prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.11&nbsp;<B>No
Third-Party Rights</B>. The provisions of this Agreement are for the exclusive benefit of the Parties and their successors and permitted
assigns, and no other person shall have any right or claim against any Party by reason of these provisions or be entitled to enforce any
of these provisions against any Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.12&nbsp;<B>Counterparts</B>.
This Agreement may be executed in counterparts, each of which shall be deemed an original document, and all of which, together with this
writing, shall be deemed one instrument. This Agreement may be executed by facsimile or PDF signatures, or electronic signatures complying
with the ESIGN Act of 2000 (such as DocuSign), which signatures shall have the same force and effect as original signatures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.13&nbsp;<B>Expenses</B>.
Each Party shall pay its own costs, charges and expenses incurred in connection with the negotiation, preparation and completion of this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.14&nbsp;<B>Binding
Effect</B>. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives, successors
and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.15&nbsp;<B>Construction</B>.
The Parties hereto acknowledge and agree that: (a) each Party and its counsel reviewed and negotiated the terms and provisions of this
Agreement and have contributed to its revision; (b) the rule of construction to the effect that any ambiguities are resolved against the
drafting Party shall not be employed in the interpretation of this Agreement; and (c) the terms and provisions of this Agreement shall
be construed fairly as to all Parties hereto and not in a favor of or against any Party, regardless of which Party was generally responsible
for the preparation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.16&nbsp;<B>Cumulative
Remedies</B>. No remedy referred to in this Agreement is intended to be exclusive unless explicitly stated to be so, but each shall be
cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.17&nbsp;<B>Performance
by Affiliates</B>. A Party may perform some or all of its obligations under this Agreement through Affiliate(s) or may exercise some or
all of its rights under this Agreement through Affiliates, subject to the terms of this Agreement. However, each Party shall remain responsible
and be guarantor of the performance by its Affiliates and shall cause its Affiliates to comply with the provisions of this Agreement in
connection with such performance as if such Party were performing such obligations itself, and references to a Party in this Agreement
shall be deemed to also reference such Affiliate. In particular and without limitation, all Affiliates of a Party that receive Confidential
Information of the other Party pursuant to this Agreement shall be governed and bound by all obligations set forth in Article&nbsp;VI<I>,
</I>and shall be subject to the intellectual property provisions of Article&nbsp;V as if they were the original Party to this Agreement
(and be deemed included in the actual Party to this Agreement for purposes of all intellectual property-related definitions). A Party
and its Affiliates shall be jointly and severally liable for their performance under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<I>Remainder of Page Left Intentionally Blank;
Signature Page Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Parties
have by duly authorized persons executed this Agreement as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-variant: small-caps"><B>Paragon Therapeutics, Inc.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-variant: small-caps"><B>Oruka Therapeutics, Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ K. Evan Thompson</TD>
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Lawrence Klein</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name:&nbsp;</TD>
    <TD>K. Evan Thompson</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Lawrence Klein</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">Title:</TD>
    <TD STYLE="width: 35%">Chief Operating Officer</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 5%">Title:</TD>
    <TD STYLE="width: 35%">Chief Executive Officer</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase">[Signature Page to License
Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>9
<FILENAME>ea023044501ex10-31_orukathe.htm
<DESCRIPTION>IL-23 LICENSE AGREEMENT BY AND BETWEEN PARAGON THERAPEUTICS, INC. AND ORUKA THERAPEUTICS, INC., DATED DECEMBER 17, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: normal small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"> </P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-variant: normal">Exhibit
10.31</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>[***]
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I)&nbsp;IS
NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</B></FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">IL-23 LICENSE AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>This
License Agreement</B></FONT> (&ldquo;<B>Agreement</B>&rdquo;) is entered into and effective as of December 17, 2024 (the &ldquo;<B>Effective
Date</B>&rdquo;), by and between Paragon Therapeutics, Inc., a Delaware corporation (&ldquo;<B>Paragon</B>&rdquo;), and Oruka Therapeutics,
Inc., a Delaware corporation (&ldquo;<B>Oruka</B>&rdquo;). Paragon and Oruka are also referred to herein individually as a &ldquo;<B>Party</B>&rdquo;,
or collectively as the &ldquo;<B>Parties</B>.&rdquo;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: normal; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: normal; text-transform: uppercase">Recitals</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Whereas</B>,</FONT>
Paragon has developed a proprietary platform technology for the discovery and development of antibodies against therapeutically relevant
targets<FONT STYLE="background-color: white">;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps; background-color: white"><B>Whereas</B>,</FONT>
<FONT STYLE="background-color: white">pursuant to that certain Amended and Restated Antibody Discovery and Option Agreement by and among
Paragon, Oruka and Paruka Holding, LLC, a Delaware limited liability company, dated as of March 28, 2024 (as such agreement may be further
amended from time to time, the &ldquo;<B>Option Agreement</B>&rdquo;), </FONT>Oruka has engaged Paragon to identify, evaluate and develop
one or more antibody candidates directed to certain therapeutic targets and has been granted an exclusive option to enter into one or
more separate license agreements to develop, manufacture and commercialize the resulting antibodies with respect to a given target;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Whereas</B></FONT>,
Oruka has exercised such option with respect to the Licensed Target (as defined below), and the Parties desire to memorialize the exclusive
license from Paragon to Oruka with respect to such Licensed Target, all on the terms and subject to the conditions set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Now
Therefore, </B></FONT>in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">Article&nbsp;I</FONT><BR>
<BR>
DEFINITIONS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following initially capitalized
terms have the following meanings (and derivative forms of them shall be interpreted accordingly):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1&nbsp;&ldquo;<B>Achievement
of Development Candidate</B>&rdquo; means the first to occur of: (a)&nbsp;nomination by Oruka&rsquo;s Board of Directors of an Oruka Product
as a &ldquo;Development Candidate&rdquo;; and (b)&nbsp;the&nbsp;initiation by or on behalf of Oruka or its Affiliate or Sublicensee of
a toxicology study with respect to an Oruka Product that employs applicable then-current good laboratory practice standards, the results
of which are intended to be submitted as part of an IND.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.2&nbsp;&ldquo;<B>Acquired
Program</B>&rdquo; has the meaning set forth in Section 2.2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.3&nbsp;&ldquo;<B>Acquiring
Entity</B>&rdquo; means, collectively, the Third Party referenced in the definition of Change of Control and such Third Party&rsquo;s
Affiliates, other than (a) the applicable Party in the definition of Change of Control, and (b) such Party&rsquo;s Affiliates, determined
immediately prior to the closing of such Change of Control ((a) and (b) collectively, the &ldquo;<B>Pre-Existing Entities</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.4&nbsp;&ldquo;<B>Affiliate</B>&rdquo;
means any entity controlled by, controlling, or under common control with a Party hereto. For the purpose of this definition, &ldquo;control&rdquo;
(including, with correlative meaning, the terms &ldquo;controlled by&rdquo; or &ldquo;under common control&rdquo;) means the direct or
indirect ownership of more than fifty percent (50%) of the voting interest in, or more than fifty percent (50%) in the equity of, or the
right to appoint more than fifty percent (50%) of the directors or management of, such corporation or other business entity. Notwithstanding
the foregoing, (a) with respect to either Party, Affiliates of such Party do not include <FONT STYLE="font-variant: small-caps">[***]</FONT>
or its Affiliates other than such Party and its subsidiaries, (b) Paragon and its Affiliates, on the one hand, and Oruka and its subsidiaries,
on the other hand, shall not be deemed to be Affiliates of each other, and (c) Affiliates of Paragon do not include new entities formed
by or on behalf of Paragon for the sole <I>bona fide </I>purpose of further developing, manufacturing, commercializing or otherwise exploiting
Antibodies and Antibody products (excluding any Licensed Antibody Technology or Other Licensed Technology) using, among other sources,
funds from Third Party investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.5&nbsp;&ldquo;<B>Agreement</B>&rdquo;
has the meaning set forth in the preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.6&nbsp;&ldquo;<B>Annual
Net Sales</B>&rdquo; means total Net Sales by Oruka, its Affiliates and Sublicensees in the Territory of all of the Products in a particular
Calendar Year, calculated in accordance with U.S. generally accepted accounting principles (GAAP) consistently applied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.7&nbsp;&ldquo;<B>Anti-Corruption
Laws</B>&rdquo; has the meaning set forth in Section 7.2(q)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.8&nbsp;&ldquo;<B>Antibody</B>&rdquo;
means any molecule, including <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.9&nbsp;&ldquo;<B>Applicable
Law</B>&rdquo; means any national, supra-national, federal, state or local laws, rules, guidances, and regulations, in each case, as applicable
to the subject matter and the Party at issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.10&nbsp;&ldquo;<B>Bankruptcy
Code</B>&rdquo; has the meaning set forth in Section 8.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.11&nbsp;&ldquo;<B>Bankruptcy
Event</B>&rdquo; has the meaning set forth in Section 8.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.12&nbsp;&ldquo;<B>Business
Day</B>&rdquo; means any day other than Saturday, Sunday or a national holiday in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.13&nbsp;&ldquo;<B>Calendar
Quarter</B>&rdquo; means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and
December 31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.14&nbsp;&ldquo;<B>Calendar
Year</B>&rdquo; means each successive period of twelve (12) months commencing on January 1 and ending on December 31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.15&nbsp;&ldquo;<B>Change
of Control</B>&rdquo; means, with respect to any entity, any of the following: (a)&nbsp;the sale or disposition of all or substantially
all of the assets of such entity or its direct or indirect controlling Affiliate to a Third Party; or (b) (i) the acquisition by a Third
Party, alone or together with any of its Affiliates, other than an employee benefit plan (or related trust) sponsored or maintained by
such entity or any of its Affiliates, of more than fifty percent (50%) of the then-outstanding shares of voting capital stock of such
entity or its direct or indirect parent entity that holds, directly or indirectly, beneficial ownership of more than fifty percent (50%)
of the then-outstanding shares of voting capital stock of such entity (a &ldquo;<B>Parent Entity</B>&rdquo;), or (ii) the acquisition,
merger or consolidation of such entity or its Parent Entity with or into another entity, other than, in the case of clause (i) or (ii),
an acquisition or a merger or consolidation of such entity or its Parent Entity in which the holders of shares of voting capital stock
of such entity or its Parent Entity, as the case may be, immediately prior to such acquisition, merger or consolidation will beneficially
own, directly or indirectly, at least fifty percent (50%) of the shares of voting capital stock of the acquiring Third Party or the surviving
corporation in such acquisition, merger or consolidation, as the case may be, immediately after such acquisition, merger or consolidation,
and in each case of (a) or (b), whether through a single transaction or a series of related transactions, but excluding any and all <I>bona
fide</I> financing transactions or internal reorganizations for tax purposes (including the change of place of incorporation or domicile
of such entity).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.16&nbsp;&ldquo;<B>Claim</B>&rdquo;
has the meaning set forth in Section 9.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.17&nbsp;&ldquo;<B>COC
Program</B>&rdquo; has the meaning set forth in Section 2.2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.18&nbsp;&ldquo;<B>Combination
Product</B>&rdquo; has the meaning set forth in Section 1.59.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.19&nbsp;&ldquo;<B>Commercialize</B>&rdquo;
or &ldquo;<B>Commercializing</B>&rdquo; means any and all activity to market, promote, distribute, offer for sale, sell, have sold, seek
reimbursement, import, have imported, export, have exported, or otherwise commercialize an Antibody or product, including any Licensed
Antibody, Derived Antibody, Product, Multispecific Antibody, Multispecific Product, as applicable, and including interacting with Regulatory
Authorities following receipt of Regulatory Approval and seeking and maintaining any required Reimbursement Approval. When used as a noun,
&ldquo;<B>Commercialization</B>&rdquo; means any and all activities involved in Commercializing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.20&nbsp;&ldquo;<B>Commercially
Reasonable Efforts</B>&rdquo; means those efforts and resources, including reasonably necessary and qualified personnel, equivalent to
the efforts and resources that a reasonable international biopharmaceutical company or a pharmaceutical company, in each case, that is
of comparable size and resources to the applicable Party would typically devote as part of an active and continuing program of development
and commercialization of a pharmaceutical or biologic product of similar market potential, at a similar stage of its product life, taking
into account the competitiveness of the marketplace and the proprietary position, regulatory status, and relative safety and efficacy
of such product. Commercially Reasonable Efforts requires, with respect to an obligation, that the applicable Party (a) assign responsibility
for such obligation to specific employees who are held accountable for progress and monitor such progress on an on-going basis, (b) set
and seek to achieve reasonable objectives for carrying out such obligation, and (c) make and implement reasonable decisions and allocate
resources designed to advance progress with respect to such objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.21&nbsp;&ldquo;<B>Confidential
Information</B>&rdquo; of a Party means Know-How and any and all non-public scientific, business, regulatory or technical information
that is disclosed or made available by or on behalf of one Party (the &ldquo;<B>Disclosing Party</B>&rdquo;) to the other Party (the &ldquo;<B>Receiving
Party</B>&rdquo;) in connection with this Agreement, regardless of whether such information is specifically marked or designated confidential,
whether in writing, orally, visually, or otherwise. Notwithstanding any provision of this Agreement to the contrary, the Licensed Antibody
Technology shall be the Confidential Information of Oruka.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.22&nbsp;&ldquo;<B>Control</B>&rdquo;
(including any variations such as &ldquo;<B>Controlled</B>&rdquo; and &ldquo;<B>Controlling</B>&rdquo;) means, with respect to any technology
(including Know-How) or other Intellectual Property Rights, possession by a Party or one of its Affiliates of the ability (whether by
ownership, license or otherwise (other than by a license, sublicense or other right granted pursuant to this Agreement)) to grant a license
or a sublicense of or under such technology or Intellectual Property Rights without violating the terms of any agreement or other arrangement
with any Third Party; <I>provided, that</I> if following the Effective Date (a)&nbsp;Paragon would Control any Patent that would be included
in the Licensed Antibody Technology or Other Licensed Patents but for an obligation to pay royalties or other consideration for the Development,
Manufacture or Commercialization of an Oruka Product in the Territory in connection with a grant to Oruka of a license under such Patent,
and (b)&nbsp;Oruka, pursuant to Section 2.8, consents to being a sublicensee of such Patent and complies with the Reimbursement Obligation,
then such Patent shall be deemed Controlled by Paragon. Notwithstanding the foregoing, a Party and its Affiliates shall not be deemed
to &ldquo;Control&rdquo; any technology or Intellectual Property Rights that (i) prior to the consummation of a Change of Control of such
Party is owned or in-licensed, or (ii)&nbsp;after the consummation of a Change of Control of such Party, becomes owned or in-licensed
(to the extent such technology or Intellectual Property Rights are developed outside of the scope of the activities conducted hereunder
and without use of or reference to any technology or Intellectual Property Rights Controlled by such Party or any Affiliate of such Party
immediately before such Change of Control, or any Confidential Information of the other Party), in each case ((i) or (ii)), by a Third
Party that becomes an Affiliate of such Party after the Effective Date as a result of such Change of Control or an assignee of such Party
after the Effective Date as the result of an assignment of this Agreement in connection with a Change of Control unless prior to the consummation
of such Change of Control or assignment, such Party or any of its Affiliates also Controlled such technology or Intellectual Property
Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.23&nbsp;&ldquo;<B>Cover</B>&rdquo;
or &ldquo;<B>Covering</B>&rdquo; means, with respect to a particular product, any Patent, that, in the absence of a license granted under,
or ownership of, such Patent, the making, using, selling, importation, or exportation of such product would infringe a valid and unexpired
claim of such Patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.24&nbsp;<B>&ldquo;Derived
Antibody&rdquo;</B> means any Antibody that is created by or on behalf of Oruka (other than an Antibody created by Paragon under the Option
Agreement), its Affiliates or its or their licensees and: (a) is derived from or constitutes a modification of a Licensed Antibody, including
<FONT STYLE="font-variant: small-caps">[***]</FONT>, (b) <FONT STYLE="font-variant: small-caps">[***]</FONT> and (c) <FONT STYLE="font-variant: small-caps">[***]</FONT>.
For avoidance of doubt, any Antibody <FONT STYLE="font-size: 10pt">that </FONT><FONT STYLE="font-variant: small-caps">[***] </FONT><FONT STYLE="font-size: 10pt">will
be deemed a Derived Antibody, irrespective of origin, so long as such Antibody satisfies the requirements of (a), (b) and (c).</FONT>
Notwithstanding the foregoing, a Derived Antibody shall not include (i) <FONT STYLE="font-variant: small-caps">[***]</FONT>, or (ii) <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.25&nbsp;&ldquo;<B>Designated
Multispecific Antibody</B>&rdquo; has the meaning set forth in Section&nbsp;2.6(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.26&nbsp;&ldquo;<B>Develop</B>&rdquo;
or &ldquo;<B>Developing</B>&rdquo; means any and all activity to discover, evaluate, test (including clinical and non-clinical testing),
research, or otherwise develop an Antibody or product, including any Licensed Antibody, Derived Antibody, Product, Multispecific Antibody,
or Multispecific Product, as applicable. When used as a noun, &ldquo;<B>Development</B>&rdquo; means any and all activities involved in
Developing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.27&nbsp;&ldquo;<B>Directed
To</B>&rdquo; means, with regard to an Antibody or product, that such Antibody or product is developed or designed to (a) <FONT STYLE="font-variant: small-caps">[***]</FONT>,
and (b) <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.28&nbsp;&ldquo;<B>Disclosing
Party</B>&rdquo; has the meaning set forth in Section 1.21.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.29&nbsp;&ldquo;<B>Dispute</B>&rdquo;
has the meaning set forth in Section 10.7(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.30&nbsp;&ldquo;<B>Dollar</B>&rdquo;
means a U.S. dollar, and &ldquo;$&rdquo; shall be interpreted accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.31&nbsp;&ldquo;<B>Effective
Date</B>&rdquo; has the meaning set forth in the preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.32&nbsp;&ldquo;<B>Exclusivity
Period</B>&rdquo; means the period commencing on the Effective Date and continuing until the fifth (5th) anniversary of the Effective
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.33&nbsp;&ldquo;<B>FDA</B>&rdquo;
means the United States Food and Drug Administration, or a successor federal agency thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.34&nbsp;&ldquo;<B>Field</B>&rdquo;
means the prophylaxis, palliation, treatment and diagnosis of human disease and disorders except the therapeutic area of inflammatory
bowel disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.35&nbsp;&ldquo;<B>First
Commercial Sale</B>&rdquo; means the first sale of an Oruka Product by Oruka, or one of its Affiliates or its or their Sublicensees, to
a Third Party after receipt of all Regulatory Approvals required to market and sell the Oruka Product have been obtained in the country
in the Territory in which such Oruka Product is sold. Sales for purposes of testing the Oruka Product and sample purposes shall not be
deemed a First Commercial Sale. Furthermore, for purposes of clarity, the term &ldquo;First Commercial Sale&rdquo; as used in this Agreement
shall not include: (a) <FONT STYLE="font-variant: small-caps">[***]</FONT>; (b) <FONT STYLE="font-variant: small-caps">[***]</FONT>; nor
(c) <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.36&nbsp;&ldquo;<B>Force
Majeure</B>&rdquo; has the meaning set forth in Section 10.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.37&nbsp;&ldquo;<B>Governmental
Authority</B>&rdquo; means any national, international, federal, state, provincial, or local government, or political subdivision thereof,
or any multinational organization or any authority, agency, or commission entitled to exercise any administrative, executive, judicial,
legislative, police, regulatory, or taxing authority or power, or any court or tribunal (or any department, bureau or division thereof,
or any governmental arbitrator or arbitral body).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.38&nbsp;&ldquo;<B>IND</B>&rdquo;
means an investigational new drug application or equivalent application that is required to commence clinical trials for a product in
the Territory and filed with the applicable Regulatory Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.39&nbsp;&ldquo;<B>Indemnified
Party</B>&rdquo; has the meaning set forth in Section 9.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.40&nbsp;&ldquo;<B>Indemnifying
Party</B>&rdquo; has the meaning set forth in Section 9.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.41&nbsp;&ldquo;<B>Intellectual
Property Rights</B>&rdquo; means any and all proprietary rights provided under (a) patent law, including any Patents; (b) copyright law;
(c) trademark law; or (d) any other applicable statutory provision or common law principle, including trade secret law, that may provide
a right in Know-How, or the expression or use thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.42&nbsp;&ldquo;<B>Inventions</B>&rdquo;
means all Know-How, and all Intellectual Property Rights therein, that are conceived, reduced to practice, discovered, developed, or made
by or on behalf of either Party or any Third Parties acting on their behalf (or any of their Representatives, Affiliates, licensees, or
sublicensees) in the course of performing activities under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.43&nbsp;&ldquo;<B>JAMS
Rules</B>&rdquo; has the meaning set forth in Section 10.7(a)(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.44&nbsp;&ldquo;<B>Know-How</B>&rdquo;
means all technical information and know-how in any tangible or intangible form, including (a) inventions, discoveries, trade secrets,
data, specifications, instructions, processes, formulae, materials (including cell lines, vectors, plasmids, nucleic acids and the like),
methods, protocols, expertise and any other technology, including the applicability of any of the foregoing to formulations, compositions
or products or to their manufacture, development, registration, use or marketing or to methods of assaying or testing them or processes
for their manufacture, formulations containing them or compositions incorporating or comprising them, and (b) all data, instructions,
processes, formulae, strategies, and expertise, whether biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical,
physical, analytical, or otherwise and whether related to safety, quality control, manufacturing or other disciplines. Notwithstanding
the foregoing, Know-How excludes any Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.45&nbsp;&ldquo;<B>Licensed
Antibody</B>&rdquo; means the Antibodies listed in <U>Exhibit B</U> as &ldquo;Licensed Antibodies&rdquo; that are Directed To the Licensed
Target and that were discovered, generated, identified or characterized by Paragon in the course of performing the Research Program. Notwithstanding
the foregoing, the Licensed Antibodies shall not include (a) <FONT STYLE="font-variant: small-caps">[***]</FONT>, or (b) <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.46&nbsp;&ldquo;<B>Licensed
Antibody Invention</B>&rdquo; means (a) any invention or discovery, whether or not patentable, that was discovered or reduced to practice
by or on behalf of Paragon under the Research Program that constitutes the composition of matter of, or any method of specifically making
or using, any Licensed Antibody; and (b) all Intellectual Property Rights therein, that in each case is Controlled by Paragon or its Affiliates
as of the Effective Date or during the Term. Notwithstanding the foregoing, the Licensed Antibody Inventions shall not include (i) <FONT STYLE="font-variant: small-caps">[***]</FONT>,
(x) <FONT STYLE="font-variant: small-caps">[***]</FONT>, or (y) <FONT STYLE="font-variant: small-caps">[***]</FONT>, or (ii) any Intellectual
Property Rights therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.47&nbsp;&ldquo;<B>Licensed
Antibody Patents</B>&rdquo; means all Patents that Cover the composition of matter of, or any method of specifically making or using,
any Licensed Antibody, that in each case are Controlled by Paragon or its Affiliates as of the Effective Date or during the Term, excluding
in each case any claims in such Patents that Cover the composition of matter of, or any method of specifically making or using (a) <FONT STYLE="font-variant: small-caps">[***]</FONT>,
or (b) <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.48&nbsp;&ldquo;<B>Licensed
Antibody Technology</B>&rdquo; means (a) the Licensed Antibody Inventions; (b) the Licensed Antibody Patents; (c) the Sequence Information;
(d) the Results; (e) the Research Program Materials; and (f)&nbsp;all Intellectual Property Rights therein Controlled by Paragon or its
Affiliates as of the Effective Date and during the Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.49&nbsp;&ldquo;<B>Licensed
Component</B>&rdquo; has the meaning set forth in Section 1.59.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.50&nbsp;&ldquo;<B>Licensed
Target</B>&rdquo; means IL-23.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.51&nbsp;&ldquo;<B>Losses</B>&rdquo;
has the meaning set forth in Section 9.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.52&nbsp;&ldquo;<B>MAA</B>&rdquo;
means (a) a New Drug Application in the United States, as defined in the United States Federal Food, Drug and Cosmetics Act, and applicable
regulations promulgated thereunder by the FDA; (b) a Biologics License Application in the United States, as defined in the United States
Public Health Service Act; or (c) any application filed with any Regulatory Authority in a country other than the United States that is
equivalent to either of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.53&nbsp;&ldquo;<B>Major
Market Country</B>&rdquo; means any of the following: <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.54&nbsp;&ldquo;<B>Manufacture</B>&rdquo;
or &ldquo;<B>Manufacturing</B>&rdquo; <FONT STYLE="font-size: 10pt">means </FONT>any and all activity <FONT STYLE="font-size: 10pt">to
make, have made, produce, manufacture, process, fill, finish, package, label, perform quality assurance testing, release, or ship </FONT>an
Antibody or product, including any Licensed Antibody, Derived Antibody, Product, Multispecific Antibody, or Multispecific Product, as
applicable, <FONT STYLE="font-size: 10pt">or any component thereof.</FONT> When used as a noun, &ldquo;<B>Manufacture</B>&rdquo; or &ldquo;<B>Manufacturing</B>&rdquo;
means any and all activities involved in Manufacturing an Antibody or product, including any Licensed Antibody, Derived Antibody, Product,
Multispecific Antibody, or Multispecific Product, as applicable, or any component thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.55&nbsp;&ldquo;<B>Milestone</B>&rdquo;
has the meaning set forth in Section 4.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.56&nbsp;&ldquo;<B>Milestone
Payment</B>&rdquo; has the meaning set forth in Section 4.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.57&nbsp;&ldquo;<B>Multispecific
Antibody</B>&rdquo; means any Antibody that is comprised of (a) <FONT STYLE="font-variant: small-caps">[***]</FONT>, and (b) <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.58&nbsp;&ldquo;<B>Multispecific
Product</B>&rdquo; means any product that comprises or contains any Multispecific Antibody.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.59&nbsp;&ldquo;<B>Net
Sales</B>&rdquo; means the gross amounts received for Oruka Product by Oruka, its Affiliates and Sublicensees for sales or other commercial
disposition of such Oruka Product in the Territory to unrelated Third Parties, less the following, in each case related specifically to
the Oruka Product and actually incurred, paid or accrued by Oruka, its Affiliates or Sublicensees and not otherwise recovered by or reimbursed
to Oruka, its Affiliates or Sublicensees;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;<FONT STYLE="font-variant: small-caps">[***]</FONT>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;<FONT STYLE="font-variant: small-caps">[***]</FONT>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;<FONT STYLE="font-variant: small-caps">[***]</FONT>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;<FONT STYLE="font-variant: small-caps">[***]</FONT>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;<FONT STYLE="font-variant: small-caps">[***]</FONT>;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;<FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net Sales will include <FONT STYLE="font-variant: small-caps">[***]</FONT>.
Net Sales will be calculated only once for the first <I>bona fide</I> arm&rsquo;s length sale of the Oruka Product by Oruka, its Affiliates
or its Sublicensees to a Third Party, and will not include sales between or among <FONT STYLE="font-variant: small-caps">[***]</FONT>.
Net Sales shall not include any amounts invoiced for <FONT STYLE="font-variant: small-caps">[***]</FONT>, (ii) <FONT STYLE="font-variant: small-caps">[***]</FONT>,
or (iii) <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net Sales shall be determined from the books and
records of Oruka<I>, </I>Affiliates of Oruka or any Sublicensee maintained in accordance with U.S. generally accepted accounting principles
(GAAP) consistently applied. Oruka further agrees in determining Net Sales, it (or its applicable Affiliate or Sublicensee) will use Oruka&rsquo;s
(or such Affiliate&rsquo;s or Sublicensee&rsquo;s) then current standard procedures and methodology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an Oruka Product is sold as a Combination Product (as defined below),
the Net Sales of such Combination Product for the purpose of calculating royalties and sales-based milestones owed under this Agreement
for sales of such Combination Product, shall be determined as follows: <FONT STYLE="font-variant: small-caps">[***]</FONT>. If any Other
Component in the Combination Product is not sold separately, Net Sales shall be calculated by <FONT STYLE="font-variant: small-caps">[***]</FONT>.
If both the Licensed Component and any of the Other Components are not sold separately, the adjustment to Net Sales shall be determined
by the Parties <FONT STYLE="font-variant: small-caps">[***]</FONT> to reasonably reflect <FONT STYLE="font-variant: small-caps">[***]</FONT>
of such Licensed Component in the Combination Product to the total fair market value of such Combination Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For purposes of this definition, &ldquo;<B>Combination Product</B>&rdquo;
means any pharmaceutical product that contains two (2) or more active ingredients, including (A) one (1) or more Licensed Antibodies,
Derived Antibodies or Multispecific Antibodies (the &ldquo;<B>Licensed Component</B>&rdquo;), and (B) one (1) or more active pharmaceutical
or biological ingredients that are not (x) a Licensed Antibody, Derived Antibody or Multispecific Antibody, or (y) an Antibody owned or
controlled by Paragon or its Affiliate, the rights to which have been licensed to Oruka or its Affiliate under a separate agreement (&ldquo;<B>Other
Component(s)</B>&rdquo;), either as a <FONT STYLE="font-variant: small-caps">[***]</FONT>, <FONT STYLE="font-variant: small-caps">[***]
</FONT>or <FONT STYLE="font-variant: small-caps">[***]</FONT>, and <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.60&nbsp;&ldquo;<B>Notice
of Dispute</B>&rdquo; has the meaning set forth in 10.7(a)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.61&nbsp;&ldquo;<B>Oruka</B>&rdquo;
has the meaning set forth in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.62&nbsp;&ldquo;<B>Oruka
Antibody Patents</B>&rdquo; means all Patents that Cover the composition of matter of, or any method of specifically making or using any
Licensed Antibody or Derived Antibody that, in each case, are owned or in-licensed by Oruka or its Affiliates or Sublicensees as of the
Effective Date or during the Term, <I>provided that</I>, if a Change of Control of Oruka occurs, the Oruka Antibody Patents shall not
include any Patents owned or in-licensed by the Acquiring Entity as of the closing of such Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.63&nbsp;&ldquo;<B>Oruka
Cross License Patents</B>&rdquo; means any Patents Controlled by Oruka or its Affiliates as of the Effective Date or during the Term that
Cover the composition of matter or method of treatment of the Retained IL-23 Project Antibodies. Notwithstanding the foregoing, the Oruka
Cross License Patents shall not include any Patents that Cover (a) <FONT STYLE="font-variant: small-caps">[***]</FONT>, or (b)&nbsp;<FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.64&nbsp;&ldquo;<B>Oruka
Indemnitee</B>&rdquo; has the meaning set forth in Section&nbsp;9.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.65&nbsp;&ldquo;<B>Oruka
Intellectual Property</B>&rdquo; means any Patents, Know-How or other Intellectual Property Rights that are Controlled by Oruka and are
necessary for, and actually used (or held for use) by Oruka or its Affiliates as of the effective date of termination of this Agreement
in the Development, Manufacturing, or Commercialization of Oruka Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.66&nbsp;&ldquo;<B>Oruka
Invention</B>&rdquo; means (a) any Invention that is owned or Controlled by Oruka, and (b) all Intellectual Property Rights therein, <I>provided
that</I>, in each case (a) &ndash; (b), Oruka Inventions shall not include (i) any Inventions owned or Controlled by Paragon or its Affiliate,
the rights to which have been licensed to Oruka or its Affiliate under this Agreement or a separate agreement, or (ii) any Intellectual
Property Rights therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.67&nbsp;&ldquo;<B>Oruka
Multispecific Antibody</B>&rdquo; means any Multispecific Antibody that is Developed, Manufactured, Commercialized or otherwise exploited
by Oruka, its Affiliates or Sublicensees, excluding in each case, and subject to Section 2.7, any Paragon Multispecific Antibody.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.68&nbsp;&ldquo;<B>Oruka
Multispecific Patents</B>&rdquo; means those Patents that Cover the composition of matter of, or any method of specifically making or
using, an Oruka Multispecific Antibody.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.69&nbsp;&ldquo;<B>Oruka
Multispecific Product</B>&rdquo; means any product that comprises or contains any Oruka Multispecific Antibody.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.70&nbsp;&ldquo;<B>Oruka
Product</B>&rdquo; means, individually or collectively, as applicable, Licensed Antibodies, Derived Antibodies, Products, Oruka Multispecific
Antibodies and Oruka Multispecific Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.71&nbsp;&ldquo;<B>Other
Component(s)</B>&rdquo; has the meaning set forth in Section 1.59.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.72&nbsp;&ldquo;<B>Other
Licensed Know-How</B>&rdquo; means all Know-How Controlled by Paragon or its Affiliates on the Effective Date or during the Term that
(a) was used by or on behalf of Paragon in the performance of the Research Program, and (b) is necessary to Develop, Manufacture, Commercialize
or otherwise exploit (i) Licensed Antibodies, or (ii) Products, Multispecific Antibodies or Multispecific Products, in each case solely
to the extent comprising or containing a Licensed Antibody. For clarity, the Other Licensed Know-How shall exclude (x) the Licensed Antibody
Technology, and (y) any Know-How Controlled by Paragon or its Affiliates relating to (1) that <FONT STYLE="font-variant: small-caps">[***]</FONT>,
or (2) <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.73&nbsp;&ldquo;<B>Other
Licensed Patents</B>&rdquo; means any Patents other than Licensed Antibody Patents Controlled by Paragon or its Affiliates as of the Effective
Date or during the Term that (a) include a claim that expressly recites the sequence of a Licensed Antibody or Derived Antibody, and (b)
are necessary to Develop, Manufacture or Commercialize Licensed Antibodies or Derived Antibodies in the Field in the Territory. Notwithstanding
the foregoing, the Other Licensed Patents shall not include (i) Paragon Multispecific Patents, (ii) the Paragon Platform Patents (as defined
in the Option Agreement), or (iii) any Patents that Cover (x) that <FONT STYLE="font-variant: small-caps">[***]</FONT>, or (y) <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.74&nbsp;&ldquo;<B>Other
Licensed Technology</B>&rdquo; means all (a) Other Licensed Know-How, and (b)&nbsp;Other Licensed Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.75&nbsp;&ldquo;<B>Paragon</B>&rdquo;
has the meaning set forth in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.76&nbsp;&ldquo;<B>Paragon
Cross License Patents</B>&rdquo; means any Patents (other than Licensed Antibody Patents or Other Licensed Patents) Controlled by Paragon
or its Affiliates as of the Effective Date or during the Term that Cover the composition of matter or method of treatment of the Licensed
Antibodies. Notwithstanding the foregoing, the Paragon Cross License Patents shall not include (a) the Paragon Multispecific Patents,
(b) the Paragon Platform Patents (as defined in the Option Agreement), or (c) any Patents that Cover (i) <FONT STYLE="font-variant: small-caps">[***]</FONT>,
or (ii) <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.77&nbsp;&ldquo;<B>Paragon
Indemnitee</B>&rdquo; has the meaning set forth in Section 9.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.78&nbsp;&ldquo;<B>Paragon
Multispecific Antibody</B>&rdquo; means any Multispecific Antibody that is Developed, Manufactured, Commercialized or otherwise exploited
by Paragon or its Affiliate or licensees (other than Oruka and its Affiliates and Sublicensees), excluding in each case any Oruka Multispecific
Antibodies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.79&nbsp;&ldquo;<B>Paragon
Multispecific Patents</B>&rdquo; means those Patents that Cover the composition of matter of, or any method of specifically making or
using, a Paragon Multispecific Antibody, in each case excluding the Licensed Antibody Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.80&nbsp;&ldquo;<B>Paragon
Patents</B>&rdquo; has the meaning set forth in Section 5.2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.81&nbsp;&ldquo;<B>Paragon
Third Party Agreement</B>&rdquo; has the meaning set forth in Section 2.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.82&nbsp;&ldquo;<B>Parent
Entity</B>&rdquo; has the meaning set forth in Section 1.15.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.83&nbsp;&ldquo;<B>Party</B>&rdquo;
has the meaning set forth in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.84&nbsp;&ldquo;<B>Patent
Challenge</B>&rdquo; has the meaning set forth in Section 5.3(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.85&nbsp;&ldquo;<B>Patent
Infringement</B>&rdquo; has the meaning set forth in Section 5.3(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.86&nbsp;&ldquo;<B>Patents</B>&rdquo;
means <FONT STYLE="font-size: 10pt">(a) unexpired patents and patent applications, (b) any and all patent applications filed either from
such patent or patent applications or from a patent application claiming priority from any of those, including divisionals, provisionals,
continuations, continuations-in-part, and reissues, (c) substitutions, renewals, registrations, re-examinations, revalidations, extensions,
supplementary protection certificates and the like of any such patents and patent applications, and (d) any and all foreign equivalents
of the foregoing</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.87&nbsp;&ldquo;<B>Phase
I Trial</B>&rdquo; means a human clinical trial in any country of the type described in 21 C.F.R. &sect;312.21(a), or the foreign equivalent
thereof, regardless of where such clinical trial is conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.88&nbsp;&ldquo;<B>Phase
II Trial</B>&rdquo; means a human clinical trial in any country of the type described in 21 C.F.R. &sect;312.21(b), or the foreign equivalent
thereof, regardless of where such clinical trial is conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.89&nbsp;&ldquo;<B>Phase
III Trial</B>&rdquo; means a human clinical trial in any country of the type described in 21 C.F.R. &sect;312.21(c), or the foreign equivalent
thereof, regardless of where such clinical trial is conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.90&nbsp;&ldquo;<B>Post-Effective
Date Patents</B>&rdquo; has the meaning set forth in Section 5.2(b)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.91&nbsp;&ldquo;<B>Pre-Existing
Entities</B>&rdquo; has the meaning set forth in Section 1.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.92&nbsp;&ldquo;<B>Product</B>&rdquo;
means any product that comprises or contains any Licensed Antibody or Derived Antibody other than as part of a Multispecific Antibody
or a Multispecific Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.93&nbsp;&ldquo;<B>Prosecute</B>&rdquo;
or &ldquo;<B>Prosecution</B>&rdquo; has the meaning set forth in Section 5.2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.94&nbsp;&ldquo;<B>Prosecuting
Party</B>&rdquo; has the meaning set forth in Section 5.2(b)(iii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.95&nbsp;&ldquo;<B>Publication</B>&rdquo;
has the meaning set forth in Section 6.6(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.96&nbsp;&ldquo;<B>Receiving
Party</B>&rdquo; has the meaning set forth in Section 1.21.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.97&nbsp;&ldquo;<B>Regulatory
Approval</B>&rdquo; means all clearances, approvals (including approval of an MAA as well as any applicable pricing and/or reimbursement
approvals), licenses, registrations or authorizations of any Regulatory Authority necessary to commercially distribute, sell and market
a pharmaceutical product in a country or territory under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.98&nbsp;&ldquo;<B>Regulatory
Authority</B>&rdquo; means any supranational, multinational, federal, national, state, provincial or local regulatory agency, department,
bureau or other Governmental Authority with authority over the clinical development, manufacture marketing or sale of an Oruka Product
in a country or region, including the FDA in the United States and the EMA in Europe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.99&nbsp;&ldquo;<B>Reimbursement
Obligation</B>&rdquo; has the meaning set forth in Section 2.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.100&nbsp;&ldquo;<B>Remaining
Recovery</B>&rdquo; has the meaning set forth in Section 5.3(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.101&nbsp;&ldquo;<B>Representatives</B>&rdquo;
of a Party means such Party&rsquo;s officers, directors, employees, contractors, subcontractors, agents and consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.102&nbsp;&ldquo;<B>Research
Program</B>&rdquo; means the Research Program (as defined in the Option Agreement) conducted by the Parties pursuant to the Option Agreement
with respect to the Licensed Target.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.103&nbsp;&ldquo;<B>Research
Program Materials</B>&rdquo; means the tangible materials resulting from the Research Program that are Controlled by Paragon or its Affiliates
as of the Effective Date or during the Term that are listed in <U>Exhibit C</U> attached hereto, as may be amended in writing from time
to time upon mutual agreement of the Parties. For clarity, Research Program Materials shall not include materials that are consumed or
destroyed in the performance of the Research Program or that are not available to be transferred by Paragon to Oruka without violating
the terms of any agreement or other arrangement with a Third Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.104&nbsp;&ldquo;<B>Results</B>&rdquo;
means all data, results, analysis, conclusions, outcomes, information, documentation and reports that are generated by or on behalf of
Paragon in performance of the Research Program, excluding in each case any other Licensed Antibody Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.105&nbsp;&ldquo;<B>Retained
IL-23 Antibody Patents</B>&rdquo; means all Patents that Cover the composition of matter of, or any method of specifically making or using,
the Retained IL-23 Project Antibodies that in each case are owned by Paragon as of the Effective Date and are set forth on <U>Exhibit
E</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.106&nbsp;&ldquo;<B>Retained
IL-23 Project Antibodies</B>&rdquo; has the meaning set forth in the Option Agreement. A list of the Retained IL-23 Project Antibodies,
identified by individual sequence identifier numbers, is set forth on <U>Exhibit D</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.107&nbsp;&ldquo;<B>Retained
IL-23 Project Antibody Licensee</B>&rdquo; means any assignee or licensee of Paragon with respect to Paragon&rsquo;s rights in the Retained
IL-23 Project Antibodies and the Retained IL-23 Antibody Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.108&nbsp;&ldquo;<B>Reversion
Products</B>&rdquo; has the meaning set forth in Section 8.5(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.109&nbsp;&ldquo;<B>Review
Period</B>&rdquo; has the meaning set forth in Section 6.6(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.110&nbsp;&ldquo;<B>ROFN
Information</B>&rdquo; has the meaning set forth in Section 2.7(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.111&nbsp;&ldquo;<B>ROFN
Negotiation Period</B>&rdquo; has the meaning set forth in Section 2.7(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.112&nbsp;&ldquo;<B>ROFN
Period</B>&rdquo; has the meaning set forth in Section 2.7(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.113&nbsp;&ldquo;<B>Royalty
Payments</B>&rdquo; has the meaning set forth in Section&nbsp;4.2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.114&nbsp;&ldquo;<B>Royalty
Term</B>&rdquo; means, on an Oruka Product-by-Oruka Product and country-by-country basis, the period commencing on First Commercial Sale
of the applicable Oruka Product in the applicable country in the Territory and ending, with respect to the particular Oruka Product and
country at issue on the latest of the following dates: (a) the twelfth (12th) anniversary of the date of First Commercial Sale of such
Oruka Product in such country; or (b) the expiration of the last-to-expire Valid Claim of a Licensed Antibody Patent or an Oruka Antibody
Patent Covering the Manufacture, use or sale of such Oruka Product in the country at issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.115&nbsp;&ldquo;<B>Sequence
Information</B>&rdquo; means any files of Paragon containing all Licensed Antibody sequences generated under the Research Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.116&nbsp;&ldquo;<B>Sublicensee</B>&rdquo;
means any Affiliate of Oruka or any Third Party with respect to Oruka, to whom Oruka grants a sublicense of, or other authorization or
permission granted under, the rights granted to Oruka in Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.117&nbsp;&ldquo;<B>Target</B>&rdquo;
means a protein molecule that (a) is chemically distinct from other molecules, and (b) wherein a binding entity derives recognized therapeutic
value from binding to such molecule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.118&nbsp;&ldquo;<B>Term</B>&rdquo;
has the meaning set forth in Section&nbsp;8.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.119&nbsp;&ldquo;<B>Territory</B>&rdquo;
means worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.120&nbsp;&ldquo;<B>Third
Party</B>&rdquo; means any person or entity other than Paragon or Oruka or an Affiliate of either Paragon or Oruka.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.121&nbsp;&ldquo;<B>Third
Party Claim</B>&rdquo; has the meaning set forth in Section 9.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.122&nbsp;&ldquo;<B>Transfer
Period</B>&rdquo; has the meaning set forth in Section 2.5(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.123&nbsp;&ldquo;<B>US</B>&rdquo;
or &ldquo;<B>United States</B>&rdquo; means the United States of America and its possessions and territories, including Puerto Rico.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.124&nbsp;&ldquo;<B>Valid
Claim</B>&rdquo; means, with respect to a particular country, a claim (including a process, use or composition of matter claim) of an
issued and unexpired patent (or a supplementary protection certificate thereof) that has not (a) irretrievably lapsed or been abandoned,
permanently revoked, dedicated to the public or disclaimed, or (b) been held invalid, unenforceable or not patentable by a court, governmental
agency, national or regional patent office or other appropriate body that has competent jurisdiction, which holding, finding or decision
is final and unappealable or unappealed within the time allowed for appeal.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">Article&nbsp;II</FONT><BR>
<BR>
LICENSES; TECHNOLOGY TRANSFER; MULTISPECIFIC ANTIBODIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1&nbsp;<B>License
Grants</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;Subject
to the terms of this Agreement, Paragon hereby grants to Oruka a royalty-bearing, exclusive (even as to Paragon and its Affiliates, subject
to Paragon&rsquo;s retained rights under Section 2.4) license, including the right to sublicense through multiple tiers, under the Licensed
Antibody Technology to Develop, Manufacture, Commercialize, or otherwise exploit Licensed Antibodies, Derived Antibodies and Products
in the Field in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;Subject
to the terms of this Agreement, including Section 2.7, Paragon hereby grants to Oruka a royalty-bearing, non-exclusive right and license,
including the right to sublicense through multiple tiers, under the Licensed Antibody Technology to Develop, Manufacture, Commercialize
or otherwise exploit Multispecific Antibodies and Multispecific Products in the Field in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;Subject
to the terms of this Agreement, Paragon hereby grants to Oruka a royalty-bearing, non-exclusive license, including the right to sublicense
through multiple tiers, under the Other Licensed Patents to Develop, Manufacture, Commercialize or otherwise exploit Licensed Antibodies,
Derived Antibodies, Multispecific Antibodies, Products and Multispecific Products in the Field in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;Subject
to the terms of this Agreement, Paragon hereby grants to Oruka a royalty-bearing, non-exclusive license, including the right to sublicense
through multiple tiers, under the Other Licensed Know-How to Develop, Manufacture, Commercialize or otherwise exploit (i) Licensed Antibodies,
or (ii) Products, Multispecific Antibodies or Multispecific Products, in each case solely to the extent comprising or containing a Licensed
Antibody, in the Field in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;Subject
to the terms of this Agreement, Paragon hereby grants to Oruka a non-exclusive license, including the right to sublicense through multiple
tiers, under the Paragon Cross License Patents to Develop, Manufacture, Commercialize or otherwise exploit the Licensed Antibodies solely
in the Field in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;Subject
to the terms of this Agreement, Oruka hereby grants to Paragon a non-exclusive license, including the right to sublicense through multiple
tiers, under the Oruka Cross License Patents to Develop, Manufacture, Commercialize or otherwise exploit the Retained IL-23 Project Antibodies
solely in the Territory in the therapeutic area of inflammatory bowel disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2&nbsp;<B>Exclusivity</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;Subject
to the terms of this Section 2.2, to the maximum extent permissible under Applicable Law, during the Exclusivity Period, Paragon shall
not, and shall ensure that its Affiliates do not, directly or indirectly, conduct any activity, either on its own or with, for the benefit
of, or sponsored by, any Third Party, including granting any license to any Third Party that would permit such Third Party, to develop,
manufacture, commercialize or otherwise exploit any monospecific Antibody that is Directed To the Licensed Target in the Field. It will
not be a violation of this Section 2.2(a) if Paragon or its Affiliate, directly or through a Third Party, (i)&nbsp;conducts screening
activities solely for the purposes of ensuring compliance with this Section&nbsp;2.2(a), (ii)&nbsp;conducts activities in accordance with
the terms of this Agreement, the Option Agreement or any other written agreement between the Parties, or (iii) conducts activities with
the prior written consent of Oruka.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;Notwithstanding
anything herein to the contrary, if a Change of Control occurs with respect to Paragon or its Parent Entity, and the Acquiring Entity
(or any of such Acquiring Entity&rsquo;s successors or assigns, other than the relevant Pre-Existing Entities) as of the Change of Control
has a program or product (or rights thereto) that would otherwise violate Section&nbsp; 2.2(a) (each, a &ldquo;<B>COC Program</B>&rdquo;),
then (i) Section&nbsp;2.2(a) shall not apply with respect to such COC Program, and (ii) such Acquiring Entity will be permitted to continue
such COC Program after such Change of Control and such continuation will not constitute a violation of Section&nbsp;2.2(a), <I>provided,
that</I> the Licensed Antibody Technology and Confidential Information of Paragon and Oruka relating to the Oruka Products is not used
in the COC Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;Notwithstanding
anything herein to the contrary, if Paragon or its Parent Entity (i) acquires a Third Party entity that has a program or product (or rights
thereto) that would otherwise violate Section&nbsp;2.2(a), or (ii) acquires asset(s) from a Third Party entity that would otherwise violate
Section&nbsp;2.2(a) (each, an &ldquo;<B>Acquired Program</B>&rdquo;), then (1) Section&nbsp;2.2(a) shall not apply with respect to such
Acquired Program, and (2) Paragon or its Parent Entity will be permitted to continue such Acquired Program after such acquisition and
such continuation will not constitute a violation of Section&nbsp;2.2(a), <I>provided, that</I> the Licensed Antibody Technology and Confidential
Information of Paragon and Oruka relating to the Oruka Products is not used in the Acquired Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3&nbsp;<B>Sublicenses</B>.
Oruka shall have the right to grant sublicenses under the rights granted to it in Section&nbsp;2.1 to its Affiliates and Third Parties;
<I>provided, that</I> (a)&nbsp;each such sublicense shall be granted in writing and each such relevant sublicense agreement shall be consistent
with all relevant terms, conditions and restrictions of this Agreement, (b) Oruka will provide Paragon with a true and complete copy of
each sublicense agreement (other than sublicense agreements with Third Party service providers) and any amendments thereto within <FONT STYLE="font-variant: small-caps">[***]</FONT>
days following the execution thereof (which sublicense agreement and amendments may be redacted except to the extent necessary for Paragon
to determine Oruka&rsquo;s compliance with this Agreement), and (c)&nbsp;Oruka shall remain responsible for all of its payments and other
performance obligations due under this Agreement, notwithstanding any license or sublicense that it may grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.4&nbsp;<B>No
Implied Licenses; Reservation of Rights</B>. Except as expressly set forth herein, no right or license under any Patents, Know-How or
Intellectual Property Right of either Party is granted or shall be granted by implication hereunder. All such rights or licenses are or
shall be granted only as expressly provided in this Agreement, and each Party reserves to itself all rights not expressly granted under
this Agreement. Notwithstanding anything to the contrary under this Agreement, Paragon retains rights under the Licensed Antibody Technology
solely to perform its obligations and exercise its rights under this Agreement and the Option Agreement; provided, that during the Term,
Paragon shall not, and shall ensure that its Affiliates do not, (a) use the Licensed Antibody Technology to, or (b) grant a license to
a Third Party under the Licensed Antibody Technology to, Develop, Manufacture, Commercialize, or otherwise exploit the Licensed Antibodies
or Derived Antibodies, in each case as part of a Product, in the Territory for the therapeutic area of inflammatory bowel disease; provided,
further, that the foregoing proviso does not, and is not intended to, limit Paragon&rsquo;s rights under Section 2.6. Oruka acknowledges
and agrees that it has no rights under this Agreement or the Option Agreement with respect to any Antibodies that were discovered, generated,
identified or characterized by Paragon in the course of performing the Research Program (including the Retained IL-23 Project Antibodies)
other than the Licensed Antibodies and the Derived Antibodies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.5&nbsp;<B>Information
Transfer and Support to Oruka</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;As
soon as possible and within not more than <FONT STYLE="font-variant: small-caps">[***]</FONT> days after the Effective Date, Paragon shall
provide Oruka with the Results and Sequence Information in existence as of the Effective Date not already provided to Oruka under the
Option Agreement. Additionally, on a continuing basis during the term of the Research Program, as soon as possible and within not more
than <FONT STYLE="font-variant: small-caps">[***]</FONT> days after additional Results or Sequence Information come into existence or
are identified by Paragon that in each case have not already been provided to Oruka under the Option Agreement, Paragon shall disclose
and transfer such additional Results and Sequence Information to Oruka.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;Upon
the reasonable request of Oruka made from time to time during the Term, Paragon shall promptly disclose and transfer to Oruka tangible
embodiments of the Other Licensed Know-How that is the subject of Oruka&rsquo;s request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;The
Parties acknowledge and agree that <U>Exhibit C</U> has been agreed by the Parties as of the Effective Date, and that materials that are
different than or in addition to the materials set forth on <U>Exhibit C</U> may result from the Research Program to the extent that the
Research Program continues to be performed following the Effective Date. Upon the reasonable request of Oruka made at any time prior to
the end of the <FONT STYLE="font-variant: small-caps">[***]</FONT> day period following the expiration of the Research Term (as defined
in the Option Agreement), the Parties shall update <U>Exhibit C</U> to reflect the tangible materials, including samples, reagents, nucleic
acids and Antibodies, resulting from the Research Program that constitute Research Program Materials hereunder. During the period beginning
on the Effective Date and ending <FONT STYLE="font-variant: small-caps">[***]</FONT> months after the expiration of the Research Term
(the &ldquo;<B>Transfer Period</B>&rdquo;), at <FONT STYLE="font-variant: small-caps">[***]</FONT> request and expense, Paragon will provide
Oruka or a Third Party designated by Oruka with any Research Program Materials, provided that any Third Party recipient of such Research
Program Materials shall be bound by the relevant terms of this Agreement and that the Research Program Materials are used solely to further
Develop, Manufacture and Commercialize the Oruka Products. For clarity, <FONT STYLE="font-variant: small-caps">[***]</FONT> shall be responsible
for any out-of-pocket costs incurred by Paragon or its Affiliates to store and maintain the Research Program Materials during the Transfer
Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;Each
Party shall bear all costs and expenses incurred by such Party in connection with the disclosure and transfer of any Results and Sequence
Information as set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;During
the <FONT STYLE="font-variant: small-caps">[***]</FONT> day period following completion of the Research Program, in the event Oruka makes
any reasonable request for assistance in order to understand the Licensed Antibody Technology and use the Licensed Antibody Technology
to continue the uninterrupted Development of the Licensed Antibodies, Paragon shall provide up to <FONT STYLE="font-variant: small-caps">[***]</FONT>
month of additional assistance during such period, at <FONT STYLE="font-variant: small-caps">[***]</FONT> cost and expense at the then
current <FONT STYLE="font-variant: small-caps">[***] </FONT>Rate (as defined in the Option Agreement) in the Option Agreement.&nbsp; Paragon
shall consider and discuss in good faith any additional requests for assistance made by Oruka, which assistance may be provided upon mutual
agreement of the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.6&nbsp;<B>Paragon
Rights with Respect to Multispecific Antibodies</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;Subject
to the terms of this Agreement, including Section 2.6(b) below and Section 2.7, Paragon reserves and retains the non-exclusive right under
the Licensed Antibody Technology to Develop, Manufacture, Commercialize and otherwise exploit Multispecific Antibodies and Multispecific
Products in the Field in the Territory. If Paragon exercises such right, then Paragon shall pay royalties to Oruka in accordance with
Article&nbsp;IV (at the rate specified in Section 4.2(b)), <I>mutatis mutandis</I>, with respect to any Multispecific Antibodies and Multispecific
Products that are Commercialized by Paragon or its Affiliates or sublicensees (other than Oruka and its Affiliates and Sublicensees) in
the Field in the Territory, <I>provided, that</I> references to Oruka Antibody Patents in clause (b) of the Royalty Term definition and
Section 4.3 shall be disregarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;Oruka
has designated <FONT STYLE="font-variant: small-caps">[***]</FONT> Licensed Antibody or Derived Antibody as its lead compound and <FONT STYLE="font-variant: small-caps">[***]</FONT>
Licensed Antibody or Derived Antibody as its backup compound, as set forth on <U>Exhibit B</U> (each such designated Licensed Antibody
or Derived Antibody, a &ldquo;<B>Designated Multispecific Antibody</B>&rdquo;). Paragon&rsquo;s rights under Section&nbsp;2.6(a) shall
expressly exclude the right to Develop, Manufacture, Commercialize or otherwise exploit (i) Multispecific Antibodies that have identical
sequence identity within their variable regions as a Designated Multispecific Antibody, or (ii)&nbsp;Multispecific Products that comprise
or contain any Multispecific Antibody referenced in clause (i). For the avoidance of doubt, if Paragon engaged in Development or Manufacture
of a Multispecific Antibody that meets the criteria of clause (i) or (ii) above prior to the Effective Date, then Paragon shall not be
in breach of this Agreement, <I>provided that</I>, Paragon ceases all such Development or Manufacture within <FONT STYLE="font-variant: small-caps">[***]</FONT>
days following the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.7&nbsp;<B>Right
of First Negotiation</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;Commencing
on the Effective Date and continuing until the <FONT STYLE="font-variant: small-caps">[***]</FONT> anniversary thereof (the &ldquo;<B>ROFN
Period</B>&rdquo;), Paragon will promptly notify Oruka in writing if (i) Paragon has developed a descriptive research plan with respect
to the Development of a Multispecific Antibody or a plan to license or grant rights in a Multispecific Antibody to a Third Party, or (ii)
Paragon enters into <FONT STYLE="font-variant: small-caps">[***]</FONT> negotiations pursuant to an offer to or from any Third Party relating
to the foregoing. Together with such notice, Paragon will provide to Oruka all material information and research plans developed by Paragon
with respect to such Multispecific Antibody (the &ldquo;<B>ROFN Information</B>&rdquo;). Oruka will have <FONT STYLE="font-variant: small-caps">[***]</FONT>
days from receipt of the ROFN Information to deliver a written notice to Paragon of Oruka&rsquo;s desire to engage in negotiations for
an agreement concerning the Development, or exclusive license or grant of rights to, such Multispecific Antibody.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;If
Oruka does not provide such written notice to Paragon of its interest to engage in such negotiations within such <FONT STYLE="font-variant: small-caps">[***]</FONT>
day period, then (i) Paragon shall be free to enter into an agreement with a Third Party with respect to the grant of a license or other
rights to such Multispecific Antibody and corresponding Multispecific Products without further obligation to Oruka under this Section
2.7, and (ii) Oruka&rsquo;s license under Section 2.1(b) shall automatically exclude any right to Develop, Manufacture, Commercialize
or otherwise exploit the identical Multispecific Antibodies Developed by or on behalf of Paragon and corresponding Multispecific Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;If
Oruka does provide Paragon such written notice within such <FONT STYLE="font-variant: small-caps">[***]</FONT> day period, the Parties
will negotiate <FONT STYLE="font-variant: small-caps">[***]</FONT> on an exclusive basis for a period of up to <FONT STYLE="font-variant: small-caps">[***]</FONT>
months from the date of Oruka&rsquo;s notice (&ldquo;<B>ROFN Negotiation Period</B>&rdquo;), an agreement for the Development, or exclusive
license or grant of rights to, such Multispecific Antibody and corresponding Multispecific Products. Prior to and during the ROFN Negotiation
Period, Paragon shall not enter into an agreement with respect to such Multispecific Antibody with any Third Party that will prevent Paragon
from entering into an agreement with Oruka for the Development, or exclusive license or grant of rights to, such Multispecific Antibody
and corresponding Multispecific Products. Unless and until the Parties have entered into an agreement with respect to such Multispecific
Antibody and corresponding Multispecific Products, Oruka shall have no rights or license with respect to such Multispecific Antibody and
corresponding Multispecific Products except as otherwise expressly provided in Section 2.1. In the event that the Parties have not entered
into an agreement with respect to such Multispecific Antibody and corresponding Multispecific Products prior to the expiration of the
ROFN Negotiation Period, then (i) Paragon shall be free to enter into an agreement with a Third Party with respect to the grant of a license
or other rights to such Multispecific Antibody and corresponding Multispecific Products without further obligation to Oruka under this
Section&nbsp;2.7, and (ii) Oruka&rsquo;s license under Section 2.1(b) shall automatically exclude any right to Develop, Manufacture, Commercialize
or otherwise exploit the identical Multispecific Antibodies Developed by or on behalf of Paragon and corresponding Multispecific Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.8&nbsp;<B>Third
Party In-Licenses</B>. If Paragon (or its Affiliate) enters into any in-license agreement with a Third Party after the Effective Date
with respect to any Patent that would, if Controlled by Paragon, be included within the Licensed Antibody Patents or the Other Licensed
Patents (each such agreement, a &ldquo;<B>Paragon Third Party Agreement</B>&rdquo;), Paragon shall notify Oruka in writing that it entered
into such Paragon Third Party Agreement and provide a copy of such Paragon Third Party Agreement to Oruka, which may be redacted solely
concerning <FONT STYLE="font-variant: small-caps">[***]</FONT> or other confidential terms not applicable to sublicensees. Oruka shall
have the right, by delivery of notice to Paragon, to elect to take a sublicense under such Patents in-licensed by Paragon under such Paragon
Third Party Agreement. If Oruka elects to become a sublicensee thereunder pursuant to this Section 2.8, then (a) the applicable Patents
under such Paragon Third Party Agreement shall be included within the Licensed Antibody Patents or the Other Licensed Patents, as applicable,
that are licensed to Oruka under Section 2.1, (b)&nbsp;Oruka shall reimburse Paragon for Paragon&rsquo;s pro rata share of royalties or
other consideration, as mutually agreed by the Parties, payable by Paragon under the Paragon Third Party Agreement for Oruka&rsquo;s Development,
Manufacture, Commercialization or other exploitation of an Oruka Product in the Field in the Territory in connection with the grant to
Oruka of such Patents (the &ldquo;<B>Reimbursement Obligation</B>&rdquo;), and (c)&nbsp;Oruka shall comply with the terms of such Paragon
Third Party Agreement to the extent applicable to Oruka as a sublicensee of such Patents. In the event of any conflict between the terms
of this Agreement and any Paragon Third Party Agreement applicable to a sublicense granted by Paragon to Oruka in accordance with this
Section 2.8, the terms of the Paragon Third Party Agreement shall control solely to the extent necessary for the Parties to maintain compliance
with such Paragon Third Party Agreement. Oruka shall comply with the Reimbursement Obligation by paying to Paragon any amounts subject
to the Reimbursement Obligation within the earlier of (i)&nbsp;<FONT STYLE="font-variant: small-caps">[***]</FONT> days after Oruka&rsquo;s
receipt from Paragon of an invoice for such payment, and (ii) the date when such payment is due to the counterparty licensor under the
applicable Paragon Third Party Agreement, <I>provided that</I> such payment shall not be due prior to the date when such amounts are payable
by Paragon to the counterparty licensor under the applicable Paragon Third Party Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">Article&nbsp;III</FONT><BR>
<BR>
DEVELOPMENT, MANUFACTURING &amp; COMMERCIALIZATION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1&nbsp;<B>Oruka
Responsibilities</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;As
between the Parties, Oruka shall be solely responsible for and shall have the sole right to control, all aspects of the Development, Manufacturing,
and Commercialization of the Oruka Products in the Field in the Territory during the Term, including distribution, product positioning,
product strategy, product branding, core messaging, marketing, promotion, detailing activities and all decisions relating to the setting
of prices in the Territory, invoicing and booking sales, establishing all terms of sale, and all regulatory activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;As
between the Parties, Oruka shall be solely responsible for, and shall have the sole right to control, the selection, registration and
maintenance of all trademarks associated with the Oruka Products in the Field in the Territory. As between the Parties, Oruka shall solely
own such trademarks in the Territory and pay all relevant costs thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2&nbsp;<B>Regulatory</B>.
As between the Parties, Oruka shall control all regulatory matters, including the regulatory strategy, regulatory filings, regulatory
activities (including clinical trials for Oruka Products) and communication with each Regulatory Authority for the Oruka Products in the
Field in the Territory. Oruka shall have the right to reference any relevant data included within the Licensed Antibody Technology for
the purposes of regulatory filings and safety reporting, including all nonclinical data, pre-approval and post-approval clinical use data,
and regulatory data with respect thereto, and Paragon shall cooperate as reasonably requested by Oruka with respect to providing to Oruka
when requested, and on a timely basis, any of the foregoing information, data filings or reporting. Oruka or its designee shall be the
party to file an application to each applicable Regulatory Authority in the Territory for, and to obtain and maintain, in its own name,
Regulatory Approval for the Oruka Products in each country in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3&nbsp;<B>Diligence;
Reporting</B>. Oruka shall use Commercially Reasonable Efforts (a)&nbsp;to Develop and seek Regulatory Approval for at least one Oruka
Product in the Field in the United States and at least one other Major Market Country, and (b) upon receipt of Regulatory Approval for
a given Oruka Product in a given country, to Commercialize such Oruka Product in such country, in each case ((a) or (b)) either by itself
or through its Affiliates or Sublicensees or its or their respective contractors. Additionally, on or before <FONT STYLE="font-variant: small-caps">[***]</FONT>
of each year during the Term, Oruka shall deliver to Paragon a report summarizing its material development efforts with respect to the
Oruka Products, including a summary of current and anticipated preclinical and clinical activities, a summary of the status of any regulatory
filings and any anticipated regulatory filings, and achievement of any Milestones, during the preceding <FONT STYLE="font-variant: small-caps">[***]</FONT>;
<I>provided, however</I>, that Oruka may satisfy the reporting obligations set forth in this Section 3.3 by providing Paragon with copies
of any annual report or other filings with a securities exchange that include the relevant information. For the avoidance of doubt, if
Oruka determines, in its sole discretion, that it is inconsistent with the use of Commercially Reasonable Efforts to pursue Commercialization
of an Oruka Product in any country (other than the United States), it will not be considered a material breach of this Agreement to cease
Development or Commercialization of such Oruka Product with respect to such country.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">Article&nbsp;IV</FONT><BR>
<BR>
FINANCIAL TERMS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1&nbsp;<B>Milestone
Payments</B>. Oruka shall make the following one-time, non-refundable and non-creditable payments to Paragon (or to such other designee(s),
as requested by Paragon in an invoice) (each payment, a &ldquo;<B>Milestone Payment</B>&rdquo;), based on the achievement of the corresponding
milestone (each, a &ldquo;<B>Milestone</B>&rdquo;) by Oruka, its Affiliates, or its Sublicensees with respect to the first Oruka Product
to achieve such Milestone. Oruka shall, within <FONT STYLE="font-variant: small-caps">[***]</FONT> Business Days after it or its Affiliates
achieve a Milestone, or within <FONT STYLE="font-variant: small-caps">[***]</FONT> Business Days after it learns that its or its Affiliate&rsquo;s
Sublicensee has achieved a Milestone, notify Paragon of the achievement of such Milestone in writing. Following receipt of such notice,
Paragon shall invoice Oruka for such Milestone Payment, which invoice shall specify whether Paragon or its designee should receive such
Milestone Payment and the bank account information into which such Milestone Payment should be paid. Oruka shall make such Milestone Payment
to Paragon or Paragon&rsquo;s designee within <FONT STYLE="font-variant: small-caps">[***]</FONT> days after receipt of Paragon&rsquo;s
invoice. Each Milestone Payment shall be paid no more than once, and Oruka&rsquo;s total Milestone Payments hereunder shall not exceed
Twenty-Two Million Dollars ($22,000,000). For avoidance of doubt, upon achievement of any Milestone, all prior unachieved Milestones shall
be deemed thereby achieved and, if the Milestone Payment for any such prior Milestone has not previously been paid, it shall thereupon
also be paid at the same time that the Milestone Payment for such subsequent achieved Milestone is paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: center; padding-bottom: 1.5pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; font-weight: bold; text-align: center">Milestone</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-left: 5.4pt">Milestone Payment</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 8%; font-weight: bold; text-align: center; padding-bottom: 1.5pt; padding-left: 5.4pt">#1</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 45%; text-align: left; padding-bottom: 1.5pt">Achievement of Development Candidate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: center; padding-bottom: 1.5pt; padding-left: 5.4pt">One Million Five Hundred Thousand Dollars ($1,500,000)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center; padding-bottom: 1.5pt; padding-left: 5.4pt">#2</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left; padding-bottom: 1.5pt">First dosing of a human patient in a Phase I Trial of an Oruka Product</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; padding-left: 5.4pt">Two Million Five Hundred Thousand Dollars ($2,500,000)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center; padding-bottom: 1.5pt; padding-left: 5.4pt">#3</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left; padding-bottom: 1.5pt">First dosing of a human patient in a Phase II Trial of an Oruka Product</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; padding-left: 5.4pt">Three Million Dollars ($3,000,000)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center; padding-bottom: 1.5pt; padding-left: 5.4pt">#4</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left; padding-bottom: 1.5pt">First dosing of a human patient in a Phase III Trial of an Oruka Product</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; padding-left: 5.4pt">Five Million Dollars ($5,000,000)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center; padding-bottom: 1.5pt; padding-left: 5.4pt">#5</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left; padding-bottom: 1.5pt">Receipt of Regulatory Approval from the FDA of an Oruka Product</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; padding-left: 5.4pt">Ten Million Dollars ($10,000,000)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2&nbsp;<B>Royalties</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;<B>Royalty
Rate for Products</B>. During the applicable Royalty Term (which shall be measured on a country-by-country and Product-by-Product basis),
Oruka shall pay tiered royalties to Paragon (or to such other designee(s), as requested by Paragon) as set forth in the table below on
Annual Net Sales of all Products sold by Oruka, its Affiliates or its Sublicensees in the Field in the Territory (together with any royalties
payable under Section 4.2(b), the &ldquo;<B>Royalty Payments</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 89%; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.25in; margin: 0pt 0 0pt 0.25in; text-align: left"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>Annual Net Sales of the Products in a Given Calendar Year</B></P></TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: center">Royalty Rate</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-variant: normal; text-align: justify"><FONT STYLE="text-transform: capitalize">Portion
    of Annual Net Sales of the Products in a given Calendar Year above $0 but up to and including $[***]</FONT></TD><TD STYLE="font-variant: small-caps">&nbsp;</TD>
    <TD STYLE="font-variant: small-caps; text-align: right">[***]</TD>
    <TD>%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-variant: normal; text-align: justify"><FONT STYLE="text-transform: capitalize">Portion
    of Annual Net Sales of the Products in a given Calendar Year of more than $[***], up to and including $[***]</FONT></TD><TD STYLE="font-variant: small-caps">&nbsp;</TD>
    <TD STYLE="font-variant: small-caps; text-align: right">[***]</TD>
    <TD>%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-variant: normal; text-align: justify"><FONT STYLE="text-transform: capitalize">Portion
    of Annual Net Sales of the Products in a given Calendar Year of more than $[***]</FONT></TD><TD STYLE="font-variant: small-caps">&nbsp;</TD>
    <TD STYLE="font-variant: small-caps; text-align: right">[***]</TD>
    <TD>%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;<B>Royalty
Rate for Oruka Multispecific Products</B>. During the applicable Royalty Term (which shall be measured on a country-by-country and Oruka
Multispecific Product-by-Oruka Multispecific Product basis), Oruka shall pay royalties to Paragon (or to such other designee(s), as requested
by Paragon) equal to <FONT STYLE="font-variant: small-caps">[***]</FONT> percent (<FONT STYLE="font-variant: small-caps">[***]</FONT>%)
of Net Sales of all Oruka Multispecific Products sold by Oruka, its Affiliates or its Sublicensees in the Field in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;If
any Oruka Product contains (a) a combination of more than one Licensed Antibody, Derived Antibody and/or Multispecific Antibody, or (b)
a combination of (i) one or more Licensed Antibodies, Derived Antibodies or Multispecific Antibodies, and (ii)&nbsp;one or more other
Antibodies owned or Controlled by Paragon or its Affiliates, the rights to which have been licensed to Oruka or its Affiliates under a
separate agreement, then, in each case (a) or (b) unless otherwise agreed by the Parties, the royalty rate for the Royalty Payments payable
to Paragon with respect to such Oruka Product (x) shall be determined in accordance with the Royalty Rate chart set forth in Section 4.2(a)
if such Oruka Product does not contain a Multispecific Antibody, and (y) shall be determined in accordance with Section 4.2(b) if such
Oruka Product contains a Multispecific Antibody.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3&nbsp;<B>Royalty
Reductions for No Valid Claim</B>. If, during any Calendar Quarter during the Royalty Term for a particular Oruka Product in a particular
country, no Valid Claim of a Licensed Antibody Patent Covers the Manufacture or Commercialization of such Oruka Product in such country,
then the applicable royalty rate for the Royalty Payments set forth in Section 4.2 for such Calendar Quarter shall be reduced by <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4&nbsp;<B>Payment
Reports</B>. Within <FONT STYLE="font-variant: small-caps">[***]</FONT> days after the end of <FONT STYLE="font-variant: small-caps">[***]</FONT>
days for <FONT STYLE="font-variant: small-caps">[***]</FONT> in which an Oruka Product is sold, Oruka shall provide to Paragon a written
report, on an <FONT STYLE="font-variant: small-caps">[***]</FONT> basis, stating the <FONT STYLE="font-variant: small-caps">[***]</FONT>,
including <FONT STYLE="font-variant: small-caps">[***]</FONT>; <FONT STYLE="font-variant: small-caps">[***]</FONT>. All Royalty Payments
described in such written report shall be made by Oruka at the same time it submits such written report to Paragon. All such Royalty Payments
shall be paid to Paragon or Paragon&rsquo;s designee, <I>provided that</I> in the case of payment to a designee, Paragon has notified
Oruka in writing <FONT STYLE="font-variant: small-caps">[***]</FONT> days prior to the due date for any Royalty Payment of the designee
to be paid and the bank account information for such designee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5&nbsp;<B>Payment
Method</B>. All payments due under this Agreement to Paragon shall be made in U.S. Dollars by bank wire transfer in funds to an account
designated by Paragon from time to time reasonably in advance of any payment due date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.6&nbsp;<B>Taxes</B>.
The Parties agree to cooperate with one another and use reasonable efforts to minimize obligations for any and all income or other taxes
required by Applicable Law to be withheld or deducted from any Royalty Payments, Milestone Payments or other payments made by Oruka to
Paragon or its designee(s) under this Agreement, including by completing all procedural steps, and taking all reasonable measures, to
ensure that any withholding tax is reduced or eliminated to the extent permitted under Applicable Law, including income tax treaty provisions
and related procedures for claiming treaty relief. To the extent that Oruka is required to deduct and withhold taxes on any payment to
Paragon or its designee(s), Oruka shall: (i) deduct such taxes from such payment to Paragon or its designee(s), (ii) pay the amounts of
such taxes to the proper Governmental Authority in a timely manner, and (iii) promptly submit to Paragon an official tax certificate or
other available evidence of such withholding sufficient to enable Paragon or its designee(s) to claim such payment of taxes. For the avoidance
of doubt, Oruka&rsquo;s remittance of such withheld amounts to the appropriate Governmental Authority, together with payment to Paragon
or its designee(s) of the remaining amount owed, shall constitute full satisfaction of the applicable payment due to Paragon. Oruka shall
provide Paragon with any reasonably requested tax forms or certificates available to Oruka in order to allow Paragon or its designee(s)
to recover, as permitted by Applicable Law, withholding taxes, value added taxes or similar obligations resulting from payments made hereunder
or to obtain the benefit of any present or future treaty against double taxation that may apply to such payments. Paragon shall promptly
provide Oruka with any requested tax forms that may be reasonably necessary in order for Oruka to not withhold tax or to withhold tax
at a reduced rate under an applicable bilateral tax income treaty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.7&nbsp;<B>Foreign
Exchange</B>. If any currency conversion shall be required in connection with the calculation of amounts payable hereunder, including
in connection with the calculation of Net Sales, such conversions shall be made using the methodology used by Oruka in preparing its publicly
filed financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.8&nbsp;<B>Late
Payments</B>. Any amount owed by Oruka to Paragon under this Agreement that is not paid within the applicable time period set forth herein
will accrue interest at the per annum rate of <FONT STYLE="font-variant: small-caps">[***]</FONT> percentage point above the then-applicable
United States prime rate as quoted in the <I>Wall Street Journal (East Coast Edition)</I> (or if it no longer exists, a similarly authoritative
source), calculated on a <FONT STYLE="font-variant: small-caps">[***] </FONT>basis, or, if lower, the highest rate permitted under Applicable
Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.9&nbsp;<B>Blocked
Currency</B>. If by Applicable Law of a country in which Net Sales occurred, conversion of funds into Dollars or transfer of funds from
such country to the United States is restricted, forbidden or delayed for more than <FONT STYLE="font-variant: small-caps">[***]</FONT>
days, then Oruka can elect, at its sole discretion, that the amounts accrued in such country and owed by Oruka to Paragon under this Agreement
shall be paid to Paragon in such country in local currency by deposit in a local bank designated by Paragon, unless the Parties otherwise
agree in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.10&nbsp;<B>Records;
Inspection</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;Oruka
shall, and shall cause its applicable Affiliates to, create and keep complete and accurate records of its sales and other dispositions
of all Oruka Products, including all records that are reasonably necessary for the purposes of calculating all payments due under this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;Upon
reasonable advance written notice to Oruka, Paragon shall have the right to retain a nationally recognized (in the US) independent certified
public accounting firm to perform on behalf of Paragon an audit, conducted in accordance with U.S. generally accepted accounting principles
(GAAP), of such books and records of Oruka or its applicable Affiliates as may be reasonably necessary to verify the accuracy of any reports
provided pursuant to Section 4.4 hereunder for any Calendar Quarter in which an Oruka Product was sold, ending not more than <FONT STYLE="font-variant: small-caps">[***]</FONT>
calendar months prior to the date of such request. Such audits shall be conducted during normal business hours, shall not occur more frequently
than <FONT STYLE="font-variant: small-caps">[***] </FONT>in each Calendar Year and shall not be conducted more than <FONT STYLE="font-variant: small-caps">[***]
</FONT>with respect to any reporting period, in each case other than for cause. All information disclosed or observed during any audit
pursuant to this Section 4.10 shall be the Confidential Information of Oruka, and Paragon shall cause the accounting firm to retain all
such information as Confidential Information, including, if requested by Oruka, by requiring such accounting firm to enter into a customary
confidentiality agreement with Oruka prior to the initiation of any such audit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;Upon
completion of any audit hereunder, the accounting firm shall provide both Oruka and Paragon a written report disclosing whether the reports
submitted by Oruka are correct or incorrect, whether the amounts paid are correct or incorrect, and in each case, the specific details
concerning any discrepancies. No other information regarding Oruka&rsquo;s records shall be provided to Paragon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;Paragon
shall bear its internal expenses and the out-of-pocket costs for engaging such accounting firm in connection with performing such audits;
<I>provided, however</I>, that if any such audit uncovers an underpayment by Oruka that exceeds <FONT STYLE="font-variant: small-caps">[***]
</FONT>percent (<FONT STYLE="font-variant: small-caps">[***]</FONT>%) of the total owed for such payment or payment period, as applicable,
then Oruka shall reimburse Paragon or its designee(s) for the amounts actually paid to such accounting firm for performing such audit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;If
such accounting firm concludes that Oruka has in aggregate underpaid amounts owed to Paragon during the audited period, Oruka shall pay
Paragon or its designee(s) the amount of the discrepancy within <FONT STYLE="font-variant: small-caps">[***] </FONT>days of the date Paragon
delivers to Oruka such accounting firm&rsquo;s written report and an invoice for such amounts. If such accounting firm concludes that
Oruka has in aggregate overpaid amounts owed to Paragon during the audited period, then Oruka may, at its election, either credit such
overpaid amount against any future payment obligation to Paragon or require Paragon to refund such amounts within <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">Article&nbsp;V</FONT><BR>
<BR>
INTELLECTUAL PROPERTY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1&nbsp;<B>Ownership</B>.
As between the Parties (a) Paragon solely owns the Licensed Antibody Technology, the Other Licensed Patents and the Retained IL-23 Antibody
Patents, (b) Oruka solely owns the Oruka Inventions, including any Derived Antibodies and Oruka Multispecific Antibodies to the extent
they constitute Oruka Inventions, (c) each Party solely owns all Intellectual Property Rights owned or Controlled by such Party as of
the Effective Date or that come into the ownership or control of such Party during the Term outside the scope of this Agreement, and (d)
ownership of Inventions shall be determined in accordance with U.S. laws of inventorship. Other than rights granted to Oruka under this
Agreement with respect to the Licensed Antibody Technology and the Other Licensed Patents, nothing in this Agreement shall affect Paragon&rsquo;s
rights in any Patents, Know-How or other Intellectual Property Rights owned or controlled by Paragon or its Affiliates, now or in the
future. Other than rights granted to Paragon under Section 8.5(c) of this Agreement with respect to the Oruka Intellectual Property, nothing
in the Agreement shall affect Oruka&rsquo;s rights in any Patents, Know-How or other Intellectual Property Rights owned or controlled
by Oruka or its Affiliates, now or in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2&nbsp;<B>Patent
Prosecution</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;<B>Prosecution
Generally</B>. For the purpose of this Article&nbsp;V, &ldquo;<B>Prosecute</B>&rdquo; and &ldquo;<B>Prosecution</B>&rdquo; shall include
any patent interference, opposition, pre-issuance Third Party submission, <I>ex parte</I> re-examination, post-grant review, <I>inter
partes</I> review or other similar proceeding, appeals or petitions to any board of appeals in a patent office, appeals to any court for
any patent office decisions, reissue proceedings and applications for patent term extensions and the like.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;<B>Prosecution
of Licensed Antibody Patents</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">(i)&nbsp;As
between the Parties, with respect to any patent applications for Licensed Antibody Patents that have not been filed prior to the Effective
Date and any resulting patents (the &ldquo;<B>Post-Effective Date Patents</B>&rdquo;), Paragon shall have the sole right, but not the
obligation, to prepare, file, Prosecute and maintain the Post-Effective Date Patents until the date on which the Final Deliverable (as
defined in the Option Agreement) for the Research Program is delivered to Oruka, and during such period Paragon shall provide Oruka with
drafts of all proposed filings to any patent office with respect to Post-Effective Date Patents in reasonably adequate time before submission
of such filings for Oruka&rsquo;s review and comment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">(ii)&nbsp;As
between the Parties, with respect to (x) any patent applications and resulting patents for Licensed Antibody Patents that were filed prior
to the Effective Date, and (y) the Post-Effective Date Patents after the date on which the Final Deliverable (as defined in the Option
Agreement) for the Research Program is delivered to Oruka, Oruka shall have the first right to prepare, file, Prosecute and maintain the
Licensed Antibody Patents, in each case, at Oruka&rsquo;s sole expense. Oruka shall provide Paragon (and, at the direction of Paragon,
shall also provide directly to the Retained IL-23 Project Antibody Licensee) with copies of all material correspondence from and to any
patent office relating to such Licensed Antibody Patents, and Oruka shall provide Paragon (and, at the direction of Paragon, shall also
provide directly to the Retained IL-23 Project Antibody Licensee) with drafts of all proposed filings to any patent office with respect
to such Licensed Antibody Patents before submission of such filings, with reasonably adequate time for Paragon&rsquo;s (and the Retained
IL-23 Project Antibody Licensee&rsquo;s) review and comment, which review shall be at Paragon&rsquo;s (and the Retained IL-23 Project
Antibody Licensee&rsquo;s) sole expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">(iii)&nbsp;Each
Party, when acting as the prosecuting Party (in such capacity, the &ldquo;<B>Prosecuting Party</B>&rdquo;) will take into consideration
the non-Prosecuting Party&rsquo;s reasonable comments (and, if Oruka is the Prosecuting Party, the Retained IL-23 Project Antibody Licensee&rsquo;s
reasonable comments) prior to submitting such filings. At the Prosecuting Party&rsquo;s request, the non-Prosecuting Party will sign all
documents and take any other actions required for filing, maintenance and grant of Licensed Antibody Patents. Oruka shall reimburse Paragon
for any costs and expenses actually incurred by Paragon to the extent Paragon is prosecuting or maintaining any Licensed Antibody Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">(iv)&nbsp;The
Prosecuting Party shall notify the non-Prosecuting Party of any decision not to prepare or file, or to abandon, cease Prosecution or not
maintain any Licensed Antibody Patent anywhere in the Territory. The Prosecuting Party shall provide such notice at least <FONT STYLE="font-variant: small-caps">[***]</FONT>
days prior to any filing or payment due date, or any other due date that requires action, in connection with such Licensed Antibody Patent.
In such event, the non-Prosecuting Party shall have a backup right, but not the obligation, to prepare, file, or continue Prosecution
or maintenance of, such Licensed Antibody Patent, at its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">(v)&nbsp;Each
Party shall cooperate with the other Party in the preparation, filing, Prosecution and maintenance of Licensed Antibody Patents, including
in each case by providing the prosecuting Party with data and other information as appropriate and executing all necessary affidavits,
assignments and other paperwork.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;<B>Prosecution
by Paragon</B>. Except with respect to Licensed Antibody Patents (which are addressed in Section 5.2(b)), Paragon (directly or indirectly
through the Retained IL-23 Project Antibody Licensee) shall be solely responsible for, and have sole discretion over, preparing, filing,
Prosecuting and maintaining any Patents (including the Other Licensed Patents, Paragon Multispecific Patents and Retained IL-23 Antibody
Patents) that it owns in whole or in part or otherwise Controls (the &ldquo;<B>Paragon Patents</B>&rdquo;). Paragon&rsquo;s Prosecution
of any Paragon Patents shall be at Paragon&rsquo;s sole expense. Notwithstanding the foregoing, in Prosecuting any Paragon Multispecific
Patents, Paragon hereby agrees that during the Term, neither Paragon nor any of its Affiliates or licensees will file, or assist any Third
Party in filing, any Patent that includes a claim that expressly recites the sequence of a Licensed Antibody or Derived Antibody other
than as part of a Paragon Multispecific Antibody. In the Prosecution by Paragon or the Retained IL-23 Project Antibody Licensee of any
Retained IL-23 Antibody Patents, (i) Paragon shall provide or cause to be provided (directly or indirectly through the Retained IL-23
Project Antibody Licensee) to Oruka copies of all material correspondence from and to any patent office relating to such Retained IL-23
Antibody Patents, and (ii) Paragon shall provide or cause to be provided (directly or indirectly through the Retained IL-23 Project Antibody
Licensee) to Oruka drafts of all proposed filings to any patent office with respect to such Retained IL-23 Antibody Patents before submission
of such filings, with reasonably adequate time for Oruka&rsquo;s review and comment, and Paragon or the Retained IL-23 Project Antibody
Licensee, as applicable, will take into consideration Oruka&rsquo;s reasonable comments prior to submitting such filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;<B>Patent
Prosecution Costs Prior to the Effective Date</B>. No later than <FONT STYLE="font-variant: small-caps">[***]</FONT> days after the Effective
Date, Oruka shall reimburse Paragon for any actual costs and expenses incurred by Paragon that are related to the Prosecution of any Licensed
Antibody Patents prior to the Effective Date and that have not already been paid by Oruka. Oruka will promptly reimburse Paragon for any
future Prosecution costs and expenses incurred by Paragon with respect to the Licensed Antibody Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;<FONT STYLE="background-color: white"><B>CREATE
Act</B>. Notwithstanding anything to the contrary in this Agreement, each Party will have the right to invoke the Cooperative Research
and Technology Enhancement Act of 2004, 35 U.S.C. &sect; 103(c)(2)-(c)(3) (the &ldquo;<B>CREATE Act</B>&rdquo;) when exercising its rights
under Article&nbsp;V of this Agreement, without the prior written consent of the other Party. Where such Party intends to invoke the CREATE
Act, it will notify the other Party and the other Party will cooperate and coordinate its activities with such Party with respect to any
submissions, filings or other activities in support thereof. </FONT>The Parties acknowledge and agree that this Agreement is a joint research
agreement (JRA) as defined in the CREATE Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;<FONT STYLE="background-color: white"><B>Disclosure
of Antibody Patents</B>. Upon the request of Paragon, Oruka shall deliver to Paragon a list of the then-existing Oruka Antibody Patents.
Upon the request of Oruka, Paragon shall deliver to Oruka a list of the then-existing Retained IL-23 Antibody Patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3&nbsp;<B>Patent
Enforcement and Defense</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;<B>Notice
of Patent Infringement and Patent Challenge</B>. Each Party shall give the other Party notice of any known or suspected infringement by
a Third Party (&ldquo;<B>Patent Infringement</B>&rdquo;) of any Licensed Antibody Patent and any known or suspected challenge by a Third
Party against the validity or enforceability (&ldquo;<B>Patent Challenge</B>&rdquo;) of any Licensed Antibody Patent or Retained IL-23
Antibody Patent within <FONT STYLE="font-variant: small-caps">[***]</FONT> days after such Patent Infringement or Patent Challenge comes
to such Party&rsquo;s attention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;<B>Oruka&rsquo;s
First Right to Enforce or Defend</B>. Oruka shall have the first right, but not the obligation, to bring and control any legal action,
including by declaratory judgment action, patent litigation or similar proceeding, in connection with any Patent Infringement or Patent
Challenge with respect to the Licensed Antibody Patents in the Territory at its own expense and discretion as it reasonably determines
appropriate. Oruka shall keep Paragon (and, at the direction of Paragon, the Retained IL-23 Project Antibody Licensee) informed and reasonably
consult with Paragon (and, at the direction of Paragon, the Retained IL-23 Project Antibody Licensee) in the course of such legal action.
Paragon shall have the right to be represented in any such legal action by counsel of its choice at its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;<B>Paragon&rsquo;s
First Right to Enforce or Defend</B>. Paragon (or, at Paragon&rsquo;s discretion, the Retained IL-23 Project Antibody Licensee) shall
have the sole right, but not the obligation, to bring and control any legal action, including by declaratory judgment action, patent litigation
or similar proceeding, in connection with any Patent Infringement or Patent Challenge with respect to the Paragon Patents in the Territory
at its own expense and discretion as it reasonably determines appropriate. Paragon (directly or indirectly through the Retained IL-23
Project Antibody Licensee) shall keep Oruka informed and reasonably consult with Oruka in the course of legal action to enforce or defend
any Retained IL-23 Antibody Patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;<B>Settlement</B>.
In connection with any such legal action or proceeding, Oruka shall not enter into any settlement admitting the invalidity or unenforceability
of Licensed Antibody Patents without the prior written consent of Paragon (such consent not to be unreasonably conditioned, withheld,
or delayed), and Paragon shall not enter into any settlement admitting the invalidity or unenforceability of the Retained IL-23 Antibody
Patents without the prior written consent of Oruka (such consent not to be unreasonably conditioned, withheld, or delayed).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;<B>Paragon&rsquo;s
Backup Right to Enforce or Defend</B>. If Oruka does not initiate a legal action for Patent Infringement or Patent Challenge with respect
to any Licensed Antibody Patent within <FONT STYLE="font-variant: small-caps">[***]</FONT> days after a notice from Paragon under Section
5.3(a), then Paragon shall have a backup right, but not the obligation, to initiate such legal action at its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;<B>Allocation
of Recoveries</B>. Any recoveries resulting from such legal action initiated by Oruka or Paragon hereunder relating to Patent Infringement
or Patent Challenge in each case solely with respect to the Licensed Antibody Patents, including pursuant to a settlement, shall be applied
as follows: (i) first to reimburse the <FONT STYLE="font-variant: small-caps">[***]</FONT> of each of the Parties in such action; and
(ii) second, any amounts remaining after paying the amounts due each Party under clause (i) (the &ldquo;<B>Remaining Recovery</B>&rdquo;)
shall be allocated as follows: (1) <FONT STYLE="font-variant: small-caps">[***]</FONT>; or (2) <FONT STYLE="font-variant: small-caps">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&nbsp;<B>Cooperation
with Patent Enforcement</B>. At the request of the enforcing Party (and at the requesting Party&rsquo;s expense), the other Party shall
reasonably cooperate and provide any information or assistance in connection with any legal action under this Section 5.3, including executing
reasonably appropriate documents, cooperating in discovery and, if required by Applicable Law, joining as a party to the legal action
at its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4&nbsp;<B>Third
Party Patent Proceedings</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;<B>Oruka&rsquo;s
First Right to Challenge Third Party Patents</B>. Oruka shall have the sole and exclusive right, but not the obligation, to bring and
control any legal action to challenge any Patents controlled by a Third Party, including by declaratory judgment action, patent interference,
opposition, pre-issuance submission, <I>ex parte</I> re-examination, post-grant review, <I>inter partes</I> review, patent litigation
or similar proceeding, in each case that are necessary or useful to Develop, Manufacture, Commercialize or otherwise exploit any Oruka
Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;<B>Cooperation
by Paragon</B>. At the request of Oruka, Paragon shall cooperate and provide any information or assistance in connection with any legal
action under this Section&nbsp;5.4, including executing reasonably appropriate documents, cooperating in discovery and, if required by
Applicable Law, joining as a party to the action at Oruka&rsquo;s cost and expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.5&nbsp;<B>Common
Interest Agreement</B>. At the request of either Party to conduct the activities under this Article&nbsp;V, the Parties shall cooperate
in good faith to enter into a customary, mutually-agreed common-interest agreement intended to preserve attorney-client privilege with
respect to disclosures and communications by or on behalf of either Party or its Affiliates in connection with such activities.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">Article&nbsp;VI</FONT><BR>
<BR>
<FONT STYLE="font-variant: small-caps">PROTECTION OF CONFIDENTIAL INFORMATION.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.1&nbsp;<B>Confidentiality</B>.
Except to the extent expressly authorized by this Agreement, the Receiving Party agrees that, during the Term, for <FONT STYLE="font-variant: small-caps">[***]</FONT>
years thereafter, and, with respect to any Know-How that constitutes a trade secret, for long as such Know-How constitutes a trade secret,
it shall keep confidential and shall not publish or otherwise disclose to any Third Party, and shall not use for any purpose other than
as expressly provided for in this Agreement, any Confidential Information of the Disclosing Party. The Receiving Party may disclose Confidential
Information of the Disclosing Party to those of the Receiving Party&rsquo;s Representatives who have a need for such information, <I>provided
that</I> the Receiving Party shall advise such Representatives of the confidential nature thereof, shall ensure that each such Representative
is bound in writing by obligations of confidentiality and non-use at least as stringent as those contained in this Agreement, and shall
be responsible for the compliance of its Representatives with the terms of this Agreement. The Receiving Party shall use at least the
same standard of care as it uses to protect proprietary or confidential information of its own (but in no event less than reasonable care)
to ensure that its Representatives do not disclose or make any unauthorized use of the Confidential Information of the Disclosing Party.
The Receiving Party shall promptly notify the Disclosing Party upon discovery of any unauthorized use or disclosure of the Confidential
Information of the Disclosing Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.2&nbsp;<B>Exceptions</B>.
The Receiving Party&rsquo;s obligations under Section 6.1 shall not apply to any Confidential Information of the Disclosing Party that
the Receiving Party can prove by competent evidence: (a) is now, or hereafter becomes, through no act or failure to act on the part of
the Receiving Party in breach of this Agreement, generally known or available; (b) is known by the Receiving Party at the time of receiving
such information from the Disclosing Party; (c) is hereafter furnished to the Receiving Party by a Third Party, as a matter of right and
without restriction on disclosure; or (d) is independently discovered or developed by the Receiving Party, without the aid, use or application
of any Confidential Information of the Disclosing Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.3&nbsp;<B>Authorized
Disclosure</B>. Notwithstanding the provisions of this Article&nbsp;VI, the Receiving Party may disclose Confidential Information of the
Disclosing Party, without violating its obligations under this Agreement, to the extent the disclosure is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;required
by a valid order of a court or other Governmental Authority of competent jurisdiction or as otherwise required by Applicable Law, rule,
regulation (including securities laws), government requirement, or as may be required in connection with any filings made with, or by
the disclosure policies of, a stock exchange (including, for clarity, any such disclosures required to be made by Paragon or its Affiliates
or licensees in connection with the Development, Manufacture, Commercialization or other exploitation of Multispecific Antibodies), <I>provided
that</I> the Receiving Party shall give reasonable prior written notice to the Disclosing Party of such required disclosure and, at the
<FONT STYLE="font-variant: small-caps">[***] </FONT>request and expense, shall cooperate with the Disclosing Party&rsquo;s efforts to
contest such requirement, to obtain a protective order requiring that the Confidential Information so disclosed be used only for the purposes
for which the order was issued or the law required, or to obtain other confidential treatment of such Confidential Information;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;reasonably
necessary to file or Prosecute patent applications, Prosecute or defend litigation or otherwise establish rights or enforce obligations
under this Agreement, or obtain or maintain approval to conduct clinical trials or Regulatory Approvals, in each case, in accordance with
this Agreement (including, for clarity, any such disclosures that are reasonably necessary to made by Paragon or its Affiliates or licensees
in connection with the Development, Manufacture, Commercialization or other exploitation of Multispecific Antibodies); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;under
appropriate confidentiality provisions substantially equivalent to those in this Agreement (but of shorter duration if customary in the
case of subclause (ii)): (i) in connection with the performance of its obligations or as reasonably necessary or useful in the exercise
of its rights under this Agreement, including the right to grant licenses or sublicenses as permitted hereunder and the right to Develop,
Manufacture, Commercialize and otherwise exploit Antibodies and products (including Multispecific Antibodies and Multispecific Products)
to which it has rights hereunder, or (ii) to actual or <I>bona fide</I> potential licensees, acquirers, merger partners, assignees, collaborators,
investment bankers, investors or lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.4&nbsp;<B>Use
of Names</B>. Except as set forth in Section 6.6(b), neither Party shall use the other Party&rsquo;s name or trademarks in any advertising,
sales, or promotional material or in any publication without the prior written consent of the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.5&nbsp;<B>Confidentiality
of this Agreement</B>. This Agreement and its terms are considered Confidential Information of both Parties, and each Party shall keep
confidential and shall not publish or otherwise disclose the terms of this Agreement without the prior written consent of the other Party,
except as expressly permitted by Section 6.3, and except that both Parties may disclose this Agreement and its terms to its legal, financial
and investment banking advisors; <I>bona fide</I> potential and actual investors, acquirers, merger partners, assignees, collaborators,
investment bankers, lenders, licensees, sublicensees or strategic partners in connection with license or partnering transactions, due
diligence or similar investigations by such Third Parties or in confidential financing documents; and counsel or other advisors for the
foregoing; <I>provided</I>, in each case, that any such Third Party agrees to be bound by obligations of confidentiality and non-use at
least as restrictive as those set forth in this Article&nbsp;VI (<I>provided that</I> the confidentiality term applicable to such Third
Party may be shorter so long as it is commercially reasonable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.6&nbsp;<B>Publicity</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;Subject
to Section 6.6(b), neither Party will generate or allow any publicity regarding this Agreement or the transactions contemplated hereunder
without the other Party first approving such press release or publication in writing, except for any public disclosure by or on behalf
of a Party that is, upon the advice of such Party&rsquo;s counsel, required by Applicable Law or the rules of a stock exchange on which
the securities of such Party are listed (or to which an application for listing has been submitted) and except that a Party may, once
a press release or other public written statement is approved in writing by both Parties, make subsequent public disclosure of the information
contained in such press release or other public written statement without the further approval of the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;The
Parties shall collaborate and cooperate <FONT STYLE="font-variant: small-caps">[***] </FONT>to devise a Publication (as defined below)
strategy for the Oruka Products that is acceptable to both Parties. Prior to publicly presenting or publishing any data, results or analyses
relating to an Oruka Product generated by or on behalf of Oruka pursuant to this Agreement (each such proposed presentation or publication,
a &ldquo;<B>Publication</B>&rdquo;), Oruka will provide Paragon with a copy of such proposed Publication to review with adequate time
for Paragon&rsquo;s review and comment prior to the earlier of its presentation or intended submission for publication (such applicable
period, the &ldquo;<B>Review Period</B>&rdquo;). Oruka will take into consideration Paragon&rsquo;s reasonable comments prior to finalizing
the Publication. Upon Paragon&rsquo;s request, Oruka shall remove any Confidential Information of Paragon from such Publication that Oruka
is not required to disclose pursuant to Applicable Law or the rules of a stock exchange on which the securities of Oruka are listed.&nbsp;
In addition, Paragon shall have the right to request the delay of such Publication for up to <FONT STYLE="font-variant: small-caps">[***]</FONT>
days to enable filing of Patents, which request Oruka will take into consideration and discuss with Paragon before release of the Publication.
Paragon will not publicly present or publish any Publication including Confidential Information of Oruka relating specifically to the
Licensed Antibodies or Derived Antibodies without Oruka&rsquo;s prior written consent, which consent may be withheld for any reason or
no reason; <I>provided, that</I> the foregoing shall not limit Paragon&rsquo;s right to publicly present or publish any Publication relating
to Multispecific Antibodies. Each Publication shall include proper attribution, including the use of such Party&rsquo;s trademarks and
name, to the non-publishing Party, as applicable, and each non-publishing Party expressly authorizes the inclusion of such reference in
the applicable Publication and licenses the use of such trademarks and name solely for inclusion in any such Publication.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">Article&nbsp;VII</FONT><FONT STYLE="font-weight: normal"><BR>
<BR>
</FONT>REPRESENTATIONS, WARRANTIES AND COVENANTS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.1&nbsp;<B>Mutual
Representations</B>. Each Party represents and warrants to the other Party that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;it
is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other
power and authority to enter into this Agreement and to carry out the provisions hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;it
is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;no
consent, approval, permit, governmental order, declaration or filing with, or notice to, any Governmental Authority or any Third Party
is required by or with respect to such in connection with the execution and delivery of this Agreement and the consummation of the transactions
contemplated hereby; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;this
Agreement is legally binding upon it, enforceable in accordance with its terms, and does not and will not conflict with any agreement,
instrument, or understanding, oral or written, to which it is or may become a party or by which it may be or become bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.2&nbsp;<B>Representations
of Paragon</B>. Paragon hereby represents and warrants to Oruka as of the Effective Date that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;Paragon
has set forth in <U>Exhibit A</U> a true, correct and complete list of all the Licensed Antibody Patents existing as of the Effective
Date (including title, all inventors, owners, assignees, filing date, grant date, expiration date and status);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;Unless
otherwise set forth in <U>Exhibit A</U>, Paragon exclusively owns all Licensed Antibody Patents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;There
are no licenses or sublicenses pursuant to which Paragon licenses as of the Effective Date any of the Licensed Antibody Technology, nor,
to Paragon&rsquo;s actual knowledge, are any such licenses necessary to Develop, Manufacture and Commercialize the Licensed Antibodies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;Paragon
has the right under the Licensed Antibody Technology to grant to Oruka the licenses and other rights set forth in this Agreement, and
it has not granted any license or other right under the Licensed Antibody Technology that is inconsistent with the licenses and other
rights granted to Oruka hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&nbsp;There
is no pending or, to Paragon&rsquo;s knowledge, threatened litigation, nor has Paragon received any written notice from any Third Party,
asserting or alleging that the development, manufacture or commercialization of the Licensed Antibody Technology prior to the Effective
Date infringed or misappropriated the intellectual property rights of such Third Party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&nbsp;To
Paragon&rsquo;s knowledge, Paragon has not withheld from Oruka any information with respect to the Licensed Antibody Technology that would
reasonably be expected to be materially adverse to Oruka&rsquo;s Development, Manufacture, or Commercialization of any Product in the
Territory as contemplated under this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&nbsp;To
Paragon&rsquo;s knowledge, Paragon has, and any of Paragon&rsquo;s Affiliates involved in the Research Program have, (i) conducted all
research and development under the Research Program in accordance with Research Plan (as defined in the Option Agreement), and (ii) conducted
the Research Program in compliance with all Applicable Laws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&nbsp;To
Paragon&rsquo;s knowledge, Paragon has provided true, correct and complete copies of all Results developed under the Research Program
and all other deliverables required under the Research Program have been provided or delivered to Oruka and are true, correct and complete
in all material respects;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;Paragon
has properly filed, Prosecuted and maintained all Licensed Antibody Patents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&nbsp;Paragon
has complied with all duties of disclosure and has not engaged in any inequitable conduct with respect to all Licensed Antibody Patents
that were filed prior to the Effective Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&nbsp;All
Licensed Antibody Patents listed in <U>Exhibit A</U> that have been issued as of the Effective Date are in full force and effect and are,
to Paragon&rsquo;s knowledge, valid and enforceable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)&nbsp;Other
than the Patents listed in <U>Exhibit A</U>, as of the Effective Date, neither Paragon nor any of its Affiliates own or have any rights
in, to or under any Patents Covering the composition of matter of, or any method of specifically making or using, any Licensed Antibody;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)&nbsp;There
are no judgments against or awards or settlements against Paragon or any of its Affiliates, and there are no claims, actions, or proceedings
pending or, to Paragon&rsquo;s knowledge, threatened, nor to Paragon&rsquo;s knowledge are there any formal inquiries initiated or written
notices received that are reasonably likely to lead to the institution of any such legal proceedings, in each case (i) relating to any
Licensed Antibodies, Derived Antibodies or Licensed Antibody Technology or alleging that any Third Party has any right to or under any
Products, Licensed Antibodies, Derived Antibodies or Licensed Antibody Technology that would conflict with the rights granted in this
Agreement; or (ii) alleging that any Licensed Antibody Patent is unpatentable, invalid, unenforceable or infringed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(n)&nbsp;(i)
Each Representative employed or engaged by Paragon or its Affiliate to conduct the activities under the Research Program have assigned
or licensed, or are under contractual obligations to assign or license, to Paragon all inventions conceived, reduced to practice or otherwise
related to Licensed Antibodies, Derived Antibodies and Licensed Antibody Technology; (ii) to Paragon&rsquo;s knowledge, no Representative
employed by Paragon or its Affiliate that conducts activities under a Research Program has any obligations under agreements or Applicable
Law to assign any interest in any such inventions to any Third Party; and (iii) each Representative employed or engaged by Paragon or
its Affiliate to conduct the activities under a Research Program have existing obligations under agreements or Applicable Law to maintain
as confidential Paragon&rsquo;s Confidential Information as well as confidential information of other parties (including of Oruka and
its Affiliates);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(o)&nbsp;None
of Paragon, its Representatives, or any other person used by Paragon in the performance of the Research Program or otherwise in connection
with this Agreement has been or is (i) debarred, convicted, or is subject to a pending debarment or conviction, pursuant to section 306
of the United States Food Drug and Cosmetic Act, 21 U.S.C. &sect; 335a, (ii) listed by any government or regulatory agencies as ineligible
to participate in any government healthcare programs or government procurement or non-procurement programs (as that term is defined in
42 U.S.C. &sect; 1320a-7b(f)), or excluded, debarred, suspended or otherwise made ineligible to participate in any such program, or (iii)
convicted of a criminal offense related to the provision of healthcare items or services, or is subject to any such pending action. Paragon
agrees to inform Oruka in writing promptly if Paragon or any person who is performing activities on its behalf under the Agreement is
subject to the foregoing, or if any action, suit, claim, investigation, or proceeding relating to the foregoing is pending or threatened;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(p)&nbsp;No
funding, facilities, or personnel of any Governmental Authority or any public or private educational or research institutions were used
to develop or create any Licensed Antibody Technology, and neither Paragon nor any of its Affiliates has entered into a government funding
relationship that would result in rights to any Products, Licensed Antibodies, Derived Antibodies or Licensed Antibody Technology residing
in the U.S. Government, the National Institutes of Health, or other agency, and the licenses granted hereunder are not subject to overriding
obligations to the U.S. Government as set forth in Public Law 96-517 (35 U.S.C. &sect;&sect;&nbsp;200-204), or any similar obligations
under the laws of any other country in the Territory; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(q)&nbsp;To
the <FONT STYLE="font-variant: small-caps">[***] </FONT>knowledge of <FONT STYLE="font-variant: small-caps">[***] </FONT>of Paragon, with
respect to this Agreement and the Option Agreement, neither Paragon nor any of its directors, officers, employees, distributors, consultants,
agents, representatives, sales intermediaries, or other Third Parties acting on behalf of Paragon or any of its Affiliates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">(i)&nbsp;has
taken any action in violation of any applicable anti-corruption laws, anti-money laundering laws or laws restricting or regulating global
trade (collectively, &ldquo;<B>Anti-Corruption Laws</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">(ii)&nbsp;has
conducted or initiated any internal investigation with respect to any alleged act or omission arising under or relating to any potential
noncompliance with any Anti-Corruption Law, or been the subject of current, pending, or threatened investigation, formal or informal inquiry,
enforcement proceedings, or received any notice, request, or citation for alleged violations of such laws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">(iii)&nbsp;has
engaged in any direct or indirect dealings or transactions in or with a person, entity or country found on the Specially Designated Nationals
and Blocked Persons List maintained by the U.S. Office of Foreign Assets Control, or engaged in any direct or indirect dealings with Sudan,
individuals ordinarily resident in Sudan, or entities incorporated under the laws of Sudan prior to October 12, 2017; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">(iv)&nbsp;has
offered, paid, given, promised to pay or give, or authorized the payment or gift of, received, or solicited anything of value, directly
or indirectly, to any public official, for the purposes of: influencing any act or decision of any public official in his or her official
capacity; inducing any public official to do or omit to do any act in violation of his or her lawful duty; securing any improper or undue
advantage; or inducing any public official to use his or her influence with a government, Governmental Authority, or commercial enterprise
owned or controlled by any government (including state-owned or controlled veterinary, laboratory or medical facilities) in obtaining
or retaining any business whatsoever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.3&nbsp;<B>Covenants
of Paragon</B>. Paragon hereby covenants to Oruka during the Term that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;Paragon
will not grant a Third Party any license or other right in the Licensed Antibody Technology or the Other Licensed Technology that would
conflict with the rights and licenses granted to Oruka hereunder with respect to such Licensed Antibody Technology;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;Paragon
will, and will direct each Affiliate of Paragon and subcontractor conducting activities under this Agreement to, conduct all such activities
in compliance with Applicable Laws, including all applicable Anti-Corruption Laws and U.S. sanctions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;Paragon
will comply with the terms of each Paragon Third Party Agreement, will maintain each Paragon Third Party Agreement, will not amend a Paragon
Third Party Agreement in a manner that (i) adversely effects Oruka in any material respect, or (ii)&nbsp;increases any financial obligations
under a Paragon Third Party Agreement that will result in an increase in Oruka&rsquo;s Reimbursement Obligation, in each case of (i) and
(ii) without Oruka&rsquo;s prior written consent, and will not take any actions that could reasonably cause any Paragon Third Party Agreement
to lapse or terminate; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&nbsp;Paragon
will, and will direct each applicable Affiliate of Paragon to, execute and deliver such additional documents and instruments and to perform
such additional acts as may be necessary or appropriate to enable Oruka to exercise its rights and obligations under Sections 5.2, 5.3
and 5.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.4&nbsp;<B>Compliance
with Laws</B>. Each Party shall, and shall ensure that its Affiliates and its and its Affiliates&rsquo; Representatives and sublicensees,
comply with Applicable Laws in all material respects in the performance of its obligations and the exercise of its rights under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.5&nbsp;<B>DISCLAIMER
OF WARRANTIES</B>. EXCEPT AS EXPRESSLY SET FORTH HEREIN, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, DURABILITY, MERCHANTABLE QUALITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT
OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">Article&nbsp;VIII</FONT><BR>
<BR>
TERM; TERMINATION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.1&nbsp;<B>Term</B>.
The term of this Agreement shall commence on the Effective Date and shall expire on a country-by-country and Oruka Product-by-Oruka Product
basis on the expiration of the Royalty Term for such Oruka Product in such country, in each case, unless earlier terminated by a Party
as set forth below in this Article&nbsp;VIII (the &ldquo;<B>Term</B>&rdquo;). Upon expiration (but not termination) of the Agreement,
the licenses granted in Section 2.1 shall survive and become royalty-free, fully paid-up, perpetual and irrevocable with respect to the
applicable Oruka Product in the applicable country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2&nbsp;<B>Termination
by Oruka</B>. Oruka shall have the right to terminate this Agreement in its entirety or on a country-by-country or Oruka Product-by-Oruka
Product basis for any or no reason upon sixty (60) days&rsquo; prior written notice to Paragon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.3&nbsp;<B>Material
Breach</B>. Either Party may terminate this Agreement in its entirety for the material breach of this Agreement by the other Party, if
such material breach remains uncured ninety (90) days (or thirty (30) days with respect to any failure to make any payments owing to a
Party hereunder) following notice from the non-breaching Party to the breaching Party specifying such breach, <I>provided that</I>, in
the event of a dispute regarding the existence or cure of a material breach, no termination shall become effective until such dispute
is finally resolved pursuant to Section 10.7 in favor of the non-breaching Party and the breaching Party fails to cure such material breach
within ninety (90) days thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.4&nbsp;<B>Insolvency</B>.
Each Party will have the right to terminate this Agreement in the event of a Bankruptcy Event with respect to the other Party. &ldquo;<B>Bankruptcy
Event</B>&rdquo; means the occurrence of any of the following: (a) the institution of any bankruptcy, receivership, insolvency, reorganization
or other similar proceedings by or against a Party under any bankruptcy, insolvency, or other similar law now or hereinafter in effect,
including any section or chapter of the United States Bankruptcy Code, as amended or under any similar laws of the United States or any
state thereof (the &ldquo;<B>Bankruptcy Code</B>&rdquo;), where in the case of involuntary proceedings such proceedings have not been
dismissed or discharged within <FONT STYLE="font-variant: small-caps">[***] </FONT>days after they are instituted, (b) the insolvency
or making of an assignment for the benefit of creditors, (c) the institution of any reorganization, arrangement or other readjustment
of debt plan of a Party not involving the Bankruptcy Code, or (d)&nbsp;appointment of a receiver for all or substantially all of a Party&rsquo;s
assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.5&nbsp;<B>Effect
of Termination of this Agreement</B>. If this Agreement terminates for any reason (excluding expiration under Section 8.1), whether with
respect to a particular Oruka Product, particular country or in its entirety, then the following shall apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;All
licenses and other rights granted by Paragon under this Agreement with respect to the terminated Oruka Product(s) and terminated country(ies)
shall terminate, except as required for Oruka, its Affiliates and/or its Sublicensees to perform any of its obligations that survive termination,
including to continue to complete or wind down (at <FONT STYLE="font-variant: small-caps">[***] </FONT>expense in the event of a termination
by Oruka under Section 8.3) any ongoing clinical trials for any Oruka Product, as may be required by Applicable Law or ethical principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;No
later than <FONT STYLE="font-variant: small-caps">[***] </FONT>days after the effective date of such termination, each Party shall return
or cause to be returned to the other Party, or destroy, all Confidential Information received from the other Party and all copies thereof
related to the terminated Oruka Product(s) in the terminated country(ies); <I>provided, however</I>, that each Party may retain any Confidential
Information reasonably necessary for such Party&rsquo;s ongoing obligations and rights under this Agreement which do not terminate, and
each Party may keep one (1) copy of Confidential Information received from the other Party in its confidential files for record purposes
and such copy shall remain subject to Article&nbsp;VI of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;Upon
Paragon&rsquo;s written request to Oruka (which must be provided to Oruka within <FONT STYLE="font-variant: small-caps">[***] </FONT>days
after the effective date of termination), Paragon and Oruka shall <FONT STYLE="font-variant: small-caps">[***] </FONT>discuss <FONT STYLE="font-variant: small-caps">[***]</FONT>,
for a period of up to <FONT STYLE="font-variant: small-caps">[***] </FONT>days following such written request, terms and conditions under
which Oruka may be willing to grant to Paragon <FONT STYLE="font-variant: small-caps">[***]</FONT>, <FONT STYLE="font-variant: small-caps">[***]
</FONT>license under the Oruka Intellectual Property to Develop, Manufacture, Commercialize or otherwise exploit the terminated Oruka
Products in the Field in the terminated countries that were the subject of any Development, Manufacturing or Commercialization activities
performed by Oruka or its Affiliates under this Agreement prior to such termination, (&ldquo;<B>Reversion Products</B>&rdquo;), as well
as the potential transfer of materials, ongoing clinical trials, and applicable regulatory filings and relevant data generated by Oruka
with respect to the Reversion Products and necessary for the continued Development, Manufacture, Commercialization and exploitation of
such Reversion Products, such agreement to include commercially reasonable financial and other terms, which terms shall take into consideration
Oruka&rsquo;s contributions made in the Development, Manufacture, Commercialization and other exploitation of the Reversion Products,
provided, that Oruka is under no obligation to enter into such license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.6&nbsp;<B>Survival
of Sublicenses</B>. Upon termination of this Agreement, at the written request of any Sublicensee who is not then in breach of its sublicense
agreement, such sublicense agreement will survive such termination of this Agreement, and Paragon will negotiate <FONT STYLE="font-variant: small-caps">[***]</FONT>
the terms and conditions of a direct license with such Sublicensee that is consistent with the terms of this Agreement (as adjusted for
the scope of license, products, field of use and other provisions of the original sublicense). Each sublicense that may be amended to
become a direct license between Paragon and a Sublicensee shall ensure that any and all economic rights, payments or benefits due to Oruka
will be preserved and payable to Oruka and will designate Oruka a third-party beneficiary to enforce such rights. In each such instance,
Oruka will have the right to review and approve the terms of such agreement between Paragon and such Sublicensee as related to Oruka&rsquo;s
economic rights, which approval shall not be unreasonably withheld, conditioned or delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.7&nbsp;<B>Accrued
Rights; Survival</B>. The expiration or termination of this Agreement for any reason shall not release either Party from any liability
or obligation that, at the time of such expiration or termination, has already accrued to the other Party or that is attributable to a
period prior to such expiration or termination, nor will expiration or any termination of this Agreement preclude either Party from pursuing
all rights and remedies it may have under this Agreement, or at law or in equity, with respect to breach of this Agreement. In the event
of expiration or any termination of this Agreement, the following provisions of this Agreement shall survive such expiration or termination
in accordance with their respective terms and conditions: Article&nbsp;I (Definitions); Section 2.1 (License Grant from Paragon) (upon
expiration (but not termination) of this Agreement as set forth in Section 8.1 (Term)); Section 2.3 (Sublicenses) (with respect to any
payments or other performance obligations prior to conversion (if any) to a direct license pursuant to Section 8.6); Section 2.4 (No Implied
Licenses; Reservation of Rights); Section 4.1 (Milestone Payments) (with respect to any outstanding payment obligations incurred prior
to the date of termination or expiration); Section 4.2 (Royalties) (with respect to any outstanding payments accrued prior to the effective
date of termination); Section 4.4 (Payment Reports) (with respect to the last Calendar Quarter of the Term to the extent not already reported
and any outstanding payment obligation with respect to any royalty payments accrued prior to the date of termination or expiration); Section
4.5 (Payment Method) to 4.9 (Blocked Currency) (for the duration of any outstanding payment obligations under this Agreement); Section
4.10 (Records; Inspection) (for the duration set forth therein); Section 5.1 (Ownership); Section 7.5 (Disclaimer of Warranties); Article&nbsp;VI
(Protection of Confidential Information) (for the duration set forth therein); Section 8.5 (Effect of Termination of this Agreement);
Section 8.6 (Survival of Sublicenses); Section 8.7 (Accrued Rights; Survival); Article&nbsp;IX (Indemnification); and Article&nbsp;X (Miscellaneous).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">Article&nbsp;IX</FONT><BR>
<BR>
INDEMNIFICATION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">9.1&nbsp;</FONT><B>By
Oruka</B>. Oruka hereby agrees to defend, indemnify and hold harmless Paragon, its Affiliates and its or their Representatives (each,
an &ldquo;<B>Paragon Indemnitee</B>&rdquo;) from and against any and all losses, damages, liabilities, expenses and costs, including reasonable
legal expense and attorneys&rsquo; fees (collectively, &ldquo;<B>Losses</B>&rdquo;), to which any Paragon Indemnitee may become subject
(a) as a result of any claim, demand, action, or other proceeding by any Third Party (&ldquo;<B>Third Party Claim</B>&rdquo;) to the extent
such Losses result from: (i) the gross negligence, recklessness or willful misconduct of any Oruka Indemnitee in the performance of this
Agreement; (ii)&nbsp;Oruka&rsquo;s breach of any of its representations, warranties or covenants under this Agreement; or (iii) Oruka&rsquo;s
Development, Manufacture and Commercialization of the Oruka Products; and (b) to the extent such Losses result from the termination, suspension,
revocation or other loss of any Licensed Antibody Patents as a result of any negligence or breach of this Agreement by Oruka, its Affiliates
or Sublicensees, in each case ((a) to (b)), except in each case to the extent that any Losses are attributable to the breach of this Agreement
by, or the negligence, recklessness or willful misconduct of, or otherwise indemnifiable by, any Paragon Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"></FONT></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">9.2&nbsp;</FONT><B>By
Paragon</B>. Paragon hereby agrees to defend, indemnify, and hold harmless Oruka, its Affiliates, and its or their Representatives (each,
a &ldquo;<B>Oruka Indemnitee</B>&rdquo;) from and against any and all Losses to which any Oruka Indemnitee may become subject (a) as a
result of any Third Party Claim to the extent such Losses result from: (i) the gross negligence, recklessness or willful misconduct of
any Paragon Indemnitee in the performance of this Agreement; or (ii) Paragon&rsquo;s breach of any of its representations, warranties
or covenants under this Agreement; and (b) to the extent such Losses result from: (i) the termination, suspension, revocation or other
loss of any Licensed Antibody Patents as a result of any negligence or breach of this Agreement by Paragon or its Affiliates; or (ii)
any claim or demand from any employee or contractor of Paragon or its Affiliates who is an inventor of any Licensed Antibody Patents with
respect to ownership thereof, in each case ((a) to (b)), except to the extent that any Losses are attributable to the breach of this Agreement
by, or the negligence, recklessness or willful misconduct of, or otherwise indemnifiable by, any Oruka Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.3&nbsp;<B>Indemnification
<FONT STYLE="background-color: white">Procedures</FONT></B><FONT STYLE="background-color: white">. </FONT>The Party claiming indemnity
under this Article&nbsp;IX (the &ldquo;<B>Indemnified Party</B>&rdquo;) will give written notice to the Party from whom indemnity is being
sought (the &ldquo;<B>Indemnifying Party</B>&rdquo;) promptly after learning of the Third Party Claim for which indemnity is being sought
(&ldquo;<B>Claim</B>&rdquo;). The Indemnifying Party&rsquo;s obligation to defend, indemnify and hold harmless pursuant to Section&nbsp;9.1
or Section&nbsp;9.2, as applicable, will be reduced to the extent the Indemnified Party&rsquo;s delay in providing notification pursuant
to the previous sentence results in material prejudice to the Indemnifying Party; <I>provided, however,</I> that the failure by an Indemnified
Party to give such notice or otherwise meet its obligations under this Section 9.3 will not relieve the Indemnifying Party of its indemnification
obligation under this Agreement. At its option, the Indemnifying Party may assume the defense and have exclusive control, at its own expense,
of any Claim for which indemnity is being sought by giving written notice to the Indemnified Party within <FONT STYLE="font-variant: small-caps">[***]
</FONT>days after receipt of the notice of the Claim. The Indemnified Party will provide the Indemnifying Party with reasonable assistance,
at the Indemnifying Party&rsquo;s expense, in connection with the defense. The Indemnified Party may participate in and monitor such defense
with counsel of its own choosing at its sole expense; <I>provided, however, </I>the Indemnifying Party will have the right to assume and
conduct the defense of the Claim with counsel of its choice. The Indemnifying Party will not settle any Claim without the prior written
consent of the Indemnified Party, not to be unreasonably withheld, unless the settlement involves only the payment of money. The Indemnified
Party will not settle any such Claim without the prior written consent of the Indemnifying Party. If the Indemnifying Party does not assume
and conduct the defense of the Claim as provided above, (i) the Indemnified Party may defend against, and consent to the entry of any
judgment or enter into any settlement with respect to the Claim in any manner the Indemnified Party may deem reasonably appropriate, <I>provided,
that</I> the Indemnified Party reasonably consults with the Indemnifying Party prior to entering into any settlement, and (ii) the Indemnified
Party reserves any right it may have under this Article&nbsp;IX to obtain indemnification from the Indemnifying Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.4&nbsp;<B>Limitation
of Liability</B>. EXCEPT FOR LIABILITY FOR BREACH OF <FONT STYLE="text-transform: uppercase">Article&nbsp;VI, FOR Breach of Sections 2.1
or 2.2, for breach of any intellectual property rights held by a party, for the fraud or willful misconduct of a party</FONT> OR FOR INDEMNIFICATION
CLAIMS UNDER THIS <FONT STYLE="text-transform: uppercase">Article&nbsp;IX</FONT>, IN NO EVENT SHALL EITHER PARTY BE ENTITLED TO RECOVER
FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT, EVEN IF THE OTHER PARTY
HAD NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.5&nbsp;<B>Insurance</B>.
During the Term and for a period of <FONT STYLE="font-variant: small-caps">[***] </FONT>years thereafter, each Party shall maintain at
its expense insurance coverage consistent with normal business practices and adequate to cover the risks associated with its performance
of any activities hereunder. Each Party hereby expressly acknowledges and agrees that the maintenance of such insurance coverage shall
not relieve it of its obligations under this Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0cm"><FONT STYLE="text-transform: uppercase">Article&nbsp;X</FONT><BR>
<BR>
MISCELLANEOUS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.1&nbsp;<B>Independent
Contractor Relationship</B>. Paragon&rsquo;s relationship with Oruka is that of an independent contractor, and nothing in this Agreement
should be construed to create a partnership, joint venture, or employer-employee relationship. Neither Party is an agent of the other
Party or authorized to make any representation, contract, or commitment on behalf of the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.2&nbsp;<B>Force
Majeure</B>. Neither Party will be charged with any liability for delay or failure in performance of an obligation under this Agreement
(other than any obligation to pay monies when due) to the extent such delay or failure is due to a cause beyond the reasonable control
of the affected Party, such as war, riots, labor disturbances, epidemic, pandemic, fire, explosion, and compliance in good faith with
any Applicable Law (in each case, a &ldquo;<B>Force Majeure</B>&rdquo;). In addition, a Force Majeure event may include reasonable measures
affirmatively taken by a Party or its Affiliates to respond to the COVID-19 pandemic or any other pandemic (or other Force Majeure event),
such as requiring employees to stay home, closures of facilities, delays of clinical trials, or cessation of activities in response to
the pandemic. The Party affected by a Force Majeure will give prompt written notice to the other Party of the nature of the cause of any
material delay or failure to perform, its anticipated duration and any action being taken to avoid or minimize the effect. The Party affected
will use its diligent efforts to avoid or remove such causes of delay or failure to perform and to mitigate the effect of such occurrence,
and will continue performance in accordance with the terms of this Agreement whenever such causes are removed. The Party affected will
give prompt written notice to the other Party of such resumed performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.3&nbsp;<B>Entire
Agreement; Amendment</B>. This Agreement and the Option Agreement, together with all Exhibits attached hereto, constitutes the final,
complete, and exclusive agreement of the Parties with respect to the subject matter hereof and supersedes all prior and contemporaneous
understandings and agreements, relating to its subject matter. This Agreement (including its Exhibits) may not be changed, modified, amended,
or supplemented except by a written instrument signed by both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.4&nbsp;<B>Non-Waiver</B>.
The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this
Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that
instance or in any other instance. Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular
matter and, if applicable, for a particular period of time and shall be signed by such Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.5&nbsp;<B>Severability</B>.
Should one or more of the provisions of this Agreement become void or unenforceable as a matter of Applicable Law, then this Agreement
shall be construed as if such provision were not contained herein and the remainder of this Agreement shall be in full force and effect,
and the Parties will use their best efforts to substitute for the invalid or unenforceable provision a valid and enforceable provision
which conforms as nearly as possible with the original intent of the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.6&nbsp;<B>Assignment</B>.
Neither this Agreement nor any rights or obligations hereunder may be assigned by either Party without the prior written consent of the
other Party (which consent shall not be unreasonably withheld); <I>provided, however</I>, that (a) Paragon may assign to an Affiliate
or a Third Party financing source its rights to receive some or all of the payments payable hereunder together with the right to receive
Confidential Information of Oruka, <I>provided</I> Paragon shall not be permitted to share Oruka Confidential Information unless and except
to the extent necessary to obtain Affiliate or Third-Party financing, <I>provided, further, that</I> any such Affiliate or Third Party
agrees to be bound by obligations of confidentiality and non-use at least as restrictive as those set forth in Article&nbsp;VI; and (b)&nbsp;either
Party may assign this Agreement and its rights and obligations hereunder without the other Party&rsquo;s consent to (i) its Affiliates
or (ii) its successor to all or substantially all of the business of such Party to which this Agreement relates, whether by merger, sale
of stock, sale of assets or otherwise. The assigning Party shall provide the other Party with prompt written notice of any such assignment
set forth in clauses (a) and (b) above. Except for an assignment pursuant to clause (a) above, the rights and obligations of the Parties
under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties, and the name
of a Party appearing herein will be deemed to include the name of such Party&rsquo;s successors and permitted assigns to the extent necessary
to carry out the intent of this section. Any assignment not in accordance with this Agreement shall be void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.7&nbsp;<B>Dispute
Resolution</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;The
Parties recognize that a <I>bona fide </I>dispute as to certain matters may arise from time to time during the Term relating to either
Party&rsquo;s rights or obligations hereunder or otherwise relating to the validity, enforceability or performance of this Agreement,
including disputes relating to alleged breach or termination of this Agreement but excluding any disputes relating to Article&nbsp;VI
or disputes relating to the determination of the validity, scope, infringement, enforceability, inventorship or ownership of the Parties&rsquo;
respective Intellectual Property Rights (hereinafter, a &ldquo;<B>Dispute</B>&rdquo;). In the event of the occurrence of any Dispute,
the Parties will follow the following procedures in an attempt to resolve the dispute or disagreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">(i)&nbsp;The
Party claiming that such a Dispute exists will give notice in writing (a &ldquo;<B>Notice of Dispute</B>&rdquo;) to the other Party of
the nature of the Dispute. The Dispute will be referred to the then Chief Executive Officer of Paragon and the then Chief Executive Officer
of Oruka who will meet no later than <FONT STYLE="font-variant: small-caps">[***] </FONT>days following the initial receipt of the Notice
of Dispute and use reasonable endeavors to resolve the Dispute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">(ii)&nbsp;If,
within <FONT STYLE="font-variant: small-caps">[***] </FONT>days of initial receipt of the Notice of Dispute, the Dispute has not been
resolved, or if, for any reason, the meeting described in Section 10.7(a)(i) hereof has not been held within <FONT STYLE="font-variant: small-caps">[***]
</FONT>days of initial receipt of the Notice of Dispute, then the Parties agree that such Dispute will be finally resolved through binding
arbitration to be administered by JAMS pursuant to its Comprehensive Arbitration Rules and Procedures and in accordance with the Expedited
Procedures in those Rules (the &ldquo;<B>JAMS Rules</B>&rdquo;), as specifically modified by the provisions of this Section 10.7(a)(ii)
and Section 10.7(a)(iii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">(iii)&nbsp;The
arbitration will be conducted by a panel of three arbitrators. Within <FONT STYLE="font-variant: small-caps">[***] </FONT>days after the
initiation of the arbitration, each Party will nominate one person to act as arbitrator, and the two arbitrators so named will then jointly
appoint the third arbitrator within <FONT STYLE="font-variant: small-caps">[***] </FONT>days of their appointment, who will serve as chairman
of the panel. All three arbitrators must be independent Third Parties having at least <FONT STYLE="font-variant: small-caps">[***] </FONT>years
of dispute resolution experience (which may include judicial experience) or legal or business experience in the biotech or pharmaceutical
industry. If either Party fails to nominate its arbitrator, or if the arbitrators selected by the Parties cannot agree on a person to
be named as chairman within such <FONT STYLE="font-variant: small-caps">[***]</FONT>-day period, JAMS will make the necessary appointments
for such arbitrator(s) or the chairman. Once appointed by a Party, such Party will have no <I>ex parte </I>communication with its appointed
arbitrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">(iv)&nbsp;Notwithstanding
the provisions of Section 10.7(a)(iii), if the Dispute involves an amount in question of less than $<FONT STYLE="font-variant: small-caps">[***]</FONT>,
then the arbitration will be conducted by one arbitrator, selected in accordance with the JAMS Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 108pt">(v)&nbsp;The
place of arbitration will be in Boston, Massachusetts or such other venue as the Parties may mutually agree. The arbitration proceedings
and all communications with respect thereto will be in English. Any written evidence originally in another language will be submitted
in English translation accompanied by the original or a true copy thereof. The arbitrator(s) shall have the power to decide all matters
in Dispute, including any questions of whether or not such matters are subject to arbitration hereunder. The arbitration will be governed
by the Federal Arbitration Act, 9 U.S.C. &sect;&sect;1 <I>et seq., </I>and judgment upon the award rendered by the arbitrators may be
entered in any court having competent jurisdiction thereof. The existence, content and results of any arbitration proceedings pursuant
to this Section 10.7 will be deemed the Confidential Information of both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;Notwithstanding
any provision of this Agreement to the contrary, either Party may immediately initiate litigation in any court of competent jurisdiction
seeking any remedy at law or in equity, including the issuance of a preliminary, temporary or permanent injunction, to preserve or enforce
its rights under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;The
Parties agree that any disputes relating to Article&nbsp;VI or disputes relating to the determination of the validity, scope, infringement,
enforceability, inventorship or ownership of the Parties&rsquo; respective Intellectual Property Rights shall be subject to the exclusive
jurisdiction of the state and federal courts in Boston, Massachusetts and each Party hereby submits to such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.8&nbsp;<B>Governing
Law</B>. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without reference
to conflicts of laws principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.9&nbsp;<B>Notices</B>.
Any notice to be given under this Agreement must be in writing and delivered either in person, by internationally recognized express courier,
or by email, to the Party to be notified at its address(es) given below, or at any address such Party has previously designated by prior
written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earliest of: (a) the date of actual receipt;
(b) if delivered by express courier, the next Business Day the express courier regularly makes deliveries; or (c) if delivered by email,
upon the date upon which the receipt of such email is confirmed by return email. Together with any notice provided by a Party to the other
Party in accordance with this Section 10.9, the Party shall send a copy of such notice by email to the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 1in">If to Paragon:</TD>
    <TD>Paragon Therapeutics, Inc.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>221 Crescent Street</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Building 23, Suite 105</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Waltham, MA 02453</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Attn: Chief Operating Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Email: [***]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>If to Oruka:</TD>
    <TD>Oruka Therapeutics, Inc.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>855 Oak Grove Avenue, Suite 100</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Menlo Park, CA 94025</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Attn: General Counsel</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Email: [***]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.10&nbsp;<B>Interpretation</B>.
Except where the context expressly requires otherwise, (a)&nbsp;the use of any gender herein shall be deemed to encompass references to
either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b)&nbsp;the words &ldquo;include&rdquo;,
&ldquo;includes&rdquo; and &ldquo;including&rdquo; shall be deemed to be followed by the phrase &ldquo;without limitation&rdquo;, (c)&nbsp;the
word &ldquo;will&rdquo; shall be construed to have the same meaning and effect as the word &ldquo;shall&rdquo;, (d)&nbsp;any definition
of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or
other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements
or modifications set forth herein), (e) any reference herein to any person or entity shall be construed to include such person&rsquo;s
or entity&rsquo;s successors and assigns, (f) the words &ldquo;herein&rdquo;, &ldquo;hereof&rdquo; and &ldquo;hereunder&rdquo;, and words
of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references
herein to Sections or Exhibits shall be construed to refer to Sections or Exhibits of this Agreement, and references to this Agreement
include all Exhibits hereto, (h) the word &ldquo;notice&rdquo; means notice in writing (whether or not specifically stated) and shall
include notices, consents, approvals and other written communications contemplated under this Agreement, (i) provisions that require that
a Party, the Parties or any committee hereunder &ldquo;agree,&rdquo; &ldquo;consent&rdquo; or &ldquo;approve&rdquo; or the like shall
require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or
otherwise (but excluding e-mail and instant messaging), (j) references to any specific law, or article, section or other division thereof,
shall be deemed to include the then-current amendments thereto or any replacement or successor law thereof, and (k) the term &ldquo;or&rdquo;
shall be interpreted in the inclusive sense commonly associated with the term &ldquo;or.&rdquo; The headings of clauses contained in this
Agreement preceding the text of the sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference
only and shall not constitute any part of this Agreement or have any effect on its interpretation or construction. Ambiguities and uncertainties
in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the
ambiguity or uncertainty to exist. This Agreement has been prepared in the English language, and the English language shall control its
interpretation. In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral, or other communications
between the Parties regarding this Agreement shall be in the English language. To the extent there is any inconsistency or conflict between
the terms and conditions of this Agreement and any Exhibit, the terms and conditions of this Agreement will prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.11&nbsp;<B>No
Third-Party Rights</B>. The provisions of this Agreement are for the exclusive benefit of the Parties and their successors and permitted
assigns, and no other person shall have any right or claim against any Party by reason of these provisions or be entitled to enforce any
of these provisions against any Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.12&nbsp;<B>Counterparts</B>.
This Agreement may be executed in counterparts, each of which shall be deemed an original document, and all of which, together with this
writing, shall be deemed one instrument. This Agreement may be executed by facsimile or PDF signatures, or electronic signatures complying
with the ESIGN Act of 2000 (such as DocuSign), which signatures shall have the same force and effect as original signatures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.13&nbsp;<B>Expenses</B>.
Each Party shall pay its own costs, charges and expenses incurred in connection with the negotiation, preparation and completion of this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.14&nbsp;<B>Binding
Effect</B>. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives, successors
and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.15&nbsp;<B>Construction</B>.
The Parties hereto acknowledge and agree that: (a) each Party and its counsel reviewed and negotiated the terms and provisions of this
Agreement and have contributed to its revision; (b) the rule of construction to the effect that any ambiguities are resolved against the
drafting Party shall not be employed in the interpretation of this Agreement; and (c) the terms and provisions of this Agreement shall
be construed fairly as to all Parties hereto and not in a favor of or against any Party, regardless of which Party was generally responsible
for the preparation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.16&nbsp;<B>Cumulative
Remedies</B>. No remedy referred to in this Agreement is intended to be exclusive unless explicitly stated to be so, but each shall be
cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.17&nbsp;<B>Performance
by Affiliates</B>. A Party may perform some or all of its obligations under this Agreement through Affiliate(s) or may exercise some or
all of its rights under this Agreement through Affiliates, subject to the terms of this Agreement. However, each Party shall remain responsible
and be guarantor of the performance by its Affiliates and shall cause its Affiliates to comply with the provisions of this Agreement in
connection with such performance as if such Party were performing such obligations itself, and references to a Party in this Agreement
shall be deemed to also reference such Affiliate. In particular and without limitation, all Affiliates of a Party that receive Confidential
Information of the other Party pursuant to this Agreement shall be governed and bound by all obligations set forth in Article&nbsp;VI<I>,
</I>and shall be subject to the intellectual property provisions of Article&nbsp;V as if they were the original Party to this Agreement
(and be deemed included in the actual Party to this Agreement for purposes of all intellectual property-related definitions). A Party
and its Affiliates shall be jointly and severally liable for their performance under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Remainder of Page Left Intentionally Blank;
Signature Page Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Parties
have by duly authorized persons executed this Agreement as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-variant: small-caps"><B>Paragon Therapeutics, Inc.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-variant: small-caps"><B>Oruka Therapeutics, Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">/s/ K. Evan Thompson</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">/s/ Lawrence Klein</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name:</TD>
    <TD>K. Evan Thompson</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Lawrence Klein</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD>Chief Operating Officer</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase">[Signature
Page to License Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>10
<FILENAME>ea023044501ex10-32_orukathe.htm
<DESCRIPTION>CELL LINE LICENSE AGREEMENT BY AND BETWEEN WUXI BIOLOGICS IRELAND LIMITED AND ORUKA THERAPEUTICS, INC., DATED MARCH 4, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.32</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT
TREATS AS PRIVATE OR CONFIDENTIAL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CELL LINE LICENSE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Cell Line License Agreement (&ldquo;Agreement&rdquo;),
effective as of March 4, 2024 (&ldquo;EFFECTIVE DATE&rdquo;), is entered and made by and between WuXi Biologics Ireland Limited, having
an address at Dundalk Science &amp; Technology Park, Mullagharlin, Dundalk, Co Louth A91 X56F, Ireland (collectively, &ldquo;WuXi Biologics&rdquo;)
and Oruka Therapeutics, Inc., a Delaware corporation,&nbsp;with an office at 221 Crescent Street, Building 23, Suite 105, Waltham, MA
02453 (&ldquo;Licensee&rdquo;). WuXi Biologics and Licensee may be referred to herein individually as a &ldquo;Party&rdquo; and collectively
as the &ldquo;Parties.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>1.</B></FONT></TD><TD STYLE="text-align: justify"><B><U>Definitions</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.1</TD><TD STYLE="text-align: justify">&ldquo;<B>Affiliate</B>&rdquo; of a person means any other person that directly or indirectly Controls, is
Controlled by, or is under common Control with, the person.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.2</TD><TD STYLE="text-align: justify">&ldquo;<B>Client Product</B>&rdquo; means <FONT STYLE="font-size: 10pt">[***] </FONT>of interest to Licensee,
which is designated by the Licensee to be produced by the Licensed Cell Line. Each&nbsp;different Client Product covered under this Agreement
shall be specified in Appendix I. An amendment to this Agreement is required for each new Client Product produced by the Licensed Cell
Line.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.3</TD><TD STYLE="text-align: justify">&ldquo;<B>Confidential Information</B>&rdquo; of a Party (the &ldquo;<B>Disclosing Party</B>&rdquo;) means
all non- public scientific, technical, financial regulatory or business information and materials&nbsp;disclosed by or on behalf of the
Disclosing Party to the other Party (the &ldquo;<B>Receiving Party</B>&rdquo;) or its Related Persons (defined below) in connection with
this&nbsp;Agreement. Confidential information shall be identified as confidential in writing&nbsp;or, if disclosed verbally or by observation,
summarized in writing and submitted to the Receiving Party within <FONT STYLE="font-size: 10pt">[***]</FONT> of the oral or visual disclosure
thereof; provided, however, information need not be labeled or marked&nbsp;&ldquo;confidential&rdquo; to be deemed Confidential Information
hereunder, if under the&nbsp;circumstances it is, or should be, understood to be confidential. The Confidential&nbsp;Information of both
Parties includes the existence, terms and objectives&nbsp;of this Agreement, and the nature of any dispute and the outcome of any&nbsp;arbitration
proceedings arising out of or in connection with this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.4</TD><TD STYLE="text-align: justify">&ldquo;<B>Construct</B>&rdquo; means a <FONT STYLE="font-size: 10pt">[***]</FONT> developed by&nbsp;WuXi
Biologics that is used for delivering genetic code and for transfecting and/or transforming the Host Cell Line for purposes of creating
the Licensed Cell Line.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.5</TD><TD STYLE="text-align: justify">&ldquo;<B>Control</B>&rdquo; over an entity means (a) owning 50% or more of the voting securities or other
ownership interests of such entity or (b) having the power to direct the management or policies of such entity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.6</TD><TD STYLE="text-align: justify">&ldquo;<B>Drug Product</B>&rdquo; means the final dosage form which contains Client Product, in association
with other active or inactive ingredients.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.7</TD><TD STYLE="text-align: justify">&ldquo;<B>Drug Substance</B>&rdquo; means bulk Client Product, which has not yet been packaged into its
final dosage form.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.8</TD><TD STYLE="text-align: justify">&ldquo;<B>Host Cell Line</B>&rdquo; means the proprietary host cell line developed by WuXi Biologics,&nbsp;and
designated by WuXi Biologics as the <FONT STYLE="font-size: 10pt">[***]</FONT>, that is used to make the Licensed Cell Line.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.9</TD><TD STYLE="text-align: justify">&ldquo;<B>Licensed Cell Line</B>&rdquo; means a transformed or transfected (using WuXi Biologics&rsquo;
Construct(s)) version of the Host Cell Line that produces the Client Product.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.10</TD><TD STYLE="text-align: justify">&ldquo;<B>Licensed Know-How</B>&rdquo; means any know-how and non-public information owned &nbsp;or controlled
by WuXi Biologics that is used or incorporated in the Process, and that is necessary or useful to operate the Process as further described
in the Technology Transfer Package. The word &ldquo;control&rdquo; when used in connection with&nbsp;Licensed Know-How includes both exclusively
and non-exclusively licensed know-how and non-public information, as well a right of WuXi Biologics to transfer such know-how and non-public
information to Licensee. As used in this&nbsp;definition &ldquo;know-how&rdquo; means all confidential and proprietary commercial, technical,
scientific and other know-how and information, trade secrets, knowledge, technology, methods, processes, practices, formulae, instructions,
skills, techniques, procedures, experiences, ideas, technical assistance, designs, drawings, assembly procedures, computer programs, specifications,
data and results (including biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, preclinical,
clinical, safety, manufacturing and quality control data and know-how, and including study designs and protocols).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.11</TD><TD STYLE="text-align: justify">&ldquo;<B>Marketing Authorization Approval</B>&rdquo; means, with respect to a country or extra-national
territory, any and all approvals (including a New Drug Application or Biologics License Application approved by the FDA), licenses, registrations
or authorizations of any Regulatory Authority necessary in order to commercially distribute, sell or market a product in such country
or some or all of such extra-national territory, including any pricing or reimbursement approvals.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.12</TD><TD STYLE="text-align: justify">&ldquo;<B>Materials</B>&rdquo; means the biological materials, including the Licensed Cell Line, provided
to Licensee pursuant to the license granted under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.13</TD><TD STYLE="text-align: justify">&ldquo;<B>Media and Feeds</B>&rdquo; means any proprietary media and feeds used in the Process.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.14</TD><TD STYLE="text-align: justify">&ldquo;<B>Net Sales</B>&rdquo; means the amount <FONT STYLE="font-size: 10pt">[***]</FONT> by Licensee&nbsp;and
its Affiliates or sublicensees for bona fide sales of Client Product to a third-party <FONT STYLE="font-size: 10pt">[***]</FONT>, less:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">[***]</FONT>;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">[***]</FONT>;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">[***]</FONT>;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">[***]</FONT>;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">[***]</FONT>;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">[***]</FONT>; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">[***]</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Net Sales will not include <FONT STYLE="font-size: 10pt">[***]</FONT>.
Such amounts will be determined from the books and records of <FONT STYLE="font-size: 10pt">[***]</FONT>, maintained in accordance with
GAAP consistently applied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.15</TD><TD STYLE="text-align: justify">&ldquo;<B>Process</B>&rdquo; means a process for manufacture of Client Product utilizing Licensed Know-How,
Materials and Media and Feeds as described in the Technology Transfer Package.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.16</TD><TD STYLE="text-align: justify">&ldquo;<B>Regulatory Authority</B>&rdquo; means any applicable supranational, national, regional, state
or local regulatory agency, department, bureau, commission, council, or other government entity involved in regulating development of
and granting regulatory approval for a pharmaceutical product, including the FDA and EMA.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.17</TD><TD STYLE="text-align: justify">&ldquo;<B>Related Persons</B>&rdquo; means a Party&rsquo;s Affiliates and their respective directors,
officers, employees and agents.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.18</TD><TD STYLE="text-align: justify">&ldquo;<B>Research Cell Bank</B>&rdquo; is a <FONT STYLE="font-size: 10pt">[***]</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.19</TD><TD STYLE="text-align: justify">&ldquo;<B>Technology Transfer Package</B>&rdquo; means all information and data describing the Process,
together with all Licensed Know-How, Materials and Media and Feeds necessary or useful for the development and manufacture of Client Product
using the Licensed Cell Line and/or the Process.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.20</TD><TD STYLE="text-align: justify">&ldquo;<B>Third Party</B>&rdquo; means any person other than the Parties to this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.21</TD><TD STYLE="text-align: justify">&ldquo;<B>Third Party Manufacturer</B>&rdquo; means (i) a Third Party whose primary business is contract
manufacturing, or (ii) a Third Party who has a contractual arrangement with Licensee or with a sublicensee of Licensee that includes manufacturing
of Client Product and/or Drug Product by such Third Party for Licensee or such sublicensee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>2.</B></FONT></TD><TD STYLE="text-align: justify"><B><U>License</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.1</TD><TD STYLE="text-align: justify">WuXi Biologics hereby grants to Licensee and its Affiliates a non-exclusive, worldwide license, with the
right to grant sublicenses as provided in Section 2.3, to the Licensed Know-How and the Licensed Cell Line, Materials, and Media and Feeds,
for the purpose of conducting the Process, including the following licensed activities:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: -22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 103.5pt"></TD><TD STYLE="width: 22.5pt">i.</TD><TD STYLE="text-align: justify">to make, have made, import, sell and otherwise use Client Product; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 103.5pt"></TD><TD STYLE="width: 22.5pt">ii.</TD><TD STYLE="text-align: justify">to make, have made, use, sell, have sold, offer for sale, import, keep and otherwise deal in and further
commercialize Drug Substance and Drug Product for any and all purposes.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.2</TD><TD STYLE="text-align: justify">The Licensee or its Affiliates may contract with a Third Party Manufacturer for the limited purpose of
developing and manufacturing Client Product on behalf of the Licensee or its Affiliates, provided that, such Third Party Manufacturers
are bound by the contract to comply with the confidentiality and use terms of this Agreement, and that the Licensee or its Affiliates
will remain liable for any Third Party Manufacturers&rsquo; breach of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">2.2.1</TD><TD STYLE="text-align: justify">For the benefit of doubt, a Third Party Manufacturer cannot manufacture Client Product, Drug Substance
or Drug Product utilizing the Licensed Cell Line and Licensed Know-How without first being contracted with a Licensee, its Affiliates
or sublicensee.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">2.2.2</TD><TD STYLE="text-align: justify">A Third Party Manufacturer that has been granted a sublicense cannot grant, issue or transfer a sublicense
to another Third Party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.3</TD><TD STYLE="text-align: justify">Subject to the terms and conditions of this Agreement, Licensee shall have the right to grant sublicenses
to a Third Party for the rights granted to Licensee under this Agreement. Each sublicense agreement shall be in writing and provided that
the applicable sublicensee is bound by all applicable terms and conditions of this Agreement, and Licensee or its Affiliates shall remain
liable for any sublicensee&rsquo;s breach of this Agreement. Licensee shall inform WuXi Biologics in writing any and all such sublicenses.
<FONT STYLE="font-size: 10pt">[***]</FONT>. Licensee will notify WuXi Biologics in writing of any sublicense agreement with a sublicensee
within <FONT STYLE="font-size: 10pt">[***]</FONT> of the execution of such agreement. Any sublicense granted by Licensee to any rights
licensed to it hereunder will terminate <FONT STYLE="font-size: 10pt">[***] </FONT>upon the termination of the license by WuXi Biologics
under the terms of this Agreement; provided, that such sublicensed rights will not terminate if, as of the effective date of such termination,
a sublicensee is not in material default of its obligations under its sublicense agreement, and within <FONT STYLE="font-size: 10pt">[***]</FONT>
of such termination, the sublicensee agrees in writing to be bound directly to WuXi Biologics under a license agreement substantially
similar to this Agreement with respect to the rights sublicensed hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.4</TD><TD STYLE="text-align: justify">Except as expressly provided in this Agreement, nothing in this Agreement shall be&nbsp;deemed to have
granted Licensee (by implication, estoppel or otherwise) any right, title, license or other interest in or with respect to any intellectual
property, Know-How or information owned or controlled by WuXi Biologics.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.5</TD><TD STYLE="text-align: justify">Invoicing of License fees will commence <FONT STYLE="font-size: 10pt">[***]</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: -13.5pt"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>3.</B></FONT></TD><TD STYLE="text-align: justify"><B><U>Transfer of Materials and Licensed Know-How</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">WuXi Biologics shall notify Licensee in writing
within <FONT STYLE="font-size: 10pt">[***]</FONT> following the date on which WuXi Biologics completes transfection of the Host Cell Line
to generate the Licensed Cell Line. Thereafter, <FONT STYLE="font-size: 10pt">[***]</FONT> upon written request and the completion of
due payment by Licensee (and in any event within <FONT STYLE="font-size: 10pt">[***] </FONT>following designation of a Third Party Manufacturer),
WuXi Biologics shall disclose, make available, and conduct a full transfer, and shall cause its Affiliates to disclose, make available,
and conduct a full transfer to Licensee, its Affiliates, or any one or more of its Third Party Manufacturers designated by Licensee, all
Materials and Licensed Know-How, that is necessary or reasonably useful for Licensee and Third&nbsp;Party Manufacturers to solely develop
and manufacture the Client Product. The Parties shall agree to a schedule for such transfer of the Materials and Licensed Know-How. WuXi
Biologics will provide <FONT STYLE="font-size: 10pt">[***] </FONT>assistance to enable such Third Party Manufacturer to manufacture Client
Product, provided, however, it is the Third Party Manufacturer&rsquo;s full responsibility to manufacture such Client Product after the
transfer, WuXi Biologics will not be responsible for the Third Party Manufacturer&rsquo;s success or failure to manufacture any Client
Products. Initiation of such technology transfer will be determined by Licensee. WuXi Biologics will be reimbursed for such activities
by Licensee on an <FONT STYLE="font-size: 10pt">[***] </FONT>rate. WuXi Biologics will provide <FONT STYLE="font-size: 10pt">[***]</FONT>
requested ongoing technical support if requested by Licensee with such support reimbursed <FONT STYLE="font-size: 10pt">[***] </FONT>rate
basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>4.</B></FONT></TD><TD STYLE="text-align: justify"><B><U>License Fee</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As consideration for the license granted
in Section 2 of this Agreement, and the representation and warranty set forth in Section 10 of this Agreement, Licensee agrees to pay
WuXi Biologics a fixed non-creditable, non-refundable license fee of USD <FONT STYLE="font-size: 10pt">[***]</FONT> for the Licensed Cell
Line used in Client Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>5.</B></FONT></TD><TD STYLE="text-align: justify"><B><U>Cell Line Royalties</U></B><U>.</U></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">If Licensee manufactures <FONT STYLE="font-size: 10pt">[***]</FONT>
commercial supplies of the applicable Drug Substance using&nbsp;manufacturing facilities other than WuXi Biologics&rsquo; or its Affiliates&rsquo;
manufacturing facilities, Licensee shall pay to WuXi Biologics a Royalty of <FONT STYLE="font-size: 10pt">[***]</FONT> on the applicable
Drug Product&rsquo;s global Net Sales sold by Licensee, its Affiliates, or sublicensees, paid to WuXi Biologics <FONT STYLE="font-size: 10pt">[***]</FONT>.
If Licensee manufactures <FONT STYLE="font-size: 10pt">[***]</FONT> commercial supplies of the applicable Drug Substance using WuXi Biologics&rsquo;
or its Affiliates&rsquo; manufacturing facilities, the Royalty shall be <FONT STYLE="font-size: 10pt">[***]</FONT>, depending on <FONT STYLE="font-size: 10pt">[***]</FONT>.
If Licensee manufactures all of its commercial supplies of the applicable Drug Substance by WuXi Biologics or its Affiliates, no Royalty
is applicable and no Royalty payment shall be due hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>6.</B></FONT></TD><TD STYLE="text-align: justify"><B><U>Payment Terms</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Licensee shall pay WuXi Biologics&rsquo;
undisputed invoice(s) within <FONT STYLE="font-size: 10pt">[***]</FONT> of receipt by Licensee. Such payments will be made by wire transfer
to the account designated by WuXi Biologics. Invoices must be submitted, and payment must be made,&nbsp;<FONT STYLE="font-size: 10pt">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>7.</B></FONT></TD><TD STYLE="text-align: justify"><B><U>Bank Account Details</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Unless the Parties otherwise mutually
agree in writing, and such mutual agreement is set forth in a particular invoice, Licensee shall pay each invoice by wire transfer to
the account designated by WuXi Biologics. With respect to Net Sales invoiced in U.S. dollars, the Net Sales and the amounts due hereunder
will be expressed in U.S. dollars. With respect to Net Sales invoiced in a currency other than U.S. dollars, payments will be calculated
based on standard methodologies employed by Licensee or its Affiliates or sublicensees for consolidation purposes for the <FONT STYLE="font-size: 10pt">[***]</FONT>
for which remittance is made for Royalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>8.</B></FONT></TD><TD STYLE="text-align: justify"><B><U>Restriction</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Licensee agrees that no attempt will
be made by or on behalf of Licensee to modify or reverse engineer the Licensed Cell Line or attempt to reverse engineer, recreate or assemble
the Construct(s). Licensee shall only use the Licensed Cell Line in the way as permitted by this Agreement and shall not use or have used
the Licensed Cell Line for any purpose other than as provided hereunder, including operating the Process, the manufacture of Client Product,
Drug Substance and Drug Product, and for other purposes&nbsp;reasonably related to securing Marketing Authorization Approval for the Client
Product and/or Drug Product. Licensee shall not transfer the Licensed Cell Line to any Third Party except to a permitted sublicensee,
as described in Section 2.2 above, permitted Third Party Manufacturer, or an assignee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>9.</B></FONT></TD><TD STYLE="text-align: justify"><B><U>Indemnity</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">9.1</TD><TD STYLE="text-align: justify"><U>Licensee</U> agrees to indemnify, hold harmless and defend WuXi Biologics, its Affiliates, and their
respective directors, officers, employees and agents harmless&nbsp;(collectively, &ldquo;WuXi Indemnitees&rdquo;) from and against any
and all liabilities and damages (including reasonable attorneys&rsquo; fees) resulting from any&nbsp;and all claims from any Third Party
(&ldquo;Claims&rdquo;) to the extent arising from the use of the Licensed Cell Line, Client Product, Drug Substance or Drug Product by
Licensee; except to the extent WuXi Biologics is obligated to indemnify Licensee in accordance with Section 9.2 of this Agreement, and
provided further that Licensee shall have no obligation to indemnify any such Claims that arise from WuXi Biologics&rsquo; (i) negligence
or intentional misconduct in connection with the Licensed Cell Line (ii) material breach of this Agreement (including the representations
and warranties set forth in Section 10); or (iii) Host Cell Line components of the Licensed Cell Line or any Media and Feeds.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">9.2</TD><TD STYLE="text-align: justify">WuXi Biologics will indemnify Licensee, its Affiliates, its sublicensees and their respective directors,
officers, employees and agents, and their respective successors, heirs and assigns (collectively, &ldquo;Licensee Indemnitees&rdquo;),
and defend and hold each of them harmless, from and against any and all Losses in connection with any and all Third-Party Claims against
Licensee Indemnitees to the extent arising from or occurring as a result of: (i) the breach by WuXi Biologics of any provision of this
Agreement; or (ii) any negligence or willful misconduct on the part of any WuXi Indemnitee in connection with the Host Cell Line components
of the Licensed Cell Line, except in each case to the extent Licensee is obligated to indemnify WuXi Biologics in accordance with Section
9.1&nbsp;of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">9.3</TD><TD STYLE="text-align: justify">Each party must notify the other party within <FONT STYLE="font-size: 10pt">[***]</FONT> of receipt of
any claims made for which the other party might be liable hereunder. The indemnifying party will have the sole right to defend, negotiate,
and settle such claims. The indemnified party will be entitled to participate in the defense of such matter and to employ counsel at its
expense to assist in such defense. No compromise or settlement of any Claim may be made by the indemnifying Party without the indemnified
Party&rsquo;s written consent; provided, however, that the indemnifying party will have final decision-making authority regarding all
aspects of the defense of any claim. The party seeking indemnification will provide the indemnifying party with such information and assistance
as the indemnifying party may reasonably request, at the expense of the indemnifying party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -13.5pt"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">9.4</TD><TD STYLE="text-align: justify">Limitation of Liability. NEITHER PARTY WILL BE LIABLE UNDER ANY LEGAL THEORY (WHETHER TORT, CONTRACT OR
OTHERWISE) FOR SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE EXERCISE
OF ITS RIGHTS HEREUNDER, INCLUDING LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, HOWEVER CAUSED, EVEN IF THE
PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, EXCEPT AS A RESULT OF A BREACH OF THE CONFIDENTIALITY AND NON-USE OBLIGATIONS
IN SECTION 11. NOTHING IN THIS SECTION 9.4 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>10.</B></FONT></TD><TD STYLE="text-align: justify"><B><U>Representations and Warranties</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.1</TD><TD STYLE="text-align: justify">WuXi Biologics represents and warrants that: (i) it is a corporation duly organized validly existing and
in good standing under the laws of the Republic of Ireland; (ii) the execution, delivery and performance of this Agreement have been duly
authorized by all necessary corporate action on the part of WuXi Biologics; (iii) the performance of WuXi Biologics&rsquo; obligations
under this Agreement will not conflict with its charter documents or result in a material breach of any agreements, contracts or other
arrangements to which it is a party; (iv) WuXi Biologics will not before the termination of this Agreement enter into any agreements,
contracts or other arrangements that would be materially inconsistent with its obligations under this Agreement; (v) WuXi Biologics has
sufficient facilities, experienced personnel and other capabilities reasonably suited to enable it to perform its obligations under this
Agreement; (vi) WuXi Biologics has the right to grant the licenses or sublicenses, as the case may be, therefor granted under this Agreement;
(vii) WuXi Biologics is the sole and exclusive owner of the Licensed Know-how and Licensed Cell Line, or otherwise has the right to license
the Licensed Know-how and Licensed Cell Line and grant rights to Licensee as set forth in this Agreement and during the Term of the Agreement,
(viii) to the best of its knowledge WuXi Biologics is and will remain entitled to grant to Licensee the licenses and rights specified
or contemplated by this Agreement, and to the Licensed Know-How, (ix) as of the Effective Date, neither WuXi Biologics nor any of its
Affiliates has received any notice challenging WuXi Biologics&rsquo; ownership or right to use the Licensed Know-How in relation to the
Licensed Cell Line and, Host Cell Line component of the Licensed Cell Line, (x) to the best of WuXi Biologics&rsquo;s knowledge, there
are no valid grounds for any claim against WuXi Biologics or any of its Affiliates except for any claims caused by Licensee&rsquo;s DNA
sequence related to the Client Product incorporated into the Licensed Cell Line.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">10.2</TD><TD STYLE="text-align: justify">Licensee represents and warrants that: (i) it is a corporation
duly organized validly existing and in good standing under the laws of the Commonwealth of Massachusetts; (ii) the execution, delivery
and performance of this Agreement have been duly authorized by all necessary corporate action on the part of Licensee; (iii) the performance
of Licensee&rsquo;s obligations under this Agreement will not conflict with its charter documents or result in a material breach of any
agreements, contracts or other arrangements to which it is a party; (iv) Licensee has sufficient facilities, experienced personnel and
other capabilities reasonably suited to enable it to perform its obligations under this Agreement; and (v) Licensee will not before the
termination of this Agreement enter into any agreements, contracts or other arrangements that would be materially inconsistent with its
obligations under this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">10.3</TD><TD STYLE="text-align: justify">Disclaimer of Warranties. OTHER THAN AS PROVIDED IN THIS AGREEMENT,
THE LICENSED KNOW-HOW, AND LICENSED CELL LINES ARE PROVIDED AND LICENSED TO LICENSEE &ldquo;AS IS&rdquo;, THE PARTIES MAKE NO REPRESENTATIONS
AND EXTEND NO WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT THERETO OR TO THE PRODUCTS, INCLUDING, BUT
NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSEVALIDITY OF THE RIGHTS LICENSED HEREUNDER, OR NONINFRINGEMENT
OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>11.</B></FONT></TD><TD STYLE="text-align: justify"><B><U>Confidentiality</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.1</TD><TD STYLE="text-align: justify">Subject to the exceptions listed below, during the term of this
Agreement and for <FONT STYLE="font-size: 10pt">[***]</FONT> thereafter, the Receiving Party shall, and shall ensure that its Related
Persons will, (a) maintain the Disclosing Party&rsquo;s Confidential Information in confidence, (b) not use such Confidential Information
other than in connection with this Agreement, and (c) not disclose such Confidential Information to any Third Party other than (i) those
of its Related Persons that have a need to know such Confidential Information in connection with the Activities conducted pursuant to
the Agreement and are obligated to maintain such Confidential Information in confidence and (ii) to the extent required by applicable
law or judicial order, or to the extent reasonably necessary to prosecute or defend litigation or arbitration in relation to this Agreement,
and, in either case, only after the Receiving Party gives the Disclosing Party <FONT STYLE="font-size: 10pt">[***]</FONT> advance written
notice of such requirement and <FONT STYLE="font-size: 10pt">[***]</FONT> cooperates with the Disclosing Party&rsquo;s efforts to limit
or avoid such disclosure, to seek a protective order or secure confidential treatment of the Confidential Information, and/or to seek
any other remedies available to the Disclosing Party at law or in equity. Notwithstanding the foregoing, the existence of this Agreement
and its non-technical terms may be disclosed confidentially in connection with a potential financing, collaboration or acquisition or
in discussion with a potential acquirer of Client Product.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.2</TD><TD STYLE="text-align: justify">The Receiving Party&rsquo;s obligations set forth in Section
11.1 do not apply to Confidential Information if (a) the information is public knowledge or becomes public knowledge after disclosure
through no act or omission of the Receiving Party or any of its Related Persons, (b) the information can be shown by the Receiving Party
to have been lawfully in its possession prior to disclosure, (c) the information was rightfully received on a non-confidential basis
from a Third Party that was not obligated to maintain the information in confidence, or (d) the Receiving Party can show that equivalent
information was developed independently by the Receiving Party without reference to the Disclosing Party&rsquo; Confidential Information.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.3</TD><TD STYLE="text-align: justify">Licensee may disclose the Confidential Information of WuXi Biologics
to a Third Party for the purpose of exercising Licensee&rsquo;s license rights hereunder (including disclosure to potential Third Party
sublicensees), provided that Licensee shall, prior to such disclosure, ensure that each Third Party to which disclosure is to be made
is made aware of the obligations contained in this Agreement and agrees to be subject to obligations of confidentiality and non-use no
less onerous than those contained in this Agreement. Any breaches of the obligations of confidentiality and non-use contained in this
Agreement by such Third Party shall be treated as a breach of such obligations by Licensee.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.4</TD><TD STYLE="text-align: justify">Notwithstanding anything to the contrary in this Agreement, a
Party may disclose this Agreement and its terms, and material developments or material information generated under this Agreement, in
securities filings with the U.S. Securities and Exchange Commission (or equivalent foreign agency) and any rules of stock exchanges where
the Parties may be listed to the extent required by applicable law after complying with the procedure set forth in this Section 11.4.
In such event, unless otherwise required to comply with applicable law, the Party seeking such disclosure will prepare a draft confidential
treatment request and proposed redacted version of this Agreement to request confidential treatment for this Agreement, and the other
Party will <FONT STYLE="font-size: 10pt">[***]</FONT> give its input in a <FONT STYLE="font-size: 10pt">[***]</FONT> in order to allow
the Party seeking disclosure to file its request within the timelines proscribed by applicable laws and regulations. The Party seeking
such disclosure shall exercise <FONT STYLE="font-size: 10pt">[***]</FONT> to obtain confidential treatment of this Agreement from the
U.S. Securities and Exchange Commission (or equivalent foreign agency) as represented by the redacted version reviewed by the other Party.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">11.5</TD><TD STYLE="text-align: justify">The provisions of this Section 11 shall survive termination or
expiry of this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>12.</B></FONT></TD><TD STYLE="text-align: justify"><B><U>Termination</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">12.1</TD><TD STYLE="text-align: justify"><U>Voluntary Termination by Licensee.</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Licensee shall have the right to terminate
this Agreement upon <FONT STYLE="font-size: 10pt">[***]</FONT> prior written notice to WuXi Biologics, and upon payment of all undisputed
amounts due to WuXi Biologics through such termination effective date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">12.2</TD><TD STYLE="text-align: justify"><U>Termination for Default</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify"><U>Nonpayment</U>. In the event Licensee fails to pay any undisputed
amounts due and payable to WuXi Biologics hereunder, and fails to make such payments within thirty (30) days after receiving written
notice of such failure, WuXi Biologics may terminate this Agreement <FONT STYLE="font-size: 10pt">[***]</FONT> upon written notice to
Licensee.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify"><U>Material Breach</U>. In the event Licensee commits a material
breach of its obligation under this Agreement and fails to cure that breach within <FONT STYLE="font-size: 10pt">[***]</FONT> after receiving
written notice thereof, WuXi Biologics may terminate this Agreement <FONT STYLE="font-size: 10pt">[***]</FONT> upon written notice to
Licensee.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">12.3</TD><TD STYLE="text-align: justify"><U>Termination Upon Bankruptcy</U>. If either Party makes an
assignment for the benefit of creditors, appoints or suffers appointment of a receiver or trustee over all or substantially all of its
property, files a petition or commences a proceeding under any bankruptcy or insolvency act in any state or country or has any such petition
or application filed against it which is not discharged within <FONT STYLE="font-size: 10pt">[***]</FONT> of the filing thereof, then
the other Party may thereafter terminate this Agreement effective <FONT STYLE="font-size: 10pt">[***]</FONT> upon written notice to such
Party. All rights and licenses granted under or pursuant to this Agreement by WuXi Biologics are, and will otherwise be deemed to be,
for purposes of the relevant provisions of the Bankruptcy and Insolvency Act, R.S.C. 1985, c. B-3 (&ldquo;BIA&rdquo;), including Sections
65.11(7), 65.13(9), 72.1 and 246.1 of the BIA; and the relevant provisions of the Companies&rsquo; Creditors Arrangement Act, R.S.C.
1985, c. C-36 (&ldquo;CCAA&rdquo;), including Sections 32(6) and 36(8) of the CCAA (the BIA and CCAA being referred to collectively as
the &ldquo;Insolvency Legislation&rdquo;), a grant of a &ldquo;right to use&rdquo; &ldquo;intellectual property&rdquo; as used in the
Insolvency Legislation. The Parties agree that Licensee and its Affiliates and sublicensees, as licensees of such rights under this Agreement,
will retain and may fully exercise all of their rights and elections under the Insolvency Legislation subject to the payment of amounts
provided for herein. Without limiting Licensee&rsquo;s rights under the Insolvency Legislation, if WuXi Biologics becomes insolvent or
makes an assignment for the benefit of its creditors or there is filed by or against it any bankruptcy, receivership, reorganization
or similar proceeding pursuant to or under the Insolvency Legislation or otherwise, Licensee will be entitled to a copy of any and all
information specified in the Technology Transfer Package unless WuXi Biologics, or its trustee or receiver, elects within <FONT STYLE="font-size: 10pt">[***]
</FONT>to continue to perform all of its obligations under this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">12.4</TD><TD STYLE="text-align: justify">Expiration or termination of this Agreement for any reason will
not relieve either party of any obligation accruing prior to such expiration or termination, including section 5 (Cell Line Royalties)
shall survive termination or expiry of this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>13.</B></FONT></TD><TD STYLE="text-align: justify"><B><U>Miscellaneous</U></B>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">13.1</TD><TD STYLE="text-align: justify"><U>Assignment</U>. This Agreement may not be assigned or otherwise
transferred by either Party (subject to Licensee&rsquo;s right to sublicense its rights hereunder) without the prior written consent
of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed; <I>provided, however</I>, that a Party
may, without such consent, assign this Agreement in its entirety (a) to an Affiliate, or (b) to a Third Party in connection with a merger,
acquisition, consolidation or a sale involving all or substantially all of the assets or business of such Party. Any attempted assignment
or transfer in violation of this Section 13.1 shall be void.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">13.2</TD><TD STYLE="text-align: justify"><U>Regulatory Assistance</U>. WuXi Biologics will provide assistance
to Licensee, and any sublicensee, in respect of Licensee&rsquo;s or such sublicensee&rsquo;s regulatory filing activities for the Client
Product and/or Drug Product, at Licensee&rsquo;s or such sublicensee&rsquo;s reasonable cost and expense on <FONT STYLE="font-size: 10pt">[***]
</FONT>rate.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">13.3</TD><TD STYLE="text-align: justify"><U>Governing Law</U>. The laws of the State of New York, USA,
without regard to any choice of law principle that would require the application of the law of another jurisdiction, govern all matters
relating to this Agreement and the enforcement thereof. The parties expressly reject any application to this Agreement of (a) the United
Nations Convention on Contracts for the International Sale of Goods; and (b) the 1974 Convention on the Limitation Period in the International
Sale of Goods, as amended by that certain Protocol, done at Vienna on April 11, 1980.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">13.4</TD><TD STYLE="text-align: justify"><U>Arbitration</U>. The parties shall engage in good faith consultation
to resolve any dispute arising out of or in connection with this agreement. Such consultation will begin <FONT STYLE="font-size: 10pt">[***]
</FONT>after one party has delivered to the other party a request for consultation. If the dispute cannot be resolved within <FONT STYLE="font-size: 10pt">[***]
</FONT>following the date on which the request for consultation is delivered, then either party may submit the dispute to JAMS International
Arbitration Rules (&ldquo;Arbitration&rdquo;). The Arbitration tribunal will consist of three arbitrators. Within <FONT STYLE="font-size: 10pt">[***]
</FONT>after the commencement of the Arbitration, each Party shall select one person to act as arbitrator, each of whom must be a practicing
or retired attorney or judge have at least <FONT STYLE="font-size: 10pt">[***]</FONT> of litigation experience within the biopharmaceutical
industry. The two arbitrators so selected shall select the chair within <FONT STYLE="font-size: 10pt">[***]</FONT> of the commencement
of the Arbitration, whom must a practicing or retired attorney or judge have at least <FONT STYLE="font-size: 10pt">[***]</FONT> of litigation
experience within the biopharmaceutical industry. If the arbitrators selected by the Parties are unable or fail to agree upon the third
arbitrator within the allotted time, the third arbitrator shall be appointed by JAMS in accordance with the JAMS International Arbitration
Rules. All arbitrators shall serve as neutral, independent and impartial arbitrators. (ii) The Arbitration shall be conducted in accordance
with the expedited procedures set forth in the JAMS International Arbitration Rules. The place of arbitration will be Manhattan, New
York. The official language of the arbitration will be English. The arbitration proceedings will be confidential, and the arbitrator
may issue appropriate protective orders to safeguard each party&rsquo;s Confidential Information. During the course of arbitration, the
parties shall continue to implement the terms of this agreement. The arbitral award will be final and binding upon the parties, and the
party to the award may apply to a court of competent jurisdiction for enforcement of the award. Notwithstanding the foregoing, each party
has the right to institute an action in a court of proper jurisdiction for injunctive or other equitable relief pending a final decision
by the arbitrator.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">13.5</TD><TD STYLE="text-align: justify"><U>Counterparts</U>. This Agreement may be executed in two (2)
or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
This Agreement may be executed by facsimile, .pdf or other electronically transmitted signatures and such signatures shall be deemed
to bind each Party hereto as if they were the original signatures.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF, the Parties hereto have caused
this AGREEMENT to be duly executed as of the Effective Date set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WuXi Biologics Ireland Limited</B></P></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Oruka Therapeutics, Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Zhisheng Chen</FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Lawrence Klein</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zhisheng Chen</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lawrence Klein</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> of 14</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Appendix I</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> of 14</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>11
<FILENAME>ea023044501ex10-33_orukathe.htm
<DESCRIPTION>AMENDMENT NO. 1 TO THE CELL LINE LICENSE AGREEMENT BY AND BETWEEN WUXI BIOLOGICS IRELAND LIMITED AND ORUKA THERAPEUTICS, INC., DATED NOVEMBER 20, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.33</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT
TREATS AS PRIVATE OR CONFIDENTIAL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDMENT NO. 1 TO THE CELL LICENSE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THIS AMENDMENT NO. 1 TO THE CELL LINE LICENSE
AGREEMENT</B> (&ldquo;<B>Amendment</B>&rdquo;), effective as of November 20, 2024 (the &ldquo;Amendment Effective Date&rdquo;), is entered
into and made by and between <B>WuXi Biologics Ireland Limited</B>, (&ldquo;WuXi Biologics&rdquo;), and <B>Oruka Therapeutics,</B> Inc.
(&ldquo;Licensee&rdquo;). WuXi Biologics and Licensee may be referred to herein individually as a &ldquo;Party&rdquo; and collectively
as the &ldquo;Parties.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, WuXi Biologics (and Licensee have entered
into that certain Cell Line License Agreement, dated as of March 4, 2024, (the &ldquo;<B>License Agreement</B>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, the Parties now desire to amend the License
Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOW, THEREFORE, in consideration of the foregoing,
of the mutual promises set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Parties hereto, intending legally to be bound, hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>1.</B></FONT></TD><TD STYLE="text-align: justify">The current <I>Section 5 Cell Line Royalties</I> shall be re-numbered to Section 5.1</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>2.</B></FONT></TD><TD STYLE="text-align: justify">A new <I>Section 5.2 Buy-out Payment</I> is hereby added into the License Agreement as the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.2.</TD><TD STYLE="text-align: justify"><B><U>Buy-Out Payment</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Notwithstanding the foregoing, in lieu
of Licensee paying WuXi Biologics the Royalty provided for in Section 5.1, Licensee, or its sublicensee or assignee may, at any time,
in its sole discretion, pay to WuXi Biologics, on a Drug Product-by-Drug Product basis, a fixed non-creditable, non-refundable royalty
buyout payment as set forth below (a &ldquo;Royalty Buyout Payment&rdquo;). Once WuXi Biologics has received the Royalty Buyout Payment
from Licensee, or its sublicensee or assignee, all future royalty obligations with respect to such Drug Product will be extinguished and
Licensee will no longer owe any Royalty with respect to such Drug Product. Upon the applicable Royalty Buyout Payment being fully paid
with respect to a Drug Product, the rights and licenses granted with respect to such Drug Product under this Agreement (including for
clarity in Section 2.1) shall become fully paid-up, royalty free, perpetual and irrevocable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 63pt"></TD><TD STYLE="width: 36pt">5.2.1</TD><TD STYLE="text-align: justify">For the <FONT STYLE="font-size: 10pt">[***] </FONT>Drug Product <FONT STYLE="font-size: 10pt">[***]</FONT>,
the Royalty Buyout Payment shall be <FONT STYLE="font-size: 10pt">[***]</FONT>.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 63pt"></TD><TD STYLE="width: 36pt">5.2.2</TD><TD STYLE="text-align: justify">For the <FONT STYLE="font-size: 10pt">[***]</FONT>, Drug Product(s) <FONT STYLE="font-size: 10pt">[***]</FONT>,
the Royalty Buyout Payment shall be <FONT STYLE="font-size: 10pt">[***]</FONT>.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 63pt"></TD><TD STYLE="width: 36pt">5.2.3</TD><TD STYLE="text-align: justify">For clarity, <FONT STYLE="font-size: 10pt">[***]</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>3.</B></FONT></TD><TD STYLE="text-align: justify">Except as expressly modified by this Amendment, the License Agreement shall remain unchanged and in full
force and effect in accordance with its terms and the Parties hereby ratify and reaffirm the License Agreement as amended hereby.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>4.</B></FONT></TD><TD STYLE="text-align: justify">This Amendment may be executed in any number of counterparts, with each counterpart constituting an original,
but all of which shall together constitute one and the same instrument. Delivery of an executed counterpart of a signature page of this
Amendment by facsimile or electronic transmission (including .pdf file) shall be effective as delivery of a manually executed counterpart
of this Amendment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>5.</B></FONT></TD><TD STYLE="text-align: justify">Any capitalized term used in this Amendment and not otherwise defined herein shall have the meaning given
to that term in the License Agreement. This Amendment and the rights and obligations of the Parties hereto shall be governed, construed,
and enforced in accordance with the governing law as stated in the License Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature page follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF, the Parties hereto have caused
this Amendment to be duly executed as of the Amendment Effective Date set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in">WuXi Biologics Ireland Limited</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in">Oruka Therapeutics, Inc.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; text-indent: 0in; width: 35%"> /s/ Zhisheng CHEN</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; text-indent: 0in; width: 35%"> /s/ Lawrence Klein</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in">Name:</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">Zhisheng CHEN</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">Name:</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">Lawrence Klein</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in">Title:</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">Title:</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">President and Chief Executive Officer</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>12
<FILENAME>ea023044501ex19-1_orukathe.htm
<DESCRIPTION>INSIDER TRADING POLICY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit
19.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex19-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>INSIDER
TRADING POLICY</U><BR>
<BR>
August 29, 2024</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">I.&nbsp;INTRODUCTION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Federal
and state laws prohibit buying, selling or making other transfers of securities by persons who have material information that is not
generally known or available to the public. These laws also prohibit persons with such material nonpublic information (&ldquo;<U>MNPI</U>&rdquo;)
from disclosing this information to others who trade. Trading while in possession of MNPI is often referred to as &ldquo;insider trading.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Who
Is Subject to this Policy</I>. Oruka Therapeutics, Inc. (the &ldquo;<U>Company</U>&rdquo;) has adopted the following policy (this &ldquo;<U>Policy</U>&rdquo;)
regarding trading in securities by all of its directors, officers and employees, as well as certain contractors and consultants who are
so designated by the General Counsel (&ldquo;GC&rdquo;)<FONT STYLE="font-size: 10pt"><SUP>1</SUP></FONT> from time to time (together,
&ldquo;<U>Company Personnel</U>&rdquo;) as well as their family members who reside with them, anyone else who lives in their household
and any family members who do not live in their household but whose transactions in Company securities (as defined below) are directed
by them or are subject to their influence or control (collectively, &ldquo;<U>Family Members</U>&rdquo;), and corporations or other business
entities controlled, influenced or managed by them or their Family Members, and trusts for which such persons are a trustee or in which
they have a beneficial or pecuniary interest (collectively, &ldquo;<U>Controlled Entities</U>,&rdquo; and together with Company Personnel
and Family Members, &ldquo;<U>Insiders</U>&rdquo;). Unless otherwise indicated, all references to &ldquo;you&rdquo; in this Policy should
be read to include all of your Family Members and Controlled Entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Which
Securities Are Subject to this Policy</I>. This Policy applies to transactions, whether direct or indirect, in the Company&rsquo;s securities,
including its common stock, options to purchase common stock, restricted stock or restricted stock units or any other type of securities
that Company may issue from time to time, including but not limited to preferred stock and convertible debentures, as well as derivative
securities relating to the Company but that are not issued by the Company, such as exchange-traded put or call options or swaps relating
to the Company&rsquo;s securities (collectively, &ldquo;<U>Company securities</U>&rdquo;). Similarly, this Policy applies to all securities,
including common stock, options to purchase common stock or any other type of securities, that are issued by a Company Counterparty (as
defined below), as well as any derivative securities that are relating to the Company Counterparty but that are not issued by such Company
Counterparty, such as puts, calls or swaps.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">At
                                            any time when the Company does not have an active GC, the duties and responsibilities assigned
                                            to the GC under this Policy shall be fulfilled by the Chief Financial Officer (&ldquo;<U>CFO</U>&rdquo;).
                                            At any time when the Company does not have an active CFO, the duties and responsibilities
                                            assigned to the CFO under this Policy shall be fulfilled by the principal financial officer.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Application
of this Policy to Company Counterparties</I>. The principles discussed in this Policy also apply to nonpublic information that you obtain
in the course of your employment or other involvement with the Company about another public company with which the Company has a preexisting
or prospective relationship, such as the Company&rsquo;s customers, suppliers, contract research, manufacturing, licensing or other collaboration
partners, companies in which the Company has an investment or a firm with which the Company is negotiating a major transaction, such
as a joint venture, licensing transaction, collaboration arrangement or material acquisition or disposition (a &ldquo;<U>Company Counterparty</U>&rdquo;
or &ldquo;<U>Company Counterparties</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>No
Exceptions.</I> The prohibition against trading while in possession of MNPI is absolute and unconditional. The securities laws do not
recognize any mitigating circumstances, and, in any event, even the appearance of an improper transaction must be avoided to preserve
the Company&rsquo;s reputation for adhering to high standards of conduct. There is no exception for small transactions or transactions
that may seem necessary or justifiable for independent reasons, such as the need to raise money for an emergency expenditure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Individual
Responsibility.</I> You are responsible for ensuring that you (as well as your Family Members and Controlled Entities) do not violate
federal or state securities laws or this Policy. The Company has designed this Policy to promote compliance with the federal securities
laws and to protect the Company and you from the serious liabilities and penalties that can result from violations of these laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Consequences
for Violating Insider Trading Laws.</I> If you violate insider trading laws, you may have to pay civil fines for up to three times the
profit gained or loss avoided by such trading, as well as criminal fines of up to $5 million. You also may be subject to criminal charges
and may have to serve a jail sentence of up to 20 years. In addition, the Company may face civil penalties up to the greater of $1 million,
or three times the profit gained or loss avoided as a result of your insider trading violations, as well as criminal fines of up to $25
million. Both the Securities and Exchange Commission (&ldquo;<U>SEC</U>&rdquo;) and The Nasdaq Stock Market (&ldquo;<U>Nasdaq</U>&rdquo;)
are very effective at detecting and pursuing insider trading cases. The SEC has successfully prosecuted cases against employees trading
through foreign accounts, trading by family members and friends and trading involving only a small number of shares. Therefore, it is
important that you understand the breadth of activities that constitute illegal insider trading. This Policy sets out the Company&rsquo;s
policy in the area of insider trading and should be read carefully and complied with fully.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Administrative
Provisions</I>. All Company Personnel will be required to certify their understanding of and intent to comply with this Policy by signing
the Receipt and Acknowledgment attached hereto periodically. This Policy will be reviewed, evaluated and revised by the Company from
time to time in light of regulatory changes, developments in the Company&rsquo;s business and other factors.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">II.&nbsp;POLICIES
AND PROCEDURES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>A.&nbsp;Trading
Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.&nbsp;<I>General
Prohibition.</I> You may not buy, sell, gift or otherwise transact in securities of the Company or a Company Counterparty when you are
in possession of MNPI about that company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.&nbsp;<I>No
Tipping.</I> You may not convey MNPI about the Company or a Company Counterparty to anyone else, including family members. You also may
not suggest that anyone purchase or sell any company&rsquo;s securities while you are aware of MNPI about that company. These practices,
known as &ldquo;tipping,&rdquo; also violate U.S. securities laws and can result in the same civil and criminal penalties that apply
if you engage in insider trading directly, even if you do not receive any money or derive any benefit from trades made by persons to
whom you passed MNPI. This policy against &ldquo;tipping&rdquo; applies to information about the Company and its securities, as well
as to information about Company Counterparties. Persons with whom you have a history, pattern or practice of sharing confidences&mdash;such
as family members, close friends and financial and personal counselors&mdash;may be presumed to act on the basis of information known
to you; therefore, special care should be taken so that MNPI is not disclosed to such persons. This policy does not restrict legitimate
business communications on a &ldquo;need to know&rdquo; basis. MNPI, however, should not be disclosed to persons outside the Company
unless you are specifically authorized to disclose such information and such disclosure is made in accordance with the Company&rsquo;s
policies regarding the protection or authorized external disclosure of information regarding the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.&nbsp;<I>No
Speculative Trading.</I> It is against Company policy for you to engage in speculative transactions in Company securities. As such, you
may not engage in: (a) short sales (selling Company securities you do not own); (b) transactions involving publicly traded options or
other derivatives, such as trading in puts or calls with respect to Company securities; and (c) other hedging transactions (such as &ldquo;cashless&rdquo;
collars, forward sales, equity swaps and other similar arrangements). Additionally, securities held in a margin account or pledged as
collateral may be sold without your consent, if you fail to meet a margin call or if you default on a loan, and thus a margin or foreclosure
sale may result in unlawful insider trading. Because of this danger, you are also prohibited from including Company securities in a margin
account or pledging Company securities as collateral for a loan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.&nbsp;<I>Applying
the Trading Policy.</I> As stated above, these restrictions also apply to your Family Members and Controlled Entities. For purposes of
this Policy, references to &ldquo;trading,&rdquo; &ldquo;transact&rdquo; and &ldquo;transactions&rdquo; include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">purchases
                                            and/or sales of securities in public markets;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">sales
                                            of securities obtained through the exercise of stock options or vesting of other equity awards
                                            granted by the Company;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">making
                                            gifts of securities; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">using
                                            securities to secure a loan.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Transactions
in mutual funds that are invested in Company or Company Counterparty securities are not transactions subject to this Policy as long as
(a) the Insider does not control the investment decisions on individual stocks within the fund and (b) Company or Company Counterparty
securities do not represent a substantial portion of the assets of the fund.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, transactions pursuant to a Rule 10b5-1 Trading Plan (as defined below) are subject to certain exceptions and requirements set
forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Insiders
should consult the <U>GC</U> if they have any questions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.&nbsp;<I>Company
Transactions.</I> From time to time, the Company may engage in transactions in its own securities. When engaging in transactions in Company
securities, it is the Company&rsquo;s policy to comply with all applicable securities laws and regulations and state corporate laws.
This includes consultation, as appropriate, with the CEO, CFO, GC and outside counsel, and, if required or advisable, approval by the
Board of Directors or appropriate board committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>B.&nbsp;What
is</B> &ldquo;<B>Material Nonpublic Information</B>&rdquo;<B>? When is Information &ldquo;Public&rdquo;?</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.&nbsp;<I>Material
Information</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Information
is generally considered &ldquo;material&rdquo; if there is a likelihood a reasonable investor would consider such information important
in making an investment decision to buy, hold or sell securities. Either positive or negative information may be material. There is no
bright-line standard for assessing materiality; rather, materiality is based on an assessment of all of the facts and circumstances.
The GC or other attorneys designated by the GC should be consulted and shall determine whether information is material, but, in general,
any information that could reasonably be expected to affect the Company&rsquo;s or a Company Counterparty&rsquo;s stock price should
be considered material. Depending on the circumstances, common examples of information that may be material include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">significant
                                            new product or product candidate developments, innovations or discoveries (including new
                                            targets and new indications);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">pending
                                            U.S. Food and Drug Administration, European Medicines Agency or other regulatory action;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">clinical
                                            data or significant interactions, filings, approval or rulings by a regulatory agency relating
                                            to the Company or a Company product;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">clinical
                                            trial enrollment status and results (including interim results) and status of pre-clinical
                                            or clinical studies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">changes
                                            in intellectual property status, including patent filings, issuances or potential interference
                                            and infringement proceedings;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">changes
                                            in research or business strategies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">financial
                                            and operating results, estimates, forecasts and projections, including earnings, cash runway,
                                            revenue or similar financial information;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">unpublished
                                            financial reports or projections, including knowledge of changes of research analyst views
                                            or ratings;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">extraordinary
                                            borrowing or liquidity problems;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">changes
                                            in control or sale of all or part of the Company&rsquo;s business, including potential partnerships;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">changes
                                            in directors, senior management or auditors;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">information
                                            about current, proposed or contemplated transactions, business plans, financial restructurings,
                                            acquisition targets or significant expansions or contractions of operations;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">changes
                                            in dividend policies, the declaration of a stock split or the proposed or contemplated issuance,
                                            redemption or repurchase of securities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">public
                                            or private debt or equity offerings;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">negotiations
                                            regarding an important license, distribution agreement, joint venture or collaboration agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">material
                                            defaults under agreements or actions by creditors, clients or suppliers relating to the Company&rsquo;s
                                            credit rating;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">information
                                            about major contracts;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">gain
                                            or loss of a significant customer or supplier;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">significant
                                            product pricing or reimbursement changes;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">significant
                                            cybersecurity incidents, events or risks that affect the Company or third-party providers
                                            that support the Company&rsquo;s business operations, including computer system or network
                                            compromises, viruses or other destructive software, and data breach incidents that may disclose
                                            personal, business or other confidential information;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">product
                                            recalls;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">impending
                                            financial problems such as impending bankruptcy or liquidity problems;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            interruption of production or other aspects of a company&rsquo;s business as a result of
                                            an accident, fire, natural disaster, public health emergency or breakdown of labor negotiations;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">major
                                            environmental incidents;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">institution
                                            of, or developments in, major actual or threatened litigation, investigations or regulatory
                                            actions or proceedings;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">information
                                            about Company affiliates and Company Counterparties; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            imposition of a trading &ldquo;blackout&rdquo; by the Company on transactions in Company
                                            securities or the securities of a Company Counterparty.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Federal
and Nasdaq investigators will scrutinize a questionable trade after the fact with the benefit of hindsight, so you should always err
on the side of deciding that the information is material and not trade. The mere fact that a person is aware of MNPI is a bar to trading.
It is no excuse that such person&rsquo;s reasons for trading were not based on the MNPI. If you have questions regarding specific transactions,
please contact the GC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.&nbsp;<I>Nonpublic
Information</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nonpublic
information is information that is not generally known by or available to the public. We consider information to be available to the
public only when:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">it
                                            has been released to the public by the Company through appropriate channels (e.g., by means
                                            of a press release, a filing with the SEC or a widely disseminated statement from a senior
                                            officer); and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">enough
                                            time has elapsed to permit the investment market to absorb and evaluate the information.
                                            As a general rule, you should consider information to be nonpublic until two full trading
                                            days have lapsed following the time of public disclosure.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
fact that rumors, speculation or statements attributed to unidentified sources are public is insufficient to be considered &ldquo;generally
available to the public&rdquo; even when the information is accurate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>C.&nbsp;Unauthorized
Disclosure; Prohibition on Certain Public Speaking</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
Company Personnel must maintain the confidentiality of Company information for competitive, security and other business reasons, as well
as to comply with securities laws. All information you learn about the Company or its business plans is potentially nonpublic information
until it is publicly disclosed. You should treat this information as confidential and proprietary to the Company. You may not disclose
it to others, such as Family Members, other relatives or business or social acquaintances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, you are prohibited from participating as an &ldquo;expert,&rdquo; consultant, advisor and/or in any capacity for an &ldquo;expert
network&rdquo; and/or any other outside firm that compensates individuals for speaking with investors and other investment professionals.
This prohibition is designed to protect the Company, its stockholders and you. Indeed, United States criminal authorities and the SEC
have prosecuted numerous public company employees who received monetary compensation by expert networks to speak with investors and disclose
confidential company information that investors then used for trading purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Legal
rules govern the timing and nature of our disclosure of material information to outsiders or the public. Violation of these rules could
result in substantial liability for you, the Company and its management. For this reason, we permit only specifically designated representatives
of the Company to discuss the Company with the news media, securities analysts and investors and only in accordance with the Company&rsquo;s
Policy On Public Disclosures And Communications With The Investment Community. If you receive inquiries of this nature, refer them to
the CEO.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>D.&nbsp;When
and How to Trade Company Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.&nbsp;<I>Overview</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Directors,
officers, as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;) (such
officers, &ldquo;<U>Section 16 Officers</U>&rdquo;, and together with directors, &ldquo;<U>Section 16 Persons</U>&rdquo;), and certain
other employees, contractors and consultants who are so designated by the GC from time to time (such designated employees, contractors
and consultants, together with Section 16 Persons, and each of their respective Family Members and Controlled Entities, &ldquo;<U>Restricted
Persons</U>&rdquo;) are for purposes of this Policy required to comply with the restrictions covered below. Even if you are not a Restricted
Person, however, following the procedures listed below may assist you in complying with this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.&nbsp;<I>Blackout
Periods</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
time to time, due to certain developments (such as a significant event or transaction) during which there may exist MNPI about the Company
or a Company Counterparty, the Company may implement special blackout periods during which the Company may notify particular individuals
that they should not transact in Company securities or the securities of a Company Counterparty, as applicable (subject to the exceptions
set forth in Section II.D.4 or pursuant to an approved Rule 10b5-1 Trading Plan pursuant to Section II.E). If you are subject to a special
blackout period, you should not trade in the applicable company&rsquo;s securities during such time and you should not disclose to others
the fact that you are prohibited from trading, as the existence of a special blackout period may, itself, be deemed MNPI. These special
blackout periods, which may vary in length, will be determined by the GC and be communicated to the appropriate personnel via e-mail.
Termination of a blackout period will also be communicated to the appropriate personnel via e-mail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>However,
it is not the Company&rsquo;s policy to impose special blackout periods every time that MNPI exists or every time that an Insider may
be in the possession of MNPI. Thus, the absence of a special blackout period should not be interpreted as permission to trade. In addition,
if you are subject to the Company&rsquo;s pre-clearance policy (described below), you must pre-clear transactions even if you initiate
them while a blackout period is not in place.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Even
if a special blackout period is in place, you may exercise Company stock options if no shares are to be sold &ndash; you may not, however,
effect sales of stock issued upon the exercise of stock options (including same-day sales and cashless exercises). Generally, all pending
purchase and sale orders regarding Company securities must be executed or cancelled before a special blackout period is implemented so
as to avoid any transactions during such period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
light of these restrictions, if you expect a need to sell Company stock at a specific time in the future, including executing sales to
satisfy tax withholding obligations in connection with the exercise of stock options, vesting of restricted stock or settlement of restricted
stock units in the future, you may wish to consider entering into a prearranged Rule 10b5-1 Trading Plan (as discussed below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.&nbsp;<I>Pre-clearance</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company requires all Restricted Persons to contact the GC<FONT STYLE="font-size: 10pt"><SUP>2</SUP></FONT> in advance of effecting any
purchase, sale, gift or other trading of Company securities and to obtain prior approval of the transaction, other than transactions
made under an approved Rule 10b5-1 Trading Plan pursuant to Section II.E below. All requests must be submitted to the GC at least two
business days in advance of the proposed transaction.<FONT STYLE="font-size: 10pt"><SUP>3</SUP></FONT> <B>This pre-clearance policy applies
to Restricted Persons even if they are initiating a transaction while a blackout period is not in place.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
a transaction is approved under the pre-clearance policy, the transaction must be executed during the cleared trading period approved
by the GC (not to exceed five (5) trading days), but regardless may not be executed if you acquire MNPI concerning the Company during
that time. If a transaction is not completed within the period described above, the transaction must be approved again before it may
be executed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
a proposed transaction is not approved under the pre-clearance policy, you may not transact in Company securities, and you should not
inform anyone within or outside of the Company of the restriction. For the avoidance of doubt, there should be no presumption that the
GC will grant any or all pre-clearance requests and there shall be no obligation to inform a Restricted Person of the reasons for any
request approval or denial. Any transaction under a Rule&nbsp;10b5-1 Trading Plan will not require pre-clearance at the time of the transaction,
but the adoption, amendment, modification or termination of any such Rule 10b5-1 Trading Plan is subject to the pre-clearance and other
restrictions set forth in Section II.E and Appendix A, &ldquo;Guidelines for Rule&nbsp;10b5-1 Trading Plans&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.&nbsp;<I>Exceptions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
restrictions contained in this Policy shall not apply to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            exercise of Company stock options if (a) no shares are to be sold to third parties or (b)
                                            there is only a &ldquo;net exercise&rdquo; (defined as the Company withholding shares to
                                            satisfy your tax obligations or to cover the exercise price or equivalent);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;sell
                                            to cover&rdquo; transactions involving a sale of shares of common stock directed by the Company
                                            in its sole discretion in order to cover the Company&rsquo;s or such individual&rsquo;s or
                                            entity&rsquo;s withholding tax obligations in connection with the grant, vesting or settlement
                                            of equity awards pursuant to the Company&rsquo;s equity incentive plans and agreements, for
                                            example, from the vesting or settlement of restricted stock units under such plans;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>2</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
                                            the purposes of this Section D.3, GC includes a person delegated authority by the GC to pre-clear
                                            trades.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>3</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Transactions
                                            by the GC (or the GC&rsquo;s Family Members and Controlled Entities) are required to be approved
                                            in advance by the Chief Executive Officer (&ldquo;<U>CEO</U>&rdquo;) or CFO.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            vesting of Company stock options, restricted stock, restricted stock units or other equity
                                            incentive awards according to their terms;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            withholding of shares to satisfy the exercise price or a tax withholding obligation upon
                                            the grant, vesting or settlement of equity awards pursuant to the Company&rsquo;s equity
                                            incentive plans and agreements, for example, from the vesting or settlement of restricted
                                            stock units under such plans;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">purchases
                                            of shares through the Company&rsquo;s Employee Stock Purchase Plan in accordance with your
                                            pre-established participation elections;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">transferring
                                            shares to an entity that does not involve a change in the beneficial ownership of the shares
                                            (for example, transferring shares from one brokerage account to another brokerage account
                                            that you control);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">sales
                                            of Company securities as a selling stockholder in a registered public offering, including
                                            a &ldquo;synthetic secondary&rdquo; offering, in accordance with applicable securities laws;
                                            or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                            other purchase of Company securities from the Company or sale of Company securities to the
                                            Company in accordance with applicable securities and state laws.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>To
the extent applicable and such elections are permitted, your elections regarding (1) participation in &ldquo;net exercise&rdquo; or &ldquo;sell
to cover&rdquo; transactions or (2) participation in or an increase in contributions to the Company&rsquo;s Employee Stock Purchase Plan,
in each case, including changes from any defaults established by the Company, may only be made when you are not subject to a blackout
period and are not in possession of MNPI.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>E.&nbsp;Rule
10b5-1 Trading Plans</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Rule
10b5-1 under the Exchange Act provides an affirmative defense from insider trading liability if trades occur pursuant to a pre-arranged
trading plan that meets specified conditions (a &ldquo;<U>Rule 10b5-1 Trading Plan</U>&rdquo;). A Rule 10b5-1 Trading Plan is a written
trading plan between you and your broker and must either specify the number of securities to be bought or sold, along with the price
and the date, or provide a written formula for determining this information. Alternatively, such Rule 10b5-1 Trading Plan can delegate
investment discretion to a third party, such as a broker, who then makes trading decisions without further input from the person implementing
the plan. A Rule 10b5-1 Trading Plan must be established at a time when you are not aware of any MNPI and must not permit you to exercise
any subsequent control or influence over how, when or whether the purchases or sales are made. Under this Policy, the adoption, amendment,
modification or termination of a Rule 10b5-1 Trading Plan must meet the requirements set forth in Appendix A, &ldquo;Guidelines for Rule
10b5-1 Trading Plans,&rdquo; including applicable pre-clearance procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Because
the SEC rules on trading plans are complex, you should consult with your broker and be sure you fully understand the limitations and
conditions of the rules before you establish a Rule 10b5-1 Trading Plan (or a transaction that is intended to constitute a &ldquo;non-Rule
10b5-1 trading arrangement&rdquo; within the meaning of SEC rules).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>F.&nbsp;Noncompliance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Anyone
subject to this Policy who fails to comply with this Policy will be subject to appropriate disciplinary action, up to and including termination
of employment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>G.&nbsp;Post-Termination
Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
Policy, other than the pre-clearance provisions, will continue to apply to your transactions in Company securities after your employment
or service with the Company has terminated until such time as you are no longer aware of MNPI or until that information has been publicly
disclosed or is no longer material.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Questions
about this Policy should be directed to the GC.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>RECEIPT
AND ACKNOWLEDGMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">I,
________________________________, hereby acknowledge that I have received and read a copy of the Oruka Therapeutics, Inc. Insider Trading
Policy (this &ldquo;<U>Policy</U>&rdquo;). I agree to comply with this Policy and certify that I will communicate with all members of
my household to inform them of the obligations in this Policy that apply to them. I understand that violation of SEC regulations may
subject me to severe civil and/or criminal penalties, and that violation of this Policy may subject me to discipline by Oruka Therapeutics,
Inc. up to and including termination for cause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Signature</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Date</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[RECEIPT
AND ACKNOWLEDGMENT]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>APPENDIX
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><BR>
<U>Oruka Therapeutics, Inc. Guidelines for Rule 10b5-1 Trading Plans</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
discussed in the Policy, Rule 10b5-1 under the Exchange Act provides an affirmative defense from insider trading liability. In order
to be eligible to rely on this affirmative defense, you must enter into a Rule 10b5-1 Trading Plan for transactions in Company securities
that meets certain conditions specified in Rule 10b5-1, including the guidelines set forth below. These guidelines generally do not apply
to any transactions that are intended to constitute &ldquo;non-Rule 10b5-1 trading arrangements&rdquo; within the meaning of SEC rules.
Capitalized terms used in these guidelines without definition have the meaning set forth in the Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">These
guidelines are in addition to, and not in lieu of, the requirements and conditions of Rule 10b5-1. The GC will interpret and administer
these guidelines for compliance with Rule 10b5-1 and the Policy. No personal legal or financial advice is being provided by the GC or
other members of the Company regarding any Rule 10b5-1 Trading Plan or proposed trades. You remain ultimately responsible for ensuring
that your Rule 10b5-1 Trading Plans and contemplated transactions fully comply with applicable securities laws. It is recommended that
you consult with your own attorney or other advisor about any contemplated Rule 10b5-1 Trading Plan. <B>Note that for any Section 16
Persons, the Company is required to disclose the material terms of his or her (and any Family Members&rsquo; and Controlled Entities&rsquo;)
Rule 10b5-1 Trading Plan, other than with respect to price, in its periodic report for the quarter in which the Rule 10b5-1 Trading Plan
is adopted or terminated or modified (as described below).</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Pre-Clearance
                                            Requirement. </B>The Rule 10b5-1 Trading Plan must be submitted for pre-approval in advance
                                            to the GC (or, in the case of the GC, to the CEO or CFO) at least five trading days prior
                                            to the entry into the plan in accordance with the procedures set forth in the Policy and
                                            these guidelines. The Company may require that you use a standardized form of Rule 10b5-1
                                            Trading Plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Time
                                            of Adoption. </B>Subject to pre-clearance requirements described above, the Rule&nbsp;10b5-1
                                            Trading Plan must be adopted at a time:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">when
                                            you are not aware of any MNPI; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">when
                                            you are not subject to a blackout period.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Plan
                                            Instructions. </B>Any Rule 10b5-1 Trading Plan must be in writing, signed and either:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">specify
                                            the amount, price and date of the sales (or purchases) of Company securities to be effected;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">provide
                                            a formula, algorithm or computer program for determining when to sell (or purchase) the Company&rsquo;s
                                            securities, the quantity to sell (or purchase) and the price; or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">delegate
                                            decision-making authority with regard to these transactions to a broker or other agent without
                                            any MNPI about the Company or its securities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the avoidance of doubt, you may not subsequently influence how, when or whether to effect purchases or sales with respect to the securities
subject to an approved and adopted Rule 10b5-1 Trading Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 11; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>4.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>No
                                            Hedging.</B> You may not have entered into or alter a corresponding or hedging transaction
                                            or position with respect to the securities subject to the Rule 10b5-1 Trading Plan and must
                                            agree not to enter into any such transaction while the Rule 10b5-1 Trading Plan is in effect.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Good
                                            Faith Requirements.</B> You must enter into the Rule 10b5-1 Trading Plan in good faith and
                                            not as part of a plan or scheme to evade the prohibitions of Rules 10b-5 and&nbsp;10b5-1
                                            under the Exchange Act. You must act in good faith with respect to the Rule 10b5-1 Trading
                                            Plan for the entirety of its duration.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>6.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Certifications
                                            for Section 16 Persons.</B> Section 16 Persons and their Family Members and Controlled Entities
                                            that enter into Rule 10b5-1 Trading Plans must certify that they are: (1) not aware of any
                                            MNPI about the Company or the Company securities; and (2) adopting the Rule 10b5-1 Trading
                                            Plan in good faith and not as part of a plan or scheme to evade the prohibitions of Rules
                                            10b-5 and 10b5-1 under the Exchange Act.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>7.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Cooling
                                            Off Periods.</B> The first trade under the Rule 10b5-1 Trading Plan may not occur until the
                                            expiration of a cooling-off period as follows:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
                                            Section 16 Persons (as well as their Family Members and Controlled Entities), the later of
                                            (1)&nbsp;two business days following the filing of the Company&rsquo;s Form 10-Q or Form
                                            10-K for the completed fiscal quarter in which the Rule 10b5-1 Trading Plan was adopted and
                                            (2)&nbsp;90 calendar days after adoption of the Rule 10b5-1 Trading Plan; provided, however,
                                            that the required cooling-off period shall in no event exceed 120 days.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
                                            other Insiders, 30 days after adoption of the Rule 10b5-1 Trading Plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>8.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>No
                                            Overlapping Rule 10b5-1 Trading Plans.</B> You may not enter into overlapping Rule 10b5-1
                                            Trading Plans (subject to certain exceptions). Please consult with the GC for any questions
                                            regarding overlapping Rule 10b5-1 Trading Plans.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>9.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Single
                                            Transaction Plans.</B> You may not enter into more than one Rule 10b5-1 Trading Plan designed
                                            to effect the open-market purchase or sale of the total amount of securities as a single
                                            transaction during any rolling 12-month period (subject to certain exceptions). A single-transaction
                                            plan is &ldquo;designed to effect&rdquo; the purchase or sale of securities as a single transaction
                                            when the terms of the plan would, for practical purposes, directly or indirectly require
                                            execution in a single transaction.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>10.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Modifications
                                            and Terminations.</B> Modifications/amendments and terminations of an existing Rule 10b5-1
                                            Trading Plan are strongly discouraged due to legal risks, and can affect the validity of
                                            trades that have taken place under the plan prior to such modification/amendment or termination.
                                            Under Rule 10b5-1 and these guidelines, any modification/amendment to the amount, price or
                                            timing of the purchase or sale of the securities underlying the Rule 10b5-1 Trading Plan
                                            (a &ldquo;<U>Material Modification</U>&rdquo;) will be deemed to be a termination of the
                                            current Rule 10b5-1 Trading Plan and creation of a new Rule 10b5-1 Trading Plan. As such,
                                            the modification/amendment of an existing Rule 10b5-1 Trading Plan must be reviewed and approved
                                            in advance by the GC in accordance with the pre-clearance procedures set forth in the Policy
                                            and these guidelines, and any Material Modification will be subject to all the other requirements
                                            set forth in these guidelines regarding the adoption of a new Rule 10b5-1 Trading Plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
termination (other than through an amendment or modification) of an existing Rule 10b5-1 Trading Plan must be reviewed and approved in
advance by the GC in accordance with the pre-clearance procedures set forth in the Policy and these guidelines. Except in limited circumstances,
the GC will not approve the termination of a Rule 10b5-1 Trading Plan unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">you
                                            are not aware of any MNPI; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">when
                                            you are not subject to a blackout period.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">A-2</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>13
<FILENAME>ea023044501ex21-1_orukathe.htm
<DESCRIPTION>LIST OF SUBSIDIARIES OF THE REGISTRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 21.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Subsidiaries of Oruka Therapeutics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; width: 49%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U STYLE="text-decoration: none">Name of Subsidiary</U></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U STYLE="text-decoration: none">State or Jurisdiction in Which Incorporated or Organized</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Oruka Therapeutics Operating Company, LLC &nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Delaware </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 10pt">Oruka Therapeutics Australia Pty Ltd.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">Australia</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>14
<FILENAME>ea023044501ex23-1_orukathe.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-align: center; text-indent: -27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-align: center; text-indent: -27.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-283243) of Oruka Therapeutics, Inc.
of our report dated March 6, 2025 relating to the financial statements, which appears in this Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
PricewaterhouseCoopers LLP<BR>
Boston, Massachusetts<BR>
March 6, 2025</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>15
<FILENAME>ea023044501ex31-1_orukathe.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-indent: 0pt; text-align: right; margin: 0pt"><B>Exhibit 31.1</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right">&nbsp;</P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0pt"><B>Certification of Principal Executive Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</B></P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">I, Lawrence Klein, certify that:</P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Annual Report on Form 10-K of Oruka
Therapeutics, Inc.;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I are
responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c.</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d.</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I have
disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the
audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Date: March 6, 2025</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 40%; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Lawrence Klein</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">Lawrence Klein</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>Chief Executive Officer</I></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>(Principal Executive Officer)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; text-align: justify; margin: 0pt">
<P STYLE="text-indent: 0pt; text-align: justify; margin: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>16
<FILENAME>ea023044501ex31-2_orukathe.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification of Principal Financial Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Arjun Agarwal, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Annual Report on Form 10-K of Oruka
Therapeutics, Inc.;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I are
responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c.</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d.</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I have
disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the
audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: March 6, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-size: 10pt; width: 40%"><FONT STYLE="font-size: 10pt">/s/ Arjun Agarwal</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">Arjun Agarwal</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>Senior Vice President, Finance and Treasurer</I></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>(Principal Financial Officer and<BR>
 Principal Accounting Officer)</I></FONT></TD></TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>17
<FILENAME>ea023044501ex32-1_orukathe.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 32.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certifications of the</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Principal Executive Officer and Principal Financial
Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant To 18 U.S.C. Section 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As Adopted Pursuant To</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Section 906 of The Sarbanes-Oxley Act Of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Annual Report on Form 10-K
of Oruka Therapeutics, Inc. (the &ldquo;Company&rdquo;) for the year ended December 31, 2024, as filed with the Securities and Exchange
Commission on the date hereof (the &ldquo;Report&rdquo;), each of the undersigned officers of the Company hereby certifies, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">1)</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">2)</TD><TD STYLE="text-align: justify">The information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Company.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 60%"><FONT STYLE="font-size: 10pt">Date: March 6, 2025</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; width: 40%"><FONT STYLE="font-size: 10pt">/s/ Lawrence Klein</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">Lawrence Klein</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>President and Chief Executive Officer</I></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>(Principal Executive Officer)</I></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Arjun Agarwal</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">Arjun Agarwal</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>Senior Vice President, Finance and Treasurer</I></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>(Principal Financial Officer and<BR>
 Principal Accounting Officer)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>18
<FILENAME>ea023044501ex97-1_orukathe.htm
<DESCRIPTION>INCENTIVE COMPENSATION CLAWBACK POLICY
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><font style="font-size: 10pt">Exhibit
97.1</font></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="ex97-1_001.jpg" alt=""></font></p>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"><u>INCENTIVE
COMPENSATION CLAWBACK POLICY</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"><b>August 29, 2024</b></font></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font-size: 10pt"><b>I.</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>Recoupment
                                            of Incentive-Based Compensation</b></font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 10pt">It
is the policy of Oruka Therapeutics, Inc. (the &ldquo;<u>Company</u>&rdquo;) that, in the event the Company is required to prepare an
accounting restatement of the Company&rsquo;s financial statements due to material non-compliance with any financial reporting requirement
under the federal securities laws (including any such correction that is material to the previously issued financial statements, or that
would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period),
the Company will recover on a reasonably prompt basis the amount of any Incentive-Based Compensation Received by a Covered Executive
during the Recovery Period that exceeds the amount that otherwise would have been Received had it been determined based on the restated
financial statements. This Incentive Compensation Clawback Policy (this &ldquo;<u>Policy</u>&rdquo;) has been adopted by the Board of
Directors (the &ldquo;<u>Board</u>&rdquo;) of the Company and the Compensation Committee (the &ldquo;<u>Committee</u>&rdquo;) of the
Board. The Committee may amend or change the terms of this Policy at any time for any reason, including as required to comply with any
laws, rules, regulations and listing standards that may be applicable to the Company.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 10pt"><b>&nbsp;</b></font></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font-size: 10pt"><b>II.</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>Policy
                                            Administration and Definitions</b></font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 10pt">This
Policy is administered by the Committee and is intended to comply with, and as applicable to be administered and interpreted consistent
with, and subject to the exceptions set forth in, Listing Rule 5608 adopted by The Nasdaq Stock Market (&ldquo;<u>Nasdaq</u>&rdquo;)
to implement Rule 10D-1 under the Securities Exchange Act of 1934, as amended (collectively, &ldquo;<u>Rule 10D-1</u>&rdquo;).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 10pt">For
purposes of this Policy:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><font style="font-size: 10pt">&ldquo;<u>Covered
Executive</u>&rdquo; means any &ldquo;executive officer&rdquo; of the Company as defined under Rule 10D-1.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><font style="font-size: 10pt">A
&ldquo;<u>Financial Reporting Measure</u>&rdquo; is (i) any measure that is determined and presented in accordance with the accounting
principles used in preparing the Company&rsquo;s financial statements and any measure derived wholly or in part from such a measure,
and (ii) any measure based in whole or in part on the Company&rsquo;s stock price or total stockholder return.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><font style="font-size: 10pt">&ldquo;<u>Incentive-Based
Compensation</u>&rdquo; means any compensation granted, earned or vested based in whole or in part on the Company&rsquo;s attainment
of a Financial Reporting Measure that was Received by a person (i) on or after October 2, 2023, and after the person began service as
a Covered Executive, and (ii) who served as a Covered Executive at any time during the performance period for the Incentive-Based Compensation.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><font style="font-size: 10pt">Incentive-Based
Compensation is deemed to be &ldquo;<u>Received</u>&rdquo; in the fiscal period during which the relevant Financial Reporting Measure
is attained, regardless of when the compensation is actually paid or awarded.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><font style="font-size: 10pt">&ldquo;<u>Recovery
Period</u>&rdquo; means the three completed fiscal years immediately preceding the date that the Company is required to prepare the accounting
restatement described in this Policy and any transition period of less than nine months that is within or immediately following such
three fiscal years, all as determined pursuant to Rule 10D-1.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><font style="font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><font style="font-size: 10pt"><b>III.</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>Determination
                                            by the Committee</b></font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 10pt">If
the Committee determines the amount of Incentive-Based Compensation Received by a Covered Executive during a Recovery Period exceeds
the amount that would have been Received if determined or calculated based on the Company&rsquo;s restated financial results, such excess
amount of Incentive-Based Compensation shall be subject to recoupment by the Company pursuant to this Policy. For Incentive-Based Compensation
based on stock price or total stockholder return, where the amount of erroneously awarded compensation is not subject to mathematical
recalculation directly from the information in an accounting restatement, the Committee will determine the amount based on a reasonable
estimate of the effect of the accounting restatement on the relevant stock price or total stockholder return. In all cases, the calculation
of the excess amount of Incentive-Based Compensation to be recovered will be determined on a pre-tax basis (i.e., without regard to any
taxes paid with respect to such compensation). The Company will maintain and will provide to Nasdaq documentation of all determinations
and actions taken in complying with this Policy. Any determinations made by the Committee under this Policy shall be final and binding
on all affected individuals.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><font style="font-size: 10pt"><b>IV.</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>Methods
                                            of Clawback</b></font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 10pt">The
Company may effect any recovery pursuant to this Policy in any manner consistent with applicable law, including by requiring payment
of such amount(s) to the Company, by set-off, by reducing future compensation, or by such other means or combination of means as the
Committee determines to be appropriate. The Company need not recover the excess amount of Incentive-Based Compensation if and to the
extent that the Committee determines that such recovery is impracticable, subject to and in accordance with any applicable exceptions
under the Nasdaq listing rules and not required under Rule 10D-1, including if the Committee determines that the direct expense paid
to a third party to assist in enforcing this Policy would exceed the amount to be recovered after making a reasonable attempt to recover
such amounts. The Company is authorized to take appropriate steps to implement this Policy with respect to Incentive-Based Compensation
arrangements with Covered Executives.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><font style="font-size: 10pt"><b>V.</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>Not
                                            Exclusive Remedy</b></font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 10pt">Any
right of recoupment or recovery pursuant to this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment
that may be available to the Company pursuant to the terms of any other policy, any employment agreement or plan or award terms, and
any other legal remedies available to the Company (including, but not limited to, Section 304 of the Sarbanes-Oxley Act of 2002); provided
that the Company shall not recoup amounts pursuant to such other policy, terms or remedies to the extent it is recovered pursuant to
this Policy. The Company shall not indemnify any Covered Executive against the loss of any Incentive-Based Compensation pursuant to this
Policy (or provide any advancement of expenses in such instance), nor will the Company pay or reimburse or agree to pay or reimburse
any insurance premium to cover any such loss.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><font style="font-size: 10pt"><b>VI.</b></font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>Certification</b></font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 10pt">All
Covered Executives subject to this Policy will be required to certify their understanding of and intent to comply with this Policy periodically.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 10pt">&nbsp;</font></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-size: 10pt"><b>ACKNOWLEDGMENT
AND CERTIFICATION</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 10pt">By
signing below, the undersigned covered executive (the &ldquo;<u>Covered Executive</u>&rdquo;) acknowledges and confirms that the Covered
Executive has received and reviewed a copy of the Oruka Therapeutics, Inc. (the &ldquo;<u>Company</u>&rdquo;) Incentive Compensation
Clawback Policy (as interpreted or modified from time to time pursuant to the terms hereof, the&nbsp;&ldquo;<u>Policy</u>&rdquo;), and
in addition, the Covered Executive acknowledges and agrees that, for good and valid consideration, including continuing participation
in the Company&rsquo;s incentive compensation programs, the receipt and sufficiency of which the Covered Executive hereby acknowledges,
the Covered Executive will be bound by and abide by the Policy as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><font style="font-size: 10pt">(a)</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">the Covered
                                            Executive is and will continue to be subject to the Policy and the Policy will apply both
                                            during and after the Covered Executive&rsquo;s employment with the Company;</font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><font style="font-size: 10pt">(b)</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">to the
                                            extent necessary to comply with the Policy, the Company hereby amends any employment agreement,
                                            equity award agreement or similar agreement that the Covered Executive is a party to with
                                            the Company;</font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><font style="font-size: 10pt">(c)</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">the Covered
                                            Executive shall abide by the terms of the Policy, including, without limitation, by returning
                                            any compensation to the Company to the extent required by, and in a manner permitted by,
                                            the Policy, and understands and agrees that the Covered Executive shall not be entitled to
                                            any (i) indemnification for any liability (including any amounts owed by the Covered Executive
                                            in a judgment or settlement of any Clawback Proceeding (as defined below)), or loss (including
                                            judgments, fines, taxes, penalties or amounts paid in settlement by or on behalf of the Covered
                                            Executive) incurred by the Covered Executive in connection with or as a result of any action
                                            taken by the Board of Directors (the &ldquo;<u>Board</u>&rdquo;) of the Company or the Compensation
                                            Committee (the &ldquo;<u>Committee</u><b><i>&rdquo;</i></b>) of the Board to enforce the
                                            Policy (such action, a &ldquo;<u>Clawback Proceeding</u>&rdquo;) or (ii) indemnification
                                            or advancement of any expenses (including attorneys&rsquo; fees) from the Company and or
                                            any subsidiary of the Company incurred by the Covered Executive in connection with any Clawback
                                            Proceeding; <i>provided, however</i>, that if the Covered Executive is successful on the
                                            merits in the defense of any claim asserted against the Covered Executive in a Clawback Proceeding,
                                            the Covered Executive shall be indemnified for the expenses (including attorneys&rsquo; fees)
                                            the Covered Executive reasonably incurred to defend such claim;</font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><font style="font-size: 10pt">(d)</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">any amounts
                                            payable to the Covered Executive shall be subject to the Policy as may be in effect and reasonably
                                            interpreted, or modified from time to time in the sole discretion of the Committee or as
                                            required by applicable law or the requirements of any securities exchange on which the Company&rsquo;s
                                            securities are listed, and that such reasonable interpretation, or modification will be covered
                                            by this acknowledgment;</font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><font style="font-size: 10pt">(e)</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">the Company
                                            may recover compensation paid to the Covered Executive through any method of recovery the
                                            Committee or its delegate deems appropriate, including without limitation, by reducing any
                                            amount that is or may become payable to the Covered Executive, and the Covered Executive
                                            agrees to comply with any reasonable request or reasonable demand for repayment by the Company
                                            in order to comply with the Policy;</font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-size: 10pt"><b>[ACKNOWLEDGMENT
AND CERTIFICATION]</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font-size: 10pt">(f)</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">the Company
                                            is not responsible for and shall not make the Covered Executive whole for any effect under
                                            any tax law or regulation of the recovery of any compensation pursuant to the Policy or for
                                            any taxes paid by the Covered Executive on compensation that is subject to recovery or is
                                            recovered pursuant to the Policy; and</font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><font style="font-size: 10pt">(g)</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">the Covered
                                            Executive hereby knowingly, voluntarily and intentionally waives, and agrees not to assert
                                            any claim regarding, any and all rights to indemnification, advancement and other rights
                                            from the Company or any subsidiary of the Company to which the Covered Executive is now or
                                            may become entitled under any indemnification agreement between the Covered Executive and
                                            the Company (including any provisions related to non-exclusivity of rights contained therein),
                                            the Company&rsquo;s Certificate of Incorporation and Bylaws, the governing documents of each
                                            subsidiary of the Company and the Delaware General Corporation Law, in each case to the extent
                                            such waiver and agreement is necessary to give effect to the preceding provisions of this
                                            Acknowledgment and Certification.</font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&nbsp;</font></td>
  <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><font style="font-size: 10pt">&nbsp;</font></td>
  <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><font style="font-size: 10pt">Signature</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&nbsp;</font></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&nbsp;</font></td>
  <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&nbsp;</font></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">Print Name</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&nbsp;</font></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&nbsp;</font></td>
  <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&nbsp;</font></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">Date</font></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-size: 10pt"><b>[ACKNOWLEDGMENT
AND CERTIFICATION]</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>19
<FILENAME>orka-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 06 01:03:35 UTC 2025 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2024" targetNamespace="http://www.orukatx.com/20241231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:orka="http://www.orukatx.com/20241231" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="orka-20241231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="orka-20241231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="orka-20241231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="orka-20241231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.orukatx.com/role/ConsolidatedBalanceSheet" id="orka_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals" id="orka_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ConsolidatedComprehensiveIncome" id="orka_r_ConsolidatedComprehensiveIncome">
        <link:definition>995303 - Statement - Consolidated Statement of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals" id="orka_r_ConsolidatedComprehensiveIncome_Parentheticals">
        <link:definition>995304 - Statement - Consolidated Statement of Operations and Comprehensive Loss (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ShareholdersEquityType2or3" id="orka_r_ShareholdersEquityType2or3">
        <link:definition>995305 - Statement - Consolidated Statement of Convertible Preferred Stock and Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ShareholdersEquityType2or3_Parentheticals" id="orka_r_ShareholdersEquityType2or3_Parentheticals">
        <link:definition>995306 - Statement - Consolidated Statement of Convertible Preferred Stock and Stockholders&#8217; Equity (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ConsolidatedCashFlow" id="orka_r_ConsolidatedCashFlow">
        <link:definition>995307 - Statement - Consolidated Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation" id="orka_r_NatureoftheBusinessandBasisofPresentation">
        <link:definition>995308 - Disclosure - Nature of the Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies" id="orka_r_SummaryofSignificantAccountingPolicies">
        <link:definition>995309 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing" id="orka_r_ReverseRecapitalizationandPreClosingFinancing">
        <link:definition>995310 - Disclosure - Reverse Recapitalization and Pre-Closing Financing</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/FairValueMeasurements" id="orka_r_FairValueMeasurements">
        <link:definition>995311 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/CashequivalentsandMarketableSecurities" id="orka_r_CashequivalentsandMarketableSecurities">
        <link:definition>995312 - Disclosure - Cash equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities" id="orka_r_AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>995313 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/NotePayablewithRelatedParty" id="orka_r_NotePayablewithRelatedParty">
        <link:definition>995314 - Disclosure - Note Payable with Related Party</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity" id="orka_r_ConvertiblePreferredStockandStockholdersEquity">
        <link:definition>995315 - Disclosure - Convertible Preferred Stock and Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/StockBasedCompensation" id="orka_r_StockBasedCompensation">
        <link:definition>995316 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/SegmentDisclosures" id="orka_r_SegmentDisclosures">
        <link:definition>995317 - Disclosure - Segment Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/IncomeTaxes" id="orka_r_IncomeTaxes">
        <link:definition>995318 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/OptionAgreementsandLicenseAgreements" id="orka_r_OptionAgreementsandLicenseAgreements">
        <link:definition>995319 - Disclosure - Option Agreements and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/CommitmentandContingencies" id="orka_r_CommitmentandContingencies">
        <link:definition>995320 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/NetLossPerShare" id="orka_r_NetLossPerShare">
        <link:definition>995321 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/RelatedPartyTransactions" id="orka_r_RelatedPartyTransactions">
        <link:definition>995322 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/SubsequentEvents" id="orka_r_SubsequentEvents">
        <link:definition>995323 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/AccountingPoliciesByPolicy" id="orka_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables" id="orka_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>996001 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancingTables" id="orka_r_ReverseRecapitalizationandPreClosingFinancingTables">
        <link:definition>996002 - Disclosure - Reverse Recapitalization and Pre-Closing Financing (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/FairValueMeasurementsTables" id="orka_r_FairValueMeasurementsTables">
        <link:definition>996003 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/CashequivalentsandMarketableSecuritiesTables" id="orka_r_CashequivalentsandMarketableSecuritiesTables">
        <link:definition>996004 - Disclosure - Cash equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" id="orka_r_AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>996005 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables" id="orka_r_ConvertiblePreferredStockandStockholdersEquityTables">
        <link:definition>996006 - Disclosure - Convertible Preferred Stock and Stockholders&#8217; Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/StockBasedCompensationTables" id="orka_r_StockBasedCompensationTables">
        <link:definition>996007 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/SegmentDisclosuresTables" id="orka_r_SegmentDisclosuresTables">
        <link:definition>996008 - Disclosure - Segment Disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/IncomeTaxesTables" id="orka_r_IncomeTaxesTables">
        <link:definition>996009 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/CommitmentandContingenciesTables" id="orka_r_CommitmentandContingenciesTables">
        <link:definition>996010 - Disclosure - Commitment and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/NetLossPerShareTables" id="orka_r_NetLossPerShareTables">
        <link:definition>996011 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/RelatedPartyTransactionsTables" id="orka_r_RelatedPartyTransactionsTables">
        <link:definition>996012 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails" id="orka_r_NatureoftheBusinessandBasisofPresentationDetails">
        <link:definition>996013 - Disclosure - Nature of the Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails" id="orka_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996014 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable" id="orka_r_ScheduleofPropertyandEquipmentTable">
        <link:definition>996015 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable" id="orka_r_ScheduleoftheAssetsandLiabilitiesTable">
        <link:definition>996016 - Disclosure - Reverse Recapitalization and Pre-Closing Financing - Schedule of the Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" id="orka_r_ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable">
        <link:definition>996017 - Disclosure - Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets Measured (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable" id="orka_r_ScheduleofCashEquivalentsandMarketableSecuritiesTable">
        <link:definition>996018 - Disclosure - Cash equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable" id="orka_r_ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable">
        <link:definition>996019 - Disclosure - Cash equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable" id="orka_r_ScheduleofMarketableSecuritiesatEstimatedFairValueTable">
        <link:definition>996020 - Disclosure - Cash equivalents and Marketable Securities - Schedule of Marketable Securities at Estimated Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" id="orka_r_ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable">
        <link:definition>996021 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails" id="orka_r_NotePayablewithRelatedPartyDetails">
        <link:definition>996022 - Disclosure - Note Payable with Related Party (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails" id="orka_r_ConvertiblePreferredStockandStockholdersEquityDetails">
        <link:definition>996023 - Disclosure - Convertible Preferred Stock and Stockholders&#8217; Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable" id="orka_r_ScheduleofConvertiblePreferredStockTable">
        <link:definition>996024 - Disclosure - Convertible Preferred Stock and Stockholders&#8217; Equity - Schedule of Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable" id="orka_r_ScheduleofCommonStockReservedforFutureIssuanceTable">
        <link:definition>996025 - Disclosure - Convertible Preferred Stock and Stockholders&#8217; Equity - Schedule of Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/StockBasedCompensationDetails" id="orka_r_StockBasedCompensationDetails">
        <link:definition>996026 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable" id="orka_r_ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable">
        <link:definition>996027 - Disclosure - Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra9a2jfwGt44jro+lUyqzQL6/x1O9iJrf+dH3ymvrZRNb86/I06x7A9ljBSSeLHwUVO8zSU2wTDcbvo9VMwGaa97CnFY/03o9uN+p3vuWpjO+delTt6UkRTcW0ow0twDKhn42QRPQiXZ8W6BtQZBlbaaE/ZqMIFvXldcHURFnzzSEFkycIw+onLjKElg+fX0XqSMIr7KQdjfiP8BeKLKMGU69+JjAA0fvPQQsyOoCLeXaez6xpO0c+kR8ehpfxj1dE=] CSR-->
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofStockOptionActivityTable" id="orka_r_ScheduleofStockOptionActivityTable">
        <link:definition>996028 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofRSAActivityTable" id="orka_r_ScheduleofRSAActivityTable">
        <link:definition>996029 - Disclosure - Stock-Based Compensation - Schedule of RSA Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable" id="orka_r_ScheduleofEmployeeWarrantActivityTable">
        <link:definition>996030 - Disclosure - Stock-Based Compensation - Schedule of Employee Warrant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable" id="orka_r_ScheduleofCompanysStockBasedCompensationExpenseTable">
        <link:definition>996031 - Disclosure - Stock-Based Compensation - Schedule of Company&#8217;s Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable" id="orka_r_ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable">
        <link:definition>996032 - Disclosure - Stock-Based Compensation - Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/SegmentDisclosuresDetails" id="orka_r_SegmentDisclosuresDetails">
        <link:definition>996033 - Disclosure - Segment Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable" id="orka_r_ScheduleofSegmentLossfromOperationsTable">
        <link:definition>996034 - Disclosure - Segment Disclosures - Schedule of Segment Loss from Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/IncomeTaxesDetails" id="orka_r_IncomeTaxesDetails">
        <link:definition>996035 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable" id="orka_r_ScheduleofLossBeforeIncomeTaxExpenseTable">
        <link:definition>996036 - Disclosure - Income Taxes - Schedule of Loss Before Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable" id="orka_r_ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable">
        <link:definition>996037 - Disclosure - Income Taxes - Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable" id="orka_r_ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable">
        <link:definition>996038 - Disclosure - Income Taxes - Schedule of Components of the Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofNetDeferredTaxAssetsTable" id="orka_r_ScheduleofNetDeferredTaxAssetsTable">
        <link:definition>996039 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofUnrecognizedTaxBenefitsTable" id="orka_r_ScheduleofUnrecognizedTaxBenefitsTable">
        <link:definition>996040 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails" id="orka_r_OptionAgreementsandLicenseAgreementsDetails">
        <link:definition>996041 - Disclosure - Option Agreements and License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/CommitmentandContingenciesDetails" id="orka_r_CommitmentandContingenciesDetails">
        <link:definition>996042 - Disclosure - Commitment and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable" id="orka_r_ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable">
        <link:definition>996043 - Disclosure - Commitment and Contingencies - Schedule of Company&#8217;s Supplemental Cash Flow Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable" id="orka_r_ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable">
        <link:definition>996044 - Disclosure - Commitment and Contingencies - Schedule of Company&#8217;s Operating Lease Liabilities Showing the Aggregate Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/NetLossPerShareDetails" id="orka_r_NetLossPerShareDetails">
        <link:definition>996045 - Disclosure - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable" id="orka_r_ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable">
        <link:definition>996046 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable" id="orka_r_ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable">
        <link:definition>996047 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/RelatedPartyTransactionsDetails" id="orka_r_RelatedPartyTransactionsDetails">
        <link:definition>996048 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable" id="orka_r_ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable">
        <link:definition>996049 - Disclosure - Related Party Transactions - Schedule of Related Party Accounts Payable and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/SubsequentEventsDetails" id="orka_r_SubsequentEventsDetails">
        <link:definition>996050 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfPropertyAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract"/>
  <xs:element name="ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract"/>
  <xs:element name="ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract"/>
  <xs:element name="ScheduleOfConvertiblePreferredStockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfConvertiblePreferredStockAbstract"/>
  <xs:element name="ScheduleOfCommonStockReservedForFutureIssuanceAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfCommonStockReservedForFutureIssuanceAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract"/>
  <xs:element name="ScheduleOfStockOptionActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfStockOptionActivityAbstract"/>
  <xs:element name="ScheduleOfRsaActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfRsaActivityAbstract"/>
  <xs:element name="ScheduleOfEmployeeWarrantActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfEmployeeWarrantActivityAbstract"/>
  <xs:element name="ScheduleOfCompanySStockBasedCompensationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfCompanySStockBasedCompensationExpenseAbstract"/>
  <xs:element name="ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract"/>
  <xs:element name="ScheduleOfSegmentLossFromOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfSegmentLossFromOperationsAbstract"/>
  <xs:element name="ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract"/>
  <xs:element name="ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract"/>
  <xs:element name="ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract"/>
  <xs:element name="SubscriptionReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_SubscriptionReceivables"/>
  <xs:element name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
  <xs:element name="TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
  <xs:element name="TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
  <xs:element name="IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos"/>
  <xs:element name="IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost"/>
  <xs:element name="IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe"/>
  <xs:element name="IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger"/>
  <xs:element name="IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr"/>
  <xs:element name="IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant"/>
  <xs:element name="IssuanceCostOfPIPEFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_IssuanceCostOfPIPEFinancing"/>
  <xs:element name="ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock"/>
  <xs:element name="ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares"/>
  <xs:element name="IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts"/>
  <xs:element name="CashAcquiredInConnectionWithTheReverseRecapitalization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_CashAcquiredInConnectionWithTheReverseRecapitalization"/>
  <xs:element name="NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock"/>
  <xs:element name="NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock"/>
  <xs:element name="ReclassificationOfTheParukaWarrantFromLiabilityToEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity"/>
  <xs:element name="OptionAgreementsAndLicenseAgreementsTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_OptionAgreementsAndLicenseAgreementsTextBlock"/>
  <xs:element name="SubscriptionReceivablePolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SubscriptionReceivablePolicyTextBlock"/>
  <xs:element name="ClassificationOfConvertiblePreferredStockPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock"/>
  <xs:element name="NotePayableToRelatedPartyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_NotePayableToRelatedPartyPolicyTextBlock"/>
  <xs:element name="ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock"/>
  <xs:element name="ComprehensiveLossPolicyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ComprehensiveLossPolicyPolicyTextBlock"/>
  <xs:element name="OtherIncomeExpenseNetPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_OtherIncomeExpenseNetPolicyTextBlock"/>
  <xs:element name="RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock"/>
  <xs:element name="ScheduleOfConvertiblePreferredStockTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfConvertiblePreferredStockTableTextBlock"/>
  <xs:element name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
  <xs:element name="ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock"/>
  <xs:element name="FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable"/>
  <xs:element name="FairValueCashEquivalentsAndMarketableSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_FairValueCashEquivalentsAndMarketableSecurities"/>
  <xs:element name="MarketableSecuritiesDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_MarketableSecuritiesDomainDomain"/>
  <xs:element name="CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable"/>
  <xs:element name="CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems"/>
  <xs:element name="AccruedResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_AccruedResearchAndDevelopment"/>
  <xs:element name="ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable"/>
  <xs:element name="ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable"/>
  <xs:element name="StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable"/>
  <xs:element name="StockBasedCompensationScheduleofStockOptionActivityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_StockBasedCompensationScheduleofStockOptionActivityDetailsTable"/>
  <xs:element name="StockBasedCompensationScheduleofRSAActivityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_StockBasedCompensationScheduleofRSAActivityDetailsTable"/>
  <xs:element name="StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised"/>
  <xs:element name="WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable"/>
  <xs:element name="StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable"/>
  <xs:element name="StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems"/>
  <xs:element name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_DeferredTaxAssetsLeaseLiabilities"/>
  <xs:element name="DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_DeferredTaxLiabilitiesRightOfUseAsset"/>
  <xs:element name="NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable"/>
  <xs:element name="RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable"/>
  <xs:element name="NatureoftheBusinessandBasisofPresentationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_NatureoftheBusinessandBasisofPresentationDetailsTable"/>
  <xs:element name="AdditionalPaidInCapitalTransacationCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_AdditionalPaidInCapitalTransacationCost"/>
  <xs:element name="ExchangeRatio" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ExchangeRatio"/>
  <xs:element name="CommonStocksConversionRatio" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_CommonStocksConversionRatio"/>
  <xs:element name="InvestorsClosingShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_InvestorsClosingShares"/>
  <xs:element name="PreFundedWarrantsOfCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_PreFundedWarrantsOfCommonStockShares"/>
  <xs:element name="NumberOfSharesPurchased" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="orka_NumberOfSharesPurchased"/>
  <xs:element name="NumberofAggregateShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_NumberofAggregateShares"/>
  <xs:element name="PrefundedWarrantstoPurchaseAnAggregateShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_PrefundedWarrantstoPurchaseAnAggregateShares"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="NotePayablewithRelatedPartyDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_NotePayablewithRelatedPartyDetailsTable"/>
  <xs:element name="ConvertiblePreferredStockandStockholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable"/>
  <xs:element name="ClassOfWarrantsExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ClassOfWarrantsExercisable"/>
  <xs:element name="ClassOfWarrantOrRightExpirationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ClassOfWarrantOrRightExpirationDate"/>
  <xs:element name="ClassOfWarrantOrRightWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ClassOfWarrantOrRightWarrantsExercised"/>
  <xs:element name="CommonStockConversionRatio" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_CommonStockConversionRatio"/>
  <xs:element name="WarrantsToPurchaseCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="orka_WarrantsToPurchaseCommonStock"/>
  <xs:element name="StockBasedCompensationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_StockBasedCompensationDetailsTable"/>
  <xs:element name="ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares"/>
  <xs:element name="EmployeeStockPurchasePlanESPPCashContributionsToESPP" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP"/>
  <xs:element name="ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum"/>
  <xs:element name="EstimatedFairValueOfWarrantsToBeGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_EstimatedFairValueOfWarrantsToBeGranted"/>
  <xs:element name="ClassOfWarrantOrRight" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ClassOfWarrantOrRight"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_IncomeTaxesDetailsTable"/>
  <xs:element name="IncomeTaxesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_IncomeTaxesDetailsLineItems"/>
  <xs:element name="OperatingLossCarryforwardsAsAPercentageOfTaxableIncome" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome"/>
  <xs:element name="OptionAgreementsandLicenseAgreementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_OptionAgreementsandLicenseAgreementsDetailsTable"/>
  <xs:element name="NonRefundableMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_NonRefundableMilestonePayments"/>
  <xs:element name="RoyaltyPayableOnProductSales" type="xbrli:stringItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="orka_RoyaltyPayableOnProductSales"/>
  <xs:element name="DevelopmentCostsPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_DevelopmentCostsPercentage"/>
  <xs:element name="MilestoneConsiderationPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_MilestoneConsiderationPaid"/>
  <xs:element name="OtherDevelopmentCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_OtherDevelopmentCost"/>
  <xs:element name="ResearchInitialFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_ResearchInitialFee"/>
  <xs:element name="CommitmentandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_CommitmentandContingenciesDetailsTable"/>
  <xs:element name="NonRefundableLicenseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_NonRefundableLicenseFee"/>
  <xs:element name="NetLossPerShareDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_NetLossPerShareDetailsTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_SubsequentEventsDetailsTable"/>
  <xs:element name="MarketableSecuritiesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="orka_MarketableSecuritiesAxis"/>
  <xs:element name="ARCACommonStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ARCACommonStockMember"/>
  <xs:element name="AchievementOfDevelopmentCandidateMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_AchievementOfDevelopmentCandidateMember"/>
  <xs:element name="AntibodyProductsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_AntibodyProductsMember"/>
  <xs:element name="ClinicalDevelopmentMilestonesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ClinicalDevelopmentMilestonesMember"/>
  <xs:element name="ConvertibleNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ConvertibleNoteMember"/>
  <xs:element name="EmployeeStockPurchasePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_EmployeeStockPurchasePlanMember"/>
  <xs:element name="EmployeeWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_EmployeeWarrantsMember"/>
  <xs:element name="ExternalMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ExternalMember"/>
  <xs:element name="FairmountHealthcareFundIILPMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_FairmountHealthcareFundIILPMember"/>
  <xs:element name="FairmountMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_FairmountMember"/>
  <xs:element name="FairmountsOwnershipInterestInParagonMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_FairmountsOwnershipInterestInParagonMember"/>
  <xs:element name="FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember"/>
  <xs:element name="MarketableSecuritiesCurrentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_MarketableSecuritiesCurrentMember"/>
  <xs:element name="MarketableSecuritiesLongTermMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_MarketableSecuritiesLongTermMember"/>
  <xs:element name="MarketableSecuritiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_MarketableSecuritiesMember"/>
  <xs:element name="MarketableSecuritiesNoncurrentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_MarketableSecuritiesNoncurrentMember"/>
  <xs:element name="NominationOfADevelopmentCandidateMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_NominationOfADevelopmentCandidateMember"/>
  <xs:element name="ORKAZeroZeroOneLicenseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ORKAZeroZeroOneLicenseAgreementMember"/>
  <xs:element name="ORKAZeroZeroOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ORKAZeroZeroOneMember"/>
  <xs:element name="ORKAZeroZeroTwoLicenseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ORKAZeroZeroTwoLicenseAgreementMember"/>
  <xs:element name="ORKAZeroZeroTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ORKAZeroZeroTwoMember"/>
  <xs:element name="OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember"/>
  <xs:element name="OperatingExpenseExcludingStockBasedCompensationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_OperatingExpenseExcludingStockBasedCompensationMember"/>
  <xs:element name="OrukaCommonStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_OrukaCommonStockMember"/>
  <xs:element name="OrukaSeriesAConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_OrukaSeriesAConvertiblePreferredStockMember"/>
  <xs:element name="OtherMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_OtherMember"/>
  <xs:element name="PIPEFinancingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_PIPEFinancingMember"/>
  <xs:element name="ParagonMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ParagonMember"/>
  <xs:element name="ParagonMilestonePaymentsForOptionAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ParagonMilestonePaymentsForOptionAgreementMember"/>
  <xs:element name="ParagonReimbursableOptionAgreementsFeesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ParagonReimbursableOptionAgreementsFeesMember"/>
  <xs:element name="ParagonReimbursableOtherResearchExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ParagonReimbursableOtherResearchExpensesMember"/>
  <xs:element name="ParagonReimbursablePatentExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ParagonReimbursablePatentExpensesMember"/>
  <xs:element name="ParukaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ParukaMember"/>
  <xs:element name="ParukaWarrantMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ParukaWarrantMember"/>
  <xs:element name="ParukaWarrantObligationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ParukaWarrantObligationMember"/>
  <xs:element name="PreFundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_PreFundedWarrantsMember"/>
  <xs:element name="PreMergerOrukaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_PreMergerOrukaMember"/>
  <xs:element name="PrefundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_PrefundedWarrantsMember"/>
  <xs:element name="RegulatoryMilestonesMemberMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_RegulatoryMilestonesMemberMember"/>
  <xs:element name="RestrictedStockAwardsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_RestrictedStockAwardsMember"/>
  <xs:element name="SeriesAConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SeriesAConvertiblePreferredStockMember"/>
  <xs:element name="SeriesANonVotingConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SeriesANonVotingConvertiblePreferredStockMember"/>
  <xs:element name="SeriesANonVotingConvertiblePreferredStockholdersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SeriesANonVotingConvertiblePreferredStockholdersMember"/>
  <xs:element name="SeriesBConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SeriesBConvertiblePreferredStockMember"/>
  <xs:element name="SeriesBNonVotingConvertiblePreferredStockAmountMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember"/>
  <xs:element name="SeriesBNonVotingConvertiblePreferredStockholdersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember"/>
  <xs:element name="StockOptionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_StockOptionsMember"/>
  <xs:element name="TwoThousandTwentyFourEmployeeStockPurchasePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember"/>
  <xs:element name="TwoThousandTwentyFourStockIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_TwoThousandTwentyFourStockIncentivePlanMember"/>
  <xs:element name="USGovernmentAgencySecuritiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_USGovernmentAgencySecuritiesMember"/>
  <xs:element name="CashEquivalentsAndMarketableSecuritiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_CashEquivalentsAndMarketableSecuritiesAbstract"/>
  <xs:element name="OptionAgreementsAndLicenseAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_OptionAgreementsAndLicenseAgreementsAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>20
<FILENAME>orka-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 06 01:03:35 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedBalanceSheet" roleURI="http://www.orukatx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedComprehensiveIncome" roleURI="http://www.orukatx.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedCashFlow" roleURI="http://www.orukatx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleoftheAssetsandLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofMarketableSecuritiesatEstimatedFairValueTable" roleURI="http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofLossBeforeIncomeTaxExpenseTable" roleURI="http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable" roleURI="http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable" roleURI="http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"/>
  <calculationLink xlink:role="http://www.orukatx.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="orka_SubscriptionReceivables" xlink:href="orka-20241231.xsd#orka_SubscriptionReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="orka_SubscriptionReceivables" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="3" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.orukatx.com/role/ConsolidatedComprehensiveIncome" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseNonoperating" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.orukatx.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra9a2jfwGt44jro+lUyqzQL6/x1O9iJrf+dH3ymvrZRNb86/I06x7A9ljBSSeLHwUVO8zSU2wTDcbvo9VMwGaa97CnFY/03o9uN+p3vuWpjO+delTt6UkRTcW0ow0twDKhn42QRPQiXZ8W6BtQZBlbaaE/ZqMIFvXldcHURFnzzSEFkycIw+onLjKElg+fX0XqSMIr7KQdjfiP8BeKLKMGU69+JjAA0fvPQQsyOoCLeXapRbeZPdCjNqzPMeA9uVGc=] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromNotesPayable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="orka_CashAcquiredInConnectionWithTheReverseRecapitalization" xlink:href="orka-20241231.xsd#orka_CashAcquiredInConnectionWithTheReverseRecapitalization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="orka_CashAcquiredInConnectionWithTheReverseRecapitalization" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="orka_AccruedResearchAndDevelopment" xlink:href="orka-20241231.xsd#orka_AccruedResearchAndDevelopment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="orka_AccruedResearchAndDevelopment" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="5" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="orka_DeferredTaxAssetsLeaseLiabilities" xlink:href="orka-20241231.xsd#orka_DeferredTaxAssetsLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="orka_DeferredTaxAssetsLeaseLiabilities" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <loc xlink:type="locator" xlink:label="orka_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="orka-20241231.xsd#orka_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="orka_DeferredTaxLiabilitiesRightOfUseAsset" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>21
<FILENAME>orka-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 06 01:03:35 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedBalanceSheet" roleURI="http://www.orukatx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedComprehensiveIncome" roleURI="http://www.orukatx.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedComprehensiveIncome_Parentheticals" roleURI="http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ShareholdersEquityType2or3" roleURI="http://www.orukatx.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://www.orukatx.com/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedCashFlow" roleURI="http://www.orukatx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NatureoftheBusinessandBasisofPresentation" roleURI="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ReverseRecapitalizationandPreClosingFinancing" roleURI="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_FairValueMeasurements" roleURI="http://www.orukatx.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_CashequivalentsandMarketableSecurities" roleURI="http://www.orukatx.com/role/CashequivalentsandMarketableSecurities"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NotePayablewithRelatedParty" roleURI="http://www.orukatx.com/role/NotePayablewithRelatedParty"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConvertiblePreferredStockandStockholdersEquity" roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_StockBasedCompensation" roleURI="http://www.orukatx.com/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SegmentDisclosures" roleURI="http://www.orukatx.com/role/SegmentDisclosures"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_IncomeTaxes" roleURI="http://www.orukatx.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_OptionAgreementsandLicenseAgreements" roleURI="http://www.orukatx.com/role/OptionAgreementsandLicenseAgreements"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_CommitmentandContingencies" roleURI="http://www.orukatx.com/role/CommitmentandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NetLossPerShare" roleURI="http://www.orukatx.com/role/NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_RelatedPartyTransactions" roleURI="http://www.orukatx.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SubsequentEvents" roleURI="http://www.orukatx.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_AccountingPoliciesByPolicy" roleURI="http://www.orukatx.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ReverseRecapitalizationandPreClosingFinancingTables" roleURI="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancingTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_FairValueMeasurementsTables" roleURI="http://www.orukatx.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_CashequivalentsandMarketableSecuritiesTables" roleURI="http://www.orukatx.com/role/CashequivalentsandMarketableSecuritiesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConvertiblePreferredStockandStockholdersEquityTables" roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_StockBasedCompensationTables" roleURI="http://www.orukatx.com/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SegmentDisclosuresTables" roleURI="http://www.orukatx.com/role/SegmentDisclosuresTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_IncomeTaxesTables" roleURI="http://www.orukatx.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_CommitmentandContingenciesTables" roleURI="http://www.orukatx.com/role/CommitmentandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NetLossPerShareTables" roleURI="http://www.orukatx.com/role/NetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_RelatedPartyTransactionsTables" roleURI="http://www.orukatx.com/role/RelatedPartyTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofPropertyandEquipmentTable" roleURI="http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleoftheAssetsandLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" roleURI="http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofCashEquivalentsandMarketableSecuritiesTable" roleURI="http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable" roleURI="http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofMarketableSecuritiesatEstimatedFairValueTable" roleURI="http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofConvertiblePreferredStockTable" roleURI="http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofCommonStockReservedforFutureIssuanceTable" roleURI="http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable" roleURI="http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofStockOptionActivityTable" roleURI="http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofRSAActivityTable" roleURI="http://www.orukatx.com/role/ScheduleofRSAActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofEmployeeWarrantActivityTable" roleURI="http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofCompanysStockBasedCompensationExpenseTable" roleURI="http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable" roleURI="http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofSegmentLossfromOperationsTable" roleURI="http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofLossBeforeIncomeTaxExpenseTable" roleURI="http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable" roleURI="http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofNetDeferredTaxAssetsTable" roleURI="http://www.orukatx.com/role/ScheduleofNetDeferredTaxAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofUnrecognizedTaxBenefitsTable" roleURI="http://www.orukatx.com/role/ScheduleofUnrecognizedTaxBenefitsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable" roleURI="http://www.orukatx.com/role/ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable" roleURI="http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable" roleURI="http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable" roleURI="http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NatureoftheBusinessandBasisofPresentationDetails" roleURI="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NotePayablewithRelatedPartyDetails" roleURI="http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConvertiblePreferredStockandStockholdersEquityDetails" roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_StockBasedCompensationDetails" roleURI="http://www.orukatx.com/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SegmentDisclosuresDetails" roleURI="http://www.orukatx.com/role/SegmentDisclosuresDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_IncomeTaxesDetails" roleURI="http://www.orukatx.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_OptionAgreementsandLicenseAgreementsDetails" roleURI="http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_CommitmentandContingenciesDetails" roleURI="http://www.orukatx.com/role/CommitmentandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NetLossPerShareDetails" roleURI="http://www.orukatx.com/role/NetLossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_RelatedPartyTransactionsDetails" roleURI="http://www.orukatx.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SubsequentEventsDetails" roleURI="http://www.orukatx.com/role/SubsequentEventsDetails"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://www.orukatx.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesAConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesAConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesAConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:href="orka-20241231.xsd#orka_SeriesBNonVotingConvertiblePreferredStockAmountMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SubscriptionReceivables" xlink:href="orka-20241231.xsd#orka_SubscriptionReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_SubscriptionReceivables" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockValue" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="25" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesAConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesAConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesAConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:href="orka-20241231.xsd#orka_SeriesBNonVotingConvertiblePreferredStockAmountMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ConsolidatedComprehensiveIncome" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockholdersMember" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockholdersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockholdersMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember" xlink:href="orka-20241231.xsd#orka_SeriesBNonVotingConvertiblePreferredStockholdersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseNonoperating" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_InterestExpenseMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesRelatedParty" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:href="orka-20241231.xsd#orka_SeriesBNonVotingConvertiblePreferredStockAmountMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="orka-20241231.xsd#orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="orka-20241231.xsd#orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="orka-20241231.xsd#orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceCostOfPIPEFinancing" xlink:href="orka-20241231.xsd#orka_IssuanceCostOfPIPEFinancing"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_IssuanceCostOfPIPEFinancing" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" xlink:href="orka-20241231.xsd#orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" xlink:href="orka-20241231.xsd#orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="25" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ShareholdersEquityType2or3_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" xlink:href="orka-20241231.xsd#orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_OtherNoncashExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_Depreciation" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_CashAcquiredInConnectionWithTheReverseRecapitalization" xlink:href="orka-20241231.xsd#orka_CashAcquiredInConnectionWithTheReverseRecapitalization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="orka_CashAcquiredInConnectionWithTheReverseRecapitalization" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" xlink:href="orka-20241231.xsd#orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock" xlink:href="orka-20241231.xsd#orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity" xlink:href="orka-20241231.xsd#orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity" order="31" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/FairValueMeasurements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/CashequivalentsandMarketableSecurities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:href="orka-20241231.xsd#orka_CashEquivalentsAndMarketableSecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/NotePayablewithRelatedParty" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/StockBasedCompensation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/SegmentDisclosures" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/OptionAgreementsandLicenseAgreements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_OptionAgreementsAndLicenseAgreementsAbstract" xlink:href="orka-20241231.xsd#orka_OptionAgreementsAndLicenseAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="orka_OptionAgreementsAndLicenseAgreementsTextBlock" xlink:href="orka-20241231.xsd#orka_OptionAgreementsAndLicenseAgreementsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_OptionAgreementsAndLicenseAgreementsAbstract" xlink:to="orka_OptionAgreementsAndLicenseAgreementsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/CommitmentandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/NetLossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerUnitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerUnitAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerUnitAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/RelatedPartyTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SubscriptionReceivablePolicyTextBlock" xlink:href="orka-20241231.xsd#orka_SubscriptionReceivablePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="orka_SubscriptionReceivablePolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_NotePayableToRelatedPartyPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_NotePayableToRelatedPartyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="orka_NotePayableToRelatedPartyPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ComprehensiveLossPolicyPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_ComprehensiveLossPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="orka_ComprehensiveLossPolicyPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_OtherIncomeExpenseNetPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_OtherIncomeExpenseNetPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="orka_OtherIncomeExpenseNetPolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="22" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancingTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/CashequivalentsandMarketableSecuritiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:href="orka-20241231.xsd#orka_CashEquivalentsAndMarketableSecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfConvertiblePreferredStockTableTextBlock" xlink:href="orka-20241231.xsd#orka_ScheduleOfConvertiblePreferredStockTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="orka_ScheduleOfConvertiblePreferredStockTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:href="orka-20241231.xsd#orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/StockBasedCompensationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock" xlink:href="orka-20241231.xsd#orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/SegmentDisclosuresTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/CommitmentandContingenciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/NetLossPerShareTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerUnitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerUnitAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerUnitAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerUnitAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable" xlink:href="orka-20241231.xsd#orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_FairValueCashEquivalentsAndMarketableSecurities" xlink:href="orka-20241231.xsd#orka_FairValueCashEquivalentsAndMarketableSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="orka_FairValueCashEquivalentsAndMarketableSecurities" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashEquivalentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesMember" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="orka_MarketableSecuritiesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesLongTermMember" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesLongTermMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="orka_MarketableSecuritiesLongTermMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" xlink:href="orka-20241231.xsd#orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" xlink:href="orka-20241231.xsd#orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" xlink:to="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesAxis" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" xlink:to="orka_MarketableSecuritiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesDomainDomain" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="orka_MarketableSecuritiesAxis" xlink:to="orka_MarketableSecuritiesDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesDomainDomain_0" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="orka_MarketableSecuritiesAxis" xlink:to="orka_MarketableSecuritiesDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesCurrentMember" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesCurrentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_MarketableSecuritiesDomainDomain" xlink:to="orka_MarketableSecuritiesCurrentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesNoncurrentMember" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesNoncurrentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_MarketableSecuritiesDomainDomain" xlink:to="orka_MarketableSecuritiesNoncurrentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_USGovernmentAgencySecuritiesMember" xlink:href="orka-20241231.xsd#orka_USGovernmentAgencySecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="orka_USGovernmentAgencySecuritiesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_MarketableSecurities" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_AccruedResearchAndDevelopment" xlink:href="orka-20241231.xsd#orka_AccruedResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="orka_AccruedResearchAndDevelopment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable" xlink:href="orka-20241231.xsd#orka_ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesBConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesBConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_PreferredStockValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:href="orka-20241231.xsd#orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesBConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesBConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_TwoThousandTwentyFourStockIncentivePlanMember" xlink:href="orka-20241231.xsd#orka_TwoThousandTwentyFourStockIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="orka_TwoThousandTwentyFourStockIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember" xlink:href="orka-20241231.xsd#orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_PrefundedWarrantsMember" xlink:href="orka-20241231.xsd#orka_PrefundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_PrefundedWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaWarrantObligationMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantObligationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_ParukaWarrantObligationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_EmployeeWarrantsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra9a2jfwGt44jro+lUyqzQL6/x1O9iJrf+dH3ymvrZRNb86/I06x7A9ljBSSeLHwUVO8zSU2wTDcbvo9VMwGaa97CnFY/03o9uN+p3vuWpjO+delTt6UkRTcW0ow0twDKhn42QRPQiXZ8W6BtQZBlbaaE/ZqMIFvXldcHURFnzzSEFkycIw+onLjKElg+fX0XqSMIr7KQdjfiP8BeKLKMGU69+JjAA0fvPQQsyOoCLeXXb7rXpRsbaDqNjkW3xViUs=] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_EmployeeWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofStockOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationScheduleofStockOptionActivityDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofStockOptionActivityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_StockBasedCompensationScheduleofStockOptionActivityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationScheduleofStockOptionActivityDetailsTable" xlink:to="srt_StatementScenarioAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofRSAActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationScheduleofRSAActivityDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofRSAActivityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_StockBasedCompensationScheduleofRSAActivityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationScheduleofRSAActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_EmployeeWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised" xlink:href="orka-20241231.xsd#orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable" xlink:href="orka-20241231.xsd#orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems" xlink:to="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaWarrantObligationMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantObligationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="orka_ParukaWarrantObligationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="orka_EmployeeWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_StockOptionMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeStockPurchasePlanMember" xlink:href="orka-20241231.xsd#orka_EmployeeStockPurchasePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="orka_EmployeeStockPurchasePlanMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_OperatingExpenseExcludingStockBasedCompensationMember" xlink:href="orka-20241231.xsd#orka_OperatingExpenseExcludingStockBasedCompensationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="orka_OperatingExpenseExcludingStockBasedCompensationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ExternalMember" xlink:href="orka-20241231.xsd#orka_ExternalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="orka_ExternalMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_OtherMember" xlink:href="orka-20241231.xsd#orka_OtherMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="orka_OtherMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember" xlink:href="orka-20241231.xsd#orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_OperatingExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_DeferredTaxAssetsLeaseLiabilities" xlink:href="orka-20241231.xsd#orka_DeferredTaxAssetsLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="orka_DeferredTaxAssetsLeaseLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="orka-20241231.xsd#orka_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="orka_DeferredTaxLiabilitiesRightOfUseAsset" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofNetDeferredTaxAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofUnrecognizedTaxBenefitsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDilutedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable" xlink:href="orka-20241231.xsd#orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="orka_EmployeeWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_RestrictedStockAwardsMember" xlink:href="orka-20241231.xsd#orka_RestrictedStockAwardsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="orka_RestrictedStockAwardsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_StockOptionsMember" xlink:href="orka-20241231.xsd#orka_StockOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="orka_StockOptionsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaWarrantMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="orka_ParukaWarrantMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable" xlink:href="orka-20241231.xsd#orka_RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="orka_RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonReimbursableOptionAgreementsFeesMember" xlink:href="orka-20241231.xsd#orka_ParagonReimbursableOptionAgreementsFeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="orka_ParagonReimbursableOptionAgreementsFeesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonMilestonePaymentsForOptionAgreementMember" xlink:href="orka-20241231.xsd#orka_ParagonMilestonePaymentsForOptionAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="orka_ParagonMilestonePaymentsForOptionAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonReimbursableOtherResearchExpensesMember" xlink:href="orka-20241231.xsd#orka_ParagonReimbursableOtherResearchExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="orka_ParagonReimbursableOtherResearchExpensesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonReimbursablePatentExpensesMember" xlink:href="orka-20241231.xsd#orka_ParagonReimbursablePatentExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="orka_ParagonReimbursablePatentExpensesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <loc xlink:type="locator" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" order="26" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:href="orka-20241231.xsd#orka_NatureoftheBusinessandBasisofPresentationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_NatureoftheBusinessandBasisofPresentationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_OrukaCommonStockMember" xlink:href="orka-20241231.xsd#orka_OrukaCommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="orka_OrukaCommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_PreMergerOrukaMember" xlink:href="orka-20241231.xsd#orka_PreMergerOrukaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="orka_PreMergerOrukaMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ARCACommonStockMember" xlink:href="orka-20241231.xsd#orka_ARCACommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="orka_ARCACommonStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_OrukaSeriesAConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_OrukaSeriesAConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="orka_OrukaSeriesAConvertiblePreferredStockMember" order="3" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_PIPEFinancingMember" xlink:href="orka-20241231.xsd#orka_PIPEFinancingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="orka_PIPEFinancingMember" order="5" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_PrefundedWarrantsMember" xlink:href="orka-20241231.xsd#orka_PrefundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_PrefundedWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_AdditionalPaidInCapitalTransacationCost" xlink:href="orka-20241231.xsd#orka_AdditionalPaidInCapitalTransacationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_AdditionalPaidInCapitalTransacationCost" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ExchangeRatio" xlink:href="orka-20241231.xsd#orka_ExchangeRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_ExchangeRatio" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_CommonStocksConversionRatio" xlink:href="orka-20241231.xsd#orka_CommonStocksConversionRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_CommonStocksConversionRatio" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_InvestorsClosingShares" xlink:href="orka-20241231.xsd#orka_InvestorsClosingShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_InvestorsClosingShares" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_PreFundedWarrantsOfCommonStockShares" xlink:href="orka-20241231.xsd#orka_PreFundedWarrantsOfCommonStockShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_PreFundedWarrantsOfCommonStockShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_NumberOfSharesPurchased" xlink:href="orka-20241231.xsd#orka_NumberOfSharesPurchased"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_NumberOfSharesPurchased" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_NumberofAggregateShares" xlink:href="orka-20241231.xsd#orka_NumberofAggregateShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_NumberofAggregateShares" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_PrefundedWarrantstoPurchaseAnAggregateShares" xlink:href="orka-20241231.xsd#orka_PrefundedWarrantstoPurchaseAnAggregateShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_PrefundedWarrantstoPurchaseAnAggregateShares" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_NetIncomeLoss" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAndCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_InvestmentsAndCash" order="20" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="orka-20241231.xsd#orka_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="orka_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalDepositInsuranceCorporationPremiumExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_NotePayablewithRelatedPartyDetailsTable" xlink:href="orka-20241231.xsd#orka_NotePayablewithRelatedPartyDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="orka_NotePayablewithRelatedPartyDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NotePayablewithRelatedPartyDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NotePayablewithRelatedPartyDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NotePayablewithRelatedPartyDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NotePayablewithRelatedPartyDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_FairmountHealthcareFundIILPMember" xlink:href="orka-20241231.xsd#orka_FairmountHealthcareFundIILPMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="orka_FairmountHealthcareFundIILPMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertibleNoteMember" xlink:href="orka-20241231.xsd#orka_ConvertibleNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="orka_ConvertibleNoteMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_PreMergerOrukaMember" xlink:href="orka-20241231.xsd#orka_PreMergerOrukaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="orka_PreMergerOrukaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:href="orka-20241231.xsd#orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_FairmountMember" xlink:href="orka-20241231.xsd#orka_FairmountMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="orka_FairmountMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_PreMergerOrukaMember" xlink:href="orka-20241231.xsd#orka_PreMergerOrukaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="orka_PreMergerOrukaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_PIPEFinancingMember" xlink:href="orka-20241231.xsd#orka_PIPEFinancingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="orka_PIPEFinancingMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_PreFundedWarrantsMember" xlink:href="orka-20241231.xsd#orka_PreFundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_PreFundedWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_EmployeeWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaWarrantMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_ParukaWarrantMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ClassOfWarrantsExercisable" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_ClassOfWarrantsExercisable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ClassOfWarrantOrRightExpirationDate" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRightExpirationDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_ClassOfWarrantOrRightExpirationDate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ClassOfWarrantOrRightWarrantsExercised" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRightWarrantsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_ClassOfWarrantOrRightWarrantsExercised" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_CommonStockConversionRatio" xlink:href="orka-20241231.xsd#orka_CommonStockConversionRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_CommonStockConversionRatio" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_WarrantsToPurchaseCommonStock" xlink:href="orka-20241231.xsd#orka_WarrantsToPurchaseCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="orka_WarrantsToPurchaseCommonStock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="21" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/StockBasedCompensationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="orka_StockBasedCompensationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_TwoThousandTwentyFourStockIncentivePlanMember" xlink:href="orka-20241231.xsd#orka_TwoThousandTwentyFourStockIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="orka_TwoThousandTwentyFourStockIncentivePlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="2" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="orka_TwoThousandTwentyFourStockIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember" xlink:href="orka-20241231.xsd#orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaWarrantObligationMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantObligationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_ParukaWarrantObligationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_EmployeeWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP" xlink:href="orka-20241231.xsd#orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_EstimatedFairValueOfWarrantsToBeGranted" xlink:href="orka-20241231.xsd#orka_EstimatedFairValueOfWarrantsToBeGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="orka_EstimatedFairValueOfWarrantsToBeGranted" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ClassOfWarrantOrRight" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRight"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="orka_ClassOfWarrantOrRight" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/SegmentDisclosuresDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_IncomeTaxesDetailsLineItems" xlink:href="orka-20241231.xsd#orka_IncomeTaxesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_IncomeTaxesDetailsTable" xlink:href="orka-20241231.xsd#orka_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="orka_IncomeTaxesDetailsLineItems" xlink:to="orka_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome" xlink:href="orka-20241231.xsd#orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_IncomeTaxesDetailsLineItems" xlink:to="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_OptionAgreementsandLicenseAgreementsDetailsTable" xlink:href="orka-20241231.xsd#orka_OptionAgreementsandLicenseAgreementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="orka_OptionAgreementsandLicenseAgreementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonMember" xlink:href="orka-20241231.xsd#orka_ParagonMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="orka_ParagonMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ORKAZeroZeroOneLicenseAgreementMember" xlink:href="orka-20241231.xsd#orka_ORKAZeroZeroOneLicenseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="orka_ORKAZeroZeroOneLicenseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ORKAZeroZeroTwoLicenseAgreementMember" xlink:href="orka-20241231.xsd#orka_ORKAZeroZeroTwoLicenseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="orka_ORKAZeroZeroTwoLicenseAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ORKAZeroZeroOneMember" xlink:href="orka-20241231.xsd#orka_ORKAZeroZeroOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="orka_ORKAZeroZeroOneMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ORKAZeroZeroTwoMember" xlink:href="orka-20241231.xsd#orka_ORKAZeroZeroTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="orka_ORKAZeroZeroTwoMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaWarrantObligationMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantObligationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_ParukaWarrantObligationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_NominationOfADevelopmentCandidateMember" xlink:href="orka-20241231.xsd#orka_NominationOfADevelopmentCandidateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="orka_NominationOfADevelopmentCandidateMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ClinicalDevelopmentMilestonesMember" xlink:href="orka-20241231.xsd#orka_ClinicalDevelopmentMilestonesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="orka_ClinicalDevelopmentMilestonesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_RegulatoryMilestonesMemberMember" xlink:href="orka-20241231.xsd#orka_RegulatoryMilestonesMemberMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="orka_RegulatoryMilestonesMemberMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember" xlink:href="orka-20241231.xsd#orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_AntibodyProductsMember" xlink:href="orka-20241231.xsd#orka_AntibodyProductsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="orka_AntibodyProductsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_AchievementOfDevelopmentCandidateMember" xlink:href="orka-20241231.xsd#orka_AchievementOfDevelopmentCandidateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="orka_AchievementOfDevelopmentCandidateMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_NonRefundableMilestonePayments" xlink:href="orka-20241231.xsd#orka_NonRefundableMilestonePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="orka_NonRefundableMilestonePayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_RoyaltyPayableOnProductSales" xlink:href="orka-20241231.xsd#orka_RoyaltyPayableOnProductSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="orka_RoyaltyPayableOnProductSales" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsForFees" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_DevelopmentCostsPercentage" xlink:href="orka-20241231.xsd#orka_DevelopmentCostsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="orka_DevelopmentCostsPercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_MilestoneConsiderationPaid" xlink:href="orka-20241231.xsd#orka_MilestoneConsiderationPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="orka_MilestoneConsiderationPaid" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_OtherDevelopmentCost" xlink:href="orka-20241231.xsd#orka_OtherDevelopmentCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="orka_OtherDevelopmentCost" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ResearchInitialFee" xlink:href="orka-20241231.xsd#orka_ResearchInitialFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="orka_ResearchInitialFee" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherExpenses" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/CommitmentandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_CommitmentandContingenciesDetailsTable" xlink:href="orka-20241231.xsd#orka_CommitmentandContingenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="orka_CommitmentandContingenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_CommitmentandContingenciesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseVariableLeaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseVariableLeaseIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseVariableLeaseIncome" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_NonRefundableLicenseFee" xlink:href="orka-20241231.xsd#orka_NonRefundableLicenseFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="orka_NonRefundableLicenseFee" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/NetLossPerShareDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_NetLossPerShareDetailsTable" xlink:href="orka-20241231.xsd#orka_NetLossPerShareDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="orka_NetLossPerShareDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NetLossPerShareDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_RelatedPartyTransactionsDetailsTable" xlink:href="orka-20241231.xsd#orka_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="orka_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_RelatedPartyTransactionsDetailsTable" xlink:to="srt_OwnershipAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonMember" xlink:href="orka-20241231.xsd#orka_ParagonMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="orka_ParagonMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaMember" xlink:href="orka-20241231.xsd#orka_ParukaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="orka_ParukaMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_FairmountHealthcareFundIILPMember" xlink:href="orka-20241231.xsd#orka_FairmountHealthcareFundIILPMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="orka_FairmountHealthcareFundIILPMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_FairmountsOwnershipInterestInParagonMember" xlink:href="orka-20241231.xsd#orka_FairmountsOwnershipInterestInParagonMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="orka_FairmountsOwnershipInterestInParagonMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="orka-20241231.xsd#orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_SubsequentEventsDetailsTable" xlink:href="orka-20241231.xsd#orka_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="orka_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>22
<FILENAME>orka-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 06 01:03:35 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities, convertible preferred stock and stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net loss (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balances (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balances (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net cash operating activities (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash at beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents at end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Nature of the Business and Basis of Presentation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_lbl" xml:lang="en-US">Reverse Recapitalization and Pre-Closing Financing [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DisclosureTextBlockSupplementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_lbl" xml:lang="en-US">Schedule of the Assets and Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Net assets acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Measurements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:href="orka-20241231.xsd#orka_CashEquivalentsAndMarketableSecuritiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CashEquivalentsAndMarketableSecuritiesAbstract_lbl" xml:lang="en-US">Cash equivalents and Marketable Securities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="orka_CashEquivalentsAndMarketableSecuritiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Cash and Cash Equivalents [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesAxis" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_MarketableSecuritiesAxis_lbl" xml:lang="en-US">Marketable Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MarketableSecuritiesAxis" xlink:to="orka_MarketableSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_lbl" xml:lang="en-US">Schedule of Marketable Securities at Estimated Fair Value [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_MarketableSecurities_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl0" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableAbstract_lbl" xml:lang="en-US">Note Payable with Related Party [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_NotesPayableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl" xml:lang="en-US">Convertible Preferred Stock and Stockholders&#8217; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Stock-Based Compensation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Stock Options Outstanding, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Beginning Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">Ending Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Unvested balance, Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Grant Date Fair Value, Unvested balance, Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Beginning Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Ending Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0" xml:lang="en-US">Aggregate Intrinsic Value, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_lbl" xml:lang="en-US">Schedule of Loss Before Income Tax Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US">Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Income tax (benefit) expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of Components of the Deferred Tax Assets and Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Schedule of Net Deferred Tax Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl0" xml:lang="en-US">Deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US">Less valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xml:lang="en-US">Schedule of Unrecognized Tax Benefits [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl0" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_OptionAgreementsAndLicenseAgreementsAbstract" xlink:href="orka-20241231.xsd#orka_OptionAgreementsAndLicenseAgreementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OptionAgreementsAndLicenseAgreementsAbstract_lbl" xml:lang="en-US">Option Agreements and License Agreements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OptionAgreementsAndLicenseAgreementsAbstract" xlink:to="orka_OptionAgreementsAndLicenseAgreementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitment and Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Schedule of Company&#8217;s Supplemental Cash Flow Information Related to Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental disclosures of non-cash operating and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Schedule of Company&#8217;s Operating Lease Liabilities Showing the Aggregate Lease Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Future lease payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total discounted lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerUnitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerUnitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerUnitAbstract_lbl" xml:lang="en-US">Net Loss per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerUnitAbstract" xlink:to="us-gaap_EarningsPerUnitAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable securities, current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl0" xml:lang="en-US">Due in one year or less</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_SubscriptionReceivables" xlink:href="orka-20241231.xsd#orka_SubscriptionReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SubscriptionReceivables_lbl" xml:lang="en-US">Subscription receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SubscriptionReceivables" xlink:to="orka_SubscriptionReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xml:lang="en-US">Marketable securities, long-term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl0" xml:lang="en-US">Due in 1-2 years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability, current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Less: current portion of lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Related party accounts payable and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl0" xml:lang="en-US">Accounts payable and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Non-current portion of lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US">Operating lease liability, noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 13)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US">Convertible preferred stock, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US">Convertible preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US">Convertible preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US">Convertible preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Convertible preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Series B non-voting convertible preferred stock, $0.001 par value; 251,504 and no shares authorized as of December 31, 2024 and February 6, 2024, respectively; 137,138 and no shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Carrying Value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Non-voting convertible preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Non-voting convertible preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Non-voting convertible preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Non-voting convertible preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl1" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 and $0.001 par value as of December 31, 2024 and February 6, 2024, respectively; 545,000,000 and 65,000,000 shares authorized, 37,440,510 and 3,197,975 shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development personnel-related expense (excluding stock-based compensation)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xml:lang="en-US">Related party amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesRelatedParty" xlink:to="us-gaap_CostsAndExpensesRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and administrative personnel-related expense (excluding stock-based compensation)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Unrealized loss on marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share attributable to stockholders, basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Loss per share &#8211; Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share attributable to stockholders, diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Loss per share &#8211; Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted-average shares used in computing net loss per share attributable to stockholders, basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted average shares outstanding &#8211; Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted-average shares used in computing net loss per share attributable to stockholders, diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted average shares outstanding &#8211; Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of Series A convertible preferred stock, net of issuance costs of $69</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="orka-20241231.xsd#orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of Series A convertible preferred stock, net of issuance costs of $69 (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" xlink:href="orka-20241231.xsd#orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts_lbl" xml:lang="en-US">Issuance of Series A Convertible Preferred Stock, Net of Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" xlink:to="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="orka-20241231.xsd#orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse capitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="orka-20241231.xsd#orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse capitalization (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos_lbl" xml:lang="en-US">Issuance of common stock and pre-funded warrants in the Pre-Closing Financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" xlink:to="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost_lbl" xml:lang="en-US">Issuance of common stock and pre-funded warrants in the Pre-Closing Financing (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" xlink:to="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe_lbl" xml:lang="en-US">Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" xlink:to="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger_lbl" xml:lang="en-US">Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" xlink:to="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr_lbl" xml:lang="en-US">Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" xlink:to="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant_lbl" xml:lang="en-US">Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" xlink:to="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceCostOfPIPEFinancing" xlink:href="orka-20241231.xsd#orka_IssuanceCostOfPIPEFinancing"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_IssuanceCostOfPIPEFinancing_lbl" xml:lang="en-US">Issuance costs of PIPE Financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceCostOfPIPEFinancing" xlink:to="orka_IssuanceCostOfPIPEFinancing_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" xlink:href="orka-20241231.xsd#orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock_lbl" xml:lang="en-US">Conversion of Series A non-voting convertible preferred stock to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" xlink:to="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" xlink:href="orka-20241231.xsd#orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares_lbl" xml:lang="en-US">Conversion of Series A non-voting convertible preferred stock to common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" xlink:to="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US">Issuance of common stock under employee stock purchase plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Reclassification of the Paruka warrant from liability to equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US">Non-cash interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Non-cash lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xml:lang="en-US">Related party accounts payable and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Proceeds from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl0" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from issuance of notes payable to related party, net of issuance costs paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xml:lang="en-US">Proceeds from the Pre-Closing Financing, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from the PIPE Financing, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CashAcquiredInConnectionWithTheReverseRecapitalization" xlink:href="orka-20241231.xsd#orka_CashAcquiredInConnectionWithTheReverseRecapitalization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_CashAcquiredInConnectionWithTheReverseRecapitalization_lbl" xml:lang="en-US">Cash acquired in connection with the reverse recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CashAcquiredInConnectionWithTheReverseRecapitalization" xlink:to="orka_CashAcquiredInConnectionWithTheReverseRecapitalization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability arising from obtaining operating right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1_lbl" xml:lang="en-US">Assets acquired in connection with the reverse capitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" xlink:href="orka-20241231.xsd#orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock_lbl" xml:lang="en-US">Non-cash accrued interest on convertible note converted to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" xlink:to="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock" xlink:href="orka-20241231.xsd#orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock_lbl" xml:lang="en-US">Non-cash exchange of Pre-Merger Oruka Series A preferred stock for Series B convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock" xlink:to="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Conversion of Series A non-voting convertible preferred stock to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity" xlink:href="orka-20241231.xsd#orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity_lbl" xml:lang="en-US">Reclassification of the Paruka warrant from liability to equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity" xlink:to="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Issuance costs of Pre-Closing Financing and reverse recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US">Net accretion of premiums and discounts on marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Other non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Purchases of marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_lbl" xml:lang="en-US">Other liabilities assumed in connection with the reverse recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl0" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesAConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesAConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesAConvertiblePreferredStockMember" xlink:to="orka_SeriesAConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Non-Voting Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Series A Non-Voting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember_lbl1" xml:lang="en-US">Series A Non-Voting Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:href="orka-20241231.xsd#orka_SeriesBNonVotingConvertiblePreferredStockAmountMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember_lbl" xml:lang="en-US">Series B Non-Voting Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember_lbl0" xml:lang="en-US">Series B Non-Voting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xml:lang="en-US">Research and development stock-based compensation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl2" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1" xml:lang="en-US">General and administrative stock-based compensation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseMember_lbl" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseMember" xlink:to="us-gaap_InterestExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockholdersMember" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockholdersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockholdersMember_lbl" xml:lang="en-US">Series A Non-Voting Convertible Preferred Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesANonVotingConvertiblePreferredStockholdersMember" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockholdersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember" xlink:href="orka-20241231.xsd#orka_SeriesBNonVotingConvertiblePreferredStockholdersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember_lbl" xml:lang="en-US">Series B Non-Voting Convertible Preferred Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl0" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Gain (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Nature of the Business and Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xml:lang="en-US">Reverse Recapitalization and Pre-Closing Financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US">Schedule of the Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Hierarchy for Financial Assets Measured</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xml:lang="en-US">Marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesCurrentAbstract_lbl" xml:lang="en-US">Marketable securities, current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesCurrentAbstract" xlink:to="us-gaap_DebtSecuritiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesNoncurrentAbstract_lbl" xml:lang="en-US">Marketable securities, long-term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesNoncurrentAbstract" xlink:to="us-gaap_DebtSecuritiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_FairValueCashEquivalentsAndMarketableSecurities" xlink:href="orka-20241231.xsd#orka_FairValueCashEquivalentsAndMarketableSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_FairValueCashEquivalentsAndMarketableSecurities_lbl" xml:lang="en-US">Cash equivalents and marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairValueCashEquivalentsAndMarketableSecurities" xlink:to="orka_FairValueCashEquivalentsAndMarketableSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Cash Equivalents and marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Schedule of Cash Equivalents and Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Amortized Cost, Cash Equivalents and Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US">Fair Value, Cash Equivalents and Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of Available-for-Sale Securities in an Unrealized Loss Position</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xml:lang="en-US">Less than 12 months, Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xml:lang="en-US">12 months or longer, Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xml:lang="en-US">12 months or longer, Unrealized Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xml:lang="en-US">Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xml:lang="en-US">Schedule of Marketable Securities at Estimated Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Accrued employee compensation and benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued professional and consulting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_AccruedResearchAndDevelopment" xlink:href="orka-20241231.xsd#orka_AccruedResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_AccruedResearchAndDevelopment_lbl" xml:lang="en-US">Accrued research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AccruedResearchAndDevelopment" xlink:to="orka_AccruedResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Note Payable with Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Preferred Stock and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfConvertiblePreferredStockTableTextBlock" xlink:href="orka-20241231.xsd#orka_ScheduleOfConvertiblePreferredStockTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ScheduleOfConvertiblePreferredStockTableTextBlock_lbl" xml:lang="en-US">Schedule of Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfConvertiblePreferredStockTableTextBlock" xlink:to="orka_ScheduleOfConvertiblePreferredStockTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock Issuable Upon Conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Total shares of common stock reserved</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1" xml:lang="en-US">Shares reserved for future issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:href="orka-20241231.xsd#orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US">Schedule of Common Stock Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in Years), Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Stock Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Stock Options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Stock Options, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of Stock Options Outstanding, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Vested and expected to vest, September 30, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in Years), Vested and expected to vest, September 30, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Stock Options Outstanding, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Exercisable,</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in Years), Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of RSA Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Unvested balance, Number of Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Number of Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock" xlink:href="orka-20241231.xsd#orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock_lbl" xml:lang="en-US">Schedule of Employee Warrant Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock" xlink:to="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average,Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_lbl" xml:lang="en-US">Number of Employee Warrants Outstanding, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised" xlink:href="orka-20241231.xsd#orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised" xlink:to="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of Employee Warrants Outstanding, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Ending Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of Employee Warrants Outstanding, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding_lbl" xml:lang="en-US">Number of Employee Warrants Outstanding, Vested and exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Vested and exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable" xlink:href="orka-20241231.xsd#orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested and exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable" xlink:to="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Company&#8217;s Stock-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Total stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US">Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Disclosures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US">Schedule of Segment Loss from Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of Loss Before Income Tax Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Domestic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and development credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of the Deferred Tax Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0" xml:lang="en-US">Tax credit carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" xml:lang="en-US">Accruals and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_DeferredTaxAssetsLeaseLiabilities" xlink:href="orka-20241231.xsd#orka_DeferredTaxAssetsLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_DeferredTaxAssetsLeaseLiabilities_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DeferredTaxAssetsLeaseLiabilities" xlink:to="orka_DeferredTaxAssetsLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intangibles</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Capitalized R&amp;D expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US">Deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US">Schedule of Net Deferred Tax Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US">Changes related to tax positions taken in the current year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OptionAgreementsAndLicenseAgreementsTextBlock" xlink:href="orka-20241231.xsd#orka_OptionAgreementsAndLicenseAgreementsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OptionAgreementsAndLicenseAgreementsTextBlock_lbl" xml:lang="en-US">Option Agreements and License Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OptionAgreementsAndLicenseAgreementsTextBlock" xlink:to="orka_OptionAgreementsAndLicenseAgreementsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitment and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xml:lang="en-US">Schedule of Company&#8217;s Supplemental Cash Flow Information Related to Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Company&#8217;s Operating Lease Liabilities Showing the Aggregate Lease Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total anti-dilutive securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Related Party Accounts Payable and Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_lbl" xml:lang="en-US">Accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xml:lang="en-US">Less than 12 months, Unrealized Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xml:lang="en-US">Unrealized Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Tax benefit derived by applying the federal statutory rate to income before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Permanent differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in the valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="orka-20241231.xsd#orka_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="orka_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US">Right- of- use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="orka_DeferredTaxLiabilitiesRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer and office equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money market funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US">US Treasury Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl0" xml:lang="en-US">Treasury Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl1" xml:lang="en-US">U.S. treasury securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xml:lang="en-US">US Government Agency Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl0" xml:lang="en-US">U.S. government agency securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US">Commercial Papers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommercialPaperMember_lbl0" xml:lang="en-US">Commercial papers	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommercialPaperMember_lbl1" xml:lang="en-US">Commercial papers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US">Corporate Debt Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl0" xml:lang="en-US">Corporate debt securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsMember_lbl" xml:lang="en-US">Cash Equivalents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesMember" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_MarketableSecuritiesMember_lbl" xml:lang="en-US">Marketable Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MarketableSecuritiesMember" xlink:to="orka_MarketableSecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesLongTermMember" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesLongTermMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_MarketableSecuritiesLongTermMember_lbl" xml:lang="en-US">Marketable Securities,Long-Term [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MarketableSecuritiesLongTermMember" xlink:to="orka_MarketableSecuritiesLongTermMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesCurrentMember" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesCurrentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_MarketableSecuritiesCurrentMember_lbl" xml:lang="en-US">Marketable securities, current [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MarketableSecuritiesCurrentMember" xlink:to="orka_MarketableSecuritiesCurrentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_USGovernmentAgencySecuritiesMember" xlink:href="orka-20241231.xsd#orka_USGovernmentAgencySecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_USGovernmentAgencySecuritiesMember_lbl" xml:lang="en-US">U.S. government agency securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_USGovernmentAgencySecuritiesMember" xlink:to="orka_USGovernmentAgencySecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesNoncurrentMember" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesNoncurrentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_MarketableSecuritiesNoncurrentMember_lbl" xml:lang="en-US">Marketable securities, long-term [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MarketableSecuritiesNoncurrentMember" xlink:to="orka_MarketableSecuritiesNoncurrentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesBConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBConvertiblePreferredStockMember" xlink:to="orka_SeriesBConvertiblePreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_SeriesBConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Shares issuable on conversion of Company Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBConvertiblePreferredStockMember" xlink:to="orka_SeriesBConvertiblePreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_PrefundedWarrantsMember" xlink:href="orka-20241231.xsd#orka_PrefundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_PrefundedWarrantsMember_lbl" xml:lang="en-US">Pre-funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PrefundedWarrantsMember" xlink:to="orka_PrefundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaWarrantObligationMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantObligationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ParukaWarrantObligationMember_lbl" xml:lang="en-US">Paruka Warrant Obligation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParukaWarrantObligationMember" xlink:to="orka_ParukaWarrantObligationMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_ParukaWarrantObligationMember_lbl0" xml:lang="en-US">Paruka warrant obligation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParukaWarrantObligationMember" xlink:to="orka_ParukaWarrantObligationMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Outstanding and Issued Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Stock Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockOptionMember_lbl1" xml:lang="en-US">Stock options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl2" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl2"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_EmployeeWarrantsMember_lbl" xml:lang="en-US">Employee Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EmployeeWarrantsMember" xlink:to="orka_EmployeeWarrantsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_EmployeeWarrantsMember_lbl0" xml:lang="en-US">Employee warrants	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EmployeeWarrantsMember" xlink:to="orka_EmployeeWarrantsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_TwoThousandTwentyFourStockIncentivePlanMember" xlink:href="orka-20241231.xsd#orka_TwoThousandTwentyFourStockIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_TwoThousandTwentyFourStockIncentivePlanMember_lbl" xml:lang="en-US">2024 Stock Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TwoThousandTwentyFourStockIncentivePlanMember" xlink:to="orka_TwoThousandTwentyFourStockIncentivePlanMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_TwoThousandTwentyFourStockIncentivePlanMember_lbl0" xml:lang="en-US">Two Thousand Twenty Four Stock Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TwoThousandTwentyFourStockIncentivePlanMember" xlink:to="orka_TwoThousandTwentyFourStockIncentivePlanMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember" xlink:href="orka-20241231.xsd#orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US">2024 Employee Stock Purchase Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember" xlink:to="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock Award [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl0" xml:lang="en-US">Restricted Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_RestrictedStockMember_lbl1" xml:lang="en-US">RSA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeStockPurchasePlanMember" xlink:href="orka-20241231.xsd#orka_EmployeeStockPurchasePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US">Employee stock purchase plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EmployeeStockPurchasePlanMember" xlink:to="orka_EmployeeStockPurchasePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OperatingExpenseExcludingStockBasedCompensationMember" xlink:href="orka-20241231.xsd#orka_OperatingExpenseExcludingStockBasedCompensationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OperatingExpenseExcludingStockBasedCompensationMember_lbl" xml:lang="en-US">Operating Expense Excluding StockBased Compensation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OperatingExpenseExcludingStockBasedCompensationMember" xlink:to="orka_OperatingExpenseExcludingStockBasedCompensationMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_OperatingExpenseExcludingStockBasedCompensationMember_lbl0" xml:lang="en-US">Operating Expense Excluding Personnel Related And Stock Based Compensation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OperatingExpenseExcludingStockBasedCompensationMember" xlink:to="orka_OperatingExpenseExcludingStockBasedCompensationMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ExternalMember" xlink:href="orka-20241231.xsd#orka_ExternalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ExternalMember_lbl" xml:lang="en-US">External [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ExternalMember" xlink:to="orka_ExternalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OtherMember" xlink:href="orka-20241231.xsd#orka_OtherMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OtherMember_lbl" xml:lang="en-US">Other [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OtherMember" xlink:to="orka_OtherMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember" xlink:href="orka-20241231.xsd#orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember_lbl" xml:lang="en-US">Operating Expense Excluding Personnel Related And Stock Based Compensation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember" xlink:to="orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_RestrictedStockAwardsMember" xlink:href="orka-20241231.xsd#orka_RestrictedStockAwardsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_RestrictedStockAwardsMember_lbl" xml:lang="en-US">Restricted Stock Awards	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RestrictedStockAwardsMember" xlink:to="orka_RestrictedStockAwardsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_StockOptionsMember" xlink:href="orka-20241231.xsd#orka_StockOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_StockOptionsMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_StockOptionsMember" xlink:to="orka_StockOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaWarrantMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ParukaWarrantMember_lbl" xml:lang="en-US">Paruka Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParukaWarrantMember" xlink:to="orka_ParukaWarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonReimbursableOptionAgreementsFeesMember" xlink:href="orka-20241231.xsd#orka_ParagonReimbursableOptionAgreementsFeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ParagonReimbursableOptionAgreementsFeesMember_lbl" xml:lang="en-US">Paragon reimbursable Option Agreements&#8217; fees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonReimbursableOptionAgreementsFeesMember" xlink:to="orka_ParagonReimbursableOptionAgreementsFeesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonMilestonePaymentsForOptionAgreementMember" xlink:href="orka-20241231.xsd#orka_ParagonMilestonePaymentsForOptionAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ParagonMilestonePaymentsForOptionAgreementMember_lbl" xml:lang="en-US">Paragon milestone payments for Option Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonMilestonePaymentsForOptionAgreementMember" xlink:to="orka_ParagonMilestonePaymentsForOptionAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonReimbursableOtherResearchExpensesMember" xlink:href="orka-20241231.xsd#orka_ParagonReimbursableOtherResearchExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ParagonReimbursableOtherResearchExpensesMember_lbl" xml:lang="en-US">Paragon reimbursable other research expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonReimbursableOtherResearchExpensesMember" xlink:to="orka_ParagonReimbursableOtherResearchExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonReimbursablePatentExpensesMember" xlink:href="orka-20241231.xsd#orka_ParagonReimbursablePatentExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ParagonReimbursablePatentExpensesMember_lbl" xml:lang="en-US">Paragon reimbursable patent expenses	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonReimbursablePatentExpensesMember" xlink:to="orka_ParagonReimbursablePatentExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xml:lang="en-US">Category of Item Purchased [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Aggregate gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from Issuance of convertible note (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_AdditionalPaidInCapitalTransacationCost" xlink:href="orka-20241231.xsd#orka_AdditionalPaidInCapitalTransacationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_AdditionalPaidInCapitalTransacationCost_lbl" xml:lang="en-US">Additional paid-in capital transaction costs (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AdditionalPaidInCapitalTransacationCost" xlink:to="orka_AdditionalPaidInCapitalTransacationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ExchangeRatio" xlink:href="orka-20241231.xsd#orka_ExchangeRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ExchangeRatio_lbl" xml:lang="en-US">Exchange ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ExchangeRatio" xlink:to="orka_ExchangeRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CommonStocksConversionRatio" xlink:href="orka-20241231.xsd#orka_CommonStocksConversionRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_CommonStocksConversionRatio_lbl" xml:lang="en-US">Conversion ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommonStocksConversionRatio" xlink:to="orka_CommonStocksConversionRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_InvestorsClosingShares" xlink:href="orka-20241231.xsd#orka_InvestorsClosingShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_InvestorsClosingShares_lbl" xml:lang="en-US">Investors shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_InvestorsClosingShares" xlink:to="orka_InvestorsClosingShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Exchange shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Number of shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_PreFundedWarrantsOfCommonStockShares" xlink:href="orka-20241231.xsd#orka_PreFundedWarrantsOfCommonStockShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_PreFundedWarrantsOfCommonStockShares_lbl" xml:lang="en-US">Pre-funded warrants of common stock shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PreFundedWarrantsOfCommonStockShares" xlink:to="orka_PreFundedWarrantsOfCommonStockShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued_lbl" xml:lang="en-US">Warrants exchange</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NumberOfSharesPurchased" xlink:href="orka-20241231.xsd#orka_NumberOfSharesPurchased"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_NumberOfSharesPurchased_lbl" xml:lang="en-US">Aggregate of purchased shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NumberOfSharesPurchased" xlink:to="orka_NumberOfSharesPurchased_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Purchase price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NumberofAggregateShares" xlink:href="orka-20241231.xsd#orka_NumberofAggregateShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_NumberofAggregateShares_lbl" xml:lang="en-US">Aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NumberofAggregateShares" xlink:to="orka_NumberofAggregateShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Convertible shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl0" xml:lang="en-US">Converted shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_PrefundedWarrantstoPurchaseAnAggregateShares" xlink:href="orka-20241231.xsd#orka_PrefundedWarrantstoPurchaseAnAggregateShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_PrefundedWarrantstoPurchaseAnAggregateShares_lbl" xml:lang="en-US">Prefunded warrants to purchase an aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PrefundedWarrantstoPurchaseAnAggregateShares" xlink:to="orka_PrefundedWarrantstoPurchaseAnAggregateShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xml:lang="en-US">Net of issuance costs (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAndCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsAndCash_lbl" xml:lang="en-US">Cash, cash equivalents, and marketable securities (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_InvestmentsAndCash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalDepositInsuranceCorporationPremiumExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FederalDepositInsuranceCorporationPremiumExpense_lbl" xml:lang="en-US">Federal Deposit Insurance Corporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:to="us-gaap_FederalDepositInsuranceCorporationPremiumExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Initial principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Aggregate proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Interest rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Unpaid accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Purchase price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">RSAs price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ClassOfWarrantsExercisable" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ClassOfWarrantsExercisable_lbl" xml:lang="en-US">Warrants exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantsExercisable" xlink:to="orka_ClassOfWarrantsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price per warrant (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Exercise price per warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ClassOfWarrantOrRightExpirationDate" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRightExpirationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ClassOfWarrantOrRightExpirationDate_lbl" xml:lang="en-US">Expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRightExpirationDate" xlink:to="orka_ClassOfWarrantOrRightExpirationDate_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ClassOfWarrantOrRightWarrantsExercised" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRightWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ClassOfWarrantOrRightWarrantsExercised_lbl" xml:lang="en-US">Warrants exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRightWarrantsExercised" xlink:to="orka_ClassOfWarrantOrRightWarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Employee warrants issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Issuance costs (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xml:lang="en-US">Converted shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Converted shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CommonStockConversionRatio" xlink:href="orka-20241231.xsd#orka_CommonStockConversionRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_CommonStockConversionRatio_lbl" xml:lang="en-US">Conversion ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommonStockConversionRatio" xlink:to="orka_CommonStockConversionRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_WarrantsToPurchaseCommonStock" xlink:href="orka-20241231.xsd#orka_WarrantsToPurchaseCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_WarrantsToPurchaseCommonStock_lbl" xml:lang="en-US">Warrant purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_WarrantsToPurchaseCommonStock" xlink:to="orka_WarrantsToPurchaseCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Term of warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares_lbl" xml:lang="en-US">Annual increase in shares available for issuance as a percentage of outstanding diluted stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares" xlink:to="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Purchase price of common stock expressed as a percentage of its fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xml:lang="en-US">Maximum contribution of employee&apos;s eligible compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP" xlink:href="orka-20241231.xsd#orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP_lbl" xml:lang="en-US">Total amount of annual salary that an employee is permitted to utilize to purchase company shares under ESPP</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP" xlink:to="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant-date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">RSAs issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum_lbl" xml:lang="en-US">Warrant To Purchase Number Of Shares As A Percentage Of Outstanding Diluted Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" xlink:to="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum_lbl0" xml:lang="en-US">Warrant purchase percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" xlink:to="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_EstimatedFairValueOfWarrantsToBeGranted" xlink:href="orka-20241231.xsd#orka_EstimatedFairValueOfWarrantsToBeGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_EstimatedFairValueOfWarrantsToBeGranted_lbl" xml:lang="en-US">Estimated fair value of warrants to be granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EstimatedFairValueOfWarrantsToBeGranted" xlink:to="orka_EstimatedFairValueOfWarrantsToBeGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ClassOfWarrantOrRight" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRight"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ClassOfWarrantOrRight_lbl" xml:lang="en-US">Warrants issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRight" xlink:to="orka_ClassOfWarrantOrRight_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Total unrecognized compensation cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Operating segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Reporting segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance due to continuing loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome" xlink:href="orka-20241231.xsd#orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome_lbl" xml:lang="en-US">Operating loss carryforwards as a percentage of taxable income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome" xlink:to="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NonRefundableMilestonePayments" xlink:href="orka-20241231.xsd#orka_NonRefundableMilestonePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_NonRefundableMilestonePayments_lbl" xml:lang="en-US">Non-refundable milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NonRefundableMilestonePayments" xlink:to="orka_NonRefundableMilestonePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_RoyaltyPayableOnProductSales" xlink:href="orka-20241231.xsd#orka_RoyaltyPayableOnProductSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_RoyaltyPayableOnProductSales_lbl" xml:lang="en-US">Royalty payable on product sales, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RoyaltyPayableOnProductSales" xlink:to="orka_RoyaltyPayableOnProductSales_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Initiation fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_DevelopmentCostsPercentage" xlink:href="orka-20241231.xsd#orka_DevelopmentCostsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_DevelopmentCostsPercentage_lbl" xml:lang="en-US">Development costs, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DevelopmentCostsPercentage" xlink:to="orka_DevelopmentCostsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_MilestoneConsiderationPaid" xlink:href="orka-20241231.xsd#orka_MilestoneConsiderationPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_MilestoneConsiderationPaid_lbl" xml:lang="en-US">Milestone consideration paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MilestoneConsiderationPaid" xlink:to="orka_MilestoneConsiderationPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OtherDevelopmentCost" xlink:href="orka-20241231.xsd#orka_OtherDevelopmentCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OtherDevelopmentCost_lbl" xml:lang="en-US">Development costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OtherDevelopmentCost" xlink:to="orka_OtherDevelopmentCost_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ResearchInitialFee" xlink:href="orka-20241231.xsd#orka_ResearchInitialFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ResearchInitialFee_lbl" xml:lang="en-US">Research initial fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ResearchInitialFee" xlink:to="orka_ResearchInitialFee_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0" xml:lang="en-US">Lease initial period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Remaining lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Lease discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseVariableLeaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseVariableLeaseIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseVariableLeaseIncome_lbl" xml:lang="en-US">Variable lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseVariableLeaseIncome" xlink:to="us-gaap_OperatingLeaseVariableLeaseIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NonRefundableLicenseFee" xlink:href="orka-20241231.xsd#orka_NonRefundableLicenseFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_NonRefundableLicenseFee_lbl" xml:lang="en-US">Non-refundable license fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NonRefundableLicenseFee" xlink:to="orka_NonRefundableLicenseFee_lbl"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra9a2jfwGt44jro+lUyqzQL6/x1O9iJrf+dH3ymvrZRNb86/I06x7A9ljBSSeLHwUVO8zSU2wTDcbvo9VMwGaa97CnFY/03o9uN+p3vuWpjO+delTt6UkRTcW0ow0twDKhn42QRPQiXZ8W6BtQZBlbaaE/ZqMIFvXldcHURFnzzSEFkycIw+onLjKElg+fX0XqSMIr7KQdjfiP8BeKLKMGU69+JjAA0fvPQQsyOoCLeXaFG6nwBk5NogH0VTocojq8=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable_lbl" xml:lang="en-US">Weighted-average number of shares of as-converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" xlink:to="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="orka-20241231.xsd#orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk and Other Risks and Uncertainties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US">Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SubscriptionReceivablePolicyTextBlock" xlink:href="orka-20241231.xsd#orka_SubscriptionReceivablePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SubscriptionReceivablePolicyTextBlock_lbl" xml:lang="en-US">Subscription Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SubscriptionReceivablePolicyTextBlock" xlink:to="orka_SubscriptionReceivablePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock_lbl" xml:lang="en-US">Classification of Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock" xlink:to="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NotePayableToRelatedPartyPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_NotePayableToRelatedPartyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_NotePayableToRelatedPartyPolicyTextBlock_lbl" xml:lang="en-US">Note Payable to Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NotePayableToRelatedPartyPolicyTextBlock" xlink:to="orka_NotePayableToRelatedPartyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock_lbl" xml:lang="en-US">Research and Development Contract Costs Accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" xlink:to="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US">General and Administrative Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ComprehensiveLossPolicyPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_ComprehensiveLossPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ComprehensiveLossPolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ComprehensiveLossPolicyPolicyTextBlock" xlink:to="orka_ComprehensiveLossPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Share Attributable to Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OtherIncomeExpenseNetPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_OtherIncomeExpenseNetPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OtherIncomeExpenseNetPolicyTextBlock_lbl" xml:lang="en-US">Other income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OtherIncomeExpenseNetPolicyTextBlock" xlink:to="orka_OtherIncomeExpenseNetPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OrukaCommonStockMember" xlink:href="orka-20241231.xsd#orka_OrukaCommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OrukaCommonStockMember_lbl" xml:lang="en-US">Oruka Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OrukaCommonStockMember" xlink:to="orka_OrukaCommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_PreMergerOrukaMember" xlink:href="orka-20241231.xsd#orka_PreMergerOrukaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_PreMergerOrukaMember_lbl" xml:lang="en-US">Pre-Merger Oruka [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PreMergerOrukaMember" xlink:to="orka_PreMergerOrukaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ARCACommonStockMember" xlink:href="orka-20241231.xsd#orka_ARCACommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ARCACommonStockMember_lbl" xml:lang="en-US">ARCA common stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ARCACommonStockMember" xlink:to="orka_ARCACommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OrukaSeriesAConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_OrukaSeriesAConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OrukaSeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US">Oruka Series A Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OrukaSeriesAConvertiblePreferredStockMember" xlink:to="orka_OrukaSeriesAConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_PIPEFinancingMember" xlink:href="orka-20241231.xsd#orka_PIPEFinancingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_PIPEFinancingMember_lbl" xml:lang="en-US">PIPE Financing [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PIPEFinancingMember" xlink:to="orka_PIPEFinancingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertibleNoteMember" xlink:href="orka-20241231.xsd#orka_ConvertibleNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ConvertibleNoteMember_lbl" xml:lang="en-US">Convertible Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ConvertibleNoteMember" xlink:to="orka_ConvertibleNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_FairmountHealthcareFundIILPMember" xlink:href="orka-20241231.xsd#orka_FairmountHealthcareFundIILPMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_FairmountHealthcareFundIILPMember_lbl" xml:lang="en-US">Fairmount Healthcare Fund II, L.P. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairmountHealthcareFundIILPMember" xlink:to="orka_FairmountHealthcareFundIILPMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_FairmountHealthcareFundIILPMember_lbl0" xml:lang="en-US">Fairmount [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairmountHealthcareFundIILPMember" xlink:to="orka_FairmountHealthcareFundIILPMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_PreFundedWarrantsMember" xlink:href="orka-20241231.xsd#orka_PreFundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre-Funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PreFundedWarrantsMember" xlink:to="orka_PreFundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_FairmountMember" xlink:href="orka-20241231.xsd#orka_FairmountMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_FairmountMember_lbl" xml:lang="en-US">Fairmount [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairmountMember" xlink:to="orka_FairmountMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonMember" xlink:href="orka-20241231.xsd#orka_ParagonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ParagonMember_lbl" xml:lang="en-US">Paragon [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonMember" xlink:to="orka_ParagonMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ClinicalDevelopmentMilestonesMember" xlink:href="orka-20241231.xsd#orka_ClinicalDevelopmentMilestonesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ClinicalDevelopmentMilestonesMember_lbl" xml:lang="en-US">Clinical Development Milestones [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClinicalDevelopmentMilestonesMember" xlink:to="orka_ClinicalDevelopmentMilestonesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_RegulatoryMilestonesMemberMember" xlink:href="orka-20241231.xsd#orka_RegulatoryMilestonesMemberMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_RegulatoryMilestonesMemberMember_lbl" xml:lang="en-US">Regulatory Milestones Member [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RegulatoryMilestonesMemberMember" xlink:to="orka_RegulatoryMilestonesMemberMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ORKAZeroZeroOneLicenseAgreementMember" xlink:href="orka-20241231.xsd#orka_ORKAZeroZeroOneLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ORKAZeroZeroOneLicenseAgreementMember_lbl" xml:lang="en-US">ORKA-001 License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ORKAZeroZeroOneLicenseAgreementMember" xlink:to="orka_ORKAZeroZeroOneLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ORKAZeroZeroTwoLicenseAgreementMember" xlink:href="orka-20241231.xsd#orka_ORKAZeroZeroTwoLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ORKAZeroZeroTwoLicenseAgreementMember_lbl" xml:lang="en-US">ORKA-002 License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ORKAZeroZeroTwoLicenseAgreementMember" xlink:to="orka_ORKAZeroZeroTwoLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NominationOfADevelopmentCandidateMember" xlink:href="orka-20241231.xsd#orka_NominationOfADevelopmentCandidateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_NominationOfADevelopmentCandidateMember_lbl" xml:lang="en-US">Nomination Of A Development Candidate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NominationOfADevelopmentCandidateMember" xlink:to="orka_NominationOfADevelopmentCandidateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember" xlink:href="orka-20241231.xsd#orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember_lbl" xml:lang="en-US">First Dosing of Human Patient in Phase1Trial Milestone [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember" xlink:to="orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ORKAZeroZeroOneMember" xlink:href="orka-20241231.xsd#orka_ORKAZeroZeroOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ORKAZeroZeroOneMember_lbl" xml:lang="en-US">ORKA-001 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ORKAZeroZeroOneMember" xlink:to="orka_ORKAZeroZeroOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ORKAZeroZeroTwoMember" xlink:href="orka-20241231.xsd#orka_ORKAZeroZeroTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ORKAZeroZeroTwoMember_lbl" xml:lang="en-US">ORKA-002 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ORKAZeroZeroTwoMember" xlink:to="orka_ORKAZeroZeroTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_AntibodyProductsMember" xlink:href="orka-20241231.xsd#orka_AntibodyProductsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_AntibodyProductsMember_lbl" xml:lang="en-US">Antibody Products [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AntibodyProductsMember" xlink:to="orka_AntibodyProductsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_AchievementOfDevelopmentCandidateMember" xlink:href="orka-20241231.xsd#orka_AchievementOfDevelopmentCandidateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_AchievementOfDevelopmentCandidateMember_lbl" xml:lang="en-US">Achievement of Development Candidate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AchievementOfDevelopmentCandidateMember" xlink:to="orka_AchievementOfDevelopmentCandidateMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_AchievementOfDevelopmentCandidateMember_lbl0" xml:lang="en-US">Achievement Of Development Candidate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AchievementOfDevelopmentCandidateMember" xlink:to="orka_AchievementOfDevelopmentCandidateMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="stpr_CA_lbl" xml:lang="en-US">California [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaMember" xlink:href="orka-20241231.xsd#orka_ParukaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ParukaMember_lbl" xml:lang="en-US">Paruka [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParukaMember" xlink:to="orka_ParukaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_FairmountsOwnershipInterestInParagonMember" xlink:href="orka-20241231.xsd#orka_FairmountsOwnershipInterestInParagonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_FairmountsOwnershipInterestInParagonMember_lbl" xml:lang="en-US">Fairmount&apos;s Ownership Interest in Paragon [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairmountsOwnershipInterestInParagonMember" xlink:to="orka_FairmountsOwnershipInterestInParagonMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Statement of Income Location, Balance [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Schedule of Property and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable" xlink:href="orka-20241231.xsd#orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable_lbl" xml:lang="en-US">Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets Measured (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable" xlink:to="orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US">Schedule of Fair Value Hierarchy for Financial Assets Measured [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Financial Instruments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xml:lang="en-US">Marketable Securities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xml:lang="en-US">Marketable Securities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_MarketableSecuritiesDomainDomain" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_MarketableSecuritiesDomainDomain_lbl" xml:lang="en-US">MarketableSecuritiesDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MarketableSecuritiesDomainDomain" xlink:to="orka_MarketableSecuritiesDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" xlink:href="orka-20241231.xsd#orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable_lbl" xml:lang="en-US">Cash equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" xlink:to="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" xlink:href="orka-20241231.xsd#orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems_lbl" xml:lang="en-US">Cash equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" xlink:to="orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable" xlink:href="orka-20241231.xsd#orka_ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable_lbl" xml:lang="en-US">Convertible Preferred Stock and Stockholders&#8217; Equity - Schedule of Convertible Preferred Stock (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable" xlink:to="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems_lbl" xml:lang="en-US">Schedule of Convertible Preferred Stock [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:href="orka-20241231.xsd#orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable_lbl" xml:lang="en-US">Convertible Preferred Stock and Stockholders&#8217; Equity - Schedule of Common Stock Reserved for Future Issuance (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:to="orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockLineItems_lbl" xml:lang="en-US">Schedule of Common Stock Reserved for Future Issuance [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="us-gaap_ConversionOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable_lbl" xml:lang="en-US">Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable" xlink:to="orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationScheduleofStockOptionActivityDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofStockOptionActivityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_StockBasedCompensationScheduleofStockOptionActivityDetailsTable_lbl" xml:lang="en-US">Stock-Based Compensation - Schedule of Stock Option Activity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_StockBasedCompensationScheduleofStockOptionActivityDetailsTable" xlink:to="orka_StockBasedCompensationScheduleofStockOptionActivityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationScheduleofRSAActivityDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofRSAActivityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_StockBasedCompensationScheduleofRSAActivityDetailsTable_lbl" xml:lang="en-US">Stock-Based Compensation - Schedule of RSA Activity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_StockBasedCompensationScheduleofRSAActivityDetailsTable" xlink:to="orka_StockBasedCompensationScheduleofRSAActivityDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl0" xml:lang="en-US">Schedule of RSA Activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable_lbl" xml:lang="en-US">Stock-Based Compensation - Schedule of Employee Warrant Activity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable" xlink:to="orka_StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1" xml:lang="en-US">Schedule of Employee Warrant Activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl" xml:lang="en-US">Schedule of Company&#8217;s Stock-Based Compensation Expense [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable_lbl" xml:lang="en-US">Stock-Based Compensation - Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable" xlink:to="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems_lbl" xml:lang="en-US">Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems" xlink:to="orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_lbl" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_lbl" xml:lang="en-US">Schedule of Segment Loss from Operations [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable" xlink:href="orka-20241231.xsd#orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable_lbl" xml:lang="en-US">Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable" xlink:to="orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDilutedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDilutedLineItems_lbl" xml:lang="en-US">Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_EarningsPerShareDilutedLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable" xlink:href="orka-20241231.xsd#orka_RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable_lbl" xml:lang="en-US">Related Party Transactions - Schedule of Related Party Accounts Payable and Other Current Liabilities (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable" xlink:to="orka_RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:href="orka-20241231.xsd#orka_NatureoftheBusinessandBasisofPresentationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NatureoftheBusinessandBasisofPresentationDetailsTable_lbl" xml:lang="en-US">Nature of the Business and Basis of Presentation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="orka_NatureoftheBusinessandBasisofPresentationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Nature of the Business and Basis of Presentation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="orka-20241231.xsd#orka_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="orka_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ChangeInAccountingEstimateLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NotePayablewithRelatedPartyDetailsTable" xlink:href="orka-20241231.xsd#orka_NotePayablewithRelatedPartyDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NotePayablewithRelatedPartyDetailsTable_lbl" xml:lang="en-US">Note Payable with Related Party (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NotePayablewithRelatedPartyDetailsTable" xlink:to="orka_NotePayablewithRelatedPartyDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Note Payable with Related Party [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:href="orka-20241231.xsd#orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable_lbl" xml:lang="en-US">Convertible Preferred Stock and Stockholders&#8217; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl0" xml:lang="en-US">Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_StockBasedCompensationDetailsTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_StockBasedCompensationDetailsTable" xlink:to="orka_StockBasedCompensationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_lbl" xml:lang="en-US">Stock-Based Compensation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Jurisdiction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IncomeTaxesDetailsTable" xlink:href="orka-20241231.xsd#orka_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IncomeTaxesDetailsTable" xlink:to="orka_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IncomeTaxesDetailsLineItems" xlink:href="orka-20241231.xsd#orka_IncomeTaxesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IncomeTaxesDetailsLineItems_lbl" xml:lang="en-US">Income Taxes (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IncomeTaxesDetailsLineItems" xlink:to="orka_IncomeTaxesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xml:lang="en-US">Long-Term Purchase Commitment, Category of Item Purchased [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OptionAgreementsandLicenseAgreementsDetailsTable" xlink:href="orka-20241231.xsd#orka_OptionAgreementsandLicenseAgreementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OptionAgreementsandLicenseAgreementsDetailsTable_lbl" xml:lang="en-US">Option Agreements and License Agreements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="orka_OptionAgreementsandLicenseAgreementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Option Agreements and License Agreements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CommitmentandContingenciesDetailsTable" xlink:href="orka-20241231.xsd#orka_CommitmentandContingenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CommitmentandContingenciesDetailsTable_lbl" xml:lang="en-US">Commitment and Contingencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommitmentandContingenciesDetailsTable" xlink:to="orka_CommitmentandContingenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Commitment and Contingencies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NetLossPerShareDetailsTable" xlink:href="orka-20241231.xsd#orka_NetLossPerShareDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NetLossPerShareDetailsTable_lbl" xml:lang="en-US">Net Loss Per Share (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NetLossPerShareDetailsTable" xlink:to="orka_NetLossPerShareDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xml:lang="en-US">Net Loss per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_RelatedPartyTransactionsDetailsTable" xlink:href="orka-20241231.xsd#orka_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RelatedPartyTransactionsDetailsTable" xlink:to="orka_RelatedPartyTransactionsDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl0" xml:lang="en-US">Related Party Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SubsequentEventsDetailsTable" xlink:href="orka-20241231.xsd#orka_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SubsequentEventsDetailsTable" xlink:to="orka_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Events [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_AccruedResearchAndDevelopment_lbl0" xml:lang="en-US">Accrued research and development.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AccruedResearchAndDevelopment" xlink:to="orka_AccruedResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_AdditionalPaidInCapitalTransacationCost_lbl0" xml:lang="en-US">The amount of additional paid-in capital transacation cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AdditionalPaidInCapitalTransacationCost" xlink:to="orka_AdditionalPaidInCapitalTransacationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_CashAcquiredInConnectionWithTheReverseRecapitalization_lbl0" xml:lang="en-US">Represent the amount of cash acquired in connection with the reverse recapitalization.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CashAcquiredInConnectionWithTheReverseRecapitalization" xlink:to="orka_CashAcquiredInConnectionWithTheReverseRecapitalization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ClassOfWarrantOrRight_lbl0" xml:lang="en-US">Number of warrants or rights issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRight" xlink:to="orka_ClassOfWarrantOrRight_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ClassOfWarrantOrRightExpirationDate_lbl0" xml:lang="en-US">The class of warrant or right expiration date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRightExpirationDate" xlink:to="orka_ClassOfWarrantOrRightExpirationDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum_lbl1" xml:lang="en-US">class of warrant or right to purchase percentage of outstanding diluted stock maximum.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" xlink:to="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ClassOfWarrantOrRightWarrantsExercised_lbl0" xml:lang="en-US">The class of Warrant or Right warrants exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRightWarrantsExercised" xlink:to="orka_ClassOfWarrantOrRightWarrantsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ClassOfWarrantsExercisable_lbl0" xml:lang="en-US">Represent the number of warrants exercisable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantsExercisable" xlink:to="orka_ClassOfWarrantsExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock_lbl0" xml:lang="en-US">Classification of Convertible Preferred Stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock" xlink:to="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_CommonStockConversionRatio_lbl0" xml:lang="en-US">Percentage of common stock conversion ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommonStockConversionRatio" xlink:to="orka_CommonStockConversionRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_CommonStocksConversionRatio_lbl0" xml:lang="en-US">Percentage of common stock conversion ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommonStocksConversionRatio" xlink:to="orka_CommonStocksConversionRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ComprehensiveLossPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Comprehensive loss policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ComprehensiveLossPolicyPolicyTextBlock" xlink:to="orka_ComprehensiveLossPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_DeferredTaxAssetsLeaseLiabilities_lbl0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DeferredTaxAssetsLeaseLiabilities" xlink:to="orka_DeferredTaxAssetsLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_DeferredTaxLiabilitiesRightOfUseAsset_lbl0" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from right of use assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="orka_DeferredTaxLiabilitiesRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl0" xml:lang="en-US">Description of minority interest ownership percentage by noncontrolling owners.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_DevelopmentCostsPercentage_lbl0" xml:lang="en-US">Percentage of development costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DevelopmentCostsPercentage" xlink:to="orka_DevelopmentCostsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP_lbl0" xml:lang="en-US">This item represents the amount of cash contributions during the period made by the entity to the Employee stock purchase plan (ESPP).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP" xlink:to="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_EstimatedFairValueOfWarrantsToBeGranted_lbl0" xml:lang="en-US">Estimated fair value of warrants to be granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EstimatedFairValueOfWarrantsToBeGranted" xlink:to="orka_EstimatedFairValueOfWarrantsToBeGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ExchangeRatio_lbl0" xml:lang="en-US">Exchange ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ExchangeRatio" xlink:to="orka_ExchangeRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_FairValueCashEquivalentsAndMarketableSecurities_lbl0" xml:lang="en-US">Amount of cash equivalents and marketable securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairValueCashEquivalentsAndMarketableSecurities" xlink:to="orka_FairValueCashEquivalentsAndMarketableSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_InvestorsClosingShares_lbl0" xml:lang="en-US">Number of investors closing shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_InvestorsClosingShares" xlink:to="orka_InvestorsClosingShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_IssuanceCostOfPIPEFinancing_lbl0" xml:lang="en-US">Issuance cost of PIPE financing.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceCostOfPIPEFinancing" xlink:to="orka_IssuanceCostOfPIPEFinancing_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos_lbl0" xml:lang="en-US">Issuance of common stock and pre-funded warrants in the preclosing financing, net of offering costs of $[x] million.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" xlink:to="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost_lbl0" xml:lang="en-US">Issuance of common stock and pre-funded warrants in the preclosing financing, net of offering costs of $[x] million.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" xlink:to="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr_lbl0" xml:lang="en-US">Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the Private Placement, net of offering costs of $[x] million.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" xlink:to="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant_lbl0" xml:lang="en-US">Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the Private Placement, net of offering costs of $[x] million.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" xlink:to="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe_lbl0" xml:lang="en-US">Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the Reverse Merger.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" xlink:to="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger_lbl0" xml:lang="en-US">Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the Reverse Merger.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" xlink:to="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts_lbl0" xml:lang="en-US">Issuance of Series A convertible preferred stock, net of issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" xlink:to="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_MilestoneConsiderationPaid_lbl0" xml:lang="en-US">The milestone consideration paid amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MilestoneConsiderationPaid" xlink:to="orka_MilestoneConsiderationPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_NonRefundableLicenseFee_lbl0" xml:lang="en-US">Amount of non refundable license fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NonRefundableLicenseFee" xlink:to="orka_NonRefundableLicenseFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_NonRefundableMilestonePayments_lbl0" xml:lang="en-US">Non-refundable milestone payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NonRefundableMilestonePayments" xlink:to="orka_NonRefundableMilestonePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock_lbl0" xml:lang="en-US">Represent the amount of non-cash accrued interest on convertible note converted to common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" xlink:to="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock_lbl0" xml:lang="en-US">Represent the Non-cash exchange of Pre-Merger Oruka Series A preferred stock for Series B convertible preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock" xlink:to="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_NotePayableToRelatedPartyPolicyTextBlock_lbl0" xml:lang="en-US">Note Payable to Related Party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NotePayableToRelatedPartyPolicyTextBlock" xlink:to="orka_NotePayableToRelatedPartyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_NumberOfSharesPurchased_lbl0" xml:lang="en-US">Number of shares purchased.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NumberOfSharesPurchased" xlink:to="orka_NumberOfSharesPurchased_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_NumberofAggregateShares_lbl0" xml:lang="en-US">Number of aggregate shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NumberofAggregateShares" xlink:to="orka_NumberofAggregateShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome_lbl0" xml:lang="en-US">Operating loss carryforwards that can be utilized in any tax year as a percentage of taxable income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome" xlink:to="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_OptionAgreementsAndLicenseAgreementsTextBlock_lbl0" xml:lang="en-US">The entire disclosure of option agreements and license agreements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OptionAgreementsAndLicenseAgreementsTextBlock" xlink:to="orka_OptionAgreementsAndLicenseAgreementsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_OtherDevelopmentCost_lbl0" xml:lang="en-US">Represent the amount of development costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OtherDevelopmentCost" xlink:to="orka_OtherDevelopmentCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_OtherIncomeExpenseNetPolicyTextBlock_lbl0" xml:lang="en-US">Represents of other income (expense), net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OtherIncomeExpenseNetPolicyTextBlock" xlink:to="orka_OtherIncomeExpenseNetPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_PreFundedWarrantsOfCommonStockShares_lbl0" xml:lang="en-US">Pre-funded warrants of common stock shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PreFundedWarrantsOfCommonStockShares" xlink:to="orka_PreFundedWarrantsOfCommonStockShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_PrefundedWarrantstoPurchaseAnAggregateShares_lbl0" xml:lang="en-US">Number of prefunded warrants to purchase an aggregate shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PrefundedWarrantstoPurchaseAnAggregateShares" xlink:to="orka_PrefundedWarrantstoPurchaseAnAggregateShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Represents of recently adopted accounting pronouncements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity_lbl0" xml:lang="en-US">Represent the amount of reclassification of the paruka warrant from liability to equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity" xlink:to="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock_lbl0" xml:lang="en-US">Research and development contract costs accruals.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" xlink:to="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ResearchInitialFee_lbl0" xml:lang="en-US">The amount of research initial fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ResearchInitialFee" xlink:to="orka_ResearchInitialFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_RoyaltyPayableOnProductSales_lbl0" xml:lang="en-US">Royalty payable on product sales, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RoyaltyPayableOnProductSales" xlink:to="orka_RoyaltyPayableOnProductSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of common stock reserved for future issuance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ScheduleOfConvertiblePreferredStockTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of convertible preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfConvertiblePreferredStockTableTextBlock" xlink:to="orka_ScheduleOfConvertiblePreferredStockTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_lbl0" xml:lang="en-US">Number of Warrants, Exercised (in Shares).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average exercise price as of the grant date of equity-based award plans other than stock (unit) option plans.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Weighted average remaining contractual term for option awards Vested and expected to vest, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest_lbl0" xml:lang="en-US">Fair value of share-based awards for aggregate Intrinsic Value, Vested and expected to vest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Weighted average remaining contractual term for option awards Vested and expected to vest, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">The number of equity-based payment instruments, excluding stock (or unit) options, that Vested and expected to vest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice_lbl0" xml:lang="en-US">The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding_lbl0" xml:lang="en-US">Number of employee warrants outstanding, vested and exercisable shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Vested and Exercisable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares_lbl0" xml:lang="en-US">Share based compensation arrangement diluted stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares" xlink:to="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of Share-Based Payment Arrangement, Warrant Activity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock" xlink:to="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock_lbl0" xml:lang="en-US">Represent the amount of conversion of non-voting convertible preferred stock to common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" xlink:to="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable_lbl0" xml:lang="en-US">Intrinsic value of Vested and exercisable award under share-based payment arrangement. Excludes share and unit options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable" xlink:to="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares_lbl0" xml:lang="en-US">Number of shares conversion of non-voting convertible preferred stock to common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" xlink:to="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_SubscriptionReceivablePolicyTextBlock_lbl0" xml:lang="en-US">Subscription receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SubscriptionReceivablePolicyTextBlock" xlink:to="orka_SubscriptionReceivablePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_SubscriptionReceivables_lbl0" xml:lang="en-US">Amount of subscription receivable from investors who have been allocated common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SubscriptionReceivables" xlink:to="orka_SubscriptionReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Number of shares classified as temporary equity issued during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Number of shares classified as temporary equity issued conversion of convertible securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Value of stock classified as temporary equity conversion of convertible securities during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_WarrantsToPurchaseCommonStock_lbl0" xml:lang="en-US">The shares issued of warrants to purchase common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_WarrantsToPurchaseCommonStock" xlink:to="orka_WarrantsToPurchaseCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised_lbl0" xml:lang="en-US">Weighted average exercise price per share exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised" xlink:to="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl0" xml:lang="en-US">Stockholders&apos; Equity, Reverse Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl0" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl1" xml:lang="en-US">Marketable Securities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl1" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl0" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SeriesAConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Series AConvertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesAConvertiblePreferredStockMember" xlink:to="orka_SeriesAConvertiblePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl0" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_AntibodyProductsMember_lbl0" xml:lang="en-US">Antibody Products Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AntibodyProductsMember" xlink:to="orka_AntibodyProductsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl0" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl0" xml:lang="en-US">Preferred Stock, Convertible, Shares Issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl0" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ClassOfWarrantOrRight_lbl1" xml:lang="en-US">Class Of Warrant Or Right</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRight" xlink:to="orka_ClassOfWarrantOrRight_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl0" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock_lbl1" xml:lang="en-US">Noncash Exchange Of Pre Merger Oruka Series APreferred Stock For Series BConvertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock" xlink:to="orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalDepositInsuranceCorporationPremiumExpense_lbl0" xml:lang="en-US">Federal Deposit Insurance Corporation Premium Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:to="us-gaap_FederalDepositInsuranceCorporationPremiumExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger_lbl1" xml:lang="en-US">Issuance Of Common Stock To Former Stockholders Of ARCABiopharma Inc In Connection With The Closing Ofthe Reverse Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" xlink:to="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfRsaActivityAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfRsaActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfRsaActivityAbstract_lbl" xml:lang="en-US">Schedule Of Rsa Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfRsaActivityAbstract" xlink:to="orka_ScheduleOfRsaActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares_lbl1" xml:lang="en-US">Shock Issued During Period Shares Conversion Of Nonvoting Convertible Preferred Stock To Common Stockin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" xlink:to="orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NotePayableToRelatedPartyPolicyTextBlock_lbl1" xml:lang="en-US">Note Payable To Related Party Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NotePayableToRelatedPartyPolicyTextBlock" xlink:to="orka_NotePayableToRelatedPartyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_WarrantsToPurchaseCommonStock_lbl1" xml:lang="en-US">Warrants To Purchase Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_WarrantsToPurchaseCommonStock" xlink:to="orka_WarrantsToPurchaseCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl0" xml:lang="en-US">Investment Income, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfPropertyAndEquipmentAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="orka_ScheduleOfPropertyAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ParagonReimbursableOptionAgreementsFeesMember_lbl0" xml:lang="en-US">Paragon Reimbursable Option Agreements Fees Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonReimbursableOptionAgreementsFeesMember" xlink:to="orka_ParagonReimbursableOptionAgreementsFeesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_PIPEFinancingMember_lbl0" xml:lang="en-US">PIPEFinancing Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PIPEFinancingMember" xlink:to="orka_PIPEFinancingMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract_lbl" xml:lang="en-US">Schedule Of Available For Sale Securities In An Unrealized Loss Position Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract" xlink:to="orka_ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl0" xml:lang="en-US">Other Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested And Exercisable Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl0" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl1" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember_lbl2" xml:lang="en-US">Series ANon Voting Convertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock_lbl1" xml:lang="en-US">Research And Development Contract Costs Accruals Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" xlink:to="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl0" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl1" xml:lang="en-US">Temporory Equity Issued During Period Shares Conversion Of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_EmployeeStockPurchasePlanMember_lbl0" xml:lang="en-US">Employee Stock Purchase Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EmployeeStockPurchasePlanMember" xlink:to="orka_EmployeeStockPurchasePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_PreMergerOrukaMember_lbl0" xml:lang="en-US">Pre Merger Oruka Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PreMergerOrukaMember" xlink:to="orka_PreMergerOrukaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl0" xml:lang="en-US">Payments for Other Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value Hierarchy For Financial Assets Measured Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract" xlink:to="orka_ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfCompanySStockBasedCompensationExpenseAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfCompanySStockBasedCompensationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfCompanySStockBasedCompensationExpenseAbstract_lbl" xml:lang="en-US">Schedule Of Company SStock Based Compensation Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfCompanySStockBasedCompensationExpenseAbstract" xlink:to="orka_ScheduleOfCompanySStockBasedCompensationExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl0" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfCommonStockReservedForFutureIssuanceAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfCommonStockReservedForFutureIssuanceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfCommonStockReservedForFutureIssuanceAbstract_lbl" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfCommonStockReservedForFutureIssuanceAbstract" xlink:to="orka_ScheduleOfCommonStockReservedForFutureIssuanceAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl0" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecurities_lbl0" xml:lang="en-US">Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_lbl0" xml:lang="en-US">Noncash or Part Noncash Acquisition, Other Liabilities Assumed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl1" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_RoyaltyPayableOnProductSales_lbl1" xml:lang="en-US">Royalty Payable On Product Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RoyaltyPayableOnProductSales" xlink:to="orka_RoyaltyPayableOnProductSales_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl2" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl0" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember_lbl1" xml:lang="en-US">Series BNon Voting Convertible Preferred Stock Amount Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SeriesBConvertiblePreferredStockMember_lbl1" xml:lang="en-US">Series BConvertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBConvertiblePreferredStockMember" xlink:to="orka_SeriesBConvertiblePreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl1" xml:lang="en-US">Temporory Equity Issued During Period Value Conversion Of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_RegulatoryMilestonesMemberMember_lbl0" xml:lang="en-US">Regulatory Milestones Member Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RegulatoryMilestonesMemberMember" xlink:to="orka_RegulatoryMilestonesMemberMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl0" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl2" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OrukaSeriesAConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Oruka Series AConvertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OrukaSeriesAConvertiblePreferredStockMember" xlink:to="orka_OrukaSeriesAConvertiblePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseVariableLeaseIncome_lbl0" xml:lang="en-US">Operating Lease, Variable Lease Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseVariableLeaseIncome" xlink:to="us-gaap_OperatingLeaseVariableLeaseIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl0" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract_lbl" xml:lang="en-US">Schedule Of Anti Dilutive Effect Excluded From Potential Computation Of Diluted Net Loss Per Share Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract" xlink:to="orka_ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl0" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos_lbl1" xml:lang="en-US">Issuance Of Common Stock And Prefunded Warrants In The Preclosing Financing Net Of Offering Cos</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" xlink:to="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NonRefundableLicenseFee_lbl1" xml:lang="en-US">Non Refundable License Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NonRefundableLicenseFee" xlink:to="orka_NonRefundableLicenseFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl0" xml:lang="en-US">Proceeds from Issuance of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued_lbl0" xml:lang="en-US">Class of Warrant or Right, Unissued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_RestrictedStockAwardsMember_lbl0" xml:lang="en-US">Restricted Stock Awards Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RestrictedStockAwardsMember" xlink:to="orka_RestrictedStockAwardsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl0" xml:lang="en-US">Conversion of Stock, Amount Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Outstanding Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl0" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfConvertiblePreferredStockAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfConvertiblePreferredStockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfConvertiblePreferredStockAbstract_lbl" xml:lang="en-US">Schedule Of Convertible Preferred Stock Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfConvertiblePreferredStockAbstract" xlink:to="orka_ScheduleOfConvertiblePreferredStockAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl2" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OtherDevelopmentCost_lbl1" xml:lang="en-US">Other Development Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OtherDevelopmentCost" xlink:to="orka_OtherDevelopmentCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ORKAZeroZeroOneLicenseAgreementMember_lbl0" xml:lang="en-US">ORKAZero Zero One License Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ORKAZeroZeroOneLicenseAgreementMember" xlink:to="orka_ORKAZeroZeroOneLicenseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl1" xml:lang="en-US">Description Of Minority Interest Ownership Percentage By Noncontrolling Owners</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ParukaWarrantMember_lbl0" xml:lang="en-US">Paruka Warrant Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParukaWarrantMember" xlink:to="orka_ParukaWarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NumberofAggregateShares_lbl1" xml:lang="en-US">Numberof Aggregate Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NumberofAggregateShares" xlink:to="orka_NumberofAggregateShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl0" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ORKAZeroZeroTwoMember_lbl0" xml:lang="en-US">ORKAZero Zero Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ORKAZeroZeroTwoMember" xlink:to="orka_ORKAZeroZeroTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockholdersMember_lbl0" xml:lang="en-US">Series ANon Voting Convertible Preferred Stockholders Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesANonVotingConvertiblePreferredStockholdersMember" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockholdersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl0" xml:lang="en-US">Temporary Equity, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock_lbl1" xml:lang="en-US">Share Issued During Period Value Conversion Of Nonvoting Convertible Preferred Stock To Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" xlink:to="orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl0" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Granted Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember_lbl0" xml:lang="en-US">Two Thousand Twenty Four Employee Stock Purchase Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember" xlink:to="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfEmployeeWarrantActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfEmployeeWarrantActivityAbstract_lbl" xml:lang="en-US">Schedule Of Employee Warrant Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="orka_ScheduleOfEmployeeWarrantActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_MarketableSecuritiesMember_lbl0" xml:lang="en-US">Marketable Securities Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MarketableSecuritiesMember" xlink:to="orka_MarketableSecuritiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl0" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl0" xml:lang="en-US">Other Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_AccruedResearchAndDevelopment_lbl1" xml:lang="en-US">Accrued Research And Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AccruedResearchAndDevelopment" xlink:to="orka_AccruedResearchAndDevelopment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_AdditionalPaidInCapitalTransacationCost_lbl1" xml:lang="en-US">Additional Paid In Capital Transacation Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AdditionalPaidInCapitalTransacationCost" xlink:to="orka_AdditionalPaidInCapitalTransacationCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember_lbl0" xml:lang="en-US">Series BNon Voting Convertible Preferred Stockholders Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr_lbl1" xml:lang="en-US">Issuance Of Common Stock Series ANonvoting Convertible Preferred Stock And Prefunded Warr</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" xlink:to="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl0" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_DevelopmentCostsPercentage_lbl1" xml:lang="en-US">Development Costs Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DevelopmentCostsPercentage" xlink:to="orka_DevelopmentCostsPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl0" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfConvertiblePreferredStockTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Convertible Preferred Stock Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfConvertiblePreferredStockTableTextBlock" xlink:to="orka_ScheduleOfConvertiblePreferredStockTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ClassOfWarrantOrRightExpirationDate_lbl1" xml:lang="en-US">Class Of Warrant Or Right Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRightExpirationDate" xlink:to="orka_ClassOfWarrantOrRightExpirationDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl0" xml:lang="en-US">Debt Instrument, Increase, Accrued Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl2" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl0" xml:lang="en-US">Payments to Acquire Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_EmployeeWarrantsMember_lbl1" xml:lang="en-US">Employee Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EmployeeWarrantsMember" xlink:to="orka_EmployeeWarrantsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_TwoThousandTwentyFourStockIncentivePlanMember_lbl1" xml:lang="en-US">Two Thousand Twenty Four Stock Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TwoThousandTwentyFourStockIncentivePlanMember" xlink:to="orka_TwoThousandTwentyFourStockIncentivePlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember_lbl0" xml:lang="en-US">First Dosing Of Human Patient In Phase One Trial Milestone Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember" xlink:to="orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesNoncurrentAbstract_lbl0" xml:lang="en-US">Debt Securities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesNoncurrentAbstract" xlink:to="us-gaap_DebtSecuritiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Other Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl1" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl1" xml:lang="en-US">Marketable Securities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl0" xml:lang="en-US">Marketable Securities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CommonStocksConversionRatio_lbl1" xml:lang="en-US">Common Stocks Conversion Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommonStocksConversionRatio" xlink:to="orka_CommonStocksConversionRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OrukaCommonStockMember_lbl0" xml:lang="en-US">Oruka Common Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OrukaCommonStockMember" xlink:to="orka_OrukaCommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl1" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_CA_lbl0" xml:lang="en-US">CALIFORNIA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_FairmountsOwnershipInterestInParagonMember_lbl0" xml:lang="en-US">Fairmounts Ownership Interest In Paragon Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairmountsOwnershipInterestInParagonMember" xlink:to="orka_FairmountsOwnershipInterestInParagonMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Temporary Equity Stock Issued During Period Shares New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialPaperMember_lbl2" xml:lang="en-US">Commercial Paper [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Expected To Vest Outstanding Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ParagonMember_lbl0" xml:lang="en-US">Paragon Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonMember" xlink:to="orka_ParagonMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl0" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock_lbl1" xml:lang="en-US">Noncash Accrued Interest On Convertible Note Converted To Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" xlink:to="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl0" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SubscriptionReceivablePolicyTextBlock_lbl1" xml:lang="en-US">Subscription Receivable Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SubscriptionReceivablePolicyTextBlock" xlink:to="orka_SubscriptionReceivablePolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl0" xml:lang="en-US">Other Nonoperating Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl0" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OtherIncomeExpenseNetPolicyTextBlock_lbl1" xml:lang="en-US">Other Income Expense Net Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OtherIncomeExpenseNetPolicyTextBlock" xlink:to="orka_OtherIncomeExpenseNetPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ClinicalDevelopmentMilestonesMember_lbl0" xml:lang="en-US">Clinical Development Milestones Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClinicalDevelopmentMilestonesMember" xlink:to="orka_ClinicalDevelopmentMilestonesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl0" xml:lang="en-US">Costs and Expenses, Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesRelatedParty" xlink:to="us-gaap_CostsAndExpensesRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl0" xml:lang="en-US">Number of Reportable Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock_lbl1" xml:lang="en-US">Classification Of Convertible Preferred Stock Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock" xlink:to="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_MilestoneConsiderationPaid_lbl1" xml:lang="en-US">Milestone Consideration Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MilestoneConsiderationPaid" xlink:to="orka_MilestoneConsiderationPaid_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OptionAgreementsAndLicenseAgreementsTextBlock_lbl1" xml:lang="en-US">Option Agreements And License Agreements Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OptionAgreementsAndLicenseAgreementsTextBlock" xlink:to="orka_OptionAgreementsAndLicenseAgreementsTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl0" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl1" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe_lbl1" xml:lang="en-US">Issuance Of Common Stock To Former Stockholders Of ARCABiopharma Inc In Connection With The</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" xlink:to="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseMember_lbl0" xml:lang="en-US">Interest Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseMember" xlink:to="us-gaap_InterestExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares_lbl1" xml:lang="en-US">Share Based Compensation Arrangement Percentage Of Annual Increase In Shares Reserved For Issuance As Percentage Of Outstanding Diluted Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares" xlink:to="orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_PrefundedWarrantstoPurchaseAnAggregateShares_lbl1" xml:lang="en-US">Prefunded Warrantsto Purchase An Aggregate Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PrefundedWarrantstoPurchaseAnAggregateShares" xlink:to="orka_PrefundedWarrantstoPurchaseAnAggregateShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_FairmountMember_lbl0" xml:lang="en-US">Fairmount Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairmountMember" xlink:to="orka_FairmountMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract_lbl" xml:lang="en-US">Schedule Of Weighted Average Assumptions Used In Calculating The Fair Value Of The Awards Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract" xlink:to="orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_FairValueCashEquivalentsAndMarketableSecurities_lbl1" xml:lang="en-US">Fair Value Cash Equivalents And Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairValueCashEquivalentsAndMarketableSecurities" xlink:to="orka_FairValueCashEquivalentsAndMarketableSecurities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl2" xml:lang="en-US">US Treasury Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_FairmountHealthcareFundIILPMember_lbl1" xml:lang="en-US">Fairmount Healthcare Fund IILPMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairmountHealthcareFundIILPMember" xlink:to="orka_FairmountHealthcareFundIILPMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity_lbl1" xml:lang="en-US">Reclassification Of The Paruka Warrant From Liability To Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity" xlink:to="orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_MarketableSecuritiesLongTermMember_lbl0" xml:lang="en-US">Marketable Securities Long Term Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MarketableSecuritiesLongTermMember" xlink:to="orka_MarketableSecuritiesLongTermMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl0" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested And Exercisable Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfStockOptionActivityAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfStockOptionActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfStockOptionActivityAbstract_lbl" xml:lang="en-US">Schedule Of Stock Option Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfStockOptionActivityAbstract" xlink:to="orka_ScheduleOfStockOptionActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl1" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised_lbl1" xml:lang="en-US">Weighted Aver Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Exercise Price Per Share Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised" xlink:to="orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl1" xml:lang="en-US">Corporate Debt Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl0" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ParukaMember_lbl0" xml:lang="en-US">Paruka Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParukaMember" xlink:to="orka_ParukaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl0" xml:lang="en-US">Proceeds from Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ParagonReimbursablePatentExpensesMember_lbl0" xml:lang="en-US">Paragon Reimbursable Patent Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonReimbursablePatentExpensesMember" xlink:to="orka_ParagonReimbursablePatentExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CashAcquiredInConnectionWithTheReverseRecapitalization_lbl1" xml:lang="en-US">Cash Acquired In Connection With The Reverse Recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CashAcquiredInConnectionWithTheReverseRecapitalization" xlink:to="orka_CashAcquiredInConnectionWithTheReverseRecapitalization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl1" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested And Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable" xlink:to="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Other Current Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome_lbl1" xml:lang="en-US">Operating Loss Carryforwards As APercentage Of Taxable Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome" xlink:to="orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl0" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ORKAZeroZeroTwoLicenseAgreementMember_lbl0" xml:lang="en-US">ORKAZero Zero Two License Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ORKAZeroZeroTwoLicenseAgreementMember" xlink:to="orka_ORKAZeroZeroTwoLicenseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_DeferredTaxLiabilitiesRightOfUseAsset_lbl1" xml:lang="en-US">Deferred Tax Liabilities Right Of Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="orka_DeferredTaxLiabilitiesRightOfUseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_USGovernmentAgencySecuritiesMember_lbl0" xml:lang="en-US">USGovernment Agency Securities Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_USGovernmentAgencySecuritiesMember" xlink:to="orka_USGovernmentAgencySecuritiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_MarketableSecuritiesNoncurrentMember_lbl0" xml:lang="en-US">Marketable Securities Noncurrent Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MarketableSecuritiesNoncurrentMember" xlink:to="orka_MarketableSecuritiesNoncurrentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP_lbl1" xml:lang="en-US">Employee Stock Purchase Plan ESPPCash Contributions To ESPP</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP" xlink:to="orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl1" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl1"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract_lbl" xml:lang="en-US">Schedule Of Basic And Diluted Net Loss Per Share Attributable To Stockholders Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract" xlink:to="orka_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ParagonMilestonePaymentsForOptionAgreementMember_lbl0" xml:lang="en-US">Paragon Milestone Payments For Option Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonMilestonePaymentsForOptionAgreementMember" xlink:to="orka_ParagonMilestonePaymentsForOptionAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NonRefundableMilestonePayments_lbl1" xml:lang="en-US">Non Refundable Milestone Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NonRefundableMilestonePayments" xlink:to="orka_NonRefundableMilestonePayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl0" xml:lang="en-US">Accrued Employee Benefits, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_lbl0" xml:lang="en-US">Interest Expense, Nonoperating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OtherMember_lbl0" xml:lang="en-US">Other Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OtherMember" xlink:to="orka_OtherMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost_lbl1" xml:lang="en-US">Issuance Of Common Stock And Prefunded Warrants In The Preclosing Financing Net Of Offering Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" xlink:to="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl2" xml:lang="en-US">Restricted Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum_lbl2" xml:lang="en-US">Class Of Warrant Or Right To Purchase Percentage Of Outstanding Diluted Stock Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" xlink:to="orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_InvestorsClosingShares_lbl1" xml:lang="en-US">Investors Closing Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_InvestorsClosingShares" xlink:to="orka_InvestorsClosingShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl1" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ParagonReimbursableOtherResearchExpensesMember_lbl0" xml:lang="en-US">Paragon Reimbursable Other Research Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonReimbursableOtherResearchExpensesMember" xlink:to="orka_ParagonReimbursableOtherResearchExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl1" xml:lang="en-US">Accrued Liabilities and Other Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_DeferredTaxAssetsLeaseLiabilities_lbl1" xml:lang="en-US">Deferred Tax Assets Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DeferredTaxAssetsLeaseLiabilities" xlink:to="orka_DeferredTaxAssetsLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ExchangeRatio_lbl1" xml:lang="en-US">Exchange Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ExchangeRatio" xlink:to="orka_ExchangeRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ExternalMember_lbl0" xml:lang="en-US">External Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ExternalMember" xlink:to="orka_ExternalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ORKAZeroZeroOneMember_lbl0" xml:lang="en-US">ORKAZero Zero One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ORKAZeroZeroOneMember" xlink:to="orka_ORKAZeroZeroOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl0" xml:lang="en-US">Money Market Funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl0" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_MarketableSecuritiesAxis_lbl0" xml:lang="en-US">Marketable Securities Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MarketableSecuritiesAxis" xlink:to="orka_MarketableSecuritiesAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_EstimatedFairValueOfWarrantsToBeGranted_lbl1" xml:lang="en-US">Estimated Fair Value Of Warrants To Be Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EstimatedFairValueOfWarrantsToBeGranted" xlink:to="orka_EstimatedFairValueOfWarrantsToBeGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1_lbl0" xml:lang="en-US">Noncash or Part Noncash Acquisition, Other Assets Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xml:lang="en-US">Recently Adopted Accounting Pronouncements Policy Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl0" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl0" xml:lang="en-US">Payments of Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_StockOptionsMember_lbl0" xml:lang="en-US">Stock Options Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_StockOptionsMember" xlink:to="orka_StockOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl2" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NominationOfADevelopmentCandidateMember_lbl0" xml:lang="en-US">Nomination Of ADevelopment Candidate Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NominationOfADevelopmentCandidateMember" xlink:to="orka_NominationOfADevelopmentCandidateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested And Expected To Vest Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl1" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsMember_lbl0" xml:lang="en-US">Cash Equivalents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable_lbl0" xml:lang="en-US">Weighted Average Number of Shares, Contingently Issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" xlink:to="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl1" xml:lang="en-US">Unrecognized Tax Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CommonStockConversionRatio_lbl1" xml:lang="en-US">Common Stock Conversion Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommonStockConversionRatio" xlink:to="orka_CommonStockConversionRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_PrefundedWarrantsMember_lbl0" xml:lang="en-US">Prefunded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PrefundedWarrantsMember" xlink:to="orka_PrefundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ResearchInitialFee_lbl1" xml:lang="en-US">Research Initial Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ResearchInitialFee" xlink:to="orka_ResearchInitialFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl1" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl0" xml:lang="en-US">Marketable Securities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_PreFundedWarrantsMember_lbl0" xml:lang="en-US">Pre Funded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PreFundedWarrantsMember" xlink:to="orka_PreFundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember_lbl0" xml:lang="en-US">Operating Expense Excluding Personnel Related And Stock Based Compensation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember" xlink:to="orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts_lbl1" xml:lang="en-US">Issuance Of Series AConvertible Preferred Stock Net Of Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" xlink:to="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl0" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OperatingExpenseExcludingStockBasedCompensationMember_lbl1" xml:lang="en-US">Operating Expense Excluding Stock Based Compensation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OperatingExpenseExcludingStockBasedCompensationMember" xlink:to="orka_OperatingExpenseExcludingStockBasedCompensationMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NumberOfSharesPurchased_lbl1" xml:lang="en-US">Number Of Shares Purchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NumberOfSharesPurchased" xlink:to="orka_NumberOfSharesPurchased_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl0" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ARCACommonStockMember_lbl0" xml:lang="en-US">ARCACommon Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ARCACommonStockMember" xlink:to="orka_ARCACommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl0" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IssuanceCostOfPIPEFinancing_lbl1" xml:lang="en-US">Issuance Cost Of PIPEFinancing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceCostOfPIPEFinancing" xlink:to="orka_IssuanceCostOfPIPEFinancing_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl0" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl0" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl0" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock_lbl1" xml:lang="en-US">Share Based Payment Arrangement Warrant Activitiy Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock" xlink:to="orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract_lbl" xml:lang="en-US">Schedule Of Award Types Of Company SStock Based Compensation Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract" xlink:to="orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl1" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ParukaWarrantObligationMember_lbl1" xml:lang="en-US">Paruka Warrant Obligation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParukaWarrantObligationMember" xlink:to="orka_ParukaWarrantObligationMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant_lbl1" xml:lang="en-US">Issuance Of Common Stock Series ANonvoting Convertible Preferred Stock And Prefunded Warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" xlink:to="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl0" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SubscriptionReceivables_lbl1" xml:lang="en-US">Subscription Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SubscriptionReceivables" xlink:to="orka_SubscriptionReceivables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ComprehensiveLossPolicyPolicyTextBlock_lbl1" xml:lang="en-US">Comprehensive Loss Policy Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ComprehensiveLossPolicyPolicyTextBlock" xlink:to="orka_ComprehensiveLossPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_PreFundedWarrantsOfCommonStockShares_lbl1" xml:lang="en-US">Pre Funded Warrants Of Common Stock Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PreFundedWarrantsOfCommonStockShares" xlink:to="orka_PreFundedWarrantsOfCommonStockShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ConvertibleNoteMember_lbl0" xml:lang="en-US">Convertible Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ConvertibleNoteMember" xlink:to="orka_ConvertibleNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl0" xml:lang="en-US">Temporary Equity, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_MarketableSecuritiesCurrentMember_lbl0" xml:lang="en-US">Marketable Securities Current Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MarketableSecuritiesCurrentMember" xlink:to="orka_MarketableSecuritiesCurrentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ClassOfWarrantOrRightWarrantsExercised_lbl1" xml:lang="en-US">Class Of Warrant Or Right Warrants Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantOrRightWarrantsExercised" xlink:to="orka_ClassOfWarrantOrRightWarrantsExercised_lbl1"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfSegmentLossFromOperationsAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfSegmentLossFromOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfSegmentLossFromOperationsAbstract_lbl" xml:lang="en-US">Schedule Of Segment Loss From Operations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfSegmentLossFromOperationsAbstract" xlink:to="orka_ScheduleOfSegmentLossFromOperationsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl0" xml:lang="en-US">Interest Expense, Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAndCash_lbl0" xml:lang="en-US">Investments and Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_InvestmentsAndCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl0" xml:lang="en-US">Proceeds from Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl1" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl1" xml:lang="en-US">US Government Agencies Debt Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl0" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_AchievementOfDevelopmentCandidateMember_lbl1" xml:lang="en-US">Achievement Of Development Candidate Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AchievementOfDevelopmentCandidateMember" xlink:to="orka_AchievementOfDevelopmentCandidateMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl1"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract_lbl" xml:lang="en-US">Schedule Of Cash Equivalents And Marketable Securities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="orka_ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesCurrentAbstract_lbl0" xml:lang="en-US">Debt Securities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesCurrentAbstract" xlink:to="us-gaap_DebtSecuritiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ClassOfWarrantsExercisable_lbl1" xml:lang="en-US">Class Of Warrants Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassOfWarrantsExercisable" xlink:to="orka_ClassOfWarrantsExercisable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Related Party Accounts Payable And Other Current Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract" xlink:to="orka_ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>23
<FILENAME>orka-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 06 01:03:35 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedBalanceSheet" roleURI="http://www.orukatx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedComprehensiveIncome" roleURI="http://www.orukatx.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedComprehensiveIncome_Parentheticals" roleURI="http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ShareholdersEquityType2or3" roleURI="http://www.orukatx.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://www.orukatx.com/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConsolidatedCashFlow" roleURI="http://www.orukatx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NatureoftheBusinessandBasisofPresentation" roleURI="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ReverseRecapitalizationandPreClosingFinancing" roleURI="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_FairValueMeasurements" roleURI="http://www.orukatx.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_CashequivalentsandMarketableSecurities" roleURI="http://www.orukatx.com/role/CashequivalentsandMarketableSecurities"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NotePayablewithRelatedParty" roleURI="http://www.orukatx.com/role/NotePayablewithRelatedParty"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConvertiblePreferredStockandStockholdersEquity" roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_StockBasedCompensation" roleURI="http://www.orukatx.com/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SegmentDisclosures" roleURI="http://www.orukatx.com/role/SegmentDisclosures"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_IncomeTaxes" roleURI="http://www.orukatx.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_OptionAgreementsandLicenseAgreements" roleURI="http://www.orukatx.com/role/OptionAgreementsandLicenseAgreements"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_CommitmentandContingencies" roleURI="http://www.orukatx.com/role/CommitmentandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NetLossPerShare" roleURI="http://www.orukatx.com/role/NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_RelatedPartyTransactions" roleURI="http://www.orukatx.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SubsequentEvents" roleURI="http://www.orukatx.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_AccountingPoliciesByPolicy" roleURI="http://www.orukatx.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ReverseRecapitalizationandPreClosingFinancingTables" roleURI="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancingTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_FairValueMeasurementsTables" roleURI="http://www.orukatx.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_CashequivalentsandMarketableSecuritiesTables" roleURI="http://www.orukatx.com/role/CashequivalentsandMarketableSecuritiesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConvertiblePreferredStockandStockholdersEquityTables" roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_StockBasedCompensationTables" roleURI="http://www.orukatx.com/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SegmentDisclosuresTables" roleURI="http://www.orukatx.com/role/SegmentDisclosuresTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_IncomeTaxesTables" roleURI="http://www.orukatx.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_CommitmentandContingenciesTables" roleURI="http://www.orukatx.com/role/CommitmentandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NetLossPerShareTables" roleURI="http://www.orukatx.com/role/NetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_RelatedPartyTransactionsTables" roleURI="http://www.orukatx.com/role/RelatedPartyTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofPropertyandEquipmentTable" roleURI="http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleoftheAssetsandLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" roleURI="http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofCashEquivalentsandMarketableSecuritiesTable" roleURI="http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable" roleURI="http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofMarketableSecuritiesatEstimatedFairValueTable" roleURI="http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofConvertiblePreferredStockTable" roleURI="http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofCommonStockReservedforFutureIssuanceTable" roleURI="http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable" roleURI="http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofStockOptionActivityTable" roleURI="http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofRSAActivityTable" roleURI="http://www.orukatx.com/role/ScheduleofRSAActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofEmployeeWarrantActivityTable" roleURI="http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofCompanysStockBasedCompensationExpenseTable" roleURI="http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable" roleURI="http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofSegmentLossfromOperationsTable" roleURI="http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofLossBeforeIncomeTaxExpenseTable" roleURI="http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable" roleURI="http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofNetDeferredTaxAssetsTable" roleURI="http://www.orukatx.com/role/ScheduleofNetDeferredTaxAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofUnrecognizedTaxBenefitsTable" roleURI="http://www.orukatx.com/role/ScheduleofUnrecognizedTaxBenefitsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable" roleURI="http://www.orukatx.com/role/ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable" roleURI="http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable" roleURI="http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable" roleURI="http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NatureoftheBusinessandBasisofPresentationDetails" roleURI="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NotePayablewithRelatedPartyDetails" roleURI="http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_ConvertiblePreferredStockandStockholdersEquityDetails" roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_StockBasedCompensationDetails" roleURI="http://www.orukatx.com/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SegmentDisclosuresDetails" roleURI="http://www.orukatx.com/role/SegmentDisclosuresDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_IncomeTaxesDetails" roleURI="http://www.orukatx.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_OptionAgreementsandLicenseAgreementsDetails" roleURI="http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_CommitmentandContingenciesDetails" roleURI="http://www.orukatx.com/role/CommitmentandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_NetLossPerShareDetails" roleURI="http://www.orukatx.com/role/NetLossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_RelatedPartyTransactionsDetails" roleURI="http://www.orukatx.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20241231.xsd#orka_r_SubsequentEventsDetails" roleURI="http://www.orukatx.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#ai" roleURI="http://xbrl.sec.gov/dei/role/document/AuditInformation"/>
  <presentationLink xlink:role="http://www.orukatx.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesAConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesAConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesAConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesANonVotingConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:href="orka-20241231.xsd#orka_SeriesBNonVotingConvertiblePreferredStockAmountMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBNonVotingConvertiblePreferredStockAmountMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubscriptionReceivables" xlink:href="orka-20241231.xsd#orka_SubscriptionReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="SubscriptionReceivables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesAConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesAConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesAConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesANonVotingConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:href="orka-20241231.xsd#orka_SeriesBNonVotingConvertiblePreferredStockAmountMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBNonVotingConvertiblePreferredStockAmountMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ConsolidatedComprehensiveIncome" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesANonVotingConvertiblePreferredStockholdersMember" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockholdersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesANonVotingConvertiblePreferredStockholdersMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBNonVotingConvertiblePreferredStockholdersMember" xlink:href="orka-20241231.xsd#orka_SeriesBNonVotingConvertiblePreferredStockholdersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBNonVotingConvertiblePreferredStockholdersMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_InterestExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesRelatedParty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="5.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesANonVotingConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:href="orka-20241231.xsd#orka_SeriesBNonVotingConvertiblePreferredStockAmountMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBNonVotingConvertiblePreferredStockAmountMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="orka-20241231.xsd#orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="orka-20241231.xsd#orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="orka-20241231.xsd#orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" xlink:href="orka-20241231.xsd#orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceCostOfPIPEFinancing" xlink:href="orka-20241231.xsd#orka_IssuanceCostOfPIPEFinancing"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceCostOfPIPEFinancing" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" xlink:href="orka-20241231.xsd#orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" xlink:href="orka-20241231.xsd#orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ShareholdersEquityType2or3_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" xlink:href="orka-20241231.xsd#orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashAcquiredInConnectionWithTheReverseRecapitalization" xlink:href="orka-20241231.xsd#orka_CashAcquiredInConnectionWithTheReverseRecapitalization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="CashAcquiredInConnectionWithTheReverseRecapitalization" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" xlink:href="orka-20241231.xsd#orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock" xlink:href="orka-20241231.xsd#orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReclassificationOfTheParukaWarrantFromLiabilityToEquity" xlink:href="orka-20241231.xsd#orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="ReclassificationOfTheParukaWarrantFromLiabilityToEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/FairValueMeasurements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/CashequivalentsandMarketableSecurities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="CashEquivalentsAndMarketableSecuritiesAbstract" xlink:href="orka-20241231.xsd#orka_CashEquivalentsAndMarketableSecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/NotePayablewithRelatedParty" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/StockBasedCompensation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/SegmentDisclosures" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/OptionAgreementsandLicenseAgreements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="OptionAgreementsAndLicenseAgreementsAbstract" xlink:href="orka-20241231.xsd#orka_OptionAgreementsAndLicenseAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="OptionAgreementsAndLicenseAgreementsTextBlock" xlink:href="orka-20241231.xsd#orka_OptionAgreementsAndLicenseAgreementsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsAndLicenseAgreementsAbstract" xlink:to="OptionAgreementsAndLicenseAgreementsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/CommitmentandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/NetLossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerUnitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerUnitAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerUnitAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/RelatedPartyTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubscriptionReceivablePolicyTextBlock" xlink:href="orka-20241231.xsd#orka_SubscriptionReceivablePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SubscriptionReceivablePolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClassificationOfConvertiblePreferredStockPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ClassificationOfConvertiblePreferredStockPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NotePayableToRelatedPartyPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_NotePayableToRelatedPartyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="NotePayableToRelatedPartyPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ComprehensiveLossPolicyPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_ComprehensiveLossPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ComprehensiveLossPolicyPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherIncomeExpenseNetPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_OtherIncomeExpenseNetPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="OtherIncomeExpenseNetPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="orka-20241231.xsd#orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancingTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/CashequivalentsandMarketableSecuritiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="CashEquivalentsAndMarketableSecuritiesAbstract" xlink:href="orka-20241231.xsd#orka_CashEquivalentsAndMarketableSecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfConvertiblePreferredStockTableTextBlock" xlink:href="orka-20241231.xsd#orka_ScheduleOfConvertiblePreferredStockTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="ScheduleOfConvertiblePreferredStockTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:href="orka-20241231.xsd#orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/StockBasedCompensationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock" xlink:href="orka-20241231.xsd#orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/SegmentDisclosuresTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/CommitmentandContingenciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/NetLossPerShareTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerUnitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerUnitAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerUnitAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerUnitAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable" xlink:href="orka-20241231.xsd#orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract" xlink:to="FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_USTreasurySecuritiesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_CommercialPaperMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_MarketableSecuritiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesNoncurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueCashEquivalentsAndMarketableSecurities" xlink:href="orka-20241231.xsd#orka_FairValueCashEquivalentsAndMarketableSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueCashEquivalentsAndMarketableSecurities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CashEquivalentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MarketableSecuritiesMember" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="MarketableSecuritiesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MarketableSecuritiesLongTermMember" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesLongTermMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="MarketableSecuritiesLongTermMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_USTreasurySecuritiesMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_CommercialPaperMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" xlink:href="orka-20241231.xsd#orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" xlink:href="orka-20241231.xsd#orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract" xlink:to="CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MarketableSecuritiesAxis" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" xlink:to="MarketableSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MarketableSecuritiesDomainDomain" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MarketableSecuritiesAxis" xlink:to="MarketableSecuritiesDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MarketableSecuritiesCurrentMember" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesCurrentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MarketableSecuritiesAxis" xlink:to="MarketableSecuritiesCurrentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MarketableSecuritiesNoncurrentMember" xlink:href="orka-20241231.xsd#orka_MarketableSecuritiesNoncurrentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MarketableSecuritiesAxis" xlink:to="MarketableSecuritiesNoncurrentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="USGovernmentAgencySecuritiesMember" xlink:href="orka-20241231.xsd#orka_USGovernmentAgencySecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="USGovernmentAgencySecuritiesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CommercialPaperMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable" xlink:to="CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_MarketableSecurities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedResearchAndDevelopment" xlink:href="orka-20241231.xsd#orka_AccruedResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedResearchAndDevelopment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfConvertiblePreferredStockAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfConvertiblePreferredStockAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable" xlink:href="orka-20241231.xsd#orka_ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConvertiblePreferredStockAbstract" xlink:to="ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SeriesBConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesBConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBConvertiblePreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_PreferredStockValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCommonStockReservedForFutureIssuanceAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfCommonStockReservedForFutureIssuanceAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:href="orka-20241231.xsd#orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCommonStockReservedForFutureIssuanceAbstract" xlink:to="ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyFourStockIncentivePlanMember" xlink:href="orka-20241231.xsd#orka_TwoThousandTwentyFourStockIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTwentyFourStockIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyFourEmployeeStockPurchasePlanMember" xlink:href="orka-20241231.xsd#orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTwentyFourEmployeeStockPurchasePlanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesBConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesBConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrefundedWarrantsMember" xlink:href="orka-20241231.xsd#orka_PrefundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PrefundedWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ParukaWarrantObligationMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantObligationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="ParukaWarrantObligationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="EmployeeWarrantsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable" xlink:to="us-gaap_ConversionOfStockLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract" xlink:to="StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra9a2jfwGt44jro+lUyqzQL6/x1O9iJrf+dH3ymvrZRNb86/I06x7A9ljBSSeLHwUVO8zSU2wTDcbvo9VMwGaa97CnFY/03o9uN+p3vuWpjO+delTt6UkRTcW0ow0twDKhn42QRPQiXZ8W6BtQZBlbaaE/ZqMIFvXldcHURFnzzSEFkycIw+onLjKElg+fX0XqSMIr7KQdjfiP8BeKLKMGU69+JjAA0fvPQQsyOoCLeXejouv44IJN32220uhWModU=] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="EmployeeWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofStockOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionActivityAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfStockOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationScheduleofStockOptionActivityDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofStockOptionActivityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="StockBasedCompensationScheduleofStockOptionActivityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationScheduleofStockOptionActivityDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationScheduleofStockOptionActivityDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofRSAActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRsaActivityAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfRsaActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationScheduleofRSAActivityDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofRSAActivityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsaActivityAbstract" xlink:to="StockBasedCompensationScheduleofRSAActivityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationScheduleofRSAActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationScheduleofRSAActivityDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfEmployeeWarrantActivityAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfEmployeeWarrantActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="EmployeeWarrantsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable" xlink:href="orka-20241231.xsd#orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised" xlink:href="orka-20241231.xsd#orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompanySStockBasedCompensationExpenseAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfCompanySStockBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanySStockBasedCompensationExpenseAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract" xlink:to="StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ParukaWarrantObligationMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantObligationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="ParukaWarrantObligationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="EmployeeWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_StockOptionMember" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeStockPurchasePlanMember" xlink:href="orka-20241231.xsd#orka_EmployeeStockPurchasePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="EmployeeStockPurchasePlanMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable" xlink:to="StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfSegmentLossFromOperationsAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfSegmentLossFromOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentLossFromOperationsAbstract" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OperatingExpenseExcludingStockBasedCompensationMember" xlink:href="orka-20241231.xsd#orka_OperatingExpenseExcludingStockBasedCompensationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="OperatingExpenseExcludingStockBasedCompensationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ExternalMember" xlink:href="orka-20241231.xsd#orka_ExternalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="ExternalMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherMember" xlink:href="orka-20241231.xsd#orka_OtherMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="OtherMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember" xlink:href="orka-20241231.xsd#orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsLeaseLiabilities" xlink:href="orka-20241231.xsd#orka_DeferredTaxAssetsLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="DeferredTaxAssetsLeaseLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="orka-20241231.xsd#orka_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="DeferredTaxLiabilitiesRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofNetDeferredTaxAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofUnrecognizedTaxBenefitsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_OperatingLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract"/>
    <loc xlink:type="locator" xlink:label="NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable" xlink:href="orka-20241231.xsd#orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDilutedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract" xlink:to="NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable" xlink:to="us-gaap_EarningsPerShareDilutedLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="EmployeeWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedStockAwardsMember" xlink:href="orka-20241231.xsd#orka_RestrictedStockAwardsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="RestrictedStockAwardsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionsMember" xlink:href="orka-20241231.xsd#orka_StockOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="StockOptionsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ParukaWarrantMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="ParukaWarrantMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract" xlink:href="orka-20241231.xsd#orka_ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable" xlink:href="orka-20241231.xsd#orka_RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract" xlink:to="RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ParagonReimbursableOptionAgreementsFeesMember" xlink:href="orka-20241231.xsd#orka_ParagonReimbursableOptionAgreementsFeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ParagonReimbursableOptionAgreementsFeesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ParagonMilestonePaymentsForOptionAgreementMember" xlink:href="orka-20241231.xsd#orka_ParagonMilestonePaymentsForOptionAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ParagonMilestonePaymentsForOptionAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ParagonReimbursableOtherResearchExpensesMember" xlink:href="orka-20241231.xsd#orka_ParagonReimbursableOtherResearchExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ParagonReimbursableOtherResearchExpensesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ParagonReimbursablePatentExpensesMember" xlink:href="orka-20241231.xsd#orka_ParagonReimbursablePatentExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ParagonReimbursablePatentExpensesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:href="orka-20241231.xsd#orka_NatureoftheBusinessandBasisofPresentationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="NatureoftheBusinessandBasisofPresentationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OrukaCommonStockMember" xlink:href="orka-20241231.xsd#orka_OrukaCommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="OrukaCommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreMergerOrukaMember" xlink:href="orka-20241231.xsd#orka_PreMergerOrukaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="PreMergerOrukaMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ARCACommonStockMember" xlink:href="orka-20241231.xsd#orka_ARCACommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="ARCACommonStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrukaSeriesAConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_OrukaSeriesAConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="OrukaSeriesAConvertiblePreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="SeriesANonVotingConvertiblePreferredStockMember" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="PIPEFinancingMember" xlink:href="orka-20241231.xsd#orka_PIPEFinancingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="PIPEFinancingMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesANonVotingConvertiblePreferredStockMember_0" xlink:href="orka-20241231.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesANonVotingConvertiblePreferredStockMember_0" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrefundedWarrantsMember" xlink:href="orka-20241231.xsd#orka_PrefundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PrefundedWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_ClassOfStockLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalPaidInCapitalTransacationCost" xlink:href="orka-20241231.xsd#orka_AdditionalPaidInCapitalTransacationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="AdditionalPaidInCapitalTransacationCost" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeRatio" xlink:href="orka-20241231.xsd#orka_ExchangeRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ExchangeRatio" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStocksConversionRatio" xlink:href="orka-20241231.xsd#orka_CommonStocksConversionRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="CommonStocksConversionRatio" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestorsClosingShares" xlink:href="orka-20241231.xsd#orka_InvestorsClosingShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="InvestorsClosingShares" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreFundedWarrantsOfCommonStockShares" xlink:href="orka-20241231.xsd#orka_PreFundedWarrantsOfCommonStockShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="PreFundedWarrantsOfCommonStockShares" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesPurchased" xlink:href="orka-20241231.xsd#orka_NumberOfSharesPurchased"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="NumberOfSharesPurchased" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberofAggregateShares" xlink:href="orka-20241231.xsd#orka_NumberofAggregateShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="NumberofAggregateShares" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrefundedWarrantstoPurchaseAnAggregateShares" xlink:href="orka-20241231.xsd#orka_PrefundedWarrantstoPurchaseAnAggregateShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="PrefundedWarrantstoPurchaseAnAggregateShares" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_NetIncomeLoss" order="18.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAndCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_InvestmentsAndCash" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="orka-20241231.xsd#orka_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ChangeInAccountingEstimateLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalDepositInsuranceCorporationPremiumExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_FederalDepositInsuranceCorporationPremiumExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="NotePayablewithRelatedPartyDetailsTable" xlink:href="orka-20241231.xsd#orka_NotePayablewithRelatedPartyDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="NotePayablewithRelatedPartyDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotePayablewithRelatedPartyDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotePayablewithRelatedPartyDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PreMergerOrukaMember" xlink:href="orka-20241231.xsd#orka_PreMergerOrukaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="PreMergerOrukaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotePayablewithRelatedPartyDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNoteMember" xlink:href="orka-20241231.xsd#orka_ConvertibleNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleNoteMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotePayablewithRelatedPartyDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FairmountHealthcareFundIILPMember" xlink:href="orka-20241231.xsd#orka_FairmountHealthcareFundIILPMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="FairmountHealthcareFundIILPMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotePayablewithRelatedPartyDetailsTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:href="orka-20241231.xsd#orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="ConvertiblePreferredStockandStockholdersEquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PreMergerOrukaMember" xlink:href="orka-20241231.xsd#orka_PreMergerOrukaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="PreMergerOrukaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PIPEFinancingMember" xlink:href="orka-20241231.xsd#orka_PIPEFinancingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="PIPEFinancingMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FairmountMember" xlink:href="orka-20241231.xsd#orka_FairmountMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="FairmountMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PreFundedWarrantsMember" xlink:href="orka-20241231.xsd#orka_PreFundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PreFundedWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="EmployeeWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ParukaWarrantMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="ParukaWarrantMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfStockLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClassOfWarrantsExercisable" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ClassOfWarrantsExercisable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClassOfWarrantOrRightExpirationDate" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRightExpirationDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ClassOfWarrantOrRightExpirationDate" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClassOfWarrantOrRightWarrantsExercised" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRightWarrantsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ClassOfWarrantOrRightWarrantsExercised" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="14.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockConversionRatio" xlink:href="orka-20241231.xsd#orka_CommonStockConversionRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="CommonStockConversionRatio" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchaseCommonStock" xlink:href="orka-20241231.xsd#orka_WarrantsToPurchaseCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="WarrantsToPurchaseCommonStock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/StockBasedCompensationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsTable" xlink:href="orka-20241231.xsd#orka_StockBasedCompensationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="StockBasedCompensationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyFourStockIncentivePlanMember" xlink:href="orka-20241231.xsd#orka_TwoThousandTwentyFourStockIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTwentyFourStockIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyFourEmployeeStockPurchasePlanMember" xlink:href="orka-20241231.xsd#orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTwentyFourEmployeeStockPurchasePlanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ParukaWarrantObligationMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantObligationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="ParukaWarrantObligationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeWarrantsMember" xlink:href="orka-20241231.xsd#orka_EmployeeWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="EmployeeWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyFourStockIncentivePlanMember_0" xlink:href="orka-20241231.xsd#orka_TwoThousandTwentyFourStockIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="TwoThousandTwentyFourStockIncentivePlanMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares" xlink:href="orka-20241231.xsd#orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeStockPurchasePlanESPPCashContributionsToESPP" xlink:href="orka-20241231.xsd#orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="EmployeeStockPurchasePlanESPPCashContributionsToESPP" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EstimatedFairValueOfWarrantsToBeGranted" xlink:href="orka-20241231.xsd#orka_EstimatedFairValueOfWarrantsToBeGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="EstimatedFairValueOfWarrantsToBeGranted" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClassOfWarrantOrRight" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRight"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="ClassOfWarrantOrRight" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/SegmentDisclosuresDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="orka-20241231.xsd#orka_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsLineItems" xlink:href="orka-20241231.xsd#orka_IncomeTaxesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="IncomeTaxesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLossCarryforwardsAsAPercentageOfTaxableIncome" xlink:href="orka-20241231.xsd#orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="OperatingLossCarryforwardsAsAPercentageOfTaxableIncome" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="OptionAgreementsAndLicenseAgreementsAbstract" xlink:href="orka-20241231.xsd#orka_OptionAgreementsAndLicenseAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="OptionAgreementsandLicenseAgreementsDetailsTable" xlink:href="orka-20241231.xsd#orka_OptionAgreementsandLicenseAgreementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsAndLicenseAgreementsAbstract" xlink:to="OptionAgreementsandLicenseAgreementsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ORKAZeroZeroOneLicenseAgreementMember" xlink:href="orka-20241231.xsd#orka_ORKAZeroZeroOneLicenseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ORKAZeroZeroOneLicenseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ORKAZeroZeroTwoLicenseAgreementMember" xlink:href="orka-20241231.xsd#orka_ORKAZeroZeroTwoLicenseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ORKAZeroZeroTwoLicenseAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ORKAZeroZeroOneMember" xlink:href="orka-20241231.xsd#orka_ORKAZeroZeroOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ORKAZeroZeroOneMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ORKAZeroZeroTwoMember" xlink:href="orka-20241231.xsd#orka_ORKAZeroZeroTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ORKAZeroZeroTwoMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NominationOfADevelopmentCandidateMember" xlink:href="orka-20241231.xsd#orka_NominationOfADevelopmentCandidateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="NominationOfADevelopmentCandidateMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ParagonMember" xlink:href="orka-20241231.xsd#orka_ParagonMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="ParagonMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ParukaWarrantObligationMember" xlink:href="orka-20241231.xsd#orka_ParukaWarrantObligationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="ParukaWarrantObligationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ClinicalDevelopmentMilestonesMember" xlink:href="orka-20241231.xsd#orka_ClinicalDevelopmentMilestonesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="ClinicalDevelopmentMilestonesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegulatoryMilestonesMemberMember" xlink:href="orka-20241231.xsd#orka_RegulatoryMilestonesMemberMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="RegulatoryMilestonesMemberMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember" xlink:href="orka-20241231.xsd#orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AntibodyProductsMember" xlink:href="orka-20241231.xsd#orka_AntibodyProductsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="AntibodyProductsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AchievementOfDevelopmentCandidateMember" xlink:href="orka-20241231.xsd#orka_AchievementOfDevelopmentCandidateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="AchievementOfDevelopmentCandidateMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsandLicenseAgreementsDetailsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NonRefundableMilestonePayments" xlink:href="orka-20241231.xsd#orka_NonRefundableMilestonePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NonRefundableMilestonePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyPayableOnProductSales" xlink:href="orka-20241231.xsd#orka_RoyaltyPayableOnProductSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RoyaltyPayableOnProductSales" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" xlink:href="orka-20241231.xsd#orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsForFees" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DevelopmentCostsPercentage" xlink:href="orka-20241231.xsd#orka_DevelopmentCostsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="DevelopmentCostsPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestoneConsiderationPaid" xlink:href="orka-20241231.xsd#orka_MilestoneConsiderationPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MilestoneConsiderationPaid" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherDevelopmentCost" xlink:href="orka-20241231.xsd#orka_OtherDevelopmentCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="OtherDevelopmentCost" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchInitialFee" xlink:href="orka-20241231.xsd#orka_ResearchInitialFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ResearchInitialFee" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherExpenses" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/CommitmentandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentandContingenciesDetailsTable" xlink:href="orka-20241231.xsd#orka_CommitmentandContingenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentandContingenciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentandContingenciesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="stpr_CA" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentandContingenciesDetailsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseVariableLeaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseVariableLeaseIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseVariableLeaseIncome" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonRefundableLicenseFee" xlink:href="orka-20241231.xsd#orka_NonRefundableLicenseFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="NonRefundableLicenseFee" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/NetLossPerShareDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerUnitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerUnitAbstract"/>
    <loc xlink:type="locator" xlink:label="NetLossPerShareDetailsTable" xlink:href="orka-20241231.xsd#orka_NetLossPerShareDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerUnitAbstract" xlink:to="NetLossPerShareDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareDetailsTable" xlink:to="us-gaap_EarningsPerShareBasicLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="orka-20241231.xsd#orka_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="srt_OwnershipAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ParagonMember" xlink:href="orka-20241231.xsd#orka_ParagonMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ParagonMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ParukaMember" xlink:href="orka-20241231.xsd#orka_ParukaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ParukaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairmountHealthcareFundIILPMember" xlink:href="orka-20241231.xsd#orka_FairmountHealthcareFundIILPMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="FairmountHealthcareFundIILPMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="FairmountsOwnershipInterestInParagonMember" xlink:href="orka-20241231.xsd#orka_FairmountsOwnershipInterestInParagonMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="FairmountsOwnershipInterestInParagonMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="orka-20241231.xsd#orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="orka-20241231.xsd#orka_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/Cover" xlink:type="extended"/>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/AuditInformation" xlink:type="extended"/>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &W! $# 2(  A$! Q$!_\0
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M8'/7*C(YJ(O4Z*B;7+;<Y%)+BV<.@VR*,JZCGH?2KD6J:I=/&TRI=JH('FQ
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M'MR<UI6L@&T<8QC-9T=M= _\>T_3_GD:N)!<QXQ!*./[AJ&7&YL1*#G'-2[
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.\.I^7[H 4@DD\]*UM(N+JZT:RN+Z 07<L"/-$/X'(!(_.DALNT444 %%%%
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M:4PW%IYWELQRWED.N 22<$-R?3BFZ1X2@T>ZM9(KEY8H+-[4I*@)<O)O+$C
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M$ SR$7 Z\\^M6=/L/$%HMM#+JVF2VT05&5--D1V4#'#>>0#[X/TJ]_;.E?\
M02L_^_Z_XT?VSI7_ $$K/_O^O^-'M(?S+[U_F'LY]G]S_P C(;PA"_AA-):Z
M87$,CS6][&FUX)"[,&7GMNP>>1GUJ_=Z/-?'1Y+B[4S6%P)W98L"4[&0X&?E
M^]GOTJQ_;.E?]!*S_P"_Z_XT?VSI7_02L_\ O^O^-'M(?S+[U_F'LY]G]S_R
M+U%4?[9TK_H)6?\ W_7_ !H_MG2O^@E9_P#?]?\ &CVD.Z^]?YA[.?9_<_\
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MX+(0 6C(==I.,G.X9YQ5>#P/IQNHY-3VZM%#;""&._B$NP[BSN2V068D= ,
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M5G_W_7_&C^V=*_Z"5G_W_7_&CVD.Z^]?YC]G/L_N?^1>HJC_ &SI7_02L_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#S[6/_ 'P__P 56ZP\VKH\^>8T(2<7>Z\CT^BO+_\ A9&K_P#/M8_]\/\
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MS_GTT[_OV_\ \71]6J!_:-#S^X]AHKQ[_A:^N?\ /IIW_?M__BZ3_A;&N?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MES^R-5_Z!MY_WX;_  H_LC5?^@;>?]^&_P *^HZ*/KC[#_LV/\Q\M_V/JO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3_XUCEJ:6HY(]A\\^[^]_P"9L?\ "3:Y_P!!K4?_  *?_&D_X2;7?^@UJ/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,HE3S7(S@QD9/0YS@*,=>';6P/17/0J*Y]/$-[=ZO<VVGZ3]IM+.X6VN9_M
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M_MK_ .C7KYVWU]$_#,,/A[I6X$$B4\CL97Q7)B_@7J>EER_>OT.LHHHKS#W
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MJP4$FSYNMAJSJ2:B]V<>6I"]=A_PJ[Q)_=M/^_W_ -:D_P"%6^)/2T_[_?\
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M_O\ ?_6I/^%2>*/2S_[_ /\ ]:CVU/N'U6M_*SB-U(6KM_\ A4GBCTLO^_\
M_P#6I/\ A4?BCTLO^_\ _P#6H]M3_F']5K?RLX<M2%Z[C_A47BGTLO\ O_\
M_6I/^%0^*?2R_P"__P#]:CVU/^8?U6M_*SAM](6KN?\ A4/BGTLO^_\ _P#6
MI/\ A4'BKTLO^_\ _P#6I^VI_P P?5:W\K.%+4A>NZ_X4_XJ]++_ +__ /UJ
MLV7P7\033 7EY96T7=E9I&_ 8 _6E[>GW&L+6_E.'TK3KK6=4M].LXR\\[A5
M'IZD^P')^E?4FE:?%I.DVFGPY,=M$L8)ZG QG\>M8WA3P3I7A* _9$,MTXQ)
M=2@;V'H/0>P_'-=)7GXBM[1V6R/7PN']BKO=A1117,=@4444 %%%% !1110
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M"USK=WBZU&![$3I,B/9 SPE2#B.4,-H)'4J3R>?3IJ*7]?U]P?U_7WA1110
M4444 %%%% %74O\ D%7G_7!__037C+*N25Y(&<#O7L^HX&EW9/3R7_\ 037C
M"%!*7;9R<>^.V?UKHH[,XL5NB:)5P-S$9&<>E>A^!E"Z+.%.1]I;!_X"M>=1
MW*L7PH.TX/->B^!75]#F*C ^T-_Z"M75^$RP]O:'3T445R'I&?KI \/ZD2<
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M7R"!@CH?2NO#[,\G,6TXV\SN].QJ,3WR?NY6.,*QXQZBO5OA^"-"G![73?\
MH*UX?HES<VEV(H1N$K<J?NLOJ#7N?@0@Z+<;3D"Y;_T!:JNK1)P$N:7F=111
M17$>P5-3N/LFE7ESQ^Y@>3GIPI->.:[XO%A>L[!9YI4QO#\)STQV%>M^(BH\
M-:J6D,2BSFS(.JC8>?PKYQDT:V*EY]7ABD9L[)!\VSL3SU/7%=%&*=[G!BYS
M32B=D==L-5TV:WLR99W7'EJ-K-],UWGPPM'L?!ZPR0O$XN')1SD]N]>+Z?KE
MGH4K)80"XR"'GEX+?0=A7M_P[U)M6\++=LH4M,XP#G&,"JJJT2<-)3J7ZV.L
MHHHKE/1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"G/JVFVTS0W&H6L4
MJ_>22958=^034?\ ;NC_ /05L?\ P(3_ !KR_P ;MCQ???\ ;/\ ]%K7.%Z[
M8X9.*=SPZN9SA.45%:/S/<_[>T?_ *"UC_X$)_C1_;VC?]!:P_\  E/\:\*+
MTPM5?5%W(_M:?\J_$]W_ +?T;_H+V'_@2G^-'_"0:-_T%[#_ ,"4_P :\&+T
MTM1]4CW#^U9_RK\3WO\ X2#1?^@O8?\ @2G^-)_PD.B_]!C3_P#P)3_&O B]
M-+4?5(]Q_P!JS_E7XGO_ /PD.B?]!C3_ /P)3_&C_A(M$_Z#.G_^!2?XU\_%
MJ86I_5(]Q_VI/^5?B?0?_"1:'_T&=/\ _ I/\:/^$CT/_H,Z=_X%)_C7ST7I
MI:CZI'N']J3_ )5^)]#_ /"1Z%_T&M._\"D_QI4\0Z+(X1-8T]F/0+<H2?UK
MYT+TTO1]47<?]J3_ )5^)]/*RNH9&#*>00<@TM?.NA^)]3\/7*R65PWEYR\#
M',;_ %']1S7NOA[7K7Q'I,=_:\9.V2,GF-QU!_ST-<U6A*GKT/0PV+C7TV9J
MT445@=@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!1UK_D!:C_ ->TG_H)KY9+$#)Y&>O7%?5.J*'TB]5NC0.#_P!\FOFC5=+3
M3KHPLS&&1-T+]3GT/^?2NK#O<\S'P;LS/25=W0'T)KW/X0R&3PE=$C'^G./_
M "''7A#0F)\"16'4$ _X5[E\&3GP?=Y_Y_W_ /1<=:U_@.7 Z5ODST2BBBN
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9&JJ^#:N8R1UVDEL=NOO4K:X]]#U>BO)K?\ L_\ L[1_[*_Y#7D2_P!L;?\
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M7L#T/5Z*Y;P6BVYUZRA41VMMJDD<$2C"Q+L1MJCL,DG'O74T@"BBB@ HHHH
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MTVOE[\]-N_(W=,TTK@]/Z]3O;?7--NM,EU&.[5;6'<)GE!C,17[P8, 5(]"
M:M6=W!?V4%Y;/YEO/&LD;X(W*1D'!YZ5R.CQVNIVOB2_54GLY;YYK23JC%84
M4NO8C<&P1Z9K9\'?\B5H?_7A!_Z *+:?=^(O^";=1SPBXMY(69U612I:-RC#
M(Z@CD'W%244AF/I_AZ.ROUOI[^]O[F.(P127;(3&A() VJN<X&2<DXZUL444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOQ5FUU5+K]W)$0<<GM6)J/AVXDN=\$@D1VSR>12BE>S"<G]DO6FK7L@7S9Y
MQZ_,:6ZO;WS T=Y/C^Z'I\6GRP6ZH,NW0GJ16;K<TEI$L,:AV; 9LXP,T[*Y
M,FTM2.76]0\X1_;)U![[^0:H7&O:W,<6EY.0N<X?D^]*DY92A/F,&P-_&?\
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MYX8CUI\B[&?MY1W9W=OXH\0Q$1S:_=O,Y)YDP!]*2X\6>(V5EAUNZ,W7'F$
M"L?1H[;4YWW.CMM'ROC(ZY]^^*L:QI5M9,C:?&S.K!A@[<^N<\=Z.5=BE*3C
M>Y8LO&WB6>]%L^K7BS*IW(7P#S^=68_%WB19BCZK>.,<8D-8=O8?:=1^UM+Y
M31\*H R!C!S6M(^Q S#D<!MIYI.*[!&4K;ET^)=?=.=6OLC/28C^1_SBH!XU
MUAB88=9NR01DB8L1[9)]JJ6^711)&R$'G..?RSCM56&:QMKC[.&C$K<X)Y-+
ME1IS2[EG4/''B*VA:<ZK?%5P,)(15&T\=^-;X-/#J4JQ#HKRG)_*K,H5AL2-
M0F/T_G5:2%4/R@+N/)4<C/?ZT<J#FEW*UAXX\9W6L/!/KFHQ+&"7$9R%Q]<\
M=*ZBU\6>()+?>VK7N#]P.Y#$>I^O6N>L[413F5%8NJ %R<M)[?AQ5V^O;;3K
M(2R*9'Z(BG )]S2Y4-2EW-2Y\7ZS:1F5]9O6903Y2R'+8K*7XFZG(RA-6OBS
M#(4$G'L?>N*.JW+7K7:RE)F/0#C'I@TV[U:1H/(:)%)^\R'&119$>U;V.SG^
M)&L1,H_MNZ+/SM\PC;]?3Z4V\\6^+;JT6XL/$-\N!]WS.M<$NG74R+)# [QL
M,JPQ_GM38;V>V#>5(Z'N!W-)I#YWW.A?Q[XYBA\R37M15"2H)?N.M0O\1O&:
M$!O$6H#O@OVZCM67'KEU$F))#*N>4<9!%/D>TO--G?[+'%*B[E:/.!SR#Q4V
M1:G+N:S?$'QHL*,?$&H -DAO,R"/2H3\1?&A''B._P#^_E<KYIPJAOE&>/K5
MZQ1)6<_*?+4MM89!'O\ G2L@YI+J;7_"Q_&BD[O$M]CTWUJ:7\1O$TDMO'=:
M_J3K).OF>6^65 >0,XY-<RC32//]CD<0K&>PX4]>!Q4UM?V]I:3));H\CX16
M P"O.X\=#[]\FA) YR[FWJ/Q(\4O>R&T\07Z1$X"[^%_QJQI7Q \5F&6XGUR
M_G .U(Q)R6_PK(L$TR:Q=;FWDCA5O];$H)9B#M&6/ '<#KZBJEU:SVD#RV\3
M1Q8WY+AM@;L,?SZT[(3E+N=(_P 1/%EGJ0-QKUS)$"&,22 _*>V1W%2^(?''
MBFT$,UMXAOECFP5PYZ8_S^5<'$C3LB+DL3C:.<UT\VDRW/AT6(F$MTA#HAP,
M>H_4TVE82F[[EO2OBCXA@8B^UV]G5L ?/C;SZ_2K>HZU\1[:W^V1:YJ#6;-M
M67S, >F<_7K7&6OAV]&HVT%S#L$DH4@N.F>3[#WKTGQ');ZIX<,5I,(U4M'&
MC,2GR [@.Y("\'W%3;N:)OHSDF\?>-( YD\47+[>!MFR&/'3\^OM5RS\?^,;
M^X6V'B"Z#'.',H3)QW/ %86JZ1_9;6AF/G%T/F*F1M/89QUP0>E0V4$EQ,ZP
M;(UVM^\8XQGIGGU(&?>A)"<Y'76'Q&\2:=>!+C7+N[.=KQ3.,$]P&&,$>N<&
MM3Q/X\UZWT*VU#2]2OT6Z7:':7=Y1S@@CIG@X->=VNF27,%Q(GFO<0$LR(FX
M!!]YL]L$C\ZU94N;?2(X7W;)%W MGY\\%,=<8Y^H%/ET!3DF5X_B7XU((/B.
M_P#KO%6U^(_BR2%-OB341.,A@7X;TQ7'3PO;S;6! /*Y]*?U&=H!S4I%2D^Y
MV=K\1_&1!4ZU?2%ONDN>N.0/6NFN?$GB^'0S,OB"\6>.(.69\@D=0:\_\/W1
MM;Q1O0+(P!5QQ_/BO5;NUBO(BC6ZO#*N)(V'K6B2L1&3;W.+UOXC^+$NHT@U
MJ^A(A1GVRY!)[^W6LZ/XC>,W8+_PD6H;CP!YF/Z4[QQHPMXX+BUC*00IY3*.
M=HSQ[D?Y[UQ\<Q5LJ><$=/6H=K[&CO;1G7M\1/&2$;O$FH<CJ),CTJ4?$GQ9
M(!CQ!?H1@?ZW.:Y '*G<3]*<O' (II(S<I=SN;?XA>*F(W:_?$]_WM;%EXV\
M2W$T<;:W>_.P&3)P*\Y59+>1?.5DR =IX.*V8)U*XC!4D=.IK2*78Y93DNK/
M0SXWU^-%$U]=K+CY!N;YN>O4?UKKK36+^:S62;4KF-Y%^9?-^:,]_P#ZQKRK
M1/L_GEKHMB,$+G^]VXQS4BWSR7#2[B#NR#W%-P3V+C6:U;/8-.L=9GA\^3Q#
M=;-QY#_YQ6A_:#Q/Y1OYI' QN+8S7,>&]1DF\.LTH C$IV[> 3@9_"G&=7FB
M(.5 R6!^Y[5ERZG7&:Y;HP/$FM^)M,U!I8=9NVMI&^XLGW#Z?2LV+QKKT@);
M5;U>W$IP/0G-;'B73#>Q+(B?*3PV[_/-<S8:9#/<AEG"1C^)_ESCJ#SCOVK5
M*-MCDJ.:EHS3/B7Q*T?FC7+I>,A#+@GW /:MC1]:\33"&5]2NF9FVF*1CR/6
MJ-]I<:I9WMM,LJG*[6E"C;ZY(]ZV]/T[276$^6GG1Y&Y922S=@?T_*D[6V*B
MIWW.VL+V^<!;AW!*@\G\ZR-;O=2M)@T=Y,J$$D"0U9T"\:_N6+J1@8)*XP>F
M*U=:TC[=I\BP_P"N4$H,XR?2L%9,[E[T=#S6V\8:G=791[ZZ3:VS"RGUP">U
M9FJ^)_$,=_,EKJ][L1>5$F=M8=U:W%G>+:A9(KH/RF>03[^V!6WH]W(]M=65
M[(KM,I5=Y(93@CK@\<]ZZ.5;GGJI*3Y6[%6'QAX@!S)K=Z?;S#6M9^*-:N=T
M/]J7GG,,HPFXKE;BU^R2>7/%(F<E6[$>U:%DEK#Y<TMQY3KU7G)'8T^5=B%.
M:=KG;:3KNLF+;>7=SN4]6?&X?6N@M=5O&XDN)">Y#'%<CID5V;@EYO/@= 8W
M''\NIYK<CG6)PN,L!GD5E**.RG)V-B2]O1(5^T2X[?/BFO<WMU&\"7D\;L"%
M*N00?7-8\VM6T5Q%',^PMQSWYJ9;S$V]#SV(%3RFO-YG$:IX@\3V$GSZM>KM
M^1E\S^(56@\6^(G>-!J]Z[NP^3S#G%=Q?:39ZS(7F#QF1LR;<$$_E7!ZI9KX
M4U*6*%VGF>,A'9<; >_N:VCROH<56,T^9/0MZ]XPUJUNU@M]7O%*+\X$AZGG
M^6*?H/C#7+G4(HY=4NI%8'@O7&1QW5Y<GY6DN"<ELYS]:[C0?#L=I&DLBG[3
MU)/;CH!5.,4K&2J5)S]UZ'5+J^ILV/MMQR0.&)KDKOQ%KB:Q/ ?$%W%$)#]Z
M0C:,_P">]=!*A"-M'0^G4UP,L]S(;E97RZN6D)&<\X(J(11TU9-1W.G'B*\N
MK9XI=8GN.^WS6&1^!YKG3K<EM,[0R%HP1PPXQ64LFVXC9<#+@GTI[ZDZR;%C
M0!6Y)&>/3Z5JHI'*ZMUJ=]!?I?Z?%/&!M93G<!D'G^HKF-5T*WNM0^TLY (&
M5[-V')JUI4TBP2V^5^95E4=, C)Q^=6+]))( UNW[Y>@(P#ZU&S-T^>%F8=[
MX52\B#VR>0P&.?NGVKUWX6:5'I'A>>WCD+[KMG8GU*(/Z5YUI\US K6TK,ZG
M)W@8')X^IYQ7JW@8DZ)+DY_T@_\ H*UG5;Y;&N'C'GNCIJ***Y3O*FJ;QI-X
M8T9Y! ^U$&2QVG  [FO.M/L=7EU**26SO(HC$6*M"P )(X/'6O4*Y>Q\3SW/
MBVZTV6&)+!O,2SF&=TLD6WS03G'5B!_N-51GRZ$RC?4SI["Z:? M9BN>IC/2
MIXK&X#(I@D"_[AXJ32/&$&H^'X9Y7B74I+22<1B-Q&S*#D*QX)&.0&)'M3[+
MQII#:-!=W]VL$IM8KB4"&0+AMH)3@[E#,!E2<9YJN=BY-;!;6LD,AB6VE"_W
MMIIT^F^;.A,+< _,%(-6)/%>BPE!+<31EE#L)+69?*4G ,F5_=@D<%\9JT^L
M:<MLT_V@!1<&USY;$^;G&,8S^/3'.<<U+DUJ+D3T,K[(]E&5MK1RWKM)Y]:E
MB@NE!=ED+L/[IXI%\7Z-!8V\USJ EWP),\\%I+Y:JW1GP&\H'MO-0VGBVWO=
M2N[7/V06VH+9AIK>0B?,>[@X 4]>3D8 /\0--M[#Y%8MO+/;0EH;25G/^R37
M.7%KJ5W,9)K.9FP3DQ'_  KHU\7: T4TOV[$<433EVAD"O&OWFC)7$@'JF:<
M/%>AF*:0W;KY6S*M!(KN'.$**5RX8\ J#GM0IV)G2YMV<;-IFI #98W )8?=
MA;'\J8-.U6><>;9W7L?)8#^5>@66L6&HQQO:O+())&B_U$@*.HY5P5_=G_>Q
M^M8OB#7Y=-\06VG_ -JZ1I<$EJTQGU%"P9@P&T?O4'0Y[]*KVK[$>P6]S9T^
MU%K:Q1A-IVC/'>I[EVBCS&C.QZ8&:Y'4_%>H:;%?>7+IUZ+?1O[0CN(HV$<K
M;R!@;S\N ._XUH/XPT^XU/1;/3-2TV\DO)RDZ0SK(R*(F;("MQRH'/K4W;?]
M>?\ D;6M_7]=S5C$YR7#9/M4K[TB+!&9@. !4'B35/[!\.7^IK$97MX6=4"L
MV6QQG:"0,]3V]JS+/Q5:6]N/[5U!)+AY(XUCM]-N(W#M'O"["78DCG].M),.
M4K7<^ICS9(;.Z,B@[?W;?I6+N\0O#.7M[XL58!3$WIGCBNM?Q=HH:5$FF>1%
MD*K]FE D9!ED5MN&88.5&2,'C@T[3==34_!T>O$?8U>U,[>;$["+"Y)V\%@/
M;&1TZU2J65[$.DY.USR]='UB3/FZ7?$L>3Y#Y_E5_3])U2"3;]AOT53D%864
ML/3.*] 3Q7H@F%N]Z3*KQQ2.+>41J[J"NYL;5W;AC)[XZT[Q)K)T%--E(7RK
MB]6WE)1G8*58_*%Y+9  X/7I5NJ]K&<<.M[F%!87<4&^2*[D?&53RSA1Z=,U
M5M]0U==X?2+["YV?N&YX^E==9Z_I5_+!%;W):6<R!(VB=&!CQO#!@"I&1PV#
MS5.7QGX>AQOO7.8S*=EM*VU Q0L<+PH92"3P/Q%1[3R-/9]F><7UEKUY?R2'
M3;\(Q& ;=R![]*[6QTN32]/6%;:5R@YV1GYCWK9'BC1"MRWVS MPK/NB<%@Q
MPI0$?.&/ *YR>E1_\)=H7EAC=2JQG^S^4UK*)?,VEMIC*[@2!D<<]J'4OT%&
ME;6YYYJ^G:S<:R;RST^_C.W!_<-CC\*Z/P\VJ3?NKNPN80J\L\3*&)^HKKK?
M5].N=*?4X[E!9QAC))("GE[?O!@P!4C!R" :Q(O&5C)K-U$\HBT^"SCG+S02
M12;V<J!M8 D$ 8P.<\9INI?2PXTK:W&:AI<TIC=8Y<@\[%//UIDMA<M%@6\F
M57(.PY)_*M7_ (2K1?($GVF4L9?)\@6TIGWXW8\K;OZ<_=Z<]*C?Q5H\8:[?
M4X?L(MDGX@<L SE Q;TSQMQD$'-+G97(CGS;ZD=H^QW!Y[Q'C]*T8;"XDV^9
M!(N .JG_  K5_P"$GT;R)93<R*8I%B:)K>02[V&5 C*[VR.1@'/:IM/US3M4
M -E)-*/.:!C]GD&QU&2&ROR_CCGCKQ1SMBY$C/BL/LZ+#!:F*)<X5(\ =_YU
M2U?29;ZQE@,4N&4CY5.3^E7+OQ1::;XMETO4KVPLK4623QR7$PC9G+L",L<$
M84=JIZ'XJN-2UA(Y/L;Z;<S7,%I/;Y.YXFX!;<0=R9(Q_=-)3;'*FK69C>%?
M"#:.9;B:!FGSA&\H@@?C7<;)'C&Y6SZ8J+1;^?59=0F*1K917+06Q .YPG#L
M3G&-VX# [54U3Q)%I'B.*QNP1:O9O<9B@DEDW*X'1 3MP23Q^-$IMO7^NHHT
MU%60^\BE\A@()']E4G->>^+M*UF\E\JVL+MH(U#82!SN)Z]!Z8KT>?Q3H=NT
M8>^#+)&LV^.-Y$1&^ZSLH(0'L6(I9O$NCP7XLI+IA*95@WB&0Q"0]$,@78&.
M1P3GD>M.,W'H3.FI+<\+'AO7%)VZ)J _[=7_ ,*V=.@\01H]O>Z+JDT+#" V
MKG:?Q'2NQ;X@W"V%R/L2_;(M/N;M7\J3RLQR,JJ?;"\G=UXZUT]IXIT>ZV(+
MEDE9HTV2021Y+YVD;E&5)! ;H3QFK]LVMC%86,>IX])X5U@6LDT=A?\ FJW"
M_9G!(]@!5WPKHNN1ZL6N-/OH8D0EO-MW ?L "1UR<_A7L1U*R"7S^:2M@2+@
MA&.PA0Q P/F."#QFH+S7])L AN;M5\R(2H K,74D 8 !R22  .3V'%'MGV*6
M&BG>YQEU;:DMO,T&GW.Y$.Q1"W..@QBN7&C:_K%U!)>6%[%%MRR&W<#(/N.]
M>E7?BJU$NF-9R(]O-=O!=>;&ZR0A8GD(*'#*WRC@CH>E7KKQ+HUG;17-Q>!(
M9;4W:-Y;G,0VY;@<??7CKS255K6Q4J"?4YJRTV[CA4&WG4XZ^4<UI6MK/&I+
M6\I8C.2A!_E2ZKXWTVQM/-MTGN)5N88'B^SRJRB1L!]I3)&,D$##$8!S6FOB
M+2&U'["+H^=YGE9\I_+\S&=GF8V[_P#9SGVJ>=FG(D9MRE[]D^2"0$D#"(<C
MWQBLLZ1=32M-)!,.>!Y9!X[_ ) 5T*>*M#<S;;P[8HWD+F&0(ZIRY1MN),=]
MI-6M.UBRU8(UF+ED=2Z2/:2QHPXY#,H!SD8YY[9P:2FP=-=3G98+U-JQVDWK
MGRVIMQ:7JL%6"X96<$D1GV]!]:ORWNMW6N:M:V5WIMM;V"QD&YM7D+;DW'+"
M50!QZ5F6/CQ[A6,UHGG36ML]G:1L?,FFEWY4$G&WY <X&!DFA3N#I^9;N]/E
MDMN+>7/<!#G\*\PU/3_$T=[*MGI.HB%,JH6S8J1ZCY?ZU[I81WGV&+^T# ;L
MKF3R%(0'T&23QZ]_:L^3Q/HL6I2Z>]VPN(9%BE_<R;(V8 J&?;M7.1C)Y/ Y
MJE4:=B)45)7O8\1;1O%3Z1.9;#59&FD"^3]GDX Y)QCUQ^M:UEI.O1ZQ%')I
MM^UJT2R'=;.0)%((R2.O'3VKTK0_%UI?LUO>R+#=_:Y[=,0R+&VQV &\C;NV
MKDC.>^*MQ>+="E,FV[<!(7N SV\JK)&GWF1BH$@'^SFFZNFPEA[/<\QU+1=2
MOFDC;2;Y1(VTM';,./4\56/A6_6XAMETJ]6U:,H72W<,O?.<=<UZ>?''AT=;
MJX'[KSLFQG \K./,^Y]S_:Z>]6QXHT0K<M]LP+<*S[HG!8,<*4!'SACP"N<G
MI3]J^P?5T];GAFM>"=4C6TCL])OY2SD2/]F=BOUP.G?\ZVO#OAO5;"QO'DTR
M]\U@%7-LP)P<9QCT'ZUZPOBG16M9+C[3(HCF$#1-;RK-YA&0OE%=Y)'. .E-
M;Q;H*P0S"]+I*AD CAD=D4'!9U524 (()8#!!S1[9VV)6%BG>YXO-;>)+35&
MFA\-ZA* A_Y=)#DLN#V[9Q5IO!,M];I+)HU]$^PX MF0C/J,5ZI9^*K:77[^
MQGFA\I98([(PJSM-YD>\GC.1WR  !UJ5/%>DPP1?:+XS2R))*OV>SF.Y$<JQ
MV@,>#P?IGI1[9[V%]6CLV>)Z=X8U[0[V60Z+?W1V (R6LAZD9[5IZEIWB*9P
MD.AWW QDVSX_,"O89_%.AV[1A[X,LD:S;XXWD1$;[K.R@A >Q8BJ%CXL@O\
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M0YR@V@B/ISCU.>"BDG8IZFEKWA34-1U2ZO;62U^8631)*[+EH)6=@Q"G (8
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-** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'F H8# 2(  A$! Q$!_\0
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M/VMOACXOTQ_AM/X?.GZ/K>D:)K"7&F^)8_"VFZ79O87E]"P!_4#'-',"8V#
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MSXU.J0/\+]82-X;FWNU&MZU<V>IZT]S;QSPC2\:_\$]/V/OB!K7[2GB/Q7\
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M5^9]IWE% 0,2P.T ;NV:7UO"Z_OZ?_@2_P _\P<)I7Y7]W]?>;N9?[\?Y_\
MUJ,R_P!^/\__ *U5+66WN07MI(9K<X\N>*X%RCGN,AG"D>@<@^U6MB=R/^^<
M?TJXUHS7-#WXK>2:T7>V[^6Y.O56\A<R_P!^/\__ *U&9?[\?Y__ %J-L7^1
M_P#8T;8_\@?X4_:1>BO=Z+1K7UMIZ@&9?[\?Y_\ UJ,R_P!^/\__ *U(PC56
M( . ,Y X&1GMCI_+M4 FMFR58,JG#G@[3P!VXR<#CU_-RJ0A93E&,G\,6UJW
MLK[*_F+WGM%M=]"QF7^_'^?_ -:C,O\ ?C_/_P"M30(B 5^8'N,8_/'6E54)
M V_R/;TVTTY/51NNZG%JW?0>NMXM6WVT7=ZBYE_OQ_G_ /6HS+_?C_/_ .M3
M_+7T'_?*_P#Q-'EKZ#_OE?\ XFGKV_'_ ( KKNOO0PF;LT9/8?Y%-_?_ ,>S
M;WVYS[8_''X5+L7T'_?*_P#Q-(Z_*V#T!/0=AGL ?UH];)=[[>>P77=?>/'0
M?045%;DF($DDY/).3U]Z*>G1W71K9^?S&1W+,J94;F4 A0=NYADA<\?>("^G
M->)7/Q5UJWO+ZR'@779VL[EXY)H+K3(U,8R$:/[9*JA6(4<CH25^8BO;KE-Z
M !58]0&SC*?,#\I!RI&1@@Y Y'6OD?Q-:W6H:IJ<]IX.CU^^2]<)+)HNO6=P
MS*<*!J<U^NG,B#YCYT3+*H,<6)7C8?%<9YKF.687#RP$N63E>5D[RL_A375V
MLKNRW/3RVE1KN=.M#F26KT3M?6STZ/KZ>1TNL^/&\66-SI&H^#XK&&X$?FG6
M]5CN,&VFCNHIFT_3!NG6"6".8K')P4WMN1&!YG0=2U+2;A8[?QGI5M:LT@<6
M5IK%R9U"/LBL-+OYGL+1H6VM,_D F%)"@\S:5+#PM\2+R..2[M8=#23A;%)'
MQ BC<H+!-45<D $&PF# E28@QGB+SPMXRM9E,VES2Q])+W1=-\*&Z7L'^TSW
M5G?L0Q!8+I$S2)N0B)6::/\ -?[<SO%RC.K2K.7,FK245>_=I6OY[>A[U.CA
MJ4)4Z+@HR35I<LGKUW?3;:SVLSMFUZ_D*FW^(^GQ+@^9#J'AVZ:0\?PK9W6G
M2\'G]U=QXQEO,C#1/SEYXC\1J[?V;XHOM;D4\6^C^%]8E+\X9D6;QFI*0J3/
M)SD11R$ D $71K];8I>^*?$+Q,H$D&H>'+ZVAMR2-JO?+*VB_*^W:)[61)GV
MPQ!)9(W6A'X=\-6^Y=1\7Z1+<2NIB&K:?INB"+#!L!=*;1_M3$#Y))KZ-T?;
M*/-9?)D[X8K-JD6Y\]&'*W.7MHN48V]Z4;2^**U5NJ,WA:*3;:?9.'X=79]W
M^1=LM?\ &US(%?QS900!9#+ NBVMI=P,D;O%'.=:\2LZ.\RI&WE7 !R5^<'8
MURW\0WTL<?\ :GB/43=.[(?LVJZO91;,$;Q#H&B:LFX#YE87XB#8,IDA#JVP
M-"=X8)-.O+B]MT"XN+?Q]KJVZ= #$)++6K>U R J?;D5LB(%BP5H=4B\260C
M6*?QY/ ^T23Z3)X7\0V\(W# >35/#<MW(N<*3@L =YX!(2Q&(BU*./Q4I1=U
M&51N,FM4I+FV?7R,_84F[<L5>RNU&ROHMUK?L_DF8MEJ_@[3I+L2Z1XCNKCS
M%:YU"WU'1H)+Y2P ^T7.C:EX=O;M(V/FO'K%C<S2(A18FF95.U)\0]72>QTS
MP]INF:?;7GG+::WJYU&2P'E0O.PNK%;;1+J&0I$T:26D&JB2=H_-D6$R3IDZ
MA)I48A36/B!XNTV:52@METG2[2?>ZE5W#3_"BP[T9@P))Y7@C JOI^GZ*3*-
M/\9>/IG8".XEMM+TQ9+IXSYH$LT/A)KUW8J )/F*]7945G$T<3F:KN2Q"3J/
MEB[3]UMV3:OLNJ6K6Q3PM&SUO;HTVKV\[)^MFN_8ZV/Q7\0K:-Q)+X<U^X97
M>"32;#4+2&(HI?8ZW][9P2AU4INEN$V[@Z[G"HW'WWQ"^)L41CO-&CL)_P#2
M)W%GK?A.X98C&XB<Z>DVO:FZHY1_(AM)"P7#RVD>^[@Z&#2X;L>5+H'B*]?Y
ME2X\4>)KCR;@ $L6MK74?[0A!3<56#P_/\^Q95@A\RXA;=>"%$:3:7HFE:+<
M2@+-=67B;Q7:LRJV[$I1-%6100<"6_A ;!7S6VPR;8G%YTJ=2,<7"<Y0E&$8
MJI%RE)623D[)MM*[T74F-"A%Q;IJR:YM(K;6VFS:UTT.9T/Q5XTED2[UO7-4
ML('B5H?-T:UTC3M1)(!62.=O%MS&8@1(DUHNB>;(J))$T+O"V]J?BF\U&*>V
MNS!J=@%02BXN]"6T.)%*%QJ/AR",?O A3?(OS[0N7VJ:T'PWU$7#7MUXO@,E
MP D<XMKC69K7;\PB2_U#Q#J4BB0CRB##(KB0H0 VY<[5_"4&D2)-<:[I5QJ$
MW"6MU\//#>HWUP",'[*+46DK?*2SO-=Q%8@\C;]IC?SJ3S]TYNO3J2@H2Y[5
M8WY+-RM=OI>WJ=,5A;IQHOFNFGHU?OHKM::V]&<_JLME?K$+F*62*U79;Q)X
MNT$6]M&WR,(+:PT^XFC7RR1Y=O;E3TD"Q&1AQ&I+I2%;6VTFYU*R;/VB[O7L
M9]*LL G9.I\"ZK/,)VQ;Q[;&;,TT98PKNGCZJZ\.>+;E]UIX2N5C)^2ZL_#7
MPMMGF7KN2#5-6ENX2P'3S%(!PV1D54&G>*K,D0:;XRL[J,,1_P 4Q\+[D!@I
MR$6UUJ.?& P)BD4H"6/RA@?D,UCC9U/<C7IQ;U<I-Z=;\O;[SVL(X*4?@T<6
MTK7M==]O*^ASD.H:]#%]BTIX[+2(N;+2O#.FZRMRK@Y:0PV+^#K5]G,LFZQ0
MM&K[5R0#8LK_ %]I,ZWKWBB]MT;=]BC\)>*D=0H+(KC2O$NH7T^U@K,T5G.
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M-QMJW97LEW[^1:=;-ILL[P>)="+S,?,$WQ2T>TNI1G)*26?P_>1 HRSF,$A
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MWU_#!JL4L=O83(R:A;1.D.G6R374J>1;R+7PII?[)7Q7B\13:SGP.UAK^O\
M[,GC*_FT_4-8378;WX5WW@N[\10Z5"_AU(]3M];AT>XGT5KYBVJ>*#I8U/=
MTL@K^(/V,M<\1>&?"VAR:_X5\+ZO%K'[2=UXQ\5:1#<R:G=Z7\5=4\9GPW%_
M:-]IFD2WT>DV>N:;9^+;"?5(X]/%L;'0XIQ%:VL@Z<'=>Q>NVJ7Z?UY%5<MX
M73]G0S>M6<ERJ5.,FDY>ZG:5G9/;U>KL?=$/Q;^$][I.K^)-$\2?#+5?#V@3
M/:>(-;TCQ9X?A_L6[WK%=Z;?7=KJENEF]P&:YTZZN%GNI[?_ $2T833P/4-G
M\9_A7J5K>7>B^*/"5Y#:Z)?^+KM[?QUI$)M_#&DWVI:3<>*?] U":X/A*WDT
MV6TU":.)KZ*_D$\P22,R+\-R?LL_%?Q%H^HZK)9_"SP]KMGJ'P=N/#/A+P[I
M>O:=\*O%$_PJU;4M:MM;\4P:];:5<RMXDBUC3=)U2#1]+UTO'I.DH]M?P:=;
MPIA_$?X+^--=OO@O\-K+P]X?\*>.O&-]K&A_$S_A4/A#Q5I'PPT?X*>+_$B^
M-O%FA7'C:!%MU\7WE]X1M],L4O[474EWXP\10'POID6O:AJ:92H>Z[4Y-V=E
MI[SMI:ZTN]+6?W$1R;(8OFJ8^K[.+YZEY<RC"-G-249OG2BG=IJ]VN5--/["
ML/VF/A+K">-I=,^*7ABSMO &MZ?X>\5W^K^,K]-$M+N>STB2PM8WN5:4VM\]
MZME%J=LIOI]6MY_MCM;M=,?=M%U;3M?L;/4]#_X1VYLKVU6ZM;VTL[WQ/'=(
M_6>PU:WD2*Y&TEV2<Y6/<0N[:*_.KQW^QW\6]4\1^,=1\+0?#)--O_BY:?$[
M0;'6+[7-/NK^&^\"CPEKOAGQ;::?X-U&WGT])]5GUBSE6RNTNY;[68YS''JV
MH3O]B_ ;X6:M\*/A-X9\$ZU;R76HV$,\^JQZ'KU]>:;%J5UK>OZO=)I4>J1:
M1)%861UFWTFVCATP1PV6E6%I&D<-E;B'&-*,6G4C[-IWY96;EY)[:]+_ #1E
MG.&R/#X>A/+,7"M*JX1<(T9J47*U^:5[7DW9O:+V=KM^Q12VN\H_B.$,"=\<
MNF:1I@B(R0$M[ZUDN9><#Y7R!AB< U()3+,D,7B-I@3\L<6FZ/<YV@N-HBM5
M;Y2 V0PQC)X!!S)ULRR/<Q:OYD0)1=16"]@08P=RR&0$!22N!PV#VK7CU:&T
MA@,=U>7$=SPEKIFBVKME 6P/W83Y=I+;L?*#CG%=D:6'J0DW*"]U^Z[7>CT3
M6B;V1X56@J,83?VFDE9IIMZ>OR]#1^RZQ(A,/B#42S;<(-":0, P/*6#0W;
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MO[&I_LL4^25DZE%MNSL=VUUIMNW[M)GOXU3]YI\2P2LY(4O#*BJR8!8L01E
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MJER\"7D4DIB#H?;GBI49)PK1E)23C))J*:::;5[M<W1=+=SWIX?A.IAZ<JN
MQ,)^ZYJ->@YO5\R3Y;)\JB^:2MS2DES))H'[<UK)#8:8/ VOC7]?\5^#O NG
MV4&K:7=Z+J5YX\TW7]3TB]TGQ2UNHURPG.BQVWB1XH[>YT[73#&7DL(I<];?
M_MJ7.D:N(]=^&&M6EGIWQ8TCX5W^KQ:SH5QIVF^,O$>CZ5K&D6:V2Q&5[=9K
MRU@74HH_D$Y#/Y;,*W-)_9S^&%BUG<V_AW7+J^T7Q'H_BB*:\\<>,M<URVU_
MP?87^C:? ]WJ6ISS7>AV]MK5Q-9:=),;2S,TDUM"DFW'*V7[-7A1O&WBSQ;X
MHDU#5]5U/XBR?$#3["RU/Q3::'I=[_PB_AS1])$OA^.]&EW5]9V^E7]KIE_]
MF-UHTET]]I\D%Q"C+;S?&6=\13:UNE"2TMY]?P^9Q5<'PA4E>&78F*25N>O1
MDV[]5!6Y''IO=/>-B+1/VRM>\4Z?\-+K0?A?K,,WQ9NM2MOAQIUWK&@E-4TS
MP]I-[JGB'4;_ %&9#-:S6D=E)-91,0UWIUL-+3%O<F)O&O'G[8'C&ZNKG5]$
MUG4M'\+)\&M$\32Z7;^'_"^LZWI'B/\ X7UIGP^UVS@EO[-X;JQ2TTW6-*^V
M!F>RBL9]:M"MW<1LWT0W[.7PLN/"_@SPK-:ZI:Z7\/Y\>#+S0O$7C#1=:T&\
M-GJ&FW*:/XPT[4+?7HI-2M]6E:<1WD2(UE;S'FSA:.?5?V<?A)J6CS:7<>$7
MAME\+VO@BVMQKWB9;)=(TC7X/&6GVLLGVT22W'_"3V-MK6JW6&?691=17CW#
M7L_F9_VO6_Y_)?+_ "7K^'FS2E#ARC[L<OBX/XFN7VB3TO&4M.:UM>]V]TEX
M;HG[77C+0_$?Q+@\;PR:CJ%_\7_$G@+P)H5C=^'=*TA-&\">#[+6M2N;G79[
M.1CK5Y;S9:VF0M=7:V]G&5DEC9?3O#_[8C>)==N+;2/#/B)H;'X6:=\7]=U3
M5[WPAX?M])TS5++6M2LK.W&JVWEZK.9M&N(4N+BXL]-A%U+<ZG<V^G?;)1T-
MY\!?@_?-J=Q<:;(\E_XZU?XB07^E^*_&>CZ_;:WK&F6&EZI=:?KUEJ%OJ-A!
MK%M9-I]S:VUU$C+(K2*4C!7:B^!OPWTY]: \*RB#Q!X)T[X>ZW''K'B&XC?P
MIH:W$1T=KJ?4[:1]2MK?4[@1:DURLT@FEMUE87,L<I_:V(O[E>/-?W;I_%KR
MMV\[7-''AB4>5X"LVXVLYT7%WY;QM:+:=I>[==-6]#YYN?VTO%>O:GX=\+^#
M_#+1WMC\6/ 'P]U^.34+:\M=1T#Q19Z[=HWAC5IX+9;F&6WT>2SGUV[@L=-L
M[MUT_P +:5=Q-;^(;75T']J2Y@C_ +$CTGQ5\0]<TRY^,GBG4_\ 2+?P=+I'
M@+X9?%?6?"&I7,,GB)KB+7;BSU&VBT@Z7;[8-:N7CO9$^42KZ##^S/\ ">*2
M[FBT#7(M9NK[PAKM[JMWX^\8&_NO%GA#1]7TO1=1M]5B\6WFH02II6JW-I>R
M19:Y^USVMR6BNI\W_$7[-WPGO8X5N]-U+32]YX_MXM4TS7_%7A_69K?XA^(]
M0\8ZYIEW?:/?6UUJWAJ34=2O_M6E:A+)87;P9E@D<"I>.Q$_>Q%2,VM?=32T
M[WWMUO\ GJ7_ ,('*Z<,%3A"TE!6ASIINW*_LR=WRM6MHV[/E/-XOVRM%O+>
M_P!1TGP/K=_X8T:S^$MWJWB*[O(;"[B7XLC2K'2;$:9<+)<7FLV^H7D+:C!I
MCP:=#I[7MX"R1LC_ &6GB&YTP?9[234(X\PSQE)2+95N$5Q&8XG W /@\=>>
M@Q7@A^"7PF.FZ_:6GAZ[M=-\4KX'M]9M-&FU:RT]X?AC<64_A6RTV S+!I=O
MIDVGVUTL44*(;6*>WC"K.V?<[;3(/(B;3Y;6-]D;"5T:4V\2J(T#)(,7,KK^
MZ9V#,H<OG*\<M3%UJDDJ-=0;:2NI6O?32+7EY[GC9G1RVOR1IX:=.,))VE.$
MFTK-K1;MWMNK-;:I=)IWCK75ED59X@BKP]Q9R7A0X_YXQD2N6)VDJ1MSO;(4
M@]?I?C3Q"^Z26QM+Y%.2[0S:>.?E!#WDDEM'@G($D9W'Y$(D9"/-X[>X@S)+
M;-<J ?,N(;I[(;,89RL3(?E'( ZGCH<5MV<>D7$:RP.S1$,/->[FAF#8(*C>
MP\\ \,3G"Y;MQPSS+,J<YQ5=.5).2=IV;CJK*]]UU/D<?@<!/FE["223NKQV
M2VTTZGJP^(L=O"PN-,AR(W9W35M,?8$4NP1?*/S$#:A ^5F![<?)_A7Q7;^)
M/VHM;^Q6M]!:GX7^(05@O-&GU#S!XD\ Y*QW=LT+[B K-("R(6>(B148>DWE
MG?J7^P76GB/:Q$9AADN6P#@K*RD\8RV3DH&'>O _A9>7>@?M4^(K_6KEIUD^
M%^MA!9PP,ZJ_B?X?Q$!5SV;G'1<YXXK? \18RO4]EBJL8TTTJLI;*GM-VW5H
MWU/D<RRRA1A]8I0;:3J1IKXFXKF44_ANWHM+79]M1PZ9;.!J+^-=-\P\276H
MZP;1@>SSZ3=)86XD)V*OD;79EB4 N",*UBTV+XT_#J?3]4N;W/@7XER2+=:[
MJ]W):NNH?"N5)8K6\F>(/YS%]Y 9'D>5?W@W5NKXXLVWKI.EZS>-)/(AFB$:
M21N8V\L+R-J;\!ATV;L"OE3]IGXP_$#X?^(_AUXF^'/AS3[WQ#/IWC;3;FPU
M(&ZDFM[J^\":W.$LX[JS26*TTK1;J:=3<QK%:V[N RQ>6_SO%_$63Y#P]5S'
M$5IXBC1Q3Q%2.#INKB.2E)U)JC13YZU7EB_9TJ;4ZD[0BTY*W)A<NQ>/Q,<#
M3I.%2M1<HNIK"\HM*$K*ZNVDWJM6VK71^D06W;;G:20,$@'(0-M[?P^9(%ZX
MWN1C><RAT3!5C\N< ' &YE<X '&757.!RZACR :_'*Z_; _:<&C^)]0L/"_P
M_O5T3QOI?ANQN5BOD34K)=#\2ZSJ\JHGB<QQQVS>'9TU*ZC(EL[!;JZBQ);J
M5HQ_MH?M*)X@O=(_X1OP.YM?&MKHL0:"\+RVDWB.[\%2?,?%!2/PS'XK66Q/
MBJ97EMS;A[N.6WADCK\__P")D> </@:-+ZIQ;3EHIR_U7Q_-).R:@^;23UY7
M)M)[Z'?'@;.*LITO]GO&ZDI3:6VNMF]%Y7L[^1^S7FQYS]PC!#KD,"JHJX(
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M%4@B15-=&TGB:UA"K'X?\@0RA)4%W;P!#$X/R3S&V4L#A Z<,5"8?::\BO\
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M23LHPA*-HQE)NT92]U/5Z'G3^$+[PU:2V&JZ/J,5N=FRZF07T%PQD7:&P'9
M7V[,?=8J> ":PYW,9-KIVKFVNEQG36M9;^903R+?S@R6I9,[BH3";AW%?0NI
M>-;R^_=V-NMC;M*J-)(WF%_,PN84S^Y)8CA=OTSP> \.6-S?ZYKL]I')(\EQ
M9VMQ-,C@9;2-,FE;S1\XR[RRYR=TC,Q.68G+%^'N 4,-+"XBORQJ4W.A4<I.
M<5)-PO%\KYDN756UVL>YAJN8PH5)YHH4JBA)J]6#=TK[)O7LDV[GFUQ;7_D!
MM2T;6'6-=R7%W<R7-CR>':UWNL0SC8BJ!YA0=*X]Y=?U!WBT_4H(XHVVBW@M
M7L67!S@QXCCG*XR2P. -P.X"OIJ*:SMS=!8-4NK:QFDCN)+2WMI8F:%6>0O+
M(/-(7;N.3G YX->FVNA>%]8L+*[DTC2KI+J%9X)+FSMWN&R1E60Q-&^>C!LC
MJ5&0#55>"L!BZ?LL%7I?6:*YIT>2HYT^5-MR:=M+:V] EQ%A\MA%U,/5Q#E\
M+IU*4;/=-^T3_P SXKL-.U<8?4[U;B('#Q3&U"L7^1!NN$E0$2,I1=A=V 6)
MDD9'7JH_ GB.Z0-I>G^(+6&<KNDBM/LT$G*N (=7>>>Z1L;2^GF$1(3.08T*
MGZ,O?#6A:;XE\)/8:'IMN;F[U1+LP:=:0A%32+]X]WEPKP9%08/\1!'K7=:E
M/9:9")YQ!!:1*/,RH2(;]L:950!GS'4+Q]\KCFM<!P9AXJI'%UZ=-4XRE-\E
M12Y8J\N5MZ.R=F]$[7/-K\:XVM-4\%2G24VH*,Y0G)\SLDN1)7;>A\:W/@C7
M-)\Z36O#KB%0I^W17']K0*&<+F[2<R26C.3Y:+:@+YKHK H6-<U?0B.-_P"Q
M+"R:5=N])P8)&.Y0VP.H "C+'ID ]#7UW!XAT*_NC;6\T/VB7>$5]_F2;%9V
M\LN.@1&8\_=!'J*S-6T#1+N.>6>PTV4[2X>>T@DW.IW(K.8RQWN%7@Y)(![U
M=?@K"U:526!Q=6I45.;IP<I<LIJ+<(O6UI.R?DSUL!Q1CZ4H1QL9*+G%35TG
MRMI26OE>WX['QO++X@4$/+9VH(R8T"2_0 #CK@=,]^U789[E;>(/ K2,'W7"
M84<(3AD&"V[&WGC+9^GKUAX.\-7&G6]W=0"/RVO\W27DT2ND=W) A=01OW6U
MO:NI;)5KUV'^L.Z!-)\'2 ?9%WY9D FN[AP64$GRP[$#."3M[=\5PT>$\QIJ
M]:=&DU?W9<SDWKHK/?6R[]#ZZAG=*NTZ6&K2C=-R4J;25]6]/)O3\+H\!FF6
M1IS<V+NRDA0L>5?G!+<'(P2<'^52::UTTAFC4Q*ISODX9?D9%.3R#M)C'/W3
MMZ'%>SZAX5TR<^8GG6JK\P-K/*<X(('E$F-U/1L@C:2PY KEK'PY')',;N2Z
MN(9;MDBC&+1"D9+8DFAPZA=NX $;BH0\-BMX<-XMSBG5II.2N^2KHKZO1WT^
M1]%A\SI-74)K3JX[N_DKVOK:^QQ]XTR6DQ+VI2-?-$4AV12O'()TA=DY19YU
M56D RC/YO49KX&T']L3P4?#KWGB[PMXLAU/^S/$_B?Q+I?@33V\1Z?I/A.U^
M(GB?X?W?B/5+ZX/VE_L?_".ZG?/Y3DKFY#$K+*&_3Q[3P]9K/%(EC$1&V1*T
M4LOW3\BO=)+&6D^YM?*ONV$<U\EZ'^Q%\/=#T?Q;H4?B?Q5<VGC3X7Z]\);V
MXN9M&BN[71O$WC'Q=XSOK[1G@MP4N99_&^M1+.2)2UHLH)E12.ZCD<$ZD9SC
M-TXR=TI6=D]+-WUM^)Z^"SC*Z#G_ &CA\15A)?'3J4X*DMW-\T9-\BNVDFW:
MRW9\_P"A?M2>(]3^(T^B6W@<:5X3E^+=I\,XM1U:PU:35M1^U^#;KQF=9M[:
MVO8$>Z>UT^Q#:4LC.5G.VUNVQ;3>FW'[67@Y)/$XN]!\?:--X1M]'UVXT;7/
M!]_HVJ>(--UCQ'!X9TN^T&WFN9==G@N-1N8K>WC%CX<_LV*>74(I+K[.8)_1
MH_V3_ HU$XUSQ)'/#\4'^.$MC9WFCV"MX@U#X>R_#S2M.LI(;&<6R#2+<$B*
MW.W5KE)B4ED\U?//#?[!OPT\"R:S)_PF_CC4I]?T_P ,:#)+J3^&X[AX?!_B
MZ#QY8"[DM_#-E+JEXU_;*NKZ_=737\VEVTZB:5T2,O\ LBC;7EBM;MIVBK:M
MK>R]?(]1YWPA5IU'"-=R4'R0CRWJ/5**?+;FDK[)6NFG?11>%_VK_A[K'B;1
MO"0T;QKH>J:EXJU;PA-=:_X:U#1]/T_QOHEF^L_\(=XBNYKF6"'Q/+X=^V7<
M%IY4FF:KI)FDG8ZC)#CF)/VS/A2=*AU2Y\._$N6P7PIIOC;1I[WP)J=V[^"[
MB=6;7H=0TN<GRM'U)FM[Z]DM[MX8VLS]BOWCCLYO;K3]E3X;3^-SXT74?%*Z
MDWQ@U?XU+9.-!5?[2\1>'CX>O]'A06PSX3M1&AL W[XWEPD;KLFD)QM2_8:^
M&NI^&(O#4_B'Q+#:6OP0U7X&)>I=:49T\/7.KZ/JIUN-X[.X<7$\VE07C7/E
ML&N%2XG8%#,I'((5$W2<*D5=II26BVW[K\3CAG/#$G!5:.*H2GRJ5VI6<K)[
M*[LVUWY=M[&;KOQV\!>&_%.D>$[_ ,*^+ NN3(FB:[<Z/>MX5UZ]FT4ZO'I-
MEJ"W\\3W.IZ?-)#(-,M24N9D:\O;&X7^QI^&\._M@Z#?>"/!?B?5_!GCZU\2
M^)?#%]XIN?!.@:!)>:MH/A>TO(_[2\<:F3<^2/!C7LFE'2;Y#]NNQ;R6$NZ"
M:9*]&E_8L\#:Q\0]'^*.H>-_%D;:;XF\/>-K;2+F7P7+:KK/AC0;71/[,/B"
M^\*Q^)[Q7TK33.=%;5H])T]IY+ZSC\Z)%;!L?V&?"4.C^%]!T3XM^-],U?0/
M"]S\-YO$&FOX3.J^(/AEJ9AU!_"E[IMM9Q1+HVFW=G;C3]<B_P")A'<7TV6*
M74P?.624HRY'*$*C=J<7%W<WI&VU]6K7^Z]C:&;\*<\E*6(3A:3NF^=IM\BY
M;\KE:UTK)VUY7(R=4_:U^'/A_4M:L1H7C#7=,\+_ /")R>)O$]CH5Q_8&D6/
MC&/P]<^'=;U"ZN9#':6U^WB6&YU6VB4(8[+[5<(4M]R^]>$O%>E^,I?$]KI+
M3*O@[Q#=^$-5^V0H;5M8L+72]2U*:VNER;FP@FU&*QCA4M'!J1U"0*)'F+<!
MXR_9?M_"_P ,OC%8?##13XTU/XMZ-HNG:7X(\5ZYH&AZ);VL/@S0?AY8(FM3
M6<P9=.M+2^UF32[A6CNHH;K3;9(WO%+>H_LV_!^Y^%GPJ\->&/$ETNN>*;-+
MS4?%&KR#5;LZIXJ\0SOK^O2SZAJ\UP=4:*]UB2T:^C(,YT^W#';#&J9/)<1&
M<85''E;2DU&=K-Z^=K=_UN<6-S?A^4)U<+[7VD;RIPE;F<HK2[TC?F36CMU6
MD6EK-NBD,J0P[0S&::TMW,C-(C0;CA1YC,K^6S-D^6S#IUV+2)S&@$URK<"(
M-)) 8UR"410R[%*@@A0 0<8P37J\:06J,'CB@'\**J1*W8<*H''7\/PJQ#IM
MEJ!W2V5K,H.?,(B>1,9/R.5) R #AAD$@GFNA9#!6<)0<[^ZE&=^;[*WZL\.
MMFB2565.:A=-^]&]MWV6G6VAXK?SRPW#Q-:7$JE0#*;B4(/4%U8L W(XZY (
MP34=K?-,T,=UIK3V\+,(B\TUR8"ZE288Y=RQEMV'*[3L9B3Q7LVHZ!IMJT5^
MMJ9TBF@CDLQ<M%%*+F:.U+2;#R(1-YX!!&Z,=*ZVW/@^R,=F?[(202N1OMXY
MBP>)MT4UPR,<!20H=L%]H SP>+_5FK+$_O<;AZ/M9J*C.G6;3D[6;3MUZ'B8
MS.*;34,/5J)IKFC*G9*RU:LW9'S?J%Y#:2K#/I?V> @^2(H_-:YW*<A[J-2\
M.W.\KD [3&1AB#\N^#=0MK;]ICQ!*NGEP/AOKX6-;BX@FPWB7P ,)."K1@9W
M$!@&4%.0Q%?J!<^"_#VH0'R8_L(E5F2?3+E;>$$?,6^RNIM&+#@&2,E2P=-L
M@1A\%G0K#PW^TUJT?VB^U19?AGJ#-'<?V5>JV_QKX=1\Q,;4ME(H02+F,CR8
MB2XB6,_.9SPSC\##&5*<X5Z7L*[YJ4*L/=4)7:YV^FJU/)>94\;4IX>%*<91
MG%>]*#4FY)))15];6U/:]-U>!]0LK:VMKVR-W=P1E;2[N9F,LL@19)(RP26-
M&8-/Y@(\D2$DXKPOX[V5S:>.?A*([^ZN9[G3?BO:VMO+);VCW-S'X&":J([V
M;*V:3Z(VH6-K=\?9'G62-U*YKZ/T_4;$3[M-TNX6[BNU,:&/3K=\(0T@CVZQ
M<LL7EAS(J6[JT0=6"J2R_/OQT^$/Q+^-GB_X:^%_ -_H/AWQ!I^D?$"_EO\
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MMI?%V^1%=D2I,BLP8M(Z%"1&J")OE !P%R,A1QDCC/-<U9%6M(HD&W,YSM&
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MT;6/@UKT?ASXF76E_%V?7_B/X^_M+18?#GAG35T^3P;ITEQI>OM=:7::BO\
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MXU!94#8(&TX4D5S5[J.M7]SI^HV6BWEUI^ES23"XO#'8WVLO/;S6A?3K!-J
M6Z3--)+<*CR6D4J(2Q .QX;T^UCT:PFBAA#R16ERY1$1G66.[4!V506^;RWR
M2?FC4\E5(T=1U&RMY4AN+JS264JH6>1'8X(P,.<G'\/8$ CISM4JMT5/$XNC
M!M7IT^6::G]F^MM[:)$485)8BHOC>J4DF_7?6_GK]]C'E\1V%VNT7,<%S(%Q
M8WJFQG22$B7=',0L+20E"X;.24 5@Y KS+7_ .RK"1]29;2TF</]HU MIMM<
ML'<,0)[A&$RO)M+EMYP3(F)5C9>X\2)I6IV\UKJ-K:ZA;0HLA@OHXYH24*R1
M,BRJZJ8I5CE0JOR/&K Y4-7SQ<Z1IESXGUF>YM[;4(K$V%IID=]<2746ER01
M337;64<_F+:>;!K5I'<" 1^=%!%%(&1%4>5FN)FZ%."2K\_N\\;)*^G-:5WI
MY:Z;GV_#V#J0;DT[2MI%.+LU:S;U:UO;H];-G/>+?$=OJ6G3V6F&\U4W<UM%
M>QZ':WFJ-)I[7D U7SKVY*:="RZ9]K8@1-O"^7#B5T-2VFOZ+JB&U@N+,F1)
M!/97S20R&(+);I8SK<@*+J:&5[FX6'=Y@$F\%'9CSOB/Q_:Z?J-SI&GZ)J>L
M?8MGVN>PAMH;"V5F50(58J&?)P#&N<D-VS4T<NC^,M+M=3N+*$J+N989+V;R
M=:L;V.VEC:>'42KR64S6_F6K7,<BRBVEDB1L/MKX.6*PL\1*C2K1Q%:B^:O0
MIIJ<(P:<[N5X[)]UWON?JM# UZ&&IU91M&IRJ%D]&[6;3>RWMH]-+62-.Q\'
M^%["[&I6>F1I>0R>= ))3<?8)G0Q++IL,^8[8D.4+PA"(G<#TKC/CA>VMO\
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MLVP6_F;=S"386*L16W<WWB![>2./5$CEFB,46[3+:2WB9N$!NF4S1JKX*%"
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M>G:)HNKZ?;ZN?#OC=[:T\1>$M3T'6=66X\0:99S>'O#WC71[G3K^]DM$DNM
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MT,/BRZN/ (TW3K74=;?2V\/W]BUK8"/S;;YM_;J@AU[]I#X;Z;JZ+J-GX?\
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MPAX8\(_"+P#H'C75-6BM['0O 6GZQ\7]7U6ZN]4TWPS?_$SQ1\-O&'A._P!
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M66%P&!^:.9(Y%/564,"" 1YO_P (1JLDJVEYJUI-I0F+/"+9?/O8F)!BN)R
MTB8(\Q)"RR1AHV!5S7S68X;&U,?AGA*V)E3^LT7+W[Q<?:1NI)/5-7NNQ[%.
M=.G1JPG!SG*G)*2M9-Q:3U5W9ZZ:_,]^L)2UO!*#(JF,EHR6+!IUAN$!&>!&
MKLJCC8I"J .**FL!&L*$X \N-=W0N44+EB.6(4!0220..F "OU/ TJ\<+14Y
MI24==_\ @GQN(=JU167Q/HGW[EZ9@B[B"0,C"YSR0!T[ G+=@N2>*\PU30E&
MI3:GIERMC?!S)=G+1V5UN&W=-'%M69D#;PSABKJK9R,UZ;,?E !/RYS@D$G!
MX^A(P1W'&".OA.L:EXB\Z_:"]LH+>&6ZABM7BVL[3120Q()5 :,-)(@+C[OW
MCP#7@<89A0R_!4:U>,GSW4:4914Y/^5.7NW;T7F>GEF%EBJDHQE&-K7<KZIW
MNE:^MK[C9?$VJ3SSZ=:+8H;;>L^HG=)!(TJF%C!;N#&[LKE6."0&+<XYHP6"
M1/)/)*;V^<P&:\N%W3HL"O';I%(^Z14ABFEAA0,!%%-)&@5)&5L?0=092-)U
M)(;?5[*/SY;42R/L$A($L%PP(NRRDEAEC&I9N-M=1N60X &]N-Q.TG'/+8SC
M [FOQ?%9GC,RE4>*Q"C@X1DZ%"/,JL+)M<\[\DK:7LN]MS[#"X'#T;<T5.2:
MM+9*S6K3UMOU[;F;JUG_ &A#F)(_ML>W[-.R*9(Y=Z[?WF-ZH3\DH! :)G5@
M5)!K:7J+30/'<;XKBT9XKM)2Q<W,:DF6(DDBS=05B4?NPY7 X%;>4!*L%4$-
MDB0$_=).0.O3!Z^]<QK=M<0M#JMBD=Q+"%6XBFD:*.XLPR^?'*Z?,PAA,D\"
ML"HGCC( (!'@5'3IOVN'JKFC[T[WD[+5[,]%N%-KFCRT]&Y:6MUMWTO;IW,8
M^(M5O)[A+".WCCMWVNURJDNH.& W#)!&01T()!SG%0G59KJ29EABAUC2H);@
M20FTMQ- \31_9Y9;F-X#$58^6DJLJR[#$%F",)!HMO<K+J6E:M]GL[H&X%O>
M1I=LA49F5))]\PC0!GCB3Y78*AX8BNQ\&>")]1G&J74['3[K""=8#:W&HQQ!
MF,+VP"M!"I3)! 6504((<BEP]D&?YOQ#3P[3>!JRIU*M9TZOLXX=S7M--[JF
MV[IV#'XW+<-A*E:E*,JSI3=*"E&ZJ<K<$U=W][HNW8Y:;P_J GN+X:=J=BVH
M);7#VILY[ZRD$ML066YMG&GVPD=@Q)@Q(Y"@;V4CH=!^'6LZC!+_ &L9-)L)
M@B,L)M)KV2%)%DB$#7T<UO $E5'*O&=BJQA"S>6P^BDMXUXB01JL4<2?*%)5
M!@#/!PJY&.@Y %2QP[&S@8YR   >#UP>:_9L%X3\.X?%1Q=>FJU6,XU$X)Q3
ME&2DK\]]VM3XW%<3YCB*'L(R5.+CRN^MXM--:;:;;_D>+R_"U46!!J1U*W@0
MK82ZDEZVH6P8@R1QZGIMQ;M!"RY!2.)(Y<F(KM<U6N/AC*UG=V\-Q;Q?:(7$
MB0P7PEG"C>86O;F9Y DH7RY ^Y9(W:)@0YKWC ]!^0J-XXRK9C0Y&#E5.0>"
M#QT()!]0<5[/_$.N&I5I59875ZQV]U]&W;IY?(\_^V<RY:<%7M&$HN2L[.*:
M<DK=U??OJ?*_B6PNB+-=1@.E76GZ@L=G'>&::ROU_LZZ3;)=QY:%@LTTEL-P
M#7+JA.)9,\I?1ZHT+)=Z+<:;;\#[7J364\4H# K]D6-FD(E8!$\P!AO!ZU]D
M7%K:W$317%M#/$<,8Y88Y4)0#!V.K*2  !D< 8Z5YSXJ\":=>:6QTG2M-CU&
M*YMKU5^S06YFC2[A>1&>*-6=Q$KFWB8F-YPB28C9L?G7$7A3?$U,;@9Q=.BI
M5Z<%3K.473O./PNSMRJUD?19?Q3[)1HXBE-QJ-0G44Z:C&,VHN;4M;1NY-:N
MR=G?4\;L[NST+3;:"::XFU"YE-\8HHP]TY,31)Y^[E@(F\M&DSL5L+@*,7+#
MQ)]MG$%YI][I4C%A UP5FCG 1F)+AB8\JIVXP2Q4<@US^K+-%KU]=/!?NYAC
M@>,PF/4-/6(@[;NSR+>*"1AY<+VOS,SJ7^4DUSFLZ]8:&+6[OQ>0QO-#)Y+H
MJ75SY4J.+:W1290UT5^SDIT29B> :_*(8S,\-G,,KEAJ\81Q%.E.4Z4U&K!U
M%&45>-X\R;UFVEU/M\-AJ..P_M,+6A6G4BW&E"[G*<DK4T[VNW:,6UJSO/$E
M[I>C:9>ZEJ,EO:6<$)EN+BYE!D\DD(YMXCEI;@[MMK"HS)<M#'@A^?AGQ7XB
M\6:UKFHZYX8N#X.MKW38[.U!TBPU#Q'<:0DR,FL:A;WNEZM8VS7I46WV3[#<
M,L$S-,(D4S1^EZWJ>J>--4_M7Q#";>!H))-)\.(Q>TTVUAO8_L\^IQD^1>:C
MN56C:2-I8) DJ%&C4C*N-/2=#"45E+%PA52F\\L^TC!9AD%L9()4G'3]7P?#
M4*4*>.FHN522G""C)2A*Z<>=M\KBG\2BKM)V=WI^H<(Y#0PM*-?-$I*?*OJ\
MN9<B;3?->\92MI=)*UUMJ_%M+^)WQ,\.7K2ZKK/_  G]G*_V:>VU;2/#NF:O
M+!=3@S6.E7/A.71+-9[J=U:*#5]!NX[NZV0SM 9FN8OJ#PCXHT+XC:'<:MI!
M8+#<SV6L6%["@U'2;X6IAGTO6[7YE2[6(+$[P![22!=BNP"BO$]6\-ETE 54
MB*/'))L7]S;RH8KJ9%P-S16SS2A /WI7R\$,:Y7P9XJU+X<>(-;.D>'[?6S>
MZ3&E];2:JFBZ=%]FN3!%<?;/[.U6/3K.^>*]N!IL>G2CRI=/V) PAN8>Z<*D
M&HSA0E&^O)3DIKORM[-]+Z)Z]&?8\0Y+@L3A*<L@P]+ZTH12P\6D\0VTHTDU
M:E&<KVC.:2Z2NFK>F^-['3].U$>'=)TK2X88M,CNI3?7%_=V,2,Z+"ECX=0B
MS=7D6.-_+C401_Z2 /(%=-X NHY+:\TV'1['2'TV^AC*Z5:W=I8S"XM8TW6\
M.];:W+&* R@(-ZPQC!9$*\-<_%;PYXMBBN?&OA#5_#-VB-!:ZYX=U2'6=.@A
M3+O%;ZC'=Z?J-]',BM#-;W&AS1A)'*)%@2Q>V_#ZV\&7OAZ36? ]_:ZQI2R2
M7%_J%NL]Q<O>6J-)<0ZI:7-WI\MG]F@C=PXN8D4QC<LD>Z&3YREE6)H8W$XJ
M5>4Z%6,[4(\ZJ133T;;Y+^:1\=CJU3*,-3P^:Y=5PN*;C"G"2C-2J2:44JD%
MRN\I1C9V5W:RLF>87\FE:=X+\)76J6%U>ZB-*T6PTP:=,UI>P))I2M>K!>1,
MD]K ]K 6OUA=?/M(3%(KKA:3PMK>M7-_)I\.J3V-T[27%HWB"U%VMW$P>9X]
M(U**\M+_ %%HQYDUP+Z\0(@EE4.R[6KS^*OA)K?A[0M(C^)W@NVUK0K'36:1
M=?TG5I+*6WTR.ROEO],C\1:7LWQ:BT,WG:AYT(831&:>*.-NX^'6@^'=4FF\
M5:-XRT/Q-;V4;68NO"T<$>B6(*-#.][*]YJUY<2>5*^#-J!CMY2DR$[*Q^KY
MG4Q6'6&YXX65:E&M=R;5)R7M&^5](-MO;NTD34QE"AA*LJF'G2G.$N1U*%HQ
ME)6C:3AR<J;2:3N[NRE)Q0[4_#GB/6TCB.MZ3;.DZ72W=IH\JWD$T;1O)-!+
M)KM[LEFCA$$TOV=W:W9H\J,,MC5M9O\ P3IYO=:NM(FB>WC@@='DCU+4@LDQ
MC@6UVF.<&6]N7PV5@-U=7"[7>1FYKQ=\<+31[W^R/!.C0^+=2MIUM-2DOM0N
M]+T6U@+*B3C4;*WNY;F263;&HB@F+.Z)*4B:1U\L\6>+=8\83Z+?^(M%_LR'
M3[27RX].O+S4-*M[@W2(SR2W>CVQ0R1L8"_GQ,Z2&)O,5S&_TT,MY)1FJK;C
M*,K+FUL[VO>WYZFV595F>/JX6KBL)"EEM2M2YZU2$;5:3G'G5-)<R<H7M)Z)
M.[NKHP]7U35_%][+J&H^;:P&28V&C^:V=/\ /F2>XGGDSMN3>21H[C!_?B*8
MY>)6&S9^&DO82MY%YX,9(=N98FB'FPSQR$%A);3)'<Q;6#>9&FS!P1M:7I*2
MO#*JQOYFZ<-M#0B)D8(ML""L>&(+! ,C=G/-=-=36NB:?<7UV#'!:IYC&-DB
M;>75(55WMKM%9YFC0'[/(<MA=C;776&!IJI.I7UA*_.W>T8OXF[K9+=(_2,=
M5PU+!+*L%A[4ZD'0G"+@W4A4C[.4(V2M*:;2;>[NV]SV'X8^/+BW>P\+^)98
M6O/LT<&DZ](XCM=9A )2VN5<[8M2A127E?\ >RE/+R2Y#>U>)YO(TBX8(-SS
M6UM*JG>H5KF$,R,#P&0_-C@C(.00*_-N;XC7-]$5OO"4,FEF6>>*2WU@-K=O
M+ CRQ7]O:+H5DK7,<D:2AUNHI JDJ9'"Q/\ 7/PB^(R^*DN?#NHPWNKQ+:W.
MI:)JDEF9?[1T5+NPM3]LLXR)I+ZQOI%A-R?WH3S 2%9P?#SW)E.A.67U*=1S
MIS4(PA.Z;B^5.VC2=MEMV/Q/B_A7%9%4I9HJ?+A93C4G3:DI0@FIR<IR?([+
M>*2UU3>QUM];VJ0/;QQPG;%NL1;HD=S]I;B.2!T ='AD*S,Z$,%1CN'->H>$
MO"MYJUM?WS7*0?;[BSGC@N;*:[M&$%HUM<&.&)XF+R3$2SM&Z[W'F3;U#*S-
M(\%KJE_!Y.FS6ELLF^[U"[M+V">%55G1-,DN)6%N)G5(+A8@!);231ME7(KZ
M L;.ULHH+2WC$=O#'Y<,2J%A'WBQ6, (I.6)(498DG)-=7 /A[.=6KC,]C#%
M4YKFITXPJ0=-[IR=6\7;M%7=M#\>XAXB<I0C@VZ4XR5Y-Q:;Z?!L_4\KO?A5
M::JD4.KZQ=W$&TK_ &58Q65AILJ@$J)HFBDNY%B<+,L:W"9:-!)O0LC<IK/P
MTUFWFFN-*N5OUD8R3>3'#'=2.L7D![A9;BTCO98X2(UDN+D/&BAD+%%C;Z1V
M)_<7GK\H_P *8T<8&X(@(Z':N1VX.,C@D?0XK](S'PZX4S"BZ=3 2A[K7-3E
M%2U3U7NZ/6Z\SYO"Y[F6'JNK*MSRNI1T=DUJKW?1]OFF?,-AH6LZ)"UPGAK6
M)YIO+ANKZ1=/+-'YJA%?R]9O)GMT<@O&()56/<0J@;TI:!>R27^L))-9W-Y'
M<QQ210>>T$*&50L#+>#"$$@;;8;-^"0%R1]2NBNH4INP1A5.TCD$[6&"O&<X
M(R,CO7/:OX5TC5MLL]BJSH=Z7"3-;3Q2=I8[F$BXCD![I(HD'[MR8W<'YC'^
M%N70P=2&5U,12J4Z51TZ=24IJI.,&X0M"WQ223N=E+/ZU2NZF+4JCFUK%Q7+
M=VN^;=):NSVT1\E?9;&_2;[;!#->^??-.MZJO(B17!*-%)*&9!&%!0*0 !M'
M!K<\/W@L;77IXO,O;>TO+6.P0J8Q'++$$CCAC.!(@F9';8, (9,97(]'U?X;
MW]LKW.GKI^N F1C;:K96MM>O@EQ##=)$#<AV&9#=,=R!^6?::XK5;:\TBXU)
M[VWCT^VT/3Q<:;;1,)7GFN("LUS*@&)7M9I!;Q2MEHD.U&45^0U^#<VR/%U<
M5CI7H0O4?+3K)4X0O.4I.=XM1BFW;L?94\UP./P]&C0?)6BXIJ<H-S?\J4;2
M3D]%?2[U;V.@T>*6UMBTSYN+D_;+UV.2UQ-\I@C8Y;]V&W, 3@*<C!-:IE##
M:/? R<#((.!C'*Y!]02.E>6Q_;[J+SY[Z]22=X+E$MKR>%+99[9E+B!)%16<
MM\Q !).23BNA\-WMPYN[*\F:8V8W0W3.SLZG[QFD8DML7+'<3]*\[!9O@\QQ
M5;!P4X^S4DYR<7&ITM!)<R<MDY/1[G95PDJ5+VDYP3EM"SYMK;[/?RMK;SZ2
M[C@DMI()HHWB,;$))Q'&V"5E&.4:)P)590&#J""#S6?INH:#J<=]H^LW6]M&
MO[=+&\@,[73)-;D/ +Q09DC"LX<+(%(SD&H)KN75)ULK NELS;;F^#%=X3+[
M+:1<%0S*$E"GYHF=2"I-;=M8Q6/FK;*D0;:TS1JL9E< +OD*!2[E25W-N;!*
MYQU^KRO%U<NDU3_>P>D*52\H-O11FF_>@]I);K1'FXC#0K048)0FFGS=TO17
MO?UWVVMUNC6VA6=N]QIKJ7ED,,UQ>7\UW=20QY94:XG>22.*(J)5A+B,; JJ
M&(JM=:E>:N\]MI-R8;*T9/[1U981&T<(D7S%M 0/-W+NBD8'"QN[=!QP5^VG
MZ41?R"8VT5Q;_:=)BE,.GWYN;B*U!NK87-G;3F-IA.OG2#$L4;#<RJC=I'XD
MT]X&LX]&O[:V998HVAMK%K:W62!T=D%M?ZC<1AE8K^XT^8$L1($B+RI]MAL^
MP>-P\X8B=3"5Z,)2C2P]2%.C5G&+:@X:/EG)*+5KM.Q\_BL#7I5(IPE4BYQ;
M:_EYHW6NOPIV;T6E]C)N/&'A22"XLKG3[F3285%M--/I]O)I\EK;B-GN&M3&
M8G#BWCB+E"0H0GB,8T+BROM*DTV+PE=PV=KJ$L>EI:7LCMIRV=U:27ZWNGPC
M]S;7$$,;R01QHBS2(D#_ "2,*\ZBM)V\[2QJNEKIL@F@-UJ,>H6LUO;7(>.6
MW56T6S@E\V.1H$5[A$WR*<.0$;TKQ$UM9:79V$%V]I=:?<Z<UG'.LLUU/:V<
M(-Q+:Q:=%<W#^98K<0$M S+ TB-L3)KOP>8>TI22KTJ,'%J3J7?+%K5^ZULK
MOU,*^%C=*G&46TVE+WMK6;Y;:)VO;:]W96,SQ#IFGZ396USJL<WB"_DOX;![
MC56:>VE0RK^\NM*EWV.E1DGRXY[*&.2X8QPRDQRLM1Z+?&6XL_#FJZ;I7V+4
M+2\CMK2QCCDLA;P.USY4MBR?963$0(1HRJ. Z@.H(VM0\0^%]4TYHM1^T16%
MU&C+/>V>LZ>MLZ,CK*+VYTJ&.U*RI&T)>5 \VR($EPIY@P6&@/:RZ/>W6J:A
MJD,D%A>7TVFW-KI=JJM.]S##;Q"9VN8T>W\UF5RTV]R=I!SQN/H_7:.-CB:=
M6EAZ*C.$;WDHKWFG)\MFD]'K9F^'C:G*E.E.4YWC&?NI1E)*S=[M*+U=KWMI
M>YV,OAK2K>U>#3;F?0P<,HTS4!:1Q/P"XTF<'1Y@(]RN+BW8I$6>$K.L3#R_
MQCK>N7&@>(]-L=2LM1L(],N;"YU&;27MR-RE)!#):&/39)G4F,L86.'_ '>'
MVM72M%JK6RAM?U!+YTF'G(TMQ;(98V3$EC(QAD4A]J[T(A)$R;6C5AYWK<[V
M.@7FC:L8+>]CCNIK>[D=O+O&*,S/#$O[B-]F2W0XRH.:\'..)95X*&!I5*<'
M[M63G3:E!VYE:&OPM[G1A\%4I5)3JN-1;P24DXNSUUT=K+;4_-S_ ()V>(E\
M!^,?^"@7C"TLCJ7_  A_@#X->(O+N)[B*34[K0--^.^KBVNI((I[DK.\+HK"
M&8CS7^3$C$_?WP-_;2\&>./@)XA^/_QDU'PA\!?!OA\_#EO$6M^-?&$&G^%/
M#*?$+X4_"/Q=IIU+Q+K46B65JDGB;XGP>%K?S=0M?M-_;V;0S-<:BBR?%G_!
M,K3+/6?B]^W'I.JV]M>V&KZ3\ ].O[2="]MJ%A?+\:[:\L9U2:WWI>VTKVK!
MI50B8^8)$W1M^F7P\_9?^"OPQUC[?X$\):GX7BCTJSTC_A'[7Q;XFD\#M;V7
MA3POX+LXYOA])XCN/!UUJEEX1\(^'-%CU:X\/W-W%I^GI#%>*D=OY?[EE,G/
M+\NJ3;?-@8V[I\D;7[K\CX##VYL?_P!AD_\ TZSP_P 6?M2>/M NOC6-2\,?
M"[P/X/\ A#X2\"_$N;XJ_%#XT6.E^ '^$/BC7OC%HFO_ !&\4:EX?\&Z[H?A
MVWT:+X,:EXHTC3[K65%YX?U.WD\03^#-?E;P&_S?\.O^"C7Q$\5_%$_#[7O@
MS_PBUX?BO^S]\+;3PO=Z7\8KN[GN_BS\"_A3^T%X\NKWXAS?";3/AIH'B#X0
M^#?&_C;Q+JWPV\7ZEH/B^]\!_"JYU#4[[0?%>LW/A:+]%?B;^SQ\)?C+-._C
MSPU<:K)?S^!]0GO=/\0:_H&H377PNU?5]?\ AW=R:QX9U/1]:A?POXB\33^+
M-$6VU&W_ +/UR"'5(=MTC/)0TO\ 9J^"NB6.K6VG>!-/ENM<\7_#SXAZAJFL
MZGJ>IZ]J?CCX2:%X*\/?#7Q'K/BF^U6]\4W^L^&=(\">#[/3M2N;ZYOK?3]-
M_L]YVL[F6";MG\$_\,OR.NG)0G"4E>,9)M;72O=7^9Y%^RG^TYJG[1&BZSJ>
MO>&M#\&:C:^%?A-X]M?"FE^(=;UW6SX%^-_P[T7X@>$-9F&H>'O"&I3:<K76
MN>%!XJ\/:%JOAG6/&GASQ=X9T;5X]3\ >+M,TS\"_B7X:\7^%O%OQZ^%GB'P
M?XRB^(GC7XF_M7^)/!GA33?!WBC6Y_%^D^*_B7XN\6^'+GPPVDZ*AU*.?P[X
MKT:._D:=(8'G%W=R+%"[#^F?X?? SX7_  BN9+WX?>$K'PS<7'AOP-X-DEMO
MM]RI\'^ ;#4=,\'>'X+2X8VFAV&E6EY>O#!806ML-0U._EDA%Q?32R_S5?$O
MQ]X]\5>./BU\7M3\9^-]/\<_#/XE_M):!\.+S3_$^LZ/I_@[1O GC_Q!X:TK
MP_8:#IM_#I\]O<:=\/O#T^M,8534%BO_ #EDD)KX;CZ,)X;+(SORRQ-",MK<
MKG2<T[_W;V\WJK']+_12GG=#B'BO^RYX>]+@O&8=NM"M*/M<,L9B:=3EIIN5
M.<VJ<HNTDKM-_"?5?_!0R7_A6'QF^'WQ$\;$:)X(G^"FD^!!XTU"WGD\)P>.
M/#7BB_FU#PM?3Z$^KW6E:I<6FJ6-U;VFLW&G6%[)!<V4)N+V=H9?O7_@F_;7
MG_"A[S77T[5;33O%'C[Q'K'AAM4MI[2_U'3X[6UL7NY[:2&:Z,=U>Z:\EM<7
M5K-,VFE0I$60?B3_ (*)^(M<^)GCCP'\%/$>K7H^'4_P,\/_ !&\2:/I&I7O
MAU?$'BR_\5[+&\FO-,GAD2PMH_"JW.E63[EM-2O!<*$+N]??'[ /B'Q%XJ^!
MEW'XFU;5=;O/#?CKQ7X;T?5M8F^UZB-+MTMM8T+3)]3O9KBZU&[TR'48HK;4
M[MI;A80D<,R84",NJ8*KQUF%6DIQEC<FP;IQ]V\)8.E'F4[7OSQA'EY+6LU+
M>[]GCRMQ+/Z,W"D,PCE\J3XPI8&<Z-'$J48RS;B''QJP<O<27]G8FC*^J=>E
M-2<8U(PV?@G^USJ?Q6^/GQM^#%]X,LO#>F_"#Q)X_P!'C\71ZW/<0ZW;^"=4
M\ 67F75OJ&AK#IZF/QR9KR=)C&D=D"DBHI8U]6_:W@UO7_@^WP+UCX(?&CX?
M?'/SK3X;:OX7^+C:QXB\8#PUJ7B;P]\2_$6GKH&E>(_#MO\ #?X1ZG;>#%\<
M?$.'Q'>R7=WXEO\ PW9Z+9>-M/\ !^E?$7V27]E7X'GQY-\3;3PEJ7A_QSJ&
MNZSXCU'Q'X.\;>//!5WK.IZY<:/+>'7SX3\0:%8Z[#?2:+I;7=AJYN;2ZDTV
MQ26*81QA+OBK]FWX->,/'2?$KQ%X36\\:Q>%YO"-X3XB\2Z?X<U?P<TE_=2>
M%/%7@>R\0-X9\1^$KJXU+4;K4/#^K:3?:7J<]_>RWMI*]Y<R/]\?R8?FAXR_
MX*@^.? ?Q1F^$/C#X6^&/!]]H'@K]I'X@>,?&,^F_M%>(- TO1/@)H_[)VKW
M,TGA]/@II?Q1TOP)KMU^TOXETV'XSZUX2T?P/:VGPI3Q+8-<:%XVT.VA^\_C
M#KNM^+/V,_BCXG\0:#J'A/Q!XE_9K\5Z[JGAN[OK+5K[POJ^K_#S5;FZT'4+
MO3MFG3ZEH5Q*UE<:GIMIINEWUU#-/;0*T=LD72>$_P!D?]GWP%JEMKOA[X4:
M#)KNG^#_ !K\/&UG7;K4_$NLZCX&^(#^"'\8^%;N_P!<GOYK_2]?L/A3\-;*
M73[N2XLETGPCH>@^7#8:190QU?V@_#FE^%/V1_C3X4T.W-AI'AG]GOQYH6D1
MO,]Q+%IFA?#OQ!H6F-&=JK]L-I:V_P"^0*[1J"68Q*!SXN3AA<3-)MPP]:22
MW;C2F[+S?0QQ$7.A6@G9SI5(IO9.46KLU+..&R@2WAD$RX5[DN\6[[6UM:%Y
MVC!RT[ [6D.9"I;<2O%?*OPR!;]L_P 0C),1^"WB$E#]S=_PF?P\&[:>"W&<
MXSZU[';VMH]NET)!:M$)$DU!)/)U"*46EL)+JYD4K/,43<Q21F,J Q'*NPKP
M?X.:F+S]KO4Q<#_B92?!+Q+-<QP_*J)%XU^'D%K?2$8\M+^ [_[/)"I,RW!3
M?&&'\T<)YI#%<39UE]7#U:%2GB*E>-:K*#A/DG*2A&,4IJ4FK)MM(_2JF%DL
MER[$QE&2>&A1E!)W3E#D<W+X6ENU\5DO)GW?XTADN/#.JV<#-'-?VJ:? \9*
M/'<:A+'9021LF&22.:='C=2&5U5E((!'%D10_''X71P(D2#P'\6[<)$@C18H
M=8^&$44050%$<9LG,: ;4R=H4=>\U\G[#"<G(U'0V!R>&76;%E8>A5@&4CD$
M CD5P\ZJ/CK\+\ #_B@_BNW0?>;4_A:[-_O,\LK,>I:61B<NQ/Z1BJ:EC,LE
MSI)8W"O9M_QZ;V7DCQJKY,-73V="JF^UX25_E>Y],)U/T_J*=(<(3]/YBHP>
M3U'TR/U.:BN9!';SR[9)?+C=Q"I(DE**6$:,"/G<@*G3+$"OTVC4I.G"+;:B
MDI>Y/5+=;'RDTVI*+]YIV=KI2UM>SZ/_ (!2U-G%I<&,LK^5Q(JB0QY8 S;#
M)$7$()E98W\\JA%NDD_EQO\ SPZMJ]GH/Q _9:\%^*==TW2OB#\+]6^*-K\<
M8M0FVS:/XHO[3PSXGU7XA>*;*^L$\0)8>*[&)?B+H>LW\%E;2^&;[17OKB_U
M=+RRF_6+X(?M@^%OCG\8?C_\']*\)>(] UCX"P:3<:U?Z[+8PZ?K::E\6_V@
M?@]"VC2M(UH%DU?X :S?1K<;(VCU2V+LAQ(8_B?KGA*[^($W@J7X"P?$GQEH
M_P -=8^(7AG5?%GAWPOHOA*^B\)>(O"%IJ'A_2/%_B6TUB 7MI)XPMM8U<::
M([$)9.]L?MJP2#U\NS+"X'VB<)SC4C*+2CJE)-/64;:7/C>*N&,3Q#3PL:.,
MIX.="K"=2=2%><9QC).22HN,E=+=OU-O]DE=0/@?Q#K+W"IX6\8?$?QIXT^&
M^EF.\CGL/ 6NWR7.EWAGNU%YJEKXJU-];\:6NIW)CM+>Q\2:7HUG9PBRC$?U
MNY_=D$J V<[A\N,\@C/0\@DGIG-?FMX:_;[\+P:+^S*GCGX>^*/!6O?M%>(-
M6_X1_0;7Q!X:\0V?ASX:6OBWP]\-O!_QE\3:Q ENW_"MO'?Q,^(_P;\%>$M0
MMHVUO4X/BOH&M7T$EKIFNO;?8/QD^)MC\(?@U\3/BS=6M[KFG?#/X>>-O'NH
M:0E[!IVHZMIO@/2M3UO4M*M;S4%FM;6_:"Q;3S>3*\ET\OFHYE2&0<->O0JU
M*DX<T(S4DHN$G:^UVDKVOK;Y'T66X*.7Y?A\&ZRJSHQBIU(J4>>UK\O,W)-V
M]WFV;5[ZGYN_\%@]$\3ZM\"?!NMZ=9WUWX6\,?$6VU3Q@+))F\BSF\/ZQ9:?
MJ5]#&DT:Z;'J5Q8B74KJVGM-(#QZK<HT-J0?QH_9-\/>*O%O[6?P6C\!)=7N
MLZ5XX^$_B[Q)>:,DVN1Z9X"@T?P*VNS^)M;TNWL-/L/#^M>'H]1T*'6',MAK
MLVH1>'38J-3R/Z=OV>/C=HG[3WP>/Q(70%\.Z7>?$3XW?"^^T?6[K3[Q)F^"
MGQF\>_"+4+K[9#;&RN]/UZ#P)J7B*"S,6W[!JYMQ-:_8_M,/S#XO_:$N_A7X
M+^+/C3X%?LHZ)JFJ?#;XLV7PFUOPWJWBCPK\&]5\3W7B3PS\,[[P WA(>&O!
M_CZ6\G\8:Y\2O"?@WPQ%J>F6=\NHWVBVNI0Z/:-?6?A7W\OXAP^"R[%8*5&=
M26)PU7#JI&*2BZM-T^=J47+2[EIJW;NS\AXA\))9]QKE_%CSJM0IX'$X7$0P
M<WB92<\-6A5BG*G-47!\B33CW6J/TZL 5B +LR^7 B&1V:239'N>5V8DN6$L
M:EB2<J,GI5\  KGJQ! [GGO_ $Z_AQ7YM? ?]NZ3XU_M0?%#]F]/"?PV\-:G
M\'KWQ1HGBC3V^/7AK5OBPEWX9.@&;7;?X-:?X=&OKX%\_P 2:7X=F\6ZIKUG
M;7^L@7&GZ4($-?I$K*45N<\<YSC\>O\ ];GVKYV=:E*$X\TES*2^"?5)*^E[
M+JMWWW/VFC'V&'ITHU(RE!)3=G[]M[7=U?6U[V;UOJ$X)CEVC)SD#>8\D;C]
M]>5]>.O3H:^(O@7;:_#X<U;6K.&QN;.7XC?&:U.FVP#7<YB^,?C]@8Y)5V;H
M&FGN#N.0K3E1OD)/VX\@VL1U()QSU_+Z_@?7FOE?X!*A^&^HADW*/BM\;,*L
M:2$$_&+QV,JC@KG)Y/89/4"OA.*8TJF:X"$Z\:4XT7)1E3J2YO>NDI1LE?N]
M%?6VI[N5U72C6ER-J4+=M'%]_P /F>B_\)9H\$;?VG*^DRI@2)?F90"2%P)
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M[SMJK['P$JE2<Y2E.3BT[1;;LW>_E:UO/07 ."0,CH?3MQZ<<4445W?CY=R
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M:]_"9U/#<L'!>RNN9+E3Y;V=KK1VV/QBM@*=:]KJ;^%[KF>UUOO:]K/MJ>W
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MV\XWE1E**3NTKZ6UOHW;_+YDVKE#IMV946<0VLTD4;J) 'CC9T(5@0%#*I.
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MT70KB+3KS5DM_P"S&^,TE_?W[6>Z\%I8PWLVH7BV^^=H8I_*CEE8(WZ76O\
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M?N))K6[FTEUCCGN+?29(VGUN:Z\FYMI+>:WL?M"E0WW/]F8[_H'G\D?S!#Q
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MXN!G<0LBNP!"!W(0_--_X*^%*WCP1_#/PE=RQ8SCPWHA&0>0&:R."0"!W).
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M^2/$TY5/;0C%1<G%TYMM).ZT=M;==-3-\>_L*_LQ?$SPK<^'O&OA&/7[6V^
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M2VVM:^\ _#N'6[%&\'^$9H;FVU2 0Q:-HZ(L]O=V11W"VNWS$0N@8@,%9D!
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MTXRB[.3A)6DDXVBG9M+I<ABMX84CB*1^0(TBAA$:E46, A<XYV[00,8!7/)
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M9H8M2N]5FT^2Z-L+B(RBU%EK5[-<Q&,,LGG0R 0L[$+@NOU. N[) Y&"2,Y
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MQ+^S<1)QXUX@Q4Z4*,IUO88C 97EEXPC%RE*$LLJ5VDO?IU:<(?O(S9B^(/
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M7$T,J^,?VB/%EWI]I*P*7NMRGXUV-KH]D_F:(/LS1ADACD#?4*K4;2^L4/\
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M/=_F7W?\$****V="23?,G9;68FXI-\R=EM_3"BBBH]G+M_7W$*:;2L]?0*"
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M/J?S-7_;68+W8RI<KT:E%MVZVZ7MWN)Y5@7?W)WMI[R^1Z /%.F DB.4$]2
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M7G3YXN*FD[KG3C=*ZMM\@P?M=ZKI_P 1/#7P4\<_!#QOX*^-WQ M]%U+P/\
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M\+4C5BO=YIP7-.[Y8I6TU23;Z]-;'U*+B-4 153=UV +N(_O;0,_KG]:8)E
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MY^,VE?%WPE\.?$?A'PY\*OV=-%^#-[\-_&OA_P 0_LL_%[XS^,="Q!>Z;?\
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MTZUAU#4K=QZ=\'_C_P" ?B[\./A=\3[+^V?!NF?%30[#Q%X3\)_$_1;GX?\
MQ"N+9YI(/LNM>!]=N%UC2-;N?W-DWAF6^DFTA#;:IJUUJ&H:I! OX4^ _P#@
MEG\>? /Q?\._$_5/@M\!?B-%I_\ P4^_X*"_M&:+HNH>*_#.G'PG\"_VL?"Y
MT;X7^--.M-4\*>(5M?&GPXUVST?QK/X<L=/:*&73H)[ V]_##?0>._LT?\$D
MOVM?V?U^#:^,O@#^RO\ M+WD_P"RS^RI\";.;XI^-->N=/\ V5?%WP,^*7B#
MQ]XV\<>"F7P#9^+]1T+Q58^*_P"V=(N/ NN>'=?B\=:9I6B-<_V')=Q5I/#4
M%";52%U%M/E?;U[C52LVOW<M7;XDE^2V_I[,_J0UGQ#H7AVWBE\0ZQI6C27-
MZ=%A>:[T][:ZU2SBD0BVCN+[3IV)EN;?3Y[6V9I;G5I+2 SQ3.DZ,EU_0X]7
MM=#&LZ.NNZG:O?V6DQZEIUYJ+QI/>K'K%AIL6J>=J>CVIA6*XBBMQ YAM;>Z
MM[J754O4_)?_ (*)?L;_ !2^.OQA^#OQ6\)?L^_ +]KKPAX-^ _[2GP1\1?L
M]_M ^)[SP9X1\,>-/CM??#G6O!?QFT6]/@GQYI,E]X=TKP7XG\'^+VL=3T?4
M]$T'Q=?-\*H5U:[UG1]:^,O@'_P2J_:,^''[9\OQI^*?A[X?ZGX2N_BU\)OV
M@=*^)?PF\7>!/"^C?"71_A5^SQX*^$M[\*K&P^)O[-?Q)_:47PEHGB#P[XI\
M,>'_ (>0?'_PQ\/?%/P=N=(O/$CV7B;3_%OA?6^>GA(3L_K%)+1N\9WM?UU_
M 3JU83C&=.5G))OF5E=V=]NGZ66U_P!9_P!E3_@HC^S?^V5JWA72?@K>>,KV
M\\<? '1_VF]"?7_#$VCVA^%&J_%?XC_!'3IKEY'V6NJS>-?AGK[2P[#)+#Y)
M8XQM^[,#T'Y"OP;_ ."4'_!.?]HW]CKQK\)]<^,MMX,L['P1_P $]O!G[+VN
MV_AWQA'XOO8?BEHW[6/[1OQ\NX9;Q]*\.O+:#P%\9/"CK>II=NSWOVZSAM-2
MM;.36K;]Z_**\GD#Z?3U-<V)]E1?(GSN7NIQ5DF]$W?72^IUQJPW3O9]T_.U
M[V].Q!@>@_(48'H/R%6,#T'Y"C ]!^0KE]F^Z_$T]NOY7]Z*^!Z#\A1@>@_(
M58P/0?D*,#T'Y"CV;[K\0]NOY7]Z*^!Z#\A1@>@_(58P/0?D*,#T'Y"CV;[K
M\0]NOY7]Z*^!Z#\A1@>@_(58P/0?D*,#T'Y"CV;[K\0]NOY7]Z*^!Z#\A1@>
M@_(58P/0?D*,#T'Y"CV;[K\0]NOY7]Z*^!Z#\A1@>@_(58P/0?D*,#T'Y"CV
M;[K\0]NOY7]Z*^!Z#\A1@>@_(58P/0?D*,#T'Y"CV;[K\0]NOY7]Z*Q  . .
MA[>U<GXS_P"19U/_ *\[C_T&NV"J>JCH>P]#7+^,T3_A&=3^5?\ CSN/X1_=
M^E14IOV<]5\,N_8J-9.45RM7:5[K2]S\P/\ @F1_R77]L;_L&?L^?^A_&BOV
M>8 I&/7OCT'%?C+_ ,$T"L?QS_;+<E45-(_9\=G)C18T5OC4SR,TF$5$4%G8
M]%4GKBOV!M-6T_484N-/U.UO[8.T;7>GW5KJ%MO7(:-FMG<(P/#  ;"03P*_
M6</%^PP"NM,%!_\ E.+_ "/PZO%4\7F5VI*ICY15GRV;J-;R:7:[V74UC'GJ
M<_49_K2%,!<$G:R;44[ Q##8C'D"-FPLG!'EEA@YQ54SHP*PW$(E96$>Z4SQ
M>:RL(S*RY,*+(59EXR 5'6J\EY;M(EI)(89KBVN+BUBDF@\R6UAN!$URL+N;
MEC82W&F+=R*/W3ZC:"0G<-NE22C";E:RC)NZ;5DFW=+5JR=TE<J-**:E9>ZT
M_P"-3Z-/>^Q^7W[:W[2_Q0^$UIXBLOA@M]/!X4T/0-3O+K0](/B#5]6\2^(M
M;M!=7DEI+X>\8:Q;:'X;TF^_X2G6K+PYH&I:Y=:'%>:3X<AAU6TT^2V^"K7]
MJ?\ :PUVU\#R:%X^L=6M/%?B_P 1^!9=5TKXTZ%J\-CJ>E:+XV\0W,#/I7P*
MODU"YGT?PS).NG/<^$_&?@C5)M5\/:WI%O\ V=I]]#^HO[67[(R_'W4)=8T^
M^TJX74;+0['Q/HNM:OK'AFW%UX=U:UUCPYX@T?Q%H-AJ.LZ+K.BZU;VNI65_
MI=J]T\L!LS-!;WEQ*GS+IO\ P3R^(5OHD?AY8/ UW VHZYK\E_JWQ?\ B?XA
M\4S:]XET'4="U;6KGQ/JW@JXU2ZBFTOQ!K&B:9;SW3'2;&W\/_9S%#I5HD'[
MSP=FWAWALAPT<WEET<8X+GC5PDI592:=USRISM*3VM9-<NBBDB*RQ$I/V=HP
M[JI%^[Z1=W9?.]TKL^+7_;T^/.L>#_$GB7PIXZUK6M0\,^.M#\.W'AF7X@>$
M)+J7P1X^\4:!X9\ >.[2]T3X5ZE;VTVO7U[$8_#>OW.E:WH<FDZNU[J=K;ZA
M?%O=O _[5W[3>B?$M_#7B?Q"?M$7A5_%EOIJ>)[7QE9ZI)HT7ARPN=*OOMOP
MD\,7-AI&IW^N7MEH.MVFJZ3KNH:C"9?%-KIR:?I^F:_[+KW_  3M\5^(8K9;
MOPA\*HH+.QT.VCM;7QYXXTV+[#X<\2Z3XP\-Z//]B^'Z-<KX:UW0H;RW+AH)
MX;_5-.VK;ZM>I/J:-_P3Q\9P>.=1\7ZA>>'-*U/Q&'TC6?$.G?$7Q[K]OI.E
MZI=65MX@F\%_#_6/"^F^%_">LZY%HD-QJ.M:-/IMY>7^H2ZG<7%U>+B3V,=G
M/A;5P6,I4:>!]M/#8B-'EPZ4E5=.?)RM4;*2FDT[WNDW<QC"NI1;J)I--JTM
M5?5:NVNVNGXGZB?#+Q7%\0?A]X-\:FU^R)XL\.:5KHL)9#=BTEUW3(-0NK'S
MV++<);>>T*3Y(,6Z ?(2M=]Y<8VX1!M(9<*O#+&85(XX(B)C!&"(_D!VDBN4
M\&^&M)\%^%_#_A#0K,:=HWAG2;71-#L%5%%GHVD11:?;*#&JJHG2*&8QC"_=
M.T&,XZQ>,9)R>@/M7\Y5Y0>-Q"H1:P_/-PNU=1YY<B=MY*#2EK:]UK9M]<YJ
MVEU=6M?RW[6$9$PQVKD\D[1DD*%!Z=0H !Z@ #H!7@O[3P'_  S7\>3@9_X4
MW\31G'./^$.UH8_+BO?:\"_:@!/[./Q_4< ?!?XH$ ' !'@O7#D8Z=.HY].:
MF2O%KNFOP9S5':G-]HO]#ME(CABDV*RI%!(ZX'SHD5@\B@'AF9%8*I^\V!WK
MXL\"2VNG_MC:U<WEW;1P0_!WQ3:I>W#+90O<7'C+X?7:6H1Y(%GOK>!6WR%O
M-2 , =@*U]O"#<$7(4>6,$C(4K-<!,#& 0(HE4CH(X]N-BX^=?B+^S3X3^(^
MH-JNMVYEES*2Y=&+BXD@>;<C@E_.DM;5Y=V=[VUN[$M!&5_*L1#V>(Q6%;O+
MZRZ[FM(\JDVXV?O7:6^Q^T8*?^RX"R:?]GZ?^"T?18\0Z$<#^UM)/S%L?;+?
M[S J6_X__O$$@GJ02"<&LK4O$.A(4<:MI0>,YC87EN70L=C;,7Q*[E+*VWJ"
M<\$U\>G]A_X9G@6(![$0P9_1*9_PPU\-&()T\.PZ9A@!_!BO'<]>>G>HY8=G
M^'^9IS3[K\?\C[)B\7>'C&#/J^F(ZXVC[1;@M@CD_P"F\D?>!SGCMBGGQ?X:
M));6=..[&XBY@W-@@C)^W9." >3QBOC5_P!AGX;-@OIH.WH66!]O;@$'UQQZ
MTS_AAKX9_P#0/7_P'@_^(I\L.B=_D"E.ZNU:^NY]E/XQ\+*"S:W8QCC+FX@;
M'( R/MS9R<#H<9SQC(B'B[0I"!::MI[[_D$LEY"D>U\HXD0WV"CHS*P((PQ&
M"!Q\=G]AKX9D8-@I'H;> C_T"D_X8:^&>"/[/7!ZC[/!@YZY&RDX*:<)749I
MQDXNTDI:.SZ.ST\S13C=<T6XW5TFM5U2OU:/?+CPG\/=0UK6+V\UB:*ZU*2*
M>_&E_$O7-!L+EE7R6N#::;K<%O)/#:-(@9D9_*S$#L)6N%T:Y^$^O>./$?@R
MVO/$L<>FV:RV-[<_%'X@06^KW+G_ $EX&&O1VUW+#"9IC*SEAL+*=^VN C_8
M:^&0*(+!53.T 6T!5=V5)"[,#&X]!ZU7B_96\(:[J&K^$[V>XN-'T.RT%K>T
MG;S(@989W81129B3,J1R/L49:)2<E5(J&#P\8\KKX]67N.G7C%PE]F2N]XO5
M-6U%*<5.,J<>5)IM2LVTFGI;KH?1EEH'@?PQJ\>L6.LW=T;>T\M/[;\=^*-=
M2"1S"+@1P:QK]W:;9TMX4N-T>'2&)CEH8MJW/A[X?ZK>ZKJVI3:0NJ:O;Z-I
M^HWPUQK:(2^$M0EU32;MVBU!9)/[$U:\35K5"28;I7EA*32,[?/(_88^%ZCY
M+)00&  B@Z.I1Q@)T9&96'=20<@FE;]A[X;, &LRP#RR -#"0))PHGD&5.'F
M"J)6^](%4.3@8Y*V3Y9*7+'#PKX>HF\0L>E7J3F_BJ*4%RIZMZZ^9LL76B_<
MDX+O%VDO.+V36Z?>Q[99>!?A+I&I0ZO9V_A^!X-2'B*,?\)-/-9VDHT'5?"=
MS/:6+7Y@M],NM&U_6%M-)BC2VL[N_>^2%9-[FM:?"OX.6.G2:5';Z:+:2\,_
M[SQ9-(VH-9Z1<:'LN,ZEGRK?2[]+""*0E8["..R51;A8J\;/[#GPT.[-CG?D
M-F"$[@4,9#93YLQLT9SG*,5/RDBFG]AKX9DDG3U)8N6)MX"6,C(SDG9R7:.-
MG)^\R(3DJN.?_5OAQ[Y9@+=>2BE+_MUM64NS>S+6/Q2U6)Q#:LTI5+Q;6J4E
MUCW75:'MVH^#OA;<(+5CHD5NEOI$-O+'XLNK&\M#I-W+-;-8ZC:ZBMU;26T-
MWJ,4$,$B+/%?WVGR?Z+J=Y'+FZQ\.OAAJ::_%;W>EZ,-4\,#PYJ<NGWNEW4#
M^%7T_3]&NH(-$U.XET72;^[T+3+#0I;RVM1<W.EVEII\A:&WMXXO(U_8:^&*
M8(TY %)(Q;VX )X)'R<$YZT-^PW\+V4C^SHUZL"(+<8)&&(/E\%AE21R02#P
M:PK<*\/R4O9Y?3@K/=1?Y(N.:8Z\?WD-&NCOOOK?7;?2Z6C/;M2^'GPKOM2D
MU2^-N-4FU#3'N3'X@O+>&]:T\-6>D6[RPZ7JD.C_ -F:IH.C:98>(;::W>UU
M6+3K&SNHIOLMFL79>%_#O@?PWJVKZKH8T^WU/Q)=V\U]?+JKZ@;N:)I2EK9P
M/=3C3].MOM-W+!!&D=N))YS&@>=B? /#G["_PL34I0U@C1_85C*""#&QB#MQ
MY>,>9A]O]X XSBO:/ W[)G@'P'K5OK6BVD45U QS*T, D:/RWC\IV6,,R!7.
MU6)56 ( (S7M91P7DE/EQ%#"4*5>FXU85'#55(.\6K).ZDDUJ<.+SK%1;I3?
M-"7NR2=GRRNFM7LU>U^Y]36L>^WBCD8EE4-N1B P8=<C_P"M]**LQ*J*%4*J
M(B(N  #@>@X^G3OQ17WE*,J5.%/FORQ2NMG]^I\Y47M)RFM.9MV]6WTTZCY"
M C,<?*I(/'!QVS7EURNZZG?^$NS$=BQX)QZDGDGDC\:]0DY!!Y!5\@]#A>,B
MO.+D 7$P  &[I@8ZGM7A9ZKQH+O)?^E(]'+YJG*K=-^T3BK65N9/5WZ+R*.!
MZ#\A1@>@_(58P/0?D*,#T'Y"O"]F^Z_$] KX'H/R%&!Z#\A5C ]!^0HP/0?D
M*/9ONOQ KX'H/R%&!Z#\A5C ]!^0HP/0?D*/9ONOQ KX'H/R%&!Z#\A5C ]!
M^0HP/0?D*/9ONOQ KX'H/R%&!Z#\A5C ]!^0HP/0?D*/9ONOQ KX'H/R%&!Z
M#\A5C ]!^0HP/0?D*/9ONOQ KX'H/R%&!Z#\A5C ]!^0HP/0?D*/9ONOQ KX
M'H/R%&!Z#\A5C ]!^0HP/0?D*/9ONOQ KX'H/R%&!Z#\A5C ]!^0HP/0?D*/
M9ONOQ*BKRBN[2_$K$ = .H[>XKS_ .*$P@\%ZU*>-L5H <XP7U&T12#V(+ @
M^M>E!5_NCH>P[ X_*O*/C0XB^'VIOTS-HZL1QN#:[IBD-Z@@X(/4&LZ\&J-9
MW6E*;Z](MGJ</553SS!1E3E.#Q^$4G%I+E^L4[[KLSYX^&BK>^,=(MP 75I)
MG) +,R6\\@8YZD%>O)S^!/VN^]EF\J6*"=V=+::92\4=U'$QMFE0',L0F$?F
M0G(F3=$P*N17Q)\%F,OQ#TXY./L-\PY/41SJ" >A .T=PN0#BOMYT8A3$2LB
M2++&4=8F\Q6##9(;6\$<CD!5D^S2,"V5,;8D3GP,54Y6W:+?O+K;KY;,^U\5
M++/,#AO:1Y7EL*\%9[.G*3AZZ)*VES^>+]N'_@H;^TAX=\:?M:^!OV7_ !#X
M2^&UU^S[\=O^"='[(^B>+O&W@;2O&VC?\+._:Y\8Z=JOQ"\:ZGH][?:4=5T?
MPG\-_&7PDM/#_A]M2M5M=075(K-D9VC?Q_Q;_P %,_VY/V=O%_QT_8A^)U[\
M"OBQ^V%;_M)?L(?L^?L[?M":1X%\1?#WX1I:?MRZ9XYU7PGXO^-OPYAUW5-5
MT"?X:Z1\+/&\BVMIKP:[U"_\'Z>EK<6UPEG-^A7QA_X)0> OCO\ $G]K?6/%
MGQ&\?^$/AM^UEXO_ &4OCWJ4/PR\2Z3X8^)'@3]I#]F0ZWX<T7Q]X1U_4? F
MJV-M8>)_"?ACX5W$.D7=C/ /$G@S7)6^SW/B0WJ]EI'_  2(_9#LOA3\7/AY
MXP7XO?%#Q7\<_%/@3XD?$O\ :,^*GQ9\3:W^TCKGQ(^$A>]^$_CG2_BR5L+[
MP!XO^$\PF;X?W'PXLM.MO"]I/?Z=]E/AO5-;TJ^^@IK"Q7*U+73F;BK725WK
MJD[_ "\V?EW*UJI)-;:-I/\ S[KJ>'>(_C=^WA^QO\#_ (B_$K]KWXN?LW_'
MKPY\'?CW^SI8W/Q!^$/@K4OAKXL\5_ #XR>/O"/@OXLQ?$?X77Z>+-*^&FL>
M!4\=MXQ\"MX2\4ZC-X]\.>%(9;R]T+5+BWT]?;O^"@/_  4_^&?_  3Q_P"$
M1O?B-\-?B5\0]/\ $_A_Q?XPU#5?!_BK]GKPU:>'_"G@&.TDU8F/XK_&+X<S
M^+=<UBWUZ231/!7@G2/&_B.Y26_M[.SO/$-W;V5SPDW_  2.^''AWX.>.?A7
MX<\=_%3X@^(_VBOCO^S?\3/VMOC[^T)XTU/XI?';XT>"/V=OB#X%\=P>#]0\
M5:7H-GH:)!I?@#1_A7X0\-:?I/AC3O#W@S7-:\3BXO+C39+:X]E_:[_X)H?!
MC]L;XD:;\5?'7C7X[>!?$^G_  '^*W[-?B:T^#?Q A\(Z=\1O@#\5;O^U?&'
MPS\;FY\/>)[B^TN75$TW6M-N_#FO^'9]1:]M-"\3Z7XE\,Q:CX7U/14\(G?G
M3=[V6E^ME9Z>GZ W6T]^';X9::>=[/I?35[G#P_\%1/#'B3XH>-/A]\&OV9?
MVI?C?X0^'MFWAWQ)\<_AGX*\&WGPCT/XPW7P;M/C/HOPTOM0U3Q['XHT2];P
MY+X8T#5_$_BSPKI?PG\/>,]9TK3_ !!XDTU'./S@_94_X+8^./B1#X"^,'QS
M\ >+O!_@RZ_X)OS?ME?$+X4^$/ACX.N-&M1IO[6-C\%KOXZ:5\5/$?Q]U?7H
M_AWX<^'.L_VWK7AC4-!LM9B\&:9XB\?W^NZEJJ0>#M _3?PO_P $K?V>/!7Q
MQ\-?&W2O&?Q[B;1]6\&>)-;^#L7Q2NM%^"/Q&^,W@;X=V?P@\'?&7QMX$%KI
M+:C\8/\ A6WAG2= O!HVH:7X2U^_@T3Q!KW@XG3(98N,_9]_X(Z?LL_ &6Z;
M1O$WQH^)6EZE^R-XW_8G_P"$9^)_C/3?%7AQ/V;/B)\2+[XIW/@31/LOA/0?
M$>-,EOM<\-:)KZ2ZYK=KX,NEO"TFHQA&<HX:47%J2YE:[:LKIIMJ^W5^FVXU
M*LG?G@[-2>DM;.][_/1^:UV9YY\?/^"X'P#^"%O\3+^S^"WQP^(W@WX2_&KQ
M1\$+[XA>&-=_9Y\(^"?$_B3P3X.T#XC_ ! MO _BOXP_'CX?OXDOM!M/$>GZ
M GA_0;9?'MWXLT/5Y-(T.>P_L_45^7=._P""U?C[XM?$7XY:3\/OA3XS^'7P
MJ\#^+?\ @EU)\-/C''X(\"^+)=6TS]MSQE\$KF\\/^-?#6M?&&UO- \1?%+P
ME\6M/B^&[Z3I-V?#>@Z#XP\?>)I;+6=&LO ?C+[4M?\ @C%^ROI?PC_9U^"_
MA7Q[^T)X&\.?L]>$/C?X*M/$G@7XE:+HOCKXP^ OVH9]!O/VB/#WQCUVR\$6
MLOB-/B/KOA'PEJ6IZSIVE^&M5N9]%TI=(UBSL;OQ'+=5M+_X(O\ [,_AW5-.
MGTKQ_P#M">'= L_A_P#L6>!_$'@*T^(>B6O@SXB7W[ WBSP!KO[/_P 2/%EC
MJOPV7Q5#X_T70OAEX?\ !&K^+-,U+2/#T/@F_P#%!MM/E\4RVOBVP(4\'&+3
MFG=6NGU:LGJW_5^R(J>VD_XD%>^CC)MJ_O+IW?>U[[-CO#O_  6/^ VM_$C6
M/#ME\)_V@8/A/9:W\=_A[X!_:3N/"?A.;X'?&/XH?LN^#_%WCGXL^ ? LVG>
M+XO&%GJ%II?@7Q_%X8U;QCX \%>%?&.NZ#XHL+6[NKG3_#SS>C_L;?\ !3SP
M)^V%\6YO@I;_  "_:)^ GB^?]G#X>_M6>!Q\=]$\ :;:?$SX#?$'7KKPQX;\
M9>%)_!/C[QE,[WNL O+'K,&G7!L[=RT8>-5&-HW_  1]_9:T/XH>*?B%I.L_
M'#3M U^;XR^*/!OP+'Q3N7^ ?PA^,O[07AGQ3X!^,OQC^%7PYNM*NT\._$_Q
M=H/CC6=(@U/7+CQ;X+\$VNM:@?!7A^TG\0WL<OT'\&?V#/@=\#/C)X+^./@C
M4_&DWB_P%^QY\,OV(=(MM6UC3+G1I?@[\+?$%QXG\')J-E:^'M/N+OQVNH3Z
ME=:]K5MJ.GZ1=1E=GA"RN7CO(LJM#!.$VI)U%"3@[_:2]WUU_P" *-.:DFYQ
MLFF[*7?7[S[095!3 '(&>!SP:3 ]!^0J?$9QA7SVW#@?J>V:7 ]!^0KR_9ON
MOQ.DKX'H/R%&!Z#\A5C ]!^0HP/0?D*/9ONOQ KX'H/R%&!Z#\A5C ]!^0HP
M/0?D*/9ONOQ KX'H/R%&!Z#\A5C ]!^0HP/0?D*/9ONOQ KX'H/R%&!Z#\A5
MC ]!^0HP/0?D*/9ONOQ KX'H/R%&!Z#\A5C ]!^0HP/0?D*/9ONOQ KX'H/R
M%&!Z#\A5C ]!^0HP/0?D*/9ONOQ K$  X Z'M[5RGC(;O#6ICULKGVZ(37:A
M5)&5!Y'85SWBZR>]T#5;.V5EGN;"YA@,002+++&R(R%H+@ AB"?W+' .UHVQ
M(BE2<HN/,H\R:YFFTK]6EK9>6HUS-I07-)Z1C=*\G=)7>BNVE=Z=S\:/V*]#
MUOQ#XG_X*$:%X>E,>O:O\._@WI^BE[E;*)]5NM/^.,6GQ3WKO&+*VFNFBBNK
MU)89K2W>6Y@G@FCCE3[%\CQ?X>L]+U/X4?":?X!V>N^._#W@;5?!U_-X9_M+
M5=#\0VUYH_BSQE;Z%X(U+QCX1\.:IX .JP?$:._T_P 96[>)=%\%^+=.U.XM
MK1=&UK7/D;P'\/OVIO@#\2_BYXP^$<'@6ZC^*@\+PZO!XL\+:WJRZ>G@6^\5
M'2%LDTOXB>'S']KC\9ZBK"VTQ04TU"RK%#\GKP^+W_!0=4*?V+\#O+*&,HOP
MR\<X,9)RF/\ A;."A+$E?NG<Q(Y.?T3!YEA)T*%ZJA[##>RES6?,U!1<DT]%
MHW9J]K'X[C>'L^KXO'T89=7G&K7G5=6G4IJT+R;47=-2L]'LG:^FAZPFD_'+
MP[J-[8Z9IWQ/M]-.J>(+JS\5:EXQ\$7NCZ1H^F_$+Q+J'B/4/$FC7%WJ?BGQ
M*WB7X;WO@C_A ](F\%WZZ/JZWFFWEOX)T^:XGO\ QJVT7]K/7M.T+X@:3X4\
M<+J$?@/6-*T+2_$&O>"+GQKI6I^+(_V<Y]?U2[N;+Q'!%=VOB*\\/?$6\@L8
M?B9HTMFEO9:7>:QX%O!-X;\+WE^+O_!07*JNB_!%,>7M*_#+QR-ODLTD.,?%
MKCRG9VCQ]QG9EP6)*Q_%[_@H%;K%'!HWP.0PAE@5?AAXX5(@S+(ZQJ/BP%0,
MR*Y"@!G56^\ 1K_:F7P]YXFBU'WFI)N+4=6G%-W32U778\Z7!N<*,G+!9G&*
MC=R6(IOE2NY2Y4[O36RUT21TWAW_ (;2E2S35;/QE#>-\(_&'GW,C^#HK[3O
M$%E#XTM?"0T?3[?XH^)K"^\07ES8^')TM=0\,>(Y@UTEU=_%_68D;3[GZ7^"
M?ASXJ:9K!G\;ZKX@O; ZK\:])EAU?78M:LI-)TKXCZ?;?!'4-.W22RJVL?".
M:XGO+LN+_6C;B_U\RZF9*^0_^%P_\%"O+>'^Q?@5Y3JRO%_PJ_QMY;JZ-&ZL
MG_"U]K*T;O&P((*.RG*L05'QA_X*'DOY>E?!#S9/,(!^''CV-9)I 2"Y3XMY
M+/)M))!);&3FH689;C:D'*O034X^RC&G62<[KE2M9.[M;SL=F%X:Q]&'M(83
M,,1R+GG.6+H4X4HP5W.K"JU.4(I<TDO>Y59:H_6S*H%)Y?:1N_BPVTL-W) 8
MHI('!*@GH*:'3^$8/.""?Q[=QG/UK\1?@W^U-_P4-^*WP]T7QX-#^!=O'J]U
MXCMHHX_A[\0& _L3Q3K7AMF6,_%O8<S:%<YSG&YCP0*]0_X7'_P4.R#_ &7\
M$01Z?#;QX!Z=!\6L'\143S7+J=65"550FKQ4G3FK-Z*SZ:]7MN[F]#+LZQ.'
MGB:.4UITJ=7V3E'$X9WULY+7;K;XGZGZUAMH&?NKT'8>F!V_*CS5R#CD?7_"
MOR6_X7+_ ,%#_P#H%_!'_P -KXZ_^>U2#XQ_\%#-P+:7\$0._P#Q;7QWCICI
M_P +; _SFFLQP:LH8JF[M.2DFW+ND^;1O97T78Z)Y+GL(0F\HQ#C)I752CHG
MU=^B\C];!*I('K]?\*\+_:<=3^SK\>%P/F^#WQ)4^X/A#6 P/J&4D,.A!P<Y
M-?!?_"Y/^"A9!$6D_!.1]K;43X:^.0Y^4DE2WQ;P-HRW/9371Z->?MF?&73/
M$OPY^)M[\*_#/A3Q?X9UGP]K=_H_PR\9QZK'I.K:9=VFHO93O\2-82.?[+)*
MHD_LZX*ABP\EL7$52S+"*,FJEVHMI)QU=GI=RLKF<LGSF491EEE>$9)IS<Z3
M4$[7DU%W:BM6EJ^A^C YZ\XV8]O]'MG_ /0Y)'_WY';JS$J54D$JI(Z$@$CM
MP>O3BB)?+2".59$G-M;.3)#/;"42+<RNC6U\TMS'<QL\<;?.'6"VCC8^5&J"
MQ@>@_(5\!BZ?-C:N(4DXU6[12=X\S>K>SM?6Q^I8+VBPN$;I37LL,J$DVKWY
M4G/_  K>V]B   Y  /J.#2DDC!)(]#R*FP/0?D*,#T'Y"LN1?SK[G_F=)
M<@ 'U'!I<GU/YFIL#T'Y"C ]!^0HY%_.ON?^8$.3ZG\S1D^I_,U-@>@_(48'
MH/R%"@DT^=.SVL_\P&Q,PFAPS#]]"."1P9$!'T()!'<$@\5Y_H8!\;^.,@';
M!X="Y&=H^SW?"YZ#V&!7H:@!T( !$D9!QR"'4@CW!Z5PN@*O_";>..!S8^&V
M/ ^\8[H$_4CC/7%: =D  <@ 'U'!I<GU/YFIL#T'Y"C ]!^0H]QZ.5T]'Z=>
MH$.3ZG\S1D^I_,U-@>@_(48'H/R%'L\.M5=-:K;?IU A))&"21Z'D4Q@,'@=
M#V'I5G ]!^0HVKAN!]UNP_NFE)Q49/F3LGI\O4J*O**[M+\37\/ ?VG+Q_RY
MQ'\=Z\UW&U>3M7)ZG Y^O'-<%H9(U!R"03;*"0<< D@?0$"NYC))7))X[D^E
M?295*]'2ZT7YL\/&34L3*-FK-:_X6_SN2[5QC:,#H,# _"BEHKU3$CDZ?\!?
M_P!!KSFY_P"/F;_>_J:]&DZ?\!?_ -!KSFY_X^9O][^IKP,\VH?XU_Z6CLPG
MQ?\ ;R_)D-%%%>,>H%%%% !1110 4444 %%%% !1110 44C,%!)Z#^IQ47G+
M_G/^% $U%0^<O^<_X4><O^<_X4 345#YR_YS_A1YR_YS_A0-;KIJM>Q84@,,
MH),Y7:79!E@5#%EP0J$AVQU"D'@FOGWX[^*M%M_"VH^%Y[](]7O%LVLX%@D*
MW+V^HVEVXAN&7:C0QP/,2&S^ZP#EJ]\6< \2>42"-Y!;&X%<8QSNSM'NU<%X
MZ\$:/X\TN73-2CE2>),6M_&=DMI*SJ5>!@5>)I"!&QC9249@V5)!SKKFH5HK
M>5*:5_.+/;R"MA,%FN"KXQMT8XS#3JSBM84XUX.<G%W<E&*;:CJ]UJD?&'PI
M\6Z7X<\866JZU<1V5C';O9M/(LK())(98T 6$&0M/,\<>5Y+N&;@$U^A-E>0
M:E9V^HV+[[695DC*JT;Q@C*O()<38;.$SR#@]CCY<^&7P&N?#^JS:QXOF@O)
M[*YDM]&LPJS0&!$<)?7$+@H;DH<I.R^8) K*VX U]2EPNTA0Q5%C>5N9"B<(
MI<Y;:"  #D#&  *X\'"<(6L[VLG;17ZOR5MMSZ+Q)SG),]SS!X[+:DE##X..
M$Y)>\YS4>2,HN"Y5'6[YM5?R9,"0<@D'##(ZX8J6&?1BBEAW*J3DJ,(OREBO
MREQM<KP77^ZQ'WA['(J'SE_SG_"CSE_SG_"NQ1G=7DFKZI7NUUM\CX$D95<L
M757+A0Q8!BP3&P,2#D)@;0<[<#&,4;$!R$4'CG:,\=.<=NWI4?G+_G/^%'G+
M_G/^%:<M-:I2NM5=JU^@#UCC5!&J(L8ADM@BJH06\K!Y;<* %$,C@/)%CRW8
M!F4D9IQ56!5@&4M*Q! (+3S"XF8@\%IIU6:4]9)@)')<!JB\Y?\ .?\ "CSE
M_P Y_P *.:3T;NGHUKMU_ ++LON1,>=^>?,=I),\[Y&18F=\_>=HT2-F.6**
MJ$E5 "!5 D 50)MWG   2[C*6\P?Q[C<3EMV<F:7.?,?=%YR_P"<_P"%'G+_
M )S_ (4<M/M+[T!.22&!)(<[G!Y#MY1@W,/XCY!,.3D^43']PXH+,=N6)V*4
M3)/RH2I*+_=4E5)48!*J<<"H/.7_ #G_  H\Y?\ .?\ "CEI]%*_35;@3Y/J
M?SI*A\Y?\Y_PH\Y?\Y_PH FHJ'SE_P Y_P */.7_ #G_  I/1-[V6PUJTMKO
M<FHJ'SE_SG_"CSE_SG_"H4VVER/7S7^1;@DF^=.RVL_\R:BH?.7_ #G_  H\
MY?\ .?\ "M/>_E?W_P# (6K2VN]R:BH?.7_.?\*/.7_.?\*"W!)-\Z=EM9_Y
MDU%0^<O^<_X4><O^<_X4&9-14/G+_G/^%'G+_G/^% $U!!?CJ>0">>.XY]1D
M'U!(J'SE_P Y_P */.7_ #G_  HLGH]GOZ=0^;7G%VDO.+Z-='T8ALXR"ICB
M()5BI1""4\W82.Y3SYMI/*^=+C'F/D%E IR8(>/^F4?T]*7SE_SG_"E\\>I_
M,_X4G&-G&+DHR335];/1K30:2A=TJE>,I)J3<XNZ:UV5[_>)]E@;@00@G_ID
MGU]!5>XL8!&28H$)>-1(T:KM+R*@.Y1N!RW'8DX;Y2:L>>O^2?\ "@S[A@$@
MG ZGH2,CH.",@CN#BL71IP3G"[G%.45-\T'*.J4DM7&Z]Y+="C4JTI*K[6I+
MV;4^5RTERM.STV;:OY7/#?BKXF\=^']=^&WA7X?Z=X&;7/'&I^(-.N;OQ\VH
MQ:;;6VA>'M6\0_:;>TT%DN9FG32FMT<,C!Y4:0F)74\AJNI?M$Z#+8Q:UKG[
M,&F7&JRK#I"7EYXOTNXN+ECB-+.*YOXI+JY9L?9HDR\DWEHHRPKK?&V5^./[
M.T,1$:S2?$I=HPL?G'P'=10S2*/E8P-<RN&8$H))=I&]\_G#_P %>_"=C96'
MPM^+NJ/96UEHG_"?^']/UR\M#=1>$?&XM8/%'@;QBTB6E]/8?V/J7@NXBL=6
MBMI)-)BU&[DC98)KE7]^OC*F"P&&Q,*.&]I1<*S:@TG[-J5]?-=>]V' _"$?
M$/CG&\-XW.*F5U,9B\7E>&=/VJH5*ZP<L1"*I4Y1J6K)^RBD^93:O=-(^JOA
M?\.OV@O@'\/_  WX ;Q5^SC?6%CJ?C2YTW4?$,7C/2);ZX\3^.O$/C9M'M;&
M.Z>XFDT^+5)(8V@@=DM'N"H6%I2?1=6\0_M"^"KWPS<>--&^!M_X>UGQOX9\
M(7Z^"=1\:MKL(\7ZI8Z987%M!XETQ("8[G4+=I&^UH([43-"6D5$/Y*?MY>,
M/$/[1WQX_9^^"*>!]1MKOQ;\,/AMK'AJQU"VN7U*+6?C#XTM(?'FMVVIBP T
M7Q9\!OASX8GU*]U)[V#5?#USK^F%+R>;Q7;.G[3?&6%;7PK\,;!'80VOQ@^"
MMJMNP(6)M-^(6D6N >DAV-&F[!^6WB7.(EQC@LS_ +7EBG6H4+N%2*G&"4E>
M,O>6EU)*S7;KY=/%GAX^!>&.$L6LQQ4*W$M3$XU8%U*CJX&G@LYS/*U#$SE+
MV=:.)K916G3E1BH^SK4XMRE"HY>T-;6C 2"U@CW.^R/8C[H&DGC23=CG#VCJ
M#Z,?6D^R6IR#;6Y&#P88R. 2.J^M$16.&+  5;:V4 # "E?,V@ <+YLLDF ,
M;Y'?&YV)>LH8@#J<^O89]*X:D*$95(*-3FA&34N:-KI.VEKVN<V&E.6#I^TJ
MUI72O:2_4SC:VN7_ -&@Z$?ZF/H2 1]WH02#['%-^S6VW;]G@VE&C*^5'MV,
M"K)C;C8RDJR]""00035N3ACCCKT^IJ.N-N5G9V=G9ZZ/H]^A25)-/FQ$K.]I
M3@XNW1JVSZ^0[>Y+DNQ,CF60[CEY#D&1SGYG(9@7;+')YY-&]_[S?]]'_&FT
M4X2DH24WS2::3ULFU9/76R>I$958SG[T/9232@DTXW5O3[AV]_[S?]]'_&C>
M_P#>;_OH_P"--HK+EJ?S+_R88[>_]YO^^C_C1O?^\W_?1_QIM%"C4;24EJ[?
M:_R&DVTEJV[)=VQV]_[S?]]'_&C>_P#>;_OH_P"--HJ^2<&G*I'1IVY9W=NF
MVC?F3+F@[2BTWHM5N2QLQDB!9L>;'W/]]?>N T"1_P#A-/&?SOS#X>4_,>5%
MM>D*>>0" 0.@(!KO8RPD0KLR&4_. 5 !RQP>,A<E?1L$<UP6AQR'QGXME%O-
M%;M9>'2DSYV3.;>[!()ZGD\\U<JL7%[K1ZM.RTWVZ&T*,YJ]K):ZM?H=YO?^
M\W_?1_QHWO\ WF_[Z/\ C3:*Y>>5TE+FN[:*7^1FXM3C"UW*2BM5NW8=O?\
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MCZGV"POM$\+:K?W%WK)^$\UY%/IWB+6Y]!M88H)HO+6S@*<OXIB_:MTSQ?\
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M\&8V^&O@G4=76::VC\5:=8>+OB=XN\?:X^DWL6FZ-';Z==_$WQ-KVH:'I?\
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M=13T5NK\R3S4_NC\O_L:/-3^Z/R_^QJM17C'HEGS4_NC\O\ [&CS4_NC\O\
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M\U+,,-ADX7J\E71:<O,FXVZN2TOMKJ?>050BQA5"(Q9$  168Y9E4<*Q/)(
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MGQ2FJ/>1W=EH5F5]\_;M\=^.=-^%.B?"SX62?9?B?^T1XRLO@UX?N%EDMY]
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M&[=3VN"LPGDO$*RFI4:PF90C"AS2M&A*L^2%*?,_>DG))^SLFUHC])J*<O\
MJ\]^.>_;O3:_.::YXN5^6R;L]W;T[G[6HWG.*::@I/FZ2LKZ==>EPHHHI$-V
M3;V2;^X***/\_E0W"S4JD8MIV33;;MHE;N.FIS3G[.2A%<S;<=4M7;Y=QKN(
MU9RADV@LL8:%#(X^XFZ<-"-S[5Q(-IS@XSD?GUHGQ'^./[4OCSQQ9_!SQE%\
M%_@+\,O$.J> [;XKZ7X*TSQEXL^-?C'PU<0P>*=6^&P\7)J/A*+X:>$[ZY_X
M1:\\3ZK87,_B'7GE;3FE_L^*:/[7\=W3+X0\5RPN\3P^&];='B8HRR+IER4=
M64@AE8 JP((8 @YKY+_X)RV]C_PPW^S,QMK93)\,M$F=Q!$K/.TMU/YSL%RT
MIN+N[F,A)<S75S)G=/(S?38"/U;*I9I2HJO*G/EA&RM":^&I4NFI4XNSE%>\
MXW2U/+QCY\PIX*4I*G.G[2I*#U]EO.$%>_.XW47\*E:^AW0^ OQ;E5DC_;6_
M: GW1E7>T\'?LFS26IVYFF>VM_V<YT@ACCWNZ7^N"01AA$TTX2*3C](_9(\9
M:'XO\8^-](_:[^/=KXK\<1^';?Q9K$/A[]F6_CU:/P39W>D:79#3[GX%&&Q2
MU76)+N.*)1'&SS&)5,K$_;<J!E*RQK,DR;&>51(3&0<H2^24894J<@@X(ZT$
MDYR2=Q+-DYW,VW+'/4G8N2>3M7/08B'%.9QE:#R^C&;Y:KEAYM.$M)74;=+W
M(GE.5U9P]I4Q\FI1]G#VC3Y[^ZE)II7=E=I6ZGRG)\ OC%+&T9_;0_:#Y&X;
M?!G[+%JP*?.I6=?@!<K&P*C;Y\+6CMB.\:*T::5/,_#/Q:^,/P3^/OA#X#?'
MWQ)I'Q*\+?&FWU!?@M\:K+P_HGA+Q%_PENA65QJ'B7P)\1_"WAG47\,VEQ-8
MV;7_ (<\4>'](T31=2-M<6-GIT+W3!?O8@[2%)4[6(9<@J0"=RD<@KC((Y!&
M:^!_VW75/&'[$$! 2*#]MWP']GP-JR&Y^'/Q/MKD8  82VQ:*48_>1#RWROR
MUT99F&(S:KB:->C@ZL5"HHU*=&4;737-'F5TUT?1V)Q6"AE[IU*6)Q,5S1:P
M]2JFZEFG[.Z?+[WPZJVNQ]\ G+1XY5IC,Q[36LHM)(8^X7<WF%1@$@,1D4M,
M20-D<98I*3W,LT*23N3_ 'YG_>2L?FD?YG)/-/KYS&R@L74H->PE3;MSZJHU
M]F/+9IRM9<VE][GJTHUZE*%;EM%V<HWO**ZMVTT04J_>7W90?<%@"/H02".X
MXI*5?O)_OI_Z&*YGL_1_D;15Y17=I?B;/AUF^V)\S<V4A/)Y(NT4$^I"DJ#V
M4X''%>B=E_S_  FO.?#O_'Y'_P!>,O\ Z6I7HB<JF?\ /#5]3E'\+_MU?FSQ
M,944J\H)-.$M6[6>K^?WDE%%%>P8$3]1]/ZFO-KH#S;G@?\ 'W)V]J])?J/I
M_4UY=>,WVFY&XX^UR\9..A[5X&>NT:#[27_I2/3ROXL1_P!>Y?DQM%09/J?S
M-&3ZG\S7A>T79_@=I/14&3ZG\S1D^I_,T>T79_@!/14&3ZG\S1D^I_,T>T79
M_@!/14&3ZG\S1D^I_,T>T79_@!/14&3ZG\S1D^I_,T>T79_@!/14&3ZG\S1D
M^I_,T.:::L]5Y W9-]B5_NG\/YBHU"ET#@;2Z!LXX&X?-ST*_>4]00""",TF
M['))([@D_P#UZ8\BE<!5QE?,)'(A# SE<@8<0B0QG((<*1R!69M2IN34KI).
M^M^EWZ=#X6_;56#Q'>?LR?#_ ,TQ:KX@_:+\%>,UB#8/]D_#?0/$GQ%UN;''
MR6ES8Z=8^B1W;1C".5/IC!0@   C9UC( '!O+AIR"/\ GJ)+8R_W_(AW9,:8
M\Y_;@TRY\.Z)\,OVA-/TN[U>\^ /CJ?4_$>G62L;FZ^&GQ"T>;PGXYEM2HWB
MY\/66I07TK+CR8;)2<")2.^MYUN(+>X@DBO(Y(YFBN(,&VFMY&M+@WD6!LV7
M<MTLMBXZ6"QI&?*4"OON'+>Q5I)NRNENMMSYC-K^VC>+2YTTWL]5M8Y+XE>)
MK?P3X#\9^+9&$IT#P_?ZA%;,OF+<3QPLMO;I"V5EEN)WCAACVDO*Z* 2PK\?
MK<:I>-?:QKUU%J>N^(+M-6\1:R%_=ZQJMY;RF[C$+Y,<>GR%[;1V;(M]$+6-
ML4M7,9_3']J=FM_@CXHEMY'60ZU\/%:9&99$#_$KP@CJ'4AU5T9HW4'#(S(V
M0V*_-=.@]X[0'W$*74$(/KY4"+#%G_5Q*L:80!1Z]?=>J_.)P#BB$1@JI$2>
M7$"H(BC_ +D?'R)_LKA?:E "_= 7((.!C((P1QV(X([C@TM%9IV:?9@,V!%8
MQ0"0Q@SK#'B-W>#]^GDLN"MP'C#6[KAUG$;(0X!'N7[./Q#O?!/Q-L/!4]W/
M+X8^)<U_#/:M++)!I?C;0]+N]5L-1L8RYBM(=;T&UU*+4IH51K_4DA:X:60*
M1XG&=LL1Z$2Q;3W1_,78ZGJKQOM=&&"KJ&!! -=#\/=@^*7PM@C ,S^,]%MK
M)0!F9(='UJZOH\=T>U2Y,J<JZEPX(8YUC-.459ZM+IW$]GZ/\C]@^=SL<A@_
MDM'_  KM7>& Z L!@D<G..:6I'(S*VT;IW@G)P,J&6Z7 /7!VJ#Z@#TXCKK3
MLT^S3^YF"5VEW$(W84+O+LJ!<9W%V"A2.<ALX(QR"17R=^VJ8K[X"ZIX9\J.
M]U+QMXI^&OA/PS;A%DNY_$?C#Q]X:NX);?(+B?2QIYU:.5");>33TN(V22!'
M7ZR)< F,L),'8RDAE?!VLI!!#*<,K @@@$<BO"O'NEZ=XD^._P"R=X5U:V\W
M39_B5XL\3-;*%"?;? OPC^(6JZ1=A""@FT[5;_2+JVFP)+:2U@DA9'BC*\F:
MM4L'6JMJ2=&H^5:/2#TN].AU8&FZF)IV:7LZL).]_>Y9)V5MKVZGZ)1*RQ;Y
M@JW$[B[D1 !%']K$I?RE'RI)(UNIF90#(4!<G P^F&7S)&D>0*YF.(%7,/D*
MDBQB(@%5*LY9L8Y9_P"^V7/*FT\H@&"69Q$, @D;RI + %5&,LQ"C!(-?E<Y
M<U6=2UE.]EU5^_3[CZY*3:7+:[2OVN]]A:*XJ^L_'MQ=S7.C^)/#5EI4H MX
M+[PMK.IW$1!!/F7<.I6%L <$ N\88D!=S$*U3^S_ (E?Q>,?!V.^WP3JN?P_
MXJP]_P!*DV]B[-\RTWT?0] HKSR73OB28VV>,/"F[C&SP3JI;J,X!\5@=,YY
MZ9JI_9GQ/;C_ (3;PW!G_EJ/ UZ2O?I<>*WA^;[OSJ>ORX?:0$^S?=?B>G45
MYC_8WQ/;Y3\1M! />+P';F3CGY0?$9'UR.F:3^P/B<>%^)&FY[8\ 61/OPWB
M,*>/4_3FC7[,'4?2G%I2F^D(N6B<MDWHGN+E4/>E)*,?>D[-VBM6[+5V6MEJ
M>G[(Y"J3",QLZ*WFDB)26&UY<9S&C8=U((95*L""17COCGP!_P )3:^-]/FL
M8?$WAOXCZ%JN@^,K*#4VT;55GU:P_P"$?NK2QOI>8;:?2) Z'.P?9H",&&,K
MIR>&_B68W,GQ/T^,;3N#> -.1-I&&#$^)!\K+E2#D-DKT-,'AOXCSJL__"V+
M%I)LJI'P_P!+8?)&T7^NDUF^5<0%XQNMI 8V:(; V]>K+\?C<+6E4P5;"RC1
M?M,91^M4%7PE&G[U:I.FY\U5TX*4N2E'GFURQ]YH\O&Y5A<UA-5*=7$1<)*$
MHTIQA=II-N4;6N]WT//-=^%.F>)]$\2^'=9^%UO?Z+XL\%Z5\,]4T74O%L-U
M9G0M!O?%7]E:2;>.-B][!J'BCQ#<6M^B[VMI(+</Y,SAMSPQX6N/!4>L'1_
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M_(_6H*3G!<K5Y1U^:\C5\._\?D?_ %XR_P#I:E>B)]R/_/9J\\\-_P#'T/\
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MB_PGXHU#PM\:_ 6B^#/ACXN\0:1\,=)TGQ-J^JZ_X\ZS]GC]F+XK_!;]G_\
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M1V7E6.I>%_#.GJ=/T_,&M[8-7M894_0=]RLZO&J3/<;W Q(BP+#Y</EOR%8
M(AP<[!MX'%-54;/DK&4B"LWV<8@M5:..W^QQNX#LH58@R(=I$:$C"#"@!1M4
M8'3 X&/3 XK\WQ^8XK&XAU)32I-W5.5W)*^UU[M[:'U-"C&A2C!6]HK<TUHG
MMTWZ!1117+[1=G^!OS3[K\?\@HHHI^T[)W^0<T^K5OF(0#C(!PRL,C.&1@R,
M/1E8!E(Y5@""" :3:N\2;5\Q8_*5\#>(MYD\L-C<(_,)DV [=Y+XW'-.IRY)
M ">8><)NVYX/.<C[OWL9YQCO51J3G*,4G)RDHJ*>LFW9):;O82U=AC ,H1@&
M09PK %1FW%F<*<CFT M3QS;@0?ZH!::Y*QX4 "-H)4!4,BR6JHEO)L((S;QQ
MHL3 ;XHXU6(KM4!1N20)*Q,C9V)+):0XP"2%MXP]Y<  $YBB?:/WC[8U=A(Z
M[EPYAC!*C>S3Q!&+#:WF263(I#8VD@_-@#D@TW@<P7M95<#7Q&&<)\].G%3D
MZ;BU)*%GSMQ;2C%-R>BU9$JF'C)0J5X4^9J-];QN[7335K;Z'RGXQ_9OM;V^
MN=<^'?B&R\%7&JSF75-/FTJ3Q+X8U&X9F.]-+?6/#[:',7DD<3:?J>G%YF"3
M_:H));2XB\*?LW2?;;>Z^(7B<>,%TR6*7_A'-,T:#1_#Z(C Q#4H9;S6_P"U
M(TE$<L$4NI.(;B*"4;C$ >L_:!\(^&-9T!/'7C'XU?$#X*Z#X)L]9O-7UGPG
M\3+KP!H5_936LFJ1W?BJ]TR*U>\T[3+.PN)66>.XN!;B6"Q,=S-&P^>OV,_A
M3XIU7X;_  >^-OC'XS?M$>(]:\1:)KOBF/POXY^(FIZGX:U#1O$EQJUEX);7
M?"=U86\5F%\%RV^L:608;J^U".#6-4$E]&0WQ.'\!/#2A6J<4XK!5:>>2QD<
MRH4L1E%>5'ZS1J+$4:=:%:+HR@ZL8J:J1=)Q;51.+9Z]+Q%XDJ0AD-#&5/J%
M%QIPJTY-3C'X.:$F[J45K%WT:3/OE+*TC3R18VT<<EPSK (HY D2(3&7^4KG
M>%8$C[X!Z]*]_H.DZG;3V5WI=K=P7D<EK<0-%$IFM[KR8[F-69<(\D<4>U^"
MLD,#@AHHRNR2@4!$56P%<JH4L!R Q YYP1DGUXJ-T$B/&21YBL@95E=E9@51
MPL,%Q)E&(8,L+[,;FVJ"Z_4U\KR:IA_8RRW*ZE)Q<*])Y)D\(U:4DXU*=.5.
MASTG.+DHS6L6[K5(YX5\=2G4KT,RS!XJ2<J3JUVZ7M5K3<XQDIN*DE?D:G9>
MZ[I'YZ>/?AOK?PHO;A].T[4_$G@*\NIH]"N]*M3>:QX:>-99GT74;8AFN[=?
MWD=M<R;E#R(4^<KGTGX2?"#4]4O],\<^/-/CT_3[&.+4/!'@^[E::]L92IC&
MOZI"2T#2!)C+864J,=,O1!>VZQ7%M%(O _ME_"GQ)I/@#XR_&_P?\9OVB_#V
MOZ-X?M/$T7A?PG\2-=T_P=8Z1X5N+>+7!9>%M-TN.:!9O#%G<ZY)+8Q@6][+
M_;%PDPAE$GO_ , ?!?A?0M N/%O@OXU_$KXW^%_'MCI&J:7XH\<_$JU^(VAS
MV*_;;C3=1\&W.F6<=C8V5[#=W<6JQ1V=KJTKQ:0-1>:*U0+^8Y=]%;P]R7/,
M7Q_E5>OFV/Q\GB:F3SC4K4,LDG[7VE"BY3A*5%ZPA3A&3E&T;Z,]_$>*>=8K
M!0R/%NKAY4HJEB<9*I%QKTG%0J*,8I5(.4>;5MWOJDVSW]8XLJ\32@@-ORQV
MN9&WOOY^;=(?,;=G,@#G+8(DIBD(<^:JCV\P D\*#]HL6AY; RZG&<KA]I#Q
MF0R,NU7BQY\<<CW*J"0JEGCL(H("6*\&6//W%W,=I_750=-T(4L!CZ=&AA_8
MQC_9V)IPC+EY5.4Y04(03U;ELKMGR:Q&&G6E4IUXSE5]WF=].;1/?97V7RL%
M%%%1-\FC3OU6EUZDQK3E4G32=HW]^_NNW;2_WA1114>T79_@:<T^Z_'_ ""E
M'4?4?H<C]:2BE*:<9+E;NGI=:Z;$RE/EE>2BK.[=[)=_D>9_&GX8^'OC/\,/
M'/PM\3P6\NC^-/#&KZ'+/<0I,NEW5S;O/IFNQJZ/B?0-6BLM>MG0"6.[TZ&6
M)EF1''PS^S3XZ\17WAO4?A%\4M3M9OCO\#;T> _B=;+),)M5FM(X)M \;6'F
MDOJ.B>-O#\VF^(%U%C(EO>7KZ/YF^P"+^F8#$G8K22E)!%&NW=-*8V$4&6^7
M$[E86W'85D8-\N:^%OVG_P!G_P 2ZEKMK^T=^SZ\.F?'KP;H:6VIZ(;B.UL?
MC5\-M%DFOIOA5X^^TJVG0:TNJS3/X1UN\BNTTJ_:WN(_+C\QA]IPMFN&PT?8
M8^M&,*EJ=-2=E2E/W5.5WJH-W:CK9:.Y^<>(^43K2PN<Y?#7#4.;%*$)2J58
M4TI3Y>32[C%V4KZG1_$_P-I7Q,^''C?X?:T\L.E^-/"FN>&[RXM\K<VL>KZ9
M<V8O+61</%=V<DJ75K/&5D@N(8IHF61%8?SROI^J:+=ZOX>UZ$6_B'POK>H>
M%/$5MMV[-:\->3I%S<PK_#IU]';0WFF( (UM;E?*&QN?WJ^#OQR\&_&31]0?
M14U+1/$_A^6/2_'GPW\2VEUHOC?X9ZYY2LOAGQ3H^J.=9L]3?S;K4=+U2:XU
M&Q\5:+8G4M.NK>W5;4_*G[6?[*-SXTN-0^+7PDM8C\0'M)_^$J\(Q"QL+#Q]
M%:VJ107=FL]WI5C%XEL8((;R2>2_L-0U>VTT:+'J$+743)^I<.XN6'Q%25:+
M>#KWA2Q*DE22GHIV?O.*O=I.[6BU/YD\3N'*O$U"&:94HU:N#P526(PKA-8B
M*ITG*35[)M<KM%*[>BU/R_HJGJK7?AW43H_BC3M4\*:T/L_VW0O%6G:QX8U>
MTO#;.TD+Z-XDT[2-4CMV"F6"XM9KZ&X 5XK/4;!I/$5LVYU73[(P27-_:6Z%
MXB&GO-/PZEU!C3RH[F']Z#Y0:Z@D9=^]%$JJ1]F\1AKWC7A4BM7*-TDEN]7>
MUC^9Y8#'T:SI2PE>&(B_W=.5*=ZE1?!!/ELG*5HIRT3>IHQ@%B"7"E)0YC ,
MH0QN',>>DFPGRR,,KX92& -?3O[%_P +[SXA?&RR\:3VM[;^&_@U;GQ!%>O"
MBV.L^,M=L-2\.:1ID.T;'70M.O==UZ]C /E:S!X8U A;JRLI8O,_A5\!_BA\
M:[ZTL_"6DW>A^'GAFO-2^(_B#2-2T[PU:0+<!H;/0+O5#]D\9:[/(L=CI]GI
M%E:1K>7-NUZ7L4N$;]L/A/\ "?PI\&_!NF^"_!Z,]GI[O/J5_=NW]KZYK.H6
M\3ZMK^L+]RUU*6>WM[%]+MV:U@MEB8 &WBV^%FN9T8TJU*G4YE.E4A:+6O-%
MK]3]=\+N",RQN9T,SS+"2I1PV)H8F,:D)<W[FK&KH[*/V=WH>EY+.3D^6$"H
MN?E4DIOVKT7=L7. ,[1GH,/52S*@8J78)N"JY <[20K_ "Y /!/W3\PY I%P
M& *JP)Q@L44;N-Q9<$!,[\#KMP>":\[^)OQ-\$_"GPG?^+_'FO1Z)I%H\<%M
M-Y!N;C4+V6Y@M;"TTO2;(-J6J7=U?SVUM%';12#?*)+C_1DF(^1IP=:+LU3C
M;WJDMH*VLVE9VBM7;5VT/Z7JXJ&&=103G5P\95*&'C;GK58)RITH.SBIU))1
MBY)J[NU8Y/X^_&C3O@AX"F\1RZ5>>)O%6IWB>&_AOX'T](WU?QYXWU*YATSP
MWX?MHH@9XAJ>M7EC;76J(N=%LWN-7+QBQ,B^U?LH_ A/V>/@[H?@*]O_ .W_
M !9>W^L>+OB7XM;D>+OB?XENQJ?C+6#&Q9R(]2GET6RN9R\_]F:%;1AQ#.BU
MX#^SG\'O%OQ4\=6O[5/[0/@^]\&^(=.FO+;]G[X*ZW<*VH_"#PU)9SZ??>-O
M&&G0E])_X6QXUL[]Y-0%K$LWA/2-0MM.TJ>.WO-0B;]$UBP&D(!8DLS$98EQ
M&K$L>26$40)))81IGA%Q\5Q1FV':6"H3YIP]V=2,ERU%LTHWYE?;WOF?;\#9
M!B/:3SO-DG*M^\PN&<9JKAZM^:G*<I?NY<DK-^S2>FE@  Z #Z<4445\/[1=
MG^!^H\T^Z_'_ ""BBBCVB[/\ YI]U^/^04444>T79_@'-/NOQ_R"BBH;B18H
M)97QY<2F2;)(8PQ_/,L1%[IQ^T-$'6V NX\W!C&V?/D2OGOI9Z^@N>2U<DDM
M6W?1=7\EJ345\NZM^TQIVF?&JY^#6F^!O&?B#4M&O=&T7Q+XGM9_ T.EZ+K/
MB2R34O#>EOX?U7QEI'BC5].U*UEM=0U;Q-X5\*>*5\,0ZJR:O)::/H5_>6??
M3_'SX+06WB:1_BOX&6T\*WL&CZO<GQ9I"W&D7-_>7&AZ?;ZC%<012">Z\0+<
M:,9_.N9[?6;35=%6XDO?#4]Q<]OU'&2IQG3P\ZD9V^&RM>V]][>1A4Q="/NR
MQ-.SNF_>LEM?T\MT>R@JI#N 5C82%&)"R>61((6QG*S%1$4(*N'*,"K$5\2_
MM>>%O%/B#Q;^QE=Z%H>LZY8^%OVN_ GB7Q'/8VL4]MI/AO3?!_Q+L-1U?4IB
M#*JI>7]M;>=)\Q;RHV)4 5[]K7QM^'6E>"]?^(-EXFT?Q1H6DZ?K.K11>$]6
MT>_NM1O](\&2>-Y?#'A^>ZU[3+9M9?PII<VJ^9K5QINCZ;]HGU74M3TK3X+K
M4K9MY\:_A]I?DG6/%WAW0-%N=)\27OB+7+OQ5X>TJUT34="\0>#O#.KZ5K,=
MYJ<^IVMY!J_Q$T.PCLM)MKJWL-<NUL]7U]-:UGP_8ZOZ&7T\;@LP^NRP->I#
MZO*C[.,H1E=QMS<TDXVZVW.;%5L'B:4:4<91C+X;M2:=[=FG\OT/7?F1Q!(K
M^:ENXDD\J)8S]FDLDMVR@R))K6[61F'S/M^8D<45YUI?Q4^&6NV$6OZ7X]\*
MWVEW,6CW9O+76-&:W#:UXFOO!VCEGCU:&.PTZ;Q%I[>#?G@2^N=>L%L[A"%8
M#F+/]HKX(ZCJL.A:7\6_AI>^(+RXM(-,T=/''AX7EYJ6H"]BM94M)+@&72]0
MU.S%OI\ N51HX+R*W5V)B?DG@<?456,<'5O5Q*K15X_S7Y'WD]KK2YW/&87F
MHR^L07LL.Z+;O:_*X\R?\JWMO;TL>V4=F_W6_P#037SWK'[4GP1TF;19;;QQ
MH&MZ7J_BZR\%76H:5KNEMI_A[6]2\,>//%EG)XH:>6[U?3[;4C\.=8T;1CI]
MH\5QJ=Q;6\FRSDN)(_<M'U?3M>TC3-<TF[M=5T?6-.MM0T;6;*[2[LM3TRZM
M4FTZ\M9K-8K>47L)N;TR7$6Y[:>R8,6$6,,7@\9A*:G7PU2"DM4VO=[MZ=/(
MFCB:5>HX4J\*G+NXWUMO:_IU.R\,?\A2?_KU3^9KT? ]!^5><^%_^0K-_P!>
MR?SKT0D[P,\8Z?G7T.4KEP\)?SJR75:]?OZ'FXY7K?<_NDQ]%%%>N<I!*3O0
M9.#G(SP< D9'?! /U%>2WW_']<CM]KFX[?Q]J]<D W#CH./;K7DMUS<7I/)%
M[+@GDC[W0]:^?SYVA1?:5_\ R9'IY5I/$/?]W+3Y%:BBBOF_:+L_P/0E.332
M@TVFD[K1M>@4444>T79_@8<M7R_'_(****/:+L_P#EJ^7X_Y!1111[1=G^ <
MM7R_'_(****/:+L_P#EJ^7X_Y!1110YIIJSU7D.,:KE%-JS:3WV;] HIK?=/
M^>]19/J?S-9-V3>]DW;O8ZO8/^9?<R>BJY+$%%D$3R@P1RN4"123@PQR,9%9
M (Y'5SD$_+\I#8(1KI#<.G[E"@8[6$OF0K=^7-'I\Y6\\C^T6%M+?6Q>T>1-
M+$Z1>6CLU53BZBNDUI>SU_+03H?S25NMKIVZVOU[%D *RL!AD=)$8<,CQL'C
M=2.5='571@058!@00#1_?_Z:>=YG^W]H.ZXW_P![SV):;=GS2<ON-0^>@R24
M50"S&26&!-@Y??-<O##"I4$-*TB-&"6C)D" L2\CE) ,(8$LH66)':V. ACA
MFN7FN[?<05U*UCD60@*S^67(IQK)/E;2L[I7U[VVUML*,53:Y)QM=74HMMJ^
MV_7[O+J_/_B)\&_A5\7+!-,^)?P[\&^.;:*%8+4^)=!M-1NK"*.1)D&EZD+:
M35=(DCDC62&XTRXMY+>15ESL5@?E)_V,_%WA>]F@^"W[2/Q"^%_A69G-OX+\
M2^']"^*VCV .X,GA_6?'E[_; BC0MY=LVIVL5JB[HTE\L6\OWAYR_P"<_P"%
M.23)VIL!.?ONR)P,Y9E .!C.,X8@*>#6U''YCAURTJDE'9WNW^?8SJX3"8B2
ME6BI-.^B2\^K/@T?L<_%&0/-JO[8_P 9;F^?D2:1X<^'.E:7$Q/+-H\6A7@=
M%&2$76X A 8F8*8)*R?L8_$C5M^G>,?VP/BKXF\*2,D5_HFB^&OA]X1U/5M-
M=U%WI\OB'3+&#4HEFA++<M:3+>7-OYUK;2)-.C#[X\YAA&D<,Q.UVE@MXKC@
MDK;6Y837&T LYC5MJ!I&PBL:&?,9$H,D<<<K"-I73&(V),14Y$PZPJN/,E"1
MGAC6_P#:V:=:DOO?^9FLOP$6FJ>J:>T>FO>QP?PU^$_PX^$'AF/P;\./".D>
M$]!MSYT6G6UK-!=7:RC;+JVJ2ZH)M?U+6;R0L+R[U2\GC>.24Q8R!7HF3YC2
MY/FO(DKR_P#+1I8XC#'(S_>:1(6:)')++$QC!"$BJJ7.&F#7,3[9%@E7?:B2
M.:1KB]L[*2SLB1:7;:-)8:A(]PBR31.222XR_P Y?\Y_PKCJSGB9J=>-2<T[
MQ:DDD^C:>MKVO;H=*I8=)*"4&]-E9/:^^W7N3L2V Q+!6+J&).'8$,PSG#,"
M06')!()P:2H3..RJQ[!V9%YXRS  X7[V/XL;3P:9->0VL32W<R6T4<4MQ<74
M\MA:QK8V\;3W]S;Q7+*\BV=E'/=2R*I\N*%Y#]S(7)):V_K[ANA9?Q(_<_\
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M:^.?"0D::1/#FO2MIEI>2IJUG+I>I6EMJMI\Q:[\9?C7\ ;P:3^U!\)+NZ\
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M_"ER?4_F:,GU/YFOF#V^6'9_A_F)YDGI^J_X4>9)Z?JO^%+D^I_,T9/J?S-
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M\)/J6B:7X$^-'A'4[[4/$?AT74FG1>"_^"CGCKQA'I]K8_L]V^E:UK_C71?
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MO)M[]G:UR&L;.WM,1._3=0_[>7\O7>]NJ/@3QM_P60_:+\&7GQX\$ZA^SK\
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M\>:SI/A70M+U+Q1%ITEW+IJ:SJ%E86]UK*V4U_?/;+J$UR+?[=?-$$-U/O\
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M&ZTWP??ZYIWB'49O$&D:AI/A>VU:V%QI>DW3ZCJD%QJ^$[#]D;1(=;T?X?\
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MTPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *.S?[K?\ H)HHS@$GG@_R-1-VA-VO:,G9;NRO9>I45>45W:_,
MZ/PI_P A:;_KT'_H+5Z8O0?0?RKSKPI"W]J3R=EM%R/KQS['/'%>@KD, 2?S
MXZ&OMLH3G@Z4FN2RO9ZM[.VA\QC8VQ-5<R>K?7[O70EHHHKU3D(F;& /NC!/
MTZ]?I]*\[\1:<\<[7L/S6TAW/C[JLQ"A@.F68[2V,G//>O2"JGJ >W('3TJO
M<V\4MN\+11,AV_(T:,G#AONL-N1C(XX;!ZURXW#+%4'25HSY6HRDKKF:LF[:
M[ZFF$J/#U_:2?-%R5TM+*^N^FQXQ17=7?A.&4F2RE>!R>1(6:(<\[4/RC@\#
M'N.@K./A*\QS>0-[%"@/_ D&X>O'7H>":^1KY9BJ$E'D=2[MS032]=;Z'OK'
MX=K27R>C^[7]3EJ*Z?\ X12\'(GM\^SRL?R<;3^/U'.*7_A%;X\&>#'OE1^:
M#</P^AXS6?U#%?\ /J7W/_(KZ[1[_BOR:3_ Y>BNG_X12\'(GM\^SRL?R<;3
M^/U'.*7_ (16_P#^>T/Y+_\ $T?4,5_SZE]S_P @^NT>_P![2_-(Y>BNH_X1
M6^/!G@Q[Y4?F@W#\/H>,TG_"*7@Y$]OGV>5C^3C:?Q^HYQ1]0Q7_ #ZE]S_R
M#Z[1[_BOS2:_$YBBNH_X16__ .>T/Y+_ /$T?\(K?'K/#^ 7/\A_.CZABO\
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MWF?EGMR>P#RL?^^7!4\>O3J.<4?4,3_S[E]S#ZYAO^?T/Q_RL<O174GPI?\
M\4T('<G*C\610PY].O0\9I!X3O,_+/;D]@'E8_\ ?+@J>/7IU'.*/J&)_P"?
M<ON8?7,-_P _H?C_ )6.7HKJ3X4O_P"*:$#N3E1^+(H8<^G7H>,TW_A$[O\
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M[?BCF]OB?^?4_O1^@%E^UC^SFNI?$C2[_P".?PNTF]^%'CCPU\-O'\>L^/\
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M4T>W\(Z':>'] E\/^$)[37)M!TWQ%9.Z[?B@]OB>M.:75MK3S^1[[XA_;/\
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M!@^A_(T8/H?R-3T46GWI_P#@'_ #DCY_^!2_S(,'T/Y&C!]#^1J>BBT^]/\
M\ _X <D?/_P*7^9!@^A_(TH4DXP1[XJ:BAQFTU>GK_<_X U"*=]?_ G_ )C0
M H_F<?\ Z_\ /- 89P,<YY_#N,?UI<#T'Y"C ]!^57%-*SM\E9?B/EC>^M]_
MZU%HHHIC"BBB@ HHHH *A>WAD617BB82H\<@:-&#I)CS$<$8=),?.K9#?Q T
M44 (;>,G)1"0_F F-20_'S_[_ ^;KP.>!3#9VY#@PPD.I1P84(="[2%7!&&4
MR.[E3D%W9B-S$DHH"[[LD\E#C(4X)8?*.&8,&8>A8,P)')#,#U.0P1MC>B.
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M'(.1&H.0SN#D=P\DC@]F=V'+,2?9HMJILCV)LV)Y:[5\L@Q[5Z+Y9 *8 VD
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8% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX:^ ?#EQJOQCT#3+V72_#UI9O>6DD5X9+>0QQ@O$Y52R-E3M&0<"OM(?L#_
MH#_DBWPE_P#"0T__ .-4 <O_ ,/7?V;/^BV_#G_P<1?XT?\ #UW]FS_HMOPY
M_P#!Q%_C74?\,#? G_HBOPE_\)#3_P#XS1_PP-\"?^B*_"7_ ,)#3_\ XS0!
MR_\ P]=_9L_Z+;\.?_!Q%_C1_P /7?V;/^BV_#G_ ,'$7^-=1_PP-\"?^B*_
M"7_PD-/_ /C-'_# WP)_Z(K\)?\ PD-/_P#C- '+_P##UW]FS_HMOPY_\'$7
M^-'_  ]=_9L_Z+;\.?\ P<1?XUU'_# WP)_Z(K\)?_"0T_\ ^,T?\,#? G_H
MBOPE_P#"0T__ .,T <O_ ,/7?V;/^BV_#G_P<1?XT?\ #UW]FS_HMOPY_P#!
MQ%_C74?\,#? G_HBOPE_\)#3_P#XS1_PP-\"?^B*_"7_ ,)#3_\ XS0!R_\
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M .,T <O_ ,/7?V;/^BV_#G_P<1?XT?\ #UW]FS_HMOPY_P#!Q%_C74?\,#?
MG_HBOPE_\)#3_P#XS1_PP-\"?^B*_"7_ ,)#3_\ XS0!R_\ P]=_9L_Z+;\.
M?_!Q%_C1_P /7?V;/^BV_#G_ ,'$7^-=1_PP-\"?^B*_"7_PD-/_ /C-'_#
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MZ(K\)?\ PD-/_P#C- '+_P##UW]FS_HMOPY_\'$7^-'_  ]=_9L_Z+;\.?\
MP<1?XUU'_# WP)_Z(K\)?_"0T_\ ^,T?\,#? G_HBOPE_P#"0T__ .,T <O_
M ,/7?V;/^BV_#G_P<1?XT?\ #UW]FS_HMOPY_P#!Q%_C74?\,#? G_HBOPE_
M\)#3_P#XS1_PP-\"?^B*_"7_ ,)#3_\ XS0!R_\ P]=_9L_Z+;\.?_!Q%_C1
M_P /7?V;/^BV_#G_ ,'$7^-=1_PP-\"?^B*_"7_PD-/_ /C-'_# WP)_Z(K\
M)?\ PD-/_P#C- '+_P##UW]FS_HMOPY_\'$7^-'_  ]=_9L_Z+;\.?\ P<1?
MXUU'_# WP)_Z(K\)?_"0T_\ ^,T?\,#? G_HBOPE_P#"0T__ .,T <O_ ,/7
M?V;/^BV_#G_P<1?XT?\ #UW]FS_HMOPY_P#!Q%_C74?\,#? G_HBOPE_\)#3
M_P#XS1_PP-\"?^B*_"7_ ,)#3_\ XS0!R_\ P]=_9L_Z+;\.?_!Q%_C1_P /
M7?V;/^BV_#G_ ,'$7^-=1_PP-\"?^B*_"7_PD-/_ /C-'_# WP)_Z(K\)?\
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MT_\ ^,T?\,#? G_HBOPE_P#"0T__ .,T <O_ ,/7?V;/^BV_#G_P<1?XT?\
M#UW]FS_HMOPY_P#!Q%_C74?\,#? G_HBOPE_\)#3_P#XS1_PP-\"?^B*_"7_
M ,)#3_\ XS0!R_\ P]=_9L_Z+;\.?_!Q%_C1_P /7?V;/^BV_#G_ ,'$7^-=
M1_PP-\"?^B*_"7_PD-/_ /C-'_# WP)_Z(K\)?\ PD-/_P#C- '+_P##UW]F
MS_HMOPY_\'$7^-'_  ]=_9L_Z+;\.?\ P<1?XUU'_# WP)_Z(K\)?_"0T_\
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MMOPY_P#!Q%_C74?\,#? G_HBOPE_\)#3_P#XS1_PP-\"?^B*_"7_ ,)#3_\
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MQ%_C74?\,#? G_HBOPE_\)#3_P#XS1_PP-\"?^B*_"7_ ,)#3_\ XS0!R_\
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M .,T <O_ ,/7?V;/^BV_#G_P<1?XT?\ #UW]FS_HMOPY_P#!Q%_C74?\,#?
MG_HBOPE_\)#3_P#XS1_PP-\"?^B*_"7_ ,)#3_\ XS0!R_\ P]=_9L_Z+;\.
M?_!Q%_C1_P /7?V;/^BV_#G_ ,'$7^-=1_PP-\"?^B*_"7_PD-/_ /C-'_#
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MZ(K\)?\ PD-/_P#C- '+_P##UW]FS_HMOPY_\'$7^-'_  ]=_9L_Z+;\.?\
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M7?V;/^BV_#G_ ,'$7^-=1_PP-\"?^B*_"7_PD-/_ /C-'_# WP)_Z(K\)?\
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MT_\ ^,T?\,#? G_HBOPE_P#"0T__ .,T <O_ ,/7?V;/^BV_#G_P<1?XT?\
M#UW]FS_HMOPY_P#!Q%_C74?\,#? G_HBOPE_\)#3_P#XS1_PP-\"?^B*_"7_
M ,)#3_\ XS0!R_\ P]=_9L_Z+;\.?_!Q%_C1_P /7?V;/^BV_#G_ ,'$7^-=
M1_PP-\"?^B*_"7_PD-/_ /C-'_# WP)_Z(K\)?\ PD-/_P#C- '+_P##UW]F
MS_HMOPY_\'$7^-'_  ]=_9L_Z+;\.?\ P<1?XUU'_# WP)_Z(K\)?_"0T_\
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MMOPY_P#!Q%_C74?\,#? G_HBOPE_\)#3_P#XS1_PP-\"?^B*_"7_ ,)#3_\
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MQ%_C74?\,#? G_HBOPE_\)#3_P#XS1_PP-\"?^B*_"7_ ,)#3_\ XS0!R_\
MP]=_9L_Z+;\.?_!Q%_C1_P /7?V;/^BV_#G_ ,'$7^-=1_PP-\"?^B*_"7_P
MD-/_ /C-'_# WP)_Z(K\)?\ PD-/_P#C- '+_P##UW]FS_HMOPY_\'$7^-'_
M  ]=_9L_Z+;\.?\ P<1?XUU'_# WP)_Z(K\)?_"0T_\ ^,T?\,#? G_HBOPE
M_P#"0T__ .,T <O_ ,/7?V;/^BV_#G_P<1?XT?\ #UW]FS_HMOPY_P#!Q%_C
M74?\,#? G_HBOPE_\)#3_P#XS1_PP-\"?^B*_"7_ ,)#3_\ XS0!R_\ P]=_
M9L_Z+;\.?_!Q%_C1_P /7?V;/^BV_#G_ ,'$7^-=1_PP-\"?^B*_"7_PD-/_
M /C-'_# WP)_Z(K\)?\ PD-/_P#C- '+_P##UW]FS_HMOPY_\'$7^-'_  ]=
M_9L_Z+;\.?\ P<1?XUU'_# WP)_Z(K\)?_"0T_\ ^,T?\,#? G_HBOPE_P#"
M0T__ .,T <O_ ,/7?V;/^BV_#G_P<1?XT?\ #UW]FS_HMOPY_P#!Q%_C74?\
M,#? G_HBOPE_\)#3_P#XS1_PP-\"?^B*_"7_ ,)#3_\ XS0!R_\ P]=_9L_Z
M+;\.?_!Q%_C1_P /7?V;/^BV_#G_ ,'$7^-=1_PP-\"?^B*_"7_PD-/_ /C-
M'_# WP)_Z(K\)?\ PD-/_P#C- '+_P##UW]FS_HMOPY_\'$7^-'_  ]=_9L_
MZ+;\.?\ P<1?XUU'_# WP)_Z(K\)?_"0T_\ ^,T?\,#? G_HBOPE_P#"0T__
M .,T <O_ ,/7?V;/^BV_#G_P<1?XT?\ #UW]FS_HMOPY_P#!Q%_C74?\,#?
MG_HBOPE_\)#3_P#XS1_PP-\"?^B*_"7_ ,)#3_\ XS0!R_\ P]=_9L_Z+;\.
M?_!Q%_C1_P /7?V;/^BV_#G_ ,'$7^-=1_PP-\"?^B*_"7_PD-/_ /C-'_#
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MZ(K\)?\ PD-/_P#C- '+_P##UW]FS_HMOPY_\'$7^-'_  ]=_9L_Z+;\.?\
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M7?V;/^BV_#G_ ,'$7^-=1_PP-\"?^B*_"7_PD-/_ /C-'_# WP)_Z(K\)?\
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MT_\ ^,T?\,#? G_HBOPE_P#"0T__ .,T <O_ ,/7?V;/^BV_#G_P<1?XT?\
M#UW]FS_HMOPY_P#!Q%_C74?\,#? G_HBOPE_\)#3_P#XS1_PP-\"?^B*_"7_
M ,)#3_\ XS0!R_\ P]=_9L_Z+;\.?_!Q%_C1_P /7?V;/^BV_#G_ ,'$7^-=
M1_PP-\"?^B*_"7_PD-/_ /C-'_# WP)_Z(K\)?\ PD-/_P#C- '+_P##UW]F
MS_HMOPY_\'$7^-'_  ]=_9L_Z+;\.?\ P<1?XUU'_# WP)_Z(K\)?_"0T_\
M^,T?\,#? G_HBOPE_P#"0T__ .,T <O_ ,/7?V;/^BV_#G_P<1?XT?\ #UW]
MFS_HMOPY_P#!Q%_C74?\,#? G_HBOPE_\)#3_P#XS1_PP-\"?^B*_"7_ ,)#
M3_\ XS0!R_\ P]=_9L_Z+;\.?_!Q%_C1_P /7?V;/^BV_#G_ ,'$7^-=1_PP
M-\"?^B*_"7_PD-/_ /C-'_# WP)_Z(K\)?\ PD-/_P#C- '+_P##UW]FS_HM
MOPY_\'$7^-'_  ]=_9L_Z+;\.?\ P<1?XUU'_# WP)_Z(K\)?_"0T_\ ^,T?
M\,#? G_HBOPE_P#"0T__ .,T <O_ ,/7?V;/^BV_#G_P<1?XT?\ #UW]FS_H
MMOPY_P#!Q%_C74?\,#? G_HBOPE_\)#3_P#XS1_PP-\"?^B*_"7_ ,)#3_\
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MQ%_C74?\,#? G_HBOPE_\)#3_P#XS1_PP-\"?^B*_"7_ ,)#3_\ XS0!R_\
MP]=_9L_Z+;\.?_!Q%_C1_P /7?V;/^BV_#G_ ,'$7^-=1_PP-\"?^B*_"7_P
MD-/_ /C-'_# WP)_Z(K\)?\ PD-/_P#C- '+_P##UW]FS_HMOPY_\'$7^- _
MX*N?LV$_\EM^'/\ X.(O\:ZC_A@;X$_]$5^$O_A(:?\ _&:!^P/\"E.1\%?A
M+_X2&G__ !F@#LOA#\;/"/Q_\&Q^(O!/B31_%.AS2-$E]IMRMQ"77[R[E/4>
ME=17Q%_P03TRVT7]D?QK9V=O!:6=G\2_$5O;P0QB.."-+E0J*HX55'  X K[
M=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ S7C_[;7[#?PV_X
M*#? ^^^'WQ0\/IKF@W#"6&1&\J\TZ< [9[>7!V2#/7D'HP()%>P48S0!^5\/
M_!K'X*T?3V\/Z7^TG^TUI'@5AY2^&+?Q6JV2PG[T6WR]NTCC[M?;W["'_!/+
MX4_\$UO@]_PA?PI\.C1]/N9A-?WD\GG7^JS<@2W$QP78 D   *#@ 5[E10!\
M,_\ !07_ ((!_!?]OCXNQ?$F34/&7PS^)42J)/$?@R^CL+J\V]&E#(RL^ !O
M&UL#K5?]A'_@WS^#?[$_QLB^)U[K'C7XL?$FT7;9^(/&>H"^FL?[K1+M"JZ]
M YR1GC%?=U% #1"H_A7N>GJ<G]>:=110 4444 ?"/_!>[_DDO[/_ /V7'PY_
MZ*OJ^[J^$?\ @O=_R27]G_\ [+CX<_\ 15]7W=0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!\4_\$)?^36?'W_94?$G_ *5"OM:OBG_@A+_R:SX^_P"RH^)/
M_2H5]K4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'PC_P %[O\ DDO[/_\ V7'PY_Z*OJ^[J^$?^"]W_))?
MV?\ _LN/AS_T5?5]W4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?%/\ P0E_
MY-9\??\ 94?$G_I4*^UJ^*?^"$O_ ":SX^_[*CXD_P#2H5]K4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
MPC_P7N_Y)+^S_P#]EQ\.?^BKZONZOA'_ (+W?\DE_9__ .RX^'/_ $5?5]W4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !37.*=39* &[J-U%% !NHW444 &ZC=110 ;J-U%% !NHW4
M44 &ZC=110 ;J-U%% !NHW444 &ZC=110 ;J-U%% !NHW444 &ZC=110 ;J-
MU%% !NHW444 &ZC=110 ;J-U%% !NHW444 &ZC=110 ;J-U%% !NHW444 &Z
MC=110 ;J-U%% !NHW444 &ZC=110 ;J-U%% !NHW444 &ZC=110 ;J-U%% !
MNHW444 &ZC=110 ;J-U%% !NHW444 &ZC=110 ;J-U%% !NHW444 &ZC=110
M ;J-U%% !NHW444 &ZC=110 ;J-U%% !NHW444 &ZC=110 ;J-U%% !NHW44
M4 &ZC=110 ;J-U%% !NHW444 &ZC=110 ;J-U%% !NHW444 &ZC=110 ;J-U
M%% !NHW444 &ZC=110 ;J-U%% !NHW444 &ZC=110 ;J-U%% !NHW444 &ZC
M=110 ;J-U%% !NHW444 &ZC=110 ;J-U%% !NHW444 &ZC=110 ;J-U%% !N
MHW444 &ZC=110 ;J-U%% 'Q7_P $(#G]E?Q]_P!E1\2?^E*U]L5\3?\ !!__
M )-7\??]E1\2?^E*U]LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'PC_P7N_Y)+^S_ /\ 9<?#G_HJ^K[N
MKX1_X+W?\DE_9_\ ^RX^'/\ T5?5]W4 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$_\ P0?_ .35O'W_ &5'Q)_Z4K7VQ4/<T"BBBD 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\(_\ !>[_ ))+^S__
M -EQ\.?^BKZONZOA'_@O=_R27]G_ /[+CX<_]%7U?=U !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 57
ME)#'_>JQ5.<_O'^M5'<SJ2LKC\GTHR?2H=[>IHWMZFM.4Y^8FR?2C)]*AWMZ
MFC>WJ:.47,39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D
M^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',
M39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;
MU-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[
MV]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I
M1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*
M',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31
MO;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E
M0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39
M/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-
M'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]
M31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D
M^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',
M39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;
MU-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[
MV]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I
M1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*
M',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31
MO;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E
M0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39
M/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-
M'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]
M31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D
M^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',
M39/I1D^E0[V]31O;U-'*',39/I1D^E0[V]31O;U-'*',39/I2$G'2HM[>II0
MYSU-'*.,NA\9_P#!"'_DU;QY_P!E1\2?^E*U]M5\3_\ !"#_ )-6\>_]E0\2
M?^E*U]L5B=<=@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ?"/_!>[_DDO[/_ /V7'PY_Z*OJ^[J^$?\ @O=_
MR27]G_\ [+CX<_\ 15]7W=0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8J^/O^RH>(__ $I6OMNN:6YZT/A04444B@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X1_P""]W_))?V?_P#LN/AS
M_P!%7U?=U?"/_!>[_DDO[/\ _P!EQ\.?^BKZONZ@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TK"NY
MO]+D^M;IZ5S-ZW^ES?[U=.&5V>;F4^6")3-2^=5/=1NKK43R?;ESSJ/.JGNH
MW4^0/;ESSJ/.JGNHW4<@>W+GG4>=5/=1NHY ]N7/.H\ZJ>ZC=1R![<N>=1YU
M4]U&ZCD#VY<\ZCSJI[J-U'('MRYYU'G53W4;J.0/;ESSJ/.JGNHW4<@>W+GG
M4>=5/=1NHY ]N7/.H\ZJ>ZC=1R![<N>=1YU4]U&ZCD#VY<\ZCSJI[J-U'('M
MRYYU'G53W4;J.0/;ESSJ/.JGNHW4<@>W+GG4>=5/=1NHY ]N7/.H\ZJ>ZC=1
MR![<N>=1YU4]U&ZCD#VY<\ZCSJI[J-U'('MRYYU'G53W4;J.0/;ESSJ/.JGN
MHW4<@>W+GG4>=5/=1NHY ]N7/.H\ZJ>ZC=1R![<N>=1YU4]U&ZCD#VY<\ZCS
MJI[J-U'('MRYYU'G53W4;J.0/;ESSJ/.JGNHW4<@>W+GG4>=5/=1NHY ]N7/
M.H\ZJ>ZC=1R![<N>=1YU4]U&ZCD#VY<\ZCSJI[J-U'('MRYYU'G53W4;J.0/
M;ESSJ/.JGNHW4<@>W+GG4>=5/=1NHY ]N7/.H\ZJ>ZC=1R![<N>=1YU4]U&Z
MCD#VY<\ZCSJI[J-U'('MRYYU'G53W4;J.0/;ESSJ/.JGNHW4<@>W+GG4>=5/
M=1NHY ]N7/.H\ZJ>ZC=1R![<N>=1YU4]U&ZCD#VY<\ZCSJI[J-U'('MRYYU'
MG53W4;J.0/;ESSJ/.JGNHW4<@>W+GG4>=5/=1NHY ]N7/.H\ZJ>ZC=1R![<N
M>=1YU4]U&ZCD#VY<\ZCSJI[J-U'('MRYYU'G53W4;J.0/;ESSJ/.JGNHW4<@
M>W+GG4>=5/=1NHY ]N7/.H\ZJ>ZC=1R![<N>=1YU4]U&ZCD#VY<\ZCSJI[J-
MU'('MRYYU'G53W4;J.0/;ESSJ/.JGNHW4<@>W+GG4>=5/=1NHY ]N7/.H\ZJ
M>ZC=1R![<N>=1YU4]U&ZCD#VY<\ZCSJI[J-U'('MRYYU'G53W4;J.0/;ESSJ
M/.JGNHW4<@>W+GG4>=5/=1NHY ]N7/.H\ZJ>ZC=1R![<N>=1YU4]U&ZCD#VY
M<\ZCSJI[J-U'('MRYYU'G53W4;J.0/;ESSJ/.JGNHW4<@>W+GG4AER*J;J-Q
MI..@XUM4?)__  09Y_93\>_]E0\1_P#I0M?;E?$?_!!G_DU3Q[_V5#Q'_P"E
M"U]N5YLMSZ6F[Q3"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /A'_@O=_P DE_9__P"RX^'/_15]7W=7PC_P
M7N_Y)+^S_P#]EQ\.?^BKZONZ@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "B@]*:6PG>@!U%0QW<;S-&LBM)&1N0-EESZBIJ49)[!ZA111
M3 ***#TH **R?&_C&T\"^'9]0O)%CCB7C<?O&L3X%?$.X^)_P^AU:Y55E>:2
M/Y5P"%/!_*@#L:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1Y_O1R!]:+?G4>=53S_>CS_>CD#ZT6_.H\ZJGG^]'G^]'('UHM^=1YU5//\
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MC!G<@%\D<C/M7PY\1-6\'_$K_@I7X@D\=:II]OX=T-6M=M[\T;M$ I4#D=:
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M)_L2X\AO-C^VKG;$\4>]BW'W6/R@^M 'JM%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX*X&.P_X(A?\%6/B%^VAJOQ<^#?QLTG2[;XR_!6X>UU66PA$=KJJ+))"7V=
M0Z@<#!# X'2@#Y>TGPCXR_X.5/\ @H3\7-$USX@>,/!_[,/P5OCH4&DZ#<FT
M/B&\W,K>:<E6;Y';<ZOA2F.I%<5^WQ^RGXB_X-A_B-\-/C9\"_'OCS4/A1K/
MB%-'\6>$=9U!+JTN$</+L";53+1QR .%WJR@AASGUO\ X,KYFU3]B[XRZE<R
M-/J5YX_+7$LAW2.?L-NWS,>3EF8\]R3WKUW_ (.\+&"Y_P"".NL22*K30>*]
M)>#(R5<R.I(]#M9AD=F([T ?I?X2\26OC;POI>M6,ADL=6M(KRV;/WXY45U/
MY$5HUXQ_P3CFDN_^">GP'EN&:2>;X>>'Y)6<[F=SIMN68GN2Q))/>O9Z "BB
MOE;X_?\ !1?QI\&/BSK7AO2_V9_C9XZL-**+%K>AV4,EE?;@"?++,"<4 >=?
M\%[O^22_L_\ _9<?#G_HJ^K[NK\B_P#@IM^V_P"+/VE]/^!^@:Y\ OBQ\,+.
MW^+_ (?O4U3Q':1QV\C*MS\@VL<$Y(K]=* "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *,444 &.:***  ]*JZGI%MK4"174,=Q''(DH21
M0R[D8.IP>X8 @]B :M44 &WV]Z*** .+_:+OIM/^!/BV2W5C)_9=PA(SE5:,
MAFXYX!)_"O/KNRUJS^*E_+H-[:V+6/@RUFC62#=YI5Y2%Y. #M /]:]D\7^'
M8_%_A+5-)F_U.J6DMH_^[(A0_H:X2#]GMM3$=]J&NZM8ZM-HZZ->_P!F31K#
M/"I./OQ%P<$_,"",G!'6@#E]5^-%]=_#6;Q1H]KIUKJE]/8VOVAK<%]DBC=N
M/5@#R!2^(/B'XR\,7WB^-M:L9HO"MSIJKNLL&=+EDW!CGL&_"O0=1^!6@WWA
MK^R52XM;+S8)0D#K'L,(PH&!@#CGW-2:_P#!G2O$4GB%KB2\_P"*EDM)+O;(
M!C[.5*;>.,[1GKF@#R[4_P!H;Q!J7B_4VT^Q\02+H^K?V:EA;>';JYAN0KE)
M&:X0;$Z]6.!C/:L[X%?$'4;G0/$&E0V\9L])BU&\U#[=;9^UR,#LC12<%%Z,
M.A'%>NV_P7ATS6+RZTW7=?TF'4+A+JYM+1X%@ED!!9L-$64OCYRK MD\YYJE
M9?LW>'].@189=1C>-;I!*)$\PK<*5D4G9R.<@'@'F@#E;WQ%XN;5_!=AHFO6
M&[6[:&XFL?[-4?8;41H7D+>9[D#WX%7M.^,FM7GPR\*ZI-]G^U:MXEATF<K$
M55X6N&B8@=C@=:W-._9_31O$S:I9^*O%%K-)##;LB?8V3RHAA8QNMRRJ>X!'
M//%%W^SSI][?:7))K&NBUT?48]4M[*-K>*U\Y'WC*)$.-V2<$'D\\T >>V?Q
M.^('B#2O"$\.L:1:R>+-7N;7:MD6-M;1NR[ER<%P%)YXSCWK5N_BQJ>E:%?:
M?=Z]<+JVBZQ+81R6VDR7<VH)' CJ6CCYY9L''7I7=:;\#='TJR\-V\<E\5\+
MW,MU9EI1EFD8LV[CD98^E5-5_9[TO4=:O-0BU37;&XU"::6?[//& XE38Z?,
MA(7&" .A - '%O+XB\=_$GP_=66K)H]W-X2GN9YFM"GG,+J':K1N0T:]<YSU
M-6O@]\0;KQI\6]#O&CCA;7/"4MU?HB_?N8+F"('/H!(^!VW&NF;]G73H9=,D
ML]:\0:?)I>F2:2C02PGSX)#EO,W1'<<X.>.0#UK0^'GPO_X0;Q!<2)'9KIUM
M86^GZ8J*&GB12[2L[;!\TC&,M@D$QC/04 =E1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 C_=/TKQSQ#SKU]_UW:O8W^X?I7CGB#_ )#M]_UW:O:R7^(SX/CS
M_=Z7J4Z***^F/RF(4444%!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 444A(5?FSCO@T *?;/X#FN'^-/[17A/X$:9)=:YJ2QS$8
MCLXB)+B5NP"]B3QSQ7C/[6O[?%O\.KFX\,^#Y(;S7A\MU?'!BL,\84=&?^M?
M$?B+Q'J/BK6)=1U2\NK[4+AF,UQ<MN=L]AW ]J[L/@G4]Z>B/G\QSR-%NG1L
MV?0WQD_X*5>*O%US):>&(;?PW8\@2@>?=R+ZG/"?AR*^?_%?C;6?&]XTVN:I
MJ.J3.V\27<S2 'T ).*RR<Q[/X,YV]ORI$41CY0%^@KU:=&$%:*/D<1C*U:7
M-4D*.!0#@445J<H#@Y[CG-+$QBG\Q<K)G[P.&_.DHH>NX'I7PQ_:Z^(/PD:-
M=-\0W5Y9QD'[)?LUQ#M!^Z-Q.T=LCI7U1\#/^"D?AOQ_<0Z?XHA7P[J4F(_/
M#EK:9CQ_P$<]>U?!IYH=P_\ K"&4==W3'O[5RU,'"ION>EA<UQ%!Z.Z[,_8*
MROH=4LH;JWFBN+>9=T;1N&C8>H8=3[&IJ_-/]F_]L+Q+^SYJBV_F3:MH,S W
M&GS.=L8SUA/8X[5^A?PQ^)ND_%[P=8Z]HMQ'=6%VG(!^>)^ZL.V/UKQZ^'E2
M>NQ]IE^:4\4M-'V.AHHHK$](**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%%3(</CCZH\(_X(#D#]D[Q[_V4[Q!_P"E"U]SU\,?
M\$!R!^R=X]_[*=X@_P#2A:^YZ^%J_&_4_H7 _P"[P]$%%%%9G4%%%% !1110
M!4UW0K'Q/HMWINI6=IJ.GW\+07-K=1+-#<QL,,CHP(92"00000:^!OC7_P $
M1IOAAX[O/B)^RKXZO?@GXYFD:YN-,5FD\/:JWWA'+;#Y55B #P>":^Z/B9XZ
ML_A=\-_$'B;4MW]G^'=-N=3NMIPWE01-(^/^ J:_#_X0ZA^V1_P7$\7>,O'7
M@SXJ7WPQ\$>';U[72K6VU:\TJW\X$[8E6V<&1PNT[Y.,D9/- 'O7QP_;J3XF
M?#:^_9]_;K^&^I?#.ZU@+'IWC?3(6N]$N+M3MBNXG0'RG#$G'H2.,YKS/P'_
M ,&X'BSXH:):Z7H/[2T.J_!&YN([JSM;#SYT:+<''^C^8;<2@<@GE6QGFO3/
M^"2O[4?BS]IOXF?$G]DS]J+2]/\ 'VI^%X;EHIM7B^V_:U@E\B59'DRS.-^Y
M7)W#J"#BO0O&_P#P2*^*7[$'B6\\9?L;_$&;08Y',]W\.O$=PUSH6IGJ5C9R
M1"S<J&(&W.=U 'VY^RG^S!X4_8W^ ^@?#WP9:-:Z'H$ C1I#NEN9#]^61OXG
M8\D_0= *]$KY]_X)Y_M9>-/VJ/ASKC?$+X;:I\,_&'A34CI.HV-R=T%U(HR9
MH&[QGMU^M?05 !1110 4444 %%%% !UHHHH 0J">@_*EHHH **** "BBB@#X
M1_X+W?\ ))?V?_\ LN/AS_T5?5]W5\(_\%[O^22_L_\ _9<?#G_HJ^K[NH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-HVG*T1QU*M*R#'U91[CK5[X2_\ !=_]GWXJZO#8W.JZ_P"$9KAEB3^VM/\
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MJ, >GS\UXNQ(4XZXXK.C&U,]+$R_?ML_2!9?.56_O*&_\=6EK ^%?B&/Q?\
M#G1-020R&ZLUW,3D[EQGGWQ6_7#Y'MPE>*84444%!1110 4'I_C10>: .=^*
MWPSL/C'X U+0]1B5H-20QB1OO6\H!VR#Z'!_"ORQ^(G@B\^&GC34M!U%9(KJ
MPF:([E^\@/RG\17ZWL@?=]W+=217R%_P43_9WU#QM\1?"^K:%9O<7GB!QI5Q
ML7[LN05D?U '<]J[,#6Y)<LMCY_/\$ZM)5(+WE^0[_@E?\.Y+33/$7BB:,I]
MK:/3[5B.=JD,^#^ )^E>X>(]<V_$59T^Y:R(G'89&:UOA_X(T_\ 9Z^#=CH]
MJO&G089P<-/<,/F8GO\ X5PLERTMPTS$[IF+GFN#%UN>HVCZ3(<#[&ARR['N
M&W(7V.3]"**9;DR01-S]P9]_EI]..Q,M'8***,9JB2*]O+?3[*:XNI$AM8$,
MDTCMM6- ,L2>P R<U^ '_!3W_@H!XA_;G^.EY9Z?)=Q^!]'O&L-%TB%V9;MT
M;;YSQ@[7<M]TD$],5^PO_!5'XDW'PM_X)^?%36+-C'-_8S:=N!VL!=RQVNX'
MU'FG!K\<_P#@CI\)['XN_P#!0KP)9ZE&D]EH\D^KNC*'61[:(RPY!X(\U5/U
M&>M>QE<(QA+$R5^4SJ2Z'T?^RG_P;OZM\1/!-CKGQ*\63>&[C4HA-;:1I]LL
M\\<9&5>1V^[[K7*_MQ?\$%_$7[/?PYU#Q=X%\17'C71=)C>:_LI[017MM$BE
MGD4#[^%!(7OBOVED42HRL RM@L",AL=,T31QW09;CYHY%V29YRG<?3%<\<UQ
M//SMZ=BO9JQ^('_!%S_@HYJG[.OQDTWX<^)M2>?P%XLNDM;=)G++HEZ_$;+D
MX1&8@$# K]%O^"W0V?\ !,GXGE?[^EC.[Y2O]K6G(]N<U^*?[9_PY7X"?M@?
M$;P]IO\ H\>@^(KF2T5!L6-3(&C"@= N> .G:OUV_P""DGCEOB9_P1!U#Q+-
M\TFO>'O#>H]>@EO--DZ^Y5OS-=6-IQ]M3KQ^TU<E2T:/RC_X)\?LC0_MO_M&
MV?@.?7IO#L-S97%ZUVEJ)R#&A( !Q^61FOO6;_@VBTH0M_Q>#4%^4\GPX,#_
M ,B5\3_\$L_VI?#/['?[5UCXR\7#5)-'@T^ZM"ME")9/,="!P>M?INW_  <+
M? F$;UM_'Q9.0!I*<X_&NC,*F-56U&]O(BG&-KR/R_\ ^"B?_!/W6OV OB=I
MNA:GJEKXDT;7+3[3IVHB Q"55^\I3.,_6OU0_P""#7Q_U7XT?L5?V;KEU<7F
MH>"=6ET6.>:1I&E@\N.1,LQ)X!('H*_.;_@J#^W%'_P4E^./A6U\$^&]8&FZ
M+ UAIEK/&3>ZA*Y^8A$R!G.,G\:_4W_@D)^QYJ_['/[(UIIGB1?)\3>);Y];
MU*(@?N-Z!8XN.X  (K#'2?U2*K_&7"*OIL?F_P#\'!K$?MZQX9E_XI>SY!_Z
M:U]_?\$0=1M])_X)C^#[N\N+:SM;6[U*22:=@J1*+V?+$GH !R>P%? '_!P<
M=O[>L9]/"]F>/^NM>5ZK_P %#=>T3]@?PU\"_#7GZ7:QR7K^)+R.5EDO%GN9
M"L",""(V5BKKT(8@@Y-='U:5?"PA'R)YFI'K?_!7O_@J'<?M<>+[CX?^![JZ
MC^'>D77ES/;J?.\0W*G 8*/O1HW13PU?47_!&[_@D]_PJ*QT_P"*WQ(T]6\6
M74*RZ'H\JATT:$_,L[@_\M3PRGJIQC!KP?\ X(#_ +)G@'XS_$'5/'7B#4+/
M5O$'@V:/^S/#SHH\KD%;IE/WO+8!@<<$5^R@&U<=L 8^G2N+'5E17U:CI;=]
MRXJ^K!0H;YLX8Y8]S7D'[>7[0T/[+G[)?C?QDTL<=[8Z<T&FJXX>]F4I"/H'
M*DCZUZ^HW, ._%?E?_P<?_M$XTWP3\+=/G8S7#OX@U6-'( 3[L*,.F-W(SWQ
M7GX2C[2O&!4K)'Y:VNGZIK]GJ6J00WEXNG+]MOYN6\HR21Q^9(WJTDG4\FOU
M6_X-P_C^NH^&O&OPPO+C,NESKKNF([$[XG_=S*H/8/AL#^+GK7._\$E?V#H?
MC+_P3H^,5W?6JK??$Z-]-T666,-E+12T4G([W(1L_P!Y >H!KX[_ .":?Q]F
M_90_;H\%ZSJ$CV-JVH?V#K<;_*L5O.3"Y8?[$A#\]",]:^BQ%2.)I3I1^SL9
M*ZE<_HJHIO0;MZMP&4@_*P./Z'-.)XZJ/<L.*^53-@R!]YMJ]SZ5_/\ _P#!
M3#]J?Q%^WI^V7=:+IEPUUH.GZP/#OAG3U=C#(WF!%FV9QN>0A=P&37[R?$G7
M6\,_#G7]2C9"^GZ;<7*D-T*1LP_E7\\7_!-W3?\ A*?^"@?PI2X7S/,\46MT
MY;YBS1S&?GVW*#]1FO8RN*7/6?V49SET/LKQ=_P;EZEHOP$DU73?'3WOCJWL
M1>?V<U@4MIWV;_LZ-G[Q/R[CT)KQS_@B3^V1K'[.W[5>D^ [ZX?_ (1'QU>#
M29;*:0E+.]Y6*103A=TN 2.M?NDN5'R_*>V.,5_-3XLNF^&?[<.H7%NOV<>'
M?'$KPK'\@A\C425"X^[CMCI6V$K3Q,)TZSNK7)DN75'[+_\ !:']LC4/V2/V
M3V30;HV_B?QI,=*LYT8H]K" ?.D3'(<*3AASG%?F=_P33_X)@:I_P4+U'Q)K
M^M>(YM \-:3<"&[O]GG7.HW;'<P!/).#WKZ"_P"#E?Q/-<?$3X4:66VQVNGW
MUTP!X#.\07\@2![&OHC_ (-Z]%73OV#VF5%634O$UV[.!AG/EXR3WK.G*6&P
M/M:>DF]RE9RL?FW_ ,%#/V!O$7_!,WXP^'9[#Q)=7>GZFIN]#UZW!M[BTGA<
M$J2F"&4X((/6OU^_X)9_M:7'[9/[(7A_Q)JCJ/$%@[:-J^P<B>(?*P![L,$Y
MZYYKYI_X.2])6\_9^^'>H*B>8OB.2 /M^8*]JSD9]"5R1W(K/_X-J/$$E]\)
M_B=I[,SBWU6RN@C99=\D+!FQZM@9/4T8B3KX%5I_$GN*,K2LCN/VK_\ @O/X
M5_9V^)_BKP39^ ?$&N:]X=NGLI))+F."V=PF><<@>XY K\I_VROVR_%W[<GQ
M=;Q5XPN+<?9U,%A80 _9M-B8_P"K0=R?XCW/)K]Y/B!_P3<^!_Q.\87WB+Q#
M\-M$U37-4F\ZZN9Q*KW$AXW'GENV37XC?\%3?A9H'P5_;X\?>%_"^E0Z+HND
M2V8M;.VC)CB5]/M7;'8?,S,<=V)ZFMLKEAY2M".MMV*I=:G[K?L2$M^QG\(R
MW)_X0S2#D^]G%G\^:]1KR[]B/_DS'X1_]B7H_P#Z1Q5ZC7AS^)^ILM@;I_A7
MP#_P<'_$FSL?V/=.TW3=>L[;7+?Q7:":VL[W_2HHC;3L<JIR%RH8CID U]_$
M;AC#-[*<$_2OQP_X+A_\$_[KX7^)O$/QP/BFVOK?Q7X@MK*'1TLF1K?=:/R6
M!YP,_P#?1KJR^,)5XJ;)EL='_P &[_Q<ATOQ#\5Y/$WB:"W#0:=]EDU;42-W
M-SO*!VZD*.G7:/2OUHNKN*UAEGFDAABB!=Y))A'''@@$ECP%P<\\5_/S_P $
MW?\ @G/??\%#-5\706GBZ'PHWA6.RD+/9-,TYD>7;WZCD#TS7VG_ ,' G[5_
MB;X>:'X7^%/A6\O]-M]>L#J&NW5HDD1GMP5BCA#*#M5R#N3."#@CFNK'8>-3
M%<D'J]^EB(W2/M7QQ_P4!^"?PSU*6QUKXI^#+.\C;:\3:G&Q1O\ >4$?GQ75
M?"?]IGX>?'(&/PCXV\,>))E7>8].U**>0#W7C]!7XR_L0_\ !$[QA^U_\'(_
M'TWB;2_".EZE*RVL4UK+<7,VWJS!=NT'U(KQ']J']G/QI_P3@_:>DT*'7(QX
MDT=8+^RUG2F>+)W!DW8(*G(')Z4++:,Y.G3J7DON'S/J?T?2RK!$TCM'&B L
MS.P55 [DG@#WKS?2OVS?A#K^O6NEV/Q4^'5QJ5]<"UM;./Q%9O<S3LWEB%8P
MY9W+D *.22 *@_8O^,\_[17[*O@7QG>%3?Z]I$=Q<;!A?,!V-^9YK^=+P7\0
M+CX4_'+2?%EK"+J\\.:_#K$4;()/.EAN6F (/#;F09!ZUSX/ ^VE*+=N4'.R
M/Z1?B;^TM\/_ (-ZU9Z9XJ\8:#HNI:I-'!9V-Q>HMU.[D*J*@YRQ( SW-=UA
M2. S<X 4\D9 &/<YK\//A;_P3#_:6_:)^+>A_%7Q%H"M]NU6VU22\U74P]P+
M82K( $8DX"CA>G:OOC_@LS^W1??L;_LY66E^')FM_%_CK?863 XFL;9$ FF#
M=5DYRK#D$ ]JBK@TIQITY7;_  &FSWSXG_MI?"?X*Z\NF>*?B)X/T/4F.W[-
M<ZD@9/\ >ZA3]:VM:_:)\ >%_ EEXHU3QQX1T_PWJ$BP6VK7.KV\-C/(5+E1
M,7VYV@^F*_![]B+_ ()Q_$#_ (*+^)=>UBUU:TT[3M/FQJ>O:L6D:>=N64==
MS <\U%^VK\!/BI^PGHL?P<\:7T.I>$=1U"/Q!IDD#,]O)/'$8F:+/$>2P+ 8
M)QS79_9=)S5)5/>ZBYG:Y^^GPS^-7@WXTV=W-X/\6^&?%4>GLL=Q+H^I17T<
M1;IEHR0/QK>U#5;71=.FOKRXM[&QLT:2XFN)?+AMU499I)&.U0!DY["OS-_X
M-I8]WPS^*H58]QU&PQN&5R86//XX)KY^_P""T/[?FO\ [0O[0NK?#3PU?7*^
M"_"-Y]@-O;S.O]LW@(1MX4_.%8X&0<5R1R^4L0Z$7HMV5SZ7/U3U/_@HE\"]
M$UQM.O/BUX%M[Q7"8_MB(HASCEL8Q]3BO5O"GB[2_&^@PZGHNI:?K&F7&&BO
M;2?[1!)[AT++^!P*_(?P'_P;A^,O$_PEM=9O?B!I6C^*-0LQ<PZ.=,:10S+N
M$;R^8-I/ )VG'H<8KYY_8^_:L\<_\$R/VGIM+U"6[CT?3=1.F^)M(WL86C#@
M-+&F<!BN2& S6W]GT9Q?U>=Y+H3SOJ?MS^VWXXTOPI^RG\2([G4K33;V\\):
ML;))KE8Y)V%G+C8"<YSTQSFOQ1_X)+?$N]MO^"AGPZ;6O$%U_99N;Q;@WM^R
MPX%I/LWEC@DR!2">A /:OT7_ ."PW["+?MI_#2Q^).G^*K;2=-\!>&[[6/(-
MHTS:C'Y!N(U5@<*?EVY[9K\COV0_V=Y?VMOVDO#/P^CUB'0Y_$4DR)>/#YJQ
M;+>>7.W(SPIXR,CBNK+J=/V$KO7KY$RD^8_I5T;7+/Q+I\=[I]Y:W]I,7,4]
MM*LD4@4[#@KP<$U:'7_/^!_D:\@_8._9AF_8Y_9<\,_#V;58=<DT'[43>QVY
M@$OG3R2CCYNBLHZ] /2O7R<5X4K)M+8VN8'Q&^*WA?X/>'XM4\7>)-%\*::T
MHMUO=8O8K"!G92P >;"D\5F_#G]H'P'\8TOF\(^./"?B@Z4BO>OI.LV]XMJK
M=#(4)5?J>E?'7_!Q0@7]A+1U55Q_PF-J,= ?]&NCCZ95?R'I7Y<_LBZS\3_&
M6E^+OA3\+-/O]0U?XD-;-J+V<S13/9V_FA@[@@)"YD4/G[P'.>*]'"Y<JM+V
MO-8ESULD?T#?#[]I3P'\7O%VJ:!X5\6>']<UO1HUEO;2RO!));*S;26."O'M
MFM#XG?&KP?\ !+2/MWC#Q1X?\+VF,K+JE_';K(?]G?AF/L%YK\^/^"4O[$?Q
M'_X)KK\4O'/Q&T2SM=)M_"[7:PVUXDLC_9U:9Q\H)R0I'K7Y^Q:9\4/^"HW[
M8MO:WE]/>>(O%]_,MO<7;21V.DP("Q" J-J"(<(N-Q'J:*>!IRJ-<_NKJ%WV
M/W#T;_@H[\!=>U$6UO\ %KP/)/(P11_;"*"3P,?+7L>EZQ9ZYH\-_974-_:7
M"[X9[9U>.9?9@2K9]N:_%+]JC_@@SXK_ &<O@/X@\=1^.-!\0?\ "-V_VO4;
M)+)[?9'GYMK,<,0,XKI/^#>7]ISQ!HG[0M_\,[B_N+OPOK^ER7EM;22L19W$
M +$H"<+G'..M.K@:;I.K0GS)$J3O8_6CXG_'3P3\$DM9/&7C#POX52Z,BVYU
MK5+>Q6YV'#;"[C)'O4/AS]H+P'XN\%W_ (CTCQMX4U;P_I+-%>ZM:ZQ;S6-L
M5&XAI$) ..IK\X_^#EU=NB?!O;\K?:=8P0.A_P!%_P 3^9KX[_8A_97^+W[=
MW@?4OAQX/U"VT?P+I&H_VSJT][(T=E]JD6(*CE>9&4(S*#G:2>F:5'+XSH*M
M*=@YG>Q^UFC?\%"?@AXA\3KI%E\4_ TFH/*L2Q?VQ&?-8D *I(P22<#FO8;:
MYCN[:.2&:.>&=?,BEC8.CK[,.M?SW?MZ?\$L/''[!V@Z7JWB&^T7Q!X<U:;[
M$E[I[,PBF*%PCJWKC&37WQ_P;P?M,ZY\4OA5XQ\ ZYJ-Q?1^"9K>XTZXGE:5
MA;S>8I0%B<*N!@#@8%&(P$(T?;4I<R'&=W9GZ.$9'1F]@0"?Q/'YUY3XQ_;G
M^#O@7Q>N@ZQ\2O!MAK#OY1MI-2561NFUB,J#GC-?'G_!>7]O_6/@EX3TOX7^
M#[Z32?$'BVU-YJ]U$[+):VI^3RE(.5WC(P.N:^(/V&/^"0?C[]N?P#>>-+/4
MM)\,^'9)'CM;K4\O)J4PSN8]RN>II8? QE3]K7ERKH.4NQ^XOCO]H[X>_#"P
MTV\\2>//!OAZUUK?+IT^I:W:6L>HHF 3$\C!649YQS6O\/?BCX9^,&B'5/"?
MB+0_$VEK(81>:5?Q7L!8<D%XB17\[O[9?@OXG?L\:GH_P;^(TS3P_#Z:XN]#
M<R-)"8+M8@3"QY\LF)R%& &9CU)K]5/^#?)XX_\ @G]FX8) GB2\+L3@(HCS
MU[8Z^U&(R]4:/ME*]]B>;6Q]L^)_%FE^!M!FU36-2T[2=-MPSR7-_=);PHJC
M))9NP )KRBR_X*,_ F^U\Z;%\6/ ?VQ6"[#J\>UCG& =N*_&W]O3]L'QO_P4
MI_:PC\,Z#-<2:!-JR:)X:T6*1UAN',FP32(#AF+?Q8R!TKW#QE_P;B^--+^%
M%QJ6G^.=+U3Q3;V8NO[#_LME5SMRT0D)^\?N@GO5QP-*$5]8G9OH/FE>R/V!
MTS5[76]-@OK&Z@O;&[4/#<02*\<@/<,"5(^F#5FOPK_X)$_M^>)/V2OVC=,\
M$^(KS4)/ _B>^71;[3[B0L-&O#*(A(H)PJ!CDX["OW44;"5)W,JYSV)R/Z'-
M<N*PLJ$^5ZI[%1V"BBBN<84444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1114R'#XX^J/"/^" Y _9.\>_\ 93O$'_I0M?<]
M?#'_  0'('[)WCW_ +*=X@_]*%K[GKX6K\;]3^A<#_N\/1!11169U!1110 4
M'FBB@!KA55F;:!]XD^W>O-OVD/V0/AI^U[X5_L?XC>#=#\5684K%)=P#[3:9
M[PSKB2(]\HP.>:]+HH _-'XI?\&M/P!\::Q)=^']>^('@]7Y%M;WT5] A]A<
MQNW_ (]GWJ'X<_\ !K%\!?"FHI-KGB;XD>*(]P+V[W\%G#*,\JWE1!@"."49
M6&>"#@U^FA.!2!MW0@T >7?LT?L5?"O]C[PZNF_#CP/H/A>/;MDN+>W#7ER.
M/];<-F63I_$QKU*BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^$?^
M"]W_ "27]G__ ++CX<_]%7U?=U?"/_!>[_DDO[/_ /V7'PY_Z*OJ^[J "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPZ#%??'_  3]_P""V/PL_9]_8^\->#?%&B^)K36O#,#6[)IUFCQWS[B=Q/\
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MDDH$W8*DMQ]#Q7EYI4J2E&-1*Z[&D-KA1117GE!1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MIY'6OH91@_+D-VQUKRO]KW]C[P9^VK\*)O"GC"T\R$.9K"^@'^EZ9+C&Z/\
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M44$T >&?\%,?CEJW[-O[!'Q4\;:%(UOK6B:#,;&=0<VTTA6%)1CGY&D#_P#
M:_./_@UX_8\OM0U'QC^T9J^ORW-[K#W7A=; _/-,X-M/+=3R'EG9CP"2><GW
M_5?]H_X&:;^TO\"/&'@'6G>+3?%VE7&F2S(H=K?S8R@D53P61B'&>Z@\$9K\
M#] ^(W[5O_!OI\0_$F@VFBK>^!]3U%KQ#J%C+>>']2+D*DZRQ'?',RJH< KG
M: 2,< &;^S]^RCXD_P""W'_!4KXD-XP\47&CVNC75_>W]W$H:XL;-+L6T=I
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ML9:?X9UQHI/%FO7;ZUK9CY6.>0*!$#WV*JC/KGTKZTH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /A'_@O=_P DE_9__P"RX^'/_15]7W=7PC_P7N_Y
M)+^S_P#]EQ\.?^BKZONZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH 1_N'Z5XYX@_Y#M]_UW:O8W^X?
MI7CGB#_D.WW_ %W:O:R7^(SX/CS_ '>EZE.BBBOIC\IB%%%%!04444 %%%%
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M^PWB#_@Y-\!VL_\ Q+_AQXTO%_O7,T,+?^.UK>%_^#COX5ZDR#5O!?CK2&;
M80+#.H^IZ_ES7XQ%1BO8OV+/V*O%G[;WQFM?"_ARWDALE</J>J2)_H^G0<;V
M+="X7)"]R,5=7*\)3CS3O;U,U6DV?OI^RA^VAX!_;1\,7VL^ =2OM2M-.E$%
MP+BPDMVB?&<9/#8[UZN>:X7]G']GGPW^R[\'='\$^%[00:5I<8PV )+V7'SW
M#D=23Z_2NZKYF7+S/DV.A7"BBBD 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 9HW$T44 $?[G[OR\YXXH*@R%L?,>I[FBB@ 4;/N_
M+]**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H(R*** #' _V>GM
M1_7K[T44 #GS<;OFV],\XH9BS!CRRYP3VSUHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*_SBCRO\XJ]Y ]!1Y ]!1[4/JK*/E?YQ1Y7^<5>\@>@H\@>@H]J'U5E'RO\
M.*/*_P XJ]Y ]!1Y ]!1[4/JK*/E?YQ1Y7^<5>\@>@H\@>@H]J'U5E'RO\XH
M\K_.*O>0/04>0/04>U#ZJRCY7^<4>5_G%7O('H*/('H*/:A]591\K_.*/*_S
MBKWD#T%'D#T%'M0^JLH^5_G%'E?YQ5[R!Z"CR!Z"CVH?564?*_SBCRO\XJ]Y
M ]!1Y ]!1[4/JK*/E?YQ1Y7^<5>\@>@H\@>@H]J'U5E'RO\ .*/*_P XJ]Y
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MHGAUX&L(L=57R24SSDXYR<GK784 %%%% !1110 4444 %%%% !1110 4444
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M;P)X#O=0U33]4U:UATVVTA&33-,C?S/(+?>DE)X,AZC'3ZT >@4444 %%%%
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M"MTDNIEACDE2!&;N[MM4?B2*\GU3QMK&O:(JZ?=6NM747B**RM+V*+;'"K$
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M1BBO2.$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ",BFXY-.IO<_A0!\8
M_P#!:M5;X$>%]P'_ "'UP?\ MVGK\U\5^E'_  6L_P"2%^%O^P^O_I-/7YKU
M^D<,_P"Y+U9_+OBE_P CR7HOR!5^8<=Z^@/^"6ZA?VT?"S8&XP7>3CG_ (]'
MKP!/OCZU] ?\$N/^3SO"O_7"[_\ 21Z]#-?]TJ>A\WPG_P CC#_XD?KJ.3^%
M.IHZ_A3B,BOR9']C'YY^/_"WBS]BO]J&\\66^DR:QI<UU-<PS%"ZS1R_>3/9
MNV>U?4?P"_; \$?M&W=O%&L=EKMN-RV]VHW*_?8Q[YKI3\<_AU\1);W1KK5M
M'NVMY&AGMKL+C<.#][BOA[]K30/#_P +/VB-)G^'-V/.D5)PEI)N6&;?PJ%>
MF3CIZTP/3?\ @K7_ ,A7P>?2.8YQ6[\4/VRM8\.Q^$?!/P]BM]2UJ6SA%S,8
M_-2,E5  ';!ZUSW_  54:26;P/YIV2?99&8 <[LKG^M<#\)C-^Q?^TAI-YKU
ML)]*U>&,"\D7<0C@8=2?3/)]J /IKX^>.?B9\(/V<K'Q!'>6%UKUK(K:BJVX
M\L(_' _V:WOV,?VBI/CY\)&U+4I(5U2PD:.[V_* !SG'YUZ-K.GZ;\5OA_<V
MN^.YTW6K1D#X#*5=>&QZC@_45^<_A?XGZQ^QWXU\<>&#O+7<<EH@Y"H3G#CT
M.#UH ^@/ _[7OC#XN?M9R^%]#N+./PS!=NKO]FWMY2?[7OTS7/>,_P!N;XBZ
M+\:O$7A/1]/M=8N%N/LNGI'#E@W3.._XUUW_  3(^$4VB>![[QAJ4+1ZAKSD
M1 CA8\YR/K7E?PN<K_P4DO,$C_B8R#B@#V'P!\7/C!IGPG\<:UXTL8M+N-'L
M?/T_S+=4W-@G) ZC.,U)^R-^T+XU^/GP<\9:A,UM+K^G[8]/5$ 3S#&2,CI@
MD"O4OVLEW_LX^,!ZZ;(/TKP?_@E+J$=E\.O&%Q<2+#;V\\#N['"JH67)/X#]
M* ,?Q_\ %G]HSX:^%[K6-8DTFQT^S4DE[>/<_?\ .NB_88_:)^)?QX^(-TVM
MS6]QX9T^)UFE2U$>^4CY0&]J\U_:$^+6J?MI?&V'P;H-U]G\,V4NWS9&"Q.P
M(#.V3SCJ*^R/@IX \.?"3P19^'=#ELV6!?WA216>XDQ\S'G)_I0!X;\$/VL?
M%?CS]K_5/!>H36;Z1:7%]'%''%M<>47V@MU["O:/ /B[Q!JOQ U*QU&'%G#G
M9^YV^5CI\W?-?)O[+3%O^"C7B#.3_IVI_P#M2OO"@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_@@N,?LJ>//^RG^(_P#TH2OMZO&J?$S[BA_#04445!J%%%% !1110 5\ _\
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M8)L7_A+- L-:"I]T"YMTF&/;YJ["@ HHHH ^$?\ @O=_R27]G_\ [+CX<_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4%CBE*5@]CJCY#_X(+#;^REX^_[*CXD_]*%K[<KXD_X(-\?LJ^/O^RH>(_\
MTH6OMNO.EN?34](I!1114E!1110 4444 !YKY%_X+;_M>:U^Q7_P3\\2>)O#
MMU+9>(-9NH= L+M&*R6+W._=.A[.D:NP/8J*^NCR*^3/^"U7[&NM?MO_ +!/
MB+POX:CDN/$VDW,.NZ7:H0'NY8-VZ%"> [QO(JD]V'J: /Q2O?\ @D)XP/\
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M]G/]GCX?ZHFKZEI6KWQN-1\07"$#;M98GRR%X@_EX0.QYR: /U*_X)Y^$)_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQR _88CMXY^9CG'<L?6H_AN?$'A'2K[3[[6+R\N(_![:ANFG9F29BVULL?O
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M8< D?A6'KWACQ;(W@^YTWX?R6UEX4,T$>DRZA:%5#0[(YU*R%048YP 6QG%
M',^)/&5S%\%]%\5:EXPU"/48-!CN-,LK>Y>*:[NHV;=).J<21L H);W[U]1
MYKY5NO@K\2M'\#7NFQ^';+5+_6O"\&B-<-J4033726?SL @%A)'*IX_B1>X&
M/J:WW&VCWKL?:-R@Y"GTH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  ]*
MR;F#,TGUK6K.N?\ CX?ZUI3=F<N*C>**WD_YQ1Y/^<5-16_,</L[D/D_YQ1Y
M/^<5-11S#]F0^3_G%'D_YQ4U%','LR'R?\XH\G_.*FHHY@]F0^3_ )Q1Y/\
MG%344<P>S(?)_P XH\G_ #BIJ*.8/9D/D_YQ1Y/^<5-11S![,A\G_.*/)_SB
MIJ*.8/9D/D_YQ1Y/^<5-11S![,A\G_.*/)_SBIJ*.8/9D/D_YQ1Y/^<5-11S
M![,A\G_.*/)_SBIJ*.8/9D/D_P"<4>3_ )Q4U%','LR'R?\ .*/)_P XJ:BC
MF#V9#Y/^<4>3_G%344<P>S(?)_SBCR?\XJ:BCF#V9#Y/^<4>3_G%344<P>S(
M?)_SBCR?\XJ:BCF#V9#Y/^<4>3_G%344<P>S(?)_SBCR?\XJ:BCF#V9#Y/\
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MHHH **** "BBB@#X1_X+W?\ ))?V?_\ LN/AS_T5?5]W5\(_\%[O^22_L_\
M_9<?#G_HJ^K[NH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH 1AE:^%OV]?V#M4N?%%]XT\&V3ZA%?MYVH:? F95DZM(BC[V<<CN>*^ZJ,
M5XN>Y%ALUPSP^(^3ZI]T>MDV<XC+<0L1AWZI[-'XHWFAZAINHFQN;.ZM[Y7"
M^0]NR3 YZ;"IS] >:^BOV-OV#_$'Q-\5Z?K?B;39-)\+6,BS+'<K^_U!E8':
MRGHAZ'/8U^D/V>,9_=I\W7Y>M.V+G.T9]<5\/EGA=A,-B%6K57-+5*R7WGV6
M9>)&+Q.'="E34+[N[?W$-C91V%O'#$JI'$H50.P Q_A4]&,&BOU",4E9'YNV
MV[L****H HHHH **** "BBB@ HHHH **** "BBB@ HHH)P* "BFNZQ_>.,G
MS2></[R?G0)R2W'T4SSA_>3\Z3SUP<L./>@7,B2BF@YP0?E^M.H*"B@\BO,=
M3_:W\!Z'\0KKPU+K1DOM/^2[DBB>2"S?&1'(XS\Y]!GTXH ].HKB](_:)\%Z
M[>QV]KKUO)+(X108I$!).!RR@5V4,R7$2O&RR(W(93D'\: '4444 %%%% !1
M110 4444 %%!H!H **** "BBB@ HHHH **** #'-%%%  1F@C-%% !1110 8
MS1110 ,-PP>0>"#WHVCCC[O3VHHH ****  C<.:,444 %%%% !1110 4444
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MQ1Y/^<5-11<.4A\G_.*/)_SBIJ*+ARD/D_YQ1Y/^<5-11<.4A\G_ #BCR?\
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M^WD^"T?P9C=@J12:%'9+>29Z98 2L<_WB37Y)_M??M??\$\_'5U?2>$_V?\
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M\"IJT?@[3%UR:&XU?[,AO)(DV1M*1EL+V&>* -:BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "FR4ZFR4 -HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4G7\U)% %C1-#L?#6E06&FV=KI]C:H(X;>VB6**%1T"JH  ]@*M444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'PC_ ,%[O^22_L__ /9<?#G_ **O
MJ^[J^$?^"]W_ "27]G__ ++CX<_]%7U?=U !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !5+Q)X>L_%OA^^TO4+>.ZL-2@>VN(9%#++&ZE
M64@\<@FKM% 'Q-^Q]_P3GG^"OCSXWZ=>12KH^OV;Z-HETX&);6XA;?\ B"5!
M^E=#_P $L/V(+K]FGPCJFO\ B2W6/Q1K5Q+$$90?LUNLA";?[NX#/':OKBB@
M KA_VAO@K8_M"?"+6O">HXCCU2W989B-WV>;!VO^!].H)%=P>:CN[F.RM)9I
MI%ABA0N[L<!% R2?I0!\C?"[XK_&K]EG23X2\6?#W6/']A8+Y6G:QI$X<O'G
M"B0MD\#'N*I?$+PA\:_VG(+;Q9/X8M?#,OA"\AU7P[I%W(OVFX)0I/%(>Q9<
M@9XYKZ:\#_&[0_&6E:7-)<0Z9=ZQ&TMO97,JK.R GG'N!G'I6E!\4/#EWI-Q
M?1ZYIC6=M+Y$LHN%VH_3:3GK0!\S_$WXY?%;]HWP'>^"-%^%?B+PIJFK)]CO
MM3U)T%K:*>'9#W[D>U<WXH^'>N_L_"Q\&^)OAO)\4OA]I^D);:--I]LBW5G+
MR94=NNWD[1GO7V,_C?1XX%D;4[$1L$(;SEYW_<_/M7&:?^T=8:QX M-;M+&:
M:6ZE*"R\U5E5 Y4OSVXS0!\4>$?V'?B%%\.]+\86GAF&6_\ #>N37NE^&=2D
MW%M.DY\C!XSCH/4YKT83>)_B\]KHOAOX#Q>$]06:,ZCJ.L+&]JB C>(P1SWX
M'TKZ_'Q$T%I)E76--9K==TH6X4^6,XYYXY.*75?B#H6B%A>:OIUL8Y#$PDG5
M=K@ E3SU (- 'AW[+GPMUSP-^U7\7M1U#3;JUTK5&L(["Z:+9!=B.VC5C&?0
M-D5X[\??V<_''BZT_:86Q\.:E>?\)%K&A7NDK&J[M0CMBKS"('[S8! ^HK[-
M?XG^'$TFYOSK6F&SLV"33"=2D;'H"<]37.Q_M%Z#<_$B\\,1W-M]LCL+>]LY
MFN%\F_,QD"(A]<Q_K0!XO^U1ILGQO_X)[ZEJ6M:1J'@C5/#-LNI6\.J)LFMI
M[494C:> V,#'4''2N-_95@\;_"/]C+5?B)8^']0\7?$KXG7'VM0B!WBW QP-
M(6^8QKP<'C!KUK]H7P'K'[;'[/FE:9H-\NBVNH:JBZ[$[GS/(@=UEA!'0EU
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %&,T44 &*,444 &*,444 &*,444 &*,444 &*,444 &*,
M444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/_!"7_DUGQ]_V5'Q)_Z5"OM:OBG_ ((2_P#)K/C[_LJ/B3_TJ%?:U !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^BKZONZOA'_@O=_R27]G_P#[+CX<_P#15]7W=0 4444 %%%% !1110 4444
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M#^*"V%OXRU*S_LO2M,LYUN$TJW)W2.SH-AD<\$C.><]J\&_X*N?\$ROVCO\
M@H#_ ,%0_%T7A[3]8D^&MN=-CTS4]6U0G2=* TZV%Q]G@=MH_>L[LJ %V!)Y
M- 'M_P#P:HZ)?6O[&WQ"U.XC=+75O&D[V^>C;8D#$?F*_4:O&?V"?V3_  W^
MQ'^R[X<^'?AF:&^@T5#]NO4?<U_>-@S2N<DEB>.3D!0.U>S4 %%%% !1110
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M%% 'Q3_P0E_Y-9\??]E1\2?^E0K[6KXI_P""$O\ R:SX^_[*CXD_]*A7VM0
M4444 %%%% !1110 !<=J\P_:'_;/^%/[*>BO??$3Q]X9\*1J"1'>W:^>Y R
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MP/UK4K+\%ZGI>M^$-+NM%^SMH\UM&UD(%"QK%M&P*!PH P,#IC%:E !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!\4_P#!"7_DUGQ]_P!E1\2?^E0K[6KXI_X(2_\ )K/C[_LJ
M/B3_ -*A7VM0 4444 %%%% !1110!7U;1[37].FL[ZUM[VSN!ME@GB$D<@]&
M5@0?QKXX_:K_ .""7[./[44=U=+X/7P)KT^YEU'PN_\ 9XWG^)K=?W+<\GY
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M3XIZC^PEI\GQD;QO_P )O_;-\)O^$L2X74!%Y@$8/VCY]O4#\17U]0 4444
M%%%% !1110 4444 %%%% !1110 4444 ?"/_  7N_P"22_L__P#9<?#G_HJ^
MK[NKX1_X+W?\DE_9_P#^RX^'/_15]7W=0 4444 %%%% !1110 4444 %%%%
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MAH85G>18$="481!,JQ&17J-M!':1)%&BI'&H1% P$ & !]!4U!4'''W>GM0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?%/_!"7
M_DUGQ]_V5'Q)_P"E0K[6KXI_X(2_\FL^/O\ LJ/B3_TJ%?:U !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FXY/X4
MZF]S^% 'QC_P6I_Y(1X8]M>7'M^XFK\UZ_2C_@M8"/@1X6(_Z&!0?_ >>OS7
MK](X9_W)>K/Y?\4_^1[+T7Y"K]X?6OH'_@EP?^,T/"Q[F&[R?7_1'KY^3[X^
MM?0'_!+C_D\[PK_UPN__ $D>O0S;_=*GH?,\)_\ (XP_^)'Z[#G\JSO&7AQ/
M&/A#5='DFEMX]5LYK-I8CAXA(A0LI]1G(]ZT5_I2U^3+8_L8_"SXR> /%W[,
M_P 3&M+N/4-%UC1Y\V5W;.PR8I,QO'(OW7'#  ]:^N?V(_\ @LMF\M_"GQ8D
M4G<(;;Q'$N%<\ ).O7/J_P")H_:G&H:1\4/$VA^)=-76-)NKZ>6.VOQN5HY"
M&66)VSL..-RX(KY3^,W[)%KK5M-JO@F::9(HWFNM&OC^_A4 EFB;^,8SQWZ4
MP/V]T?6+7Q!I5O?6-Q#=V=T@DAFB;<DBGH0:LU\1_P#!#GXFZUXG_9]U_P .
M:Y<2-=>%]4,$$4I)>")A]WGH 0./<U[7;?MG6]Q^W"WP7_L.X6X72FU3^T3+
M^[( SMQ0![C17AVI_MH6^F_MOV?P7_L*XDN+K2_[1_M/[0H1/D+[=F,]!7M6
MJ7O]FZ9<7&PR?9XFDV@XW8!.,_A0!/17BG[#7[8UO^VG\-M3\16^BS:&NFZB
M^GF*2=9?,*J"6&.@YJ+PA^V;;^+/VY?%7P5_L6XAG\-:5'J1U+S,QS[HK639
MCL0+D#\* /<**^<?A!_P46T3XH?M>>*/A#-I-QI>IZ#=7%K;W<DP\N^>%FWA
M1ZX -:W[=7[=>B_L2>#]-OKVPDUG4M6F\NWL8I CE1U<^W_UZ />**\#_:-_
M;B3]F^P\#:UJGAB^N/"WBQH8[O48I0?[+>4*5##'(&<D]\=JZC]IK]K7P[^S
M3\#F\;7F=4@NE0:;:V\@$FHR2 ;%3ZY&3VS0!ZI17E>J?M+?\(;^R9+\3O$V
MBR:');Z.VJ3:5+<+Y@.TLL0;H6;C Z\UQ?[#/[?UG^V>WB2U_P"$=O/"^K>'
M_)D^Q7<P:2XAD4E9!QPN1C\10!]$45R/@CX@:SXE\27-E?>%[S2;2WC8B\EN
M5=)7#[=@4#/3G-==0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2)A=J%OX=QR,]LUT,?P>TNVOS<)J]]%'#+'.\2S($#ID D8XZG\S5/Q!\(=
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M=7A+ME@]Q<2W#Y_X'(:V: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /BG_@A+_R:SX^_[*CXD_\ 2H5]K5\4_P#!"7_DUGQ]_P!E1\2?
M^E0K[6H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /A'_@O=_P DE_9__P"RX^'/_15]7W=7PC_P7N_Y)+^S
M_P#]EQ\.?^BKZONZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH ****  C<*\]^+7P(7XGZO:WW]I-9R6;>9&GDA@7 P
MISG@@]"!D5Z%10!YA!^SW/#>3W']H:/<27,YF<7VE-=X&X$*,RJ,#''& 3TK
M,TO]E233+BY;^V--D2[?=C^Q_FMCYDC[X29CY<@WX#@9&T?2O8J",T <KX;^
M%MMX9\)S:3;R*L,[K*Y2%4WN%0%F QDL5!)SD^M8%Y\ [G5;C3OM>N+)!IMP
MK(B695C#&]O)$F[S#\X:W3=)C+*Q4C%>DT4 >>^+/@):ZGI<_P#9DEK8:G-C
M=<BV53<#<"Z2E>61P &4Y##@U#?_ +/T>N:':07=]&L]NJ A(/,@3 C#!$8X
M4'8P.,9#GWSZ110!R/PX^'^I?#]%MY=9M[^Q6)(PALV28LHQDR&5L]N-O:NN
MHHH **** #&:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /BG_ ((2_P#)K/C[_LJ/B3_TJ%?:U?%/_!"7_DUGQ]_V5'Q)_P"E0K[6
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** /A'_@O=_R27]G_P#[+CX<_P#15]7W=7PC_P %[O\ DDO[/_\
MV7'PY_Z*OJ^[J "BBO._BU^TIX?^%L,D'G+J6J+Q]D@;<8_=ST4#J>_M0!Z)
M17@OPS_;<L_$&IM9^)+&+1_-/[BYBD+PE?\ :/4?6O<M,U*WU>QCNK6XCN+>
M90R21L&5A[&@"Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!\4_\ !"7_ )-9\??]E1\2?^E0
MK[6KXI_X(2_\FL^/O^RH^)/_ $J%?:U !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\(_P#!>[_DDO[/_P#V
M7'PY_P"BKZONYAD>GN.U?"/_  7N_P"22_L__P#9<?#G_HJ^K[NH ^2/VF_V
MI_%=U\1;SP9H]I>:3#&[P%XU/VB[VD?,'Z*A'Z'G-?/7B?XP^$OAS.R^(O$F
MFVMQNW20H_G7"O[JO5OIS7Z+?$?X6Z;\1]->*Z@A6X9&B%R(QYRHPPRAL9 (
M[9KY+^,W_!(O0?%)FFTT*MQ,2QD &0?4^M 'GUWJEGJ7@S2]9L;B;^S]:A-W
M:B2U:$R1'Y5<!O4U7^'?[2GB[X0>*;?^P[BYOK:5@'TW#21S\] O0,>F>V:^
MDM'_ &5/^$X_9V\+^%[IH])U[PK"MBERZ<M"K9P .V ,#H"*X/XC^/O _P"P
M1XN\,^%-)\)WOQ"^)7B=@+:!"JON+!5.6!" L1SVZYH ^M?A_P"([CQ;X+TW
M4KRSDT^YO(%DDMWZQ$]JV*^5;?\ X*0:I\//C#X9\'_%+X<ZIX'G\83+!IMZ
M+R.YMB[,%578=#DC//%>I>&/VQ/!_BC]I+Q!\*[>XN!XE\.V:WMS))&%M2I$
M?"OGEAO&1[&@#UBBH)]0M[)MDMQ#&V,@/( 2/Q-(NJVK6T<PN;<PR<(_F#:_
MT/0T 6**RO$?C/3_  SH-_J$TRR0Z=;27<J0D/(8T4LQ"YYX!KD/V<_VG_"_
M[3OPR_X2SP[-<1Z3]MEL"UY'Y)\V,@$#)]2* /1**H:AXGL=-LIIY+F)E@B>
M9EC;>Y502Q"CDX [4SPIXJL_&FAPZC8-(UK/G:7C*-P<=#0!I4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\4_\$)?^36?
M'W_94?$G_I4*^UJ^*?\ @A+_ ,FL^/O^RH^)/_2H5]K4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'PC_P7
MN_Y)+^S_ /\ 9<?#G_HJ^K[NKX1_X+W?\DE_9_\ ^RX^'/\ T5?5]W4 %%%%
M !CFO@GXW!8?^"VG@&2Z95@DT=4@,G(+XX"^Y..E?>Q.!7SS^UO^QOX3_:(^
M)'AW7)/%6I>"?&WAV(W-GJ>G2JDZQ!@ 3NQT8C!S0!X3_P %WFMW\(_#.&/#
MZE)K;;$7/F-& N<8Y_*O/O G[(/@+XG_ /!8+XI>"]7TEY/#]CHXU6"WBO[B
M-Q,RV!SN# A5+'"YP,_6OH^T_P""=FEZU\6O#OBKX@?%;Q+X^E\(/]NL;+5)
M85@B*$/O89.5X^;@ C.:W/B3^PYH_B_]I*Y^*'A?XA:MX+\3ZA8?9[S^S6A>
M.[B 4%G!Y(PB<DG[H]!@ ^,AH5K\=_VZOC5'XN^'OB?XK0^&=4?2])L].U)[
M5-&MHII40###. HXZ<#BN_\ V:_V7]-T;]FCQQ#\?/#.N:;X%\)ZA+JGAZVU
M#594DMK=@3Y",C@DG@8'<U[=XH_81T71?B]KGQ"\*?%CQ%X-U'Q$8O[6_LQH
M)%O96<)YC@8Y:1LGCJ2>M1^./V$XOVD?@C#X<UKXX>,M<T^ZN3K/GR20F1XF
M1=JLIS\BD;@#P">E 'SC^P-^R;:^)M-^(WQDM])O?#OA;^SKVV\-:7)++(TT
M7E./-<N>>W-5?V3_ (B?#'P/_P $J(X?B?IFI:SI.J^+[F&TLM/+)<SW"K$P
M4.K*PR203GG?^-?37PN_94L?@[K5EH=S\>?&&NZ2UJ;*/P_-<1&U>&;]THV+
ME5&6XX&.HQ7GDW[ GPAMO!NH?"&;XJZA%=6&H2>(+.!D5+C26Q\[J3\K#@9Y
MP0H!!% 'AFN^$_"WPU_;0^ TG@OX>>*OAA!XBUZ*VU"'4[R>;^U('NX5V,C.
MWRNK%3GC#8/'7]8M,TNUT6R2WL[>WM+>/[D4,8C1?H!P*^/_  5_P3[\._$?
MXL>"?&5U\9O%7CS5/!-_'JMF;J:.X5TCF1A'GDJFY #@]Z^R* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:]7_ %9QW1+[SY+_ (BID/\ -+_P%GZ?T5^;WPY_X+M67@+6Y;GXT3:'X?\
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M $.^N?\ A-7_ /\ &J /N:BOAG_B(U_91_Z'?7/_  FK_P#^-4?\1&O[*/\
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MO_\ XU0!]S45\,_\1&O[*/\ T.^N?^$U?_\ QJC_ (B-?V4?^AWUS_PFK_\
M^-4 ?<U%?#/_ !$:_LH_]#OKG_A-7_\ \:H_XB-?V4?^AWUS_P )J_\ _C5
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M_P#_ !JC_B(U_91_Z'?7/_":O_\ XU0!]S45\,_\1&O[*/\ T.^N?^$U?_\
MQJC_ (B-?V4?^AWUS_PFK_\ ^-4 ?<U%?#*_\'&?[*+,!_PG&M\G'/AJ_P#_
M (U4<W_!Q]^R?!'YC>.-:6'=L$K^';U$9O0%HQD^PR30!]U45\-#_@XQ_91*
M!AXXUIE(SQX;O_\ XU2?\1&O[*/_ $.^N?\ A-7_ /\ &J /N:BOAG_B(U_9
M1_Z'?7/_  FK_P#^-4?\1&O[*/\ T.^N?^$U?_\ QJ@#[FHKX9_XB-?V4?\
MH=]<_P#":O\ _P"-4?\ $1K^RC_T.^N?^$U?_P#QJ@#[FHKX9_XB-?V4?^AW
MUS_PFK__ .-4?\1&O[*/_0[ZY_X35_\ _&J /N:BOAG_ (B-?V4?^AWUS_PF
MK_\ ^-4?\1&O[*/_ $.^N?\ A-7_ /\ &J /N:BOAG_B(U_91_Z'?7/_  FK
M_P#^-4?\1&O[*/\ T.^N?^$U?_\ QJ@#[FHKX9_XB-?V4?\ H=]<_P#":O\
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M$U?_ /QJC_B(U_91_P"AWUS_ ,)J_P#_ (U0!]S45\,_\1&O[*/_ $.^N?\
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M_P )J_\ _C5 'W-17PS_ ,1&O[*/_0[ZY_X35_\ _&J/^(C7]E'_ *'?7/\
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MFK__ .-4?\1&O[*/_0[ZY_X35_\ _&J /N:BOAG_ (B-?V4?^AWUS_PFK_\
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MC_B(U_91_P"AWUS_ ,)J_P#_ (U0!]S45\,_\1&O[*/_ $.^N?\ A-7_ /\
M&J/^(C7]E'_H=]<_\)J__P#C5 'W-17PS_Q$:_LH_P#0[ZY_X35__P#&J/\
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M-_Z!]C_WX7_"KU%>?B,14K3YZKNSZ3+<KPN H+#X2'+!=$4?^$8TW_H'V/\
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MF_\ 0/L?^_"_X4?\(QIO_0/L?^_"_P"%7J* */\ PC&F_P#0/L?^_"_X4?\
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M/L?^_"_X4?\ ",:;_P! ^Q_[\+_A5ZB@"C_PC&F_] ^Q_P"_"_X4?\(QIO\
MT#['_OPO^%7J* */_",:;_T#['_OPO\ A1_PC&F_] ^Q_P"_"_X5>HH H_\
M",:;_P! ^Q_[\+_A1_PC&F_] ^Q_[\+_ (5>HH H_P#",:;_ - ^Q_[\+_A1
M_P (QIO_ $#['_OPO^%7J* */_",:;_T#['_ +\+_A1_PC&F_P#0/L?^_"_X
M5>HH H_\(QIO_0/L?^_"_P"%'_",:;_T#['_ +\+_A5ZB@"B?#&FD?\ (.L?
M_ =?\*^,_P!A_1K.X_X*T_MLPR6EM)#9R^"Q!&T2E81)I$KR;1C"[F 9L=2
M3S7VU7D_P?\ V3='^#7[2WQ:^)UEJ&H76K?&!])?4K:?;Y-F=/M6MHO+QS\R
ML<Y[XH ]*_X1C3?^@?8_]^%_PH_X1C3?^@?8_P#?A?\ "KU% %'_ (1C3?\
MH'V/_?A?\*/^$8TW_H'V/_?A?\*O44 4?^$8TW_H'V/_ 'X7_"C_ (1C3?\
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M^%7J* */_",:;_T#['_OPO\ A1_PC&F_] ^Q_P"_"_X5>HH H_\ ",:;_P!
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MQWH WO\ A&--_P"@?8_]^%_PH_X1C3?^@?8_]^%_PJ]10!1_X1C3?^@?8_\
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M'_",:;_T#['_ +\+_A5ZB@"C_P (QIO_ $#['_OPO^%'_",:;_T#['_OPO\
MA5ZB@"C_ ,(QIO\ T#['_OPO^%'_  C&F_\ 0/L?^_"_X5>HH H_\(QIO_0/
ML?\ OPO^%'_",:;_ - ^Q_[\+_A5ZB@"C_PC&F_] ^Q_[\+_ (4?\(QIO_0/
ML?\ OPO^%7J* */_  C&F_\ 0/L?^_"_X4?\(QIO_0/L?^_"_P"%7J* */\
MPC&F_P#0/L?^_"_X4?\ ",:;_P! ^Q_[\+_A5ZB@"C_PC&F_] ^Q_P"_"_X4
M?\(QIO\ T#['_OPO^%7J* */_",:;_T#['_OPO\ A1_PC&F_] ^Q_P"_"_X5
M>HH H_\ ",:;_P! ^Q_[\+_A0?#&FG_F'6/_ 'X7_"KU% 'P[^TEI%I'_P %
MNOV;[5;6W6VG\)>(3)$(ALD*PL5RN,';VSTK[4_X1C3?^@?8_P#?A?\ "O-/
M'O[(VB^/OVN? ?QAN-0U&+7/ &F7VEV=G&5^SSI=J5=G[Y /%>LT 4?^$8TW
M_H'V/_?A?\*/^$8TW_H'V/\ WX7_  J]10!1_P"$8TW_ *!]C_WX7_"C_A&-
M-_Z!]C_WX7_"KU% %'_A&--_Z!]C_P!^%_PH_P"$8TW_ *!]C_WX7_"KU% %
M'_A&--_Z!]C_ -^%_P */^$8TW_H'V/_ 'X7_"KU% %'_A&--_Z!]C_WX7_"
MC_A&--_Z!]C_ -^%_P *O44 4?\ A&--_P"@?8_]^%_PH_X1C3?^@?8_]^%_
MPJ]10!1_X1C3?^@?8_\ ?A?\*/\ A&--_P"@?8_]^%_PJ]10!1_X1C3?^@?8
M_P#?A?\ "C_A&--_Z!]C_P!^%_PJ]10!1_X1C3?^@?8_]^%_PH_X1C3?^@?8
M_P#?A?\ "KU% %'_ (1C3?\ H'V/_?A?\*/^$8TW_H'V/_?A?\*O4$X% 'P_
M^S+HMG+_ ,%K_P!IFU:TM6M;7PSX:EAA,2F.%Y(&,C*N, L>6(Y/?-?:7_",
M:;_T#['_ +\+_A7F?P^_9&T7X=?M<?$#XP6VI:E-K7Q$T[3]-O;.4K]FMTLT
M*1LF!G)!YS7K5 %'_A&--_Z!]C_WX7_"C_A&--_Z!]C_ -^%_P *O44 4?\
MA&--_P"@?8_]^%_PH_X1C3?^@?8_]^%_PJ]10!1_X1C3?^@?8_\ ?A?\*/\
MA&--_P"@?8_]^%_PJ]10!1_X1C3?^@?8_P#?A?\ "C_A&--_Z!]C_P!^%_PJ
M]10!1_X1C3?^@?8_]^%_PH_X1C3?^@?8_P#?A?\ "KU% %'_ (1C3?\ H'V/
M_?A?\*/^$8TW_H'V/_?A?\*O44 4?^$8TW_H'V/_ 'X7_"C_ (1C3?\ H'V/
M_?A?\*O44 4?^$8TW_H'V/\ WX7_  H_X1C3?^@?8_\ ?A?\*O44 4?^$8TW
M_H'V/_?A?\*/^$8TW_H'V/\ WX7_  J]10!1_P"$8TW_ *!]C_WX7_"FR>%=
M+EC96TW3V5A@@VZ$$?E6A0>E 'Q3_P $)CG]EKQ\>_\ PM#Q&,_2Y4#\@ /H
M*^UJ\E_8\_9'T?\ 8T^'FM>'=$U+4-2M-:\0W_B&1[PJ726[DWN@P.@.,5ZU
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %&.:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 $9/TZ4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,U]!5^3G_!TC^S7X\\6:#\!_C;X/\.WGC72_@/XF?6=?T"",RM=6YDM95D*
M$LB_9W5N"-LAH ?XH_X./_BU\-/"D?C;Q=^PK\9_#_PM8">7Q))J!=[>U(W>
M>\'V0!%"98[I O'WA7Z)?L=_M<^"_P!N;]GGP_\ $SP#?-?>'?$,.^+S%VRV
M\@X>*1?X74\$5^>O[3?_  <@?L]?&'_@GEJT?@>ZN?&'Q"^)FC7'A?2O <5H
MZWXU"ZMV@$<BE<>4LDB@L,[AC YKWC_@WI_88\6?\$__ /@FMX=\'^.(UM?%
M&K:A<Z_>V2/N73_M.UE@ZX#*H&0.Y- 'W!1110 4444 %%%% !1110 4444
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M-=55;2KVSU?2[:ZL9;>YL[B-98)86#QR(0"K*1P01@@CCI5F@ HHHH ****
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M$-$NUVW%W:&82B\9>, JH X'+OC(&2 ?K;1110 4444 %%%% !1110 4444
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MT?4I/$&N:Q>G5?$.M2Q^6^I7C*%R!U"*!A0<G&<]: /J:BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /'O^"AO_ "8%\<O^R?:]_P"FZXKX
MB_X-#O\ E#9HO_8U:Q_Z-2M;]OC]E;_@HQ^T#XS^)'AWX>_%/]G?2?@]XP@N
M=*L]-UBUNX]3CT^X@,,D<DB6$V'*NWS*YP>G3GQ'_@G3_P $J?\ @HW_ ,$Z
M/ 'A_P"'_A3XL?LUVOPXLM9_M'4;39?7EW)')(K7 C,FG)\S*" "Z<X^9>H
M/UL^-GQL\+_LZ_"S7/&GC/6+/0?#7AVTDO;Z]NI B1QHI8@9/+$ X4<D\"OQ
MQ^$OPP\8?\',W[:.F_%CQQI^H>&_V2/A/JA_X171+I2K>+[I&7,SHPVLC@ .
MW9/D[D5](?\ !P=_P2D^/_\ P55\*> O#'PM\>^"?#?A+0GGO-=TOQ!>WEK#
MJMV60P2%8()Q(L>UBJR#"ECCW\N^'W[#/_!5SX2^!='\,^%?C=^RKX?\/^';
M6.RTRPL]'9(;:)!C ']C<$CDXZDD]Z /UMT72+7P]I-KI]C;PVEC8Q);V]O
M@6.WC10JHJC@*H   Z 5<KY\_P""</@;]H[P%\%=0L_VG/&'@7QOX[;59);.
M_P#"L!ALTLC'&$C(-M;_ #AQ(2=G0CDU]!T %%%% !1110 4444 %%%% !11
M10 4444 %%%% !114.H&<6$_V41M<^6WE"1BJ%\?+N(!(&<9.#]#0!^<?_!V
M&<?\$4/B%[ZOHN??_B80U]1_\$H?^477[.'_ &3#PW_Z:[:OSF_;=_X)=?\
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M%O\ X)F_\%!/^"EOARR^'/[1GQ6^%OA#X3K>02:U#X1@D-]KT4<BML88"DG
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M6BA4@$G: @("@*N #DD@'Z#T444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7S7^U;_P $?OV;?VWOB))XN^*/PJT7Q7XFEM4LVU*6ZNK><Q)PBYAE
M0?+G@XS7TE/'YT#H&:,LI7<N,KGN,@C\P:_*&Q_8T_X*<?LC+<:%\,?CU\.O
MB[X369C8R^/X9)-5MD9V8!YF5G<J#CF0C     % 'S3^T;X!U#_@WD_X*\?
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M 4444 %%%% !1110 4444 %!&3].GM110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %!7)SCD=#110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 % &***  C-%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %&T#MTX%%% !1CFBB@ QDT444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4%03THHH **** #K1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1C-%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%%  PW#!Y!X(/>BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@  Q0
M1FBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ VCT[YH
MHHH ,<T8R:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M  C)^G3VHHHH *.M%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% "% 6S@9'0XZ4M%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 '6@C-%% !CFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
8@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>image_003a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
M  $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!
M40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y
M.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4
ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/D
MY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4 ;5%%% !1110 4444 %%%% !1110 4444 %%%(2V&P.>V3UH 6BOA'XP_\
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M&!@GJ0.?VDK^9W_@DU&O_$2)I+>7'N/C3Q;DA>?^/74.G8?@* /V<_X*2?\
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MX!^./B!;Z3K'A+XD>%-)O) D>L7UE ]M "<!I]DA\H'@]6X(^E?G1_P;9_\
M!/OX=_MU?M0^+)OB5HT'B'1/ VDPW]KI,X+6]Q/)-M'F<\A #QW]J]7_ .#H
MO_@G7\)?V3+?X7^*OAOX0TGP?+XJEU/3M6LM.B,=K>JD4;J[)G;N!D[ =* /
MW^\/>(+'Q;H%CJFFW4-]IVI6Z75K<1-NCGB=0R.I[@J01]:N$;A7R/\ \$(?
M$]]XO_X))?!6]U&XFN[H:3<6QED.6*0WMQ"@^@1% ]@*^N* /Y3OB1\)M)^/
M_P#P7R\6^ _$(NI- \7?'34]*OXX)VB8Q7&M30G!!XQNW>_MUK]C?&W_  :Q
M?LO^(/#UU;Z5#XZ\/WTB,(;NWU^1Q$QR060C# 9Z9' ZU^3/AO\ Y669/^SB
M+C_U(9:_J*H _EO^"?B;QQ_P0@_X+"S^&[K6)[BRTG7+;1]9.\K;Z_I5V4:W
MFE'($@ADB8'DJ1MSE=Q_IG^)GQI\+_!OX:7OC#Q-K6GZ+X7TVV^UW&HW4HCA
M2(C(()ZD\8 Y.:_G&_X.CI;.;_@J]JZV>WS4\.:0EYL;YOM9>$Q?CY92O?O^
M#G[]HC7-#_9]_9W^%(N&AT[6/#L7B#7(,G_3S%#'"BN.X5LMSGTH ^DOBC_P
M=M_L_P#@SQ-)9Z'X3^(GB73XB0-4%M;6=K=8."8=\N]QU'S*N2/3!/U9_P $
M^O\ @L+\%_\ @I%)=6'@?5-2TOQ-8Q>?<>'M=@2UU)8^N]45W61<8;*L>""0
M.<?._P#P1W_X(H? _P /?L"> _$'COX?^'?'/B[XBZ%:Z]JM[K-FEP8UN8A+
M#%$#GRPD+QIE3DE<\9P/R?\ V_\ X0K_ ,$6/^"Q4%Q\-YKS3M'T&\L/$>CA
MI-K_ &&?#W-J6'5/,\U02.F..* /Z-OVQ/VVOAQ^P?\ "27QI\2_$$.AZ0)/
M)MXP-]U?RGD10Q\%VQ] .Y&17YXR_P#!WQ\"T\2R6Z_#GXJ2:;&^TW(AL1<@
M?WC;&X#A<?,.>00>]>,?\'?7@CQ9XBU'X/\ BBSM[ZZ\ VMC=V\LJ0M):VU]
M+S%++@'^$CKC/K7EW[&__!2S]A;Q#^RGI/PM^+/P#L?"5_:Z6-+O/%UAHEOJ
MP-T4V/>&[ 6ZB)?+A,2!<[<D+R ?MO\ L3?M_P#PM_X*#?#1_%'PQ\1)J]K;
M,([VTE3RKS3G).$FCR=I(&1@D$$<UYQ_P41_X++_  5_X)J7%KIGC;4]2U?Q
M7?1>?!X>T*%+K4!%VDD#.JQ)SU=AQS@BOF7_ ((-?\$_?A'^S3XV\3?$;X-_
MM%)\5/#NKZ2UA>Z3'IWV/R&$BM'/+&TID#*J;1NC7<#G/K^0?P6_:;^&/[0?
M_!4[4OBS^TM=:AJ/@74=5OM7O;,6[7HN=IQ:V<B* 7A2,1K@8#!<X&<4 ?L=
M^S[_ ,'5O[.OQA\>VN@>(--\9?#]KZ4Q1:EJL5M-IR\X!DEAE8IG_=-?I3I?
MB*QUK0(-5M;RVN-,NH%NH;I) 89(BNX.&Z;2O.?2OYSO^"S/[4W[$'[5_P"S
MQ:3_  5\/P>&OB)H=[ D4>F^$/[(@U"S*_-#,JJ-W\)5\9'OQC[$_P""%GQH
M\<_M,_\ !#+XP^!;&^GOO%G@V#6O#F@2^:S3JEQ8">"/+?-N62=U4GMM Q@4
M >M_M8?\'/O[/G[-7Q&U+PKI-EXL^(NJZ3.]M=3:'%;K8I(N RB>:50V&RI(
M& 5/6MS]BO\ X.2/V>_VQOB#IOA%I-?\ ^)-7?R;*+Q!' MG=RDX$<=S%(Z,
MV>.<<Y'45^&'_!,?]IWX:_L+_M$:U<?'CX)CXE+<6XTZXL[^UADN-$NEEW33
M?9ITVS%FW=2,AMV><5]N>./V?_V$O^"KG[1>E:Q\+?BY;_L[^*)HXD7PT_AN
M/3S)?1R!TF1?.2&-B@&40_-NW9R2* /WU5MPZ%>>]07UU'9V\T\\BQV\";Y'
M9L*@7))/L!S5/P-H<WACP5I&FW%Y)J4^G64-K)=NNUKMD0*92,G!;&[&3UKR
M3_@I5\0[SX2_\$_OC)XBT^00WVE^$=1EA?'W7,#*#]>: /Q\_9@U2Z_X+9_\
M'!-_XRUM?[4^&OPI::>QMLF2WBMK1Q%:+@XV^;=*\S'G[Q7G[U>L?\'>O[.7
M]L_##X6?%2VBD,FBWEQX:U614^4VMRHD0$]AYB/_ -]>W,/_  9T?#JSM/A#
M\9/%;1@ZI>:GIVEF0CGRX[=Y"?\ @329(]5Z\U]_?\%F/V<W_:I_X)M?%CPI
M;VZW&H1Z)+JNG?+N9+JUQ,H R.6564'MN/!Z4 >8_P#!OU^T5;>/?^".W@K5
M-6O%9_A]%J.CZG*[;A;I:3221@_[ML\'X"OYT?'WA_Q5\;O#OQ&^/C>='IW_
M  F]O'<SA?,$=YJ3W5W&P/'^K:V3C^+[1GY=N&^X/^"4W[;'_"D_^"+O[9GA
MDW36]]9VL%QI\9DPT<FKH-,E=>.2C*C8XSMQ\O6O1OV2/V*!XK_X-;?C!K'V
M%FU;Q#K%QXOL'*?,B:7+#"N/7'V:Z7/'WR<'&" ?I5\?_P!L=;S_ ((3:O\
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M#JN3^.: /Z<[W5+;3M.EO+BX@M[.&,S23R2!8XT R6+'@*!SD\8K\T_VC/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0KLK6\L;<@ <DUJ?LJ?L?_#K]B3X7?\ "%_#'PY'X8\-_;);_P"R"ZGNR9I
MH=S+.[R-D*!\S'   P   #\,?^#L3]G'5/AW^VYX6^*WV%+KPWXRT6"Q,T\;
MM;B_M7(:W; P-]OMP21SQ@U]:^%?VN/^"9>O?LWV_CO4O!WP?AU;^SUN+OP_
M<^'8Y=7CN0N3"4,99B3T<\%2#[5^F/[0'[//@S]J7X6:EX+\?>']/\2^&]4
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M2$*3G@$=:^E?V)?^"8/P7_X)\:7<1?#'PC;:7?W@VW>J73&YU"Y7T:5N0/8
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MSLSL22>6)P, < "N[HH  -HHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHJ&;4;>WDVR3PQMC.&< T 3457_MBT_Y^K?_ +^#_&C^V+3_ )^K?_OX/\:
M+%%5_P"V+3_GZM_^_@_QIT>I6\K*JW$+,QP '!R: )J*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI
M"P7J0,G ]Z %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHIN[_.: '45#=7R6<+22,L<<:EF=VVJH
M'4D]J\!\7?\ !4CX(>"M>N--O/&4375JVR3R+*XFC!QGAT0J>O8UA7Q5&BDZ
MTE&_=I'J97DF89E)PR^A.JUOR1<K>MDSZ$HKYI/_  5T^ H/_(XS?AI-X?\
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M.:MX7\5:O_:DD$BJI6\@;8"H&_YACKDYYQ7Z;4 %%%% !1110 4444 %%%%
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M^!?@:Z_9X_9Q\-:#XB\27GB*Z\*:/''JFN:A*6FNVBCW2SN22<$@\$G"X]*
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M-@9SA?\ &O1?!_B>'QEX<M=2MXY88KH,520#<N&*G./I0!I444TOA]N.O>@
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M+?0]NE 'H'FKO"[EW-T&>306.?NU_/U\9OVB?B1XB_:L\4_MO:;KVL?\*Q\
M_&"P\%II*W4J:?=Z7 L=M/. &VA&)W-\APS'DDYK]]=/U6S\7>%(;^QN%N+#
M5+1;BWF0G$D<B;E<'T*L"* +T-U'<1(Z.K+(-RD,#D4[S5W ;E^;@<]3U_E7
MXE_\$1_^"5?@/_@H#^Q'!\0_B!XO^+4GB*XU^^M3_9_B^:WACCC8;0J8.T8;
M&.>5SWP/OO\ 9>_X(O?"O]DKXXZ/X^\,^(OBI?:QHB31P0:SXJFO;-UEB:-M
MT14!L!N.>#^5 'UW17S1^UK_ ,%=/@3^Q1\0D\(^./%ER/%C1+.^CZ3IEQJ=
MY;QL RO(D*-L#!@0"<D$'&#7H_[*/[9?PW_;<^&Q\6?#'Q-:^)M'AN7L[DI&
M\,]C.OWHIHI LD; \8*\]LCF@#U"BHY;E8X3)E54+ORYV@#N2>V!7QI\4_\
M@X _99^$/Q%O_#>I_$&:ZN-)N!::A>:;H]W?6-A+C)66>*-D7"D$G)'/J"*
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M@OX/R?$#5?$6EV/@N&P75&UB6;%K]F90RRANX((P!R<BOEOX9?\ !P/^RO\
M%7XA:?X;L?B%/8W&L7'V73KS4M'N[/3]0DS@+'</&$.3T)(% 'VE17YY?\%I
M?^"LMG^Q%X\^#?AGP]X^;PUK>I>+]*O_ !9 N@RWZR>%I7E2XF63[-*GWD
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M;^ROK'Q\^"_QB^+?A?Q5X N+6X73]9\4O?Z=KR27$<36KPR+\S-OR,9X!X]
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M3@ 8')Y_.OEW]J3_ (+.?L]_L@_$R]\&>+/&%[=>*M+A^T7^F:'HUWJT]@F
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M (*H_ W]A;Q38^'_ (B>,C8>)-2@^U6VCV&FW6I7TL6<;_+MXW*C/]['KTH
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MOVP/A_\ %GX8_$[P[X%O_A[HT]AI\6J:1_:02YFD8R7 5@4!,;!,8S\N<]J
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK'.:=32,GZT
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M*_2E3E:^;-5_8DU6_P#^"KNG?M"_VYIZZ/8?#QO!/]DF)OM#RM>O<^=O^Z%
M;;MQGC.>U '@O_!4SP_::9_P56_83UJ."WCU>X\2ZU8SW4:;);B'[/:XC)!S
MM!<M@Y].^:S_ /@DUX,TSXJ?\%,/VSOB3XBLX;SQQH?CP^%=-GNE$LFG:9;A
MXXA#D?(KI&F=OH>3DU]'?MA_L2ZI^TO^U9^SS\0;+6K'3;/X*ZY?:K=VL\+/
M)J*W$,2!4(X4KY><G.=W;&:\;^/W_!.+XV?"7]LGQ;\</V7_ !MX+T35/B-;
MVZ>*_"_C"*X;2[^YBPHNHI(5=HV9 ,C8<MN.[G  .3^._A;3O@A_P<<? O5O
M"]O#IMS\6/!.L67BJ&T3R_MWV6-WM[B8#AR/+6,$@8" Y/2OT=>4H/X<X]>Y
MX';]:^*_V*?^"=OQ)T']KK4_V@_VB/&WA_QA\5)M)'A_0[#PY;S0Z+X<LLL9
M!!YN'=I-PW$HGS;^H(-?9FK+=/I%U]@,"WS0L+<RY\M7Q\N[ )P#SP* /Q__
M &D/VF?&GQ=_X+R7OBKP)\'?$GQLT#]FG1'\/PV>F7D5M#:ZO<KNN)][!OWB
M"4QXV_\ +/.:Q)/VI/'GPE_X+E_#/XS>-O@CXN^"/AWXR6(^'NM-JMY'=PZE
M>)C[+.\B*H4A%C4+@_<!W=A]_P#_  2O_P""?6H?L!_#7QLGB3Q!9>+/&WQ!
M\37?B77=8M8&ACN9)6.Q5#$M\J]23U8@# R9_P#@K/\ \$^I?^"C_P"RS_PA
M^EZO9^&_%FB:O::_X>UBYB>5-/O+=PP)"$'E21Q[4 ?*O_!?/X8W'QI_;Y_8
MA\)VWBC7O!<VO:]K]M'K&BW*6]]9-MTPAXR<Y^G%>G#_ ((B^,HSN7]M3]K1
MFVX&_P 7MC/^ZNT?@!^?6MC_ (*$_P#!-WXN?M9>)OV>_&'@OXC>%_"7CSX)
MI<S3ZAJ&FO=Q:A=7$=HLCHN,J UL3SU\SMCG'7]EO_@H1M_Y.?\ A6OLO@6(
MC_QZ,G\S0!TW_!0G_@FUXH_: _X)D1_!OP[XZO\ Q-XJT2^M=3MM7\9W;74N
MO3PW#3B"ZE!!(;<$&<@*J YQFOF_]HK]LWSOA3X;\"_MM?LD^)O"?@_1=3LW
M@\5>%KQ=3T6PNHW AGW0B-K6/=@$;V[G'0#Z5^.__!.SXM?M<?L'V_@7XD?%
MRTD^+FBZVFOZ1XQT33CI]O;3PR%H(V@B,>Z/;\K9ZYS@X%>3?%O]@_\ ;4_;
MH^&)^$_QK^(WP+TSX6ZI);KKU]X4L;^;6=9MX9ED\K$HBCB9RBY8' QT/< _
M1?PEJ%E?^%]/N--FCN-+FMHY+2968K)"R@QD%B2<H5Y)R>M?,W[3Z?\ "^_^
M"C/P-^&Z'SM)\ 6UY\4=?B)RA>+-EI((XY^U27$H.3C[+C!W;E^F/"/A.S\"
M^#])T.P5UT_1;2&RME=MS"*)!&F3W(4#FO(/V>_V>->\&?M/_&3XF>*'TN?4
M/'=[8:?HJ6TKS-8:-8VBI'&Q95"L]U)<S%!D#S1R2#0![G7Q[^VK^SU^S-_P
M4R^.5Q\$_'T\EU\5/!NE)K<2Z<9['5M)LY>%EBNMFS:6<' 8X)Z=:^P@<BOC
MO]O[_@FEXH^.OQ\\*_'#X,>/XOAC\:O"-@VD"^N[5KK3=<T]F+FTNHU.=NXY
M#;6XXQ0!X%\5O^";7[3'_!/[X?:WXL_9]_:<\4>)M*\-VD^I)X(^(,:ZE;O!
M$N]TBN2VX':/XDQTY' KI?CM_P %;)/&O_! JZ^/%OILNE^+/'>CR^&M-TV-
M@TQUB:XET\K'_P "C>5<=1CIUJ3QA^RA_P % /VHO!5]X#^(GQ>^!_@7P=K<
M#V.K:IX,TV]NM:NK9\B1$\Y(HTW*2N5*\'OSGJ/C)_P1>L_&7AG]F7X<^'=7
MTO2O@W\!]736]3T6XMY)+CQ#<1DNK;E8!"97>0D[N7/'>@#Y!\!6?Q@\/_\
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M  3G_;U^,WQ:^'/PGT'X]^"OBWJ$.H7D-GJD>G>(M%D2)%,*EU?=&!D!% !
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MDPOO2&XDG"+"I(&?+!' ^5B,U^B.F:;!HVFV]G:Q)!:VL:PPQH,+&BC"J!Z
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MWQ0UC_A%IK/P%H_BM/$+S,)M"U**RAFCN%?*MN\P[3@@MO(ZFO-/BA_P3O\
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MX9\926=O?>)OBA?:MK/B:_GC5YK^X.I746U\Y^54C5=I]#ZUH?$?]E_]F?\
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MCWQ!\+;"[LKGPAKMU]F^VP3$EIH),,JRC.T$KD$#%?7?[-?_  L;_A2FB_\
M"VO^$0_X6 ?/.J_\(NT[:4/W\GDB$SA9#B#R@Y8#+A\#&*^<_P#@H'^P;\5_
MBG^TCX%^-_P)\?:)X3^(W@C39]&ETOQ&MQ)H6NV<K%RDRPY96#$X8(QZ=,4
M>0_!G]LCX9_'O_@HO\.9/CA\ ?''P._:,L[*ZT[PG>:M,TVGZE"Z RPQW412
M.8G?\JO&<9QD8Q5SQ5^TW\/?AC_P4R^*UY\#_@/X^^.'QZNH++3?&NK6%Y%:
M:3HBQP1QPV[75RWEPMLC3<L:$D@YYS71?#+_ ()]_M!?M"?M<?#GXK?M->-O
MAI);_".2XO/#7AKP#9W2VK7LR1H;B:>YPY "?<P<D\%1@53\0?L"_M)_LP?M
M8?%3QU^SKXF^#]]X7^,VJ1Z[K6B^/;>^#Z7? ?/);R6P;>&=G<*VT MCG&:
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M3&: /.O^"P?@^Q^%_P#P4!_8R^)WARU6S\<:I\1X_"E]+:@1R:IIUS&$D6;
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M=_'3KBO7Z.M  *:4R?X<'J,4X<"B@  P*0@XZ\^XI:*  # I-N>YZY^E+10
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M  !@>M%%%  .*",T44  &*!FBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA1M'^)HHH ;M/]XTH7 I:* &F,$YY_.G 8HHH **** $9=XQS^!Q2*NVG44
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M+/'CB;/LOGEF(]G"G/27)%IM=KN3T8B+M&VI!TINWWIP&!7TQ^+@1FC'-%%
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MY4X&@ HHHH ***,\T %% .:,T %%%% !1110 449HSQ0 44W?_LM06V_U]J
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M+_$Q_P"XC)_C3A\<O&H_YG#Q/CT_M*3_ !KY'_B+6&_Z!Y?>CZK_ (A;B?\
MG_'[F?L9YG-"ON_^O7XYCXY>-0P_XK#Q1CN/[2DY_6OI3_@GC^V%XHOOBO:^
M#?$&H7.L:?JZ2&VEN7+RV\BC=]XY+ ],<8KU,I\3,'C<3'#2I2CS:)W3U^1Y
MN:^'>,P>&EB54C/EU:2:T^9]]9H!R*:HRM.' K]*/ST*** <B@ HHSS1F@ H
MH!S10 4444 %%)N^;%+G- !1110 4444 %%%&<T %%%% !1110 4444 %%%%
M !1110 444 \T %% HH **** "BBB@ HHHH **** "BBB@ HHHH **,]>/\
MZ]-+8_A_*@!U% .110 44W?\QZ<>AYIP.: "BBFLV/\ >[9[T .HH!S0#DGV
MH **,T4 %%(#EC[4,VV@!:* >*0G Z9]A0 M% Z44 %%%% !12%L&A6W#_"@
M!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0?L"Z;XP^'>NWVE:U_PE6D2V=Q87;0?;8V=F6-V RT;_ "%E/!QBO*?VXO\
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M=#T/([^'?\$0/"&E_#[]H7]L/0M#T^VTO1]'^)<EE96=N@2*VAC:Y1$4#@
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M8W_8G^(OQ/T?3K'5M3\&Z6;ZWL[PL(+AO,1,.5(;'S=O2OSL^(/['/AOX9_
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M/_!7G]FKX,Z9X]\=:MX'LOA?J:W4&I:J93K-Q"TNRXNE4*DD@"#YMH/ ZXH
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M[H&Q@XKZ*_X+3_%CXP?!S]E+]FV31?%MUX4^)>K?$K0-%U:?1+MOL=[-);W
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MQ>6B1V=R+ZW%Q#]G8.7?"$;MR)@],C!/KBON=EY^7KD&OR2_X)I?L1P>&O\
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M>XU/PMHOA'6_[+TWPW:B22.WS$%;SMRHCD'9DENF[@ _5BZF6VB>1VPJ NV
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M"./Q(^"7[-^K?$CPO^T]\>-0^.GAO3)=<FN]2UP76CZG/%&TLMK]BP D;X*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,/?(_*B)62-0S;FQR<=30!^+_P"RE\>OV-/#'[,.B^%/AY\&]3^(_P"T9<:
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MV)=?^$LEMX1_9;\-ZO\ 'RXMWCM?AX_PF7[:NJ,F#'+(+<(8M_\ RT#@E<'
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MP4J_8=O;'2]0OK'2/%&N2WUQ;VS2QV:&VM K2,!A 2",FOF7]JCQ)\(?A/\
M\%E_BEKW[9FDZAJ'@.XT;3S\+I]4TJ]U7P^L8MX1=)'!"DB>>9MX.]!SNZY!
MK]AY8O,7[VUL_> YQGD?C3+JQBOHECFCCFC4YVNH8'\Z /QG\)?M1?#/P1_P
M6@^"/CKP_P##'4O@_P#!;7/"][X2\.ZL?"3Z1;>)+^:5RK)#'&K1Q[F9<R*-
MV-V<-7U9^Q/X0U;3/^"X?[96KW6D:E9Z5J5CX52SO);9DM[MDTN .8WZ/SP<
M="IK[KN],M[YH6FAAD:W;?$SH&,3>JY'!]Q4P4 YP,]SCK0!\)?%;PAJT_\
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M"A^8_A9^T?(N2 R^ 9,-]/WM??*HJ*JJH"KP !TI1Q0!\7_%'_@I'XH^-?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ '3FBBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M#THHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
K!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E <0# 2(  A$! Q$!_\0
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M=:?PU>^()_%F@PZ+9^(XKC[))X>NM4DOULK?78[HBWDTB:9-02?]TUN)/EH
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M@E=);R2WMU:>9+=9&BA5I7 0$T :%%%% !1110 4444 %%%% !1110 4444
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MNFW>MZW=W!TBTLX-%BL8;IYM1W3O;BVEV@'Q)_P3FTS]L#PS\7KW0_CYX_\
MC[\0/!/C7]BG]FCXG:GJ7QE6VGM?"W[1VO?VY9?%?PMX5NX-,T]-"FLK6+2I
M=6\*H)8[&[1;UL3W$S2>5_\ !/;QUXM_9$T?QY\*/BGX*_:8\0Z_\6/^"B'Q
MJ\*R>*?B:DB^"?!VA>,_$.K>(O!GC+2?$^N&VBUG0?%>C?9KID\/MJ+76L27
MYE%A#I\X'Z0O_P % /V5TB\+W"?$.YN;/Q+86VIWE_:>$_%UU8^ ["^\077A
M&UN/BG<QZ,8OAMYWBNPOO#[1>+3ID\6H6EP9XXK.-KNOD;6_^"BW[-GQ0UBP
MT'XN_"_QG8>!/#VL_'O4AK6K^#/%VNW6@:S^SSX]T7X;ZKXL.F>']'NY+#PW
M)I'B[4-?N?%$\L5IH=G!/93/)>,5C /I_P" G[:4WQS^*C?#-?@WXK\(VM[\
M*;;XM:)XMN_$7AK7+67P_?ZI;:9I,?B/1]*N)-5\&WOB'[5)=^%[?7XX+K7+
M;2M8NK>V6SM(KF?XP_9V_9?_ &]OAU^V#!XS^(/BOQMJ7P&UOQ'XP\8:Q9+^
MV#XE\?\ A2W?4(]6AT.Q\0?"WQ?\-;+59/$ -U8O%IW@GQ5I7PXTR.)7^P7-
MUI]HTWK_ ,:_'7[-_P"PA\0/@W\;/!/P,AU5/VE]>M/"/Q,^*'@O4]0$_A/X
M6^%_ B:C8_$;5-%>:>VU_P ,>$M$L-'BO5L[>"[TGPV;K5(2T%K=H_?3_P#!
M1;X;>'OBO8^"/B%/X1\ >"M2^*OQA^&5C\2_$?C73M/\/WLGPQ^'GPR\?Z7J
M5M-=K!92GQ;;?$0VUI:I>$Q1Z2UU'+.+D)$ ?F]\3?#6E>.?^"KVDKX._9.^
M)/PT/PO^($7Q,B_:6?X.>,-:L_VD?VB)_AU>^$_"^@^(OC#8"YB^''[-O@;2
M;RWA\400/Y/BK6$6.TTI$M'N)?*_^"AWPC_X*P_&3Q5^S+XI^*/[/_PE^(?A
MCX,?&_X&^+M!\.?LZ_%SQ#!X6;X@2?%*QDUKQAXN\.^,_#D?B34],T3P3$NA
MP:G=K%I'A)=1U[Q((+US!]G_ $0M_P#@I_=>-]?T#1_A9HGP,_L?Q#J'[19T
MWQY\4/C;;^"? 6KZ%\!?&7AGP@E[HGB"/1-1M;ZY\5OXD74(8@5M]-L[&ZDE
MFFC1G'U_\/\ ]LKP)XE_9E^&G[2GBW0O$GA+3/B3%:6FD^#].TG4O&OB*^\0
MW>IW^D6NE^';;PW874WB&TU:XTV>_P!#UB"WM["^T26UU266WMY@: /S@_9#
M\8?ME7__  43^*FG_&*Y_:C_ .&.[Z7XJ']E>;QKI5@OAJ^\36NJZ%_PL'3?
MBAJ5K OB"7PMHEZ=3MOV;;SQ+':0ZMX<COKG=-<+9@_FI^UK^R-^V'I/Q;_;
M]^,_P8^&WC[QCX+_ &C_ -L_X2_#KXO?"DZ7<RP^(OAGX7NO@QXK\"?M%_#R
MQ*,E_)X(U_1/$/AGQ3<6^T7NBWTDDC/_ &657^B:;_@HU^R5#;>%KT?$+4[F
MT\4Z)IOB5;FS\$>-KNW\->']3\67?@)=8\<S0:')'X-L;'QI97'AC57UYK1M
M/U1"DZB -,MG1?VX_A?XT_:-^'G[/OP\BU+Q5+XO@^,3:CXU&D>(-,\*V=S\
M'XM&@UBW\+Z]J&DPZ'XU5-<U*XT'5)=#U*6/3;[3Y>;F/<\8!^$VN_LG_M?7
M/ASXE:U9:IXTA^&5W_P68\.?$Z/]G4?!;P]/=ZWX1M_C!X+U.X^-$'Q#=AXM
M3PLEK:2ZRY@C.F):Z?.-XB9\^I_\$]/^"8GQ*U;XE>%?VCOBK<>%/A%9?!K]
MM/\ :N^+/A'P9I7P-M/"7QV\;+XE^(/C?2]"7X@_&J77'U3Q%\,-;TK5O[?T
M[P[%X>BM;ZQ?3(WN72!''ZZ^&_V^?A%/\3_BK\*O&RZQX-\0_#KXE^-?A]9:
ME+X?\2WOA77SX+\"V'Q$N0OBV'1QX>M?$=YX8?6-5M_"RZA-?M9:)<2(6FD6
MW7O/&/[;7[.W@5-!_MOQ?J$][XKT#P#XC\+:/H7A7Q/XBUSQ'8_%&SU^_P#
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MDH>&OV(0,$4.07"C<0, MCD@<X!/:G44 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 &!Z4444 ?SX_P#!>C_D;/\
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M@FU/1=)\)7?CFY?5/$GQ)N]0\-B'P3/\+]#D^&VM:+/J:>([JVM;62^ )/\
M@O/G_A*_^"-YP<?\/>/V=L^Q/@SXGX![9X/Y&OZ#J_CC_P""G/["OCW]FG]H
MO_@EA\4_%'[=/[6O[2FD^-O^"LGP6TS3?A1\<_$WA?6OAWX&?7++X@^(8=4\
M)V6C>'M'U"TU'0[>R/A[2GNKR[B&BWMW'*GG;)*_L<H **** "BBB@ HHHH
M**** "BBB@ HHHH ***"<<F@ IKNJ*6=@J@9)8X %9EWJ<<!*18EE&>!RJXX
M.X@]<G( P3BL*:>:X),SE\]%SA5]E48&/KD^F*YYXB$-%[S[+9:]6;TZ$ZBO
MI&-]WN_1%_6+R.[T^_L+>:6*6[LKNUCNH1AK=[B"2!)XF)!+PF02K@?>4#(Z
MU_.1X+_98_:H?X0?LV_L1:M^S);^$IO@!^U#HWQ@\0?MB1>)_!TO@SQ%X/\
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M ,%Z/^1L_P""-_\ VEX_9V_]0SXG5_0=0 4444 %%%% !1110 4444 %%%%
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M)1DMG:49)JZV:T73Y:O3:C4IRC:<')-/I.,FI+Y-27R?J^SHHHKV#R@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_-__@J=^U9\
M3_V/OV5[CXJ_">+PCI6NZK\2?AW\.=7^*?Q%T7Q#XD^&7P#\+^.-<&DZ[\;_
M (CZ#X5']NZKX3\"6Y2>[MK:2WMC=W=D^HW4%@MP]?I!7\O'_!;VP^(WAO\
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M-_PDIE\C[3Y0T'[;_:OF?9O](*?9-P@_>X\O+#\DOVNOV:_@%^T]^WU^SO\
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M$=P' ]>HK]B/7W_3Z5]9Q0U]8PT$T^6C-NW]^H^OHCYGA*#6%Q4W]JO"-_\
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M*>+?$=U=RVK^%%7PQK.N:3?1*J&WG%_>Z2=,9+AX@K3QM&SOA2 ?1=%?E_\
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M*** "D.,$$$@@Y&,Y'3'Z_SI:* .,GB,$TD1&-K$J./NM\RGCMS@&H20!D\
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M35;6ST[PX\4+WFHZ=?:A&3^^!_I-K\7O^"0V@_";PWX?\<Z/\/\ _@EGX_\
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MX_TK5/#FM&Q\,V<MF-6T\ZA+:_:O(U&66\(MDA=9_-M66/EUWXVG &:_-?\
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M>5NR,@'=T5Y!_P +_P#@J;MK$?%'P2;M+ZTTUX!KUFT@O;Z4P6L&!)C,LX,
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M7A^STV&RLH=$MGLK=(+B\MKK6+A8_,N[^21V)_.1/^"W/_!&70(#;:#^W_\
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M%$>."%M,U:PALPMS?B*XT^XBFVP7"S!T^2?^(@G_ ((R_P#207X'?]]^,/\
MYEJ/^(@G_@C+_P!)!?@=_P!]^,/_ )EJ /JY_P!E"[_X1L:+%?>&8KQ/@OK/
MPQ6]72F7&K:QXYMO%\FN*XC$RP%+=X9E#?:9;IEF)(R:X/Q!^QY\2?$5YJT]
M_P"-?#4OG:#\6="L9YQK=Q;S1?$9;?\ LZ1_#J1V^C:+#HXM8H-4AT[[5<:Z
MP>^N+Q)I&B'AO_$03_P1E_Z2"_ [_OOQA_\ ,M1_Q$$_\$9?^D@OP._[[\8?
M_,M0!^CGPB^'/B3PCK'COQ3XLG\-)K7CBX\,K)I7A"WN[?0--L_">@0Z!8O&
MU\D5Q<7VH1Q-<W;&&*.V3R+.$S1VZRO[C7XY'_@X)_X(R@X_X>"_ [D9X?Q@
M1^8\+8!]CS1_Q$$_\$9?^D@OP._[[\8?_,M0!^QM%?CE_P 1!/\ P1E_Z2"_
M [_OOQA_\RU'_$03_P $9?\ I(+\#O\ OOQA_P#,M0!^QM%?CE_Q$$_\$9?^
MD@OP._[[\8?_ #+4?\1!/_!&7_I(+\#O^^_&'_S+4 ?L;17XY?\ $03_ ,$9
M?^D@OP._[[\8?_,M0/\ @X(_X(RGC_AX+\#OQD\7C]3X6Q0!^QM%?CE_Q$$_
M\$9?^D@OP._[^>+_ /YEJ/\ B()_X(R_])!?@=_WWXP_^9:@#]C:*_'+_B()
M_P"",O\ TD%^!W_??C#_ .9:C_B()_X(R_\ 207X'?\ ??C#_P"9:@#]C:*_
M'+_B()_X(R_])!?@=_WWXP_^9:C_ (B"?^",O_207X'?]]^,/_F6H _8VBOQ
MR_XB"?\ @C+_ -)!?@=_WWXP_P#F6KT[X,_\%H_^"6O[0WQ1\&_!7X*_MH_"
M7XB?%/XA:J=$\%^"M";Q.=7\0ZLMI<WQL;#[;X>M+4S?9+.YG_?7,2%(6PV[
M (!^G]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %?FGX+_ .";?AKP;\:M"\=)\:?B5J_P6\$_&KQK^T?\-_V9[^T\
M-KX$\$_&_P"(%MKL>O\ BF'Q+;V$?BW6-"L[[Q7XIUWPSX/U&\;3-"U_7KS4
M(YKA8[6&W_2RB@#\<?\ @I#_ ,$SH?VL->_8>U3X/^#/@CX33]GS]MWX;_M$
M_%Q]9\*:7I=QXQ^'/A?1/%UCXB\.6K:1H<QUK5-6O]=L;HV&M,NFW;6TDMW*
M94CS^EP_9\^ 9&?^%'_"#GG_ ))KX+YSW_Y O?K7Y2_MSS^,_B/^T1^T%X/D
M^/WQ5^!WAS]F/_@GY+^TS\-(?AAXXD\"1:I\5[_Q5\4;:?QYXS:**0>,?#_@
MBW^''AO23X9U-9O#WE>)M2&I6[W&HV4D7ZE_LS>-_$?Q,_9T^ _Q&\7PK!XK
M\>_!_P"&_C#Q+&D/V9/[=\1^$-'U?59([;"_9XIKZ[GFC@P/)218P %H T/^
M&>_@'_T0_P"$'_AM/!G_ ,I:/^&>_@'_ -$/^$'_ (;3P9_\I:]?HH \@_X9
M[^ ?_1#_ (0?^&T\&?\ REH_X9[^ ?\ T0_X0?\ AM/!G_REKU^B@#R#_AGO
MX!_]$/\ A!_X;3P9_P#*6@_L^? (=?@A\(!]?AKX+_\ E+7K]><?%O1OB)XA
M^'GB?1/A3XTTKX=>/=3L/LF@^.-8\.)XNL_#$LLT0NM73PW-=V-MJ]]:V/VE
MM-MKRY%B-0-M+>PW-K'+;R@'YB^%O^":FF:-_P %4_BK^V1?^ _@=<_ ;QE^
MR)X(^!N@^ D\':-+K&G_ !"\/>/9/$NI^(YM!?0AH%O8W6D%+&/4()6U*5@(
M9$$ 4U^D7_#/GP"_Z(A\(/\ PVG@O_Y2U^$WP5\3?%GX[? S_@DW\ /B;^T#
M\8(-)^/2?M4:E\:?BGX8\93>!OBI\5];^!Z>*)O!GAZY\::-'#>Z0FKWL\OB
M?5M,T%[22]M/"L>FP-'ID$\9_43_ ()K?$#QG\1?V4?#-_XZ\9ZA\2-7\*>.
MOB[\,['XD:O)!/K'Q \,_#+XG^*_!'A;Q=K%[:Q0VFIZMJV@Z+8/J.JVL20:
MG>)->JH:=J /I7_AGOX!_P#1#_A!_P"&T\&?_*6C_AGOX!_]$/\ A!_X;3P9
M_P#*6O7Z* /(/^&>_@'_ -$/^$'_ (;3P9_\I:/^&>_@'_T0_P"$'_AM/!G_
M ,I:]?HH \@_X9[^ ?\ T0_X0?\ AM/!G_REH'[/GP#4Y'P0^$(*X((^&O@P
M$$<@C&BY!R.#ZUZ_7Y(_\%,[#3_,\%7NH_'3]HS3?$^M>%O%7@WX _LM_LQ>
M(IO!_P 0OC%\>=3>"XT3QM=:UI*/JUQX=\!:>B-JTOB*6S^'7A:QFO/$/BB>
M?_1[&< H_P#!-/\ X)KZ3^R=\-?C]X3^-O@'X&>-=:^)7[8/[1?QU\)WVE>#
MM%UR'2/AW\4_&<FO^#O#=S<:WH$4UG>Z)IK"VN--LPVFV+$Q64CQ88_H[_PS
MW\ _^B'_  @_\-IX+_\ E+7\]GQ<\1?M.Z1X*_:]^*/Q7_:6^)'AG]H/_@G?
M\&OV1!X2T'P'XQ70OA?XJ^(VO?#3PWXS^(VN^//!=O:1V/Q*@^*_C/4=2\',
M^J0I:/96_P!G\/6]G?'<G],.D74U]I.F7MS;FTN+S3[.[N+4A@;:>YMXYI;<
MA@&!AD=H\, PV\\YH \Q_P"&>_@'_P!$/^$'_AM/!G_REH_X9[^ ?_1#_A!_
MX;3P9_\ *6O7Z* /(/\ AGOX!_\ 1#_A!_X;3P9_\I:/^&>_@'_T0_X0?^&T
M\&?_ "EKU^B@#R#_ (9\^ 7_ $1#X0?^&T\%_P#REKXQ_P""B'[ G@S]J']B
M']IK]GSX._#7X)>#OB?\7/A7KW@OP3XIU+P/X>T?3]#U[43 ;6_N]4T;0I-4
ML88?)?-Q8H\Z,5V*<U^E;'"D@9..GK[<5^ ?[2/B'Q_\#_VH_A/^T7X._:%^
M*/Q,^'/BO]K1OA%\6=2TOXL:+J7PR^%[ZKX9U'POX0_9.C_9ITFU6.^N=2\9
M-H.K:U\4&U1O&OA>_N6OM0TR[T^ZS9@'Z@?L^?LC?"3X9_ 3X(_#?QA\(/@U
MJ_BSX??"+X;>!O$^K6_P]\*7EOJGB+PGX,T70=:U&VN[S1%O+N"^U+3[JYAN
M;I1<W$<JRS*)785Z_P#\,]_ /_HA_P (/_#:>#/_ )2U^(7[%'CGXJVOCC_@
MG/\ &?6/CG\4_B#XG_;X\,_M%:M^T'\/?%WC*;Q#X!T:^\*:++XRT*;X?^"Y
M(1:?#V/X5:U!'\.WBT?[/'-97@L]>2?5<3'^AR@#R#_AGOX!_P#1#_A!_P"&
MT\&?_*6C_AGOX!_]$/\ A!_X;3P9_P#*6O7Z* /(/^&>_@'_ -$/^$'_ (;3
MP9_\I:/^&>_@'_T0_P"$'_AM/!G_ ,I:]?HH \@_X9[^ ?\ T0_X0?\ AM/!
MG_REK\[OVN_^"=LOQ9_:L_X)J_'3X)>&/A!\/M _9&_:&\9_%/XKQVGA^P\,
M:[XD\+Z_\-]1\):=IWA\^']%1-3OK;5;I;F2TU*XM;:.)OM$4K2KY4GZ1_&?
MXJ^&_@=\*/B%\7_%\>KS^&OAQX2UOQAK-KX?TJ[UO7;VRT2RENWL-&TBPBGN
M]0U.^=$M+&VAB.^XFC\QHXP[K_+QX1_X*$_$_P")EE^W\\7[3>I1^.?B1J7[
M!DWAC1_"MMJ^EZ5^R?\ #;XW_$>Y^''Q*TGP'J.NZ):VD'B'P=X9U?2$\1>,
M;\,U]X]U"ZUNQC;3[&TB@ /ZU,__ *CUHK\R/V&T\0?#G]H3]MG]F&/XG?$+
MXJ?#+X(ZU\"-<^'NI_%+Q9<>/?&?A.[^+'PYOM?\8>";SQE?H-5U33[34])M
MM>TJSU66XO=(@UZ2V\XVKVP'Z;T %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
2%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &+ V<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]^I/_BZ\_P $D  DGL!2$$$@@@CL:%0I]@6+K?S'H!^,OB/_ )]-,_[]2?\
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MKEM9\<6.ER^3 #=S#[P1L*OU/K2>.=:?3=,%M"<3765#9^ZHQDCWYQ^->6
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M?_XNN!--H^KT^P_K=;^8[_\ X7!XA_Y]--_[]O\ _%TA^,/B'_GTTW_OT_\
M\77 'K2&FL/3[#^MUOYCO_\ A</B+_GTTS_OV_\ \72?\+B\1?\ /IIO_?I_
M_BZ\_-(588R",C(S1["GV#ZW6_F/0/\ A<?B+_GTTS_OT_\ \72?\+D\1_\
M/IIG_?J3_P"+KSZFFCZO3[!];K?S'H7_  N7Q'_SZ:9_WZD_^+I/^%S>)/\
MGTTO_OU)_P#%UY[AMN=IQG&>U(58*&(.#T..#1["GV']:K=ST/\ X7/XC_Y\
M]+_[]2?_ !=)_P +G\1_\^>E_P#?J3_XNO.Z0T?5Z?8?UJM_,>A_\+H\2_\
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M]-_\31_PK?5_^?FS_P"^F_\ B:]2HH^LU.XO[-P_8\L/PUU?_GYL_P#OIO\
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MW8_]]O\ _$UZ[13^LU.X?V=0['D/_"K-:_Y_+'_OM_\ XFD_X57K7_/Y8_\
M?3__ !->OT4?6:G<?]GT.QX__P *JUK_ )_+'_OI_P#XFD_X53K7_/W8?]]O
M_P#$U[#11]9J=P_L^AV/'?\ A5.M?\_EA_WT_P#\30?A1K1_Y?+#_OM__B:]
MBHH^LU.X?V?0['C?_"I];_Y_+#_OI_\ XFC_ (5-K?\ S^6'_?;_ /Q->R44
M?6:G</[/H=CQK_A4VM_\_EA_WV__ ,32?\*EUS_G\T__ +[?_P")KV:BCZS4
M[A_9]#L>,?\ "I-</_+YI_\ WV__ ,31_P *DUS_ )_-/_[[?_XFO9Z*/K-3
MN/ZA0['BY^$6N_\ /[I__?;_ /Q-)_PJ+7/^?W3_ /OM_P#XFO::*/K-3N'U
M"AV/%3\(-=[7NG_]]O\ _$TG_"H-=_Y_=/\ ^^W_ /B:]KHH^LU.X?4*/8\3
M_P"%/Z]_S^Z?_P!]O_\ $TG_  I[7O\ G^T[_OM__B:]MHH^LU.X?4*/8\1_
MX4[K_P#S_:=_WV__ ,32?\*<UX_\OVG?]]O_ /$U[?11]:J]P^H4>QXA_P *
M<U__ )_M._[[?_XFD/P;UX_\OVF_]]O_ /$U[A@>E%'UJKW#ZA1['AW_  IK
M7_\ G^TW_OM__B*3_A3.O_\ /]IO_?;_ /Q->Y44?6JO<?U&CV/#/^%,:_\
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M2;5?MMT4M#*#*X#L0 "?04>+?M]Q=^&-2F:^L =7MH#I\CQ[>6;+L4+9)
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M#J2,$>Q'8CH1V-6Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M - - %;P=/-=>"- N+B5Y9I=.MWDDD8LSL8U)))Y))[UM,<5A>!_^2?^&_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,OR^3]EW>7^'X]<UW^F?VN%8:G]DS@;?LX;\<Y_#I0!>FGAMT#S2I&I. 78
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M1110 4444 %%%<OXSUB_TR'3X=.=EGO+GRB(HA+-L",Q,:$A21@9W< 9/7%
M'45F^(O^19U7_KSF_P#0#7&W'BO6_P"PY]226"*33=*74;FW:$YG;,H:(\_N
M\>20<9(8]2!@KXV^)?AO1;>^T74+N:*_GLF*QK S#YT.WD#% '2^!_\ DG_A
MO_L%VO\ Z*6MZL'P/_R('AO_ +!=M_Z*6MZ@!,>] &*6B@!&&X8I"@/6G44
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MB0.U.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(3B@#.D@TO2[,3&"VMX+3?*&$8419R7(],Y;/U-<OIZ02N?$L\ $4C$:39%
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ II7/>G4F10 F
M!UKP#XO:#!%K4VOZ7<0W!W*+Z&)PSVSD; S '(5LCMU'OQZ-\3/$CZ3I4&GV
MEVL%Y?OL)4_.D0!W,/3/"Y]SC!%>&ZD_V]GTFQ2,",!I)3^>/S'Z4 9UGI:0
M7-JQ=5DDW2@#IGC\^,UTLFMQVKI'.N#C%<S-83_9+&=I&E*@@L#CY>@-:O\
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M8MQ!J-E!=1@[@LR!L'U&>A^E&G:+IFDJ5L-/M;7(P3#$%)^I')H O#@4M%%
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MJBHH-WDIN5E.T95CDCVSDYJ6@85551_:#_\ 7)?YFK)Z5CKJB'7FLO+D%P8
M^S<F=FXC=C=G&3Z4";2W-D# Q12*<J#2T#"BF3&00N8MOF8^7=TS[UF:;=ZA
M<SW"W,=LD<,AC)C=B2< ]P..:!7-:BDR*3(]:!E>^NFM(A(MM-..XB*@@>IW
M$<56T.]:\TVW8VL\"B)-IE*_,,=1M8_K7.?$>_M8-"6)]1MX)2X?RGE"M*HR
M" .IY(/X5@> ]0UUM VZ19)/%(P"W%W+L@BP,-@#YV.>H  XZU2B[7L9N:YK
M7/3+R^MK"UEN;J9(8(EW/(YP%%<O)>ZAXI@D-I--I&C#DWY&V:X7N8\_<7'\
M9Y]!WJO;V=K<3O/<SS>)-21LJ"N+6!NP4?<7Z_,U;T>CSWLGGZQ(DW=;5!^Y
M3ZC^,_7\J-%L%G+?8X'Q+I;7D-FNB:?.--MPD<(6-BKY?EP><@^IY/7O7H'A
M:T>Q\/6MM(Q9T!W91EP2Q.,-SQG%6[K3VN=@2[GMT3&$A"8X.0>5)]/RJS;Q
M-#$$>5Y6'\;XR?R 'Z4F[E)69+1112*"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIA
MFC#!2P#-T4GDU4U?5+?2-(N]0N=WDV\9=@HR3[#W)X% #=:UBUT+3);^\)$,
M>.%&68D@  ?4UY?K?Q+U^[F$6BVEO919R'N,/(P^G1?_ ![ZUF^-/B%-K?A]
M[-=*2%WE22)_M&\C##JNT=1GOQGVKD/M.L3.C+;JF.S'K^E &A?IJFO7\M_K
M-S&UPX"@H@&%'0#CM_,FJ-SID-OI<\T3'S9, NW5B2%Q]*06M^)4:ZG^\> O
M ^E7M05(M/>.1LJXVX7J#V(]\XH =!:[K94N-IW 8Q4/V6[=V0S%8EX&T<U1
MM8M7F7=]HA B. C(03[Y!X_*HSK%]9#?+&LR,?F*'&T_B>1^5 %2YTC-X3),
M 2?O$E3^AJQ<68""VLXO.B$6)3G&#GCG\6K1A2WO<W5X869A\D3$,%'OVS^=
M7X8?(A MQ'M_N*H _2@#G[/3+J<JDWF/$G(68@CVXJVNER12M+!!$'#<,.*V
M&<[/FVQ@=>:C26&*'S#-\N><F@#.>2XN91%)$I?(R>P&:U(+6ZOYQIMG9-<3
MRC&V-<@#U8]A[FLV'6[./<KAADG#[3@_CBNJ^'GB5-#O-5EG@N98KI5D6**,
MLY8$A<$X"C;DG)'3US0![38Q/;V%O#(YDDCC5&<_Q$#!-6*YZ'QKH;Z?]KGN
MA:C.UHIB-X/T!.?J,C\JYS5?&NKRW:+H5E%]ES@37:N#*3Z*,%5'OR?08Y /
M1**Q=&UEM1ED@N;;[/<H VT/N5E.>0<#\1CN*VJ "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNVF:MI,4%H[?VE<32"3[*H!ZJ&&#D?Q$8P>M '0Y'K6=XB_Y%G5?^O.;_P!
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M9 Q]Y03M.<\'G!7/.:9IWA*#3-3^TQ7UT]JCR2V]B^SRH))"2[+A=W.6P"Q
MW' ';H N* %HHHH *R?$6H7VEZ1<7=A9K=2QHS;7D"(@"EMS'KCC& "22.@R
M1K57OK1+^PN+.1F5)XFB8KU 88X_.@#E]0\4WT-SJ M8;8Q:9I\5_=>86S('
M\PE$Q]TA8F.3G)(&!UK1MM6DD\83Z8+VWEC2W,CP+_K8&!3&X>C!B0>^,<8.
M8M2\'6VHW:S_ &^\M@\"6UW' RA;N)"2J/D$X^9AE2"0Q&:Z((!CVH =1110
M 4444 %%%% !1110 4444 %%%% !1110 444C' Z4 >2?&&^L8M2T:%XF-W$
M6D:08PL3 C'N2R9]L'UK@+I9H)A>V\&^-H]K+D CW%;?B:^E\3:U=:A<E5$.
M^WMT QLC#'&?4\D\],FLFWU%)HTM8O\ 6J,<CCB@"&WUJ&_F2W0F.11E@PP1
M^!ILFE7*WK);WACB?Y\%<X/?'(JEKFE21SI>V\N)EY/T%7K6^O  C0B>6,?,
MZ# ((!'XT ):VD2:A+'<C>2202.,GDTHABT^691:^<A^9'502OJ#5R!C=1M)
MP)&Z\=*#,+.-W*%DZDT 48(I]6*RW!:.U'W%7*L?KW_E5Z.!=/RK>8\.<AF8
ML1]>]4['[7Y(ERBK,2ZJ1D@'I2WE[>+NM! 'D=>JG.!ZT 17NIWT<T=Q#:J+
M=A@%VPS9Z''^?I3SJ\4EL%V.9R>(SZ_X5*C--L25#Y,7/S##'%4Y8)M0_?AB
M+0\JD9VMCUS_ $% $FHZY-;6^9+?9D@!@<@5IV<D M%8R!MR[F)-<[:L82TL
M=O)<(F0IEER1ZXS5^ :9?V)>,P03%&RW"[,\'('U[U<%>21G5ERP;-SP]H-M
MJ\/]J)'<0M)N1Q&PX&2"02,@GGI6]K1?3K2TT^SS'$[A68#&T5L^&+*/3/#%
MHGF!P8PQ=>C9YR/;FC4K%]3V3)E3#T5A]X_2BH[R8J,>6",_4-(T^PTIKIYG
M&%SYC,2RGU![&N?MK34?$,7VNXBGGMR?W6951\=B5VX_,_E5:U>X\0:Y-IMX
MP6*Q(;RCT<Y)!/J*W+_7)QJL&BZ6$BG(R\CCA5]O4U!J9.GZ2^F:[LN0HDN"
M"0'W;,<#G R3GL /2KWQ'94MK&)][1M,I9%],&MFU\**-0^UWUW)-*!E22 !
M^ K&\965E";5Q)+)<^>@1G8D+\W./PH 32+&/4K*&.WN[BY@#+E'QM&/7UKK
M6TVR&HJZVD0<KEF"C/YURWAN^DBU&>TM(@Q Q)S\N>HKIY+^#2[=Y[R1(Y2<
M'<V!GMC- %:[T:UFU!XWBVJZAD91RK#K6 VF>(O"DL^JZ3JKB+<6FBN&W(X)
MY)!_GU]ZZM+^U6VDOI[F+9&I8ONPH%<W->:IX\C^P^'R$M9"4N99EQM7U_\
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MC_A7^A1:VVL+%*+MKT7Y(DX,H4KTQTP3Q[T :?A?5)]8T"WN[E0MR&DAF"C
M\R-VC<@=AN0__7K9K)\-:4VBZ!:V4KJ\RAI)F4D@R.Q=R,\XW,:UJ "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *",T44 </JWPOT;4KJXNHKB\LY9V9V6%U,9<G))5E/?G (ZUY7X
MMT2]\(RB"\\IV9#+!=1 A9 #@\=B.,CGJ.:].^(_BV^T%+6QT]Q!-<JTAN<
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MZW?2K8>7J-Q->3R#=;R6ZA&3/S8;:. .X)KO&&16*WAV$Z9:VB2R(]JP>&<
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M  */_P 31_PO6Y_Z $?_ (%'_P")H^K5.P?6Z7<]JS1FO%?^%ZW'_0!B_P#
MH_\ Q-'_  O6Y_Z $?\ X%'_ .)I?5ZG8/K=+N>U9HS7CVH_&JXL-4N[,:)&
MX@F>+<;DC.TD9QM]JK?\+UN/^@#'_P"!1_\ B:%AZCZ \7274]JS1FO%?^%Z
MW/\ T (__ H__$T?\+UN?^@!'_X%'_XFCZO4[!];I=SVJBO%?^%Z7/\ T (_
M_ H__$T?\+UN/^@#'_X%'_XFG]6J=@^MTNY[5FC->*_\+UN?^@!'_P"!1_\
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M_AWX- ">'?A[K/B+38+^R-O96SRM^\EF?=@,0<( 5.#D8)'3KWKU;PSX"LM
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MH_\ "H?%W_/K;?\ @0M73G&.\C.I3G+:)PE:OB+_ )"47_7C9_\ I-'73?\
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M!+3-XI:*W0INWD ]SQD^E;.K_"KQ5>:W?W4-M;F*:XDD0F=0<%B13M+^'?Q
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MUH [VQ\;_P!IW.H:?:Z+?1:M:0).MG>%(C*C_=(8,P ]<\CTSQ7'IXZ\2?\
M"%V=S<SV-M?W.MOIL]\82;>T0.PW8R.., L1[FNO\.^#KG2M?O=;U'67U2^N
M8([8.T"Q!(TZ#"]23R3Q]!5=/ EQ;^&I]*LM;>WEDU"2]\[[.KHP=BQC>-CA
MDYQC(S@?2@"3X=^*KCQ/I%\+N6">YTZ_ELI+J 8CN=I!611DX!!'<_K78U@>
M$_"\7A;3)K99S<7%S<O=7,Y0)YDKGDA1PHP  !TQ6_0 4444 %%%% !1110
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M.3]T=_:F"GR=1_NC^5 #<GU/YTF3ZG\Z** #)]3^=1SW$=M"TTTHCC099V.
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MM[>/.R*-0%&3D\?4DU;HH<F]V"A%.Z04444B@HHHH **** "BBB@ I",TM%
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MPJK13Y2><M;U_O"C>O\ >%5:*.4.<M;U_O"C>O\ >%5:*.4.<M;U_O"C>O\
M>%5:*.4.<M;U_O"C>O\ >%5:*.4.<M;U_O"C>O\ >%5:*.4.<M;U_O"C>O\
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M=36UA>K/-"-S (RY&2-RD@!AD'D9%<K:^ KV*$6TMY$8AI]S$9%!#?:)VRS
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M9X?-U#-%<VEN##+'(T<D+G[V,'KQT-/U/0-?_P!%%E>6-ZT44L7F:E"-ZA^
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MMEI5E>REO,GM;,WGDX*[DY"\XP,D8_I65:_$+2I;QK>Y#VS06BW%R[!BD3$
M^7G'S'GKQG@#)-4;_P (ZYJR:VUW<V<<NJ-;Q QR.P@@1LL!E1DG\,]>.E+-
MX0U&277T\G3;BVU*:%@DLLB[HT  C.T?(0!PPS]*+1ZA>?0ZS2=<T[7(9)=/
MN/-6)]DBE&1D;K@JP!'Y56;Q7H:ZM_9AU"/[47\O;M;;O_N[\;=WMG-1^%],
MU/3+&:+5+TW#O,7B7S6D\F/ PF]@"Q'J17-P>"-6\J/2IY[+^RTU$W[S)N,T
MOS;@A&, ^K9/:IM&Y3E))61L:9XZTR_U>ZTZ9UMI8[QK.#>2?.9>ISC:N3G
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MGR0)<ZE$#,BR(4#.NUONL64$*#V)P#4EQXIT6VU=-+FOE6\=E0($8@,WW5+
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
@ !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %Z U@# 2(  A$! Q$!_\0
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M_P"?'4O^^(__ (NE_P"%R:"?^7+4O^^$_P#BZ\1!YZTH-+ZK3#Z]7_I'MO\
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M_BJ\III.*7U:F5_:-<]7_P"%IZ/_ ,^=_P#]\)_\52?\+4T;_GSO_P#OA/\
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MD'T/''08I>SJ+9FGMJ,GJC2@\.Z*+V6TN[V6*>"VB:7SI1%%YK<LIDV-M !
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MMMIVNPVUI*TD3:?-(+R-\B<^6^<=@ 1BF'1-/AT33Y+G39X;R\=!&%F+ 1Y
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M\_\ @)_]G2_\*4'_ $'C_P" G_V=>M44>WJ=P^J4?Y3R4?!0?]!X_P#@)_\
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M/^@V?_ ;_P"RI?\ A3X_Z#9_\!O_ +*O4**/;U.X?4Z'\IYA_P *A'_0:/\
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M  K+_J+?^2__ -E7H5%'MJG</J.'_E//#\,/^HL?_ ?_ .RI/^%7_P#47/\
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M@T?_  &_^SKT_%%'MZG</J5#^4\O_P"%0C_H-'_P&_\ LJ/^%0#_ *#9_P#
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MF2>WF021R(<AE/((JQ7G^D>'O$TOAC2AI^O2^'@(G9[0V,4Q7>[,H.[[I56
MQ[5:^&NKZMJNGZY'K-_]NN-/UFXL4G\E(MR1A0/E4 =23^- ';4444 %%%%
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MYY-6N;*YC6,B*.XA'0[&R"K<D;E93D@XPR_CJT %%%% !1110 4444 %%%%
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M#3/!\>E>#;[P]#=LR7(N!YOE*FPR[B<*H  !;@  =JZFB@#F+S0M3U*.Z/\
M:KVL.H6PBNK1XA,L1*X;RFR-IYQR&!QG')HD\,74+7<>EZQ)96MXBI)'Y6]H
MRJ!-\3Y!5BJKR=PR <9SGIZ* ,>SL)8]<GNG0I!%!':V^Z0N7 RS,2<GDE1S
MS\I/>MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJCJ>K6NDQ0O<^:QG
ME\J)(8FD=VVEL!5!/16/X55N/$UA:06\DR7H:XWF.$6<K2D+]XE I8 <<D=Q
MZB@#8KR_X<BWDO?$*3%_-'BK4'B"],@+G/YUZ-8:A:ZI807UE,LUM.@DBD7H
MRGH:\]^&,D?]H>)XC"&<^(]1=9/[N#$"/QW?I4RV&COK1KL75XEQ@Q!P8&X^
M[M&1^!S^=70:H212+K$-QYX6$Q-$8RQ^9\Y! Z= U7Q2CV!BT4458@HHHH *
M*** *U[I]GJ5O]GOK6&YA)SY<T8=<^N#Q5,>&]#6:&9='T\2P8\EQ;)NCP<C
M:<<8/(Q6KFC-%Q610L-%TS2VD;3].M+0R8WFWA6/=CIG &>IJGX@T6;4I-.O
M;*XC@O\ 3[CSH7E0LC J5=& (."&/(]!6WFJ][?6NG6CW5[<16]NGWY97"JO
M;DGB@-CC+_P/=ZQ%=2ZI>6LEQ=7EM--&D)$0BA/$8!))R"V23WZ<55F^&H%A
M<:/;W-NNBR:C'?);O$=R ']Y'D8RI' SR!QS78_\)+HG]F_VE_:UE]@W;?M/
MGKY>[TW9QGVI8/$6BW-JMS!JME+ TH@$B3J5,AZ)D'[Q].M SF+GP1>M97FC
M6>H16NB75XEQY4<>)84R&DC0] &89''&2,'-2Z=X"CL;G40VK:E-:WKQSLQN
MFCF$R[@27CVY!!''^S74KJU@]Q<P+>0--:J&N(Q(-T0(R"PS\N1SS4MG>VVH
M6J75G<1W%O(,I+$P96'L1UH X?\ X0"ZEFEM)]4#Z09[NX2/83*&GC9""Q/(
M7S'(/4YYJWI'@Z[L[+4X[R]@FFN]/BL(VCB*JB1HRJ2"3DDN2>U=-'K&FRZC
M)IT=];/?1#<]LLJF11QR5SD=1^8HMM9TV\@FGMKZVFAA)$LD<JLJ$<G<0<#'
MO0!DRZ!,?A\WAT2AIAI?V(2 8#,(MF<?6IX;*>_U'2M5G'E1P63C[,ZD.LLF
MPY/T"D8_VC6O#=07-O'<02I+#(H=)$8%64C((/<8K.D\4Z!%-%#)K6GI+*JM
M'&]R@9@PRI )R<CI0!RVI_#ZXUB5UNKZVBCCBNTA>VM1&[F?.?,P<'&>WWCR
M>:WM&TC4K?7;W5M2N+22:YMH8"MM$R ;&<Y))).=_P#3MFM.'7-*N-0?3X=2
MM)+V/.^W293(N.N5!R.M65NH&N7MEE0SH@=HPPW!22 <>A(/Y&@#E#X0NDM=
MEOJ$=O.-4N=16=8LE3*DJKP>"5\P'G@[:RG\ :G<VUREUJD;S3Q6B,[&60DP
MRERWS,<;LG@8 [#K7H%O=V]VKM;S)*$=HV*,&VLIP5..X/:FW=]:V-N9[NXB
M@A!"EY7"J"3@#)]20* .=T[PBMO%?17-[<XGU.>_3[+.\&/,.0K;2-V/R-9X
M\"W'V&>W^VQYEL=1M =AX-S+Y@;_ (#T/K76V^KZ==WUQ96][;RW5MCSH8Y
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MX+C6M1\/ZG;S_P!IW*2&PN$2XCE=DD\_]XH+*N<#;G: H/2O;BH/!Z4;<=Z
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MMN><^%GUR/XCW-W=ZI=26D[!2S6$ZI< YVJ%*@1[?4G [9YKTF#4M40WAO\
M2&BC@0O&]M.)O.Z\*,*V>!P1WZFN#T;P3XOT[QC>7PUXBWP-L\X,WVGT5DW#
MH,\Y&.W4UUCW7C2V8[M,TB_3MY-R\+'WPRD?K6E2S>AG1YDM;D.N?$31M"LK
M>>X-P99GVBV:)HY0,X9BC@$ <_7'%=-8W]MJ-E%>6DRS6\J[DD4Y#"O&_BKJ
MEW)%8'4/#RVYW##7"!\$')"RQR?=(P"I4>OI76V.KZ"="TXZS:W5D]M'N7&G
M7%M''GG (R .!_$1Q2E32@F$:S<W%G?[A1N&<9KS[6/$VA77G:AI_C?[')'
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MUS7B$NUSX@T!(;K[?K%Y;S64J0.T84)"A<R ;5V&)V.2#P,<D5Z/@9SBC H
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M'MR>^><57\,W/BE=7O+#4M3TS58+6017$L5N]O-"YC5P-N"C@AEZ$8SU.,4
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M,, EFZ$\ GW;WJ9#74]0%8OB^Z:R\):M<+$)2EJYV$9!X(Y]JVA7-_$![M/
MFL-98\[[.V<X^Y_'U_V-U6MR)?"S"U*X72-$T5HWD,VF36T\C2\YBDS&^#W
M$A^F!74WMH(M8MM6-\+>*.-H)D?[DJL1M[X5@V,'!SDCOQ%X@LWN/#T]M%;K
M,983 XQ\P1A@D>XX/X57T)AXE\"VJ:BC,UQ;>3< \-O'R/\ 0Y!^E"?0E_F=
M*.@I:S-*U:#4S=QP[UDM+A[>5)!AE9>A]P000?0_45I"D6G=7%HHHH&%%%%
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M>6<H62ZC*8D' Y3'8#M716.MV&IN\=M< NHSM(P2/4 ]:CT 2BS998;R(J0
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MTLK]L0JRHV,2@')0D],C(![$U?BD5\X(.#@X.>:DT78DHHHI%!1110 4444
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M@QL/4'&#W!K6S0QIBT444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:9JDQDMW+?+#.02\9ST#8W+[Y'I5;JQF_==^ALR*NDJ@MK5F@EF)E"9)0MW
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M*<.E2W=W*BK(****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?W\>G8_@:Z])%D0,K!E89!!ZBN5(# @C(/!%-L-2DT-EM[AMVFEL)(>/LP[
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M%X6AN]"72_#I,3ZDBWOERRL/(\M\[OF.!N"<T >I_;[/_GZ@_P"_@H^WV?\
MS]P?]_!7%K\&_A_CGP[%_P"!$W_Q=._X4U\/_P#H78__  (F_P#BZ .R^WV?
M_/W!_P!_!1]OL_\ G[@_[^"N-_X4U\/_ /H78_\ P(F_^+H_X4U\/_\ H78_
M_ B;_P"+H [+[?9_\_<'_?P4?;[/_G[@_P"_@KC?^%-?#_\ Z%V/_P ")O\
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M#Y^D9$WV@'S(_P#6?W^O7WIPN/#(&!<Z3CS?._UL?^LSG=]>>M9/_"I/ ?\
MT+=K_P!]/_\ %4?\*D\!_P#0MVO_ 'T__P 50!K>?X8!)%SI )E\[_61_P"L
M_O?7WI/.\+X_X^-(_P!;Y_\ K(_]9_?_ -[WK*_X5)X#_P"A;M?^^G_^*H_X
M5)X#_P"A;M?^^G_^*H U!+X7 XGTC_7&X_UD?^L_O]?O>].-QX9(P;G2<&7S
MN9(_O_WNO7WK O\ X3>"%T^Y,'ANV\X1/LVLY.[!QCGUK"\ _"KPY/X)TR3Q
M#X;0:J5?[1Y^]7SO;&1GCC% '=B7PL"Q$^D#=,)V_>1\R<?/]>!S[4HG\,#=
MBYTD;Y?/;$D?,G][KUX'/M61_P *D\!?]"W:_P#?3_\ Q5+_ ,*D\!_]"W:_
M]]/_ /%4 :KR^%Y-WF7&D-NF6<YDCYD7&UOJ-J\^U#S>%Y,[[C26S,LYS)'S
M(,8;KU&!S[5E?\*D\!_]"W:_]]/_ /%4?\*D\!_]"W:_]]/_ /%4 :YN/#+!
MP;K22'E69@98^74@ANO4%5_(4WS?"^93]HTC,LJSO^\C^:1<88\]1M7GVK*_
MX5)X#_Z%NU_[Z?\ ^*I/^%2> O\ H6[7_OM__BJ -16\)H\KB71P\LHFD8/'
MEG&"&)]057GV%.$_AA1)MN=)!DF$[_O8_FD&,,>>ORCGVKSN[^%FAK\4M/BA
M\-#^P#ISM,1O\KS]QQDYZXQ77#X2> \?\BW:_P#?3_\ Q5 &K)+X7F#B6XTA
M]\JS-F2/YG7&UCSU&U>?84LDWA>;?YEQI#;YEG;,L?,BXVM]1M7GVK*_X5)X
M#_Z%NU_[Z?\ ^*H_X5)X#_Z%NU_[Z?\ ^*H UVN?#3;\W>DD22+*X,L?S.N,
M,>>HVKS_ +(IIE\+EIF^T:06FD660F2/YW7&UCSR1M7!]JRO^%2> _\ H6[7
M_OI__BJ/^%2> _\ H6[7_OI__BJ -7SO"^92+C2<RRK-(?-C^9UQM8^XVKS[
M4RY/A.[607,FC2B1U=][QG<RXVD_3:OY5F?\*D\!_P#0MVO_ 'T__P 57.>/
M?A5X;@\%:E)X?\-Q_P!JA%^S^1O9]V]<X&?3- '<2R^%YUD62XTAA+(LKAI(
MSN=<;6/J1M7\A3VN?#3"4&ZTDB5UDDS+'\S+C!//)&U?R%8=O\)? IMHO,\-
MVV_8-V6?.<<_Q5+_ ,*D\!_]"W:_]]/_ /%4 :IE\+LTS&XTC=,R/(3)&=[+
MC:3SSC Q]*&F\,,T[&XT@M,Z22$R1_.RXVD\\D8&/I65_P *D\!_]"W:_P#?
M3_\ Q5'_  J3P'_T+=K_ -]/_P#%4 :IE\+EIF-QI!,TB2R9EC^=UQM)]2-H
MQ]*2:7PQ.LJRW&D.)F5I TL?S%<8)YYQ@?E67_PJ3P'_ -"W:_\ ?3__ !5'
M_"I/ ?\ T+=K_P!]/_\ %4K :,H\)3).DDFC.L[*TH+Q8<K@J3ZX('Y4Z"3P
MM!!+!%<:2L4K!I%$J8<C&">>>@_*LL_"3P'_ -"W:Y_WG_\ BJYGP[\*O#DG
MBCQ.NH^&D_L])X?[/,F\*4\OY]ISR-U%D%SOI+GPU,)Q)=Z6_P!HV^=NFC/F
M;>F[GG&!4]OJ&AK=R/;WM@;BY90YCF0M(P&%[\GH!6!_PJ3P'_T+=K_WT_\
M\54]G\+_  5I][;WEKX?MXKBWD66*16?*NI!!Z]B!3 ZZBBB@ HHHH ****
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M1*\_G(01R?D3;CZU,\]Y+INGZQ).]II?B;6[J[NB]VUF$B"[((Y94#%!\I/
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M 4444 %%%% !1110 4444 %%%% !1110 4444 )M'IUI&C1P0RA@>H/(IU%
M#3&A4*5! Z"EVCTI:* &F-"P8J"PZ'N*=110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
<4 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &O! P# 2(  A$! Q$!_\0
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MG_W\H_X37PU_T&K/_ONOG&E%'U./<7]I3_E7XGT;_P )IX:_Z#5I_P!]TO\
MPFGAK_H-6G_?=?.0I:/JD>X?VE/^5?B?1G_":>&_^@U:?]]T?\)GX;_Z#-I_
MWW7SJ*6CZI'N+^TY_P J_$^B?^$S\-_]!FT_[[H_X3/PW_T&;3_ONOG<4M'U
M2/</[3G_ "K\3Z(_X3+PY_T&;3_ONC_A,O#G_09M/^^Z^>*44?5(]P_M.?\
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M3_AKFOU>"2Z[=?[UCSP*2^T#YLXQ[UK:GH7]DRS03ZE9-=18#6\8E+9..,E
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M0=5=2"/P->O&<9*\6>#.G*#M)6&THI*451F.% H% H 44ZFBG4"%%**04HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB>*_^0/!_P!A*P_]*X:VZ0!1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% &)XK_P"0/!_V$K#_ -*X:VZQ/%?_ "!X/^PE8?\ I7#6
MW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMD'Y<9&#QQ0!K452TS5['5X9);*8N(W\N1'1HWC;KM9& 93R."!5V@#$T/\
MY#'B;_L))_Z26];=8FA_\ACQ-_V$D_\ 22WK;H **** "BBB@ HHHH ****
M"BBB@ HHJ*XN(K6!YYFVQH,LV"<?E0!+16=:ZYIUY<+!;W.^1LX78PS^8K1H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *'F>]'
MF>]5-YHWFNSD/%]N6_,]Z/,]ZJ;S1O-'('MRWYGO1YGO53>:-YHY ]N6_,]Z
M/,]ZJ;S1O-'('MRWYGO1YGO53>:-YHY ]N6_,]Z/,]ZJ;S1O-'('MRWYGO5F
MW;=&3[UE[S6A8',#9_O?T%9U(VB=&&J\U2Q:HHHKG/2"BBB@ HHHH **** "
MBBB@"&\EC@LIYIG*11QLSL.J@#)->7:1'=VNF>")+R*&#2X;L&VNHY"T\ID5
MQ&)$P F[=\V&?G'U'JLD:2QM'(H9'!5E/0@]JP+7PA:6\EFKWM[<6=BX>TLI
MF0Q0,!A2"%#M@'C<S8_ 4+1W]/U_S!ZJWJ<455_@]=7T@ N_[1DN?,Q\WG"[
M.#]> *]5'05S3>";!YF4WM]]@>Z^V-IV]/(,N[=G[N_&[YMN[&>U=-3Z?UV2
M_0'O]_YW.3\2ZE=20P6K:)?Q0C5+)?M;O!Y1 NXL' D+X../ESR,@<XZRL3Q
M7_R!X/\ L)6'_I7#6W2 **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **3-
M&:!7%HI,T9H"XM%)FC- 7%HI,T9H"XM%)FC- 7%HI,T9H"XM%)FEH&%%%% !
M1110 4444 %%%% !1110!QNO)<7?C_1H--DCMM0M[.>8W%Q$98O*)52FP,I+
M;MISN&,=\US6C#RM9\/VC@E[;7;]+J3^"6<Q.VY1V!W' YQTR>M>D:EHUCJI
MB:ZCD$D6?+E@G>&1 >H#H0P!P,C.#BH)?#.CRZ7'IS6>+>*3SDV2.KK)DG>)
M =V_)/S9R<GFG%V_KS!Z_P!>5C*\/E?^$Z\6B/[F^UW8Z;_*Y_'&VNAOY+^.
M!3IUM;7$V[!2XN&A4+@\Y5'YSCC'X^L>F:18Z/ \-C"4$CF21GD:1Y&/\3.Q
M+,>!R2>E7J71(.K9SOA=[I[WQ&U[###<'4EWQPRF5!_HMOC#%5)XQV']:Z*L
M30_^0QXF_P"PDG_I);UMT %%%% !1110 4444 %%%% !1110 5F^(/\ D!7?
M^Y_45I44GJ-:'-:7J4+R)%/K0N$,9!@:UV <<_-CL,U3M"@%P)A($-M)]A\S
M^YSG\>GX5V-0S^3.)+1Y5#R1G*!ANVGC.*;U$M#D=-V>;8_V;YOVSRF^T;MV
M,;>,YXQZ8J6P\K[3:?93<"_W'[:6W=,'.>WTKJK6W2TM8[>,L4C4*"W6GR2)
M%&9)'5$'5F. /QIL#D]*\B+46@MP+F1T</,OFHPX/WU;@TRQNHI/[%MEW>;#
M*XD!4C:>>,UUR312.R)(C,N-RA@2,],T^D!Q<=H4\-M=0(?->4K*V6/[O<<C
M Z#IG%:_A@,+>?;)$UN6'EK$)-JGN!O&?YUNT4 ]0HHHH **** "BBB@ HHH
MH **** "BBB@ HHJ&2ZMX<^;<1)CKN<"@#)HJM_:%IVG5O\ <^;^5'VU3]R&
MX?Z1$?SQ7?='SW)+L6:*J_:)V^[92 ?[;J/ZFEWWK=((4'^U(3_(47#D?],L
MT56VWK=98$^D9/\ 6C[/<-]Z\8?[B*/YYHOY!RKN6:*K?8R?O75PW_ \?R H
M^P0?Q>:Q_P!J5C_6B["T>_X%DD 9)Q437,"?>GC7ZN!48T^S!S]FC)_VES_.
MI5MX4^[#&OT4"C4/=\R(ZA9C@7$9/HIS_*C[?!_#YK'_ &8F/]*L@ # &!11
MJ%X]BM]M!^[;W!_[9D?SK7TJ0RVK,T3QG>1A\9Z#T)JC6EI_^H;_ 'OZ"LJM
M^4ZL(U[71%JBBBN4]<**** "BBB@ HHHH **** "BBB@ HHHH Q/%?\ R!X/
M^PE8?^E<-;=8GBO_ ) \'_82L/\ TKAK;H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *KWUY'864MU*&,<2[B$&3
M5BLWQ!%)-H-Y'$C22-'@*@R3SV%9U9.,&X[V+II.:3V'G5X#>QVD<<LLK)O?
MRP"(E[;CGBJT7B2QFTB74D$IBB;:Z8&\'('3.._K5*SL9M#O8?)2>:UO(PLY
M(+,DH'WCZ YQ6(VC7\'AR*6WMIO,F'EW,&P[B ^5;'7(Z?0URRK55T[_ "U5
MO7^NQV0HTG;7M^M_3^NYUE[KMO9W'V=8+JZG"AFCMHMY0'H3Z4YM>L!IJWPD
M9HV;8JJIWE_[N/6LX27.BZM>S-I]U=07>QU>V3>RD#&".U55T^_BBCU,VK&0
M7K7+6BD%@C#'XMWI^UJ7?^6VOXZ:D*E3LOEUWT_ UH?$5I+!=2-#<PR6R>9)
M#+'M?;Z@9_K4_P#;%NUS;V\4<LLLZ"3:@!\M3W?GBLRYNKO5-/U,KI4T$1MB
MD9E3$KMSQM]*BL+"?0[FRFACN)H;J-8[H$%F1\9#'T Z>U-59W7;36WF^GW>
MFX.E"S[]K^7?^NQ?N/$EI!/+&L%W.D)VRS0PEDC/?)]JMQZM;37L%K$6<S0^
M<C@#:5_GG\*Q;.XO-%MY]/;2KJX<R.T4L2[D<,>-Q[5%#97>AR:9<O:3W2Q6
MS12K;KO96+9Z=QSBIC6GHWMI?3;?3^OU&Z,-E\M=_,UI?$$,8G*6=[/Y$QB<
M0Q!L$#.>O2I-*UJ/5LF&TO(H]NX231[5;GL03FJFCV]Q]DU.XEMY(3=RO(D;
MCY@".,CL?:K7AR*2#P_9Q31O'(J$%7&".3V-:4Y5')<STM?;S_IF=2-.,79:
MWMOY%W?1OJKYE'F5Z/(>/[9%K?1OJKYE'F4<@>V1:WT;ZJ^91YE'('MD6M]&
M^JOF4>91R![9%K?1OJKYE'F4<@>V1:WT;ZJ^91YE'('MD6U;YA]:FJA')F11
M[BK]9S5CIHSYDPHHHJ#8**** "BBB@ HHHH **** "BBB@ HHHH Q-#_ .0Q
MXF_["2?^DEO6W6)H?_(8\3?]A)/_ $DMZVZ "BBB@ HHHH **** "BBB@ HH
MKF_%>I7=D+>*V<Q+("6=>IQCC- '245A>%[^YOK&7[2Q<QOM5SWXZ?Y]:W:
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M* NQ=Q]:-Q]:2B@+L7<?6C<?6HS+&.KJ/J::;F!>LT8^K"EH/WBS"3Y\?/\
M$/YUL5@V]W;-=1(+B(L7 "AQD\UO5SUMT>G@DU%W"BBBL#O"BBB@ HHHH *P
M=6\7:;I-RUIY=Y?7B??MM/M7N'3C(W;1A?Q(K>KFM=U^ZTF*^1[%[53&WV;4
M,>9!OV\&7 RG/<C;[]J3&D3:7XPTS5+E+5H[ZPNY.$@U"T>W9SC.%W##'@\
MDUOURO@QM8GMIY]3GFGM7V-;-<RP2N3SN(:$!=I^7'?K75535B4%%5[V_LM,
MMC<W]W!:P*0#+/((U!/3DG%,DU73HM.&HR7]JEB5#"Y:91$0>AW9QBD,MT5!
M9WMIJ%LMS974-S WW989 ZGZ$<5/0!B:'_R&/$W_ &$D_P#22WK;K$T/_D,>
M)O\ L))_Z26];= !1110 4444 %%%% !1110 5%<6L%W'Y=Q$DB9SAAFI:*
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M/02D'#3-_JU_'^(^P_.FK#-J8$EU^ZM3RL"MR_NY'\A^-:*(L:!$4*H&  ,
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M4E%.Y'*1[:-M1:A?VNEV$U]>R^5;0+OD?!.T?0<FLC1?&WASQ#>&TTO4UGN
MN[RS&Z$CVW 9_"J2DU=(E\J:3>YN;:-M25#<7$=K&'D65@6"XBB:0Y)QT4$X
M]^@[U-RN5#MM&VI**+ARD>VC;4=I>VM_&\EK.DR([1LR'(W#@C/M5BBX<J(]
MM&VH+74K.^NKNVMYM\MHXCG7:1L8C.,D8/![5;IW8<J&!>13Z**125@HHHI#
M"BBB@ HHHH *Y'5_AWHFL>*8=<N;6VD8QM'=0RP[Q/P-K9S\K#'7G(XKKJX'
MQ'J=_:ZOJ7E>.[73H;2%;B6U;2A,8$. ,ON&23T'7GI2ZCZ'6:1X?TC04E32
M=/M[-92#((4V[B.F:TJY3P-J=QJEG=RW.O?VHZ2!"C:=]C> XSAD))Y!!!KJ
MZIDH****0PHHHH Q-#_Y#'B;_L))_P"DEO6W6)H?_(8\3?\ 823_ -)+>MN@
M HHHH **** "BBJ=W=2*XMK10]TPSS]V,?WF_H.] "W=[Y#K!$GFW+C*1@XX
M]2>PKE_$NFWY:&X=GN<@A]B_*A] .P]ZZNTLTM58@EY7.9)6^\Y_P]NU6* ,
M+PK;W-OI;"X5D5G)C5A@@5NT44 %%%% !1110 5Q_P#PFMY%XFCT>[T,6_V@
MR+:R&^B=I&49&Y%R4!]>:Z\C<I'/(QQ7$Z5\/Y]-U#3YVUZ6X@L+AYH('ME'
MRN""&8'+-S]X_E0MPZ%JW\<PSQ:2WV,H]Y'-)<J9/^/18@=Y/'S8(QVK/TOX
MG6VHR7"M8)%_HTEQ:XO8Y&E"+N*NJY,;8[$'OZ5K:?X*M+'6M:OWF:6/4E*"
M K@0JW+@'/\ $3GH*S-*^&Z:8+J/^T()8GMW@@_XED*21!E*Y:0#<YP?49[T
MM?P_$:M?Y_@6;3Q?K-YX=&KQ>%F"R;# CZA$@=2,EBS8V@'@<9/H*AA^(9O-
M)L)K#1WNM2O)Y(%LDN5P#'RY\SH0!@@]\U9N_!4TVB:)96VL/;7.D@>7<"W5
MU?Y=I)C8XSCIUQ7/:[X8U+P[INGS:9)J%[<P:A+/]LM85>>)9/O Q'B3/K\O
MTJG:[[$J]C2E^):06$TDNDF&\6^>SCMI[M(PQ502S2-A4Z^_..372^&O$$'B
M72%OH4$;!VBEC$BR!'7J R\,.X(Z@UP^D^!KC7="N)[YI[*\DU*6\MFOK9)7
MVL O[V)OE).,X[$"N[\/:*N@Z2EGYD4K[BTDD5K';JS'OL0 #]3[T>OE^@WO
MH:M%%%( HHHH **** "BBB@ HHHH **** "BBB@!LD4<T312HLD;C#*PR"/0
MBJMKI.FV5M);6FGVD%O)G?%%"J*V>N0!@UY[K7BCQ1/K&HMH\B6]KIMRMMY<
MJVXCG?CAWDD5ESGC:#GZU=O=?UR3QU)X8LM0@4W"QSB;"%[- ,R(!C#,< C.
M< _EJJ4FEKO_ ,/^6IBZL4WIM_PWYZ'</IUC+9)9265N]H@4+ T2E% Z87&!
MC'%.@L[6U\W[/;0Q><YDE\M N]CU9L=3[FO,M2\3^)5M==UBTUJWBLM.U 6T
M%I);([3[< KNX(SG/ SUY%3:IXI\0S0:SK5EJ5M8V6DW'V=;&2W5VN6&,AF)
MRN2>,4U2D^N_ZV_S0G5BNGY=+_Y,]"L])TW3W+V6GVELQ783#"J';G..!TR2
M?QJ:*TMH)YIX;>*.6<@RR(@#2$# +$=?QK@O$^M^)+'6[>5[N72=$*QXN$L$
MND+MU$Q+!D&<#CUZU)J7BF_AL?%5W!>J!;31V5@NQ,";:-Q'!)^9NASTI>SD
M];[_ .:7ZC]I%-JW]6;.V?3[*2]CO7L[=KN,;4G:)3(H] V,B@Z?9&_%\;.W
M-X%V"X,2^8%]-V,XKB;K6?$)U?6O)U!8[#1;>%YPMNC/.X0NZ@D<;NA/;L*B
M\)ZWXJO]=L7U":*2QO[8W!@=;>,PKC*F,+(TCKD@$L!^%-4W:]_Z_P""#JQO
M:W]:?E='?&UMS=B[-O$;D)Y8FV#>%SG;NZXSVJ:O/_B!>WE^[:5I=LL[Z>BW
M]XLN#&\?("%/^6AZG&0/EKH/!=WIUUX8M5TNZFNK: >4)ID*EB.N,]AG'H,8
M[5'(^3F*YUS\IT%%%%0:!1110 4444 %%%% !6)XLT2;7_#\MC;31Q7 DCFB
M:0$H61PX#8[$C!K;K-U^WU.[T2YAT>_CL+YE_=W$D8<)SSP?;//:DQK<X*_\
M+ZE;Z+?_ -KZCI5O-K=^DVHW#R%5AB4KLCBR 6;C'..M>G 8  KQ>UTZ;2_%
MFD:KXCTB[NXHDE2XU,SG4(G<XV, !^[ (/\ ",9KVFJ^S_7H3U(YYHK:"2>:
M18XHU+N[' 4#DDUYS8W%]J/Q.T;5[II([:[LKK[':L,>7"NS:Q']Y\[CZ#:.
MU>C7%O#=6\EO<0QS0R*5>.10RL#U!!X(KFO^$!T.+Q-IVL6>G:=:K9QR#R(;
M)%#NVW:^1C!7!QP>O:DOBO\ ULQOX6E_6QQQMH9/A[<^+/+5=<%^\XO<8E 6
MY*B/=UV;1MV],5ZT#D UQ[^")V@DTS^UE&A27GVMK3[-^]YD\PQB3?C9NY^Y
MG'&:["GT_KLOU!_%?U_/_(Y/Q+K=K-#!8K%?B8:I9+N?3YUBRMW%G]X4"8XX
M.<'C&<BNLK$\5_\ ('@_["5A_P"E<-;=( HHHH **** "O/M1U74EUB8_:)H
MVCD(5 2  #P,=_ZUZ#TK)D U2X#VT<:QJ<&\* L?://\_P J ,#4_$NI0WOE
M1E81&%W+L!R< G.:W[" ZG;0WM\WF[P&6'&(T_#N?<TY_#VERE"]MN9?XMQR
MWUYYKF==U.^M]6D@AFDMXH<+&D9VC&/;K0!T>H>'+'4;GSY/,1R &\L@!OS%
M5/%$[^'? ]_-I)6VDM8<PE4!"G([$$'\:U]+GEN=+MIIQB1T!;C&??\ 'K5?
MQ#I']O:!>:7Y_D?:4V>9LW;><],C/YU,KVT'&U]3SO0O%^K7-\T=KXC_ +<A
M-E++<-_9OV?[&RIE3G&&R>/PK;\*>-K^].BV6K:;,C:A;,\-\SH!.ZC+?(OW
M1Z>OI7826/F:.^G^9C=;F'?M_P!G&<5S\'@H0KX=4Z@Q&CPR196+:9MZ;<@[
MOEQU[U?7^O/_ (!*6G]>7_!(8?',Z>(O[)U+16LS(DKP,MY',[[ 20R)G:2
M>YYHT#QXVKVMW?7.EK:Z?;PM-Y\=]%.< 9PZ*=R-CM@U#I/P_N=,O=/G;Q#-
M,M@95@3[*B[5=<=>[=#N;.<=*?;^ 9)-5GO=9UC^T/,@DMU6.SCMVV.,'<R?
M?..F>AYI=/D/J2>%_'T'B/4S8O:):R21&:WV7D<^]!C.X(<HW(^4^_I3/&MY
MXFTP/J6GZA;VUA J[81;&9IW)Y\QB,1H!_%GZGI4WA;P./#=ZT[7MO<JJ>7"
M%TZ&%T'^U(HW,<=\C/>G:_X+EUC4I[JUUF>P2\@%O?1)$L@GC&< $_<."1D4
M/I8%UN=3"YD@CD)0EE!)0Y7D=CW%/J&TM8K*S@M8!MBAC6-!Z # J:F[7T$K
MVU"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X_XD
M>9<>'(=*AE$<VIWD-JK$9P"V2<=\ 5@^*?#NHZ=H%YJFK:])JM[' ;2S M4@
M6(RD(3A>IP<9KTFYNK>R@:>ZGB@A09:25PJCZD\5"FJ:?)8-?I?6K62@DW"S
M*8P!U.[.*TC-Q5DNO^7Z?F93@I2NWT_S_6WW'F7B'1=&\/7VF6FL_:U\/R0L
M]W*K2-]HN  JARO(  X P*+&&];3_#.E/'*$EU&>\M(;C.]((E9H@V3GJ1U[
M8KTBRU[1]2G,%AJUC=2@;O+@N$=L>N :RX+'1+?6+OQ3)K)GP#!OGNU:"UY
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M&!<#&8\' /U5NM*[3NOZ_JP]TTRWX%N8M3U;Q#JRWMK<RW,\:$6>YHD1%*H
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M6;:!;VTD[9P3]V-6(''7&/SJAH>AOI<]_>75V+N_OY1)/*L7EI\JA555RV
M.Y)Y-;-/HA=6<[X7NX[Z]\1W$2S*CZDN!-"\3\6MN.5<!AT[CWKHJQ-#_P"0
MQXF_["2?^DEO6W2&%%%% !115:]N_LL:A$\R>0[8H_[Q_P !W- #+R[=)%M;
M4![J09&>D:_WF]OYU+:VJ6L9526=CN>1OO.?4TVRM/LJ,SMYD\AW2R'^(_T
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M$2*-8T4*BC  Z 5#96HM+?86WR,=TCGJ['J:L4 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M8GBO_D#P?]A*P_\ 2N&MNL3Q7_R!X/\ L)6'_I7#6E?W!MK.21!F0_+&OJQX
M _,T 06O^E:C/=GF.+,$7X??/Y\?\!K0J&TMQ:6D4 .=B@$^I[G\34U !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWPM_T+>C_P#@#%_\31_PAOA;_H6]'_\  &+_ .)H VZ*Q/\ A#?"W_0MZ/\
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M^)H_X0WPM_T+>C_^ ,7_ ,30!MT5B?\ "&^%O^A;T?\ \ 8O_B:/^$-\+?\
M0MZ/_P" ,7_Q- &W16)_PAOA;_H6]'_\ 8O_ (FC_A#?"W_0MZ/_ . ,7_Q-
M &W17+:SX$T&\T/4+6QT'1X+R:VDC@E^QQKY<A4A6R%R,$@Y'-7O^$-\+?\
M0MZ/_P" ,7_Q- &W16)_PAOA;_H6]'_\ 8O_ (FC_A#?"W_0MZ/_ . ,7_Q-
M &W16)_PAOA;_H6]'_\  &+_ .)H_P"$-\+?]"WH_P#X Q?_ !- &W16)_PA
MOA;_ *%O1_\ P!B_^)H_X0WPM_T+>C_^ ,7_ ,30!MT5B?\ "&^%O^A;T?\
M\ 8O_B:/^$-\+?\ 0MZ/_P" ,7_Q- &W16)_PAOA;_H6]'_\ 8O_ (FC_A#?
M"W_0MZ/_ . ,7_Q- &W16)_PAOA;_H6]'_\  &+_ .)H_P"$-\+?]"WH_P#X
M Q?_ !- &W16)_PAOA;_ *%O1_\ P!B_^)JC%X$T%=<N[I]!T<V<EM#'%%]C
MC^616E+MC;@9#QC(Y.WGH* .IHK$_P"$-\+?]"WH_P#X Q?_ !-'_"&^%O\
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MB_\ B: -NBN6T;P)H-GH>GVM]H.CSWD-M''/+]CC;S) H#-DKDY()R>:O?\
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M4X>601N\<$?+R;5W''H !R3P*I7/BATTK19[:Q$U]J^P6]LTVQ5)0N=S[3@
M \A3VXJSXL _X1#6FP,BPG /_ #7*3NECIW@#5[E_+L;1%6XE;[L0DMRJLQ[
M#.!D\#-"\^Z_7_('Y>?Z'6:'KCZI/?V=U:"UOK"58YXEE\Q#N4,K*V 2"#W
MZ'BMBN2\*S)J7B;Q)JUJRR6$\D$4$Z<I-LC^9E/<9;&1QQ76T^B%U84444AA
M1110 4444 %%%% !1110 5SZ^++2;Q5;:';1--YJ3%[D'"*T>T,@_O'+8..!
MTZY Z"N1U0!?B?X=   ^PWG3ZQT+=+^MF#V?]=46QKVK7FLZE9:5I5E-#82)
M#)-<WSPEG*!R JQ/T##O71CIS7FVN+X6%OKZP6,=MXG9Y3;BXQ]KEG*C;)!D
MEMIXQLP.#D#!KT&P%P-/MA=D&Y$2^:1W? S^N:%\(/<L4444 %%%% !1110
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M;-8%UX%N[W0-'TN6Y@C^R:9+9S.A8_.RH 5X&1E3GH:73[OU_P" %M?Z\O\
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M1S7,D0@600)IEP92"Q <87)4XXPO;.<&G6/B?3M6OX(;*\.&:6-H9K.6-V9
MNX L%V[=PSD'.>V#6=K.A:\]_+=Z--9QO+8Q69:69HV4!V9RI"-@X( ..#SC
MCF73=!OH=1T>9[*PL;;3HIXA#;W+S;@X3!R8TYR#G/UYS0OZ_'_@!T_KR_X)
M4UOQ7<6'B*^T\ZUH>F16UM%-'_:$99IF;?D#]ZG3:.@/6M#0/$-YJVHI!<6T
M4"MID%X54EBKR,X(SG!'RC'%)<Z=K=MXDU'4+"UTZY@O+:&';<W3Q%"F_/ B
M8$'?ZCI6?I/AO6O#=W%)I\6G7L8L([9Q-<O;[65W<E0(W^7Y\#GM0O/^M_\
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MVVE1Q28R/FD8$EC@8^78#DY!XQM7WAA+^\U2=[DJ+ZSBME"IS$R%V5P<\G+
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MACOVK;UKP_::Z(A=23)Y:2H/*8#B1"C=0>Q./>J][X3T^_:,SO<9BM1:H5<
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M_P!0O+G8B17,SH)(0K!EVE4&2& .6R3WS6OIVG-8)+YM_>7LDK9:2Z=2>F
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M-&>YFD\U+DEYHTAE.'C   .W(&YNG.#75:3H$>E7E[>&^O+RYO @EDN60YV
M@8"JH'!]*SCX&TYYH/,N[Z2SMWD>&Q9T\E-ZLK+]W<00YZL<=L#BCM_7?_@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
;"BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>ex10-17_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-17_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !W 64# 2(  A$! Q$!_\0
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MPQI,A., 2Z$Z*#P,\U^*A9W"QL\'DK\R11(L7E,/X+?!*VMM_P!,;1('&?\
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M:_D(_P""EW[8FK_M&_&K4? >@:R+CX+_  JU;4=-\)KIA\JU\6>([53I>O\
MBV6:WD-GJ=I;7,DFE>%+Z.%H;#13)/ ;JXO]6O-2^SX+X6Q/%6=5,._:1P.#
MC&MC:\.:U.G&+;5.+C%SG.=DO9\[C&\FO=L?SW](KQPP'@AP#C.(:4L-7XAS
M2MB,-PIE-6_M,SS:AR/$YO0@G+VN78"G+VN+:2A%.,.92G=?/7[5_P"UM\1/
MVJ?BC=^+?'$MQIWA?3U>V\ ?#NTO_MNA>!K*01B=X)&M;4:MJ^H&" ZIK%W:
M1/<&*W%I:V"6&FI9_);IMV;"([9#=2[(R[6ERMQ@B=G_ 'MU?1)_S[!;=6^]
MY@YK7TCP[KOBC4]/TGP[INL>)=:U>2WBTS3=#TC4=3U*_>X( %I9V]NUQ<HN
M>9;6.:W('^O&#7[ ?LS?\$;OC!\2[G2/$/QWU>W^$O@NZ6._N?#MC,\WQ0NK
M2[BCDT^T-G'+!:^$DE64&\34W;5[&16MYM&\Q6V?U?4S3A3@>C+#8FIA\KC1
M@J<J252I.U./PTJ%*-2M4D].:?+)R;YJE2\G(_Q7X?X/\7_I <79KG64Y9Q!
MQEQ#F]64^)<Z>'G3RJA*?*HJICL8\/E^71C&-H4IUJ*C9JE23OS?C0Z1$[8\
MK(>D;21&3U_U.X7/Y0'CGUJ>.WF";OM<-MWQ=/<V??K_ *1;Q_7I7]D/PI_X
M)G?L3> ))Y=.^&>G?$G5K8Q17UY\4-6D^(SPK<;@4DT+5Y;GPS;3PJC.JP:%
M!+D*4D^9<?;6A_"'X7^%XROAOX<^!-  Q@:)X/\ #VFD]>=T&G@\XQR3GU[5
M^8YAXZX"C*I2R[(ZE65'2H\0HTWJDU:%>[>FK;DMMMK_ -<\,?L\^/\ ,L)#
M$<2^(O".55J[_=0P>6XOC2#5M6\1C*>50C_A5]/M-W2_S_GEC1=\D$$<?]Z5
M9X_PY# '\>.:F(X4BVM\/]QM\CI_P-H/.V#WPU?Z%C^'-)D78^G::ZGJKZ=;
M,.WJN:\Q\3_LY_ KQK;7%IXN^#?PF\2PW((D77/AOX2U0X/]UKS3)B".S=1R
M,X.*X\-X[Q_Y?\.):I-_6D[*ZN[>]>RN[73=K)ZZ>]B/V<&:+^!XKX.2UT?"
MV<J_;5\4NUGOIKY'\$+K?2!0#-)(4\SRT9)O-3GY;1[*2Z2^EX/[NU,G?YJK
MH^Q_WH8C'0Y)'Z_R-?UP?%O_ ((U?LD^/XKRX\'6?B3X2:Q<P321MX9U.;6M
M ?5&5O)OKK0/%DVKE(TDV^99Z)J>A++&-@FB<^:/P@_:(_X)J?M+_L^K>ZU<
M>'D^)O@6WGRGB[X<0:EK4UKIVR1_MNN^&6L8]<TE4CA:6YOH(=5\,6D11[GQ
M/$717^^X?\1N$^(Y*C5C'"8YV4:-9O#2=_Y*LI>PE=II<M5-_P O?^9/%7Z)
MWC!X9818W,,BRSB'(H-N>;\'475J12O\>!:_M..FKYL)**7VK:Q_/J-@K9/3
MO_3Z]:>R*22""&&UEP/+>/LC*<@_[_7^C[B%(W+1N\ML& $X@DC=HSG]X;=A
MOA8<#[/<&"X/!$620&&-1A@Y,><;]F#GTVEOZX]*_1X\LXJK6FN5V7-!QK1O
M:Z4G3<U&5NC:;[;'\P2IUH3C5<I4:LY-*"C4]K"HFXNC6IJ*JX?$II_[/6A3
MKVU=/M^NO_!+C]MK4_@#XWTGX/\ C6[CN_A#\3/%VD:-;:GJ=[+]K^&7BC5Y
MQINF7%M]I\VUC\&^(-=*Z=JUN6L8],5XM9MKF*));)_ZR(9V9%)B";GD7.3M
M#?P.K8P8Y 1M89'4#/;_ #QT#M#</YLBVPFCD6"-BDK2M$(F,UR#F2&-@)[6
M)8HVMKG,PF<D ?V8_P#!-[]HR[_:0_9D\(ZYJ=S+/XQ\#N?A?X]FN3(SW/B#
M0;"QOX=08&*(H^J^'=2T;6&C5KA;:>^FL3<W$EH]Q+_-_C-PA0P5:'%> A&G
M0KU'3S6C"/)'#5'%RIIQ3_>R2BXN5*,XN48VDG)\W^KOT#?&S,<YI9QX0Y_C
MZ^.J8".(S;@#%XJI*K4P67X.@L1C^$:M2<%*?U?#N.*I8F<G05.56E"M.=H1
M_1RBBF,Q'\.?0YX_D:_ C_3):NWYZ?B]!]%(20,XR?3/]<?TIH9L9*8^I_Q
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M]MKXC:C\!_@1XC\0:7^RQX6O9=$O+?39Y)+3XZ^(],\81/I_CFZ@LM.M+_\
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M?[4'[0][I%[9^!T\'^&O@[H/B"[M)8M/UOQ3<ZY+XO\ %FCZ/=<Q7D_A[2]
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MUITEYH_B7PA R&/4OB)!:P6/A-[6YNK1]9TC3/#-G!=VQT>>#5_ZFT:0I\V
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MQCK&EG?HB>*?%G]G^'5O-'T2\ U;3M*T'PSI(768--U*>ZGET?2DL_WAO?\
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MJ2]/>*VF_E_];6T3X9_$3Q$1!X<^'_C+Q%B;[0R:#X8U_47>?O(\UG;.V/\
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MF&#E@Z4H1=!.=*KS^\TVG1E-15DDN=I[M[H_,;X]_P#!1OXR>#_VP=>_8T^
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MT/VI2EK.Z[#&(D$7FG^@K]C'5_AU<_#*^\._#W]L=?VU&T'Q)>S:_P#$B_\
MB3\.?B5XGTF771;MIOAS4[WX:6]MHNE06L-I.+?3KO2+&?R[N=UE"08/1FN
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M^+_[;R_"O]O3]E#]B#_A61UV/]J'PA\6?%#?$T^-/[+/@=OAIX-\5>+A8_\
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M*?A!\3?@O^T/X=UK3[F74(Y9[G7M/\6?#RXT*^MA:6LC:9J&B>;*E\&BF>.
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ME45M8W[WW3333UT?H8U:5.K"KAJM&-;#8M-8E3Y7%IJUI1E=R5NR?3L*L>$
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MLY]>IC:7H&F:'I]EI&C6%EI>DZ?"MK8Z9IUE;V%A8V<>#;VEE9V"V]K;0VS
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M6)UD0&Y<_P 0/7UQ_G]/>J9M(&W%@V74JS*[)DDLQE"(5A6<ECF=8A,1@>8
MJ@%%85I2IU>>#<9=T_3Y?@*E&-6CR5(QG![QDDT]][GQ]^TS_P $^/V./VP!
M'=_M"_ 7P/X\UZWTXZ/:^-?LU]X6^(MGI1^9M,L?B3X)O?#GCZPTPMECIMEX
MC@L2Q),&XDG^?WXO_P#!JU\&]7:]O?@+^U%\0_ ]Q(?MUKHGQ)\$^%/B+9RO
MM&;5M2T23X?26L;L3^]%A=;<J"CC<X**]_*.-^*.'&GE.;8B@DXQY)M5J=E)
MZ<E53BNS<5!M:;)6^6S;P^X1XC3JYKDV&K5%=JI3YJ$[\J?Q47!O?K?[]3\J
M/BG_ ,&U7_!17P*;B?P0?@G\9K5?^/2U\)_$5O#&N7)')$MI\1M'\(:+;$#K
MCQ'<#/0GOX#!_P $$O\ @JV\Z12_LH+%&?O3/\<_V;VV 9!/EQ_&)V;\#^%%
M%?J&$\7>*J$$U1R.H^6[=3*H.[5E>T:\4K]4M.Q^(YAX/<)*KR1J9U%.<8Z9
MI)M)WZRP\M?Z=SZE^$__  ;0?M\>-Y$NOBAXL^"GP4T>*X\K45U7Q3?^.?$T
M,6%;SK+2/ ^E:EH%Z<,I$4_C'3CSC=UQ^N/P8_X-;/V7_"&J:=J_QS^/_P 6
M_C.UA=">ZT#0=/TOX5^&-?M<@'0]>$5WXY\:-H! P++0O'.@78."=08#%%%?
M*YYXD<7XN#G+-)4+-KEPU*%):1IN[?OSO[S^TK+1;L_0,A\(. :$7)Y*J\KK
M7$5ZM72[TM>*MHFULVEIHK?OM^S]^QI^S#^RMI%YHG[//P3^'GPIMM3MX+76
M+WPQX;L8=?U^"U)-K!XE\4W*7'B7Q-;VV^1;:'7]6U$6<;F.P:T0*H^C3:)A
M5$T@541"N $=$# H\07R%5MPW>1# ^%"[]ORT45\)5Y\8V\55K8AZ7=:K.;>
M^_-)WLM%V6BLM#]*H4Z.!2C@\/0PT==*5&$%T_EBOZ\]5H4445!W!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
00 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>ex10-18_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-18_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !Y 6<# 2(  A$! Q$!_\0
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M_$<_A2?:K?$;>8 )7$<9(9=[D$A0"H.2 2/H:CVE-S]GSP]I_)S+GUV]W?\
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MH4\76E)PH-I14:M>;Y91DY)0=1\T'&TI25I+_.'Z5'T/<HSW+\T\0/"W+J6
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M.<<0<>83'XJ>)IY9B*=/ )MSA0O6S&E6A%W:4G*&'C);J2C%J[2/Y#/V^/\
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M].TZSCL]-TZQL82MM8:99V=K%:QVMG'M1W!AB@MU*KTFY<*$&0Q&#R"??H,
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MV>ST:V^W>*-;O+Z[NKO7=>\365B&U!DT&#4/$-SIT%UJ,,\MA:75S#_H8?\
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MH[*ZD,;2VMK/XWU6TG,-[9744'ZP_P#!N1^QMK/[/7[(WB#XW>/-"BT[Q_\
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M]VSYK1T:LT_4X1R"&4\'Y7DN:Y?E\\3]4>&QD<13I*4_;75XJ<&V_>?-&_\
M+H]+?Y@?[9_[,?QF_P""5'[<+>'O#OB2_P!#O_ OB33/BM^SY\3]*:[M6USP
MS-J=U+H6JQ3WAC6\UF"6QG\'^/=%9CIEYXB.NZ) EQX=U#3[F[_OD_X)K?\
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M;K3+:<K%=QZ7B#_@U3^(=G?[?#/[:?A/5=+'!&O_  3\3:)?KTQF31_B3JR
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M>30HXJI"&(CC\NQ"4Z&/P<U#VM&=-J2G)P52,(\K;YVDG>S^HY?^">,?P/\
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M?YM]=+L_)\?X$\,U\2O8YAF6%@I2O"G[*2ES6W<K:JSLU&]G9Z)'^91\,/\
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AHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>ex19-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex19-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !9 0H# 2(  A$! Q$!_\0
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M8?#<08?"X;,<NJSLH4IYC@LPPG,X^WJ4H<U6'\*%?=/_  3X_:SU?]DWX_\
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M=>7/*#C)4FZE*-7]Z***_ W_ (+4?\%A?%/_  3;N_@S\/?@OX4^'GCWXO\
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MI^FVXSSOG4#J<_11PBJ\-\7+#4H4Y5\QSY0I4H*$84<OKTL/0H0A%)1C3PN
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M$:%)(AO[Z+0/%N@^.?%NLPVVX2FPT#0] \J[O54PVNHZQHEO(?-U"WCD^4X
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M=8?\FI_LS?\ 9P][_P"JV\4U_.K_ ,$_/^":?[6W_!4NUET_1/%MUX5^!_P
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MW+IWA30C=:KHDOBG4X1*6TKPW=^(M*TC3M>U9A!-Y.EZ3>7>H7)BD%O;2E&
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M5KSITHIU/W;T2[U*_P!%TB^UG23H.KWNEV%WJNAF^M]3.C:E<6D4U]I)U*S
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, !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>ex97-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex97-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !M 2$# 2(  A$! Q$!_\0
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MJ:G?SQ6MCI^G6$$EU>WUY=3,D-O:VMM%)/<3RNL<44;R.P521_'K_P %%_\
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MBU2QE1+K2=>TJ215:;2=<TR:VU/3Y6 ?R+@13+'<131I_2]_P37_ +3^&?\
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M?\]?_!0#Q#9?LF?LI_!;]B7P!>F#5/%NB2Z_\4=3@<)?:MI4.H-J'B&XNY4
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MFFUS3H.G@L5*,;OV-64[<L)./T%1117Y8?UL%%%% 'XJ?\%9?V(/$G[1>K?
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M\'$T4-B?M4J_M5_L>VA2 &1OM,&C_!@S0 *"3)'T=1RI!!P0:_I5_P"#C?\
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MNW-]:6-G>R-Y46A?$26Z=O+@!'^@/7YWXA9)2R?B*M6P?++*\ZI0SG+*E/\
MA2H8VU6K3IM)+EI8BI/EBK<M*O25E:R_5/"_B&MGO"V'H8_FCG.059Y#G%*H
M_P!]'$Y?>C1JU$VWS5L-2AS2>DJN'K--WNRBBBOAC]%"BBB@ HHHH _+S]JW
MP_\  3]K[XB^)/V.OB)?2?"[]H;P9H5C\1_@1XFU00!?&OA?Q!8"+4M6\'/(
M]NGB73+'6M,U#PY\0?!0D76-/_LFP\163&V>VOK7Y"_8#\%_$K]DK]H7X@?L
MN?M!^&9=*\+_ ![\/SVOA/7XP]WX$\8^)/#=G?EK;0?$#1Q6TLOB'PC?ZJDF
MDW/V76X9]-M;.[T^.5HRWV;_ ,%-?V%+O]L7X6Z%K_PUU0^$OVD?@K>W?BSX
M+^+;749=!N;F]803:CX.N_$%HT5YI%OK;V5I/I&KQSI_87B&SL+YG2QEU-9O
MQ4^!/_!:[XZ? K5Y/@?^W?\ !V_^)][\/=:MM,U/6[C3]-\._&7PGK&BSHMO
M<^(]"U:.+PSXJU*P$7VG3]<LY_#FHWQ:/4DU75#.MY)^J9%''9GPOB\NRB4,
MRH2H\N/R*OB(T<PRW'0G&KA\VR6O5:A6PM>O2HUZF#JN"IXCZS2IU83G2<_Y
MQXTX;R+!>)&2<9YJJG#N>8+%QE@>*<+@Y8K).)LDJT*N"Q_#7%F!HKVE+&T,
MMQ>+P.&S;#<]9X3ZC5Q&'Q6&HUJ=&]\:?A;JWP7^*/C+X:ZO'(&\.:M,FE74
MB,BZIX<NR;KP_JL)8#?'>:9)!YA!(2[CN8&/F0N!Z-^R]^TKXF_9K\>'7;"*
M;6?!VO"VLO''A191&-4L8'8V^IZ:9&6"W\0:0)9GL)Y-L=S#+<:==.D%P)H/
MJGQY^VG_ ,$G/VTCX=\0>./CGJOPL\7Z1:2Z5:MXDTS6O &O&QN)OM"Z=J]Q
MJ/A_6O#.HVEG<&::UD@U246LMU<A+O9-(A\_NHO^"/O@^,:CXD_;0M_$-L-Q
M2PT?QA:ZK/,1\PC-KX.\(WVJMN7Y (S Q8C$BD$5]&LV6*RU8#/<ASYXJKAU
M0QN&ADF.K0JU8I1E4HUJ4'33G*$:\)QJ1=*HWRR]Q.7X[5\,,_R3BN>><!\4
M<)4\MPF93QV19G5XKRO!XC"8:I.52GA<;@\2G6G&C2K5<!7I3I5J6-PL$ITU
M[:<:?[O?#'XJ>!/C%X3L/&?P^U^TU[1;Y%\SR7"7^EW>T&;3-9T]S]JTO4[5
MLI/9W2(_ EB,MO)%-)Z'7\TUW_P6#_X)_?LNKJEA^R=\"_'GQ'UR]@6QU'Q/
M.;CP/H^L);DM;R7OB#QG-JOBN_A68+*L<?A6&)5+^28F8@_+5_\ \%NO^"@W
M[07BI/ _[-?P>\$Z-KNH2^7IN@^"/!'B/XN^,T1W/ES7EQJ5S'HMNBJ<2WEW
MX;L]/C">9+)&@?/PJ\/\\Q5:M6PF#J8#+4W.G7SZOA,!6IT=VZ].%6O**@M.
M>4:+<4I3C"3E$_IW">)^48/ 8*AG>-P68\0N$:6+PW!]#,LUP-7%:1_V.MB<
M/A&W5:YG2B\1&G.4H4JE:DJ=1_U_5XO\0=8^,TD4]A\.O"&FP[MR?V]K&MZ2
M;E5/'F6&DM,;='ZE);^XD4 _-9[A7X9> OV=/^"NOQ%TF3XA_M=?M]R?LC^
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MM;N_T"_BU32+E[SP[JFCZHC65_!%<(L5]''(R!)DDC+(?Q-_X*7>#=7^)_\
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M8>$-#C0NRH=/T>&<K_K9Y7RY^9OE5><*JCV"JH'X   ?0"OU4_9Z_P""*?\
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MUSQF/!&EW&B>$!XAOXU$VHCPYI%U<:=I/GLWV.TFDABPC$4WQ?\ #+X?>/\
M5O FN^-?!^@>)]8^&'BH>./AYJ6LZ?#>W?@[Q>-)U/01XCT":52VGZL-&UG5
M=-%W"1(+2_N8<[96KNJ*U]M6YU4]M5]I&"IQJ>TJ<ZIJDZ"IJ?/SJ"HMT5!2
M452;I**IMP>7L*'LW2]A1]E*I*K*G[*G[.56558B524.3D=25=*O*;BYRK)5
M92=3WSAHOAE\/H?B3=_&&+P?H$?Q2OO!=I\.KSQZFG0#Q/<^!+#6KGQ'9>$Y
MM5"_:7T.VUV\NM6AL"WDI?7$LX7>Y->5?';]D+]F#]IZ\\-ZA^T)\"OAK\8;
M[P?;:E9^%[OQ[X:L=>N-!M=8ELYM5M],ENT9[6*_ET^RDNDC($K6L)8$H*^C
MJ*NEB\70JTZ]'%8FC7I05*E6I8BO2K4J:C*"ITZM.K"I3IJ,Y14(3A!1E**B
MHRDGE6P6"Q%&KA\1@\)7P]>HZU:A6PV'JT*U64HS=6K1J4:E*K5<X0FZE2G.
M;E"$G-RC%Q\L^#OP1^$7[/G@FV^&_P $?AWX5^%W@*SU#4M6M?"?@W2H-&T.
M#4M8N#=:I>Q6-L%B6XOKDF:YD S))\QYK!O/V9_V?M0^'GQ"^$M]\'OA_>?#
M3XL>)_$/C7XD^![GPY83>'/&GB_Q7K$'B'Q%XFU_39(F@OM=U77K6UUJYU-U
M%X-4MK:_BECNH(I4]QHH^MXKVLZWUK$^VJ585ZE;ZQ6]K4K4Y^TIUIU/:^TG
M5IU&ZE.K*<JD)MSA.,FY-_4L%[*GA_J>$]A2HU,/2H?5L/[&EAZU/V56A3I>
MQ]G"C5I6I5:,*<:52FE3G3G!**X+QY\+OAY\4/A_K/PJ^(OA#1/&OPY\1:7;
MZ)K_ (-\1VBZIH.M:1:RVTT.FZK971D2_L_,M+=I8+DRQW C"7 E1G5H_B!\
M*/AK\5?"<7@3XC^!_#7C+P=;ZGX<UJU\.:]I5M>Z59ZOX/U:QU[PKJEE:N@2
MRO\ P]K.F:?J6CW=KY,]A=6D$ML\905Z#141KUX<G)6K0]G4E6I\E6I'V=:2
M4958<LX\E648J,JD.6<HI1<W%)%SP]"I[3GH49^UI1H5>>E3G[2C%N4:-3FA
M+GI1E*4HTY\U.,I-J";;?"_$/X9?#[XLZ#;>%_B7X.T#QQX=L_$/AKQ9:Z-X
MDT^'4]/M_$O@[6K+Q'X6UN*WG5D34=!U[3K'5M,N0/,M;ZUAGC(9 :[JBBH<
MYN$:;G-P@YRA!RDX0E4Y7-P@VXQ<W"'.XQ3GRQYG+EC;10@IRJ*$%4FH1G-1
MBISC3YO9QG-)2DH<\^12DU#FERJ/,[_-/QT_8W_97_:;U?0=?_:"^ ?PQ^+^
MM>%M-N]'\.ZIX[\,6.O7NC:7?727MY8:?<72,]O:W-W&EQ-$A"O*BN1D5Z9\
M)/@Y\+/@+X%TOX9?!GP%X9^&GP_T6?4;G2?"'A#3(-(T+3[C5[^?4]3FM;"W
M"Q127VH75Q>7+*,R3S22-RQKTJBMYXW&5,/3P<\7BIX2E)2I86>)KSPU.2YF
MI4\/*M*A"2<YM.%*+3G/7WI<W-# 8&GBJF.IX+!T\;6BX5<9#"X:&+JP?(G"
MIBHT(XBI%JG!.,Z\XODA=>['E^6-;_8>_8]\2_&:V_:'U_\ 9H^"VL?&VUU"
MUUB+XEZA\/\ P]=>*&UNP55L-?N+V6R9;SQ#8!(OL.OW<4^L6306[6U[$UO
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-10 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208163166112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Oruka
Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000907654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-22873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">36-3855489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">855 Oak Grove Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Menlo Park<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">606-7910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ORKA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,440,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208263282384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorTable', window );"><strong>Auditor [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Opinion on the Financial Statements</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have audited the accompanying
consolidated balance sheets of Oruka Therapeutics, Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2024
and February 6, 2024, and the related consolidated statements of operations and comprehensive loss, of convertible preferred stock and
stockholders&#8217; equity and of cash flows for the period from February&#160;6,&#160;2024 (inception) to December&#160;31,&#160;2024, including
the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial
statements present fairly, in all material respects, the financial position of the Company as of December&#160;31,&#160;2024 and February
6, 2024, and the results of its operations and its cash flows for the period from February&#160;6,&#160;2024 (inception) to December&#160;31,&#160;2024
in conformity with accounting principles generally accepted in the United States of America.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208163903952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 61,575<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">314,073<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SubscriptionReceivables', window );">Subscription receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,221<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">376,869<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, long-term</a></td>
<td class="nump">18,069<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">162<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">876<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">43<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">396,019<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable</a></td>
<td class="nump">3,462<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">3,346<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">213<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">13,043<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, non-current</a></td>
<td class="nump">755<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">13,798<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 and $0.001 par value as of December 31, 2024 and February 6, 2024, respectively; 545,000,000 and 65,000,000 shares authorized, 37,440,510 and 3,197,975 shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively</a></td>
<td class="nump">37<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">463,018<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(41)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(83,724)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">382,221<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders&#8217; equity</a></td>
<td class="nump">396,019<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Related party accounts payable and other current liabilities</a></td>
<td class="nump">6,022<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non-Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockAmountMember', window );">Series B Non-Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series B non-voting convertible preferred stock, $0.001 par value; 251,504 and no shares authorized as of December 31, 2024 and February 6, 2024, respectively; 137,138 and no shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively</a></td>
<td class="nump">$ 2,931<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_SubscriptionReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivable from investors who have been allocated common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_SubscriptionReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208162076416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">545,000,000<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">37,440,510<span></span>
</td>
<td class="nump">3,197,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">37,440,510<span></span>
</td>
<td class="nump">3,197,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non-Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockAmountMember', window );">Series B Non-Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Non-voting convertible preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Non-voting convertible preferred stock, shares authorized</a></td>
<td class="nump">251,504<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Non-voting convertible preferred stock, shares issued</a></td>
<td class="nump">137,138<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Non-voting convertible preferred stock, shares outstanding</a></td>
<td class="nump">137,138<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208166145072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Operations and Comprehensive Loss<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">11 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 75,060<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">13,063<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">88,123<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(88,123)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">5,863<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(1,468)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income, net</a></td>
<td class="nump">4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">4,399<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(83,724)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(41)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (83,765)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to stockholders, basic (in Dollars per share) | $ / shares</a></td>
<td class="num">$ (3.87)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to stockholders, diluted (in Dollars per share) | $ / shares</a></td>
<td class="num">$ (3.87)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable to stockholders, basic (in Shares) | shares</a></td>
<td class="nump">16,789,362<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share attributable to stockholders, diluted (in Shares) | shares</a></td>
<td class="nump">16,789,362<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockholdersMember', window );">Series A Non-Voting Convertible Preferred Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to stockholders, basic (in Dollars per share) | $ / shares</a></td>
<td class="num">$ (3,873.25)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to stockholders, diluted (in Dollars per share) | $ / shares</a></td>
<td class="num">$ (3,873.25)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable to stockholders, basic (in Shares) | shares</a></td>
<td class="nump">495<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share attributable to stockholders, diluted (in Shares) | shares</a></td>
<td class="nump">495<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockholdersMember', window );">Series B Non-Voting Convertible Preferred Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to stockholders, basic (in Dollars per share) | $ / shares</a></td>
<td class="num">$ (322.81)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to stockholders, diluted (in Dollars per share) | $ / shares</a></td>
<td class="num">$ (322.81)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable to stockholders, basic (in Shares) | shares</a></td>
<td class="nump">51,946<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share attributable to stockholders, diluted (in Shares) | shares</a></td>
<td class="nump">51,946<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">Includes related party amount of $42,640 for the period from February 6, 2024 (inception) to December 31, 2024</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">Includes related party amount of $1,364 for the period from February 6, 2024 (inception) to December 31, 2024</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">Includes related party amount of $1,468 for the period from February 6, 2024 (inception) to December 31, 2024</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208163290000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Operations and Comprehensive Loss (Parentheticals)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Related party amount</a></td>
<td class="nump">$ 42,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Related party amount</a></td>
<td class="nump">1,364<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Related party amount</a></td>
<td class="nump">$ 1,468<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208161539504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Convertible Preferred Stock and Stockholders&#8217; Equity - 11 months ended Dec. 31, 2024 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series A</div>
</th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series A Non-Voting</div>
</th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series B Non-Voting</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Series A</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Feb. 05, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in Shares) at Feb. 05, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,197,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,207,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A convertible preferred stock, net of issuance costs of $69</a></td>
<td class="nump">$ 2,931<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A convertible preferred stock, net of issuance costs of $69 (in Shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse capitalization</a></td>
<td class="num">$ (2,931)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,931<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">2,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse capitalization (in Shares)</a></td>
<td class="num">(20,000,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">137,138<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">26,445<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">26,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,722,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos', window );">Issuance of common stock and pre-funded warrants in the Pre-Closing Financing</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">248,437<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">248,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost', window );">Issuance of common stock and pre-funded warrants in the Pre-Closing Financing (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">20,061,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs of Pre-Closing Financing and reverse recapitalization</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(20,504)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(20,504)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe', window );">Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,999<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger', window );">Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,208,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr', window );">Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 56,097<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">144,433<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">144,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant', window );">Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,439<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IssuanceCostOfPIPEFinancing', window );">Issuance costs of PIPE Financing</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (3,263)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,592)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(8,592)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock', window );">Conversion of Series A non-voting convertible preferred stock to common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (52,834)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">52,832<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">52,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares', window );">Conversion of Series A non-voting convertible preferred stock to common stock (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,439)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Reclassification of the Paruka warrant from liability to equity</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,357<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">10,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,562<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">4,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(65,037)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(83,724)<span></span>
</td>
<td colspan="2" class="num">$ (1,918)<span></span>
</td>
<td class="num">(83,724)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,931<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 463,018<span></span>
</td>
<td class="num">$ (41)<span></span>
</td>
<td class="num">$ (83,724)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 382,221<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in Shares) at Dec. 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">137,138<span></span>
</td>
<td class="nump">37,440,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">The weighted-average number of shares of as-converted Company Series A Preferred Stock used in the loss allocation was 495,191 for the period from February 6, 2024 (inception) to December 31, 2024.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IssuanceCostOfPIPEFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance cost of PIPE financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IssuanceCostOfPIPEFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and pre-funded warrants in the preclosing financing, net of offering costs of $[x] million.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and pre-funded warrants in the preclosing financing, net of offering costs of $[x] million.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the Private Placement, net of offering costs of $[x] million.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the Private Placement, net of offering costs of $[x] million.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the Reverse Merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the Reverse Merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of conversion of non-voting convertible preferred stock to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares conversion of non-voting convertible preferred stock to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares classified as temporary equity issued conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock classified as temporary equity conversion of convertible securities during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208161568512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Convertible Preferred Stock and Stockholders&#8217; Equity (Parentheticals)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts', window );">Issuance of Series A Convertible Preferred Stock, Net of Issuance Costs</a></td>
<td class="nump">$ 69<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Series A convertible preferred stock, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208162336944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Cash Flows<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (83,724)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">14,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net accretion of premiums and discounts on marketable securities</a></td>
<td class="num">(2,245)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash interest expense</a></td>
<td class="nump">1,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,128)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">3,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">3,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Related party accounts payable and other current liabilities</a></td>
<td class="nump">6,022<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(57,837)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(329,938)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(330,127)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid</a></td>
<td class="nump">2,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes payable to related party, net of issuance costs paid</a></td>
<td class="nump">24,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Proceeds from the Pre-Closing Financing, net</a></td>
<td class="nump">227,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from the PIPE Financing, net</a></td>
<td class="nump">188,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_CashAcquiredInConnectionWithTheReverseRecapitalization', window );">Cash acquired in connection with the reverse recapitalization</a></td>
<td class="nump">4,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">449,539<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">61,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at beginning of period</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">61,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of non-cash operating and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liability arising from obtaining operating right-of-use asset</a></td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1', window );">Assets acquired in connection with the reverse capitalization</a></td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1', window );">Other liabilities assumed in connection with the reverse recapitalization</a></td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock', window );">Non-cash accrued interest on convertible note converted to common stock</a></td>
<td class="nump">1,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock', window );">Non-cash exchange of Pre-Merger Oruka Series A preferred stock for Series B convertible preferred stock</a></td>
<td class="nump">2,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Series A non-voting convertible preferred stock to common stock</a></td>
<td class="nump">52,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity', window );">Reclassification of the Paruka warrant from liability to equity</a></td>
<td class="nump">$ 10,357<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_CashAcquiredInConnectionWithTheReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of cash acquired in connection with the reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_CashAcquiredInConnectionWithTheReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of non-cash accrued interest on convertible note converted to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the Non-cash exchange of Pre-Merger Oruka Series A preferred stock for Series B convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of reclassification of the paruka warrant from liability to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, classified as other, acquired in a noncash or part noncash acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities, classified as other, assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208263435392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of the Business and Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of the Business and Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>1.
Nature of the Business and Basis of Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Background
and Basis of Presentation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Oruka
Therapeutics, Inc., together with its subsidiaries (collectively, the &#8220;Company&#8221;), formerly known as ARCA biopharma, Inc.
(&#8220;ARCA&#8221;), is a clinical-stage biotechnology company that is the result of the reverse recapitalization discussed below. Prior
to the reverse recapitalization, the private company Oruka Therapeutics, Inc. (&#8220;Pre-Merger Oruka&#8221;) was established and incorporated
under the laws of the state of Delaware on February&#160;6, 2024 (referred to in the Notes as the inception of the Company). The Company
is headquartered in Menlo Park, California. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis
(&#8220;PsO&#8221;) and other inflammatory and immunology (&#8220;I&amp;I&#8221;) indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
accompanying consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiaries. Intercompany
balances and transactions have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared
in conformity with United States (&#8220;U.S.&#8221;) generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in
these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;)
and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Reverse
Recapitalization and Pre-Closing&#160;Financing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">On
August 29, 2024 (the &#8220;Merger Closing&#8221;), the Company completed the acquisition (the &#8220;Merger&#8221;) of Pre-Merger Oruka
pursuant to an Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024 (the &#8220;Merger Agreement&#8221;). Following
the transactions contemplated by the Merger Agreement, Pre-Merger Oruka merged with and into Atlas Merger Sub Corp., a wholly owned subsidiary
of ARCA and following that, Pre-Merger Oruka then merged with and into Atlas Merger Sub II, LLC (&#8220;Second Merger Sub&#8221;), with
Second Merger Sub being the surviving entity. Second Merger Sub changed its corporate name to &#8220;Oruka Therapeutics Operating Company,
LLC.&#8221; On August 29, 2024, the Company changed its name from &#8220;ARCA biopharma, Inc.&#8221; to &#8220;Oruka Therapeutics, Inc.&#8221;
and its Nasdaq ticker symbol from &#8220;ABIO&#8221; to &#8220;ORKA&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Following
consummation of the Merger, the Company effected a 1-for-12 reverse stock split (the &#8220;Reverse Stock Split&#8221;) of the common
stock, par value $0.001 per share, of the Company (&#8220;Company Common Stock&#8221;), which became effective on September 3, 2024.
The Company Common Stock commenced trading on a post-Reverse Stock Split, post-Merger basis at the opening of trading on September 3,
2024. The Company is led by the Pre-Merger Oruka management team and remains focused on developing biologics to optimize the treatment
of inflammatory skin diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Immediately
prior to the execution and delivery of the Merger Agreement on April 3, 2024, certain new and existing investors of Pre-Merger Oruka
entered into a subscription agreement with Pre-Merger Oruka (the &#8220;Subscription Agreement&#8221;), pursuant to which, and on the
terms and subject to the conditions of which, immediately prior to the Closing, those investors purchased shares of common stock of Pre-Merger
Oruka (&#8220;Pre-Merger Oruka Common Stock&#8221;) and Pre-Merger Oruka pre-funded warrants for gross proceeds of approximately $275.0
million (which includes $25.0 million of proceeds previously received from the issuance of the Convertible Note (as defined in Note 7)
and accrued interest on such note which converted to shares of Pre-Merger Oruka Common Stock) (the &#8220;Pre-Closing Financing&#8221;).
The Company incurred transaction costs of $20.5 million which was recorded as a reduction to additional paid-in capital in the consolidated
financial statements. At the Merger Closing, the shares of Pre-Merger Oruka Common Stock and Pre-Merger Oruka pre-funded warrants issued
pursuant to the Subscription Agreement were converted into shares of Company Common Stock and pre-funded warrants of Company Common Stock
in accordance with the Exchange Ratio (defined below).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
accordance with an Exchange Ratio determined by terms of the Merger Agreement and upon the effective time of the First Merger (the &#8220;First
Effective Time&#8221;), (i) each then-issued and outstanding share of Pre-Merger Oruka Common Stock including outstanding and unvested
Pre-Merger Oruka restricted stock and shares of Pre-Merger Oruka Common Stock issued in connection with the Subscription Agreement, were
converted into the right to receive a number of shares of Company Common Stock, equal to the Exchange Ratio of 6.8569 shares of Company
Common Stock, which were subject to the same vesting provisions as those immediately prior to the Merger, (ii) each share of Pre-Merger
Oruka Series A convertible preferred stock, par value $0.0001 (&#8220;Pre-Merger Oruka Series A Preferred Stock&#8221;), outstanding
immediately prior to the First Effective Time was converted into the right to receive a number of shares of ARCA Series B non-voting
convertible preferred stock, par value $0.001 per share (&#8220;Company Series B Preferred Stock&#8221;), which are convertible into
shares of Company Common Stock, at a conversion ratio of approximately 83:3332:1 (iii) each outstanding option to purchase Pre-Merger
Oruka Common Stock was converted into an option to purchase shares of Company Common Stock, (iv) each outstanding warrant to purchase
shares of Pre-Merger Oruka Common Stock was converted into a warrant to purchase shares of Company Common Stock, and (v) each share of
Company Common Stock issued and outstanding at the First Effective Time remain issued and outstanding in accordance with its terms and
such shares. Subsequent to the close of the merger, the common stock shares were then subject to the reverse stock split of 1-for-12
effected on September 3, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
part of the Pre-Closing Financing and the Merger Closing, investors in the Pre-Closing Financing received 22,784,139 shares of Company
Common Stock in exchange for 39,873,706 shares of Pre-Merger Oruka Common Stock (which includes the issuance of 2,722,207 shares of Company
Common Stock in exchange for 4,764,032 shares of Pre-Merger Oruka Common Stock on the conversion of Convertible Note along with the accrued
interest through the conversion date) and 5,522,207 Company pre-funded warrants in exchange for 9,664,208 Pre-Merger pre-funded warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Pre-Merger Oruka
was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the fact that, immediately
following the Merger: (i) Pre-Merger Oruka stockholders own a substantial majority of the voting rights in the combined company; (ii)
Pre-Merger Oruka&#8217;s largest stockholders retain the largest interest in the combined company; (iii) Pre-Merger Oruka designated
a majority of the initial members of the board of directors of the combined company; and (iv) Pre-Merger Oruka&#8217;s executive management
team became the management team of the combined company. Accordingly, for accounting purposes: (i) the Merger was treated as the equivalent
of Pre-Merger Oruka issuing stock to acquire the net assets of ARCA, and (ii) the reported historical operating results of the combined
company prior to the Merger are those of Pre-Merger Oruka. Additional information regarding the Merger is included in Note 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">On
September 3, 2024, the Company effected the Reverse Stock Split, a 1-for-12 reverse stock split of Company Common Stock. The par value
per share and the number of authorized shares were not adjusted as a result of the Reverse Stock Split. The shares of Company Common
Stock underlying outstanding stock options, common stock warrants and other equity instruments were proportionately reduced and the respective
exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.
All references to common stock, options to purchase common stock, outstanding common stock warrants, common stock share data, per share
data, and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect
of the Reverse Stock Split for all periods presented, unless otherwise specifically indicated or the context otherwise requires.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>PIPE
Financing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">On
September 11, 2024, the Company entered into a Securities Purchase Agreement for a private placement (the &#8220;PIPE Financing&#8221;)
with certain institutional and accredited investors. The closing of the PIPE Financing occurred on September 13, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;Pursuant
to the Securities Purchase Agreement, the investors purchased an aggregate of 5,600,000 shares of Company Common Stock at a purchase
price of $23.00 per share, an aggregate of 2,439 shares of the Company&#8217;s Series A non-voting convertible preferred stock, par value
$0.001 per share (&#8220;Company Series A Preferred Stock&#8221;), at a purchase price of $23,000.00 per share (each Company Series A
Preferred Stock is convertible into 1,000 shares of Company Common Stock), and pre-funded warrants to purchase an aggregate of 680,000
shares of Company Common Stock at a purchase price of $22.999 per pre-funded warrant, for aggregate net proceeds of approximately $188.7
million (net of issuance costs of $11.9 million).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Liquidity
and Going Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Since
its inception, the Company has devoted substantially all of its resources to advancing the development of its portfolio of programs,
organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations.
Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and
regulatory approvals to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever,
the Company expects to finance its operating activities through a combination of equity offerings and debt financings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative
cash flows from operations since inception. For the period from February 6, 2024 (inception) to December 31, 2024, the Company has incurred
a net loss of $83.7 million and used net cash of $57.8 million for its operating activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2024, the Company had cash, cash equivalents, and marketable securities of $393.7 million. The Company&#8217;s management
expects that the existing cash, cash equivalents, and marketable securities will be sufficient to fund the Company&#8217;s operating
plans for at least twelve months from the date these consolidated financial statements were issued. The Company expects that its research
and development and general and administrative costs will continue to increase significantly, including in connection with conducting
future pre-clinical activities and clinical trials and manufacturing for its existing product candidates and any future product candidates
to support commercialization and providing general and administrative support for its operations, including the costs associated with
operating as a public company. The Company&#8217;s ability to access capital when needed is not assured and, if capital is not available
to the Company when, and in the amounts needed, the Company may be required to significantly curtail, delay, or discontinue one or more
of its research or development programs or the commercialization of any product candidate, or be unable to expand its operations or otherwise
capitalize on the Company&#8217;s business opportunities, as desired, which could materially harm the Company&#8217;s business, financial
condition and results of operations.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208160104880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>2.
Summary of Significant Accounting Policies </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Use
of Estimates</i></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
preparation of the Company&#8217;s consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates,
assumptions, and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at
the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant
estimates and assumptions reflected within these consolidated financial statements include but are not limited to research and development
expenses and related prepaid or accrued costs and the valuation of stock-based compensation awards and related expenses. The Company
bases its estimates on known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances.
On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results
could differ materially from those estimates or assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Concentrations
of Credit Risk and Other Risks and Uncertainties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Financial
instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities.
The Company&#8217;s investment policy limits investments to high credit quality securities issued by the U.S. government, U.S. government-sponsored
agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company&#8217;s
cash, cash equivalents and marketable securities are held by financial institutions that management believes are of high credit quality.
The financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits.
Accounts at the Company&#8217;s U.S. banking institution are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;)
up to $250,000 per depositor. As of December 31, 2024, the balance at the Company&#8217;s U.S. banking institution exceeded the FDIC
limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its accounts are monitored by management
to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash
equivalents, and bond issuers.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company is dependent on third-party organizations to research, develop, manufacture, and process its product candidates for its development
programs, including its two most advanced programs, ORKA-001 and ORKA-002. The Company expects to continue to be dependent on a small
number of manufacturers to supply it with its requirements for all products. The Company&#8217;s research and development programs could
be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company&#8217;s
research and development activities are performed under its agreements with Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) (see Note&#160;12).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Cash
and Cash Equivalents</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to
be cash equivalents. The cash equivalents were comprised of investments in money market funds, U. S. treasury securities, U.S. government
agency securities, and debt securities and are stated at fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Marketable
Securities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company invests in marketable securities, primarily securities issued by the U.S. government and its agencies, commercial paper and corporate
debt securities. The Company&#8217;s marketable securities are classified as available-for-sale and reported at fair value, with unrealized
gains and losses included as a component of accumulated other comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">For
available-for-sale debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more
likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria
regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value and recognized
in other income (expense) in the results of operations. For available-for-sale debt securities that do not meet the aforementioned criteria,
the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment,
management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating
agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit
loss exists, an allowance is recorded for the difference between the present value of cash flows expected to be collected and the amortized
cost basis of the security. Impairment losses attributable to credit loss factors are charged against the allowance when management believes
an available-for-sale security is uncollectible or when either of the criteria regarding intent or requirement to sell is met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Any
unrealized losses from declines in fair value below the amortized cost basis as a result of non-credit loss factors are recognized as
a component of accumulated other comprehensive loss, net of unrealized gains. Realized gains and losses and declines in fair value, if
any, on available-for-sale securities are included in other income, net, in the results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Marketable
securities with stated maturities of greater than three months from the date of purchase but less than one year from the consolidated
balance sheet date are classified as current, while marketable securities with maturities in one year or beyond one year from the consolidated
balance sheet date are classified as long-term. The cost of securities sold is determined using the specific-identification method. Interest
earned and adjustments for the amortization of premiums and discounts on investments are included in interest income on the consolidated
statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Debt
Issuance Costs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Debt
issuance costs incurred in connection with the Convertible Note (see Note&#160;7) are recorded as a reduction of the carrying value of
the notes payable liability on the Company&#8217;s balance sheet and are amortized to interest expense over the term of the loan using
the effective interest method. At the effective time of the Merger the Converted Note was converted to common stock and is no longer
on the balance sheet as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Subscription
Receivable&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable
is paid prior to the date the financial statement is available to be issued.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Fair
Value Measurements&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Certain
assets and liabilities are carried at fair value under U.S.&#160;GAAP.&#160;Fair value is defined as the exchange price that would be
received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize
the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are
to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered
observable and the last is considered unobservable:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"></td><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
                                            1&#160;&#8212;&#160;Quoted prices in active markets that are identical assets or liabilities.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"></td><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level&#160;2&#160;&#8212;&#160;Observable
                                            inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar
                                            assets or liabilities, quoted prices in markets that are not active for identical or similar
                                            assets or liabilities, or other inputs that are observable or can be corroborated by observable
                                            market data.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"></td><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level&#160;3&#160;&#8212;&#160;Unobservable
                                            inputs that are supported by little or no market activity that are significant to determining
                                            the fair value of the assets or liabilities, including pricing models, discounted cash flow
                                            methodologies, and similar techniques.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy
described above (see Note 4). The carrying values of the Company&#8217;s prepaid expenses and other current assets, accounts payable
and accrued expenses and other current liabilities approximate their fair values due to their relatively short maturity period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Property
and Equipment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Property
and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over
the estimated useful life of each asset as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Estimated<br/>
    Useful Life</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Furniture and fixtures</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3-5 years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computer and office equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">3-5 years</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Classification
of Convertible Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Prior
to the reverse recapitalization, the Company had classified its Pre-Merger Oruka Series A Preferred Stock outside of stockholders&#8217;
equity on the Company&#8217;s consolidated balance sheet because the holders of such stock have certain liquidation rights in the event
of a deemed liquidation event that, in certain situations, is not solely within the control of the Company and would require the redemption
of the then-outstanding convertible preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Upon
the closing of the Merger, the Company converted its Pre-Merger Oruka Series A Preferred Stock to Company Series B Preferred Stock and
has classified the Company Series B Preferred Stock within stockholders&#8217; equity on its consolidated balance sheet because the Company
Series B Preferred Stock is not redeemable or puttable to the Company by the holder under any circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
connection with the PIPE Financing (see Note 1) the Company issued Company Series A Preferred Stock, and has classified the Company Series
A Preferred Stock outside of stockholders&#8217; equity on the Company&#8217;s consolidated balance sheet because the holders of such
stock have certain rights (see Note 8) that, in certain situations, is not solely within the control of the Company and would require
the redemption of the then-outstanding convertible preferred stock. In November 2024, the Company Series A Preferred Stock shares were
converted to common stock, and as of December 31, 2024, there were no shares of Company Series A Preferred Stock outstanding.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Note&#160;Payable
to Related Party</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company accounted for the Convertible Note (as defined in Note 7) at amortized cost. The Company considered if optional conversion features
are required to be bifurcated and separately accounted for as a derivative. Costs related to the issuance of the Convertible Note were
recorded as a debt discount, amortized over the term of the Convertible Note (see&#160;Note&#160;7) and were accounted for as interest
expense in other income (expenses) within the consolidated statement of operations and comprehensive loss using the effective interest
method. At the effective time of the Merger, shares of Pre-Merger Oruka Common Stock issued pursuant to the conversion of the Convertible
Note (including accrued interest) automatically converted into shares of Company Common Stock (see Note 1).</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Research
and Development Contract Costs Accruals</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component
of the Company&#8217;s research and development expenses, with a substantial portion of the Company&#8217;s ongoing research and development
activities conducted by third-party service providers, including contract research organizations (&#8220;CROs&#8221;) and contract manufacturing
organizations (&#8220;CMOs&#8221;), and the Company&#8217;s related-party Paragon (see Note&#160;12).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company accrues for expenses resulting from obligations under its two antibody discovery and option agreements (the &#8220;Option Agreements&#8221;)
(see Note 12), by and among Paragon, Paruka Holding LLC (&#8220;Paruka&#8221;), an entity formed by Paragon as a vehicle to hold equity
in the Company, and the Company as well as agreements with CROs, CMOs, and other outside service providers for which payment flows do
not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services
received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These
estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with
internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant
judgments and estimates in determining the accrual balance in each reporting period. If advance payments are made to Paragon, a CRO,
CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services
are performed. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the
Company&#8217;s results of operations. As of December 31, 2024, the Company has not experienced any material deviations between accrued
and actual research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Leases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">At
the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies
a lease as either an operating or finance lease and recognizes a right-of-use (&#8220;ROU&#8221;) asset and a current and non-current
lease liability, as applicable, in the balance sheet if the lease has a term greater than one year. Lease terms may include options to
extend or terminate the lease when it is reasonably certain that the Company will exercise its option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">At
the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future
minimum lease payments over the expected remaining lease term. The Company determines the present value of lease payments using the implicit
rate, if it is readily determinable, or the risk-free discount rate for a period comparable with that of the lease term. For operating
leases, lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, lease expense
includes amortization expense of the ROU asset recognized on a straight-line basis over the lease term and interest expense recognized
on the finance lease liability. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments,
incentives received or initial direct costs. As of December 31, 2024, the Company has one operating lease and no finance leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for lease and non-lease components related to operating leases as a single lease component. The Company has elected
that costs associated with leases having an initial term of 12 months or less are recognized in the consolidated statement of operations
and comprehensive loss on a straight-line basis over the lease term and are not recorded on its consolidated balance sheets. Variable
lease expense is recognized as incurred and consists primarily of real estate taxes, utilities, and other office space related expenses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Segment
Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company operates as a
single reportable and operating segment. Its Chief Executive Officer, serving as the Chief Operating Decision Maker (&#8220;CODM&#8221;),
oversees operations on an aggregated basis to allocate resources effectively. In assessing the Company&#8217;s financial performance,
the CODM regularly reviews total operating expenses and consolidated net loss.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Research
and Development Costs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Research
and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock-based compensation,
employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities, as well as allocated
human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Nonrefundable
advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid
expenses on the accompanying consolidated balance sheet. The prepaid amounts are expensed as the related goods are delivered or the services
are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable advance
payments represent a one-time cost for obtaining goods or services, with anticipated benefits to be utilized within a year of period
end, the payment is expensed immediately.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>General
and Administrative Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">General
and administrative expenses consist primarily of salaries and bonuses, stock-based compensation, employee benefits, finance and administration
costs, patent and intellectual property costs, professional fees, as well as allocated human resource costs, information technology costs,
and facility-related costs, including rent, maintenance, utilities and depreciation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Commitments
and Contingencies</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities.
The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the
loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the
balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but
not probable; however, it discloses the range of reasonably possible losses. As of December 31, 2024, no liabilities were recorded for
loss contingencies (see Note&#160;13).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock-Based
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company estimates the fair value of its stock awards using the Black-Scholes option pricing model, which uses as inputs the fair value
of the Company&#8217;s common stock, and certain management estimates, including the expected stock price volatility, the expected term
of the award, the risk-free interest rate, and expected dividends. Expected volatility is calculated based on reported volatility data
for a representative group of publicly traded companies for which historical information is available. The Company selects companies
with comparable characteristics with historical share price information that approximates the expected term of the equity-based awards.
The Company computes the historical volatility data using the daily closing prices for the selected companies&#8217; shares during the
equivalent period that approximates the calculated expected term of the stock options. The Company will continue to apply this method
until a sufficient amount of historical information regarding the volatility of its stock price becomes available. The risk-free interest
rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. For employee
and non-employee awards (except the Paruka warrant) the Company uses the simplified method, under which the expected term is presumed
to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to lack of historical
exercise data. For the Paruka warrant, the contractual term is used for the expected term. The expected dividend yield is assumed to
be zero as the Company has no current plans to pay any dividends on common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company measures restricted common stock awards (&#8220;RSAs&#8221;) using the difference, if any, between the purchase price per share
of the award and the fair value of the Company&#8217;s common stock at the date of grant.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company grants stock options, restricted stock awards, and warrants that are subject to service or performance-based vesting conditions.
Compensation expense for awards to employees and directors with service-based vesting conditions is recognized using the straight-line
method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards
to non-employees with service-based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for
the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each
reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation
expense until it is probable that the performance-based vesting condition will be achieved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company has issued stock options, warrants, and RSAs with service-based and performance-based vesting conditions.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company recognizes the compensation expense for the option to purchase common stock under the Employee Stock Purchase Plan (&#8220;ESPP&#8221;),
based on the fair value of the common stock estimated using the closing price of the Company&#8217;s common stock as reported on the
date of offering, less the purchase discount percentage provided for in the plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company classifies stock-based compensation expense in its consolidated statement of operations and comprehensive loss in the same manner
in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified,
as applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Comprehensive
Loss</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Comprehensive
loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and events other than those
with stockholders. The Company&#8217;s unrealized gains and losses on marketable securities represent the only component of other comprehensive
loss that are excluded from the reported net loss and that are presented in the consolidated statement of comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Net
Loss per Share Attributable to Stockholders</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Basic
and diluted net loss attributable to stockholders per share is presented in conformity with the two-class method required for participating
securities (Pre-Merger Oruka Series A Preferred Stock). Basic earnings per share is computed by dividing net income available to each
class of shares by the weighted-average number of shares of common stock and participating securities outstanding during the period.
Pre-funded warrants were included as the exercise price is negligible and these warrants are fully vested and exercisable. Company Series
A Preferred Stock and Company Series B Preferred Stock share the same characteristics as Common Stock and have no substantive preference
attributed to them and, accordingly, have been considered as classes of Common Stock in the computation of net loss per share regardless
of their legal form.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Net
loss is allocated to common stock based on its proportional ownership on an as-converted basis. Net loss is not allocated to participating
securities as they do not have an obligation to fund losses. The weighted-average number of shares outstanding of common stock reflects
changes in ownership over the periods presented. See Note 8 &#8212; Convertible Preferred Stock and Stockholders&#8217; Equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Diluted
net loss per share is computed by dividing the net loss attributable to stockholders adjusted for income (expenses), net of tax, related
to any diluted securities, by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for
the period. For purposes of this calculation, stock options to purchase common stock, employee warrants to purchase common stock, and
unvested RSAs are considered potential dilutive common shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company generated a net loss for the periods presented. Accordingly, basic and diluted net loss per share is the same because the inclusion
of the potentially dilutive securities would be anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Other
income, net</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Other
income, net, consists of interest earned on the Company&#8217;s cash, cash equivalents, and marketable securities; interest expense on
the convertible note from a related party and foreign currency transactions gains and losses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Income
Taxes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#8217;s tax
returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis
of assets and liabilities using enacted tax rates in effect for the&#160;years in which the differences are expected to reverse. Changes
in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred
tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence,
that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established
through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable
profits expected and considering prudent and feasible tax planning strategies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to
determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will
be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained,
the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount
of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement.
The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered
appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or penalties related to
uncertain tax positions as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Recently
Adopted Accounting Pronouncements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
November&#160;2023, the FASB issued ASU 2023-07, Segment Reporting (Topic&#160;280): Improvements to Reportable Segment Disclosures (&#8220;ASU&#160;2023-07&#8221;),
which enhances the segment disclosure requirements for public entities on an annual and interim basis. Under this standard, public entities
will be required to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure
of segment profit or loss. Additionally, current annual disclosures about a reportable segment&#8217;s profit or loss and assets will
be required on an interim basis. Entities will also be required to disclose information about the CODM&#8217;s title and position at
the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment of segment
performance and deciding how to allocate resources. Finally, ASU&#160;2023-07 requires all segment disclosures for public entities that
have only a single reportable segment. The amendments in ASU&#160;2023-07 are effective for fiscal&#160;years beginning after December&#160;15,
2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. Early adoption is permitted. The Company adopted
ASU 2023-07 in 2024 and additional required disclosures have been included in Note 10.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Recently
Issued Accounting Pronouncements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
December&#160;2023, the FASB issued ASU&#160;2023-09, Income Taxes (Topic&#160;740): Improvements to Income Tax Disclosures. This ASU
expands disclosures in an entity&#8217;s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S.&#160;and
foreign jurisdictions. This update is effective beginning with the Company&#8217;s 2025 fiscal year annual reporting period. The Company
is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
November 2024, the FASB issued ASU 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU requires more detailed disclosures, on an annual and interim
basis, about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense
captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and
interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. This ASU may be applied either prospectively
or retrospectively. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208267430048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Recapitalization and Pre-Closing Financing<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Reverse Recapitalization and Pre-Closing Financing [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Reverse Recapitalization and Pre-Closing Financing</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>3.
Reverse Recapitalization and Pre-Closing Financing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
described within the Reverse Recapitalization and Pre-Closing Financing section in Note 1, on August 29, 2024, the reverse recapitalization
between Pre-Merger Oruka and ARCA was consummated. The Merger was accounted for as a reverse recapitalization in accordance with U.S.
GAAP. At the effective time of the Merger, substantially all of the assets of ARCA consisted of cash and cash equivalents and other nominal
non-operating assets and liabilities. No goodwill or intangible assets were recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
part of the recapitalization, the Company acquired the assets and liabilities listed below (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">August
    29,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,940</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">114</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(54</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 6.85pt"><span style="font-family: Times New Roman, Times, Serif">Net
    assets acquired</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208160397216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>4.
Fair Value Measurements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following tables present the Company&#8217;s fair value hierarchy for financial assets measured as of December 31, 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    3</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Cash equivalents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Money market
    funds</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,350</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-157; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-158; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,350</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. treasury securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,660</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-159; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,660</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. government agency
    securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-160; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,988</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-161; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,988</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Commercial
    papers</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-162; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,177</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-163; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,177</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    cash equivalents</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,350</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,825</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-164; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">52,175</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable securities,
    current</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. treasury securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">190,792</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-165; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">190,792</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. government agency
    securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-166; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,966</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-167; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,966</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commercial papers</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-168; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">34,811</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-169; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">34,811</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Corporate
    debt securities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-170; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">75,504</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-171; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">75,504</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    marketable securities, current</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">314,073</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-172; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">314,073</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable securities,
    long-term</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. treasury securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,607</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-173; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,607</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">U.S.
    government agency securities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-174; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,462</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-175; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,462</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    marketable securities, long-term</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,069</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-176; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,069</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total cash equivalents
    and marketable securities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,350</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">377,967</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-177; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">384,317</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There were no transfers in
or out of Level&#160;3 during the period from February 6, 2024 (inception) to December 31, 2024.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208263362912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_CashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash equivalents and Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash Equivalents and marketable Securities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>5.
Cash equivalents and marketable Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Cash
equivalents and marketable securities, which are classified as available-for-sale, consisted of the following as of December 31, 2024
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Amortized
    Cost</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Gross
    Unrealized Gains</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Gross
    Unrealized Losses</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Fair
    Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Cash equivalents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Money market
    funds</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,350</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-178; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-179; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,350</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. treasury securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,656</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-180; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,660</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. government agency
    securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,988</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-181; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-182; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,988</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Commercial
    papers</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,180</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-183; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,177</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    cash equivalents</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">52,174</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">52,175</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable securities,
    current</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. treasury securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">190,748</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">55</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">190,792</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. government agency
    securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,967</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,966</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commercial papers</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">34,808</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-184; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">34,811</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Corporate
    debt securities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">75,537</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(40</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">75,504</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    marketable securities, current</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">314,060</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">66</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(53</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">314,073</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable securities,
    long-term</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. treasury securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,639</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-185; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(32</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,607</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">U.S.
    government agency securities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,485</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-186; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(23</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,462</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    marketable securities, long-term</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,124</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-187; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(55</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,069</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total cash equivalents
    and marketable securities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">384,358</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">70</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(111</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">384,317</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the available-for-sale securities in an unrealized loss position, aggregated by major security type and length
of time in a continuous unrealized loss position, for which an allowance for credit losses was not recorded as of December&#160;31, 2024,
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>Less
    than 12 months</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>12
    months or longer</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>Fair
    <br/>
    Value</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Unrealized<br/>
    Losses</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Fair
    <br/>
    Value</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Unrealized<br/>
    Losses</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>Fair<br/>
    Value</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Unrealized<br/>
    Losses</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Cash equivalents</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commercial
    papers</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,199</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-188; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-189; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,199</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable
    securities</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable
    securities, current</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S.
    treasury securities</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">49,904</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-190; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-191; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">49,904</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S.
    government agency securities</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,713</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-192; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-193; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,713</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Corporate
    debt securities</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,468</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(40</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-194; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-195; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,468</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(40</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable
    securities, long-term</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S.
    treasury securities</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,607</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(32</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-196; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-197; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,607</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(32</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">U.S.
    government agency securities</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,462</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(23</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-198; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-199; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,462</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(23</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.5in; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">130,353</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(111</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-200; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-201; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">130,353</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(111</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company evaluated its securities for credit losses and considered the decline in market value to be primarily attributable to current
economic and market conditions and not to a credit loss or other factors. Additionally, the Company does not intend to sell the securities
in an unrealized loss position and it is not more likely than not that the Company will be required to sell the securities before recovery
of the unamortized cost basis, which may be at maturity. There were no material realized gains or realized losses on marketable securities
for the period presented. Given the Company&#8217;s intent and ability to hold such securities until recovery, and the lack of significant
change in credit risk of these investments, the Company does not consider these marketable securities to be impaired as of December 31,
2024. As of December 31, 2024, the Company did not record an allowance for credit losses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the contractual maturities of the Company&#8217;s marketable securities at estimated fair value (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Due in one year or less</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">314,073</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Due in 1-2 years</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,069</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">332,142</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_CashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_CashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208277010160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>6.
Accrued Expenses and Other Current Liabilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Accrued
expenses and other current liabilities consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31, <br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued employee compensation and
    benefits</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,041</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued professional and consulting</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">221</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued research and
    development</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,084</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,346</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208266257424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note Payable with Related Party<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Note Payable with Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Note Payable with Related Party</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>7.
Note&#160;Payable with Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
March&#160;2024, Pre-Merger Oruka entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the &#8220;Purchase
Agreement&#8221;) with Fairmount Healthcare Fund&#160;II, L.P. (&#8220;Fairmount&#8221;), whereby Pre-Merger Oruka issued a convertible
note (the &#8220;Convertible Note&#8221;), with an initial principal amount of $25.0 million that, at the time of issuance, could be
converted into Pre-Merger Oruka Series&#160;A Preferred Stock (or a series&#160;of preferred shares that is identical in respect to the
shares of preferred shares issued in its next equity financing) or shares of Pre-Merger Oruka Common Stock in exchange for aggregate
proceeds of $25.0&#160;million. The Convertible Note accrued interest at a rate of 12.0% per annum. At issuance, the Convertible Note
required all unpaid interest and principal to mature on December&#160;31, 2025 (the &#8220;Maturity Date&#8221;) and prepayment was not
permitted without prior written consent of Fairmount.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company assessed all terms and features of the Convertible Note in order to identify any potential embedded features that would require
bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the embedded features. The Company
determined that the share settled redemption feature was clearly and closely related to the debt host and did not require separate accounting.
The Company determined that the conversion options of the Convertible Note were not clearly and closely associated with a debt host.
However, these features did not meet the definition of a derivative under ASC&#160;815, Derivatives and Hedging, and as a result, did
not require separate accounting as a derivative liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company paid debt issuance costs of less than $0.1&#160;million in relation to the Convertible Note. The debt issuance costs were reflected
as a reduction of the carrying value of Convertible Note on the consolidated balance sheet and were being amortized as interest expense
over the term of the Convertible Note using the effective interest method. For the period from February&#160;6, 2024 (inception) to December
31, 2024, the Company recognized interest expenses related to the Convertible Note of $1.5 million, which includes non-cash interest
expense related to the amortization of debt issuance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Immediately
prior to the completion of the Merger (see Note 1), the Convertible Note was converted into shares of Pre-Merger Oruka Common Stock based
on the aggregate principal amount of $25.0 million, plus unpaid accrued interest of $1.5 million divided by the conversion price which
was determined based upon the Company&#8217;s fully-diluted capitalization immediately prior to the Merger. At the effective time of
the Merger, the Pre-Merger Oruka Common Stock issued upon the conversion of the Convertible Note (including accrued interest) automatically
converted into 2,722,207 shares of Company Common Stock. As of December 31, 2024, the Convertible Note is not outstanding.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208263416576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Convertible Preferred Stock and Stockholders&#8217; Equity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>8.
Convertible Preferred Stock and Stockholders&#8217; Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Pre-Funded
Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
August 2024, pursuant to the Subscription Agreement and immediately prior to the Closing, certain new and current investors purchased
pre-funded&#160;warrants, which, at the effective time of the Merger, were exercisable for 5,522,207 shares of Company Common Stock at
a purchase price of approximately $9.70 per warrant. After the Merger, there are 5,522,207 pre-funded warrants outstanding and are exercisable
for 5,522,207 shares of the Company Common Stock at an exercise price of $0.01 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
September 2024, in connection with the PIPE Financing, the Company issued and sold 680,000 pre-funded warrants, at a purchase price of
$22.999 per warrant, exercisable for 680,000 shares of Company Common Stock at an exercise price of $0.001 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
pre-funded warrants were recorded as a component of stockholders&#8217; equity within additional paid-in-capital and have <span style="-sec-ix-hidden: hidden-fact-202">no</span> expiration
date. As of December 31, 2024, <span style="-sec-ix-hidden: hidden-fact-203">none</span> of the pre-funded warrants have been exercised and 6,202,207 pre-funded warrants remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Employee
Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
July 2024, Pre-Merger Oruka entered into a Subscription Agreement that provided for, among other things, the issuance of warrants to
certain of Pre-Merger Oruka&#8217;s employees and directors immediately prior to the closing of the Merger. During the period from February
6, 2024 (inception) to December 31, 2024, 3,054,358 employee warrants were issued at an exercise price of $7.80 per warrant. These warrants
vest over a period of four years. Per the terms of the Employee Warrant Agreement, the holders of the Company&#8217;s warrants shall
not have any of the rights or privileges of a stockholder of the Company in respect of any shares purchasable upon the exercise of the
warrant or any portion thereof unless and until a certificate or certificates representing such shares have been issued or a book entry
representing such shares has been made and such shares have been deposited with the appropriate registered book-entry custodian. The
Company recognizes compensation cost related to warrants on a straight-line basis over the requisite service period, which is the period
in which the related services are received. As of December 31, 2024, <span style="-sec-ix-hidden: hidden-fact-204">none</span> of the warrants have been exercised and 3,054,358 warrants
remain outstanding.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Convertible
Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
March&#160;2024, Pre-Merger Oruka issued and sold an aggregate of 20,000,000 shares of Pre-Merger Oruka Series&#160;A Preferred Stock
to Fairmount (see Note 15), at a purchase price of approximately $0.15 per share, for aggregate gross proceeds of $3.0&#160;million.
Pre-Merger Oruka incurred less than $0.1&#160;million of issuance costs in connection with this transaction. Upon the issuance of the
Pre-Merger Oruka Series&#160;A Preferred Stock, the Company assessed the embedded conversion and liquidation features of the securities
as described below and determined that such features did not require the Company to separately account for these features.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
August 2024, upon the closing of the Merger, the Company converted the Pre-Merger Oruka Series A Preferred Stock to 137,138 shares of
Company Series B Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
September 2024, in connection with the PIPE Financing, the Company issued and sold an aggregate of 2,439 shares of the Company Series
A Preferred Stock at a purchase price of $23,000.00 per share.&#160;In November 2024, the 2,439 shares of the Company Series A Preferred
Stock were converted to 2,439,000 shares of Company Common Stock. As of December 31, 2024, there are <span style="-sec-ix-hidden: hidden-fact-205">no</span> outstanding shares of Company
Series A Preferred Stock.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2024, convertible preferred stock consisted of the following (in thousands, except share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Preferred<br/>
                                            Stock<br/>
                                            Authorized</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Preferred<br/>
    Stock Issued <br/>
    and<br/>
    Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Carrying<br/>
    Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Common
    Stock<br/>
    Issuable<br/>
    Upon<br/>
    Conversion</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series B convertible preferred
    stock</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">251,504</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">137,138</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,931</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,428,149</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock (the
&#8220;Series A Certificate of Designation&#8221;) filed in connection with the PIPE Financing, holders of Company Series A Preferred
Stock were entitled to receive dividends on shares of Company Series A Preferred Stock equal to, on an as-if-converted-to-Company Common
Stock basis, and in the same form as, dividends actually paid on shares of Company Common Stock. Except as provided in the Series A Certificate
of Designation or as otherwise required by law, the Company Series A Preferred Stock did not have voting rights. The Company Series A
Preferred Stock shall rank on parity with the Company Common Stock and Company Series B Preferred Stock upon any liquidation, dissolution
or winding-up of the Company. Subject to the terms and limitations contained in the Series A Certificate of Designation, the Company
Series A Preferred Stock issued in the PIPE Financing will not become convertible until the Company&#8217;s stockholders approve the
conversion of the Company Series A Preferred Stock into shares of Company Common Stock in accordance with the listing rules of the Nasdaq
Stock Market (the &#8220;Stockholder Approval&#8221;), which, on issuance, resulted in the Company Series A Preferred Stock being classified
outside of stockholders&#8217; equity on the Company&#8217;s consolidated balance sheet. Following the Stockholder Approval in November
2024, each share of Company Series A Preferred Stock was automatically converted into 1,000 shares of Company Common Stock.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock (the
&#8220;Series B Certificate of Designation&#8221;) filed in connection with the Merger, holders of Company Series B Preferred Stock are
entitled to receive dividends on shares of Company Series B Preferred Stock equal to, on an as-if-converted-to-Company Common Stock basis,
and in the same form as, dividends actually paid on shares of Company Common Stock. Except as provided in the Series B Certificate of
Designation or as otherwise required by law, the Company Series B Preferred Stock does not have voting rights. The Company Series B Preferred
Stock shall rank on parity with the Company Common Stock as to the distribution of assets upon any liquidation, dissolution, or winding-up
of the Company. Each share of Company Series B Preferred Stock is convertible at the option of the holder, at any time, and without the
payment of additional consideration by the holder. As of December 31, 2024, each outstanding share of Company Series B Preferred Stock
was convertible into common stock at a ratio of approximately 83.3332:1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Paruka
Warrant</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">On
December 31, 2024, the Company settled its 2024 obligations under the Paruka Warrant Obligation (defined below) by issuing Paruka a warrant
to purchase 596,930 shares of Company Common Stock at an exercise price of $19.39 per share. The warrant has a term of 10 years, is fully
vested, and is exercisable in part or full at any time during the term of the warrant. As of December 31, 2024, the warrant issued under
the Paruka Warrant Obligation is outstanding and unexercised. See Note 9 for additional information on the Paruka Warrant Obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2024, the Certificate of Incorporation provides for 545,000,000 authorized shares of Company Common Stock. As of December
31, 2024, 37,440,510 shares of Company Common Stock were issued and outstanding, including 2,207,553 shares of RSAs issued and outstanding.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2024, the Company had common stock reserved for future issuance as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares issuable on conversion of
    Company Series B Preferred Stock</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,428,149</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Shares issuable upon exercise of pre-funded warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,202,207</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares issuable upon exercise of warrant under
    the Paruka Warrant Obligation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">596,930</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding and issued stock options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,567,760</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding and issued employee warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,054,358</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares available for grant under 2024 Stock
    Incentive Plan</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,246,324</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Shares available for
    grant under 2024 Employee Stock Purchase Plan</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">460,529</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 13.7pt"><span style="font-family: Times New Roman, Times, Serif">Total
    shares of common stock reserved</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,556,257</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FeaturesOfConvertiblePreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208263407184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>9.
Stock-Based Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>2024
Equity Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
2024 Equity Incentive Plan (&#8220;2024 Plan&#8221;) was adopted by the board of directors of Pre-Merger Oruka on February&#160;6, 2024.
The 2024 Plan provided for Pre-Merger Oruka to grant stock options, restricted stock awards, restricted stock units, and other stock-based
awards to employees, officers, directors, consultants, and advisors. Equity Incentive Stock options granted under the 2024 Plan generally
vest over four&#160;years, subject to the participant&#8217;s continued service, and expire after ten&#160;years, although two non-employee
stock options were &#160;granted with vesting terms less than four&#160;years. As of December 31, 2024, there are no shares of common
stock available for issuance.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>2024
Stock Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">On
August 22, 2024, the 2024 Stock Incentive Plan (&#8220;2024 Stock Plan&#8221;) was approved by the Company&#8217;s stockholders and on
August 29, 2024, the board of directors of the Company (the &#8220;Board&#8221;) ratified the 2024 Stock Plan. The 2024 Stock Plan allows
for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock units, other stockholder-based awards
and incentive bonuses. The 2024 Stock Plan is administered by the Compensation Committee of the Board (the &#8220;Compensation Committee&#8221;)
or another committee designated by the Board to administer the Plan. The initial share pool under the 2024 Stock Plan is 4,634,891 shares
of Company Common Stock. During the period from February 6, 2024 (inception) to December 31, 2024, 388,567 shares were subject to outstanding
stock options, and as of December 31, 2024, there were 4,246,324 shares available in the pool. The shares that may be issued under the
2024 Stock Plan will be automatically increased on January 1 of each year beginning in 2025 and ending with a final increase on January
1, 2034 in an amount equal to 5% of the diluted stock (including Company Common Stock, preferred stock and unexercised pre-funded warrants)
on the preceding December 31, unless a lower, or no, increase is determined by the Compensation Committee. Current or prospective employees,
officers, non-employee directors, and other independent service providers of the Company and its subsidiaries are eligible to participate
in the 2024 Stock Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>2024
Employee Stock Purchase Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
2024 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) became effective on August 29, 2024, at which time 463,489 shares of Company
Common Stock were reserved for issuance. Eligible employees may purchase shares of Company Common Stock under the ESPP at&#160;85% of
the lower of the fair market value of the Company Common Stock as of the first or the last day of each offering period. Employees are
limited to contributing&#160;15% of the employee&#8217;s eligible compensation and may not purchase more than $25,000&#160;of stock during
any calendar year. The ESPP will terminate&#160;ten years&#160;from the first purchase date under the plan, unless terminated earlier
by the board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
shares that may be issued under the ESPP will be automatically increased on January 1 of each year beginning in 2025 and ending with
a final increase on January 1, 2034 in an amount equal to 1% of the diluted stock (including Company Common Stock, preferred stock and
unexercised pre-funded warrants) on the preceding December 31, unless a lower, or no increase is determined by the Compensation Committee.
During the period from February 6, 2024 (inception) to December 31, 2024, 2,960 shares of Company Common Stock were issued out of the
ESPP and as of December 31, 2024, there were 460,529 shares of Company Common Stock available in the pool.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">For
the period February 6, 2024 (inception) to December 31, 2024, stock-based compensation expense related to the ESPP was less than $0.1
million.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock
Option Valuation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the weighted-average assumptions used in calculating the fair value of the awards for the period from February&#160;6,
2024 (inception) to December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period from<br/> February 6,<br/> 2024<br/> (Inception) to<br/> December 31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (in years)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.1</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">100.21</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.26</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-206; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock
Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the stock option activities under the 2024 Plan and 2024 Stock Plan for the period of February&#160;6, 2024
(inception) through December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number of<br/> Stock<br/> Options<br/> Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/> Average<br/> Exercise<br/> Price Per<br/> Share</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term <br/> (in Years)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Aggregate<br/> Intrinsic<br/> Value<br/> (in&#160;Thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Balance as of February 6, 2024 (inception)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-208; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-209; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-210; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-211; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; width: 52%"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,567,760</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11.39</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-212; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-213; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-214; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-215; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,567,760</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11.39</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.4</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,470</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Vested and expected to vest, December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,567,760</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11.39</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.4</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,470</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable, December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-216; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-217; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-218; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-219; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif">The
weighted average grant-date fair value per share of stock options granted during the period from February&#160;6, 2024 (inception) to
December 31, 2024 was $9.12 per share. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying
Company Common Stock and the exercise price of outstanding, in-the-money employee stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Restricted
Stock Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
February 2024 and March&#160;2024, the Company issued 2,207,553 shares of RSAs to certain employees, directors, and consultants at a
price of $0.0001 per share, the then par value of Pre-Merger Oruka Common Stock. Such RSAs have service-based vesting conditions only
and vest over a four-year period, during which time all unvested shares are subject to forfeiture in the event the holder&#8217;s service
with the Company voluntarily or involuntarily terminates. As of December 31, 2024, none of the RSAs had vested. For the period February
6, 2024 (inception) to December 31, 2024, stock-based compensation expense related to RSAs was less than $0.1 million.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the RSA activity for the period from February&#160;6, 2024 (inception) through December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/>
    RSAs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/>
    Average<br/>
    Grant Date<br/>
    Fair Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Unvested balance as of February 6, 2024 (inception)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-220; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-221; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; padding-bottom: 1.5pt; padding-left: 13.7pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,207,553</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-222; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Unvested balance as of December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,207,553</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-223; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Option
Agreements and the Paruka Warrant Obligation</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
part of the Option Agreements, on December&#160;31, 2024 the Company granted and on December&#160;31, 2025, will grant Paruka a warrant
to purchase a number of shares equal to 1.00% of outstanding shares as of the date of the grant on a fully-diluted basis, with an exercise
price equal to the fair market value of the underlying shares on the grant date (the &#8220;Paruka Warrant Obligation&#8221;).</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
grant dates for the issuance of warrants were expected to be December&#160;31, 2024 and December&#160;31, 2025 as all terms of the award,
including number of shares and exercise price, will be known by all parties. The Company determined that the 2024 and 2025 grants are
two separate grants, as there would be no obligation for the 2025 grant had the Company exercised or terminated all of the options under
the Option Agreements prior to December 31, 2024. The service inception period for the grant precedes the grant date, with the full award
being vested as of the grant date with no post-grant date service requirement. Accordingly, the warrant expected to be granted to Paruka
was accounted for as a liability on the balance sheet on the service inception date and, after the initial recognition, the liability
is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the consolidated statement of operations
and comprehensive loss as stock-based compensation expenses under research and development expenses. Accordingly, the Company measured
the grant date fair value of the warrant granted on December 31, 2024 at $10.4 million. For the period from February 6, 2024 (inception)
to December 31, 2024, $10.4 million was recognized as stock-based compensation expense related to the Paruka Warrant Obligation in the
consolidated statement of operations and comprehensive loss. As of December 31, 2024, there was no unamortized expense related to the
December 31, 2024 Paruka Warrant Obligation. On issuance of the warrant to Paruka, the fair value of the warrant was reclassified from
liability to equity on the consolidated balance sheet as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Employee
Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As stated above, on July
3, 2024, the Subscription Agreement was amended and restated, among other things, for employee warrants to be issued to certain Pre-Merger
Oruka employees and directors immediately prior to the closing of the Merger. Pursuant to this amendment, during the period from February
6, 2024 (inception) to December 31, 2024, the Company issued 3,054,358 warrants at an exercise price of $7.80 per warrant, which are accounted
as equity in the consolidated financial statements. The employee warrants were subject to performance and service based vesting requirements
and upon completion of the Merger the performance-based requirements had been achieved.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the warrant activity for the period from February&#160;6, 2024 (inception) through December 31, 2024:&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/>
Employee<br/> Warrants<br/>
Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/> Average<br/> Exercise<br/> Price Per<br/> Share</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term <br/> (in Years)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Aggregate<br/> Intrinsic<br/> Value<br/> (in&#160;Thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Balance as of February 6, 2024 (inception)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-224; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-225; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-226; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; width: 52%"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,054,358</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.80</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-227; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-228; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-229; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-230; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,054,358</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.80</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.5</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">35,400</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Vested and expected to vest, December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,054,358</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.80</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.5</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">35,400</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable, December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-231; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-232; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-233; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
weighted average grant-date fair value per share of warrants granted during the period from February&#160;6, 2024 (inception) to December
31, 2024 was $6.27 per share. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying
Company Common Stock and the exercise price of outstanding, in-the-money warrants.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the weighted-average assumptions used in calculating the fair value of the warrants for the period from February&#160;6,
2024 (inception) to December 31, 2024:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period from<br/> February 6,<br/> 2024<br/> (Inception) to<br/> December 31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (in years)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.1</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">99.02</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.15</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-207; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock-Based
Compensation Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the classification of the Company&#8217;s stock-based compensation expense in the consolidated statement of
operations and comprehensive loss (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from<br/>
    February 6,<br/>
    2024<br/>
    (Inception) to<br/>
    December 31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,992</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,927</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 13.7pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,919</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2024, total unrecognized compensation cost related to the unvested stock options was $12.7 million, which is expected
to be recognized over a weighted average period of approximately 3.2 years. As of December 31, 2024, total unrecognized compensation
cost related to the unvested RSAs was less than $0.1 million, which is expected to be recognized over a weighted average period of 3.1
years. As of December 31, 2024, the unrecognized compensation cost related to the employee warrants was $16.3 million, which is expected
to be recognized over a weighted average period of 3.3 years.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the award types of the Company&#8217;s stock-based compensation expense in the consolidated statement of operations
and comprehensive loss (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from<br/>
    February 6,<br/>
    2024<br/>
    (Inception) to <br/>
    December 31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paruka Warrant Obligation</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,357</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Employee warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,899</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,626</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Employee stock purchase
    plan</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">37</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,919</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208160104880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Disclosures<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Disclosures</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>10.
Segment disclosures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company operates and manages its business activities on a consolidated basis and operates in one reportable segment.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company operates as a single reportable and operating segment.
Its Chief Executive Officer, serving as the Chief Operating Decision Maker (&#8220;CODM&#8221;), oversees operations on an aggregated
basis to allocate resources effectively. In assessing the Company&#8217;s financial performance, the CODM regularly reviews total operating
expenses and consolidated net loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">The
measure of segment assets is reported on the balance sheet as total consolidated assets. The Company&#8217;s long-lived assets consist
primarily of property and equipment, net. As of December&#160;31, 2024 all of long-lived assets were in the U.S.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">The
table below is a summary of the segment loss from operations, including significant segment expenses (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from<br/>
    February 6,<br/>
    2024<br/>
    (Inception) to December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development personnel-related
    (excluding stock-based compensation)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,959</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative personnel-related
    (excluding stock-based compensation)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,054</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development stock-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,992</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative stock-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,927</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">External research and development</span></td><td></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">57,680</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,429</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">General and administrative,
    excluding personnel-related and stock-based compensation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,082</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Total
    operating expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">88,123</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Loss
    from operations</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(88,123</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208263335824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>11.
Income Taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: hidden-fact-238">No</span>
provision for income taxes was recorded for the period from February&#160;6, 2024 (inception) to December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the loss before income tax expense by jurisdiction for the periods indicated:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from<br/>
    February 6,<br/>
    2024<br/>
    (Inception) to <br/>
    December 31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="font-family: Times New Roman, Times, Serif">Domestic</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">83,724</span></td><td style="width: 1%; text-align: left">)<span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Foreign</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-234; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Loss
    before income tax expense</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">83,724</span></td><td style="padding-bottom: 2.5pt; text-align: left">)<span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For the period from February
6, 2024 (inception) to December&#160;31, 2024, the Company recognized&#160;no&#160;provision or benefit from income taxes. The difference
between the Company&#8217;s provision for income taxes and the amounts computed by applying the statutory federal income tax rate to income
before income taxes is as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period from<br/> February 6,<br/> 2024 <br/> (Inception)&#160;to<br/> December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Tax benefit derived by applying the federal statutory rate to income before income taxes</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.00</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.18</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.41</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.87</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in the valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25.46</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Income tax (benefit) expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.00</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
components of the deferred tax assets and liabilities consist of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 9pt">Net operating loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,260</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,080</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,063</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Accruals and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">424</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Intangibles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,477</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Capitalized R&amp;D expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,994</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,501</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Right- of- use asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(184</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Total deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(184</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,317</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Deferred tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">The Company has established
a full federal and state valuation allowance equal to the net deferred tax assets due to uncertainties regarding the realization of the
deferred tax asset based on the Company&#8217;s lack of earnings history. The valuation allowance increased by $21.3&#160;million primarily
due to continuing loss from operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Beginning balance as of February 6, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">21,317</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Ending balance as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">21,317</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of December&#160;31, 2024, the Company had U.S. net operating loss carryforwards (&#8220;NOL&#8221;) of $10.8&#160;million. The federal
NOL carryforwards do not expire and can be utilized to offset up to 80% of the taxable income in any tax year. For the period from February
6, 2024 (inception) to December&#160;31, 2024 the Company had federal tax credit carryforwards and state tax credit carryforwards of
$3.8&#160;million and $0.4&#160;million, respectively. The federal credits will expire starting in 2044 if not utilized, and the state
research credit can be carried forward indefinitely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tax Reform Act of 1986 limits the use of net operating loss carryforwards in certain situations where changes occur in the stock ownership
of a company. The annual limitation may result in the expiration of net operating losses and credits before utilization. The Company
has not performed a Section 382 analysis through December 31, 2024. To the extent that an assessment is completed in the future, the
Company&#8217;s ability to utilize tax attributes could be restricted on a year-by-year basis and certain attributes could expire before
they are utilized. The Company will examine the impact of any potential ownership changes in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">A
reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from<br/>
    February 6,<br/>
    2024<br/>
    (Inception) to<br/>
    December 31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Beginning balance as of February 6, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-237; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Changes
    related to tax positions taken in the current year</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,047</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Ending balance
    as of December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,047</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The
Company includes penalties and interest expense related to income taxes as a component of income tax expense, as necessary. As of December
31, 2024, the Company had&#160;no&#160;accrued interest or penalties related to uncertain tax positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company will be filing initial year income tax returns in the United States federal jurisdiction and state jurisdictions. Due to net
operating loss carryforwards, the statute of limitations will remain open for income tax examination.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208263342080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Option Agreements and License Agreements<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_OptionAgreementsAndLicenseAgreementsAbstract', window );"><strong>Option Agreements and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_OptionAgreementsAndLicenseAgreementsTextBlock', window );">Option Agreements and License Agreements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>12.
Option Agreements and License Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
March&#160;2024, the Company entered into two antibody discovery and option agreements (&#8220;Option Agreements&#8221;) with Paragon
and Paruka. Under the terms of each agreement, Paragon identifies, evaluates, and develops antibodies directed against certain mutually
agreed therapeutic targets of interest to the Company. From time to time, the Company can choose to add additional targets to the collaboration
upon agreement with Paragon and Paruka. Under the Option Agreements, the Company has the exclusive option to, on a research program-by-research
program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual
property resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and products directed
to the selected target(s)&#160;(each, an &#8220;Option&#8221;). The Company has initiated certain research programs with Paragon that
generally focus on discovering, generating, identifying and/or characterizing antibodies directed to a particular target (each, a &#8220;Research
Program&#8221;), including for IL-23 and IL-17A/F for ORKA-001 and ORKA-002, respectively. The exclusive option with respect to each
Research Program is exercisable at the Company&#8217;s sole discretion at such time as specified in the Option Agreements (the &#8220;Option
Period&#8221;). There is no payment due upon exercise of an Option pursuant to the Option Agreements. For each of these agreements, once
the Company enters into the corresponding license agreements, it will be required to make non-refundable milestone payments to Paragon
of up to $12.0 million under each respective agreement upon the achievement of certain clinical development milestones, up to $10.0 million
under each respective agreement upon the achievement of certain regulatory milestones, as well as a low single-digit percentage royalty
for antibody products beginning on the first commercial sale in each program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company may terminate any Option Agreement or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior written
notice to Paragon, provided that it must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable
obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate
any Option Agreement or a Research Program immediately upon written notice to the Company if, as a result of any action or failure to
act by the Company or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended,
discontinued or otherwise delayed for a certain consecutive number of&#160;months. Each party has the right to terminate the Option Agreements
or any Research Program upon material breach that remains uncured or the other party&#8217;s bankruptcy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>Paragon
Therapeutics &#8211; License Agreements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
September 2024, the Company exercised the Option to acquire certain rights to ORKA-001, and in December 2024, it entered into the corresponding
license agreement with Paragon (the &#8220;ORKA-001 License Agreement&#8221;), pursuant to which Paragon granted the Company a royalty-bearing,
world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting IL-23
in all fields other than the field of inflammatory bowel disease (&#8220;ORKA-001 Field&#8221;). In December 2024, the Company exercised
the Option with respect to ORKA-002 for the IL-17A/F program, and in February 2025, it entered into the corresponding license agreement
with Paragon (the &#8220;ORKA-002 License Agreement&#8221; and together with the ORKA-001 License Agreement, the &#8220;License Agreements&#8221;),
pursuant to which Paragon granted the Company a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize
or otherwise exploit certain antibodies and products targeting IL-17A/F in all fields (&#8220;ORKA-002 Field&#8221; and together with
the ORKA-001 Field, the &#8220;Fields&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
License Agreements provide the Company with exclusive licenses in the Fields to Paragon&#8217;s patent applications covering the related
antibodies, their method of use and their method of manufacture and Paragon has agreed not to conduct any new campaigns that generate
anti-IL-23 monospecific antibodies or anti-IL-17A/F monospecific antibodies for the ORKA-001 Field or the ORKA-002 Field, respectively,
for at least five years. Each of the ORKA-001 and ORKA-002 License Agreements may be terminated on 60 days&#8217; notice to Paragon,
on material breach without cure, and on a party&#8217;s insolvency or bankruptcy to the extent permitted by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the terms of each of the ORKA-001 and ORKA-002 License Agreements, the Company is obligated to pay Paragon non-refundable milestone
payments of up to $12.0 million under each respective agreement upon the achievement of certain clinical development milestones and up
to $10.0 million under each respective agreement upon the achievement of certain regulatory milestones, including a $1.5 million fee
for nomination of a development candidate (or initiation of an IND-enabling toxicology study) and a further milestone payment of $2.5
million upon the first dosing of a human patient in a Phase 1 trial for each of ORKA-001 and ORKA-002. In addition, the Company is obligated
to pay Paragon a low single-digit percentage royalty for antibody products for each of ORKA-001 and ORKA-002. For each of the License
Agreements, the royalty term ends on the later of (i) the last-to-expire licensed patent or our patent directed to the manufacture, use
or sale of a licensed antibody in the country at issue or (ii) 12 years from the date of first sale of a Company product. There is also
a royalty step-down if there is no Paragon patent in effect during the royalty term for each program.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Additionally,
as part of the Option Agreements, on December&#160;31, 2024 the Company granted and on December&#160;31, 2025, will grant Paruka a warrant
to purchase a number of shares equal to 1.00% of outstanding shares as of the date of the grant on a fully-diluted basis, with an exercise
price equal to the fair market value of the underlying shares on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Option Agreements, on a research program-by-research program basis following the finalization of the research plan for each respective
research program, the Company was required to pay Paragon a one-time, nonrefundable research initiation fee of $0.8&#160;million related
to the ORKA-001 program. This amount was recognized as a research and development expense during the period from February&#160;6, 2024
(inception) to December 31, 2024. In June 2024, pursuant to the Option Agreements with Paragon, the Company completed the selection process
of its development candidate for IL-23 antibody for ORKA-001 program. The Company was responsible for 50% of the development costs incurred
through the completion of the IL-23 selection process. The Company received the rights to at least one selected IL-23 antibody in June
2024. During the period from February 6, 2024 (inception) to December 31, 2024, the Company exercised its option for ORKA-001 and recorded
a $1.5 million milestone payment related to the achievement of development candidate as research and development expense in the Company&#8217;s
consolidated statement of operations and comprehensive loss. In addition, during the period from February 6, 2024 (inception) to December
31, 2024, the Company recorded a $2.5 million milestone payment related to the first dosing of a human subject in a Phase 1 trial of
ORKA-001 in December 2024 as research and development expense in its consolidated statement of operations and comprehensive loss. The
Company&#8217;s share of development costs incurred for the period from February 6, 2024 (inception) to December 31, 2024 was $13.5 million
(excluding research initiation fee and milestones), which were recorded as research and development expenses. An amount of $2.8 million
related to ORKA-001 is included in related party accounts payable and other current liabilities as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company was also required to reimburse Paragon $3.3&#160;million for development costs related to ORKA-002 incurred by Paragon through
December&#160;31, 2023 and certain other development costs incurred by Paragon between January&#160;1, 2024 and March&#160;6, 2024 as
stipulated by the Option Agreements. This amount was recognized as a research and development expense during the period from February&#160;6,
2024 (inception) to December 31, 2024. The Company is also responsible for the development costs incurred by Paragon from January&#160;1,
2024 through the completion of the IL-17 selection process. The Company recognized an amount of $0.8&#160;million payable to Paragon
for the research initiation fee related to ORKA-002 following the finalization of the ORKA-002 research plan. This was recognized as
research and development expenses in the period from February 6, 2024 (inception) to December 31, 2024. During the period from February
6, 2024 (inception) to December 31, 2024, the Company exercised its option for ORKA-002 and recorded a $1.5 million milestone payment
related to the achievement of development candidate as research and development expense in its consolidated statement of operations and
comprehensive loss. The Company accounted for development costs of $7.8 million (excluding research initiation fee, milestone, and reimbursements
of development costs through December 31, 2023) for the period from February 6, 2024 (inception) to December 31, 2024 as research and
development expenses. An amount of $2.7 million related to ORKA-002 is included in related party accounts payable and other current liabilities
as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company expenses the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified
within research and development expenses in the accompanying consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company concluded that the rights obtained under the Option Agreements represent an asset acquisition whereby the underlying assets comprise
in-process research and development assets with no alternative future use. The Option Agreements did not qualify as a business combination
because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent
a group of similar identifiable assets. The research initiation fee represents a one-time cost on a research program-by-research program
basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts
paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of ongoing development cost,
monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior
to the effective date of the Option Agreements that is associated with services being rendered under the related Research Programs are
recognized as research and development expense when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif">For
the period from February&#160;6, 2024 (inception) to December 31, 2024, the Company recognized $42.0 </span>&#160;<span style="font-family: Times New Roman, Times, Serif">million
of expenses in connection with services provided by Paragon and Paruka under the Option Agreements.&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_OptionAgreementsAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_OptionAgreementsAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_OptionAgreementsAndLicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of option agreements and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_OptionAgreementsAndLicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208263329552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitment and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitment and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>13.
Commitment and Contingencies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>Leases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
April 2024, the Company entered into an operating lease agreement for the Company&#8217;s headquarters in Menlo Park, California, which
commenced on June 15, 2024 with an initial term of 39.5 months. The Company leases office space under this noncancelable operating lease
agreement. Lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining
the present value of lease payments, the Company used its incremental borrowing rate when measuring operating lease liabilities as discount
rates were not implicit or readily determinable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2024, the Company had $0.9 million of operating lease right-of-use assets, operating lease liability, current of $0.2
million, and operating lease liability, noncurrent of $0.8 million on its consolidated balance sheet. As of December 31, 2024, the operating
lease arrangement had a remaining lease term of 33 months and a discount rate of 17.95%. For the period from February 6, 2024 (inception)
to December 31, 2024, the Company recorded operating and variable lease expense of $0.3 million in general and administrative expenses
in its consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table presents the Company&#8217;s supplemental cash flow information related to leases (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from<br/>
    February 6,<br/>
    2024<br/>
    (Inception) to<br/>
    December 31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash paid for amounts included
    in the measurement of lease liabilities</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">116</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes a maturity analysis of the Company&#8217;s operating lease liabilities showing the aggregate lease payments
as of December 31, 2024 (in thousands):&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>Year
    ending December 31,</b></span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">369</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">494</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2027</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">380</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total undiscounted lease
    payments</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,243</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    imputed interest</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(275</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total discounted lease
    payments</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">968</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    current portion of lease liability</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(213</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.375in; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Non-current
    portion of lease liability</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">755</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>Cell
Line License Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In March 2024, the Company
entered into the Cell Line License Agreement (the &#8220;Cell Line License Agreement&#8221;) with WuXi Biologics Ireland Limited (&#8220;WuXi
Biologics&#8221;). Under the Cell Line License Agreement, the Company received a non-exclusive, worldwide, sublicensable license to certain
of WuXi Biologics&#8217; know-how, cell line, biological materials (the &#8220;WuXi Biologics Licensed Technology&#8221;) and media and
feeds to make, have made, use, sell and import certain therapeutic products produced through the use of the cell line licensed by WuXi
Biologics under the Cell Line License Agreement (the &#8220;WuXi Biologics Licensed Products&#8221;). Specifically, the WuXi Biologics
Licensed Technology is used in certain manufacturing activities in support of the ORKA-001 and ORKA-002 programs.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
consideration for the license, the Company agreed to pay WuXi Biologics a non-refundable license fee of $150,000, which was recognized
as a research and development expense during the period from February&#160;6, 2024 (inception) to December 31, 2024. Additionally, to
the extent that the Company manufactures its commercial supplies of bulk drug product with a manufacturer other than WuXi Biologics or
its affiliates, the Company is required to make royalty payments to WuXi Biologics at a rate of less than one percent of net sales of
WuXi Biologics Licensed Products manufactured by the third-party manufacturer. Pursuant to an amendment to the Cell Line License Agreement
effective in November 2024, a provision was added that permits the royalties owed under the agreement to be bought out on a&#160;product-by-product&#160;basis
for a&#160;lump-sum&#160;payment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
                                            Cell Line License Agreement will continue indefinitely unless terminated (i) by the Company
                                            upon six months&#8217; prior written notice and its payment of all undisputed amounts due
                                            to WuXi Biologics through the effective date of termination, (ii) by WuXi Biologics for a
                                            material breach by the Company that remains uncured for 60 days after written notice, (iii)
                                            by WuXi Biologics if the Company fails to make a payment and such failure continues for 30
                                            days after receiving notice of such failure, or (iv) by either party upon the other party&#8217;s
                                            bankruptcy.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208160410768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerUnitAbstract', window );"><strong>Net Loss per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>14.
Net Loss per Share</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Basic
and diluted net loss per share attributable to stockholders were calculated as follows (in thousands, except share and per share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from February 6, 2024<br/>
    (Inception) to <br/>
    December 31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Loss<br/>
    Allocation</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/>
    Average<br/>
    Shares<br/>
    Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Loss
    Per<br/>
    Share,<br/>
    Basic and<br/>
    Diluted</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common Stock</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(65,037</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,789,362</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3.87</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Company Series A Preferred Stock <sup>(1)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,918</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">495</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,873.25</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Company Series B Preferred
    Stock <sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(16,769</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,946</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(322.81</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(83,724</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The weighted-average number of shares of as-converted Company Series A Preferred Stock used in the loss allocation was 495,191 for the period from February 6, 2024 (inception) to December 31, 2024.</span></td></tr></table>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The weighted-average number of shares of as-converted Company Series B Preferred Stock used in the loss allocation was 4,328,844 for the period from February 6, 2024 (inception) to December 31, 2024.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">For
the computation of basic net loss per share attributable to stockholders, the amount of weighted-average shares outstanding excludes
all shares of unvested restricted common stock as such shares are not considered outstanding for accounting purposes until vested. The
amount of weighted-average shares outstanding includes the pre-funded warrants as the exercise price is negligible and these warrants
are fully vested and exercisable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to stockholders for
the periods presented because including them would have had an anti-dilutive effect were as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31, <br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding employee warrants to
    purchase common stock</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,054,358</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding unvested restricted stock awards</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,207,553</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding and issued common stock options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,567,760</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding and issued
    warrant to Paruka</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">596,930</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 13.7pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,426,601</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerUnitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerUnitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208268813712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>15.
Related Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Paragon
and Paruka each beneficially own less than 5% of the Company&#8217;s capital stock through their respective holdings of Company Common
Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Fairmount
beneficially owns more than 5% of the Company&#8217;s capital, currently has one representative appointed to the Board, and beneficially
owns more than 5% of Paragon. Fairmount appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment
of any executive officers of Paragon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following is a summary of related party accounts payable and other current liabilities (in thousands):&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31, <br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paragon reimbursable Option Agreements&#8217;
    fees</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,482</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paragon milestone payments for Option Agreement</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paragon reimbursable other research expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">515</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Paragon reimbursable
    patent expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,022</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208267430048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>16.
Subsequent Events</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
February 2025, the Company entered into a lease agreement for an office space located in Waltham, Massachusetts. The lease is for an
initial period of 54 months. The Company expects to pay approximately $1.6 million over the lease term.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208263417312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (83,724)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208165582016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208266217280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
collect, use, store, and transmit confidential, sensitive, proprietary, personal, and health-related information in the ordinary course
of our business. As such, we leverage third-party information technology service providers who have implemented and maintain various
information security processes designed to identify, assess, and manage material risks from cybersecurity threats to our information
technology systems, including critical computer networks, third party hosted services, communications systems, hardware and software,
and our data residing on these systems. Our Senior Vice President, Finance is responsible for overseeing these third-party service providers
and processes.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Cybersecurity
risks are identified by monitoring and evaluating our threat environment, and then assessed by various methods, for example, by manual
and automated tools designed to identify and combat cybersecurity threats, analyzing reports of threats, conducting scans and assessments
of the threat environment and to identify vulnerabilities, the use of detection and response services and conducting reviews of third-party
service providers, among other things. Depending on the threat environment, we implement and maintain various technical, physical, and
organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats
to our information systems and data, including, for example, physical security and access controls, asset management, systems monitoring,
incident detection and response, risk assessment, the implementation of security standards and certifications, encryption of data, network
security controls, and a recovery/business continuity plan, among other mitigation tactics. Our recovery/business continuity plan is
designed to mitigate and remediate identified cybersecurity incidents and escalate certain incidents as appropriate to management and
the Audit Committee. We plan to conduct due diligence on and audits of key technology vendors, contract research organizations, and other
third-party contractors and suppliers. Additionally, we conduct periodic employee training that covers cyber and information security,
among other topics.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">Our assessment and management
of material risks from cybersecurity threats are integrated into the Company&#8217;s overall risk management process. Our Senior Vice
President, Finance, who reports directly to the Chief Executive Officer, together with our senior management, is responsible for assessing
and managing cybersecurity risks with support from our third-party information technology service providers that employ information technology
consultants with over 20 years of experience managing cybersecurity programs. Our cybersecurity program aligns to the National Institute
of Standards and Technology (NIST) Cybersecurity Framework (CSF) and is consistently updated as NIST recommendations change year over
year. Our Senior Vice President, Finance, together with our senior management and other employees works closely with our information technology
service providers to evaluate material cybersecurity threats against our overall business objectives as part of our cybersecurity incident
response.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">The Board of Directors, as a whole and at the committee level, has oversight for the most significant risks facing us and for
our processes to identify, prioritize, assess, manage and mitigate those risks. The Audit Committee has been designated by our Board to
oversee cybersecurity risks. The Audit Committee receives regular updates on cybersecurity and information technology matters and related
risk exposures from our Senior Vice President, Finance. The Board also receives updates from management and the Audit Committee on cybersecurity
risks on a regular basis.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The Audit Committee has been designated by our Board to
oversee cybersecurity risks.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The Board also receives updates from management and the Audit Committee on cybersecurity
risks on a regular basis.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock', window );">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</a></td>
<td class="text">we have not identified any risks from known cybersecurity threats, including as a result of any prior cybersecurity
incidents, that have materially affected us, but we face certain ongoing cybersecurity risks or threats that, if realized, are reasonably
likely to materially affect us.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 8-K<br> -Section 1.05<br> -Subsection a<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 6-K<br> -Section General Instruction<br> -Subsection B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208163433936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Use
of Estimates</i></b>&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
preparation of the Company&#8217;s consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates,
assumptions, and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at
the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant
estimates and assumptions reflected within these consolidated financial statements include but are not limited to research and development
expenses and related prepaid or accrued costs and the valuation of stock-based compensation awards and related expenses. The Company
bases its estimates on known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances.
On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results
could differ materially from those estimates or assumptions.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Concentrations
of Credit Risk and Other Risks and Uncertainties</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Financial
instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities.
The Company&#8217;s investment policy limits investments to high credit quality securities issued by the U.S. government, U.S. government-sponsored
agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company&#8217;s
cash, cash equivalents and marketable securities are held by financial institutions that management believes are of high credit quality.
The financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits.
Accounts at the Company&#8217;s U.S. banking institution are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;)
up to $250,000 per depositor. As of December 31, 2024, the balance at the Company&#8217;s U.S. banking institution exceeded the FDIC
limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its accounts are monitored by management
to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash
equivalents, and bond issuers.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company is dependent on third-party organizations to research, develop, manufacture, and process its product candidates for its development
programs, including its two most advanced programs, ORKA-001 and ORKA-002. The Company expects to continue to be dependent on a small
number of manufacturers to supply it with its requirements for all products. The Company&#8217;s research and development programs could
be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company&#8217;s
research and development activities are performed under its agreements with Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) (see Note&#160;12).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Cash
and Cash Equivalents</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to
be cash equivalents. The cash equivalents were comprised of investments in money market funds, U. S. treasury securities, U.S. government
agency securities, and debt securities and are stated at fair value.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Marketable
Securities</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company invests in marketable securities, primarily securities issued by the U.S. government and its agencies, commercial paper and corporate
debt securities. The Company&#8217;s marketable securities are classified as available-for-sale and reported at fair value, with unrealized
gains and losses included as a component of accumulated other comprehensive loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">For
available-for-sale debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more
likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria
regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value and recognized
in other income (expense) in the results of operations. For available-for-sale debt securities that do not meet the aforementioned criteria,
the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment,
management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating
agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit
loss exists, an allowance is recorded for the difference between the present value of cash flows expected to be collected and the amortized
cost basis of the security. Impairment losses attributable to credit loss factors are charged against the allowance when management believes
an available-for-sale security is uncollectible or when either of the criteria regarding intent or requirement to sell is met.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Any
unrealized losses from declines in fair value below the amortized cost basis as a result of non-credit loss factors are recognized as
a component of accumulated other comprehensive loss, net of unrealized gains. Realized gains and losses and declines in fair value, if
any, on available-for-sale securities are included in other income, net, in the results of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Marketable
securities with stated maturities of greater than three months from the date of purchase but less than one year from the consolidated
balance sheet date are classified as current, while marketable securities with maturities in one year or beyond one year from the consolidated
balance sheet date are classified as long-term. The cost of securities sold is determined using the specific-identification method. Interest
earned and adjustments for the amortization of premiums and discounts on investments are included in interest income on the consolidated
statements of operations and comprehensive loss.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Debt
Issuance Costs</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Debt
issuance costs incurred in connection with the Convertible Note (see Note&#160;7) are recorded as a reduction of the carrying value of
the notes payable liability on the Company&#8217;s balance sheet and are amortized to interest expense over the term of the loan using
the effective interest method. At the effective time of the Merger the Converted Note was converted to common stock and is no longer
on the balance sheet as of December 31, 2024.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SubscriptionReceivablePolicyTextBlock', window );">Subscription Receivable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Subscription
Receivable&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable
is paid prior to the date the financial statement is available to be issued.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Fair
Value Measurements&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Certain
assets and liabilities are carried at fair value under U.S.&#160;GAAP.&#160;Fair value is defined as the exchange price that would be
received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize
the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are
to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered
observable and the last is considered unobservable:</span></p><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"></td><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
                                            1&#160;&#8212;&#160;Quoted prices in active markets that are identical assets or liabilities.</span></td></tr></table><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"></td><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level&#160;2&#160;&#8212;&#160;Observable
                                            inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar
                                            assets or liabilities, quoted prices in markets that are not active for identical or similar
                                            assets or liabilities, or other inputs that are observable or can be corroborated by observable
                                            market data.</span></td></tr></table><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"></td><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level&#160;3&#160;&#8212;&#160;Unobservable
                                            inputs that are supported by little or no market activity that are significant to determining
                                            the fair value of the assets or liabilities, including pricing models, discounted cash flow
                                            methodologies, and similar techniques.</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy
described above (see Note 4). The carrying values of the Company&#8217;s prepaid expenses and other current assets, accounts payable
and accrued expenses and other current liabilities approximate their fair values due to their relatively short maturity period.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Property
and Equipment</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Property
and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over
the estimated useful life of each asset as follows:</span></p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Estimated<br/>
    Useful Life</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Furniture and fixtures</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3-5 years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computer and office equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">3-5 years</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock', window );">Classification of Convertible Preferred Stock</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Classification
of Convertible Preferred Stock</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Prior
to the reverse recapitalization, the Company had classified its Pre-Merger Oruka Series A Preferred Stock outside of stockholders&#8217;
equity on the Company&#8217;s consolidated balance sheet because the holders of such stock have certain liquidation rights in the event
of a deemed liquidation event that, in certain situations, is not solely within the control of the Company and would require the redemption
of the then-outstanding convertible preferred stock.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Upon
the closing of the Merger, the Company converted its Pre-Merger Oruka Series A Preferred Stock to Company Series B Preferred Stock and
has classified the Company Series B Preferred Stock within stockholders&#8217; equity on its consolidated balance sheet because the Company
Series B Preferred Stock is not redeemable or puttable to the Company by the holder under any circumstances.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
connection with the PIPE Financing (see Note 1) the Company issued Company Series A Preferred Stock, and has classified the Company Series
A Preferred Stock outside of stockholders&#8217; equity on the Company&#8217;s consolidated balance sheet because the holders of such
stock have certain rights (see Note 8) that, in certain situations, is not solely within the control of the Company and would require
the redemption of the then-outstanding convertible preferred stock. In November 2024, the Company Series A Preferred Stock shares were
converted to common stock, and as of December 31, 2024, there were no shares of Company Series A Preferred Stock outstanding.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NotePayableToRelatedPartyPolicyTextBlock', window );">Note Payable to Related Party</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Note&#160;Payable
to Related Party</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company accounted for the Convertible Note (as defined in Note 7) at amortized cost. The Company considered if optional conversion features
are required to be bifurcated and separately accounted for as a derivative. Costs related to the issuance of the Convertible Note were
recorded as a debt discount, amortized over the term of the Convertible Note (see&#160;Note&#160;7) and were accounted for as interest
expense in other income (expenses) within the consolidated statement of operations and comprehensive loss using the effective interest
method. At the effective time of the Merger, shares of Pre-Merger Oruka Common Stock issued pursuant to the conversion of the Convertible
Note (including accrued interest) automatically converted into shares of Company Common Stock (see Note 1).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock', window );">Research and Development Contract Costs Accruals</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Research
and Development Contract Costs Accruals</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component
of the Company&#8217;s research and development expenses, with a substantial portion of the Company&#8217;s ongoing research and development
activities conducted by third-party service providers, including contract research organizations (&#8220;CROs&#8221;) and contract manufacturing
organizations (&#8220;CMOs&#8221;), and the Company&#8217;s related-party Paragon (see Note&#160;12).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company accrues for expenses resulting from obligations under its two antibody discovery and option agreements (the &#8220;Option Agreements&#8221;)
(see Note 12), by and among Paragon, Paruka Holding LLC (&#8220;Paruka&#8221;), an entity formed by Paragon as a vehicle to hold equity
in the Company, and the Company as well as agreements with CROs, CMOs, and other outside service providers for which payment flows do
not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services
received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These
estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with
internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant
judgments and estimates in determining the accrual balance in each reporting period. If advance payments are made to Paragon, a CRO,
CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services
are performed. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the
Company&#8217;s results of operations. As of December 31, 2024, the Company has not experienced any material deviations between accrued
and actual research and development expenses.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Leases</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">At
the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies
a lease as either an operating or finance lease and recognizes a right-of-use (&#8220;ROU&#8221;) asset and a current and non-current
lease liability, as applicable, in the balance sheet if the lease has a term greater than one year. Lease terms may include options to
extend or terminate the lease when it is reasonably certain that the Company will exercise its option.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">At
the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future
minimum lease payments over the expected remaining lease term. The Company determines the present value of lease payments using the implicit
rate, if it is readily determinable, or the risk-free discount rate for a period comparable with that of the lease term. For operating
leases, lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, lease expense
includes amortization expense of the ROU asset recognized on a straight-line basis over the lease term and interest expense recognized
on the finance lease liability. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments,
incentives received or initial direct costs. As of December 31, 2024, the Company has one operating lease and no finance leases.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for lease and non-lease components related to operating leases as a single lease component. The Company has elected
that costs associated with leases having an initial term of 12 months or less are recognized in the consolidated statement of operations
and comprehensive loss on a straight-line basis over the lease term and are not recorded on its consolidated balance sheets. Variable
lease expense is recognized as incurred and consists primarily of real estate taxes, utilities, and other office space related expenses.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Segment
Reporting</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company operates as a
single reportable and operating segment. Its Chief Executive Officer, serving as the Chief Operating Decision Maker (&#8220;CODM&#8221;),
oversees operations on an aggregated basis to allocate resources effectively. In assessing the Company&#8217;s financial performance,
the CODM regularly reviews total operating expenses and consolidated net loss.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Research
and Development Costs</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Research
and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock-based compensation,
employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities, as well as allocated
human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Nonrefundable
advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid
expenses on the accompanying consolidated balance sheet. The prepaid amounts are expensed as the related goods are delivered or the services
are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable advance
payments represent a one-time cost for obtaining goods or services, with anticipated benefits to be utilized within a year of period
end, the payment is expensed immediately.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>General
and Administrative Expenses</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">General
and administrative expenses consist primarily of salaries and bonuses, stock-based compensation, employee benefits, finance and administration
costs, patent and intellectual property costs, professional fees, as well as allocated human resource costs, information technology costs,
and facility-related costs, including rent, maintenance, utilities and depreciation.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Commitments
and Contingencies</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities.
The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the
loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the
balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but
not probable; however, it discloses the range of reasonably possible losses. As of December 31, 2024, no liabilities were recorded for
loss contingencies (see Note&#160;13).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock-Based
Compensation</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company estimates the fair value of its stock awards using the Black-Scholes option pricing model, which uses as inputs the fair value
of the Company&#8217;s common stock, and certain management estimates, including the expected stock price volatility, the expected term
of the award, the risk-free interest rate, and expected dividends. Expected volatility is calculated based on reported volatility data
for a representative group of publicly traded companies for which historical information is available. The Company selects companies
with comparable characteristics with historical share price information that approximates the expected term of the equity-based awards.
The Company computes the historical volatility data using the daily closing prices for the selected companies&#8217; shares during the
equivalent period that approximates the calculated expected term of the stock options. The Company will continue to apply this method
until a sufficient amount of historical information regarding the volatility of its stock price becomes available. The risk-free interest
rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. For employee
and non-employee awards (except the Paruka warrant) the Company uses the simplified method, under which the expected term is presumed
to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to lack of historical
exercise data. For the Paruka warrant, the contractual term is used for the expected term. The expected dividend yield is assumed to
be zero as the Company has no current plans to pay any dividends on common stock.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company measures restricted common stock awards (&#8220;RSAs&#8221;) using the difference, if any, between the purchase price per share
of the award and the fair value of the Company&#8217;s common stock at the date of grant.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company grants stock options, restricted stock awards, and warrants that are subject to service or performance-based vesting conditions.
Compensation expense for awards to employees and directors with service-based vesting conditions is recognized using the straight-line
method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards
to non-employees with service-based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for
the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each
reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation
expense until it is probable that the performance-based vesting condition will be achieved.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company has issued stock options, warrants, and RSAs with service-based and performance-based vesting conditions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company recognizes the compensation expense for the option to purchase common stock under the Employee Stock Purchase Plan (&#8220;ESPP&#8221;),
based on the fair value of the common stock estimated using the closing price of the Company&#8217;s common stock as reported on the
date of offering, less the purchase discount percentage provided for in the plan.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company classifies stock-based compensation expense in its consolidated statement of operations and comprehensive loss in the same manner
in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified,
as applicable.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ComprehensiveLossPolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Comprehensive
Loss</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Comprehensive
loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and events other than those
with stockholders. The Company&#8217;s unrealized gains and losses on marketable securities represent the only component of other comprehensive
loss that are excluded from the reported net loss and that are presented in the consolidated statement of comprehensive loss.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share Attributable to Stockholders</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Net
Loss per Share Attributable to Stockholders</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Basic
and diluted net loss attributable to stockholders per share is presented in conformity with the two-class method required for participating
securities (Pre-Merger Oruka Series A Preferred Stock). Basic earnings per share is computed by dividing net income available to each
class of shares by the weighted-average number of shares of common stock and participating securities outstanding during the period.
Pre-funded warrants were included as the exercise price is negligible and these warrants are fully vested and exercisable. Company Series
A Preferred Stock and Company Series B Preferred Stock share the same characteristics as Common Stock and have no substantive preference
attributed to them and, accordingly, have been considered as classes of Common Stock in the computation of net loss per share regardless
of their legal form.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Net
loss is allocated to common stock based on its proportional ownership on an as-converted basis. Net loss is not allocated to participating
securities as they do not have an obligation to fund losses. The weighted-average number of shares outstanding of common stock reflects
changes in ownership over the periods presented. See Note 8 &#8212; Convertible Preferred Stock and Stockholders&#8217; Equity.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Diluted
net loss per share is computed by dividing the net loss attributable to stockholders adjusted for income (expenses), net of tax, related
to any diluted securities, by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for
the period. For purposes of this calculation, stock options to purchase common stock, employee warrants to purchase common stock, and
unvested RSAs are considered potential dilutive common shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company generated a net loss for the periods presented. Accordingly, basic and diluted net loss per share is the same because the inclusion
of the potentially dilutive securities would be anti-dilutive.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_OtherIncomeExpenseNetPolicyTextBlock', window );">Other income, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Other
income, net</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Other
income, net, consists of interest earned on the Company&#8217;s cash, cash equivalents, and marketable securities; interest expense on
the convertible note from a related party and foreign currency transactions gains and losses.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Income
Taxes</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#8217;s tax
returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis
of assets and liabilities using enacted tax rates in effect for the&#160;years in which the differences are expected to reverse. Changes
in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred
tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence,
that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established
through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable
profits expected and considering prudent and feasible tax planning strategies.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to
determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will
be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained,
the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount
of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement.
The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered
appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or penalties related to
uncertain tax positions as of December 31, 2024.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Recently
Adopted Accounting Pronouncements</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
November&#160;2023, the FASB issued ASU 2023-07, Segment Reporting (Topic&#160;280): Improvements to Reportable Segment Disclosures (&#8220;ASU&#160;2023-07&#8221;),
which enhances the segment disclosure requirements for public entities on an annual and interim basis. Under this standard, public entities
will be required to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure
of segment profit or loss. Additionally, current annual disclosures about a reportable segment&#8217;s profit or loss and assets will
be required on an interim basis. Entities will also be required to disclose information about the CODM&#8217;s title and position at
the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment of segment
performance and deciding how to allocate resources. Finally, ASU&#160;2023-07 requires all segment disclosures for public entities that
have only a single reportable segment. The amendments in ASU&#160;2023-07 are effective for fiscal&#160;years beginning after December&#160;15,
2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. Early adoption is permitted. The Company adopted
ASU 2023-07 in 2024 and additional required disclosures have been included in Note 10.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Recently
Issued Accounting Pronouncements</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
December&#160;2023, the FASB issued ASU&#160;2023-09, Income Taxes (Topic&#160;740): Improvements to Income Tax Disclosures. This ASU
expands disclosures in an entity&#8217;s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S.&#160;and
foreign jurisdictions. This update is effective beginning with the Company&#8217;s 2025 fiscal year annual reporting period. The Company
is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
November 2024, the FASB issued ASU 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU requires more detailed disclosures, on an annual and interim
basis, about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense
captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and
interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. This ASU may be applied either prospectively
or retrospectively. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Classification of Convertible Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ComprehensiveLossPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Comprehensive loss policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ComprehensiveLossPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_NotePayableToRelatedPartyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Note Payable to Related Party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_NotePayableToRelatedPartyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_OtherIncomeExpenseNetPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of other income (expense), net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_OtherIncomeExpenseNetPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of recently adopted accounting pronouncements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development contract costs accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_SubscriptionReceivablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_SubscriptionReceivablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208277008080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Property
and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over
the estimated useful life of each asset as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Estimated<br/>
    Useful Life</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Furniture and fixtures</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">3-5 years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computer and office equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">3-5 years</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208263382928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Recapitalization and Pre-Closing Financing (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Reverse Recapitalization and Pre-Closing Financing [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of the Assets and Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
part of the recapitalization, the Company acquired the assets and liabilities listed below (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">August
    29,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,940</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">114</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(54</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 6.85pt"><span style="font-family: Times New Roman, Times, Serif">Net
    assets acquired</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208160090672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value Hierarchy for Financial Assets Measured</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following tables present the Company&#8217;s fair value hierarchy for financial assets measured as of December 31, 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    1</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    2</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Level
    3</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Cash equivalents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Money market
    funds</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,350</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-157; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-158; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,350</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. treasury securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,660</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-159; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,660</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. government agency
    securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-160; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,988</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-161; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,988</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Commercial
    papers</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-162; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,177</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-163; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,177</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    cash equivalents</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,350</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,825</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-164; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">52,175</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable securities,
    current</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. treasury securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">190,792</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-165; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">190,792</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. government agency
    securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-166; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,966</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-167; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,966</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commercial papers</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-168; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">34,811</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-169; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">34,811</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Corporate
    debt securities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-170; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">75,504</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-171; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">75,504</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    marketable securities, current</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">314,073</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-172; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">314,073</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable securities,
    long-term</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. treasury securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,607</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-173; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,607</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">U.S.
    government agency securities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-174; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,462</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-175; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,462</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    marketable securities, long-term</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,069</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-176; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,069</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total cash equivalents
    and marketable securities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,350</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">377,967</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-177; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">384,317</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208167274288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_CashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash equivalents and Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Cash Equivalents and Marketable Securities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Cash
equivalents and marketable securities, which are classified as available-for-sale, consisted of the following as of December 31, 2024
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Amortized
    Cost</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Gross
    Unrealized Gains</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Gross
    Unrealized Losses</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Fair
    Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">Cash equivalents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Money market
    funds</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,350</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-178; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-179; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,350</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. treasury securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,656</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-180; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,660</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. government agency
    securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,988</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-181; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-182; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,988</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Commercial
    papers</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,180</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-183; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,177</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    cash equivalents</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">52,174</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">52,175</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable securities,
    current</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. treasury securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">190,748</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">55</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">190,792</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. government agency
    securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,967</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,966</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commercial papers</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">34,808</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-184; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">34,811</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Corporate
    debt securities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">75,537</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(40</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">75,504</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    marketable securities, current</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">314,060</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">66</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(53</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">314,073</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable securities,
    long-term</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. treasury securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,639</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-185; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(32</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,607</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">U.S.
    government agency securities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,485</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-186; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(23</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,462</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    marketable securities, long-term</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,124</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-187; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(55</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,069</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total cash equivalents
    and marketable securities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">384,358</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">70</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(111</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">384,317</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Available-for-Sale Securities in an Unrealized Loss Position</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the available-for-sale securities in an unrealized loss position, aggregated by major security type and length
of time in a continuous unrealized loss position, for which an allowance for credit losses was not recorded as of December&#160;31, 2024,
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>Less
    than 12 months</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>12
    months or longer</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>Fair
    <br/>
    Value</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Unrealized<br/>
    Losses</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Fair
    <br/>
    Value</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Unrealized<br/>
    Losses</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>Fair<br/>
    Value</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Unrealized<br/>
    Losses</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Cash equivalents</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commercial
    papers</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,199</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-188; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-189; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,199</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable
    securities</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable
    securities, current</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S.
    treasury securities</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">49,904</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-190; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-191; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">49,904</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S.
    government agency securities</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,713</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-192; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-193; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,713</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Corporate
    debt securities</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,468</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(40</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-194; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-195; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,468</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(40</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marketable
    securities, long-term</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S.
    treasury securities</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,607</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(32</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-196; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-197; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,607</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(32</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">U.S.
    government agency securities</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,462</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(23</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-198; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-199; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,462</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(23</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.5in; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">130,353</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(111</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-200; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-201; font-family: Times New Roman, Times, Serif">&#8212;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">130,353</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(111</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Marketable Securities at Estimated Fair Value</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the contractual maturities of the Company&#8217;s marketable securities at estimated fair value (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Due in one year or less</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">314,073</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Due in 1-2 years</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,069</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">332,142</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_CashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_CashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208263282384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Accrued
expenses and other current liabilities consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31, <br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued employee compensation and
    benefits</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,041</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued professional and consulting</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">221</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued research and
    development</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,084</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,346</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208160396960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ScheduleOfConvertiblePreferredStockTableTextBlock', window );">Schedule of Convertible Preferred Stock</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2024, convertible preferred stock consisted of the following (in thousands, except share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Preferred<br/>
                                            Stock<br/>
                                            Authorized</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Preferred<br/>
    Stock Issued <br/>
    and<br/>
    Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Carrying<br/>
    Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Common
    Stock<br/>
    Issuable<br/>
    Upon<br/>
    Conversion</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series B convertible preferred
    stock</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">251,504</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">137,138</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,931</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,428,149</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Schedule of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2024, the Company had common stock reserved for future issuance as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares issuable on conversion of
    Company Series B Preferred Stock</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,428,149</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Shares issuable upon exercise of pre-funded warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,202,207</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares issuable upon exercise of warrant under
    the Paruka Warrant Obligation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">596,930</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding and issued stock options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,567,760</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding and issued employee warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,054,358</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares available for grant under 2024 Stock
    Incentive Plan</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,246,324</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Shares available for
    grant under 2024 Employee Stock Purchase Plan</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">460,529</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 13.7pt"><span style="font-family: Times New Roman, Times, Serif">Total
    shares of common stock reserved</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,556,257</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ScheduleOfConvertiblePreferredStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ScheduleOfConvertiblePreferredStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FeaturesOfConvertiblePreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208263206560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the weighted-average assumptions used in calculating the fair value of the awards for the period from February&#160;6,
2024 (inception) to December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period from<br/> February 6,<br/> 2024<br/> (Inception) to<br/> December 31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (in years)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.1</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">100.21</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.26</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-206; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the weighted-average assumptions used in calculating the fair value of the warrants for the period from February&#160;6,
2024 (inception) to December 31, 2024:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period from<br/> February 6,<br/> 2024<br/> (Inception) to<br/> December 31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (in years)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.1</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">99.02</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.15</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-207; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the stock option activities under the 2024 Plan and 2024 Stock Plan for the period of February&#160;6, 2024
(inception) through December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number of<br/> Stock<br/> Options<br/> Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/> Average<br/> Exercise<br/> Price Per<br/> Share</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term <br/> (in Years)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Aggregate<br/> Intrinsic<br/> Value<br/> (in&#160;Thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Balance as of February 6, 2024 (inception)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-208; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-209; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-210; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-211; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; width: 52%"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,567,760</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11.39</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-212; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-213; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-214; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-215; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,567,760</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11.39</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.4</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,470</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Vested and expected to vest, December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,567,760</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11.39</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.4</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,470</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable, December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-216; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-217; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-218; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-219; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of RSA Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the RSA activity for the period from February&#160;6, 2024 (inception) through December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/>
    RSAs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/>
    Average<br/>
    Grant Date<br/>
    Fair Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Unvested balance as of February 6, 2024 (inception)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-220; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-221; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; padding-bottom: 1.5pt; padding-left: 13.7pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,207,553</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-222; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Unvested balance as of December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,207,553</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-223; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock', window );">Schedule of Employee Warrant Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the warrant activity for the period from February&#160;6, 2024 (inception) through December 31, 2024:&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/>
Employee<br/> Warrants<br/>
Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/> Average<br/> Exercise<br/> Price Per<br/> Share</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term <br/> (in Years)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Aggregate<br/> Intrinsic<br/> Value<br/> (in&#160;Thousands)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Balance as of February 6, 2024 (inception)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-224; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-225; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-226; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; width: 52%"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,054,358</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.80</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-227; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-228; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-229; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-230; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,054,358</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.80</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.5</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">35,400</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Vested and expected to vest, December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,054,358</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.80</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.5</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">35,400</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable, December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-231; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-232; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-233; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Company&#8217;s Stock-Based Compensation Expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the classification of the Company&#8217;s stock-based compensation expense in the consolidated statement of
operations and comprehensive loss (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from<br/>
    February 6,<br/>
    2024<br/>
    (Inception) to<br/>
    December 31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,992</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,927</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 13.7pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,919</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the award types of the Company&#8217;s stock-based compensation expense in the consolidated statement of operations
and comprehensive loss (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from<br/>
    February 6,<br/>
    2024<br/>
    (Inception) to <br/>
    December 31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paruka Warrant Obligation</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,357</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Employee warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,899</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,626</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Employee stock purchase
    plan</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">37</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,919</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of Share-Based Payment Arrangement, Warrant Activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208263311120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of Segment Loss from Operations</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">The
table below is a summary of the segment loss from operations, including significant segment expenses (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from<br/>
    February 6,<br/>
    2024<br/>
    (Inception) to December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development personnel-related
    (excluding stock-based compensation)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,959</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative personnel-related
    (excluding stock-based compensation)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,054</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development stock-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,992</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative stock-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,927</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">External research and development</span></td><td></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">57,680</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,429</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">General and administrative,
    excluding personnel-related and stock-based compensation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,082</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Total
    operating expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">88,123</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Loss
    from operations</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(88,123</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208161209856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Loss Before Income Tax Expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the loss before income tax expense by jurisdiction for the periods indicated:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from<br/>
    February 6,<br/>
    2024<br/>
    (Inception) to <br/>
    December 31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="font-family: Times New Roman, Times, Serif">Domestic</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">83,724</span></td><td style="width: 1%; text-align: left">)<span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Foreign</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-234; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Loss
    before income tax expense</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">83,724</span></td><td style="padding-bottom: 2.5pt; text-align: left">)<span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes</a></td>
<td class="text">The difference
between the Company&#8217;s provision for income taxes and the amounts computed by applying the statutory federal income tax rate to income
before income taxes is as follows:<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period from<br/> February 6,<br/> 2024 <br/> (Inception)&#160;to<br/> December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Tax benefit derived by applying the federal statutory rate to income before income taxes</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.00</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.18</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.41</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.87</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in the valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25.46</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Income tax (benefit) expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.00</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of the Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
components of the deferred tax assets and liabilities consist of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 9pt">Net operating loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,260</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,080</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,063</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Accruals and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">424</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Intangibles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,477</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Capitalized R&amp;D expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,994</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,501</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Right- of- use asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(184</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Total deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(184</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,317</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Deferred tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of Net Deferred Tax Assets</a></td>
<td class="text">he Company has established
a full federal and state valuation allowance equal to the net deferred tax assets due to uncertainties regarding the realization of the
deferred tax asset based on the Company&#8217;s lack of earnings history. The valuation allowance increased by $21.3&#160;million primarily
due to continuing loss from operations.<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Beginning balance as of February 6, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-236">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">21,317</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Ending balance as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">21,317</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">A
reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from<br/>
    February 6,<br/>
    2024<br/>
    (Inception) to<br/>
    December 31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Beginning balance as of February 6, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-237; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Changes
    related to tax positions taken in the current year</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,047</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Ending balance
    as of December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,047</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208267436416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitment and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Company&#8217;s Supplemental Cash Flow Information Related to Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table presents the Company&#8217;s supplemental cash flow information related to leases (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from<br/>
    February 6,<br/>
    2024<br/>
    (Inception) to<br/>
    December 31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash paid for amounts included
    in the measurement of lease liabilities</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">116</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Company&#8217;s Operating Lease Liabilities Showing the Aggregate Lease Payments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes a maturity analysis of the Company&#8217;s operating lease liabilities showing the aggregate lease payments
as of December 31, 2024 (in thousands):&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>Year
    ending December 31,</b></span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">369</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">494</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2027</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">380</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total undiscounted lease
    payments</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,243</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    imputed interest</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(275</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total discounted lease
    payments</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">968</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    current portion of lease liability</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(213</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.375in; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Non-current
    portion of lease liability</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">755</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208263423488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerUnitAbstract', window );"><strong>Net Loss per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Basic
and diluted net loss per share attributable to stockholders were calculated as follows (in thousands, except share and per share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period
    from February 6, 2024<br/>
    (Inception) to <br/>
    December 31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Loss<br/>
    Allocation</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted<br/>
    Average<br/>
    Shares<br/>
    Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Loss
    Per<br/>
    Share,<br/>
    Basic and<br/>
    Diluted</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common Stock</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(65,037</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,789,362</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3.87</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Company Series A Preferred Stock <sup>(1)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,918</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">495</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,873.25</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Company Series B Preferred
    Stock <sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(16,769</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,946</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(322.81</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(83,724</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The weighted-average number of shares of as-converted Company Series A Preferred Stock used in the loss allocation was 495,191 for the period from February 6, 2024 (inception) to December 31, 2024.</span></td></tr></table>

<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The weighted-average number of shares of as-converted Company Series B Preferred Stock used in the loss allocation was 4,328,844 for the period from February 6, 2024 (inception) to December 31, 2024.</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to stockholders for
the periods presented because including them would have had an anti-dilutive effect were as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31, <br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding employee warrants to
    purchase common stock</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,054,358</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding unvested restricted stock awards</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,207,553</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding and issued common stock options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,567,760</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding and issued
    warrant to Paruka</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">596,930</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 13.7pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,426,601</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerUnitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerUnitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208160360688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Related Party Accounts Payable and Other Current Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following is a summary of related party accounts payable and other current liabilities (in thousands):&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December
    31, <br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paragon reimbursable Option Agreements&#8217;
    fees</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,482</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paragon milestone payments for Option Agreement</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paragon reimbursable other research expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">515</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Paragon reimbursable
    patent expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,022</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208159014640">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 03, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 03, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 06, 2024 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_AdditionalPaidInCapitalTransacationCost', window );">Additional paid-in capital transaction costs (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_PreFundedWarrantsOfCommonStockShares', window );">Pre-funded warrants of common stock shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,522,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Warrants exchange | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,664,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (83,724)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash operating activities (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57,837)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Cash, cash equivalents, and marketable securities (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=orka_PrefundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Aggregate gross proceeds (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Net of issuance costs (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_CommonStocksConversionRatio', window );">Conversion ratio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">83:3332:1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (16,769)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_InvestorsClosingShares', window );">Investors shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,784,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Exchange shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,764,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,722,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_PrefundedWarrantstoPurchaseAnAggregateShares', window );">Prefunded warrants to purchase an aggregate shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">680,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non-Voting Convertible Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,918)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (65,037)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Series A Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Convertible shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_OrukaCommonStockMember', window );">Oruka Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1-for-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PreMergerOrukaMember', window );">Pre-Merger Oruka [Member] | Pre-funded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Aggregate gross proceeds (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Issuance of convertible note (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PreMergerOrukaMember', window );">Pre-Merger Oruka [Member] | Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Exchange shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,873,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_ARCACommonStockMember', window );">ARCA common stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ExchangeRatio', window );">Exchange ratio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.8569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_OrukaSeriesAConvertiblePreferredStockMember', window );">Oruka Series A Convertible Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non-Voting Convertible Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PIPEFinancingMember', window );">PIPE Financing [Member] | Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NumberOfSharesPurchased', window );">Aggregate of purchased shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PIPEFinancingMember', window );">PIPE Financing [Member] | Series A Non-Voting Convertible Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NumberofAggregateShares', window );">Aggregate shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PIPEFinancingMember', window );">PIPE Financing [Member] | Series A Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Exchange shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">The weighted-average number of shares of as-converted Company Series B Preferred Stock used in the loss allocation was 4,328,844 for the period from February 6, 2024 (inception) to December 31, 2024.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">The weighted-average number of shares of as-converted Company Series A Preferred Stock used in the loss allocation was 495,191 for the period from February 6, 2024 (inception) to December 31, 2024.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_AdditionalPaidInCapitalTransacationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional paid-in capital transacation cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_AdditionalPaidInCapitalTransacationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_CommonStocksConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of common stock conversion ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_CommonStocksConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_InvestorsClosingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investors closing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_InvestorsClosingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_NumberOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_NumberOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_NumberofAggregateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of aggregate shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_NumberofAggregateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_PreFundedWarrantsOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-funded warrants of common stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_PreFundedWarrantsOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_PrefundedWarrantstoPurchaseAnAggregateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of prefunded warrants to purchase an aggregate shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_PrefundedWarrantstoPurchaseAnAggregateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=orka_OrukaCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=orka_OrukaCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PreMergerOrukaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=orka_PreMergerOrukaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=orka_ARCACommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=orka_ARCACommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=orka_OrukaSeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=orka_OrukaSeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PIPEFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=orka_PIPEFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208159044832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalDepositInsuranceCorporationPremiumExpense', window );">Federal Deposit Insurance Corporation</a></td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalDepositInsuranceCorporationPremiumExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for Federal Deposit Insurance Corporation (FDIC) insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalDepositInsuranceCorporationPremiumExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208163873728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Furniture and fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Computer and office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Furniture and fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Computer and office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208263423488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Reverse Recapitalization and Pre-Closing Financing - Schedule of the Assets and Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Aug. 29, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Schedule of the Assets and Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208163761552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets Measured (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 52,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">314,073<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrentAbstract', window );"><strong>Marketable securities, long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, long-term</a></td>
<td class="nump">18,069<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_FairValueCashEquivalentsAndMarketableSecurities', window );">Cash equivalents and marketable securities</a></td>
<td class="nump">384,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">6,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrentAbstract', window );"><strong>Marketable securities, long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_FairValueCashEquivalentsAndMarketableSecurities', window );">Cash equivalents and marketable securities</a></td>
<td class="nump">6,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">45,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">314,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrentAbstract', window );"><strong>Marketable securities, long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, long-term</a></td>
<td class="nump">18,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_FairValueCashEquivalentsAndMarketableSecurities', window );">Cash equivalents and marketable securities</a></td>
<td class="nump">377,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrentAbstract', window );"><strong>Marketable securities, long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, long-term</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_FairValueCashEquivalentsAndMarketableSecurities', window );">Cash equivalents and marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">6,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">6,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">19,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">190,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrentAbstract', window );"><strong>Marketable securities, long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, long-term</a></td>
<td class="nump">13,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">19,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">190,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrentAbstract', window );"><strong>Marketable securities, long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, long-term</a></td>
<td class="nump">13,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrentAbstract', window );"><strong>Marketable securities, long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, long-term</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agency Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">3,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">12,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrentAbstract', window );"><strong>Marketable securities, long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, long-term</a></td>
<td class="nump">4,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agency Securities [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrentAbstract', window );"><strong>Marketable securities, long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, long-term</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agency Securities [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">3,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">12,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrentAbstract', window );"><strong>Marketable securities, long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, long-term</a></td>
<td class="nump">4,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agency Securities [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrentAbstract', window );"><strong>Marketable securities, long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, long-term</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Papers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">22,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">34,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Papers [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Papers [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">22,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">34,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Papers [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">75,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="nump">75,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Marketable securities, current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities, current</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_FairValueCashEquivalentsAndMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_FairValueCashEquivalentsAndMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208162798768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">$ 384,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="num">(111)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">384,317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">52,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">52,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member] | Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">6,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">6,350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member] | U.S. treasury securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">19,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">19,660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member] | U.S. government agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">3,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">3,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member] | Commercial papers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">22,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">22,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=orka_MarketableSecuritiesMember', window );">Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">314,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">314,073<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=orka_MarketableSecuritiesMember', window );">Marketable Securities [Member] | U.S. treasury securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">190,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">190,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=orka_MarketableSecuritiesMember', window );">Marketable Securities [Member] | U.S. government agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">12,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">12,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=orka_MarketableSecuritiesMember', window );">Marketable Securities [Member] | Commercial papers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">34,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">34,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=orka_MarketableSecuritiesMember', window );">Marketable Securities [Member] | Corporate debt securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">75,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">75,504<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=orka_MarketableSecuritiesLongTermMember', window );">Marketable Securities,Long-Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">18,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">18,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=orka_MarketableSecuritiesLongTermMember', window );">Marketable Securities,Long-Term [Member] | U.S. treasury securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">13,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">13,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=orka_MarketableSecuritiesLongTermMember', window );">Marketable Securities,Long-Term [Member] | U.S. government agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">4,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Cash Equivalents and Marketable Securities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses, Cash Equivalents and Marketable Securities</a></td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value, Cash Equivalents and Marketable Securities</a></td>
<td class="nump">$ 4,462<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=orka_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=orka_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=orka_MarketableSecuritiesLongTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=orka_MarketableSecuritiesLongTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208162464368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair Value</a></td>
<td class="nump">$ 130,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized Losses</a></td>
<td class="num">(111)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or longer, Fair Value</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or longer, Unrealized Losses</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">130,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">(111)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial papers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair Value</a></td>
<td class="nump">18,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or longer, Fair Value</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or longer, Unrealized Losses</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">18,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_MarketableSecuritiesAxis=orka_MarketableSecuritiesCurrentMember', window );">Marketable securities, current [Member] | U.S. treasury securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair Value</a></td>
<td class="nump">49,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized Losses</a></td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or longer, Fair Value</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or longer, Unrealized Losses</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">49,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_MarketableSecuritiesAxis=orka_MarketableSecuritiesCurrentMember', window );">Marketable securities, current [Member] | U.S. government agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair Value</a></td>
<td class="nump">4,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or longer, Fair Value</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or longer, Unrealized Losses</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">4,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_MarketableSecuritiesAxis=orka_MarketableSecuritiesCurrentMember', window );">Marketable securities, current [Member] | Corporate debt securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair Value</a></td>
<td class="nump">39,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized Losses</a></td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or longer, Fair Value</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or longer, Unrealized Losses</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">39,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_MarketableSecuritiesAxis=orka_MarketableSecuritiesNoncurrentMember', window );">Marketable securities, long-term [Member] | U.S. treasury securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair Value</a></td>
<td class="nump">13,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized Losses</a></td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or longer, Fair Value</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or longer, Unrealized Losses</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">13,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_MarketableSecuritiesAxis=orka_MarketableSecuritiesNoncurrentMember', window );">Marketable securities, long-term [Member] | U.S. government agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair Value</a></td>
<td class="nump">4,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized Losses</a></td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or longer, Fair Value</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or longer, Unrealized Losses</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">4,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="num">$ (23)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_MarketableSecuritiesAxis=orka_MarketableSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_MarketableSecuritiesAxis=orka_MarketableSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=orka_USGovernmentAgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=orka_USGovernmentAgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_MarketableSecuritiesAxis=orka_MarketableSecuritiesNoncurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_MarketableSecuritiesAxis=orka_MarketableSecuritiesNoncurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208162280704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash equivalents and Marketable Securities - Schedule of Marketable Securities at Estimated Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Schedule of Marketable Securities at Estimated Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Due in one year or less</a></td>
<td class="nump">$ 314,073<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Due in 1-2 years</a></td>
<td class="nump">18,069<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total</a></td>
<td class="nump">$ 332,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208277256880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Schedule of Accrued Expenses and Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued employee compensation and benefits</a></td>
<td class="nump">$ 2,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional and consulting</a></td>
<td class="nump">221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_AccruedResearchAndDevelopment', window );">Accrued research and development</a></td>
<td class="nump">1,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total</a></td>
<td class="nump">$ 3,346<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208161308448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note Payable with Related Party (Details) - Convertible Note [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Note Payable with Related Party [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_PreMergerOrukaMember', window );">Pre-Merger Oruka [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Note Payable with Related Party [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Initial principal amount</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate, percentage</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Unpaid accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_PreMergerOrukaMember', window );">Pre-Merger Oruka [Member] | Fairmount Healthcare Fund II, L.P. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Note Payable with Related Party [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Initial principal amount</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Aggregate proceeds</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Note Payable with Related Party [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,722,207<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=orka_ConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=orka_ConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=orka_PreMergerOrukaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=orka_PreMergerOrukaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=orka_FairmountHealthcareFundIILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=orka_FairmountHealthcareFundIILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208161853232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,440,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,197,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,440,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,197,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=orka_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="nump">680,000<span></span>
</td>
<td class="nump">5,522,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,522,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,202,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="nump">$ 22.999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ClassOfWarrantOrRightExpirationDate', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ClassOfWarrantOrRightWarrantsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember', window );">Employee Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,054,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Employee warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,054,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantMember', window );">Paruka Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_WarrantsToPurchaseCommonStock', window );">Warrant purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ClassOfWarrantsExercisable', window );">Warrants exercisable</a></td>
<td class="nump">680,000<span></span>
</td>
<td class="nump">5,522,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,440,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,440,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,207,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,207,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Converted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Converted shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Fairmount [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Converted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_CommonStockConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">83.3332:1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PreMergerOrukaMember', window );">Pre-Merger Oruka [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,873,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PreMergerOrukaMember', window );">Pre-Merger Oruka [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PreMergerOrukaMember', window );">Pre-Merger Oruka [Member] | Series A Preferred Stock [Member] | Fairmount [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PIPEFinancingMember', window );">PIPE Financing [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="nump">2,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Converted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ClassOfWarrantOrRightExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The class of warrant or right expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ClassOfWarrantOrRightExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ClassOfWarrantOrRightWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The class of Warrant or Right warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ClassOfWarrantOrRightWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ClassOfWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the number of warrants exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ClassOfWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_CommonStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of common stock conversion ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_CommonStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_WarrantsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The shares issued of warrants to purchase common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_WarrantsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=orka_FairmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=orka_FairmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PreMergerOrukaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=orka_PreMergerOrukaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PIPEFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=orka_PIPEFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208160276224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity - Schedule of Convertible Preferred Stock (Details) - Series B Convertible Preferred Stock [Member]<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems', window );"><strong>Schedule of Convertible Preferred Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock Authorized</a></td>
<td class="nump">251,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock Issued</a></td>
<td class="nump">137,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock Outstanding</a></td>
<td class="nump">137,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Carrying Value (in Dollars) | $</a></td>
<td class="nump">$ 2,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock Issuable Upon Conversion</a></td>
<td class="nump">11,428,149<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208154986432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity - Schedule of Common Stock Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 29, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="nump">27,556,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Outstanding and Issued Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="nump">1,567,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=orka_PrefundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="nump">6,202,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantObligationMember', window );">Paruka Warrant Obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="nump">596,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember', window );">Employee Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="nump">3,054,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBConvertiblePreferredStockMember', window );">Shares issuable on conversion of Company Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="nump">11,428,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember', window );">2024 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="nump">4,246,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember', window );">2024 Stock Incentive Plan [Member] | Outstanding and Issued Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="nump">388,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember', window );">2024 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="nump">460,529<span></span>
</td>
<td class="nump">463,489<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208165651136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 22, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,556,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,440,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,197,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,919,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_EstimatedFairValueOfWarrantsToBeGranted', window );">Estimated fair value of warrants to be granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,567,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember', window );">2024 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,246,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares', window );">Annual increase in shares available for issuance as a percentage of outstanding diluted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">RSA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,207,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">RSAs issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,207,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">RSAs price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantObligationMember', window );">Paruka Warrant Obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum', window );">Warrant To Purchase Number Of Shares As A Percentage Of Outstanding Diluted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember', window );">Employee Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,054,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ClassOfWarrantOrRight', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,054,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember', window );">2024 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,634,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,246,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember', window );">2024 Stock Incentive Plan [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember', window );">2024 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="nump">463,489<span></span>
</td>
<td class="nump">460,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares', window );">Annual increase in shares available for issuance as a percentage of outstanding diluted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock expressed as a percentage of its fair value</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum contribution of employee's eligible compensation</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP', window );">Total amount of annual salary that an employee is permitted to utilize to purchase company shares under ESPP</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ClassOfWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ClassOfWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>class of warrant or right to purchase percentage of outstanding diluted stock maximum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the amount of cash contributions during the period made by the entity to the Employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_EstimatedFairValueOfWarrantsToBeGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of warrants to be granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_EstimatedFairValueOfWarrantsToBeGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement diluted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208160387008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards (Details)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">100.21%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.26%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember', window );">Employee Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">99.02%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208162773408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 06, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Stock Options Outstanding, Ending Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,567,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Ending Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 11.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in Years), Ending Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">9 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 15,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Stock Options Outstanding, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,567,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Vested and expected to vest, September 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in Years), Vested and expected to vest, September 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Stock Options Outstanding, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Exercisable,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in Years), Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,567,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock Options, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Stock Options, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208161171648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of RSA Activity (Details) - Restricted Stock Award [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of RSA Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance (in Shares)</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Unvested balance, Beginning</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Unvested balance, Number of Granted</a></td>
<td class="nump">2,207,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in Shares)</a></td>
<td class="nump">2,207,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Unvested balance, Ending</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208162339760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Employee Warrant Activity (Details) - Employee Warrants [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Employee Warrant Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance (in Shares)</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance (in Shares)</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value, Beginning Balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in Shares)</a></td>
<td class="nump">3,054,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance (in Shares)</a></td>
<td class="nump">$ 7.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm', window );">Ending Balance (in Shares)</a></td>
<td class="text">9 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
<td class="nump">$ 35,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber', window );">Number of Employee Warrants Outstanding, Vested and expected to vest</a></td>
<td class="nump">3,054,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Vested and expected to vest</a></td>
<td class="nump">$ 7.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term, Vested and expected to vest</a></td>
<td class="text">9 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">$ 35,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding', window );">Number of Employee Warrants Outstanding, Vested and exercisable</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Vested and exercisable</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable', window );">Aggregate Intrinsic Value, Vested and exercisable</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Granted</a></td>
<td class="nump">3,054,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice', window );">Weighted Average,Granted</a></td>
<td class="nump">$ 7.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised', window );">Number of Employee Warrants Outstanding, Exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised', window );">Weighted Average Exercise Price Per Share, Exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Employee Warrants Outstanding, Forfeited</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Forfeited</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Warrants, Exercised (in Shares).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the grant date of equity-based award plans other than stock (unit) option plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards Vested and expected to vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for aggregate Intrinsic Value, Vested and expected to vest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards Vested and expected to vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that Vested and expected to vest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of employee warrants outstanding, vested and exercisable shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-Average Exercise Price Per Share, Vested and Exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of Vested and exercisable award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208160092320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Company&#8217;s Stock-Based Compensation Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Schedule of Company&#8217;s Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 14,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Schedule of Company&#8217;s Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">11,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Schedule of Company&#8217;s Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,927<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208161046000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems', window );"><strong>Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 14,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=orka_ParukaWarrantObligationMember', window );">Paruka warrant obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems', window );"><strong>Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">10,357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=orka_EmployeeWarrantsMember', window );">Employee warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems', window );"><strong>Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">2,899<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_StockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems', window );"><strong>Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=orka_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems', window );"><strong>Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=orka_ParukaWarrantObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=orka_ParukaWarrantObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=orka_EmployeeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=orka_EmployeeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=orka_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=orka_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208263095952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Disclosures (Details)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Reporting segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208163022736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Disclosures - Schedule of Segment Loss from Operations (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">11 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Schedule of Segment Loss from Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development personnel-related expense (excluding stock-based compensation)</a></td>
<td class="nump">$ 75,060<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative personnel-related expense (excluding stock-based compensation)</a></td>
<td class="nump">13,063<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">88,123<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(88,123)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=orka_OperatingExpenseExcludingStockBasedCompensationMember', window );">Operating Expense Excluding Personnel Related And Stock Based Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Schedule of Segment Loss from Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development personnel-related expense (excluding stock-based compensation)</a></td>
<td class="nump">3,959<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative personnel-related expense (excluding stock-based compensation)</a></td>
<td class="nump">5,054<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development stock-based compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Schedule of Segment Loss from Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development personnel-related expense (excluding stock-based compensation)</a></td>
<td class="nump">11,992<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative stock-based compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Schedule of Segment Loss from Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development personnel-related expense (excluding stock-based compensation)</a></td>
<td class="nump">2,927<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=orka_ExternalMember', window );">External [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Schedule of Segment Loss from Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development personnel-related expense (excluding stock-based compensation)</a></td>
<td class="nump">57,680<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=orka_OtherMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Schedule of Segment Loss from Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development personnel-related expense (excluding stock-based compensation)</a></td>
<td class="nump">1,429<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember', window );">Operating Expense Excluding Personnel Related And Stock Based Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Schedule of Segment Loss from Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative personnel-related expense (excluding stock-based compensation)</a></td>
<td class="nump">$ 5,082<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">Includes related party amount of $42,640 for the period from February 6, 2024 (inception) to December 31, 2024</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">Includes related party amount of $1,364 for the period from February 6, 2024 (inception) to December 31, 2024</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=orka_OperatingExpenseExcludingStockBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=orka_OperatingExpenseExcludingStockBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=orka_ExternalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=orka_ExternalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=orka_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=orka_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208165672480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Change in valuation allowance due to continuing loss from operations</a></td>
<td class="nump">21,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 10,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome', window );">Operating loss carryforwards as a percentage of taxable income</a></td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 3,080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Tax credit carryforwards</a></td>
<td class="nump">3,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IncomeTaxesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IncomeTaxesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards that can be utilized in any tax year as a percentage of taxable income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible loss carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208160274160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Loss Before Income Tax Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract', window );"><strong>Schedule of Loss Before Income Tax Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (83,724)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">$ (83,724)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208160487744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax benefit derived by applying the federal statutory rate to income before income taxes</a></td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Permanent differences</a></td>
<td class="num">(0.18%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="num">(3.41%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="num">(0.87%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in the valuation allowance</a></td>
<td class="nump">25.46%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax (benefit) expense</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208163426800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of the Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 05, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 2,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">3,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">3,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Accruals and other</a></td>
<td class="nump">424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_DeferredTaxAssetsLeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">1,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized R&amp;D expenses</a></td>
<td class="nump">10,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">21,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right- of- use asset</a></td>
<td class="num">(184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(21,317)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208160839616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Net Deferred Tax Assets (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Schedule of Net Deferred Tax Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Beginning balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">21,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Ending balance</a></td>
<td class="nump">$ 21,317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208163425968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Schedule of Unrecognized Tax Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Changes related to tax positions taken in the current year</a></td>
<td class="nump">1,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 1,047<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208165612000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Option Agreements and License Agreements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Expenses</a></td>
<td class="nump">$ 42.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_RegulatoryMilestonesMemberMember', window );">Regulatory Milestones Member [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NonRefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantObligationMember', window );">Paruka Warrant Obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum', window );">Warrant purchase percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=orka_ParagonMember', window );">Paragon [Member] | Clinical Development Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NonRefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=orka_ParagonMember', window );">Paragon [Member] | Regulatory Milestones Member [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NonRefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=orka_ParagonMember', window );">Paragon [Member] | Antibody Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_RoyaltyPayableOnProductSales', window );">Royalty payable on product sales, description</a></td>
<td class="text">low single-digit percentage royalty for antibody products<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_NominationOfADevelopmentCandidateMember', window );">Nomination Of A Development Candidate [Member] | Paragon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NonRefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneLicenseAgreementMember', window );">ORKA-001 License Agreement [Member] | Paragon [Member] | Clinical Development Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NonRefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="nump">12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoLicenseAgreementMember', window );">ORKA-002 License Agreement [Member] | Paragon [Member] | Clinical Development Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NonRefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneMember', window );">ORKA-001 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_DevelopmentCostsPercentage', window );">Development costs, percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 13.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneMember', window );">ORKA-001 [Member] | Paragon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Initiation fee</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneMember', window );">ORKA-001 [Member] | Paragon [Member] | First Dosing of Human Patient in Phase1Trial Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NonRefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneMember', window );">ORKA-001 [Member] | Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Accounts payable and other current liabilities</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneMember', window );">ORKA-001 [Member] | Research and Development Expense [Member] | Paragon [Member] | First Dosing of Human Patient in Phase1Trial Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_MilestoneConsiderationPaid', window );">Milestone consideration paid</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneMember', window );">ORKA-001 [Member] | Research and Development Expense [Member] | Paragon [Member] | Achievement Of Development Candidate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_MilestoneConsiderationPaid', window );">Milestone consideration paid</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoMember', window );">ORKA-002 [Member] | Paruka Warrant Obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum', window );">Warrant purchase percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoMember', window );">ORKA-002 [Member] | Paragon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_OtherDevelopmentCost', window );">Development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ResearchInitialFee', window );">Research initial fees</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoMember', window );">ORKA-002 [Member] | Paragon [Member] | First Dosing of Human Patient in Phase1Trial Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NonRefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoMember', window );">ORKA-002 [Member] | Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Accounts payable and other current liabilities</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoMember', window );">ORKA-002 [Member] | Research and Development Expense [Member] | Paragon [Member] | Achievement Of Development Candidate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_MilestoneConsiderationPaid', window );">Milestone consideration paid</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>class of warrant or right to purchase percentage of outstanding diluted stock maximum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_DevelopmentCostsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_DevelopmentCostsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_MilestoneConsiderationPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The milestone consideration paid amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_MilestoneConsiderationPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_NonRefundableMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-refundable milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_NonRefundableMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_OtherDevelopmentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_OtherDevelopmentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ResearchInitialFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of research initial fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ResearchInitialFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_RoyaltyPayableOnProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty payable on product sales, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_RoyaltyPayableOnProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_RegulatoryMilestonesMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_RegulatoryMilestonesMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=orka_ParagonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=orka_ParagonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_ClinicalDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_ClinicalDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_AntibodyProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_AntibodyProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_NominationOfADevelopmentCandidateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_NominationOfADevelopmentCandidateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_AchievementOfDevelopmentCandidateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_AchievementOfDevelopmentCandidateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208165467408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 15, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitment and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 876,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">213,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, noncurrent</a></td>
<td class="nump">$ 755,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lease discount rate</a></td>
<td class="nump">17.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseVariableLeaseIncome', window );">Variable lease expense</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NonRefundableLicenseFee', window );">Non-refundable license fee</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitment and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">39 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining lease term</a></td>
<td class="text">33 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_NonRefundableLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of non refundable license fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_NonRefundableLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseVariableLeaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from variable lease payments paid and payable to lessor, excluding amount included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-6A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseVariableLeaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208163546304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Schedule of Company&#8217;s Supplemental Cash Flow Information Related to Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Schedule of Company&#8217;s Supplemental Cash Flow Information Related to Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 116<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208161307744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Schedule of Company&#8217;s Operating Lease Liabilities Showing the Aggregate Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Schedule of Company&#8217;s Operating Lease Liabilities Showing the Aggregate Lease Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">1,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(275)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total discounted lease payments</a></td>
<td class="nump">968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion of lease liability</a></td>
<td class="num">(213)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of lease liability</a></td>
<td class="nump">$ 755<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208160444016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Net Loss per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable', window );">Weighted-average number of shares of as-converted</a></td>
<td class="nump">495,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Net Loss per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable', window );">Weighted-average number of shares of as-converted</a></td>
<td class="nump">4,328,844<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares) are considered outstanding common shares and included in the computation of basic Earnings Per Share as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent). Outstanding common shares that are contingently returnable (that is, subject to recall) are treated in the same manner as contingently issuable shares. Contingently issuable shares include shares that (a) will be issued in the future upon the satisfaction of specified conditions, (b) have been placed in escrow and all or part must be returned if specified conditions are not met, or (c) have been issued but the holder must return all or part if specified conditions are not met. The number of contingently issuable shares is determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208161956688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">11 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss | $</a></td>
<td class="num">$ (83,724)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding &#8211; Basic | shares</a></td>
<td class="nump">16,789,362<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding &#8211; Diluted | shares</a></td>
<td class="nump">16,789,362<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share &#8211; Basic | $ / shares</a></td>
<td class="num">$ (3.87)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per share &#8211; Diluted | $ / shares</a></td>
<td class="num">$ (3.87)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss | $</a></td>
<td class="num">$ (1,918)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding &#8211; Basic | shares</a></td>
<td class="nump">495<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding &#8211; Diluted | shares</a></td>
<td class="nump">495<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share &#8211; Basic | $ / shares</a></td>
<td class="num">$ (3,873.25)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per share &#8211; Diluted | $ / shares</a></td>
<td class="num">$ (3,873.25)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss | $</a></td>
<td class="num">$ (16,769)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding &#8211; Basic | shares</a></td>
<td class="nump">51,946<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding &#8211; Diluted | shares</a></td>
<td class="nump">51,946<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share &#8211; Basic | $ / shares</a></td>
<td class="num">$ (322.81)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per share &#8211; Diluted | $ / shares</a></td>
<td class="num">$ (322.81)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss | $</a></td>
<td class="num">$ (65,037)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding &#8211; Basic | shares</a></td>
<td class="nump">16,789,362<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding &#8211; Diluted | shares</a></td>
<td class="nump">16,789,362<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share &#8211; Basic | $ / shares</a></td>
<td class="num">$ (3.87)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per share &#8211; Diluted | $ / shares</a></td>
<td class="num">$ (3.87)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">The weighted-average number of shares of as-converted Company Series A Preferred Stock used in the loss allocation was 495,191 for the period from February 6, 2024 (inception) to December 31, 2024.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif">The weighted-average number of shares of as-converted Company Series B Preferred Stock used in the loss allocation was 4,328,844 for the period from February 6, 2024 (inception) to December 31, 2024.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208161367520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share (Details)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">7,426,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_EmployeeWarrantsMember', window );">Employee Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">3,054,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_RestrictedStockAwardsMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">2,207,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_StockOptionsMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">1,567,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_ParukaWarrantMember', window );">Paruka Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">596,930<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_EmployeeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_EmployeeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_ParukaWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_ParukaWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208162341440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=orka_FairmountsOwnershipInterestInParagonMember', window );">Fairmount's Ownership Interest in Paragon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage</a></td>
<td class="text">beneficially
owns more than 5%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Paragon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage</a></td>
<td class="text">beneficially own less than 5%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Paruka [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage</a></td>
<td class="text">beneficially own less than 5%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Fairmount [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage</a></td>
<td class="text">beneficially
owns more than 5%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of minority interest ownership percentage by noncontrolling owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=orka_FairmountsOwnershipInterestInParagonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=orka_FairmountsOwnershipInterestInParagonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=orka_ParagonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=orka_ParagonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=orka_ParukaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=orka_ParukaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=orka_FairmountHealthcareFundIILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=orka_FairmountHealthcareFundIILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208163107824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions - Schedule of Related Party Accounts Payable and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonReimbursableOptionAgreementsFeesMember', window );">Paragon reimbursable Option Agreements&#8217; fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Related party accounts payable and other current liabilities</a></td>
<td class="nump">$ 1,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonMilestonePaymentsForOptionAgreementMember', window );">Paragon milestone payments for Option Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Related party accounts payable and other current liabilities</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonReimbursableOtherResearchExpensesMember', window );">Paragon reimbursable other research expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Related party accounts payable and other current liabilities</a></td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonReimbursablePatentExpensesMember', window );">Paragon reimbursable patent expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Related party accounts payable and other current liabilities</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Related party accounts payable and other current liabilities</a></td>
<td class="nump">$ 6,022<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonReimbursableOptionAgreementsFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonReimbursableOptionAgreementsFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonMilestonePaymentsForOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonMilestonePaymentsForOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonReimbursableOtherResearchExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonReimbursableOtherResearchExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonReimbursablePatentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonReimbursablePatentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46208356615344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event [Member]<br> $ in Millions</strong></div></th>
<th class="th">
<div>Feb. 28, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease initial period</a></td>
<td class="text">54 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future lease payment</a></td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>116
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M8/#;+N9[4V_6H&@7.S+PT[)_TRZ+(6+)XU!2'IOZ.FUW8NJVNFIM]_P!GY5
MLQ.>I*0)ER^9!^EM:JO$@G1 0HU+>]9F\5"#Q-K@^230K6*J:V7Y6Y$0&2:/
M(*)*8@"NM<20K8>INCGN2X75.M34]QI0]J8[4-64 K139<LZ8<GP]+(H3-51
MQLUMU]Y<!Y(J_$-KQ"T6MZ7WJ+VJ9YX+FTO%4.[(LH95N(;X5=HD"LDRC+)E
M;10HL$,4/JY0^K)V"%U%=F@/[;=!P%*E2<"6O!R+@= 0S<>M-6]OJ(-35=$<
MVL.Y8N IM8;"VIP:"=OA&2O$)N';Q< A817KH3W8-[>U/<Z+583!=IA'L+47
M]!SF817GX3F!_M0,&>(X=ML[F[7)#C25*H!V66"9HMK&;41KJP-_TE3^]M8[
M@%7J -KE03Y-IZ;'H JP/YLV*7H6!J@2!L@N#!8LCD.IA4V^/00LT9-%DT 1
M@0]?F:0 XH_& ^G;XWYQ&.U90*!*0"!H#6T/D@5/&Q:M*!?O_Y@BZ%]E2D^^
MF(_@'?2!Y0S>D[5#]EK&P2XY],RK8Y[00^" =^Z%Z\+,!8K++>% '<Q3K0\!
M6X-/ZCP8+U7LV&=-LL*?Z9*GA+^ (A?BJ'.CV-(L%1:]7(')>.*XKJO_LO)>
M=2LVA.N@E,H-X^&_=.4 [#OCL>M,8%X8.W#F.S-_LB\;"J$#6A;'4BFDNM [
M2_<.&F?9H+7\QH*UCVT'EZW4&+)G3VY7JU"?S]7>H\^YPS ! =F&:B\RLN"V
MZO6P"YL;D*'<$=V(*@F%3DJH-$ZC+(]7J X6J^'8Z)3K3D4")HQ[)FK+JN&X
M>0BWM]UA BI5A4ZJJA)K1==A$!JC%VI+I^$4^SI;> C2LWA"E7A"=O&4!S!Q
M= LT4K6E$YZB=H[$4.Z8/U6Z"+U&%]4"KJ.CU4X=T4.==%##LZ9*3*QRI&SQ
MGPEG2)V8#EF&<L?@*IF$[#+I&\T]ZI[P(YWK('0LL:<G:X>TE79"LUZ.E*B#
M+K) ]V3M,.M=22ULEUK[*=Z2+*G4.&">?SC#[>2,YZ+F\=/>J?/W%UR)*VS/
MSCQ0KC7D+5C45NE]N4HS[67DZE5E]67M<! JE85?]V#GE*?C7A_O]&7M$+KV
M@.?$$Y[CV[*3:TKC$+S]*4Y!W_/C(%Q)'FR7/*7+?U5'VY\L._:>Z_T=A(W%
M$7JR=C@>E5;"DWZ\OX,(LD#W9.T0NM)5V*ZK.GK_V_--!7W/B2M<"31L%VB%
M]]^]Q?L[Y*DLCM"3M</QJ#0=GO:97<"]*KR^K!VR5PH/V[-CI2_H)-\N]P6+
M6G=:68<K@";0F;CY*3YA[73!F_(2$/L.Q-.&\?\EOU",7/V=!C3#S1.4?7S/
M6,:CVJLX^CVH+X0_AHD $5TKR^Z%KW9+GK]:E-](MLW>SEDR*5F<76XH44ZL
M"ZC?UXS)_8U^X:=\P6O^'U!+ P04    "  ]@&9:@S1*JLD#  "1%   &
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M0D@$$F)HQR(J-X'>\KG,F?R._&HS%#B&?&VVA?9-(<YYR-,YU*G>+?UQ.GQ
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M&X@S!^(L@#@.$,?MP&G7_X\7JB+]T5[ZH_^B](\-#*-F!ZKE_VJAH"ST&:$
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MB]6>+JB CW;T4$8P%,B" MFXZ06+9QOQ1*_;9EVR5/3TH'8P*,T%I2VA:-5
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MH1?P?%F!"_H/M$#\?=.'_P)02P,$%     @ /8!F6OGH2EM@)0  .7@  !D
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M@Q34>JZNRZ+ECP%_8/# W'Y"K03N3D,F5N.2&P_"1@$)J<5*WV>MQ$#NX0&
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M&HFQUV2N:KX3C\$/Z4"*'D P-FV%JAU> G_. )B-:!);_3JJ6ZK:2N0@I#"
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M,.(5)N9#='--&4BQ42+7JQ;]-F9GM+0UYGJ"LYB&"QXT,%A;=!E6XLPS8V-
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MC^J^@T@%<W:U6\&K9Z=?/W_ 0]OZ!P@+_3@L:+.AW=(_-\Z"3X@/P/>K%LR
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MG GQ!>CGJ,",06O<SM-VE+EQM$A2,%/[B/P"/W7\G@F4I.Z$BLPU2$7]AHE
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M;S@W:H@2CJ&,43'%3DTI.WBFIAN>QWRABG=2:LQ1)9<A-Q82W!J? &^A/,N
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M(OF4#X?A: ::]E"UOPN":2$IY>T_ZS*X)V?/2;-PC->38'PQX+^#Q;$#LR,
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M,3FQWS+Z'Z5>TS?T<UV6.J/+E120"W$!/%]H7?H?>$#]GRJN_@M02P,$%
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M_'")[S@P9(#KN=:N_:  W<MP_B]02P,$%     @ /8!F6KVTJR_$!P  ?!,
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M)=SXGJ^W0.S8;X6M+7 PI]TQ 8,XG$Z9S!RN+8K#K@,[QP+=4FOGG0.=G)3
MO/&3QAVTD5+:U@G71.^I!Q;L.G'=(/HX.P$U%>02&2 FP_(/LP>>-@3 C+0^
MQ1$4^!E^N.P'3$E2Z[;S&>)YIE:ET&8I*TIE[@@?!^,1XF5)_..<\253<)I[
M#*XKK18'6,<LNUXVPTH+<M/O/8Y.;-2GRX#HDH"&#@(%V''VT-R^)K,8NGB^
M1N.$;:WJQ7(WOZ!/-9Y9:FYVR2W$',<9X_J=] -3+FAB:N+(:EMKX4HW>,E]
M;4\CEO4)X%G36BWG&+M(79VG=.( !XN)]43*7>$<S]?'])\(5C9P-">UHZ+)
M/P]3 &<P4.E-]6Z!U68LQYU.N" DUGT6T>M*$0 2)]@=<I<)6U&/V'5 TVR9
MP$J_2\"/EFG):^'YT0^=M&6A*0_KLC<*V\U4^&)ZW)EL^A/_WZ9T \]SND&X
M-@GCE4+ZN]RW_!&3=1,I$E_3V;N#B(;A]"7=!Z_3O=ONRK5%'AR7UREPQ.C"
M<]=Q"2 T7T$9T(V)/=^VYW?3U)H;',GN[@5F2+M*N&,,ISY[O>5?\'JWP6V$
MTY F>@Z!N3>N]KSJIH9M[$9;T;H\0W)G2 _'B=)EE8.R?YT02*:RRZWOQ',I
M>R""-!W;;ET'-\S>7X;U.S\6@$Z"MTAOV+OC.);<4%7#YUK05R7BI)>WJ*9P
M/ ?MNWZ/>U]$"J$7[KN/J]/2^H\CW6KW:>G:?U'9;/??I7[A&NF-(4ID$ U'
MIQ\&3/MO/?[!JLI]7YDK:U7A?BX%!V*T >\SA5IN'LA ]\'MZO]02P,$%
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ML<N='ZHW]Y^I2ME(I;1VI$:Z8D>E*SN"42&EC_1&%IMHQ\;*V5/.4GL"RP[
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M.6EP3 A2K7L:SO=6^J"<L@G(0$-ZG!>H]=[GS:*'XA7W!#Z*,')DA2P%O@F
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M,DXZ0CPUW@\@MM &^4A;P54!Q$7)"BBI#;W;#6W'8<LR:5-=ERXA6<O62 M
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M#)=7_4SU*-Y/IN^YWE;(6$*!JN%H.O&9[J>]?F-5ZR:LC;(XK[EEB0,R:!+
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ME$HHT$X8S2S4F_@VN]DM23X(_"9@[T[6C#PIC'FFS<_5)DZ)$$@H/2%P_+W
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M*349?!Y'8-H.T"Z<KH/KEMJ1A\.THJ:)Q@?0>:FUVR]\@;X-S_\ 4$L#!!0
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M_WE __.C./LY&@M78=<IU-]U&1.7R84J08\A-V6@S%#!PS>^NKO%%C51,,\
M8QO7DF+86E2_F6UF1N"=%DJ'#:A%!6X#R G$!'QR;7V%CYT IY]T0#ABRJD3
MG")KQ@0]U$ <E?\#;,H5&(3BK+,2%L>4UR;: Q)C202J=M@,[!BR!T>DZ=88
M,[QVM,)I\:YIS<2AQC3ER6&+)Z&W"]+\(#=GF7VV]"TJ&SP?'O%F[6AWS[(6
MO4W4!:ZJ9D7#'P/\P P (^0+RFHP FLR/-3!O/' ]>19DK(H]7V6U7S('3P
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M)!KK2/G"(=V(1>:8^,DAFLH,$NO,0GBXNJE/#D$L"@]XR_P)93 #2Y<>3FY
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MM@3P<BD0.)4"6;8LI59>F2$M?A-!%$^*S)>6O'/#EP.VU(2SP!FU)(-ZAM!
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M)#*!)J&1*6CC3PE9G5""HWO]JI;8W6*7&\%CL_4H$F);X\7QGL/W+ M^Q7+
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MTN!V<&:!ZQB4#<#[E92F/5B";L&G?P%02P,$%     @ /8!F6I"*L)2@ P
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M!X1VP/D-Y^IHZ 7Z%]3J/U!+ P04    "  ]@&9:[\7V57D%  "W#P  &0
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M90/2',#]0@A]F!@'P[?2_#]02P,$%     @ /8!F6A)3#J%#!0  ^!(  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S8N>&ULS5C=4^,V$'_W7Z')M3?'C$EL
MY],<9"9P<.W#]1@^'SI]4.Q-K$&V7$E.2/_ZKF3'! ANH*7M2R)+VMW?:G]:
MK72X%/).)0":W*<\4T>M1.O\H--140(I56V10X8C,R%3JO%3SCLJET!C*Y3R
M3N!Y@TY*6=8:']J^<SD^%(7F+(-S2521IE2NCH&+Y5'+;ZT[+M@\T::C,S[,
MZ1PN05_GYQ*_.K66F*60*28R(F%VU)KX!\>AF6\GW#!8JHTV,9Y,A;@S'S_'
M1RW/  (.D38:*/XMX 0X-XH0QN^5SE9MT@ANMM?:SZSOZ,N4*C@1_);%.CEJ
MC5HDAADMN+X0RY^@\J=O]$6"*_M+EM5<KT6B0FF15L*((&59^4_OJW7812"H
M! *+NS1D47ZAFHX/I5@2:6:C-M.PKEII!,<R$Y1++7&4H9P>7VH1W>T?HU\Q
M.1$IQEI1NUR?KNB4@]H[[&@T8R9WHDKE<:DR>$&E[Y-O(M.)(J=9#/%C!1W$
M5X,,UB"/@T:-7R!JDZ[ODL +>@WZNK737:NO^UJG?YU,E9;(E-^VN5TJ[6U7
M:G;/@<II!$<MW!X*Y ):XX\?_('WN0%RKX;<:](^OL3=&!<<B)B16TLUB/<G
M"Y"X<\A$X9[*C0>*7!NG6$9.*(\*CFYE<Z(3(&>427)#>6%5F)[)DLI8;7.T
M$<IV1Z\2<&:"XQZW!@UWJHW._@!E[2W7L&D%FV[ +BK8T1/8,P-[L0F;6M@$
M\Y']S$$R$9.9%"DY@ZDL,+60@>L8JI!/+(O 6M@C6A#D$:13D#67#LCYAOCI
M?8ZY G%HD*F1)2N@4NV10=M_&%P( X\SO2*^Y[4#G_Q(+IBZVY]) '0!A4%I
M(JD&TFL' QRN96.V8#%D,5DQX#'Y^&$4^,%G\N\M'JZ=I)G^?RQ?&+:]H''U
M_/X.J]>PN_KU[NKOO+ML<B#?K=MD8@X-Q+IMES2J?/,N4=:\R!_.+*89CA68
M2\N0V="<<XK#N!;VJ\1L^YX$%AW:"*N=[3P*:R)%,4^VQ?:7PG9L))R'QF0^
MES W03JF:#4R?-QFZQ&%U@'[H6X][_EJZ(D&?+<_&+K#@8=COM_NAD@#D!$S
M3'\NA0?T#)C>.O88X#,_MU@*VSW3[KN]H4=ND(ZHURPUU 079('=[NNU54Z8
MP&^3WF6%&N@^J.D^V)GN%Y>31I8W:GHSRXW5BMRKO\I%SXGT,FF=DK3.!FF=
MZVQ1QG#Z-ZCJK(D9N($W=/O][L;8"Q:>QW>+<%,\AW4\ASO'\S3-N5AA+KTM
M4WUC<!O5OOV@KRR_1X#_VZS4=;U^S^WV1S@V;(^\=TM*SPR%[3XVNYA%O%?G
MI&9E[YN21C6%1SM3V)3D-%M9[<//BKQ8KIO*(%.PC=F-UM[,[(ACV<5F+"KM
M5T754[SV"-^?6KS1)EXH\9I2S6K#VDUP%E,3/Z7Q#V^[&K4Z>.>6M*SM3)"-
M$@F)N0HO@'"AE"VO="(*A>-J[\ I"S'';"WG CVB,DJL; P+O'GG5K,YDMPP
M#)ROD*$!;B?0&*^5S%Q[S/T84U08#)TKH7$8Y_?<T ^; AS6 0YW#K"]>9"K
M50[JGXIWH_$WQ]O>-8A> WV78).'8#MO"/8YE<4=K;/]]REG\Q( 1L_#73]T
MZB.AKOX#=Q2&SN5&J:FP<AD$@X>Y91V:%\@C],W)36W9W8D8G8W7B!3DW+ZY
M*/2KR'3Y,%'WUL\ZD_(UXV%Z^2;TC<HY0VP<9BCJM8=8<\ORG:7\T"*W;QM3
MH;5(;3,!BI6RF8#C,R'T^L,8J!^[QG\"4$L#!!0    ( #V 9EH!(%W9 P,
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M/DKKY7!XNY98"4_9O@(2'CU:7: ]@UG-EI@TT&B//;S"76!21<XDN/@ 3#K
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M8QS15'F3*Q^,S-WM:28-[F+NYQ*77U)6 -_G4IKJP3JHK]/3?P%02P,$%
M  @ /8!F6C5TY;9U P  ; @  !D   !X;"]W;W)K<VAE971S+W-H965T,SDN
M>&ULG5;;CMLV$'W75PR4(-@%TI4EWW8=VX#7:=  F]98;UL411]H:6P1X44E
MJ3CNUW=(R8J#=8P@+S9)S9PYAS.CT72OS4=;(CKX+(6RL[ATKIHDB<U+E,S>
MZ H5/=EJ(YFCK=DEMC+(BN D19+U>J-$,J[B^32<K<Q\JFLGN,*5 5M+R<SA
M'H7>S^(T/AX\\EWI_$$RGU9LAVMTOU<K0[ND0RFX1&6Y5F!P.XL7Z>1^Z.V#
MP1\<]_9D#5[)1NN/?O.^F,4]3P@%YLXC,/K[A$L4P@,1C7];S+@+Z1U/UT?T
M=T$[:=DPBTLM_N2%*V?Q;0P%;EDMW*/>_X*MGD PU\*&7]BWMKT8\MHZ+5MG
M8B"Y:O[9Y_8>OL<A:QVRP+L)%%B^98[-IT;OP7AK0O.+(#5X$SFN?%+6SM!3
M3GYNOM12<D>W[("I I9:.:YVJ'*.%JZ>V$:@O9XFCD)YAR1O8>\;V.P;L&D*
M'PBJM/"S*K#X&B ACAW1[$CT/KN(^!;S&^BGKR'K98,+>/U.>#_@]7]$^-^+
MC76&*N:?<](;X,%Y8-]%$UNQ'&<QM8E%\PGC^:L7Z:CWY@+M04=[< E]OJ:N
M+&J!H+?$659,'5Z]N,W2\1L+Z[JJ!'I)3,"2V1+>4<_!>]7TKF^"1Q3,80%.
MPP-2,=MS^BXR.*_OJ<1HJP6%HTL$Y\L&PE/E++@2GW&UIUQSSW7KN?(3KN8+
M5Q&XPA57!*9K2QFSUY-HA8;K(MH:+:.@MV*\ $( )G7M0W.5BYH*, J>")*
M:A/B^AL,N" XVW#!G<_\2TC3$5Q(U+!+U/"'$_5;A8;Y<FN2  \G!-9E>X?$
M=K';&=S1);1V*W;PS,\F[2*;[T]:\W+F_Q$31N\95QON#M0A3!PLMU[,N6SJ
M3M#S&[4G@E@GJ+&K6D$1"]#4XR@W:+H^?Y;QOY"9"%7A ;^R7H2$1^0TI!SV
M1W=^.8+!W< OQM"_[45/VA=;3=XV]]946X%&=*0!Z>MLT(\>T-I)Q&55>Q-.
MAG1E#JZR\1"N6Y1O8]R-;EN$O#;&%UJE32CH9P5W(,RT3YB_:O53:QU=L'X)
MX^'P;'$F)Q- HMF%.6<A4&R&07?:C=)%,T&^F#=S^ ,S.ZXL!=^2:^]F3)5E
MFMG6;)RNPCS9:$?3*2Q+^AQ XPWH^59K=]SX -T'QOQ_4$L#!!0    ( #V
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M7W]*DGS[H"CPFJ3/ZU4:_0]02P,$%     @ /8!F6A>'U7,Y @  W 0  !D
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MGG>;5U4^6SV<J%0?J>H7Z)_?YWGU_$U=X"DOOJPV^_+_4$L#!!0    ( #V
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M!-(LP/F5$/JE8XIB^Z1%?P%02P,$%     @ /8!F6K*Z"#BH!   !1X  !D
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MN)C#B&5,Q A'7,#$?:3C761KX7:3A1J>[8IGNY;GDSM35%K#)2JZ(N!&,6&
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M&6*%$%7WKB:*%Z9CSKG"_FN&"=YX0.@#N+_@7&TFVD%SAPK_ %!+ P04
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M1%W'@.L)ZOV,,;GLZ 6:"U[X%U!+ P04    "  ]@&9:(DXBP1P"   !!0
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MA$!3SA)TGP&G.@D"G8Y!TB@69^@$12GZ,6<+0=-0]&VIP.D0=E "N2Z D!U
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MTW4U Z<WH=-9:D=]4[@MJ5-%XR?0^Y76;C_P#KK>-_L'4$L#!!0    ( #V
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MJHK'#=Y[0=D.^'TEI7ENV)M5?9.>_@=02P,$%     @ /8!F6O.O0U-P @
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MR E"@9EU"(P^&[Q&(1P0R?BYPPQZ2A=XN-ZC?_:Y4RYK9O!:B6\\M]4\^!!
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M?O#BT0W%&\'6^=,/YDP(%N<O5P3+J&1?D']?,":>WF0&J@=HS/X#4$L#!!0
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MT!\T@ZQM8*OA-F/V7L9\XQD=$TA'R'??(<_Q@HX!+<SR/W=TA-SPK#PQRS_
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M>KC%?$VH4"!72NJ,QBHCY%4U7S4DVY;U[9))52V7AQO &7#=05U?,29?&CI
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MX$IW93LL]3,(PCCH]27G:F>8!.YAS;X#4$L#!!0    ( #V 9EJE#OE:"@4
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M(%AZA^H@OY]1*C8OJD#QT\K@7U!+ P04    "  ]@&9:1\5-F$4#   V#@
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M!J;WR6::;#9:5&Z"FPEMYD&W+,T$#M(:F/=S(?1Z8P/XF7[\%U!+ P04
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MI:*E$K<JQ;5*;*?2/F&JU<9V-?-4OY[CX22<^M=MPKTI/9'PJ"$\>I1U,LI
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ /8!F6IE<G",0!@  G"<  !,
M             ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M"  ]@&9:W>=^?]8'  #X-   &               @($-"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ /8!F6L$4R*7R P   @H  !@
M             ("!&1   'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    ( #V 9EH]I-&GV 8  .PE   8              " @4$4  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  ]@&9:@S1*JLD#  "1
M%   &               @(%/&P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ /8!F6D@12PV !0  -!H  !@              ("!3A\
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( #V 9EJ[Q\.-
MG0(  !0'   8              " @00E  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    "  ]@&9:= A#'"P+  !97   &
M@('7)P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ /8!F
M6B1UDJAF @  +P4  !@              ("!.3,  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    ( #V 9EJTB^3*U 8  "8<   8
M      " @=4U  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #V 9EH&D<E$DP8  .D1   9              "
M@0E\  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ /8!F
M6HVK<1&6 @  (@8  !D              ("!TX(  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    "  ]@&9:/#<LV9H&  "'$   &0
M        @(&@A0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   ( #V 9EJ2V\!:9PL  /TC   9              " @7&,  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ /8!F6H;1"T97#@  8#$
M !D              ("!#Y@  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    "  ]@&9:IAZ-74D$   E"@  &0              @(&=I@
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( #V 9EJ]M*LO
MQ <  'P3   9              " @1VK  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ /8!F6B/]B<0C#P  *C(  !D
M ("!&+,  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  ]
M@&9:QS89I'0(   '%0  &0              @(%RP@  >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( #V 9EJ>B/+-K 0  'X+   9
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M970R-RYX;6Q02P$"% ,4    "  ]@&9:$XY290@)  !O&P  &0
M    @(% VP  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (
M #V 9EH5S$<Q%B<  )B$   9              " @7_D  !X;"]W;W)K<VAE
M971S+W-H965T,CDN>&UL4$L! A0#%     @ /8!F6DBE#2VY @  [P4  !D
M             ("!S L! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"
M% ,4    "  ]@&9:^+L3XJ@"  #L!0  &0              @(&\#@$ >&PO
M=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( #V 9EJ0BK"4H ,
M $T)   9              " @9L1 0!X;"]W;W)K<VAE971S+W-H965T,S(N
M>&UL4$L! A0#%     @ /8!F6N_%]E5Y!0  MP\  !D              ("!
M<A4! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  ]@&9:
MTG\REJ("   %!@  &0              @($B&P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;%!+ 0(4 Q0    ( #V 9EJV^U+EO ,  #<)   9
M      " @?L= 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%
M  @ /8!F6A)3#J%#!0  ^!(  !D              ("![B$! 'AL+W=O<FMS
M:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  ]@&9: 2!=V0,#  !"!P
M&0              @(%H)P$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+
M 0(4 Q0    ( #V 9EK)-R@AP04  %H/   9              " @:(J 0!X
M;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ /8!F6C5TY;9U
M P  ; @  !D              ("!FC ! 'AL+W=O<FMS:&5E=',O<VAE970S
M.2YX;6Q02P$"% ,4    "  ]@&9:TY##NF($  #)"@  &0
M@(%&- $ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( #V
M9EI]!LSXRP(  $0&   9              " @=\X 0!X;"]W;W)K<VAE971S
M+W-H965T-#$N>&UL4$L! A0#%     @ /8!F6N3LBT,H#   NX<  !D
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M=#0V+GAM;%!+ 0(4 Q0    ( #V 9EKXK\Y._P8  *T\   9
M  " @2Y; 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @
M/8!F6H9<'E%^!0  PB0  !D              ("!9&(! 'AL+W=O<FMS:&5E
M=',O<VAE970T."YX;6Q02P$"% ,4    "  ]@&9:XP-^]HH"   =!P  &0
M            @($9: $ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4
M Q0    ( #V 9EKZ3=APL0(  !T(   9              " @=IJ 0!X;"]W
M;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ /8!F6NGO2KD-!
MWA(  !D              ("!PFT! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX
M;6Q02P$"% ,4    "  ]@&9:5\#BC]T+  #3E   &0              @($&
M<@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( #V 9EH/
M#EW M@(  -X&   9              " @1I^ 0!X;"]W;W)K<VAE971S+W-H
M965T-3,N>&UL4$L! A0#%     @ /8!F6K*Z"#BH!   !1X  !D
M     ("!!X$! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #V 9EK 8R<=%P0  !<2   9              "
M@2^; 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ /8!F
M6ONCC+;- @  3PD  !D              ("!?9\! 'AL+W=O<FMS:&5E=',O
M<VAE970V,"YX;6Q02P$"% ,4    "  ]@&9:PW$NISL#  #L#0  &0
M        @(&!H@$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0
M   ( #V 9EHB3B+!' (   $%   9              " @?.E 0!X;"]W;W)K
M<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ /8!F6N*)J?Z8!   T1<
M !D              ("!1J@! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q0
M2P$"% ,4    "  ]@&9: GW>+$$#   '"P  &0              @($5K0$
M>&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( #V 9EJ0[!+.
M:P(  /4%   9              " @8VP 0!X;"]W;W)K<VAE971S+W-H965T
M-C4N>&UL4$L! A0#%     @ /8!F6I9_PUSU @  )0@  !D
M ("!+[,! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    "  ]
M@&9:&L+1U<D#  !5#P  &0              @(%;M@$ >&PO=V]R:W-H965T
M<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( #V 9EKSKT-3< (  /0%   9
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M970W,BYX;6Q02P$"% ,4    "  ]@&9:=\WL33$#  !="P  &0
M    @(%JS@$ >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    (
M #V 9EI0.*J@A (  &0'   9              " @=+1 0!X;"]W;W)K<VAE
M971S+W-H965T-S0N>&UL4$L! A0#%     @ /8!F6J4.^5H*!0  9AD  !D
M             ("!C=0! 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"
M% ,4    "  ]@&9:1\5-F$4#   V#@  &0              @('.V0$ >&PO
M=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( #V 9EK A:<?X (
M -\+   9              " @4K= 0!X;"]W;W)K<VAE971S+W-H965T-S<N
M>&UL4$L! A0#%     @ /8!F6NS$-*.? P  M1,  !D              ("!
M8> ! 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q02P$"% ,4    "  ]@&9:
MTE7VORD"  #%!   &0              @($WY $ >&PO=V]R:W-H965T<R]S
M:&5E=#<Y+GAM;%!+ 0(4 Q0    ( #V 9EK%HX4=50,   X6   -
M      "  9?F 0!X;"]S='EL97,N>&UL4$L! A0#%     @ /8!F6I>*NQS
M    $P(   L              ( !%^H! %]R96QS+RYR96QS4$L! A0#%
M  @ /8!F6B\=@XCD!0  :30   \              ( ! .L! 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( #V 9EJ[2=+?8@(  +0N   :
M  "  1'Q 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M #V 9EK=)VL+& (  (4M   3              "  :OS 0!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@    !7 %< V!<  /3U 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>199</ContextCount>
  <ElementCount>396</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>95</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995300 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995301 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995302 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995303 - Statement - Consolidated Statement of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ConsolidatedComprehensiveIncome</Role>
      <ShortName>Consolidated Statement of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995304 - Statement - Consolidated Statement of Operations and Comprehensive Loss (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals</Role>
      <ShortName>Consolidated Statement of Operations and Comprehensive Loss (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995305 - Statement - Consolidated Statement of Convertible Preferred Stock and Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statement of Convertible Preferred Stock and Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995306 - Statement - Consolidated Statement of Convertible Preferred Stock and Stockholders??? Equity (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ShareholdersEquityType2or3_Parentheticals</Role>
      <ShortName>Consolidated Statement of Convertible Preferred Stock and Stockholders??? Equity (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995307 - Statement - Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Nature of the Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation</Role>
      <ShortName>Nature of the Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Reverse Recapitalization and Pre-Closing Financing</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing</Role>
      <ShortName>Reverse Recapitalization and Pre-Closing Financing</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995311 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995312 - Disclosure - Cash equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/CashequivalentsandMarketableSecurities</Role>
      <ShortName>Cash equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995313 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995314 - Disclosure - Note Payable with Related Party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/NotePayablewithRelatedParty</Role>
      <ShortName>Note Payable with Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995315 - Disclosure - Convertible Preferred Stock and Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity</Role>
      <ShortName>Convertible Preferred Stock and Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995316 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995317 - Disclosure - Segment Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/SegmentDisclosures</Role>
      <ShortName>Segment Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995318 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995319 - Disclosure - Option Agreements and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/OptionAgreementsandLicenseAgreements</Role>
      <ShortName>Option Agreements and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995320 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995321 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995322 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995323 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Reverse Recapitalization and Pre-Closing Financing (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancingTables</Role>
      <ShortName>Reverse Recapitalization and Pre-Closing Financing (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/FairValueMeasurements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Cash equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/CashequivalentsandMarketableSecuritiesTables</Role>
      <ShortName>Cash equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/CashequivalentsandMarketableSecurities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Convertible Preferred Stock and Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables</Role>
      <ShortName>Convertible Preferred Stock and Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/StockBasedCompensation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Segment Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/SegmentDisclosuresTables</Role>
      <ShortName>Segment Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/SegmentDisclosures</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/IncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Commitment and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/CommitmentandContingenciesTables</Role>
      <ShortName>Commitment and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/CommitmentandContingencies</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/NetLossPerShare</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/RelatedPartyTransactions</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Nature of the Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails</Role>
      <ShortName>Nature of the Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Reverse Recapitalization and Pre-Closing Financing - Schedule of the Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable</Role>
      <ShortName>Reverse Recapitalization and Pre-Closing Financing - Schedule of the Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets Measured (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets Measured (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Cash equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable</Role>
      <ShortName>Cash equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Cash equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable</Role>
      <ShortName>Cash equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Cash equivalents and Marketable Securities - Schedule of Marketable Securities at Estimated Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable</Role>
      <ShortName>Cash equivalents and Marketable Securities - Schedule of Marketable Securities at Estimated Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Note Payable with Related Party (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails</Role>
      <ShortName>Note Payable with Related Party (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/NotePayablewithRelatedParty</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Convertible Preferred Stock and Stockholders??? Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders??? Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Convertible Preferred Stock and Stockholders??? Equity - Schedule of Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable</Role>
      <ShortName>Convertible Preferred Stock and Stockholders??? Equity - Schedule of Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Convertible Preferred Stock and Stockholders??? Equity - Schedule of Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable</Role>
      <ShortName>Convertible Preferred Stock and Stockholders??? Equity - Schedule of Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/StockBasedCompensationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable</Role>
      <ShortName>Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofStockOptionActivityTable</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Stock-Based Compensation - Schedule of RSA Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofRSAActivityTable</Role>
      <ShortName>Stock-Based Compensation - Schedule of RSA Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Stock-Based Compensation - Schedule of Employee Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable</Role>
      <ShortName>Stock-Based Compensation - Schedule of Employee Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Stock-Based Compensation - Schedule of Company???s Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable</Role>
      <ShortName>Stock-Based Compensation - Schedule of Company???s Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Stock-Based Compensation - Schedule of Award Types of Company???s Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable</Role>
      <ShortName>Stock-Based Compensation - Schedule of Award Types of Company???s Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Segment Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/SegmentDisclosuresDetails</Role>
      <ShortName>Segment Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/SegmentDisclosuresTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Segment Disclosures - Schedule of Segment Loss from Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable</Role>
      <ShortName>Segment Disclosures - Schedule of Segment Loss from Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/IncomeTaxesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Income Taxes - Schedule of Loss Before Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable</Role>
      <ShortName>Income Taxes - Schedule of Loss Before Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Income Taxes - Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable</Role>
      <ShortName>Income Taxes - Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Income Taxes - Schedule of Components of the Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable</Role>
      <ShortName>Income Taxes - Schedule of Components of the Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofNetDeferredTaxAssetsTable</Role>
      <ShortName>Income Taxes - Schedule of Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofUnrecognizedTaxBenefitsTable</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Option Agreements and License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails</Role>
      <ShortName>Option Agreements and License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/OptionAgreementsandLicenseAgreements</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Commitment and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/CommitmentandContingenciesDetails</Role>
      <ShortName>Commitment and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/CommitmentandContingenciesTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Commitment and Contingencies - Schedule of Company???s Supplemental Cash Flow Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable</Role>
      <ShortName>Commitment and Contingencies - Schedule of Company???s Supplemental Cash Flow Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Commitment and Contingencies - Schedule of Company???s Operating Lease Liabilities Showing the Aggregate Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable</Role>
      <ShortName>Commitment and Contingencies - Schedule of Company???s Operating Lease Liabilities Showing the Aggregate Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/NetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/NetLossPerShareTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable</Role>
      <ShortName>Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable</Role>
      <ShortName>Net Loss Per Share - Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996048 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996049 - Disclosure - Related Party Transactions - Schedule of Related Party Accounts Payable and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable</Role>
      <ShortName>Related Party Transactions - Schedule of Related Party Accounts Payable and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ea0230445-10k_orukathe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996050 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/SubsequentEvents</ParentRole>
      <Position>79</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="ea0230445-10k_orukathe.htm">ea0230445-10k_orukathe.htm</File>
    <File>orka-20241231.xsd</File>
    <File>orka-20241231_cal.xml</File>
    <File>orka-20241231_def.xml</File>
    <File>orka-20241231_lab.xml</File>
    <File>orka-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_003a.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="698">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>122
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0230445-10k_orukathe.htm": {
   "nsprefix": "orka",
   "nsuri": "http://www.orukatx.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "ea0230445-10k_orukathe.htm"
     ]
    },
    "schema": {
     "local": [
      "orka-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "orka-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "orka-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "orka-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "orka-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 323,
   "keyCustom": 73,
   "axisStandard": 24,
   "axisCustom": 1,
   "memberStandard": 30,
   "memberCustom": 50,
   "hidden": {
    "total": 242,
    "http://fasb.org/us-gaap/2024": 185,
    "http://www.orukatx.com/20241231": 54,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 199,
   "entityCount": 1,
   "segmentCount": 95,
   "elementCount": 859,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 698,
    "http://xbrl.sec.gov/dei/2024": 39,
    "http://xbrl.sec.gov/cyd/2024": 8,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/dei/role/document/AuditInformation",
     "longName": "995300 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "995302 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
     "longName": "995303 - Statement - Consolidated Statement of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statement of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals",
     "longName": "995304 - Statement - Consolidated Statement of Operations and Comprehensive Loss (Parentheticals)",
     "shortName": "Consolidated Statement of Operations and Comprehensive Loss (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c13",
      "name": "us-gaap:CostsAndExpensesRelatedParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c13",
      "name": "us-gaap:CostsAndExpensesRelatedParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.orukatx.com/role/ShareholdersEquityType2or3",
     "longName": "995305 - Statement - Consolidated Statement of Convertible Preferred Stock and Stockholders\u2019 Equity",
     "shortName": "Consolidated Statement of Convertible Preferred Stock and Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c21",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c21",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.orukatx.com/role/ShareholdersEquityType2or3_Parentheticals",
     "longName": "995306 - Statement - Consolidated Statement of Convertible Preferred Stock and Stockholders\u2019 Equity (Parentheticals)",
     "shortName": "Consolidated Statement of Convertible Preferred Stock and Stockholders\u2019 Equity (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "orka:IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "orka:IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.orukatx.com/role/ConsolidatedCashFlow",
     "longName": "995307 - Statement - Consolidated Statement of Cash Flows",
     "shortName": "Consolidated Statement of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation",
     "longName": "995308 - Disclosure - Nature of the Business and Basis of Presentation",
     "shortName": "Nature of the Business and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "995309 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing",
     "longName": "995310 - Disclosure - Reverse Recapitalization and Pre-Closing Financing",
     "shortName": "Reverse Recapitalization and Pre-Closing Financing",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.orukatx.com/role/FairValueMeasurements",
     "longName": "995311 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.orukatx.com/role/CashequivalentsandMarketableSecurities",
     "longName": "995312 - Disclosure - Cash equivalents and Marketable Securities",
     "shortName": "Cash equivalents and Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "longName": "995313 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.orukatx.com/role/NotePayablewithRelatedParty",
     "longName": "995314 - Disclosure - Note Payable with Related Party",
     "shortName": "Note Payable with Related Party",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity",
     "longName": "995315 - Disclosure - Convertible Preferred Stock and Stockholders\u2019 Equity",
     "shortName": "Convertible Preferred Stock and Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.orukatx.com/role/StockBasedCompensation",
     "longName": "995316 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.orukatx.com/role/SegmentDisclosures",
     "longName": "995317 - Disclosure - Segment Disclosures",
     "shortName": "Segment Disclosures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.orukatx.com/role/IncomeTaxes",
     "longName": "995318 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreements",
     "longName": "995319 - Disclosure - Option Agreements and License Agreements",
     "shortName": "Option Agreements and License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "orka:OptionAgreementsAndLicenseAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "orka:OptionAgreementsAndLicenseAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.orukatx.com/role/CommitmentandContingencies",
     "longName": "995320 - Disclosure - Commitment and Contingencies",
     "shortName": "Commitment and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.orukatx.com/role/NetLossPerShare",
     "longName": "995321 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.orukatx.com/role/RelatedPartyTransactions",
     "longName": "995322 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.orukatx.com/role/SubsequentEvents",
     "longName": "995323 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R27": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c198",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c198",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.orukatx.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "996001 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancingTables",
     "longName": "996002 - Disclosure - Reverse Recapitalization and Pre-Closing Financing (Tables)",
     "shortName": "Reverse Recapitalization and Pre-Closing Financing (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.orukatx.com/role/FairValueMeasurementsTables",
     "longName": "996003 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.orukatx.com/role/CashequivalentsandMarketableSecuritiesTables",
     "longName": "996004 - Disclosure - Cash equivalents and Marketable Securities (Tables)",
     "shortName": "Cash equivalents and Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "longName": "996005 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables",
     "longName": "996006 - Disclosure - Convertible Preferred Stock and Stockholders\u2019 Equity (Tables)",
     "shortName": "Convertible Preferred Stock and Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "orka:ScheduleOfConvertiblePreferredStockTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "orka:ScheduleOfConvertiblePreferredStockTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.orukatx.com/role/StockBasedCompensationTables",
     "longName": "996007 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.orukatx.com/role/SegmentDisclosuresTables",
     "longName": "996008 - Disclosure - Segment Disclosures (Tables)",
     "shortName": "Segment Disclosures (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.orukatx.com/role/IncomeTaxesTables",
     "longName": "996009 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.orukatx.com/role/CommitmentandContingenciesTables",
     "longName": "996010 - Disclosure - Commitment and Contingencies (Tables)",
     "shortName": "Commitment and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.orukatx.com/role/NetLossPerShareTables",
     "longName": "996011 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.orukatx.com/role/RelatedPartyTransactionsTables",
     "longName": "996012 - Disclosure - Related Party Transactions (Tables)",
     "shortName": "Related Party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
     "longName": "996013 - Disclosure - Nature of the Business and Basis of Presentation (Details)",
     "shortName": "Nature of the Business and Basis of Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c43",
      "name": "orka:AdditionalPaidInCapitalTransacationCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "996014 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FederalDepositInsuranceCorporationPremiumExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FederalDepositInsuranceCorporationPremiumExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable",
     "longName": "996015 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c56",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c56",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable",
     "longName": "996016 - Disclosure - Reverse Recapitalization and Pre-Closing Financing - Schedule of the Assets and Liabilities (Details)",
     "shortName": "Reverse Recapitalization and Pre-Closing Financing - Schedule of the Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c60",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c60",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable",
     "longName": "996017 - Disclosure - Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets Measured (Details)",
     "shortName": "Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets Measured (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable",
     "longName": "996018 - Disclosure - Cash equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)",
     "shortName": "Cash equivalents and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable",
     "longName": "996019 - Disclosure - Cash equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details)",
     "shortName": "Cash equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable",
     "longName": "996020 - Disclosure - Cash equivalents and Marketable Securities - Schedule of Marketable Securities at Estimated Fair Value (Details)",
     "shortName": "Cash equivalents and Marketable Securities - Schedule of Marketable Securities at Estimated Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:MarketableSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable",
     "longName": "996021 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
     "longName": "996022 - Disclosure - Note Payable with Related Party (Details)",
     "shortName": "Note Payable with Related Party (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c106",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c106",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
     "longName": "996023 - Disclosure - Convertible Preferred Stock and Stockholders\u2019 Equity (Details)",
     "shortName": "Convertible Preferred Stock and Stockholders\u2019 Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c113",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable",
     "longName": "996024 - Disclosure - Convertible Preferred Stock and Stockholders\u2019 Equity - Schedule of Convertible Preferred Stock (Details)",
     "shortName": "Convertible Preferred Stock and Stockholders\u2019 Equity - Schedule of Convertible Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c134",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "orka:ScheduleOfConvertiblePreferredStockTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c134",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "orka:ScheduleOfConvertiblePreferredStockTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
     "longName": "996025 - Disclosure - Convertible Preferred Stock and Stockholders\u2019 Equity - Schedule of Common Stock Reserved for Future Issuance (Details)",
     "shortName": "Convertible Preferred Stock and Stockholders\u2019 Equity - Schedule of Common Stock Reserved for Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "orka:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c54",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "orka:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.orukatx.com/role/StockBasedCompensationDetails",
     "longName": "996026 - Disclosure - Stock-Based Compensation (Details)",
     "shortName": "Stock-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "orka:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "orka:EstimatedFairValueOfWarrantsToBeGranted",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable",
     "longName": "996027 - Disclosure - Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c146",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c146",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable",
     "longName": "996028 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.orukatx.com/role/ScheduleofRSAActivityTable",
     "longName": "996029 - Disclosure - Stock-Based Compensation - Schedule of RSA Activity (Details)",
     "shortName": "Stock-Based Compensation - Schedule of RSA Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c147",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c147",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable",
     "longName": "996030 - Disclosure - Stock-Based Compensation - Schedule of Employee Warrant Activity (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Employee Warrant Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c119",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "orka:ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c119",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "orka:ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable",
     "longName": "996031 - Disclosure - Stock-Based Compensation - Schedule of Company\u2019s Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Company\u2019s Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c13",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable",
     "longName": "996032 - Disclosure - Stock-Based Compensation - Schedule of Award Types of Company\u2019s Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Award Types of Company\u2019s Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c153",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.orukatx.com/role/SegmentDisclosuresDetails",
     "longName": "996033 - Disclosure - Segment Disclosures (Details)",
     "shortName": "Segment Disclosures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable",
     "longName": "996034 - Disclosure - Segment Disclosures - Schedule of Segment Loss from Operations (Details)",
     "shortName": "Segment Disclosures - Schedule of Segment Loss from Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c157",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.orukatx.com/role/IncomeTaxesDetails",
     "longName": "996035 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:OperatingLossCarryforwardsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:OperatingLossCarryforwardsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable",
     "longName": "996036 - Disclosure - Income Taxes - Schedule of Loss Before Income Tax Expense (Details)",
     "shortName": "Income Taxes - Schedule of Loss Before Income Tax Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable",
     "longName": "996037 - Disclosure - Income Taxes - Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable",
     "longName": "996038 - Disclosure - Income Taxes - Schedule of Components of the Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Components of the Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.orukatx.com/role/ScheduleofNetDeferredTaxAssetsTable",
     "longName": "996039 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Assets (Details)",
     "shortName": "Income Taxes - Schedule of Net Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.orukatx.com/role/ScheduleofUnrecognizedTaxBenefitsTable",
     "longName": "996040 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails",
     "longName": "996041 - Disclosure - Option Agreements and License Agreements (Details)",
     "shortName": "Option Agreements and License Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.orukatx.com/role/CommitmentandContingenciesDetails",
     "longName": "996042 - Disclosure - Commitment and Contingencies (Details)",
     "shortName": "Commitment and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LesseeOperatingLeaseDiscountRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.orukatx.com/role/ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable",
     "longName": "996043 - Disclosure - Commitment and Contingencies - Schedule of Company\u2019s Supplemental Cash Flow Information Related to Leases (Details)",
     "shortName": "Commitment and Contingencies - Schedule of Company\u2019s Supplemental Cash Flow Information Related to Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable",
     "longName": "996044 - Disclosure - Commitment and Contingencies - Schedule of Company\u2019s Operating Lease Liabilities Showing the Aggregate Lease Payments (Details)",
     "shortName": "Commitment and Contingencies - Schedule of Company\u2019s Operating Lease Liabilities Showing the Aggregate Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.orukatx.com/role/NetLossPerShareDetails",
     "longName": "996045 - Disclosure - Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c184",
      "name": "us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c184",
      "name": "us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable",
     "longName": "996046 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders (Details)",
     "shortName": "Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c184",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable",
     "longName": "996047 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.orukatx.com/role/RelatedPartyTransactionsDetails",
     "longName": "996048 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c192",
      "name": "orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c192",
      "name": "orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable",
     "longName": "996049 - Disclosure - Related Party Transactions - Schedule of Related Party Accounts Payable and Other Current Liabilities (Details)",
     "shortName": "Related Party Transactions - Schedule of Related Party Accounts Payable and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c193",
      "name": "us-gaap:AccountsPayableOtherCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c193",
      "name": "us-gaap:AccountsPayableOtherCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.orukatx.com/role/SubsequentEventsDetails",
     "longName": "996050 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c197",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c197",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0230445-10k_orukathe.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "orka_ARCACommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ARCACommonStockMember",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARCA common stock [Member]",
        "label": "ARCACommon Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses and Other Current Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails",
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party accounts payable and other current liabilities",
        "verboseLabel": "Accounts payable and other current liabilities",
        "label": "Accounts Payable, Other, Current",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Trade, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r52"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net accretion of premiums and discounts on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedEmployeeBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued employee compensation and benefits",
        "label": "Accrued Employee Benefits, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Liabilities and Other Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Expenses and Other Current Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional and consulting",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "orka_AccruedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "AccruedResearchAndDevelopment",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development",
        "documentation": "Accrued research and development.",
        "label": "Accrued Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r71",
      "r136",
      "r601",
      "r623",
      "r624"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8",
      "r18",
      "r456",
      "r459",
      "r511",
      "r619",
      "r620",
      "r967",
      "r968",
      "r969",
      "r980",
      "r981",
      "r982",
      "r984"
     ]
    },
    "orka_AchievementOfDevelopmentCandidateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "AchievementOfDevelopmentCandidateMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Achievement of Development Candidate [Member]",
        "verboseLabel": "Achievement Of Development Candidate [Member]",
        "label": "Achievement Of Development Candidate Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r793",
      "r1108"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r637",
      "r980",
      "r981",
      "r982",
      "r984",
      "r1049",
      "r1109"
     ]
    },
    "orka_AdditionalPaidInCapitalTransacationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "AdditionalPaidInCapitalTransacationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital transaction costs (in Dollars)",
        "documentation": "The amount of additional paid-in capital transacation cost.",
        "label": "Additional Paid In Capital Transacation Cost"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r362"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Issuance costs of Pre-Closing Financing and reverse recapitalization",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r91"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of the Paruka warrant from liability to equity",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r38",
      "r91"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r842",
      "r853",
      "r871",
      "r906"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r845",
      "r856",
      "r874",
      "r909"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r875",
      "r901",
      "r910",
      "r914",
      "r922"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable",
      "http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r404"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "orka_AntibodyProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "AntibodyProductsMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antibody Products [Member]",
        "label": "Antibody Products Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total anti-dilutive securities",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r110",
      "r131",
      "r157",
      "r194",
      "r203",
      "r217",
      "r220",
      "r261",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r451",
      "r453",
      "r489",
      "r595",
      "r674",
      "r757",
      "r758",
      "r793",
      "r816",
      "r1008",
      "r1009",
      "r1065"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r137",
      "r157",
      "r261",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r451",
      "r453",
      "r489",
      "r793",
      "r1008",
      "r1009",
      "r1065"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AuctionMarketPreferredSecuritiesStockSeriesLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Convertible Preferred Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r832",
      "r849"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r832",
      "r849"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r832",
      "r849"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains, Cash Equivalents and Marketable Securities",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Losses, Cash Equivalents and Marketable Securities",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost, Cash Equivalents and Marketable Securities",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r269",
      "r594"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Marketable Securities at Estimated Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Cash Equivalents and Marketable Securities",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r269",
      "r467",
      "r588",
      "r780",
      "r783",
      "r994",
      "r1053",
      "r1054",
      "r1055"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/ScheduleofRSAActivityTable",
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accrued liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of the Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r832",
      "r849"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of the Business and Basis of Presentation",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r83",
      "r84"
     ]
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "CA",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California [Member]",
        "label": "CALIFORNIA"
       }
      }
     },
     "auth_ref": []
    },
    "orka_CashAcquiredInConnectionWithTheReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "CashAcquiredInConnectionWithTheReverseRecapitalization",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash acquired in connection with the reverse recapitalization",
        "documentation": "Represent the amount of cash acquired in connection with the reverse recapitalization.",
        "label": "Cash Acquired In Connection With The Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable",
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable",
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r129",
      "r744"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/CashequivalentsandMarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents and marketable Securities",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r80",
      "r153"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r80"
     ]
    },
    "orka_CashEquivalentsAndMarketableSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "CashEquivalentsAndMarketableSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents and Marketable Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r962",
      "r1076"
     ]
    },
    "us-gaap_CashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents [Member]",
        "label": "Cash Equivalents [Member]",
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "CashequivalentsandMarketableSecuritiesScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents and Marketable Securities - Schedule of Available-for-Sale Securities in an Unrealized Loss Position (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingEstimateLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingEstimateLineItems",
     "presentation": [
      "http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable",
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r133",
      "r134",
      "r135",
      "r157",
      "r183",
      "r184",
      "r186",
      "r188",
      "r197",
      "r198",
      "r261",
      "r293",
      "r295",
      "r296",
      "r297",
      "r300",
      "r301",
      "r331",
      "r332",
      "r336",
      "r339",
      "r347",
      "r489",
      "r628",
      "r629",
      "r630",
      "r631",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r662",
      "r683",
      "r705",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r950",
      "r975",
      "r985"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of the Business and Basis of Presentation [Line Items]",
        "terseLabel": "Convertible Preferred Stock and Stockholders\u2019 Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r197",
      "r331",
      "r332",
      "r334",
      "r336",
      "r339",
      "r345",
      "r347",
      "r628",
      "r629",
      "r630",
      "r631",
      "r770",
      "r950",
      "r975"
     ]
    },
    "orka_ClassOfWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ClassOfWarrantOrRight",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued",
        "documentation": "Number of warrants or rights issued.",
        "label": "Class Of Warrant Or Right"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails",
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable",
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails",
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price per warrant (in Dollars per share)",
        "verboseLabel": "Exercise price per warrant",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "orka_ClassOfWarrantOrRightExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ClassOfWarrantOrRightExpirationDate",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration date",
        "documentation": "The class of warrant or right expiration date.",
        "label": "Class Of Warrant Or Right Expiration Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee warrants issued",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant To Purchase Number Of Shares As A Percentage Of Outstanding Diluted Stock",
        "verboseLabel": "Warrant purchase percentage",
        "documentation": "class of warrant or right to purchase percentage of outstanding diluted stock maximum.",
        "label": "Class Of Warrant Or Right To Purchase Percentage Of Outstanding Diluted Stock Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightUnissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightUnissued",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exchange",
        "label": "Class of Warrant or Right, Unissued",
        "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "orka_ClassOfWarrantOrRightWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ClassOfWarrantOrRightWarrantsExercised",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercised",
        "documentation": "The class of Warrant or Right warrants exercised.",
        "label": "Class Of Warrant Or Right Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ClassOfWarrantsExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ClassOfWarrantsExercisable",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercisable",
        "documentation": "Represent the number of warrants exercisable.",
        "label": "Class Of Warrants Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ClassificationOfConvertiblePreferredStockPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classification of Convertible Preferred Stock",
        "documentation": "Classification of Convertible Preferred Stock.",
        "label": "Classification Of Convertible Preferred Stock Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ClinicalDevelopmentMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ClinicalDevelopmentMilestonesMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Development Milestones [Member]",
        "label": "Clinical Development Milestones Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Agreements and License Agreements [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable",
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable",
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Papers [Member]",
        "verboseLabel": "Commercial papers\t[Member]",
        "netLabel": "Commercial papers [Member]",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r292",
      "r810",
      "r811",
      "r812",
      "r813"
     ]
    },
    "orka_CommitmentandContingenciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "CommitmentandContingenciesDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment and Contingencies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 13)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r103",
      "r597",
      "r661"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r285",
      "r286",
      "r729",
      "r1002",
      "r1007"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r730"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Issuable Upon Conversion",
        "verboseLabel": "Total shares of common stock reserved",
        "netLabel": "Shares reserved for future issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "orka_CommonStockConversionRatio": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "CommonStockConversionRatio",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion ratio",
        "documentation": "Percentage of common stock conversion ratio.",
        "label": "Common Stock Conversion Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r806",
      "r807",
      "r808",
      "r810",
      "r811",
      "r812",
      "r813",
      "r980",
      "r981",
      "r984",
      "r1049",
      "r1107",
      "r1109"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r662"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r65",
      "r662",
      "r680",
      "r1109",
      "r1110"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 and $0.001 par value as of December 31, 2024 and February 6, 2024, respectively; 545,000,000 and 65,000,000 shares authorized, 37,440,510 and 3,197,975 shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r599",
      "r793"
     ]
    },
    "orka_CommonStocksConversionRatio": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "CommonStocksConversionRatio",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion ratio",
        "documentation": "Percentage of common stock conversion ratio.",
        "label": "Common Stocks Conversion Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of the Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r141",
      "r143",
      "r148",
      "r589",
      "r611",
      "r612"
     ]
    },
    "orka_ComprehensiveLossPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ComprehensiveLossPolicyPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "documentation": "Comprehensive loss policy.",
        "label": "Comprehensive Loss Policy Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer and office equipment [Member]",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk and Other Risks and Uncertainties",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r118"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockAmountConverted1",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Series A non-voting convertible preferred stock to common stock",
        "label": "Conversion of Stock, Amount Converted",
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "us-gaap_ConversionOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Common Stock Reserved for Future Issuance [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible shares",
        "verboseLabel": "Converted shares (in Shares)",
        "label": "Conversion of Stock, Shares Converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "orka_ConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ConvertibleNoteMember",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Note [Member]",
        "label": "Convertible Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Converted shares of common stock",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r40",
      "r64",
      "r90",
      "r342"
     ]
    },
    "orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ConvertiblePreferredStockandStockholdersEquityDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock and Stockholders\u2019 Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ConvertiblePreferredStockandStockholdersEquityScheduleofCommonStockReservedforFutureIssuanceDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock and Stockholders\u2019 Equity - Schedule of Common Stock Reserved for Future Issuance (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ConvertiblePreferredStockandStockholdersEquityScheduleofConvertiblePreferredStockDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock and Stockholders\u2019 Equity - Schedule of Convertible Preferred Stock (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable",
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable",
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Debt Securities [Member]",
        "verboseLabel": "Corporate debt securities [Member]",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r772",
      "r774",
      "r780",
      "r794",
      "r805",
      "r1104"
     ]
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpensesRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party amount",
        "label": "Costs and Expenses, Related Party",
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r306",
      "r334",
      "r518",
      "r539",
      "r593",
      "r745",
      "r747"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]",
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r931"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Board of Directors Oversight [Text Block]",
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r931"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]",
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r835",
      "r928"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes Integrated [Flag]",
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r929"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes Integrated [Text Block]",
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r929"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r834",
      "r927"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r834",
      "r927"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r834",
      "r927"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]",
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r930"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]",
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r931"
     ]
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedParty"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note Payable with Related Party",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r155",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r291",
      "r292",
      "r302",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r318",
      "r325",
      "r326",
      "r328",
      "r497"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r53",
      "r54",
      "r100",
      "r102",
      "r164",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r790",
      "r976",
      "r1003",
      "r1004",
      "r1005",
      "r1059",
      "r1060"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial principal amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r497",
      "r498",
      "r766",
      "r767",
      "r790"
     ]
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid accrued interest",
        "label": "Debt Instrument, Increase, Accrued Interest",
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period."
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate, percentage",
        "label": "Debt Instrument, Interest Rate During Period",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r321",
      "r1059"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable with Related Party [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r327",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r790",
      "r976",
      "r1059",
      "r1060"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity date",
        "label": "Debt Instrument, Maturity Date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r765",
      "r1054",
      "r1055"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Issuance Costs",
        "label": "Debt, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12 months or longer, Fair Value",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r273",
      "r764"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12 months or longer, Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r273"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than 12 months, Fair Value",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r273",
      "r764"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less than 12 months, Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r273"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r271",
      "r764"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r272"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/CashequivalentsandMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-Sale Securities in an Unrealized Loss Position",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r764",
      "r1001"
     ]
    },
    "us-gaap_DebtSecuritiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesCurrentAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities, current",
        "label": "Debt Securities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesNoncurrentAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities, long-term",
        "label": "Debt Securities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Company\u2019s Stock-Based Compensation Expense [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r101",
      "r428"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangibles",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized R&amp;D expenses",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "orka_DeferredTaxAssetsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.",
        "label": "Deferred Tax Assets Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Net Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "us-gaap_DeferredTaxAssetsOtherLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOtherLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Other Loss Carryforwards",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible loss carryforwards, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesDetails",
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credits",
        "verboseLabel": "Tax credit carryforwards",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accruals and other",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable",
      "http://www.orukatx.com/role/ScheduleofNetDeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "negatedLabel": "Less valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right- of- use asset",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from right of use assets.",
        "label": "Deferred Tax Liabilities Right Of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r863",
      "r864",
      "r878"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r36"
     ]
    },
    "orka_DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "documentation": "Description of minority interest ownership percentage by noncontrolling owners.",
        "label": "Description Of Minority Interest Ownership Percentage By Noncontrolling Owners"
       }
      }
     },
     "auth_ref": []
    },
    "orka_DevelopmentCostsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "DevelopmentCostsPercentage",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development costs, percentage",
        "documentation": "Percentage of development costs.",
        "label": "Development Costs Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r364",
      "r395",
      "r396",
      "r398",
      "r776"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureTextBlockSupplementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureTextBlockSupplementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Recapitalization and Pre-Closing Financing [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r863",
      "r864",
      "r878"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r832",
      "r849"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r832",
      "r849",
      "r902"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r832",
      "r849",
      "r902"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic Tax Jurisdiction [Member]",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to stockholders, basic (in Dollars per share)",
        "verboseLabel": "Loss per share \u2013 Basic",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r181",
      "r183",
      "r186",
      "r187",
      "r188",
      "r193",
      "r446",
      "r449",
      "r464",
      "r465",
      "r590",
      "r613",
      "r749"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://www.orukatx.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r186"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to stockholders, diluted (in Dollars per share)",
        "verboseLabel": "Loss per share \u2013 Diluted",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r183",
      "r186",
      "r187",
      "r188",
      "r193",
      "r446",
      "r449",
      "r464",
      "r465",
      "r590",
      "r613",
      "r749"
     ]
    },
    "us-gaap_EarningsPerShareDilutedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDilutedLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r186"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Share Attributable to Stockholders",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r190"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r189",
      "r191",
      "r192"
     ]
    },
    "us-gaap_EarningsPerUnitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerUnitAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax (benefit) expense",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r779"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax benefit derived by applying the federal statutory rate to income before income taxes",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r415",
      "r437",
      "r779"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in the valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r779",
      "r979",
      "r1042"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r779",
      "r979",
      "r1042",
      "r1043"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStatutoryFederalIncomeTaxRatetoIncomeBeforeIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r779",
      "r979",
      "r1042",
      "r1044"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "orka_EmployeeStockPurchasePlanESPPCashContributionsToESPP": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "EmployeeStockPurchasePlanESPPCashContributionsToESPP",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total amount of annual salary that an employee is permitted to utilize to purchase company shares under ESPP",
        "documentation": "This item represents the amount of cash contributions during the period made by the entity to the Employee stock purchase plan (ESPP).",
        "label": "Employee Stock Purchase Plan ESPPCash Contributions To ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "orka_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock purchase plan [Member]",
        "label": "Employee Stock Purchase Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_EmployeeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "EmployeeWarrantsMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable",
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable",
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable",
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Warrants [Member]",
        "verboseLabel": "Employee warrants\t[Member]",
        "label": "Employee Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r125",
      "r145",
      "r146",
      "r147",
      "r165",
      "r166",
      "r167",
      "r169",
      "r174",
      "r176",
      "r178",
      "r196",
      "r262",
      "r263",
      "r276",
      "r349",
      "r435",
      "r436",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r463",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r499",
      "r500",
      "r511",
      "r609",
      "r619",
      "r620",
      "r621",
      "r637",
      "r705"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r842",
      "r853",
      "r871",
      "r906"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r850",
      "r868",
      "r903"
     ]
    },
    "orka_EstimatedFairValueOfWarrantsToBeGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "EstimatedFairValueOfWarrantsToBeGranted",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated fair value of warrants to be granted",
        "documentation": "Estimated fair value of warrants to be granted.",
        "label": "Estimated Fair Value Of Warrants To Be Granted"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "orka_ExchangeRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ExchangeRatio",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange ratio",
        "documentation": "Exchange ratio.",
        "label": "Exchange Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "orka_ExternalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ExternalMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "External [Member]",
        "label": "External Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r783"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Hierarchy for Financial Assets Measured",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1051",
      "r1052"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable",
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r482",
      "r781"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value Hierarchy for Financial Assets Measured [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r482",
      "r781"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable",
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r482",
      "r781"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r480",
      "r481",
      "r483",
      "r526",
      "r527",
      "r528",
      "r766",
      "r767",
      "r772",
      "r773",
      "r774",
      "r780",
      "r783"
     ]
    },
    "orka_FairValueCashEquivalentsAndMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "FairValueCashEquivalentsAndMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents and marketable securities",
        "documentation": "Amount of cash equivalents and marketable securities.",
        "label": "Fair Value Cash Equivalents And Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r478",
      "r479",
      "r480",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r587",
      "r780",
      "r784"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r351",
      "r356",
      "r468",
      "r481",
      "r526",
      "r772",
      "r773",
      "r774",
      "r780"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r351",
      "r356",
      "r468",
      "r469",
      "r481",
      "r527",
      "r766",
      "r767",
      "r772",
      "r773",
      "r774",
      "r780"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r468",
      "r469",
      "r470",
      "r471",
      "r481",
      "r528",
      "r766",
      "r767",
      "r772",
      "r773",
      "r774",
      "r780",
      "r783"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r480",
      "r481",
      "r483",
      "r526",
      "r527",
      "r528",
      "r766",
      "r767",
      "r772",
      "r773",
      "r774",
      "r780",
      "r783"
     ]
    },
    "orka_FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "FairValueMeasurementsScheduleofFairValueHierarchyforFinancialAssetsMeasuredDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets Measured (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_FairmountHealthcareFundIILPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "FairmountHealthcareFundIILPMember",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fairmount Healthcare Fund II, L.P. [Member]",
        "verboseLabel": "Fairmount [Member]",
        "label": "Fairmount Healthcare Fund IILPMember"
       }
      }
     },
     "auth_ref": []
    },
    "orka_FairmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "FairmountMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fairmount [Member]",
        "label": "Fairmount Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_FairmountsOwnershipInterestInParagonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "FairmountsOwnershipInterestInParagonMember",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fairmount's Ownership Interest in Paragon [Member]",
        "label": "Fairmounts Ownership Interest In Paragon Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FeaturesOfConvertiblePreferredStockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FeaturesOfConvertiblePreferredStockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock and Stockholders\u2019 Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FederalDepositInsuranceCorporationPremiumExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FederalDepositInsuranceCorporationPremiumExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal Deposit Insurance Corporation",
        "label": "Federal Deposit Insurance Corporation Premium Expense",
        "documentation": "Amount of expense for Federal Deposit Insurance Corporation (FDIC) insurance."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable",
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r274",
      "r275",
      "r327",
      "r345",
      "r461",
      "r488",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r610",
      "r764",
      "r780",
      "r781",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r794",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1050",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057"
     ]
    },
    "orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Dosing of Human Patient in Phase1Trial Milestone [Member]",
        "label": "First Dosing Of Human Patient In Phase One Trial Milestone Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r875",
      "r910"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r875",
      "r910"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r875",
      "r910"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r875",
      "r910"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r875",
      "r910"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r831",
      "r861"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures [Member]",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "verboseLabel": "General and administrative personnel-related expense (excluding stock-based compensation)",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r685"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals",
      "http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable",
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "verboseLabel": "General and administrative [Member]",
        "netLabel": "General and administrative stock-based compensation [Member]",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r832",
      "r849"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r414"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income tax expense",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r107",
      "r109",
      "r591",
      "r607",
      "r751",
      "r757",
      "r987",
      "r989",
      "r990",
      "r991",
      "r992"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Loss Before Income Tax Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofLossBeforeIncomeTaxExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r414"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails",
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable",
      "http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable",
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r283",
      "r284",
      "r473",
      "r477",
      "r482",
      "r616",
      "r618",
      "r690",
      "r742",
      "r782",
      "r1078"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails",
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable",
      "http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable",
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r473",
      "r477",
      "r482",
      "r616",
      "r618",
      "r690",
      "r742",
      "r782",
      "r1078"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r415",
      "r416",
      "r422",
      "r433",
      "r779",
      "r1047"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r415",
      "r416",
      "r422",
      "r433",
      "r779",
      "r1047"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r409",
      "r415",
      "r419",
      "r420",
      "r421",
      "r425",
      "r432",
      "r438",
      "r440",
      "r441",
      "r442",
      "r633",
      "r779"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r123",
      "r177",
      "r178",
      "r194",
      "r206",
      "r220",
      "r413",
      "r415",
      "r439",
      "r614",
      "r779"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r411",
      "r412",
      "r425",
      "r426",
      "r431",
      "r434",
      "r627"
     ]
    },
    "orka_IncomeTaxesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "IncomeTaxesDetailsLineItems",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_IncomeTaxesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "IncomeTaxesDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party accounts payable and other current liabilities",
        "label": "Increase (Decrease) in Accounts Payable, Related Parties",
        "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r954",
      "r974"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other non-current assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r875",
      "r901",
      "r910",
      "r914",
      "r922"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r926"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r926"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r926"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r322",
      "r329",
      "r768",
      "r769"
     ]
    },
    "us-gaap_InterestExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseMember",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Expense",
        "label": "Interest Expense [Member]",
        "documentation": "Primary financial statement caption encompassing interest expense."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r971"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r864",
      "r865",
      "r866",
      "r867"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r204",
      "r220",
      "r757",
      "r970"
     ]
    },
    "us-gaap_InvestmentsAndCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsAndCash",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents, and marketable securities (in Dollars)",
        "label": "Investments and Cash",
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r1075",
      "r1076"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/CashequivalentsandMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Marketable Securities at Estimated Fair Value",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "orka_InvestorsClosingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "InvestorsClosingShares",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investors shares",
        "documentation": "Number of investors closing shares.",
        "label": "Investors Closing Shares"
       }
      }
     },
     "auth_ref": []
    },
    "orka_IssuanceCostOfPIPEFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "IssuanceCostOfPIPEFinancing",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance costs of PIPE Financing",
        "documentation": "Issuance cost of PIPE financing.",
        "label": "Issuance Cost Of PIPEFinancing"
       }
      }
     },
     "auth_ref": []
    },
    "orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and pre-funded warrants in the Pre-Closing Financing",
        "documentation": "Issuance of common stock and pre-funded warrants in the preclosing financing, net of offering costs of $[x] million.",
        "label": "Issuance Of Common Stock And Prefunded Warrants In The Preclosing Financing Net Of Offering Cos"
       }
      }
     },
     "auth_ref": []
    },
    "orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and pre-funded warrants in the Pre-Closing Financing (in Shares)",
        "documentation": "Issuance of common stock and pre-funded warrants in the preclosing financing, net of offering costs of $[x] million.",
        "label": "Issuance Of Common Stock And Prefunded Warrants In The Preclosing Financing Net Of Offering Cost"
       }
      }
     },
     "auth_ref": []
    },
    "orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing",
        "documentation": "Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the Private Placement, net of offering costs of $[x] million.",
        "label": "Issuance Of Common Stock Series ANonvoting Convertible Preferred Stock And Prefunded Warr"
       }
      }
     },
     "auth_ref": []
    },
    "orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing (in Shares)",
        "documentation": "Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the Private Placement, net of offering costs of $[x] million.",
        "label": "Issuance Of Common Stock Series ANonvoting Convertible Preferred Stock And Prefunded Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization",
        "documentation": "Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the Reverse Merger.",
        "label": "Issuance Of Common Stock To Former Stockholders Of ARCABiopharma Inc In Connection With The"
       }
      }
     },
     "auth_ref": []
    },
    "orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization (in Shares)",
        "documentation": "Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the Reverse Merger.",
        "label": "Issuance Of Common Stock To Former Stockholders Of ARCABiopharma Inc In Connection With The Closing Ofthe Reverse Merger"
       }
      }
     },
     "auth_ref": []
    },
    "orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series A Convertible Preferred Stock, Net of Issuance Costs",
        "documentation": "Issuance of Series A convertible preferred stock, net of issuance costs.",
        "label": "Issuance Of Series AConvertible Preferred Stock Net Of Issuance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease discount rate",
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company\u2019s Operating Lease Liabilities Showing the Aggregate Lease Payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted lease payments",
        "terseLabel": "Future lease payment",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "verboseLabel": "Lease initial period",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r53",
      "r54",
      "r55",
      "r57",
      "r58",
      "r59",
      "r62",
      "r157",
      "r261",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r452",
      "r453",
      "r454",
      "r489",
      "r660",
      "r750",
      "r816",
      "r1008",
      "r1065",
      "r1066"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities, convertible preferred stock and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r104",
      "r603",
      "r793",
      "r977",
      "r1000",
      "r1058"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r128",
      "r157",
      "r261",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r452",
      "r453",
      "r454",
      "r489",
      "r793",
      "r1008",
      "r1065",
      "r1066"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Category of Item Purchased [Axis]",
        "documentation": "Information by category of items purchased under a long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]",
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Marketable Securities",
        "documentation": "Amount of investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r963"
     ]
    },
    "us-gaap_MarketableSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_MarketableSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "MarketableSecuritiesAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities [Axis]",
        "label": "Marketable Securities Axis"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable": {
       "parentTag": "us-gaap_MarketableSecurities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable",
      "http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities, current",
        "verboseLabel": "Due in one year or less",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "orka_MarketableSecuritiesCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "MarketableSecuritiesCurrentMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities, current [Member]",
        "label": "Marketable Securities Current Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_MarketableSecuritiesDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "MarketableSecuritiesDomainDomain",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MarketableSecuritiesDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "orka_MarketableSecuritiesLongTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "MarketableSecuritiesLongTermMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities,Long-Term [Member]",
        "label": "Marketable Securities Long Term Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_MarketableSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "MarketableSecuritiesMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities [Member]",
        "label": "Marketable Securities Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable": {
       "parentTag": "us-gaap_MarketableSecurities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable",
      "http://www.orukatx.com/role/ScheduleofMarketableSecuritiesatEstimatedFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities, long-term",
        "verboseLabel": "Due in 1-2 years",
        "label": "Marketable Securities, Noncurrent",
        "documentation": "Amount of investment in marketable security, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "orka_MarketableSecuritiesNoncurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "MarketableSecuritiesNoncurrentMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities, long-term [Member]",
        "label": "Marketable Securities Noncurrent Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_MarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Table]",
        "documentation": "Disclosure of information about investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/CashequivalentsandMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash Equivalents and Marketable Securities",
        "label": "Marketable Securities [Table Text Block]",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]",
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r862"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r290",
      "r358",
      "r405",
      "r471",
      "r555",
      "r615",
      "r617",
      "r625",
      "r652",
      "r653",
      "r713",
      "r715",
      "r717",
      "r718",
      "r720",
      "r740",
      "r741",
      "r763",
      "r770",
      "r775",
      "r783",
      "r784",
      "r788",
      "r789",
      "r803",
      "r1010",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse Recapitalization and Pre-Closing Financing",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r97"
     ]
    },
    "orka_MilestoneConsiderationPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "MilestoneConsiderationPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone consideration paid",
        "documentation": "The milestone consideration paid amount.",
        "label": "Milestone Consideration Paid"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r290",
      "r358",
      "r405",
      "r471",
      "r555",
      "r615",
      "r617",
      "r625",
      "r652",
      "r653",
      "r713",
      "r715",
      "r717",
      "r718",
      "r720",
      "r740",
      "r741",
      "r763",
      "r770",
      "r775",
      "r783",
      "r784",
      "r788",
      "r803",
      "r1010",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable",
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds [Member]",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "orka_NatureoftheBusinessandBasisofPresentationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "NatureoftheBusinessandBasisofPresentationDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of the Business and Basis of Presentation (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "terseLabel": "Net cash operating activities (in Dollars)",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r82"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow",
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "netLabel": "Net loss (in Dollars)",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r82",
      "r108",
      "r126",
      "r140",
      "r142",
      "r147",
      "r157",
      "r168",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r177",
      "r178",
      "r185",
      "r261",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r446",
      "r449",
      "r465",
      "r489",
      "r608",
      "r682",
      "r703",
      "r704",
      "r814",
      "r1008"
     ]
    },
    "orka_NetLossPerShareDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "NetLossPerShareDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r864",
      "r865",
      "r866",
      "r867"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "orka_NominationOfADevelopmentCandidateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "NominationOfADevelopmentCandidateMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nomination Of A Development Candidate [Member]",
        "label": "Nomination Of ADevelopment Candidate Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r875",
      "r901",
      "r910"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "orka_NonRefundableLicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "NonRefundableLicenseFee",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable license fee",
        "documentation": "Amount of non refundable license fee.",
        "label": "Non Refundable License Fee"
       }
      }
     },
     "auth_ref": []
    },
    "orka_NonRefundableMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "NonRefundableMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable milestone payments",
        "documentation": "Non-refundable milestone payments.",
        "label": "Non Refundable Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash accrued interest on convertible note converted to common stock",
        "documentation": "Represent the amount of non-cash accrued interest on convertible note converted to common stock.",
        "label": "Noncash Accrued Interest On Convertible Note Converted To Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "orka_NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash exchange of Pre-Merger Oruka Series A preferred stock for Series B convertible preferred stock",
        "documentation": "Represent the Non-cash exchange of Pre-Merger Oruka Series A preferred stock for Series B convertible preferred stock.",
        "label": "Noncash Exchange Of Pre Merger Oruka Series APreferred Stock For Series BConvertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets acquired in connection with the reverse capitalization",
        "label": "Noncash or Part Noncash Acquisition, Other Assets Acquired",
        "documentation": "Amount of assets, classified as other, acquired in a noncash or part noncash acquisition."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other liabilities assumed in connection with the reverse recapitalization",
        "label": "Noncash or Part Noncash Acquisition, Other Liabilities Assumed",
        "documentation": "Amount of liabilities, classified as other, assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense)",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_NotePayableToRelatedPartyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "NotePayableToRelatedPartyPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note Payable to Related Party",
        "documentation": "Note Payable to Related Party.",
        "label": "Note Payable To Related Party Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "orka_NotePayablewithRelatedPartyDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "NotePayablewithRelatedPartyDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable with Related Party (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable with Related Party [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.orukatx.com/role/SegmentDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating segment",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r758",
      "r988"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.orukatx.com/role/SegmentDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reporting segment",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r988"
     ]
    },
    "orka_NumberOfSharesPurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "NumberOfSharesPurchased",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate of purchased shares",
        "documentation": "Number of shares purchased.",
        "label": "Number Of Shares Purchased"
       }
      }
     },
     "auth_ref": []
    },
    "orka_NumberofAggregateShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "NumberofAggregateShares",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate shares",
        "documentation": "Number of aggregate shares.",
        "label": "Numberof Aggregate Shares"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ORKAZeroZeroOneLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ORKAZeroZeroOneLicenseAgreementMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORKA-001 License Agreement [Member]",
        "label": "ORKAZero Zero One License Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ORKAZeroZeroOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ORKAZeroZeroOneMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORKA-001 [Member]",
        "label": "ORKAZero Zero One Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ORKAZeroZeroTwoLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ORKAZeroZeroTwoLicenseAgreementMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORKA-002 License Agreement [Member]",
        "label": "ORKAZero Zero Two License Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ORKAZeroZeroTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ORKAZeroZeroTwoMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORKA-002 [Member]",
        "label": "ORKAZero Zero Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Expense Excluding Personnel Related And Stock Based Compensation [Member]",
        "label": "Operating Expense Excluding Personnel Related And Stock Based Compensation Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_OperatingExpenseExcludingStockBasedCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "OperatingExpenseExcludingStockBasedCompensationMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Expense Excluding StockBased Compensation [Member]",
        "verboseLabel": "Operating Expense Excluding Personnel Related And Stock Based Compensation [Member]",
        "label": "Operating Expense Excluding Stock Based Compensation Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "terseLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r751",
      "r987",
      "r989",
      "r990",
      "r991",
      "r992"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Company\u2019s Operating Lease Liabilities Showing the Aggregate Lease Payments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total discounted lease payments",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, current",
        "negatedLabel": "Less: current portion of lease liability",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, non-current",
        "verboseLabel": "Non-current portion of lease liability",
        "netLabel": "Operating lease liability, noncurrent",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r505"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_OperatingLeaseVariableLeaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseVariableLeaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease expense",
        "label": "Operating Lease, Variable Lease Income",
        "documentation": "Amount of operating lease income from variable lease payments paid and payable to lessor, excluding amount included in measurement of lease receivable."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r510"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r792"
     ]
    },
    "orka_OperatingLossCarryforwardsAsAPercentageOfTaxableIncome": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "OperatingLossCarryforwardsAsAPercentageOfTaxableIncome",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards as a percentage of taxable income",
        "documentation": "Operating loss carryforwards that can be utilized in any tax year as a percentage of taxable income",
        "label": "Operating Loss Carryforwards As APercentage Of Taxable Income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance due to continuing loss from operations",
        "label": "Operating Loss Carryforwards, Valuation Allowance",
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "orka_OptionAgreementsAndLicenseAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "OptionAgreementsAndLicenseAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Agreements and License Agreements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_OptionAgreementsAndLicenseAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "OptionAgreementsAndLicenseAgreementsTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Agreements and License Agreements",
        "documentation": "The entire disclosure of option agreements and license agreements.",
        "label": "Option Agreements And License Agreements Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "orka_OptionAgreementsandLicenseAgreementsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "OptionAgreementsandLicenseAgreementsDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Agreements and License Agreements (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of the Business and Basis of Presentation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_OrukaCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "OrukaCommonStockMember",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oruka Common Stock [Member]",
        "label": "Oruka Common Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_OrukaSeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "OrukaSeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oruka Series A Convertible Preferred Stock [Member]",
        "label": "Oruka Series AConvertible Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment and Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized loss on marketable securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r260"
     ]
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Accounts Payable and Other Current Liabilities",
        "label": "Other Current Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "orka_OtherDevelopmentCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "OtherDevelopmentCost",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development costs",
        "documentation": "Represent the amount of development costs.",
        "label": "Other Development Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses",
        "label": "Other Expenses",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76"
     ]
    },
    "orka_OtherIncomeExpenseNetPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "OtherIncomeExpenseNetPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "documentation": "Represents of other income (expense), net.",
        "label": "Other Income Expense Net Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "orka_OtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "OtherMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other [Member]",
        "label": "Other Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense",
        "label": "Other Noncash Expense",
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "label": "Other Nonoperating Income",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r855",
      "r873",
      "r908"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r858",
      "r876",
      "r911"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r858",
      "r876",
      "r911"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_PIPEFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "PIPEFinancingMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PIPE Financing [Member]",
        "label": "PIPEFinancing Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ParagonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ParagonMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails",
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paragon [Member]",
        "label": "Paragon Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ParagonMilestonePaymentsForOptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ParagonMilestonePaymentsForOptionAgreementMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paragon milestone payments for Option Agreement [Member]",
        "label": "Paragon Milestone Payments For Option Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ParagonReimbursableOptionAgreementsFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ParagonReimbursableOptionAgreementsFeesMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paragon reimbursable Option Agreements\u2019 fees [Member]",
        "label": "Paragon Reimbursable Option Agreements Fees Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ParagonReimbursableOtherResearchExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ParagonReimbursableOtherResearchExpensesMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paragon reimbursable other research expenses [Member]",
        "label": "Paragon Reimbursable Other Research Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ParagonReimbursablePatentExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ParagonReimbursablePatentExpensesMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paragon reimbursable patent expenses\t[Member]",
        "label": "Paragon Reimbursable Patent Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ParukaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ParukaMember",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paruka [Member]",
        "label": "Paruka Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ParukaWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ParukaWarrantMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paruka Warrant [Member]",
        "label": "Paruka Warrant Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ParukaWarrantObligationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ParukaWarrantObligationMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails",
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable",
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paruka Warrant Obligation [Member]",
        "verboseLabel": "Paruka warrant obligation [Member]",
        "label": "Paruka Warrant Obligation Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net of issuance costs (in Dollars)",
        "label": "Payment of Financing and Stock Issuance Costs",
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initiation fee",
        "label": "Payments for Other Fees",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance costs (in Dollars)",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "orka_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants [Member]",
        "label": "Pre Funded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_PreFundedWarrantsOfCommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "PreFundedWarrantsOfCommonStockShares",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded warrants of common stock shares",
        "documentation": "Pre-funded warrants of common stock shares.",
        "label": "Pre Funded Warrants Of Common Stock Shares"
       }
      }
     },
     "auth_ref": []
    },
    "orka_PreMergerOrukaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "PreMergerOrukaMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Merger Oruka [Member]",
        "label": "Pre Merger Oruka Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleSharesIssuable",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Converted shares",
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "documentation": "Number of common shares issuable upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r806",
      "r807",
      "r810",
      "r811",
      "r812",
      "r813",
      "r1107",
      "r1109"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-voting convertible preferred stock, par value (in Dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r331"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-voting convertible preferred stock, shares authorized",
        "verboseLabel": "Preferred Stock Authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r662"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-voting convertible preferred stock, shares issued",
        "verboseLabel": "Preferred Stock Issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r331"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-voting convertible preferred stock, shares outstanding",
        "verboseLabel": "Preferred Stock Outstanding",
        "netLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r662",
      "r680",
      "r1109",
      "r1110"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B non-voting convertible preferred stock, $0.001 par value; 251,504 and no shares authorized as of December 31, 2024 and February 6, 2024, respectively; 137,138 and no shares issued and outstanding as of December 31, 2024 and February 6, 2024, respectively",
        "verboseLabel": "Carrying Value (in Dollars)",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r598",
      "r793"
     ]
    },
    "orka_PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "PrefundedWarrantsMember",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded Warrants [Member]",
        "label": "Prefunded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_PrefundedWarrantstoPurchaseAnAggregateShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "PrefundedWarrantstoPurchaseAnAggregateShares",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prefunded warrants to purchase an aggregate shares",
        "documentation": "Number of prefunded warrants to purchase an aggregate shares.",
        "label": "Prefunded Warrantsto Purchase An Aggregate Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate proceeds",
        "label": "Proceeds from Convertible Debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow",
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid",
        "verboseLabel": "Gross proceeds (in Dollars)",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from Issuance of convertible note (in Dollars)",
        "label": "Proceeds from Issuance of Debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the PIPE Financing, net",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of notes payable to related party, net of issuance costs paid",
        "label": "Proceeds from Notes Payable",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the Pre-Closing Financing, net",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r953",
      "r972"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r509"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r509",
      "r592",
      "r606",
      "r793"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r119",
      "r122",
      "r605"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r290",
      "r350",
      "r358",
      "r390",
      "r391",
      "r392",
      "r405",
      "r471",
      "r529",
      "r538",
      "r555",
      "r615",
      "r617",
      "r625",
      "r652",
      "r653",
      "r713",
      "r715",
      "r717",
      "r718",
      "r720",
      "r740",
      "r741",
      "r763",
      "r770",
      "r775",
      "r783",
      "r784",
      "r788",
      "r789",
      "r803",
      "r808",
      "r1006",
      "r1010",
      "r1054",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072"
     ]
    },
    "orka_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Pronouncements",
        "documentation": "Represents of recently adopted accounting pronouncements.",
        "label": "Recently Adopted Accounting Pronouncements Policy Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ReclassificationOfTheParukaWarrantFromLiabilityToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ReclassificationOfTheParukaWarrantFromLiabilityToEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of the Paruka warrant from liability to equity",
        "documentation": "Represent the amount of reclassification of the paruka warrant from liability to equity.",
        "label": "Reclassification Of The Paruka Warrant From Liability To Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/SegmentDisclosuresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Loss from Operations",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits [Abstract]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r850",
      "r868",
      "r903"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "orka_RegulatoryMilestonesMemberMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "RegulatoryMilestonesMemberMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory Milestones Member [Member]",
        "label": "Regulatory Milestones Member Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r357",
      "r515",
      "r516",
      "r596",
      "r604",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r679",
      "r681",
      "r712"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails",
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "verboseLabel": "Related Party [Member]",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r515",
      "r516",
      "r517",
      "r518",
      "r596",
      "r604",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r679",
      "r681",
      "r712"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r516",
      "r1064"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails",
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items]",
        "terseLabel": "Related Party Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r686",
      "r687",
      "r690"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails",
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r357",
      "r515",
      "r516",
      "r596",
      "r604",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r679",
      "r681",
      "r712",
      "r1064"
     ]
    },
    "orka_RelatedPartyTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "RelatedPartyTransactionsDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r513",
      "r514",
      "r516",
      "r519",
      "r634",
      "r635",
      "r636",
      "r688",
      "r689",
      "r690",
      "r709",
      "r711"
     ]
    },
    "orka_RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "RelatedPartyTransactionsScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions - Schedule of Related Party Accounts Payable and Other Current Liabilities (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r306",
      "r334",
      "r518",
      "r539",
      "r593",
      "r746",
      "r747"
     ]
    },
    "orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Contract Costs Accruals",
        "documentation": "Research and development contract costs accruals.",
        "label": "Research And Development Contract Costs Accruals Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development personnel-related expense (excluding stock-based compensation)",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r742",
      "r757",
      "r1073"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails",
      "http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable",
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development [Member]",
        "netLabel": "Research and development stock-based compensation [Member]",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "orka_ResearchInitialFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ResearchInitialFee",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research initial fees",
        "documentation": "The amount of research initial fees.",
        "label": "Research Initial Fee"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r840",
      "r851",
      "r869",
      "r904"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r841",
      "r852",
      "r870",
      "r905"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r859",
      "r877",
      "r912"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "orka_RestrictedStockAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "RestrictedStockAwardsMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Awards\t[Member]",
        "label": "Restricted Stock Awards Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/ScheduleofRSAActivityTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Award [Member]",
        "verboseLabel": "Restricted Stock [Member]",
        "netLabel": "RSA [Member]",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r91",
      "r602",
      "r622",
      "r624",
      "r632",
      "r663",
      "r793"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r165",
      "r166",
      "r167",
      "r169",
      "r174",
      "r176",
      "r178",
      "r262",
      "r263",
      "r276",
      "r435",
      "r436",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r455",
      "r457",
      "r458",
      "r460",
      "r463",
      "r499",
      "r500",
      "r619",
      "r621",
      "r637",
      "r1109"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability arising from obtaining operating right-of-use asset",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r792"
     ]
    },
    "orka_RoyaltyPayableOnProductSales": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "RoyaltyPayableOnProductSales",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty payable on product sales, description",
        "documentation": "Royalty payable on product sales, description.",
        "label": "Royalty Payable On Product Sales"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate gross proceeds (in Dollars)",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange shares",
        "verboseLabel": "Number of shares issued",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price per share (in Dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "auth_ref": [
      "r179",
      "r359",
      "r951",
      "r983"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Anti Dilutive Effect Excluded From Potential Computation Of Diluted Net Loss Per Share Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "orka_ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfAvailableForSaleSecuritiesInAnUnrealizedLossPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Available For Sale Securities In An Unrealized Loss Position Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Award Types Of Company SStock Based Compensation Expense Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfBasicAndDilutedNetLossPerShareAttributableToStockholdersAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Basic And Diluted Net Loss Per Share Attributable To Stockholders Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfCashEquivalentsAndMarketableSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Cash Equivalents And Marketable Securities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company\u2019s Supplemental Cash Flow Information Related to Leases",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfCommonStockReservedForFutureIssuanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Common Stock Reserved For Future Issuance Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Reserved for Future Issuance",
        "documentation": "Tabular disclosure of common stock reserved for future issuance.",
        "label": "Schedule Of Common Stock Reserved For Future Issuance Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfCompanySStockBasedCompensationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfCompanySStockBasedCompensationExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Company SStock Based Compensation Expense Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Award Types of Company\u2019s Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "orka_ScheduleOfConvertiblePreferredStockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfConvertiblePreferredStockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Convertible Preferred Stock Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfConvertiblePreferredStockTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfConvertiblePreferredStockTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Convertible Preferred Stock",
        "documentation": "Tabular disclosure of convertible preferred stock.",
        "label": "Schedule Of Convertible Preferred Stock Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of the Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Basic and Diluted Net Loss Per Share Attributable to Stockholders",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Statutory Federal Income Tax Rate to Income Before Income Taxes",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r779",
      "r1042"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company\u2019s Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "orka_ScheduleOfEmployeeWarrantActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfEmployeeWarrantActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Employee Warrant Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Hierarchy For Financial Assets Measured Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Loss Before Income Tax Expense",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of RSA Activity",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "orka_ScheduleOfPropertyAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfPropertyAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r509"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Assets and Liabilities",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "orka_ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Related Party Accounts Payable And Other Current Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfRsaActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfRsaActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Rsa Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfSegmentLossFromOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfSegmentLossFromOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Segment Loss From Operations Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r93"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "orka_ScheduleOfStockOptionActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfStockOptionActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Stock Option Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r778"
     ]
    },
    "orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheAwardsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Weighted Average Assumptions Used In Calculating The Fair Value Of The Awards Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r649",
      "r650",
      "r651",
      "r714",
      "r716",
      "r719",
      "r721",
      "r728",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r743",
      "r771",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r804",
      "r808",
      "r1012",
      "r1077",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1105",
      "r1106"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/SegmentDisclosures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Disclosures",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r194",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r207",
      "r208",
      "r209",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r228",
      "r752",
      "r755",
      "r756",
      "r757",
      "r759",
      "r761",
      "r762"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r223",
      "r226",
      "r753",
      "r754",
      "r760"
     ]
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofSegmentLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Loss from Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expenses",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "orka_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Convertible Preferred Stock",
        "label": "Series AConvertible Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_SeriesANonVotingConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "SeriesANonVotingConvertiblePreferredStockMember",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Non-Voting Convertible Preferred Stock",
        "verboseLabel": "Series A Non-Voting",
        "netLabel": "Series A Non-Voting Convertible Preferred Stock [Member]",
        "label": "Series ANon Voting Convertible Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_SeriesANonVotingConvertiblePreferredStockholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "SeriesANonVotingConvertiblePreferredStockholdersMember",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Non-Voting Convertible Preferred Stockholders",
        "label": "Series ANon Voting Convertible Preferred Stockholders Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/NetLossPerShareDetails",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A",
        "verboseLabel": "Series A Preferred Stock [Member]",
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r965",
      "r1011"
     ]
    },
    "orka_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Convertible Preferred Stock [Member]",
        "verboseLabel": "Shares issuable on conversion of Company Series B Preferred Stock [Member]",
        "label": "Series BConvertible Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_SeriesBNonVotingConvertiblePreferredStockAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "SeriesBNonVotingConvertiblePreferredStockAmountMember",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Non-Voting Convertible Preferred Stock",
        "verboseLabel": "Series B Non-Voting",
        "label": "Series BNon Voting Convertible Preferred Stock Amount Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_SeriesBNonVotingConvertiblePreferredStockholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "SeriesBNonVotingConvertiblePreferredStockholdersMember",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Non-Voting Convertible Preferred Stockholders",
        "label": "Series BNon Voting Convertible Preferred Stockholders Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/NetLossPerShareDetails",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Preferred Stock [Member]",
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r965",
      "r1011"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Employee Warrants Outstanding, Exercised",
        "documentation": "Number of Warrants, Exercised (in Shares).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Employee Warrants Outstanding, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Forfeited",
        "documentation": "Weighted average exercise price as of the grant date of equity-based award plans other than stock (unit) option plans.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable",
      "http://www.orukatx.com/role/ScheduleofRSAActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested balance, Number of Granted",
        "verboseLabel": "Number of Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable",
      "http://www.orukatx.com/role/ScheduleofRSAActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance (in Shares)",
        "periodEndLabel": "Ending Balance (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r378"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRSAActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Unvested balance, Beginning",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Unvested balance, Ending",
        "terseLabel": "Weighted Average Grant Date Fair Value, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r378"
     ]
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ending Balance (in Shares)",
        "documentation": "Weighted average remaining contractual term for option awards Vested and expected to vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest",
        "documentation": "Fair value of share-based awards for aggregate Intrinsic Value, Vested and expected to vest.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term, Vested and expected to vest",
        "documentation": "Weighted average remaining contractual term for option awards Vested and expected to vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Employee Warrants Outstanding, Vested and expected to vest",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that Vested and expected to vest.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Expected To Vest Outstanding Number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable",
      "http://www.orukatx.com/role/ScheduleofRSAActivityTable",
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Schedule of RSA Activity [Line Items]",
        "verboseLabel": "Schedule of Employee Warrant Activity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r363",
      "r365",
      "r366",
      "r367",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum contribution of employee's eligible compensation",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for grant",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Stock Options Outstanding, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Exercisable,",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant-date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Stock Options Outstanding, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price Per Share, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Stock Options Outstanding, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Vested and expected to vest, September 30, 2024",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average,Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Granted Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance (in Shares)",
        "periodEndLabel": "Ending Balance (in Shares)",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Outstanding Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Employee Warrants Outstanding, Vested and exercisable",
        "documentation": "Number of employee warrants outstanding, vested and exercisable shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested And Exercisable Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Vested and exercisable",
        "documentation": "Weighted-Average Exercise Price Per Share, Vested and Exercisable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested And Exercisable Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Vested and expected to vest",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested And Expected To Vest Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSAs issued",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "orka_ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual increase in shares available for issuance as a percentage of outstanding diluted stock",
        "documentation": "Share based compensation arrangement diluted stock.",
        "label": "Share Based Compensation Arrangement Percentage Of Annual Increase In Shares Reserved For Issuance As Percentage Of Outstanding Diluted Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r368",
      "r387",
      "r388",
      "r389",
      "r390",
      "r393",
      "r399",
      "r400",
      "r401",
      "r402"
     ]
    },
    "orka_ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Employee Warrant Activity",
        "documentation": "Tabular disclosure of Share-Based Payment Arrangement, Warrant Activity.",
        "label": "Share Based Payment Arrangement Warrant Activitiy Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Series A non-voting convertible preferred stock to common stock",
        "documentation": "Represent the amount of conversion of non-voting convertible preferred stock to common stock.",
        "label": "Share Issued During Period Value Conversion Of Nonvoting Convertible Preferred Stock To Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value, Beginning Balance",
        "periodEndLabel": "Aggregate Intrinsic Value, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "orka_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Vested and exercisable",
        "documentation": "Intrinsic value of Vested and exercisable award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested And Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of warrant",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in Years), Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in Years), Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in Years), Vested and expected to vest, September 30, 2024",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price of common stock expressed as a percentage of its fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price per share (in Dollars per share)",
        "verboseLabel": "RSAs price per share",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balances (in Shares)",
        "periodEndLabel": "Balances (in Shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "orka_ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Series A non-voting convertible preferred stock to common stock (in Shares)",
        "documentation": "Number of shares conversion of non-voting convertible preferred stock to common stock.",
        "label": "Shock Issued During Period Shares Conversion Of Nonvoting Convertible Preferred Stock To Common Stockin Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r154"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and Local Jurisdiction [Member]",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/NetLossPerShareDetails",
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable",
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r133",
      "r134",
      "r135",
      "r157",
      "r183",
      "r184",
      "r186",
      "r188",
      "r197",
      "r198",
      "r261",
      "r293",
      "r295",
      "r296",
      "r297",
      "r300",
      "r301",
      "r331",
      "r332",
      "r336",
      "r339",
      "r347",
      "r489",
      "r628",
      "r629",
      "r630",
      "r631",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r662",
      "r683",
      "r705",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r950",
      "r975",
      "r985"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r65",
      "r68",
      "r69",
      "r125",
      "r145",
      "r146",
      "r147",
      "r165",
      "r166",
      "r167",
      "r169",
      "r174",
      "r176",
      "r178",
      "r196",
      "r262",
      "r263",
      "r276",
      "r349",
      "r435",
      "r436",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r463",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r499",
      "r500",
      "r511",
      "r609",
      "r619",
      "r620",
      "r621",
      "r637",
      "r705"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r649",
      "r650",
      "r651",
      "r714",
      "r716",
      "r719",
      "r721",
      "r728",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r743",
      "r771",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r804",
      "r808",
      "r1012",
      "r1077",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1105",
      "r1106"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r196",
      "r500",
      "r556",
      "r626",
      "r648",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r662",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r681",
      "r684",
      "r685",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r705",
      "r809"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "auth_ref": [
      "r179",
      "r359",
      "r951",
      "r952",
      "r983"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome_Parentheticals",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r196",
      "r229",
      "r500",
      "r556",
      "r626",
      "r648",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r662",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r681",
      "r684",
      "r685",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r705",
      "r809"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r843",
      "r854",
      "r872",
      "r907"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "orka_StockBasedCompensationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "StockBasedCompensationDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Award Types of Company\u2019s Stock-Based Compensation Expense [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "StockBasedCompensationScheduleofAwardTypesofCompanysStockBasedCompensationExpenseDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation - Schedule of Award Types of Company\u2019s Stock-Based Compensation Expense (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "StockBasedCompensationScheduleofEmployeeWarrantActivityDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation - Schedule of Employee Warrant Activity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_StockBasedCompensationScheduleofRSAActivityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "StockBasedCompensationScheduleofRSAActivityDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRSAActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation - Schedule of RSA Activity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_StockBasedCompensationScheduleofStockOptionActivityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "StockBasedCompensationScheduleofStockOptionActivityDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation - Schedule of Stock Option Activity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Awards (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization (in Shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Units",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r40",
      "r64",
      "r65",
      "r91"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under employee stock purchase plan (in Shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r65",
      "r91"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock (in Shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r65",
      "r91",
      "r628",
      "r705",
      "r723"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares",
        "label": "Stock Issued During Period, Shares, Other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r65",
      "r91",
      "r374"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization",
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r65",
      "r68",
      "r69",
      "r91"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under employee stock purchase plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r65",
      "r91"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r65",
      "r91",
      "r637",
      "r705",
      "r723",
      "r815"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable",
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheAwardsTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding and Issued Stock Options [Member]",
        "verboseLabel": "Stock Option [Member]",
        "netLabel": "Stock options [Member]",
        "label": "Stock Options [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "orka_StockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "StockOptionsMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options [Member]",
        "label": "Stock Options Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balances",
        "periodEndLabel": "Balances",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r68",
      "r69",
      "r85",
      "r664",
      "r680",
      "r706",
      "r707",
      "r793",
      "r816",
      "r977",
      "r1000",
      "r1058",
      "r1109"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock and Stockholders\u2019 Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r156",
      "r330",
      "r332",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r346",
      "r349",
      "r462",
      "r708",
      "r710",
      "r727"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "orka_SubscriptionReceivablePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "SubscriptionReceivablePolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription Receivable",
        "documentation": "Subscription receivable.",
        "label": "Subscription Receivable Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "orka_SubscriptionReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "SubscriptionReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription receivable",
        "documentation": "Amount of subscription receivable from investors who have been allocated common stock.",
        "label": "Subscription Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r521"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r521"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r521"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r522"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Deferred Tax Assets",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "orka_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Company\u2019s Supplemental Cash Flow Information Related to Leases [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash operating and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, value",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r295",
      "r296",
      "r297",
      "r300",
      "r301",
      "r403",
      "r600"
     ]
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, par value (in Dollars per share)",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r39"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares authorized",
        "label": "Temporary Equity, Shares Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares issued",
        "label": "Temporary Equity, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares outstanding",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "orka_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series A convertible preferred stock, net of issuance costs of $69 (in Shares)",
        "documentation": "Number of shares classified as temporary equity issued during the period.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series A convertible preferred stock, net of issuance costs of $69",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "orka_TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse capitalization (in Shares)",
        "documentation": "Number of shares classified as temporary equity issued conversion of convertible securities.",
        "label": "Temporory Equity Issued During Period Shares Conversion Of Convertible Securities"
       }
      }
     },
     "auth_ref": []
    },
    "orka_TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse capitalization",
        "documentation": "Value of stock classified as temporary equity conversion of convertible securities during the period.",
        "label": "Temporory Equity Issued During Period Value Conversion Of Convertible Securities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable",
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r327",
      "r345",
      "r461",
      "r488",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r610",
      "r780",
      "r781",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r794",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1050",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "TwoThousandTwentyFourEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Employee Stock Purchase Plan [Member]",
        "label": "Two Thousand Twenty Four Employee Stock Purchase Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_TwoThousandTwentyFourStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "TwoThousandTwentyFourStockIncentivePlanMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Stock Incentive Plan [Member]",
        "verboseLabel": "Two Thousand Twenty Four Stock Incentive Plan [Member]",
        "label": "Two Thousand Twenty Four Stock Incentive Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/OptionAgreementsandLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable",
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US Government Agency Securities [Member]",
        "verboseLabel": "U.S. government agency securities [Member]",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r772",
      "r1074"
     ]
    },
    "orka_USGovernmentAgencySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "USGovernmentAgencySecuritiesMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government agency securities [Member]",
        "label": "USGovernment Agency Securities Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAvailableforSaleSecuritiesinanUnrealizedLossPositionTable",
      "http://www.orukatx.com/role/ScheduleofCashEquivalentsandMarketableSecuritiesTable",
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US Treasury Securities [Member]",
        "verboseLabel": "Treasury Securities [Member]",
        "netLabel": "U.S. treasury securities [Member]",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r772",
      "r774",
      "r780",
      "r1074"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofUnrecognizedTaxBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r423",
      "r778"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofUnrecognizedTaxBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes related to tax positions taken in the current year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r778"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r116",
      "r117",
      "r120",
      "r121"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofNetDeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "orka_WarrantsToPurchaseCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "WarrantsToPurchaseCommonStock",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant purchase",
        "documentation": "The shares issued of warrants to purchase common stock.",
        "label": "Warrants To Purchase Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "orka_WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.orukatx.com/20241231",
     "localname": "WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Exercised",
        "documentation": "Weighted average exercise price per share exercised.",
        "label": "Weighted Aver Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Exercise Price Per Share Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to stockholders, diluted (in Shares)",
        "verboseLabel": "Weighted average shares outstanding \u2013 Diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r188"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesContingentlyIssuable",
     "presentation": [
      "http://www.orukatx.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of shares of as-converted",
        "label": "Weighted Average Number of Shares, Contingently Issuable",
        "documentation": "Shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares) are considered outstanding common shares and included in the computation of basic Earnings Per Share as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent). Outstanding common shares that are contingently returnable (that is, subject to recall) are treated in the same manner as contingently issuable shares. Contingently issuable shares include shares that (a) will be issued in the future upon the satisfaction of specified conditions, (b) have been placed in escrow and all or part must be returned if specified conditions are not met, or (c) have been issued but the holder must return all or part if specified conditions are not met. The number of contingently issuable shares is determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedComprehensiveIncome",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to stockholders, basic (in Shares)",
        "verboseLabel": "Weighted average shares outstanding \u2013 Basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r188"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-20/tableOfContent"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-6A"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-5"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>123
<FILENAME>0001213900-25-021165-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-021165-xbrl.zip
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M[N[>(WG"_N!ZU;-]>#9-XE3_[\L/O[K'R_;GW:./2G.<J@2"P.GM=G<'W?[
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M3DV//D.(1>0]X5$-KG/I^W"HS9X6%5C<EXP#*^-RT:L_3;O!8%OC$3%UF-"
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M'YU+)V"VCV!SE9=3Q%+X N#(J;]. CB<M@%:V7NK%?">8<QW)\Y#+]3(RT#
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MZ(3TB,N%([:_(.T4B*KD5#VG ?C^M>4S45A9I_2,2*[XK4P83Q0'DY+<4LK
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MYB&>_1G#Y^B^S1(70+61;*[4.<RZ*D*N"Q_!A ]V':0%P>)>I+0UE+=W\)<
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MG\%&12:?3=J#!@TN(6VOVE*=::RA+I']174<ILD#.:;Z-S:&AT%4#>9Q&A?
MM+CXC<B))=$6>!P9?XA(4,5UW4VM3.2S7%N<+?[G;&!3C-JFZ6&T.&UNDY,
M,#SU'?=Z!+E,$I4VMX.$N!(CON/U/W "R.L:61=PU_,DPPY?WL)#*1 D?1PD
M6W:\8K1 &A!@CZN! :0-^CWZNW]/;,T?AVNZ5A/!^WB.G@N0YDR)6T9ZM\EN
M2E1PC $)<[ :SEY'\K,I'H0Q[K "):<8)80N!+UK>J6 =QUAK0(L+0IJLDD(
MXYH)DP4&)Q!MH)%Q&(635%WR@=74FL"H-1UQ+')W!>)Z5#ING*@9=B+$B+W7
MDQ#]EC%#K>W4#4=L<PAZ'6& U2@.8+#*A@IEX.F8/M?)2/.O4&'7HFSB2F?$
MJE#0C'1D]M!!5,85%YBXTH3$ (W.T^KLXZ058]4!> .PRC@+9#Z.01I.9_XU
MZ/L\;T^\LW'I;W\\XKW>ZHG?F$V<@) $"30J*^1YG.BP+1EZ=[P.[@/J0ZPI
ME81DFG(&"B;0H-EK;R)E@YAH9JS%9/0<_@1_FN%-1?-2+NX0\T% ]?/M/3"W
M+XSV9P!E&/:0XH4R$ZZ**=X$S/&U-4#0+L?,&W%2 +\3)PEQ"IEO1YK S'0Y
MS2+2]"IIT.FEPG2X"(.N+ZT#'%=-TJQP"<,FX"XMFK:<X^[7\%[E:I*E 2K^
MJ&]''5.C9J@Q,-5A65>(1&'B4O-YXF$FX&1-^A@-@4G>W5O]#(46:?E.:@4M
M#X/-E5O\O"OVXBL0;*[5*HC[ Q#=2W/E9;*W@45=47?'6FHB9Z/5;@#=OVHT
M#?W",^[-1JPV$O!EJ\-/W^I MKIEV]J>O^6V]9^LM6W!+;<M_,1M&Y WD8LE
M7,-W!?+6'(NP%;[[,/#T$S;0F*OEXGAS+:\M>*AUCZCKEO!:^%2CL:HFN2:?
MF6AB<G)PGF/3/+HY3C C8QB9K:"517F+BZ)B?9;&LSMJP]Q>,)P4.2Y19B"Q
MU$',_)C-UYA>$PYV]P]@DX<%QW$79CK#1)L[1&!1%2'KX-48E.D6.WHGJ8.V
ML?M66;L;FCF;XN4*\+8X30=A*=CE,<*8C4;_NBL-)Q /.39)2*!KREH5I_92
M" :['HJ/R?\%>?]F)B3U6XJ^><&T8FX*8^18,<+0$>S)A2Y)\<HITD.QGY30
MD>-<@:I9<?HQ_.R17.><^7]>ICK',E@2)(/UI]SCNC1)S813J<1HMK,+,74Y
M<)/&^%6EF[J@:=S(%J":2,*UEU!CE  ,?V!G2+\:E_(V!=C01*4FNR.C'H.<
M7X[B9:3F[,.,==$F"JZR/(FNT!_IA((] LJ^]C>_AB:RXN(63#\P3'^S*?X^
MZ:AKX5^>;/$O*_$O^UO\RX]SFSY/<K_U,9%;M>,.<^9)+(XJL$\(_(E)!B#Z
MT'F'< O)5C4]Z8Q:4H.T@E*@J?=V!R:185%6-K)\\>DD)F7!*S+_*&^3#(J
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MBFWT(C[-<_\>OX@UT*K<9;0$Y([OLP4GC50F%9!J:594-6Z=;(8?T[2*C3M
M7\C"X@\G,4"H7V*.INZJ"H>=3!"DH(1A1,FANH@+I\$KHG1?P-XI"?LQ:8E;
M =T>'X%NAX!NCQX<@6YWV<3\%.[R>V?KEIE3 JF^<(ZYI @*X;W5CZF!)G\>
ML<LG63.-W59(V*VX8E3#1V2Q9/+IBE!;O<M=T#MU,%8P *6"*,&WE <NH<93
MI>T9LZ#ZI!*5J&E&!(QA+&*79HS4OMA92O+5TQ>OK1$I2G@:"^!)R<X>*CY8
M--=5L :X/Q+7?Y[E>!#S;HN.LU<1 J/!-2R92P@J/'(?]A6S+]'(QX7XI;>C
M>7RDVI4'@5CORJO*11<C,1"M[+H*ZTZ6X&S'XQ#CJ.XHB8KM*,3XWZX6AO>@
M[_$:7FS!9P2JZUT?GL6XAO6VT;\CL=9S/_E5[.(JH8CX#CY<A.I 5HXXVAS7
M02;5 X75L45"'HX*4*"7E@F9OW6D+6Y7+J1)<6D)GXI)%@]^,QU%GE^6S05%
M4+(]HU*9M3R!G.^L&[O%-/LA'^07K+0F/<#8WT577B=G2T>:U<N]( Z:]>"H
M/GCX-8>,$^LK!8!R-&)=UI1 Y^!U33BD<'K6X4C/Y]O.I0ST_1T2U54OH34\
MFRQ=KC89E2$EH2BM_'&C2K _8X-02_LDI<\5RY&%;AP\YSN5[:?[K0>HN'5R
M* J32"2*['4'.V<8K]8(N350A5.ZUME'A:QTUL#'CB<\9\I9NNWA0'7E9G>$
M1'X@WE6W%0-O!6NO(8B @83<NEUPB9: .HB8E46#MA&X;DT (+@S)@J=QY<0
MU@N/!HO>%/].1M'I('GE2<QMBN_SLR!L$HB(JA/\81,D2R'C[#UAW[)^6Q$S
M1)4,QBM53OYQ5 $A!U1/E@Q%&B=]W:+EK[:<S'[T,#__]E7^^,&#TR\>L!;J
M\">C >18PMY*&<E#G&(P'8)T6>D\,^+TI)P9P8>@#UH"6)+*@=KDH+^',GF*
M"M):O&0@W4N?<2_HP2WRY\N./1IP&FT93'.?\0,$2"H'BACZU9M$)@DFR->#
M3]2CL^K@( \-Q^H]]1"6/07#FACK4D6<*6P+"WB:?[,=.-^P6J4'31ZT#'_P
M', P/B]@!I/U.WTP#MB;"!!=-!1 Y 4)N\F[""B1,MFZT]EK7Q'[HU4>RC$U
M=%#.@:59E9;V W+4-JU-9@S^*3*S<PY<.%VM/OBS[HL4(PLVQ.,X/8KD+<C,
M4_4<U'*-1C.,;9)#?%UU9@:)$9EU,)RXPG2\!;4>_F7)*:!>F)"3K9C>"++G
MPE=M3':=QMEE8!:0FYX3E2D?VC"\.5##?\OO/;SO^=<EJH>Q5(-A!_SEC$,O
M-3DGM:.N*98;Z-?YO4?W:9@XH>&CS1Q<!.S@>(1W H >V9*C"Q:>^?@^4=QH
M,R[GQ(5+=7D-^! ,_*IZ,U&IDTT]$N^_]_G]L=FX3V:*#SJRS=E*?*>P)=_!
MZJ)'7V,K;>^C,S.?4"N@ERTUQ*M'SKQ!B%\"/KN^A0*7G'HJ01NH-OXD^#/X
M7Z$Y(&'4!!^F"Y?04,Q]1C[3!2ZF<97Q#"_(B45B-]AZ960S8@-0T)^"G AZ
MG<G#-2S,R"DI -+R<;^KO@0\^(G1K?#2YFZ;$!]3@.16P<[/C\'.@\'.A\=@
MYY_G-OT^5^B509FA<+QM_)+-Z_[NNTF?DL?'A<.BEJOM0,EMWBCUMH+]0F&0
M9215,H^ACRX7)?+]'Q2NGOQ2J%=@F?E?DP5]3;%&EH+4%T[+<0GR60>GHI,(
MH-H]2S2CN&Z[-[UO6D\P+W9@AI6AZQF,&A_#8K//8UI=J&NR9 ',;YQP%7O@
M^A<&L#T_\^8SL<5<6,RV)R>($%W\9HW?U6NP&/YS&U8YF#\<IVJ[K,Q75;F0
MSQ9B\)'=P3UK]D?#?J9F^4L%HW% W=[)T7MRH>+S,=PDV"6!<!E=%KQ^+J^@
M\4EH?,)(]4/9]H9=UDFFC\%/.#2?Z4$YB0=CSRFO^ZP<V+_54FSU^G)'!.,Y
M8G0K9(H=9_N)P%&Z1DI(,J[KS8_,Z8!F%%J?VK=80G1H<Q2[06Z:$8-5[)7_
MB.0WK<^4V.26G(N.8(_PS?JL#UXR,+K<*W#_=&IU(L&!&1O(UWW8Z?HEM:H>
MS2VN5LMCZM'@O)?H"?6;HLX#F' VO5L8(#NH;!5+**53)WBQ165E\#N99XIY
M_M,-<DZE>7S12A=,1BO8B%WFIB.':VI-BMCGA6ZD][;<82$7%3MU<)_CH?'N
MC2U]A-XDWZ3>%O-P\SJ&41 ?W7:HD"R:6DC+]TQ>H$,W(G/'UT5W(D$>2]I9
M91$NWV]FD8_#7>,K$7,G$5L+WSFL"_%$FSP\S9XKT%S1-]8XUL.,PK.1KN/N
M$7.7X2KRR_8ZG(,@ 6,A $X1ST <-?/1:OAN6^P@4I**),V2<!UO,%[UA,0-
MG\A7Y2+>]V?<G\1G_DKSYA+5=8,,)&Z0"+S)DEQ,.*AEMXB^=I%F,#CJ)E13
M=(NKCA WX0Y0K&9<;NF(/]BGGI8'794YE3H!=(XX(01M40<B@5=3VWW*\E'E
M_X]P=KW>]4.USJ,!.'H:YPY7^I@CT/7/Y!:\1(#I3$-1K_R9NU/)GH\IO/'>
MB-]F%_64+[^ &+;D.YO+VSY1!F1=RRX:!X6*$W33*ZG]FC:IKINM%.NJ2/ ]
MG$V,%-E4^GTD+R-7 X*]W>+D355M*'2>- %2:FYJZ 3L+&$4@*984#<?^6AA
M4KI'6%]"G)F''DA'[061)%L9=_C:NIVH\P@*/!)O'*Q!*49_8LL[<HRT*N@S
M970:"!W:2K9GU0Y[.6KI:2D)JU5%9OS2;R4%^,^$W9,0H8[9\U#5MK3[TYR8
MRRNX+2?S$,'8%;%ST<NMI,37WDU\13Z>'(F]U6'4;S!U*?G26\I*%D)?X?A/
M4N*/TEYC??SZ2ZZO!>YY35:5K.AE6"_)/[@QZ%_#&S/-G_F.\1&N[0=NY@;O
MG^QJ]*_"TR; *?(QH_,*=VA9 V>+8>E)R CWC"I9\(C8199SP--5W4P?'9\%
M77$_WI%18=:P0O]7Y0Q,E.PG,)=#1G<RDL\X5R*60<ITT^+&PE<W"NPW)6LP
M7D\[MX:=7K= C4=HC@"RQ7#5LZM!"29G'U$+N,YDAN>A5"F\@Y%,(SK]:'HF
MC&36J2SL7R9M-U7F&9U)2@'$UEKD=6#&GE[+T\+_-UN^@Q==N:8'1*8(O4\)
M\-^*(<(_09>;?:-&NM]?R_W6=*<H5QS^A"Q>V56)!&* 5:4]2,U+94%LV1 -
MM.A9I>Y\[.VA!2'=E7T%P6)XVX1Y!CM]GH+]QS&<Z4<SG]E$S5YO+5G7&\H<
M2FQ+*>"4)ZV=;S$7GWL6+;/=$!$- \NVI(J"HH%4WZ6K>9J?VPD\+.UY_@1K
M6^TR"T-)WQRFL2.U)9?$LN1SDSI\T(L$817/9*3&X\O/C1?KM1"G$%0R=0PR
MWU$O+<\1K=UUE45G4!H'<UUN#7,68:79B>=ECNKWX%I27\FXEEEZ,B6-G-33
M$45AN/S$M 7\PZX8G6?C@@' D5RUM]37$AP"D!)-940P*%<1IS3L2.D4!UQV
M?$AYAP6VQ^A,ALE-'S6'/2SI_)+8\K45]JVCH_/G-K=_X@!$"N^TFSL!Z3Q$
MX"D$U*)9WQ?-F>VC.4_S[TM\*A@)<_!,[_B&A(O?;OL5B%0Y"&Z/3E'(26M8
M-;^O:,CA.9#UTL0:&7C$<L#-3<QDAC%JQ5P[4+C-1&9EO:)83,LKMKMQM51D
M:A=XS*;7D*&W&3(S 3C 2K:" "!<F=/7+.YJ%8U3D-8)GDT'7W#/)7SXU[1A
M]E"DRQ(K31'1J<&2_%:88QEF+C;#:?XC?= #)9I>4K:](KFG$,]_N]OW[-BQ
MY]BQYU_2L<=?N=MV,HQ"5HH&4@GG:VZ*2,>D:B(VPC"^+R$;OM4X1$RYEB_!
MQ@,0,EWK/TW'EZ,H.(J"]QL7(,BW;*MZ77*[<JXQ)TU^V:XX-$)&A)F"8]OA
M>#N/M_-X.V^EJ)?;_I8=TUSJW_I/!74KD9F$M2\AI>W=QU-VOX(_V%.3S6#7
MWVHTA"MH-2N^S*NW-?,GC&L!C]+A*!V.TN$VX]+XQVWN8U_5OU(.J"-<7:/H
MO%Q$S4A\;("\8Z ('/MN8,)R_LF"CL>K>[RZQZM[FW%)BY[;]1&OYEU5$1*J
MV[14;A>;XQ!CM\0)%]6L[!@&B,LZ7VVIJ(<\[66U &(NOR1 &#A+-<QVO,3'
M2WR\Q+<9UQJ9"_"WW>86K]N%,6>("F7X#7'U$7N9D&Q8&%]!&L @:RI5TYI7
M2?/:/^D5_E#3N54YWA?'<KR#Y7B/CN5X'_L=.ZK)HYI\OW'=-KGCU9SV/UJ%
M?0M/?((RDV?1='W)I4"=QJ(+XK$UU*@'M21<7K?+>DE_)JABB7V[]/5^8GV_
M@SP2XW].S7R4&D>I\7[CJIM_;IOW25%W%JV*V)9Y?5539]]Y5Z.2=(5X>) B
M";O9G^IBW@D C +-YJNVKUS=<Y^B$ K?I_*FZ@8/PM96E=3 <@V^Z[9!8S+B
MYF+LM-5H$$MXTHF/.)VG6MLP]M-(=:ZJQ1@#/-%N552%XKEB<RQ^ ,TN<A,Z
MH*8"B+GWW K$I$$-"67WJKSN]\I+PR,OZUEMU.C)^K3+Y0F]C,A+3_-O)P%J
M&9,%)D@^+*)!TZ;))Q5(M]G.5O6<0/.C3'+AO=J]C8SH+UQF KE.W.;\I;)W
M,O>8\MJC./R"*D5C/U>K-!#.HSYN'H"(2F!O#%UCMD9C[&('/7R5:_$5TX*3
M-' 3#BX\2DI2X[$XS5\#W)^NOG(5K&%0S+L6[:BDWI#8-_?GFW$URZJNKJ2^
MLS_PV(%H7]%ZU5CPN!EZLXN4JV'2H#0"ET_=S;=K;F?@&$BM&XA>2X+QS*K+
M\@IP;L0VXE[P$J*:];*5FG![^>B9KD)6@4K3E2BI26>@<X;G9^/S+->J-LS0
M1T)L>:<D_.]L&5X'G1P^7'9]QOW"B;EB7BDG0/Z4H]57D*IWJHSR$V)0@=9]
MR5( ^S)(]00V[ RE!PL2GN<0)&< ^:$H:6V]\7 %G8>&;ST-6\N>T:L*5(CU
MBNLON&FN(^<X.[>^N=9=-:,&RT,]P(\( ERH);0FJ ]#A#Q!"XQ@#-A(TYZP
MO#7MDO_WT8,'7QDS]C<OSY^[;KW"+0+11!P"P9F;=50P4BVR2!+ ['0D-?<+
M#9T>N:PO+H/.D5-/B59Y[\SN0J'L(T/+% I!%W*5#"TT0],;B,<3@WAW=G/V
M7Y\2<PCK(<'4PV>,=T*+AGKI6L5ZEM532>R"4P5B8D7I+3Y6@MPM\?V'=]2S
MHP![+N/+D_9?'JB@< :3RO" :#56E3ARR^W*"(P YO<=AR?H:F*YJAY_*R%$
M83$82=ME=D-M9D%] (PU!)6SC?(;AL^5J]W@ 8OX;KU._[T 5Y$'-E+!IW)E
M!\'CKB_1763I@B0M">)=BD6GXZGII(V% W5BBRH8ALR]GVM_6ACA,RX4GTL9
MJS2=(LN,&%)MY%KQ6_:'5Q3VX 6182K'+=7Y+2/NVHFZA-?5>+4&.D#4[IGJ
M5:_JQ;9<%9G?X(EMG<623VY(O0K/;4@F8[&#3)R#9(AK@4"-;&UM795/,B)M
MTA3T2B?UQ,*V3K4K!('A'U"U0E^\K**O)[[@E13FL952.;MR8O#P,JTHGT\:
M\4:[3=^7]]F4O)]XN+L57!=$'2NE8%_Y:B))C"[+/IO6H1;SQD.\?S32WD^B
M,LLF^FCDJ^O!"W9Z+Z<X'(:D,K>=44&B:1>J4B1HOR<BR+B_U5MIP#CJ'<&N
M;G<!?R%V561R*/Y>@9+5+3D/22VVT]ADQ5Q7JY7>AT@#--OQ##/?P8/]J'7:
M2A?^GB>&OMQVBQ6??JM@M64G#S_:%OF>;6$7*TANHCBC^',;5F>1X2![_W%"
MX4\H>B:@Y97G>#6FP\7*5ZX)6-)65/RZ,9>O$KUFSAJ0\$9JOKB_IXO<Q@YQ
MX\-*SP@G-JZ6+YS>[I7&9>7"69]DT1TMDS^W94(LAID=AR(?M=LUDA"5Q%Z8
M4J_H*FT]KR&\;1!PJ_#U;9?O*ASZV-^>KHDIY$1T&NW(=3CZW"<P#*5J^E$@
M:(^S(FUF=/-XU^6B<DSU+N[(@W[X*),A2\T5C[9M''W#OK#?'_%I_H2+O:@_
M_<-')WBJ<"$PQ-N<>*R[Y=\HW!K&F[%$$TE/S(\;+B=#A-#)QPFC)*)313<2
M@=\V/$[IUH2\3)ZH7W0Y/!:L*NQ4Z&1<#UQ%\G(TDB1Z!?Q 2V;-</!K"+(3
M*:^'5VI?'!C"0P+.&VECTI"4,V2I_-G1A:.3RUPJZI"J''1++ O?JS,:I;%A
M^?L]J1SI/L\&WD;*M@1%AF[&F2/U4_9X4WP+X P7ZL:.'JRNK#M[U]2T(HP9
MFK)@BKYR4</Z1H_4>E!FILUEV:U+XMH0C0OM=X'Z[88_P;09\KD= MS'$-X'
MG\/91##"=5O+@T.W"M*()4\J':(@(LN0VB1$0>.HBO8$ 5\0_K2^U&1LE-NQ
M+<9OFUIUM(U9XL^JZ5C,M&2"Z>6FEI47X9[VT@$C9IYN/SB5:6@/7U%8_5Y]
MGWP>$KN1#D';S^ZW_BVR>W7XSL._@D5DN-1V4IZR@=UTHF#@3 F(6H)<(ZZ6
M\.V)KPMO5+OBZG[E(QD+UG#OKR@=  +@\KK?UH,]6[6F+8]\"9-GDW4Y5MSF
MZ-E"4E3M7GUU/__\T?X(1]_-Z+LF&O%\&U6-',)%2W8V][C' SY_=$(/%3E[
ME#C_.NOX)OCDET?XY$'XY.,C?/)XF]Y??T^$E!#-(<-3(C2;:A'44T<!.;+:
MO1870?ES4T.!O8:1AL2T?27Q!X+$M3ZLP=4)"K%^*U*;FMAH>>B4A4L&,VD&
M#O;""JCI"2*BDS=)-'K;.(>GH@"1*.7D%9;HHK:E\26%AB#5GDE8Y:^"]@N.
MA=)C5<8SYE:,8\03L \)\DG 1@SJ7SHHM8889:M^4(/:$4G3\[R'4/<:Z?(\
MI57OC1A$4X04V[&IC7W/_]X&L_S1@X=_-<+$+/+:X4C,K1,J<TE+(Z*]")'!
M9*3#J3*+)]&@E'4YH>7C-6SH2^!KSYQ"MJY$(%F#([ELYUM-_UO/AVAQ82P^
M9Y7_V.1/JGFUGH4S\.A!$?Z#_SX/NI_ HYK,Q+M>/GL-.D/E0:6 POF/_^?Y
MDY.'7R'F6E>8TVKE>WWV6.!P4=6R48\]I:/G/K5OB-YND"Y8' %%J)AG9VT#
MF7>*.3\Y[!;6PNI#B+Y_+_CMZ5 G35:](=15C8]*Z<-J#H>D%E0:H,C8-]-&
M4&%@\'MI-#T2*@,G$2T.K)&"?>-Y_[(KZ9/CHG/!'"(*U4X0A'L):U[.A_B9
M\>46;%7!PR/1-M-$DQ(Z$M\=M'5P0)1#D%AP2\F6\*U :F--U7?TSF(4W&6B
M2!F/'_:(-M9'BG'!I(_!T;[\X',XZT&;'&0*1>>"3+OFC7_>+%>*8Q"N18(P
MA$T.(N2100J>OW(PAG[4+1(R;57*!7<MX98M4912;I)38BZTK@$M@S>$+X1A
M@>&.&@^PA-/N"/T1VG33'/X59/!D+V0_!7LA?_IV8)Z,NX\$^A0N\W-J!94:
MIX4&0,;<X47>7C=5)]2GTAR1KI@&)*!KH! Y+K/=4&H[7]97E43!V7*L]!"H
MDF4BA3YSEB6A&UMN12OMF,"P$O,3E(=TGU\AC[K0T'OEF7"I96;L<P,-%^0#
MAWK=$VQ8B/ .NXV ,<)_SZ6A%'<:/KDL5\L8F!-41B&YUF'@.!19;99NX%P"
MQ6N>__"$+4U8MO8'-QW,CG6WC8BT(UD-A>$!*,33TU_MZ=BR(EB@VWYO?+2;
MX^_HL_ W"WC17W3SUN7;>KU=9Q1^U$@EKR(]76 5P2SKPE@Y:*3+;Q'#B':)
M$;!\42\H-T,-!RH7UB3S?X&UJ</AKZ@'"KVO'<I5<D9B("NNE*9\@HE3A>$\
M_#R?3.M$,GE[,6S?L-_42YI?DG8T*2W',^44AAT*!N>%M3.*(Z*\^QY\GJA7
M'="<C<X2;60NVX6@KMD IAA>\I>$5C"K!W7#Z*4+<67& 3Z]-6ZM )9)<GE,
M-BT9O>KMINZ2G+RL2["OR?\B$_"9X)$SX726?)MZA&7C7CBKYB6C0@I9).FR
M#+97(66MWB)"BQ[@_@CXJPW8.*6O+DON(![O>9;Z$<F#63*)K^2V=E&5BQ4Q
MO>U_VM8C70L3?RKYM.*-NCG+4[@P8JC[Y<Z_SN?F3_/7+?BK9[&/-2U,%81^
MTDFJ!X"">&4G)5:LN%/_@V/DT+O>UE]7B-?7_5INI!P;PH.T'471 0<)@U<_
ME1H"5I=X#0/G&SG&<B+2N,9'@2NX2PK]]UE6Y 5F#E#\O5:UG$>2Z;O;?><3
M@HV_Y+0L15^"$N-\OW88=WZON[Z.A,9UU.$6UU3'1*$%B5$I<XT+.I#?$R3/
M-MS7CM%A$B.B3#$7&4S+FMJ!'G;:%43J0V;02F1)45T.U5$9R[3B"%?!,V.'
M_V_)\,Z:H3[Y1SU_,T,^X37AE:I,7<.S?[Q6U_#KY&O?EJL@<<Y9<1(N7K[Q
M;<3$?^W ]<$9#0J=3O_+8)?XSFIH,8"@I/Q*/-2'7WWUI0WCV?.79]%')1IV
M<31EM0H;F'"THS-\5VX1M)U!O9'V#>\/IZ6C<!Q6Z>AU?O YH'@C'#*K\^NG
MB_&".]+C&O!=&_CND/T(8GQJ3\$@EWJU KIF1SFQ>3U(?ZIY%;0M?FR!W18F
MZ$VYXZ89ZRT UAP,(ZPA0H"%](?LJF#3D:E6Y%4MHY+P9"= IP0KK"6]P8J>
M1W.(\MS@W['.'L&,K-8$#ZXZZFD8O8PP,A(8:@P *"54\\WN!DXLL<K968NS
MBDEH'UN?=6VPLG:,KB1I@:?3BF. 5\A>'F_(!Y^#WI#)/32K&#^$XQBL1+8J
MU,7<)%INU,$%)Y&PZ,U"J@ZT^E3 L7J$Z;,4EZ!KR<?,*3;&, _E&REUMEIV
M=C+;_"IX9XHJ"Y,IV/LBOV[;;5J/2G?'MJDHH)G;G;1;UQ<9&EQ$) @N@324
MJBYJ"7C+LWN74XA/M]Y1^$_>;"F] GRY07;AKVY8_;JR9&JO52ZQ;-VL[0@#
M1ZDX(/01Y[<BV $6O@DJD7)]-9?F=C,FW=C1"$ V'R8<]K"]%EFV07\H:H\J
ML=>K%L"D1%QIFZU,^K!2592CUO,N!2 L%PE4*(*K:7%U][D['V^]B$J37_CW
M?A>Z\+4PJ6:7\7[L\D5+SA-U]5ER[(F\3EE0DGIQ#8.;O^W<?-5GA5.X6N5S
MHD995]7@F[V%D1+[F)9W:-T?R4E4X>WO8^J8IB-PM>/C-R65XYPL+4&PL84!
MXMS(B3=F!]\8RY&IF)]1H&S5;9"4"SNT8F!3Q%V%(X2,5C\$]UB"6_@$K";-
M?4498)W&*TARJ@?$J:35/)GM3O"_2 [[QN/AK]OU5@I'7+-S7HL:I>>EMK4>
M55F?B8XF#D=HZ%V<(=WCL+#(9660/F%6T-NK:G%A-Y]7C[0E%8PO <MKV+..
M J2F4T%0&'TB73B.E93R.5SONRWU/P7-=;Y/?+ DMT'B;3#!QUGUX#X4<KQ
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MZ>;@5'4+PO6P)[AAZ-80E+MV!_ M(3;;<'F9NFO/LXV\"@V-Q[6QQ,9WQ)9
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MI]D/$[]E!J(QUH0MEA>J[EVA;)_?>_T<=6*//GOXU<,O[Y]Z-<8/6Y?!>JO
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M\I+SUN$4LJT'CU: +R2[$Z!&79BW"[$"8HVY33:$=D9>^7V7>C>9>OKSVQ1
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MB6Z8NYI\+3I5JGUFBWFF*&&(,CT1)RF:1K1+;>-\U&'15WOO$>KJ;\^;]M"
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M1,ZZNFFQWNY8TYA;M&;'QB(!9F@GAR%Q1=>#$+8MME4A_-Y$%;CEM)%P%^L
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M>T]9DJ'^ VBIHA 3Q19F:5=@@KNNP/<8Y4UX(R5=7KM3.*^[G(@2J4<!. B
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M'OF]NSYDVRUG>=3@_TA;\!?P]J,%;[NE?EY/^LP12VX[:#IVS:WRA#$UAP3
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MF1'P\NIQKHYQ4NIL;]'F<0B3"/H(:MJ&%]@/&SHC^F;=5'[8Z)TX"MK8G1/
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M]@FM0/C([K_,S]IQ.EO7IWC-C,E2)YZ(Q@FPU>TTD%!6AXZR0G S@JY"+*B
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MP_$?0!%"83-B*+QQ)S1]I9D]>3DLNFN B1U@3#HFRO:"SHTSR9MB[_Y+PM(
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M0AGU86^M^V0>SL(D?;%@DDYBDCY=,$G+;OI=.L4DT!=XD4+BB^(U.<QZ")M
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MG6_R0Q_$_PBQH<J#R1@[Q[0[S4%K<37E8^//4%:2O%!VDV>X-R![-LXY!+B
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MG/WK-\Y]1-P@F?607U4U'&#:JJI,/N)QXS[./0>D@5<0CE'WES,S/@BD#AD
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MK3!F=3/O\G7N'/).)Q,45OPO;)\ !C%0A']/RKB:$11LMJ!SAY!N--<P2(!
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M<3R'+/!HXM!"'"B!XTX8),?4D3&J-O40LWJ))*'M^_E X?J,@"9PYOI:TV1
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MSR6#WB1L0)TH>("C+@N5,.)L. ITG#2-UXV/2:-6P!O6SA)A:!--!G[+6[Z
M47<+21,T)9=#:3*F"M:X[=106C108-)C(Q'$;9G$:*/B0X[DGR 4MA?P"/0
M?$"_W9[YO0":V M7$^I0,$O,+<KJ1P@328">G6'O^ZM@!').]@GE;0D(20/(
M3<HW\,6B^Z;U.Z-@@M$BL:F$[0Y0;^!4-B7U/&E^L!/,779BZ6U:_S^<V>,<
M]Z$/;<"V5TC>-\3LW[MPBSED+NU)W=;8J3)L7$O)1J6WO[S\UFH)*-\.?R5*
M#%"RX5!M*,G9*PQ<A;#R5U^]""NQ[$J9&^I%MT-V '\@EY,IPJ]KTS;)%0%
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M@B/0(<<"&PE#H;E')Z901G'8D=TZ[!AEP$(9<4IR-\HMA9H?10F6?"+!D3+
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MD2WHP+?;,0J2 F40X312],+/Y$!3/KTU[G7BCH,._XXL?F#5:'L1Q1R<"G+
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MR5VQQXP+:KPD0'&N4._<B9T2NA/"ELF4]C+9V?YYDP?.IP]<=A65M?>'KC^
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M+))9O_X]R]T @@M$4B(E=$17RB2(NYU[]O,<NH<FXM7L2]2T@5O9@EL1-G:
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M/;! )$49;+46H_12-RR>3M/^S!E4R .UKD^>'>44B,CMDH4B<4:FTP&G*B=
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M ?*T*/Y@QW>]=YW6OM/I'CN=@X/WTUQ&,+KCXU_S=RSPAJEF _BO#_;)"BQ
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M+XCG$!;4/6P#!1/1B" 1K7:]7*&80?L6;;9:,<93D-R06&,/(99QZ0A=0&O
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ML.LZ^Q^8<_+-IAIK@X?HS@^*C9:4?EKEFDDXX-;IJK \HN89B!=,UC'HMD$
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MVM^2WRK7DV Z6[Z:Y(!0/?O>(UIO]Q'H4N<1QD\3^\N7ZZD4C.?3V*NMZXO
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MUZ>"K"8IUF\8DY9"LV$)XMBA5Y>RO5Z+&(_;O&LLKY:24]A@:8L*UEY<=+V
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MTLF5(YDJ;*C. 6(P&3^FN2;^?[P/=MO 8:67E8&PKFF=M+AI[-&I-3[I+ P
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M#G=X^F$,7.KQ"-@.NJ0U_G5L4\!0?-H:.#Y6F'*!GT1.$'-/#."[<P\,A['
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M6?9J+'&\)5[#7/:DS*C,DU/XQ0A]AZ[,*^*>M+LHC&-LR\3;@<+7P<2/PM_
MHNE43S#\5B:9IKL6Q[\!7B[RT"[@6CU7.'# +F2 <\C6;U,M6S'_WJHTFI/:
M6>ND>[S8B,\"HO#)ZN#,VPNPW0G<_QX/F-^W[ L;),4.TX?#Y)W%EF?A(],X
MY # ]UXXBWUTX/ +3)N[ZCWSN+A+TS31]VN_!=7?92.LID37#/WNA#M:YHLA
MD%+B&5PA54#PV\S40:2(O1)?WV6H5K/[TPZTROC*"%$ W8S[KU/L$!W2X9M/
MP+.] 3PI^^O<Y>3O^->.APTDN>]"8"@A[@7LH1ADL>U^XWBQ#X&"++]6# 8
M,#%?A2Q7!WYR9_Q8R"35EJ@U_!%U:Z)=2?>:[GBT\AR/QV#VZ7Q=XUNL*""+
M,QQ$0]B(SH'Q._D<VWX =-,PB^1"NJ5<E0IWDO?A)<^CCQ6]HQ%W9*JZ.9FO
M;O]$N-IO)6508"CC")S7O9\AO6#O&LP!S[#P]57I8%V3#C:?#G9BTL%*243
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MB5=C-NQ*#M$@=E/U5A81U&SFRJ!LLO*-XDSVM>0V:9X!D9_J$3"5P]NS^8\
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M"#T!B/K[@+AVQ0B@9.Q%[A$V+ 1%1QN[&.M.G;KTZ-2U$"A3"7D4_*,$P,4
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M3^K%$(4G:K -$T4F^H=R5*4M&CC!%.6<RU?(L,M6IPSL,MVLE>[VE;'*M1%
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M.1_%-Q[@*5C4=BEK(]0(6]#\, 1+][_4^EQ0J$BC>2O20MY)PSD_<96JC@K
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MW61F_MFKH=K=T5=E6OM<!E9>T?GUY?57F>@-1)>&TIKO,@@DVDW.D<$"B?$
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MT<H8%*VK]D[B[*YV^\X@G"6\OYT$DE@S+4O*K,W[X*;VDZ5?!K_BN7O]*@%
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MH$?UT..@6O3^>!M65/4[]7:SW+Q-*M7OZ9!G<J\_9A-X97AF69^F^I= U6\
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MU0ZGO )U&:A$C662NU.XS'#H.9)8@9VKS1Y;_PP?&*Q5%U6("H[R!!/&$G'
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M#H&7P64!KEJ!M;$ F7?Q4 :<CB#3XT0S.5O#1<L*0(,GX)DE.RP+R2O$$4X
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M@^K9W,1;N3IS;^60"0[M3BJW9+]NR?),_4Y!H2H)7UX)OYP,^A49E)0,=F7
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MJG)04)J))?Q8-4S\,&8OS/%F]"+YO9P[DV0]9186O(R-%$5D*_WE+<MKU6R
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M"=-MBZ5+F9<VV$[ )]ACN&.G(Q$J]VU/[MM.AQ54MW3(<$?!%U47<;87<8B
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MTA*1BJ$FW"EZ(99&LK$YMCMN#/&SV<2&G> B3E EG*@N$PYK #?'%\C;=1
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M;$2UL(SW)F%,& MS[<GQ*19"%S!M:9ZO+5I;GRI/3OHR.PY __FR2TG"H;S
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M++R$[!78P%1CM'!@I;1M<:9F?*:Z@K(G-<[>HL95%%(*(0BOF%BV P8<_,[
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M0S&7 @S1.#[&=%NF7.O9"KI%.-SG5!A8XOK:7E5?FZFO'53UM:5DH\U'\H&
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MZT$>EK/IWW53X*1;)4]BX9\\GS"H1AY.6K D4NV06B;6;)?EL%$<E@4?DN%
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MKTD^+4T(S1X^+?L.C3QB<@!J#VWL8^!#;9%A<2@M7.L+-C[P ;U"?[_P 6Q
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M4D6\V?4LM&B.8N#EX$)1&?U&WND)!"U 4K)2J#PPPN0E73()LU!YD&)O=2S
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MX(?8C RL!9N'V(D]*-0X$C6*Y=Y^!\F!M]M.)UEL-2XE#HJ1!!4L0%G)QB(
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M \$E(#Z\/IN_WCIB=HH^2FWX'Y$Z[D'0W"7_S%-?6XM;1\6.4,2O(J!>,V>
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MICL)<'C4GTDHI,D^X73U/9\K#.<RP<O9U,D[E+.7Y?40FIQ@UNB7>ATY&?W
M]R6RD:7?BR7=*3'[$]/)4?>.9H2S8K-X+P!;GF+I3WYC8;V?5MO'J5QKE!5
MV1MP][:'9O7$0UM/O+J>N&?KB9\H/SV(I4?FQ!<4AR ]S8)A]A4-;6OS[<(>
M0/T[L]RQHM!"/ ^O-BX<!B,BR-MI8=VJV25FYL6HX]'4B+%;#'Y>7]E+PWYP
M9I6K+[;)(>T_FG)<&]U94Z]ZR\#/)F6NY5"-E,TK4J97 F^,X4/^M'B>OIAM
MI@_OLW@2E5B6;#[/JMO/512\7,]2*K)<N[?:<M<'3;UN6+"Z&@721K@#C.B[
M[^0) 2/@IW][UGVV(3EJ>^F1"?(+][&.:AR]E, ?/#\L%\>L),)U!=;F1N_U
MB"V*;[!S7H=!&M<@M+?["-TN]FZ)JN6ZW]]KRN-N=/%IV3CF30/TRKW)V-[L
M."/]?AWI+[= ?E9X-3:8PN#H+;50S$7:^P"!01O\',NF\?."0R<_R; _V'W!
M9XFA N^IK^KK\"+G.AQ;C.X)1K^&"?>+ALDNX:Y:R%OO:-:%IZ*+\4&WW7>[
MO9';'0P.J\ZHKHWLOJCS0@LN_5&[U4&G/J<8? A=_<X=??V-;K!5@>[<Y?KC
MS6ZD7J7SXIZ]0XSC[,3.:G#^4')'+3DJ+4E]<^YTE#VW.QK==)J/OD^+P(W7
M''4[W1M/TR+0(M B\$$0V.L<N\-NSR)P7Q%H.7#/$3CHMMV33F?;"'Q81T,&
M4?#O/S$/'"XLG=B:PT$7Y@C"ZA7<(A8>DH+OU:FH)=S'@OXAF>Y^1>6&"SW$
MABPR+#(L,BPR+#(L,BPR]@X9=S&/_ZIOGK$U^Y?:?Q$T>0NP:ONO?3)_:V+J
MEG>*"W4& W<T6)5YL)+LL279NJB-Q8;%QH^+C<ZPZW9Z78N-G<"&Y8U=P@:F
M:TY&PZ=B N]H6+C<]W5/K6++4;OM4UID6&189%AD6&189%AD["$R'K9F8FN&
M,+;_)V!J1@#LD_UKH\(V*KQ7V+"Q%HL-BXU5DJKO#DY6E4E:;%C>^'&QT>NT
MW7Y_\ 1MX)T*$*L14&KL$XV!VE?3V++5;GN6%AD6&189%AD6&189%AE[B(RG
M5"^L!GT2/'K89V70YSY9OS8P?.-")T-W--R.1VF18:,MNXR-WHD[/-Y."9Y%
MAF6-7<9&[[CGCHX?06W('HK#NL&V%BOEA088'N[8HN&'L(WE#&8",9O;O7;&
M^_Z:S.4F09;-2L*O/W#;[;9513N!#6L86&Q8;%AL[#XV.F S6[6Q(\CH#49;
MP\83+2?^.H=/8P+GM"7G)N^Q%6P#QS<<46_@]D8V<KP;V.@,K4^R.]CH=MW^
MR!;;[P8RK!&\2]CH]]KN</ (Y=TR<GQL(\>;+#0:]-Q!]RE:P_L41/ZT%!%/
M<"JL#2(_=8[K]=O68-L9;%@;P6+#8L-B8_>Q,6R[H[;MF;<;R.BWMX>-IU1X
M?-8B4'X7LUDDKMD;\>W;7AN_-G9\TQ$-W9.5PZBL%+.QXQ\7&]V^>](_MLC8
M"618VW>7L-$;G+C'O4?(J\C8\<C&CC=9Z'@P=(?M[62[?J"J8QDB?N<%/)AX
M^]^SV(:(;SZB8QLBWAUL6%/ 8L-BPV)C][$QZ+GM8QLBW@UD]+K;PX:VCE\F
M?.R+7WZ>>I>_./B_GU_B7W]>FNO\Q#KM9;)^E5=LP:,+#X#%1]M%P_A?:9QX
ML^N2;=QNW=$$+NUKJ;>A]O!_CH[ *!;^]"?V.?7%T3F_$.SHB)[2RTF@CY)P
M28#K71Q)WT!]I@9P=P<XS]SXL?0'O/^ .]#!Y\9A-!61?-EK'[P*UFD-X#3B
MT/>F][=/VEQEBR\K>_REBLW"=JN;?6:>8O9K(A$PZWU?^3!_>]9^IM^HAY.W
MVR]>L:;$<L.YJ_.$;4]@5?SP^RL ,??H-C_$5ZSL_<'2X.&5O;L-7Z9VW7[V
M\I<[ON&N/'#0.5PA0)I 4\.L=ZKV%R2?-_T?7X#SG<0L$C-?3!(Q97,1"2\
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M41Y-8R#,J3<#Y"!A-@+H:[CT)NRX,V('BF5.OYSAOQ7Q'J*VU'H9C5*$CT^
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M2[1@OC=#[PT@DT>MSL3*E*<@4T9/1J;TW>'H^)8RI7NOIL*3EBG/N^[PI/L
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M*%$%/_I[ZTOK:,S!_''103J:^%Z ^IV!G2-X!/O(/AE[H,0Y"$U:E@<>O.&
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M"EOQ55%1Q+V8D,_XQ44D+C#"!: ][[:SOE4.SDG%J"%V'-(J/QP#BZ@B4DH
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MZ:6 S[ZD7B+0I7+9!Q'X(9@+T3>7G9VRD_Z#IGY^.)EIS*7=B=3I'O:*+I!
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M"MBN$!*U8:\GID9@T"D/W>'),9[TYK 4*6K4=GO'G0I%-8*D0GTM;)E>OTG
ME]'PG5?&75)G>]];> FGX>Y-X #H,:3_@HBPV(U^)9]L!% C*'+@<6%*,KS
M#O;>9 XKP7_R!V)LH9]$'JR]OJMFE: U'3<"34^]SSKKQ'+PL2)/.6T !Q2$
MD88?C[$@[R3YJ,D$.*Y 'G)31"TS/$@ZI76OPM3'H11QZB?8AC\_E!K( 3L
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M!F<"I,D]<KW1WRN C:HT=P";V8?X6SDI$)P[H IX'QAI8^^">SX[;['?PWF
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MH%: 4#]0JTI=$EX(BKN@:]L(BM()9U 9.Y5G@;@Q@* BH=P8E3\IC,6ZE6\
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MRU!/]I4X+IA:O(+0O,_9:7$.[SON1=+U_TUP/YE/,'" -A%[_]YE?[;.6^Q
M!2^R1QWUO2[%P^G"L/CX6L%B5##&X&%CS")?1OV6'7BZ%@2C*@#4A9J')R,,
M9 3D0_@JGKVD::>&G!.T*/1NEVHD WO>;G4&:$?(E^KQJ5D]RL0X,)R=5JA<
MK;*'JD&D(^2!XP4@Z\"6@N6 8988V9"[Q96[@U:; 89]"B"A?9$% 5BD-MWI
MOB#@L$)I(8?0YH<"$B*F<A<9DJ%WCB3@ZK4M5D&.G,OLC5-*J6%P)GO?!E#"
M*[@/WT\F42JI2L*;9](K%':0!DON3?5OG.PW9-:U!MG+@>.\:9YXE"<?TR2@
M#%O#86O890?/!ZW! #]&:S!4Y4A+/LDB3I\%_E8W\_NR]+WD,,?RH8-3A;ZK
M6=6SN@C1F8SQY**P\D1>\IKG*U=4(QB_U=.Z,QGJ'(!=#-:_AT._*= '?%.L
MK3)VJ8)>^':U4YU4+7)2S#[P@$OCMLJH&9UZL3R[ .=1XK-@>N//**A7X<T6
M.Q> ._8;CZX\$$,8Z5,A,2.@!N_DC%Z#^Y2AL<+KK(U\;WMHEHX]MNG8->G8
MODW'/E&&>AQK>IV0MX;R+NP!#&4CQ-/3AO(*I:T20V5-FQO*;M4F*%C;^)LO
MZ1@S=E0UF?_223!]%<3I M,_-YH(Y1KG5:^5%T*RG['WI-9!*6=V[Y3U3MS1
M<0^OH3IKK.C"]2"T?D[<X;#O=MNCS>P@-*FJUBF5<G_W%M*N>=X]!M/2T=;?
M@<S8>6K>=LGPA%]G;S("R5AV[E%!?A0NI"FC2[05TBKF*)FP)?/5P;VFL#I:
M^*[*'>8WD>#0^^XQ[+_=ZZ[S/<Q36V?$E?",$$FU00%'->URM2&+D5_ >%:'
MGV%9AD8]<!%F,\_'E6.9]QV+  Q,BC^O26V6)5H6=)[P)3:>T@E/A)?RSU3%
M*G/3E*Z%+2C>J=31;T1DY2><.M+*21G\!$*:WI(*Z$_4L:KC6<M8^RW/GM[4
MT#5M#!YR:AQ'J,#Q#9+;MU7XT29;?<GOG9J#%7-VRS\C9L[_*5UK8Q8C"H!F
MC8HJV]]B/XT?#?'_O[TO?V[;2!;^G7\%GM[;K^Q='01OVHFKJ,M1+$N,)">[
M^^K5UA 8BK!!@!D DIB__IN> 4" &(HG0 ":5$662!P]W3U]31_]4"C/2/A'
M6,>[$BM(6A>$UKS]U8RBONZ-TMC0<*[HF=VDJUWV4K9</N<YM-STN3"\'*2S
MDP8\S4.5>D#MKIQB55@2=@]K;?6PUI#CK(HXB*S=/>Q6VX>USJ*.:F48996%
M9O@=6P0<Y]GQ+#>N?5\=?!J+>L6RF?@2?5!58?#)(FZ4S=VSI4>]6SOL+IPQ
M*:GQJLC>Z<!(*J>[K</JGFB1KA6?B>7^]4ZYOCXK)H=E-Q[ML%FM'S8:3;GC
M<T$/.3PP+_*W0>4OE<'M12-?90M8V0)V\Q:PLA%- 1K1Y+ #[)5_/+]6TY7U
MCO)%C6D6'>^O!<9*J0#*7"I D U"\!@9O&\?/U>.IQ*O!0A+AX6L$^2,LFM#
M(SLPQ#LP\+Y&%5DKM/\%W..)R_*$60&BXI<.*6'ID")+>?.RAENK$E)+4=4@
MAR[:*6RNY&16\B4J-HF64]SW>_$*"LUO;^-0 X7UNH9, 3_=9RZ'#O+0.-=,
M0JZ)/CO!4\&;!,EU_1Y?D.BUD?RC=\;[RGR12O.PE:A1B982'/IU**R@859U
MP@HMZL?T5E9\HB1J7PX;]6[DD;S*18E4N526/Q[ 8J_P:UR,]\+</8J%4+?-
MP]'JO+8X^O**L,:F5CNFS@P#*/G&(-^.X G453,01E'HDP_D>5WS0B( A2>F
M0',2=N'_P*+5R/."KN7^\R!7D;63%8$6M J>U<@D@)G/:J1(#FM:CBNQ5#TA
M0VV9M1?9>:\D[%4V2-B+\VV2Y2+%,6LEZE46)>K-$51FY\GL/)F=M]/L/)EZ
M5VRJ\N)6@+$7R[/C EG2M:!TA7C'Y8*42DG%HE!1)DO.V0F^J=*L994L*3QR
M+4.2UC[R[&J':I7U7))Y=D4E8:<NB5=8XKU^%"\)F.<LUU;[L)D/X2FS6_.7
M/Y)9-H_:K+["@S*;)UMJU"0E<D*)>E7NBUQDN:F-PVZC>]C>$RU*D&6\H#ZP
M(#R6G>QMOV:-R1V?L5W2DI3(!R5DOG=>-"%8)/N342OF>^<N<ZSPJ6^W'HD-
M@>)JG?JWZ-'OMTI_9STS9 9</M;P!ZZPK"0V0HEEN,V29R)CH!;0\5CPF:+;
MD&X<2?@QIXK];(F'#T5S>RK!J .>0?3=-BR7I=D8UJ,3W!'-XXGVB9U_G?/:
M^\)NK[$FLBS;"(\GICW%V*DX,!T=1EZS.]FD;IYMMLY+??Q$(463":P,Z\&7
MX;L';!HXO2ML0,O&:HR0$_00=@G27!B2SB0T(QB?*,Z;'_,G!V,F6/IB8B!4
M!*I#9>"YT.(6Z 4/B"1IT=5P+I@#DJ(ER( \#B@.37(MR)2$N2-LM@E/? ]X
M WKH/N&1H9D80 :2PJQWN-JP JI._+FL[$@3+O/SY8@]- (.#%(H9T2*H+C8
M&S%/PF2]1KP=V8CWE4:\3=F(-R\;JA!@7ZTWCCHR*X'GKB_OXGH[UVAUL79?
M"Y)O8=-\F/CD!(FPB;<=AF]B@XB,H0&KQT]4A+!L87B_CI^P:;,9HJXQL'5C
MS1HMKC]A.L,C51>.&RJ.L0?:DRIK9MNPSI\$33#5D)KB4EIC/M@EK)^"B5X.
M&T[E+V0M,"(H]CO!LEF/#C;]&>#\C8?*U?51K:Z\N[W[TCNJ5M7W# GT0[7=
M.[D,/Z^]/^987@L(E@V^F!C/F-H7OOV 7RB0#C,6^(6N#982U=[AC#"JCA\)
M&A\-ID?A&+)UH/'OIQZ(8]"W1T:@(VOV?@J634S]F7*(8E*K!29W@:UCF@*+
MA-M"A^M-3C=<$_O3-7U2&YSU@P$,]&,3R.2Q@1?V!(.!3"_T3!B,-JOAHS87
MA9"E/V^%$/I>G^L/8=Z -P1#CV!N<4)S64CSIZ+G+]_4"S<&3UFW7=A+'%;=
MT]P-]XN_^GD.5=X!%P$L004*YZ3(;)19HVD-3X)&TQ,H1EEWJGVP"\+I:"Y5
M@:%1:UA#$T&5#$R]&]C/V(0Q<A@YF$T]FY7S<''X/*N0T->" JS2VV 7*$BC
MYBKAJ&?LQBI+0DB!!-S2]L>0:#:AW#"Q^=2]@(5#AVHM2**%/UQ07/O/"_=Q
M6&ADS^;0*6J;US/%IM.Q3S+!2BT#K(0B,H$1AHI+/" >3 -N,$PT??')16+B
M]8"5X&A^U?\(9AA@&V>,?L!4'8L*1J@>82*!JGQH9PU#A/GX/X:A0 %2=O8F
M\,'_J+5(3;&WF8P'U$+;]Z?HFMCT1B8PM)%!Y4NPC0*%J)F&!4=$@?!AWX=0
M.^M)U6 QU?G%; $@P8^>R7;[6J!$E@#^)Q43)O=#6;D093\3'^G&H^$&TYW!
MT"7V%)G<A0T$[#04J%1745/06E>:^:L;&@3,D%".*PXR0<L$Q5I,"1PKETRM
M4(.026+Z+Y-@&I6[VLBV?2VHZ_ _F[N)S/74GB_.P_D[IC]"%"A%/79N'D6W
M1,0R/%;.J>-/-VXH68-R<VK4K%="'QV4)-@BQ)\:[X,YQQE13J68T0V=VXW.
M9@HX8F^R1P:30OW(!%1E@L_) ')<^D\X_@^, A[J#)3TA. 1O1DXW+2=]73P
M*R--%7_L*!7E/?;FQ!=0X@E1&'^^>6AOZAL(DP#[/"9(:0S/=( Z3*3-)L)K
M'A7G]'6F09U?DQ_IVL$X^0C6!LB$+@=K >&,,!;4S!7; 2V>$QU4$U?\K;C,
MM6.UKE#BAH$%85P<,$ @R^\"+Z+/Y1WUK"Y _,U_S@**QIA/#(8AP?83!LES
M6'G$%MMS]/? ?9SZ4R=.Z/[11@@"I/3BO_BGH9$\;^%&=!$7BL<PC9M+XWEP
MXLNBPHKN X,RJ%Y!D6LICX=F<F"NQ;X-C31W1)<U5[(*/1N>^!9B7S]3Z0C>
M$4Q8]@#PV:0*Y#BVQA$;"KR!I[,U_($#_YW[\MS+!5_;G]T7@\A_E^VY)AO8
MQDU_\D0MHP ,*-VE8LX/ZC+]Q<>Q(/"8(J8^]"^)S"".RG!FI04N;:U^K-Q2
MN9KP-9FJ\<D"=PE)P>8N^Z8KET8ND])4V.#(..D*&T XY9I4YUK++\.&"<NA
M)@_$E<^J_E(BM)A- HQ@/0$4,W2Y48L46  $-?3*["1%1U,@MDF-CP 4'9LP
MJGL:;"8J*F%&M/8##!'F709$G-.&W <--V&< 6>@^Q.U*RRZ'PZ?UCW,+:ZP
M;)R=$P1;>3+7/""QPV60?>]KF!?) BF\-&03#\/,<2:,=S>-OU!T6E2<R\(F
M S,I6IE_=+R+QC.SSF:^$N7'F9""P[@CME6I]Q1QGL)'1K;G$ >#3CNA!3G;
M(*PQ0.B5AU;U0\0VXI!H]J-E_ 4*QHFB:I$MF!0A;(>&_F5+>1<*P_= &('E
M1IWP7SUJY7)S;>E.BYG><63Z8S-#@6WZP[Y8(RJ'!S!=IR*TDQGM>!0AHAT#
MVU.$NGDB@O_NL+93<%>S&O9MB+W/=GC0TV/M/"('NX*AGQR<Q#KB+P\[:L6#
M#530FQBQ3E>1L%5L@>Q4$5!?X82(>3&Q5B]!2 30%Z@E6&0LS@/,0\"R1DO\
MF%?<F,HB-R;JQ;SFF0C[9 @]E66.2@4<%<:=@4]YN)S=.4]'F5X1,7T<O5'$
MU42(JRQ '/>=];"_!E)&WAB$IS?X#L8"1&Z5/NMCHBHN8:?7PQG1C/GHUPHX
MAI&ZP 2;X53A.'T0$"EL8;-XMT307]D*_6S#_H]:G^$ZZ$X3"$%.CN7H<(XK
M/2LV1UDH?B,XCWB@AK6=2XEB+F\EE*C%5N.KMP1-GKAWY8G[*R?N+7GBGDN6
M+L0:J,RNA,E(5/:8CATS7 DVQ@,/9E@&YNO_U(_KH2P$:R$IV9,2LC:3]I%$
MJ<!,FI=U=:YB_"@*EY2OZ(_($P?8?<:8FC_(8JHCT SP/)8Z$"H3*F4I0B<>
MA]2?6N^?>4?\OXQMZ:A>FTG^F&$XHU+<,ET-0>S=\]AYU5RM\'#&<G,U1$M,
M<T8=ET#_18Z$ DM\D>_CLU(ERDK+W;?PTIF71OTXGYA)*BXU!WP3=(%YLM0P
M"6WPW5B8E54-^-K.#/B%YQ"5%0WX71J7@4$%DX/CC%_AC ]\UX[PW:[L^PU-
MQ_8KIF--FHYO0L]>>@2H!NG2AQ5Q  3RFB$!*.A::5EP-NGG#;.L(2"NN--G
ML@4DO8_>32]2CZNSF 7]'X[Y7+K[6/PV,D:<A95YMT@6I!IZD#>F&Z;'S[18
M_I)MA?E5@MUA)8_PFC'O&HY3%I^F!*TEA\@@0*(?V%4@30Y"+7 GB]E371:F
MITN^WD_9RQ7%P-@RAH:&YNPE?NIA.1Z!$U!9]I*7-?R!*RSK,=[=&8[)8I2<
MSX0(]CKLN+!&@]'8P99ADUF1!4O*"WO&AM?Z<2"NMOQK_<\J@>*">*7/,%S-
M+P0JC*DK'I-_P853 8 A9$%0C8HS2'ND:(7E34">N&!9\B.O<ZIVGR%41?^1
M8F4/8N4./QGX^;#28_4]$-(DRAUR9UQ V3#:[9\SZ)UO+?7]PVHI;?*PACZU
ML4EP7N<GYY_Q?M&"A'WJ2+""+":@$*NG@KQ>ZBEHX%<^4D7/3II#QJ#V0X(1
MHF8S.PWNF2Q1%MI4@^%<67J+GQN@^3[S!-:@"-? LP3\0K0P=C 3/["8(,V:
M&_6L@784@L-*]$#LWO>LU4;C'7K_3GT?V$CGG\^NI33:^QJ@S)<9G*PT$>G4
MTV;N]#,!%1+QV:B^@;!6E-4X'Q^'Y2)&\-$A4UK)>L7#&2<=4E8"J]<_L0PB
M,!46> JN.DQ4,0H[S<_7DO+\&O"FQ\Q@#Q,LC/$8ZP8[.F78X1D3_%*_Y''6
MQZ3"=A)\Y=\-0>1'&S8)1P:DHQ+,MD2H<EFV"^R/8,@$=-]GQUB+$<FWK,>W
M+G5@_* 1Z S6(3\J'6"I/4\W^% !>"4^!'6"6#X/^YN%&&PP52"3AB\2V&6"
M&<]$-K-_^$@=?4@T]',-V=NHA @.F,,W5L(W\N I@V]^][.L%+9PS;:&E!?<
M: T.MX%\\>?[A%PX'88G@/1FTZ#OP?JL_@ P#2E L_<<QA*4*)@D6JI._W98
M1VKF--*GF8C$9902N=V9OY]AAI^N@<!B\:)PSD*0EVD]V285D14' BM^Q6V8
MBB2>?F BGC?LG_@/J0BG5.5)HB]\[A2%Q'!8O"7(<./?0%HY:PUUJ+RKO8^=
MQ3*7>EH)W%QOX!B4Q]GJ(9[*=0!O4^]/V*B_5WA<,\:1L/_ILUBVFJ^O.*LP
MH"S_]X"4AV%:FS\<@R=M"/B3<1%GET,6)Z-$]].4V=[SN9N?6[,_& KA'F (
MGOSG#VH UJ1*SSP4;00.4? &%HD(=Q^4X#B1"!/\S;8 W0_4 '>4"-L?^D$K
MIM*AJAIV>,"34$;U/,+L(;R@9<;[!L^997F5%F5C[#B5(7JR"8\,@\#B7_+4
M1U:[]H0H<_J!8P0I]I%&2E2BDB!:-LM><] 8,P[W^5HSB.:-(>JA^15$O';'
M]0.0$%6-DSIDR&C!U-QBI&K>3PEVHRH/A%\Y$&[+ ^&2;JA4/.]SW]:I7(4&
M$(3NI".=HG0K! ;C;@^W3OR$1"/"*LQ!8-YVQ&8V6;\6^@T+(09?A4KU'3?(
M A>#NR#!M]2V&$;JC-]7 G4_\]VCMAUH\X@/0Q>"N,T:JX1S**98,$G08V?6
MXH5;6U!V'5I _I%DU("HL% !P#!##UA(K$+!Q$^(V;[AJ45P^C&/M!AJN-D?
M?5YXY,'>%BUKG[7+L7T;BQ+X&CT3]N0O)C8L;OP%9X1]:L"P\A&VEK.1@8?*
M1>AYWG+/,V+2*5^(05G*H@!19!PJ9XB8RCD:#W[8S\X/XU#I W3*+X@\TU=5
M[A%E3DJ5+Y[Y Q'+X&^A>HE04^_!(ZY)[44XCX)0+5V;7RTB=+C\JA&%H6 8
M'/G JF^0HZ,_*6<YS-XE'K4=I06V]S5PLE1B9.&^D<V<559RA!U_'Z' APT^
M]H_P9SOE>63[#99>89/C@$U@T\R>6&%/9*D%?CS//^.8OU\94V2 8X8"SPY>
M"T8?S^F)^,G<\_:-?WM"@9SEF?A-LIYMS_0[*PRA!B72'&!6=1(%X[NG/S*G
MG,T1)H35=,VB&GYB3UAC.(R$>^;E!/A=D1(M^C@7/]H$:IPK[)277LA\UD?/
M@!H<"SMA\39]FQ-%7T@'7]2"7Q>XB@X3BZ%X6R 9907COM=P955FB>V]N[/>
M*]W6$DJ&E;U%3]+.B7.L7%/@D/*9(,@ Z%F,&7Z!'FQ _CLT'=OTWS]LVS'Q
ME$=/OE*OGMY9N;.I5H;H@_6,Z%?GR*)&OO+5<+414\OTTE\1+.?2G%H6CZO'
MMFLB<8>I0=:I3@^*V?A>H#O)KQA.K+FR:,WG=#=]-;01HD#='2NGH/3LYSFT
M^3A9484^^UMR@=RI^&""3GLRB.LQT0!!8=[B;9:&%>LH"0"56]6Q'T@Q])\/
MT'\H@L!H1I_27.!V3M.5B\<5E;);GW(H! Y-I<=SM4 Z7F+?E+SWJTN/TSZ9
ME//A8Y"'5*F\1A7IY.9A#9""/DOI9>%X-A=\5BN,6 Q[".2C1I')<HSUV $
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M*KC\-S%R<- ;8X#=9XPMY:NAC1 VE5-B.*[]S+X3SPKUZZJC,T:EPG@=-'D
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ME!9\-K")CDGXV:E))8RB'C<GKN+8IJ$?1. &7'Q0++I/Z,91J_22M0D4 L'
MJ@J@HI\=Q+ 0K/^C\C"=T)7W"!H8VD?E!HTQQ]&-#;A0U6KTMI/@/H8G0'.(
MH448&Q",?AP-\- F],D3AOTHN"T!N(#9 Q%MX>. (1:^/ HOK&1&TWTP*-L@
ME%"F.4$Z!,M^/J@>Q(F_"M6?#=T=P:75OX7\1;65B28.16OP6_@5!4:C[P*4
MO7P\*%;H(%QLYV];D*6^NRC"#/O; +1;S\:'J-G=!B2Q_5U/!A?.@ N"&>Y!
MO@;8 7UB6)HQH:+KX@5KGFL\8>5V2*^D%L7$(XZ'^"RQ.X]N K6.CM3&._1>
ML8FB-G7_CPFQQY[YR&P-RE+T3GCRK.$T?;0V0A;=R#V-N0!JM[[#P\ \4E<D
MXW>Q*5+A08FW,N--K6\#9A["VOL\7J1:J"9CV<O43;+8:*FZN30L1'^EOQ5,
MW>2$C++^4F(H9QC*@Z[(R1%HO4:=%ZDW7M<;M=VX*9!EOJI>43O*M^/[X[-C
MT!>LLXY:;U9Y)YZ(RCF-:1D&B-0T4HY*#.4$0Y<>L0QGM'=ML[5G$L?+=\^A
MXF^Z30YH6Z;>+%$[W;8@&Q(XDNH4!N:9/9Y@RV$Z2#DST3/0769(2C#* 88H
M5)0):&5S#W8MN]6J>GQU<R_%MW_CE65"*X)_GMY=*U>6XU*SG@OH<UOS^.AZ
MB2@)1F'!>-.".'>6,TC?^[-??$QLG^Y5=/Z-2M\']&);]GC* +EX<:EU#+;Q
MO3;"8Z0  RD7XP'6=0P=8*P? ^301TLQ+<$H 1CE%--IF\9"-;![B7W6N]Z1
MQ!:"G!/^WC5L7+8S>&+R/2+;SY"I>2:/@00B/93HQP78MA(,"<9;%^D[,+(S
MDN/G%Y<[R_64<CPBQ\_QT+ ,*<8E&.4#XZV(\4):YM>]4VF9IR'1K]$ FU*8
M2S#*!<9;$>;%L<G[=Q=2@J<AP?L$0S,$&5R18)00C'(*\F*EGZO51@$X)1,P
MSF"6*BN(5ZZ &9$6)OJ=(Q<IP#7*.QP<7P+;&!;+\XZ>@.J^<'Z_]_7D."LW
M)Q27&"H5AD+!O4JK$K^#1K)_1GK](2+=*J"$Y"C:L4((G+B]1UBO6VM"O6[D
M9@:K8_P%O4XBS4G8PT2=27:T3K:X9$..Q!HWHL4,BRNUV8@USX UK=9S8R6T
MBQMN[,Y,.(!F5]N4F5</3CYM^83C6M.PMF"-V-E,+M*U9L;>JO\%1N%Q0KB(
M)8MDR#PS9 XY,E:3M#97PJ TRFV1^D<'^J]=O(R,@>$J4%#*+G9M!1&LZ#"6
M35<LVU78)+SJQR'L"/:["BQ)U@)CXI&)#4E[]E )*R,[0?5EO,R1*#;]D#P;
M#H9FM=_IY4%7.=-  \,TW"F_$[EK >&_^%BY][31/"Z>#=-DRQV$BS<6-KDS
M+$"3-54H4N@>6@L*8:&GO_!Y9$A94@)9\M^Y$R57E@Y\CYVU&)<^B)IE;%BC
M1E\&GB[PK!:4L]EDJDQ,9$FF+0'3"L:?YH)U?7VU'N<B2S^AG.IH5'M2]\)1
M1N@)4T&/+<4>&RZ(]V@1_Y6+QTJKJKY#[]\UWX.JN<./0;+B_=$7KDNAC).J
M@+6U,54D3 6XZ >%A+YNR!4[U763B<GV%S+-*=U7$[]#.R@:7U,&X&(?#:RS
M0+BN]?30A*Z&0+M&ATU?91KIXNPC="9X,G2L'RHC^QE3_CYDJI9/<.6+IMMJ
M&MY+A<'0@';+T!3!)1BYX?375?]+M.:I-09'M8BJC%D(U/A@. F1$*.M$V(4
MZ\=K00'=(9!A*=";EMM'?M=:_T7*.\,7G,P<\.VB__W[W__^?[Y=]%[ 60.L
M(<_!:T%"ESQE9AB56R/ZVO?,,AG3-Q- ,A#]G4$_I; !=MSIA+78-:PAM EE
M?!J2C(2]_=G3UH)#H_N5[D)"=R9[*17Y'F-.1F;*?0[E%N.)PL6^CG+"JEI@
MKL_IZD*>"7-P_W<K8'X:A(&*P:>%01GV RF&_O,!^D^UUH:0 _J4WR6!2*NH
MK>-9OV5J!(_I6Z>O+C.5E?@?&JQ%^TY4U6H-@/.\AAO;PL?%7L(B,JS48KDA
M6RR_TF)9+7.+Y9WP]-;G AN)_4Z*8G\7*[J_^GS3>_AV=W$OI7P>UM#WS=R*
M'\X""]H@S.2/1\;JO"/E._U]8/@O:0IV"*88E1L6L]OC(YVH3>HHU#:F+@48
MHCJW:?D(!H!DP*<UT"_HJ\&<'N 1,H>!3\",<'X!>S+!'D2_V .1YXYL8OR%
M=<IMQ]DS6>H;ON#-V9,)),^%2 ]\Y0"9K@,^_?F@=K +X+FZ2X&Y;J$#%(/Z
M@>X9-,$>?2^]XLK2XALEC230'5#99]D6<&QFQ-TA07WX&\4&O][* /X\LM]N
MUWR.7/R!@?,5$6VDM-C \&:*&;Z[7L'I],-KT"[S=M9)D5S$E%M ?^*<,(BO
MT3,_0/MB8L-Z6SR87E)46L90*J)M"R@#[F% [9J#%@EBR5EYXZQDY&9M9V*;
M!1F?H+Z"A;G7/812SD8&'B9;3/]T8D1=$(Z:_:[Q7=CQVF_*- ?R^SF87TFE
MS&UX9,V 3S .,=<AG_[M'Q=WE=M+I??P<'MW<_$O&?G)PQJ^W-S^4>E=7RO]
MB[O[VYM[Y?1?RL,O%_<72O^._KQYN/</63&BYND$$\>VJ**QG>@D33298$0@
M/F/:SW#81D%U/1?S4V#ZK6U (.F<',\96NS[K_3C'OGN697>(R+/R#Q4OL,-
M_M&> R>]<+9WJ$!XR"9P6*T@?^*G0U%!UZJYAQQ"UI,-HD.38#8HC!5GX!@V
M73T<T8Z,<? 8!H)_A&B:BH8@P '!K$,(0,$*^?<0P.+1,!8A"\-4L4FA[#%P
M;@Z5%0Z]YY"#$QX'NT$>&[V.I9*%Y14.0$(19_F!-C=(CSNLA"N*1-K@ 6&T
M[<P>CPW'8<OSS_$) EZ!6<+AZ2<9LS_I(F?D!.P@0Q<ADZ')F2$/, )GZ[K-
M4FL@7J?P$)UN6QA"<D\&<3W,(+"')3TR*M(:EL5T-PC>SM@>(K<LF< /T/*=
M[P=FA[9)_P)VX_("\CDK?NS6?W$D".P7'<VV'M\>_%,=DL&4,+NAW&Q5\)BN
M..$LU7A $(R:CP7NY(PJ4&^[=#W# 7H?%9_&LW--0$*JSE8JN&_64\#]@^&:
M$N^O+Z69 MXA'+GC,X"5I$*.JNYD7:+$T)[/+?:@2'>*D.5!=<E"<=!8^$T<
MSU+^'QI//BKGU'37J)<FL;@8-':$QJ 1'*.56HV]?@ A^20.V@HA9(F\?&F[
M'"U7,H3$4!&V3 $,1!;U5_RHO^2@Q:#=8\OP"]M_IQI*"0]Z#_VQO[S,Z8%@
MY'@$2RM16HF"E?-#-K;QY)9;TTA,3M>.3]_N:9KM62X<>D@K,J\J,4?+E0PA
M,52$+5, *_(>C1%Q1\H7S_R!B&5()GHMT(@,0C]G /EG\:<V(KI$FK08!7X'
MWUH\K"BWE]1B!=5B.5JN9 B)H2)LF0(8?E^(X;C0J?P4F3*6\0IH\O!8&GF+
M5QYL(P:0W$I271517>5HN9(A)(:*L&4*8.&=(6(JYV@\^&$_.S]DZ$':>-+&
MVRSN2S<2 T9N)JFRBJNR<K1<R1 20T78,@6P\OJ8/D?Y!9%GF;<N33QIXFU8
M[P^[B$$C=Y)45L545CE:KF0(B:$B;)D"V'=G:(R);2D/'F%M'20+20M/6GB;
M!/'8/F+PR+TD%596(\=WU&(KO_W8,H!,-)AG76B7C?#9= VJ6DL3M:D/CH=.
M9P<%GQR?.\Z-8%,WG(F)IC"(RL+TC<;+AQ%&%*&?%*7"_C)T'5O!7_2J2YC!
M"GTL81XKY?P[//SY0&L<L'ZU_.HCZ#-Y5#U0+*K5?C[PG*-'A"8?SI SZEDZ
M_'/QIV<\(1/Z%?;<,T0(-+1DP[@.%,\R^$,]1S]07ASC@V68=)<1#P \B4/Q
M:7VXU'FXJ-7Q S.A..N9>.810J';,33U)#2U !J;_$ ?[KV!HQ%C K?>80U3
M)%&PG+7!4#:@5WT>+WV")\C0+UY@U"ZFE+N%UJ4]Q\'NQOC9!+#&*@2[L2TM
M0YB:2639$VIA3OLFLER**^#P"33DO,$;0+0V/*UY>&XI- AJ5J\Q<O"=\3AR
M;X??*!F!?!N@:&V(V@F(9MRS';'6AZ4S#XM?TNOTT138Z(%0D9?.EA= TQ5
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M503LTMC.?J2G0$2UEIX"Y$8)M9:>"N1&)[66G1/D1D6UEAT4Y$9CM40:RP[
M7+3YSVSKB7HW] VW0_Z[:\22J#83"AN WUX/?(;@=:#?E;\FDF<BI993U(O
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M>\A\P&1<6T&CK$]!-5F;OCL*7M$%&)9C:&G-WA;)#76]\G7VY6T@$[92+)L
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ML 4"E.VUV\E*Y"H>M0H;,>J;R)H[7'MXMA]&MN<@2W]XID^>7MH>8>2[LC0
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M"/12"MFGX"?4_W^BGXW<L?GI_P-02P,$%     @ /8!F6C'2A.P:,@  .?\
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MU-*Z'.<0\5KFP(3"2C(OCRG0T+=6V-<=\8+*#))1((Y,31X9V!'T;&?P/8S
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MG$TBC[I=DF-J3=8.ZW'T35C+YDQ0JH;*"EL-U4O+2A+08-!_$EYJV)ZDS2T
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M)]0^5V^Q;\(=#]3M;QZHNSEV]JEG^_#5N^-_$[G\>/;3VY?_'U!+ P04
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MW'$.1WT I7:_(;8A99T^%8"+(0XP?,#D0-C \+MQ*[..;CI&J7%K^Q:27 _
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M,]'#>KK*;WA$!./&H=.CR85.]@(!+*M[T..3?GR_J;U<7WEV'S=HXQ5/DAR
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MQP\/W[_^#['+/XY^?/?R_P-02P,$%     @ /8!F6FSP](18+P  U>\  !\
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M,^^Z=,D/>/B/<4.U6R/EJO*IXZ00?*U>L^+)X>^LM":K2F7XMJ?'S^JF:KB
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M"!-4Z<.G7LA'%LT?'DTG,)I,IV?#\?CXY-.'FE=SWQ=GPU'^O?9D)E5(52/
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M%.R=[@0;B^^E1:5C2E:LG;3<J@MD:9HFJ>DBCUSU:I7\_?$TQ>LV4>!5*EI
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MF\JJG(R#'VK@7]F=TVJ1J%JW@8E!./LYF)XN1[MATH2A''#*P$M:+TK#V^'
M-,75AJR#[%$Z0Y!!%<TO./H6]+*ECB$NLB3WW"3C);>"<KVG*V5PZ#;P0P>(
MS,4"8G41A7_?\5RTZ\3E*+9]-TFI50R!VN3,RZWL^ZV2,8<\%30,/)4KB8+4
MD6GTRC.#.FQ6P"?[T64Q4USSC5-(QS8NT;@GZ^50IL"'.JGI-BO5-01V==Q%
MM.YFV,^9'MXSQ1U2%W5W3 '#S*E.((OT'G!_G,Y2C15(G?$N6\]F4H0,-PJ(
M@2YSYTGTBK';X"+T)DJZA$U$E#%OG:<$D7/+\+%7K"IS;?8X$DXR%_#56#&&
MI^NBZ2)>-=7;I%:U_WLVU=G<2:$8ZJWEG69JY:*FI!U@(V!>PEM,WDWNBHK[
M0U]L*I4FD&^JTGT[?H1(.R5RA:EU4CJ>&(7]FSM[91G)25QYDKH/(TTK]RT?
M1R6G8RDPV4-MI;M22QK90:N'R$[+DS$<4!C3%-3[&\RO9W!:X&"LB"<K:<!0
M2VKIZ:+]94HZW<%?[F&9PSDTWG"_ZWSB:L=6YV:O8'"=B=RF[3ONWK[MBK2N
M+7S/C1BU]J'.Z>"AAJZT[/G-LJC<@,_J<L: 3]E,X>PJ",9]DX:511#IIG3^
M[I&9VFF=NBO[W5)YF:-H- %.[T$U'&Q^4JV_)^!?$@RA5*#%9;3?2%NR[4PM
M%?^L4J9KFC$&!Q02+[&1Q1EP8R+1$M&#N15[Y[-9]&^=ZGO8! R07V^J?\TS
M557"I*^=#XV=(W.,WH?":7>?2H>$=MTAQ5%0$ZR+WMRJLCNMHS2+7.-<4Z8*
MSSL?.JK3W!9M8%\Z@ B#R/*FT<@DQQ;O(Y9KG])>4#& ZPT'/1KBJ]@J]E".
MOJJM$M T/!HL7\]@^>H!KK6"M2\>@[4Z6/OB,5C[8&7Y</^E"=9Z_=G.\CU=
MHLZUZ [R8J<-,]CU@F.HR6!10O:$CG.@K_@S#"W96O;(,NI0EDYXTC(O-A5S
M(HQTJ]?UIZ]W<A457<R^NGMRY2:1$Z< W0EIZ?EQ7]!DWKHCJ\8V[8RH:O($
MWT;06-K^9Y'FUCY4HFD[UOFA;73+"+DVPP6#Q=%P,E&L3:+2YE@?NXQRC(G2
M1$5"]>HQ,ZMJWS4%$>_@\L/$*  2R*,W#J(]Q'^J,FUU)!^5W[R7CVV9*(U/
MT:+L06V\*\76[YQ3VCH\:'JPU.90/:W[;&D0QO=UX\,M%M27VA23CN7.7,F0
MAX-P<#WK;6RXS[!5+-4$9OS-J(1ED)!+9B);1I9C)Q$[31>S23H?P:38F(##
MIF*L+Y!YQ&K1CS@A;X%?&(DU0D>HTH3;BR65 #V1>**K4"Q&")GNA.:OOURU
M8H:GN@6H&:3KW@T'O1:>F.5ZIXB!9XQU@]]JM6CO1FCUH>[9YL82+BF%F?K"
MWP[:ZU6@5WMGC.9V_*"'GH;0(DO[= ."7&,;M8K@? TA^8RJM:%:;]/RR:2R
M %40_,(GR*614>*RH[R&CZ*5^M<;G:=A'-H44RC?#TGTW0^S^UWXZ&T":)#4
M1";:2?ON4Q2Y;BI<9VIE+"V1G,ZWZQ=/6P?+WR=-.#>PXX1LQ7HCR >%S1TK
MK[G.RCLYVDPE999R08E)4]Z3/L';U\.!SC)1R,=)+R3(07%=X$DT+40M"P^3
MXT>:,-X-:G?WHBAE+B;#/-.@/;"@J6:QHAZ'AJ'".Q%6K$XW&,A_M <LPD%X
M\8/6>/7RH.X5E3D<^(*^Q@M$ZX[_*W5J_!.V7O-QSX^M[;Y0:[N3TW^<OGGW
M_NWI^26>_$?GO[X^.K[\]>+L_)?HK\E\\2HZ?O?V[>G%\=G1F[/_Y^CR[-WY
MEL56GCI=[032?*'K0,'7K+>X@@3IF#HY_-TC=F0:NP0<@*;UA?&9\$H;<Q0+
M(2982$)^M[$PO(R$M5BQRPXG%CH,UVE'?? M1FI )F.+828I4EJ.&C;9-:VO
M;MW, ]&?PI5P+LV6]KI1R2QNR)198F]TL'9F]#<LRD=5TS\1X%3P_2=8/Y,1
M[9MMAT"F'W(.2=/A*B!^K53-(!UX>3@GQZKJ*)5@4T#S@8Z*XB/S"!"+@*JP
MY7):$=,</LR:R'!!;,90JED#S\9)LR/<HEVQ5@SVN\<8K([!?O<8@WV0<FQB
M'??3[O$=U#LKJDQ)<W6LTB"%:<JKR.%3N2Z'("U4)A.%JI(8SXMQ2H4<QI&[
MBY+?CXZJ[EXT[IOJ."/V42+7PAE!<&Q0M#-9^LS(3$@@D->MLZ)L+[(+<U((
MO?8ZTZ^C!:VC9I[4-?7!:[70LU?8H]?Y<$I':>5^YK5:VK&W&\.5E+FLF8##
M1,^,=.UJ2NIYDVO.61)$"L_;MXV.FOJJP*(D$]3H%-/AH$].5_.0FZ(BSMQJ
ML9M@]'&]8*I39TLP4;S*;3,5SB#O\F2J"!&,)*5DN-CI8U\]-[.(HT'#1NV!
M3PV.?L+=9. 1M?W$7(U52/0+MNF<Y]-;^1D9IN-FQ>-G,\8%T@D3DKVRQ ]+
M79H?D.HX21X.1HA%)?8_A1?,;_F!Q+&)'%1P6\)6Q;KID8>-=D'-,;^$GDGL
M!Z%G4"^UI+6X1% Y7.XD)ARN0)J<E"@Y=9A"@P9(_IS01:<H!KK+*&\$?X^D
MDLT2U!"OAFXHE\.I'J-#9&^LU[!?Q)E]$R,N9?CXK=.+MN_ "0C"C&PGG%&1
M!$YUNAL?]X1U;C(DHC%,)J=3+#FM;$< B]S@G:K4QZAOM9(:BV>17TWSOYLJ
MQ\X#]-<\Q:WSH385VMX=.$GP-OF-JO30IX%ATZ)+B'&TRYP6#A2^9VBP^Z-9
MBEW.@P2#_F*L;PUO[)>=TF$=_$ZZ>LB//$[8'<QC8;'%:'=7\XXCI3BQ=Q/(
M13?R"RO;W1IUO7MY(Z2E5BN846:N[C&\:=7!U@N_8!-W,R@FTJ7CVRR1"BGP
M8%U9TB4&;E!;M!#,T!RD.OT/:2UJ+2!U&1.G!$:)P'6@IW0"Q^WV:DX%N3LI
M2$WSPHF,&CS1!1ES<$B8@X!.6/.'.:AC_TYD2((X-I5.I;CGNWMD4>C>>5:7
M;4#7C:]2>%U3[H,EO:!LJQHDO/(:?N)HU::T=>W6'E?%#3RUY$I8RE5J_B(P
M:)#18:JYUT1->$3LMO1<\]/K; VH&TIEF$/-:[ Q+A8$-Y873?*\(?X:$@>3
M]M/3*-B)2L'ZL=6D/HVY59SP+#MUXMH8<8Z_VVJ=#?Q:]Z2HS-%#?@22[Y2*
M#U(-2TB)X\OT)['^ "I-:F"W6F_B@8]Y;A6&CV1:.C009>SX--MI-2OT5.1N
MC$,TS8-T)Y4)X583N[_Z*J7)9\)J:$.'IXN@.V-='7JO$[XI8W],77R9U,4_
M_A!C_@--KPSR]=GYT3FF)8:#R].+MQ^VS'!\YJ0ES(F$T#!NIA.:C4A])[Z(
M)CF 7^RAR\)]Z<%];/))HMG]\2/0KV"9T$>F2X]C*NQPVI6T""L^[:CL5-CA
M-*E\#TO_CI2F3D!+<SDG_>R@.\R;1?)B/JP#'"WJS\*GB']4<UK7@0H/!W-S
MMXY&K>91[B,<?C;?UHNU<><9?%T8\BF5F7MZF$ ",EP!C^N'>VL6WZ.U5/1S
M4^&9644G%AV0UB$?$\8]>"2)'4:L6X5_WH>#<U#FE3ZMJV P%KC@3"NW4.0Q
M3OQ!"DK1 39T"((_P0Z8$0T0O14<'\0M5[:UUKR)-&C"5L>T[OY>2S&#%?7U
M$D(DF/H2X0FU-#-R.;(<+Y]Z,]*81$*&@^ 9IH7.*,D_$DJG\0TLQK[JWF%=
MP]1/0IK!))UT*(SNWY$ .Z-O@][,F]Q#A!Q0B[,XK2<A_I1F>#]")MC.-Y2(
M";X@UNC8_C (&(UMTT0S^KJHL5"A?2N'V-HMX/HT5HB#O;R!2Y9[ES<%_C+#
MZ3\!Z4I*<,;_Z_ P?O+D"?Z_,/QT6;SD"Z_R-S@/RFB7)C<[POHC&H**N!@T
M&2<<$QLMG>V3,T(9Y2:<+,UIS'@;>I"]"+<A%S&KZ[1HL-*(FZ7 Q))ERY/"
MD%%JX)%D56&F7JJ-J@1;=5"_#EV U#T.W<:0Z9[J*'Q?M/9);+?KY%\KT?CR
M,=&H$XTO'Q.-=Y/ERZ.?WYQ&QZ=OWKP_.CDY.__E?[YY\@W]_>']T;'^6\\3
M2\@8==VB@JG2_WH%RG]27^'(G_SE5;3N6WQ#$_/CY85^P+4JJ7),OPE/]BOB
MW)N52+>'#R_*'Z)_7H&S_8V>V,N3V^Y !]&-PO0)^S9=DFEGY_+DIS5NVB7;
MP8.\FP;CO6W3O8KN^4:.J?N[O53O,M[ZLG=]*>LJX,M]>WFQN425L]'.X9-G
M\>'3E_'A\^>['<(E0O[R+VL/]/\^:$^[WBA_N=L4@AXRF^S9\[_X3\O4%)3.
MD6].N&&C8\0?(5IVP]'T/5B_YKM<&4OH-9JQ?X.)Q4C7)=B<%5I=UCXZB)^+
M>?09%JU/#:R[/(=Z0NZ^&.$",,G8I*C(W\9"XJL&=!X<*#6UW: ,QOLK3#N<
M19<4_NL(,ZXUHJZ7<<W1VQ;A\',NPAH[9]WU>/JUUN.++,@55J:''L)3XR \
M@!WP[*O-^)>8<I+[<,:??\X9_XSB_OQS3O[%+:E53=;R^N3H\XHY^(7AE!\\
MZ9OS;\GF_#R&[]>-RCHP)UWGMZWP<#,'R^& VG%0?:1D@SE [?0'<W$J+M7Z
MC@2P=!QGKA)LR3/176TI>;4W6N[I'!S!?_@I^+'.?1$H!Z/2;HP+,7JP1'@[
MCX]_O0AWU!/@WO7YOP4NP7%T[IF T9$C3J^>PW4?$&JMD8T&*E-ANJ4O -T9
M?UZ-9=^I/5I&2H_KET8P$1>4^N6OW$R (9I.T:4LD)MM,$R)?WA)=T(L?P17
MN..LN=VIZIC9,):38R0YN_L$\O_N'X)*;"W7GO=I\'P,CGSM,02AZFDR3[/E
M#[<]G:ZMTO\H7EK]0;W,E'X+N/O//_&VYR5;]_\\'4$060=.ET2_$ +J&"[(
M)TD9_4LE)>Y()YO;]O'N/+<+;&B4SVRH"X7I=Y@MO;6=M_%LD.-WN!//_^>;
MPV\V?K>[[19MXGSQ5S=G)[[K!3GJ_BS\>=:SR_B^^S)N:I5O-'%H7Z/9=]"M
M8>1C'1UZ^9>OH&Y:$2F]"N\1,88&"$X%Z),N.V0M'1,=44^(_WH2C9HZ^G6A
MJ1#/#,SOO]R,WKUEU@E,?85I:R%DNCRAS=^HRW=[$._X&=[N^];;4;W"YS,V
MOLI$^7+]&<[7AR8)?_D=U/.J,-47U,E_/CT,%[Y%5,,EHAI8Y\;=^OA@_TGT
M,\=E/L\N?R!JZOXR]"!VW>?5OX]*]X^PYK^'IOWZAO!6*-U'E?KPMM>C2KVO
M2NW":CZ0Q>W1G2:;],?,)?DT#)U9%,YA='-??]G,BM2%=CX:KUTQ,IV"B=H9
MF/NF7EQ&M]T(/L5J_;NUL= TL%AE@EGIG0T@RW_9I1JQ(*&S:K$^=Y+GCY]]
M^;R$.]\_XF U#O;[1QSL@Y1CK^,0)F7]FDWI)DPU_:26YZ,T3W21IUO-T,'H
M$7>TK,XGWR*N?T7+X]$N%MRWGD3-@'-J]$(/;3^+JK%;3V.2X]Z>#Y9JE"?
MO;TT!'-O=)/CV51VLZN'A4VQ94>A@X5/.Z)-H;J%D/DY[%7/R? $FTXO$B80
ML52ER'G=I@XPS 'P4VI98_MA]! YTR#E6"[U^5X[#>=-^8GA+W5.R<Z*7E^
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M<8L1PM4DHL7VZXB1 $,!YYZV(#TX*FZ0-<\P!8,>K1NT-1HTMQ+DRTO&;@\
MQ[=SSQ774O.:NK6[?]L"BBXR65QEM$U(7SG+73FK['98HN R'9I(1[-B.<DH
M*M48IY12(%8[!$HW;FL<5$S7& N'DW6BS!8%PPEV/[KHKLX'W8!A$_@E[3A?
MW1H>%";#-#2Q9**I7$U30UZ"/8F%I&[:D',N2B:987BF)E'+2&NQ)4=J!FD.
M<8F6)J2E![#?,E#TOK-+Y-#X\@*%JV*>,?)L#MMSRJR)S;7!0#"<Y2JXB%_>
M_0CT;$T,FJS8Z0B6&&+N"MTH14U<BD;0FIMF9LOLFG6R.(=/'K,XDL4Y?/*8
MQ7FPLOQL_SMCH\/!JN 7P\&ID**:GK7$%TJ4MV-J]8<AS-3UN(QMU=,A<9QD
M&#4U;1?E[-4%?$8[.\8AAEW6N9?)7<<Z+*J'5[4\PJ;28: YN9G,&M]4+I<Z
M/!/T_R(I-87P@O+8&7/QHO&?8D^'E(QKT(>LX;=+_SUSVAV_H3;#/H7CD>DQ
M2$:.Z^H$C3]]7YY(]H2R"X,H#O._VPP2'6\P(])BX@2P48;2')LJ9DBW/"X;
MC %@RU\XLB7^M:!3+6_F?,QM%B2-!'"!NF)1I,CS144E5#![I?(].]3AP"<<
M!_L28P;"Z@\V:JT,'N+'LY_^B=+Z <Y4>*F_%TV9@Y3MG"(Y^7&!_WO*G-N[
M%#"C_M%3#.3E1905L%VQO6E:U<PPS082-F,5^S5!$F_P(>"^8P5>AMY&&CRS
M"?1$(JS(O@]# 4,0=S"^S%4ZN\)YIU?M]P>' [#ZMF[W?&]VS\]9,?Z($<QC
M4:Y&XX8!"4HK.2T(.-+N('?&I*$GL:N@X4<<WB)>11T*0R-0!\#,%6@TBXNI
MGR*ND2_#Y$EC&[$Q-9* S3=*P3C/.422)4M4DCHE3FG^C1,1TJ.9E<<8[D0-
M=^)(J#B[*;5=IYG5P*2=,N/N%W=132M"W>U[P]^PJM@11!^8U$Z;FJRQ1\Y?
M4S"R,\P8ZT2\DW2W27FPUREFYI"";ML&.GCB-.;!5'OU:C@XR[E3 ?=1WB)0
MF2&O$)RC\/#:7E;C!*.GN&.<0]1!C& #FC$Z<LRB_%&IA8XI*NDH +*,7Y<\
MVZ@T: .2XJ'-Q&C'M-*]!(62WT ).SLJ4"R2[VB:FW<ZMSI_[3;V,6:@#GMV
MIPJ&@]L[W?X)94)#<7\E5E,GXJM3%#KAQZS!)K83MX(572V;!!S#.*LDHSC2
MN)CEZ7\4QA:EC<"'W0B'M% T+AU3PL..36J=:Z& 35K.J9&!*C'<@0;)2,'S
MIPY_+H4C0'!J.N D%-\!MJ&DSTSE&*I \V<\5@N\U'D<F&%@PH-\@W3L_')T
M]![,(1T?Q%:2+-..L'M8J^Y-E%0KPS/P<M>XH!+4I0TU7MJ6'P0$,!&A";=T
MX*[R#B[CF</GJU,< 4"C/PM_D^@TO")Z<3*T[WE.C_7CY_"#JW8&5:QLFED)
M:^U''ZC+-2ZEXZ'9-15\CA0EC#0M]Q48KE7LT!B3P</#GY;,N(MNVJ:O8E!Q
M?LV,5:.V 88,])XSU\;!64$@&27_IH75<UIU4!8$%3LG2MW,,II$65%QEJ88
M5:J\MM-*63&<>R-BTO_=MEQAS8''K->\"T&,4XSSU^C]GCD/U#NDLX\9'3XB
M].W]KG6)( S0Y;=W!6'M>Z)SBI#G$39%B_%?')7@' 2*7#@ BGVQ<0P6)NC3
M OOR(+;+/CBET*_V46G5>%MYHIZ"D9S: (=FI*:IWJ*#9ZW8Z,%C;%3'1@\>
M8Z,/4HX-PIT-*)UBM[N;=:@3N.Q2<3[.#59"JPY73R9M\)7H;[R+;KM@&V<A
MZHKRM5X+2+2<J7/(F-MEY/)'[-W!AET1H-3[$QR<>^Q(MUL-1^:VWA4I2;#J
M<GVJL">^P.@HIFE!P/FX<G5ZJ69)2:9'.U'+MI;UL@U S.8WMT>+[DQ$^DQB
M64],PC8H!38Q/*@^+1!G7!F\6='4>\5T;X&!)=V_%VT%E<^H67OW4=@1:A=;
MW/Z$#+;;N[ZE[=,/G+$Q@YX3":[H_+6-ON /N2U%M9DQ=;\B.)UCYS8:%!DR
M\#P#0# ('F.;):XSP,$JGZNQ5.E\!&;62KR#=FYMT*INR'71D:;.%<-?=2[1
M-FT3Y90A=<X2JBCLZ%>Y6" $CZ+5.9NA.M+I;E:*&FUSXZD>MV: )AD]-!&"
M5F7H2C"776:#'35*<WGOSC/ZEOA*1G%(N\S*HC>Z)LHHXM91Q'TG34\@LRED
MGBA4O<;$ZUT1S#SJA4TGWHD-@^=MHL*V*;OT0>6.8.)@M!YH,!VHL@3M83:\
MP9:T %N2[#0?<1_K!AU%9V[NL9R/?0V_2%_#Q[:&GWFH,LBS\\O3-V].CR]_
MQ<Z&[R_>O3^]N/S7EF4EGCO-#=_=Y*!QK]*% )Z/*K#<ZALE55HZI8.5ER98
M4F2(TBQN<D[[K&QTKVV]=Z3?S*5<80:O@D6&HNOM;:E,3#X^RZ\QME'D?CP>
M=&!'-:RA4.@MBFWA?^&?2Q?2&#QS. #WBOT+G(NE]_9XCIZ!9&:HQY$6X3UA
M7+&\D^MB>XIJ2??R[1)S%IY.I]*]^H2QJVP'$'8-HSX\*85>+P(_\EU-V))O
MV6I)C69VE4JGX&H, PQ[WPK6=K+KWG_JS$-7^2BA7CI#VEERPXD7^GU!]]L7
M$:"(H)0-SV"KUFZ)<"?4HJOM8R!SP\$=A [!^HSI;C^+7S.AI0C*@F34TI38
MW.U_\^)F[V](.U[JNNKUA&*\;J5USC>7= 6?_;?,IS&J?,+QE_O/49[#YL==
MDZPW0\>[M.90]4VAYSH/!^O.X)J[RI_ GBKSGNG;-I5_Z%0PU003@&G%[N+;
MG(;&V;"S,!S\HG-Q#&YY[>=R[;;Q3+78H>[7=W/;W)(Z"B^1:=<7Z0ZHY(HP
M4\6"R[ I@#)5"-# SK$+G;>.$?ZWEU:8&1DC4UI:3O0AA6&WJJ*+?CS[27VB
M:G!%8"SXC?J4S(5[ FY25/4>:8X(6T^J&_H)/13;%L#/*OD=?FFWJ,:U4[F+
MXOQ& @97DA%J9Z%JSJ[K?-&H2$HJ]M47295ZS243TY3:A<IW\AMPU$H"S7D3
MPA?#233F\IL8@Q<5MI6W8V%;0$(>MM!*[H!'&)L #+[4!T:6?OR=-</#SX <
M/F9 = ;D\#$#\B#EV&5S\_0Y:)L^=HNOT3?HJUD!\N0=305T5&$;X\#-BP,S
MT-&Z@2[MG5EV7 B.PT $> HCTKTTM'%XAH,3#>AB8($NCEK(_7;\_CCO\<1J
MN4O.HMH&]CWX( )CDBD:$[<^#A(^!W$Q8;28(#Z$KH=3"0<?1^9LIY%BB9PI
MRUHQH@A#C9D#,=&0%V:9P\3("<<]"::SDQ!UPE3S\Y =OB#;W9C8-@Y_H2J5
ME.CYE04<X7-$O$H4U7&KV+L3MY 3!8Q(#XJ]6B5>,)(RF=:&:@_+#@FL@;8U
MGK&^A,BYW):A59.3YBX&*9D@NV ML'G6F(XM0_N9QJ^?;PK(G.P<62GXPF,D
MJ?G=H71??X_?>9,CA57?1F=T67M#KK'];Q2"G>RN%^A..\YA":INVT>6-&;-
M?11U;B,'9'GW?>0F4(PZF5(+1@,Z7%MK# >]4QBWDMI)RY-F%28)U7T_K]-5
M2SLN%JEES)QC<23"E"B-7BV*G"JBAP-A"YAT[VNJ;Z?(DN3Y5@S?!N)6C*I;
MN5#UTOK:9?5(0B42M72(V0Z!%@*)134T[2"(";5,+-(HWYAP61*&D;RUVSKE
MI+73:8(Y+G)7"?F!H40&2%>:+H#M./B(G=H=4[Z0+)(Q5[G[=D'[)ZXU$%&Q
M59U\Y&@J!7U!(LN$E0+>*2_RO> >SIH;8+*LN8,@%9R+.6!%N/:C(Z[R6'5;
MP@/&K!$ZA\!#Q]0L;91),6[X\4*6H6B;"-'!6%>82Y4CBB^/)F;MHW(*%^!O
MV>OO,I)Q96JN"%\-$M#07D9OX$TMS$.# ]*<RWW<**<?AC<%*I6W[GAJ:(VI
MH_Z]6WWKMM*U[*1+%)Q0: P26".YNV5+,&(ZF,+&L#G%(I8>%4LU?C*")4;S
M>*P0Y.LX6W@!_-8NV,K5PB]O$)$64BQ'EUW[I76.T":3>@!0L9G"FL/-6>3,
M/J;<.NT6%T2C29%H%NQ>,Z1;9/#(CJMD"\9=0*65A]4^Y@WX$G6MA *U9]4<
M$R2ACA3-HL.CB58[-!)!3_/&6TFBG7!513&-5X_< !J*FWQ;3[;K\%PSC"D>
M712M"\D/7R0;@-=&UDHK;'=_&?/1K,HJ \RO3;>P_)'P%DUTBC \9]DV2^K$
M*9=J@=U=!AK6^?H6I'-,*4D"-MLDN0;1B(>#I,(CS)Y<FFH*)N>F*#]N4=S5
M(';;\2I[0'("XO035@0%-F^_N2M-!U!S)Y,)_*1B_T?G_YX3K6\0&ADIG==F
M?Z!*J>)Y6@@+$RF:5@UKQ#0YAH*@0VKIR+9.CS["S6!M/K\_6XMWL$"U%LT_
M7[(K:,Z:L_)45(1CY9P?IC!,UH*HHB49'\:5Y"$=L:3]MA7OI<_T(=JZP?I>
M0'1>U+C(59WD9C[0<9D57#>2MR;5/"OH%:$5@*&?A$-V)%4AXIJW  (Q;-A4
M*R3Z3:Z/N6E'QP3;*H',4GV4\/X6>)J;BTIS(QAV\67%-/ N$1HM =<BK5'%
MM7HI57UBT$Y'VWLXBV%D @@QM.9+MP@)Z9Q($O#GW>+T=<BK'WX&Z.EC!DAG
M@)X^9H >I!R;*H1N? .H?'1/WW>F'RC,R.<MK#(QAVU<*MGFMV[E..(UO6EV
MG;N<ZDY?VA:D9R['9<<)I?6FHR/U8=6=FXE,:L9/ZB09R/1DR<D=0BEK!,Z^
M22 X!'+][PI6!F.9W=&N^>)K(<.^4GS@010;>!(<-BZ\X1:QL&>.+TZ/+D]!
M*L:UW@F^00(KQ7@OF6:"7@F97QM+Z* E20C"PGP$Z7_4E;KL':&LZ3 \\ZDZ
M@+[3_ I]'G+&C\9TB!\^>?(LCIX^)\3A\7[T5Q >T*('3YZ"=;USN+N'_WFZ
MV[;Q^$4C>4\;',0 )'@Q)49!A$Z+P6H:0>=C?KH@E#A?12/L3;29=(4"QAJ5
M+:1PO+_]Z)\4!7'@F^3A,<NS.TUV@;"-%4^L$]QQ/4I37^5\1M=;3Y0CUP76
MM^&?*=?RI."II:IR8A6.1^AGA:6TKQ( C@[9&W20<S<*VRZ8JQU?MICN:U*F
M2Y=>>?PQ+VXR-9E)*ICIEIDGQ\,JIF@P_D9T5J65&//USM\OCG:C,/]CEWZ;
M5,'TKJK@A$LZ0253OK43-A%AJ:E4>E+XVB&_\,\XR:+YC1.RM#*; 4MC]H@,
MS)1:AJH;9FQUD<&?%;7Y-+!J3C$2(ZH0M\F)FN)YM\4(SG,* Y.PBG-YED_1
MP[63I!O:H$@JPQ9YZJ#Z25AGJ1Q4KN:4*+,84*BC*-9=-:0.2;TX3QLML;F7
MZ__NN &&8'C>*=0RTCJ"YI.^08SUJZ%]) /084A=.(9O=HW=?Y F@NIL293
MU2'BB'"@WGRM/<K-B\DD&L_FLYP_X8)2/M8?'U5)5"8=[&?8$CR#T:S<IOWA
M(.):&/S7!%>XT*:8Z!..GX JD8X6MR$=5N891J4._>D*%1283,V23&='W$XU
M1#HWSC#Z78!%^5LSF?'.E42*  ! 2'618]$-/^[(N#@AIVXA&@ZL%-W)GP@R
M5QU)$ 9>V9 IUI36+M; 5--@#P$;5/?GGUC.+(<?1N+51) YYDYH8S:9Q(H=
MPC\VULGSTL@'=R':C-^XUIP--\8Z\40)T[CP6.FB>?=.W-ZA@;?.=.!P?%5(
M@N[K)H<>3*R_'4->;R_>#<;X9]Z,[0#[Y]V";EIKBR1TK1CPL\<8L(X!/WN,
M 3](.79CP!]476?&P&9D19<V"D^QPM=B[CF,"E8Y+&SX>_.<*)EH!%A-'&NN
MI=WDOJV]NC)AO4B2Z>2NJ>3I"X'OC) IQ+<.F) ;B7!T7YF8D!Y"A+R[11K/
MQD<[SN2?&4USVZ%\IJDV32]>H=5#1(XG45/KL-SJQ[B''B&FOY"GY>8I$NWB
M$OS7IY86W,!P\'S_*?C<PF3289#< 85DYBG<?-MM*4ZM5!YER+QMBI@NN"E1
MJIRV!:7YK-U.*)Q7/>5^G;0+$>#E=B'>'2)+^B*060]?)#"2.WE2+K&#2R:;
M..HU=L 46)^ *:P$"Q&PIU/%_<S8/26*&YULPN=NLCU@SNF=)$BI8]0:@<S3
M^HJQ*=0#K5*H8AGBH%EUG#Y:M-$6R=(0!,DE""%TTB6\"F!](Q$IOE(K>W%A
M[B@2X4&<'>;WA.4'W41WD@YV-VL+BTW7#S?Z[3;MWYG=OR:K5>3"GBO;Q@G?
MRE:NVW%TPD7390[VG4)_WJ4AE%Q4)FMI+X8I?=8\@\!-!6E8+4JO"_7#%"VA
M>@AQV./1>9K&8?"PF+.G[@XW6$%O/"ZBT #<8S-,89I /X[$'D=MZ'2[VV+&
ME"*2B@)NAV[:1+A#IJ9B7_74>0!Y!MOQVXL<B]"^MV7U6YQG6!U'M>>A&_SW
MDF:=,56*XC#2 79(A1F(.\1TB-FT,ZA#O2G-F%S8I<^:XB4K6MU:UPD$>>P4
M8"#TT5-\)DJ**&"DZ A)D9W2$Y.RIHJ!S5B\,KIJE9HV&<[>B;I66;&(H[=)
MWF"'RP:A\\=8^U-B5RUJY.OB2D%Y9$7*"$AI<"%T]MNT8T8]IV ;VQP>?)U=
M'3[W007JON^DXG&#,NP\KJ+/>UH-!^L?5]8[\JM $2;EHJ2V[MAZ[HC:?(Y2
M=J;;J!FX2)^T6<PS3[0T2S 3+N@5EY*L1?OC>@8M8:6JBUE13*)I0D4???S]
M<31ON$QNCQ L7%!:Y'NV'YS%O1 RB/%]E(\IT?&N03WG:KDWSJAO,4CE=0J2
MKJ2"WW'")@;949G2U28WI=XCTG]>/Q-OC@)FK=X*)SM]7XD>=+5,?F%&RG7"
MZ<\?P^DZG/[\3Q%.?Q@LIW\@0E9?F9[](<;\!YI>/<CU(C;O+]Y=GAY?GKT[
M'P[>O8Z.WYV_/CLY/;\\.WH3G9V_?G?Q]@B_W-]*%-X+AR[WV&^V(\DE*=/S
M:]IM&9.T-?T/.UQMV##SCXP5G)@FW.-4:\5AN18F%#9"5RT5MM0D$"Y%)&,V
M3+M(GPPEIY#0:H9<M$U!XK $6V%*G4>#/5W1;J73W_QTQ:_ /JI==(O;Q*C5
MQXI:L%57OJNE^T;IX7H^K/][#*7JN@I#Y&CJPBB*;)?*]/*8:L+0-DWN<F5O
M*5RD$]L313#>EQU+C!W8S%NXMT0;]M9[LJP93LK@]L9%N-#('4+85U@9J1,V
MN7)[1Z1NRRJG;P9U*:O)W^Z25&%[G5SCJM"-VD^4 7HK#(Y^0PW)" ZN8_O@
MPO"G6 2(;GK'_4!PP%)%Y++3591,5Q,AX9:+[:Y8\ ,LI4=I,(0!*+$U93?R
MFGE'<$8Q/I)8X'C(DRS15,)%F6I9PR5$_7=27:*-%G.P!KH,'($G55A*T"TP
M/$?>^(DRI *#*J(Z#>'7'%/U+\%<FHI1D;"8-6YN]EI5+;$.;TU27^IT1'0'
MPU IUH0R*T$D[5X3A[E+T3-W*6'I+F+7RT\*VI5&](EK0"A,FMQ1E8T5[COO
MN.&@?P9-29)3/1%LKV91N/Z[0%[#\96.4]4UVK4V\Y:Y[2\<+F(^.7'3RE':
ML6Y&E[E;W*>UAB/:T?B8(%SJD^&NLA-Q$Y N78=MG5$M*H8ZSA>*#WK4D^36
M(4L^]82_(7(-<\Z"1TT 93SLRZ*9(74).LG$KI*D&6T8^438(+A4N7L<L!O1
M_='I25]!V7:B!B6>7,,S<)N^(KI]N)Z_&BV[C0^.@1#Y58$Q*_E:^M:X>H+2
MS5VS"$\:TY/L'$R;,H=SW)8GMI\;!J,I$C9'_#8U_V9$*D6]-4)&M_>F!<V=
MS<@YRPF-P>GMFBW-KF8*\0D'>;5I%HS*+^M*4C"79.,[-'G<0'@3TV#;=KZM
M9SDRFG0XL"5'W<6'PE-RS73//33<9]VF=*^=U;$^9B0=RW^=%H*-H),Q4$6!
M6=_N,^&>%&GUPQ9E!'0.34>_*1>0<"E*1!$L9F5@MF]30O@+[E+BBX'%$G%A
MPBJK>W\#WZB:I&.;!'"<A%6YX;+),%U5JADUYD8<G8WY8QURR>%?;&6Q"UK5
MC$7?E5>9'VFZ*<OS>O(/NDARCHX0?DJ_'RU9RSOBL2A@K$S8&",*IB[&'S$_
M"$;73#D#9><+<W0I^ST":'0#O690C JD9Z_J-D&Y,\OQT?$JI,A8;?(D].;'
M3&Z&%U3R8V;']?5HV;V[ T*56XX]ZJ,F;>/PSA/?[?I,4^4L!3G(B9C:FR")
M=,;!2=/$_<10[;%9;,=TBATU(^P#@PX*WM(=M%$ZQ4AZGHO-CQ/#>\RV&):B
MVA7ZL"J<ULP()J46S7D6]K<GEB"'BI6?A>V[B9)_$LGUL)',!&LV.1DK2X?G
MC-2PEO5<D*[TGGU#_0H*[:NG5FTF<CCP^K8C&0\A^PSI; >GK\M)2Q80@EI;
M!1U.4AM.80[ 2/,66SCHGH*Z3+Y]#%);;U[ETK+?4O[T.LG<O-L8E",,$=<^
ME1X2%ZR=$7YP)+\(J''#'D2H,+QZ\;LI3(=-P^1[O4F^585Z+$F4"?S]52C:
MO]NS,];*N;UXS+GIG-N+/T7.[<\GQZ98D)2I5Q(:1#0=AZAJ1N@KX3>@K/"0
M!4VI\MI&B<-.9Q37P\,5S.J:R$P9J(,P%8-.B#13.0&FZ"@>&71RNKO+N.L>
M!2<M?]U(J!>D)=.Y4\E:&)84^ DS"Q?Y6VZ6'M?+IQ4T=:P,*!/%7''Y_,C\
MB?QP6 =(S<HM(EYSJ9B[:%38<+ "%F;H+3U<6*M1X8*Q81X/8F_;0OQ!B^E/
M?LYA5S; L,U[8F;'Z?B.P1"$J7.4";FE,(=T]M,(YCY"L2+[>E'48F"9XPL.
MR3$9;27\$]YP)A"\G#Y@2D^Z;%QD60*Z$8_KBBI*K\%T8$Z$)/](E_-G\#V=
MD!B1*7]G6J8'$ *Q4-M?1:!1/5<>X2<F)A0UOJJO7/K.%_LOP CT"!N]S$ +
M]VV\AQQS!&AS8PX.AO[1].!+)N#8UD1Z%&,N(<-WY!JX>8'/3)Q^ 9P3XT3:
M2-N3F_$>;=NJ/^]+(9,$^!J,1>'2U]>H %#S<<X([5/-8 _Z:E5<"T[B*PU3
MX_R5:O.>8 J6W,H-<[#]J:R-A ,$49E]X.1FC7H&X]ONB*>QAD]3#AZM=_>5
M_0!@O6I2L38-_B"8*%):(<\RY7#H,E^?$5 3LYZ@S5ZMTJ14N,$JUZB_SZI4
M18_&KLZV!YL<=#6&&69P:NC'=!W:\A-F/J?+Z Q%?(FT%4 P NBL"3@Z,R9C
MM3AK'ILYWG6;6QO03WDL_& K:3+/\"2#I'TE\$0ADS"<8C+?.@9!H0>FR'WE
M1HQP!=IN(GMU>3 HB[6@\!AGEN^:3AX.3#[9)"2NE<TH>[J\*W0=[3C#C[QX
M5_O)U+HPL=%,S7GCU6U(0%+;=E5A$!HIT:>-C;5"U(PZ;/8[UP _ +7\PM8!
MTY;1F)[M<9U-=/Y#,_I-5QVOMC>(2Y#SC!Q"PFK#&\<N0#F%C9F48H1[.E?B
M@:Y:(<B%FB^8O=28K3;-UZYGXTI/CB+9IF9X3F )*[6F0"7F&"D6+!+KH\*"
M@O R-^C;0D)S>L])#\,6BADB0$E!4$MCRZ[C6UZBQ.(5R0@](YB2X&Y([8B_
M[G7%B0(G.^$W_D:C *GUX"$['& 5-OC<C?\Q8$OX]M!;( I7:6"C)KO!:9K8
M3!J8AM0H*@DG6]C\>2[U&0]>:6TY&VFY5!NXX]LGA 5!?Y9B$G7'XHB]X*2A
M.2)N(#O=PG#+^%Q)FS8EGS<Z2OFU[=>'$76^I#XSK7H';9\82E'):&R2*L$2
M!45 ,A Y9^^ZO=Q&X'S?8*4S6S0V'\'%==HIUML48\,@R/JD=&5MW])!LU00
M_(^@2KK]"UN]FG$?6V+$4FO/X0MPCI:4 G'KYF&W>6,QFG+256'!E[I5[^TX
MC47"F?:+%E$EA"5VLK#/AMO2P'[CM\;T.9K#WFR8C5W8U)AYM+LN5&E/[<[X
M)V[W1DX+M9L>A'W3?-IIE919RNG@E"BI_?<T!3!..[=I2]$S'8HUD(8#;G;9
M;A9VP4-Y3U_ZK1Z<N>GI%];Q8BN:@Z&%FZ7_(0@-U0S9X0J3:G@[:0KFTX7/
M$7MT&\[$\&L;*@AOS:YT%1DA*=&Y<S/$QE%R)7+3XRH*3RM^'WM0[;-J(7Z>
M9#*1PM$>PC,3@],Y54J;(WV-/0B=5T7):!9X_>94E 1HI#?77:$TR6AE._[Q
M8-:0&DU%UE25S],G70K-<26L$XZ<V!8HFODYT%J.RN)Z7\_\T1'&5:+#KV"4
MF0XUDI? .S3L62E>G?3><#_51ZI?L]@9!-!SJ6,"XK]HHB)CJO$VHVXC>2%_
M>:Y?[#M/QC]T8AD9^*MA.Q;;OO,.LZIGBFSFOM"MYIEU?L>#D>XGI%O1VJC!
M<1PUNG>8&\)NJC[ST@GH$2X. WT&>X0.JG.&.: ZLZ&=@%#7U5U%#)687U2M
M[O33+)54@<-WK.<<+]5]^X2RS1)V;[^>_T(<N!1.&8;DZ\>Z-)3N1GG893E_
MP JB=5*KWSVF5G5J];L_16KU88C@'VBWM )ZC_6,7T8;79R^OSC]<'I^2?6(
M'\#;^>?1Q<71^>79Z8?HZ/PD.G[WC]-S^/O#EH4ROW.*%-\2H\!PX);>Z H+
ME_3>L#KS67N3E)@AK[3YX ;<T*K:1LAR6I.;-&DR=-UG24ZE/SA;A%Y&M(5N
M7:&Q" 1UK+0+ZP.4IVC %.6B*(U/ZU3=<:?%*IHV%%KARVSP"CS9XD8@"8F!
M0_O,$AWY+?1"8&5A_"8-9X C7'^WC1!*=V&=HBZ<S4\,C21G37<OZ9Q6 ;@$
MR!83P-ZFB=7(I9P!RNS5Z0AJ+,E;%TA/> ("IVB:*;TCV-,V 'F#WF; 9E]9
M0-DN!*8%=L/NZ'>V2IVEHJD3OR3,/]IO9U%8=N2X-4:(*/CG?L6/F^80Y+:;
MYQ@M*=>Y17*B29IQ#H<#KZD3)=YA/XY2+ONA# L*C2%/SE0'WM=F\%F%&D)>
M.M1TM 3SJ. DUK8<PQ#K4&*]JLO&0)9I]^KR(_R$P2\2M8AM:H73J01M7DJ5
MGR%OHMH.>YW$- I=#<BYYJTS4VSM9\L\D08^#D-8JX7M"G-%PHJFV+S5OG!;
MK1?3(_BJ#2C[\=>?3C]=I2-$)?[X[:\_$3]#HQ!Q4I:H&R5$O\A4K4R_+HQ:
MU2M[HAAKJ&,MN 6FU_4YK2D$E3$V)F=L3'$3X&#D2)A0"TW&<?*_U:=%*B?'
M1">A,*G75+O;=/AJJ^;7'*OS82<9D-;*5;>1=D,^B78N-M'&->E=YFV:VK'-
M?F)'/.*++'I1Q&[:A#6_GF$7:-RMI:3C=O<&L\TP8VS/'5/(N1W$%IR9Z:,8
M<R-XT^= #\$K9^FBN:1]Y$.:NX:5JJT2A4F76K6)*>L KEH^BT0WYQ;YC$8\
M-'1<H[@[P&,>'0E1Z>!(T,JA.RON$N? ^9P;KCU,2:"CPYHCLZ9&2?0,=SB0
M\>HAF-?;2G=(^6J#4JT1DA PMB"..K:OLV_K*RR 5(AXL(5YM/-IJ;5286X&
M6>]6M2OE?]O<2$AW5"'@FQ$.2 \\\RI")VY5VMS1"$07$]2EW:ZN>OI*BS&@
M>R=2F>@\K9R"EXGDF6H%@V3%QIDRC%Q)*>(T@'-NDXSI?A&7A<D.=\F2,:-%
M1]BL*DJ(F,XM/MWU^C>TU<5-T603C]9]1-4OW*)2%Z!S,4$FM0?,X>7GB/M+
M(T%*.JHCF7Q#XVUTS9+3%:R%,.PJ&]HFP9G=67!BTWO4.FGF)QXC['617=N>
MR[JC-RX.' QS G/$5#4F=;^HO+@W@5S)P18C ,YY%=RL(Q9@K\D2'SDF(WI'
M=$-VW7?YU:@ZR@Q)\^Z$SW/8O3B0 ':RCX_9*I/HZNXJR,+<^QW.<;$0P!#.
M[X5 [BQ73[],<+$&_HIM'@G;X>(XP< 5,D5H(X+$FH$6YC:N64//0>*FWM>@
MTF\<BBF@$HVZ52*2=EG-?))GQ(F"J!W#2,#)%4T4P,KAT1%=M\3]Y2,.0^,P
M7OXI<!A_/CG>^:U+'_"QJB;V4)TT&C/JL_$8,U;ELV1F^Q&#L@#E7@L$ERE%
M F+;5;J$>8:B&]#RK)5Z/!<*UFR1XMGY* MVA&9:?^A7*D^Z@LLTL?9@%6*@
M_D!826D>2H,ST0R!%.DB?>QV!\ <DX/9Q>B'-GNT3<N6R;*]X^@,,;82JOC6
M]8I[E\:K!".++I>\J\ =7!(<)I]DLN%<^^QH$S%/E639O-9$Q]314%"OJ!.D
MEQ#>WO! QCK7.U?U54&4MQY2>9Y\E/!&0V7MW3TT___VOJRY;21+]UT1^@^(
MBML35 2DEF2[O,U4!"71-J=ER2W)75TQ<1] $I10)@$. $K%^^MOGBWS9 *D
M%KMM55,O7D@BD>O)LW[?.FV%::L/6QB=JBBY3"  BO-ZDY0C<FM;[D7W P5Y
MU+KHL<3"2SK%YBW#29)A9%8JB M-R51!><;]G6+D"5OU:U+-J2/Y@K)L(,J$
M$&AHJ HCIHOK0E(YN,XJYU=K X.:9%]22HB?I(E%,\T8ZUPY)!0/IQIQP$(%
MIK!?/K1H3;*/VU+L3=]7>F4:+K[ 'XB7J3V<X;&T]%7FY=^J1\Y/%$3DK1_=
M>9#9WZVR!-Y:()/FL):RY&: $T,X:)3RSMS,L:9E)MPTZXY<)^F0LW0P.W%S
M ],#?<SN"/QFQ8*.BFA=*_#/[D"FM,SNYI#O2(-0$EH@G$%F1P7Z.@&Q45E7
M<';P<06_IB6*"C-+S3$=<JCI,YT57B7H[M!G=N,"/_K%74\"2,)51^&M1>19
M(?*,  WQ[^UJK%P"9FV@8LC&"B1M\T^2H(EL:_-D\'1W564=5(.Y:2<MG%FK
M='F&FO0F7<-;<;^9N4@?LOD@_G6?W=<Z=GB1I"[<?08BG@!Q5R"9A =N$2[M
MTNHK\^!-"DP*00,!*C]7,7,1KDJE<+5U%!'4M_):I4(4+,U.BCS5*45Q&QN!
M525Y7M,2RLL0[%3M,?8<!WAFK5+, \CQ\@J9!CA(';3U]W""*U0&1ND@*1$D
MU3Q\G8$[.N:O*X)H(&YLT9OP]X*LP(\0BZ;*1:@XN?'9[L\,.)1&GXT*9 9Z
M7J.Z_@[(ZH[*^27'_BNC74,=V[".H_V]Z//.^<[A3O0?T-#;Z-FS%TE,\HO-
M"$!T-O.H<)(+0)RU^)T)X,5DE/Y@3'6SCAF*$!"YL)N'V8SB@6$S5VDRJ:^0
MTV)&DXR'4/T"=*MY:<$EL(Y-?62?ZB1<%HX0*IF.#&QN/-\/AKCW;'\WV7XY
MZ(RWMG#^,44&2PS="E7S:D85R=["(T*H&V74/D@IK(;>"4(;7,%VV1D5N\R
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MNPQAO0N?O\I\]08$V@3T>(%Z9,$\,IN_4A=TT!ALJ"LJ_[W"S 3Z&-@R9@F
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M&,N:)#.2_;!7,C"OGL(/C?##L]VG\ .''Y[M/H4?'N4^;H)#K-  ].7:I@S
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M^!6?/_D5'^U>?JUPN8Z-X5:+ACF.CB67U$.$!NSDXSX#+>/_#LX0!OKT7?1
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MLHJL]S[B6,>G/]#)"KB8D5I+%]CIYY8A"Y[Q?LF :E,,E5 UFYJ2J?DGQ.D
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ME@@1E"[#I"P1;XB5!G=O9Y60S)':K5:&2,5:?(;M,PP*VOI=_@ZC\$BX,L^
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MFK?TYQX*9T N^=\=PHB!%;80'ACEPI-]DY1 Q .=<9/KJ1*88["Y@2X /M&
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MP=2W\#(3;X,O1F 7@D-M;F0(U)=:G'F%ZSI8A,Q_SL5*)'5-8D#2TYTRMU+
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M BXGX*'A":LW"M;\7A0,.4RG5P3Q,>\3K>:UP]PP-;U.8N#I8PY <@!/'W,
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M8JX;W3=",O/$C0#_%MJA!/Q([!S1""/IQLUVP#%!'G;/?",V^'*9IY\1SKH
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MU:YMMGE:,,@WA7QH\5R3T\$MQS9/E(WXZ9=7QY\OLW'6)*]_^O:75TZQ>A>
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MF\"\,Q4!_"-I%S#0>4N49Y9L7L8H2K9#/A!,@YG<2(V.G5#S.G1NSH5:?ZK
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MHJ69=.XM*$O<-]%))J6&^HRUL"2YI861DC9+SOV2=(;Y>_XXD! ZM+BDQ/9
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MHJ@DT1HP.$D6S/X*U39+2WQ=^B"1X$9CH&3B3GNWLQK9@WF*1SA*N;8OF B
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M2V^.:$L3LI]$WKM;7:L1#%.3>+AO '+:]T3'$"+G.>R/0JVX.;#&J0>4MG
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M7]5V03V2ZW8Z3;(PEBX04)W>%KYX+>$WTQ?I0R8?Y+_N,_LZWQT>)-"%N_=
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M_?#T,?WP3<[C-CG$"@] ;ZY=S@#LYUV4BK2O,U&W,;-6>BHBK2_A8ZL#MD7
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MAMY@9<#<JN*8\<L/P9[,82]$HL8JP7W*8@%+44$D@L@/+@,_EV$XQ]V7!AN
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M#.'G"?ZMO@(94L07NM%])5-G,:A7!"QN=K0C%'[V$WF%YF#<Q%1-1[#W[HB
M%K0P)_CE>2*G\)5V6GK20.7+3!(FX(T\!/UX@XD-6?Y(4P"BU9NH*?\UFTC
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M8)K:'UV.VFYMZ 7LT4,6;&T&A<VB*S<)4CL^?I]S$;1%!=6N+[XAZ@4E,5Z
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M+@"6Q *L<F%*'@!J=%)F:F/5)T!!RK]=Q5L*A24_6\$7X(^(71MQ:=OF3J+
M8DY1J 3?S#,(,]K9LR6Z6/R# QPDQ7SK\A[E6BQQXD:]5X&K%]"6*#+8XB*%
M5PUC>O$EGX,(.MR'T#8RU*A+5*@N<:JJ@5HYQX"&[Q=DT<4N#(.MTZV]+;']
MYM=7'>%MB=VG+X1I_[#;[]K2YD[C(VWQ!H)]_6IK>WOC%_@5_WJQ\0;^^@44
M=IIIY^5K^,M T>^^M<ZS:Z#=BZ<S&05%._(]<_I$MTAK=4%OMRSL>T]?O+;
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MU?RWFU944U(!_.,DOT#'JDKDC/1.>+P?>?6(";QH;KT-UZZG"1G?AB'GY5O
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M(4F(?+YI!Q!A4M.LT&*1A32[/[+<]W'(JH<#WJH_,DVC7H@![\^]\8/&_,F
MRV%YN_E40:<P^K/41O,S&1PH)$_M/W?"%D/:-_0\!8"/[,JG5TWO+:7?K6=
M;[+AX/ACI,1;L8^56,XB$4J^+%/B"::HXC2?"!2&8Y*59:%8(RM3HK:8QPD3
M85J>^X$CHA)50$ HRJ8I68>L#,[IB:D00*3SJ)R;(H1;F-WG[,;#4PK7?L1_
M, D1GR.*#CDJ,&&ZF]-*%JI!/<$<, S2X,*+3,>5A\RH'(ZN-CZ2JT59".7
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MQ6>'M Y+!-3*N4T4! A?;LPX-)Q+V%@Z7T\&=M.BGN YYR]"S!^OC#@%J'+
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MVT\O%8).[D,ZJ/_]TX]__^G)G>3N.,N[:V)(&C^ K<[*1[-V#.L #&N>,Q+
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M1K! 2T2GLE?=)NG\/BCIP3XV63YFM5U=A$D)=K"BW^]WF\4AM'@KWM%LAKB
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MC+TT?H [CS;ARR *%V$$TN-VXROC# <VQ\>-9W_+9,.7B8B)W=(3G<]=FVX
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MPAKWOY%^(;")7[)+W,US1D*X6_D.JMA]+?.O&: _J /TI\1-T=/GOD+RVWH
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M'"+<W;NH%MRSD)Z%W (+L:1G.!>^$PU;ZG"$NE+=]")++L3+)*'GB:-2^AN
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M.BU!^;:XJ+F;-?<.]94XF!'/L316LA%CYU_WS^I6\%C<Z),9)P-)@9"AQ6J
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M?/#\],7OW!KGE_/7OS[[_U!+ P04    "  ]@&9:;>'%H3H"   P!P  '@
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MO]GZCK8YVYQXNR/0G)0_ 5!+ P04    "  ]@&9:N/AF<O\!  #Y!0  '@
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MSE8*3)-?I\O?K^/7\/X%4$L#!!0    ( #V 9EIOLR1!4P<  /DE   >
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ME]QA5[&%V8(]:C-7(AF+*&RS#?N;&$Q>FYS%6!$N->-ZP0J=VT(T&R[GN<C
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MZ7Q'G+;ITZWP+1=]\O4_4$L#!!0    ( #V 9EI%7+GQ1P0  +X1   >
M96$P,C,P-#0U,#%E>#,R+3%?;W)U:V%T:&4N:'1MY9AM;^(X$,??(_$=1DA7
M%8EGVNJV9)'"0W?1LBTJN9/VI0D.>!OLK.TL]#[]C9V$YGAH>[M[%=)5E2#8
M'O\]\YNQ'>>C]WG<+1:<CT-W@)]@_AQOY(V'7:>>?&)K/6UV>G>#+S#UOHR'
M[TN!X/H:FHU(@\=65,$M7<.]6!%>27ZHP)1*%I1P( Z=9.,TW>@J"=F"7X-D
MBZ7NP(K(!</'1JGK]+K#S9+-F(9VJ]9TZCT4,MDQL>W?@3UKI>X9GZFHLS_J
MM8)S>K#KSAP^Y9I*J[-/I68!\XEF@BL0 >@E/2SX5T\]D8S[+"(A##?4CS7[
M3N$N0"U4 N%S>&J_89S@5Q(6"VF'-U(82Q43CM8$-'^'/VK36K^&)GSC+&BV
M+QN5MQ'B*G#G(M(4O?*DZ6WFSI;[KG%E\/"6%*9$S@BGJGJW">DCN+[&P$&K
MT6B]@:3_-#.^Q@K3X;'4'7'P!>?IVM=,+TUB@,MYC$#>TTA(#=AR(^0*)ZU^
M*A;0.7<R?B#&19)$%(GV<=(1]VMP;@:?A?-OL>CTQ2HB_/%,VJ<R!$):VX^4
M2*!\CD$>4)^N9I@'[68%_=JZJ !1$+ 0V[9:,#"Q9)KA4DVZ##?^DO %+19P
M@A53R@C'?]-U3C0%5$518UY*LHY,204H\9=I#8 8E4B%7L$Y19)U67V = G6
MY.P10V.+B'%QE.&I1;%P)&?,6DB*<ZX_[)"F#Y,F$M(JV$[L,--O1I5M63(%
M#URLT5$+>GVLZ%:UB&SA31]G0FNQLJ5[AR[/[8V'T!^.QQ-W,!C=?GA?:I3L
M\W3B]K/G'R0PE1'I?2'FMS6;ZZ6QU_@-$]&[SZ;Y;KSMDS!C%JT<@=@L8) -
M2\TU:JU+QO\Y(*0!;CG-,NZ6@VYNR$&CI@"D_ =Q&&+T$8;04+@E4])O,9-T
MA1EKD4D#BT"TSTD9D/?FY?F\O WR$\@9Q%FDF^_:%QV#MY5F=G'OWFSJ)BS/
MA?:83U^_W_^/06B]'@3&L7JM[.'!U$M-F"D7+*DZ&26$2<0DDE09("K% K:3
M,,2U8D''71UY41$BHBIV6)#M]L;BG%G;IL!AKSA,@!(15MC\B26K2+73X23/
MQ2XW_YJ3' (=F F)I;GJBS DD:*X-:;?2O;T^PPAR1I+Z2$Y%V"CI*K87S21
MLYWPRB)W<W?K'>E9Z@XPBM?PF4C<.J[L;G7IU,V(;AJ+G:E2]9F[>R'Q'Z!9
MNT0G*!&R>>+\0V(N7A935W48D[6DW*?P*:2,Y[58*E(7/0G;AO"0VL,>W-/X
MDJY3U.2,\ A.%9MC5MH$ZR\9#?8/XTY]U#T9Q>?/W!K*/Z$T_^,/+/!EJ'^1
M"PS@KOP:<W 71*Y)>!J1.4%)",N4<H:'C3\1#MBB7DFOD]0R[TE*5"Q/E_+M
MW3=_-W9Z5M-3+]?W1<PUXXM7),-V6_SIR]/QVUCN;<A.E[IY_Y*\D#'O;?X&
M4$L#!!0    ( #V 9EH_\;W?LAD  %V,   =    96$P,C,P-#0U,#%E>#0M
M,5]O<G5K871H92YH=&WM/6ESVT:6WUG%_]#KW:3D*DK687D<2^,J6I)M563)
M)3'9S<<FT"1[# (,&A#-^?7[CNY& P0I>=>2'8=3-9&)HX_7[[YP_'[PX>)U
MMW/\_JQ_"G\%_N]X<#ZX.'M]_(S_PMUG]O;QFZO3/\3-X(^+LW\^&65I\4KL
M[<X*,=!39<2EFHOK;"K3'E_HB1N5Z]$3>!%>_?BE[QV)J<S'.GTE\-'=(U&H
MS\6V3/08+N5Z/"F>O#Y^\_KL\T0/=2&>[^P=/WL#J_[X=>:CP7].AV9V]'7&
MW2ZR&8WM+PRSHLBF]EJXNTBEA<II!:=G-R?7YQ\'YU>7XNJM&+P_$]=G[\YO
M!M?]R\'/N?FSS(YNQ,W9R6_7YX/SLYMNAV^?79^=BH^_7=_\!L^)P=6WW .L
MCM:_M^^V4*U7G/W/R?O^Y;LST3\9P.UN9^^7@^<]T;\1_0]GEZ=GI]]RY=_=
M^9_T/YX/^A>PAJN37]O7M3S0D?BJ:_WJD DI[IU*52Z3QR7E$&3_*DVA1XLO
MAUF=3^DT5OC^[LZA3I^\'DP4#)@DV5RG8Q$K$^5Z5N@L%::<POOZWS!! 0]-
M)1R8EDFW W^G1F0CNAS)F2YD(DR119_PXE5>?I("ALWE3)6%CF YYVFT([9^
M3F)D"G/5^SFG?PE[I33-*UF9NRM93O/8&R?9=";3A;WYM-?M2"/F*DD$_,W@
MP=PO5/AU1BHOI$[%+,]NM8&]^=6?JD3.9:Z$/5UQDN6S+)<$@ LY%UO!W*?O
M3B[\Q *6*(R*LC06<JH J#&L!7[DRA2P@IAFU2,=P0^<3J=1,+8#QDG]H?/P
M(3>7D-4<HC;%< '+-WZP-_0S@ W0Q@2'G4]T-!$3>:O$4*E4C'2"0QFA6$;!
M"6>TH7Z:E@"%:P5K* 2L\VV63P'5MG^MABDFVHA N GX*<5,YD6/5PK@K#:+
M8!DN8,DCE:LT4@*.2.ET!S $WF,<6X@X RQ+LT+,RIRFAO4, ;G@M!,%H,%Q
MX?$_87$ +5@[G"8N&S!9YZI8 "3H/.LGC#L* -SM-"%,XS+4=L1_*Q@N@G?D
M6(E%5N(:<B7CYC!+Y\2XP,,P"' I<C9+X/EATEP5W.QV$)> [@!;,P(7_'-*
M@^U\"R;@6-#CSWP%D)-E,<F0T<0-;@+$9;0I"&J'SP][N[N[^/]NQTP R>@R
M\(,IG.,-/M\3_[6[L[N[A[@H;F52 N2!']##?"Y^"%&-,"/4S&%R<]<@GM ^
MNG>Z'9HYX J.2O8/]WJ'N\_=1!7M 8L%>!+Y @$BI.#V&^&'O'LO-:;$ W0[
M2R.X-?W-$*I/AWJJ(C4= L .]GIB?W<?]#:4#0I$!?SGX!^]Y\]W>X=[-50B
M,@_0B3!F#Y[=.W@9X,NJ$X/W"V#+:0QR](>%.2DL(9 >7FWYBDI=Z[+NR:36
M"8"*@QGF[MJ84J*P@R?+&0J2@'V)=NZU(_J@Q01(M.(YDJ_ $72<+ 1.I.*>
M&)4)_)I)S0I"FJ72&&4,BI\?&1G/7Y_J6PTSQVQX&W'\[/S!$?+;<;>;<O@O
M%9%Z-/,J%2*=+.#U!2D="[P+.K+%'])ZUO J :^B/"E@+<0EQ21+8I6OX(FY
M(J6K0 62%*1(:1!ML3T&@T/CFZ,2?R1J+!$SY:W4"2(CT :/.LQD'N.#,2AP
M49'!?%MXW:FR>+L2JU;=BS68)XIUKEBA?J]31<HK$4*P"JN%I:##XO35%OF6
M3L&,025MFI5I80%(6APM"T'IQ_^QZ>?WK$ D^%M0S\<R1[Y<.&O'J>QK$!YL
MN@;&9RFPWZQ0I+TK":H>*V43E<1H,0&^HPE:X("F'$YU4?"+DE^#24C1M).2
MW4':(9D_:"F@F8>#1^6T3$# W-*$<$K=SLA:PRH!FD')4R,@H)*[;!60,A'\
M1,)/%CTTMVH066_FV"431Y&PR7^!S /;R]K2ZS0I@ ]90C -+9V@9)_TZ]\1
M=PI:-'R'B383I.-N)TI S+%!2(3;LQP "1RF*B:Y B,R(5DHYAJ,87A_/%;(
M".GF]D*!?DV. I@=604>+[U1!^U<PX*'%O"HNA=\]I(,YFYGJA31D=U3>,(]
MGAE!Q X*MR P;^"=$E]SYYJKJ42DS2U0=8[&_@P/&[!@:<D_-&>Z)!FGIC/:
M.P#(Z"D(D?SOP:NNFC2DV4$2LJ(*/-T. Z7G/"7XJ*F4!4"U6T!%HF) ?GH+
MN0<"-?U$& CR.G!4?%>H]? :OI_S/[:WQ5L-K/R5^"C'Z@@&_K-$)0OF%]O;
M-A)U?'K^NUM<Z)?>VV]Q3+_ :T/@N2KWU]XD$HYT;^<0EF0RT.5A"6O]Y/?R
M?E?P.WX&*VQ9[#!7\M/V4 &_@1W-:(?AT"]:AL9-A<L+P+ERR@",SQ".#+JO
M'FSS1_Q-&=4UDEZH#"?ZSU+'++% 92UR/2P+<O\ASWJ<=7T[SO7;+&,])  #
M"F8#B%XZMC/79'QLE[.>U<1!)!8M!@.)QA"(3E4)1:R89R5H7T-5/4GO@M8
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M$G+OKX6'!=8;YKQASBN9\V4&&D7S.P(5BQVXXL6ZM5HC/$=?80^TL++!?:>
MG<H^%:GU$P7=#E<$HG$7?NC.TL;:3^;Y)7HR^3(]W59FV&&8"2V!9D--&VI:
M34VG%1ZSV6,-"4(E;)ZP5GE9)BVT29;LI_J('$(*S94@C$.5"JT=[%94.=3;
MD=8RJ<*NUC!C2.TTB<V9P)Y12P0>A(KN3T ;6OFA::7ONK^1+1E-9%ZPWF:U
ML(I4^FB-^EYQ+FUZB%01*&WW^+B-4YE=31(F3"WJ7ZUQ=%',LVWRF'H/2D@
MC2:P&XFPP?(56'YN$Z[;OK+6$ ;DP78IKS9B7RRJYJ2N-V'E(VSVF+NSCWKK
MM]ZXUQLWJI3TD9?P P'>^U-KQMH+/U.ZW&3=-MFN NE@;VE3*.Y17>M<B&[-
M,K7= U=W>U<I^AA-$">A0 %%*1I1!K;) [L-ZP;97EHVE@@BI0D[2X:QCQX9
M;0NVHTU1I5Q2$\L-Z6](?TUP<))I2_B@K973KQ ]X):&94Y2\&2"C"7WP;&;
MPC?%M&UAM/$I.?S5$"K,-VC-T(JXQPOFQV-O J"*@JJ1<ML0?<&9H=RWT#6L
MB>"YJ6FD\V0-5]72HD<*/=8)ZH'<@A8S^?*J[.FWE!J6T1;8HB0-LF6Y-BW&
M?RIFM'H#K"#3(]8-EVM.T2G]!R]N5%3F]%T5T8\*YZ2/Z.B$.[E0S;!6HO^0
M)L-##"F]NN!.<N2IA_GCDA-_W==;%F&:%N4:GKF2?)S\K\)-'BZ'=N!*DOIC
M2K0"E+U68T09F7\'7V)Y^-SS@2NL1R!(#X3< 8%(H/53!JM;GP,70%=@B?Y9
MJI 9Y+"$*OWU<J?/,KH^<96)'L<YNF1@G+W#7=CO AN[WA2Y4@5LN 3*!9CL
M]<2)3 OD!A_Z8G=_=W^OQTP'<]4*, 9G$_QVHLWN@\&V7N[N/A4'SY]O'^[M
MOWS@]/!'1.(+."IRHOT-\+7M*X2)IE("N(1(=2E-+/\4[Y)L"'+D W^5H^*_
M9C$=HA9F*RJNKG_M[]CZB:_8J+5Q]FO2\IX'W1<OT!#<Y.8!!)[?/S?OP1+E
MGGP]!%]"B&=OKD[_()G[?O#AXO7_ E!+ P04    "  ]@&9:BO<H:&M$  !S
M30$ '0   &5A,#(S,#0T-3 Q97@T+3-?;W)U:V%T:&4N:'1M[7UI<]M&UNYW
M5>D_X/K>3)%5D")Y2<;+N(J6:%MO9$FO)">3FIJ: DE0PI@".  HF?/K[UE[
M Z#%EAQ;<3XD$0FBNT^?/GW6Y[QX>_QN]^7JRHNWP\$V_#?"?UX<[QSO#E^^
M^)'_"]_^*%^_>+6__7MT=/S[[O!O#Z9%7C^+-C?F=72<G:55M)=>1(?%69+'
M_$$<':5E-GT /X2?'NCOZO1CO9;EDQ1_OK'^\$F6/X_HPV26G>3/HC([.:V?
M1]=]__/H+"E/,O@A/KKQX.6+5R^''T^S459'C]<?O?CQ%2SE()C$)[_\+_FH
MFC]OOM!=P+\759U-EY^QA..WPVC_]>OA8338VXZ.!KOX9P2?'@VCH^'6^\.=
MXYWA$7V)CSH?[1P=O1^\VAVNKKP_V-^+AG\?'F[M'+7__.W@UV&TMW\<O1H.
M]Z+#X9N=H^/AX7 [>K^W#4,';QYL'>-;-I\^>A1' _C[W1 >VXYZ^-Q?9I/_
M+(KG_N-_*>G#?KRZLH\K^3T:'!SL[FSA_(!N@V/O_;N#WX[6PT'?#7Z7&3(]
M8+S7\"ZD"-!N?W<;"'DXV#N"K^ [G-?1SIL]> H>VH=W'?Z&B]_>.3K8/QIN
MPSQ>1[V=?K2S1P,-7AT-][:(.+U!'V88#6&0K>,=H N3XW!PO -DI,G">H]I
M]&".W=0ZC'JOZ+6#7P<[N[1LV)!W!_C.U977A_OO8GP(9C/@9<"O<#A<\='[
M5_\#4XF.]V-ZMS>?P^'_OM\YI!D=R=:&@R-OP(N'@ZVWT=8 B("C;&WM'VX/
M<,F_[1R_=;9C=:5U/W!VKW;?P^>__,X?P,8/?]W91K)M1Z]@1Z/=X9O!;K1_
ML+.',X/);.V_WSL:[L(D!T?[>_!V$!DP[:/7,*W]P]]A133?K?UW!\03.%%8
MAN[CZLK@#5(:J;<#>_5^;W=X=$2;'1V\/P3VWD.J1(?O@9R;CQ]WTG\=Z8CK
MA*7M;>_LO:%G8 .';_;AK[B-UX#/#G:'VV^05X!@6_M[>T/>$R98] I6%+T&
M L#CAV^$IN]YNL1PT>X^;#C\]7IG#RB-PPX.86EOF']H/":=/_SSZ.!P'RF+
M+/UV<!QYPZ^N\/A +US UN[^$;P&AU&R-=F %ZC?XZEY.]C=);K#EM#[\ $:
M]@C& ($ !PR7Q*P3D =HO_46& GWYW!(JXGI41(T-YC5T7M@27T>Z7,P/#S:
MWW-_-ARV3!;_MI-=70'J' ]V\+!?:]Z1F?;ZK=T'_L4UABLM+>D"TFOB%N^>
MSK'V#]__,L!5'PX.AN^/=[: QCM[6^O1EQG^2R[UX'"X]OH]73N_T:DB26!V
M&+CE'4GK_:U?OL"$ EW@F 3\UG!W]^A@@ ?_;P\V'M#?!X/M;?W[QA.YR";U
M*3ZZ\</S:%24D[1<&Q>S63*O4IB+_-\#TMY>'!^*%O?B>%N'.D_+.ALG,YU^
M7<R?1_-D,LGR$]; YJ)NK579?U.>E1GWR<,?@/2O]U%VV:D[3SYX^5M2EDE>
M1WO%>O3;VC\V-C;_^>)'_ 7JD-M73VA4U'5QUC(G7?H/EM;7>=\U%]BB<\J
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MRN.A,6 %M\$8E_/ I8+I.V-<RAA__T3&N#R\8M(DVKV%C=+QF_E,U6U@ ;^
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M5"==P=< K*=M=QINDD!VEO:#GUH-@1Z^ *O+"8N;7"FV!9%/C$PKNDE5=IG
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MTO*KMBDW?Z+#_"ZKJ \Y(<%VR*JO7"Q):TDP.PZE41#Z78XL1UL991"0.8E
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MKHR08K\H.]WI<P80H!2>B5TVA1"]M4=VZ80 SOEL",A(/?M4S<+<O5)R(B0
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M#)Q,(K!V3M5>;"M&%X?_+H[VL "-P25\8B3BIL/*-JSS@M61SR<_2.DREV(
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M5<W>]]S;Y_1]9]_S^O4;/4;WJK'&J#7^JKG6M^8WOSEG%6P6M@J\^"@A+0'
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M4+UN?HUV8\B9V&CH@![%U7)H 5Z-;GIKLE-[2.9!=%ER[2DXTRL9NPZ1G2:
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MF6F%=?_?R'L/H*B:K5UX%!44 25G5)(21')F1"0+2,Y!0=(("$@.(R@@2$9
MLN0\B$1)0P;)>1 8<HY#&/+,W(V^YYSWN_?6^>K^]?WW^ZO^*KIJ>O;JU<]:
MW7L]JV?O;@Y_FZJ3QS2AY[NS+6D0LI=VK#_1?WXZ_D?/&GC."@+>W_@+T:?,
M]5&\,V42)*:C<-!$#5 $OE!D^$>1,1.J#%UR@@968#N3@&UO?]OVXL*V$,Z?
M\#EKB.G^1BX0L"\TKP*VI1=#^V%I_XOJHD$394"U/)"MI1F#_X"6/^=F@&!]
MWN) ?[H"%VJ1;'$P0ATWM'2CH<U#8_ 5!( '[H #M0T"C94-_]YXM #_,)88
M,- ^9 ]\;. Y<WZZA@/]=EP->,YF _HW7*<5TL! /]\_BS#*J/N$I4P%OI6J
M@5Z,P,.(8X/$O[>5*GX.+K?VP'3 !DUD@%XU?_<J_D_(Q@X Y)V_G'/A90$)
M[ (BK^0.8'QA,3#;8"E_67\QU,4PZ+^^^.T.N:"T*:^K% LX$*JBHO_D8!C^
MQ[%IJ KTWZH7?K8> !"_R*CSPE(V_  0)[K]1@Q,M_:_52,NW$8+N&U32S<<
MF)CC"/#*L.I??AN"-O]"0/]5'T0;^&$R9?JW)<-#=ON/#<5VSD]M9OY8KG9L
M:'!1A?_EB,*_'/%=W43:8==96[>W+^W5/4_Y'R3+BEAMI#ND_=0T6"WF-L2K
MD<_L\YZ/:RI@_43&6ZNKKF'Y+]>T7#^-K '4U;K^;V_Q_Q<+QSJD5K%.X\U-
M8CXO[YRZAPLM1Y3YU9N\4+H'[!)'!D?<AMC'B/&-0P_P 9D)5XP)D0C2(WM(
MCF.P[.U6DR@LD:I,Q%%1*(9_FPO&+60T\7&;NQ_I0I?@DR3QWB0>E1>':IND
M7YQN<'+RG=>]%HF4O]&&YT%%RM,5<_G-I75P<SU/X\V(]*G/418.%<)?NJI/
M*MG<"PLP+5P"NN4UFRYOU64=4Q.4]7Z<,7Z"NOA[)WFP-.X$L)_JALV8F+K'
M*T>O*^XN"LW=M&N7-)P9JG=KA>]QVIX D_$!_ #/A";3V%#:QNUF6?E+[<8%
M40QG@?]@65];][3BH97FU^F'V9G==A(!*Q]C7ZKU=$FW^_B .=:PE(:"N1^6
MJJ#U#)L%/J?.)E:Y<F.;B,NS<JZ\9B0B)88HHL%ZU$RJ.8&!6R<>8W*B2VSD
MMSV-O*3I#H#I=.^N7:7HV9#B3.W7Q78,'GA4^"B:DW;3/BME4?*T=YTE&]?D
MEK N6TLLCZ=].Y:8&G\];K[=BN8LRQ\FPN&(8 K09:[BI=](BL\?&32Z["T]
M]G)H=LSA_"YK0]B]S(HISP].L7+M=):7MB4Y'>M,(<0_"O20]YKL<B<ZG(Y4
MV&_254XYGB2/BCD9A@B:<X>'A[2AMG\XPVQ*\OIS*@(*>86PKQ,\F+$G1D0_
M#GX6E=PX7I-0*9CZ)90ZYF?./ZDPM'WV5+J+$@^/WF]C+)X%AGAQIO!+?-OE
M0)O(0;=JH!Q2K+KA&(@4OI49)PEBTGA<I,+<;KEN..ECKARC6%-1>?8B>$E?
M1@8SJPNG#W54E"V?6!5F253+'U4W"G^_X#9:(0Y1[F6TD^29MSDXL4@P,KJW
MYX3/\<8YW-8+3#N^+O5([&J(Q]Q=M^@UPZ6;69??1R25L# ^J'%2'6/5>J_[
M8WA0EN*:GRSY<_QP][G2!3H@)@(+LHRQ'UOH'PN5':'H2SB0$0YT8# J*2R'
M'?@F;&JSAP,-S5=.EH&AQV6IT[$;TME79J+V!+\NF=BX6;J>JHQ@Y"8W:6-[
M<Q/@G5&9R%#[IG9'S?%?OWIM6'NW,[A'%)CU%J190M4TJ]XT1QC4%AIU_.I.
MZ"C@L,^:,2R9RRLN62JO&QEDV1^CCJ8^[_!IO-7&1V!TNU]B5WNRN:8JB:^-
MW$F>?LMAV:,S/9GQO2/]F88V\]3@W/K#0-53%71^SBK9#!U<3+OR3$Q!J;J[
M[-YBG@D\>#ZK$G7NU)&;557,,/TUNWC^UK:1A=^/JIL6X8T#*^0W N1*'#9.
M+:5.54;IML/EY*A?L=S>>8;4L1@MMYC,%]82SQ=^3LDVH]B0@52L^:(7[\-V
M^LF%[?1RZ^^+:\(#XF3V64AUARSD8[UX%[H"AI&D58;@*@V'/+<AAZ]<*@TQ
M/C(-,2YXI4+K*J.4ZRHCS:VU>3//MR_DDP!E02YLZ_@O[0Z2"K@/DE8)2;=_
M*YMYO*E2$^,B Y1++^U&D@H8#GZK'9ZMB1M[FWJ=5M3<K'/]C5;X?"$@+.MG
M[<,\Q^"&)>4A-C2MO'+>\8@!+QR>AK];W+4/?6_?^]66,.VS\67\'^K8R_7W
MZFQ+U9,43I,EIM;DGF53IB^O(X2D="2^C!YM;Z2.MSTOWZ6:,.GV*8EG&(E^
MRM33-V;R/M<S?*%E8%T,,]J&*4FP?RE-YO'!B3\U")RB&_2T5NT&YO-3TCV:
MT &BQMG SA611=V4?H,CB"PT%;Y4NG9_L/)T;:\&!Y+L+521W_(,6*J1/:M]
M>:N[=H>7AIEZ"UWTLT[>-7KZ2WD,=WWFYSCU-YG4.^6A8X'!KUC#$X/!Y]X*
M[?H_^OLZV,\Y^1 M0@C: $Q?MB5#ZFPY2^<;W562_8*T2EL.'F,'C"&6J3I]
M4RN[]WL5^H=-G:(=?8S'1QV!0-'G*]QW'9L#T,6<#V /N74,DUXX,#LO[4P]
M/A*A'^/N#\J$CSFP5K\C,$":^S^6[YK^ZN5HD*A83^O)ELXX^1'[9-)O&E]N
M80SVN4!4"BKN W#IS#T.#N_\%A^>(Z@NC[HLQ8#S?\DV!XJ$>2+] Q5:R/'6
MV-Q@IFQPUOAU*VV:U_0^FP>":>S!]F]KC^W09^+*]W/#%4GG"=L3\..$A3"#
M.=.B^&G-[\3$."EY**V_3QKU.="25]X8*FXE?;).MYT"2_\H>0V?W4\%2FWM
MJ/_3A7LJBL4I2S7:4.E[9A7R&E]MNY=C+\A>74]QOEXD*2Y.AMY1P+;@17R?
MY1L%T_M?[:;H+U5C'G3/;]TN5FE&*CF"?YVGE2FO>'SIZ^>T/U](MEOK5P)-
M9GP#TF3.H?')KOA(GV@]MH1LI]5.9@XZ#MU0,G_J?/S2%<J#7C>U,4:]S:7(
M[ELZ[CG^"D;75B>-I9N:FMI%,AJM!_\W*Q[#YVK\SVK4=IXL' @N7VZ_[FJ0
M8-'LW\+D)@4/\ PXHQB&)<CI/5DD:41$3F?/$G*WON,\T&(QGZBYCQ;9?3@V
M4,&6;G=#;?G58M [!5#BYOG5UW$3-R<O73:,BR%"Q)JB8&Q=!-'N8Q8Z#G/>
M%D)>B QWHTO9-7ZA2O*K#T:'A-@"IK;M@'#9XT;3<">B%[6<SZ@P8\.Q>#/J
ML^!^ZR$/76>4D?0#Z>B"\=>^(BOCN@/3]T#'5MI7(HF2?S%7=4+:VDLS"6@%
MAMLZ@V7L(L^S0MUV$/4N<\@8B9ZW+R=JO^W@ZRF_&9X6>*8-4OA)[YP,,*XG
M&@>Z^9C[(/KK_9ZLY)M6?B:O7BP0BF890LNX"VY17$9]/3,ST\TZEN_#MCN(
M?F(2K2P5[=H-T2X9&2;LBE9W$\Z[6,'W@ZM'9E%6X>@P&3W%S&$7A73K$DJV
MMW*/M3+MKO@[MZE'ZR),VU)9JORM#WX*O(<XL.0][P_@,L+K$]W809>H9I2O
M#-O9F4O)]WJM>9WWD_N0JK W8QG'MK?1W&I/W.<@&]=AR1T$(G>C=/&LP<W.
M6-K$H,!B":M=*MVP'19#M<UCB] G,URANHOFZ_A&NH6#!F);M:=8\*+%MS7.
MM\/ $DFJ(P[^J02_94M>J8;%/7!".H?/*MY*7+MCU EZ(U<P(EB"R6.N5U>+
M5N';<->XN+Y 4H]:$T^UV>Q^AR=Z_0''F%OE&6;LQ.6L?15I<&9W-+,RO"VQ
MWT[)R#-RSE\L[<88R_U5G?6[WDF.)>&=%[5N^$OXN9[IRR1T$(-Z;.CWG[8"
M;-])^?BN)82[WO3KW#')EE7*?P6!ZE2M&N86[V!,5F*/G78%D0[-E(>._7"9
M\BA!HET^ M-N@EO1CQ29]V A[IE!\Y4)] IY[Y62;F2"?%&NL*X0IT(/$R0.
M!'#JETREP8HS7TH<Z$Y&"">964;(?;S6.N_Q75@Z#O3Z@EZ'K#WK8U/#S:K3
M+. 3MU2J;,#WTKZ@'J3=,F04&8%NQ6,_&2P+(TH(IA--@KJT8P(\%-VLY LK
MWJ\?>7[6/=2-^LFO4-E3EF^F)K-74G(4H)S5F\&OF&<LF5W<8T'H):0?^C1B
MP3R(Q<LJ69>[(;)"D% .P3XQ[7UHW%? F><[RKURSJ)R+<]R"J' NK<8&OZX
MV;Y3\B-H;#I;*CY_==#D4VGN1(HZ\E)P^%R%T^/G;SJNA$^A2T2Y-01'>NTK
MEVUNWF@;X^NP-A_Q&Q9(D4STHJ(]5!&L/TMY9H!);G@PZD)#W4+40U;DH:'(
M5?W<<4-CE7:*]JTK?W]A)FNIJU"838+NH'F,3:,D]M5.FV/2FO#PH=(8%EXL
M_9+5ZZ3J:/+\$_\4S39K0C6?J/EQ\HC7.L"#&T^+T_NVD;^$ ,HF!@CU*L"V
M]GENZO]BYS^$NGY!Q807[/Q\)]/GTDMC@$:Y1Y+R&/[(:]C_DYU] '8&,@C*
MTS_LC/S-SA<$[/,7 0/*+EH2DN[\@YV5:\)&B4]5#J[^4YDK&Y @9 ")PA>]
MPQW_%3'*;!S(E!D'DJ98BVWSYAK,&O*F(8\IY$)\I_,O'GD XEF]= ZI**$L
M4\VT/C42,+*1E6KSVNC<Y,JIB6>]9]Q*G#OQ'3^85=FK\L>PR?6M>3*"GO3W
M^2),C^AUVC;C;^MW'7X[&0XXN15Y":QI-*1O6T6KFDG4EZBS/<=G"?E@SFP5
M /(9P%?:WU"UU0DX] &;X$ (S<%,:I%I8X2F_8K6F61?&E5,6B6IL'U[S\U3
M9VVN\Z?V)7=DS%E<J[BZKS:]<8O=B%T7TY:>RRNJ8.!;;NYWB&N=8N('MW1H
M;JRI?3=^:6PT9;KFCOP<+O,FP$QF-3-:S3G1".VQ>7984YEBA_$.6<SN=H&E
M;)X>P-'[7#:)YQ.Q9T_BU(M W_9EA^(:6?#*2D2*NY;*D8S;DJJ#DZJ5WY6-
MSW("]E=6WO$BF#2-52!!SF^.COA@7[.W7Y.KR]J;D?]/&X#^GY07QW"5ZM%S
M8<G8(CN6[XK7)[Z_%B'-?TG'3'_9<V4HO18%2XS3=6#XD!C6TCC(86K:R[8D
MJ241VL:_+EF8D>$WM5\Y4"?C3$:04:_,:6,'X]YT4<Y;BLH*5^FAE+5LCIVU
M-^__FN_"3:(WYN)7R"!8+/VC5-V!JS1!HCK;RNUED>YQ-2BF8\X80SY<5EVC
M-X^6%&^]M6$0.YUVLWUZ?GF\DWLQS#*.-320P&B68=(YV3&9MKL2M9T1EM?O
MD6[:NV++Z8PGFU^ ?"KQM3;VZ)VAZ%7E2^_;'U.LD6L87%I9>(* 8;M.B],.
M0XJ+-^4X$P;I,[][.';^;-]\T'W_CN=1<<1- ]M#!(+1T_:6C:\2E]!$6*MS
MUW>+;8[U'E=S)H_@_J^PC! W_#R =]_=SP@!_;T$[F,E<G$@F-UY8?](9C+%
ME.3&@#U\8<CAB.Y$EUQ=ABRBKS+'>0QYBWJ!*RQT:]6'LP"U/;-Y- FD?FI[
M%+U%'#[?O6C7RJ]<-[^#A]?+XOND(+=9A76'MEQ=UCE%SN&CW [1^GN:WN1,
M1OC=DA1+Y'M*H;NB$R0T1R69%;%6@SRCO'63"E12M2KN)ZB5R7AOP_EDXC=U
MM.OI+#$_EA=L?E38M[.E?!5$)GWIY$-'Y-$<B;1#$ U,K*V^]&]K8GH2[.EY
MD;7TQ)SML+CE9E33F[YG5JQN:7N<XPUT-3_G7JY+H5MB?DKL;NB:G%?Q-8GL
M_V)P(5<WDH?]N_GD'A]1Q).S6YG.(N1&*N==Q_>TE0E9\H8S$=L] E]E<L.!
M? W/.=<X.&$BN>2Q$0\]WEJQ/[3K3P)_1_.<X@,T,1.' ]U0VZQ7QOH=08^6
MX,T-GS,*-QQ*P;\<L>;+)9O%_[P0<\:IB0-]=9G!'#N@2K+S,C<<OD%?=9Q$
M)$*_5X!/\8W_J:Q8#>N'@![- <KB,R**&YHP"4S+4E;8KA$<:)7A A/=^0/P
M/QL% HU.+4.D*L_P#RV@7TZ2_MY1UG]HQ;E6</]T<I/I5Q0 #NA($^@H[:*C
MF#-VK8LV*[_!Y=[/W(@ DL$RYO..'M-?8KD8O!+P3@LT@.GW9X??GWW$99F,
M?-Z?\8%[O%LP,070 :%][+GPL0;48CWM@*@.!X(382D.,.38:@#8:P 8]$\G
M=BM_@'6.@E?I//[@6J>]?[H X"K%FB_M;(8!N*K^PL7\KR8E>7D7N*"6@-/B
MP=\%34^O34-_F_\?*J?A(5+59R1G0@"P*DQ$ 0[T3V3FZ_ #HOH_R-#<Y#Z.
MAR2;XQ>OM/0?2A7B0(^[9\Y0,W.*?QKQ'5TTTATY4$=WC(/+S,\[NIG&3TLP
M>#S0"_O9#Z6*_]G$5$M='L%DANV+V&?B!+J9.;AYT0T)ECQM_+3JH@F* 0=J
M;BC(B(!)-6%2@/'4PK:/PE=IO'"@=SM8<JBY[<P!(="FT>W"!-@?$\0 $W(Q
M8870@8='.-"E&6#82RL<3J].XT"SXCA0@(_AGS&XD,O\N]Q]0#DP[%1_M%.@
M7?[8NGIA:]#APQ( >.W..3X4&(:VWX(^?PD&_$TPF9$!89]]NRG3M)8LE- *
MXSY?S]X$O?[PZHAG4+ ZI8!X=.NMMGZ[1<<(>PR&I'1074)KL:A<,-<O%]\M
M#P1JI+Y\L8&Y^G\.1/^W2L@*5I(-!W*$QSK=KS4_"??AA/W @2+TH5/@KA\:
M12VB6V,5?@'& ZV<H1X>'9ZK L\PP?M L"-Q>*%WN&)NMI^F;IBH&53^\IH4
M=/5![ZH*=_>(NNS+M[&"\GH'21V.L7KT:3G#1K2VC"]E);/AR5WO+>>U0!YK
M&\9]WQPS3),7,+2JCFES@DN08F01JLC7R/4=%D4@1^W#:6N[NES,*1!:;*;H
MP3\E0# 9\3#DL2#@<Z+G\G,:F;D3]%C_'ROP0"P-=_3,'<8;-XG5<J'%+@W7
MRX7$6"+Y8N_-_;RR0G^C)F*J-."&=X5'U!"PA.WQO"1+_OS_+^6*+GAW0_@L
M[+PPDHRZ:\F026D#UL>U(A55M0>C>,73,JOS35[2RO)3\R)59[^WKDQ&OB%;
MGVAD5,2S&_.MU?$P_$4BEVEZGU/G\\G2NS1]7C><#6XK3LO5DZOKI5@Z?&31
M\Q8M4%K7UQC2X1"+O(4(ESO<L6"OM&'1%>& ^M=#VVYJ-GMVX_ES63%CCVU1
M8!(397IACJQ2K2EF9N:\0U@!)_+U?JE&^8AW>*%:75S?[-06OO7=YZ2/^Z'0
MOGJ9%N'+&XID5V_T+'ZCV? S$<W]Z>:NG^'/?4)SPS6B6W!]&C_RY]=.I2W.
M-^ORU9=CM=/=/8S'+WX=7Q;W_S<;W$DX=P-+\B:.<P[I?)ZLWX^W' FWU&:Z
ME_INC :!AI[>F('.RN! 84:[W>;MP@M8X&Y8K8"]J? <F?]!&=0YSRYHH./@
M!H2#!" 67K]6"J2_D)US NAN%@[TX;T>$(<KCK!7P,=CZIXVG@W:XQT3:B=I
M0"CJ&9.Z.P9>Y09BB!\)5F!XGL$*ZX_ @8Y)<: %?=FU[+RE"+/#&*S5$7Q?
M$#YW=PRZR@,%9'FP D&M!OV8JSLX$(H5!VK_[C:L/-C-V/(/V?Z/%6FGA#-
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M^#1AH*;N_V%::N! D=HKF#=0S!5$Z'>8HHD"3>..27_>K(V;Q<&>*0XD+;A
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MB4*\%C06@GCQO4I!,!J$%<T\0WB@F@<WO1F__21LG9_[*2\J68OXM':ZE!K
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M;":76?" J:G*1N):=C#[E@:QVE =X\Y;Q\^19-7;.I+ULEX=3=_DWR$DM[/
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M-] ].MW>1.V#_<T*CG"]+?5RRHX<'TY88,^^8[!H8=2T36+ ]^I4]@A\!Z/
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MEF9%_2.Q1'3)AYM;<X9#9VX^]?M53/M]8*6:F>NIMTNL/:]>[* JLG0/<:E
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M=C$0_K8W?_Y7]9<_\6W\$%FC'Z ?!XI&/_[;-'Q[( ]JB?M:D4V%C[I,0ND
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MX;(JU/50Z$TAV$2LW4/PGE&^H**F8>?@Y.+F$15[)?Y:0E)125E%54U=0]_
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M2&E4)YI4#IC>/^UF7/75]]4;FG.\?SW5&&W4,1,@43[0PI5=..MIVJ/78U@
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M?7HM2]'X<%[ 9AIOA"2-P,R0Z'/<*<D8;[29DM@0>?FA;.,(%8J1QVN:?H4
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MG2^!_C'%\2?!GA7XA6VE>)_"=EXTTS3_ !?HNF>,]"\-:=XCB\,>(]&TG5]
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MC*C6(T6,%EMK.TC&0BEML9($:_=YZ<9 Y(SRLVM/)--,VCWLKQ.?L\MQ?WD
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MF<^8TC!@0YS]8:R"]M<;=[(85"(I.$8$$LHZ*1R20 0,YKRB&>"XT/3-L@E
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M@ADAC2V4B'"5B_"%@NOAMFR&:"79"XPJD0RL2JGY5/'4 $C\C]$:ZZ_V3=$
M!C:73!A@'<D+LIR!P590RG(*L,CD9KDI\-Y+F>%HXO&Y9@XU:3594_9OVDW3
MM-0@_@4Y-6C*2:3>NA[N;XK,,LQL,%A\54A"K14[JUHQDFY7TYK\MEHTDU?S
M*>@^!?"^@10FQTBV,LX6[%[?+'=WEPYBVDS7CJ]P@",?+#2=@@V@G/6">VN
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MN;7[2ZGF&"PYMXI(@2SR!1O"-M))Q7L7AVVE&GV:W:*9X[2VCF! *-*+4N6
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MEG\;ZU$LY(E+6BR@F5%([J.1P3J1G.,W3C)W2E9V3TLW?6WXGKX+.,KH.?\
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M;?NOQ..&<\,2<%5HXJA*?*I7:E9RLGLKNS;7?EVWL9NN_';P%X;\4Z1X3O\
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MBV77Y!)J[6^H^'M6\0>"]9TJR:,:"1+<-J'ANR:Y>9 HC6&7>[0+Y7.>&/\
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M).V&:6.-CRH9@.&;-?Q=IMQJNE3VMK(L4S"":/>H>-S:7$%WY+(1@B<0&#G
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M,2?LZXZ'0/"'_"._&_X:Q7>J?VC/>?#KXKK,AM["U2=%U'X4C;+;RQ/>R(B
ME46?"@8<&,,I_+^&>&\=@LXHY@J4H\N9X:G5G*+:M]8AS3IWNHM*[5]5H;9_
MFV%Q6!Q,%.U9X6O?72=Z<E9I)-)O1IGS+^QQ^VS=?$'PQ<I\6/&7AG5_B!<?
M#3X/>,O#?@+03X5TSXD>++WQ)\,KGQEXFT7PW\/Y]1TC7-4U.>YTW4KZPT.S
M@6XL7B.FV\7F 0-Z+\1?C'\0O#GQ+O!XI\:W7PO^#=U^R)\3/CK<VUKX$L%\
M?_#74_A=KOPD?Q!?>*M0\0CQ?I.KM/H_B/78I-%LO ]AH6E:?I^H1W-G?Z]#
M:7D7Z%1Z/I:74>H)INGK?06\5I'>K9VRW<=K;K,+>VCN!'YR6\'VFX\F%7$<
M7GS;%'FOFVUI:XB?[-;^9"A2%_)CWQ))-!<2)$VW**\]O;S.JD*TL$,C O$A
M']3T)5EA86JU93Y$U;D3DTM(W:M=]&]KGY%UMRPWVM+\KG\YL_[6W[=O@[QA
M\3O#'C[7/%NFZQ\//V4?V/\ XV:M"]K^S5'X0^$?B[]J/XY_M0>&=2D_:,UR
M]\-66M^)_AA\(? O@CX?Z7\1?%?P9M+&YL]-\'^-O&%U]A-U8ZD/NOX3_M(Q
M>(/B;9V?C3]I*UL_%GBKX[_M&_"F#]F*S\(^'=:C\/Z%\*-<^(UIX:O+6YTC
MPU8?%7P)?6_PU\$>%/B9XN\6_$G6+SP?J]]X\\,^'-+T71=0^*W@BWF_3J:P
MLQ;W*I9V7[ZU^Q&.2UB:WDM_WFRUN%$;!K+?,YEA*E%265@JEF:OSP_X*$?M
MAZ/^Q?X#T77_  YX4T_Q5\;?BEK-UX1^%VAW,>F6>DS:QIVEZOK<OBOXEZQ+
MY5UIWPP\+))$=8GL+W3]6U34M;L- L]7T.^UH:S9^CE6"S/-\TPN595[3&9C
MB:E*%##I1:E5G)*G"<5&[4G=2:LE%.[M[LL<1*$*524U"--0FY3BI)QBE[TE
M=Z.*=[]_,_EC_:PUOQO\8?VDOVKM<32;_P")'Q8\>_'/XF_ _P '>#&NIKNV
MUF/PKX\U7X*_!_X;65C,\LWA[P7KFF:/I&I>(?LD4&DZ?K_B'QIXZN84O/$.
MKWUU^V?_  5;^$?BCP5^P?\ LQWQO=3UVQ_9C\>?"RV^(FL6.G3ZIIZZ/<_"
M'Q/\&-1\>ZII$<]O-<0VGC;Q7HU]K&K/=Z;<:3X=U77M0EUW1(([S5;;SC_@
MB1X+\-_$?XG_ +8'QT^-/A#P-XZ_::\0?&C2_BD/C!8>&YM'T'1O#_Q7\(ZM
M:6/ACX5>!]>UKQ#_ ,*G&GR^'/'%OXJB\.:GJ^I^/+/5])\0^*?$FJ3[0G]&
MVN:79:AI-_8W5C8:C:7EK<6USI^H0QRV.H1W,9BFL;V.2VNUDM]05C:W >UN
MO,CE.ZUN!^Y?]:XEX[Q^79[P#A(Y7A,NJ\ T?99EA*].C.6/Q*<)2G1]E3Y:
M5)*\9+$QE4E=.\=6_+AEM"IAZ]2C6J5YXFE4A3]Z7+&<X247.[NXJ33DHZM)
MVZ'\K/\ P3"^*7Q!\ :/^VE\-/!.JR6OAF/]G[Q7^T!\/8++0;+7/^%=_&+0
M[!O#VN>)=):#1KJ6^N?%UGKWAC5CX1O=$LXY=6\&^(KZR\/QIXFU;6=7_;+]
MFWX^>(]8\"^-=)\=:I>>,_C!H^N:4EI\.;;6_ >G^/[K0D^%?PVUS59K+3O%
M6J^"= <P:IKGB#4[NYN[J&!(EGCN(K_[%)IUQ_/UI'QVL_\ @FQ_P4A_;"UG
M]G3X8^'D_9F\0>)?AAX,^*7P2M;348/';WOP[\(ZCJMUXX^!/B/5O$NI>'_"
M>GVVH?$;Q/8Z1\%Y_"]E\.9;?PA"MQXA^%H\4-KFE?UH?#3QSX2^)/@[P=XZ
M\#Z[I?B_P?XW\-Z5XJ\+^*M&N;&^T;7/#VMV?]H:7J.D7VFW%]97NE7%O+#]
MAD2\G62W6&:.\U#Y[D^!XET\PS'.J/&,\DKY-DO%V%C7R>%&>&A3H5\)32Q<
MZWLJ:I5'B9TVU"C&#4'&4I2DY):Y9*DX?5(5J%6OAU>M3C&:<%%^]?F?37TT
M5C\\OVBO$GQM\,M^UV-$\0_$75[NT^#GP1\7? ?P7X.AT/PI"GQ/\2>-OCOX
M%'@/_A+-.\.WVI#P]K.MZ7X#D^)^IW[ZQJ>D^'-1;6M!U?1O#NEI+;?#WA?Q
MC^WO\._VE_B?H_C'XJ^-?%'P#^$'[3O[)/P:\3_&?Q%XMTVQEM?#OB+]E_\
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M=2H_<48RMSO2%TVKI-K1=N^ID6]WXBTVXU'4]0L%&GWUW;7*6=BBO?:2D\(
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MS2C:+:5U[NGK:QK@6^C:3'^\=8-$LI;H,SL)9%M())WBE.<M"0A 0G;]WC(
M&7I]C<CP?;Z8-T=Y_9,L"QJ!D,V]H\(WRY,<T$1_V(XUS\B@9,9U[Q,FIVMW
M+I6GV,CRZ;_HF^^O)=JDO'FXS'+&Z@I<)(2K6YE!'-:OF:[ID5NEQ%#K\$12
M&6[M89H=0A,14JQLK5HWNBIBB\PJ^8T0RDE8RI[Z=:,&DJ,Z5)M*7.XMN.S2
M:6]MO^&/FIQ24*C3J5')-6?P-NZE*]E;F=W;JM'J[>4)H^I1VMGI0T.YAOHY
MK</<I9Q10PO'>13R7#/&@997B1U$@.]F<#=@G/JWBR<Z1X3UB_D8F/0].36)
M968[I%TN2*^N [$EF!BMW#!B<H2#\I-65\8Z')<M;_;=UP2BRVS1W$%U$0><
M6(47=R8_OR;)3Y<:O(WRHU8&I>(]/\6:=K>@Z9H>KZ]#-%<Z5?//I]UI>BW(
MEB=)8)[RX=2UJZDI=+L?SH"\#!A(0>3"8>AA,/CH2G]8G7G4JT%"\7";YG!-
M3;N[VUCH56JUZRI1;C%0E%MM.S2M=;JSZ*^_9G:7$DL%C<RVZ%[JV6:6'"*[
M^9':WT>0K</\\&YT.?,P5()(KQK^WM76.'4$UF\FED:%Y5=R8IIY;E();1-+
M#E;5((G>7Y8E4^7DC&:[FRUVYT>SLH?$]HUA/LCC?4C<W-WX?,AE9E;^U59]
M3NKF1G9&-T2OFS,20K.3KP:#X9?4!J\&EZ;'=3GS5U&*TLLWK.C!FMY88Q)*
M=I8.TY,@C+$]ZVQ.$K8BC@YTYQP_LZM*=934FW",HN:]QK[*>^GY%X>=.BJ_
MM*;J2J4YJ$H\MHR::3?,G\+[6DM=MSH8F\^TMC@$31+YJA!&F&0;PT0"A@_*
ML&!!R1@]^4\%QO+X-\*LYWO)H.E3NTK%B\]Q;_OYF9LLT\Q<[Y23)(Q&YB23
M7674\:0LTKQ6J(I'G>?%&Z)P&8)(0N=I(SRRD[X_G"FN!\$ZM8ZEX6TB/3KN
M"X6TMXK7R[,DK:6]K-="VEN4GPZC=#'#"8!M20QA2(QA>BI4H1]E"FTZBE&\
MULW==-_O,82O**2M>5KO6S;=F[*^EUUV.#UO7M9FU34H[2]MK*VTZ66%86MP
MTA>)69C<-C+ @';NS\VTCD5M:%J;:QI%M<W2B2?S&02QKY<3%,G+H!ANA*Y^
MZP4CD UT.H^$]+U2YEN9HKJV>=]]S+9W3VQNWQ@-<)$5^T;B0&\T.=I/;I:@
MT5+"&.WAM@EM$&\J*%PB\J06>-,*6P<[B"=PSG-<V&I8R&*G4J8FDZ51VC'D
MJ?N[NRE+6S4=WRZNVA]0\=AUAZ-*%-PJTG%RJMPY7:UW9-2MON]CD]4L#=VM
MQ;[#(+B-X53&[][.IA23!S\RNZL#PP(R#D UBZ':Q7&BZ9.RN9/L=E$">6(M
MH[JWG&>3AYD$CC)#.B,<LJD=]="#38%N)9 )%#F.%6,T[S%6$"H@)8L9C'A@
M/D^_P%!KF-._M'1X(;2_\.WILKDM<64EB6NKFW9W,LT,L2L&B@2,R2M&"%0%
MG"E@!6_M:;KOGI3KRIRYE4@XQ@W%W5E-<V_<UAG#@DE5C+56<7:S[O79:7UN
M]NQF:KI,MUIUY!;"597A<J ,E@G[QX\-A6$B*R%3G(<K@YQ7G5AH-Y=7&F01
MZ7<V4D&S,DEK#%#;JD@,C1%%!B%Q&&A;R]OF+(8WRK,#[E;:GX<OKB2TM]>T
MV6XQ\]A#>VPO(F4;F62RO+;[9E0K%Q!. @4NX,:LK:+K:H"[S0F)5.Z66XAR
MBKRN45B[*K8.%&0!NQQQEC,!0KU</B*DU2?M:<HQ=W9J::ORNUK]CKAGTE3G
M!U4N:,EKI>ZM?773:UM;75TSE'L(R%8QCY)@GR@",! "ZX QAE!!'0YP:YO3
M+5;'09KJX*A6EU*XEDDY/V=9BB)N-]IN[8#^X4WL*B38 ),"%^V?5+*\BFM=
M#*ZS(Q*,]B)XM.M9'.-]]=S!9HF'\!M\[Y/+C<^6[9Y77FN-#\.ZC:ZK#<6G
MV>RN)!?VH=]-"2*6"&XC_?*#(5&$/S2%?,^4M6ZI4J=:GI[:"J0Y^2R7+S+F
M7O-K5?(Y99K)Q;A53=GRV?5)M=FM;=CY:M/B;XR^)_Q2^(7PW^$O@S1O&%O\
M-_#?@37]8U+6OB#!X.M3=^.M0^(-G;VUK9Z9X9\2/<10W'@W4I8!)>-Y5M_9
M[ [88\>J:3IG[3MM:1V]U\&/ MT8W)\R3XX7LDOEC^%9+OX:2Q 8^4JP(*DJ
M,,5-?)7_  3!F^V_'O\ ;*G2X^UVK:1^SO#&R(AAB2)OC68X\R8E 3<P1%&%
M+L< ,:_:>.(9XP .N ,'CTSZ_P LU]DLEP4)T.:"?M*<:]K*W+H^1]>;6UU[
MO4_/89]F^(Q&,JPQ3ITX5:E"--\S=TW'F33M9;VWMYGPJ-/_ &DA>W%TWP/\
M$$2NK[1\<8%)ERX$A(^%@^;][+N?J5EE!)$C9S;G3?VJ[F[D7_A4O@"SB(8P
MQQ?&F C*AF3S=OPK ;D#)8=,_C^@7E#V_P"^1_C4<L:HA;C@KR  >6 Z\^N/
M?I6U3*,OD[^RY8W]Y:-./VEHKZKU]&6LUSIM)8U7;26E3_,^$+.R_:;-L;>_
M^#?@4W3*\/VZ+XTQR(K3*T4$D447PM1ALE>-I71E,48:0G"8J'2;/]I&"T:-
MO@E\/Q-)<ZEJ4L*?&V21X(=2U*[DMUDC'PUW0S6]I)]AA( *2V%RD9"AJ^Y+
MTH (RI8$I&@6.1P7G80HTBPH[B(-)F=]HCCA$CS,D2NP_"O]CC6/VC?A7\;?
MB5;_ !H\(?'G7(/B-\+M)T#X4RZ_X?\ C+XR^']]XZ@_;E_;ZNGN/%OCKPWI
M/Q"\*_"6SU#X3^-O@)JFJ>,=>AMWT7X?RZ+9M9:GI_A/2=%IQR+!)NK3RZ=2
ME32J2J1KT$^16=X496JU96O:G33G)JR6J)I9SFE6G4E_:<(SI553J4G"O*<+
MM\TWRNSC!+F:6K326I]\7,7[3"*@L_@=\-6EB4R&.7XYS1W:6PSB>8_\*V#M
MO8%"6))4LIX)%20I^TH"OE?!'P$_VB*.=YHOC7=36WW@=D)'PU**<]=N,@'J
M*^5OB!?>+]<^.?Q7:?X7_M0Q2:#\/TU;Q1;?#GQ?^T)<^#/C'+K/PTT/2?$O
MPZ^ _CW2]!\%?#3P]X3\%R13:Q:^)+.?PO\ &W7_ (H6VN1^#='TO3+N*2X^
MPOV(8O%UM\';:Q\:MXIEG'Q"^-EYX5O?&^F^.?#/B#6_ =Q\4_$5_P"#M2C\
M'_%'5=?^)?AC1[70=9L]*TGPWXXUF[\0:!I-II=G>R269T6.TNMA<JISA16#
MQ$ZTX\TJ?U:4/90VE.I*3:48W]YV5K-/4NEFN;UZ%3$4LRISA3J^R=XUX.3O
M:\5.VG96NUJCGX=._:62^GN7^"'@-UE&%7_A=4L9''.))OAFT:>^Y?F^Z,$B
MM!K7]I%E9?\ A17@/!Y(/QVA5<@[@25^%N>",C'<"ON 1H2!M7G_ &13C$JC
M.%X_V0/:I67Y;_T#:]'>/^0EFV=)IO&QLFKZ5/GU/A=+?]I8;V_X4?X%!X!8
M?'H2-U_NM\+=I]"#G;P1R!CD_B%XA^/?A/P+XM\5^(O@OX3@T/PEX?U3Q7K%
MS8_&&RU6\MM+\,VDFN7\]O87/P_T>*XEAM;"618VU&V*[2\9FE58)/T51%)S
M@<=L#G.:\ _:H1#^S7^T&N$7?\%?BA$"8U=0TO@S6XUW(5(*[F ;(P%R<C&1
M;RO+YIQ=!VDG'>/5-=CFQN<YO2I5*SQB<:<)5'I-74$F]W9?/3N0QH_V97S(
MHG#+;7 CN&;[(;.#R_/D@>.SAO8YYUWW,D)DG0-&IW2!A\6_"#2O[-_:Z\3P
M75MNNA\*/$5R;XQ@I<E?&_P[D4B0@EW3 ;<22I7(.<5]N2W)L9KB'Q#:):W
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M176J6_AK2K\V]O<:G9^&;>6]\-6][)'"UTN@7-RZZA%]FU)K\/@;]N4.[?\
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M=TI:>ZWHG8]/+G)*H[^[):Q[Z77EU/4=3\4:!I)>WO=4L$G<!%M%266[@,C
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M[88GVEO.=#D 9KVO3]2CU"WBNH961YXTN9K5F(N+:<@1M!+SN$:9+HAX5E#
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M>*YJ4IJHKM1G9M1U26]]]_1_!QNK.UOM2CCM]+FU#28[>WF_=EE?4[-2DVT
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MPL^\2*,R=5!K[/?P1 #,+6_<Z;/([FUAB@#E4EN"\4,B !<)"B@)@%8E3&
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MC_Q3XNFT?3_#7@JVU#4?$6NW-W;3)'>N/L\G2>)OVF?V:_!=A?WWC/\ :9^
M7A+3;#QCK_PUU.^\1_&'X<^'+6U\?>#8;:+QE\/9QKGBZ[E3XA>'[[4-/U;Q
M/H6HRVL_@FPN+"&_T2TMKIO,_([P'_P3E_:8\)_#CQCX>N/CM\.?&GC>P^-O
M[!/QB^!GAM=2\8?$OX;>#=<_8T\4IXJUC3OB!\=/&/A74_COJ?@3XCV%K#X2
M\#^#O$VI>-M%^#>CZ7#X4M[WQ5:L+F3R_5?^"77[2MAIWQ%U.7XN?!;0/C'\
M2_VD?VY/C._C?PUXH_:$^"VDZ9#^VOIWP3F_X1/POK]OJWB'1/'WPYTKQ?\
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M;5M7W6EUH?%82#A+':WMC*FJT^*HUU)ZBF0/&00.J'_OEU;^E/+H!DL /4\
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M3ECGKEMJ[C_%M7/08ZR\\6V5M!)-*FLOY,4DNVWT758RWEHSA5:^TJWLU)P
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MX'U">]T_Q!K^@:A-=?"[5]7U_P"'=W)K'AG4]'UJ%_"_B+Q-/XLT1;;4;?\
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M^*OV;?@UXP\=)\2O$7A-;SQK%X7F\(WA/B+Q+I_AS5_!S27]U)X4\5>![+Q
MWAGQ'X2NKC4M1NM0\/ZMI-]I>ISW][+>VDKWES(_WQ_)A^:'C+_@J#XY\!_%
M&;X0^,/A;X8\'WV@>"OVD?B!XQ\8SZ;^T5X@T#2]$^ FC_LG:O<S2>'T^"FE
M_%'2_ FNW7[2_B738?C/K7A+1_ ]K:?"E/$M@UQH7C;0[:'[S^,.NZWXL_8S
M^*/B?Q!H.H>$_$'B7]FOQ7KNJ>&[N^LM6OO"^KZO\/-5N;K0=0N].V:=/J6A
M7$K65QJ>FVFFZ7?74,T]M K1VR1=)X3_ &1_V?? 6J6VN^'OA1H,FNZ?X/\
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M"OBZ<%6IRQ-!U&I0Y7"WN-\W-;EE\*>MMDN&C\&P+# T%M;P^6J);QQPQ(D
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M2J7K1XLP\*5TE3E@L2ZEXU,.E^HMLJJ/E4+N.6V@#<=O4XQD^YYJW7YD7_\
MP5 _9GTZ#49[;6/'&HPV$VE6T;67A*_\G4FOM/NKR9M%GOO++MIWE,;\ZFR_
MZ=#'I\'GPS5JZU_P4Q_9FT.]\565UXD\6FX\+ZHFDS&W\,:G>V=^XDFM;N;2
M76..>XM])DC:?6YKKR;FVDMYK>Q^T*5#?<_V9CO^@>?R1_,$/$#@Z<7)Y[A8
MV5[-3O:U^G]7T/T>V1QJ=L:*"Q<A5507>0RL^  "S2LTA/5I&+D[B37@G[4O
MEM^S?\>H\$!O@W\2DW1DQN@/@W65#(XP5V!F(P00"V, G/RS>_\ !3S]F"Q3
M51<:[XL5M&UJW\/7,#^$/$'GEKJ/4FCUQ2"$?1E_LN<M([QZFNW*V[%OE\F^
M-O\ P47_ &<_&_P;^)_A?1=1\6SZCXP\*?$;P+I45SX<U2SCEN=2\,WEC::J
MES.!;PZ5--<I%:&0"^-Q)&GDQ*S%C^S,5_R^PTW1_P"7J:T]G]N__;MS&OQ]
MPC5H5J6'S["3Q-2E4AAZ:4[U*THN-*$?.4W%+U[(^[_$7P\M+/3;G4;>>"1'
MCMS();**:>3[0]A:R3M.R%RT",URC[BRF-6R",CXN^%EE<:7^UYKZ:5;6U[<
M/\&_$33W-U,T*7@3QA\/42[O)4Q+-,J$Q12N7?E8PP4XK].4MX]0T4*R;XKR
MU>.0*67R[:Y#,@ACSM$R12*D3*H9"B[6^5!7YQ> -"O=$_;9\0V$TCS6D/P3
MU\6=SO9EEM!XV^';"VN221+=(<%]^6"KSTX_&<^X0IY?G?\ :>7T4HXFO%5.
M2+3IQ<US2F]G%+5V6JV/U3(LWK8G+\/@ZE>,HO#*K!N]FE!/D2O?F=]'>W?0
M^O==&N3:9<FYFTJS"FWDA6UN+B:X:ZBNH9+*&+<0%,UVL$)?(,:2,X(*@UR5
MKJK7'QR^&\.I64MEJ-M\/_B>MQ:!@L<4YUCX?*PAN'>)+K='&I9/,(18U;&8
MU%>I:OLDAMK7 *W6H0MM(&TI92I>,NWH1BW)*\@XSVJ'6_"_A[Q*UN-<T'1]
M9\B2Y^R'5--LKYK6VNVM[B]AM7NX)C!%=36-G/<QQ%4N);2W>57>&(IE4IXB
M=>C4I3A&I@JM/$1]I&4H2E1DJB34=4FXVU[ZGH5(J<)P?PRA*+]&FOR9ZA]O
MA&W]\D1':22W)Y'?_23G/0=>?T26^1XF53YQ?:@\N2 *2SA03B[BX&=Q"R*[
M $('<A#\TW_@KX4K>/!'\,_"5W+%C./#>B$9!Y 9K(X) ('<DX!.:V-$\$?#
M._M6,7@'PE:O'<2Q/9/X:T1I%1HF5EN/]".8V4D!6^4G&!BO6H<59LYRI.G@
MVXW5_9S_ "T:_K8X*F4TZ5/VO-?3F2Y=;KSYOZ[GDO@;]B[X6?#;Q]\1/B/X
M.\7>-M%F^,%M':?%'PS=?\(+KW@OXA:''X^^,'Q*A\/WVF^-/!.N:[!93ZC\
M<O'[7<&B^(]*1K:\TJQG$]II?V0>WR_"+P!$FEV^B0#P/!H_P\\=?"OP]'X$
MFL_"FF^'M%^(D_A/4];B\.Q^';#1[;2]3L+SP1H5]H^H0PVD]C<37SZ>5N)&
M"<_XP\%^"--T?4[VU\&>#HKM(MUJS>'-(427\DBQV:LR60<O-=RQQH<[B\@Y
MY->?Z;\'? J65E))X7T--9>R47EW!IMC*9S/"#<175O+ ([N*V"BS2.X$BQ0
M?(@78JCS\W\0,TRK%TL&\)0Q52I3]HG1C&"C=)\K51.5WIJM#?#Y(\33E4]M
M",5%R<73FVTD[K1VUMUTU,WQ[^PK^S%\3/"MSX>\:^$8]?M;;X#Z+\!?"FK7
MDFEZAXG^%_@WPFVO7?A_5_AGK$MM<:GX)^(EC=ZI'JZ>-O#$]EKIU/PGX8O%
MNA<^']/>'Z4\<?#OPSX]^&/C3X4>*'U2\\->./ >L> _$XM-2N(-:O=!\2:'
MJ?A_4HXM3@FFOX+B]T^]O88;F+=/"\BR0N&B+)XY#X0M(95#^"_A_K2I)%MN
M)- T?2[Q/*E\V(.ZZ3=K*PF._<UO*0Q+J8Y")5X_1?#FB)XS\41O\+O!6U-&
M\'_Z"R:6EC"))?%43.(8?"]DJ;HHT1]LT0E5$C??&/*?GJ^)&847A(U<)0A+
M%UJ5%)J%Z;JR45*=EJHMW:C9M;%+AURC*49PO&+DER._DOB27=M_<^O9?"G]
ME7X8?";3K_P;I.HZ]XJ\ Q>,/&/Q#T?X:_$2'P+XO\+^%?%_CCXC>(OB?K6L
M^'9)?#4/B:WNO^$L\8>(K_17UK6KYM,BUE5LVBD@"KW-[\%?AMJMYK5Q<QZM
MCQ!\8_ 7QMU:!-7GBBO?'?P_TCX>1>#[C'VDH-%TBQ^%WA"\N--;?:W5SHQ:
M,.T<:+Y5>>&-/M9;*YG\&>!;2*#4XUTO0=)\(:%<B],TL\;A)Y+ !7A&H7UV
M)>"DDUQ,"'ED9O1+'PG\-<O:3>"?"%E=PA%ETZ[\,Z,);.("1HT29K'[/<1%
MI9-D.XI%YCO& W%>GE_&F;9C"K4IX?#4XTZRH>_!RYVY<J:<$DE?O[WZ<L\F
M=/2=6%_Y5&5_/=I?/:^E^_9?#[X6>#?AJWC!_#$,L<OQ!\=:W\1?$;/=>;%=
M>*-<C@BN;S3K5[LPV%A]@MH[6*SA^1(HH"H41@5ZDLL:1[6P!P-S&,=_59LC
M\"/?(R*\63P'\/)5+CP5X18MM+2#PUH&TE?E4L4LB20IVJ>H!Q]VD;X>?#QE
M<?\ "%>$<E' *^'-&1@=IP0XL@1@X.01TQ79_K+G<G4@J.$BX1D^9TYVO%;Z
M:]"7E=.SM)7Z7@]^FTCV.:[MDBE)GB4%&RYEMT*## ON:9@I4=">!WX&:^9/
M@&VSP)JD.Z1F7XI?&:2))D$1EMG^*WCUHYH_+'E3"60+N?+9R6)+;:UK[P#\
M.X=;L4;P?X1FAN;;5(!#%HVCHBSV]W9%'<+:[?,1"Z!B P5F0$!B#Z-I.D6.
MBVR:7I6GV>DV5JUS/!86,$-M9I+?W4]]>2I#;I'"DEW>75S>W+J@:XNYYKB4
MO-*[GSL7F6+S'&T*V(HX50A2]C)1A+GO/24XR=TFFVXW=T=>'PT:,9)RYG)+
M5*VR:V=W;576AYIY45[<7LUZB33B]=-LZK,;9 < Q;PQC&.?DV^O2NR\,.[:
M?<(S-+'#<L()W)9\ $!%9B6"J.0H.!QBK]]X=TW4I&9DFM)G8-*MC(UD;@@A
MB9)(/++D@$L6)W#*G.>;]O9PV%NEK;Q"WA1TS'P3(S,JLS,.K$?>)Y(.#D'G
M'!8&5#'>WG54X2J1<*:4DXM235VWRNWD=M6<)T5!1:<%>[M;1/:VOWGI%D3Y
M4(SP8$)';.%Y^OOUHHM>+>$C@[,9'7  P,^@]**_4\-'FH4Y+2\5I_PQ\5B/
MXU3_ !/\V37!9;>5AU2)V_%4)_SS7R[XRM)M2U6>]TW9<26>HZ@EQ:2S>4ZJ
MK6L1:&0D&'RT=W.W;N4NF<2$'ZBF!,<B97YP!F0G;M)PP;'/*Y''4XSP3CD;
MGP3X?O)9+BYL(VDG<O<2022$3LY4L9H\&.7>RKO\U6SM#$Y4$?"\=<)1XLPF
M'P<I.$)S5*I47/[L*C49./)9IJ,FT[^9[629K'**]3$2ISJMQ?+R2A'E:?->
M7/HU=7TUT/F**QU75;J."'3;Z>$21LAMXA>EWA=9F ED#($'EG>V<K&'9#N4
M5[3IO@[4+XI)K/DVMB?*#Z;93273700JZ"YN+GYK4QR+'*Z6Y"OL:%\H[*?4
MK#3;33(8[:RMK>SMXL^7#9P1VT1R""9$A5$9CU)()W8.<U?(!Z@'ZBO'X=\)
M\GR+V4ISQ.(E2G":?M6HWA)2UYW*5M-;:V^1>:<2XK,)249^RI33C*+LY.$E
M:23C:*=FTNER&*WAA2.(I'Y C2*&$1J518P"%SCG;M! Q@%<\D"K6%+J,CY<
M@+C&  1@>O\ ];CTI%(!&>@_+IQQ3\QYS@9]=O/IUQGIQ7ZA3H<D(TTYNC3Y
M?903?N\MK*3ZI66EE=;MZ'@^TIMMRDWO:[3UZ;NWW:CZ*89% )ST^O\ A3#*
M#P!R?<CZ\[?3\^E:2]U-M/1-VVV]052#:5]VE]_S)J:XRIYQTYZ]Q6==:C;6
M2EKA]H//$A9_8!>#R3Z8YYX''$7_ (INKCS8;<>5$3A75BLN P((8$$=.QZ9
MR<'GAKYEA:$)RE4BJD8RE&FVN:<DFU%=+R:LKZ7.JGAJM9I0BVFTG.SY8INS
MD[:V6[MKV.VO-2L[1/W\RJRX^16^<G(QA1SSW'& 3U&:XB_\47$Q>.V7RH1D
M;PQ61AD $$<@$XSCC&<\=>;8NQ9I9'N6?G?,S2O'SG"LY9E!Y!P1D$@]LMP/
M0?D*^5Q><8G$*4:;=.$DXM.S=FK/X;:V9[.&P$*.M7EJOR32^2E?[]?O%PTA
M>:>1Y)&.5\QF8C)YQN)['L?\*3 ]!^0I>O7MT]J*\C?6;E)K9W>_GJ=_)3C\
M$>5?+] HZY!Y!!!'J#P0?8C@T44TW%IQ=I)W3[-:I_>/3KMU].H, YW.-S>6
M(LM\Q\H'(BR<GRP0"$^Z".E<UJW@WPIKE_9ZUJOA;0-7US1U,NCZM?Z#I6I:
MKILL*L\9L+V]M9;BS ((=K>6,K&7*\UTM! (((R#P0>A'H:T]M-ZSM)][=>^
MI<*E2E.,Z-6I3Y)*22DTM&G;1K1VU/DCXE^%K_P?XCGUJWT]KOPAKE]#</-I
M)GO$\.:W(LEW?7.H6H!>VM+Z=I?EM46-[ZY$LN=SL?CWQ#87-MK>KW)LKF\M
M=6OO.LM3TZ>"XAU R,$$%RDXD.D%"V5;;'*[ 10D2R(1^O)&\R9()F7;*69E
M$JA2NV5U^9D*Y0AL@J2I&TD5YS=?"3X?7%U<7T?AFRTFYNF#WDGAJZN- ^WO
MNR&OI-!:RNIY-V'5VD9A)AF)3=GDK475VDHWWNFUTUT_$_4^#_$NMP[)+$86
MMC'S04)1JT8)6:UJ*JI/E5E\,KM*[LV?F7HQU2PU"/7)_#^N26&FP:OJEN9K
M:;3[C6HET+4=+_X1_P .Z5.TU]JKK<W,5U<WJI!"8HI9U+[-K:?BF6]L;'PG
MHQG:VTJ^TFZO]1EM'9+;4M89-,;4+8O&P58M1U"_U+58HF)6XBMRVULYK]-O
M#_PZ\(^&KV36='\/06.K?9C;2ZMJ3ZCK&JRV*.)WM4UW4YKB]M+3<GF-&LP4
M,-T:^:$(\;\4_L]:3JZS#0M1L]*T:\D@F31=2TUM;T.T^SH(;8>'I5N;+4+,
MP1*L$:V]U:QP6V^%0;<&"250DH3BI1O*,HII-)735^CW=VNR/KL!XPX3'\3Q
MQV8Y>H8*G&-*HN:A*<8<UIS3Y91O"&J>KO=Z;KX#B!T'.H:&8-"N4C(#VVVV
MANHR"C+<10>6LY9&;R?,#;)_+E7#J&'U)>76^U9YHE:*<A'C!"LBE+,G=#_%
M%(6964@@K(V<ACG>B_97A@GBD&NZ"[K(K+;ZMH6OZW;OR"QBM;WQ?-#$%&70
M!0$9590&4$5K_P ":M;ZC<(_B/2IVCE>)[BW\.ZDDJGRBD42M>>(=1MP'D6*
M+;):2@*<((W$<J31H5*:M*I&2NKI*2O;U?5?\$^DQ''O#6=8JI5P:J4*6%4J
MM1U'"7M(4_?E&#I)*-U'1ROR]%9R.'\/VHBU'5K262$AIC>11Q[5:,WSI%+,
M0,;6)V22/@,_EJ6)*C&+XT\)W>LWT6JZ7?:?#/9I]AU./4XY%LVLH&,RW N8
ML2VX5D!>Z4[(5!></"LB-]?:!\%?!HT&UM]4@GO=9N(OMM[K5GJ6J:?J9\SA
M;4G3)X+F6WA+!DM7E-K&%WRQM$KH;-E\#O!L3L;JZ\1:U"'5A::MK!DLE1&#
M+#-;Z4\5E/"2 -FM0W39VE"+@1R+LZ49)PG[U.:M.*NFXNZ:3>E[-I/;4^*C
MXJX'!9EB987VTE1<W1A^[O.4=4H2=XQ4Y15G*UK*ZVO\;> ?A-XD\07ZWMO"
ME\LMTZVVKWA,7P_T:)HI$CO;?6414\67$\C+;16EG;1[;F>(WK-:)<*?O/P)
MX%M_!-M=3"[N]1UK45BM];UJ[M[>WGU&: #9'!:P@)8Z5$B[;8P[1)A8B-CM
MGL[>&"SB@M[>TLM/B@MOL=K:6>42"V5=IC1$5(TC>/*L@4*RD@@YJ141,;%5
M<*$&U0N$!R$& /E! (7H#SC-:4Z="A%QH4Y1337O-/=>1^;\5<:9]Q9B92S#
M$1>"@W+#X;WN:#7PJI*-J<H[<RBM==]&* %"A0 $W;   %W AMH'"[@2&QC(
M)!X-&"",  ?3!'T[4M%!\O"K.,'!TL/9IQ<E"2DKJUTWU6Z[,****+)Z/9[^
MG4B[6L7:2U3[-;/[P  !4# ;[P'1OJ.A_&G0L8'$D+-"ZY(>%C$X)!'WDP0&
MR5;GE20>":;133=-J5&4H2BU*+;VDM8MVZ76MAJ4I?Q>6:?Q)+5KJM>ZN=+8
M>)[B$"/4$1QN 62+[Y!/5R.2>Q/4_2NYM+^UO 6MIPYP-R @$'KRN<@^N,CZ
M BO(  .@ SUP ,U/;33VTF^TD\F4Y.0Q16X.0^TC.1D#/<^M>SA,ZQ%%Q6(?
MM(IKF<6E[MUS?%Y'G8O PJ<TZ*4&E)J+3;>E[*VB;?HD>RJ3N')[]_8U*<=_
MUK@+'Q9Y96/44P<X\R/.3QU/;D]3QQ^G86]W;7<:R6TXD5^2I;+#(SC&?EQP
M2.1Z8KZG#8[#8NFY0G%-K^'*2YG=;73M=[>K/#J4:U)^_2DEUET2[ORZ]"Y(
MN5/.".A_$9JC<6L5Q#+#-&L\4T;0S1,L;"6&0>7)'(')!B=&991@DQEM@+;1
M5L98@$G!]_QH= 1@KE00?FP1D$$'&.H8 @]B 1TKI<55A*G4C&5*<7&4&KMQ
MDG%IMZ;770SY^76,TK:NW;KY[+N>&^)OAO;2M'=Z3<R]9U03T?<N'&PH4@6D
M2%.07A3I546Z@(#T$A&1$@$1@0 A41"0+B"@M$CO1$HH 1(@5!&1#J$F])[0
MC!#"B[]W_?Y?WGN_O6O=^VG6K#TS^YS9^^SG>>:<->>#XNN'[P6'S%[46EF:
M93NFE%R-47U'*G'G$ZO,"<^+UWMRQUNL(>,4<&6N,V]:RQL_M75IZ&6$E,&.
M189)TNK4U8^QN2,V(*L:^PYG^NK WST7)#<?SJ-.C,]M]YY/#-7[=9\6</1^
MPD(B0ZG2(C?EFMX+JSC":SI9E<_/+,+$+,U#\Y^M7'B.T>RG*/?Z'("<Q9[$
MB6^S?@X9.P4$OEPHO[:QIPX185YP$_U]2!FQB[6W@S&,CIU@YJ?_&G;X>U[
M>2ZA&;]>+'V8)JRW\%'\T;/XU?R/@X'QUG91=-<GQ;0%^)377@QO/SA'$/,:
MM6[_KO_*2^N;-+T) ^IQSL/4D'B-^Y.W ^B.M$S)?@6UCP]QE56%KRXGRB-G
MFKH](K2%54&>9C=:%)3F3FSB#:UHK&LU[#?8HK0U^-0,$(RE]9/=.WX2JC)W
M]FJ7C50DP$RTVW]OOS@%6/Y@CX,:9H*!&6J/Q)^E-5WI"CCTVVQ\D84S<JM
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M]9@]>?>N83?F$L^Y1O8_D]X1U_(^?JCR<WM^<^"JZ%!YHUEZT+'.=@J*3XN
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MSG-:C+K\M-K#?F6E,9.*7,5[DWL*Z?JV4W"WP_H0C;TH%#+->&1[\?JNO5:
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M, D#8<C"D6T)4S<(.ADDJVY'>?+6/)!U[11 0Y6 ]D.%:\F*I'/\E]?F6-
MBD43=904B=6\D0%G F<3C@W3GAHIV@Y[49019/\0;82GW/_#W'N'-=5LC:-!
M$$1 .DB-"$@'18K4J$@7(KT3%9$F($H)-0H"TJ4K+2*]1GHGM(" ]*9!2H*
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M*+Z9BG"\GP^0$Z7PR]&JC.WS5H6GHO0TG27M^"$:%[_*E95YJRU6'KX7B;I
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MKUHA=]=MY<]DDQ?I0G_E<?RMY2#?'9[<1.6M^/BG#@$GRXXC_,\5GD86:IN
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M/M69AN\1J^QAD9:+4.E22GNN;IRVZ=JU0?M=/8"UX/0;LBKK4U#:!\ FQ_D
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M=V>!6/]C)_[X=<NE23O!ZNV.TPQJJFL??,\!:=#SC[\,+*3M,TE^_\PK_I(
MB^?COE5-T=4VZ:_MIJ#@2T4)^_$>A3F" F-C.7HJ)QK%QOGCV6*OUER]:FNW
ME>MPX=W@2"2ML@]A:Q[5W=2/X/X#8>"TH<?-=1/MA<)E#TGW' IF9IULV8$*
MG%5XRN2<U?B+%P.M$0L\%W0#P1@)E8:F.E>=I=LP_YRJ\H=*9@Q]T0*_.C?N
M+PSM4+XRY-B@O26"A]RFB9YJ@W$VDQ<'J -/\,C+<+M'KE285,KI+EZ:R0VK
M;_4C0=<<_3)3WRM+E4\/<,3@F\-A8S(':8N\"O91WR.U ^H>!Q[LOP1^.A$+
MVDR/:C"?1YKM<591<1<#'A*J1ZZZ*RLLE$E*0 S'98#.PI0MM6@79KW<U5%*
MSL%/OE]FMQ*V-A95I53:1+EKGCCPK'\9TW;>G$WC7Y%>-RRBT2<-J7NCO*M)
MGJ2XSX5Y_R4H7)8"OZR?@<C'F")A_R$9XAR;(&T47U+_2XSD8"6'"&3"[7Q)
M3/(E?#V>7L)_?#G,[G];A=L_S670^O=)AA%(@.Z*2]7Q,,)R];U>\=-'(]W]
MMY(&\Q@BH@D8]UM)KP2DVRD8^JSE/['<TCC4&A;KX[_=)%K5>UH1&3S4#\Y\
MW_]J/>BI[W,5\R6H0B $"1CZ%IV,'"+V947&735D[2_US[AM/=AU_;EKTWJW
MP7W@CH:>2Z5E0>L<?.9-#_?EW![N 9F;G^.<?VEM\"L;?*-UD1EM2O$TR9S5
M=/REW[>W([0^1(1AP*Q#/18!N@XY%L@P1/50-SC4C^:/MU_+Q\:19D8/'%PF
M1M/(]97_)Z&)I;I6.'8+ZHCLK8E5/DF3TSEZJ9,]\@94.BS-.&$AJ&%J>\?^
M\:7']VCE:1G$YH=^&"Q80;#'SJ)GH&[OTY&RCF)2QUK'I;*VXW9;=:I",X^.
M"JH_TJLRJXMWOEN&6I9'.[=K:SL)<ECFS8Y$F=5AW&\/=>\8?K_YXQG.KSG9
MT_+5SHT%MW)=W8WR@ME[QM>[6>_SLST 49C:I=@;=%0H)X $]G)%RYC:3!Y>
M*HZ@!G45QHM?BN+@8C5E,3>Y2_;4)!KT!A3?5_^;?._<P^('3I_F_D,(G?MC
M?A GAYR#V1D$^:@G$AO>-*5>9YOY)D'WED#5!8Z(Q;>/?]]:O??RZG():,8W
M][]IR=D77VN(P#M5NK+FLJ:Z T^$_WN,XWY4%0FD(_*?*D?E+RH$_0<1#N&@
MF=Z(-S82S\:?UB7^E"P[E.CZ$E_P[L+5P'FS15QE6Z']/&/UAU>7NA4CEYN-
M\"AZ^.W.M*&H9FB9TRR8,!5^_MS,)KQ:GJXJ2<CKCE7[:[OOJ=@9-J3?$LQ*
MM:? AB[H)/);36N5T>*B]45,7K]S'"XR?95D;.R:FZYMNX:VX[9>>?)UHF1A
MF?L&\T^]4G4+2>V>^+K^YQE6L27I=CD\=P?E&3Y1+]V<]0[:5([9)LTUZO5Q
MZKWY2L6/1T1#ZM@[4.&JD@V T7R4BMT"JD=,Y!IS "=@(*"XA,['*A/9QYM=
M\2(%%82>3L"U+&@D,*"5;_)9A*OX<FC I_Q(X\/E+@13D%00EOT1HJ.&2!6C
M2G':+^)NY^NT,"/'HW87*#B^-^U\!08-Z>A[7C,9Q -0^E^5DGH^*91"SPJ/
MY'-_35$!][9*%SI A2,NG_*2Q(;'[@/^.#UP)^>C1I]&5U[L3-ZD+$]HN2R8
MQ87WH5_<>Y+![<VT+>N)W,;F5,FPQ1 S[&+S;0V&@JCO.8-K.B(CD1X9OFDC
M?691LUC^[8RYZ%L?^Q+:?L^.48?DP?MY##V*H,Q0)]'+,074^A#RPE]&3GU_
M#@^,@>1C(Z .#VT?XB(]^.M/\4XOPY_.Z1-/9O*3"5,:1/8-J@4H[=R:GVGJ
ME:Q6P<EJUPM@^E)V2ZW&VMJ*864N? D71WET/+R&A%)1$</4JM+\E?9#TL-)
ML0?8GA3+BH'9@=>6A-E2<55VTM/A76!];T!UOV->\I,#85;IP=N@&9GH$K8?
M70G?V#T$CG\>IFDH5W_A$^.UO$?A0GOAOJ\'K7#\@ZM(21GCAZ)OF,GCWP9S
M:+4MFK/:JV8G)3^&7_L E]UC(9A?-M@WR):R=^#5P/G+/D^LJ54U(K=2[2=N
MW>Q<EL69Z)VKG^+9VU&O0MS3!D<7_;S'LG<&IL)/&2#1,G$\*ZT*)\4O9 /)
M.T[Y"!T\MSLA/'L**/&]&6BGW_=4^; S$&[:-TA]+HPO]>FB\O2GF_):F ;W
M2,OE+CU=+4(^DH#"([JDF-?DT,PDFN(5K!DF[BV:L:R:2T2\62UW1LRYE:^9
MX!,J5%%3$Z:0Q\YVRC^VR:MN7C9ZY)2JUWS4,JR3=Y62-LN"EOS"V^1]!KA(
M VOM[J]BC^2K)A;\CU?7\RRL6048_LCE!'/Q?7@L=L7XY256F9=W+DL6Q] 8
ME7#<-[ NVNZU*,%.^W(MP[]OO1<,SW+*P*\I*JC2BQ=).9FE&77:V8IZ??YU
M\J.//H$Q%<UQ/!I0,%1T[ Z,X2ASG/*#)L&4SPA"88+NN^ZQ:!J4UQ"8!*YS
M=&@P*H07/&RH'FUVFG>5?AQO+M%=1A51[:_4%&4AQ>@)E#M AZ7HX 6=IS+#
MU5 6 &H]0E+#H1A_:I;^\9N-*L2NFF)GTY4?:Q9AAUX$]4NFK*]66)NKVY/5
MBW!9\G-/#>Y88*VM5)(QN3YLKQ^X/JO>YDL0"C83?^)XP[3*\6'T,_B67:+>
MX/+XX[2A#49T#W:N _%^KFH?+86!_;R"W=M(-S@W^7KF*G><=RP#I(&/T;PJ
M^NX4%N(53D%D0(R'@RQF([8.MZ8$IG5NS*PI3_I: MOBM77X8/\C+>"'HF2,
M8X&@"%;'4&=-QTEEG]3(&VN"^;2I'9W#W:TKWYLLC%LIN8/_:I#\F<A<8I66
ME*,AG_XH,M$@H-;;92\_DA#W%E)-_P;M*$4A'ZU,X_NRN\<BO3-+@C!90XN%
M19'(\=..O N&A+A(SP@3NM;L[&KH4\EY(Z?B[.-7>DI2:;,KW"6Q=R$&0]N0
MN"6QG>_&#N_*_YB^RQ%8S]V-SEPO\PJT[5FO%W?CNM5AA)E?[6YV<!!]Z=27
M9(,2@806;JXG>@\'LK0Z(SR#8"<QO/^J[3?8'0">^P:Z2P4'FHMGH!\C_S3^
MZ@$E<Y>TBK +-\5WVV1JBFKV+^9&;V=]Z#)82'L:KY,OY&%X^'^4N(QO14;P
MY^!+_#SWYD.V=_E#],PR;Q2/Z6*-G/-4 Y\,40WP/JOQ:#33];R1E!B=Z)'@
MK.V(]9-)']VP)GT'XH]Y AX28W9[\YU/P:,YE4#(\0,X?JAKZ@S$="H(#_M9
M#8T^@G33\6M4GH%";Q?"+R/"YZYXG;#K NG/&L.CE:4*G?RV?CR9,L0N^6[F
MUS3F$,U.J0]SX#MJ0%UA07@KDTV &A"*H\=^P4HQNW#:8S9KYQA;A8'P3L4S
M4!N$T7EL"+<F5BB+"L'*I7OE_H12%KB=TH[O';YHEGAMYX!7<95$/.)\H.#>
MV-6M&\MUZ[:,IO?MC_T-:L@/3<GM=A_KA$B[*MR!FZ--S2$%VKP6/&>@UFTE
M.=T*U0U5X4%[#1F<)N4B3V[A0,ENI7;+/DS %WJC0[&J:$!X1^A97K]@8%KR
MH5'KT+,]A]])2 (4&4&%IX\-,'(E1NI=<&<'JBS'W?_:_%###4;A!S3Z'P&+
M\_116>#6\<WP-A=WYE7+NN!F_GR]?$#.G1M8QK<B\^#!*@I<ZFG#N@Z2<S$(
M.SU=/%6(N"K3+&"U_Y+HO-*(Z)PA[ZI5%6JJ:YB268-= 7+PSUN*X5,/:B>4
MJ?$M2ATPAB 9W85I'JFN(Z!V(L (U^)O2+R2;8=W9P.RL%*\UD$%F6^?79I6
M4U.\93K]<='XML9+,C&I1/:/!8N)_7IMZ]8!,83JZ;H-K^/'Z]-QP /(\ZN_
MK0,JKQ%ZNJP>Q7Y^,N&ZF'#1J.WM+./[7T5[KWZM@:.S8[+XJ>Z9=#Q9,XTA
MC)ZL%]TW- AORDDTM9XR<U%+!"?B"&,=_=-X47^_\>Q-O!/*8>A.N=../+S[
M("$F73NO1+FJ"UW9TQ7'L,(K1[ IJ^L\$6MK/)GJLD%H57(N1^QQ#<@;$,TZ
M>:C:]FW!G"8%(>*E9Z"J9F9\H+Q)Q=C>AE%7XV29?T$_ _32GY?UZ*I!(OLZ
M?X'% /XPB!D.G9][UQ.Q.Q1IRYXU=\I(_:)T2YF'2&Y$H"SZ#-<_&H>#C491
M,DTLP\JVDUC]IL] 7$=*8VM]G5]=Z-Z,ZK+!: UXE,W3T^2Q7/S@W9X9T3O\
MQ^_R(8U:RAYZ1@PO,N1@OA07:$+;7K?W@T"TOE?)HR]OEWA(VMWW%.VA#XO.
MU)+5PQ7;J#Y;_STEE?BGY<H9:,\OQO+5R3Y?>[>.Z]-K&UQ*32(P=Z6J;?V>
M4^HST (7@AP5LD<G/[]45FB^,JM 0+TCN18[R_F9UA$J$=SPS>6>VBPI(- =
M=P8*GJ4A_"!FQ= -))>G2G5^:V59&>EQOUC3$YY7$VOEB[;FI^4/_R[IL%TW
M\%K&A7GNZ_5AZ\"LF_QC0K%B6EJCKL$6ZG3C8U^H+2*,'>ULXKO?9UEB:EA$
M#W4B.'MJC.DE[&+O3-RJ%G!\<U&=[$%\(>CZ&S(0V1NR]FM/X!3%OWVP*A<]
M['8R;.TDG7=??FTE5:<EV.!'1_8#>?,!:Q1]<$PA_I:$A+&]X<I/5PDOO:T9
MFK]/G.MS)1Y8-9RN_./0?/Y6>A5$)CIW1*T:W#QE8/%G/["))\IK%7W;I[,K
M'4\MX$O3KL#Z:]Z/OJ\>2G^N"U;.0"BO4Y-9LW%[PQ8NBS+VI2$P#\D] [&;
MSV*@[E=PB^(,Y$- G%!,?;)!]/Q";LGOH?13,\C'XL;G3^U"5L6^ET.F?O'B
M5]6IZA\5@/S(5D;_V?1144;ANQ!3#:</C/\ZJN/XOQP<EW\V]YASSO,,E+7'
MF:!/+<!]L"_+?S(&(&X97-"\3Z9 KB(])PPVU*=JO35POS!1?TASYHKH=N3F
M*$G?!Q-TX]RGP<V\QO#RMT3IC\C0R6U93+AO"F@M5(_M FFKFT_MKRD)W$2G
MNJGZ%UV>[BH3*"S8Z9]O_81WYX%'86#5/5TVD&,P!LE:6EH-NPQ_QG8L];:5
MQ?& O@@PZQQ1BE-=-B=*#$QL108\& LUSNKKO4'G0=< TSPGEY!$'T(X;BJ<
M>VND^?7Q?1(UH2!"(D]P]%BO@9@TE;#B\ZC6<$L?W3Q6>G$Q:46PID/]:IK0
MI?K=4(58Z;=REZ)%U\D^)4Q**%*/0V:[4I6>)ST+_T#-)4F&JL#]4E%0,/4P
M\^O1>[I;=2@_]AON.V.A/5; AL^1R9P9,S.;1G]\MBW]\BZ%0R$% WTAQ065
MMMP<AX^FD)N8I<8'-T WW^9YQ3AXN2?GO/VH*YI%JS4??$5L"1D#J5:)Z]3]
M09+ G4A"&("E_5Z41KJ77PH6&B8^N2(NL573#WRI=RK?HRFR:ZP=R=#8P0;-
M6YOGANW3YV6:4#U/WW4I:SK*DOHKF!0H\0;.?^T,-*8>192^=?FSEX+RV[H$
M#]UM.QI1+> J8[-T=]87C?OZ'FUG(!>>F"!%(+UGCI7DX2'0*@3$X[]KWJ;V
MA%';K+:2C[CF";VDL<.5Z6/WET8T*&X[<YZ!(J\G>,6,CF(B?TWO3/ID"8UN
M;FQ6(]XC6676Z@4LGE(3^7L,?VB_O+U8-A%6@J=?=ZGVX7MHF=PR4W4+)CUX
M<&'2N"3_W&X]_/Q7_B(4VRS_FA?R<PWP.%47#'H%".U_.5>&_A$]<1L"Q*WP
MBTV])]EY*VR-B-C=DG3XLY1M/%Y"FDOJLDN:35FUH;4NK2HG8:^M+M8INZ&E
M2>LS<DN*"C[4.:M*F(W!#]$ZIV!KHTJQ$:XWJF-RM'*YOZ7:/F9G=*8)TZX^
M?*.EL<*HT1YEI)?G@/I\1R:]<6Q\5?A+9)."?]'/_@>SO2V2=Q]SD]<YV3.Q
M@PK??V5*H;I6&.>K<+4-A:SV/S%K0]2B.Y)&;/ CK4HD>2 *AWSO[3^K9+7%
M0!*N'FNVPM$S0MWRGC1-@1].[;G>X#'%";9&:87Y7]IDF\CBWR47K1=>?N%V
M60MZCXNNTF'ZR8MC+U1ZD(*+$V&Y!U&%ZHZJO]B-G'>/\@#LNF@'JM9;N8"&
MS[,!"A/NT5TAG(YFIWRCG+^6V;:XKZODV9&'R.5PUBM^1; XCE=G%9-B!Z?_
M#! JT[IPX_;/U@SU7(I?QTS]"OHTH@7?WJ9]L4J>[7ZSK$MW:4:]*</7/2 ^
M'ME$X3+"3@/[J*-<(Z1_\+)E3M-M)FAG_7ZD<-%?_WSW5V'VUL/NZ_UT([7:
MI6[1]QQRQBQ=[F.EJ:QLQ;SO>V;^0^D&YMG32M&D5Z4<C)_:^]Y"*8J8*)QH
M'T K=-[,WF-F%'%3'7AW!M+A3G1="KWXGNHW,B[K)O%YW#PZ*DN:T.]DMH"C
MC/(MR4\L<>8\C?_LPND3'L#,'K<GY[]%;VWI(F]993[GE!:8G^.]Y6Y7>M]=
MZD'M(YONTQ2S5)/O+AT,VNK&D>E.39A>(1<?,^7H'?GLQ">"[TNH)]TR<HL,
MD^R4"NOZ?0NX5EJQ69^(%:<0=9R--.3GY!3NXEP,I%:F\[50M^X<#Q;N%DCI
M0M/?8#^&QM&P'^UMD-@--!)2:U-D'DC!+T;[2"(ODT" ^AGH(@, *04ZY@RB
M]I4:"$@,.%:QKIN>QQJ#AT0;KDVRSZJ.>WXD/7F"^P3KQ&K$7,":K^#.3>&U
MKV&+7[1\8%POI[V15]V;>?!B//SXGG<DA?P_?EN=0Q1 4;,!SOU]JW#UB">"
M)4!_7#F0/;A9$+\[B5(=L<]WD5>EAU%CX:D/&Z(T&J;VFI2LM%PWE\/,RP$J
M?$U/=- -&[C<=D_G$5U8.GUH[L2<"306XOI)]EPRGE("1?@RX[7:6U8!,H2-
MLI02_$^9C]4V=EU^;GGV^8ZWYW01K#7?:MR;.GY_S$"+=,\[%0Y-'UODYXA9
M=-MNI*-O-VFO!_D;==%2WK[=\90-S'C?8]_33B=/ARFC6!NC7G!I.V]@Y.>^
M)3)/FK$A*KLF6J#*=3O?@DEXD[_ZK:"$4B?G=X&=A62RE,?% L==PZ'F]EPO
M]P:A"U.DXZG..B2'*N,T/-G3G<8"OH-1?* X%;SKLO4^B)PHF_H^@!TW8(>7
MK "_"Q!BJ1MV^6*CYXYR&&52#]% 5[]QKOH^*]#\/!Z\-D39[R,70K4?C?((
M=!*<3?50?G/_@-V2MZ+TCX_\A3NQO6P.8Q9YSP</*_@$QSD/'\X)E27A_DR6
M)IU^76"]JHX96Z[4U]?+3]X<U=Y7[1'"-ZMZO<]BIS;**F,_/O+1ZQ##-^E^
M0?_R.E?! 2M[?.HLC\C^3W&=V79P_W1<>:)<(?3-?HCKX;WHMY67D[_QLQHX
M2T>G-1KJE:\H58O<TY=D:LG/L*FKKO8^9-1=%)5)E,[5BGWN$X^+O2.'5+00
MBHDO2Q"N^W;@'VPI6O/];4Y$TJDA,'L&LCJI/!4"0AXVH?T1/\'S=;$;NVM6
M-ISK _(;[$27=I_) U612B+%""MAXZ #1NZ<,IG"KS\B09F(1[+D%Q[$S_QT
M-+4/W-G?(,[%>LZ%*@IU#(4F!*;B$1N,"V)2(;;@>HMG=<B[H\IJ!;^<9R6)
MT<Q=O;(%I.M9%*/->MQU'RJU7? T93<0MR29V&P@X;87":A.*7+ "C<5\L*T
MOZ.5CK 4@T/2==02ITO@?GT8P_ZA, &MTY]*ZLI'_P];;QT6Y1O]#8X*$H(T
MTH/2W5TBT@+2#2+-2+<,(=U(=Y>T='<I(<(,($/.T#V#Q  #K-_?N[OO[E[[
M[_W<UWGB.L^I^W/.9YABW;-:569Z,""&?OD4[8JCF68?6X>M"U.R&#1%>].X
MD&8*.GZ;F#X[=2;Z*;XI.F)WG2]+Y4WN1J5F:30R'^9H4*IJ44'MT<IB4B["
MZ9ZVWJSC^%/$LSD6%Q[)Y8T_-%HPXU24]".#D?HR!)"RL,#6!CD>F'@3@^4>
MH?(;+RO#DXGTEQZ'CX1'T1:'=8H>,2[6!LG<UY01 0E;4L[4G\^XF"8>27]A
M&J?]@?-\ME14K0H[4"%=+4/?S*:T5D]75:1M=TH[G%WAC^(WJY<8$>9MG1Q3
M-6='%HH:[?ESZ#^GH93L5<D^EF[IL 6U=O)F\EG-:%HV[,8W*]2]GM-^#:?V
M_"7"N%&4"UX [X,F:3^MUC94NN-B$;]F1,I38WTF_@RQ$/:R=<LBD?V]A+],
MWB3?Z:^?/30Z#NA3&7,\MTF,HB-!$\O_K[[)6-Z%&N_JOD53:@OU9:6RP#::
M,C;J][&MQD/:[FDO.2SP/>*<>&K8:GZC%S?I++CN<C#!OK>F8-&6>1%G45J0
M#-=E!MJX<KGL4E8 R9LMTB.V3GJ>977M@O%&]M%^J[.#QNL<W/- "HRV.G)@
MJ_/!NBWFAFJ+7@E")K]=&:$M@3J_)G4@?,<NH]NM"TE5IB)CJ57*'F5Q$0O'
MOP]4.N4^Q)<7P6B=P;LR^>50'5.S89??9K7O-9OEZ69;N C:5)J4#B;V*?*G
M1UN<!L)#_:W>,R5#,7]O<="AN_"^3I3KI00*^^)B^W1PLEL+"&;O[\[P3WV/
M?H;BTY\_[1$K5_HK=12,#2)>0=OR6"\_SZ^ .<*<>]Q@RPKXX"LRVS20%4M\
MBZU!NL0"N*KRMJ/3U9FV71>V43ODST=<6U&N]#T[C0F?;J[%0:UY*X+CK]QG
MU9]L1T>Y)DSG.;$>#X":F2")T^5>T7Z)BD[$=I IZ]&5S_E)T$*I_R^.BJ*R
MZRZUB1OOQ?*A6/8R!1^-WA37$WSV4LR]GM@S$<[D.,<EX647&(O+9D6E\.[1
M5C'%U++[/(]YG_E8=_1\7G&J W=C9 1!HBS")4^8R?/83$4T;V-3 EAHPC82
MG"C7RI<D[6Z/]!S3!K] /T-.CDA6AASW<>T'X4.D;1$S"4$"R/D1?K]* _0G
M:;.<I/ 2M"-<ZK 0K=@@K57]QVP&0>^_[2Q1?C\3ZW"_B%J%\(5+&W+SHJ1E
M:1=6&5C9)U_M9[+0&ZN\3 _A' BE>OP<M-6/9N/I3<+PKQ]-C<&6WA42M*CF
MCY!P21_S0.\]OYNU5"!.3JQ?LDPM&@K:>YT)!8H^EC.8*,_1*:F9R+NVHN5Z
M X)7Z>Q7Z<8UIQGV;'JU2O=8[TYQ;)1S<'I6'G.J$5G:]L"Q _YVK"IB. WZ
MHKQD'V-,TXV9[EK['?"NE/37((/K39_F3/([<^S;VN_R=E5>)LJ<[ ?7XV%9
MA6L(PU^E)LW)V211.P3QH9(2SI-@IYNK#;$8=V"4,\:X5@%^NI1Q+V,BA[6T
MND]C_A5R$H1-]4EGWCN&=S.6A61L1B!&;V+DKIWSJ4[36#/SS\8"?5(R:AQV
M]:TTJW1.#UQQICJLU+P47]+IU/RI98]Q&=4_G6RIK9Z_/[X<E<BS=9#NB[>[
M=NJTVH&$MZ1#G>>N7OEK&AJX7:8+G#EI7[I=)L@&W%:I5J2OIL,,#L"5; -\
M\3ICLX7+"I=A6RZT8.I;;I/O''^KC!<WL"?&!KXM[PXM)/Y)1)6T.)9K"2%G
M1AOBY;#N9=$*&V+CZZ2.0-(>'E3%^GO+T'6:VAZY$C_U$4MDQIZ!(4U4#!@/
M!1Q:HX9:#HMFDADMM3X HJ2UX7=,;V>]F9S=K>TKWUR]>W'Z\?D<>;J44:19
M:-EC7PZZT(X?3%^50!O!R][STE:WQ*]?JQ3=M8-Q+L&$-2\[T9XH6=C6!P"5
M^B<3#B4Y?^*S=:ZS127CK(]"3ATY(GL;!Z-O2A+4O&QIS46F&6R]%I5G_^09
MX%,'5.IDL)%13%-^O^"L.#"N/#HIY.M%'M35CZ\#\EK\MDVLA1@@)A,\S)&R
M<%^Q++T/I$](DM7?J3ZQ<<_@X)"9:GZ3HKGU  BRO]NJ#7($[GAH"=]<3WTJ
M:O1F%SEBT>CV/*@6N;2>M,NKLYTNO^H\F$OXG%9LFC'KXY%PREY?MZQ!K-.P
M9NGS/G#P ^X-L0I3!R(E/>@LN*_PAJK>OOD\.+E%?YMBM1R=*TMO=_L1/#V=
M%G[F_^J8G.S@34K1I>Z7<8J]_$S, P"O00)YB@GZERY:"#X ]IT,2]@XLQ\
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M'V:\V,8W63^0?82Z;R@^R'%@Y%0/+-V_N8QC9//*N%S\^XHBT9?P0O(.CGX
M,%FPW#H=_,N3GX/-;X4PWMWJI<5H2\3T V"(B'9-Z:A4 VDYMLJ_]QZ=J9WN
M[RRE@KH/V^CNWLF.EW>Q2;_W60DLIH-_M#/,EIYN&K^O-CK.XRVZIB.]B<!P
MV?ES63\>"U<J(EIT$X^6[N8=491HJ!DFXG0'%?!JQYMMW3/H=YNVM,CE-!HY
M?A"/$YEP)W$IX**6'E\>%8>D4VA#T[&I T[*-D^4?"^=-(]-%:9D1<%O@/BR
M%/\>'"'>3),P'@86^7:8XY+S7J4KL=4A^W<M@0T)8^^"R1"T&,<OT^6YN^7,
MB,!:?W9 [8IH5=V!CFAYG9,OJ0CT)K+NV\\=I\_YT] QU?K69_GJ[W+4<Y?*
M K*/=[Z33L!?C1_/'.>P/  BG=%)PIJHN_0>VF!/00'ER&$MU ,@PK55(JR*
MH(1'=NU B3$I7=-O.HA5_K8CG-,CCKXKWNL9^>NW?_8(5UO:YB:4;]:;!Z:[
M)][T%R%7V(>$:A&5;)10_887H(KEHZM&S/QF@1"%J?"@;>KN33D._CFI3T01
M-(V3!<6:HM.68)8<\X$BQA;'S4#B4?3@A^>OQ3=EW#4&QE8(N],;$\68<)3&
M-28.:BNKFR*QB EY*,XIG*#YU_[6+U!*L-9Y+D>?-CDBW3IZ#L@P'XNFV0/@
M\G!)O?DSV[<E)C)%[G>J!*Q9[')",]N=3YGF77;DNB+U[S;2?]?84UP2'6FC
M;#%XJ RY*-A)@SM.U#W?\B1#6*EPL[FCJ!R)M$2E&;K.SF@U9VZ(T'3PBN8^
MW\U:97JGLL+QJYI-@-]C< @M2.D6TTSW^T>3\XJUP[:R*KGW\_CBV?&I1 IH
MY'M0)UJZ7%8(_(KR>XSE/652N.Q8[)NR1M%V$ 6:_P.. <2^/U&1*S+2.#G3
M)I$V5Z!8F23S(_.UM:2X$^0J?=FMDH.YKMG9T7,/#:2-^8'.Y:H)]?Z(RJY_
MFB&:FGY73M-1K5VG*7JEF\?"7LDRD;NH7OB[1$CT]X3V&S.AIP\ HW8YI_?6
M'OY_&BG9*R,VV)^0WW@*J3(W\<OU.IXH%-0;&5492.PZ^EK]'.0.2#&US"E<
M22L[T"XV5JPTT8ZM@.W&I39U6QRN%RTP$DX5)ZO88SW&<AHL^P0\*;+#:01<
M-F0'">X3;1(E!#<FA<[F3H5=?NE"EW^[^#%[3P,60ITT!S"'??UIC:!7'VYK
MI$3@="1-P@85 T5>-8]*5JB" B+$\:>_#S.F.K43+(LY6R(^L6,E6PIA6+NA
M0>SW*P72\];&O-(XM\(8E@XD:[(_@;9JY8$EF:P0R(0M&F/YN2O>IGQTX0N<
MB'#/@JZ[Z?G9DCE(,D>RJ*.#<#C+($&:@6>R@J;;I'S:26?6LF8)SVJ-B2)M
M.Z9<I\([)*\"XA9NP9E_70H,4.S-[R6:*S&7U<UKB9WJP90]&W,$[-$HYF#Y
M (6J7Z6VZF%CA9"3DGL!-HB*]N3P$ZBS7.RX50 IJLR #JP"%2HJ^N\RV++]
M['EIU;]*#'0TC$]Z+<;/PQTA\6ZS<:K:)57J6C%G2CSCYI2Y,D&^+]@8M[:-
MC>CR(G6HC1BF:I]PT(4^HGKUU0V7[O'H#[K'1[Y"=-YVKEF-6P6JT^1ZE7:%
M=H4KECRR29:*]Q^8UB:P0$P)MX_>>HB5,D<HA#YRF'PJHY;"E>6*LZ<JX%#<
MW>C;D7%</'=Q;*IFV)4[)626J\&)6&+PQTH13B5049"2XN<I*(A_GK4YUQ;)
MVDO-8;5[M.VU=3'/UE98-1DSL-'8F"YM0^&@QBO:-"=H$$QF+RX-+.M[<<_Y
M])$YP)4<W9O&-?2U:^/ Q@H>RY[]6=A]+&I;\;'0QBI/\N0#P)5.6B<)786Q
M3&9V:GR[D:\5]1^6=WA'96ST0Q'^/E+2.DGM=;4D._5A"+97S[* 8V7T;$7A
MZ.*.__K!I3[5F4XY%41M-C[%.1!&]Q7I$M[W(8/0SL&.07]$C.8J^N3XQ-HG
M2< ,MKZN8>].)NTNQ#*EPVN= ,5C2LCTN=)LZFW-U.B,?=H"\OS$#?N],L[2
M,NW"&OGVG1#S),B%7AX_:,9EIN-UB,/_S&Y,%,1YU(<$CH;BSM3CXA1LT,1F
M8=ZM4DOT.0F%G_HV,*>U')T?>,]-"AZ)T'R/H#K3JQ37C]4V0Z:9Y!G:L[>U
MGE;]U-B89LG0&=>/7NW"*^U"!2<@3",=[D>858Z]'5)8$Q<,(\C #K_MYE>=
M5Q?ZR-%5MP;F&$Z4;!R\@>S^9W_KX_Z$>U8S, _:NU9Y4PZK(G.SX<4:O:8&
M/N0MA%>6W^A@6*VC%;EUY8-:=9S$R1ASG"(6AE3NU7!>>U3,_T']H'<3[6 ?
MB#2S^D)'+(_E!H)K+=MOH0J/7N^?==ZU]P$?'YXU I$A&.U<[$@\!E!/;_""
M5/_:1ZW^KW;ZVUD+0P@6SGJ_S^E6S$?%)VVI.O,MQVU1/W?I9#*[7,KQG5+2
MS$OF?):OM4_Z\2_4DZ)OGI=6^:7"E4=GPL4N<^;7(J6!*-HQ2\?%$R\CKU6^
M]Q!O)2U<OP? .,P/LM4^K[. =;\PI[8R"(YDX^-I6>NW@M^):75)1M2U)/DY
M5S0%W*E=F4)%1)J[NA+O$7-<O9H'GI>F<>CBGHXO6:,\4ZIN/UQT)%[H,R6*
M) J_58%'PMA+%?552HA=292*L%6&4^#DV 3JCU(TU!>I=^EE^M*WK/_2*;VJ
M> 4^T[/6A]^E^KH<C^<<KK9UF^S.P@7CG]*TX0>-\38-CJF5:*N*D$.:%]5]
MW_S3A(FTE"?$*B_-0I_COE3%(OG!>"ZLO=2_ZGJ'M9CR'YI1)E<WL<:@U80W
MYTJL1USK\@NU^"UOF< RWK<_V%3[$<_AP=V=C0GCLDFKLE'7^'\;"$*\);Y0
M/UZ,O_Q+;_'NLZN7<O"I()>H6J@,GNJ*Q,6]_H6Q'++_>/VOK#55773>C>H2
M;_75>K$(N;9%YY2@5G?!M47 '=Q"U4\+5N\OA[KB\]R;/_0('+ZPO,,U3/[_
MK4U?>.0&J"TN9QB>-UJR0>_MXO\%<#EJ7+LS_VSZ63\F$S/Z'[]6Z7^74F)Q
MIM5GD \ @?^8P!S^6R\K"=DIWT4'9W7^7RCD.>W7GCI_,7)3_T6".8+_-CJR
M%TE4^=\#=WC_;W1SVOO5U,"(:460W7%=[ZHSQ/V?P%U518K"_S#-GM!<#\W\
MC53-&<L?2OK>-MZ&R@;*2H_29Z$UI1P_;&U9C%5>IGV5QUKDVRS$V5LGQM C
M7!^C4Q:XCI^,WF@6ES@AM>@\BMKFZRH;._NU.;O&?6T)5ZY\KF*E;U6_F@WL
M<W(]K\B!9U/KA1BKY:][U3RNKY6DL.&N)2+ PR)6J=;?U:B2;YV YO1=^K;;
MMA5\N :Q:99G2F[M9C0FB>9-NSJL'?-X^4 Q;6CKS9]]A+(QM^)@IWE;"-@=
M;BI%+S9DP;O V)DT#*22YL/R347+&<R*+$Y1,KR<!0MR8^1J3 Y2F1?%&@]H
MT@+JYQGZ&DFI7SC\?<4[F/TET8\YU04%HHO5RF96D_Y;]=C"+9+L)2EQH"N"
M:-@2"ZR%/"F%-T2OT?[&Z,-O+T-WSI:-VD*M":=C_#]=F)K&O,P)<-92]PG(
MESU9=M[2M9/R)YY:0BL8S,DRWD\4L-(8E((VUV,+ 2))O(1D(]_WNQKBI=V1
MNKB+<?!3.IDTR8;H'D6X%'K36#B89+E\?B=5.&/!L(*>Q^7R[I=^P>\JI70:
MZ"Z]]0L=W8I-<IBF!MC ].KW=>TX=YUF=3K>6(LU,ZR2NJ8,XN@IV^]3V>:7
M.M#W'/6)?QQQBNMG/_H5UOS3&2?:RUQ(7]V?62>)I]MRV2S77[215>5-\Z.6
M/#(S_<JC!P!2=K0 010A^R0].RS9&YZ/?_1F)(2 1*M2DG>,L>H]_@?)C6_?
MSH$PM@W?F OQ\\!GB/60DPM5"WG*[ < GF8ZJ)8J!8^50S2B?MFA:\IS?+L]
M)WEII<<I<2XM@7YQ<3/97F57=2.#6FF/.1+.JIH6]I?MZ[NW%"Q=YS@=#>7A
MR OO2O%I7X/V'?]FCZAN'=**M1CU[F4;_:;O39 Z>'-SO*(C@85B:ZU3(PQF
M^N4+%N4>UOLA<F>2L=@0]W8*/S=5.C*:$96-K/0P;IO$QAK 1*$7/Q;@=1%Q
M3_)X<'##9BP>*4)8E3H__74(4"R#FHGDQQ_MC,#HT^^BH_:PYQ/D];U[=;X^
M37_7B^.<6>><RV#J/K=\8M_I-C8B3E2I <^--A==W/?<0%FHS/@>@0TY?)"%
M ,JG]'D,//#Q4*#R^WE[^XQ@SG4L94>7[!S09$R\3YOV"$'DB<,;\%#/Y&AP
M"U&(L,:;!\!P 6W'O"PG>E,CO8X%'8!,DI^7#D9X=5*O.M:S19WP]L,I?35N
M3S$6TGRV3M\@#X"1P5)SR9/VT#XBL,I=$4:Q%#V\61C!VP<$<R WHDR16D//
M[DQ5.A<QH.IAP0'OAEBBTF&&W.=Q)2L_R1PMR-K",Q;KSE?M=L1$ZP2O_3"+
M>"'QU]5CWDS4XD,\;!S,*Q\[<PU35;GV/6L((VIBFBV[NBUI7-;1A&U\&"ZT
M-HIL,S,.S(:J01S*A0?1.>@X!G&@M9$Z$P#ON 0%O?:4F\EQ2TK6KUBS&&7;
M;:,#BQ?(7P656I"_3]O;""T6J'7/Z:^X)'N<4F7&KIZ0OAKX?NUV[?K# /"*
MCNZ(UH].5U^[>:O6]A7^]*5[-(]^:>+ZD7MWR%&Q >./*$>28B9<_B)L6KT/
M7@,;UI GL9AU8!:BL2-*1U<MU5=OVY>YH76Q.\ A4 -?H%B-W^ R=@5BPM:N
M<8--KFW6-^L3_*5?^+9A'!,:RUYY+,46_-53J\;@.OJU^ \<@EI!H4@E@G@9
M:J.G.A+_#1U\FNIT2NIL*6!]EHX4BV[/EO[^9X7I+U[J!RG?%/2*IV8EKRJ
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MJ]'4T!1 2Q2SGI13U)J?.PJ=IC6U)$@G6SO3>9@)U3YFW\(C?2F0>:VVZV>
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MXZ\6P%XO24CZJ^AL.H_BW$!;#M^E1(>/.I8J*SU<A42X_L-11,$)-=7,]-3
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M<)]*?77\V:5D>U"BL>W50VRB$F\8?\7K"1WTKV-'=.W,?M^H1SL-S*VFX?]
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M4+!;*TDX BEYZE&XLP\H_(C\_0_<R@J+;BP9&VH1DK31_+<&^K%;74*<F#P
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M)+5I2Y]:[SL)%]$&JPSA'HT^'G#+Y,DJ-UR_NES;B%C2W95N8'DL94U#>9V
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M7#^OQZ,0@]>4?TE7C/>+GM1+>#89QZ<F*)MT:.H2'?M#L'5S5+@*4-X(VZU
M"S@XGJVOZ]>38XVW3\GT=Y_/;J5TT[.)2<OER0\G(P;5SB3<^/7J1D71XBS+
MQ?6\=:WIO[?^F&4*%7'WD@/-QL9<1N>(?JO?N]O>S?#:%#H905_T*-<J696\
MS"LNM.II-5LX!J57VWC4?0/:<9=O#GQ.5GC[Z5SJ,UK;ZXY'%X0L7TSB*XY>
MD=&U)OLGB-S^,A+08T,R[%_[K- PK!EJ,2_!JWZ["J*YOCM5&JJWH:.*%1#&
M6I(K_+=4UAKO8:T__V'4!>4S13'36)%5\U,-24NY.WY.QCRE$OH0.B;*/ZTQ
M(<A3 3\$EAZ;[#@=>^Q[OY.ANI$S_ZLK.+LAR /,6!AEOG>G'0W*HMM4\QC+
M4-DNK/HXL.K4A+,CYX]R=[8Z_7EU":S?B719Y;M*_NP!7<?/M(8([ZE#G^/2
M6.!;0S[X^=[1^%,.?AFWBC2_O<O)")9?7M-Y^DZI(S7_V!74H<LY\!N%#G-W
MXV64C:Q]VXI[BC^,F]FDI1?U].PX=K"4[?= X8X;5DSADAU3>"NK9A+3+JY:
M3! #(--FOWA_85J-6=>]K<U7%0;3&995 WJ740@<,O*0.=1H8.9=2V'?$I$;
MXC9I.DY*QYPF>B:=[F)%T<D9>ADNAX>\_7=Z9&A\K4>753P^98[2ZJ/.?DX9
MLAY]6(/_7$U@46/)F),N7&G$:I0F>F,C9N-Y0MZLB]2GVD%_7F7S?O]2T78M
MBL7;(H<?]J239].OW*^)5#QW\VE5^*W69</[VO<3BMY]^_[]^R!86U==O6[@
MY9?HKM;XXSE<!V.W\-TQ\+L^.2>L\DUAK7>R+*SB*]X]I#UZEUJ%*-EXI]_,
MQV5SI8S*;R 9771E)'QVL-R"/UN[1T1QU/OSAU1XB)-,DE?V1/KKV^U_'-R-
MXV_[I3SB[Y)]T/>=?_+ZL<7C8U<Z+?0O^V[="_T5)/M:OV]H*J.'MWD:BQOM
MM_WZ^5M D</'=^\JR$2>2>WG:U!;1/*VQD56?)!@6"QP]^$(UH(0/OS_YN(<
MX?D?H\S[_XN>>['!MY4QT35;?/E_@^?>Z[_BN&]>#D8]BI$Y?Y?_G"!!*UWK
M3MNS6W$:AVXNO$F'JO,;]2@EWH\4*?U/&M#?,ZE?S_P).G3R^OHA@:.SU\^P
M3+K3KLJA[_[RV1B6DGA[I=>DTW301/=SDR1^R>\75I+3&XB^^M?4NN31D2F<
MGV\/U+=*7>[_R5)[X3\90L+P)86IL:^6>#F(M+G&).&0(7?Z]]'43^8Z TDT
M;F128S147$U8D!C&2)GJ.;(F3]0?5VYTNTS+IHU#5!1:UL6L GB\VG89!1E1
M]0_!G81MRWU(HIMEVY<%-.FZLA*)WG3><PNW\'%MEZ>0<"A@7V"H]4JKI AZ
MI%"E<;0!_4.'&J-W=4<!/22^^6K=V?@FRR6!*4BO*Z0E>-QJ'%[4=%9H%W=]
MJ9F5?=!J<&7-P]G:8MB_R8C2N7![^(GVQ%R@3=WH)P-EAP*554@[E#)$QT1J
M8F+(F=I1>$UZ@D2KSDS$$DHSR)O&)SJ_C8M9T^V3!B!MKJ*(%',U$@7S"H?#
M>/ =@]>G<[0<U80F8)3LY2(/#!TB -P&;$G:!Q>>47ZP;:1.MCW\M';:"I66
M>_7JN&?1D91GE#\#ZFVD!T\U"K9F[[T1KGKZQC^6J#YJZU[;Q&<QL@=R7Q%$
M9J#?TM42F%.>E#>4OOCU?R6:+6';$3.Q;!,FU 60T(Y>>^O--JF&,I\T2+)=
MSM4P\PT#2BDF^7'*1&$OK>#RSK<A11_0WQJTHS3V0$< +U*[E1T23B.7;^!X
M/.N%3?P"/ES "'$.H^!XYOI4.8:NW U;0J!<F>GSFU "(6R^V[2?< [S>/?=
MF&>*X^BW*=!N"><B'".Z)NG77C<XRP&Q(&W4XW/UVW_&O:H A=OD#\#0SC5
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MS3&)1X'\90AL\N;)YBHP^>9]&V,>"50%O(6TR&"FZ3F',I38,OJ]I:5.\/I
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M\3LX!LG? _$L^,V$HIU=^YX&"\,OC1<_%I^=5A.L0S@TB5!FBC&<XA>[#GE
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MTJP&62CD*MOW(]$?0'"TFXZVW^*3(W0%9H&<U9I=/$;EVM>\W":NE.*21:<
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MZ"$-$AJTROLVF2[9(90!8^M%9LFJ]!68G/NL'R</MC;8@%1FL=5:5A&A3+]
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M.G':6:ME:Q<<8L9%+9I\M7KT]-S4[#O!<R\4I=LW!@>:^U"V$ [-),/3I!C
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MR7&@ZRKH]I* [-%7.PE$QGH5XJ4/\*?!K&?]7-)HMW ^]/[5T%Y42=H$3M9
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MMKC450W/_\;VJ,#B6*J8J**"D?9Y/7N<A0>WT/%"=Z&?+SY_?.F==GT?";A
ME9Z@*H8>$%RKYI<G%_8+;"K!<XXG/X"!.<Z.[HMP29)G/X7E8]]>X)W=2QNI
M"FONFZT(*[.:T2V:\LKLT"V;-CO?G5EN3*Q$:JQ%$BTX;/4?^$I,L]-^@5:>
MX#S@UHA0!N\(%0M[<X+S"&*+[\'553OW00V@-]^5KX_&;&=ZY1$]8+*]HU4
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MT3H/Z$A]'^0SK"$--A_N0W-13=?UJ,"<$1U-'YN'D=8]^Q(8-B3.B9O82P7
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M6(*1CS85R+I6/X0.0TZ_QFS90Z%4X$O&K!Y9C(M0]A]:&^ C2.LW&U0@3N<
M1@5&G7!+E+!Z=$W!#(0HY4Z*@X]2 4I7=#!LY^ZN[^15!D[]0SF4?T@@G#2O
MR(R<'_+QI0)66BVH?2/Q]:?$' J3#A6X4#*W>2 &%:("?1_A]G\RJ?^H')K@
M_Q0Q-)]-T8WSXZV.'-"_RKBB0+,-O+F3M!,.&;]]W6'R?UNRCPD5.'I6B9Q
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M>N^;FO%_<S^BZ;2'J,M_[:!31"R8PX1P#'D73*H[,_.^[[N4ZI3*X"N837J
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MNI Z>UTH@F\#*'GR@8W!G0NN5?Q 1K.L[*Z1F4><W-W3K&5:@*]8J\O4>LE
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MHO["_='-BTU$R6JE)S<B',=+/V3/VL(#<R^R2R1J6Z]R%S)[G97&B::XX[*
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MV?Q;[:R&7T_0\N&L5'IZ]B2'@Q@QYR.^^?B@T; O54_9;'3AS-3CQYWO;D*
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M<W173_&1R85VUFP?IM)-2VZYML$8?8YUR^+@%-3:&JDN=BB[Y=)7S6EP:M+
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M"\I^%6 [CXJF^:XVJ(>6NPXD(2H?&VM?)<O7T8TFHM[D-Z90NT2OV/,TMRC
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M+&W2FI82Y>1/1U3L2!;6,RGA["LJ1GGDWSMP*^P:$_A.>X*F5C:,]IA2YBQ
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MF"YC.,D44DPA[!B.R)R .RW+4K7/Y)TQSP3-:B>U<4]*E4%Q\;WK&+_&A5A
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MX]>\9S3W2L$Q2-X:""(RJ/8S$>\L*8]5)=ZQJ9E,EE5([OLPO76H9&CJ*2E
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M<0#<>Z@SG&#0;(0Q4'*_7.K<.KH_9R.L>R++_^/7_(CW&8*O2\[V(H'6&??
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M8EX5UCA@7/P%B_\0*$5F^K(U\>R.?/Q(%_E\MK7UG^Y]YW@)76I![1I G:D
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MV?^NZDEXQGEFL@;VJMLH0?V.K8^+IQ*TZD+S&[$9P=NZ-BS?:?:F_MEC+&S
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MU'IPU\9VUCCPY;MB[8DW?7/W 5A7.C1.>:MZN:$@N\2:2)XP#D\['O"D6.5
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M;X6;EG)TC'_Y19I!KRW1\G6GS[!#.NBW(HT5@)D1XC(^3KIX]N:M*$C5U+A
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M':(3$OU4&3LJ<N'8S;_%N PA ?_&)OGWU=63<A121W .S"I%1_M\MLJAC6I
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MMW/K#H!?Y3_X4MTN9#D\PAWFE ]<P/P"K0N>GPI 97>[Q;_D_Z\*JW] _&G
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MZ)WS2F6VA+F16-0'2@"?T(.JGKRKYN;R5-G$Z \7Z&Q@8ITSP*A%6.X"/#E
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MOMCKSGJH1D6FTN%B4:M\F._#QP'GPW@":.D8+"&+1XP^E,G3#$N"[:$B*>I
M2UN*@J@<5;94+3WH<]U;:7:WB-EH?"/KA)WLOOCQE2NA';3A2)0C]3$C3-L;
M]CNLP8CG8)Q4HZH$Q7IS+$1DHB*/:B:X>"3?_''!$_C'EU:*[[DUC^@;HH=^
MO+* /PET4!3AZB37RA6]\SA+9?MKY\PIQJ]LE@PH!<P#!7^C;]4MU.ITM%X
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MN9@Z](', U*;'*LB?B*9U!&"1Y]M<N*DQ;W[M1F!9=G 7E_LHT1NK/;/I6(
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MOJ]QC7FXE]=UO:[K>E[/ZY[[QIYC$P'!LQ;6%@ '!P=P%7H!;!)PR!SMYPT
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M2L74'M][^WC)#1W@F'/QRXFV8XHG[:ZM0@Q[V>-3'P2VMS&&3<V@&35O(/"
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MPM=?X2ADY3]?00F*Y1EF2=<^B*.QXMOX(6-YUW/\3IPFY5<>MXB3B+I0]DC
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M$%*@>3(?L73]V("0L0AE&ATY*.4XVG:YC=;!>EHC,L)Z$:7TN:^9^F-S2-;
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MU&O*>',D:2>CJ[1UZ)K_Q92HT_:H:&O93-$/>:%K?Z9JGE'B_W<_)_D?25<
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M=7 D"9T(>%-KB=C^"5G$PX'">&@&^\3J?%"97$?9\=/!;K*33?21751L^]$
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M4O5<JLYBZI(%ZA6<<6W90CHO"Z1C<I^"AN<CE_)^AH-,H7ELF>EN 53O$.3
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M26WU C]L0:<+_;,5[J?>S\%<!:/;/SA5I7S[$_/+YU5U,X"PB=CM>]NK42F
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M8U+3_1+H+%]/CP11C4\WU'-^_.PH-7ABI3_LS',6>/]K'>!Q[*8O, \,U<E
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M3((P8]=[KP+7S9JS'MG53U;&VC-])PPU8.<]H]9UTL6.^?T\_[@_^]"J2^H
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M><6F!4%WP,=-:("G6+QSA&.@[V>RJQV)K6+W5X6OI)0'_YB3\X.;XT%=%EO
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M%0X>@K'E0BG+HGXL(E>_DB$5Y+T%[$U)Z9:ZPA)@G+M)/!%'OL1CE<AO<>H
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M%[/ICK@4<S"><403:1?]U'PZ\4WT8^:WK_V6KW4N^JULZOL!FV-,=X9S5%T
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M$D:E!\(:89OE%-QQ /5#NWZZPXQ$D&JO^"3WUZ/#/I%?U*.0N?%'.CX:XLD
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M%]/JR):QS/A^N%:?\4&C658Z$7W)+T'E5L 7LSQM$=^;#RU:RFY<=F1_;-M
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MUN'? WK6](H<8$$M9W$KTVR]F/6_GYO:424',#=00F-O G7:7J7.GCE\Z:O
M,:?+OSZV]ZR4/U\IG?5_  N"I*"._CO8Q3A%6TNB#MH#1M1K'M3*O0<,O6J=
M!UBK1IH\HZ[5R<4[VTUNR=4DUWPSY),8WD]%$]@YP_^I6C_D@M-E'K!77R2K
M0*JLHN?UO;.6%/_F.)I>MNL+I.,2'[BE%)S".AYM[=1X $IZP-)". 2V9;DI
MC_4RSRZ(SS6'!FOV!E@K=FGG'?K)L8E8@Z>SQ %3-OY_9Z_J46SP-#X0F;0/
MRX2*,'RF232+Y [_".+,7-E4R)7"UL:G_$,3$&U7M65+^P%QS&<?&ZS7-\G
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MKE[,-X:<_D=3H$(S'?[L[<@ REY^O^^YBWOCX1$P=J2S@E?SE5^M[YDSSL]
MK]:]"NCAK(_ZJ5O__O4Q1$LEV,A[I[K0N))E4J_F^/;&O93+<;%/"DVDO7EX
MWZ\K*T^K(+*N6M6#OUC&R7):(^1V6.CT.!?Y6P]\T7I7&?"DZP="!8%.NA:
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M[U\/569><*PJ'?I]107(+O^^(CVEA1$ 4A8OM3?63E!<"P0$%+*EK$1&\]Y
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MD'F C,52L((4<JL577K.(H'2ZH%^_ATI>!')3M'-KE;D;228%0<5>(X+,:W
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M^]^\9)D>FVT^4^+?"*\K\7E>;G"[\-V3V1NN?TK?ZNSI=8TR-3-HMK\0H)G
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MUO7SFJ;B1(XXTR\!3M>QT57Z=N]X>HDL 7:!+FCDJ?1::! 4!-A8J2T^SE>
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M_#?2WCNHR>_?]XV"HB($J5*C M)!I2DM*@(B0D2D"U$1(02("$B D"@(*%5
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MX)J!K:*5-R@,:VQW!G54R3WR0L/J'O8V2,ZU6Y.#-OC1&P.KZTI;4U4>2+M
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M+NSJE:U/OV9!-@DOCCZ#937IC!GDC[\V3G)\\C"Z(2Y(]Q(NLM%M:<A7*G[
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M9_XV>"\Z28IMK@QEPMWH[YF@\'5<,\0,=$!L/,9K=M2Z\P14$,7Q@J-@(>J
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M#+[6,H-1D*"\MA%RS=F@]T:2U]EACYCM#IE+UOT();",+BGZC0/&:(@KQCE
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M=O?$<=ALF8K!V9FYY])+HW$!T'"YNN<1KR(\]42_Q8[00V_N%WW_HX/+]B\
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MZ7Y!?8W/!&<3-G,GO2YCUF!2%G:L:1W@85;]AY7X_[,!,X/_ E!+ P04
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M1,SE00*%8*_T,6<QM/+^1<EPL.*$Z,;\7W0V2_]EW.RKF'I?W7>L*H&*?R^
M5E]#"K08H.T+E,S^M="E> 5Z@$*-C;EPB$CSU2YH75#E4/HOGOZ%'+E_7]"6
M_1'V3K$(<@?,"0A!\IV>:=!?K,FL_Z=;%24[_R"J<Y/V $S00,5?/J3_^\(=
M$@HHPD_N?(96SRW /GL+-(]/W (;,PK_X'CB#L=_]2>PIN/-H!O#Q^WH6^#;
M'FC)TN(6.-[- OVU9_V'_K8?UR?L4>Q3O!L_D5^GW="MQ$5Z^1Z4TW^#<B)
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M_5G4<<WC3"C,72%XU_I]M*G>DL M0&Q6H2)1H(?!G<>:[R1*+Z,3-@UN[E7
M @XC0COJ;1'S=<S5SHO375PF>)$_16MDF* J:L.:YULIL#+V-N>-9CCZQ[]4
MD1TNKXX7%EP,2[@%4'B^AYV*&EXVSL]7W0)3N7,(;@O->N@B(:DB:0ZDM',0
MHERL:J+^H8O5E)[A^D=J80&1T5)#)T3J?,.R7R3Q5)%DE"3Q /_BTT9,#8L(
M&(&O<=)=C)Y+$.KI"M/,!(7?@<V<VB5J0OTVGTF\#5;G9P3.6%%3MI5 S55C
MC1OK Y K&\C3>JE@U6UL)2>^9*W/GE@LMX"?32YHH"_EYF0!+$]YD'\*NKPL
MO04:H.X&%BK_",L;W7NV,RMJT(/5HJ,'\;*\!?8S;X%E,]$ES:U;X/C4Z!;P
MK+P%<'5S)"DU<F9%2VUOPAA%,;A!EU<E?]2DBZ*?ACUT9^ZTJMYK%;W3VBVZ
MI&%!^:"%%ZI%&LS$8D!Y^(_6PC]:BV["Z*"^&N2!!N;";NZ.Y^1Y(?C^Q;>
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MMJ6I#!'.#*@3R52-2[:-Q\]Q^"VD8\V47>G@PU9!C$,L3#/Y.S+9ST].]23
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MQJ;B*R02-QG.OC)Z?/#E[-8'QTE"5+@"8*X_G631TJ<I=K?JG& M(UI_+)3
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M)E@#)TW,]SSP)^93Y^^DT=(3H$%F /J*H.$!QZBMRPK#4J"D,?T$*QUH'$$
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MG"(EV#B!A?$50#D4S18]3=39BC\T:IQSS6'>1X\6PJ'GM?A_?9:_Y)NLE9-
MO0+^$:3YX[+<_%L*C6+DJ/(CS$_*NBA[_#& W+\$="79/I?R?U/GV6:SW;KD
M($J?7A%.&'Y/ZHH,V6R7QW].#=F/I6SB%0$8FS.;9>B1MIA?1B+#H*WA,4/*
MA+\I9Y"X4Y[?]87M,8F>@5+J"#,T%'T%T,]0"1KJO0)Z4+TVF[/",]D[Z]5
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MW>T$+Y@,7H-]O/0I. TU6@P%W0D6TQJ7L9E#HLB!S\V#(KHI3S1"H7E%H:^
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M_-3,))E?BI@K7%(T.E_*CW:?)L?KO2M U!UR94D&*MLE'K&VIHLT)BE@XQ6
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MJ,)SC=J%#6.$> $[-VA8OT6=BY$T;:.TS;*PGQ>^ UGAKA#$!E<_&!DGIB?
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M6W>8/=M4FA0"C#APD93T[>-<7\*P\UZVA!L%T]B;LPF0(QL0^#R"=W)ZRFB
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M5T;P?XF\Z2_(JU3^:^1_D1Q:Q?2IM[K%F$<Q^,C);Q<*]^\\@?4:A:X!L:\
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M=HW/352J(G/R;7.UO1>I;PW3FP1CK=^:LEP]37T70^"GHQG7,(13KQN\Z9:
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MYGH0^6^M2OUOV?Q^?OH_4$L#!!0    ( #V 9EHYY44'++H  %/(   -
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MD1XBHZ"BH6/ #:H> 1X@("(^0$)\^! )";[K#=\'(.$^Q*/EDD3&5WN%0N=
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M7Z,#)R<M]I!J:?J2(K^__A"XX?4F2]\B<49_.BL?W^#YDVD#=HPG*FX$B<
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MB3>6[D)"8L!.%>SFF["(T^%DRK=T$%%Y5]+.PE;@!^*291:1H'#_9"_R GF
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M#,4K+=8?_,_V=6<+PEZWEC$/?KHE$BW?7?=[TCP-=Y<P>?Z1>V43LF5 2G%
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M?4 LOX7VFO.Y:MLEP[158ULP)\_;"5=H8FOZ%Z:IO+92 !;VJ%SWAANMA[#
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M"5:_:%L'W=4%BUTE_.Z4+C J;2!*-(&Y>=F48X\4HXXNH\-/LW_%B,[UV)R
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M3(.C*=LX?^H&O73&+:B2C+.D#JD =F;T/7:<@L5-&^_ NSGJ2'?0?TD>_N^
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MYHX%+F2]<7HAXL"C&KQ%KAC<_A?@C11$="4ILH'S^J/:5A8'@1(-GHNJKN7
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MI;ECP88A[N,)E>6]#OQ)'GGH2]$@T"T:$#^D>G;,2!5,0]9&41Q!SQ.QMO?
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MB.V>0[9HX9QH64.OA!-$>$NR,8:4W9&FQIB<5!MN%BEW"_*QL-)T4C3]><A
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M3^<25&#]&^VW8>YILLFFA9$$69[DDII;$CZ$QG_&B%+1-:!T.B9W((>]ZE?
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M:'D44Q?)7$SY$!G:=*]-IRT99FI<D\>QG<[YVZDR=\.6X+F#+2/Z-5/=7*_
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MYM:D-%=6/ORX2<&AL]2'&Q$<0ZHTV*WU-('D+*SQ-"89!GV2\R#. /B\H,N
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MP)T SW6!Y@7W8-<8-@V[R][-S!87R5Z!O[44_U[+\$S1^_&?I7&J^=.HA3O
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M?.]M[&H7&LQIV7;[,'3)A7% 2LJRG4/Q>X*LI+-(&,0R Q:4G?@\C(?,W!7
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M#FXPQ,V:,M,^^?[*.BI66E%.NE8GJ@"#V#N 6=)3*5@4?\/3MC5>D(#G.%(
M'_5RO",']-%'X&37P,O9U,64,=[-EJ<6 ;AJ==%\'RO%BDRLT_[Y,EO0;O Y
M+=+ACWR"_%<;KN?0T_LZO=%3/?1<#[LZ*8A,15O?Y*<IUR=BO)?O#O1?>EIA
MRTID+J(5<C![;57$E/VJ5I<DH"3_NL( ;#%SG<<Q $J=:CR:25X(.K:5VY+B
M<,'._V"C+]R9 "U=BHQN.OTB'J-B.NX]N&.A5+0QIM))U9[O]53F5DVGPQ8I
MKMB#5$<9%UN9"6RZ//TD,<XELB0ST$PO2T1V=E<MAG!M?,;(,?]K"&DE1=6"
M/ZP]2 A=ZAA5F%J!^*(XTU*X?,J*1+F'^4>4-!>KP&8G1F*VO.)WO<$=G3#X
M ;-9G%#UH&Q,86'9/1.,/./49Z=9UK4)[,:57D$ZLT^U:3GDF$5DJ- U">?E
MONOU50\P0G;2]]IR(BT>5<;-NL9O*_>J?Z*\J@*,2TJL.DA.(1RW9GK1^RZN
M9,!>\%,0WZ)ZOB53-IBS)LKRT0G[7:DSGS02&.K6W ;(<ZX& ;BEQ>_EFXX<
ML_J;IJG4QFJW?/5(>/>Z/SGUV[%4C%H98Z)^=[Q.<>;;8*KEZY'FQRSE+WHQ
M^N_+<^3F*5E!HPWU.FVJIK"[VFX+OKH/R967C'\M(%_].=,JRN(B63,R/>*1
M1+LBZF=24Y"RY>N1$IM)]:'BG:V?D<$>*KTM81/M7!W>&NZYJHX*TX1+L=&4
MLF9LK5$>]*?YQM6I3*8! EDRV1U(;\NZF"/M_9(V+H'/*V[[F/52Q@#;>NJ3
M$;B!TJFLP$=,>,2Q*6<0PCY,82\^/UPRJVUJ/15-WUFF^12J[X/91S<^.+GA
M=J)2X1H/>T)WO0S14)Y3QN-1C8N-<)8[K;8:4ZXO=?62[PYV!=>]CHV C=U.
M.NG.B'Y8_2EKB;N@;D%< +T>3/X^+OBALTBQ0;C6\$+TCW"5.ND[]YUZ&[>I
M;COW>[X\\1P>;;"+A?5XN. ';Q/(R"J_W5_-IPM9A7035B2KD>=S[WRJF%?(
MQ3(SN@ET;]U\H/JS/T"N7V1V\%Y%1E2,,FH^,OR]5U$1Z]HGWS!,R9Z=/+A:
M\[ECM5_5EKT]8VDKMLN70(PR\>0QYCI[E@6G),MVJMK*=Q',[3. E::%^@XQ
M0?9)EOH.R:=YM5B)#27G"Q_KBF+RXY?UXVD2\:^6Y4]C^;"8,JKQ]%A701 #
MRNCG^V].9<F(W;;,0WU_<EYN'O>!Q%G7NKKV\0(K$,!]RZ>6DR&FF<;55.X6
M4^7,6]961#[))?VKK2HG7V%JR^0ZV\+2>RVMY(2]HR>[>1-A&M:FW<;7693A
MPUYC5&Q/I[X;)_*%/1O1EZ';X]EL=XQ"KO?>Y/1MAM<WQJJ3A1%BH=_R_44R
M,7_"C A5"/ [SMZXB?3C,%>@*8]@L0NQN.J+1H6YXV&Q1H?JPR[L#78--343
MI][G"?M'G5_>5/+J^D]J<%/HC!@LL 8.[Y);2(UG<95:=&0D+[TE'!WAP?BF
MN]I08UVY[F!F_  989CSR*CY$S_KX5CN1&)@AXNJ][/;4Y)#K$ZN)X]#[)I$
M?#8L>;:-W%,%*G77Z5S&NTYQ)1Y_1CL0*>!7A0AHOEJ-=\X<K5,BSLR8M#@A
MMUH_>2(0T?[(4KYZ1Y9LQ_VTD#3+W52;UE66<%E;\8YH^O";C!BCS*^*3M&U
M'/H;B0'IRK-S,WHQESF6"2?73]WS VH+?=+UP%9S'DV\F*+]E^\OS 4Z*LVQ
M= 0T7SMW>\4W5%;2T3]-$=_JO.T==YC$N5H\E K"\M;I+< YZ"/.]: <<F8+
M$KH-/@WSN++RS<Z,=241K@WGZ'GHRO I.4J)?DQBX3&)P69\F?S]:>TI>?+,
M*8860ALW.E\PRRHZ.R/A]EL_=0;"0:^XMW,>RTTTDZL3=F[BWUZW2@MTA76(
MQG)[?LLF/%2BSG2-ZH-#)1/\9.'[?:!0E6S"K:"5>*>UD<J'PLZAXFL*!#9A
M2@(PV@O45(Q*^L38HS%K-_;MUGC64S,/K:H+7F=U=*:,&^!IUWRK;8B0]7 1
M:?5]Q3U(\L!'0;=BY 6YR$H"FZ@-5VRDJ UI%DTKTE,_@/1D9RT4O5*+\AX;
M3A1*6 C0,DY\#M'S^%@L_DW0Q*U-*UQ]V*B"-W)NAJ$4C53##--O;/F&QQF=
M0;)%GS**>[YL\"EG:9*<JK9_())]9(8E_>*6^Q?Q9.9QV<K2? 2 20R5PBW/
MN^?E@[QISVMRY*G8Y*DKDV0Y**$@>GU$FY&=%:6+&I.ZE3PS77$7I2JF>7>%
MV[1WU'X7?TCTF.\D!0%,B':<;*:5+5(K)4YQPG<<7ZY+$HLC^V6)/.6ZOERW
MR<>9\&[* 'WA%^>Q!Y1JQ ?KJH2Z">\;IS)4'K::"W1=T&2+,1%J8W!-+I\=
MIVAP/E!0W'_^H=P_)6#!,[J/^ZR2"S=8-(W2W3I(HH?9)D[]LB!L>FG4(1=+
M+^_MH'S)4=NO58,D"D1.10SWUU[TE\_T)]RPR%5%L?Q%DWF%(@50RT5Q[@-=
M:V:YM'.+[DKI!4O>N&4I@J0*]2[7N'*#F3;;6R1Q&E@9]0U*Y0H@15BYH@9I
ML_D8E8*QNWESA(7LJERS]2BI.>H'ZF XSX!FBL&7I++QBQ<-=]8DN[P:&IDR
M(*LB3S(@3,#_G_Y(^1(%6GH;;CIO^)A.72'APM9I,P&]TZD)_,(N5VVJ9?MF
MP7GZ;;;VKFTK;%]KFVBE.:F>VW417=#4* "V*EJY;8FT<TF\=:\6[,L3< @\
M:/46S9-@9EO[H1-]1)72G] )5<3^=Y*&X4=AB=PS:[EXY6'ZUY16,J&W5Z.I
M8MS@$OF-Z>S.JI#.X>.S-Z/E_K9V)1R[7$NZNA]F&W%*N\OR /Q.NB(U!/"A
M6\E6E/7C=@E]5=3:!#LD(ZCN&*V,\JL!P"@$7:P'WKS4, LO:BKTR2<@V]ZQ
MI3\H9M\AQ CZ2FINR>)T1P -,I1^"\+T?S\E;M:383YX0L?B(-T_E)>.)UQ1
M&JZX#PK>?G-V54H=;4<'1,G;QB.1&]VK1#\L$.+..+\;#R_?UC PF&W8Z-T=
M<K6N#Y8O#U2K'C8.)'&3B>QYM.#&8F[1[L!9=42UX1_^H4)!\("U0)=7\T.I
M/[D'-;^\"V?[#W6NZ%.Q3061DN4SPZNF8UC:0M0U+F&R-TGM4P30T3&5M3[6
M<_FZ8S%9\PNN'P_$FRZ#2FPVB?<0!P%8<)X?>#PRW/T$LYF9$W).M;8+2QLS
M:1#SFAO;=WO"<]=0>\A4]M'@%GG;SCR,@.$RP;63I;WH:TO(U<_(VK%HW>.@
MA89S5.2.[34KWC5K '0=4)$D_+^>-.GV'XW>WN. O7DMX0!5(._27,&2H4==
MDZ&)=1DAZJFL7ZZ(&U.6%":X6T*81Z;E><^=^ZX05W2=J%(K#4X/*WJ8@N@*
M(>/GZ%/;\'P +E4=+&5XII@^[(9B!*>K#C)A7#;G_7P;[[*K9=,@Q2M'R\IU
MSJRA%%H#0Z-A<8^3_+[>1)KS+3*G,R>4Y^A2ZBO 5/DD_R/*E!WGA9IB+P(8
M+5Z:DO=\B]6.$:AMM@\+9@S^]"&N/YX*N]#PR47(._V[5VX'8IF*U5!8DJO\
MM&Y%ER9&"&NN0(? E0B5N;%EKBY[96@A,73SU.C]$XBHKZ,&\QL9'UW.(]:I
MRP07>5LI>4NSLMI[F.SS%K'#+80)D[WC A%A]05&I=R@<QSW)'BS+ +(BCN&
M_2_AX'<B365% !'"-"<$7Q' 8)6U7:FP)@)XX [:8GB- +(=1F< 0A7)_]5D
M9 $^(-WGN_X0C0!DV3?M_C_I/\Q$+A7[3!_UD/-.9RDK]B/[C*9>^=__(\9U
MTAM(#/:A6/OJ'+42,JR[-B?IEQS/;98Q)W7!1KE4G9WG-OS1J2*1/'9\@RDC
M\K4DH3+*/R0BN;O&+VJ^Q;7/J50D'CP^CMOO+:+U>4D) 6HE5>"3@PT5#>7@
MBJUO<PA ])OG><-IN_.%^@;0NF]X]>XG O@:&PB/;=%U^:<UO?:_YR+SK'1Z
MPJ*7L:OI#Q_12Q(^J1L4%1!203$..Z-\2> >+Q,L%ZC*]ZXH!\Q!1VFSLQO%
MBZ:L!7UV[ACIUT&(4B2I.L3C165 QE#VJ2KTJAI_(--]JGA4"B7F@/^!^B30
MVH\ EC@7["\Q&>%1NJ,S_SS^OLB-T+](><4<M)7O5A.@[7YLXXPTL8"\I+G.
M9J++<G.3O?,WJ5X28QRX487%?]?(6X$)N]()N^I\B7R)6TO"AG:ZAR)KAR(;
M.8=2A](/O)SF_A(+H$[%7?5Y"O=YYM<-U U\IYZ&K7@-K'B-**R$KH2)G2PW
M<,V&<\U^L>>VYW;"@+&?IQZ;S<"DE.I-=WD^OW)&-;^<Z]=PH;-((;6J&V'3
MR8"P)A^]_R<?=L>>(0R;>26A2Y+2IK?EB^]3!0_72*J9XH2?08]I ^YR4'RU
M+<Z,J#A((&HU>MZ(6>O6$_#6\9BZ@-Z2S9820D9)9"IR1Z3@UE@S<=R!=L'L
M[+3V>)67/',"CO(34M4[RMN^[M,]X8W*%6Y'U^ ?U%]F<PG5#7\>CQSY8C=L
MDW%X__">=:CE!QD )>I4Z,X*/Y,P$F)FYWS>[7P;GW0].L"IA9GO[+;O)MEM
MF5>^&;X ZT==H^R>PMT$0 0;FJH2Z 46\?OB//(,E[IUU"JW=M@H,;%_+H;'
M"X>\ZQ7L^J=Y_L87&90"_Z^DK!ZR=$UBR(N!Q%L+ [*)7&)Z.LQ<4A;8P9*/
M+'I0'"UNY!SLA G9Z?]QT1(J8U"4,+3-A1]9<$_008?9MU8_3>L]-PWN8GB9
MT]@E;S?I7&5,=:@W&B)<9-YR$H;I9>MZS9$%QS3G%+)3&:?J0$U^T[EI$)EO
M,2J8'X0<'%EB[^I7*?.1*!NHGW%0&K_WXK)@>G-E=F=WY/*DLB]$]RI$"=9T
M1KD%H<PTT%]-=':N).LWE#SQ1  &&D_K1#7A]TN(/\)7+O7'UQNZ5O?;)]?L
MEQK"T 5=*BM;I[ZJ+LQ_5JX27E8Y[^7O6-RD3LC26ML3YGT20R 0)>5!+AT9
MOL]5RM;QKI,QVR![X,'&1.^9_D[J::NM%\Z3:2I9MPZ<G)<T:]"S%B)5]X[7
MU]89A0IX< GJ1\AAB0*O,]3;]O]S]_Q*VM^0&_,(HKG+M&&-6,+43!W*T?A\
M\0-ZM4WQ>1P34O*Q5Y3.A\9?>]0JF- ;/\G<FY(]H>&Z3%[=7S_3-%;N6^JE
MK_!X*1R9G/ZZUG*1/^>8H'_IS4RJ;?B)?=))'_.W@5I73EC(:HBG4?;7@V]#
MEB=J#H]/::!Q,T,8 MM'Q5]&9]C9C6$AI3+#3.RC:?1!A&:R5"H8&L:^('(;
M7"6Y ]IA'6P'#I,W#H>/$T/X03ZZ?B]*:R!*6[JF,RLMK$$HJKRI[CTNG=RJ
M0K0R(=VA7:0$7$/<%V*.CI.$>U/Z8H$]'G)=$\:7]1UTJ.GKR1H- :C8'B>=
M]W7CJ'5:Z2=SJRC:P2EV V(BXO\V_&0AXRB:[TMR)# N7KWE^]3BR]PD<4JN
M!@)P7H&_]*E4F@Z8AT?B7^WKGTKW.<F7FD$*3H*F=B9D,"[M,B\2]4^+!N\H
M@RL?@KZK."R!A]@&U*&S,.U72EDF"$!'M,]ASG,_\/)CYOE*\#D&RXYV1H%/
M2%J]B\/<GC#X =,E&DW;2BD"L-( C09_K?""HT>)D3$2W==K3/-T']OX^=)8
MJ1P#9!:2=A(/ZLW6=5?;:2&_)L3BP7/[\7&#V/B=(YDHQ/DJ[]*;IN6F&+-'
MH,%"7Z"1E% EST $,F>+L3,U37-I)GU8Y,,BP5[ ]7P_9>GU?JI??V*FC@[X
M(@ !>%U@=16=*Q;2&8P]OP%;S''SO^DI'"4B!/"=&N\24PN\KL<#T_KGP.3?
M8/\_224^'E3^,3#5 ,[6VH_/HC58^5KQ97G]/"AE!F4&?K+@1/>]UAZ)#J$(
M.^%(5+04"4PQ0/6BRG+L9BM,FNL&/L9#%U-9*@SH2Y-DXE6?,4,>3:Z_JZ-\
M-\2_N_FR<,NL?_?U@:I'D3T=ML"#<OITG\4U7$>MT$S#IOGOV3!HTH]/'FY/
M;(0^XL7:N'Q?/^+I9AG15$0 [.KUX.(.$Z9!US'8)EAILWK48!-ZXD9CKL51
MG(M%E@D-]A#SO+^N:.O9:%G@36\6FF3T)7_6\++JN'">H3>XP.#'I,_(, G2
M?4[PE45POA=25Q_:78"(O)@LC3"H[-9A1G__I&-A9OU2)QZ\#&T(2XS(5RL[
M=YE3:AP-;-6(:G*ADW#&B>M<D<4IW?;YEFY^,8P IHBWG>WM"9VZV=;H)WUI
MV)7<5B$_JFMJ1[BO7Q3'<N-3&$4FJ!'4.K?/R4&:FWUP5[HLC*L2*?)&A=*?
MF4FW2]"("7JIJ9N[3"G8KESXS";Y96.+7I<LSUUL&5;M,V3=[R9O<A,4=^WF
M?A(GT^>=9@6C+K+EV2(N)7;F%G7B1[4T7$UK+K79><RMZW%T,EA<3/E]F["4
M8\FA([2C4O)N[&S@HP2GD^@9-HT>P@*[V@DMJ*<;Y4(.3VZFEZ4/[YS2YC%%
MYMWX;OVK'DOO9SA&3G%NY>?W29,E[MG<XTJM9U%@U0G7Z P8/& ZV2%0H!ZQ
M\[JG:)43;N]XHJ"XH.OQD,^I+H@B_-,M_N];/E_& FFC\/ FVKCM*2$?B!S?
M"XB$6BJJ4\9S#8Y-]5V8N= I<KKJS$Z=D[@-?/MR'N,1NW9 #8)*%AW9?_EF
M2FU*^6X[TMJ'8J,D03H!&228Z" CQ((5E165[]03Q+#?C\0X8?SC [:Z*S0Z
MB7G2CTQ4=EBNS7F,<T+.HY$3.'W\W_FU_T&$5&S?YAD[$P&#3/R0?\"0XIEL
M'-*/(2OYVMT OG+1;EA1ZDRQK2ERM@[WL7;U9;)6Z['-TI-'H954"4#-%4Y<
M;6TP&V:,&SS?I6+3]JNU9W'>O%BH64"]=0>-^@X/CH;K5]XUV\^AI2$9@.-Z
M&^ TZAGPF:IH.(A51O@] A 9E.N:=@*6<#U?'NC=>;-94FY]7T_ 5T"U#4(9
M)H&;)K=.6PGS<XM&4]FYG+J'<^VHH,OZ,G11UT*=9C<O!)A3F?65YG-Q$2FW
M&FR4B3@'H!Y "2-H-&IVX41!< 4$+90APY)EV!#R*MX?$JDJ3M=MQH[$>?4=
M ,=XM\R-)D)=\['%H?V%"B.W@-R]=)SMV\MF[RVN)I8L/MU^VE46)FU&)6D]
M[-!$5&,30!\JN"T)O(UE  C5U8=M4I>FV(>E7CE^Y1,X*L"CE<K.<I&D&O^I
MC)KWA5&SK!-?SMSNT[L7:5WA4 -9>*Z2@Q#W 0O>=Q-X#(HG)'/9RNGZ,MA=
M.LLQ'I0 &@S?FN."BS[FR#XYY,6[<B9$<9(U#G*3V? ;"6/Y/++U5'R:[8/K
M1S+0T3W+SNQQJ2G_+,F&NNXJN%D10/A:#' E1)&_E)R[5@B=3MA11CK=CH^9
MO<-I.]I-I,=11DI+&,<%63\);OL4](VU"N:>^,;W&,DO=G9TC^TL7B4"6U<I
MLO#C:?QPF7EZ.-)UR('*E\#'-?Y3X!IUC#5T@PQ?)@1@HIWV+0JYJ=)G<.U;
ML;(H9)M' .K6M\"UI$1&$* %%?46)+H[L[OX,G.UFEY:4G9Y8'G@#64474;6
MP=K!6@VN+/Z JL<;CS?Z&/0?U_*%:X1K./RBGK]YF:I/K4_RK)-6<' ( 0SS
M(:-==1J.D@F.<1D$8(UT$ 6GBH7T.@7Y9A"F8K6QO\U9FRAZE8HHP0RF;BY*
M0$0V5^,MU%8J_F'=T"Q\^FG\NX<$T>]Q7<'$@C]-]ANYGW#VM8)O!Y>4T^"/
M>R2T>_?%PR\N&XK>E,I3[K-]_1XEM<BRYD3J^9[UPXBPDI>CL(J[%2G'ECC*
M<K9?S[<7R:U+3\]) :?%!B@KM+P<6@H[L+7-@(5$K?#'L 0(1[_;5<INR3>"
ML,3HM">(9CY*(<ZT9#@R?FP3G1\I7;-*EY>%/LD2?C(:>YU]G72=:WJ" ,Z/
M#\=Z$, WKK3!$N7;C!#DBL7#N/Y0"#HJ)I\J_"=G]WL;:DI#8,FR?'?N!R[G
M<L.91I&CIVLZM$NE,JV<*3;(;ZOVK.^T=-:_WN_SI$M&M>ZH[R;;3X&ANN%+
M61JW'ZLT@2]&6,/+R8YICAOL+F4O>7MFG*<HS7R%/%G#OTV<)#5 SQ' I+!/
MM-FN(N]B6+W%-\ZF_,*A2$=W\;=+02K#/\V-<>_TW,%MABSQ4'S:GM-YK[S)
M=DG.,ZDH)2"0SU[T?"PQ9BV[^'40#C]C //Z=#^&IJ23 3G>R556*<IRF@"A
M?!6LP(ZTUP>OR*7BYEA9[/]DC^\15EJ\@?E%GI"+6Z5U2MQ7H,-9GS?2B_TD
MX6YKG= M7$%*2K,$MTPM0Z55I=LF.Q+X:<4L6XY9G(6.>2]5?#._9@>VC/E;
M]F:5D)3!H?R<6H4B+X29A_RS8.#'[8NG-#I\-#IRK /"M:5NO_-,V/])+J2;
M=&-#-"?1[I5!N91H(;,%R+T<4]3;&P'<@[N4:O&>NO:X$&!_#"8!F!RC>^PU
M16P'UG]&J[@A9^U7H;_%-U]=[$DL:Q2Z=3S<XL>"3K<K+C6KWBS2N0[X7\D4
M;:Q4SKS=E(6<4[=MOVR?,QOF7'G68'];#R=7Y/O4[F0T^?-)PQ#N'M5E=AVA
M3>QJ?AD>;&F8.7\OB4,+-1X0K7O<=<99&;2=FZ:6:KEM:*S+\^.KW-)A5< '
M],FW>FZ;^NIJ&@SH1 8G\.X74#Z^4P>=QBQ4MH,[P_>'HAQ?1*L/90P%9#)<
M?]&*Q>'0,<6_YTDUT<Z, Y-\9NYEF:?+WA,[S/>$;R:.##7_ K]-28PTD>8J
M0%@! ;RF1\9B\IY3__7>0$5/I\F-)MZ10":AE]0L.\.7+N!.T0)^"WF[7T9>
M8_Z?:YPE+O/+I.7'G.7O[*?J4K)?MA>P[UL,-?=QJK.IW(OBW%P_Z[]=1-2N
MXYZI7/LM;/J3L7;R@]=D#$\=.T"]T-WYLM)*/L&8\AG  2TTHJ.?J;D?O9-'
MGMN9O'OE.^C]/?V&AT/[>9->EQ],W_\0)[U'[?%$^MM(WR$1=7B!UL:= 1VI
MUYPAG[K>=>2U62ECI$V=N:F10Z3ZR] =7J3OW?;TT\^PU)!KFD1!1J)OC4Q
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M@ _D;ZV"@;D<WQP;B*G:6<;T[48E(8PJAW[%08%;,)OE73=R+6R)'%^();9
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MSJCK&;\>.^(Z?-,BJV(E,5]@2*;.25JL6!I,I@1X=^R<2IW&O NG(M/MY%T
M[2&0D0R#5\333C*70V+Y"EJQO%I5%BEHU$"FY)T]S,Y;\8VTRY)B:V7,>5<R
M]60V-\[8UYQ3:EU/%OO_%C?E(9,^%+>76PL(S,24V+]8>%O);/LBE5ML)=UW
MYUQF=S"2\=?;$YT69Z;;VGKY;[NFP:!'@%ST<"/Y)GLS?E:W>V'+=&BN$DX=
MRH$:@LY3_4:]2.W9?9M(WRRES]RNLN&_.F?%3XM$87\]Q^B_6@-*G=S'OUA$
MSE_4"H",Z67\5;7_ZN>D*%QTF/ZJVK^H=13COTXDP]JJ%66,,]E)#EL7*FKL
M?EANU%._7O(;)Z)7H%=.W(K"E%-'_[_9[/^J2#DD@6^(9C@/,Z3'AE(31GL)
M3<RB-V(-- XBZ\GP2?O6#[8R,_'R_[OAYO\#")@PUOPT<V[;RQ=V^3EGQ!.W
MVG&$:W;-GE<JD\\<KJ+(Q)3<\E^U6VO].8.=RR(;"PAN3:.EN5K/"Q(F)H"#
M,/V?B%/\WPO/$1E?S<HG-54_J[9,<N'(NX6,*GR/%EKH7E1@"N"+V]%U@:G,
MZ$_03K*GMC0/Q+/GJ1H^E]Z61M,5M]N#G"AH\C5FI@ #LQ>D^A3B_"22R&XG
MD%1G*]=Y@*^;C0T)7"[@U*+;Y]+Y-28S;FU2WH\ ([BKEKH<[3^ZGN.U$U,H
M %T'C;SEY5LVLF>MB/CRK"EJ;3[J<]EOK0M\TKE90Q.F6?M#CO-[W]I=-%FJ
M5BU!8=.A8-JTXMDA2QN!<H-[V>."V&<*F_S[T16.#1$V4%_E3[V.N%&1)R^X
MJ&1A@Z>\%1W,QXPC(YEY_F[(ML\FFQJZ\2W_]%Z[;<>^N+?0GH[82=[8!>KO
MNT/'^QK2O]-8R;Z7%H$)ZL6EL?@,M)UTXN0=W</_(6,WLY:@"Q]0%_%M"3[,
M\:AXFALRRF@FHXC^K3)*40@ =1POR2#=.9W;.9OM</5GN'%$;\;*EJTZVO)F
M-BKX#!4NV&NE%=!]L4-NC9UFMX,MC7G<TX)32?-;^B8]J&&>@Y@+Y[KMY[2Q
MHP>RVY,FC0E#?PXJ+ZEY1NFM5H-L\2\S:??R-P[]D+,G@%C,&;&K[!E[-SJ$
M,U"S&NMW6ON4C+HK6M: J/^:(\'FZ.5"]R#![M%&^?:\6:1>]/5SNF-X989]
MC*O5/YK@8[E'W@T/,Z\3?*VP_+J34)US*T%>2%M]U[>/.K]08?5!3'_7>;';
MV8+S1Q;\8$O*7$I>*S(XOFH>+)%FHZH^N7_>%5C&=*KCF8"U#*;S=LB,P2*[
M$---O$Z8MD%=+7DEEG@3-'R[>FG::GV0^&/>"KOZ=0* N5?<669J_G8'Z1]S
MZV]LF05NI?]#O-3)72Y)&GW7?MK1A1QH\LICH0?*?^B@HXWQW %I]QLK4<UT
MP3#W]RL]O5P'X7U.3W@B6.X5A6YU07_B_87T-H=_[JK\]Q:1KD;;9Z4)SAIL
MZ%OBL3=P!4/F_A+MT#4VE@L:]#T!MU_&GJ7K6NI341.!U^-QE:RL!Z]AH6%'
M)NH3$%=E!O9$37EOA:B]H0U=MSD4.<2\YTKYRID1O^>M];0QW8P/'76\B&%-
MDO>W"K+^6FHEQCG)QNX44K%C7[91UG78-?(3&*GX1PG0OTZ"_2?:IFQOT%0^
MZ;(HJEH1<GAXW2>5O/+S:V$#NZ*">/O.4O5^^JF2MLTU;= :DY,T3SQF/FEV
MW(VNZ*KV<=OE5)Q'PB]&=;0@MJ8%WWA/PQP[47?*)[RB#M:J:&$]:7XJ\NGV
M&\AAJN V"K='0%7:[$&$681:+;+ILXCUOW&7SEOSX#?3>>N2J!F:($W1[* P
MT%_C3ND%P*0_9HT?":=Z R/VMGG!?UE6#II_,T\$E-ER/A "H/9ISH=7K;9+
M_GX^G8+Z^J<#_CU@AD4T+RIM!==XX[Z)XJUV?7SKOHR24_&@-\Z*^3&?S-EA
MF\DIYL;6+=6G4+A$D?A#VE1F36MYO%DZ0^*@;(,L&YLI 99X^[8'+'R]F8W7
MVICQA!%F/<#PY52:\&4!BT ?\I/F@D5%;"_1],1V\-0_]W/_'<$TO+VN'+<G
M EFYC;U9LGYOO$[YNMI;EA9Y,F"Z%C@!E]IFBYT"F(0AJ0  B4[/B3TJ;)<V
MV _QC(LIXIZ6$F,;D?B$^#Q]9=PO83AQALMB#*F93D]*54>YCXQ(=X8\:^M;
MB8EO;SO,J.K"YC8$5M=H;!*<<FQCS!,0'CV#>'A2'672Y22HJK4DYA2Q!#>Y
M[CXXR(8L']HK]O^)@>LH2FICYT-&ZJX<(L,79L+2SD_Z"._L,(D@+^CDWFIK
MJ0=KDP*\GKG^V\_C)"1,&,HZ,C2KBE$T%^FC6)URNZ7GT,%9:Z;#<I>-%3S=
M\^8,C>2B.3TA8XL\$SCR<B;_PA)8H'WE7:<-/U\GF&VC.P@8LYSDYQ#!&RRR
MP&=6@KPH5(V_EFU/!TR!#^T\P^*2(L3P]G-=<8Q_,NG.$Y4&QM#\]LM^BB6C
M13FP7>437>]:7@?I=C+)8,VFDZ5$BX(]]\H.#[.Q0^*E%59._:@ES<UUGTXX
ML\$CP#AC,]1^[_9<))PM<@K)L(W@W[AH3DA.^SG;0[WJ;0,YD>]Z\KQ5"D?Z
MJ+<5C*B+RAK+;VFL#U(8W]]?2=8DL$L<3.K3)C,50J5W75>C<[KK]"(N<KY,
MDY6;@&_1<J4X6D,%,*6A3PMH\*U@^?!D%U^Q638[XOPYL4SGU/T>OFM=+J9N
M" $IW$!9T!#(8>AY7/,9,XIO7 ?MONC0P;?$1/Z$$%$0?I$F:,LX/$P!-HW5
M"OG FB!:Z3AK%BACA#IRNV\/,IB? RE ;-#4I$D1L6\#M14R40,UIBG)U]N.
MDQ:M!)^2TI@K->FJ25LL:'<Z3U)2B])8+^0,BOTC=, ZY%AIJO/@_!!E94YA
M+$S(6WY.>VR-+<ZE.G& FQ<?":NI&/X00O16>.\T,+Q.#J Q<0[A4L1[LR@P
MW*?HM(I CW:\0F!8'_Q79VZ(0&K-T2H3=F5YCP!=^Y?OEN70,C: 36P5>>[F
M^MG-5PK^U+O<.^FOE U^@I3&H1)02!"[6ITPP<-JN]=)\CEK?O)"RN4S9KA[
M=W++=,9#G,5'I-%TGC]5?9P5)&Q N&/ML(@FDK.6)FE,W5"NMTN23FZ:GV:_
M97FNL>S2/?$RPC.#%WY_L';DLE5@4%)ZK]0P$54A7A!RR.6RR"MMS['=H*4I
M(&4Q'S1+=M=.[2LR^L>92@ZAUU1LO]%]"O>8/I)KF"J#SI6Q'Y"/3T&T@UZ^
MR>![/LOT2E]HY[S8G8:0Z^#U) [R11/0I4'+^NEE_=<@Q@Y=--]-VH>QB>G@
M0NIH.2<DY;0]/Q?A'X<'OD(@@'8<<1\CPT\PQ +C1N#6-AS&&SZN1=ONO)ZQ
M%'IE$*":  L#E0?E?3MENI_9@<K\L[LTHG^$6/^;%BIC&%.(HKG:6%^>OJJ#
M!W^[_K5N3Z,/,8(HO:6@(PNDF"^:&X9$T.'&4DO\)EV32&O2S5*7&5N@GA9;
M-?E*_FU/I"4_-:&N8@[4[Y#9;N:XH5A";^[Y)0$!1"L^^QR$J]-V_:T4-"OK
M1:)<H_3-V=V&:E#%8%4@T?KU[][AEW@+-,U"5#:3;&R:QTMQI49RSK[6%@G\
MS[#B1WE#<(A^QE YH72:?PK.@^/#(DQH.FDKQB[XR:*5IV@;,A!B\9_N!2V/
MX<3V^![?NJY:!2;>I R)L)%=\&S!QB4>?KT(F3:,H+ZA"A&9J1Z3&5O^$UU(
M^^\=/0+X.IJ-"A=W1.K"FX7M)>.IBPD4#S8J8S<;DN*UONH[->$)<WR>Q;M8
ML); G+R@>;I[:>Q;V#;):1JKU&2KN';ZLTB(24C&@[2_3#H[V<UD1FK7 9'Q
MF9]B?IE$F7(ZRS4%"P;KY+/05PLRV5AQGN=_[V'?<RO1XNJ?.?![,VIW&D&&
M?O=>D8=Q20"E!_@@HIL]IO0'UPYI9C:0"B_S._U]3XA%2XZJ;F[M8LH7^6N/
MV$;BKXB,%E;01\1.V6JSP]U'1?[FT_Z/9(^3V(%B7#C%Y,*$)2S;TBOAOH3\
M#D*B)J&)EV<&!H+?^#%';3?T.<Y/"'+@$_&:W#?AT>]=BNE6&;,8#JLNW]8T
M5T^LD0@_)UT>T'<;_.(9X5Y\RDM2L-A!M*.E7FCE&3G3164W!Z'6FH H=ZFI
M$K[LNML"YK,^\5G;?(L ?>[?1G=9XIDXM$R4G81]],Q0GC1+4%S3&#0S5?^*
M"D>UW,8%+U_; R<OL,K@!^\37P0#PHRT@VHW\#*#?03I'(3X2U25Q:61H3&S
MUYBZ,_DGA,Z[,\E&$<D+<=_TV3N EY65?4\[.M8='!SP[9S%5'.NPRXRGENY
MB?C5)ACD_5+"<9"!&H@F:(PW+Q"2:IYZ7? ?OM$P  T@,6]PFVK_=G&N&=U\
MS#7OPO8-8])MR+&(XS[NAFQX&HU1T$U;>]C;DJJ('Q_EH0U)4':=9(M<TDM\
MD/>)_!9]Y#-WSU:1';UW^@B@9\CJ&%GQ?]X)MR:/"ENCV>]J.1V,>01\4A!D
M#D19&#HXF"ZS0ACM>6Q>:;: S>\X,W"#%L2,]>I]$F/;=R+B=WJ<1'6-Y-YT
M_\TS_O'/,3__(]IMT/?1Y2^+!LDVU$F;'G=O+ *<JB3NZ9S'@B@=)\WJX<4-
M32/8D4J:T[G-YG<<#]4O%"J^0@4C&A8G@K!9T*BS@^M=R JN?\[?20Y/+M ?
MN#H3.LQ+T\/["2.::ID_K:#$3:1/<D6]J9W.K^;]^(N-ONG.;IJG_!,MP&UM
M(O54!9,VO'_TGFD5%YW]B, ;^T".8)4M\$TTN1!4D]:A X]"7'Z!\F*UI/]X
M]UQNG6$=#VJ0W<]X%1&FX9:R@3T\KA=%2K3+IUIV\>")1%F^13;Y,6D_ I[:
M15XZ\]3_>,$<VB]0&785&R,&:[H!9#2-6N99S5H+-.:%&^N_8PP\JPF@7:=\
M+KW^7!J-6AHN="URL9KNR?[FAI/>XQ'@+E'@SG<@M0#KI.J;<XXLZJ5+78?,
M637&'*<-)WH6 2\;H%K :?G83-RT3-$/&5:2'BL9UJJ?L%TTCJ/#N9JEO5WB
MNC'CR2V:"^>4JP/GWG,"7Z4 *"-\A3'R9L3D'"W*NO,4O/-WLA71BAP+<WB'
MN[^>3N!]I@OR9(KM5AMO9BO1VQ/0=82GF($QII*'Q_6?J<@0$CQ,=9I&?P_"
M)Q-^4GL!4OZHU(#;[.67]8'] _FOF^8*"IR-SUC+#K0!6E$+Y#1*_B8S]T*<
M;3,7#WI6)W(U\6EUEWUW#/NQ9/1!1#;1'-(]IV:83Y<=VR]*E%<Y&"!EG!*S
M,-P?\FE3^D&A:K_D,8=BI-?$;9(GFE^5>/@T@9UFA^T@?B.\AJ+9'6=-+-$H
ME3F#=.!>@!-KE0>-7L784;6O@#<+I(RV+F+$X3 JY(VV)+,&UBNO=3-Q7'%.
MNGP)KC%,Q)DKX[P"S_L_]IUHY3#OAC$?XA,;3,8D]@S_V[FT/>7/7?FEX2#Z
MVOA\=(G+C]C-9G3"J&1$24S!7"K18BP<;8@979'O9$QF?F=>):GFY@Z*F%2>
MW0I%'LZ@R0MLB,':?L@A\_KG_>G;X.[BK[-%-*T1=A^?G9T&. F1#G%FS-B?
MC7[J:N4:S?+XOARB_X*>0.%ELQ7<(6]16@OM?$'.1M8AKCH++:#KCL+G?4 J
M:H_4@O N+UM(2H=7*G<'=3([QR<];?1]$MT70&P[=J>G_N).*JBQRS-1$X(]
MTQMN4HR KQ2#])*4Q#?R2UZ!&676U#/H#<$%U^G>922&.Y6=!'J"252IG:)Y
M4(Y6*R:AW2[\*_(4]S51GE)P@HXF>YCX0+=8I2RM5!%%%6%, "Q$#>]IMW9T
M^_*'\@GZRH:D"R46Z"?/(T8>Q2[D]1?ZXD.<!Y*B0I*?B'M@GGZ'8T$W)&^
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M>M25BSJG4IX" '@V,GO=(OSIB<1YXIOS^MC%]6']OS XXE'I4$#"E!\;O+D
M2SO)IWO$,P[][D]KHX09W ;+Z66$M:^%F(YP+&/XU <R^\N,KY.7?IXB0-*$
MHXC[97KWERB;(73BSRYW6H(!S<,)DD3@TP51!?[!6"QBZ2?@1 P-[.>4'YRT
MUB*X;+<PTLQ6?45UVH(HV#I#P&96GZH2!#])-06PD]@M=@IC"A]\UD<,!Y>)
MW]=YO9EV;*[ET4](^!3Y'?.34RZ=Z4H GI#86I3%A O%MBL5M65E>47M1';Z
M*]R6@:%ZH?>4/R92/Z<^> YAW][[KV"J[OT!:4W0B5%WZ->RZC.8E9>YSO28
M,LWE%XOD3Y ;U*NB":MM?(/143%9SQ)K%O3N:C4V<(PQD89>2=\PUK"#PB^>
M;H;A--B\1YSZ)#N'R]X/+HZL4,C01)=:_OWQ:U/IY5T1';^XWRTVG>Z.P(+N
M N,>=KI:1_Z!^0,+=R<MK.6-FV/A YDS9-V?/PS^[;WD2F*SW*KGN>^GGB7F
MC][2M<HRNL,?(A?DOYB>G!%XCCRSGHG@]SYXV:E+@C!7&_(H(W\;]T3]6V.9
M$.W51>GFL>G4(Z"&T[4WUJX,J<HY?/N!T#$842S%3)/6NVFRRN]TI?"WK)#^
MSA7O?,KUTEQ^#)^M&67XH'2/YS-O5\E(-O ?+B[;6K?SX/?I4]$:Z,>'XXE9
M4%>O%I2Q@2#(YT=2/!ZWPE!#.]F(;+>-M3%KQ>?.+?6J-'K/@_SD03'[6IFO
MH-@ J;56-A+D\V]3C<VQ=J96R^IUZ7-DT8>90)]IXS0EOA67G9$\3S&*,J5\
M?7 D8RK'OFECD/#;LE837H&W#&X?')MBL+WNU"X,_$V.VTMSF_P[WE0OD_<6
M+HQ :.\H.L2K&=9KXQ,^Q4JS-@-RXP* 8LY]_&.[!K#TN&= 3S:N'TA#,"6$
MKF_1H3"SBO*)!U7)=U4L:_4E80(#4NK#7]MUR1VAT/#2^OEE.^F1%3;YJTY>
MT(+>,I@ R#&4VZ/*IM::KA7#R_N<[-MW(=MUU(D\P8]$OQ"6D3 [M!F2F=I1
M4&ZB],O]4SN/M5@M >>.FP"V"&@GZ?\ =D")O\8K5'BO1C9O<FYD4),(&B:V
ME6;S",A?**[R2.0-O3FN9B\%:N9))[G^R9GD%X6ADWO$QFEC=1T!QA",]C@X
M-3P^%-:B-O=">'S+.[6XM;&:]EGB0;&1E\YUWC(;(^4[<>]'8I[Z&P?&&C*L
MEXVJPBQ2W65@;>0,F9#'ECV^8;2NT$$'-17GBZW8V']G2*WFWJ6]PMQ!)&\:
MLCL#L;:PSM&#C!&<5@>+-*U@:=>ZK?/8>=+;VUN$AW[5<708=>H 8#/&3G@5
MH7/A;5M2U9-6NVLH;GSX2T,4KNBQQI*.&*@EB9?0  ?G/0K0T8?&NB+:Q&?4
MA*_D1322Q6<JQA7'RN>#L4X_B/'<U<F\4Z-!?BRDNF$AE6#>()#$)#T0R!=@
M8Y'!.>1ZUS=GX)U&W\-:KISS6AGN]*@LD8,VT.D;*23MSMRW''X4NI>%_$>H
MSHDMY;200WL5S"S74B (CJ=AB5-N0 ?F);)YP.HMVN1K8Z*Q\5Z/J5XEK:W$
MKR2,Z(S6TJ([)G<JNRA21@\ YX-&IZZD7A?5-6TYDF:TBF*[T8*7CR".Q(R"
M,C\#7/:GITVA^";:W^U6J:M!>&6Q^;(DE:1B$ ."258@X]3V%;ESH#_\(//H
M%M(GFO8M;K)(2 7*D;FQD\DY-0_A=OZV*C;F5]O^"44UG6[&?1&U"XTZZAU.
M18O+M[5X9(R4+[@3(X8#'/ ZYK0'C#0CYQ%Z=D2/)O\ (DV.J?>*-MQ)COM)
MQ69#X*ATN\TZ^T:UL+6X2(6U\B1A%FC(Y((7AP>0<<]#[5=#\$3Z=<6$-VL,
MUK8*RQROJ%S*SY4J,0L1'&<,<XW#T [4[7^_^OZ[^1*V5_(Z.^UVRMM0M+(W
MT44\SH=C0N^]6#8 (P%)VG!.?NGBH8_%^A2K*R7K;(XVFWF"0*Z X+(2N)%'
M<KD"L*+P/>"S@AGO8YG2^#F0DY%LD;QQH..6 8$Y[EN:71?!,]HUK!?I#);V
MEL]NDOV^YF,@9=F1$YV1<=0-WMBD,Z23Q%I,5Q>V[W@$MD8A<($8E#)]P=.<
MY[9I=0U*2#4].T^W5#-=,S,7!(6)!ECP>N2H'^][5RFE>!=3M;_3+N\OK>9U
MD9]1*@YN-I!@QD?P[5ST_&MW5HS;>+M$U%O]0R363MV5I-K(3]3'CZD4^PN_
M]?UU,G0O%5SJTB>;XB\/12F616T]8";@*C,,?Z_.<+G[OX5I_P#":Z):Z=#<
M7>HB4&V6XDF@LY=BHPR&8 -Y8/8,<GWJWH6DSZ9X=&GSO&TP,QW(25^=V8=0
M.S"O.-1LY_#6@:GH,=W837M[IT,4EN[R+*9%B$>(%V?O0<#H1M/7TH71>GZ%
M+N>OJP= RG((R*Y34=?UG0;BVEU1;"6VN3*/)M5??"$C9]Q=CAQA<'Y5QD=:
MZ.U^TA2DL4:1JJB-ED)9N.=PVC;SZ$Y]NE<M;:)X@N[J\?7+;3)VNXWM_/BO
M'_T>!@?ECC,.,],DMDGO@ "97UL*-FE?^MAUGKVO,]M#<#3Y)M0TY[RT$43J
M$==I\M\N=W#CYAMZ'BM_2=9MM7L[6X@68"XMUG&Z)MH![;L;=P/;.?:N?L].
MU'2VMM4UMK)(-'TYX(_LTC.9<[<N0RC;P@^4;N3UJ]X3BOM.TVPTNYL]H2S$
MTDVXX61F),>,8XSU!^HZ9MVN[?UJ_P!"5>RO_6WZE-_%URU[J.EVT,$VJ+>M
M;6<(R!L$:,9).?NKN.2,9X YI]MXJNXO&LV@ZC#%Y'EQ+#=Q*55IRFXH06.,
M@$K]",FH)O!#276L:E"\%OJ\UZ+JQO$!+1A450C\?=)# J,C#>M67\+W&I?V
MPVI-#%)?K;M&UM(S&"6-?O*2HZ-@C]:GM_73_A_GY%/?^OZ_X'F0:9XEU77!
M!:62V4-X4DFGFEC=XXT$K1H @8%F.P_Q#&/PI\GBJ_@O#HDEM;OK9N(X(V7(
MA=&1G\W'+  (_P N3R,9YS5?0O"^M:!9V5S%-97.II T%W')(R13 R,ZL'"$
MJ06;^$@YQ[U/+X5U">[.MO<VRZX+B.:-1N,*(J,GE9X)!#OEL=3G'&*>G7^O
MZ_SZB_K\_P"ON)=3U?Q!H>F7T]Y#97 A2-X;N*,QQL2X5D:,NS @'((.#[8Y
M)?%DACU#5+:*.31;%&3S>KW4P.-L9S@*#\N2#D].F3'J^A:]XATZ_@OYK*".
M>%88[**5I(_OAF=G**22!@ *,>_8G\&E)+VQT]XK?1=0A(FMU^4V\PQMDB &
M.<#(..0#ZTO7^OZ_.P_3^OZ_*]BS/JFN:.MK=ZL+"6TGG2&1+6-U:V+G:IW,
MQ$@W%0>%ZY]JB_X26\_X5\^O^5!]K5&8)M.S(<KTSGI[U+/I>MZPMK::L;"*
MT@GCFD>VD=GN2AW*"I4",;@I(RW3'O5$^&=8_L1_#@>R_LMI2?M?FOYPB,F_
M9Y>W&?X=V_WQVI_U^*_X(G_7W$]_?^)(/$]CI<%]I0BO8YI49]/D9HPFW .)
MQN)W=>.G2MK4=;L=%6V749V$MP2D:Q0.YD8#)"JH8_A4%YI,]QXJTK5$>,06
MD$\;J2=Q+[,8XQ_"<\UF^*C>#Q%X9:PC@DN!/.0D[E$8>4V1N 8CZX-+HD-]
M7Y&E)XJT:.UM[C[6TBW 8Q)#!))(=O#?(JEAM/!R..^*;/XNT*W6)VOU=)(A
M,'AC>55C/ =RH(1?=L#@^E8UGX8UC2;Z/5;-[&XOI!.+F&:1XXAYLGF91@K'
MY2,<CD>E5['P;K&B6]W#I]Q8W']HV_E7+W!=/*?+DLB@-N7]X?E)7H.>:/Z_
MX'_!#K_7]?(U[?Q;;)=:FM](@C@O%M[46\3RR3 Q))PJ[BQ^8_='0?C5R3Q3
MHT=M;SB[,BW(8Q+#"\C$+PQ*JI90#P20,=\5RJ?#V\M)4FMYTF-O.#"GVR:V
M,D?D1Q'=)&-RMF//&X$<=^-"R\+ZGI$UK>V"6!NO+FCN(9;B8I^\</N$C[V9
M@1SD#=G^&G+R G_X2>^?X<Q>(8TMA>21(X!1C&"SA>F[.,'UJS#J>J6/B&VT
MS4[BPNDN;>6826UNT!BV%<[@TCY!W=<CD=ZJCPM>-\.(O#DKVS70B2-VR?*.
M'#'MG&/:KM_X7LTT6\L=#L;#39+Q1%+)!"L1V$X8_*.3M+8]_2D]W;^M/\P_
MK\?\BGX?\5W6IV^I-=6B":&/[7:0Q AI;9@3&3G/S':0<>W%1:)XFU'4U@N(
M[G2;^"5&:>*T)26Q.TD!]SDOSA3\JG)SC%3/X0>QU&VNM#NY[9A;R6LKW-U+
M<%$(RA02%AE6 ..!@FF/X>U74M2L+O4;?2X)[(LQO+5V,MQE"N""@V*<@D;F
MZ?C2>VG];_\  _0%Y_UM_P ']36\/ZO/JGA*QU:>$&>>V$SQ0#J2,X4$_P S
M6./%6HR:;*?L]K!?/JW]FP*^71.1\S8(+$#)P"/ZUM^&=,FT;PSINFW#1M-:
MVZQ.T9)4D#MD X_"L>;PQ??8[@PO:M=KK!U*V#LP0C(^5CC()&1D XSWJI6Y
MG;;_ (*_02OR^?\ P'_P"!/$NL2ZH-!5]/751=O"UP8',1C6)9-PCWYR=X&-
M_OFKT7B:9/!E]K%S K75EY\<D<*,RM)$S+P!DA20#WP#R>,U17PSK$6J#7U7
M3VU0W;S-;M,XB$;1+'L$FS.?D4YV>V.]:%OX>NHO!NH:6\L)O;U;EG8$^6LD
MI8X!QG:"V,X[=*EWY7W*C;F5]K_@,TKQA8O:11ZE>#[;]G%Q.4L9H8X4()!?
M=G8, \LPSCCKBK)\9Z"MM+<27KQ)$4WB6WE1\.=J,%90Q4DX# 8]ZSI?"%Q=
M6FL6\MQ%&+ZRMK>-TRQ5HU.21@9&2._(STJOJ'A;6M;O8M0OVT^">'[/&D4$
MKNC(DR2NQ8J.3LP%QQZ\U>CE_7]?U<A7Y=3:B\8:'-)%&MW(KR3>1B2VE39(
M> K[E&PGL&QGMFI]7?6H\R:=+IT-O%$TCO=(\C,1_" K*%&/XLG_ ':R+OPO
M>S_VIMEMQ]KU:VO4RS<)'Y6X'C[W[LX[=.:L>)=/UW4[J""TBL)M("YN;>:Y
M>%YVSPI(C?Y/4<9Z'C(,O;3^M"^ID#QGJU[IEWJ=C!:006%C#=W-O<1LTCET
MWE58, N%Z$@YSTK5U'6-:TXP7[+82:?-=101VT:.9F61@H?>2 ",YV[3P#\U
M4]0\.ZW='55MX]-ACUFV2&ZS.Y-NP4H2G[L>8-I&,[.14T>E^(AKXNKBUTRZ
MM+9MEBAO9$\A,8+E?).Z0CONP!P,9)-:7_K^NQ/3^OZ[DL6N:I#XKMM)NWTV
M8W*R.T%IN\RU11E6=B?F#=/NKR>,U7USQ//I_B6733K.BZ7 EFDZOJ,98RLS
M."!^]3IM'8]:NR:7K&I:II\FI+8)#I]PTZ3VSOOE^5E"["OR##<_,V<=L\%Y
MI^LP>*+C5-.MM/N89[..W*7-T\)4JSG/RQOD?,/2HZ+Y_P# *[E/3_&+R-8R
MZDMO:VTVF&\D926PWF*HVGN"#P,9Y K6MO%6CW4@B2YD28SK;^5-;R12"1E+
M*"K*",@$@D8XZUSL/@W6=.AA.F7UK%/':R1DC*C<\XE95^4[5QN4'DC@XJ.+
MP?KJ:E/J9DLVG-U;W444EW+("8U=61I&3(!#Y!"X_P!D56ER=3KX-<TZYU"2
MPBN=US&75D*,.4V[ADC!QO7\ZICQCH):,+?%E<*=ZPR%$#?=WMMPF>VXC/:L
M23PEJ]SIE[ON[:VU*?47N8Y8&8K'&ZA'7) ).S=CCJ%/':._\"2M>WRVJQ26
M-]Y8=)=0N85B"HJ$&*(A91A>Y7TSBDNE_P"OZ_09;M?&CMK%KIUQ:EFN=0NK
M59(8G*HD1(4G (R>,\@#KP*T]:U:^@O/L&EQPO=BTENF\Y2R@*,(O!'+.1^"
MM67:^%=0L]3L;R-[5Q;ZE=7#(9&'[J;(&#M/S#TZ'UK0G0VGCRVN9!^YOK$V
MJL>TB,7"_BI<_P# :6Z2ZZ_EH.]FW_6YGKXRGFU30$MXH&L;VWCDNY#G=$TH
M/E!>>[*P.1Z5,GB/4;Z\BL+&.V6>YFN#%-*C,D4$3!"[*&!8ECP 5X/MS1M?
M!-_;:#K5I]JMS=3SAM.DR=L,<;;H5;C(PV<XSUK3;P]>60TBZTR2![W3[<V[
MI.Q5+A&VELL 2IW*&!VGOQS5:?UYZ_AL3:W]=O\ /<@OM6\26<EE8R1V$=Q<
MWPMDO#"SQ2(8V?<(Q(&4@K@@L1W!/;2TW4K]=:FT?5/LTDX@%S#<6T;1K(F[
M:049F((./XCG(Z5EWNC>)+NYM-1DEL9+B"]6X2R,[+#$@C=,"3RRS,2^22H'
M'2M33=-OVUJ;6-4^SQW!@%M#!;2-(D:;MQ)=E4DDX_A&,#K0OZ_0;\OZU-NB
MBBD 4444 %%%% !7/ZAXNM=.U"\M&L+^8642374T,:F.*-LG<<L"<8.0 3QT
MKH*XN[T+4M3\3^((TNVL]/N[:"&5FMBYE7#AO+?( 8 X)PW7I1U#3J7YO&MC
M#<WD0LKZ2.UE2!IXT0H\CA2B)\VYBV\=L#N0.:)?&MG 5@DL+Y-0:<0?86$0
MEW%2X.XOY>"H)!W<].O%17/@BUNK'4K1YU,=W=Q742O"'6,QHBJK*3AQ\G(X
MR#CWJ*/P2T5A+!%)HT9FE#RPIHL8M9% P%,>[<>N<[^OMQ0!>E\6VZ>6D>F:
MG-.8/M,T"P!9+>/)&7#L.X/"Y)QP"*@?QUIH:X>*UO9[6V$+37<2*8T250RM
MRP8C!&< D>F*S/\ A6MM'' 8YK&>=(3 [7^G+<H%W,P\M2P\O&X@#)&  0<5
MI'P6@TO5[&.\")J"0HI%NJB(1HJ?=7 .=N< *!FGH W2O%=Y=#5#-HU[*UOJ
M+VD$=LB$L  >3OVKCDDL5'( R>*J2>.7N-6L;>VL+N.UEBNC<LRQB6%X< @9
M?'!Z]0<KC/-6)_!MVTMRUMJR1Q2WK7@ADMV9"63:ROMD7>.A'3!ZYJO9?#]K
M!81!J40\M[K@685=DX&5"JP ((X/3'&*G6WR_3_,:W+D7C:P2R680:C<6T$,
M3W=YY28@WJ&'F8(R<$$[%(&>PJ>'QE93W8B%E?+!]M:P^U,B>5YP. /O;L'L
M<8]<5GIX$EAT^XTV#5A'87L4<=[']FR[E45"4;=\FY5&<AO;%7X_":Q62VRW
MF%75/[1!\KMOW;.OX9_2K=K^1"OR^9/HVK7,\EW97$,D]Q:7K6TDJ;% 0J'1
MV!(_A90=H//;%)J_BNUTB:ZC^Q7MV;.#[1=&V1"(4.<9W,,D[3P,GCG JMI%
MMJ<5Y<W\<"HNHZBTDR3(0T<"Q[%(&00Q**>A^]T[UC^+[2\2\U=-,2^6;4[$
M0NJ:>T\<[ ,JA9%;$3#=@EQC&,=*A[*W]:(T5KZ_UJ;J>+X)KNY@M]*U2X%L
MD;RR0Q(P&] R@#=N).<< X[X'-.@\76TETUK<6%]9W"7$=O)'.L9\LR E&)1
MV&TD8X)Y(R*JKX2N#IU_$NI/;SWHMV)1#B,Q(JE3A@65MO."O!(K-N/"AT;2
MM=G,IN)]12+RXK&P*E)TR48 %C][:<L>,9+>E.R9"NTCISX@LET_4;^3S([6
MPD>.20J"'*?>*@$D\Y7MR#6!_P )E)!XAN$O;2^M;9;.%HK.2)#+)*\C*NW:
MQSG@8+<8YQS6Q%X<B?PA_85S*Y\R I-,N QD;EG],[B365<>"[Z_OGO[_6T>
M\6.%;>2&SV+$\3EU8J7;=G.",C/.,4MF.]T&H>-9H[[3K.VTNZ2YDOTMKN"<
M1AXE9&88(?:<@9!!(P&Z' K5T;Q1;ZY/MMK*^6!M_EW3QJ8GVG!&58E3[.%)
M[5GR>#KB>\74Y]4C?51=Q7!E%KB+;&K*$";\@8=N2QY/IQ4NG^$I+7Q"FKSW
MEO)*@<;H+)8)9@W \YE;$F!TPJ]*:\P?D2WOC&SL=0OK62ROF6Q,:SSHB% S
M@%%'S;F+$@8 //7 YJ.?QK:6N(I]-U*.],\<'V+8AERX8H>'*E3M(R&X(YQ@
MX=J/A"WU--92YG#)J4L,P4Q B-HPH&0<A@2HR"!P<5@WWA"[TXZ:VGBPBNGU
M.%V?3])6&*)523YF52689/.7QSQBDNEQOR-T^-+4W-O9Q:;J,M]-))$UJJQA
MXF0*6#DN%'#@@AB".]*GC73CMEDM[R*RD,BPWKQKY4S("6"X8MT5L94 XXS2
M6'A-K768=6GOA-=[YI+@B'8LC2*BC:-QVA1&!CGZU1T_X?V^FWB/;2:?%%$S
MM#(FEQ?:@6SC=,V<@9XPH/ R3SD OP^-+.33FOI+#4((B(_(WQJWVCS#A A1
MF4DGC!(([@4DGC2UBDBMY--U%;Y[@6WV/9'YBN4+J2=^W:0IP0Q'KC!QEO\
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MN&FN(8(R9F29HTR&4@#"Y( '/3%7=0\3:B/AM9ZU:Q/]MN8X S0JG[LNRAF
M<X[D#KR1D8S4T/@Z[L?*GT[5TBO3'-'<S36OF+-YC^86"AUVD,3CD\<'-:%Q
MX9B?PI;Z!!.T44"PJLC+N)$;*W(R.3M_6GT^[\]0Z_?^6GXE:+Q;:VX6*:'4
M98(95M9]0DCCV+,<#:^TCG) )5=@)ZU?T37DUV":>VL;N&!&9$EG"!965BIV
M@,3P1U('MFLR;P=)*US:C4@ND7-V+R6U^S@R%]P<J)-V A8 D;2>O-:^C:0-
M)T9=.,[2@-(?,4;#\[LW')QC=C.>U+=,.NARNE:]J,E]9QWNKO;:G)+MN-+O
M[40Q;><B!]F788R/G8'VR*?X8\=QW?AM+F\^T7DUM&#?7,,:!(BSD -R.0OS
M$ ' 'KP=0>&;^>*TL]0UD7EA:2I-&'MB+AV0Y7?+O(;D<D*"?7KFAIW@NU\-
MV$A-P\UL]B]M>PPVC,;G+$JX523N 9AP#D'VHO8>[-74?%UKI^I"P6QO;N=I
MD@46ZH0TC(S[<LXQA5R<X W#WQ5;Q>EEIEU?OI^JW-O!/*DSL;9?)96QLP9%
MR,\#&2?4FH=!\+SKIFB7%Y<R"]M[EKVX\V,;Y&:-D"G!X(5E'?[M))X.U%;]
M)[?6+7R$NYKQ;>YL6D3S78D,=LJY*@X'XG&<8;5M!+;^O,VM&U=-3N;Y0M[$
M\/E%X+I$7RM\8;:-O/?G)/.<<5A7OC/?J.CM;1W5OIDUU*)+N6-/*GC2*0G;
MR6&&4')"YQQD5O:3I$UA>ZC>7-U'/-?-&S^7"8U4J@3@%F.#C/7CWK#;P-+*
MME93:JKZ39O*8K86V)-CHZ%6DW<X#G!"CWSUI==/ZW_X U;K_6W_  2U)XZL
M+>SDNKJQU&WC^SFZA\R-<W$0(!9 &//S*=K;3@]*?#XIB_M<P7-MJ=L[K ##
M.L.R+S&<(Q*,3\Q7!R3C*\#FLN+X<Q1V-Q:B;38=]OY$<MMI4<4F,CYI&!)8
MX&/EV Y.0>,;5]X82_O-4G>Y*B^LXK90J<Q,A=E<'/)RP./]FGHB=1DGB^U^
MV2VEK87][/$TFY+=$/R(0&?+,!C=E<=25. <53UGQK -%O)M'BN[J5-/-V)X
M8U*VX96V,X<C/(/ #'CD5'=_#^UE2Q:(V,MQ;6WV9FU&P6Z209W%]I9=K[B3
MG/<Y!I]SX*F%I<6VFZI':1W=DMG<@V2D,%# ,@0HJ'YCD8(]AUJ6M+%1>J8_
MQ%K.I6GAS29+-;AKB]FMXI);=8MRA\9P)"%R>@R"/7%20>-+9X25T_4Y/]):
MSA)2+=<S*2&50'_V2<D*N._:M&]T/[7IVFVGVC9]BG@FW;,[_+(XQGC./?%9
M_P#PB+1V%O'!?A+RUOYKZWG:'<JM(SDJR;N1AR."#WXJW:[]2%>R] ;QO:>?
M#:Q:;J4U](\L;6B1QB2)XPK,&)<+T8$$$@^O2K&E^+;+5KJTAAMKR)+R!I[:
M::,*DH7&X#DD$9'4#/;-5]/\(FTUN/5YK_S[PO-)<$0[%D:144;1D[541C@Y
M/O4NF>%O[-.AG[9YG]EP2P_ZK'F[]O/7C&WWI+S*?D=%1112 *\]U[Q/=Z5X
MNU*PBFF3SX+14G=6>"R#-(&E;L.JCMDXSP*]"K,?0K*:]U"YG5IOM\"6\\4F
M"A1=V,#'?><\^E =#F9KO4]!\226EBLVIP6VD+-(+N^9<D2/N;)#9<]N .,9
M  JUJGC=].L8=2_L^#[!)'#(&GOECF<28/[N/!W$9Z$KG!QGK6C8^%+2Q5@+
MN]G+67V'=,ZDB(%B.0HY&[&3G@#.>M9TOP[TR2WFMEO]1B@GBCCE2-X\L455
M5MQ0L#A5X!VG'2GUU_K7_(&4=.\6:[_:5S9OI]M=S3ZK/:V^;LQK$J(&PQ$9
MXQWP22:Z'P[J,VHVGFQVHC@%Q<QR&2[>5PZ2E?EW+RIP3U&W@ $=&VWA.SM=
M8_M)+FZ+"X>Y6%BFP2.FQC]W=R.>O6IM/T:72KF*.TNG^P;KB6:*3:2\DC[Q
M_#D 9;OW&<]:%MJ+4YS4]<O--\;W\MS&\MK:VMLMK!%>.N^69V093 4DGC+$
M[0H(ZD"W=>,[ZSO4TN71HCJS3Q1"%;S,160.5<2;,X!C((VY';/?6U#PQ8:G
M<WMQ<-/ONHHHFV/M\ORF9D93C(8,V<\]!Q4,?A"S%Y%>W%Y>W5ZD\<YN)F3<
M^Q655(50H4;VX ')SFA=$QO=M$?B'76T5;&>XLS).8IY2D5TRHK)"SD= '!Q
M@$CCKBJ;^-I[55%]I'E2SVT4]K'%<A_,WNJ!6)4;3N=>FX8[]JV]:\/VFNB(
M74DR>6DJ#RF XD0HW4'L3CWJO>^$]/OVC,[W&8K46J%7 *A65U<<?>#(#GI[
M4EY@8=GXBU*U\77EMJ-KM:>>TMEA2Z,D<6Y)&+J2HSG:,C"_I5^3Q?,^HOIE
MCIBSW_VN:"-)+CRT*QHK,[-M)7[X &#SWJ3_ (0JV:6>XEU34I;V66*87;/'
MOC>,$*5 0+T8@@J0?2E3P5:0CS(M1U".\%S)<K>!XS*&=0KCE"NT@#@K],8%
M C#NO$VK1:QJJZA8F.S@MK)Q:I>E)(WDEVGYD7GGK\V,*/[QQJKXS<I#?-IH
M72+BY-K#<_: 9"^XJ"8]N I8$ [B>G%3S>"K&=W9KW4#YD,,,NZ57,GE/O1F
M9E+9SGOC!Z=,/3P=8I.O^E7K6:3M<16)D7R8Y3DEA\N[J20"Q )X%#V_KS*(
M="\67.JS:6+K2EM(]4M6N;9EN?,(VA20PVC'WA@@G/?%+J?BJ\L=1U."#2%N
M+;3($N+F8W.QBC DA%VG+ *>"0/<5?LO#=G8_P!D>5+.?[*MVMX-S#YE8*"6
MXY/RCIBLJX\+3:EXFUB>ZN+NWT^[@@B*02(%N% ;<K9!8#D#(VGD\TW:^GG_
M , 7KY?\$HZ;XHOK:YU&XDMC<Z8^KK;K.]R=\8D$84+&5(*@L,_,,9. :O7/
MC.>QU>"RNM,B N#,L,<%ZLMSF-2WS1 8 .TXPQY(SC-:+>%;!K2>V#SK'->I
M?$*RC:Z%"%''W?D''7KS5&#P%I\$EL4O]1$=K*\D$2R(@0LK*1N5 QX<\DEA
MZTOZ_ %YE&+XBQ#2;B^N;6T3RVB15BU!6"N[;=DNY5:(J?O94@#H3TK:\-^)
MX/$ O(T-J9[1U60VET+B)@PR"K@#/<$$ @BH#X*LIG:6\O\ 4+RYV(D5S,Z"
M2$*P9=I5!DA@#ELD]\UKZ=IS6"2^;?WE[)*V6DNG4GI@ *H55'T SWS3[BU.
M.MKRYUJ70TGN[Q(-7GN;J3R+AXBL:#$<892"HQM) (R<^M:GAKQ!9P:>MCJ>
MKVZW:WD]M"+JY42S*DK(O4Y8X &><FEL/"\@TZ&REGN;.33;J1K&[MF3<8FR
M0,,&&,-M(8?PY]#6[I6F0:/IZ6=N79%+,SR'+.S$LS$^I))H6W]>0WO_ %Y_
M\ X_4=7U;2+CQ=/)>&:6VT^"6W15Q'$S&4#:O/HI).2<>F -;PW)'%J$]J[:
MS%<M LI@U&<2AUS@RI\S%<G@KD8X^45IRZ!97%WJ-Q.'D_M"!+>>-C\NQ=V,
M8Y!^<]_3I1IVAQV%X]Y)>75[<M&(5EN2F4C!SM&U5&,\Y.2>YH7]?B#_ *_#
M_@F3)XUC@U.PL9[(HT\T\4[^9D6_EDA2>.=W&.G6LJ3XH6L(=YK>T@6!(WN(
MI[]4GPZAAY<97,A"L">5YR!FMG4O NCZI+JLDYN%;4_*\XQR ;3&<@KQQG S
MZU:F\,0-=RSVM_?V*3[3<0VLBHLNT  D[2RG  RA7@4ETN#\C%7XCZ?)JGV9
M39_9S=_8@?MJ_:=^[;N\C&=F[C.<]\8YK-\(>.)YO"4TBVMQJ,FFP9N)'E)E
MDD9VP ""2H'5O;@'%=;%X:BM[PRV^H:A#;-.;AK..55B,A.2<[=^"3DKNVGT
MJI:^"-/L88DM+S4(&CM3:^9%,$=UW[P20.JG..V"000:%_7]?U^ %&X\3SWO
MA:XUN VZ-ITZRDV=Z+B*:,8WC("G[K,,,H((!QP#78R2;(&E R%4MCUXKE[_
M ,*,;"ZM8I[B[GU2:)+ZZG,880KUX4*.@*C SELFMZUMKL"]2\N!+'+*?(50
M!Y4>T#;D 9YR><]>IH?PNV__  /\_P!06ZO_ %J<Q8^-=4OH;1DT"%9+VR-[
M;*U_P47&X.?+^4_,,8#9SSMYPZ/QV]Y83:AI^DF>SM+6.YO&>X".@= ^U%P0
M[!3DY*CT)K7L_"]E8_V=Y4MP?L%DUE%N9>4;;DMQ][Y!TP.O%44\!Z=%:"T@
MO=0AMGMX[:YBCD4"Z1!M&_Y<@XX)0J2*IVOH"\S+UCQ3>:E81W&F6YCTT:G;
M6YO%N2LC'S4W?(%^X<E?O9/IBFGXCV=^KPPFU1+D316[17RM<*RJQ#/$!E =
MIP<GMG&:VY_!5C-+^[O+ZWM?M,=T;.)T$1E0@AN5+<[1D9QWQGFI8?"D$ :&
M/4M16QP^RR$JB*/>"#C"[B.3@,Q ].!B)*\6OZV&GJFS.@\:Z3I'A&UFO=3M
MYK^*QADDMC<H9W8HO4$YYR#D^N:@3XB1-:WI6VL[FYMA$Q^PWPN( CMMW-(J
M94*1\WRG Y&:Z5M#LY/#Z:+*)'M$A6$$MA\*!@Y&.1@'([U67P[)]GE237=8
MDF<H5N#.JM'MY&U54)]<J<]\\5<G>39,5:*1S3^+M3O=5TPQ0VGV"6VNWF%M
MJ D67RP/F214SWX^Z<DY P,S0^.;E+1I8M$+V5JMH)9&OBTG[Y$("AE^<@N
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MIYT= [NF9]GNY,W.]:#5'1SW>CO_?&L8O[W^KU;+>(==[*,06\9H:1Q[L_G
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M%Q/VK'CV7)))Z1UQPV5&\%1@;3B%VZ#;5QNR.WX5<@:5H5=@/@XPZ/_5@S[
MX /\1*5Q&HE\&LD'J0>OPPY:7?5RSLMG*SA,GGAW/A=Z!)H:3+/<R;TK+_??
M"1][Z6EK",E*?:,& /KQ>E)A=8UOU(2@2JTX<=NC.]'JR@]?&@Y.RW-30(CP
MC\LQJ/$JT)%[(:ODEP)XY7DQB:5J=T++3CV07GCT%-DAHI-"59IAM3,E*3G6
M(=-R?Z30^!"(R.6-(:(LVK/VDG6T'X@)GLUCAD0?'O**7#4ELTHMF_F#ZS8,
M7(8]SM3$.@@#XE@M@=!JU7>S?V\(._I(#*F%T0.?ABI'ZFDDG\9KPI +PIZY
MKH=Q2566'M+55*4)TIQ=9HM0SM\+DOW_.F"*<>-X\XO<^,X9SS1F>D0G443
M+R1#) :DWDS)#%X-)D9HIX$3RET"'3&Z'NJ@.2L@I$JA%R0KF0V4VCHS9XO0
M'EP1Z+#>9JJ4Q)HK? R?&[()F=]XSI/G9Y[=7$/LK^?]W]!YK(G.H(^Q+NE5
MQ@)#G>^*:59@ =UC1AWN<(Q:#5IB-:*OE;2R?BE-W>CH3#= 'Y+!K$U9M/[<
MMR3F&,]H^.S-R?QL^\A6+<G:Q(V]9PR5K0%X2)S5H:?2D&.CQJK.MHCUN[\G
M'B4,'89 O.4Y/S$?F\-^N\FGBT R50/PD)BJ0T^%@B@@IGYRZ&\D=AK:7L#S
MLQ;FH%E93T75B<90^C;S[5K0MW6 A\1/'7HJ%2:9-;(.74+FT17;2KF&1A @
MACZDFM"'Q%YMRBJ4'+7G\6T8$R1OA1#,@%ZH8E+!%BG5P2OT^U5(TQ?PKD(*
M3;'J0A_J\5.BK%(U$9R*G5'OF>V(F6$NP3!GU8 .RW6H2DEYU8\N+],\*HYC
M;GK-:TK)\_8"=\3-LI+SB'B5L8*4-,.E!Z!96U%.H9P'U.H1%.NAV3D'!7J]
M9Z8&_?"J<P1V,_YUJ0%X2#>E#CWE-3F&3.48\/^X.^+9\?EM?<>>0=1S\P30
M23"O_J+TR2SW_M S>?GJ^@G/W6?_6#G!DMPQNEPN%@0\O;-CY/N2@JPD75TS
M5J&:IW/Y[).X#2B.U)+F*A4X1C-8O.6*;8%IR33K8/J431RY#@IQY,^,3H*'
M;3 9@.D(0G!Y09"1#9(E44XI#W/E/Z0&;I02LI1>5)B]7T,;(P88#.?H&]&W
M8'63 PV+V>4,!F80K^TPO Z+05D+QJ0N>-^0^:7]WM_!3W-4KH.84';;3(.2
M#Y?["/,?R5R_W4L["/T_SA!D+#@+W.5GEP:?72'<C91WAISR6K3:P;WLGLF'
MD"H&2)K9#@Y["*].7.(7P@+;[Z?<@J@T878GL="J7@YO6.XB!?H552B--7KZ
MI_R.N'RPL+?PW+P\B;><=KB0Y=U&N MK9RX^A'6#Y 2GV'3M05S([:A7<%.6
M\P5>-GSKQ DE(>_V>Y9$[)4014XP/W,B+PJYDHG8SBM>>:@B_"E=.D'NM][7
M+G.^IE5P.[C31>Y7X[VN<U9@51W#X&3J,2GH?T$BEWJ;'&[*BFF%%0^,^F<^
MO-/=  &K1Q-4A,KJUX03=JK^[Y/UVJ';<''O+8-4[01QGE[*6ZPPBK@EM_[1
MV34L%CY8'NDT-@ R;4/81"2L4Z4(U*Z!(F=JI3Q=D8YVSH0@..JD2N'\8'1&
MP[5F5#'J17R/[$K=D>$^V6S\5.<@G1,UF,;.G.R9$96<"KSDA '=A/F/>P30
M#I$A$A9]MEJ24#Y<IO16[-D!?MRN'(^FC>$^$8?C5.D- 64M[H"4]HYTG!I!
MM8C"UZV+=5R:85D\%2I\+!\&"=%49!ZGVQ)["I)][(S=+4T9^JWLKET^4"E6
M-ZF'5W\B&C*H-)8T]00=AR0%D+#.@@D&W3N*6W!9$@&6D]N.F9:[M_,6 _P(
M9;TEL_KTFOIAJ+ODH/R.T>>XJ#;' O=EHX6!:??> U#"\N'2K_:Z-D<"ZV@"
M(]>+)Y2)6!TTB0)EF)W#S>-3^0Y>O'A5*G'=-AUGPVCSONP Z<#6@C#/W;L@
M3W'-^P#Z72B 8O>8-'&KVF=(0".I0"-UUZR/H+%KZ[BQ*/CKAZ1>^JBA&@KK
M,:0!N<7;Z)B$7$SPCX@Z7'NI P;,/YH5H49:2RYLCJ"P)RC8+;'?<9IW7VIZ
MGUY-:>_>?5O\H@ *W65GA(RQ+T\9[ED9+MH%U1(;NQ<9C$!5KKRVW%%PAZ"<
M8++DF)1<-* !IWSY.[+A75.#)5;+:1$8XQE(!PMV<)TI0+2;3"%A9>7B4B&?
MG2LK:Y7]X+S".R=V2^^WBR3O39#:M)$Z7!1+V!M!V;T:%)AXT"&J@6B6E/HT
M2WM84I)%=-A#Y\9STVZ@N]]!"7_J_#P$.*D!J.7@UEK0*-]9!8) _%O@;%F7
M&S-KER6G239+#_[UVDL;L#/!9P\O?@.1H#&9QE!E[B%Q0E1 H=\!>K!;%*NJ
MP$$+ .D!M_?2-Y*$:MJP'IEMI0S<DIC/&9D1FCYG@'-P+AT:L'WSY1\9<DA'
M1P2EA1>LM&1*%ZP#(89C]7$@X5M9T!LH9>6V*,<W'JC#WNUIMXZ&N\*HCE8
M!4G"I>#,"X(%*^/?!3J0[;XA5)E=J?O5H:LM9U'R%)'?$W9'73YC9(H=KH_E
M+1*!,?86'2R(YB,2PK'K&9*PK>(9$I/*6BK+01+TV3;]%W@D<,#)]X\1F2XN
MH]A;,QT%W>'C8'&+&8YZF?2'1%%3RB;UF.Q]'=,LG.!%OYU3,O=B_B_PQY88
MDLUJ6SVV--)+.H3/-$^2O]D.VOFD2@0S,U(.<T!<4Z.A=)R>495$38IE]0J
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M&;R>,TJ#< 77Y/&Y-K&L."STY"0P.3!:"_996QF0I^"0^#UOY+3-.KM-%[N
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MP7SSC/NQ"7]Y,WYDNAC?%WDQ[+)9XI:7I)B._5/*Z-(4,B/7V_4C+$%*OC\
M.:S#G@U')<?"1CYB4Z?->U@[T^'#OD.X:@8<")"!O@$9^G/('9PKA8'P]P9B
MW41"QZ_[0JZ?][C@:>:]^0RTMK2GU*JW93<81G%">2Z6=D+!+](<G!59%I75
M+P,K+NW)G>)GP>%O)7Q$NBY]@K1;U/_5\BYZMJRQ9)3\GTDDW(BN)=@6>ZLP
M!%(49,?B9FS(AB;2[6.$)'2UJ7$H(8ZYM'TSL==_,/?X+B<"I+1^6Z)4:*/
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M#V\G,A/H98<)K\+G0F@;.#S!+0#;Z5SV0#MHX3_X,)[&*=ENR52S=!=8ESY
M^K:M_Z0AO/@4E<G5FM118+)^OM^L[F%I>3'8YR]8 EB;HQ =:\@?^UJ337/
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MY;D>BX*-R9(D-F9+=#Y6IB^ LLO.BV3,C2P!.Y:7FHB*L[CC46M*P)&V!14
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M9-KV,/?;205$*-Q.CDV8Z>VD@%SWJ"84C&4,S ?&$BX58;SL7@/.',8*B%"
M\=B$F<(8T8DA3*H+-!3VP:$@0MXRAG6I^S<M-#D4@+?MI=' 3)@N3L!$DQ:
M*Q*WV#T"V4N:SJ\0L([2)"CL#1'$8MYDDOV7,#/@DE?"[+N2%*QK$<$4[PU;
MBBZ,',UKE;'$WN.4G&[<I$(RWEU-(DZT=0Y-8-J>:TB,#7/R45,TH1'*D[@(
MBGN3-<$MQ/:+NB2Q-A=%2=Q0G#W:(1A5J(?=+Q4X5,*N,%$A@6I([Y$A&D1
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M$8AEF$F&-R[_2IS+!T]ULQ,\"_^(^32;*V;!.W\GJT].RWOJ62D[HLR:71N
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MI<71CE8X?X9EG%;PNDRM1TGZY'R&QTM[HU/=>-M&@+0"J&- .."LX3DN8/M
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M9>;EGT9XP[+JH@B=@R0(.IV>,(0B\WV:4.%QEMX&Y10EG\G:]NAF"/S">1Z
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MG 5E# DP2YL U 8&QZ6*Z%BTC0[7/#MZ9Y)0&B=P692PIX?^4]5IO,@39*+
M],&7E6_&39"2!=-X5M"P1+/2;D&/8IZO+JQU/0E!?#O9?$J-5P0ETRIP'&"7
MYANDV/M=;8<=6+4,.=&Z9IQX=V]/8%:P!-H_!ST[6D##OB(WGZ4)[F0#TLWJ
M"@_KEI%PIH8)NP)<-W\-K;>GXV$BL-E9LF"_G"^7$">E[$G<(%M[:*=[,EX,
M6 GATYC K\JYL([J#1+<%ES !($@8VT7W#\.(&Y^M6?<A#?1;0!+<,UH-MNF
MQT0U<L^G)4S2NKJ!%42S]&AY;1@RX=V*,>-3L!K:/Y. F@0^P:Q8$U=)3)N'
MK 4\#14LL"=,V01KIE].9W )2]0YHK&H*EA7Z%CP-HWN$>TZA94GE:_'15!M
MK\6J8G!)D6,O%_ZI?H2@I4!4/:5!U@!#93[JW0@_?,VN/[.F2GV/4N=_Q";8
M:5266[2CXCN[RC+D=2B',-<U^!,]HH U*-I&(,/.EYAM%AJZ!K)GX:H[0<:F
M^1ZA;A<8$'%D<>A2]W_5K\GA5"-C)F!5 X$4L KS9/EAB$*<DP&7W( GM&-2
MR8F5SG^,&(_L[8_8;=S\KO&;#X(Z\^0$YG")UHLXNL*#@IK,HO<#DXM1:(9P
MABW4Z!)I8\O'RD1/.(0I\(27<_D$L26\B.-R$V7TS8/_Q23D9(YK1L2LZ$U/
M\PTQ @K\8=!+$PNXT(2^=+Y,$V+LT7T+T2IB#G1#$ N>P(WWXOUYVBA+ IB1
MST#6?!>L\*>><+I76VJCMF9Q?%<4R:<TRQ D+_,:36.*3O_T3ZZ5GXQT>&TG
MX4X8NM-^-K_#MX*8I;IL;#9L;L^7^759Q+#JC&Q$]*P_,KJ&Y1CY6;B+1I@4
M(/0T6J=UE.&G8.#FY]%J_;NS]G%*4#>_*02DD%69(AM>(T8UOX?UXKXBJ:[<
MH51 +S L^5R)8F9:SWL=/7<;]<#='A:$<I$*4">9 ?.X@<UJ%97;JR5^7]T]
M[/R$,W\[NRQ2(>F]4+P"4PIW0-AGSKGU":GZ="0\N,Y1G1'S!WG[/>_JV--'
M_/3G,E^LBHWUC5F;? @-J,ND:&,F'X$T!T]MAR!J>PRJ%4U!P&+5:)(LQ%I]
MR,ONZ3NBU'J:;HHLNZ!^7$_7[MJ,A(T0UV570?.R71+-VW8:^J0T'2W\2W:C
M.33&O(#:91Z7V'N 3>!-AB]/2=CC!BV]O*;)(-#7UT65DMA'R_BWQ%2 *!0[
MG$MU?05*F$5-@E)L!J_;9NBGCS#'>P$.4HEI[V"+CC!AKQ#L8HQ=-1:GVRCE
M*,UJM'@H8?.,&<?#Q/A4W/].L$D(O*EZ/?JN<J3%G0#%M _0-VA"IT@WS*_#
ME1(QDFKGAM6?(\/'ZZ?%:I76+0T:DOX \Q@=(]V_F-0D[OO8I\>>2-]VG1"(
M#GH)'*]@)GM6=1K,D)4,+5'U>(%L^=O->IV1Q1!E3.H 7SE6M+@(&LVJQ:I)
MJC2F7X") 4P-7.;+HES1\^1-;V^0*Z49F=Y&<!*D+-&>:-.KM#X@$<]FDPW%
MM@TM(.(_#)#/B/"> 0%P':4)0/ #$3G45\BBC;--@A#8F+8KU!.2"=',"-+9
MX-HVM#=8+ET6>Y*9,30)WL*J@G#8;^M=WKZ+ZDV)_NM4QYIPX-LX,.#10+%V
M_5.ER3X. +>/Q2?\%PSF/E\M_:[%0=@SVP0DL1 WG6IS4T-*L9W;LPU\C^C=
M?8+9$WR';)]'V^K7F(U9+08)HX(5@2;B-Z'-@ZD04 ;PV/2X1_'?8%3>?2H"
M@;>E[M^HT.10#-:O0E[A&4K9!)_L1+@P+G9)(23:3MVK3]][+)@VBV)@?CWC
M_5\F;&-P=M,Q(2+L/"IQU;CJ&M)TDZZL7#&= +X"(3.2]W\DY5)70"4LU$:%
M-GB-+1VLA7(!._V?1!5)Q'269AN<V<Y3@@TM+L+FUM!A5>$81=H3?VO3 ]C'
M*UC4=9G>;VK<.79+D:<SCT66(+YGDHK7"$B"A!K:4SQ]'2SR.DUP_^D3O(4Q
M/J>A@^OY,W7$T!PXJS62 $T/Z4OQ.F P9 YL6X-027"-2!V>-;0 36H!6DHT
MK^EU4:,-.<5^X)XJ;BM>B:&/>NX RU^*5@5F:(=/Y,%)R)T=GKS;ZU;8%BP^
M6MHAPLNN)0&JCD;HD@XV,32H^&!M1B<< YH+J^NHK+=W991744P"/=Q?B^M0
M#A&JI\&?,!\#O0PD70"VC\"0-A#Z,.&UWLP81]R1=YM-+)*O/$YJ- /<#:KP
MI6#<#$&YB&-Z;W@=;<D) 9\F""G0T!)E:@IQ7:@#A\'MH?+<F1;'V-Q7\,<-
MZO[\21+(9N'=B(A.B(.MB!D1"KOO 6T0]O@Y)K+A0Q#94$V/D">;*LUA5:%M
M_C[-R3;?EY&[3/ !8YE&W1O01?SC)BU)[4<&Q.AOFQ5,]M%M&7J.F;5FSWY#
MT9N3>^)$AE^W(Y*E9T#JEQN"$4:M^H$ANYP\S/R48HM/49IAZK@24Y3!,WA?
M]_8Y$N!FM2%[Z'<E.N#CN&KZVA<?]VGVVKOHV?:AT0I/ 1:9%<8%:XDT 7T;
MXG"!U0&-S<,%=I\0Q39L^EU4?H34#7K+.UN&.%K:1-K@:&EMUB?E'!@0W6&I
MR0M>;';(MT\-\(48KH9\_)I&"3!,X\\LKR^WO-H\OJHO/:=C$J:%02NR1LW
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M]Q;P^PW.-(!^(!W3 J>7N9=3U#AI;\:&"7=C&\H^R,*>EI0E+3@KJ4V(W]*
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MV]#WSLEC0AC="0_IMX B8$_HWJ4NF_M.YL(AFH0I+6Y.%V8+G=_2Z^F-RX)
MVOA;7. 8K_&*O\8#V#O2Z>\D+A[G!/5^"\L45@MA?*6NSE?LS[M#4H,YZ?Y
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ME.@J [4]/#HZ!DTKT#6;A9=:2W+]O87RA-A U-VGPA*BQ#T%1)20*3FB7K\
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MEPB?%WPL]M_F8+_$<T.,8D[7+7$$CZ/L"9YO\AM"552+XCY]?+(>Z-L] %?
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MJ4;,U&TA#BX,L(7T\C+<Q7*;9_>X.3%&)%V!/?6:6BW.D+-;?T]$ ZBF$:_
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M='MH_KWWW,O/26,P(D<CZN^\/XRB5",2/F3GH_BQV>=BH[ZISKM401\0"T2
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M\E;#0'AS1?F_WG:#]B*L\5!&F)9Z'#,#1X/5J"BMX$!VT:<KR.&#^$*8\M!
M:U,X)G:*84BBVYYG-.HK.H@C[J=S!'/#"E8)/O!P-_'J4.*U5Q8*K=20-3(E
MX>LNRA/S?O 7;=.0UEED^]  LHT+/)AM(?%U;1GKQZ7WNT_LE++ZQ^7S=X]A
MJ 6K@4YXY#;ZS,% S54Q)E]?T$U>U#F<$.I=%4E>K-,L*0XW%=V5S?*1??$L
M#5 9&50OQR7UP$RIA9&U+%II]=,J>'8B7V+LAC,RT;2-SKYF@05 I?;W JXH
M(T@'="4&Y$I[VJ:ULM"FJ4)>B(*U))]4:!Q8;*[96F:K--G*@!8SGB!06C)2
MD<Q-4CX@K:*_/P'0X)_HMBKE;Q!Z$&$'!PT9%).R?SXVR$'9%"0$U5C%4)G1
M8J,H>_ZKW-3S/%D35MXW)Q+/*S24LZ.!V.<C\JV3BL@N."!\U$? BTK3J@U@
M3T@+BLF<T^>C,Z-$3L,[YZ+'UYP5#7=92ZDNZQH_]_#:6R.\M<3U4B^NA*VB
M1LTXJ.D$3?12'BK :0'EHK79]!0+Q(+8#?" "80KF6GH\-Q%:L"7W@SJ) 0I
MGE!E8[\"MDJ:P%92<)PJ6(<'R::[RIM380T\FED"ZPI(2Y2SLH0TVLQXQ8?:
MDA?5_&XCQ1J@8Z<[R!J4U7/Q]\NY5:J:?[ZY7MS?WLQCW4=B@CK_&G,.>,](
M"[G2ES5(BN%E)SX53#&/[99UD>2*9K&S(*S*X!L/<,NN[>5WNGVA/)EC,$"'
M,8QB1O[*KE,(1HVK!X[EPC$1%F:.ALQJA')8Z)LJ%]\S)NX]I<_2/'63W25%
M\ICW5!:I>R"J"V4IQ&!CWDMT[#5_4CLRVE N!<L#:!7,<M4 O*7?\4_60NGM
MHF):_;U.$5DA/+ ^^=_+>,LZB@>=%3Z"D[%*-XE(2'7)'!<T6M_5KL#1282-
M6BEV/;;># MLKF.*'Q0# YQ6-K'Z$C&E(=8?$_S:@.<<"<:C0X+1]F:G-7@I
M[C$A_?QJJ+.GRW:UMU_9>T#7H FNP.>?P\]:^4+N03Y?I3]Q;6L3-!7_XY,D
M<I90U1M^I9>.%*[]:*#'D5>H\SA,8L>$#2Q84;I&CZ<1:=(15X -N:-9(7OF
M&TOA^#C!!&[:++$$/@P):*/V$LUMDG<$8ZA;OC:+T$$K_!04S_0.L,'^)>#T
M)/YBR0%3=^E^5]YD+[0'DUSU1M[H_;U%<%+9)1I+9:<0)JFZC2MNC6.%Z= <
MP]10"A0$9H!'L(E_LL@T%"*(WA4_P@W=.O2FEUQTV@&,(8NL@>@$/1/5-3S$
MYELR_&D]BBV=TWT")H<5RB_V99I1IAWDNX<TPWU[KTJ7W:PA67R3@K-2X.IR
M$(9U$U^7_8V]^6L1E.]AY92C$FW8&:D')OK($MA8CMU!.!;#J^P&_8\QC?OG
MY:WI'@JQFB%#<E3,,0!]H_QXS_Z_2$&"Q"/S+4NKH=E16EBWZI;4_0I;$/;L
MFR$5-;1[!&^,WJ7CF1U4M=T_E*LB?19[G*8O,"$#'*91 =4:D[HUZ3AMX^F%
M/N1UM3=_I@0\QJ@)LDV52W,4]P:YR]_IWXM0W<@GSD*&Z2PY*9Z0Q^L;4[VY
MB J:^8I]ZDZ%\G%WZ7T2WFD["6IJ+B\;&P;[N]S\#)P-!6::AWY+SD/'DJ-
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MQ[BE?F!N2<CLQ9GP\?:);!Y(*&752"XU"7K+DD7_I,3<IW2EJ>9R]*X#_Z>
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ME*Z01H #V;28]YGP$7%D.7MB]MZ:7"<\5#E?-;+Q;)Q"-=B3B*0IDA,U55R
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M>+FA/HU2]_83*8KK;9]P+20FY,C2)7,A&V@S[#HRX2S'%>0!3TGUJ]"S8#Z
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MU.CY>DRD0XV H>3EF;>$J@>J3@,_IGX2)%'[]J](%-T].OXW[S^Q3SY"6W#
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M7L.1X9QN+RJE2!87"?B49@T$7N9%K\&(0G:,(XDH^K'8R"15I!KR+U-B!Q:
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MI4<7)&3KT:::*HM.)['')0!G <\7&D8$<EBH)I;$.9#@9$&U4A\ W6?G@I&
MH?\X\Y=GY(EXP98#RO63K4D(O1"1BP\4N21%0_USUPAZ:#'Z(_&9B>PQ'&?+
M#?4IOWEB^D1LLEH.)JY65N2U)!GA.M#@!FV&NK+@S%%]RAO=;_G6R;*=,KEX
M )\O2:#84@3]UJ@,$9*D.URC+=N^@/U<G@C&+Z#K&3C@8==+H ]'W0O9T[),
MF?3@[3C-,-"I"K2$D,!!,#!9QN,/,#Y-,BT]#>5W\%:01^_ 0#KIZ!TX>@=4
M^'+C</ND:&GZX-%UNK)"J];N%:9 Y1X:0+[G7W7_7$EV]'30A7AI:\6>N"K.
MXI)67"C-]2?!K0[R:+3]^I QS"=Z34OWO@N.S$T2NH_LZKSQ'!5]UK<&9L&/
MX@D2DD&_G96@W.8EFE$#/)@ 7%B:XZN/3JS!! O9J]4:5+#IUKHEZTPY11$G
M['Q+PG2YJ-=]I>F_*@&\J #4]%/UKV?0;I5[RWV7>C3WGN>K^^N;,%C1/= <
MA^@N.&6  X\NN9#8R%<!0$BW]BQ;<D&V0<@![C'QU_R\7 1A-RY55 1^*'.[
MS!*6V'XJZ5-3#8":2R^(\^GH?M*U(>$4T)"^IJ.SZ04XF_:BEILUYU]<+^%-
M+=K-*(5'F][*V.%22<9HD@T[#^68<&1^%E42CE1>D2U^EF.VT72RC89TJ;$7
M6N@[GHH'K?J5*=Q]]5V".<B4KD=>_:)RZ94^/P&O9&5[8+W#@2R0&[9JX/O$
M6Q#/R9JTV#-*5(%-0I/!D5:_=W9#-E[:,\N:RP3"$PUN) YI'B(79-IUA4F;
ME*".9@OFY+"&)&YSO^%$HI?H:"D0!8;URP7:7==<'[F";#CFMY!6_S*(@]CQ
M#/T&>X0RPX/OS!:W2Q!>B_IOI:[^@+96B\MF=)$C?$)604BR#=PY7Z2RX_7]
MQP6M>:-SZB>,=(=820T3$K&'9.@P<E+?"7<I$ZX9)WF+],!+V>DSBI$H;@]-
M GFA[6)LYHU7PNV,_1#%U,6GTAZ3$7@S!A'(9D1 DW-@]3@#R1Q3MH2N[82'
MM!#!?LE.1^CVK-.W5\T[ZEHD%[Y,2F.*[X\T.?2&<BC/3P/EV+2TK29UL6\G
M3.AW%V3)WXK[W2Z8Q1D'V:\-0H 6+%89<K#[3MCKE9G$;9PY8%GQQEDUOD 0
MT[WOSE<KXO*G>X4_-2!QSL,]3RL?!B8*!$9C\']#REM9O8!P3$.-[,."Z_3)
M:&1ER>PAC?[,EK\D49PZO!'$K('":Y>K)D\T#*>A!8G]\90A1>.H\&0CB%(+
M$B-X&&+*4AM;#/R(YD\_Z0-0<[9%-R1T&;FQ%)0(G5<N7]VL,LF+J>DM>])V
M^L@;H5SZ19<4]J%9%)$XXL-A,B)Y7O#L^/4FMH,(GPIVKUP6E1BID4HTA&BV
MD6L0J6L%_/HLL7;Z&Z1%U?P!@W0R#GQN-@8KIIL;9\'QEU?4>6 4BFF?)T!'
MK _PYZL&\%D%N*7WO@X&FD[%QO+7Q%8(J1,4MB_:@.EM3>C:R0G700R$U?N(
M+?=!GCIAN%L%(:]%M=62608RMB#('(A.CG=1%;"%'(P([!]7%40MO7]5H>/>
MW<:"T$=;J%@2H"P4?\O-E7(.+=.!N?42M5>4\^Z< PB,,8JH3PP(H3)G$I3[
MQ)+8\2,2/A%^[<Y<-TP<+YO?,;QT"3%Y:4(D)CE4!I>*K#00OB),D$LFF%25
M1/\J4[$U).B!4E<DW,?'(%@^4X\G_EXRDOIKRAYIV3_9/L1=H*=]:CN)"E7V
M!,+^2_\F#%P2[8V=:DF ;1'H S^58Z]/7_A")U.%$,(G6PN 3/S5D%,JYZ#.
M(,FZO\Z0@:5K9A#?D  >]J&%=Q")" OW+M2TN4J(+?ALO/GJ/LHN&E6[JV.E
MT1S3;OFNF5]=I ',E3$ZL_MH@-!@!CNNK:"P3ZH2;^6(9YR]<E=5RB!WJO7@
MKFS ]D5IY=YXJU8W%( 4IN8CL"+<MGE?@X:9AFV+Z76"&K@^*L?=<KR4X=KB
MX8'LB#GJ8.%1B^(_6CK4I4:L:YM.^[J-G3 V-(F:>-51+S)N9IL@ ?=,*(,?
MD>DD)0CJ] 4,>MDZ_S^_P]$ D^&Z) WUHTR9 CCW:R\BFY?HO1_NIPVR?151
MM+Y[%*)1LP#TOLU1=G1X2FKL4)_]X2XX_^)LJ)]^?$'B)/2C1>!Y%UF(&5AZ
MK:.KZ746X &\>Q$4;$T]E!"5S[V0XM!7/:0\L =]R*-EW%>>>#PO)ZVV3$).
MX6RN*/OT31!1&YFJ0$@AVX<C$C9E=F(;'()]@!L978KJ*#@9P6$MDB'RH--1
M(,EVZZ4=$AWOU(D>+YB-=>FO@G"3KIXW/XR#-"G 3F5T#PJ6? "R4'4]:H=,
M34ZY8E8P\"8$0)"[@*GQL[7-4XUHP*FM0QRLZE9*WK_;Q^"9_3E^)+/U.DR=
MMY7=VO&N"=$IP)XE@@')P$+: UKWN%T1]E@D[:!V)4#7C)9WS\1[(I\"/WZ$
M/I#::& ^T75DHWQJ]6D/._7<FM#\FSCAW7. )"L%=%RM/I20[&F-;5LK(<Q$
M MJUKPX?U1H?5#XR<J,6ZLOBBR05V*]Z[=.C(Q/ ':E@9>'>7]+(Y4]/GA#/
M$RNMA(/T<,#V-*J>(FGI$%,=,I,*T!3?#6)U[R;#\4[%("2A@=%0SZJ XFON
M/AR&O04P9.W?(^(2K-Q3;:S'E?=&')*S)7C81UA.T"687*8AY*A@VSZ>$R>B
MKN,OSZB7, F[)FEG\QL2IG61LS@.Z4,2<S].'*1#8QX#C^T.L)W$82!JBLM,
M!I>["BZ:4X:-P:G:VS4(YDQH&YS>N7F[&!B\4,^=D(<Q]A!S/*XLC13N!8<]
M&QCJ*'#-95GL$*<)[T=BG?^6<*V]SW>U,$^X&Q:*OV(0?5(9?M5-;Q!)T-(>
M572LC!=NAX$ZGTA&^BM]L-K)5)TGK-D):A/XJ219&3?:7!\Y+*A*^18" 4YT
M,E*=IYX31?-5BIM-M=F @_2NPU.:34I#S/S38W\9%ROJL@4 ]ENO5^0K)[:%
M0+7!ZYH'CX2\WN:F8+<]K=D%:23Z4X83G03#'K&>(7<R&#?;(4V.FP*"P?9;
M>LF72O][6;\HSS/Q'+,=6IL:6%T;^SJ1=5F4V5:C#IRC4(=5GPFOS"?+&5O,
M69/KA!]"=GSY9J)Y$D<Q$URVPU2&@5FI!ALY!*##:47B8M]C G3SG3:P'D8:
MA-!Q[SM <1#35_\J;(DA@+AD;:B!=AB83A4=Y@HHI7\# \UL%NQE&%_Z).]G
M(<7TVP:VW-0VXWDS/Z8IUGQZ>-KW/BL:(4M.G9L@9NM3Q^,NJR0#%*S:C5/0
M HE#9$.,X(4 P;D 0<VPGP4$])^/%:R6.5:WQ$W"-.&PC%D%H;J@MH0 S5^<
ML,@97$6&\&U%$<'0PHXVVCN3E:<_L+ #A)L0A/%DU[Z !=^[34Q1 U]6M&99
M5*WR&"U,VH[4M;,A5D( O>!PGW$#G.-^D2H3WRB\<+[9>L&.D,].&#I^'+7Y
MH 6FD>"KKX([(K(AS9Q8$'9]4C?._>*S=!*& BN[OO\J^-E)0+ B&\6W#\=D
MODW[+"CPLN5KV$_J@9C81C"H\0JJS+MQ^%L[5P\*W&O['FI1VT"\:Z47U-"%
MH\4I\<3%2RHQW(.56C(8G*9\<CL=GD LFU!3B[P-#--3\6[FNED?'6?'SZ7C
M+]-A/GGUA_3P3%U7: <J,R$JFEY/,UB*KI(RL#MV$41L#7Z9&W)!N=QA"#QT
M$S %N-GR5?:"P_9!@AR&[ DP@/"A^7!$NSO9578%[TQ4 (PC2@,JG?(-JL(0
M"*E1?+PX:][YC&X>DC#B6\B>5;-U2-*4O>B"$)5'J=J*Z.T85<]*_H)1(1K.
MK.(<R4_4(U$<^/N.6Q=!6$-6G;GRBV+[(XP8K$ [*&^@Z=GE&JH8998/I#0]
MO!U+8CZXX8YN%\V0'((M:-XX/,8*P]/6M9#;FP)QLYU,8+Y!4X/,2N)_"X!I
MZMTNBH'F5[UFNQ/8$:CE!JQNL;P_:.=>!R3<<)?LZ[[BB^NB&ZB9:>1?2T%$
MQ/WC.GAZZ^Z6&933W0.'DWH0=PL:_?K)\9UU:D6QY_LM>Z7'9+T[HY'K!5$2
M@B46,@1^[H!= &8X? R8JO#YT V)YK#E_:6"R'XXR)\14'5[00=<7T(@_ 9+
M67ZV-R?C)(/?8,57-KAF@1!TKFT,A FTT\?(2=>X=PWE=.!DQ1YL\['8A+]Y
M^6BB**+^^G+)TSQ7.SY?P%^F'^:3!=C9<N+HCJGH$P;K5UM'S@0E)#\3B.J2
MD"TC;B'UI9;=TJ7/2,3IM+SPG*ZZ,ACAJH%#>14/+C9U&N,,SE;'=CB=TP;S
MM<E&4V< ^,6,!>0D<,(EKS8(B<N^$LW9KB->2VE)."3@O<C;1H;.@#EX,'+!
MVRK1."9D'MXF#V[QVX)$V\"/*+/@N$]_"(G1Q60J+PE%0=)F#%2F((B,Y4J2
MH9K-_.'E^J,1.VCD7J16 ^=@+I]_1E"!GQ@A0EZ%5][DI>]2_A H_O%RLV7O
M_7FX($X4^.P-N[NBOQ)O5_UW&)&T@M"4? 1".;3#JESVOALTS"6@2X:BMYNE
MU:)DV=S&75#_U(*L*?='^;&-IQX 1B_2XH?@5"YYW^,''UJ3>Z^=. E)L(H?
MR4D2,=I$D>,O>1>.*%C=E%;-8VI B;Q%W&8>KAV?_IY".&771^#1928Y_K(,
M?;ZZH)Q]C-#[EFF"=%[SSOL@."DW.%=DA$+C<JV5#5H.E'O9R80;3'MDX@87
MK(ARVGM<3R+0TFN9-1C1)77"W:W#LY*MM<45PL%JBVMR="M='L04A(D?:;'U
M@ JON)ZO2C%Y*[7O$@!1,[)ZY;S"4@GJ-8K7E?@TYU=Z3Q=QP<T@^"KVW& )
M\HHVC>.>9V?\$PG7)$S14LE ;/LB<N:W%/W;=PS;@U:.]K/%Z4Q/^MN_B5HJ
M*T-ZP891$CE3[N=-IIG-P]Y8,7< ];=T[E)(DNMA)W+*ZRE9 @$Z<)6**C/T
MK@/_IX /YX)@I.J:$[ARE,FDX>_<CZR+]>H>+F_.\\>%OU:YAEJ^-WX3JW6W
M8(X^76OYE8]5 GL*28U+,FO4<!R7=!R7=!R7=!R7-!UE*!R#9#*J L#+>QR#
MU'82[8Y!.@[. 1V<,VB!LE!9__QNF/ML*IQK)1#>? ?%-V"=FY"/Y;%S4(-4
M&G=9RX/Y.%IN0)W:/5H.H"39R#;)6RG.PP5/1;-@<HKA3-WD[*"@/G.!3,XJ
M4C9MSU9(N(>T5[1[N2BR114C7JN$9_YH],P6?1?[6I.BK'#CX%VO)ZPUZID_
M^IF_+<6OJLZ'PV#(S(6R(#PWF:3_<+OU*'3ZF Q$Y!!O9X)6U?$@03W@!J8F
MCZ@;)YR'J1FS_,GQ$E+T6K7WJ!)"G J+I:@'J-Q,<Y!X:AUEV*3$7!"7T">R
M9)B6\FKLY2/) ,?TT\L?;$6"8F1V%+BFA2AD&?&.RI=1E/ L[OGJC#Q :^X.
M0)-@:A>AH-)#E%)SEDO*Z>1X-PY=7OJGSI;&CI<+5IXH&\EU8Y9="S5LW<LI
M:8K =OV7'(/SQ7UT_#59<#RDF%+]QDCL=S'U:QL$K$=3HG/IQHTRKUC$-:\T
MU;N^/XJWJ9@#G5L'3-U08<<E0R/B9=NG7L";@V0#A:4X(?CJR)D@VC!<I9)Q
MGGEEXC>_R@A3EH-8>/V@QWW#Z%$S9_U?L%C/T<P0.TM")I+,_*1!,=J;]_*S
M\4;O!C@1-DM0+F?NAZ$[]8;DHN(IFZ]*ZE]!RTHM-&H#78X4Q2-[Z'93G?[/
M>Y^FTC6$?WT/:QIGKX=>!3L'=YI4]?U-$C*K-ZIS4%0K*OCNZ&U[X:8+-J"X
M+DJW\$U(75O^2"&8:1PD,94*Y@T^NC 3IV U6Z]#LG9BHG!?B;X[D3/4LNF"
M#8.Z(PX.ZN*=F..>897GDY#E-^#._3YXHV>D ND*U@[=E:<11XV#0FG/?)U3
MI[3@N/6B&FT*#@[;VV;O<\X&P.R;&J0=5?>O$NZ!Y@Y-Z+P;6:CCYK,R#0M6
M0[AHM+A]3>)+WPTVY"J(H'E:77LR.K9&DH)%*JZ4MB1&3>Z<.M'C31@\4:8]
M3G;W$??TS+=I<(])E1O3IW1 !CSK9 &/W#>J0\J"Y0 .%AVN9^[<K(N,O^18
M W.W!<!D3F<;<8I8-I"?Q<+ W62S<<)=L+JE:Y^NJ,ML@'S "??P!1YU#T-N
MOJK0NSH,Q&0$30F2I3Y;'8 4GPI*!)-OG*6QK('W+0U-7OH' .=13#?,T&L(
M.-1#1P(B<A93ORRFI08:[(<;)SH@6?3EO/(JE)&T@6=N%+A=$)Z)Y)V1;1!1
M9EA%29C9O^$VR#*4V.-H0Y--/L<.^$@H@T>_".6U1ED$U,D,EN1IIXME$)-\
M]-<SC1_+$\0DKDDM6YM!W,_8MG,_MH)0OV#Z::/02E)R+=T7#,]58](8APDW
MV6Q=?"(HV(>Y2Z92_ZPL)T&'31V+_>5J*-2.F5IY/P8GC_7]6/7]K[;'B59%
M.&A_$RU^W;'/S%<S[JO/IW;"Z[MV&!A9+P:*3D H@&9.6HZ. Q[<.70=^,[A
M+^5IQ%8.H2ITW"/:*>*50;RJ1#72F.UM2.6BA:-KO-I+X_;=@M5FF1OL%O1>
M"P L(\% \;61":1SDUK=P;X#!]^*PFEI_R9FRJ58[K(R@]:=8A>J"@:;6S@U
M79!P+A*#P]-)-HAF%("\M/)0ZH:%FN,@(=(2K!2\GE3X<N'0<,-=H#\0QXL?
M72=+N;Z\O+I14'3]JV"_4"4)+D$.V+YGTU E0O\B2(<*<P/JPG')+.6;53.J
M! 95>_2X>\6<*],)ZE8W+4TO&1V6:]/KD'"?A@I,["07> ,=DX/(1SLS4L8+
MIEK*A556CZ40*/:EHWU.Q62$&Y,-P>Y/O $29?<'P],JBRN QO. 4F!IE51P
M8ZT-DH^CK,G%  G'K9"FHWZ[R(4T?.20J)=IBCSAP,(-V@9A*M9/*W6@^E=
MW)9N2'AU@NN&:7%YAJWER[(=YF1.HR0)D;IB',)MQ^HK;1;+UU]I5'2TS6:
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M:OS<"Q$Y15.12U(T1$IRR2<7WCAAO"N;_R>[\K]84*T*@*>K:56H"S!7PU0
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MXI3A3)=I+XF O7RIW+2>CJ^_1/YU40MNU*Y6+R3>P:4S QU8X4H Q(W*6=;
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MFW1#:D77@QYW PS)V1(\;.\(!'?+Y-.(Y7[(&.R3V-RK54&P-C][0;@=6;Y
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MY>7EU8U*X['>548IU1*;!^R[H"CM>^2B/?Z7O"4WB7A3,V4EH[#<"$^*"C'
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M^_]02P$"% ,4    "  ]@&9:]78B D#R P K""0 &@              @ $
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M#U@$ &5A,#(S,#0T-3 Q97@Q,"TQ.5]O<G5K871H92YH=&U02P$"% ,4
M"  ]@&9:3,:>%9H$  "F%P  'P              @ &DAP0 96$P,C,P-#0U
M,#%E>#$P+3(P7V]R=6MA=&AE+FAT;5!+ 0(4 Q0    ( #V 9EJZ&8+DCJL
M /03!  ?              "  7N,! !E83 R,S T-#4P,65X,3 M,CE?;W)U
M:V%T:&4N:'1M4$L! A0#%     @ /8!F6FZ$URKWK@  [AP$ !\
M     ( !1C@% &5A,#(S,#0T-3 Q97@Q,"TS,5]O<G5K871H92YH=&U02P$"
M% ,4    "  ]@&9:*HA^IOPT  "+4 $ 'P              @ %ZYP4 96$P
M,C,P-#0U,#%E>#$P+3,R7V]R=6MA=&AE+FAT;5!+ 0(4 Q0    ( #V 9EJP
MB>G7_@D  /$R   ?              "  ;,<!@!E83 R,S T-#4P,65X,3 M
M,S-?;W)U:V%T:&4N:'1M4$L! A0#%     @ /8!F6NA46S0C.P  4]0! !X
M             ( ![B8& &5A,#(S,#0T-3 Q97@Q.2TQ7V]R=6MA=&AE+FAT
M;5!+ 0(4 Q0    ( #V 9EIMX<6A.@(  # '   >              "  4UB
M!@!E83 R,S T-#4P,65X,C$M,5]O<G5K871H92YH=&U02P$"% ,4    "  ]
M@&9:N/AF<O\!  #Y!0  '@              @ '#9 8 96$P,C,P-#0U,#%E
M>#(S+3%?;W)U:V%T:&4N:'1M4$L! A0#%     @ /8!F6M@YB*M@!P  C2<
M !X              ( !_F8& &5A,#(S,#0T-3 Q97@S,2TQ7V]R=6MA=&AE
M+FAT;5!+ 0(4 Q0    ( #V 9EIOLR1!4P<  /DE   >              "
M 9IN!@!E83 R,S T-#4P,65X,S$M,E]O<G5K871H92YH=&U02P$"% ,4
M"  ]@&9:15RY\4<$  "^$0  '@              @ $I=@8 96$P,C,P-#0U
M,#%E>#,R+3%?;W)U:V%T:&4N:'1M4$L! A0#%     @ /8!F6C_QO=^R&0
M78P  !T              ( !K'H& &5A,#(S,#0T-3 Q97@T+3%?;W)U:V%T
M:&4N:'1M4$L! A0#%     @ /8!F6HKW*&AK1   <TT! !T
M ( !F90& &5A,#(S,#0T-3 Q97@T+3-?;W)U:V%T:&4N:'1M4$L! A0#%
M  @ /8!F6DJME_;[$P  BXT  !X              ( !/]D& &5A,#(S,#0T
M-3 Q97@Y-RTQ7V]R=6MA=&AE+FAT;5!+ 0(4 Q0    ( #V 9EK?H,TEEL
M .G7   -              "  7;M!@!I;6%G95\P,#$N:G!G4$L! A0#%
M  @ /8!F6N/\0FV?PP( 1= "  T              ( !-ZX' &EM86=E7S P
M,BYJ<&=02P$"% ,4    "  ]@&9:T8-\VVU< 0 00@( #0
M@ $!<@H :6UA9V5?,# S+FIP9U!+ 0(4 Q0    ( #V 9EJ[K.4/3/L  *\1
M 0 .              "  9G."P!I;6%G95\P,#-A+FIP9U!+ 0(4 Q0    (
M #V 9EID-7@Q8I$  )6:   -              "  1'*# !I;6%G95\P,#0N
M:G!G4$L! A0#%     @ /8!F6I6_%RM8H@  :;8   T              ( !
MGEL- &EM86=E7S P-2YJ<&=02P$"% ,4    "  ]@&9:.>5%!RRZ  !3R
M#0              @ $A_@T :6UA9V5?,# V+FIP9U!+ 0(4 Q0    ( #V
M9EH[#2JB",P  '+D   -              "  7BX#@!I;6%G95\P,#<N:G!G
M4$L! A0#%     @ /8!F6JL]>^P;'    $T! !$              ( !JX0/
M &]R:V$M,C R-#$R,S$N>'-D4$L! A0#%     @ /8!F6O/ZW5P%#P  T+0
M !4              ( !]: / &]R:V$M,C R-#$R,S%?8V%L+GAM;%!+ 0(4
M Q0    ( #V 9EK7M@>=TE@  '<=!@ 5              "  2VP#P!O<FMA
M+3(P,C0Q,C,Q7V1E9BYX;6Q02P$"% ,4    "  ]@&9:WJU-:4W6  "_UPH
M%0              @ $R"1  ;W)K82TR,#(T,3(S,5]L86(N>&UL4$L! A0#
M%     @ /8!F6H)/Z++ 7   P((& !4              ( !LM\0 &]R:V$M
F,C R-#$R,S%?<')E+GAM;%!+!08     'P ? 'X(  "E/!$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>ea0230445-10k_orukathe_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:orka="http://www.orukatx.com/20241231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="orka-20241231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-03</startDate>
            <endDate>2024-09-03</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-03</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:ARCACommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PIPEFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PIPEFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PIPEFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2024-08-29</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesLongTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesLongTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:MarketableSecuritiesLongTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="orka:MarketableSecuritiesAxis">orka:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:USGovernmentAgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="orka:MarketableSecuritiesAxis">orka:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="orka:MarketableSecuritiesAxis">orka:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="orka:MarketableSecuritiesAxis">orka:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">orka:USGovernmentAgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="orka:MarketableSecuritiesAxis">orka:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:FairmountHealthcareFundIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:FairmountHealthcareFundIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:FairmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:FairmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:FairmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreMergerOrukaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PIPEFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PIPEFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:ParukaWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:ParukaWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:ParukaWarrantObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-22</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-29</instant>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-29</startDate>
            <endDate>2024-08-29</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:ParukaWarrantObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-07</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:ParukaWarrantObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:OperatingExpenseExcludingStockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:ExternalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">orka:OperatingExpenseExcludingPersonnelRelatedAndStockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:RegulatoryMilestonesMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:RegulatoryMilestonesMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:NominationOfADevelopmentCandidateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:AntibodyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:ParukaWarrantObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:AchievementOfDevelopmentCandidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:AchievementOfDevelopmentCandidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-15</instant>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:ParukaWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">orka:ParukaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">orka:FairmountHealthcareFundIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">orka:FairmountsOwnershipInterestInParagonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:ParagonReimbursableOptionAgreementsFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:ParagonMilestonePaymentsForOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:ParagonReimbursableOtherResearchExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:ParagonReimbursablePatentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-24140">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-24141">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-24142">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-24143">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-24144">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-24145">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-24146">000-22873</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-116">Oruka Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-140">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0" id="ixv-146">36-3855489</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-173">855 Oak Grove Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0" id="ixv-177">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-24147">Menlo Park</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0" id="ixv-24148">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-186">94025</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0" id="ixv-24149">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-24150">606-7910</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0" id="ixv-240">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-245">ORKA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-24151">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-274">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-283">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-291">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-300">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-331">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-344">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-352">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-24152">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-24153">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c0" id="ixv-24154">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c1" decimals="-5" id="ixv-24155" unitRef="usd">39700000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-24156"
      unitRef="shares">37440510</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c0" id="ixv-6294">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
collect, use, store, and transmit confidential, sensitive, proprietary, personal, and health-related information in the ordinary course
of our business. As such, we leverage third-party information technology service providers who have implemented and maintain various
information security processes designed to identify, assess, and manage material risks from cybersecurity threats to our information
technology systems, including critical computer networks, third party hosted services, communications systems, hardware and software,
and our data residing on these systems. Our Senior Vice President, Finance is responsible for overseeing these third-party service providers
and processes.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cybersecurity
risks are identified by monitoring and evaluating our threat environment, and then assessed by various methods, for example, by manual
and automated tools designed to identify and combat cybersecurity threats, analyzing reports of threats, conducting scans and assessments
of the threat environment and to identify vulnerabilities, the use of detection and response services and conducting reviews of third-party
service providers, among other things. Depending on the threat environment, we implement and maintain various technical, physical, and
organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats
to our information systems and data, including, for example, physical security and access controls, asset management, systems monitoring,
incident detection and response, risk assessment, the implementation of security standards and certifications, encryption of data, network
security controls, and a recovery/business continuity plan, among other mitigation tactics. Our recovery/business continuity plan is
designed to mitigate and remediate identified cybersecurity incidents and escalate certain incidents as appropriate to management and
the Audit Committee. We plan to conduct due diligence on and audits of key technology vendors, contract research organizations, and other
third-party contractors and suppliers. Additionally, we conduct periodic employee training that covers cyber and information security,
among other topics.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c0" id="ixv-24157">Our assessment and management
of material risks from cybersecurity threats are integrated into the Company&#x2019;s overall risk management process. Our Senior Vice
President, Finance, who reports directly to the Chief Executive Officer, together with our senior management, is responsible for assessing
and managing cybersecurity risks with support from our third-party information technology service providers that employ information technology
consultants with over 20 years of experience managing cybersecurity programs. Our cybersecurity program aligns to the National Institute
of Standards and Technology (NIST) Cybersecurity Framework (CSF) and is consistently updated as NIST recommendations change year over
year. Our Senior Vice President, Finance, together with our senior management and other employees works closely with our information technology
service providers to evaluate material cybersecurity threats against our overall business objectives as part of our cybersecurity incident
response.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c0" id="ixv-24158">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c0" id="ixv-24159">The Board of Directors, as a whole and at the committee level, has oversight for the most significant risks facing us and for
our processes to identify, prioritize, assess, manage and mitigate those risks. The Audit Committee has been designated by our Board to
oversee cybersecurity risks. The Audit Committee receives regular updates on cybersecurity and information technology matters and related
risk exposures from our Senior Vice President, Finance. The Board also receives updates from management and the Audit Committee on cybersecurity
risks on a regular basis.</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c0" id="ixv-24160">The Audit Committee has been designated by our Board to
oversee cybersecurity risks.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c0" id="ixv-24161">The Board also receives updates from management and the Audit Committee on cybersecurity
risks on a regular basis.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock contextRef="c0" id="ixv-24162">we have not identified any risks from known cybersecurity threats, including as a result of any prior cybersecurity
incidents, that have materially affected us, but we face certain ongoing cybersecurity risks or threats that, if realized, are reasonably
likely to materially affect us.</cyd:MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c0" id="ixv-24163">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <dei:AuditorFirmId contextRef="c0" id="ixv-24164">238</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock contextRef="c0" id="ixv-8269">&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Opinion on the Financial Statements&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We have audited the accompanying
consolidated balance sheets of Oruka Therapeutics, Inc. and its subsidiaries (the &#x201c;Company&#x201d;) as of December 31, 2024
and February 6, 2024, and the related consolidated statements of operations and comprehensive loss, of convertible preferred stock and
stockholders&#x2019; equity and of cash flows for the period from February&#160;6,&#160;2024 (inception) to December&#160;31,&#160;2024, including
the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial
statements present fairly, in all material respects, the financial position of the Company as of December&#160;31,&#160;2024 and February
6, 2024, and the results of its operations and its cash flows for the period from February&#160;6,&#160;2024 (inception) to December&#160;31,&#160;2024
in conformity with accounting principles generally accepted in the United States of America.&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="c0" id="ixv-24165">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0" id="ixv-24166">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" id="ixv-24167" unitRef="usd">61575000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c3" decimals="-3" id="ixv-24168" unitRef="usd">314073000</us-gaap:MarketableSecuritiesCurrent>
    <orka:SubscriptionReceivables contextRef="c4" decimals="-3" id="ixv-24169" unitRef="usd">1000</orka:SubscriptionReceivables>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" id="ixv-24170" unitRef="usd">1221000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" id="ixv-24171" unitRef="usd">376869000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c4" decimals="-3" id="ixv-24172" unitRef="usd">1000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c3" decimals="-3" id="ixv-24173" unitRef="usd">18069000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" id="ixv-24174" unitRef="usd">162000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" id="ixv-24175" unitRef="usd">876000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c3" decimals="-3" id="ixv-24176" unitRef="usd">43000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c3" decimals="-3" id="ixv-24177" unitRef="usd">396019000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c4" decimals="-3" id="ixv-24178" unitRef="usd">1000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c3" decimals="-3" id="ixv-24179" unitRef="usd">3462000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c3" decimals="-3" id="ixv-24180" unitRef="usd">3346000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" id="ixv-24181" unitRef="usd">213000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c5" decimals="-3" id="ixv-24182" unitRef="usd">6022000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-24183" unitRef="usd">13043000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" id="ixv-24184" unitRef="usd">755000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c3" decimals="-3" id="ixv-24185" unitRef="usd">13798000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c7"
      decimals="4"
      id="ixv-24186"
      unitRef="usdPershares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c8"
      decimals="4"
      id="ixv-24187"
      unitRef="usdPershares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c8"
      decimals="INF"
      id="ixv-24188"
      unitRef="shares">20000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c9"
      decimals="3"
      id="ixv-24189"
      unitRef="usdPershares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c10"
      decimals="3"
      id="ixv-24190"
      unitRef="usdPershares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c11"
      decimals="3"
      id="ixv-24191"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c12"
      decimals="3"
      id="ixv-24192"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c11"
      decimals="INF"
      id="ixv-24193"
      unitRef="shares">251504</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c11"
      decimals="INF"
      id="ixv-24194"
      unitRef="shares">137138</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c11"
      decimals="INF"
      id="ixv-24195"
      unitRef="shares">137138</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c11" decimals="-3" id="ixv-24196" unitRef="usd">2931000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="ixv-24197"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c4"
      decimals="3"
      id="ixv-24198"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c3"
      decimals="INF"
      id="ixv-24199"
      unitRef="shares">545000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c4"
      decimals="INF"
      id="ixv-24200"
      unitRef="shares">65000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c3"
      decimals="INF"
      id="ixv-24201"
      unitRef="shares">37440510</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c3"
      decimals="INF"
      id="ixv-24202"
      unitRef="shares">37440510</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c4"
      decimals="INF"
      id="ixv-24203"
      unitRef="shares">3197975</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c4"
      decimals="INF"
      id="ixv-24204"
      unitRef="shares">3197975</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c3" decimals="-3" id="ixv-24205" unitRef="usd">37000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="-3" id="ixv-24206" unitRef="usd">463018000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c4" decimals="-3" id="ixv-24207" unitRef="usd">1000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="-3" id="ixv-24208" unitRef="usd">-41000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" id="ixv-24209" unitRef="usd">-83724000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-24210" unitRef="usd">382221000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="-3" id="ixv-24211" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" id="ixv-24212" unitRef="usd">396019000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c4" decimals="-3" id="ixv-24213" unitRef="usd">1000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ix_0_fact" unitRef="usd">75060000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ix_1_fact" unitRef="usd">13063000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="-3" id="ixv-24216" unitRef="usd">88123000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" id="ixv-24217" unitRef="usd">-88123000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c0" decimals="-3" id="ixv-24218" unitRef="usd">5863000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c0" decimals="-3" id="ix_2_fact" unitRef="usd">1468000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncome contextRef="c0" decimals="-3" id="ixv-24220" unitRef="usd">4000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" id="ixv-24221" unitRef="usd">4399000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-24222" unitRef="usd">-83724000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c0" decimals="-3" id="ixv-24223" unitRef="usd">-41000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c0" decimals="-3" id="ixv-24224" unitRef="usd">-83765000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-24225"
      unitRef="usdPershares">-3.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-24226"
      unitRef="usdPershares">-3.87</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c16"
      decimals="2"
      id="ixv-24227"
      unitRef="usdPershares">-3873.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c16"
      decimals="2"
      id="ixv-24228"
      unitRef="usdPershares">-3873.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c17"
      decimals="2"
      id="ixv-24229"
      unitRef="usdPershares">-322.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c17"
      decimals="2"
      id="ixv-24230"
      unitRef="usdPershares">-322.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="INF"
      id="ixv-24231"
      unitRef="shares">16789362</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ixv-24232"
      unitRef="shares">16789362</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c16"
      decimals="INF"
      id="ixv-24233"
      unitRef="shares">495</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c16"
      decimals="INF"
      id="ixv-24234"
      unitRef="shares">495</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c17"
      decimals="INF"
      id="ixv-24235"
      unitRef="shares">51946</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c17"
      decimals="INF"
      id="ixv-24236"
      unitRef="shares">51946</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CostsAndExpensesRelatedParty contextRef="c13" decimals="-3" id="ixv-24237" unitRef="usd">42640000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty contextRef="c14" decimals="-3" id="ixv-24238" unitRef="usd">1364000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty contextRef="c15" decimals="-3" id="ixv-24239" unitRef="usd">1468000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:SharesOutstanding
      contextRef="c21"
      decimals="INF"
      id="ixv-24240"
      unitRef="shares">3197975</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="-3" id="ixv-24241" unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="-3" id="ixv-24242" unitRef="usd">-2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c25" decimals="-3" id="ixv-24243" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c29"
      decimals="INF"
      id="ixv-24244"
      unitRef="shares">2207553</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c29" decimals="-3" id="ixv-24245" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c30" decimals="-3" id="ixv-24246" unitRef="usd">-2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <orka:IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts contextRef="c0" decimals="-3" id="ixv-24247" unitRef="usd">69000</orka:IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts>
    <orka:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="c26"
      decimals="INF"
      id="ixv-24248"
      unitRef="shares">20000000</orka:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="c26" decimals="-3" id="ixv-24249" unitRef="usd">2931000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <orka:TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c26"
      decimals="INF"
      id="ixv-24250"
      unitRef="shares">-20000000</orka:TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c26" decimals="-3" id="ixv-24251" unitRef="usd">-2931000</orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <orka:TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c28"
      decimals="INF"
      id="ixv-24252"
      unitRef="shares">137138</orka:TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c28" decimals="-3" id="ixv-24253" unitRef="usd">2931000</orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c0" decimals="-3" id="ixv-24254" unitRef="usd">2931000</orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c29"
      decimals="INF"
      id="ixv-24255"
      unitRef="shares">2722207</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c29" decimals="-3" id="ixv-24256" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c30" decimals="-3" id="ixv-24257" unitRef="usd">26445000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c0" decimals="-3" id="ixv-24258" unitRef="usd">26448000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost
      contextRef="c29"
      decimals="INF"
      id="ixv-24259"
      unitRef="shares">20061932</orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos contextRef="c29" decimals="-3" id="ixv-24260" unitRef="usd">20000</orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos contextRef="c30" decimals="-3" id="ixv-24261" unitRef="usd">248437000</orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos contextRef="c0" decimals="-3" id="ixv-24262" unitRef="usd">248457000</orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c30" decimals="-3" id="ixv-24263" unitRef="usd">20504000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c0" decimals="-3" id="ixv-24264" unitRef="usd">20504000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger
      contextRef="c29"
      decimals="INF"
      id="ixv-24265"
      unitRef="shares">1208883</orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger>
    <orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe contextRef="c29" decimals="-3" id="ixv-24266" unitRef="usd">1000</orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe>
    <orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe contextRef="c30" decimals="-3" id="ixv-24267" unitRef="usd">4999000</orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe>
    <orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe contextRef="c0" decimals="-3" id="ixv-24268" unitRef="usd">5000000</orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant
      contextRef="c27"
      decimals="INF"
      id="ixv-24269"
      unitRef="shares">2439</orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr contextRef="c27" decimals="-3" id="ixv-24270" unitRef="usd">56097000</orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant
      contextRef="c29"
      decimals="INF"
      id="ixv-24271"
      unitRef="shares">5600000</orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr contextRef="c29" decimals="-3" id="ixv-24272" unitRef="usd">6000</orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr contextRef="c30" decimals="-3" id="ixv-24273" unitRef="usd">144433000</orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr contextRef="c0" decimals="-3" id="ixv-24274" unitRef="usd">144439000</orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr>
    <orka:IssuanceCostOfPIPEFinancing contextRef="c27" decimals="-3" id="ixv-24275" unitRef="usd">-3263000</orka:IssuanceCostOfPIPEFinancing>
    <orka:IssuanceCostOfPIPEFinancing contextRef="c30" decimals="-3" id="ixv-24276" unitRef="usd">-8592000</orka:IssuanceCostOfPIPEFinancing>
    <orka:IssuanceCostOfPIPEFinancing contextRef="c0" decimals="-3" id="ixv-24277" unitRef="usd">-8592000</orka:IssuanceCostOfPIPEFinancing>
    <orka:ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares
      contextRef="c27"
      decimals="INF"
      id="ixv-24278"
      unitRef="shares">-2439</orka:ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares>
    <orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock contextRef="c27" decimals="-3" id="ixv-24279" unitRef="usd">-52834000</orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock>
    <orka:ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares
      contextRef="c29"
      decimals="INF"
      id="ixv-24280"
      unitRef="shares">2439000</orka:ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares>
    <orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock contextRef="c29" decimals="-3" id="ixv-24281" unitRef="usd">2000</orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock>
    <orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock contextRef="c30" decimals="-3" id="ixv-24282" unitRef="usd">52832000</orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock>
    <orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock contextRef="c0" decimals="-3" id="ixv-24283" unitRef="usd">52834000</orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c29"
      decimals="INF"
      id="ixv-24284"
      unitRef="shares">2960</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c30" decimals="-3" id="ixv-24285" unitRef="usd">53000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c0" decimals="-3" id="ixv-24286" unitRef="usd">53000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c30" decimals="-3" id="ixv-24287" unitRef="usd">10357000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c0" decimals="-3" id="ixv-24288" unitRef="usd">10357000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c30" decimals="-3" id="ixv-24289" unitRef="usd">4562000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c0" decimals="-3" id="ixv-24290" unitRef="usd">4562000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c31" decimals="-3" id="ixv-24291" unitRef="usd">-41000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c0" decimals="-3" id="ixv-24292" unitRef="usd">-41000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c32" decimals="-3" id="ixv-24293" unitRef="usd">-83724000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-24294" unitRef="usd">-83724000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c35"
      decimals="INF"
      id="ixv-24295"
      unitRef="shares">137138</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c35" decimals="-3" id="ixv-24296" unitRef="usd">2931000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c36"
      decimals="INF"
      id="ixv-24297"
      unitRef="shares">37440510</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c36" decimals="-3" id="ixv-24298" unitRef="usd">37000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c37" decimals="-3" id="ixv-24299" unitRef="usd">463018000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c38" decimals="-3" id="ixv-24300" unitRef="usd">-41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c39" decimals="-3" id="ixv-24301" unitRef="usd">-83724000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-24302" unitRef="usd">382221000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-24303" unitRef="usd">-83724000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-24304" unitRef="usd">14919000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c0" decimals="-3" id="ixv-24305" unitRef="usd">2245000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OtherNoncashExpense contextRef="c0" decimals="-3" id="ixv-24306" unitRef="usd">1468000</us-gaap:OtherNoncashExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c0" decimals="-3" id="ixv-24307" unitRef="usd">127000</us-gaap:OperatingLeaseExpense>
    <us-gaap:Depreciation contextRef="c0" decimals="-3" id="ixv-24308" unitRef="usd">27000</us-gaap:Depreciation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="-3" id="ixv-24309" unitRef="usd">1128000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c0" decimals="-3" id="ixv-24310" unitRef="usd">43000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c0" decimals="-3" id="ixv-24311" unitRef="usd">3462000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c0" decimals="-3" id="ixv-24312" unitRef="usd">3292000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c0" decimals="-3" id="ixv-24313" unitRef="usd">-14000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="c0" decimals="-3" id="ixv-24314" unitRef="usd">6022000</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-24315" unitRef="usd">-57837000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="-3" id="ixv-24316" unitRef="usd">189000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c0" decimals="-3" id="ixv-24317" unitRef="usd">329938000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" id="ixv-24318" unitRef="usd">-330127000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="c0" decimals="-3" id="ixv-24319" unitRef="usd">2931000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromNotesPayable contextRef="c0" decimals="-3" id="ixv-24320" unitRef="usd">24980000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c0" decimals="-3" id="ixv-24321" unitRef="usd">227953000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c0" decimals="-3" id="ixv-24322" unitRef="usd">188681000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <orka:CashAcquiredInConnectionWithTheReverseRecapitalization contextRef="c0" decimals="-3" id="ixv-24323" unitRef="usd">4940000</orka:CashAcquiredInConnectionWithTheReverseRecapitalization>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c0" decimals="-3" id="ixv-24324" unitRef="usd">54000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" id="ixv-24325" unitRef="usd">449539000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="-3" id="ixv-24326" unitRef="usd">61575000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" id="ixv-24327" unitRef="usd">61575000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="-3" id="ixv-24328" unitRef="usd">982000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1 contextRef="c0" decimals="-3" id="ixv-24329" unitRef="usd">114000</us-gaap:NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1 contextRef="c0" decimals="-3" id="ixv-24330" unitRef="usd">54000</us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1>
    <orka:NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock contextRef="c0" decimals="-3" id="ixv-24331" unitRef="usd">1468000</orka:NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock>
    <orka:NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock contextRef="c0" decimals="-3" id="ixv-24332" unitRef="usd">2931000</orka:NoncashExchangeOfPreMergerOrukaSeriesAPreferredStockForSeriesBConvertiblePreferredStock>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="c0" decimals="-3" id="ixv-24333" unitRef="usd">52834000</us-gaap:ConversionOfStockAmountConverted1>
    <orka:ReclassificationOfTheParukaWarrantFromLiabilityToEquity contextRef="c0" decimals="-3" id="ixv-24334" unitRef="usd">10357000</orka:ReclassificationOfTheParukaWarrantFromLiabilityToEquity>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c0" id="ixv-11731">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;1.
Nature of the Business and Basis of Presentation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Background
and Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Oruka
Therapeutics, Inc., together with its subsidiaries (collectively, the &#x201c;Company&#x201d;), formerly known as ARCA biopharma, Inc.
(&#x201c;ARCA&#x201d;), is a clinical-stage biotechnology company that is the result of the reverse recapitalization discussed below. Prior
to the reverse recapitalization, the private company Oruka Therapeutics, Inc. (&#x201c;Pre-Merger Oruka&#x201d;) was established and incorporated
under the laws of the state of Delaware on February&#160;6, 2024 (referred to in the Notes as the inception of the Company). The Company
is headquartered in Menlo Park, California. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis
(&#x201c;PsO&#x201d;) and other inflammatory and immunology (&#x201c;I&amp;amp;I&#x201d;) indications.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
accompanying consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiaries. Intercompany
balances and transactions have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared
in conformity with United States (&#x201c;U.S.&#x201d;) generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in
these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;)
and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Reverse
Recapitalization and Pre-Closing&#160;Financing&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
August 29, 2024 (the &#x201c;Merger Closing&#x201d;), the Company completed the acquisition (the &#x201c;Merger&#x201d;) of Pre-Merger Oruka
pursuant to an Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024 (the &#x201c;Merger Agreement&#x201d;). Following
the transactions contemplated by the Merger Agreement, Pre-Merger Oruka merged with and into Atlas Merger Sub Corp., a wholly owned subsidiary
of ARCA and following that, Pre-Merger Oruka then merged with and into Atlas Merger Sub II, LLC (&#x201c;Second Merger Sub&#x201d;), with
Second Merger Sub being the surviving entity. Second Merger Sub changed its corporate name to &#x201c;Oruka Therapeutics Operating Company,
LLC.&#x201d; On August 29, 2024, the Company changed its name from &#x201c;ARCA biopharma, Inc.&#x201d; to &#x201c;Oruka Therapeutics, Inc.&#x201d;
and its Nasdaq ticker symbol from &#x201c;ABIO&#x201d; to &#x201c;ORKA&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Following
consummation of the Merger, the Company effected a 1-for-12 reverse stock split (the &#x201c;Reverse Stock Split&#x201d;) of the common
stock, par value $0.001 per share, of the Company (&#x201c;Company Common Stock&#x201d;), which became effective on September 3, 2024.
The Company Common Stock commenced trading on a post-Reverse Stock Split, post-Merger basis at the opening of trading on September 3,
2024. The Company is led by the Pre-Merger Oruka management team and remains focused on developing biologics to optimize the treatment
of inflammatory skin diseases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Immediately
prior to the execution and delivery of the Merger Agreement on April 3, 2024, certain new and existing investors of Pre-Merger Oruka
entered into a subscription agreement with Pre-Merger Oruka (the &#x201c;Subscription Agreement&#x201d;), pursuant to which, and on the
terms and subject to the conditions of which, immediately prior to the Closing, those investors purchased shares of common stock of Pre-Merger
Oruka (&#x201c;Pre-Merger Oruka Common Stock&#x201d;) and Pre-Merger Oruka pre-funded warrants for gross proceeds of approximately $275.0
million (which includes $25.0 million of proceeds previously received from the issuance of the Convertible Note (as defined in Note 7)
and accrued interest on such note which converted to shares of Pre-Merger Oruka Common Stock) (the &#x201c;Pre-Closing Financing&#x201d;).
The Company incurred transaction costs of $20.5 million which was recorded as a reduction to additional paid-in capital in the consolidated
financial statements. At the Merger Closing, the shares of Pre-Merger Oruka Common Stock and Pre-Merger Oruka pre-funded warrants issued
pursuant to the Subscription Agreement were converted into shares of Company Common Stock and pre-funded warrants of Company Common Stock
in accordance with the Exchange Ratio (defined below).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
accordance with an Exchange Ratio determined by terms of the Merger Agreement and upon the effective time of the First Merger (the &#x201c;First
Effective Time&#x201d;), (i) each then-issued and outstanding share of Pre-Merger Oruka Common Stock including outstanding and unvested
Pre-Merger Oruka restricted stock and shares of Pre-Merger Oruka Common Stock issued in connection with the Subscription Agreement, were
converted into the right to receive a number of shares of Company Common Stock, equal to the Exchange Ratio of 6.8569 shares of Company
Common Stock, which were subject to the same vesting provisions as those immediately prior to the Merger, (ii) each share of Pre-Merger
Oruka Series A convertible preferred stock, par value $0.0001 (&#x201c;Pre-Merger Oruka Series A Preferred Stock&#x201d;), outstanding
immediately prior to the First Effective Time was converted into the right to receive a number of shares of ARCA Series B non-voting
convertible preferred stock, par value $0.001 per share (&#x201c;Company Series B Preferred Stock&#x201d;), which are convertible into
shares of Company Common Stock, at a conversion ratio of approximately 83:3332:1 (iii) each outstanding option to purchase Pre-Merger
Oruka Common Stock was converted into an option to purchase shares of Company Common Stock, (iv) each outstanding warrant to purchase
shares of Pre-Merger Oruka Common Stock was converted into a warrant to purchase shares of Company Common Stock, and (v) each share of
Company Common Stock issued and outstanding at the First Effective Time remain issued and outstanding in accordance with its terms and
such shares. Subsequent to the close of the merger, the common stock shares were then subject to the reverse stock split of 1-for-12
effected on September 3, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
part of the Pre-Closing Financing and the Merger Closing, investors in the Pre-Closing Financing received 22,784,139 shares of Company
Common Stock in exchange for 39,873,706 shares of Pre-Merger Oruka Common Stock (which includes the issuance of 2,722,207 shares of Company
Common Stock in exchange for 4,764,032 shares of Pre-Merger Oruka Common Stock on the conversion of Convertible Note along with the accrued
interest through the conversion date) and 5,522,207 Company pre-funded warrants in exchange for 9,664,208 Pre-Merger pre-funded warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Pre-Merger Oruka
was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the fact that, immediately
following the Merger: (i) Pre-Merger Oruka stockholders own a substantial majority of the voting rights in the combined company; (ii)
Pre-Merger Oruka&#x2019;s largest stockholders retain the largest interest in the combined company; (iii) Pre-Merger Oruka designated
a majority of the initial members of the board of directors of the combined company; and (iv) Pre-Merger Oruka&#x2019;s executive management
team became the management team of the combined company. Accordingly, for accounting purposes: (i) the Merger was treated as the equivalent
of Pre-Merger Oruka issuing stock to acquire the net assets of ARCA, and (ii) the reported historical operating results of the combined
company prior to the Merger are those of Pre-Merger Oruka. Additional information regarding the Merger is included in Note 3.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Reverse
Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
September 3, 2024, the Company effected the Reverse Stock Split, a 1-for-12 reverse stock split of Company Common Stock. The par value
per share and the number of authorized shares were not adjusted as a result of the Reverse Stock Split. The shares of Company Common
Stock underlying outstanding stock options, common stock warrants and other equity instruments were proportionately reduced and the respective
exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.
All references to common stock, options to purchase common stock, outstanding common stock warrants, common stock share data, per share
data, and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect
of the Reverse Stock Split for all periods presented, unless otherwise specifically indicated or the context otherwise requires.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;PIPE
Financing&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
September 11, 2024, the Company entered into a Securities Purchase Agreement for a private placement (the &#x201c;PIPE Financing&#x201d;)
with certain institutional and accredited investors. The closing of the PIPE Financing occurred on September 13, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;Pursuant
to the Securities Purchase Agreement, the investors purchased an aggregate of 5,600,000 shares of Company Common Stock at a purchase
price of $23.00 per share, an aggregate of 2,439 shares of the Company&#x2019;s Series A non-voting convertible preferred stock, par value
$0.001 per share (&#x201c;Company Series A Preferred Stock&#x201d;), at a purchase price of $23,000.00 per share (each Company Series A
Preferred Stock is convertible into 1,000 shares of Company Common Stock), and pre-funded warrants to purchase an aggregate of 680,000
shares of Company Common Stock at a purchase price of $22.999 per pre-funded warrant, for aggregate net proceeds of approximately $188.7
million (net of issuance costs of $11.9 million).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Liquidity
and Going Concern&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Since
its inception, the Company has devoted substantially all of its resources to advancing the development of its portfolio of programs,
organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations.
Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and
regulatory approvals to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever,
the Company expects to finance its operating activities through a combination of equity offerings and debt financings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative
cash flows from operations since inception. For the period from February 6, 2024 (inception) to December 31, 2024, the Company has incurred
a net loss of $83.7 million and used net cash of $57.8 million for its operating activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of December 31, 2024, the Company had cash, cash equivalents, and marketable securities of $393.7 million. The Company&#x2019;s management
expects that the existing cash, cash equivalents, and marketable securities will be sufficient to fund the Company&#x2019;s operating
plans for at least twelve months from the date these consolidated financial statements were issued. The Company expects that its research
and development and general and administrative costs will continue to increase significantly, including in connection with conducting
future pre-clinical activities and clinical trials and manufacturing for its existing product candidates and any future product candidates
to support commercialization and providing general and administrative support for its operations, including the costs associated with
operating as a public company. The Company&#x2019;s ability to access capital when needed is not assured and, if capital is not available
to the Company when, and in the amounts needed, the Company may be required to significantly curtail, delay, or discontinue one or more
of its research or development programs or the commercialization of any product candidate, or be unable to expand its operations or otherwise
capitalize on the Company&#x2019;s business opportunities, as desired, which could materially harm the Company&#x2019;s business, financial
condition and results of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="c40" id="ixv-24335">1-for-12</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c41"
      decimals="3"
      id="ixv-24336"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction contextRef="c42" decimals="-5" id="ixv-24337" unitRef="usd">275000000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c42" decimals="-5" id="ixv-24338" unitRef="usd">25000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <orka:AdditionalPaidInCapitalTransacationCost contextRef="c43" decimals="-5" id="ixv-24339" unitRef="usd">20500000</orka:AdditionalPaidInCapitalTransacationCost>
    <orka:ExchangeRatio contextRef="c44" decimals="4" id="ixv-24340" unitRef="pure">6.8569</orka:ExchangeRatio>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c45"
      decimals="4"
      id="ixv-24341"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c46"
      decimals="3"
      id="ixv-24342"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <orka:CommonStocksConversionRatio contextRef="c47" id="ixv-24343">83:3332:1</orka:CommonStocksConversionRatio>
    <orka:InvestorsClosingShares
      contextRef="c48"
      decimals="0"
      id="ixv-24344"
      unitRef="shares">22784139</orka:InvestorsClosingShares>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c49"
      decimals="INF"
      id="ixv-24345"
      unitRef="shares">39873706</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c48"
      decimals="0"
      id="ixv-24346"
      unitRef="shares">2722207</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c48"
      decimals="0"
      id="ixv-24347"
      unitRef="shares">4764032</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <orka:PreFundedWarrantsOfCommonStockShares
      contextRef="c0"
      decimals="0"
      id="ixv-24348"
      unitRef="shares">5522207</orka:PreFundedWarrantsOfCommonStockShares>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="c3"
      decimals="0"
      id="ixv-24349"
      unitRef="shares">9664208</us-gaap:ClassOfWarrantOrRightUnissued>
    <orka:NumberOfSharesPurchased
      contextRef="c50"
      decimals="0"
      id="ixv-24350"
      unitRef="shares">5600000</orka:NumberOfSharesPurchased>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c50"
      decimals="2"
      id="ixv-24351"
      unitRef="usdPershares">23</us-gaap:SaleOfStockPricePerShare>
    <orka:NumberofAggregateShares
      contextRef="c51"
      decimals="0"
      id="ixv-24352"
      unitRef="shares">2439</orka:NumberofAggregateShares>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c52"
      decimals="3"
      id="ixv-24353"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c9"
      decimals="2"
      id="ixv-24354"
      unitRef="usdPershares">23000</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c53"
      decimals="0"
      id="ixv-24355"
      unitRef="shares">1000</us-gaap:ConversionOfStockSharesConverted1>
    <orka:PrefundedWarrantstoPurchaseAnAggregateShares
      contextRef="c48"
      decimals="0"
      id="ixv-24356"
      unitRef="shares">680000</orka:PrefundedWarrantstoPurchaseAnAggregateShares>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c54"
      decimals="3"
      id="ixv-24357"
      unitRef="usdPershares">22.999</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction contextRef="c55" decimals="-5" id="ixv-24358" unitRef="usd">188700000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="c55" decimals="-5" id="ixv-24359" unitRef="usd">11900000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-5" id="ixv-24360" unitRef="usd">-83700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-5" id="ixv-24361" unitRef="usd">-57800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:InvestmentsAndCash contextRef="c3" decimals="-5" id="ixv-24362" unitRef="usd">393700000</us-gaap:InvestmentsAndCash>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-11859">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2.
Summary of Significant Accounting Policies &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
preparation of the Company&#x2019;s consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates,
assumptions, and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at
the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant
estimates and assumptions reflected within these consolidated financial statements include but are not limited to research and development
expenses and related prepaid or accrued costs and the valuation of stock-based compensation awards and related expenses. The Company
bases its estimates on known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances.
On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results
could differ materially from those estimates or assumptions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Concentrations
of Credit Risk and Other Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial
instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities.
The Company&#x2019;s investment policy limits investments to high credit quality securities issued by the U.S. government, U.S. government-sponsored
agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company&#x2019;s
cash, cash equivalents and marketable securities are held by financial institutions that management believes are of high credit quality.
The financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits.
Accounts at the Company&#x2019;s U.S. banking institution are insured by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;)
up to $250,000 per depositor. As of December 31, 2024, the balance at the Company&#x2019;s U.S. banking institution exceeded the FDIC
limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its accounts are monitored by management
to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash
equivalents, and bond issuers.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company is dependent on third-party organizations to research, develop, manufacture, and process its product candidates for its development
programs, including its two most advanced programs, ORKA-001 and ORKA-002. The Company expects to continue to be dependent on a small
number of manufacturers to supply it with its requirements for all products. The Company&#x2019;s research and development programs could
be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company&#x2019;s
research and development activities are performed under its agreements with Paragon Therapeutics, Inc. (&#x201c;Paragon&#x201d;) (see Note&#160;12).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Cash
and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to
be cash equivalents. The cash equivalents were comprised of investments in money market funds, U. S. treasury securities, U.S. government
agency securities, and debt securities and are stated at fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Marketable
Securities&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company invests in marketable securities, primarily securities issued by the U.S. government and its agencies, commercial paper and corporate
debt securities. The Company&#x2019;s marketable securities are classified as available-for-sale and reported at fair value, with unrealized
gains and losses included as a component of accumulated other comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
available-for-sale debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more
likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria
regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value and recognized
in other income (expense) in the results of operations. For available-for-sale debt securities that do not meet the aforementioned criteria,
the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment,
management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating
agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit
loss exists, an allowance is recorded for the difference between the present value of cash flows expected to be collected and the amortized
cost basis of the security. Impairment losses attributable to credit loss factors are charged against the allowance when management believes
an available-for-sale security is uncollectible or when either of the criteria regarding intent or requirement to sell is met.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Any
unrealized losses from declines in fair value below the amortized cost basis as a result of non-credit loss factors are recognized as
a component of accumulated other comprehensive loss, net of unrealized gains. Realized gains and losses and declines in fair value, if
any, on available-for-sale securities are included in other income, net, in the results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable
securities with stated maturities of greater than three months from the date of purchase but less than one year from the consolidated
balance sheet date are classified as current, while marketable securities with maturities in one year or beyond one year from the consolidated
balance sheet date are classified as long-term. The cost of securities sold is determined using the specific-identification method. Interest
earned and adjustments for the amortization of premiums and discounts on investments are included in interest income on the consolidated
statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Debt
Issuance Costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Debt
issuance costs incurred in connection with the Convertible Note (see Note&#160;7) are recorded as a reduction of the carrying value of
the notes payable liability on the Company&#x2019;s balance sheet and are amortized to interest expense over the term of the loan using
the effective interest method. At the effective time of the Merger the Converted Note was converted to common stock and is no longer
on the balance sheet as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Subscription
Receivable&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable
is paid prior to the date the financial statement is available to be issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Fair
Value Measurements&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Certain
assets and liabilities are carried at fair value under U.S.&#160;GAAP.&#160;Fair value is defined as the exchange price that would be
received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize
the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are
to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered
observable and the last is considered unobservable:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
                                            1&#160;&#x2014;&#160;Quoted prices in active markets that are identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level&#160;2&#160;&#x2014;&#160;Observable
                                            inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar
                                            assets or liabilities, quoted prices in markets that are not active for identical or similar
                                            assets or liabilities, or other inputs that are observable or can be corroborated by observable
                                            market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level&#160;3&#160;&#x2014;&#160;Unobservable
                                            inputs that are supported by little or no market activity that are significant to determining
                                            the fair value of the assets or liabilities, including pricing models, discounted cash flow
                                            methodologies, and similar techniques.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company&#x2019;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy
described above (see Note 4). The carrying values of the Company&#x2019;s prepaid expenses and other current assets, accounts payable
and accrued expenses and other current liabilities approximate their fair values due to their relatively short maturity period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Property
and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property
and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over
the estimated useful life of each asset as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Estimated&lt;br/&gt;
    Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3-5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computer and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3-5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Classification
of Convertible Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prior
to the reverse recapitalization, the Company had classified its Pre-Merger Oruka Series A Preferred Stock outside of stockholders&#x2019;
equity on the Company&#x2019;s consolidated balance sheet because the holders of such stock have certain liquidation rights in the event
of a deemed liquidation event that, in certain situations, is not solely within the control of the Company and would require the redemption
of the then-outstanding convertible preferred stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Upon
the closing of the Merger, the Company converted its Pre-Merger Oruka Series A Preferred Stock to Company Series B Preferred Stock and
has classified the Company Series B Preferred Stock within stockholders&#x2019; equity on its consolidated balance sheet because the Company
Series B Preferred Stock is not redeemable or puttable to the Company by the holder under any circumstances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
connection with the PIPE Financing (see Note 1) the Company issued Company Series A Preferred Stock, and has classified the Company Series
A Preferred Stock outside of stockholders&#x2019; equity on the Company&#x2019;s consolidated balance sheet because the holders of such
stock have certain rights (see Note 8) that, in certain situations, is not solely within the control of the Company and would require
the redemption of the then-outstanding convertible preferred stock. In November 2024, the Company Series A Preferred Stock shares were
converted to common stock, and as of December 31, 2024, there were no shares of Company Series A Preferred Stock outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Note&#160;Payable
to Related Party&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accounted for the Convertible Note (as defined in Note 7) at amortized cost. The Company considered if optional conversion features
are required to be bifurcated and separately accounted for as a derivative. Costs related to the issuance of the Convertible Note were
recorded as a debt discount, amortized over the term of the Convertible Note (see&#160;Note&#160;7) and were accounted for as interest
expense in other income (expenses) within the consolidated statement of operations and comprehensive loss using the effective interest
method. At the effective time of the Merger, shares of Pre-Merger Oruka Common Stock issued pursuant to the conversion of the Convertible
Note (including accrued interest) automatically converted into shares of Company Common Stock (see Note 1).&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Research
and Development Contract Costs Accruals&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component
of the Company&#x2019;s research and development expenses, with a substantial portion of the Company&#x2019;s ongoing research and development
activities conducted by third-party service providers, including contract research organizations (&#x201c;CROs&#x201d;) and contract manufacturing
organizations (&#x201c;CMOs&#x201d;), and the Company&#x2019;s related-party Paragon (see Note&#160;12).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accrues for expenses resulting from obligations under its two antibody discovery and option agreements (the &#x201c;Option Agreements&#x201d;)
(see Note 12), by and among Paragon, Paruka Holding LLC (&#x201c;Paruka&#x201d;), an entity formed by Paragon as a vehicle to hold equity
in the Company, and the Company as well as agreements with CROs, CMOs, and other outside service providers for which payment flows do
not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services
received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These
estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with
internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant
judgments and estimates in determining the accrual balance in each reporting period. If advance payments are made to Paragon, a CRO,
CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services
are performed. Changes in these estimates that result in material changes to the Company&#x2019;s accruals could materially affect the
Company&#x2019;s results of operations. As of December 31, 2024, the Company has not experienced any material deviations between accrued
and actual research and development expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At
the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies
a lease as either an operating or finance lease and recognizes a right-of-use (&#x201c;ROU&#x201d;) asset and a current and non-current
lease liability, as applicable, in the balance sheet if the lease has a term greater than one year. Lease terms may include options to
extend or terminate the lease when it is reasonably certain that the Company will exercise its option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At
the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future
minimum lease payments over the expected remaining lease term. The Company determines the present value of lease payments using the implicit
rate, if it is readily determinable, or the risk-free discount rate for a period comparable with that of the lease term. For operating
leases, lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, lease expense
includes amortization expense of the ROU asset recognized on a straight-line basis over the lease term and interest expense recognized
on the finance lease liability. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments,
incentives received or initial direct costs. As of December 31, 2024, the Company has one operating lease and no finance leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accounts for lease and non-lease components related to operating leases as a single lease component. The Company has elected
that costs associated with leases having an initial term of 12 months or less are recognized in the consolidated statement of operations
and comprehensive loss on a straight-line basis over the lease term and are not recorded on its consolidated balance sheets. Variable
lease expense is recognized as incurred and consists primarily of real estate taxes, utilities, and other office space related expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Segment
Reporting&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company operates as a
single reportable and operating segment. Its Chief Executive Officer, serving as the Chief Operating Decision Maker (&#x201c;CODM&#x201d;),
oversees operations on an aggregated basis to allocate resources effectively. In assessing the Company&#x2019;s financial performance,
the CODM regularly reviews total operating expenses and consolidated net loss.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Research
and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock-based compensation,
employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities, as well as allocated
human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Nonrefundable
advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid
expenses on the accompanying consolidated balance sheet. The prepaid amounts are expensed as the related goods are delivered or the services
are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable advance
payments represent a one-time cost for obtaining goods or services, with anticipated benefits to be utilized within a year of period
end, the payment is expensed immediately.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;General
and Administrative Expenses&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General
and administrative expenses consist primarily of salaries and bonuses, stock-based compensation, employee benefits, finance and administration
costs, patent and intellectual property costs, professional fees, as well as allocated human resource costs, information technology costs,
and facility-related costs, including rent, maintenance, utilities and depreciation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Commitments
and Contingencies&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities.
The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the
loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the
balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but
not probable; however, it discloses the range of reasonably possible losses. As of December 31, 2024, no liabilities were recorded for
loss contingencies (see Note&#160;13).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Stock-Based
Compensation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company estimates the fair value of its stock awards using the Black-Scholes option pricing model, which uses as inputs the fair value
of the Company&#x2019;s common stock, and certain management estimates, including the expected stock price volatility, the expected term
of the award, the risk-free interest rate, and expected dividends. Expected volatility is calculated based on reported volatility data
for a representative group of publicly traded companies for which historical information is available. The Company selects companies
with comparable characteristics with historical share price information that approximates the expected term of the equity-based awards.
The Company computes the historical volatility data using the daily closing prices for the selected companies&#x2019; shares during the
equivalent period that approximates the calculated expected term of the stock options. The Company will continue to apply this method
until a sufficient amount of historical information regarding the volatility of its stock price becomes available. The risk-free interest
rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. For employee
and non-employee awards (except the Paruka warrant) the Company uses the simplified method, under which the expected term is presumed
to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to lack of historical
exercise data. For the Paruka warrant, the contractual term is used for the expected term. The expected dividend yield is assumed to
be zero as the Company has no current plans to pay any dividends on common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company measures restricted common stock awards (&#x201c;RSAs&#x201d;) using the difference, if any, between the purchase price per share
of the award and the fair value of the Company&#x2019;s common stock at the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company grants stock options, restricted stock awards, and warrants that are subject to service or performance-based vesting conditions.
Compensation expense for awards to employees and directors with service-based vesting conditions is recognized using the straight-line
method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards
to non-employees with service-based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for
the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each
reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation
expense until it is probable that the performance-based vesting condition will be achieved.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company has issued stock options, warrants, and RSAs with service-based and performance-based vesting conditions.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company recognizes the compensation expense for the option to purchase common stock under the Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;),
based on the fair value of the common stock estimated using the closing price of the Company&#x2019;s common stock as reported on the
date of offering, less the purchase discount percentage provided for in the plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company classifies stock-based compensation expense in its consolidated statement of operations and comprehensive loss in the same manner
in which the award recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments are classified,
as applicable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Comprehensive
Loss&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Comprehensive
loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and events other than those
with stockholders. The Company&#x2019;s unrealized gains and losses on marketable securities represent the only component of other comprehensive
loss that are excluded from the reported net loss and that are presented in the consolidated statement of comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Net
Loss per Share Attributable to Stockholders&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic
and diluted net loss attributable to stockholders per share is presented in conformity with the two-class method required for participating
securities (Pre-Merger Oruka Series A Preferred Stock). Basic earnings per share is computed by dividing net income available to each
class of shares by the weighted-average number of shares of common stock and participating securities outstanding during the period.
Pre-funded warrants were included as the exercise price is negligible and these warrants are fully vested and exercisable. Company Series
A Preferred Stock and Company Series B Preferred Stock share the same characteristics as Common Stock and have no substantive preference
attributed to them and, accordingly, have been considered as classes of Common Stock in the computation of net loss per share regardless
of their legal form.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
loss is allocated to common stock based on its proportional ownership on an as-converted basis. Net loss is not allocated to participating
securities as they do not have an obligation to fund losses. The weighted-average number of shares outstanding of common stock reflects
changes in ownership over the periods presented. See Note 8 &#x2014; Convertible Preferred Stock and Stockholders&#x2019; Equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Diluted
net loss per share is computed by dividing the net loss attributable to stockholders adjusted for income (expenses), net of tax, related
to any diluted securities, by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for
the period. For purposes of this calculation, stock options to purchase common stock, employee warrants to purchase common stock, and
unvested RSAs are considered potential dilutive common shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company generated a net loss for the periods presented. Accordingly, basic and diluted net loss per share is the same because the inclusion
of the potentially dilutive securities would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Other
income, net&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
income, net, consists of interest earned on the Company&#x2019;s cash, cash equivalents, and marketable securities; interest expense on
the convertible note from a related party and foreign currency transactions gains and losses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#x2019;s tax
returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis
of assets and liabilities using enacted tax rates in effect for the&#160;years in which the differences are expected to reverse. Changes
in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred
tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence,
that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established
through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable
profits expected and considering prudent and feasible tax planning strategies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to
determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will
be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained,
the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount
of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement.
The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered
appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or penalties related to
uncertain tax positions as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Recently
Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
November&#160;2023, the FASB issued ASU 2023-07, Segment Reporting (Topic&#160;280): Improvements to Reportable Segment Disclosures (&#x201c;ASU&#160;2023-07&#x201d;),
which enhances the segment disclosure requirements for public entities on an annual and interim basis. Under this standard, public entities
will be required to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure
of segment profit or loss. Additionally, current annual disclosures about a reportable segment&#x2019;s profit or loss and assets will
be required on an interim basis. Entities will also be required to disclose information about the CODM&#x2019;s title and position at
the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment of segment
performance and deciding how to allocate resources. Finally, ASU&#160;2023-07 requires all segment disclosures for public entities that
have only a single reportable segment. The amendments in ASU&#160;2023-07 are effective for fiscal&#160;years beginning after December&#160;15,
2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. Early adoption is permitted. The Company adopted
ASU 2023-07 in 2024 and additional required disclosures have been included in Note 10.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Recently
Issued Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
December&#160;2023, the FASB issued ASU&#160;2023-09, Income Taxes (Topic&#160;740): Improvements to Income Tax Disclosures. This ASU
expands disclosures in an entity&#x2019;s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S.&#160;and
foreign jurisdictions. This update is effective beginning with the Company&#x2019;s 2025 fiscal year annual reporting period. The Company
is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
November 2024, the FASB issued ASU 2024-03, Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU requires more detailed disclosures, on an annual and interim
basis, about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense
captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and
interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. This ASU may be applied either prospectively
or retrospectively. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-11867">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
preparation of the Company&#x2019;s consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates,
assumptions, and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at
the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant
estimates and assumptions reflected within these consolidated financial statements include but are not limited to research and development
expenses and related prepaid or accrued costs and the valuation of stock-based compensation awards and related expenses. The Company
bases its estimates on known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances.
On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results
could differ materially from those estimates or assumptions.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-11879">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Concentrations
of Credit Risk and Other Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial
instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities.
The Company&#x2019;s investment policy limits investments to high credit quality securities issued by the U.S. government, U.S. government-sponsored
agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company&#x2019;s
cash, cash equivalents and marketable securities are held by financial institutions that management believes are of high credit quality.
The financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash deposits.
Accounts at the Company&#x2019;s U.S. banking institution are insured by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;)
up to $250,000 per depositor. As of December 31, 2024, the balance at the Company&#x2019;s U.S. banking institution exceeded the FDIC
limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its accounts are monitored by management
to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash
equivalents, and bond issuers.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company is dependent on third-party organizations to research, develop, manufacture, and process its product candidates for its development
programs, including its two most advanced programs, ORKA-001 and ORKA-002. The Company expects to continue to be dependent on a small
number of manufacturers to supply it with its requirements for all products. The Company&#x2019;s research and development programs could
be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company&#x2019;s
research and development activities are performed under its agreements with Paragon Therapeutics, Inc. (&#x201c;Paragon&#x201d;) (see Note&#160;12).&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FederalDepositInsuranceCorporationPremiumExpense contextRef="c0" decimals="0" id="ixv-24363" unitRef="usd">250000</us-gaap:FederalDepositInsuranceCorporationPremiumExpense>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0" id="ixv-11912">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Cash
and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to
be cash equivalents. The cash equivalents were comprised of investments in money market funds, U. S. treasury securities, U.S. government
agency securities, and debt securities and are stated at fair value.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy contextRef="c0" id="ixv-11924">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Marketable
Securities&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company invests in marketable securities, primarily securities issued by the U.S. government and its agencies, commercial paper and corporate
debt securities. The Company&#x2019;s marketable securities are classified as available-for-sale and reported at fair value, with unrealized
gains and losses included as a component of accumulated other comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
available-for-sale debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more
likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria
regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value and recognized
in other income (expense) in the results of operations. For available-for-sale debt securities that do not meet the aforementioned criteria,
the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment,
management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating
agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit
loss exists, an allowance is recorded for the difference between the present value of cash flows expected to be collected and the amortized
cost basis of the security. Impairment losses attributable to credit loss factors are charged against the allowance when management believes
an available-for-sale security is uncollectible or when either of the criteria regarding intent or requirement to sell is met.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Any
unrealized losses from declines in fair value below the amortized cost basis as a result of non-credit loss factors are recognized as
a component of accumulated other comprehensive loss, net of unrealized gains. Realized gains and losses and declines in fair value, if
any, on available-for-sale securities are included in other income, net, in the results of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable
securities with stated maturities of greater than three months from the date of purchase but less than one year from the consolidated
balance sheet date are classified as current, while marketable securities with maturities in one year or beyond one year from the consolidated
balance sheet date are classified as long-term. The cost of securities sold is determined using the specific-identification method. Interest
earned and adjustments for the amortization of premiums and discounts on investments are included in interest income on the consolidated
statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:DebtPolicyTextBlock contextRef="c0" id="ixv-11951">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Debt
Issuance Costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Debt
issuance costs incurred in connection with the Convertible Note (see Note&#160;7) are recorded as a reduction of the carrying value of
the notes payable liability on the Company&#x2019;s balance sheet and are amortized to interest expense over the term of the loan using
the effective interest method. At the effective time of the Merger the Converted Note was converted to common stock and is no longer
on the balance sheet as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <orka:SubscriptionReceivablePolicyTextBlock contextRef="c0" id="ixv-11963">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Subscription
Receivable&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable
is paid prior to the date the financial statement is available to be issued.&lt;/span&gt;&lt;/p&gt;</orka:SubscriptionReceivablePolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0" id="ixv-11991">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Fair
Value Measurements&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Certain
assets and liabilities are carried at fair value under U.S.&#160;GAAP.&#160;Fair value is defined as the exchange price that would be
received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize
the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are
to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered
observable and the last is considered unobservable:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
                                            1&#160;&#x2014;&#160;Quoted prices in active markets that are identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level&#160;2&#160;&#x2014;&#160;Observable
                                            inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar
                                            assets or liabilities, quoted prices in markets that are not active for identical or similar
                                            assets or liabilities, or other inputs that are observable or can be corroborated by observable
                                            market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level&#160;3&#160;&#x2014;&#160;Unobservable
                                            inputs that are supported by little or no market activity that are significant to determining
                                            the fair value of the assets or liabilities, including pricing models, discounted cash flow
                                            methodologies, and similar techniques.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company&#x2019;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy
described above (see Note 4). The carrying values of the Company&#x2019;s prepaid expenses and other current assets, accounts payable
and accrued expenses and other current liabilities approximate their fair values due to their relatively short maturity period.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0" id="ixv-12038">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Property
and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property
and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over
the estimated useful life of each asset as follows:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Estimated&lt;br/&gt;
    Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3-5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computer and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3-5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-12045">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property
and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over
the estimated useful life of each asset as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Estimated&lt;br/&gt;
    Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3-5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computer and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3-5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c56" id="ixv-24364">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c57" id="ixv-24365">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c58" id="ixv-24366">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c59" id="ixv-24367">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <orka:ClassificationOfConvertiblePreferredStockPolicyTextBlock contextRef="c0" id="ixv-12079">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Classification
of Convertible Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prior
to the reverse recapitalization, the Company had classified its Pre-Merger Oruka Series A Preferred Stock outside of stockholders&#x2019;
equity on the Company&#x2019;s consolidated balance sheet because the holders of such stock have certain liquidation rights in the event
of a deemed liquidation event that, in certain situations, is not solely within the control of the Company and would require the redemption
of the then-outstanding convertible preferred stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Upon
the closing of the Merger, the Company converted its Pre-Merger Oruka Series A Preferred Stock to Company Series B Preferred Stock and
has classified the Company Series B Preferred Stock within stockholders&#x2019; equity on its consolidated balance sheet because the Company
Series B Preferred Stock is not redeemable or puttable to the Company by the holder under any circumstances.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
connection with the PIPE Financing (see Note 1) the Company issued Company Series A Preferred Stock, and has classified the Company Series
A Preferred Stock outside of stockholders&#x2019; equity on the Company&#x2019;s consolidated balance sheet because the holders of such
stock have certain rights (see Note 8) that, in certain situations, is not solely within the control of the Company and would require
the redemption of the then-outstanding convertible preferred stock. In November 2024, the Company Series A Preferred Stock shares were
converted to common stock, and as of December 31, 2024, there were no shares of Company Series A Preferred Stock outstanding.&lt;/span&gt;&lt;/p&gt;</orka:ClassificationOfConvertiblePreferredStockPolicyTextBlock>
    <orka:NotePayableToRelatedPartyPolicyTextBlock contextRef="c0" id="ixv-12117">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Note&#160;Payable
to Related Party&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accounted for the Convertible Note (as defined in Note 7) at amortized cost. The Company considered if optional conversion features
are required to be bifurcated and separately accounted for as a derivative. Costs related to the issuance of the Convertible Note were
recorded as a debt discount, amortized over the term of the Convertible Note (see&#160;Note&#160;7) and were accounted for as interest
expense in other income (expenses) within the consolidated statement of operations and comprehensive loss using the effective interest
method. At the effective time of the Merger, shares of Pre-Merger Oruka Common Stock issued pursuant to the conversion of the Convertible
Note (including accrued interest) automatically converted into shares of Company Common Stock (see Note 1).&lt;/span&gt;&lt;/p&gt;</orka:NotePayableToRelatedPartyPolicyTextBlock>
    <orka:ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock contextRef="c0" id="ixv-12129">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Research
and Development Contract Costs Accruals&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component
of the Company&#x2019;s research and development expenses, with a substantial portion of the Company&#x2019;s ongoing research and development
activities conducted by third-party service providers, including contract research organizations (&#x201c;CROs&#x201d;) and contract manufacturing
organizations (&#x201c;CMOs&#x201d;), and the Company&#x2019;s related-party Paragon (see Note&#160;12).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accrues for expenses resulting from obligations under its two antibody discovery and option agreements (the &#x201c;Option Agreements&#x201d;)
(see Note 12), by and among Paragon, Paruka Holding LLC (&#x201c;Paruka&#x201d;), an entity formed by Paragon as a vehicle to hold equity
in the Company, and the Company as well as agreements with CROs, CMOs, and other outside service providers for which payment flows do
not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services
received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These
estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with
internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant
judgments and estimates in determining the accrual balance in each reporting period. If advance payments are made to Paragon, a CRO,
CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services
are performed. Changes in these estimates that result in material changes to the Company&#x2019;s accruals could materially affect the
Company&#x2019;s results of operations. As of December 31, 2024, the Company has not experienced any material deviations between accrued
and actual research and development expenses.&lt;/span&gt;&lt;/p&gt;</orka:ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-12146">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At
the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies
a lease as either an operating or finance lease and recognizes a right-of-use (&#x201c;ROU&#x201d;) asset and a current and non-current
lease liability, as applicable, in the balance sheet if the lease has a term greater than one year. Lease terms may include options to
extend or terminate the lease when it is reasonably certain that the Company will exercise its option.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At
the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future
minimum lease payments over the expected remaining lease term. The Company determines the present value of lease payments using the implicit
rate, if it is readily determinable, or the risk-free discount rate for a period comparable with that of the lease term. For operating
leases, lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, lease expense
includes amortization expense of the ROU asset recognized on a straight-line basis over the lease term and interest expense recognized
on the finance lease liability. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments,
incentives received or initial direct costs. As of December 31, 2024, the Company has one operating lease and no finance leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accounts for lease and non-lease components related to operating leases as a single lease component. The Company has elected
that costs associated with leases having an initial term of 12 months or less are recognized in the consolidated statement of operations
and comprehensive loss on a straight-line basis over the lease term and are not recorded on its consolidated balance sheets. Variable
lease expense is recognized as incurred and consists primarily of real estate taxes, utilities, and other office space related expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0" id="ixv-12184">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Segment
Reporting&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company operates as a
single reportable and operating segment. Its Chief Executive Officer, serving as the Chief Operating Decision Maker (&#x201c;CODM&#x201d;),
oversees operations on an aggregated basis to allocate resources effectively. In assessing the Company&#x2019;s financial performance,
the CODM regularly reviews total operating expenses and consolidated net loss.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0" id="ixv-12196">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Research
and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock-based compensation,
employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities, as well as allocated
human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Nonrefundable
advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid
expenses on the accompanying consolidated balance sheet. The prepaid amounts are expensed as the related goods are delivered or the services
are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable advance
payments represent a one-time cost for obtaining goods or services, with anticipated benefits to be utilized within a year of period
end, the payment is expensed immediately.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="c0" id="ixv-12213">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;General
and Administrative Expenses&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General
and administrative expenses consist primarily of salaries and bonuses, stock-based compensation, employee benefits, finance and administration
costs, patent and intellectual property costs, professional fees, as well as allocated human resource costs, information technology costs,
and facility-related costs, including rent, maintenance, utilities and depreciation.&lt;/span&gt;&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c0" id="ixv-12225">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Commitments
and Contingencies&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities.
The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the
loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the
balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but
not probable; however, it discloses the range of reasonably possible losses. As of December 31, 2024, no liabilities were recorded for
loss contingencies (see Note&#160;13).&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0" id="ixv-12237">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Stock-Based
Compensation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company estimates the fair value of its stock awards using the Black-Scholes option pricing model, which uses as inputs the fair value
of the Company&#x2019;s common stock, and certain management estimates, including the expected stock price volatility, the expected term
of the award, the risk-free interest rate, and expected dividends. Expected volatility is calculated based on reported volatility data
for a representative group of publicly traded companies for which historical information is available. The Company selects companies
with comparable characteristics with historical share price information that approximates the expected term of the equity-based awards.
The Company computes the historical volatility data using the daily closing prices for the selected companies&#x2019; shares during the
equivalent period that approximates the calculated expected term of the stock options. The Company will continue to apply this method
until a sufficient amount of historical information regarding the volatility of its stock price becomes available. The risk-free interest
rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. For employee
and non-employee awards (except the Paruka warrant) the Company uses the simplified method, under which the expected term is presumed
to be the midpoint between the vesting date and the end of the contractual term. The Company utilizes this method due to lack of historical
exercise data. For the Paruka warrant, the contractual term is used for the expected term. The expected dividend yield is assumed to
be zero as the Company has no current plans to pay any dividends on common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company measures restricted common stock awards (&#x201c;RSAs&#x201d;) using the difference, if any, between the purchase price per share
of the award and the fair value of the Company&#x2019;s common stock at the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company grants stock options, restricted stock awards, and warrants that are subject to service or performance-based vesting conditions.
Compensation expense for awards to employees and directors with service-based vesting conditions is recognized using the straight-line
method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards
to non-employees with service-based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for
the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each
reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation
expense until it is probable that the performance-based vesting condition will be achieved.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company has issued stock options, warrants, and RSAs with service-based and performance-based vesting conditions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company recognizes the compensation expense for the option to purchase common stock under the Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;),
based on the fair value of the common stock estimated using the closing price of the Company&#x2019;s common stock as reported on the
date of offering, less the purchase discount percentage provided for in the plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company classifies stock-based compensation expense in its consolidated statement of operations and comprehensive loss in the same manner
in which the award recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments are classified,
as applicable.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <orka:ComprehensiveLossPolicyPolicyTextBlock contextRef="c0" id="ixv-12290">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Comprehensive
Loss&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Comprehensive
loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and events other than those
with stockholders. The Company&#x2019;s unrealized gains and losses on marketable securities represent the only component of other comprehensive
loss that are excluded from the reported net loss and that are presented in the consolidated statement of comprehensive loss.&lt;/span&gt;&lt;/p&gt;</orka:ComprehensiveLossPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-12302">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Net
Loss per Share Attributable to Stockholders&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic
and diluted net loss attributable to stockholders per share is presented in conformity with the two-class method required for participating
securities (Pre-Merger Oruka Series A Preferred Stock). Basic earnings per share is computed by dividing net income available to each
class of shares by the weighted-average number of shares of common stock and participating securities outstanding during the period.
Pre-funded warrants were included as the exercise price is negligible and these warrants are fully vested and exercisable. Company Series
A Preferred Stock and Company Series B Preferred Stock share the same characteristics as Common Stock and have no substantive preference
attributed to them and, accordingly, have been considered as classes of Common Stock in the computation of net loss per share regardless
of their legal form.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
loss is allocated to common stock based on its proportional ownership on an as-converted basis. Net loss is not allocated to participating
securities as they do not have an obligation to fund losses. The weighted-average number of shares outstanding of common stock reflects
changes in ownership over the periods presented. See Note 8 &#x2014; Convertible Preferred Stock and Stockholders&#x2019; Equity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Diluted
net loss per share is computed by dividing the net loss attributable to stockholders adjusted for income (expenses), net of tax, related
to any diluted securities, by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for
the period. For purposes of this calculation, stock options to purchase common stock, employee warrants to purchase common stock, and
unvested RSAs are considered potential dilutive common shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company generated a net loss for the periods presented. Accordingly, basic and diluted net loss per share is the same because the inclusion
of the potentially dilutive securities would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <orka:OtherIncomeExpenseNetPolicyTextBlock contextRef="c0" id="ixv-12329">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Other
income, net&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
income, net, consists of interest earned on the Company&#x2019;s cash, cash equivalents, and marketable securities; interest expense on
the convertible note from a related party and foreign currency transactions gains and losses.&lt;/span&gt;&lt;/p&gt;</orka:OtherIncomeExpenseNetPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0" id="ixv-12357">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#x2019;s tax
returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis
of assets and liabilities using enacted tax rates in effect for the&#160;years in which the differences are expected to reverse. Changes
in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred
tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence,
that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established
through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable
profits expected and considering prudent and feasible tax planning strategies.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to
determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will
be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained,
the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount
of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement.
The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered
appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or penalties related to
uncertain tax positions as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <orka:RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-12374">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Recently
Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
November&#160;2023, the FASB issued ASU 2023-07, Segment Reporting (Topic&#160;280): Improvements to Reportable Segment Disclosures (&#x201c;ASU&#160;2023-07&#x201d;),
which enhances the segment disclosure requirements for public entities on an annual and interim basis. Under this standard, public entities
will be required to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure
of segment profit or loss. Additionally, current annual disclosures about a reportable segment&#x2019;s profit or loss and assets will
be required on an interim basis. Entities will also be required to disclose information about the CODM&#x2019;s title and position at
the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment of segment
performance and deciding how to allocate resources. Finally, ASU&#160;2023-07 requires all segment disclosures for public entities that
have only a single reportable segment. The amendments in ASU&#160;2023-07 are effective for fiscal&#160;years beginning after December&#160;15,
2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. Early adoption is permitted. The Company adopted
ASU 2023-07 in 2024 and additional required disclosures have been included in Note 10.&lt;/span&gt;&lt;/p&gt;</orka:RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-12386">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Recently
Issued Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
December&#160;2023, the FASB issued ASU&#160;2023-09, Income Taxes (Topic&#160;740): Improvements to Income Tax Disclosures. This ASU
expands disclosures in an entity&#x2019;s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S.&#160;and
foreign jurisdictions. This update is effective beginning with the Company&#x2019;s 2025 fiscal year annual reporting period. The Company
is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
November 2024, the FASB issued ASU 2024-03, Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU requires more detailed disclosures, on an annual and interim
basis, about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense
captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and
interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. This ASU may be applied either prospectively
or retrospectively. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="c0" id="ixv-12420">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;3.
Reverse Recapitalization and Pre-Closing Financing&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
described within the Reverse Recapitalization and Pre-Closing Financing section in Note 1, on August 29, 2024, the reverse recapitalization
between Pre-Merger Oruka and ARCA was consummated. The Merger was accounted for as a reverse recapitalization in accordance with U.S.
GAAP. At the effective time of the Merger, substantially all of the assets of ARCA consisted of cash and cash equivalents and other nominal
non-operating assets and liabilities. No goodwill or intangible assets were recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
part of the recapitalization, the Company acquired the assets and liabilities listed below (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;August
    29,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,940&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;114&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(54&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 6.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c0" id="ixv-12430">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
part of the recapitalization, the Company acquired the assets and liabilities listed below (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;August
    29,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,940&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;114&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(54&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 6.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c60" decimals="-3" id="ixv-24368" unitRef="usd">4940000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther contextRef="c60" decimals="-3" id="ixv-24369" unitRef="usd">114000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities contextRef="c60" decimals="-3" id="ixv-24370" unitRef="usd">54000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c60" decimals="-3" id="ixv-24371" unitRef="usd">5000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c0" id="ixv-12495">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;4.
Fair Value Measurements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following tables present the Company&#x2019;s fair value hierarchy for financial assets measured as of December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 52%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Money market
    funds&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,350&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-157; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-158; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,350&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,660&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-159; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,660&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. government agency
    securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-160; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,988&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-161; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,988&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Commercial
    papers&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-162; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,177&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-163; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,177&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,350&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45,825&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-164; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;52,175&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable securities,
    current&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;190,792&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-165; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;190,792&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. government agency
    securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-166; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,966&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-167; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,966&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Commercial papers&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-168; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,811&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-169; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,811&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Corporate
    debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-170; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;75,504&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-171; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;75,504&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    marketable securities, current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;314,073&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-172; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;314,073&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable securities,
    long-term&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,607&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-173; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,607&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-174; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,462&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-175; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,462&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    marketable securities, long-term&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,069&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-176; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,069&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total cash equivalents
    and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,350&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;377,967&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-177; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;384,317&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;There were no transfers in
or out of Level&#160;3 during the period from February 6, 2024 (inception) to December 31, 2024.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="c0" id="ixv-12501">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following tables present the Company&#x2019;s fair value hierarchy for financial assets measured as of December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 52%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Money market
    funds&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,350&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-157; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-158; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,350&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,660&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-159; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,660&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. government agency
    securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-160; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,988&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-161; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,988&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Commercial
    papers&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-162; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,177&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-163; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,177&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,350&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45,825&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-164; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;52,175&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable securities,
    current&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;190,792&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-165; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;190,792&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. government agency
    securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-166; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,966&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-167; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,966&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Commercial papers&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-168; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,811&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-169; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,811&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Corporate
    debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-170; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;75,504&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-171; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;75,504&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    marketable securities, current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;314,073&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-172; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;314,073&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable securities,
    long-term&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,607&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-173; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,607&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-174; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,462&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-175; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,462&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    marketable securities, long-term&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,069&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-176; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,069&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total cash equivalents
    and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,350&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;377,967&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-177; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;384,317&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c61" decimals="-3" id="ixv-24372" unitRef="usd">6350000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c64" decimals="-3" id="ixv-24373" unitRef="usd">6350000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c65" decimals="-3" id="ixv-24374" unitRef="usd">19660000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c67" decimals="-3" id="ixv-24375" unitRef="usd">19660000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c69" decimals="-3" id="ixv-24376" unitRef="usd">3988000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c71" decimals="-3" id="ixv-24377" unitRef="usd">3988000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c73" decimals="-3" id="ixv-24378" unitRef="usd">22177000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c75" decimals="-3" id="ixv-24379" unitRef="usd">22177000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c76" decimals="-3" id="ixv-24380" unitRef="usd">6350000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c77" decimals="-3" id="ixv-24381" unitRef="usd">45825000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" id="ixv-24382" unitRef="usd">52175000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c65" decimals="-3" id="ixv-24383" unitRef="usd">190792000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c67" decimals="-3" id="ixv-24384" unitRef="usd">190792000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c69" decimals="-3" id="ixv-24385" unitRef="usd">12966000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c71" decimals="-3" id="ixv-24386" unitRef="usd">12966000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c73" decimals="-3" id="ixv-24387" unitRef="usd">34811000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c75" decimals="-3" id="ixv-24388" unitRef="usd">34811000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c80" decimals="-3" id="ixv-24389" unitRef="usd">75504000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c82" decimals="-3" id="ixv-24390" unitRef="usd">75504000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c77" decimals="-3" id="ixv-24391" unitRef="usd">314073000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c3" decimals="-3" id="ixv-24392" unitRef="usd">314073000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c65" decimals="-3" id="ixv-24393" unitRef="usd">13607000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c67" decimals="-3" id="ixv-24394" unitRef="usd">13607000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c69" decimals="-3" id="ixv-24395" unitRef="usd">4462000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c71" decimals="-3" id="ixv-24396" unitRef="usd">4462000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c77" decimals="-3" id="ixv-24397" unitRef="usd">18069000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c3" decimals="-3" id="ixv-24398" unitRef="usd">18069000</us-gaap:MarketableSecuritiesNoncurrent>
    <orka:FairValueCashEquivalentsAndMarketableSecurities contextRef="c76" decimals="-3" id="ixv-24399" unitRef="usd">6350000</orka:FairValueCashEquivalentsAndMarketableSecurities>
    <orka:FairValueCashEquivalentsAndMarketableSecurities contextRef="c77" decimals="-3" id="ixv-24400" unitRef="usd">377967000</orka:FairValueCashEquivalentsAndMarketableSecurities>
    <orka:FairValueCashEquivalentsAndMarketableSecurities contextRef="c3" decimals="-3" id="ixv-24401" unitRef="usd">384317000</orka:FairValueCashEquivalentsAndMarketableSecurities>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="c0" id="ixv-13185">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;5.
Cash equivalents and marketable Securities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
equivalents and marketable securities, which are classified as available-for-sale, consisted of the following as of December 31, 2024
(in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortized
    Cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross
    Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross
    Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
    Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 52%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Money market
    funds&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,350&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-178; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-179; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,350&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,656&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-180; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,660&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. government agency
    securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,988&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-181; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-182; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,988&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Commercial
    papers&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,180&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-183; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,177&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;52,174&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;52,175&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable securities,
    current&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;190,748&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;55&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;190,792&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. government agency
    securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,967&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,966&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Commercial papers&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,808&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-184; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,811&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Corporate
    debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;75,537&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;75,504&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    marketable securities, current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;314,060&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;66&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(53&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;314,073&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable securities,
    long-term&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,639&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-185; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(32&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,607&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,485&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-186; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(23&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,462&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    marketable securities, long-term&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,124&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-187; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(55&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,069&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total cash equivalents
    and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;384,358&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;70&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(111&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;384,317&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the available-for-sale securities in an unrealized loss position, aggregated by major security type and length
of time in a continuous unrealized loss position, for which an allowance for credit losses was not recorded as of December&#160;31, 2024,
(in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Less
    than 12 months&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;12
    months or longer&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair
    &lt;br/&gt;
    Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unrealized&lt;br/&gt;
    Losses&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
    &lt;br/&gt;
    Value&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unrealized&lt;br/&gt;
    Losses&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair&lt;br/&gt;
    Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unrealized&lt;br/&gt;
    Losses&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; width: 28%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Commercial
    papers&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,199&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-188; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-189; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,199&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable
    securities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable
    securities, current&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    treasury securities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;49,904&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-190; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-191; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;49,904&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    government agency securities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,713&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-192; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-193; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,713&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Corporate
    debt securities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;39,468&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(40&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-194; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-195; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;39,468&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(40&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable
    securities, long-term&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    treasury securities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,607&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(32&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-196; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-197; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,607&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(32&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    government agency securities&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,462&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(23&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-198; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-199; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,462&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(23&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.5in; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;130,353&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(111&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-200; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-201; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;130,353&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(111&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company evaluated its securities for credit losses and considered the decline in market value to be primarily attributable to current
economic and market conditions and not to a credit loss or other factors. Additionally, the Company does not intend to sell the securities
in an unrealized loss position and it is not more likely than not that the Company will be required to sell the securities before recovery
of the unamortized cost basis, which may be at maturity. There were no material realized gains or realized losses on marketable securities
for the period presented. Given the Company&#x2019;s intent and ability to hold such securities until recovery, and the lack of significant
change in credit risk of these investments, the Company does not consider these marketable securities to be impaired as of December 31,
2024. As of December 31, 2024, the Company did not record an allowance for credit losses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the contractual maturities of the Company&#x2019;s marketable securities at estimated fair value (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;314,073&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Due in 1-2 years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,069&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;332,142&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="c0" id="ixv-13191">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
equivalents and marketable securities, which are classified as available-for-sale, consisted of the following as of December 31, 2024
(in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortized
    Cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross
    Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross
    Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
    Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 52%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Money market
    funds&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,350&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-178; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-179; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,350&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,656&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-180; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,660&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. government agency
    securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,988&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-181; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-182; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,988&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Commercial
    papers&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,180&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-183; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,177&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;52,174&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;52,175&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable securities,
    current&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;190,748&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;55&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;190,792&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. government agency
    securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,967&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,966&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Commercial papers&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,808&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-184; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,811&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Corporate
    debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;75,537&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;75,504&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    marketable securities, current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;314,060&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;66&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(53&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;314,073&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable securities,
    long-term&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,639&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-185; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(32&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,607&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,485&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-186; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(23&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,462&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    marketable securities, long-term&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,124&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-187; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(55&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,069&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total cash equivalents
    and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;384,358&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;70&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(111&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;384,317&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c83" decimals="-3" id="ixv-24402" unitRef="usd">6350000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c83" decimals="-3" id="ixv-24403" unitRef="usd">6350000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c84" decimals="-3" id="ixv-24404" unitRef="usd">19656000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c84" decimals="-3" id="ixv-24405" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c84" decimals="-3" id="ixv-24406" unitRef="usd">19660000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c85" decimals="-3" id="ixv-24407" unitRef="usd">3988000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c85" decimals="-3" id="ixv-24408" unitRef="usd">3988000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c86" decimals="-3" id="ixv-24409" unitRef="usd">22180000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c86" decimals="-3" id="ixv-24410" unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c86" decimals="-3" id="ixv-24411" unitRef="usd">22177000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c87" decimals="-3" id="ixv-24412" unitRef="usd">52174000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c87" decimals="-3" id="ixv-24413" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c87" decimals="-3" id="ixv-24414" unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c87" decimals="-3" id="ixv-24415" unitRef="usd">52175000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c88" decimals="-3" id="ixv-24416" unitRef="usd">190748000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c88" decimals="-3" id="ixv-24417" unitRef="usd">55000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c88" decimals="-3" id="ixv-24418" unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c88" decimals="-3" id="ixv-24419" unitRef="usd">190792000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c89" decimals="-3" id="ixv-24420" unitRef="usd">12967000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c89" decimals="-3" id="ixv-24421" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c89" decimals="-3" id="ixv-24422" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c89" decimals="-3" id="ixv-24423" unitRef="usd">12966000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c90" decimals="-3" id="ixv-24424" unitRef="usd">34808000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c90" decimals="-3" id="ixv-24425" unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c90" decimals="-3" id="ixv-24426" unitRef="usd">34811000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c91" decimals="-3" id="ixv-24427" unitRef="usd">75537000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c91" decimals="-3" id="ixv-24428" unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c91" decimals="-3" id="ixv-24429" unitRef="usd">40000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c91" decimals="-3" id="ixv-24430" unitRef="usd">75504000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c92" decimals="-3" id="ixv-24431" unitRef="usd">314060000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c92" decimals="-3" id="ixv-24432" unitRef="usd">66000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c92" decimals="-3" id="ixv-24433" unitRef="usd">53000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c92" decimals="-3" id="ixv-24434" unitRef="usd">314073000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c93" decimals="-3" id="ixv-24435" unitRef="usd">13639000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c93" decimals="-3" id="ixv-24436" unitRef="usd">32000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c93" decimals="-3" id="ixv-24437" unitRef="usd">13607000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c94" decimals="-3" id="ixv-24438" unitRef="usd">4485000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c94" decimals="-3" id="ixv-24439" unitRef="usd">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c94" decimals="-3" id="ixv-24440" unitRef="usd">4462000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c95" decimals="-3" id="ixv-24441" unitRef="usd">18124000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c95" decimals="-3" id="ixv-24442" unitRef="usd">55000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c95" decimals="-3" id="ixv-24443" unitRef="usd">18069000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c3" decimals="-3" id="ixv-24444" unitRef="usd">384358000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c3" decimals="-3" id="ixv-24445" unitRef="usd">70000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c3" decimals="-3" id="ixv-24446" unitRef="usd">111000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c3" decimals="-3" id="ixv-24447" unitRef="usd">384317000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef="c0" id="ixv-13857">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the available-for-sale securities in an unrealized loss position, aggregated by major security type and length
of time in a continuous unrealized loss position, for which an allowance for credit losses was not recorded as of December&#160;31, 2024,
(in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Less
    than 12 months&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;12
    months or longer&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair
    &lt;br/&gt;
    Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unrealized&lt;br/&gt;
    Losses&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
    &lt;br/&gt;
    Value&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unrealized&lt;br/&gt;
    Losses&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair&lt;br/&gt;
    Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unrealized&lt;br/&gt;
    Losses&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; width: 28%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Commercial
    papers&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,199&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-188; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-189; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,199&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable
    securities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable
    securities, current&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    treasury securities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;49,904&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-190; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-191; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;49,904&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    government agency securities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,713&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-192; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-193; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,713&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Corporate
    debt securities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;39,468&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(40&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-194; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-195; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;39,468&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(40&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Marketable
    securities, long-term&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    treasury securities&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,607&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(32&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-196; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-197; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,607&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(32&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.
    government agency securities&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,462&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(23&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-198; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-199; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,462&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(23&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.5in; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;130,353&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(111&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-200; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-201; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;130,353&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(111&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c96" decimals="-3" id="ixv-24448" unitRef="usd">18199000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c96" decimals="-3" id="ixv-24449" unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c96" decimals="-3" id="ixv-24450" unitRef="usd">18199000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c96" decimals="-3" id="ixv-24451" unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c97" decimals="-3" id="ixv-24452" unitRef="usd">49904000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c97" decimals="-3" id="ixv-24453" unitRef="usd">11000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c97" decimals="-3" id="ixv-24454" unitRef="usd">49904000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c97" decimals="-3" id="ixv-24455" unitRef="usd">11000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c98" decimals="-3" id="ixv-24456" unitRef="usd">4713000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c98" decimals="-3" id="ixv-24457" unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c98" decimals="-3" id="ixv-24458" unitRef="usd">4713000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c98" decimals="-3" id="ixv-24459" unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c99" decimals="-3" id="ixv-24460" unitRef="usd">39468000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c99" decimals="-3" id="ixv-24461" unitRef="usd">40000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c99" decimals="-3" id="ixv-24462" unitRef="usd">39468000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c99" decimals="-3" id="ixv-24463" unitRef="usd">40000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="c100"
      decimals="-3"
      id="ixv-24464"
      unitRef="usd">13607000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="c100"
      decimals="-3"
      id="ixv-24465"
      unitRef="usd">32000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="c100"
      decimals="-3"
      id="ixv-24466"
      unitRef="usd">13607000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="c100"
      decimals="-3"
      id="ixv-24467"
      unitRef="usd">32000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="c101"
      decimals="-3"
      id="ixv-24468"
      unitRef="usd">4462000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="c101"
      decimals="-3"
      id="ixv-24469"
      unitRef="usd">23000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="c101"
      decimals="-3"
      id="ixv-24470"
      unitRef="usd">4462000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="c101"
      decimals="-3"
      id="ixv-24471"
      unitRef="usd">23000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c3" decimals="-3" id="ixv-24472" unitRef="usd">130353000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c3" decimals="-3" id="ixv-24473" unitRef="usd">111000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c3" decimals="-3" id="ixv-24474" unitRef="usd">130353000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c3" decimals="-3" id="ixv-24475" unitRef="usd">111000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="c0" id="ixv-14512">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the contractual maturities of the Company&#x2019;s marketable securities at estimated fair value (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;314,073&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Due in 1-2 years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,069&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;332,142&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c3" decimals="-3" id="ixv-24476" unitRef="usd">314073000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c3" decimals="-3" id="ixv-24477" unitRef="usd">18069000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecurities contextRef="c3" decimals="-3" id="ixv-24478" unitRef="usd">332142000</us-gaap:MarketableSecurities>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="c0" id="ixv-14567">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;6.
Accrued Expenses and Other Current Liabilities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued
expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, &lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued employee compensation and
    benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,041&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued professional and consulting&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;221&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued research and
    development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,084&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,346&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c0" id="ixv-14573">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued
expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, &lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued employee compensation and
    benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,041&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued professional and consulting&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;221&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued research and
    development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,084&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,346&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="c3" decimals="-3" id="ixv-24479" unitRef="usd">2041000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c3" decimals="-3" id="ixv-24480" unitRef="usd">221000</us-gaap:AccruedProfessionalFeesCurrent>
    <orka:AccruedResearchAndDevelopment contextRef="c3" decimals="-3" id="ixv-24481" unitRef="usd">1084000</orka:AccruedResearchAndDevelopment>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c3" decimals="-3" id="ixv-24482" unitRef="usd">3346000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0" id="ixv-14638">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;7.
Note&#160;Payable with Related Party&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
March&#160;2024, Pre-Merger Oruka entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the &#x201c;Purchase
Agreement&#x201d;) with Fairmount Healthcare Fund&#160;II, L.P. (&#x201c;Fairmount&#x201d;), whereby Pre-Merger Oruka issued a convertible
note (the &#x201c;Convertible Note&#x201d;), with an initial principal amount of $25.0 million that, at the time of issuance, could be
converted into Pre-Merger Oruka Series&#160;A Preferred Stock (or a series&#160;of preferred shares that is identical in respect to the
shares of preferred shares issued in its next equity financing) or shares of Pre-Merger Oruka Common Stock in exchange for aggregate
proceeds of $25.0&#160;million. The Convertible Note accrued interest at a rate of 12.0% per annum. At issuance, the Convertible Note
required all unpaid interest and principal to mature on December&#160;31, 2025 (the &#x201c;Maturity Date&#x201d;) and prepayment was not
permitted without prior written consent of Fairmount.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company assessed all terms and features of the Convertible Note in order to identify any potential embedded features that would require
bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the embedded features. The Company
determined that the share settled redemption feature was clearly and closely related to the debt host and did not require separate accounting.
The Company determined that the conversion options of the Convertible Note were not clearly and closely associated with a debt host.
However, these features did not meet the definition of a derivative under ASC&#160;815, Derivatives and Hedging, and as a result, did
not require separate accounting as a derivative liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company paid debt issuance costs of less than $0.1&#160;million in relation to the Convertible Note. The debt issuance costs were reflected
as a reduction of the carrying value of Convertible Note on the consolidated balance sheet and were being amortized as interest expense
over the term of the Convertible Note using the effective interest method. For the period from February&#160;6, 2024 (inception) to December
31, 2024, the Company recognized interest expenses related to the Convertible Note of $1.5 million, which includes non-cash interest
expense related to the amortization of debt issuance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Immediately
prior to the completion of the Merger (see Note 1), the Convertible Note was converted into shares of Pre-Merger Oruka Common Stock based
on the aggregate principal amount of $25.0 million, plus unpaid accrued interest of $1.5 million divided by the conversion price which
was determined based upon the Company&#x2019;s fully-diluted capitalization immediately prior to the Merger. At the effective time of
the Merger, the Pre-Merger Oruka Common Stock issued upon the conversion of the Convertible Note (including accrued interest) automatically
converted into 2,722,207 shares of Company Common Stock. As of December 31, 2024, the Convertible Note is not outstanding.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c102"
      decimals="-5"
      id="ixv-24483"
      unitRef="usd">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="c103"
      decimals="-5"
      id="ixv-24484"
      unitRef="usd">25000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c104"
      decimals="3"
      id="ixv-24485"
      unitRef="pure">0.12</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c104" id="ixv-24486">2025-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="c105"
      decimals="-5"
      id="ixv-24487"
      unitRef="usd">100000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:InterestExpenseDebt
      contextRef="c106"
      decimals="-5"
      id="ixv-24488"
      unitRef="usd">1500000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c107"
      decimals="-5"
      id="ixv-24489"
      unitRef="usd">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="c105"
      decimals="-5"
      id="ixv-24490"
      unitRef="usd">1500000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c108"
      decimals="INF"
      id="ixv-24491"
      unitRef="shares">2722207</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-14678">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;8.
Convertible Preferred Stock and Stockholders&#x2019; Equity&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Pre-Funded
Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
August 2024, pursuant to the Subscription Agreement and immediately prior to the Closing, certain new and current investors purchased
pre-funded&#160;warrants, which, at the effective time of the Merger, were exercisable for 5,522,207 shares of Company Common Stock at
a purchase price of approximately $9.70 per warrant. After the Merger, there are 5,522,207 pre-funded warrants outstanding and are exercisable
for 5,522,207 shares of the Company Common Stock at an exercise price of $0.01 per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
September 2024, in connection with the PIPE Financing, the Company issued and sold 680,000 pre-funded warrants, at a purchase price of
$22.999 per warrant, exercisable for 680,000 shares of Company Common Stock at an exercise price of $0.001 per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
pre-funded warrants were recorded as a component of stockholders&#x2019; equity within additional paid-in-capital and have &lt;span style="-sec-ix-hidden: hidden-fact-202"&gt;no&lt;/span&gt; expiration
date. As of December 31, 2024, &lt;span style="-sec-ix-hidden: hidden-fact-203"&gt;none&lt;/span&gt; of the pre-funded warrants have been exercised and 6,202,207 pre-funded warrants remain outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Employee
Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
July 2024, Pre-Merger Oruka entered into a Subscription Agreement that provided for, among other things, the issuance of warrants to
certain of Pre-Merger Oruka&#x2019;s employees and directors immediately prior to the closing of the Merger. During the period from February
6, 2024 (inception) to December 31, 2024, 3,054,358 employee warrants were issued at an exercise price of $7.80 per warrant. These warrants
vest over a period of four years. Per the terms of the Employee Warrant Agreement, the holders of the Company&#x2019;s warrants shall
not have any of the rights or privileges of a stockholder of the Company in respect of any shares purchasable upon the exercise of the
warrant or any portion thereof unless and until a certificate or certificates representing such shares have been issued or a book entry
representing such shares has been made and such shares have been deposited with the appropriate registered book-entry custodian. The
Company recognizes compensation cost related to warrants on a straight-line basis over the requisite service period, which is the period
in which the related services are received. As of December 31, 2024, &lt;span style="-sec-ix-hidden: hidden-fact-204"&gt;none&lt;/span&gt; of the warrants have been exercised and 3,054,358 warrants
remain outstanding.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Convertible
Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
March&#160;2024, Pre-Merger Oruka issued and sold an aggregate of 20,000,000 shares of Pre-Merger Oruka Series&#160;A Preferred Stock
to Fairmount (see Note 15), at a purchase price of approximately $0.15 per share, for aggregate gross proceeds of $3.0&#160;million.
Pre-Merger Oruka incurred less than $0.1&#160;million of issuance costs in connection with this transaction. Upon the issuance of the
Pre-Merger Oruka Series&#160;A Preferred Stock, the Company assessed the embedded conversion and liquidation features of the securities
as described below and determined that such features did not require the Company to separately account for these features.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
August 2024, upon the closing of the Merger, the Company converted the Pre-Merger Oruka Series A Preferred Stock to 137,138 shares of
Company Series B Preferred Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
September 2024, in connection with the PIPE Financing, the Company issued and sold an aggregate of 2,439 shares of the Company Series
A Preferred Stock at a purchase price of $23,000.00 per share.&#160;In November 2024, the 2,439 shares of the Company Series A Preferred
Stock were converted to 2,439,000 shares of Company Common Stock. As of December 31, 2024, there are &lt;span style="-sec-ix-hidden: hidden-fact-205"&gt;no&lt;/span&gt; outstanding shares of Company
Series A Preferred Stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of December 31, 2024, convertible preferred stock consisted of the following (in thousands, except share data):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; font-style: italic"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Preferred&lt;br/&gt;
                                            Stock&lt;br/&gt;
                                            Authorized&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Preferred&lt;br/&gt;
    Stock Issued &lt;br/&gt;
    and&lt;br/&gt;
    Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Carrying&lt;br/&gt;
    Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common
    Stock&lt;br/&gt;
    Issuable&lt;br/&gt;
    Upon&lt;br/&gt;
    Conversion&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Series B convertible preferred
    stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;251,504&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;137,138&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,931&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,428,149&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pursuant
to the Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock (the
&#x201c;Series A Certificate of Designation&#x201d;) filed in connection with the PIPE Financing, holders of Company Series A Preferred
Stock were entitled to receive dividends on shares of Company Series A Preferred Stock equal to, on an as-if-converted-to-Company Common
Stock basis, and in the same form as, dividends actually paid on shares of Company Common Stock. Except as provided in the Series A Certificate
of Designation or as otherwise required by law, the Company Series A Preferred Stock did not have voting rights. The Company Series A
Preferred Stock shall rank on parity with the Company Common Stock and Company Series B Preferred Stock upon any liquidation, dissolution
or winding-up of the Company. Subject to the terms and limitations contained in the Series A Certificate of Designation, the Company
Series A Preferred Stock issued in the PIPE Financing will not become convertible until the Company&#x2019;s stockholders approve the
conversion of the Company Series A Preferred Stock into shares of Company Common Stock in accordance with the listing rules of the Nasdaq
Stock Market (the &#x201c;Stockholder Approval&#x201d;), which, on issuance, resulted in the Company Series A Preferred Stock being classified
outside of stockholders&#x2019; equity on the Company&#x2019;s consolidated balance sheet. Following the Stockholder Approval in November
2024, each share of Company Series A Preferred Stock was automatically converted into 1,000 shares of Company Common Stock.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pursuant
to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock (the
&#x201c;Series B Certificate of Designation&#x201d;) filed in connection with the Merger, holders of Company Series B Preferred Stock are
entitled to receive dividends on shares of Company Series B Preferred Stock equal to, on an as-if-converted-to-Company Common Stock basis,
and in the same form as, dividends actually paid on shares of Company Common Stock. Except as provided in the Series B Certificate of
Designation or as otherwise required by law, the Company Series B Preferred Stock does not have voting rights. The Company Series B Preferred
Stock shall rank on parity with the Company Common Stock as to the distribution of assets upon any liquidation, dissolution, or winding-up
of the Company. Each share of Company Series B Preferred Stock is convertible at the option of the holder, at any time, and without the
payment of additional consideration by the holder. As of December 31, 2024, each outstanding share of Company Series B Preferred Stock
was convertible into common stock at a ratio of approximately 83.3332:1.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Paruka
Warrant&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
December 31, 2024, the Company settled its 2024 obligations under the Paruka Warrant Obligation (defined below) by issuing Paruka a warrant
to purchase 596,930 shares of Company Common Stock at an exercise price of $19.39 per share. The warrant has a term of 10 years, is fully
vested, and is exercisable in part or full at any time during the term of the warrant. As of December 31, 2024, the warrant issued under
the Paruka Warrant Obligation is outstanding and unexercised. See Note 9 for additional information on the Paruka Warrant Obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of December 31, 2024, the Certificate of Incorporation provides for 545,000,000 authorized shares of Company Common Stock. As of December
31, 2024, 37,440,510 shares of Company Common Stock were issued and outstanding, including 2,207,553 shares of RSAs issued and outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of December 31, 2024, the Company had common stock reserved for future issuance as follows:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares issuable on conversion of
    Company Series B Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,428,149&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares issuable upon exercise of pre-funded warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,202,207&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares issuable upon exercise of warrant under
    the Paruka Warrant Obligation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;596,930&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding and issued stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,567,760&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding and issued employee warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,054,358&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares available for grant under 2024 Stock
    Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,246,324&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares available for
    grant under 2024 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;460,529&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 13.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    shares of common stock reserved&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27,556,257&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c109"
      decimals="INF"
      id="ixv-24492"
      unitRef="shares">5522207</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c110"
      decimals="2"
      id="ixv-24493"
      unitRef="usdPershares">9.7</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c110"
      decimals="INF"
      id="ixv-24494"
      unitRef="shares">5522207</us-gaap:ClassOfWarrantOrRightOutstanding>
    <orka:ClassOfWarrantsExercisable
      contextRef="c111"
      decimals="0"
      id="ixv-24495"
      unitRef="shares">5522207</orka:ClassOfWarrantsExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c112"
      decimals="2"
      id="ixv-24496"
      unitRef="usdPershares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c113"
      decimals="INF"
      id="ixv-24497"
      unitRef="shares">680000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c114"
      decimals="3"
      id="ixv-24498"
      unitRef="usdPershares">22.999</us-gaap:SaleOfStockPricePerShare>
    <orka:ClassOfWarrantsExercisable
      contextRef="c115"
      decimals="INF"
      id="ixv-24499"
      unitRef="shares">680000</orka:ClassOfWarrantsExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c116"
      decimals="3"
      id="ixv-24500"
      unitRef="usdPershares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c118"
      decimals="INF"
      id="ixv-24501"
      unitRef="shares">6202207</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c119"
      decimals="INF"
      id="ixv-24502"
      unitRef="shares">3054358</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c119"
      decimals="2"
      id="ixv-24503"
      unitRef="usdPershares">7.8</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c120" id="ixv-24504">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c119"
      decimals="INF"
      id="ixv-24505"
      unitRef="shares">3054358</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c121"
      decimals="INF"
      id="ixv-24506"
      unitRef="shares">20000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c122"
      decimals="2"
      id="ixv-24507"
      unitRef="usdPershares">0.15</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="c123"
      decimals="-5"
      id="ixv-24508"
      unitRef="usd">3000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c124"
      decimals="-5"
      id="ixv-24509"
      unitRef="usd">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c125"
      decimals="INF"
      id="ixv-24510"
      unitRef="shares">137138</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c126"
      decimals="INF"
      id="ixv-24511"
      unitRef="shares">2439</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c127"
      decimals="2"
      id="ixv-24512"
      unitRef="usdPershares">23000</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c128"
      decimals="INF"
      id="ixv-24513"
      unitRef="shares">2439</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c129"
      decimals="INF"
      id="ixv-24514"
      unitRef="shares">2439000</us-gaap:PreferredStockConvertibleSharesIssuable>
    <orka:ScheduleOfConvertiblePreferredStockTableTextBlock contextRef="c0" id="ixv-14752">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of December 31, 2024, convertible preferred stock consisted of the following (in thousands, except share data):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; font-style: italic"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Preferred&lt;br/&gt;
                                            Stock&lt;br/&gt;
                                            Authorized&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Preferred&lt;br/&gt;
    Stock Issued &lt;br/&gt;
    and&lt;br/&gt;
    Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Carrying&lt;br/&gt;
    Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common
    Stock&lt;br/&gt;
    Issuable&lt;br/&gt;
    Upon&lt;br/&gt;
    Conversion&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Series B convertible preferred
    stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;251,504&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;137,138&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,931&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,428,149&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</orka:ScheduleOfConvertiblePreferredStockTableTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c134"
      decimals="INF"
      id="ixv-24515"
      unitRef="shares">251504</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c134"
      decimals="INF"
      id="ixv-24516"
      unitRef="shares">137138</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c134"
      decimals="INF"
      id="ixv-24517"
      unitRef="shares">137138</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="c134"
      decimals="-3"
      id="ixv-24518"
      unitRef="usd">2931000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c134"
      decimals="INF"
      id="ixv-24519"
      unitRef="shares">11428149</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c129"
      decimals="INF"
      id="ixv-24520"
      unitRef="shares">1000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <orka:CommonStockConversionRatio contextRef="c47" id="ixv-24521">83.3332:1</orka:CommonStockConversionRatio>
    <orka:WarrantsToPurchaseCommonStock
      contextRef="c131"
      decimals="INF"
      id="ixv-24522"
      unitRef="shares">596930</orka:WarrantsToPurchaseCommonStock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c131"
      decimals="2"
      id="ixv-24523"
      unitRef="usdPershares">19.39</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c132" id="ixv-24524">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c36"
      decimals="INF"
      id="ixv-24525"
      unitRef="shares">545000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c36"
      decimals="INF"
      id="ixv-24526"
      unitRef="shares">37440510</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c36"
      decimals="INF"
      id="ixv-24527"
      unitRef="shares">37440510</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c133"
      decimals="INF"
      id="ixv-24528"
      unitRef="shares">2207553</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c133"
      decimals="INF"
      id="ixv-24529"
      unitRef="shares">2207553</us-gaap:CommonStockSharesIssued>
    <orka:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock contextRef="c0" id="ixv-14885">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of December 31, 2024, the Company had common stock reserved for future issuance as follows:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares issuable on conversion of
    Company Series B Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,428,149&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares issuable upon exercise of pre-funded warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,202,207&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares issuable upon exercise of warrant under
    the Paruka Warrant Obligation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;596,930&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding and issued stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,567,760&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding and issued employee warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,054,358&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares available for grant under 2024 Stock
    Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,246,324&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares available for
    grant under 2024 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;460,529&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 13.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    shares of common stock reserved&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;27,556,257&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</orka:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c134"
      decimals="INF"
      id="ixv-24530"
      unitRef="shares">11428149</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c54"
      decimals="INF"
      id="ixv-24531"
      unitRef="shares">6202207</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c135"
      decimals="INF"
      id="ixv-24532"
      unitRef="shares">596930</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c136"
      decimals="INF"
      id="ixv-24533"
      unitRef="shares">1567760</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c119"
      decimals="INF"
      id="ixv-24534"
      unitRef="shares">3054358</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c137"
      decimals="INF"
      id="ixv-24535"
      unitRef="shares">4246324</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c138"
      decimals="INF"
      id="ixv-24536"
      unitRef="shares">460529</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c3"
      decimals="INF"
      id="ixv-24537"
      unitRef="shares">27556257</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0" id="ixv-14995">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;9.
Stock-Based Compensation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;2024
Equity Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
2024 Equity Incentive Plan (&#x201c;2024 Plan&#x201d;) was adopted by the board of directors of Pre-Merger Oruka on February&#160;6, 2024.
The 2024 Plan provided for Pre-Merger Oruka to grant stock options, restricted stock awards, restricted stock units, and other stock-based
awards to employees, officers, directors, consultants, and advisors. Equity Incentive Stock options granted under the 2024 Plan generally
vest over four&#160;years, subject to the participant&#x2019;s continued service, and expire after ten&#160;years, although two non-employee
stock options were &#160;granted with vesting terms less than four&#160;years. As of December 31, 2024, there are no shares of common
stock available for issuance.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;2024
Stock Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
August 22, 2024, the 2024 Stock Incentive Plan (&#x201c;2024 Stock Plan&#x201d;) was approved by the Company&#x2019;s stockholders and on
August 29, 2024, the board of directors of the Company (the &#x201c;Board&#x201d;) ratified the 2024 Stock Plan. The 2024 Stock Plan allows
for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock units, other stockholder-based awards
and incentive bonuses. The 2024 Stock Plan is administered by the Compensation Committee of the Board (the &#x201c;Compensation Committee&#x201d;)
or another committee designated by the Board to administer the Plan. The initial share pool under the 2024 Stock Plan is 4,634,891 shares
of Company Common Stock. During the period from February 6, 2024 (inception) to December 31, 2024, 388,567 shares were subject to outstanding
stock options, and as of December 31, 2024, there were 4,246,324 shares available in the pool. The shares that may be issued under the
2024 Stock Plan will be automatically increased on January 1 of each year beginning in 2025 and ending with a final increase on January
1, 2034 in an amount equal to 5% of the diluted stock (including Company Common Stock, preferred stock and unexercised pre-funded warrants)
on the preceding December 31, unless a lower, or no, increase is determined by the Compensation Committee. Current or prospective employees,
officers, non-employee directors, and other independent service providers of the Company and its subsidiaries are eligible to participate
in the 2024 Stock Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;2024
Employee Stock Purchase Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
2024 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;) became effective on August 29, 2024, at which time 463,489 shares of Company
Common Stock were reserved for issuance. Eligible employees may purchase shares of Company Common Stock under the ESPP at&#160;85% of
the lower of the fair market value of the Company Common Stock as of the first or the last day of each offering period. Employees are
limited to contributing&#160;15% of the employee&#x2019;s eligible compensation and may not purchase more than $25,000&#160;of stock during
any calendar year. The ESPP will terminate&#160;ten years&#160;from the first purchase date under the plan, unless terminated earlier
by the board of directors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
shares that may be issued under the ESPP will be automatically increased on January 1 of each year beginning in 2025 and ending with
a final increase on January 1, 2034 in an amount equal to 1% of the diluted stock (including Company Common Stock, preferred stock and
unexercised pre-funded warrants) on the preceding December 31, unless a lower, or no increase is determined by the Compensation Committee.
During the period from February 6, 2024 (inception) to December 31, 2024, 2,960 shares of Company Common Stock were issued out of the
ESPP and as of December 31, 2024, there were 460,529 shares of Company Common Stock available in the pool.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
the period February 6, 2024 (inception) to December 31, 2024, stock-based compensation expense related to the ESPP was less than $0.1
million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Stock
Option Valuation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the weighted-average assumptions used in calculating the fair value of the awards for the period from February&#160;6,
2024 (inception) to December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Period from&lt;br/&gt; February 6,&lt;br/&gt; 2024&lt;br/&gt; (Inception) to&lt;br/&gt; December 31, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100.21&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.26&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-206; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the stock option activities under the 2024 Plan and 2024 Stock Plan for the period of February&#160;6, 2024
(inception) through December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of&lt;br/&gt; Stock&lt;br/&gt; Options&lt;br/&gt; Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price Per&lt;br/&gt; Share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term &lt;br/&gt; (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;br/&gt; (in&#160;Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of February 6, 2024 (inception)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-208; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-209; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-210; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-211; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-left: 0.125in; width: 52%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,567,760&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11.39&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-212; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-213; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-left: 0.125in; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-214; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-215; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,567,760&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11.39&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,470&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and expected to vest, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,567,760&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11.39&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,470&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-216; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-217; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-218; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-219; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
weighted average grant-date fair value per share of stock options granted during the period from February&#160;6, 2024 (inception) to
December 31, 2024 was $9.12 per share. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying
Company Common Stock and the exercise price of outstanding, in-the-money employee stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Restricted
Stock Awards&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
February 2024 and March&#160;2024, the Company issued 2,207,553 shares of RSAs to certain employees, directors, and consultants at a
price of $0.0001 per share, the then par value of Pre-Merger Oruka Common Stock. Such RSAs have service-based vesting conditions only
and vest over a four-year period, during which time all unvested shares are subject to forfeiture in the event the holder&#x2019;s service
with the Company voluntarily or involuntarily terminates. As of December 31, 2024, none of the RSAs had vested. For the period February
6, 2024 (inception) to December 31, 2024, stock-based compensation expense related to RSAs was less than $0.1 million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the RSA activity for the period from February&#160;6, 2024 (inception) through December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of&lt;br/&gt;
    RSAs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;br/&gt;
    Average&lt;br/&gt;
    Grant Date&lt;br/&gt;
    Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested balance as of February 6, 2024 (inception)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-220; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-221; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%; padding-bottom: 1.5pt; padding-left: 13.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,207,553&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-222; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,207,553&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-223; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Option
Agreements and the Paruka Warrant Obligation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
part of the Option Agreements, on December&#160;31, 2024 the Company granted and on December&#160;31, 2025, will grant Paruka a warrant
to purchase a number of shares equal to 1.00% of outstanding shares as of the date of the grant on a fully-diluted basis, with an exercise
price equal to the fair market value of the underlying shares on the grant date (the &#x201c;Paruka Warrant Obligation&#x201d;).&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
grant dates for the issuance of warrants were expected to be December&#160;31, 2024 and December&#160;31, 2025 as all terms of the award,
including number of shares and exercise price, will be known by all parties. The Company determined that the 2024 and 2025 grants are
two separate grants, as there would be no obligation for the 2025 grant had the Company exercised or terminated all of the options under
the Option Agreements prior to December 31, 2024. The service inception period for the grant precedes the grant date, with the full award
being vested as of the grant date with no post-grant date service requirement. Accordingly, the warrant expected to be granted to Paruka
was accounted for as a liability on the balance sheet on the service inception date and, after the initial recognition, the liability
is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the consolidated statement of operations
and comprehensive loss as stock-based compensation expenses under research and development expenses. Accordingly, the Company measured
the grant date fair value of the warrant granted on December 31, 2024 at $10.4 million. For the period from February 6, 2024 (inception)
to December 31, 2024, $10.4 million was recognized as stock-based compensation expense related to the Paruka Warrant Obligation in the
consolidated statement of operations and comprehensive loss. As of December 31, 2024, there was no unamortized expense related to the
December 31, 2024 Paruka Warrant Obligation. On issuance of the warrant to Paruka, the fair value of the warrant was reclassified from
liability to equity on the consolidated balance sheet as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Employee
Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;As stated above, on July
3, 2024, the Subscription Agreement was amended and restated, among other things, for employee warrants to be issued to certain Pre-Merger
Oruka employees and directors immediately prior to the closing of the Merger. Pursuant to this amendment, during the period from February
6, 2024 (inception) to December 31, 2024, the Company issued 3,054,358 warrants at an exercise price of $7.80 per warrant, which are accounted
as equity in the consolidated financial statements. The employee warrants were subject to performance and service based vesting requirements
and upon completion of the Merger the performance-based requirements had been achieved.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the warrant activity for the period from February&#160;6, 2024 (inception) through December 31, 2024:&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt;
Employee&lt;br/&gt; Warrants&lt;br/&gt;
Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price Per&lt;br/&gt; Share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term &lt;br/&gt; (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;br/&gt; (in&#160;Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of February 6, 2024 (inception)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-224; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-225; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-226; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-left: 0.125in; width: 52%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,054,358&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.80&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-227; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-228; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-left: 0.125in; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-229; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-230; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,054,358&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.80&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;35,400&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and expected to vest, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,054,358&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.80&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;35,400&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-231; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-232; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-233; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
weighted average grant-date fair value per share of warrants granted during the period from February&#160;6, 2024 (inception) to December
31, 2024 was $6.27 per share. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying
Company Common Stock and the exercise price of outstanding, in-the-money warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the weighted-average assumptions used in calculating the fair value of the warrants for the period from February&#160;6,
2024 (inception) to December 31, 2024:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Period from&lt;br/&gt; February 6,&lt;br/&gt; 2024&lt;br/&gt; (Inception) to&lt;br/&gt; December 31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;99.02&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-207; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Stock-Based
Compensation Expense&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the classification of the Company&#x2019;s stock-based compensation expense in the consolidated statement of
operations and comprehensive loss (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Period
    from&lt;br/&gt;
    February 6,&lt;br/&gt;
    2024&lt;br/&gt;
    (Inception) to&lt;br/&gt;
    December 31,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,992&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,927&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 13.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,919&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of December 31, 2024, total unrecognized compensation cost related to the unvested stock options was $12.7 million, which is expected
to be recognized over a weighted average period of approximately 3.2 years. As of December 31, 2024, total unrecognized compensation
cost related to the unvested RSAs was less than $0.1 million, which is expected to be recognized over a weighted average period of 3.1
years. As of December 31, 2024, the unrecognized compensation cost related to the employee warrants was $16.3 million, which is expected
to be recognized over a weighted average period of 3.3 years.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the award types of the Company&#x2019;s stock-based compensation expense in the consolidated statement of operations
and comprehensive loss (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Period
    from&lt;br/&gt;
    February 6,&lt;br/&gt;
    2024&lt;br/&gt;
    (Inception) to &lt;br/&gt;
    December 31,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Paruka Warrant Obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,357&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Employee warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,899&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,626&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Employee stock purchase
    plan&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,919&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c139"
      decimals="INF"
      id="ixv-24538"
      unitRef="shares">4634891</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c140"
      decimals="INF"
      id="ixv-24539"
      unitRef="shares">388567</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c141"
      decimals="INF"
      id="ixv-24540"
      unitRef="shares">4246324</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <orka:ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares
      contextRef="c142"
      decimals="2"
      id="ixv-24541"
      unitRef="pure">0.05</orka:ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c143"
      decimals="INF"
      id="ixv-24542"
      unitRef="shares">463489</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c144"
      decimals="2"
      id="ixv-24543"
      unitRef="pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="c143"
      decimals="2"
      id="ixv-24544"
      unitRef="pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <orka:EmployeeStockPurchasePlanESPPCashContributionsToESPP contextRef="c144" decimals="0" id="ixv-24545" unitRef="usd">25000</orka:EmployeeStockPurchasePlanESPPCashContributionsToESPP>
    <orka:ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares
      contextRef="c145"
      decimals="2"
      id="ixv-24546"
      unitRef="pure">0.01</orka:ShareBasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuanceAsPercentageOfOutstandingDilutedShares>
    <us-gaap:CommonStockSharesIssued
      contextRef="c138"
      decimals="INF"
      id="ixv-24547"
      unitRef="shares">2960</us-gaap:CommonStockSharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c138"
      decimals="INF"
      id="ixv-24548"
      unitRef="shares">460529</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c145"
      decimals="-5"
      id="ixv-24549"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0" id="ixv-15063">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the weighted-average assumptions used in calculating the fair value of the awards for the period from February&#160;6,
2024 (inception) to December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Period from&lt;br/&gt; February 6,&lt;br/&gt; 2024&lt;br/&gt; (Inception) to&lt;br/&gt; December 31, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100.21&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.26&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-206; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the weighted-average assumptions used in calculating the fair value of the warrants for the period from February&#160;6,
2024 (inception) to December 31, 2024:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Period from&lt;br/&gt; February 6,&lt;br/&gt; 2024&lt;br/&gt; (Inception) to&lt;br/&gt; December 31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;99.02&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-207; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c146" id="ixv-15091">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c146"
      decimals="4"
      id="ixv-24550"
      unitRef="pure">1.0021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c146"
      decimals="4"
      id="ixv-24551"
      unitRef="pure">0.0426</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-15138">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the stock option activities under the 2024 Plan and 2024 Stock Plan for the period of February&#160;6, 2024
(inception) through December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of&lt;br/&gt; Stock&lt;br/&gt; Options&lt;br/&gt; Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price Per&lt;br/&gt; Share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term &lt;br/&gt; (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;br/&gt; (in&#160;Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of February 6, 2024 (inception)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-208; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-209; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-210; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-211; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-left: 0.125in; width: 52%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,567,760&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11.39&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-212; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-213; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-left: 0.125in; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-214; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-215; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,567,760&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11.39&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,470&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and expected to vest, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,567,760&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11.39&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,470&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-216; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-217; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-218; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-219; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c0"
      decimals="INF"
      id="ixv-24552"
      unitRef="shares">1567760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-24553"
      unitRef="usdPershares">11.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c3"
      decimals="INF"
      id="ixv-24554"
      unitRef="shares">1567760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c3"
      decimals="2"
      id="ixv-24555"
      unitRef="usdPershares">11.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c0" id="ixv-15350">P9Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c3" decimals="-3" id="ixv-24556" unitRef="usd">15470000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c3"
      decimals="INF"
      id="ixv-24557"
      unitRef="shares">1567760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c3"
      decimals="2"
      id="ixv-24558"
      unitRef="usdPershares">11.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c0" id="ixv-15386">P9Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c3" decimals="-3" id="ixv-24559" unitRef="usd">15470000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c146"
      decimals="2"
      id="ixv-24560"
      unitRef="usdPershares">9.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c147"
      decimals="INF"
      id="ixv-24561"
      unitRef="shares">2207553</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c133"
      decimals="4"
      id="ixv-24562"
      unitRef="usdPershares">0.0001</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c147"
      decimals="-5"
      id="ixv-24563"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="c0" id="ixv-15465">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the RSA activity for the period from February&#160;6, 2024 (inception) through December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of&lt;br/&gt;
    RSAs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;br/&gt;
    Average&lt;br/&gt;
    Grant Date&lt;br/&gt;
    Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested balance as of February 6, 2024 (inception)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-220; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-221; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%; padding-bottom: 1.5pt; padding-left: 13.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,207,553&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-222; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,207,553&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-223; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c147"
      decimals="INF"
      id="ixv-24564"
      unitRef="shares">2207553</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c133"
      decimals="INF"
      id="ixv-24565"
      unitRef="shares">2207553</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <orka:ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum
      contextRef="c148"
      decimals="4"
      id="ixv-24566"
      unitRef="pure">0.01</orka:ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum>
    <orka:EstimatedFairValueOfWarrantsToBeGranted contextRef="c3" decimals="-5" id="ixv-24567" unitRef="usd">10400000</orka:EstimatedFairValueOfWarrantsToBeGranted>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c148"
      decimals="-5"
      id="ixv-24568"
      unitRef="usd">10400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <orka:ClassOfWarrantOrRight
      contextRef="c120"
      decimals="INF"
      id="ixv-24569"
      unitRef="shares">3054358</orka:ClassOfWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c119"
      decimals="2"
      id="ixv-24570"
      unitRef="usdPershares">7.8</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <orka:ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock contextRef="c0" id="ixv-15574">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the warrant activity for the period from February&#160;6, 2024 (inception) through December 31, 2024:&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt;
Employee&lt;br/&gt; Warrants&lt;br/&gt;
Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price Per&lt;br/&gt; Share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term &lt;br/&gt; (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;br/&gt; (in&#160;Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of February 6, 2024 (inception)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-224; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-225; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-226; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-left: 0.125in; width: 52%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,054,358&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.80&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-227; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-228; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-left: 0.125in; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-229; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-230; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,054,358&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.80&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;35,400&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and expected to vest, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,054,358&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.80&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;35,400&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-231; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-232; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-233; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</orka:ShareBasedPaymentArrangementWarrantActivitiyTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c152"
      decimals="INF"
      id="ixv-24571"
      unitRef="shares">3054358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice
      contextRef="c152"
      decimals="2"
      id="ixv-24572"
      unitRef="usdPershares">7.8</orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c119"
      decimals="INF"
      id="ixv-24573"
      unitRef="shares">3054358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c119"
      decimals="2"
      id="ixv-24574"
      unitRef="usdPershares">7.8</orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm contextRef="c152" id="ixv-15785">P9Y6M</orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="c119"
      decimals="-3"
      id="ixv-24575"
      unitRef="usd">35400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber
      contextRef="c119"
      decimals="INF"
      id="ixv-24576"
      unitRef="shares">3054358</orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExpectedToVestOutstandingNumber>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice
      contextRef="c119"
      decimals="2"
      id="ixv-24577"
      unitRef="usdPershares">7.8</orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm contextRef="c152" id="ixv-15821">P9Y6M</orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest
      contextRef="c119"
      decimals="-3"
      id="ixv-24578"
      unitRef="usd">35400000</orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c120"
      decimals="2"
      id="ixv-24579"
      unitRef="usdPershares">6.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c120" id="ixv-15918">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c120"
      decimals="4"
      id="ixv-24580"
      unitRef="pure">0.9902</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c120"
      decimals="4"
      id="ixv-24581"
      unitRef="pure">0.0415</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c0" id="ixv-15965">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the classification of the Company&#x2019;s stock-based compensation expense in the consolidated statement of
operations and comprehensive loss (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Period
    from&lt;br/&gt;
    February 6,&lt;br/&gt;
    2024&lt;br/&gt;
    (Inception) to&lt;br/&gt;
    December 31,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,992&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,927&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 13.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,919&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c13" decimals="-3" id="ixv-24582" unitRef="usd">11992000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c14" decimals="-3" id="ixv-24583" unitRef="usd">2927000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="-3" id="ixv-24584" unitRef="usd">14919000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="c136"
      decimals="-5"
      id="ixv-24585"
      unitRef="usd">12700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c146" id="ixv-24586">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="c133"
      decimals="-5"
      id="ixv-24587"
      unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c147" id="ixv-24588">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="c119"
      decimals="-5"
      id="ixv-24589"
      unitRef="usd">16300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c120" id="ixv-24590">P3Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c0" id="ixv-16024">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the award types of the Company&#x2019;s stock-based compensation expense in the consolidated statement of operations
and comprehensive loss (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Period
    from&lt;br/&gt;
    February 6,&lt;br/&gt;
    2024&lt;br/&gt;
    (Inception) to &lt;br/&gt;
    December 31,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Paruka Warrant Obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,357&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Employee warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,899&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,626&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Employee stock purchase
    plan&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,919&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c153"
      decimals="-3"
      id="ixv-24591"
      unitRef="usd">10357000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c154"
      decimals="-3"
      id="ixv-24592"
      unitRef="usd">2899000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c155"
      decimals="-3"
      id="ixv-24593"
      unitRef="usd">1626000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c156"
      decimals="-3"
      id="ixv-24594"
      unitRef="usd">37000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="-3" id="ixv-24595" unitRef="usd">14919000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c0" id="ixv-16118">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;10.
Segment disclosures&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company operates and manages its business activities on a consolidated basis and operates in one reportable segment.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Company operates as a single reportable and operating segment.
Its Chief Executive Officer, serving as the Chief Operating Decision Maker (&#x201c;CODM&#x201d;), oversees operations on an aggregated
basis to allocate resources effectively. In assessing the Company&#x2019;s financial performance, the CODM regularly reviews total operating
expenses and consolidated net loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
measure of segment assets is reported on the balance sheet as total consolidated assets. The Company&#x2019;s long-lived assets consist
primarily of property and equipment, net. As of December&#160;31, 2024 all of long-lived assets were in the U.S.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
table below is a summary of the segment loss from operations, including significant segment expenses (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Period
    from&lt;br/&gt;
    February 6,&lt;br/&gt;
    2024&lt;br/&gt;
    (Inception) to December&#160;31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development personnel-related
    (excluding stock-based compensation)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,959&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General and administrative personnel-related
    (excluding stock-based compensation)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,054&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,992&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General and administrative stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,927&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;External research and development&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;57,680&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General and administrative,
    excluding personnel-related and stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,082&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;88,123&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss
    from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(88,123&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments contextRef="c0" decimals="0" id="ixv-24596" unitRef="pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments contextRef="c0" decimals="0" id="ixv-24597" unitRef="pure">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="c0" id="ixv-16135">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
table below is a summary of the segment loss from operations, including significant segment expenses (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Period
    from&lt;br/&gt;
    February 6,&lt;br/&gt;
    2024&lt;br/&gt;
    (Inception) to December&#160;31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development personnel-related
    (excluding stock-based compensation)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,959&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General and administrative personnel-related
    (excluding stock-based compensation)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,054&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,992&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General and administrative stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,927&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;External research and development&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;57,680&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General and administrative,
    excluding personnel-related and stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,082&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;88,123&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss
    from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(88,123&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c157"
      decimals="-3"
      id="ixv-24598"
      unitRef="usd">3959000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c157"
      decimals="-3"
      id="ixv-24599"
      unitRef="usd">5054000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c13" decimals="-3" id="ixv-24600" unitRef="usd">11992000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c14" decimals="-3" id="ixv-24601" unitRef="usd">2927000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c158"
      decimals="-3"
      id="ixv-24602"
      unitRef="usd">57680000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c159"
      decimals="-3"
      id="ixv-24603"
      unitRef="usd">1429000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c160"
      decimals="-3"
      id="ixv-24604"
      unitRef="usd">5082000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="-3" id="ixv-24605" unitRef="usd">88123000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" id="ixv-24606" unitRef="usd">-88123000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-16253">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;11.
Income Taxes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-238"&gt;No&lt;/span&gt;
provision for income taxes was recorded for the period from February&#160;6, 2024 (inception) to December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the loss before income tax expense by jurisdiction for the periods indicated:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Period
    from&lt;br/&gt;
    February 6,&lt;br/&gt;
    2024&lt;br/&gt;
    (Inception) to &lt;br/&gt;
    December 31,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(&lt;span style="font-family: Times New Roman, Times, Serif"&gt;83,724&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-234; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss
    before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(&lt;span style="font-family: Times New Roman, Times, Serif"&gt;83,724&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;For the period from February
6, 2024 (inception) to December&#160;31, 2024, the Company recognized&#160;no&#160;provision or benefit from income taxes. The difference
between the Company&#x2019;s provision for income taxes and the amounts computed by applying the statutory federal income tax rate to income
before income taxes is as follows:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Period from&lt;br/&gt; February 6,&lt;br/&gt; 2024 &lt;br/&gt; (Inception)&#160;to&lt;br/&gt; December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Tax benefit derived by applying the federal statutory rate to income before income taxes&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.18&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.41&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.87&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in the valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25.46&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Income tax (benefit) expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
components of the deferred tax assets and liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-left: 9pt"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,260&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,080&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,063&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Accruals and other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;424&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt"&gt;Intangibles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,477&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Capitalized R&amp;amp;D expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,994&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.25in"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,501&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Right- of- use asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(184&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25in"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(184&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21,317&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-235"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"&gt;The Company has established
a full federal and state valuation allowance equal to the net deferred tax assets due to uncertainties regarding the realization of the
deferred tax asset based on the Company&#x2019;s lack of earnings history. The valuation allowance increased by $21.3&#160;million primarily
due to continuing loss from operations.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Beginning balance as of February 6, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-236"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%; text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;21,317&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt"&gt;Ending balance as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;21,317&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of December&#160;31, 2024, the Company had U.S. net operating loss carryforwards (&#x201c;NOL&#x201d;) of $10.8&#160;million. The federal
NOL carryforwards do not expire and can be utilized to offset up to 80% of the taxable income in any tax year. For the period from February
6, 2024 (inception) to December&#160;31, 2024 the Company had federal tax credit carryforwards and state tax credit carryforwards of
$3.8&#160;million and $0.4&#160;million, respectively. The federal credits will expire starting in 2044 if not utilized, and the state
research credit can be carried forward indefinitely.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Tax Reform Act of 1986 limits the use of net operating loss carryforwards in certain situations where changes occur in the stock ownership
of a company. The annual limitation may result in the expiration of net operating losses and credits before utilization. The Company
has not performed a Section 382 analysis through December 31, 2024. To the extent that an assessment is completed in the future, the
Company&#x2019;s ability to utilize tax attributes could be restricted on a year-by-year basis and certain attributes could expire before
they are utilized. The Company will examine the impact of any potential ownership changes in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;A
reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Period
    from&lt;br/&gt;
    February 6,&lt;br/&gt;
    2024&lt;br/&gt;
    (Inception) to&lt;br/&gt;
    December 31,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Beginning balance as of February 6, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-237; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Changes
    related to tax positions taken in the current year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,047&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Ending balance
    as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,047&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company includes penalties and interest expense related to income taxes as a component of income tax expense, as necessary. As of December
31, 2024, the Company had&#160;no&#160;accrued interest or penalties related to uncertain tax positions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company will be filing initial year income tax returns in the United States federal jurisdiction and state jurisdictions. Due to net
operating loss carryforwards, the statute of limitations will remain open for income tax examination.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c0" id="ixv-16264">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the loss before income tax expense by jurisdiction for the periods indicated:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Period
    from&lt;br/&gt;
    February 6,&lt;br/&gt;
    2024&lt;br/&gt;
    (Inception) to &lt;br/&gt;
    December 31,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(&lt;span style="font-family: Times New Roman, Times, Serif"&gt;83,724&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-234; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss
    before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(&lt;span style="font-family: Times New Roman, Times, Serif"&gt;83,724&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c0" decimals="-3" id="ixv-24607" unitRef="usd">-83724000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="-3" id="ixv-24608" unitRef="usd">-83724000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0" id="ixv-24609">The difference
between the Company&#x2019;s provision for income taxes and the amounts computed by applying the statutory federal income tax rate to income
before income taxes is as follows:&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Period from&lt;br/&gt; February 6,&lt;br/&gt; 2024 &lt;br/&gt; (Inception)&#160;to&lt;br/&gt; December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Tax benefit derived by applying the federal statutory rate to income before income taxes&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.18&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.41&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.87&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in the valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25.46&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Income tax (benefit) expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="4" id="ixv-24610" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c0" decimals="4" id="ixv-24611" unitRef="pure">0.0018</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c0" decimals="4" id="ixv-24612" unitRef="pure">-0.0341</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="c0" decimals="4" id="ixv-24613" unitRef="pure">0.0087</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="4" id="ixv-24614" unitRef="pure">-0.2546</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c0" decimals="4" id="ixv-24615" unitRef="pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0" id="ixv-16391">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
components of the deferred tax assets and liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-left: 9pt"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,260&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,080&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,063&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Accruals and other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;424&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt"&gt;Intangibles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,477&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Capitalized R&amp;amp;D expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,994&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0.25in"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,501&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Right- of- use asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(184&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.25in"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(184&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21,317&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-235"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c3" decimals="-3" id="ixv-24616" unitRef="usd">2260000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c3" decimals="-3" id="ixv-24617" unitRef="usd">3080000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c3" decimals="-3" id="ixv-24618" unitRef="usd">3063000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther contextRef="c3" decimals="-3" id="ixv-24619" unitRef="usd">424000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <orka:DeferredTaxAssetsLeaseLiabilities contextRef="c3" decimals="-3" id="ixv-24620" unitRef="usd">203000</orka:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c3" decimals="-3" id="ixv-24621" unitRef="usd">1477000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c3" decimals="-3" id="ixv-24622" unitRef="usd">10994000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross contextRef="c3" decimals="-3" id="ixv-24623" unitRef="usd">21501000</us-gaap:DeferredTaxAssetsGross>
    <orka:DeferredTaxLiabilitiesRightOfUseAsset contextRef="c3" decimals="-3" id="ixv-24624" unitRef="usd">184000</orka:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c3" decimals="-3" id="ixv-24625" unitRef="usd">184000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="-3" id="ixv-24626" unitRef="usd">21317000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="c0" id="ixv-24627">he Company has established
a full federal and state valuation allowance equal to the net deferred tax assets due to uncertainties regarding the realization of the
deferred tax asset based on the Company&#x2019;s lack of earnings history. The valuation allowance increased by $21.3&#160;million primarily
due to continuing loss from operations.&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Beginning balance as of February 6, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-236"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%; text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;21,317&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt"&gt;Ending balance as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;21,317&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance contextRef="c3" decimals="-5" id="ixv-24628" unitRef="usd">21300000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c0" decimals="-3" id="ixv-24629" unitRef="usd">21317000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="-3" id="ixv-24630" unitRef="usd">21317000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards contextRef="c3" decimals="-5" id="ixv-24631" unitRef="usd">10800000</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <orka:OperatingLossCarryforwardsAsAPercentageOfTaxableIncome contextRef="c3" decimals="2" id="ixv-24632" unitRef="pure">0.80</orka:OperatingLossCarryforwardsAsAPercentageOfTaxableIncome>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="c161"
      decimals="-5"
      id="ixv-24633"
      unitRef="usd">3800000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="c162"
      decimals="-5"
      id="ixv-24634"
      unitRef="usd">400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c0" id="ixv-16531">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;A
reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Period
    from&lt;br/&gt;
    February 6,&lt;br/&gt;
    2024&lt;br/&gt;
    (Inception) to&lt;br/&gt;
    December 31,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Beginning balance as of February 6, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-237; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Changes
    related to tax positions taken in the current year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,047&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Ending balance
    as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,047&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c0" decimals="-3" id="ixv-24635" unitRef="usd">1047000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c3" decimals="-3" id="ixv-24636" unitRef="usd">1047000</us-gaap:UnrecognizedTaxBenefits>
    <orka:OptionAgreementsAndLicenseAgreementsTextBlock contextRef="c0" id="ixv-16612">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;12.
Option Agreements and License Agreements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
March&#160;2024, the Company entered into two antibody discovery and option agreements (&#x201c;Option Agreements&#x201d;) with Paragon
and Paruka. Under the terms of each agreement, Paragon identifies, evaluates, and develops antibodies directed against certain mutually
agreed therapeutic targets of interest to the Company. From time to time, the Company can choose to add additional targets to the collaboration
upon agreement with Paragon and Paruka. Under the Option Agreements, the Company has the exclusive option to, on a research program-by-research
program basis, be granted an exclusive, worldwide license to all of Paragon&#x2019;s right, title, and interest in and to the intellectual
property resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and products directed
to the selected target(s)&#160;(each, an &#x201c;Option&#x201d;). The Company has initiated certain research programs with Paragon that
generally focus on discovering, generating, identifying and/or characterizing antibodies directed to a particular target (each, a &#x201c;Research
Program&#x201d;), including for IL-23 and IL-17A/F for ORKA-001 and ORKA-002, respectively. The exclusive option with respect to each
Research Program is exercisable at the Company&#x2019;s sole discretion at such time as specified in the Option Agreements (the &#x201c;Option
Period&#x201d;). There is no payment due upon exercise of an Option pursuant to the Option Agreements. For each of these agreements, once
the Company enters into the corresponding license agreements, it will be required to make non-refundable milestone payments to Paragon
of up to $12.0 million under each respective agreement upon the achievement of certain clinical development milestones, up to $10.0 million
under each respective agreement upon the achievement of certain regulatory milestones, as well as a low single-digit percentage royalty
for antibody products beginning on the first commercial sale in each program.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company may terminate any Option Agreement or any Research Program at any time for any or no reason upon 30&#160;days&#x2019; prior written
notice to Paragon, provided that it must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable
obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate
any Option Agreement or a Research Program immediately upon written notice to the Company if, as a result of any action or failure to
act by the Company or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended,
discontinued or otherwise delayed for a certain consecutive number of&#160;months. Each party has the right to terminate the Option Agreements
or any Research Program upon material breach that remains uncured or the other party&#x2019;s bankruptcy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Paragon
Therapeutics &#x2013; License Agreements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
September 2024, the Company exercised the Option to acquire certain rights to ORKA-001, and in December 2024, it entered into the corresponding
license agreement with Paragon (the &#x201c;ORKA-001 License Agreement&#x201d;), pursuant to which Paragon granted the Company a royalty-bearing,
world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting IL-23
in all fields other than the field of inflammatory bowel disease (&#x201c;ORKA-001 Field&#x201d;). In December 2024, the Company exercised
the Option with respect to ORKA-002 for the IL-17A/F program, and in February 2025, it entered into the corresponding license agreement
with Paragon (the &#x201c;ORKA-002 License Agreement&#x201d; and together with the ORKA-001 License Agreement, the &#x201c;License Agreements&#x201d;),
pursuant to which Paragon granted the Company a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize
or otherwise exploit certain antibodies and products targeting IL-17A/F in all fields (&#x201c;ORKA-002 Field&#x201d; and together with
the ORKA-001 Field, the &#x201c;Fields&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
License Agreements provide the Company with exclusive licenses in the Fields to Paragon&#x2019;s patent applications covering the related
antibodies, their method of use and their method of manufacture and Paragon has agreed not to conduct any new campaigns that generate
anti-IL-23 monospecific antibodies or anti-IL-17A/F monospecific antibodies for the ORKA-001 Field or the ORKA-002 Field, respectively,
for at least five years. Each of the ORKA-001 and ORKA-002 License Agreements may be terminated on 60 days&#x2019; notice to Paragon,
on material breach without cure, and on a party&#x2019;s insolvency or bankruptcy to the extent permitted by law.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pursuant
to the terms of each of the ORKA-001 and ORKA-002 License Agreements, the Company is obligated to pay Paragon non-refundable milestone
payments of up to $12.0 million under each respective agreement upon the achievement of certain clinical development milestones and up
to $10.0 million under each respective agreement upon the achievement of certain regulatory milestones, including a $1.5 million fee
for nomination of a development candidate (or initiation of an IND-enabling toxicology study) and a further milestone payment of $2.5
million upon the first dosing of a human patient in a Phase 1 trial for each of ORKA-001 and ORKA-002. In addition, the Company is obligated
to pay Paragon a low single-digit percentage royalty for antibody products for each of ORKA-001 and ORKA-002. For each of the License
Agreements, the royalty term ends on the later of (i) the last-to-expire licensed patent or our patent directed to the manufacture, use
or sale of a licensed antibody in the country at issue or (ii) 12 years from the date of first sale of a Company product. There is also
a royalty step-down if there is no Paragon patent in effect during the royalty term for each program.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Additionally,
as part of the Option Agreements, on December&#160;31, 2024 the Company granted and on December&#160;31, 2025, will grant Paruka a warrant
to purchase a number of shares equal to 1.00% of outstanding shares as of the date of the grant on a fully-diluted basis, with an exercise
price equal to the fair market value of the underlying shares on the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pursuant
to the Option Agreements, on a research program-by-research program basis following the finalization of the research plan for each respective
research program, the Company was required to pay Paragon a one-time, nonrefundable research initiation fee of $0.8&#160;million related
to the ORKA-001 program. This amount was recognized as a research and development expense during the period from February&#160;6, 2024
(inception) to December 31, 2024. In June 2024, pursuant to the Option Agreements with Paragon, the Company completed the selection process
of its development candidate for IL-23 antibody for ORKA-001 program. The Company was responsible for 50% of the development costs incurred
through the completion of the IL-23 selection process. The Company received the rights to at least one selected IL-23 antibody in June
2024. During the period from February 6, 2024 (inception) to December 31, 2024, the Company exercised its option for ORKA-001 and recorded
a $1.5 million milestone payment related to the achievement of development candidate as research and development expense in the Company&#x2019;s
consolidated statement of operations and comprehensive loss. In addition, during the period from February 6, 2024 (inception) to December
31, 2024, the Company recorded a $2.5 million milestone payment related to the first dosing of a human subject in a Phase 1 trial of
ORKA-001 in December 2024 as research and development expense in its consolidated statement of operations and comprehensive loss. The
Company&#x2019;s share of development costs incurred for the period from February 6, 2024 (inception) to December 31, 2024 was $13.5 million
(excluding research initiation fee and milestones), which were recorded as research and development expenses. An amount of $2.8 million
related to ORKA-001 is included in related party accounts payable and other current liabilities as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company was also required to reimburse Paragon $3.3&#160;million for development costs related to ORKA-002 incurred by Paragon through
December&#160;31, 2023 and certain other development costs incurred by Paragon between January&#160;1, 2024 and March&#160;6, 2024 as
stipulated by the Option Agreements. This amount was recognized as a research and development expense during the period from February&#160;6,
2024 (inception) to December 31, 2024. The Company is also responsible for the development costs incurred by Paragon from January&#160;1,
2024 through the completion of the IL-17 selection process. The Company recognized an amount of $0.8&#160;million payable to Paragon
for the research initiation fee related to ORKA-002 following the finalization of the ORKA-002 research plan. This was recognized as
research and development expenses in the period from February 6, 2024 (inception) to December 31, 2024. During the period from February
6, 2024 (inception) to December 31, 2024, the Company exercised its option for ORKA-002 and recorded a $1.5 million milestone payment
related to the achievement of development candidate as research and development expense in its consolidated statement of operations and
comprehensive loss. The Company accounted for development costs of $7.8 million (excluding research initiation fee, milestone, and reimbursements
of development costs through December 31, 2023) for the period from February 6, 2024 (inception) to December 31, 2024 as research and
development expenses. An amount of $2.7 million related to ORKA-002 is included in related party accounts payable and other current liabilities
as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company expenses the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified
within research and development expenses in the accompanying consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company concluded that the rights obtained under the Option Agreements represent an asset acquisition whereby the underlying assets comprise
in-process research and development assets with no alternative future use. The Option Agreements did not qualify as a business combination
because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent
a group of similar identifiable assets. The research initiation fee represents a one-time cost on a research program-by-research program
basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts
paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of ongoing development cost,
monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior
to the effective date of the Option Agreements that is associated with services being rendered under the related Research Programs are
recognized as research and development expense when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
the period from February&#160;6, 2024 (inception) to December 31, 2024, the Company recognized $42.0 &lt;/span&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;million
of expenses in connection with services provided by Paragon and Paruka under the Option Agreements.&#160;&lt;/span&gt;&lt;/p&gt;</orka:OptionAgreementsAndLicenseAgreementsTextBlock>
    <orka:NonRefundableMilestonePayments
      contextRef="c163"
      decimals="-5"
      id="ixv-24637"
      unitRef="usd">12000000</orka:NonRefundableMilestonePayments>
    <orka:NonRefundableMilestonePayments
      contextRef="c164"
      decimals="-5"
      id="ixv-24638"
      unitRef="usd">10000000</orka:NonRefundableMilestonePayments>
    <orka:NonRefundableMilestonePayments
      contextRef="c165"
      decimals="-5"
      id="ixv-24639"
      unitRef="usd">12000000</orka:NonRefundableMilestonePayments>
    <orka:NonRefundableMilestonePayments
      contextRef="c166"
      decimals="-5"
      id="ixv-24640"
      unitRef="usd">12000000</orka:NonRefundableMilestonePayments>
    <orka:NonRefundableMilestonePayments
      contextRef="c167"
      decimals="-5"
      id="ixv-24641"
      unitRef="usd">10000000</orka:NonRefundableMilestonePayments>
    <orka:NonRefundableMilestonePayments
      contextRef="c168"
      decimals="-5"
      id="ixv-24642"
      unitRef="usd">1500000</orka:NonRefundableMilestonePayments>
    <orka:NonRefundableMilestonePayments
      contextRef="c169"
      decimals="-5"
      id="ixv-24643"
      unitRef="usd">2500000</orka:NonRefundableMilestonePayments>
    <orka:NonRefundableMilestonePayments
      contextRef="c170"
      decimals="-5"
      id="ixv-24644"
      unitRef="usd">2500000</orka:NonRefundableMilestonePayments>
    <orka:RoyaltyPayableOnProductSales contextRef="c171" id="ixv-24645">low single-digit percentage royalty for antibody products</orka:RoyaltyPayableOnProductSales>
    <orka:ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum
      contextRef="c172"
      decimals="4"
      id="ixv-24646"
      unitRef="pure">0.01</orka:ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum>
    <us-gaap:PaymentsForFees
      contextRef="c173"
      decimals="-5"
      id="ixv-24647"
      unitRef="usd">800000</us-gaap:PaymentsForFees>
    <orka:DevelopmentCostsPercentage
      contextRef="c174"
      decimals="2"
      id="ixv-24648"
      unitRef="pure">0.50</orka:DevelopmentCostsPercentage>
    <orka:MilestoneConsiderationPaid
      contextRef="c175"
      decimals="-5"
      id="ixv-24649"
      unitRef="usd">1500000</orka:MilestoneConsiderationPaid>
    <orka:MilestoneConsiderationPaid
      contextRef="c176"
      decimals="-5"
      id="ixv-24650"
      unitRef="usd">2500000</orka:MilestoneConsiderationPaid>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="c174"
      decimals="-5"
      id="ixv-24651"
      unitRef="usd">13500000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="c177"
      decimals="-5"
      id="ixv-24652"
      unitRef="usd">2800000</us-gaap:AccountsPayableOtherCurrent>
    <orka:OtherDevelopmentCost
      contextRef="c178"
      decimals="-5"
      id="ixv-24653"
      unitRef="usd">3300000</orka:OtherDevelopmentCost>
    <orka:ResearchInitialFee
      contextRef="c179"
      decimals="-5"
      id="ixv-24654"
      unitRef="usd">800000</orka:ResearchInitialFee>
    <orka:MilestoneConsiderationPaid
      contextRef="c180"
      decimals="-5"
      id="ixv-24655"
      unitRef="usd">1500000</orka:MilestoneConsiderationPaid>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="c179"
      decimals="-5"
      id="ixv-24656"
      unitRef="usd">7800000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="c181"
      decimals="-5"
      id="ixv-24657"
      unitRef="usd">2700000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OtherExpenses contextRef="c0" decimals="-5" id="ixv-24658" unitRef="usd">42000000</us-gaap:OtherExpenses>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-16700">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;13.
Commitment and Contingencies&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
April 2024, the Company entered into an operating lease agreement for the Company&#x2019;s headquarters in Menlo Park, California, which
commenced on June 15, 2024 with an initial term of 39.5 months. The Company leases office space under this noncancelable operating lease
agreement. Lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining
the present value of lease payments, the Company used its incremental borrowing rate when measuring operating lease liabilities as discount
rates were not implicit or readily determinable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of December 31, 2024, the Company had $0.9 million of operating lease right-of-use assets, operating lease liability, current of $0.2
million, and operating lease liability, noncurrent of $0.8 million on its consolidated balance sheet. As of December 31, 2024, the operating
lease arrangement had a remaining lease term of 33 months and a discount rate of 17.95%. For the period from February 6, 2024 (inception)
to December 31, 2024, the Company recorded operating and variable lease expense of $0.3 million in general and administrative expenses
in its consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table presents the Company&#x2019;s supplemental cash flow information related to leases (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Period
    from&lt;br/&gt;
    February 6,&lt;br/&gt;
    2024&lt;br/&gt;
    (Inception) to&lt;br/&gt;
    December 31,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash paid for amounts included
    in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;116&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes a maturity analysis of the Company&#x2019;s operating lease liabilities showing the aggregate lease payments
as of December 31, 2024 (in thousands):&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Year
    ending December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amount&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;369&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2026&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;494&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2027&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;380&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total undiscounted lease
    payments&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,243&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    imputed interest&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(275&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total discounted lease
    payments&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;968&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    current portion of lease liability&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(213&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.375in; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-current
    portion of lease liability&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;755&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Cell
Line License Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;In March 2024, the Company
entered into the Cell Line License Agreement (the &#x201c;Cell Line License Agreement&#x201d;) with WuXi Biologics Ireland Limited (&#x201c;WuXi
Biologics&#x201d;). Under the Cell Line License Agreement, the Company received a non-exclusive, worldwide, sublicensable license to certain
of WuXi Biologics&#x2019; know-how, cell line, biological materials (the &#x201c;WuXi Biologics Licensed Technology&#x201d;) and media and
feeds to make, have made, use, sell and import certain therapeutic products produced through the use of the cell line licensed by WuXi
Biologics under the Cell Line License Agreement (the &#x201c;WuXi Biologics Licensed Products&#x201d;). Specifically, the WuXi Biologics
Licensed Technology is used in certain manufacturing activities in support of the ORKA-001 and ORKA-002 programs.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
consideration for the license, the Company agreed to pay WuXi Biologics a non-refundable license fee of $150,000, which was recognized
as a research and development expense during the period from February&#160;6, 2024 (inception) to December 31, 2024. Additionally, to
the extent that the Company manufactures its commercial supplies of bulk drug product with a manufacturer other than WuXi Biologics or
its affiliates, the Company is required to make royalty payments to WuXi Biologics at a rate of less than one percent of net sales of
WuXi Biologics Licensed Products manufactured by the third-party manufacturer. Pursuant to an amendment to the Cell Line License Agreement
effective in November 2024, a provision was added that permits the royalties owed under the agreement to be bought out on a&#160;product-by-product&#160;basis
for a&#160;lump-sum&#160;payment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
                                            Cell Line License Agreement will continue indefinitely unless terminated (i) by the Company
                                            upon six months&#x2019; prior written notice and its payment of all undisputed amounts due
                                            to WuXi Biologics through the effective date of termination, (ii) by WuXi Biologics for a
                                            material breach by the Company that remains uncured for 60 days after written notice, (iii)
                                            by WuXi Biologics if the Company fails to make a payment and such failure continues for 30
                                            days after receiving notice of such failure, or (iv) by either party upon the other party&#x2019;s
                                            bankruptcy.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c182" id="ixv-24659">P39M15D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-5" id="ixv-24660" unitRef="usd">900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-5" id="ixv-24661" unitRef="usd">200000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-5" id="ixv-24662" unitRef="usd">800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c183" id="ixv-24663">P33M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="c3" decimals="4" id="ixv-24664" unitRef="pure">0.1795</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseVariableLeaseIncome contextRef="c0" decimals="-5" id="ixv-24665" unitRef="usd">300000</us-gaap:OperatingLeaseVariableLeaseIncome>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="c0" id="ixv-16721">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table presents the Company&#x2019;s supplemental cash flow information related to leases (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Period
    from&lt;br/&gt;
    February 6,&lt;br/&gt;
    2024&lt;br/&gt;
    (Inception) to&lt;br/&gt;
    December 31,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash paid for amounts included
    in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;116&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="-3" id="ixv-24666" unitRef="usd">116000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-16754">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes a maturity analysis of the Company&#x2019;s operating lease liabilities showing the aggregate lease payments
as of December 31, 2024 (in thousands):&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Year
    ending December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amount&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;369&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2026&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;494&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2027&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;380&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total undiscounted lease
    payments&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,243&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    imputed interest&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(275&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total discounted lease
    payments&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;968&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    current portion of lease liability&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(213&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.375in; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-current
    portion of lease liability&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;755&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c3" decimals="-3" id="ixv-24667" unitRef="usd">369000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c3" decimals="-3" id="ixv-24668" unitRef="usd">494000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c3" decimals="-3" id="ixv-24669" unitRef="usd">380000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c3" decimals="-3" id="ixv-24670" unitRef="usd">1243000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c3" decimals="-3" id="ixv-24671" unitRef="usd">275000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c3" decimals="-3" id="ixv-24672" unitRef="usd">968000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" id="ixv-24673" unitRef="usd">213000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" id="ixv-24674" unitRef="usd">755000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <orka:NonRefundableLicenseFee contextRef="c0" decimals="0" id="ixv-24675" unitRef="usd">150000</orka:NonRefundableLicenseFee>
    <us-gaap:EarningsPerShareTextBlock contextRef="c0" id="ixv-16894">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;14.
Net Loss per Share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic
and diluted net loss per share attributable to stockholders were calculated as follows (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Period
    from February 6, 2024&lt;br/&gt;
    (Inception) to &lt;br/&gt;
    December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss&lt;br/&gt;
    Allocation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;br/&gt;
    Average&lt;br/&gt;
    Shares&lt;br/&gt;
    Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss
    Per&lt;br/&gt;
    Share,&lt;br/&gt;
    Basic and&lt;br/&gt;
    Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(65,037&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,789,362&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3.87&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Company Series A Preferred Stock &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,918&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;495&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,873.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Company Series B Preferred
    Stock &lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(16,769&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,946&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(322.81&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(83,724&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The weighted-average number of shares of as-converted Company Series A Preferred Stock used in the loss allocation was 495,191 for the period from February 6, 2024 (inception) to December 31, 2024.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The weighted-average number of shares of as-converted Company Series B Preferred Stock used in the loss allocation was 4,328,844 for the period from February 6, 2024 (inception) to December 31, 2024.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
the computation of basic net loss per share attributable to stockholders, the amount of weighted-average shares outstanding excludes
all shares of unvested restricted common stock as such shares are not considered outstanding for accounting purposes until vested. The
amount of weighted-average shares outstanding includes the pre-funded warrants as the exercise price is negligible and these warrants
are fully vested and exercisable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to stockholders for
the periods presented because including them would have had an anti-dilutive effect were as follows:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, &lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding employee warrants to
    purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,054,358&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding unvested restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,207,553&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding and issued common stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,567,760&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding and issued
    warrant to Paruka&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;596,930&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 13.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,426,601&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0" id="ixv-16900">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic
and diluted net loss per share attributable to stockholders were calculated as follows (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Period
    from February 6, 2024&lt;br/&gt;
    (Inception) to &lt;br/&gt;
    December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss&lt;br/&gt;
    Allocation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;br/&gt;
    Average&lt;br/&gt;
    Shares&lt;br/&gt;
    Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss
    Per&lt;br/&gt;
    Share,&lt;br/&gt;
    Basic and&lt;br/&gt;
    Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(65,037&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,789,362&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3.87&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Company Series A Preferred Stock &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,918&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;495&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,873.25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Company Series B Preferred
    Stock &lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(16,769&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,946&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(322.81&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(83,724&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The weighted-average number of shares of as-converted Company Series A Preferred Stock used in the loss allocation was 495,191 for the period from February 6, 2024 (inception) to December 31, 2024.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;&lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The weighted-average number of shares of as-converted Company Series B Preferred Stock used in the loss allocation was 4,328,844 for the period from February 6, 2024 (inception) to December 31, 2024.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c29" decimals="-3" id="ixv-24676" unitRef="usd">-65037000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c29"
      decimals="INF"
      id="ixv-24677"
      unitRef="shares">16789362</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c29"
      decimals="INF"
      id="ixv-24678"
      unitRef="shares">16789362</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c29"
      decimals="2"
      id="ixv-24679"
      unitRef="usdPershares">-3.87</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c29"
      decimals="2"
      id="ixv-24680"
      unitRef="usdPershares">-3.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="c184"
      decimals="-3"
      id="ix_3_fact"
      unitRef="usd">-1918000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c184"
      decimals="INF"
      id="ix_4_fact"
      unitRef="shares">495</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c184"
      decimals="INF"
      id="ix_5_fact"
      unitRef="shares">495</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c184"
      decimals="2"
      id="ixv-24684"
      unitRef="usdPershares">-3873.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c184"
      decimals="2"
      id="ixv-24685"
      unitRef="usdPershares">-3873.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLoss contextRef="c47" decimals="-3" id="ix_6_fact" unitRef="usd">-16769000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c47"
      decimals="INF"
      id="ix_7_fact"
      unitRef="shares">51946</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c47"
      decimals="INF"
      id="ix_8_fact"
      unitRef="shares">51946</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c47"
      decimals="2"
      id="ixv-24689"
      unitRef="usdPershares">-322.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c47"
      decimals="2"
      id="ixv-24690"
      unitRef="usdPershares">-322.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-24691" unitRef="usd">-83724000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable
      contextRef="c184"
      decimals="INF"
      id="ixv-24692"
      unitRef="shares">495191</us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable>
    <us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable
      contextRef="c47"
      decimals="INF"
      id="ixv-24693"
      unitRef="shares">4328844</us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0" id="ixv-17087">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to stockholders for
the periods presented because including them would have had an anti-dilutive effect were as follows:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, &lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding employee warrants to
    purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,054,358&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding unvested restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,207,553&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding and issued common stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,567,760&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding and issued
    warrant to Paruka&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;596,930&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 13.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,426,601&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c185"
      decimals="INF"
      id="ixv-24694"
      unitRef="shares">3054358</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c186"
      decimals="INF"
      id="ixv-24695"
      unitRef="shares">2207553</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c187"
      decimals="INF"
      id="ixv-24696"
      unitRef="shares">1567760</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c188"
      decimals="INF"
      id="ixv-24697"
      unitRef="shares">596930</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c0"
      decimals="INF"
      id="ixv-24698"
      unitRef="shares">7426601</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-17163">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;15.
Related Party Transactions&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Paragon
and Paruka each beneficially own less than 5% of the Company&#x2019;s capital stock through their respective holdings of Company Common
Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fairmount
beneficially owns more than 5% of the Company&#x2019;s capital, currently has one representative appointed to the Board, and beneficially
owns more than 5% of Paragon. Fairmount appointed Paragon&#x2019;s board of directors and has the contractual right to approve the appointment
of any executive officers of Paragon.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following is a summary of related party accounts payable and other current liabilities (in thousands):&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, &lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Paragon reimbursable Option Agreements&#x2019;
    fees&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,482&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Paragon milestone payments for Option Agreement&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Paragon reimbursable other research expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;515&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Paragon reimbursable
    patent expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c190" id="ixv-24699">beneficially own less than 5%</orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c189" id="ixv-24700">beneficially own less than 5%</orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c192" id="ixv-24701">beneficially
owns more than 5%</orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c191" id="ixv-24702">beneficially
owns more than 5%</orka:DescriptionOfMinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="c0" id="ixv-17177">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following is a summary of related party accounts payable and other current liabilities (in thousands):&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, &lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Paragon reimbursable Option Agreements&#x2019;
    fees&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,482&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Paragon milestone payments for Option Agreement&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Paragon reimbursable other research expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;515&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Paragon reimbursable
    patent expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="c193"
      decimals="-3"
      id="ixv-24703"
      unitRef="usd">1482000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="c194"
      decimals="-3"
      id="ixv-24704"
      unitRef="usd">4000000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="c195"
      decimals="-3"
      id="ixv-24705"
      unitRef="usd">515000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="c196"
      decimals="-3"
      id="ixv-24706"
      unitRef="usd">25000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c5" decimals="-3" id="ixv-24707" unitRef="usd">6022000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-17253">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;16.
Subsequent Events&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
February 2025, the Company entered into a lease agreement for an office space located in Waltham, Massachusetts. The lease is for an
initial period of 54 months. The Company expects to pay approximately $1.6 million over the lease term.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c197" id="ixv-24708">P54M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="c197"
      decimals="-5"
      id="ixv-24709"
      unitRef="usd">1600000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c198" id="ixv-24710">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c198" id="ixv-24711">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c198" id="ixv-24712">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c198" id="ixv-24713">false</ecd:Rule10b51ArrTrmntdFlag>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c4"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="c4"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:SubscriptionReceivables
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c4"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="c4"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c4"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c4"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="c4"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="c4"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="c4"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c4"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="c6"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesCurrent
      contextRef="c4"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c4"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Liabilities
      contextRef="c4"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c4"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c7"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c8"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c7"
      id="hidden-fact-19"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c8"
      id="hidden-fact-20"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c7"
      id="hidden-fact-21"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c8"
      id="hidden-fact-22"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c7"
      id="hidden-fact-23"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c9"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c10"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c9"
      id="hidden-fact-26"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c10"
      id="hidden-fact-27"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c9"
      id="hidden-fact-28"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c10"
      id="hidden-fact-29"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c9"
      id="hidden-fact-30"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c10"
      id="hidden-fact-31"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c12"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c12"
      id="hidden-fact-33"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c12"
      id="hidden-fact-34"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c12"
      id="hidden-fact-35"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="c4"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="c4"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c4"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c18"
      id="hidden-fact-39"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c18"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c19"
      id="hidden-fact-41"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c19"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c20"
      id="hidden-fact-43"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c20"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c23"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c24"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c26"
      id="hidden-fact-47"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c26"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c27"
      id="hidden-fact-49"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c27"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c28"
      id="hidden-fact-51"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c28"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c31"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c32"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c0"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="c27"
      id="hidden-fact-56"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="c27"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="c28"
      id="hidden-fact-58"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="c28"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="c29"
      id="hidden-fact-60"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="c29"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="c30"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="c31"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="c32"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="c0"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c27"
      id="hidden-fact-66"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c27"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:TempororyEquityIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c29"
      id="hidden-fact-68"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c29"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c30"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c31"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:TempororyEquityIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c32"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c26"
      id="hidden-fact-73"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c26"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c27"
      id="hidden-fact-75"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c27"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c28"
      id="hidden-fact-77"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c28"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c31"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c32"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost
      contextRef="c26"
      id="hidden-fact-81"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos
      contextRef="c26"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost
      contextRef="c27"
      id="hidden-fact-83"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos
      contextRef="c27"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost
      contextRef="c28"
      id="hidden-fact-85"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos
      contextRef="c28"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos
      contextRef="c31"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos
      contextRef="c32"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="c26"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="c27"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="c28"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="c29"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="c31"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="c32"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger
      contextRef="c26"
      id="hidden-fact-95"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe
      contextRef="c26"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger
      contextRef="c27"
      id="hidden-fact-97"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe
      contextRef="c27"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger
      contextRef="c28"
      id="hidden-fact-99"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe
      contextRef="c28"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe
      contextRef="c31"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithThe
      contextRef="c32"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant
      contextRef="c26"
      id="hidden-fact-103"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr
      contextRef="c26"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant
      contextRef="c28"
      id="hidden-fact-105"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr
      contextRef="c28"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr
      contextRef="c31"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr
      contextRef="c32"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceCostOfPIPEFinancing
      contextRef="c26"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceCostOfPIPEFinancing
      contextRef="c28"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceCostOfPIPEFinancing
      contextRef="c29"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceCostOfPIPEFinancing
      contextRef="c31"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceCostOfPIPEFinancing
      contextRef="c32"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares
      contextRef="c26"
      id="hidden-fact-114"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock
      contextRef="c26"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:ShockIssuedDuringPeriodSharesConversionOfNonvotingConvertiblePreferredStockToCommonStockinShares
      contextRef="c28"
      id="hidden-fact-116"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock
      contextRef="c28"
      id="hidden-fact-117"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock
      contextRef="c31"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:ShareIssuedDuringPeriodValueConversionOfNonvotingConvertiblePreferredStockToCommonStock
      contextRef="c32"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c26"
      id="hidden-fact-120"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c26"
      id="hidden-fact-121"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c27"
      id="hidden-fact-122"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c27"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c28"
      id="hidden-fact-124"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c28"
      id="hidden-fact-125"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c29"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c31"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c32"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c26"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c27"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c28"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c29"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c31"
      id="hidden-fact-133"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c32"
      id="hidden-fact-134"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c26"
      id="hidden-fact-135"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c27"
      id="hidden-fact-136"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c28"
      id="hidden-fact-137"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c29"
      id="hidden-fact-138"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c31"
      id="hidden-fact-139"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c32"
      id="hidden-fact-140"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="c26"
      id="hidden-fact-141"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="c27"
      id="hidden-fact-142"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="c28"
      id="hidden-fact-143"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="c29"
      id="hidden-fact-144"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="c30"
      id="hidden-fact-145"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="c32"
      id="hidden-fact-146"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c26"
      id="hidden-fact-147"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c27"
      id="hidden-fact-148"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c28"
      id="hidden-fact-149"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c30"
      id="hidden-fact-150"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c31"
      id="hidden-fact-151"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c33"
      id="hidden-fact-152"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c33"
      id="hidden-fact-153"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c34"
      id="hidden-fact-154"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c34"
      id="hidden-fact-155"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c25"
      id="hidden-fact-156"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c62"
      id="hidden-fact-157"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c63"
      id="hidden-fact-158"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c66"
      id="hidden-fact-159"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c68"
      id="hidden-fact-160"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c70"
      id="hidden-fact-161"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c72"
      id="hidden-fact-162"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c74"
      id="hidden-fact-163"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c78"
      id="hidden-fact-164"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="c66"
      id="hidden-fact-165"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="c68"
      id="hidden-fact-166"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="c70"
      id="hidden-fact-167"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="c72"
      id="hidden-fact-168"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="c74"
      id="hidden-fact-169"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="c79"
      id="hidden-fact-170"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="c81"
      id="hidden-fact-171"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="c78"
      id="hidden-fact-172"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="c66"
      id="hidden-fact-173"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="c68"
      id="hidden-fact-174"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="c70"
      id="hidden-fact-175"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="c78"
      id="hidden-fact-176"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:FairValueCashEquivalentsAndMarketableSecurities
      contextRef="c78"
      id="hidden-fact-177"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c83"
      id="hidden-fact-178"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c83"
      id="hidden-fact-179"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c84"
      id="hidden-fact-180"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c85"
      id="hidden-fact-181"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c85"
      id="hidden-fact-182"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c86"
      id="hidden-fact-183"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c90"
      id="hidden-fact-184"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c93"
      id="hidden-fact-185"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c94"
      id="hidden-fact-186"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c95"
      id="hidden-fact-187"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="c96"
      id="hidden-fact-188"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="c96"
      id="hidden-fact-189"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="c97"
      id="hidden-fact-190"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="c97"
      id="hidden-fact-191"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="c98"
      id="hidden-fact-192"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="c98"
      id="hidden-fact-193"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="c99"
      id="hidden-fact-194"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="c99"
      id="hidden-fact-195"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="c100"
      id="hidden-fact-196"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="c100"
      id="hidden-fact-197"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="c101"
      id="hidden-fact-198"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="c101"
      id="hidden-fact-199"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="c3"
      id="hidden-fact-200"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="c3"
      id="hidden-fact-201"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:ClassOfWarrantOrRightExpirationDate contextRef="c117" id="hidden-fact-202" xsi:nil="true"/>
    <orka:ClassOfWarrantOrRightWarrantsExercised
      contextRef="c117"
      id="hidden-fact-203"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="c120"
      id="hidden-fact-204"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c130"
      id="hidden-fact-205"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c146"
      id="hidden-fact-206"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c120"
      id="hidden-fact-207"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c4"
      id="hidden-fact-208"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c4"
      id="hidden-fact-209"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c149" id="hidden-fact-210" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c4"
      id="hidden-fact-211"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c0"
      id="hidden-fact-212"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      id="hidden-fact-213"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c0"
      id="hidden-fact-214"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      id="hidden-fact-215"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c3"
      id="hidden-fact-216"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c3"
      id="hidden-fact-217"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0" id="hidden-fact-218" xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c3"
      id="hidden-fact-219"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c150"
      id="hidden-fact-220"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c150"
      id="hidden-fact-221"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c133"
      id="hidden-fact-222"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c133"
      id="hidden-fact-223"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c151"
      id="hidden-fact-224"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c151"
      id="hidden-fact-225"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="c151"
      id="hidden-fact-226"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised
      contextRef="c152"
      id="hidden-fact-227"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:WeightedAverShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageExercisePricePerShareExercised
      contextRef="c152"
      id="hidden-fact-228"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c152"
      id="hidden-fact-229"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageExercisePrice
      contextRef="c152"
      id="hidden-fact-230"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableOutstanding
      contextRef="c119"
      id="hidden-fact-231"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExercisableWeightedAverageExercisePrice
      contextRef="c119"
      id="hidden-fact-232"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <orka:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExercisable
      contextRef="c119"
      id="hidden-fact-233"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="c0"
      id="hidden-fact-234"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c3"
      id="hidden-fact-235"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c25"
      id="hidden-fact-236"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c25"
      id="hidden-fact-237"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-238"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-24955">0000907654</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-24956">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-24957">FY</dei:DocumentFiscalPeriodFocus>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif">Includes related party amount of $42,640 for the period from February 6, 2024 (inception) to December 31, 2024</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif">Includes related party amount of $1,364 for the period from February 6, 2024 (inception) to December 31, 2024</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif">Includes related party amount of $1,468 for the period from February 6, 2024 (inception) to December 31, 2024</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif">The weighted-average number of shares of as-converted Company Series A Preferred Stock used in the loss allocation was 495,191 for the period from February 6, 2024 (inception) to December 31, 2024.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_4_footnote" xlink:label="ix_4_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif">The weighted-average number of shares of as-converted Company Series B Preferred Stock used in the loss allocation was 4,328,844 for the period from February 6, 2024 (inception) to December 31, 2024.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
